{
  "Genes": {
    "BRAF": {
      "background": "BRAF is a serine/threonine kinase that plays a key role in the regulation of the mitogen-activated protein kinase (MAPK) cascade (PMID: 15520807), which under physiologic conditions regulates the expression of genes involved in cellular functions, including proliferation (PMID: 24202393). Genetic alterations in BRAF are found in a large percentage of melanomas, thyroid cancers and histiocytic neoplasms as well as a small fraction of lung and colorectal cancers. The most common BRAF point mutation is V600E, which deregulates the protein's kinase activity leading to constitutive BRAF activation, as BRAF V600E can signal as a monomer independently of RAS or upstream activation (PMID: 20179705). Other BRAF mutations have been found that affect the protein's propensity to dimerize (PMID: 16858395, 26343582, 12068308). The product of these alterations is a BRAF kinase that can activate MAPK signaling in an unregulated manner and, in some instances, is directly responsible for cancer growth (PMID: 15520807). Inhibitors of mutant BRAF, including vemurafenib and dabrafenib, are FDA-approved for the treatment of late-stage or unresectable melanoma. ",
      "background_review": {
        "updateTime": 1551830403599,
        "updatedBy": "User"
      },
      "background_uuid": "56032b8d-22d9-4e78-97f4-6b3337c21d38",
      "dmp_refseq_id": "NM_004333.4",
      "dmp_refseq_id_grch38": "NM_004333.4",
      "isoform_override": "ENST00000288602",
      "isoform_override_grch38": "ENST00000646891",
      "mutations": [
        {
          "mutation_effect": {
            "description": "The class I activating exon 15 BRAF V600E mutation is located in the kinase domain of the BRAF protein and is highly recurrent in melanoma, lung and thyroid cancer, among others (PMID: 28783719, 26091043, 25079552, 23833300, 25417114, 28783719, 12068308). This mutation has been comprehensively biologically characterized and has been shown to activate the downstream MAPK pathway independent of RAS (PMID: 15035987, 12068308, 19251651, 26343582), to render BRAF constitutively activated in monomeric form (PMID: 20179705), and to retain sensitivity to RAF monomer inhibitors such as vemurafenib and dabrafenib (PMID:26343582, 28783719, 20179705, 30351999).",
            "description_review": {
              "updateTime": 1666024211803,
              "updatedBy": "User"
            },
            "description_uuid": "96aeee82-d4b8-41b0-b975-c99753c7a4a2",
            "effect": "Gain-of-function",
            "effect_review": {
              "updateTime": 1698874533062,
              "updatedBy": "User"
            },
            "effect_uuid": "a53f5aa8-a4bb-4e65-8e30-93cf7045029e",
            "oncogenic": "Yes",
            "oncogenic_review": {
              "updateTime": 1698874552752,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "1de14103-e502-40c7-a6a6-587f8fc53135",
            "short": ""
          },
          "mutation_effect_uuid": "3ef57442-f50e-4305-adc6-22fbce9a532d",
          "name": "V600E",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "ee5900b8-d984-49a6-b6db-940eb1d0e807",
          "tumors": [
            {
              "TIs": [
                {
                  "name": "Standard implications for sensitivity to therapy",
                  "name_uuid": "b728d209-492b-41cd-aaa5-a16c61a770ed",
                  "treatments": [
                    {
                      "description": "Dabrafenib is an orally bioavailable RAF inhibitor that is FDA-approved for use in patients with BRAF V600E- and V600K-mutant metastatic melanoma. FDA approval is based on the randomized Phase III trial in which dabrafenib (150 mg orally twice daily) was compared with dacarbazine (1000 mg/m2 intravenously every three weeks) in 250 patients with BRAF V600E-mutated metastatic melanoma. Dabrafenib was associated with improved progression-free survival (median 5.1 months vs. 2.7 months with dacarbazine; hazard ratio = 0.30, p<0.0001) (PMID: 22735384). Dabrafenib may also be effective against brain metastases, as demonstrated by a Phase II trial in which approximately 40% of previously untreated and 30% of previously treated patients experienced an overall intracranial response and a separate trial in which nine out of ten patients had a reduction in the size of their brain metastases (PMID: 23051966, 22608338).",
                      "description_review": {
                        "updateTime": 1676497220555,
                        "updatedBy": "User"
                      },
                      "description_uuid": "932ea075-d4b8-40ca-9c14-4f0c18470f1f",
                      "fdaLevel": "Fda2",
                      "fdaLevel_review": {
                        "updateTime": 1664301853185,
                        "updatedBy": "User"
                      },
                      "fdaLevel_uuid": "eb209d1b-9356-4433-8801-1ae30105c28d",
                      "indication": "Dabrafenib is FDA-approved for BRAF V600E mutant unresectable or metastatic melanoma.",
                      "indication_review": {
                        "updateTime": 1526570813190,
                        "updatedBy": "User"
                      },
                      "indication_uuid": "742ca3d6-3d2c-4e46-95e1-f59e1741ab77",
                      "level": "1",
                      "level_review": {
                        "updateTime": 1564662395846,
                        "updatedBy": "User"
                      },
                      "level_uuid": "3116e9e6-c847-4370-a54a-cc241a0235ba",
                      "name": "939cd40b-b515-499d-b099-fd29027c0d17",
                      "name_review": {
                        "updateTime": 1564662394008,
                        "updatedBy": "User"
                      },
                      "name_uuid": "86887f5d-62df-429b-9968-7b73c31a9504",
                      "propagation": "3B",
                      "propagationLiquid": "no",
                      "propagationLiquid_uuid": "d230f033-db25-11e9-9a5e-60f81dc75ed6",
                      "propagation_review": {
                        "updateTime": 1564662395836,
                        "updatedBy": "User"
                      },
                      "propagation_uuid": "11ecb935-3e29-4678-84af-b688820349ac",
                      "short": "Dabrafenib may also be effective against brain metastases, as demonstrated by a Phase II trial in which approximately 40% of previously untreated and 30% of previously treated patients experienced an overall intracranial response and a separate trial in which nine out of ten patients had a reduction in the size of their brain metastases (PMID: 23051966, 22608338)."
                    },
                    {
                      "description": "Vemurafenib is an orally available kinse inhibitor of V600-mutant BRAF that is FDA-approved for treatment of patients with unresectable or metastatic melanoma with the BRAF V600E mutation. Vemurafenib has been shown to have nearly equivalent activity against melanomas with BRAF V600E and V600K mutations (PMID: 24508103). In a randomized Phase III trial comparing vemurafenib (960 mg orally twice daily) with dacarbazine (1000 mg/m2 i.v. every 3 weeks) for treatment-naive, metastatic, BRAF V600E-mutant melanoma, vemurafenib was associated with better overall survival (median survival 13.6 months vs. 9.7 months; hazard ratio 0.70, p=.0008) and longer median progression-free survival (6.9 months vs. 1.6 months) (PMID: 24508103). Final overall survival data from the BRIM-3 study showed that the survival advantage of vemurafenib over dacarbazine persisted through the 4-year landmark, with survival rates for vemurafenib and dacarbazine at the 4-year landmark being 17.0% and 15.6%, respectively (PMID: 28961848). However, a trial evaluating clinical outcomes in patients with melanoma treated with either combination therapy of dabrafenib and trametinib compared to those treated with vemurafenib monotherapy demonstrated improved survival outcomes in the combination-therapy group compared to the vemurafenib group (PMID: 25399551).",
                      "description_review": {
                        "updateTime": 1676497230377,
                        "updatedBy": "User"
                      },
                      "description_uuid": "c1345c56-3915-46ef-854c-dcdd7c4afb1b",
                      "fdaLevel": "Fda2",
                      "fdaLevel_review": {
                        "updateTime": 1676497227987,
                        "updatedBy": "User"
                      },
                      "fdaLevel_uuid": "a3ee4c4c-910b-4bc6-93b1-d79c6d02b6a4",
                      "indication": "Vemurafenib is FDA-approved for BRAF V600E mutant unresectable or metastatic melanoma",
                      "indication_review": {
                        "updateTime": 1526570896151,
                        "updatedBy": "User"
                      },
                      "indication_uuid": "a9a67b2e-9842-4a7e-90d4-15fa655d307e",
                      "level": "1",
                      "level_uuid": "ed575b60-c2fa-47a5-bf5e-91ff5babda75",
                      "name": "4e91da20-6cf0-4e07-995f-7f7db4c7c077",
                      "name_review": {
                        "updateTime": 1564662394015,
                        "updatedBy": "User"
                      },
                      "name_uuid": "09c8f359-ae07-4746-a2b1-2cc3d948b09f",
                      "propagation": "3B",
                      "propagationLiquid": "no",
                      "propagationLiquid_uuid": "d230f0c0-db25-11e9-96e6-60f81dc75ed6",
                      "propagation_uuid": "d23fb0c9-5250-42d5-8ef6-c70bde49441e",
                      "short": ""
                    }
                  ],
                  "type": "SS"
                },
                {
                  "name": "Standard implications for resistance to therapy",
                  "name_uuid": "a1c931c0-e66a-403d-a185-3b7e805d39e3",
                  "type": "SR"
                },
                {
                  "name": "Investigational implications for sensitivity to therapy",
                  "name_uuid": "f16cc5c5-0ca6-4d1c-a93e-4787b387eb3a",
                  "type": "IS"
                },
                {
                  "name": "Investigational implications for resistance to therapy",
                  "name_uuid": "b4c6d61d-0f6e-4a05-b5ad-92d7e6e14bfb",
                  "type": "IR"
                }
              ],
              "cancerTypes": [
                {
                  "code": "MEL",
                  "mainType": "Melanoma",
                  "subtype": "Melanoma"
                }
              ],
              "cancerTypes_uuid": "82133ef2-0fbf-4051-8f5a-2cd89b4f6a85",
              "diagnostic": {
                "description": "",
                "description_review": {
                  "updateTime": 1547763565098,
                  "updatedBy": "User"
                },
                "description_uuid": "dabf7f29-be55-4a27-a18e-5262d53c6aa4",
                "level": "",
                "level_uuid": "5a324cb7-32f7-4a3b-8797-c8b84abfa898",
                "short": ""
              },
              "diagnosticSummary": "",
              "diagnosticSummary_uuid": "9ea7d68e-e864-4d31-b585-a538a5291710",
              "diagnostic_uuid": "fadd7702-73fb-4b8b-b4c3-15af72f70e8f",
              "prognostic": {
                "description": "",
                "description_review": {
                  "updateTime": 1547763570386,
                  "updatedBy": "User"
                },
                "description_uuid": "0fd31fcb-99b8-4252-b6c9-efdd69fcd85a",
                "level": "",
                "level_uuid": "89c8ab7c-a47a-4035-9f31-f04b66494a16",
                "short": ""
              },
              "prognosticSummary": "",
              "prognosticSummary_uuid": "e6239653-5899-493f-ad95-2af514e5773b",
              "prognostic_uuid": "fcf8ed3b-7b88-480d-97da-6a18cf824578",
              "summary": "The RAF-targeted inhibitors encorafenib, dabrafenib and vemurafenib alone or in combination with the MEK-targeted inhibitors binimetinib, trametinib and cobimetinib, respectively, are FDA-approved for the treatment of patients with BRAF V600E/K mutant melanoma.",
              "summary_review": {
                "updateTime": 1566497646436,
                "updatedBy": "User"
              },
              "summary_uuid": "814e645a-9256-493d-b2c7-6771d4328876"
            },
            {
              "TIs": [
                {
                  "name": "Standard implications for sensitivity to therapy",
                  "name_uuid": "bb56de77-7c3e-4a54-8df1-d82fe8c4b617",
                  "treatments": [
                    {
                      "description": "Dabrafenib, an orally bioavailable RAF inhibitor, and trametinib, an orally bioavailable MEK1/2 inhibitor, are FDA-approved alone or in combination for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation. FDA approval was based on a Phase II, multicenter, non-randomized, open-label study of dabrafenib in combination with trametinib in patients with chemotherapy-pretreated, metastatic, stage IV BRAF(V600E)-mutant non-small cell lung cancer, in which 36 of 57 patients (63%) achieved overall tumor response, with two patients experiencing durable complete responses and 34 patients having durable partial responses (PMID: 27283860). In the third arm of that study, which included patients with untreated, metastatic, stage IV BRAF(V600E)-mutant non-small cell lung cancer, 23 of 26 patients (64%, 95% CI 46-79) had an overall response, with two patients (6%) having durable complete response and 21 (58%) having partial response (PMID: 28919011).",
                      "description_review": {
                        "updateTime": 1676497253594,
                        "updatedBy": "User"
                      },
                      "description_uuid": "1e42d102-f5aa-49b7-b6dd-b8e30964990d",
                      "fdaLevel": "Fda2",
                      "fdaLevel_review": {
                        "updateTime": 1666713209930,
                        "updatedBy": "User"
                      },
                      "fdaLevel_uuid": "84fc3b9c-38ee-47c0-b97e-3d06998011fc",
                      "indication": "Dabrafenib and trametinib are FDA-approved for use in combination in the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation",
                      "indication_review": {
                        "updateTime": 1526571355916,
                        "updatedBy": "User"
                      },
                      "indication_uuid": "43a35889-4d2a-4599-c034-d95bad2eb041",
                      "level": "1",
                      "level_uuid": "6bb901a0-a275-4ba2-8353-1e3dc5fa0be8",
                      "name": "939cd40b-b515-499d-b099-fd29027c0d17 + fb2bb01c-c0ec-4641-abf7-87f486075022",
                      "name_review": {
                        "updateTime": 1526571355916,
                        "updatedBy": "User"
                      },
                      "name_uuid": "c63b34cb-c1fa-4784-c031-98566ad048bb",
                      "propagation": "3B",
                      "propagationLiquid": "no",
                      "propagationLiquid_uuid": "d230f173-db25-11e9-a43a-60f81dc75ed6",
                      "propagation_uuid": "ec056cc8-3e53-41bf-9e2f-956ed268903c",
                      "short": ""
                    },
                    {
                      "description": "Encorafenib, a small molecule inhibitor of RAF kinases, and binimetinib, a small molecule inhibitor of MEK1/2 kinases, are FDA-approved in combination for the treatment of patients with BRAF V600E mutant non-small cell lung cancer (NSCLC). FDA approval was based on the Phase II, open-label, multicenter, single-arm PHAROS study of encorafenib in combination with binimetinib in treatment-naïve (n=59) and previously treated (n=39) patients with BRAF V600E-mutant metastatic NSCLC (PMID: 37270692). In the Phase II PHAROS study, the objective response rate and duration of response for treatment-naïve patients were 72% (95% CI=62, 85) and 44 months (95% CI=23.1, NE), with 15% experiencing a complete response and 59% experiencing a partial response, compared to 46% (95% CI=30, 63) and 18 months (95% CI=7.4, NE) in previously treated patients, with 10% experiencing a complete response and 36% experiencing a partial response (PMID: 37270692).",
                      "description_review": {
                        "updateTime": 1697648683213,
                        "updatedBy": "User"
                      },
                      "description_uuid": "37fae80e-3989-46c9-bb82-9bbfcc0b8eae",
                      "fdaLevel": "Fda2",
                      "fdaLevel_review": {
                        "updateTime": 1697580288235,
                        "updatedBy": "User"
                      },
                      "fdaLevel_uuid": "dcb476b2-f7ec-4dbc-9a03-d036b059e355",
                      "indication": "Encorafenib and binimetinib are FDA-approved for use in combination in the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation",
                      "indication_review": {
                        "updateTime": 1697637517180,
                        "updatedBy": "User"
                      },
                      "indication_uuid": "40645fd7-8e21-4007-af8b-e8eff67607f7",
                      "level": "1",
                      "level_review": {
                        "updateTime": 1697580288244,
                        "updatedBy": "User"
                      },
                      "level_uuid": "48669f54-a123-4b96-8170-51087557b7d0",
                      "name": "001e534f-3e63-432f-90a6-d1af1759e4e2 + feb9f4a3-e374-4c75-8a3b-0f1fbcdbf677",
                      "name_review": {
                        "updateTime": 1697580272446,
                        "updatedBy": "User"
                      },
                      "name_uuid": "f9d7a2ff-3395-49ac-b86f-a141d0337167",
                      "propagation": "3B",
                      "propagationLiquid": "no",
                      "propagationLiquid_review": {
                        "updateTime": 1697580288224,
                        "updatedBy": "User"
                      },
                      "propagationLiquid_uuid": "54f9cf2a-40d5-47c4-b3be-5b12bc30bec0",
                      "propagation_review": {
                        "updateTime": 1697580329269,
                        "updatedBy": "User"
                      },
                      "propagation_uuid": "34d9a44b-564b-4306-a8f3-83f190fc0508",
                      "short": ""
                    }
                  ],
                  "type": "SS"
                },
                {
                  "name": "Standard implications for resistance to therapy",
                  "name_uuid": "6e128801-fe29-4c05-8e29-2ace7d770f24",
                  "type": "SR"
                },
                {
                  "name": "Investigational implications for sensitivity to therapy",
                  "name_uuid": "a7743abe-f25d-4306-a956-d9d4cc87037e",
                  "type": "IS"
                },
                {
                  "name": "Investigational implications for resistance to therapy",
                  "name_uuid": "224c78c7-9ba4-4b9a-8e2b-b9549706c953",
                  "type": "IR"
                }
              ],
              "cancerTypes": [
                {
                  "code": "",
                  "mainType": "Non-Small Cell Lung Cancer",
                  "subtype": ""
                }
              ],
              "cancerTypes_uuid": "49b4acf3-8959-4548-87b6-ff89409c974f",
              "diagnostic": {
                "description": "",
                "description_uuid": "f1a7b798-e5ba-48d3-8537-b58bf3e261d8",
                "level": "",
                "level_uuid": "246c5c82-8a3a-4305-8f2e-5872bb22b185",
                "short": ""
              },
              "diagnosticSummary": "",
              "diagnosticSummary_uuid": "9e390fb7-b8d3-45b2-a225-8d296b1c055b",
              "diagnostic_uuid": "3f10d54b-8c3f-4a3c-8b7f-28bb412294a4",
              "prognostic": {
                "description": "",
                "description_review": {
                  "updateTime": 1493057315640
                },
                "description_uuid": "27819fa0-c784-484d-a0d4-08915bd0a6af",
                "level": "",
                "level_uuid": "2214f6da-ed4c-482a-9979-86b17535979c",
                "short": ""
              },
              "prognosticSummary": "",
              "prognosticSummary_uuid": "b5f923a9-c691-425f-8011-024038d47807",
              "prognostic_uuid": "49142644-aaf8-485a-8e14-7b7840c7d0a6",
              "summary": "The RAF-targeted inhibitors dabrafenib and encorafenib in combination with the MEK1/2-targeted inhibitors trametinib and binimetinib, respectively, are FDA-approved for the treatment of patients with BRAF V600E mutant non-small cell lung cancer.",
              "summary_review": {
                "updateTime": 1697660116218,
                "updatedBy": "User"
              },
              "summary_uuid": "dc939314-9786-4d02-942c-004c3444c33d"
            },
            {
              "TIs": [
                {
                  "name": "Standard implications for sensitivity to therapy",
                  "name_uuid": "553cf624-37b2-43f3-85ce-bdcf3ad3edf4",
                  "treatments": [
                    {
                      "description": "Dabrafenib, an orally bioavailable RAF inhibitor, and trametinib, an orally bioavailable MEK1/2 inhibitor, are FDA-approved alone or in combination for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options. FDA approval was based on results of the Phase II study of dabrafenib combined with trametinib in patients with BRAF V600E-positive ATC in which the overall response rate in sixteen evaluable patients was 69% (11/16; 95% CI= 41%-89%)(PMID: 29072975).",
                      "description_review": {
                        "updateTime": 1676496972845,
                        "updatedBy": "User"
                      },
                      "description_uuid": "7d8c3d84-358f-4bbb-bdc0-d01cad8eda4c",
                      "fdaLevel": "Fda2",
                      "fdaLevel_review": {
                        "updateTime": 1676496970311,
                        "updatedBy": "User"
                      },
                      "fdaLevel_uuid": "39fd03c8-9fa5-48fa-a4bf-45d28f96b088",
                      "indication": "Dabrafenib in combination with trametinib is FDA-approved for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options.",
                      "indication_review": {
                        "updateTime": 1526585518932,
                        "updatedBy": "User"
                      },
                      "indication_uuid": "2ef857ba-bdde-4694-b5e1-c50e1dd179ca",
                      "level": "1",
                      "level_uuid": "299a5e4a-afc3-4266-a52b-54e617d21df5",
                      "name": "939cd40b-b515-499d-b099-fd29027c0d17 + fb2bb01c-c0ec-4641-abf7-87f486075022",
                      "name_review": {
                        "updateTime": 1526585518932,
                        "updatedBy": "User"
                      },
                      "name_uuid": "87b2f23f-8d71-4664-b259-c2384202937b",
                      "propagation": "3B",
                      "propagationLiquid": "no",
                      "propagationLiquid_uuid": "d230f233-db25-11e9-be51-60f81dc75ed6",
                      "propagation_uuid": "7fb8f013-8d32-497a-ae2e-7657d4c53f42",
                      "short": ""
                    }
                  ],
                  "type": "SS"
                },
                {
                  "name": "Standard implications for resistance to therapy",
                  "name_uuid": "11f693fd-1e1f-447f-b7ad-50fafad9ab19",
                  "type": "SR"
                },
                {
                  "name": "Investigational implications for sensitivity to therapy",
                  "name_uuid": "129e7e07-b04b-4d18-8c7e-3e63c96b2017",
                  "type": "IS"
                },
                {
                  "name": "Investigational implications for resistance to therapy",
                  "name_uuid": "f8a5fb43-ca90-4c58-a4f7-fcd79ba0a560",
                  "type": "IR"
                }
              ],
              "cancerTypes": [
                {
                  "code": "THAP",
                  "mainType": "Thyroid Cancer",
                  "subtype": "Anaplastic Thyroid Cancer"
                }
              ],
              "cancerTypes_uuid": "2e904514-5d49-4abc-9e48-579395ccbb76",
              "diagnostic": {
                "description": "",
                "description_uuid": "1dc46340-d05c-4e74-a0b5-5ad941cb5de9",
                "level": "",
                "level_uuid": "6ddfb814-38be-4508-9bca-c31a34643037",
                "short": ""
              },
              "diagnosticSummary": "",
              "diagnosticSummary_uuid": "05785623-1f00-45eb-8344-1ed566663e0b",
              "diagnostic_uuid": "2240212f-4af5-4654-92aa-608f532e6961",
              "prognostic": {
                "description": "",
                "description_uuid": "4230caa2-bc56-4750-946b-eb27ec6d1929",
                "level": "",
                "level_uuid": "4295bced-7264-490c-bab9-d844c54c3222",
                "short": ""
              },
              "prognosticSummary": "",
              "prognosticSummary_uuid": "a6319d45-7a62-4c6f-abed-50fdce0dbefd",
              "prognostic_uuid": "76d39efd-e196-43cc-8988-1eff5b709d84",
              "summary": "The RAF-targeted inhibitor dabrafenib in combination with the MEK1/2-targeted inhibitor trametinib is FDA-approved for the treatment of patients with BRAF V600E mutant anaplastic thyroid cancer.",
              "summary_review": {
                "updateTime": 1566497708238,
                "updatedBy": "User"
              },
              "summary_uuid": "a3898773-037a-4e4b-8a58-41d07b189222"
            },
            {
              "TIs": [
                {
                  "name": "Standard implications for sensitivity to therapy",
                  "name_uuid": "34b4f091-f982-4bd8-864a-c25b383725a7",
                  "treatments": [
                    {
                      "description": "Encorafenib, a small molecule inhibitor of RAF kinase, and cetuximab, an antibody that targets EGFR, are FDA-approved in combination for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation after prior therapy. FDA approval was based on results of the Phase III BEACON study of encorafenib + cetuximab versus triplet treatment (including a MEK1/2 inhibitor) versus chemotherapy in 665 patients with BRAF V600E-mutant colorectal cancer, in which the overall response rate (complete or partial response) was 20% (95% CI= 13-29) in the doublet arm (n=220) versus 2% (95% CI= <1%-7%) in the chemotherapy arm (n=221), with median overall survival of 8.4 months in the doublet arm (95% CI= 7.5-11.0) and 5.4 months in the control arm (95% CI= 4.8-6.6) (PMID: 31566309).",
                      "description_review": {
                        "updateTime": 1697636476017,
                        "updatedBy": "User"
                      },
                      "description_uuid": "1db0ba8d-3f3b-4429-9e7b-00217d10437b",
                      "fdaLevel": "Fda2",
                      "fdaLevel_review": {
                        "updateTime": 1662567258336,
                        "updatedBy": "User"
                      },
                      "fdaLevel_uuid": "89df4557-4593-4729-938f-bf561d2f17db",
                      "indication": "",
                      "indication_uuid": "de4360e8-e4c1-444e-bbdc-cf15e53133d1",
                      "level": "1",
                      "level_review": {
                        "updateTime": 1586933580265,
                        "updatedBy": "User"
                      },
                      "level_uuid": "91c33ef8-6476-432b-bd47-b1434798c4d6",
                      "name": "001e534f-3e63-432f-90a6-d1af1759e4e2 + 5fce3074-e420-4c36-9603-2423daf20118",
                      "name_review": {
                        "updateTime": 1586933016940,
                        "updatedBy": "User"
                      },
                      "name_uuid": "5d3556f9-89b7-4be9-9fa8-69fee10f032b",
                      "propagation": "3B",
                      "propagationLiquid": "no",
                      "propagationLiquid_review": {
                        "updateTime": 1586933580257,
                        "updatedBy": "User"
                      },
                      "propagationLiquid_uuid": "83d371b9-ddec-428d-c052-6d2eb1d4c534",
                      "propagation_review": {
                        "updateTime": 1586933580247,
                        "updatedBy": "User"
                      },
                      "propagation_uuid": "2ab3f90b-29ac-4a31-b099-8f9c740691c4",
                      "short": ""
                    },
                    {
                      "description": "Encorafenib, a small molecule inhibitor of RAF kinase, and panitumumab, an antibody that targets EGFR, are NCCN-compendium listed in combination as level 2A therapy for patients with BRAF V600E-positive colorectal cancer. In the Phase III BEACON study of encorafenib + cetuximab, another EGFR antibody, versus triplet treatment (including a MEK1/2 inhibitor) versus chemotherapy in 665 patients with BRAF V600E-mutant colorectal cancer, the overall response rate (complete or partial response) was 20% (95% CI= 13-29) in the doublet arm (n=220) versus 2% (95% CI= <1%-7%) in the chemotherapy arm (n=221), with median overall survival of 8.4 months in the doublet arm (95% CI= 7.5-11.0) and 5.4 months in the control arm (95% CI= 4.8-6.6) (PMID: 31566309). Panitumumab has also been used in doublet and triplet combination therapy, with a response rate in one study of 26% (PMID: 29431699).",
                      "description_review": {
                        "updateTime": 1676497034198,
                        "updatedBy": "User"
                      },
                      "description_uuid": "78a9d3f6-345f-4a7f-869c-545dd7fe5f69",
                      "fdaLevel": "Fda2",
                      "fdaLevel_review": {
                        "updateTime": 1662567256839,
                        "updatedBy": "User"
                      },
                      "fdaLevel_uuid": "5498e009-989f-4e61-a2d7-38444686f022",
                      "indication": "",
                      "indication_uuid": "b730f7a1-8e70-46fb-bc23-6e95bb467290",
                      "level": "2",
                      "level_review": {
                        "updateTime": 1564506373092,
                        "updatedBy": "User"
                      },
                      "level_uuid": "7c15b783-7b14-48d9-a040-ca77ca110d8b",
                      "name": "001e534f-3e63-432f-90a6-d1af1759e4e2 + d7b1d12a-e942-4801-bb64-916c9bdfaaf3",
                      "name_review": {
                        "updateTime": 1587009767744,
                        "updatedBy": "User"
                      },
                      "name_uuid": "d9b444f3-76b2-4f91-a919-8b8b4d853846",
                      "propagation": "3B",
                      "propagationLiquid": "no",
                      "propagationLiquid_uuid": "d230f317-db25-11e9-ad42-60f81dc75ed6",
                      "propagation_review": {
                        "updateTime": 1564506373082,
                        "updatedBy": "User"
                      },
                      "propagation_uuid": "143939ec-050e-416e-be4c-930f7d2e5020",
                      "short": ""
                    }
                  ],
                  "treatments_uuid": "a06fb981-abf2-4b3f-8b5d-0c400490e1ef",
                  "type": "SS"
                },
                {
                  "name": "Standard implications for resistance to therapy",
                  "name_uuid": "71e19ae9-2234-4cc0-b489-9141a5c39693",
                  "treatments_uuid": "d44ee9b4-59d6-484d-9b39-90c2cef6c975",
                  "type": "SR"
                },
                {
                  "name": "Investigational implications for sensitivity to therapy",
                  "name_uuid": "91e1edd2-2393-49ab-b760-d58647fa9e4f",
                  "treatments_uuid": "5d75375a-bde8-4242-a86f-3c21149f0b3e",
                  "type": "IS"
                },
                {
                  "name": "Investigational implications for resistance to therapy",
                  "name_uuid": "03e269f0-d249-407a-9410-df104441d76b",
                  "treatments_uuid": "b8b6f836-7a6e-4c4a-ae37-afcc1cd98bfb",
                  "type": "IR"
                }
              ],
              "cancerTypes": [
                {
                  "code": "",
                  "mainType": "Colorectal Cancer",
                  "subtype": ""
                }
              ],
              "cancerTypes_review": {
                "updateTime": 1542309512319,
                "updatedBy": "User"
              },
              "cancerTypes_uuid": "d44183da-4fa8-4e44-bcdf-1205e4578bce",
              "diagnostic": {
                "description": "",
                "description_uuid": "9390cf4e-f4ee-4252-93fb-d1a06ca45000",
                "level": "",
                "level_uuid": "388be3d2-790d-4373-a5db-46065eebcd6d",
                "short": ""
              },
              "diagnosticSummary": "",
              "diagnosticSummary_uuid": "d65b7150-b253-4fdd-a4e1-4c09a5181cdd",
              "diagnostic_uuid": "432336f0-9288-4589-914c-ae6f93b77b93",
              "prognostic": {
                "description": "",
                "description_uuid": "60e9ada5-1d33-433c-8fd1-5e1db5d52bda",
                "level": "",
                "level_uuid": "df685b39-0ce1-4fe7-90de-4cb467a0bdff",
                "short": ""
              },
              "prognosticSummary": "",
              "prognosticSummary_uuid": "b2f6d7fb-64b7-4f98-9ffd-5812842a85b8",
              "prognostic_uuid": "ae4ab53b-c637-400b-9c47-0ec6f4468978",
              "summary": "The RAF-targeted inhibitor encorafenib in combination with the anti-EGFR antibody cetuximab is FDA-approved for the treatment of patients with BRAF V600E mutant colorectal cancer.",
              "summary_review": {
                "updateTime": 1587156866727,
                "updatedBy": "User"
              },
              "summary_uuid": "cfcc19a6-df02-4230-85fb-992ed74d464a"
            },
            {
              "TIs": [
                {
                  "name": "Standard implications for sensitivity to therapy",
                  "name_uuid": "a64a8e47-100d-4e39-9932-da1dc931ab14",
                  "treatments_uuid": "e11c589b-624f-44ca-9bd1-9dfe9f026d31",
                  "type": "SS"
                },
                {
                  "name": "Standard implications for resistance to therapy",
                  "name_uuid": "06e6e1ba-1380-4a3b-99df-26637f33b4c1",
                  "treatments_uuid": "8a3b4639-be2f-48b9-84a4-50dd17f2eaaa",
                  "type": "SR"
                },
                {
                  "name": "Investigational implications for sensitivity to therapy",
                  "name_uuid": "7d6a7c9a-30fb-4bf5-af7b-0aa75a8dd7b3",
                  "treatments_uuid": "8b7b9453-e472-46ad-b18b-ec68b97e368e",
                  "type": "IS"
                },
                {
                  "name": "Investigational implications for resistance to therapy",
                  "name_uuid": "a7f66245-ff04-4ff0-af27-a0f7f218f6b0",
                  "treatments_uuid": "31cad244-a914-4e49-b3c0-c81b51b71399",
                  "type": "IR"
                }
              ],
              "cancerTypes": [
                {
                  "code": "ECD",
                  "mainType": "Histiocytosis",
                  "subtype": "Erdheim-Chester Disease"
                }
              ],
              "cancerTypes_uuid": "a4e9e6d9-6d68-4c59-8fc2-e97e8354ce43",
              "diagnostic": {
                "description": "This assertion is supported by (PMID: 25422482, 26637772).",
                "description_review": {
                  "updateTime": 1600293135267,
                  "updatedBy": "User"
                },
                "description_uuid": "dc0f79c3-f51d-48d6-af22-53b3f36fb94b",
                "level": "Dx3",
                "level_review": {
                  "updateTime": 1600293135267,
                  "updatedBy": "User"
                },
                "level_uuid": "725e8a75-80b5-4898-830e-39a54021ab7e",
                "short": ""
              },
              "diagnosticSummary": "The presence of a BRAF V600E mutation may assist in the diagnosis of [[tumor type]].",
              "diagnosticSummary_review": {
                "updateTime": 1600293135267,
                "updatedBy": "User"
              },
              "diagnosticSummary_uuid": "d8ad6e9b-738e-47d1-a796-f3f27485813e",
              "diagnostic_uuid": "9bf86162-5aab-4df2-bd5d-de3313c2e96f",
              "prognostic": {
                "description": "",
                "description_uuid": "c7999cb0-7e23-48bb-a426-23e2f0be64d4",
                "level": "",
                "level_uuid": "a025eeed-7dea-46d6-9482-cc9192e85e11",
                "short": ""
              },
              "prognosticSummary": "",
              "prognosticSummary_uuid": "ebc1182c-aaea-4860-bd4b-decdf196c918",
              "prognostic_uuid": "62935c07-176f-47f4-9ff0-479682cb1e33",
              "summary": "",
              "summary_review": {
                "updateTime": 1633041518406,
                "updatedBy": "User"
              },
              "summary_uuid": "8315f907-4d3a-4a0d-8b0f-406625201cd4"
            },
            {
              "TIs": [
                {
                  "name": "Standard implications for sensitivity to therapy",
                  "name_uuid": "98bb69ea-1e0d-4e24-abb0-7521060a9c2a",
                  "treatments": [
                    {
                      "description": "Vemurafenib is an orally available kinse inhibitor of V600-mutant BRAF that is FDA-approved for treatment of patients with various BRAF V600-harboring tumors, including melanoma and Edheim-Chester Disease (ECD). Vemurafenib is listed as a 2A therapeutic in the NCCN guidelines for Hairy Cell Leukemia (HCL) based on data from two Phase II trials. In one study of vemurafenib in patients with BRAF V600E-mutant HCL (n=24), the overall response rate was 100%, with 42% of patients (10 of 24) having complete responses, with a response duration of 11.7 months and one year progression free and overall survival rates of 73% and 91%, repectively (PMID: 26352686). In another study of vemurafenib in patients with BRAF V600E-mutant HCL (n=26), the overall response rate was 96%, with 35% of patients (9 of 26) having complete responses (PMID: 26352686).",
                      "description_review": {
                        "updateTime": 1676497199789,
                        "updatedBy": "User"
                      },
                      "description_uuid": "ad710a94-191a-4f31-9c25-cf330af9d191",
                      "fdaLevel": "Fda2",
                      "fdaLevel_review": {
                        "updateTime": 1676497196447,
                        "updatedBy": "User"
                      },
                      "fdaLevel_uuid": "fc3ae35d-fbea-4e0d-974c-80ab4159158a",
                      "indication": "",
                      "indication_uuid": "d6bf13c9-52c1-4fc3-b63b-32f9b5958c9a",
                      "level": "2",
                      "level_review": {
                        "updateTime": 1564509443794,
                        "updatedBy": "User"
                      },
                      "level_uuid": "d28f3780-d246-49a5-b681-f08bba46685f",
                      "name": "4e91da20-6cf0-4e07-995f-7f7db4c7c077",
                      "name_review": {
                        "updateTime": 1564016553702,
                        "updatedBy": "User"
                      },
                      "name_uuid": "4e56b02d-394e-4397-9465-a3cc2c5026cd",
                      "propagation": "3B",
                      "propagationLiquid": "no",
                      "propagationLiquid_uuid": "d230f3d7-db25-11e9-8700-60f81dc75ed6",
                      "propagation_review": {
                        "updateTime": 1564509443791,
                        "updatedBy": "User"
                      },
                      "propagation_uuid": "7f1fb2cd-44c7-4958-9003-21c5c4c65797",
                      "short": ""
                    }
                  ],
                  "treatments_uuid": "6dd5798a-150d-4129-b265-d33bcc3df1d8",
                  "type": "SS"
                },
                {
                  "name": "Standard implications for resistance to therapy",
                  "name_uuid": "f660789a-9594-4b82-9412-8166eb62cf76",
                  "treatments_uuid": "5912fef6-04e6-4c94-885c-a87fcdd798ea",
                  "type": "SR"
                },
                {
                  "name": "Investigational implications for sensitivity to therapy",
                  "name_uuid": "40a1db53-4ce0-4a04-82c3-cf9eb51fb1b5",
                  "treatments_uuid": "1d1ed13f-5f17-4f19-8e1e-be88b310d16d",
                  "type": "IS"
                },
                {
                  "name": "Investigational implications for resistance to therapy",
                  "name_uuid": "087a40d7-c94a-4453-bada-378524b588ee",
                  "treatments_uuid": "005ee041-48e9-4e68-96ed-fdadbc2a36af",
                  "type": "IR"
                }
              ],
              "cancerTypes": [
                {
                  "code": "HCL",
                  "mainType": "Mature B-Cell Neoplasms",
                  "subtype": "Hairy Cell Leukemia"
                }
              ],
              "cancerTypes_uuid": "fd8ec76d-992a-44a1-8205-5771d41851e8",
              "diagnostic": {
                "description": "This assertion is supported by (PMID: 21663470, 25480661, 22072557, 22028477, 21910720, 22531170, 22210875, 23347903, 25120816, 26071465).",
                "description_review": {
                  "updateTime": 1600293135158,
                  "updatedBy": "User"
                },
                "description_uuid": "e0504e87-9449-4605-9619-57becfcc773f",
                "level": "Dx2",
                "level_review": {
                  "updateTime": 1600293135158,
                  "updatedBy": "User"
                },
                "level_uuid": "77f61ad7-5110-4071-9a87-83b4fb6f219a",
                "short": ""
              },
              "diagnosticSummary": "The presence of a BRAF V600E mutation strongly supports a diagnosis of [[tumor type]].",
              "diagnosticSummary_review": {
                "updateTime": 1600293135158,
                "updatedBy": "User"
              },
              "diagnosticSummary_uuid": "82098d7c-b495-46db-b841-ee584037f871",
              "diagnostic_uuid": "565e1375-b008-47ab-9b14-5807616072fb",
              "prognostic": {
                "description": "",
                "description_uuid": "11efe800-3ee1-4e38-b63e-a309cee07814",
                "level": "",
                "level_uuid": "4a523390-8939-4a54-b6df-50c5cf772261",
                "short": ""
              },
              "prognosticSummary": "",
              "prognosticSummary_uuid": "6969ad14-fe53-44a3-9b21-aad749d72045",
              "prognostic_uuid": "53e409a5-7c1f-430e-b87a-ab456594b7fc",
              "summary": "The RAF-targeted inhibitor vemurafenib is NCCN-compendium listed for the treatment of patients with relapsed or refractory BRAF V600E-mutant hairy cell leukemia.",
              "summary_review": {
                "updateTime": 1566491302826,
                "updatedBy": "User"
              },
              "summary_uuid": "fe5e6dec-78e9-438d-9a22-762fcdc91ac2"
            },
            {
              "TIs": [
                {
                  "name": "Standard implications for sensitivity to therapy",
                  "name_uuid": "0d81a2bb-c58b-4c55-8f94-685374cc6435",
                  "treatments_uuid": "3de2b898-0a5c-4c71-85f1-36286c1b91ef",
                  "type": "SS"
                },
                {
                  "name": "Standard implications for resistance to therapy",
                  "name_uuid": "42e02d7e-ff51-4f18-8c1d-1b149fada116",
                  "treatments_uuid": "c7e6480b-b9ef-4e64-b187-51bceb640176",
                  "type": "SR"
                },
                {
                  "name": "Investigational implications for sensitivity to therapy",
                  "name_uuid": "03ef93c2-cde7-4db7-9b20-ebba1b3ca9a0",
                  "treatments_uuid": "790407b0-4d50-4b72-9bdb-b541dfc07298",
                  "type": "IS"
                },
                {
                  "name": "Investigational implications for resistance to therapy",
                  "name_uuid": "34661e02-977e-4ad3-ad7a-8b22486c91d3",
                  "treatments_uuid": "4b9f0c42-14db-4e4a-b82d-75e6c99c7a23",
                  "type": "IR"
                }
              ],
              "cancerTypes": [
                {
                  "code": "LCH",
                  "mainType": "Histiocytosis",
                  "subtype": "Langerhans Cell Histiocytosis"
                }
              ],
              "cancerTypes_uuid": "e1988f60-e15e-4d54-85a1-ee270f418aa3",
              "diagnostic": {
                "description": "This assertion is supported by (PMID: 24938183, 20519626, 30157397, 26637772).",
                "description_review": {
                  "updateTime": 1600293135158,
                  "updatedBy": "User"
                },
                "description_uuid": "ae746ef1-50d7-46c7-b6df-bae03b9c1f8c",
                "level": "Dx2",
                "level_review": {
                  "updateTime": 1600293135158,
                  "updatedBy": "User"
                },
                "level_uuid": "620e54eb-1026-4510-8db1-d5283f2c9bbd",
                "short": ""
              },
              "diagnosticSummary": "The presence of a BRAF V600E mutation strongly supports a diagnosis of [[tumor type]].",
              "diagnosticSummary_review": {
                "updateTime": 1600293135158,
                "updatedBy": "User"
              },
              "diagnosticSummary_uuid": "086643d5-bb51-4e6d-815a-d39d2549d792",
              "diagnostic_uuid": "97cde25b-b793-4cf6-b4e2-b787c0a398e9",
              "prognostic": {
                "description": "",
                "description_uuid": "35d807e4-03ff-402b-91af-3e520cd574ea",
                "level": "",
                "level_uuid": "1c2c28e4-cef5-44a9-a1f2-b71a9b003781",
                "short": ""
              },
              "prognosticSummary": "",
              "prognosticSummary_uuid": "b70ae517-a220-4b07-bb13-8a91b77d8c58",
              "prognostic_uuid": "e077cc50-116c-4467-8117-ecc5c4910086",
              "summary": "",
              "summary_review": {
                "updateTime": 1633445972630,
                "updatedBy": "User"
              },
              "summary_uuid": "b1bb9c06-65cf-44a4-b7ee-0f08403b897d"
            },
            {
              "TIs": [
                {
                  "name": "Standard implications for sensitivity to therapy",
                  "name_uuid": "93e82861-dd45-4d0d-b33f-39a5b162e518",
                  "treatments": [
                    {
                      "description": "The RAF inhibitor vemurafenib in combination with the MEK inhibitor cobimetinib is FDA-approved for patients with melanoma, non-small cell lung cancer, and anaplastic thyroid cancer, and is NCCN-compendium listed as recommended treatment of central nervous system cancers such as pilocytic astrocytoma, pleomorphic xanthoastrocytoma (PXA) and ganglioglioma. In a case series of two patients with BRAF V600E-mutant PXA, combination treatment of dabrafenib with trametinib led to partial responses by RANO criteria in both patients (PMID: 28984141). In a case report of a sixteen-year-old female with BRAF V600E-mutant anaplastic ganglioglioma, dabrafenib and trametinib in combination led to a significant response that was maintained at least six months after treatment initiation (PMID: 29380516). In a separate case report of a 28-year-old man with BRAF V600E-mutant anaplastic ganglioglioma, combination treatment of vemurafenib and cobimetinib led to a complete response after three months, with no evidence of recurrence after sixteen months of treatment (PMID: 30120137).",
                      "description_review": {
                        "updateTime": 1676497291840,
                        "updatedBy": "User"
                      },
                      "description_uuid": "827ea474-7d3e-4802-a25e-cc67df5aa754",
                      "fdaLevel": "Fda3",
                      "fdaLevel_review": {
                        "updateTime": 1659103528603,
                        "updatedBy": "User"
                      },
                      "fdaLevel_uuid": "e378fa71-31ae-43a2-9be7-ed70a0e3d784",
                      "indication": "",
                      "indication_uuid": "63390f0a-aa80-4e26-98c6-e2ba164b7061",
                      "level": "2",
                      "level_review": {
                        "updateTime": 1587969908339,
                        "updatedBy": "User"
                      },
                      "level_uuid": "851f2ab2-5b0f-414a-82d4-f58ef2eabf08",
                      "name": "4e91da20-6cf0-4e07-995f-7f7db4c7c077 + eb357145-3b18-4aca-b75a-5e18dd2bf4f9",
                      "name_review": {
                        "updateTime": 1661883334566,
                        "updatedBy": "User"
                      },
                      "name_uuid": "7f76d72e-ec85-4f42-91fe-b247dbe0e0e9",
                      "propagation": "3B",
                      "propagationLiquid": "no",
                      "propagationLiquid_review": {
                        "updateTime": 1587969908334,
                        "updatedBy": "User"
                      },
                      "propagationLiquid_uuid": "76cd35f5-c87e-4065-988e-a08851d11155",
                      "propagation_review": {
                        "updateTime": 1587969908329,
                        "updatedBy": "User"
                      },
                      "propagation_uuid": "27730433-510a-4dd9-a85b-d4a3960f666b",
                      "short": "removed PMID: 26287849 because this basket study only treated with single agent vemurafenib in four patients (3 PRs), not in combination with cobimetinib. \nremoved PMID: 30351999 because only treated with single agent vemurafenib."
                    }
                  ],
                  "treatments_uuid": "20098bb8-9fb4-4956-94f1-2c34b83ec764",
                  "type": "SS"
                },
                {
                  "name": "Standard implications for resistance to therapy",
                  "name_uuid": "0c311582-582d-45ed-a7c7-10cf734b5dc8",
                  "treatments_uuid": "70033d5c-ffa4-4e03-98a5-2f694c70a665",
                  "type": "SR"
                },
                {
                  "name": "Investigational implications for sensitivity to therapy",
                  "name_uuid": "33a99a5a-8ccf-46c4-a296-9ef6d349082e",
                  "treatments_uuid": "94a0708f-ffa2-4306-9370-9129c4e19514",
                  "type": "IS"
                },
                {
                  "name": "Investigational implications for resistance to therapy",
                  "name_uuid": "59ecfdb7-6879-4a03-a1db-d799c1e090af",
                  "treatments_uuid": "4602932c-c284-4b69-99ea-1574bf344cb8",
                  "type": "IR"
                }
              ],
              "cancerTypes": [
                {
                  "code": "PAST",
                  "mainType": "Glioma",
                  "subtype": "Pilocytic Astrocytoma"
                },
                {
                  "code": "PXA",
                  "mainType": "Glioma",
                  "subtype": "Pleomorphic Xanthoastrocytoma"
                },
                {
                  "code": "GNG",
                  "mainType": "Glioma",
                  "subtype": "Ganglioglioma"
                }
              ],
              "cancerTypes_review": {
                "updateTime": 1588887636809,
                "updatedBy": "User"
              },
              "cancerTypes_uuid": "8a0e5008-caaa-443a-8bd6-83a79324bfd9",
              "diagnostic": {
                "description": "",
                "description_uuid": "a50cabb0-1c7f-4175-a8a9-0d3bc4b04492",
                "level": "",
                "level_uuid": "8111e079-2c3a-48c8-a8a7-edf767c6dd53",
                "short": ""
              },
              "diagnosticSummary": "",
              "diagnosticSummary_uuid": "d2a23a0f-a886-4a23-abcc-78c383725ab6",
              "diagnostic_uuid": "490ff0ae-d940-46ed-96ce-e7da111f5ae8",
              "prognostic": {
                "description": "",
                "description_uuid": "2dc32a00-0d51-4e76-89c7-ee5d25bef139",
                "level": "",
                "level_uuid": "a92d04a7-8d0b-4cb1-afe3-ba4e5a18829b",
                "short": ""
              },
              "prognosticSummary": "",
              "prognosticSummary_uuid": "9f6359d5-1087-4917-9210-da20882b76bb",
              "prognostic_uuid": "bd7c638c-33c2-4029-b378-009caf72b600",
              "summary": "The RAF inhibitor dabrafenib in combination with the MEK1/2 inhibitor trametinib is FDA-approved for the treatment of patients with BRAF V600E-mutant solid tumors.",
              "summary_review": {
                "updateTime": 1661883320881,
                "updatedBy": "User"
              },
              "summary_uuid": "114b09bd-f15e-4f71-a3dd-048c746b20c3"
            },
            {
              "TIs": [
                {
                  "name": "Standard implications for sensitivity to therapy",
                  "name_uuid": "b631f862-051a-4a0a-889a-4e890566b7d7",
                  "treatments_uuid": "793da244-4dc3-49eb-9dc4-39f2ca12fb4f",
                  "type": "SS"
                },
                {
                  "name": "Standard implications for resistance to therapy",
                  "name_uuid": "f759c5ce-7bb7-4878-adbe-f0174412418c",
                  "treatments_uuid": "d1ecaa63-6170-4555-ac8b-07fb743d807a",
                  "type": "SR"
                },
                {
                  "name": "Investigational implications for sensitivity to therapy",
                  "name_uuid": "7973a75d-75eb-4d63-a70d-92726be8169f",
                  "treatments_uuid": "adeb8f20-597f-4f86-b79f-f1f2de3e079d",
                  "type": "IS"
                },
                {
                  "name": "Investigational implications for resistance to therapy",
                  "name_uuid": "4829f582-a24e-4ff8-93db-5dee0a021fdf",
                  "treatments_uuid": "10fb3cca-9d48-4d12-9b3d-87bb68c5f1fa",
                  "type": "IR"
                }
              ],
              "cancerTypes": [
                {
                  "code": "",
                  "mainType": "Histiocytosis",
                  "subtype": ""
                }
              ],
              "cancerTypes_review": {
                "updateTime": 1588124245765,
                "updatedBy": "User"
              },
              "cancerTypes_uuid": "e6b2a3eb-d18e-4978-974c-4f96968f8da5",
              "diagnostic": {
                "description": "",
                "description_uuid": "549be1e3-364a-422e-8179-73e53fad43c1",
                "level": "",
                "level_uuid": "0578832a-1498-4aa3-ab3e-ae5742eeeace",
                "short": ""
              },
              "diagnosticSummary": "",
              "diagnosticSummary_uuid": "0f69f8ed-1039-47b8-b080-753fe299d9e5",
              "diagnostic_uuid": "8430d413-66d5-49d4-9349-96958414e789",
              "prognostic": {
                "description": "",
                "description_uuid": "58d11fc4-cf22-4d01-8ed5-1142f5acd21d",
                "level": "",
                "level_uuid": "dc5bfe77-54e5-4dad-a69b-5160bae26b74",
                "short": ""
              },
              "prognosticSummary": "",
              "prognosticSummary_uuid": "197b4dcc-6b20-470d-b126-a53710bc6a52",
              "prognostic_uuid": "0c755197-2b43-4f75-b156-b878ca777cdc",
              "summary": "The RAF-targeted inhibitor vemurafenib is FDA-approved for the treatment of patients with BRAF V600-mutant Erdheim-Chester Disease (ECD) and there is promising clinical data in patients with non-ECD BRAF V600E mutant histiocytic neoplasms treated with vemurafenib or dabrafenib as monotherapy.",
              "summary_review": {
                "updateTime": 1633042725138,
                "updatedBy": "User"
              },
              "summary_uuid": "92d5ed0f-6425-4b2b-9a75-b7f673840cee"
            },
            {
              "TIs": [
                {
                  "name": "Standard implications for sensitivity to therapy",
                  "name_uuid": "110807f9-b094-48ba-96ce-9c26d80d16fb",
                  "type": "SS"
                },
                {
                  "name": "Standard implications for resistance to therapy",
                  "name_uuid": "ef4660bb-c057-44f6-9899-ddc5f055e3c3",
                  "type": "SR"
                },
                {
                  "name": "Investigational implications for sensitivity to therapy",
                  "name_uuid": "78c22113-482b-4c2b-b3e7-4fb3665f3cc1",
                  "type": "IS"
                },
                {
                  "name": "Investigational implications for resistance to therapy",
                  "name_uuid": "3ae69411-6348-4008-bbc7-caba2707f1e1",
                  "type": "IR"
                }
              ],
              "cancerTypes": [
                {
                  "code": "",
                  "mainType": "Other Tumor Types",
                  "subtype": ""
                }
              ],
              "cancerTypes_review": {
                "updateTime": 1547763624528,
                "updatedBy": "User"
              },
              "cancerTypes_uuid": "8e336ee9-409e-4e30-af36-cc440c6b116b",
              "diagnostic": {
                "description": "",
                "description_uuid": "d89fb488-c965-4fce-85a4-59239ba1f3f1",
                "level": "",
                "level_uuid": "34910f90-c7ee-4b1d-b909-4fb7b774bb49",
                "short": ""
              },
              "diagnosticSummary": "",
              "diagnosticSummary_uuid": "c0780aeb-13ed-4010-91d4-229a08aa54ca",
              "diagnostic_uuid": "2cfa3a15-f882-4c15-8598-0fca5c9d8386",
              "prognostic": {
                "description": "",
                "description_uuid": "0877005a-0a43-4d35-862e-4fd34b858c1b",
                "level": "",
                "level_uuid": "8970b0be-68df-41c6-8327-bedf9a4f7d19",
                "short": ""
              },
              "prognosticSummary": "",
              "prognosticSummary_uuid": "7fd63d04-f396-4e1c-a5ef-b34a3574a173",
              "prognostic_uuid": "d711d904-c479-4963-bd21-9e871355bb0f",
              "summary": "While the RAF-inhibitor dabrafenib in combination with the MEK1/2-targeted inhibitor trametinib is FDA-approved for the treatment of patients with BRAF V600E mutant solid tumors, the clinical utility of dabrafenib in combination with trametinib in patients with [[variant]] has yet to be defined.",
              "summary_review": {
                "updateTime": 1661959786866,
                "updatedBy": "User"
              },
              "summary_uuid": "215bd1c9-120d-4fc1-b906-5f317772b820"
            },
            {
              "TIs": [
                {
                  "name": "Standard implications for sensitivity to therapy",
                  "name_uuid": "8745ab87-6d3f-4f1c-a3e6-ef231a7a0881",
                  "treatments": [
                    {
                      "description": "Selumetinib is a small molecule tyrosine kinase inhibitor of MEK1/2. In stratum one of the phase II PBTC study of selumetinib in 25 patients with pilocytic astrocytoma harboring a KIAA1549–BRAF fusion or BRAF V600E mutation, seven of eighteen patients with a KIAA1549–BRAF fusion had a partial response to treatment (PMID: 31151904). Additionally, the two year progression-free survival rate for the BRAF study population (n=25) was 70% (95% CI = 47–85) (PMID: 31151904).",
                      "description_review": {
                        "updateTime": 1676497270684,
                        "updatedBy": "User"
                      },
                      "description_uuid": "a4e4a347-c833-4543-94b2-cf8c89e2cd6d",
                      "fdaLevel": "Fda2",
                      "fdaLevel_review": {
                        "updateTime": 1661884397403,
                        "updatedBy": "User"
                      },
                      "fdaLevel_uuid": "3e0a4560-6448-4f02-8ed6-40fe86a1a97c",
                      "indication": "",
                      "indication_uuid": "8630d57e-501d-4770-b2e4-1db8c6b6621c",
                      "level": "2",
                      "level_review": {
                        "updateTime": 1630018614050,
                        "updatedBy": "User"
                      },
                      "level_uuid": "1cf6846a-4368-4f3c-9061-c1686e2bf2cc",
                      "name": "3f154145-525b-4865-8baf-12b374697b2a",
                      "name_review": {
                        "updateTime": 1630018608732,
                        "updatedBy": "User"
                      },
                      "name_uuid": "9ae514fa-cea6-4a01-9f6e-ae9ca1a43049",
                      "propagation": "3B",
                      "propagationLiquid": "no",
                      "propagationLiquid_review": {
                        "updateTime": 1630018614046,
                        "updatedBy": "User"
                      },
                      "propagationLiquid_uuid": "e27e3157-11f6-4a8f-a1c7-de4679da45d1",
                      "propagation_review": {
                        "updateTime": 1630018617395,
                        "updatedBy": "User"
                      },
                      "propagation_uuid": "626dc237-05a8-449a-82ce-22d21af5d3d0",
                      "short": ""
                    }
                  ],
                  "treatments_uuid": "5bd423ba-c62c-4359-8709-5356966af526",
                  "type": "SS"
                },
                {
                  "name": "Standard implications for resistance to therapy",
                  "name_uuid": "25015e60-e047-45f1-aa17-6bfe3985d12c",
                  "treatments_uuid": "af4ddc45-3c8b-483f-9006-ced1be53985f",
                  "type": "SR"
                },
                {
                  "name": "Investigational implications for sensitivity to therapy",
                  "name_uuid": "9fdf2d51-7214-4199-a9ea-ce397f767e5a",
                  "treatments_uuid": "77528889-b09e-45db-9e6d-ad82de971730",
                  "type": "IS"
                },
                {
                  "name": "Investigational implications for resistance to therapy",
                  "name_uuid": "0e9ae1b3-ac85-4c31-a267-95c32ae79525",
                  "treatments_uuid": "675c16b2-2484-42f6-8b1a-337475280573",
                  "type": "IR"
                }
              ],
              "cancerTypes": [
                {
                  "code": "PAST",
                  "mainType": "Glioma",
                  "subtype": "Pilocytic Astrocytoma"
                }
              ],
              "cancerTypes_review": {
                "updateTime": 1630018590211,
                "updatedBy": "User"
              },
              "cancerTypes_uuid": "b7057bc7-f3cd-4a13-aac3-821a71318857",
              "diagnostic": {
                "description": "",
                "description_uuid": "6979c9a3-24fe-4f02-a13e-31093550ffb6",
                "level": "",
                "level_uuid": "9a36cff7-5832-4e6f-9177-a02a06301516",
                "short": ""
              },
              "diagnosticSummary": "",
              "diagnosticSummary_review": {
                "updateTime": 1630025154421,
                "updatedBy": "User"
              },
              "diagnosticSummary_uuid": "505ee073-9229-4555-879c-8cf206efc84e",
              "diagnostic_uuid": "f99fc63c-05fe-4286-9451-025111976523",
              "prognostic": {
                "description": "",
                "description_uuid": "9f98b952-9425-4044-89f6-22db9e0409d5",
                "level": "",
                "level_uuid": "4967cb47-6189-4735-bf73-805c2db6fa1f",
                "short": ""
              },
              "prognosticSummary": "",
              "prognosticSummary_uuid": "2232816b-6f42-4152-ab7e-c3028a4e67fc",
              "prognostic_uuid": "482b4c26-9ded-41a7-b293-1473dd721d17",
              "summary": "The RAF inhibitor dabrafenib in combination with the MEK1/2 inhibitor trametinib is FDA-approved for the treatment of patients with BRAF V600E-mutant solid tumors.",
              "summary_review": {
                "updateTime": 1661884380708,
                "updatedBy": "User"
              },
              "summary_uuid": "06d6c080-3109-4164-9558-557d0f1d319f"
            },
            {
              "TIs": [
                {
                  "name": "Standard implications for sensitivity to therapy",
                  "name_uuid": "68a5d56f-0c08-45c3-b672-a961c710c4dd",
                  "treatments": [
                    {
                      "description": "The RAF inhibitor vemurafenib in combination with the MEK inhibitor cobimetinib is FDA-approved for patients with BRAF V600E-positive melanoma, non-small cell lung cancer, and anaplastic thyroid cancer, and is NCCN-listed for patients with low-grade glioma, anaplastic glioma, and glioblastoma. Patients with various glioma subtypes harboring BRAF V600E mutations have shown responses to RAF and MEK inhibition. Three out of five patients with anaplastic astrocytoma had a response (one partial response, two stable disease) to vemurafenib monotherapy (PMID: 30351999). One patient with high-grade glioma (NOS) had stable disease in response to vemurafenib monotherapy (PMID:30351999). Four out of eight patients with glioma (NOS) had a response (one partial response, three stable disease, two progressive disease, two not evaluable) to vemurafenib monotherapy (PMID: 26287849). One patient with anaplastic oligoastrocytoma had stable disease in response to vemurafenib monotherapy (PMID: 30462564). Four of seven patients with glioblastoma multiforme had a response (one complete response, three stable disease, one progressive disease, two not evaluable) to vemurafenib monotherapy (PMID: 30351999, 24725538). Four patients with glioblastoma (including epithelioid glioblastoma) had a response (one “near-complete” response, three stable disease) to either dabrafenib monotherapy (n=2) or vemurafenib monotherapy (n=2) (PMID: 29621181, 29039591, 33117675, 34232949).",
                      "description_review": {
                        "updateTime": 1676497154113,
                        "updatedBy": "User"
                      },
                      "description_uuid": "3715bed4-7f69-4a85-b288-1e362c53ecf8",
                      "fdaLevel": "Fda3",
                      "fdaLevel_review": {
                        "updateTime": 1659103555647,
                        "updatedBy": "User"
                      },
                      "fdaLevel_uuid": "2420768a-a5a7-440d-a1ea-80127bfbdcc0",
                      "indication": "",
                      "indication_uuid": "2642aeb9-4f8a-4298-9779-1b4791964931",
                      "level": "2",
                      "level_review": {
                        "updateTime": 1633535557584,
                        "updatedBy": "User"
                      },
                      "level_uuid": "093e038e-c3f6-46eb-b850-90b588517f57",
                      "name": "4e91da20-6cf0-4e07-995f-7f7db4c7c077 + eb357145-3b18-4aca-b75a-5e18dd2bf4f9",
                      "name_review": {
                        "updateTime": 1661882614623,
                        "updatedBy": "User"
                      },
                      "name_uuid": "7b50f8a8-5662-4ad0-b63a-f2a0cf2c9fee",
                      "propagation": "3B",
                      "propagationLiquid": "no",
                      "propagationLiquid_review": {
                        "updateTime": 1633535557580,
                        "updatedBy": "User"
                      },
                      "propagationLiquid_uuid": "70cf5068-31a8-4225-82e3-5299ca1f4a66",
                      "propagation_review": {
                        "updateTime": 1633535560325,
                        "updatedBy": "User"
                      },
                      "propagation_uuid": "eb62aab5-f063-4ab9-bc1d-ae487aa4b503",
                      "short": ""
                    }
                  ],
                  "treatments_uuid": "0b8be57d-2717-4ff8-b4ee-20be0ae1410b",
                  "type": "SS"
                },
                {
                  "name": "Standard implications for resistance to therapy",
                  "name_uuid": "cadb4abd-2841-477b-bd32-d6db578b654d",
                  "treatments_uuid": "44563999-eb9e-4c5f-98d5-45acd56956ef",
                  "type": "SR"
                },
                {
                  "name": "Investigational implications for sensitivity to therapy",
                  "name_uuid": "a90d7f72-d04a-4756-98f2-935660f1fc08",
                  "treatments_uuid": "84cbbb29-4bed-4261-83e1-a90285030b7c",
                  "type": "IS"
                },
                {
                  "name": "Investigational implications for resistance to therapy",
                  "name_uuid": "402941fa-c641-4f12-9a82-754fccf97fed",
                  "treatments_uuid": "8b13699b-36f4-4ca9-a0cd-6944ab4e580f",
                  "type": "IR"
                }
              ],
              "cancerTypes": [
                {
                  "code": "DIFG",
                  "mainType": "Glioma",
                  "subtype": "Diffuse Glioma"
                }
              ],
              "cancerTypes_review": {
                "updateTime": 1633534977022,
                "updatedBy": "User"
              },
              "cancerTypes_uuid": "c9760fd0-3926-4743-abce-afb1d3374f14",
              "diagnostic": {
                "description": "",
                "description_uuid": "f40e590a-591a-4501-9c28-31089bbb139c",
                "level": "",
                "level_uuid": "6be01097-872d-48c2-9b7a-9086b86f6b7a",
                "short": ""
              },
              "diagnosticSummary": "",
              "diagnosticSummary_uuid": "21e89b4f-81f5-4c94-9d84-95fa49c2c1e8",
              "diagnostic_uuid": "f9d9774c-0021-49ba-a4b2-31ec7b887f68",
              "prognostic": {
                "description": "",
                "description_uuid": "b5061fdb-268d-49d8-81b7-cfbb7810d42a",
                "level": "",
                "level_uuid": "2c27d55e-672e-428b-95b6-1da8517166d3",
                "short": ""
              },
              "prognosticSummary": "",
              "prognosticSummary_uuid": "0b544acd-6c6e-44c7-9615-fd779fefc499",
              "prognostic_uuid": "1d25d466-26e7-4fd9-bf31-6edfd3a817c1",
              "relevantCancerTypes": [
                {
                  "code": "AOAST",
                  "mainType": "Glioma",
                  "subtype": "Anaplastic Oligoastrocytoma"
                },
                {
                  "code": "SCGBM",
                  "mainType": "Glioma",
                  "subtype": "Small Cell Glioblastoma"
                },
                {
                  "code": "HGGNOS",
                  "mainType": "Glioma",
                  "subtype": "High-Grade Glioma, NOS"
                },
                {
                  "code": "GB",
                  "mainType": "Glioma",
                  "subtype": "Glioblastoma"
                },
                {
                  "code": "OAST",
                  "mainType": "Glioma",
                  "subtype": "Oligoastrocytoma"
                },
                {
                  "code": "DIFG",
                  "mainType": "Glioma",
                  "subtype": "Diffuse Glioma"
                },
                {
                  "code": "GNOS",
                  "mainType": "Glioma",
                  "subtype": "Glioma, NOS"
                },
                {
                  "code": "GSARC",
                  "mainType": "Glioma",
                  "subtype": "Gliosarcoma"
                },
                {
                  "code": "ASTR",
                  "mainType": "Glioma",
                  "subtype": "Astrocytoma"
                },
                {
                  "code": "AASTR",
                  "mainType": "Glioma",
                  "subtype": "Anaplastic Astrocytoma"
                },
                {
                  "code": "GBM",
                  "mainType": "Glioma",
                  "subtype": "Glioblastoma Multiforme"
                },
                {
                  "code": "DASTR",
                  "mainType": "Glioma",
                  "subtype": "Diffuse Astrocytoma"
                }
              ],
              "relevantCancerTypes_review": {
                "updateTime": 1633535064482,
                "updatedBy": "User"
              },
              "summary": "The RAF inhibitor dabrafenib in combination with the MEK1/2 inhibitor trametinib is FDA-approved for the treatment of patients with BRAF V600E-mutant solid tumors.",
              "summary_review": {
                "updateTime": 1661882541101,
                "updatedBy": "User"
              },
              "summary_uuid": "d9d2b475-f103-4960-a827-3a032f107402"
            },
            {
              "TIs": [
                {
                  "name": "Standard implications for sensitivity to therapy",
                  "name_uuid": "108d30f1-f137-4f13-9ebc-3c4e9732a24b",
                  "treatments": [
                    {
                      "description": "The RAF inhibitor vemurafenib in combination with the MEK inhibitor cobimetinib is FDA-approved for patients with melanoma, non-small cell lung cancer, and anaplastic thyroid cancer, and is NCCN-listed for patients with low-grade glioma, anaplastic glioma, and glioblastoma. Patients with various glioma subtypes harboring BRAF V600E mutations have shown responses to RAF and MEK inhibition. Six patients with ganglioglioma had a partial response to either vemurafenib monotherapy (n=2), vemurafenib + cobimetinib (n=1), or dabrafenib monotherapy (n=​​3)(PMID: 25524464, 31985841, 26579623, 31502039). Twelve out of thirteen patients with pleomorphic xanthoastrocytoma had a response (one complete response, one “near-complete” response, six partial response, four stable disease) to either dabrafenib + trametinib (n=2) or vemurafenib monotherapy (n=11) (PMID: 28984141, 26287849, 30351999). Three patients with anaplastic pleomorphic xanthoastrocytoma had a response (one complete response, one “near-complete” response, one partial response) to either vemurafenib monotherapy (n=1) or dabrafenib monotherapy (n=2)(PMID: 25092772, 29039591). One patient with low-grade glioma, NOS had a partial response to dabrafenib monotherapy (PMID: 27398937). Two patients with pilocytic astrocytoma had a response (one partial response, one stable disease) to vemurafenib monotherapy (PMID: 30351999). Three of four patients with anaplastic ganglioglioma had a response (one partial response, one \"significant response\", one stable disease, one not evaluable) to either dabrafenib + trametinib (n=1) or vemurafenib monotherapy (n=3)(PMID: 29380516, 30351999). One patient with pilomyxoid astrocytoma had a partial response to vemurafenib monotherapy (PMID: 24821190).",
                      "description_review": {
                        "updateTime": 1676497179987,
                        "updatedBy": "User"
                      },
                      "description_uuid": "2d9907f5-c2da-426e-9b62-16b932cc5b60",
                      "fdaLevel": "Fda3",
                      "fdaLevel_review": {
                        "updateTime": 1659103541322,
                        "updatedBy": "User"
                      },
                      "fdaLevel_uuid": "944959f5-fdc3-4291-82ad-95a1bd237eaf",
                      "indication": "",
                      "indication_uuid": "42984ca5-d663-4081-9cc2-695b6fa98c86",
                      "level": "2",
                      "level_review": {
                        "updateTime": 1633535674388,
                        "updatedBy": "User"
                      },
                      "level_uuid": "f30a8112-563c-4ff5-96c8-6308366b8e23",
                      "name": "4e91da20-6cf0-4e07-995f-7f7db4c7c077 + eb357145-3b18-4aca-b75a-5e18dd2bf4f9",
                      "name_review": {
                        "updateTime": 1661884050447,
                        "updatedBy": "User"
                      },
                      "name_uuid": "8a864f31-163a-4868-bf67-6b1fc449a2c6",
                      "propagation": "3B",
                      "propagationLiquid": "no",
                      "propagationLiquid_review": {
                        "updateTime": 1633535674385,
                        "updatedBy": "User"
                      },
                      "propagationLiquid_uuid": "34bf354a-8da8-401f-a337-7aa21aa8d0e8",
                      "propagation_review": {
                        "updateTime": 1633535676841,
                        "updatedBy": "User"
                      },
                      "propagation_uuid": "10c00355-48be-40a1-8129-0383648ac05c",
                      "short": ""
                    }
                  ],
                  "treatments_uuid": "a27ea586-2f54-4ed3-a950-00be36be1b17",
                  "type": "SS"
                },
                {
                  "name": "Standard implications for resistance to therapy",
                  "name_uuid": "94281c9d-007c-40e8-8cf1-2e5533711409",
                  "treatments_uuid": "74748b30-818b-4825-8927-36630d51a09b",
                  "type": "SR"
                },
                {
                  "name": "Investigational implications for sensitivity to therapy",
                  "name_uuid": "1af37a34-fa87-4e38-8225-165e0b03c900",
                  "treatments_uuid": "28bc5e26-6c10-4ca6-b223-5ae2c4a322fb",
                  "type": "IS"
                },
                {
                  "name": "Investigational implications for resistance to therapy",
                  "name_uuid": "4fc45c0f-8622-437c-9a2a-128b28843b77",
                  "treatments_uuid": "2782fd2e-b751-4ab5-8a6f-17d1952e698e",
                  "type": "IR"
                }
              ],
              "cancerTypes": [
                {
                  "code": "ENCG",
                  "mainType": "Glioma",
                  "subtype": "Encapsulated Glioma"
                }
              ],
              "cancerTypes_review": {
                "updateTime": 1633535117952,
                "updatedBy": "User"
              },
              "cancerTypes_uuid": "a809a4d9-665a-472e-83c6-259a5d9213df",
              "diagnostic": {
                "description": "",
                "description_uuid": "494eba06-40fb-4959-8a15-83e720ed06df",
                "level": "",
                "level_uuid": "6a697811-b485-48ac-a0b3-ffe4ed112b3c",
                "short": ""
              },
              "diagnosticSummary": "",
              "diagnosticSummary_uuid": "c1ccd8d5-e488-4746-9e3f-1407affcf2fb",
              "diagnostic_uuid": "2d820c5c-ea27-4ce3-bf67-4d0a4971c05c",
              "prognostic": {
                "description": "",
                "description_uuid": "4a471317-6177-496d-acef-ac872d7b1af5",
                "level": "",
                "level_uuid": "f61f7d27-430f-4164-b82b-0a62b2da899f",
                "short": ""
              },
              "prognosticSummary": "",
              "prognosticSummary_uuid": "f8f4a2a6-0b96-4ccf-8a53-bc603678f7d6",
              "prognostic_uuid": "678370fe-89df-4090-a07c-0018d88be5b0",
              "summary": "The RAF inhibitor dabrafenib in combination with the MEK1/2 inhibitor trametinib is FDA-approved for the treatment of patients with BRAF V600E-mutant solid tumors.",
              "summary_review": {
                "updateTime": 1661884024879,
                "updatedBy": "User"
              },
              "summary_uuid": "5be59610-1305-4ace-a94c-30ef26d7523a"
            },
            {
              "TIs": [
                {
                  "name": "Standard implications for sensitivity to therapy",
                  "name_uuid": "862cf5c3-011e-4fa7-83b0-235cd33635fb",
                  "treatments": [
                    {
                      "description": "Dabrafenib, an orally bioavailable RAF inhibitor, and trametinib, an orally bioavailable MEK1/2 inhibitor, are FDA-approved in combination for the treatment of patients with solid tumors other than colorectal harboring BRAF V600E mutation. FDA approval was based on data from 131 adult patients with solid tumors treated with dabrafenib and trametinib in the BRF117019 and NCI-MATCH trials and 36 pediatric patients treated with dabrafenib and trametinib in the CTMT212X2101 study. Of the 131 adult patients treated with dabrafenib and trametinib, the overall response rate was 41% (54/131; 95% CI = 33-50) and of the 36 pediatric patients treated with dabrafenib and trametinib (low-grade glioma, n=34; high-grade glioma, n=2), the overall response rate was 25% (95% CI = 12-24) (PMID: 32818466, 34838156, 32758030)(Abstract: Bouffet et al. Abstract# LGG-49, Neuro-Oncology 2020. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715318/). Approval was supported by results in COMBI-d, COMBI-v and BRF113928 studies in melanoma and lung cancer (PMID: 23020132, 25399551, 27283860). In the Phase II ROAR basket trial of dabrafenib + trametinib in patients with BRAF V600E-mutated rare cancers (biliary tract cancer, n=43), the overall response rate was 53%, the median progression-free survival was nine months (95% CI = 5.5, 9.4) and the median overall survival was 13.5 months (95% CI = 10.4, 17.6) (PMID: 37059834). Of the 43 patients with biliary tract cancer, 53% of patients (23/43) had a partial response and 37% (16/43) had stable disease (PMID: 37059834). Additionally, in subprotocol H of the NCI-MATCH basket trial of dabrafenib + trametinib in patients with BRAF V600E-mutant solid tumors (n=4 patients with intrahepatic cholangiocarcinoma), the overall response rate was 100%, with 4/4 patients achieving a partial response (PMID: 32758030).",
                      "description_review": {
                        "updateTime": 1684881056069,
                        "updatedBy": "User"
                      },
                      "description_uuid": "6429f66b-751d-40ac-ae1d-134370fdb633",
                      "fdaLevel": "Fda2",
                      "fdaLevel_review": {
                        "updateTime": 1661882435979,
                        "updatedBy": "User"
                      },
                      "fdaLevel_uuid": "a99e9233-c385-49d4-93a1-d021fa4bd602",
                      "indication": "",
                      "indication_uuid": "e936ba53-4a42-4caf-8d6e-1907d227128a",
                      "level": "1",
                      "level_review": {
                        "updateTime": 1661882438890,
                        "updatedBy": "User"
                      },
                      "level_uuid": "79680fa4-6219-4b5c-9b3c-45ee9174f909",
                      "name": "939cd40b-b515-499d-b099-fd29027c0d17 + fb2bb01c-c0ec-4641-abf7-87f486075022",
                      "name_review": {
                        "updateTime": 1658447048248,
                        "updatedBy": "User"
                      },
                      "name_uuid": "6d286407-4acf-4feb-9649-472fbb1b95fe",
                      "propagation": "3B",
                      "propagationLiquid": "no",
                      "propagationLiquid_review": {
                        "updateTime": 1658447054260,
                        "updatedBy": "User"
                      },
                      "propagationLiquid_uuid": "1fb29526-28e7-4e5b-96e1-b78e5dcd3ae0",
                      "propagation_review": {
                        "updateTime": 1658447874644,
                        "updatedBy": "User"
                      },
                      "propagation_uuid": "13f60c28-581a-4131-be5e-0c0ca02e2b93",
                      "short": ""
                    }
                  ],
                  "treatments_uuid": "904b2800-b4f0-49c0-8ca2-5b85500c67e8",
                  "type": "SS"
                },
                {
                  "name": "Standard implications for resistance to therapy",
                  "name_uuid": "86a82d3a-4a3c-4553-87ca-6f1d0a6bc77e",
                  "treatments_uuid": "4265240a-f3e4-4dc2-9903-1083c5e5ba38",
                  "type": "SR"
                },
                {
                  "name": "Investigational implications for sensitivity to therapy",
                  "name_uuid": "2823805e-c057-49ea-a356-b91388b7defc",
                  "treatments_uuid": "e3b8adb1-dbab-4a5a-a6e1-984e423cd8bf",
                  "type": "IS"
                },
                {
                  "name": "Investigational implications for resistance to therapy",
                  "name_uuid": "312d0743-d195-40f3-8396-6ec6f1ab81ae",
                  "treatments_uuid": "79e61da3-be3d-4513-ba89-c26a1c83f109",
                  "type": "IR"
                }
              ],
              "cancerTypes": [
                {
                  "code": "",
                  "mainType": "Biliary Tract Cancer, NOS",
                  "subtype": ""
                }
              ],
              "cancerTypes_review": {
                "updateTime": 1658446992305,
                "updatedBy": "User"
              },
              "cancerTypes_uuid": "db15966c-0c05-42ce-c007-7b3ccf73b962",
              "diagnostic": {
                "description": "",
                "description_uuid": "5cffc3dd-192e-4982-8d8a-9e9b7ef1c3a1",
                "level": "",
                "level_uuid": "7690edd4-6650-4789-8f93-dda55bc14de3",
                "short": ""
              },
              "diagnosticSummary": "",
              "diagnosticSummary_uuid": "205220d4-3710-4897-ae67-1701b9f68b9c",
              "diagnostic_uuid": "a5a27982-c92e-4bcd-aed6-4281094584a2",
              "prognostic": {
                "description": "",
                "description_uuid": "6820209b-17a7-42e5-b8c1-d624e2476cd4",
                "level": "",
                "level_uuid": "8cc6a095-af39-4097-acd1-a820e358e776",
                "short": ""
              },
              "prognosticSummary": "",
              "prognosticSummary_uuid": "0b5609f7-7fb8-42a1-838f-3b4f7f741e3c",
              "prognostic_uuid": "eb91ce5e-b177-441f-9c0c-623a7fa6f942",
              "summary": "The RAF inhibitor dabrafenib in combination with the MEK1/2 inhibitor trametinib is FDA-approved for the treatment of patients with BRAF V600E-mutant solid tumors.",
              "summary_review": {
                "updateTime": 1661882421207,
                "updatedBy": "User"
              },
              "summary_uuid": "26d2dac0-be4d-408b-9440-14131797c627"
            },
            {
              "TIs": [
                {
                  "name": "Standard implications for sensitivity to therapy",
                  "name_uuid": "cd70da53-5b64-4ff1-baa6-e1049fdcb91f",
                  "treatments": [
                    {
                      "description": "Dabrafenib, an orally bioavailable RAF inhibitor, and trametinib, an orally bioavailable MEK1/2 inhibitor, are FDA-approved in combination for the treatment of patients with solid tumors other than colorectal harboring BRAF V600E mutation. FDA approval was based on data from 131 adult patients with solid tumors treated with dabrafenib and trametinib in the BRF117019 and NCI-MATCH trials and 36 pediatric patients treated with dabrafenib and trametinib in the CTMT212X2101 study. Of the 131 adult patients treated with dabrafenib and trametinib, the overall response rate was 41% (54/131; 95% CI = 33-50) and of the 36 pediatric patients treated with dabrafenib and trametinib (low-grade glioma, n=34; high-grade glioma, n=2), the overall response rate was 25% (95% CI = 12-24) (PMID: 32818466, 34838156, 32758030)(Abstract: Bouffet et al. Abstract# LGG-49, Neuro-Oncology 2020. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715318/). In the randomized, Phase II study of dabrafenib and trametinib in 110 patients with BRAF V600–mutant pediatric low-grade glioma (dabrafenib + trametinib treatment, n=37; carboplatin + vincristine treatment, n=37), the overall response rate was 47% (95% CI= 35%-59%) with dabrafenib and trametinib and 11% (95% CI= 3%-25%) with carboplatin and vincristine, and the progression-free survival was 20.1 months (95% CI= 12.8 mo-not estimable) with dabrafenib and trametinib and 7.4 months (95% CI= 3.6-11.8 mo) with carboplatin and vincristine (Abstract: Bouffet et al. Abstract# LBA2002, ASCO 2022. https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.17_suppl.LBA2002). FDA approval was supported by results in COMBI-d, COMBI-v and BRF113928 studies in melanoma and lung cancer (PMID: 23020132, 25399551, 27283860).",
                      "description_review": {
                        "updateTime": 1676496940625,
                        "updatedBy": "User"
                      },
                      "description_uuid": "6f0f3c4b-5619-4639-bb62-7bbd86a5c5c9",
                      "fdaLevel": "Fda2",
                      "fdaLevel_review": {
                        "updateTime": 1661884588802,
                        "updatedBy": "User"
                      },
                      "fdaLevel_uuid": "1d99c83f-16e0-4a59-a6a4-0a9f001de619",
                      "indication": "",
                      "indication_uuid": "7a2749de-22d0-4564-88c4-58c144ab48f8",
                      "level": "1",
                      "level_review": {
                        "updateTime": 1661884588805,
                        "updatedBy": "User"
                      },
                      "level_uuid": "d9ced8ba-b6ac-4d80-a3f5-3ef90f083522",
                      "name": "939cd40b-b515-499d-b099-fd29027c0d17 + fb2bb01c-c0ec-4641-abf7-87f486075022",
                      "name_review": {
                        "updateTime": 1661884582287,
                        "updatedBy": "User"
                      },
                      "name_uuid": "6d039136-d681-4915-a342-16e424f5e42c",
                      "propagation": "3B",
                      "propagationLiquid": "no",
                      "propagationLiquid_review": {
                        "updateTime": 1661884588799,
                        "updatedBy": "User"
                      },
                      "propagationLiquid_uuid": "6f49d954-d18d-4bae-9a99-b1a8095249ed",
                      "propagation_review": {
                        "updateTime": 1661884593019,
                        "updatedBy": "User"
                      },
                      "propagation_uuid": "0251f011-cf44-44ce-84c0-9e8c56f6e3f5",
                      "short": ""
                    }
                  ],
                  "treatments_uuid": "286cbb6c-2828-43ec-a8b7-2427e4a522dd",
                  "type": "SS"
                },
                {
                  "name": "Standard implications for resistance to therapy",
                  "name_uuid": "f58e1286-d1b5-41b2-c0e8-274f020f738f",
                  "treatments_uuid": "1260ee7a-730f-4fb8-b6cb-b0a9e2e8fc4b",
                  "type": "SR"
                },
                {
                  "name": "Investigational implications for sensitivity to therapy",
                  "name_uuid": "543ab6de-03f0-400f-9a5f-d88c7a556b68",
                  "treatments_uuid": "fd953b99-aa3e-4d40-b82c-78a8a8d53a2b",
                  "type": "IS"
                },
                {
                  "name": "Investigational implications for resistance to therapy",
                  "name_uuid": "0b6ca1a1-bbc7-4acd-a5ab-62ebc433ed14",
                  "treatments_uuid": "0f6fcefb-fa22-4d58-a07f-bbe093025326",
                  "type": "IR"
                }
              ],
              "cancerTypes": [
                {
                  "code": "",
                  "mainType": "All Solid Tumors",
                  "subtype": ""
                }
              ],
              "cancerTypes_review": {
                "updateTime": 1661884507325,
                "updatedBy": "User"
              },
              "cancerTypes_uuid": "26f46af9-c07e-41b1-a13c-55707762c5b1",
              "diagnostic": {
                "description": "",
                "description_uuid": "5e731fd4-4445-44ad-b820-16b476417b13",
                "level": "",
                "level_uuid": "0e1cecb7-0e3d-4ffa-93ec-b2dd5d8e68e8",
                "relevantCancerTypes_uuid": "f03b746a-9227-4c82-b731-dae41ba4f742",
                "short": ""
              },
              "diagnosticSummary": "",
              "diagnosticSummary_uuid": "65360119-3191-4a8d-a812-c4b9c50477d3",
              "diagnostic_uuid": "8dacb284-3a51-4ff0-b3fd-74ac642d9250",
              "excludedCancerTypes": [
                {
                  "code": "",
                  "mainType": "Colorectal Cancer",
                  "subtype": ""
                }
              ],
              "excludedCancerTypes_review": {
                "updateTime": 1661884549038,
                "updatedBy": "User"
              },
              "excludedCancerTypes_uuid": "6ffe69ce-3132-4b72-b805-5ee26fcb8c2d",
              "prognostic": {
                "description": "",
                "description_uuid": "ccffcae9-60ca-405f-b11f-3f61ebd6153a",
                "level": "",
                "level_uuid": "51749cca-f2b3-41d2-a973-2f7832ae5a8e",
                "relevantCancerTypes_uuid": "b96406b9-a404-4201-a558-d6849b82f4d2",
                "short": ""
              },
              "prognosticSummary": "",
              "prognosticSummary_uuid": "358966b6-a4c4-43c9-96c9-063f8c9533d6",
              "prognostic_uuid": "432077a6-4c52-48b2-91c7-7c098a6a2dd5",
              "relevantCancerTypes_uuid": "68519313-dc7c-4810-a299-6bc8b4fbf3e6",
              "summary": "The RAF inhibitor dabrafenib in combination with the MEK1/2 inhibitor trametinib is FDA-approved for the treatment of patients with BRAF V600E-mutant solid tumors.",
              "summary_review": {
                "updateTime": 1661884563863,
                "updatedBy": "User"
              },
              "summary_uuid": "a1317432-a427-476c-86f1-84c15b50d5c5"
            },
            {
              "TIs": [
                {
                  "name": "Standard implications for sensitivity to therapy",
                  "name_uuid": "038fb404-c879-4740-970a-fa29f4f69ec0",
                  "treatments_uuid": "a4378b1c-a6a2-417e-bab4-6f42a5d0be62",
                  "type": "SS"
                },
                {
                  "name": "Standard implications for resistance to therapy",
                  "name_uuid": "130dcbd6-b910-4097-aba5-79f650a90a26",
                  "treatments_uuid": "c541b7fc-147c-478b-8f68-bbf156cd3804",
                  "type": "SR"
                },
                {
                  "name": "Investigational implications for sensitivity to therapy",
                  "name_uuid": "dc728279-3828-4013-a7d6-32997607b7c8",
                  "treatments_uuid": "150bb5ff-962d-4f5a-a973-d34410503148",
                  "type": "IS"
                },
                {
                  "name": "Investigational implications for resistance to therapy",
                  "name_uuid": "9122b006-67a4-4cda-8a4e-80cd192c6186",
                  "treatments_uuid": "4f095b57-58c1-488c-beed-8a24134165ac",
                  "type": "IR"
                }
              ],
              "cancerTypes": [
                {
                  "code": "LGGNOS",
                  "mainType": "Glioma",
                  "subtype": "Low-Grade Glioma, NOS"
                }
              ],
              "cancerTypes_review": {
                "updateTime": 1680793147980,
                "updatedBy": "User"
              },
              "cancerTypes_uuid": "91390944-50a1-4320-b7be-1f35f7160adc",
              "diagnostic": {
                "description": "",
                "description_uuid": "295428ed-378b-4cf8-84f4-8790215c993f",
                "level": "",
                "level_uuid": "f966f738-09ee-446a-bfdc-31e84ef0058e",
                "relevantCancerTypes_uuid": "ec1695cc-a423-46fe-8d3f-ff86e823c056",
                "short": ""
              },
              "diagnosticSummary": "",
              "diagnosticSummary_uuid": "8fa7279f-fe50-4d31-8844-b0b5d0610992",
              "diagnostic_uuid": "738a0ae3-af28-4532-823b-20514874c009",
              "excludedCancerTypes_uuid": "60358747-30fd-4029-9427-5e6026da6776",
              "prognostic": {
                "description": "",
                "description_uuid": "8644dfcc-80e8-42c2-b3dd-a80b1705a826",
                "level": "",
                "level_uuid": "f680c9d6-0950-419d-abaf-5fdeedf40a59",
                "relevantCancerTypes_uuid": "164dcdfd-53ee-4704-a894-e96c22b245df",
                "short": ""
              },
              "prognosticSummary": "",
              "prognosticSummary_uuid": "46b6736f-de66-4a31-8d04-c5994ef39505",
              "prognostic_uuid": "a768e2a7-3c39-4bae-aa2e-e50ae1eaca86",
              "relevantCancerTypes_uuid": "057ffd81-d90c-404e-8fe8-5afc2ce25bb7",
              "summary": "The RAF inhibitor dabrafenib in combination with the MEK1/2 inhibitor trametinib is FDA-approved for the treatment of pediatric patients 1 year of age and older with low-grade glioma.",
              "summary_review": {
                "updateTime": 1680793154766,
                "updatedBy": "User"
              },
              "summary_uuid": "65384f19-67f6-4187-a4e9-b0e67c0d2d44"
            }
          ]
        },
        {
          "mutation_effect": {
            "description": "The class II BRAF L597S mutation is located in the kinase domain of the protein (PMID: 33019809). This mutation has been found in melanoma, among other cancers (PMID: 26643848). In vitro studies have demonstrated that this mutation is likely activating as measured by increased downstream signaling compared to wildtype (PMID: 22798288). Drug efficacy studies in cell lines demonstrated that the BRAF L597S mutation might be sensitive to the RAF inhibitor vemurafenib and the MEK inhibitor trametinib (PMID: 22798288). The BRAF L597S mutation has also been identified in patients with positive responses to trametinib, the allosteric MEK inhibitor TAK-733 and combined dabrafenib and trametinib treatment (PMID: 24933606, 22798288, 29903896).",
            "description_review": {
              "updateTime": 1678309069119,
              "updatedBy": "User"
            },
            "description_uuid": "b020228d-8bbf-4d1f-842f-dda76b4e6630",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1600636500420,
              "updatedBy": "User"
            },
            "effect_uuid": "bd08e589-0a0b-4ff9-b514-fe3fe1d84f30",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "f48ceb40-9fac-4681-90d7-163ed51dd6e2",
            "short": ""
          },
          "mutation_effect_uuid": "f5646eb4-a8b2-4967-9f8e-fba706538a03",
          "name": "L597S",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "90061776-866f-40c1-819a-00dbad8213d0"
        },
        {
          "mutation_effect": {
            "description": "The class II BRAF K601E mutation is located in the kinase domain in exon 15 of the protein (PMID: 28783719, 26343582). This mutation is recurrent in melanoma (PMID: 22798288, 26643848). Biological characterization of BRAF K601E mutations demonstrated that they activate the downstream MAPK pathway independently of RAS and render BRAF active as a dimer with CRAF and itself (PMID: 22798288, 20179705, 26343582). Preclinical studies with patient-derived xenograft models of colorectal cancer expressing BRAF K601E demonstrated sensitivity to treatment with PLX8394 with or without cetuximab as measured by reduced tumor growth, and resistance to treatment with cetuximab and vemurafenib as measured by no reduction in tumor growth upon treatment (PMID: 30559419, 31515458). A patient with metastatic BRAF K601E-mutated melanoma achieved a complete response to the MEK inhibitor trametinib (PMID: 28344857). In a case report, a patient with lung adenocarcinoma harboring BRAF K601E was treated with a combination therapy of dabrafenib plus trametinib and demonstrated partial response with a progression-free survival of nine months (PMID: 34590045). In another case report, a patient with papillary thyroid carcinoma harboring BRAF K601E was treated with a combination therapy of sorafenib plus denosumab and demonstrated a complete response (PMID: 35630083). In a Phase II trial, a patient with melanoma harboring BRAF K601E was treated with trametinib and demonstrated partial response with a progression-free survival of 32 weeks (PMID: 23248257). In another Phase II trial, six patients with advanced solid tumors harboring BRAF K601E were treated with vemurafenib and did not clinically respond to treatment (PMID: 29320312). In a Phase I trial, two patients with melanoma harboring BRAF K601E were treated with dabrafenib and did not clinically respond to treatment (PMID: 22608338).",
            "description_review": {
              "updateTime": 1678404575021,
              "updatedBy": "User"
            },
            "description_uuid": "31895b88-fb3f-4abb-af52-662997b7795d",
            "effect": "Gain-of-function",
            "effect_review": {
              "updateTime": 1534528886008,
              "updatedBy": "User"
            },
            "effect_uuid": "9b64a01a-fe4a-4764-bb83-50a7dddc2093",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1534528894299,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "68016989-6e6d-4221-98d3-238110b00ac6",
            "short": ""
          },
          "mutation_effect_uuid": "84d7df03-1614-475d-a88b-0d2d63bfa7b6",
          "name": "K601E",
          "name_review": {
            "updateTime": 1534528813071,
            "updatedBy": "User"
          },
          "name_uuid": "c2c6d1bc-26e8-42e0-ab86-815b9679ca42",
          "tumors_uuid": "9052181c-7b32-4d64-bddc-2374166f995e"
        },
        {
          "mutation_effect": {
            "description": "",
            "description_review": {
              "updateTime": 1493057315640
            },
            "description_uuid": "7efb7ad9-89a9-4729-bfa6-0da7724f7970",
            "effect": "",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "f36ecc3c-cc56-4ede-9f31-60e478361de8",
            "oncogenic": "",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "7e9af736-288e-453e-bbcc-8c721375b9dc",
            "short": ""
          },
          "mutation_effect_comments": [
            {
              "content": "While the RAF-inhibitors dabrafenib and vemurafenib alone and in combination with MEK inhibitors trametinib and cobimetinib, respectively, are FDA-approved and NCCN-recommended for the treatment of patients with BRAF V600E and V600K mutant melanoma, the clinical utility of these inhibitors alone or in combination in BRAF V600E/ V600K positive [[tumor type]] is currently unknown.",
              "date": "1482871522505",
              "email": "user@gmail.com",
              "resolved": "false",
              "userName": "User"
            }
          ],
          "mutation_effect_uuid": "7e2ebce5-3e50-472c-9676-a24859c636d3",
          "name": "V600",
          "name_review": {
            "updateTime": 1576783509733,
            "updatedBy": "User"
          },
          "name_uuid": "df998571-0254-4720-837c-1bef8f535c2d",
          "tumors": [
            {
              "TIs": [
                {
                  "name": "Standard implications for sensitivity to therapy",
                  "name_uuid": "aaab7586-2aed-479f-9ec0-4208b07734e4",
                  "treatments": [
                    {
                      "description": "Vemurafenib is an orally available kinse inhibitor of V600-mutant BRAF that is FDA-approved for treatment of patients with Edheim-Chester Disease (ECD) harboring BRAF V600-mutations. FDA approval was based on the open-label, nonrandomized, multicohort VE-BASKET clinical trial of vemurafenib in BRAF V600E-mutant non-melanoma cancers in which 26 evaluable patients (ECD, n=22; LCH, n=4 ) achieved stable disease or better, and the confirmed overall response rate in ECD was 54.5% (12/22; 95% CI= 32.2-75.6%). Median progression-free survival and overall survival were not reached at study completion with a median follow-up of 28.8 months (PMID: 29188284, 26287849).",
                      "description_review": {
                        "updateTime": 1676490928608,
                        "updatedBy": "User"
                      },
                      "description_uuid": "11e2b2cc-6f24-419a-aaf4-91bae8c78d19",
                      "fdaLevel": "Fda2",
                      "fdaLevel_review": {
                        "updateTime": 1676490925296,
                        "updatedBy": "User"
                      },
                      "fdaLevel_uuid": "9af069b7-d4ef-4b3c-95fd-de8f468645da",
                      "indication": "Vemurafenib is FDA-approved for the treatment of patients with unresectable or metastatic melanoma with the BRAF V600E mutation as detected by an FDA-approved test.",
                      "indication_review": {
                        "updateTime": 1525885022000,
                        "updatedBy": "User"
                      },
                      "indication_uuid": "ff43da83-5b5e-4728-a13a-ff9f9add32ad",
                      "level": "1",
                      "level_review": {
                        "updateTime": 1511807189249,
                        "updatedBy": "User"
                      },
                      "level_uuid": "92b39165-7c0a-48a5-b15f-04631ebe1b47",
                      "name": "4e91da20-6cf0-4e07-995f-7f7db4c7c077",
                      "name_review": {
                        "updateTime": 1525885022026
                      },
                      "name_uuid": "729d93d7-aa18-4bf0-9c84-13b9ecce25fb",
                      "propagation": "no",
                      "propagationLiquid": "no",
                      "propagationLiquid_uuid": "d230f5f0-db25-11e9-b3e2-60f81dc75ed6",
                      "propagation_review": {
                        "updateTime": 1565202829331,
                        "updatedBy": "User"
                      },
                      "propagation_uuid": "f643767c-ddd7-40e9-9b60-7dd796b9dd94",
                      "short": ""
                    }
                  ],
                  "type": "SS"
                },
                {
                  "name": "Standard implications for resistance to therapy",
                  "name_uuid": "6e792f86-979d-4da8-a78d-c2b754bcec82",
                  "type": "SR"
                },
                {
                  "name": "Investigational implications for sensitivity to therapy",
                  "name_uuid": "0b253d83-3ca3-4ecf-b0dd-e60f77761cde",
                  "type": "IS"
                },
                {
                  "name": "Investigational implications for resistance to therapy",
                  "name_uuid": "0743c709-eb8c-4ec9-9c76-e9b62bab43ec",
                  "type": "IR"
                }
              ],
              "cancerTypes": [
                {
                  "code": "ECD",
                  "mainType": "Histiocytosis",
                  "subtype": "Erdheim-Chester Disease"
                }
              ],
              "cancerTypes_uuid": "ab7299a3-01e5-4662-8faf-04b85a759a35",
              "diagnostic": {
                "description": "",
                "description_uuid": "1eae7057-4cc6-42c0-924e-f8acb30f71e1",
                "level": "",
                "level_uuid": "f0331876-b7b6-4c89-bb83-c073d13c002b",
                "short": ""
              },
              "diagnosticSummary": "",
              "diagnosticSummary_uuid": "f92725d0-0540-4096-92ba-684dcbbcba62",
              "diagnostic_uuid": "858949c0-71b3-4dd9-9645-97be8adfc561",
              "prognostic": {
                "description": "",
                "description_review": {
                  "updateTime": 1493057315640
                },
                "description_uuid": "0df90fdf-5fff-4fae-bd21-eba1f6a76ffa",
                "level": "",
                "level_uuid": "859fe512-9667-43ca-aeee-403b575e3649",
                "short": ""
              },
              "prognosticSummary": "",
              "prognosticSummary_uuid": "7475c07d-6d3c-4b8b-b922-f81d71d0133d",
              "prognostic_uuid": "003fb10b-fd50-416e-ac47-e581cb7d520a",
              "summary": "The RAF-targeted inhibitor vemurafenib is FDA-approved for the treatment of patients with BRAF V600-mutant Erdheim-Chester disease.",
              "summary_review": {
                "updateTime": 1566491179333,
                "updatedBy": "User"
              },
              "summary_uuid": "39484c36-282c-4392-909d-cd9ab20724df"
            },
            {
              "TIs": [
                {
                  "name": "Standard implications for sensitivity to therapy",
                  "name_uuid": "a73b6c63-b131-4561-9061-8fcfb19ece73",
                  "treatments": [
                    {
                      "description": "Vemurafenib and dabrafenib, inhibitors of BRAF V600E that are FDA-approved for patients with BRAF V600E or V600K mutant positive melanoma, are NCCN-listed for patients with Langerhans Cell Histiocytosis (LCH) harboring BRAF V600E mutations. NCCN recommendation is based on the Phase II VE BASKET study of vemurafenib in patients with BRAF V600E-mutant cancer in which four of four patients with LCH harboring BRAF V600E mutations had partial response to vemurafenib treatment (PMID: 29188284).",
                      "description_review": {
                        "updateTime": 1676490969993,
                        "updatedBy": "User"
                      },
                      "description_uuid": "fdc4d478-90a6-490d-8fcc-0c5f780af188",
                      "fdaLevel": "Fda3",
                      "fdaLevel_review": {
                        "updateTime": 1659103585181,
                        "updatedBy": "User"
                      },
                      "fdaLevel_uuid": "fa1ef8cf-0f6d-4e72-b76f-286a8c843bc3",
                      "indication": "",
                      "indication_uuid": "8b94d715-94bd-4a7a-a4a6-58f3e7bfb65b",
                      "level": "2",
                      "level_review": {
                        "updateTime": 1633445920196,
                        "updatedBy": "User"
                      },
                      "level_uuid": "5fe26c83-608e-49e4-92d5-1dcdb0397ca9",
                      "name": "4e91da20-6cf0-4e07-995f-7f7db4c7c077, 939cd40b-b515-499d-b099-fd29027c0d17",
                      "name_review": {
                        "updateTime": 1633445915074,
                        "updatedBy": "User"
                      },
                      "name_uuid": "a0a7271e-c46e-43b8-8f85-7e1418192d6c",
                      "propagation": "no",
                      "propagationLiquid": "no",
                      "propagationLiquid_review": {
                        "updateTime": 1633445920194,
                        "updatedBy": "User"
                      },
                      "propagationLiquid_uuid": "ca2ac62d-41f3-4364-afac-7ea9dfeb07b4",
                      "propagation_review": {
                        "updateTime": 1633445920192,
                        "updatedBy": "User"
                      },
                      "propagation_uuid": "1b7b1f8d-52a9-4abf-81a6-e2480fbc86cc",
                      "short": ""
                    }
                  ],
                  "treatments_uuid": "dfe1a32d-305f-4899-a58b-14a1bb15e67a",
                  "type": "SS"
                },
                {
                  "name": "Standard implications for resistance to therapy",
                  "name_uuid": "c4bac879-243a-4a28-8fd8-51b4372bb31f",
                  "treatments_uuid": "a919fe48-9ff2-4ae7-937d-3d2d2ab9904d",
                  "type": "SR"
                },
                {
                  "name": "Investigational implications for sensitivity to therapy",
                  "name_uuid": "084b493f-e6d3-4c75-9aed-8d1e9eec2178",
                  "treatments_uuid": "4d033177-21f5-40b0-badf-ccd7eaa3b84e",
                  "type": "IS"
                },
                {
                  "name": "Investigational implications for resistance to therapy",
                  "name_uuid": "2d1edc97-9506-44a4-baed-396f826b1206",
                  "treatments_uuid": "7f5fc49f-6a46-4e4d-8e72-f0fad2f41a80",
                  "type": "IR"
                }
              ],
              "cancerTypes": [
                {
                  "code": "LCH",
                  "mainType": "Histiocytosis",
                  "subtype": "Langerhans Cell Histiocytosis"
                }
              ],
              "cancerTypes_review": {
                "updateTime": 1633102532080,
                "updatedBy": "User"
              },
              "cancerTypes_uuid": "da98cd12-2999-41ad-83e0-96beb31aa593",
              "diagnostic": {
                "description": "",
                "description_uuid": "d6bbbde8-ec9a-415b-9066-adbe40bfcb12",
                "level": "",
                "level_uuid": "361dcfca-08dd-4fc9-8fea-b0ca256bf2a1",
                "short": ""
              },
              "diagnosticSummary": "",
              "diagnosticSummary_uuid": "9d8332c4-0be6-42b0-b9c9-46e278ea4667",
              "diagnostic_uuid": "0efbfd43-b378-4591-aab5-a3a90d40c493",
              "prognostic": {
                "description": "",
                "description_uuid": "9bdc21c3-6715-45dc-8816-0aed17bbfcb4",
                "level": "",
                "level_uuid": "e5585c4f-af54-41b7-9fb6-3b0c106eecc5",
                "short": ""
              },
              "prognosticSummary": "",
              "prognosticSummary_uuid": "494a77d8-cce8-4025-ab0f-d0798493a2d8",
              "prognostic_uuid": "fe6c4555-7fe5-4c91-9572-f9b79c64b1ab",
              "summary": "The RAF-targeted inhibitors vemurafenib and dabrafenib are NCCN-listed as monotherapy for the treatment of BRAF V600E-mutant Langerhans Cell Histiocytosis and vemurafenib is FDA-approved for the treatment of BRAF V600-mutant Erdheim Chester Disease.",
              "summary_review": {
                "updateTime": 1633103645994,
                "updatedBy": "User"
              },
              "summary_uuid": "b1acc1d7-c638-4217-a6e4-986b99f66f0a"
            },
            {
              "TIs": [
                {
                  "name": "Standard implications for sensitivity to therapy",
                  "name_uuid": "8f99b36a-6f69-4046-b909-82608c750f11",
                  "type": "SS"
                },
                {
                  "name": "Standard implications for resistance to therapy",
                  "name_uuid": "962c0be9-bc1b-4168-8f7a-053b03045947",
                  "type": "SR"
                },
                {
                  "name": "Investigational implications for sensitivity to therapy",
                  "name_uuid": "709c1fda-880a-4fa4-a979-9a802a159ca8",
                  "type": "IS"
                },
                {
                  "name": "Investigational implications for resistance to therapy",
                  "name_uuid": "b48bf98e-23fd-4c61-a0cf-8a0687d3ed6c",
                  "type": "IR"
                }
              ],
              "cancerTypes": [
                {
                  "code": "",
                  "mainType": "Colorectal Cancer",
                  "subtype": ""
                }
              ],
              "cancerTypes_comments": [
                {
                  "content": "Old TT summary edited by Rona: While the FDA-approved selective RAF-inhibitors dabrafenib and vemurafenib are essentially inactive as single agents in BRAF V600-mutant colorectal cancer, there is compelling clinical data supporting the use of the RAF-inhibitor vemurafenib in combination with the EGFR antibody panitumumab in patients with these tumors.",
                  "date": "1484243874073",
                  "email": "user@gmail.com",
                  "resolved": "false",
                  "userName": "User"
                }
              ],
              "cancerTypes_uuid": "5ed08233-b0a8-4ef3-a4e5-6bb2970ece44",
              "diagnostic": {
                "description": "",
                "description_uuid": "59098994-02c7-41ff-b051-db1955812ddf",
                "level": "",
                "level_uuid": "9818342b-aa78-4fa8-999a-ade3bf2b0bf6",
                "short": ""
              },
              "diagnosticSummary": "",
              "diagnosticSummary_uuid": "52adc63c-cda4-4bcf-ada7-d27ceacfa94c",
              "diagnostic_uuid": "993492c6-b647-4abd-8f0a-3fdb280813e6",
              "prognostic": {
                "description": "",
                "description_review": {
                  "updateTime": 1495051733413
                },
                "description_uuid": "7224ba0a-d316-4362-8d4b-b26bdfcc97d4",
                "level": "",
                "level_uuid": "ca0b6d16-7dea-4711-979c-e4ad4faef87e",
                "short": ""
              },
              "prognosticSummary": "",
              "prognosticSummary_uuid": "22dca7d0-2c58-440f-acc6-120e2ea40668",
              "prognostic_uuid": "f6b03ead-b3ff-41d5-9ec8-d3f19f1ed8d1",
              "summary": "The FDA-approved RAF-inhibitors dabrafenib and vemurafenib have minimal activity as single agents in BRAF V600-mutant colorectal cancer (CRC). The triplet therapy combination of encorafenib + binimetinib + cetuximab, a RAF-inhibitor, a MEK-inhibitor and an anti-EGFR antibody respectively, is NCCN-compendium listed and has received FDA-breakthrough therapy designation for the treatment of patients with BRAF V600E mutant colorectal cancer.",
              "summary_review": {
                "updateTime": 1566497497887,
                "updatedBy": "User"
              },
              "summary_uuid": "8d714d43-7ccc-416f-99b8-4f49cc046590"
            },
            {
              "TIs": [
                {
                  "name": "Standard implications for sensitivity to therapy",
                  "name_uuid": "d2bef7f5-963a-4ea5-b546-caae0701f7ae",
                  "treatments": [
                    {
                      "description": "The combination of vemurafenib, an inhibitor of V600-mutant BRAF, and cobimetinib, an inhibitor of MEK1/2, with atezolizumab, an immunotherapeutic PD-L1 antibody, is FDA-approved for patients with BRAF V600 mutation-positive unresectable or metastatic melanoma. FDA approval was based on the results of the Phase III double-blind, randomized, placebo-controlled IMspire150 trial of Atezolizumab + Cobimetinib + Vemurafenib versus Placebo + Cobimetinib + Vemurafenib in 514 patients with BRAF V600-mutant melanoma in which the median progression-free survival was 15.1 mos (95% CI=11.4,18.4) in the triplet arm versus 10.6 mos (95% CI=9.3,12.7) in the doublet + placebo arm (HR=0.78; 95% CI= 0.63, 0.97; p=0.0249) (PMID: 32534646).",
                      "description_review": {
                        "updateTime": 1676490992995,
                        "updatedBy": "User"
                      },
                      "description_uuid": "1ee0f4a5-318d-4143-8e47-9a32ebd8b9e8",
                      "fdaLevel": "Fda2",
                      "fdaLevel_review": {
                        "updateTime": 1676490990542,
                        "updatedBy": "User"
                      },
                      "fdaLevel_uuid": "d017dc29-e021-43b6-b4d5-2fa1f115e760",
                      "indication": "",
                      "indication_uuid": "4208a33d-de35-4c52-a6dd-85a0b276eb41",
                      "level": "1",
                      "level_review": {
                        "updateTime": 1596687805296,
                        "updatedBy": "User"
                      },
                      "level_uuid": "a4c90e67-a82b-4888-a512-1a60638a6585",
                      "name": "4e91da20-6cf0-4e07-995f-7f7db4c7c077 + 9a54c73a-15d8-41a8-8ea0-730f874831da + eb357145-3b18-4aca-b75a-5e18dd2bf4f9",
                      "name_review": {
                        "updateTime": 1596687800344,
                        "updatedBy": "User"
                      },
                      "name_uuid": "2e0a9edd-9248-4da3-b5f8-acdfe19039d6",
                      "propagation": "3B",
                      "propagationLiquid": "no",
                      "propagationLiquid_review": {
                        "updateTime": 1596687805291,
                        "updatedBy": "User"
                      },
                      "propagationLiquid_uuid": "67c961d9-3575-43d8-b653-c64dc6b85948",
                      "propagation_review": {
                        "updateTime": 1596687805286,
                        "updatedBy": "User"
                      },
                      "propagation_uuid": "627b61ec-51f8-453c-aa39-d9e594a4df66",
                      "short": ""
                    }
                  ],
                  "treatments_uuid": "87697f6b-37c6-472d-a706-6c0de1bc2e6f",
                  "type": "SS"
                },
                {
                  "name": "Standard implications for resistance to therapy",
                  "name_uuid": "2883b683-dcd5-46da-b526-fd54f033f348",
                  "treatments_uuid": "74e9ed89-6cfc-402b-a65d-4563a911b8f1",
                  "type": "SR"
                },
                {
                  "name": "Investigational implications for sensitivity to therapy",
                  "name_uuid": "713ec162-f411-4e56-bca1-f373841723b6",
                  "treatments_uuid": "853f9ebe-99b1-4c7d-8c35-ec8be077033d",
                  "type": "IS"
                },
                {
                  "name": "Investigational implications for resistance to therapy",
                  "name_uuid": "86c88608-6d8a-46d8-a492-0cec8542228a",
                  "treatments_uuid": "fcbffa00-b0df-47ec-8387-a40b1db608fb",
                  "type": "IR"
                }
              ],
              "cancerTypes": [
                {
                  "code": "MEL",
                  "mainType": "Melanoma",
                  "subtype": "Melanoma"
                }
              ],
              "cancerTypes_review": {
                "updateTime": 1531942969263,
                "updatedBy": "User"
              },
              "cancerTypes_uuid": "0a0da2c0-fb6d-4561-add8-9d863bb5fd39",
              "diagnostic": {
                "description": "",
                "description_uuid": "6d80deed-5b19-48e9-8402-6e7e24929730",
                "level": "",
                "level_uuid": "c9534b76-9c46-4ccf-bf10-dd46bbc09804",
                "short": ""
              },
              "diagnosticSummary": "",
              "diagnosticSummary_uuid": "28d9ca9c-8af3-496f-bd62-1e287ca973bf",
              "diagnostic_uuid": "16a76d69-7373-4e2d-9788-a363f2c5ebaf",
              "prognostic": {
                "description": "",
                "description_uuid": "02e867c7-f7d1-476b-bb05-748b28be28f4",
                "level": "",
                "level_uuid": "954019d6-6af8-4d3d-9e10-d5991209299b",
                "short": ""
              },
              "prognosticSummary": "",
              "prognosticSummary_uuid": "5d2cb7eb-9be9-435c-a05f-8a25885f1e9b",
              "prognostic_uuid": "32547ac8-e8a0-479f-b757-d9dff3f7ce38",
              "summary": "The RAF-targeted inhibitors encorafenib, dabrafenib and vemurafenib, alone or in combination with the MEK1/2-targeted inhibitors binimetinib, trametinib and cobimetinib respectively, are FDA-approved for the treatment of patients with BRAF V600E/K mutant melanoma and NCCN-compendium listed for the treatment of patients with BRAF V600-mutant melanoma. Additionally, the anti-PD-L1 antibody atezolizumab in combination with cobimetinib + vemurafenib is FDA-approved for the treatment of patients with unresectable or advanced BRAF V600-mutant melanoma.",
              "summary_review": {
                "updateTime": 1598302731610,
                "updatedBy": "User"
              },
              "summary_uuid": "49c8da54-77d7-4480-af56-bd58072c54c0"
            },
            {
              "TIs": [
                {
                  "name": "Standard implications for sensitivity to therapy",
                  "name_uuid": "ff2992f5-7039-4d7c-ae52-f61977ead31c",
                  "treatments_uuid": "91133f71-e337-40af-9c65-7d063c31a8f2",
                  "type": "SS"
                },
                {
                  "name": "Standard implications for resistance to therapy",
                  "name_uuid": "36847577-6d62-4565-aeaa-ccf86d1138d4",
                  "treatments_uuid": "33021e97-bc80-4745-bb6c-40a75ed31afd",
                  "type": "SR"
                },
                {
                  "name": "Investigational implications for sensitivity to therapy",
                  "name_uuid": "5e0068cc-bdf2-470e-b885-fc41dba3dc05",
                  "treatments_uuid": "d95ddc97-ed56-4822-9a99-d771fba3938f",
                  "type": "IS"
                },
                {
                  "name": "Investigational implications for resistance to therapy",
                  "name_uuid": "c2fc65f6-4b5b-4a56-ba5a-222565b6ab94",
                  "treatments_uuid": "7eb15195-1c5d-45a9-b000-fbba562024cc",
                  "type": "IR"
                }
              ],
              "cancerTypes": [
                {
                  "code": "NSCLC",
                  "mainType": "Non-Small Cell Lung Cancer",
                  "subtype": "Non-Small Cell Lung Cancer"
                }
              ],
              "cancerTypes_review": {
                "updateTime": 1576693884298,
                "updatedBy": "User"
              },
              "cancerTypes_uuid": "7f3f67af-cd0c-4086-b2cb-1933756b526c",
              "diagnostic": {
                "description": "",
                "description_uuid": "93ed1531-bcc4-4367-b17f-4e4da4cc6514",
                "level": "",
                "level_uuid": "0267d45e-940d-4403-8a9e-09a4c089ce5a",
                "short": ""
              },
              "diagnosticSummary": "",
              "diagnosticSummary_uuid": "4959fb2a-5e52-4626-adc6-e4a7ba41a04f",
              "diagnostic_uuid": "4edcc727-2c00-473d-967f-5373758c1678",
              "prognostic": {
                "description": "",
                "description_uuid": "64c159c1-f4ea-4054-ba17-940595a28bd3",
                "level": "",
                "level_uuid": "2150bbab-7f6e-4e44-8877-2834ab2db1fd",
                "short": ""
              },
              "prognosticSummary": "",
              "prognosticSummary_uuid": "09103409-4575-4f38-b7f3-d785c8e25486",
              "prognostic_uuid": "0e3eef99-9902-423c-9d4d-009c4b7c5509",
              "summary": "While the RAF-targeted inhibitor dabrafenib in combination with the MEK1/2-targeted inhibitor trametinib is FDA-approved for the treatment of patients with BRAF V600E mutant non-small cell lung cancer (NSCLC), this combination is not specifically approved for the treatment of patients with BRAF [[mutation]] mutant NSCLC.",
              "summary_review": {
                "updateTime": 1576693927838,
                "updatedBy": "User"
              },
              "summary_uuid": "593f072b-2d62-4436-c06f-1d01f05298a8"
            },
            {
              "TIs": [
                {
                  "name": "Standard implications for sensitivity to therapy",
                  "name_uuid": "1bb19ad2-2e15-47b6-8487-20e194cc680b",
                  "treatments_uuid": "d1db69fe-1bb9-4910-af7a-72be46c1ba50",
                  "type": "SS"
                },
                {
                  "name": "Standard implications for resistance to therapy",
                  "name_uuid": "6a924fed-00b9-457f-ba64-e82bdf83189d",
                  "treatments_uuid": "4b3b463c-0a15-49b0-95b5-e7257e0311d5",
                  "type": "SR"
                },
                {
                  "name": "Investigational implications for sensitivity to therapy",
                  "name_uuid": "26d08b79-4f29-40a2-b7a9-45b1f92aac8a",
                  "treatments_uuid": "26681b7c-1ed7-475a-965b-2bc874259edb",
                  "type": "IS"
                },
                {
                  "name": "Investigational implications for resistance to therapy",
                  "name_uuid": "171e4f89-dd5e-45f7-871e-2a12229eafb9",
                  "treatments_uuid": "1ade34ff-4a9d-40b7-9530-f9f6659e3c5f",
                  "type": "IR"
                }
              ],
              "cancerTypes": [
                {
                  "code": "",
                  "mainType": "Other Tumor Types",
                  "subtype": ""
                }
              ],
              "cancerTypes_review": {
                "updateTime": 1531942987733,
                "updatedBy": "User"
              },
              "cancerTypes_uuid": "04a73c51-ba3c-42ef-8374-e603a932c723",
              "diagnostic": {
                "description": "",
                "description_uuid": "379aa195-d59a-409f-a792-cf71301ea688",
                "level": "",
                "level_uuid": "367d1298-ab19-4b27-be14-8ee18ac39b07",
                "short": ""
              },
              "diagnosticSummary": "",
              "diagnosticSummary_uuid": "cf312d12-45cf-42db-9dec-dc07ce749b9b",
              "diagnostic_uuid": "2fb05646-589c-4949-9032-b4323dbb7afd",
              "prognostic": {
                "description": "",
                "description_uuid": "a8a580ac-5ccc-4453-af16-1f440509983b",
                "level": "",
                "level_uuid": "429fb8b3-8df4-41e5-9945-82029fd8196e",
                "short": ""
              },
              "prognosticSummary": "",
              "prognosticSummary_uuid": "2b5a1cf0-510c-422b-b658-4af01a251307",
              "prognostic_uuid": "f84eb1a4-e849-4581-a763-3433cb869aca",
              "summary": "While the RAF-targeted inhibitor dabrafenib in combination with the MEK1/2-targeted inhibitor trametinib is FDA-approved for the treatment of patients with BRAF V600E mutant melanoma, non-small cell lung cancer and anaplastic thyroid cancer, the clinical utility of dabrafenib in combination with trametinib in patients with [[variant]] has yet to be defined.",
              "summary_review": {
                "updateTime": 1566491227295,
                "updatedBy": "User"
              },
              "summary_uuid": "822ab686-6d4b-4605-8133-9387af0a4fbc"
            },
            {
              "TIs": [
                {
                  "name": "Standard implications for sensitivity to therapy",
                  "name_uuid": "918a2cd5-d7b1-4eb6-9239-aeade97f2ced",
                  "treatments_uuid": "aab7d944-d526-4cc6-bac0-1d01a6922359",
                  "type": "SS"
                },
                {
                  "name": "Standard implications for resistance to therapy",
                  "name_uuid": "bbadbe7a-fd74-4a72-8a7c-72f3ee942a74",
                  "treatments_uuid": "178c37be-0163-4be0-a9bb-b22484010d04",
                  "type": "SR"
                },
                {
                  "name": "Investigational implications for sensitivity to therapy",
                  "name_uuid": "8887f055-f66a-4128-b70a-6736cbd3c47c",
                  "treatments": [
                    {
                      "description": "Vemurafenib and dabrafenib are orally available kinse inhibitors of V600-mutant BRAF that are FDA-approved for patients with unresectable or metastatic melanoma with the BRAF V600E mutation, and are NCCN-listed for patients with histiocytic neoplasms harboring BRAF V600 mutations. In a case study of a 40-year-old man with histiocytic sarcoma harboring a heterozygous BRAF V600E mutation, the patient was treated with vemurafenib and maintained both clinical and radiologic tumor responses for three months until disease progression (PMID: 25209580). In a separate case study of a 22-year-old woman with histiocytic sarcoma harboring a BRAF V600E mutation, the patient was treated with a combination of chemotherapy, antibiotics, steroids, and vemurafenib, and remained in complete remission eighteen months after treatment initiation (PMID: 31376203). An additional case study of a six-year-old child with BRAF V600E-mutant mixed systemic Rosai-Dorfman-Destombes disease and Langerhans cell histiocytosis reported sustained clinical and radiographic responses after treatment with dabrafenib prior to disease relapse at thirteen months (PMID: 31213430).",
                      "description_review": {
                        "updateTime": 1676490946614,
                        "updatedBy": "User"
                      },
                      "description_uuid": "0f239e36-effc-4881-90c1-4162eda0d41b",
                      "fdaLevel": "Fda3",
                      "fdaLevel_review": {
                        "updateTime": 1664301380490,
                        "updatedBy": "User"
                      },
                      "fdaLevel_uuid": "eb450cde-3039-4b64-87f4-87ee52fb23d1",
                      "indication": "",
                      "indication_uuid": "ff1182b1-9535-4d2d-aecc-927aa1eaaffa",
                      "level": "3A",
                      "level_review": {
                        "updateTime": 1633446180842,
                        "updatedBy": "User"
                      },
                      "level_uuid": "60556bec-312b-480b-ac4e-30eecb57d4e8",
                      "name": "4e91da20-6cf0-4e07-995f-7f7db4c7c077, 939cd40b-b515-499d-b099-fd29027c0d17",
                      "name_review": {
                        "updateTime": 1633446175827,
                        "updatedBy": "User"
                      },
                      "name_uuid": "ccfa69b9-f284-427a-84b5-a4ffcc5606ca",
                      "propagation": "no",
                      "propagationLiquid": "no",
                      "propagationLiquid_review": {
                        "updateTime": 1633446180840,
                        "updatedBy": "User"
                      },
                      "propagationLiquid_uuid": "a748e972-aa30-4c60-bec0-848b48cc75b2",
                      "propagation_review": {
                        "updateTime": 1633446180837,
                        "updatedBy": "User"
                      },
                      "propagation_uuid": "502a6c9b-46d6-4c41-8676-d1e273e2a2d6",
                      "short": ""
                    }
                  ],
                  "treatments_uuid": "0eb9da8e-c908-4128-a879-76084d0fce69",
                  "type": "IS"
                },
                {
                  "name": "Investigational implications for resistance to therapy",
                  "name_uuid": "f002d764-0526-4f46-b67e-98b47001d735",
                  "treatments": [
                    {
                      "description": "Desc",
                      "description_review": {
                        "lastReviewed": "",
                        "updateTime": 1717517911547,
                        "updatedBy": "Test User"
                      },
                      "description_uuid": "90026d5f-5111-4372-a61e-5a5e13efab16",
                      "excludedRCTs_uuid": "ddb608a3-56af-4871-b82f-dbb2cb000202",
                      "fdaLevel": "no",
                      "fdaLevel_uuid": "bdf7e03b-bbf0-44ea-8b21-e682efd2a997",
                      "indication": "",
                      "indication_uuid": "4f72d6b6-7a9b-4c29-93a1-05fa78620c27",
                      "level": "",
                      "level_uuid": "cbc41c97-6c09-4d44-955f-46df3aa0df1b",
                      "name": "2e8ce490-86c2-45a4-a6e4-db5e5314981c",
                      "name_review": {
                        "added": true,
                        "updateTime": 1717517906834,
                        "updatedBy": "Test User"
                      },
                      "name_uuid": "69961749-0415-49e3-aa34-54cc77c57b2c",
                      "propagation": "",
                      "propagationLiquid": "",
                      "propagationLiquid_uuid": "5654225a-03a0-4d98-b31c-6bc9759dda20",
                      "propagation_uuid": "37724741-3721-466f-a43f-613cea4932c8",
                      "short": "Additional info",
                      "short_review": {
                        "lastReviewed": "",
                        "updateTime": 1717517914898,
                        "updatedBy": "Test User"
                      },
                      "short_uuid": "a63b6c91-7d3d-43ea-9f73-ddf55faa43d3"
                    }
                  ],
                  "treatments_uuid": "6113b273-d1d2-452f-8194-7299d2a020ed",
                  "type": "IR"
                }
              ],
              "cancerTypes": [
                {
                  "code": "",
                  "mainType": "Histiocytosis",
                  "subtype": ""
                }
              ],
              "cancerTypes_review": {
                "updateTime": 1633446122726,
                "updatedBy": "User"
              },
              "cancerTypes_uuid": "efaab408-c504-4386-acb1-c90a1091b92e",
              "diagnostic": {
                "description": "",
                "description_uuid": "e96ee070-a402-4e74-b61c-aaa83e26569d",
                "level": "",
                "level_uuid": "c9d9f220-667f-476e-a49f-80d414609320",
                "short": ""
              },
              "diagnosticSummary": "",
              "diagnosticSummary_uuid": "b79051c6-a3a2-4118-8934-3d914389880c",
              "diagnostic_uuid": "9379c183-d004-4bdd-ac15-35deb38bb33a",
              "prognostic": {
                "description": "",
                "description_uuid": "d89baa01-a8d8-43c5-a127-df8c7a1bc026",
                "level": "",
                "level_uuid": "805c7cdf-8e79-4922-9b5a-585d202d4ad9",
                "short": ""
              },
              "prognosticSummary": "",
              "prognosticSummary_uuid": "61f656a5-41a6-4c16-ad70-3c8ab4e0198b",
              "prognostic_uuid": "053db866-e39a-4472-b05c-5052a26e2336",
              "summary": "The RAF-targeted inhibitor vemurafenib is FDA-approved for the treatment of patients with BRAF V600-mutant Erdheim-Chester Disease (ECD) and there is promising clinical data in patients with non-ECD BRAF V600-mutant histiocytic neoplasms treated with vemurafenib or dabrafenib as monotherapy.",
              "summary_review": {
                "updateTime": 1633446213787,
                "updatedBy": "User"
              },
              "summary_uuid": "86fce41b-4b83-4bff-9d45-d96ea3767cde"
            }
          ]
        },
        {
          "mutation_effect": {
            "description": "The class I (PMID: 28783719) activating exon 15 BRAF V600K missense mutation is located in the kinase domain of the BRAF protein. BRAF V600 alterations (predominantly V600E) are recurrent in lung (PMID: 25079552, 23833300) and thyroid (PMID: 25417114) cancers, among others. In metastatic melanoma, frequency of V600K mutation is second only to V600E, the most common BRAF alteration (PMID: 26091043). Analysis of clinicopathologic features and outcome in patients with metastatic melanoma harboring activating BRAF mutations revealed that, compared to V600E, V600K mutation was significantly associated with male sex, older age (median age, head/neck primary tumor location, shorter interval to stage IV disease, and shorter overall survival from the time of diagnosis of stage IV disease (PMID: 23922205, 22535154). Comprehensive biological characterization of BRAF V600K mutation (PMID: 15035987, 26343582) has demonstrated that this mutation activates the downstream MAPK pathway independently of RAS (PMID: 19251651, 26343582), renders BRAF constitutively activated in monomeric form (PMID: 20179705) and retains sensitivity to RAF monomer inhibitors such as vemurafenib (PMID: 26343582, 28783719, 20179705). Preliminary studies suggest that BRAF V600K mutant tumors may not respond to combined BRAF and MEK inhibition as well as BRAF V600E tumors due to a decreased reliance on the MAPK pathway, though further studies are needed to validate this finding (PMID: 30630828).",
            "description_review": {
              "updateTime": 1551830420489,
              "updatedBy": "User"
            },
            "description_uuid": "9099f40e-cb70-4813-9491-9fc45010e0fd",
            "effect": "Gain-of-function",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "7f32379e-0513-4cd5-aa97-bf5ebcb9f2fe",
            "oncogenic": "Yes",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "fa5603f0-2ef7-43cf-aeb2-daf1793b84ee",
            "short": ""
          },
          "mutation_effect_uuid": "10cbd689-0a4d-4f48-a5f0-cf637124efe9",
          "name": "V600K",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "050b2afc-6c40-40d0-9b44-dcd0342a7167",
          "tumors": [
            {
              "TIs": [
                {
                  "name": "Standard implications for sensitivity to therapy",
                  "name_uuid": "c8bd2518-cbcb-4d2e-9d35-16f0bdd11220",
                  "type": "SS"
                },
                {
                  "name": "Standard implications for resistance to therapy",
                  "name_uuid": "4b4cf554-6f68-4d06-bfbd-93a3a8a389c7",
                  "type": "SR"
                },
                {
                  "name": "Investigational implications for sensitivity to therapy",
                  "name_uuid": "400497f9-0c6b-4556-bde2-a614a45f7525",
                  "type": "IS"
                },
                {
                  "name": "Investigational implications for resistance to therapy",
                  "name_uuid": "20887947-554b-4c89-a38f-94f42fcd44dd",
                  "type": "IR"
                }
              ],
              "cancerTypes": [
                {
                  "code": "MEL",
                  "mainType": "Melanoma",
                  "subtype": "Melanoma"
                }
              ],
              "cancerTypes_uuid": "bd57fc34-472f-448a-800b-e7067560dea9",
              "diagnostic": {
                "description": "",
                "description_uuid": "0fda80fc-9a8a-4e6e-8c8a-988ecea1e113",
                "level": "",
                "level_uuid": "8df1d7df-e46e-4bd0-ae77-ac477ffd4e61",
                "short": ""
              },
              "diagnosticSummary": "",
              "diagnosticSummary_uuid": "85cecd2d-8201-48df-a585-de220891d759",
              "diagnostic_uuid": "5e7ebe8b-0535-4f7c-9c71-06521cad9236",
              "prognostic": {
                "description": "",
                "description_review": {
                  "updateTime": 1493057315640
                },
                "description_uuid": "e636c77c-f7c2-4e3b-b92c-403c85911af3",
                "level": "",
                "level_uuid": "ce134fc4-7d74-4643-821a-34423afa7bed",
                "short": ""
              },
              "prognosticSummary": "",
              "prognosticSummary_uuid": "b8ba1e18-3205-4cd9-a697-c6619ea54ac1",
              "prognostic_uuid": "1392977b-448b-41e8-a6b7-8f0bb5c34ad7",
              "summary": "The RAF-targeted inhibitors encorafenib, dabrafenib and vemurafenib alone or in combination with the MEK-targeted inhibitors binimetinib, trametinib and cobimetinib, respectively, are FDA-approved for the treatment of patients with BRAF V600E/K mutant melanoma.",
              "summary_review": {
                "updateTime": 1566497781207,
                "updatedBy": "User"
              },
              "summary_uuid": "603dab24-2e01-4179-a0ac-cff1fe8c81ca"
            },
            {
              "TIs": [
                {
                  "name": "Standard implications for sensitivity to therapy",
                  "name_uuid": "49e71a59-a028-4b6b-a541-5e92bf71ec17",
                  "treatments_uuid": "0821e157-a7cf-43a1-a9ad-9ab56614abcb",
                  "type": "SS"
                },
                {
                  "name": "Standard implications for resistance to therapy",
                  "name_uuid": "e33f11c4-5ed9-4d86-b241-16b1244d860b",
                  "treatments_uuid": "dc3fa2b7-20b8-4922-8919-ad90a4d6a457",
                  "type": "SR"
                },
                {
                  "name": "Investigational implications for sensitivity to therapy",
                  "name_uuid": "2814ec2e-cd50-41bd-bd15-c926b6636b1c",
                  "treatments_uuid": "f147bfc4-be90-401b-8c7c-5536b8c5c25b",
                  "type": "IS"
                },
                {
                  "name": "Investigational implications for resistance to therapy",
                  "name_uuid": "253f5126-5f28-46dd-9eed-e2b27269d92e",
                  "treatments_uuid": "9aa22b63-37d6-47be-b0bd-59c2d982a20d",
                  "type": "IR"
                }
              ],
              "cancerTypes": [
                {
                  "code": "NSCLC",
                  "mainType": "Non-Small Cell Lung Cancer",
                  "subtype": "Non-Small Cell Lung Cancer"
                }
              ],
              "cancerTypes_review": {
                "updateTime": 1576619943849,
                "updatedBy": "User"
              },
              "cancerTypes_uuid": "72da4d11-d3a0-4777-9f5a-abf2a3844a55",
              "diagnostic": {
                "description": "",
                "description_uuid": "b0591454-9754-49a6-afec-8c434d54ab32",
                "level": "",
                "level_uuid": "c3956797-4b7b-44dc-b926-bd6fc9c5f3f0",
                "short": ""
              },
              "diagnosticSummary": "",
              "diagnosticSummary_uuid": "ef391f45-5a40-4fb6-b353-02c65a44f87b",
              "diagnostic_uuid": "31cb6912-af68-4fed-a6bd-03e759963ca1",
              "prognostic": {
                "description": "",
                "description_uuid": "2c1fc9a5-ec8e-4280-b798-147a68c433f7",
                "level": "",
                "level_uuid": "d692a246-2163-42b0-abd4-c3f60f512622",
                "short": ""
              },
              "prognosticSummary": "",
              "prognosticSummary_uuid": "3ddc76ac-4dc2-491d-86b9-5556a83d9187",
              "prognostic_uuid": "88421a7e-ba1c-44e5-be95-1650c7aa2e39",
              "summary": "While the RAF-targeted inhibitor dabrafenib in combination with the MEK1/2-targeted inhibitor trametinib is FDA-approved for the treatment of patients with BRAF V600E mutant non-small cell lung cancer (NSCLC), this combination is not specifically approved for the treatment of patients with BRAF V600K mutant NSCLC. However, laboratory data demonstrate that cells expressing BRAF V600K respond similarly to dabrafenib + trametinib as cells with BRAF V600E, and patients with BRAF V600K mutant melanoma derived similar clinical benefit to dabrafenib + trametinib as those with BRAF V600E.",
              "summary_review": {
                "updateTime": 1576620005051,
                "updatedBy": "User"
              },
              "summary_uuid": "33bea22d-cd06-4a27-95d1-23125badb1f6"
            },
            {
              "TIs": [
                {
                  "name": "Standard implications for sensitivity to therapy",
                  "name_uuid": "4e0fc9dd-17dd-47d8-b972-8266ed946a96",
                  "type": "SS"
                },
                {
                  "name": "Standard implications for resistance to therapy",
                  "name_uuid": "8d46ef5e-4368-4754-bd85-758c19c36c13",
                  "type": "SR"
                },
                {
                  "name": "Investigational implications for sensitivity to therapy",
                  "name_uuid": "84052bb1-bbf5-4f0d-989e-396f468b4071",
                  "type": "IS"
                },
                {
                  "name": "Investigational implications for resistance to therapy",
                  "name_uuid": "789cf1a0-1556-4d7e-974a-2391e427782f",
                  "type": "IR"
                }
              ],
              "cancerTypes": [
                {
                  "code": "",
                  "mainType": "Other Tumor Types",
                  "subtype": ""
                }
              ],
              "cancerTypes_uuid": "23e51db4-b52c-4a32-a700-cbe6464a3b27",
              "diagnostic": {
                "description": "",
                "description_uuid": "ad001f2b-3587-4dd1-9480-b63130fd00b7",
                "level": "",
                "level_uuid": "3d641d98-68ee-43db-916a-2ea0595aa3dd",
                "short": ""
              },
              "diagnosticSummary": "",
              "diagnosticSummary_uuid": "a074166a-13ba-41fc-b512-c8dfee4dbebf",
              "diagnostic_uuid": "87f8b73d-33e1-4e0c-9881-7e2e5cbd04ea",
              "prognostic": {
                "description": "",
                "description_uuid": "f780f185-e60f-4beb-aaae-38e8d86fd74f",
                "level": "",
                "level_uuid": "61c1dac4-44d0-4b09-a938-24931b98b20c",
                "short": ""
              },
              "prognosticSummary": "",
              "prognosticSummary_uuid": "1ac70e11-2545-4e4a-9c3d-cc7ea69b7097",
              "prognostic_uuid": "72be4c04-a659-45f8-b166-817493c84644",
              "summary": "While the MEK1/2-targeted inhibitor trametinib, alone or in combination with the RAF-targeted inhibitor dabrafenib, and the MEK-targeted inhibitor cobimetinib in combination with the RAF-targeted inhibitor vemurafenib are FDA-approved for the treatment of patients with BRAF V600K mutant melanoma, their clinical utility in patients with [[variant]] has yet to be defined.",
              "summary_review": {
                "updateTime": 1566497826371,
                "updatedBy": "User"
              },
              "summary_uuid": "5719cd2c-bf51-496f-9d5f-287583907e50"
            }
          ]
        },
        {
          "mutation_effect": {
            "description": "",
            "description_review": {
              "updateTime": 1493057315640
            },
            "description_uuid": "eefef91c-6150-4990-9e25-d3302cf31269",
            "effect": "",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "cf59dc1c-ebf7-41f3-9047-165a6fef121e",
            "oncogenic": "",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "1c3369a9-c417-4966-b777-70050c156287",
            "short": ""
          },
          "mutation_effect_uuid": "45f48fdd-a2fa-44dc-86cb-b3fd8e4bc8c1",
          "name": "V600E (comment), V600K",
          "alteration_categories": {
            "flags": [
              {
                "type": "ALTERATION_CATEGORY",
                "flag": "TEST_FLAG",
                "name": "Test Flag"
              }
            ],
            "comment": "This is a test flag"
          },
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "39b95adc-6176-4973-a6b4-c58b4d99a3d6",
          "tumors": [
            {
              "TIs": [
                {
                  "name": "Standard implications for sensitivity to therapy",
                  "name_uuid": "4c572609-41dd-4bef-af37-0ec3518aa665",
                  "treatments": [
                    {
                      "description": "Dabrafenib, an orally bioavailable RAF inhibitor, and trametinib, an orally bioavailable MEK1/2 inhibitor, are FDA-approved alone or in combination for the treatment of patients with metastatic melanoma harboring a V600E or V600K BRAF mutation. FDA approval of dabrafenib in combination with trametinib was based on results from an open-label Phase III study of combination therapy versus dabrafenib monotherapy in 247 patients with metastatic melanoma who were naive to treatment with BRAF inhibitors. Combined dabrafenib and trametinib, administered in full monotherapy doses, improved the response rate in patients with BRAF V600-mutant metastatic melanoma versus dabrafenib monotherapy (67% vs.51%; p<0.002). However, median progression-free survival improved by only 2 weeks (9.3 months vs 8.8 months; HR = 0.75) compared with dabrafenib monotherapy (PMID: 23020132). Combination therapy is associated with less cutaneous toxicity than monotherapy, but systemic toxicity may be increased (PMID: 25287827, 25399551). Follow-up trials have demonstrated that all clinical measures inclusive of overall and median progression-free survival as well as objective response rates, median duration of response and number of patients with complete response favored patients treated with combination dabrafenib and trametinib, administered in full monotherapy doses, compared to either dabrafenib or vemurafenib monotherapy, including patients who previously progressed on BRAF inhibitor monotherapy (PMID: 25287827, 25399551, 25265492). Additionally, patients with melanoma treated with dabrafenib and trametinib in both the neoadjuvant and adjuvant settings have improved survival over patients given standard of care (PMID: 29361468, 28991513, 28891408). Promising clinical data has also suggested that addition of an immunotherapy agent to combination RAF and MEK inhibitor treatment may improve rate of overall response and duration of response in melanoma patients (PMID: 31171876, 31171879, 31171878).",
                      "description_review": {
                        "updateTime": 1676497987140,
                        "updatedBy": "User"
                      },
                      "description_uuid": "87fd200c-0687-46bb-8b9f-1b1466df6eeb",
                      "fdaLevel": "Fda2",
                      "fdaLevel_review": {
                        "updateTime": 1673450733678,
                        "updatedBy": "User"
                      },
                      "fdaLevel_uuid": "f63602c0-2d43-4e60-8584-42fe7ed75d35",
                      "indication": "Dabrafenib + Trametinib is FDA-approved for BRAF V600E or V600K mutant unresectable or metastatic melanoma",
                      "indication_review": {
                        "updateTime": 1526570322418,
                        "updatedBy": "User"
                      },
                      "indication_uuid": "bf1ec7cf-105a-4bcc-958b-90b9b784e321",
                      "level": "1",
                      "level_uuid": "adfd95c8-978c-442c-a03e-b90e4180029d",
                      "name": "939cd40b-b515-499d-b099-fd29027c0d17 + fb2bb01c-c0ec-4641-abf7-87f486075022",
                      "name_review": {
                        "updateTime": 1528143989525,
                        "updatedBy": "User"
                      },
                      "name_uuid": "bc28ec2e-60ae-4a5d-9401-524e357b5bed",
                      "propagation": "3B",
                      "propagationLiquid": "no",
                      "propagationLiquid_uuid": "d230f7bd-db25-11e9-8a3b-60f81dc75ed6",
                      "propagation_uuid": "8042b434-108a-4fd3-8fc3-74428c22196b",
                      "short": ""
                    },
                    {
                      "description": "Trametinib is an oral small molecule inhibitor of MEK1/2 that is FDA-approved alone or with dabrafenib for the treatment of patients with metastatic melanoma harboring a V600E or V600K BRAF mutation. In an open-label, randomized Phase III trial, patients with BRAF V600E/K-mutated unresectable, metastatic melanoma received oral trametinib (2 mg once daily) or an intravenous regimen of either dacarbazine (1000 mg/m2) or paclitaxel (175 mg/m2) every three weeks. Trametinib demonstrated improved progression-free survival (HR for disease progression or death = 0.45) and six-month overall survival (81% vs. 67%; death HR = 0.54; p=0.01) (PMID: 22663011). However, like other MEK inhibitors, the benefit of trametinib is limited by adverse reactions, most notably grade three or four rash and diarrhea (PMID: 22663011). Trametinib is not typically used as monotherapy for patients with BRAF V600K melanoma given its lower response rate compared to BRAF inhibitors and combined BRAF and MEK inhibitors. Patients previously treated with a RAF inhibitor appear to be less likely than untreated patients to respond to trametinib treatment (PMID: 22663011), and FDA guidelines state that trametinib as a monotherapy is not indicated for these patients. Dabrafenib and trametinib are FDA-approved as a combination therapy, which has superior clinical outcomes compared to dabrafenib or trametinib monotherapy (PMID: 25399551, 25265492). Additionally, patients with melanoma treated with dabrafenib and trametinib in both the neoadjuvant and adjuvant settings had improved survival over patients given standard of care (PMID: 29361468).",
                      "description_review": {
                        "updateTime": 1676497975988,
                        "updatedBy": "User"
                      },
                      "description_uuid": "1ed3c9b2-7901-4d3f-93c3-704b1f739d85",
                      "fdaLevel": "Fda2",
                      "fdaLevel_review": {
                        "updateTime": 1676497973047,
                        "updatedBy": "User"
                      },
                      "fdaLevel_uuid": "5e9ae1e1-5b08-4ceb-bbd6-e27777262d71",
                      "indication": "Trametinib is FDA-approved for BRAF V600E or V600K mutant unresectable or metastatic melanoma",
                      "indication_review": {
                        "updateTime": 1526570997571,
                        "updatedBy": "User"
                      },
                      "indication_uuid": "e6633e69-e302-4d00-86c5-06cc708148b3",
                      "level": "1",
                      "level_uuid": "689d402e-3680-4678-b32d-e715e2fcd6a6",
                      "name": "fb2bb01c-c0ec-4641-abf7-87f486075022",
                      "name_review": {
                        "updateTime": 1526570997571,
                        "updatedBy": "User"
                      },
                      "name_uuid": "873eaae0-4bf1-4d6d-a312-f8ff9770f393",
                      "propagation": "3B",
                      "propagationLiquid": "no",
                      "propagationLiquid_uuid": "d230f854-db25-11e9-8bfa-60f81dc75ed6",
                      "propagation_uuid": "a0a37134-93b1-4fde-b967-6c5403c7b5c4",
                      "short": ""
                    },
                    {
                      "description": "The RAF inhibitor vemurafenib in combination with the MEK inhibitor cobimetinib is FDA-approved for the treatment of patients with BRAF V600-mutant metastatic or unresectable locally advanced melanoma. FDA approval was based on results from the randomized Phase III coBRIM trial of combined vemurafenib and cobimetinib versus vemurafenib and placebo in 495 patients with metastatic BRAF V600-mutant melanoma that demonstrated superior clinical benefit measures in the combination versus the control arm. Specifically, median progression-free survival was 9.9 months in the combination arm versus 6.2 months in the control arm (HR = 0.51), with a complete response rate of 10% versus 4%, respectively, and interim nine-month overall survival of 81% versus 73%, respectively (PMID: 25265494). Follow-up analysis of the coBRIM trial showed two-year overall survival was 48.3% in the combination group versus 38.0% in the monotherapy group (PMID: 27480103), and five-year followup of the BRIM7 study showed a median overall survival of 31.8 months and a five-year survival rate of 39.2% (PMID: 31732523).",
                      "description_review": {
                        "updateTime": 1676497319240,
                        "updatedBy": "User"
                      },
                      "description_uuid": "8fa3f87d-1d0d-49fa-8ae5-88d8c9c63526",
                      "fdaLevel": "Fda2",
                      "fdaLevel_review": {
                        "updateTime": 1676497315669,
                        "updatedBy": "User"
                      },
                      "fdaLevel_uuid": "ff77b93a-7c13-4459-a5b7-c2831e21d42e",
                      "indication": "Cobimetinib is FDA-approved for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib. Cobimetinib is not indicated for treatment of patients with wild-type BRAF melanoma.",
                      "indication_review": {
                        "updateTime": 1526573329010,
                        "updatedBy": "User"
                      },
                      "indication_uuid": "43263a98-6e5b-4d95-b473-6411ad113015",
                      "level": "1",
                      "level_uuid": "e2a6f384-3400-4340-91ea-a23f6e4baf96",
                      "name": "4e91da20-6cf0-4e07-995f-7f7db4c7c077 + eb357145-3b18-4aca-b75a-5e18dd2bf4f9",
                      "name_review": {
                        "updateTime": 1526573329010,
                        "updatedBy": "User"
                      },
                      "name_uuid": "19caa107-e92a-4246-9d01-6d707b9ecd4e",
                      "propagation": "3B",
                      "propagationLiquid": "no",
                      "propagationLiquid_uuid": "d230f900-db25-11e9-8a1b-60f81dc75ed6",
                      "propagation_uuid": "f6baed34-c505-4d11-863d-b92d0bcea839",
                      "short": ""
                    },
                    {
                      "description": "The combination of encorafenib, an inhibitor of V600E- or V600K-mutant BRAF, and binimetinib, an inhibitor of MEK1/2, is FDA-approved in combination for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. FDA approval was based on the results of the Phase III COLUMBUS trial of combined encorafenib plus binimetinib versus single-agent vemurafenib in 577 patients with BRAF V600E- or V600K-mutant metastatic melanoma in which the median progression-free survival was 14.9 months (95% CI = 11.0-18.5) in the encorafenib plus binimetinib group versus 7.3 months (95% CI = 5.6-8.2) in the single agent vemurafenib group (HR= 0.54, 95% CI = 0.41-0.71; p<0·0001) (PMID: 29573941). In the five-year update of the Phase III COLUMBUS trial, the progression-free survival and overall survival were 23% and 35% respectively in the encorafenib plus binimetinib group (n=192) versus 10% and 21% respectively in the single agent vemurafenib group (n=191), and the median duration of response and disease control rate were 18.6 months and 92.2% in the encorafenib plus binimetinib group versus 12.3 months and 81.2% in the single-agent vemurafenib group (PMID: 35862871).",
                      "description_review": {
                        "updateTime": 1676497332712,
                        "updatedBy": "User"
                      },
                      "description_uuid": "33f5666f-5b02-4990-8805-db4d7960a4fd",
                      "fdaLevel": "Fda2",
                      "fdaLevel_review": {
                        "updateTime": 1670363141375,
                        "updatedBy": "User"
                      },
                      "fdaLevel_uuid": "078a3425-9f14-43cf-931d-6e6fbddcd353",
                      "indication": "In combination for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation",
                      "indication_review": {
                        "updateTime": 1530811717676,
                        "updatedBy": "User"
                      },
                      "indication_uuid": "c5f94062-9ec2-4469-bc58-2ed8ffd5124e",
                      "level": "1",
                      "level_uuid": "b268ef5d-4336-47da-9f88-84003109ee9c",
                      "name": "001e534f-3e63-432f-90a6-d1af1759e4e2 + feb9f4a3-e374-4c75-8a3b-0f1fbcdbf677",
                      "name_review": {
                        "updateTime": 1530812394910,
                        "updatedBy": "User"
                      },
                      "name_uuid": "b76c8407-558c-49e9-ab3c-90a181df0044",
                      "propagation": "3B",
                      "propagationLiquid": "no",
                      "propagationLiquid_uuid": "d230f994-db25-11e9-a593-60f81dc75ed6",
                      "propagation_uuid": "fc705531-4b07-4c38-8b32-506a1c9e1c2f",
                      "short": ""
                    }
                  ],
                  "type": "SS"
                },
                {
                  "name": "Standard implications for resistance to therapy",
                  "name_uuid": "14d2e046-bd93-4cec-8275-cec61b61de68",
                  "type": "SR"
                },
                {
                  "name": "Investigational implications for sensitivity to therapy",
                  "name_uuid": "fbff6a46-ef88-4298-a411-57ba74133c1d",
                  "type": "IS"
                },
                {
                  "name": "Investigational implications for resistance to therapy",
                  "name_uuid": "5bda59c3-9f1c-4f47-bd4b-f8c76b018b6e",
                  "type": "IR"
                }
              ],
              "cancerTypes": [
                {
                  "code": "MEL",
                  "mainType": "Melanoma",
                  "subtype": "Melanoma"
                }
              ],
              "cancerTypes_uuid": "ed73b726-0c6e-4b89-8124-4299fd552bf6",
              "diagnostic": {
                "description": "",
                "description_uuid": "6d6d74b8-8979-4df4-ad6e-e630938c6733",
                "level": "",
                "level_uuid": "8a4cbbd7-7f09-4adf-90e2-4a8ff5829c85",
                "short": ""
              },
              "diagnosticSummary": "",
              "diagnosticSummary_uuid": "cf34783e-5932-4431-af4a-7a0631f05964",
              "diagnostic_uuid": "f3136962-8c08-4c2c-bae4-dd0b34c87df1",
              "prognostic": {
                "description": "",
                "description_review": {
                  "updateTime": 1493057315640
                },
                "description_uuid": "0e5945b3-9f0a-4cbe-91aa-da4b400e6773",
                "level": "",
                "level_uuid": "937041b2-af52-40cd-921c-166a108bea36",
                "short": "The prognostic value of this mutation has not been definitively established: In one study, where approximately 70% of patients harbored V600E mutation, 20% with V600K and 6% with other BRAF mutations, presence of BRAF mutation trended toward associating with inferior survival in the setting of metastatic disease however this was not statistically significant (PMID: 21343559). This trend is consistent with findings from another study which documented that BRAF-mutant melanoma is associated with worsened ECOG performance status and an increased number of involved disease sites (PMID:24714776)."
              },
              "prognosticSummary": "",
              "prognosticSummary_uuid": "529ea8bf-dd27-4d7c-a6b3-4c6b9df3602f",
              "prognostic_uuid": "3562f4d7-d81a-4d25-892b-1a58e832b6e0",
              "summary": "",
              "summary_review": {
                "updateTime": 1554822172015,
                "updatedBy": "User"
              },
              "summary_uuid": "8c91ccf7-1b8b-4dce-9833-b3160eb22ba2"
            }
          ]
        },
        {
          "mutation_effect": {
            "description": "The class I activating exon 15 BRAF V600D mutation is located in the kinase domain of the protein (PMID: 28783719). This mutation is recurrent in melanoma (PMID: 26091043, 23579220, 22614978). Comprehensive biological characterization of the BRAF V600D mutation has demonstrated that this mutation activates the downstream MAPK pathway independently of RAS and renders BRAF constitutively activated in monomeric form (PMID: 15035987, 12068308, 19251651, 26343582, 20179705). Preclinical studies with melanoma cells expressing BRAF V600D demonstrate sensitivity to treatment with CCT196969, CCT241161, AZ628, TAK-632, PLX7904, vemurafenib, dabrafenib, ASTX029 and cobimetinib plus HM95573 as measured by inhibition of MEK and ERK phosphorylation and cellular proliferation (PMID: 25500121, 17210691, 27523909, 33953400, 34330842). In a case report, a patient with pilocytic astrocytoma harboring BRAF V600D was treated with single-agent dabrafenib then subsequently treated with combination therapy of dabrafenib plus trametinib and demonstrated stable disease (PMID: 28784858). In a Phase II trial, a patient with non-small cell lung cancer harboring BRAF V600D was treated with vemurafenib and demonstrated partial response with a progression-free survival of 3.8 months (PMID: 31959346).",
            "description_review": {
              "updateTime": 1678404729619,
              "updatedBy": "User"
            },
            "description_uuid": "fa361f52-2eb3-4fd7-bcc3-e36c2cc82e71",
            "effect": "Gain-of-function",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "2d9f29be-c010-4fd7-8bf1-724be975d211",
            "oncogenic": "Yes",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "dc31c7a1-bb00-4f06-975e-5b2fc013f800",
            "short": ""
          },
          "mutation_effect_uuid": "52504fe5-36d7-41d5-b186-48e7fc1f6b69",
          "name": "V600D",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "8c23d11c-30d6-4e24-8b81-8424538f537f"
        },
        {
          "mutation_effect": {
            "description": "The class I activating exon 15 BRAF V600R missense mutation is located in the kinase domain of the BRAF protein (PMID: 28783719). BRAF V600R is the third most common mutation occurring in 5-7% of patients with BRAF-mutant melanoma (PMID: 22536370, 23237741, 22614978). Comprehensive biological characterization of the BRAF V600R mutation has demonstrated that this mutation activates the downstream MAPK pathway independently of RAS and renders BRAF constitutively activated in monomeric form (PMID: 15035987, 28783719, 26343582, 20179705). Preclinical studies with melanoma cells expressing BRAF V600R demonstrate sensitivity to treatment with AZ628, TAK-632, PLX7904, vemurafenib and dabrafenib as measured by inhibition of cellular proliferation (PMID: 27523909). In a case report, a patient with melanoma harboring BRAF V600R was treated with a combination therapy of dabrafenib plus trametinib and demonstrated partial response with a progression-free survival of 52.2 months (PMID: 36039514). In another case report, a patient with melanoma harboring BRAF V600R was treated with dabrafenib and demonstrated partial response with lesion reduction and progression-free survival of seven months (PMID: 27255157).",
            "description_review": {
              "updateTime": 1678404820013,
              "updatedBy": "User"
            },
            "description_uuid": "85df09cb-0e9f-4d29-8735-76be8b5ef017",
            "effect": "Gain-of-function",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "12d0ecbc-50f2-4179-b883-236acf79ec53",
            "oncogenic": "Yes",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "67171333-e67d-4efb-b109-1ec059584108",
            "short": ""
          },
          "mutation_effect_uuid": "29a3a096-2e68-4e03-a0e8-6769338d2731",
          "name": "V600R",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "f308cc57-83c7-496f-b0ed-95a9e9f94cc4"
        },
        {
          "mutation_effect": {
            "description": "The class I (PMID: 28783719) activating exon 15 BRAF V600G mutation is located in the kinase domain of the protein. This mutation has been found in cardio-facio-cutaneous syndrome (CFC), lung cancer and esophagogastric cancer (PMID: 26287849). Substitutions at position V600 of BRAF, including the common BRAF V600E mutation, are known to be activating and oncogenic (PMID: 12068308, 16273091, 15035987). Expression of this mutation in 293T cells demonstrated that this mutation is activating as measured by increased downstream ERK activation and increased transcription of downstream MAPK pathway transcriptional targets (e.g. ELK) compared to wildtype BRAF (PMID: 20735442). A patient with non-small cell lung cancer (NSCLC) harboring the BRAF V600G mutation had stable disease in response to treatment with vemutafenib, while a patient with sarcoma and a patient with esophagogastric cancer both harboring the BRAF V600G mutation had progressive disease in response to vemurafenib (PMID: 26287849).",
            "description_review": {
              "updateTime": 1506524614463
            },
            "description_uuid": "da1f326d-857e-43ac-93d3-6b86def33e07",
            "effect": "Gain-of-function",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "aa1b3f05-546a-4bd5-a85e-9f826728ce4d",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "fe0fcc32-3e63-485c-9c5c-e71282f366da",
            "short": ""
          },
          "mutation_effect_uuid": "38302ae5-fc23-40a5-a686-745047cd746a",
          "name": "V600G",
          "name_comments": [
            {
              "content": "edit?",
              "date": "1506458266118",
              "email": "user@gmail.com",
              "resolved": "false",
              "userName": "User"
            }
          ],
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "d65a4a5d-aaa0-4b3a-9181-0d0557289e06"
        },
        {
          "mutation_effect": {
            "description": "The BRAF V600M mutation is located in the BRAF kinase domain. This mutation has been found in melanoma (PMID: 25382067, 22536370). In vitro studies have demonstrated that this mutation, similar to other class 1 BRAF V600 mutations, activates the downstream MAPK pathway independent of RAS, as measured by increased levels of phosphorylated MEK and decreased RAS-GTP in V600E mutant cells compared to wildtype (PMID: 26343582, 28783719). The BRAF V600M mutation renders BRAF constitutively activated in monomeric form and is sensitive to inhibition by vemurafenib (PMID: 28783719, 25382067, 26343582). However, It is unknown whether the BRAF V600M mutation actually arises in cancer as noted by several studies (PMID: 22536370, 23579220, 25382067) or previous sequencing studies miscalled a V600R dinucleotide change (chromosome 7: position 140453136 AC > CT) as a single nucleotide change (chromosome 7: position 140453137 C >T).",
            "description_review": {
              "updateTime": 1640705424109,
              "updatedBy": "User"
            },
            "description_uuid": "215a3d0d-29ae-4c35-9aec-82fcaf7592c1",
            "effect": "Inconclusive",
            "effect_review": {
              "updateTime": 1640705475034,
              "updatedBy": "User"
            },
            "effect_uuid": "838d4e27-f794-42e0-8f8e-d6b4955c1b4e",
            "oncogenic": "Inconclusive",
            "oncogenic_review": {
              "updateTime": 1640705476346,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "1e543634-e853-4b7c-b61e-76537ae06c5c",
            "short": ""
          },
          "mutation_effect_uuid": "c6175124-3116-4e76-9bfa-9337a876b3c7",
          "name": "V600M",
          "name_comments": [
            {
              "content": "Incorporate OncoKB user's comments",
              "date": "1517335132801",
              "email": "user@gmail.com",
              "resolved": "false",
              "userName": "User"
            }
          ],
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "f1e524ad-264b-47f8-ae06-46b47effe858"
        },
        {
          "mutation_effect": {
            "description": "The class II BRAF L597R mutation is located in the kinase domain of the protein (PMID: 33019809). This mutation has been found in melanoma, among other cancers (PMID: 26643848). In vitro studies have demonstrated that this mutation is likely activating as measured by increased downstream signaling compared to wildtype (PMID: 22798288). Drug efficacy studies in cell lines demonstrated that the BRAF L597R mutation might be sensitive to the RAF inhibitor vemurafenib and the MEK inhibitor trametinib (PMID: 22798288). The BRAF L597R mutation has also been identified in patients with positive responses to trametinib and the allosteric MEK inhibitor TAK-733 (PMID: 24933606). In a case report, a patient with melanoma harboring BRAF L597R was treated with vemurafenib and demonstrated partial response with 30% growth inhibition of skin and lung nodules (PMID: 23715574). In another case report, a patient with lung adenocarcinoma harboring BRAF L597R was treated with a combination therapy of dabrafenib and trametinib and demonstrated partial response with a progression-free survival of twelve months (PMID: 32540409). In another case report, a patient with colorectal cancer harboring BRAF L597R was treated with a combination therapy of panitumumab plus FOLFIRI and demonstrated stable disease with a progression-free survival of 16.5 months (PMID: 31515458).",
            "description_review": {
              "updateTime": 1678404907852,
              "updatedBy": "User"
            },
            "description_uuid": "f7a2b601-dabf-482b-8763-4293f2d78125",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "57225720-7b20-42b8-aed1-561e9d1a6922",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "af609f8b-ee1e-4ff5-a363-2327464330ab",
            "short": ""
          },
          "mutation_effect_uuid": "485d0e88-bea3-4a32-950d-ca14cb9728c6",
          "name": "L597R",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "ec78dd29-35fe-4668-bfc8-9980ec162abd"
        },
        {
          "mutation_effect": {
            "description": "The class II BRAF L597V mutation is located in the kinase domain in exon 15 of the protein (PMID: 28783719, 26343582). This mutation is recurrent in melanoma (PMID: 12068308, 15035987, 26643848). Biological characterization of BRAF L597V mutation demonstrated that it activates the downstream MAPK pathway independent of RAS and renders BRAF active as a dimer with CRAF and itself (PMID: 12068308, 15035987, 22798288, 26343582, 28783719, 20179705). Preclinical studies with patient-derived lung adenocarcinoma cells expressing BRAF L597V demonstrated sensitivity to treatment with dabrafenib plus trametinib, trametinib, BGB-283 and LXH 254, as measured by cellular proliferation inhibition, and resistance to treatment with dabrafenib, encorafenib, vemurafenib, TAK-580, LY3214996, MK-8353, GDC-0994 and BVD-523, as measured by sustained cellular proliferation upon drug treatment (PMID: 32540409). In a Phase II trial, a patient with endometrial adenocarcinoma harboring BRAF L597V was treated with trametinib and demonstrated stable disease with a progression-free survival of 7.9 months (PMID: 31924734).",
            "description_review": {
              "updateTime": 1678404979537,
              "updatedBy": "User"
            },
            "description_uuid": "23eee5aa-022a-456b-9a55-f565d56832ce",
            "effect": "Gain-of-function",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "a9e6b8b3-d1fb-4685-a5ec-78811f7bb602",
            "oncogenic": "Yes",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "d138d84d-4bcf-4d28-a586-c09e8fcd6c80",
            "short": ""
          },
          "mutation_effect_uuid": "45af694a-60a6-4d89-8d00-ff46cb6771cf",
          "name": "L597V",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "9ab5474b-baa2-474e-93a9-9669cdb3dcad"
        },
        {
          "mutation_effect": {
            "description": "",
            "description_review": {
              "updateTime": 1493057315640
            },
            "description_uuid": "72cb23ee-8d7e-48c8-94aa-e2ebb19728d0",
            "effect": "",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "9a8fccb4-a191-4c71-bc24-53b77255b1e7",
            "oncogenic": "",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "b86b763c-fc89-4ba3-a7c8-e952e1b71669",
            "short": ""
          },
          "mutation_effect_uuid": "107b3986-f0d3-43f3-9c67-c885294d8126",
          "name": "L597",
          "name_review": {
            "updateTime": 1531942509001,
            "updatedBy": "User"
          },
          "name_uuid": "766b0459-ce4a-491d-b9ea-497ec702ebba",
          "tumors": [
            {
              "TIs": [
                {
                  "name": "Standard implications for sensitivity to therapy",
                  "name_uuid": "d8faea6d-337a-4f99-bb39-ff34262b7828",
                  "type": "SS"
                },
                {
                  "name": "Standard implications for resistance to therapy",
                  "name_uuid": "1132e086-0072-4884-9a50-4ffd8f3a1458",
                  "type": "SR"
                },
                {
                  "name": "Investigational implications for sensitivity to therapy",
                  "name_uuid": "9a0bc7e6-a990-4c82-92b5-c5252b79d910",
                  "treatments": [
                    {
                      "description": "Trametinib is a small molecule inhibitor of the MEK1/2 kinases that is FDA-approved in combination with a RAF inhibitor for use in BRAF V600E-positive metastatic melanoma. In a small study of trametinib in patients with non-V600E BRAF-mutated metastatic melanoma, one patient harboring a BRAF L597Q mutation achieved partial response (6.2 months) upon treatment with trametinib (PMID: 24933606). In vitro studies of cell lines engineered to express BRAF L597R or L597S mutations demonstrated sensitivity to MEK inhibition as measured by decreased activation of downstream effector proteins upon treatment with trametinib (PMID: 22798288, 29903896).",
                      "description_review": {
                        "updateTime": 1676490789512,
                        "updatedBy": "User"
                      },
                      "description_uuid": "311cd736-6520-4543-a350-520e7fe07ec7",
                      "fdaLevel": "Fda3",
                      "fdaLevel_review": {
                        "updateTime": 1676490787278,
                        "updatedBy": "User"
                      },
                      "fdaLevel_uuid": "9d9f1ae3-c5b0-46f8-87a3-45c37bd93c2b",
                      "indication": "",
                      "indication_review": {
                        "updateTime": 1493057315640
                      },
                      "indication_uuid": "cdd88e62-86d5-4e40-8264-0b1bf7c52f70",
                      "level": "3A",
                      "level_uuid": "bf6f1ff5-7361-4fcc-9d49-992f200c3b68",
                      "name": "fb2bb01c-c0ec-4641-abf7-87f486075022",
                      "name_review": {
                        "updateTime": 1517434911242
                      },
                      "name_uuid": "af5ea563-3d74-49e1-b931-ebb6f3fdeb43",
                      "propagation": "3B",
                      "propagationLiquid": "no",
                      "propagationLiquid_uuid": "d230fa7a-db25-11e9-b658-60f81dc75ed6",
                      "propagation_review": {
                        "updateTime": 1548777541137,
                        "updatedBy": "User"
                      },
                      "propagation_uuid": "6695f097-1584-4342-8d52-ad32ee6d5cc3",
                      "short": ""
                    }
                  ],
                  "type": "IS"
                },
                {
                  "name": "Investigational implications for resistance to therapy",
                  "name_uuid": "21f300a5-8a71-485b-9006-55c5312d5eb6",
                  "type": "IR"
                }
              ],
              "cancerTypes": [
                {
                  "code": "MEL",
                  "mainType": "Melanoma",
                  "subtype": "Melanoma"
                }
              ],
              "cancerTypes_uuid": "6a255f7d-fe8f-4b03-b855-6acf0952d801",
              "diagnostic": {
                "description": "",
                "description_uuid": "af797510-a4b1-4e74-b04a-03c491c567dc",
                "level": "",
                "level_uuid": "6f319aa3-ce5d-4067-b6eb-7d5dd6fd945c",
                "short": ""
              },
              "diagnosticSummary": "",
              "diagnosticSummary_uuid": "e66aa223-eead-413b-a262-7c01c82db3bc",
              "diagnostic_uuid": "55373fca-4838-41b5-847c-907add76ae7a",
              "prognostic": {
                "description": "",
                "description_review": {
                  "updateTime": 1493057315640
                },
                "description_uuid": "a20fff1a-03da-44e7-8b4d-e636cf57e37a",
                "level": "",
                "level_uuid": "b1336ff0-d138-4b52-9612-0dfdc5f461ec",
                "short": ""
              },
              "prognosticSummary": "",
              "prognosticSummary_uuid": "65b8f217-95b7-4a6c-91cd-96bafbd061f5",
              "prognostic_uuid": "4560dc16-a2c3-4179-976b-62b35426daa8",
              "summary": "There is promising clinical data in patients with BRAF L597-mutant melanoma treated with the FDA-approved MEK-targeted inhibitor trametinib.",
              "summary_review": {
                "updateTime": 1566490460272,
                "updatedBy": "User"
              },
              "summary_uuid": "30a2e81e-265e-4103-ab0b-30bc2e3da638"
            },
            {
              "TIs": [
                {
                  "name": "Standard implications for sensitivity to therapy",
                  "name_uuid": "5574c2c9-678c-49f1-b84a-df01d383dbb0",
                  "type": "SS"
                },
                {
                  "name": "Standard implications for resistance to therapy",
                  "name_uuid": "4b89cd3c-90a3-4044-a3d0-0a6419d0d0a5",
                  "type": "SR"
                },
                {
                  "name": "Investigational implications for sensitivity to therapy",
                  "name_uuid": "5b5d8764-b1c9-4564-a85f-0ee7b26deee6",
                  "type": "IS"
                },
                {
                  "name": "Investigational implications for resistance to therapy",
                  "name_uuid": "3d4e6293-a647-4486-aa84-db1549b61145",
                  "type": "IR"
                }
              ],
              "cancerTypes": [
                {
                  "code": "",
                  "mainType": "Other Tumor Types",
                  "subtype": ""
                }
              ],
              "cancerTypes_uuid": "7f78106e-8385-4271-a6ff-7829c254fd15",
              "diagnostic": {
                "description": "",
                "description_uuid": "b52fa1c4-e9a1-4396-9fed-bf8cceebafa7",
                "level": "",
                "level_uuid": "a51445be-32d8-4457-a991-0b3783b7eaf1",
                "short": ""
              },
              "diagnosticSummary": "",
              "diagnosticSummary_uuid": "b3720d0d-7a31-4642-8a1f-3d3890c32fd6",
              "diagnostic_uuid": "4fe6ae69-ae14-4d41-a008-5d9dc1be8fbc",
              "prognostic": {
                "description": "",
                "description_review": {
                  "updateTime": 1493057315640
                },
                "description_uuid": "8ecce921-fd3b-4b70-952a-23df85a002de",
                "level": "",
                "level_uuid": "358e0a36-a473-474d-8c7a-967c99702cf0",
                "short": ""
              },
              "prognosticSummary": "",
              "prognosticSummary_uuid": "1c09ec38-48f4-4ec0-8ee4-aad64aee9bc2",
              "prognostic_uuid": "0ae96a02-c236-4787-bab0-3f8d5e69e156",
              "summary": "While there is promising clinical data supporting the use of the FDA-approved MEK-inhibitor trametinib in patients with BRAF L597-mutant melanoma, its clinical utility in patients with [[variant]] is unknown. BRAF class II mutations including [[gene]] [[mutation]] are insensitive to the RAF inhibitors vemurafenib and dabrafenib. Laboratory data suggest that cancer cells with oncogenic, BRAF class II mutations may be sensitive to novel BRAF inhibitors such as PLX8394.",
              "summary_review": {
                "updateTime": 1566490514542,
                "updatedBy": "User"
              },
              "summary_uuid": "9b3811aa-85b0-40d0-90fc-f5c724b37f06"
            },
            {
              "TIs": [
                {
                  "name": "Standard implications for sensitivity to therapy",
                  "name_uuid": "79ce7ed5-52dd-42d4-a183-1a03c490180d",
                  "treatments_uuid": "9b307354-c09d-40b7-b58d-53311b1319b6",
                  "type": "SS"
                },
                {
                  "name": "Standard implications for resistance to therapy",
                  "name_uuid": "429dcf3a-b9ea-46e9-8774-6db0cb8ca8a3",
                  "treatments_uuid": "3b4b3638-d249-4494-8460-cc5e67e29d3a",
                  "type": "SR"
                },
                {
                  "name": "Investigational implications for sensitivity to therapy",
                  "name_uuid": "30e7efd8-f7d5-4b37-ba11-fd09b191b321",
                  "treatments": [
                    {
                      "description": "PLX8394 is an orally available, second-generation, small-molecule BRAF inhibitor that inhibits mutated, oncogenic BRAF without causing paradoxical MAPK pathway activation as is seen with first-generation BRAF inhibitors (PMID: 28659148). In a phase I clinical trial for patients with refractory or relapsed solid tumors with or without BRAF mutation, there were two (28%) partial responses of seven evaluable BRAF-mutant patients treated with PLX8394 and cobicistat, a CYP3A4 inhibitor (Abstract: Janku et al. Abstract# B176, AACR-NCI-EORTC 2017. http://mct.aacrjournals.org/content/17/1_Supplement/B176). Both responses were in patients with BRAF V600 mutations. Preclinical studies show that PLX8394 specifically inhibits BRAF-containing dimers and inhibits proliferation and pathway actiavtion in BRAF-mutated colorectal cancer cell lines (PMID: 26466569, 28659148, 30559419, 28783719).",
                      "description_review": {
                        "updateTime": 1571710343420,
                        "updatedBy": "User"
                      },
                      "description_uuid": "a0869579-04ee-4a26-bf5c-06bfcbefdbd7",
                      "fdaLevel": "Fda3",
                      "fdaLevel_review": {
                        "updateTime": 1676490762959,
                        "updatedBy": "User"
                      },
                      "fdaLevel_uuid": "b857bf0b-1ff2-49b0-9db7-6e18e08ce7a0",
                      "indication": "",
                      "indication_uuid": "87c51e5b-085f-4b41-9e0f-7413838076b3",
                      "level": "4",
                      "level_review": {
                        "updateTime": 1555909567001,
                        "updatedBy": "User"
                      },
                      "level_uuid": "48c8fd93-8731-45d7-8832-9444b5a3e0e3",
                      "name": "44faeeae-ad6d-4370-8c99-97955f9e0feb",
                      "name_review": {
                        "updateTime": 1555909564944,
                        "updatedBy": "User"
                      },
                      "name_uuid": "1fd2d2b7-b69a-4e58-b205-81ef99c8c2e9",
                      "propagation": "4",
                      "propagationLiquid": "no",
                      "propagationLiquid_uuid": "d230fb38-db25-11e9-b4d4-60f81dc75ed6",
                      "propagation_review": {
                        "updateTime": 1555909566998,
                        "updatedBy": "User"
                      },
                      "propagation_uuid": "a23229aa-359f-4229-b474-2c48b5611d56",
                      "short": ""
                    }
                  ],
                  "treatments_uuid": "e4e746ce-bc02-43e4-a0b1-0c948b6ecd82",
                  "type": "IS"
                },
                {
                  "name": "Investigational implications for resistance to therapy",
                  "name_uuid": "1625585e-9368-4e1c-abb9-8d1d491c5873",
                  "treatments_uuid": "23e85b9f-7d5f-401a-9983-ab781870f8de",
                  "type": "IR"
                }
              ],
              "cancerTypes": [
                {
                  "code": "",
                  "mainType": "All Solid Tumors",
                  "subtype": ""
                }
              ],
              "cancerTypes_review": {
                "updateTime": 1566316239454,
                "updatedBy": "User"
              },
              "cancerTypes_uuid": "d6bbd4ab-6b2b-4c26-96ff-eba923097d8f",
              "diagnostic": {
                "description": "",
                "description_uuid": "a3d3802a-981f-4cad-ae2d-1fa9ec879d1f",
                "level": "",
                "level_uuid": "f7583611-f66d-412a-93fc-258ea7927e06",
                "short": ""
              },
              "diagnosticSummary": "",
              "diagnosticSummary_uuid": "27e0a74a-5757-47a2-bfc3-5595660d14da",
              "diagnostic_uuid": "5132e62b-0f28-429a-bb80-709ff3fdda62",
              "prognostic": {
                "description": "",
                "description_uuid": "7f477612-d425-491e-bd83-4c51f96d9dd7",
                "level": "",
                "level_uuid": "33b1362c-593a-4a8f-ba7a-e7b559511297",
                "short": ""
              },
              "prognosticSummary": "",
              "prognosticSummary_uuid": "31d59720-a4ff-4d6d-93a9-964a9ae3050a",
              "prognostic_uuid": "ccec620a-6e5c-4c45-983f-5ebf1874a342",
              "summary": "",
              "summary_review": {
                "updateTime": 1555909561877,
                "updatedBy": "User"
              },
              "summary_uuid": "a21b857b-9158-43d2-b799-2ac484e2bd7c"
            }
          ]
        },
        {
          "mutation_effect": {
            "description": "",
            "description_review": {
              "updateTime": 1534528902729,
              "updatedBy": "User"
            },
            "description_uuid": "f01c745b-e4ba-4460-90c8-6320ff633d04",
            "effect": "",
            "effect_review": {
              "updateTime": 1534528914079,
              "updatedBy": "User"
            },
            "effect_uuid": "e628839d-34fa-4086-b0eb-9edea2ec037b",
            "oncogenic": "",
            "oncogenic_review": {
              "updateTime": 1534528911297,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "cf4a40b0-6cdf-4a47-bf05-8cdf689e6949",
            "short": ""
          },
          "mutation_effect_uuid": "5295dcc6-bfbf-414f-945d-384832d09a62",
          "name": "K601",
          "name_review": {
            "updateTime": 1531942517572,
            "updatedBy": "User"
          },
          "name_uuid": "7215cea2-ec59-4ec9-8c10-b2b0b30035b4",
          "tumors": [
            {
              "TIs": [
                {
                  "name": "Standard implications for sensitivity to therapy",
                  "name_uuid": "4cf9f109-67f1-493b-875d-e67546e015fe",
                  "type": "SS"
                },
                {
                  "name": "Standard implications for resistance to therapy",
                  "name_uuid": "ee387b3d-a019-4fd6-8db7-a8ac35b3d0fe",
                  "type": "SR"
                },
                {
                  "name": "Investigational implications for sensitivity to therapy",
                  "name_uuid": "6a71ddfc-7d7d-4abb-b981-775ca5fa193c",
                  "treatments": [
                    {
                      "description": "Trametinib is a small molecule inhibitor of the MEK1/2 kinases that is FDA-approved in combination with a RAF inhibitor for use in BRAF V600E-positive metastatic melanoma. Anecdotal evidence of clinical activity of trametinib in BRAF K601-mutant melanoma includes a patient who experienced a complete response to trametinib over 36 months (PMID: 28344857), and four patients in various other studies who achieved a partial response or stable disease upon treatment with trametinib (PMID: 23248257, 24933606). In vitro studies of cell lines engineered to express BRAF K601E demonstrated sensitivity to MEK inhibition as measured by decreased activation of downstream effector proteins upon treatment with trametinib (PMID: 22798288, 29903896).",
                      "description_review": {
                        "updateTime": 1676490736236,
                        "updatedBy": "User"
                      },
                      "description_uuid": "8b38f098-3204-4a71-bff8-ccadde61c656",
                      "fdaLevel": "Fda3",
                      "fdaLevel_review": {
                        "updateTime": 1667497580095,
                        "updatedBy": "User"
                      },
                      "fdaLevel_uuid": "bdbc69f1-79dc-43bc-8c09-34ff4d5c1506",
                      "indication": "",
                      "indication_review": {
                        "updateTime": 1493057315640
                      },
                      "indication_uuid": "fec5c65d-f7e6-495f-842a-5f400271af33",
                      "level": "3A",
                      "level_review": {
                        "updateTime": 1555909588108,
                        "updatedBy": "User"
                      },
                      "level_uuid": "71428052-935d-4f0b-8a60-48454b21dc23",
                      "name": "fb2bb01c-c0ec-4641-abf7-87f486075022",
                      "name_review": {
                        "updateTime": 1555909584824,
                        "updatedBy": "User"
                      },
                      "name_uuid": "b17106e4-9dd3-4157-90d2-0e791c15278b",
                      "propagation": "3B",
                      "propagationLiquid": "no",
                      "propagationLiquid_uuid": "d230fc1e-db25-11e9-957d-60f81dc75ed6",
                      "propagation_review": {
                        "updateTime": 1555909588105,
                        "updatedBy": "User"
                      },
                      "propagation_uuid": "c2496074-0bd4-4037-b2ad-0a505a84d3ce",
                      "short": ""
                    }
                  ],
                  "type": "IS"
                },
                {
                  "name": "Investigational implications for resistance to therapy",
                  "name_uuid": "7729e250-f644-4436-97df-ac11ba505c62",
                  "type": "IR"
                }
              ],
              "cancerTypes": [
                {
                  "code": "MEL",
                  "mainType": "Melanoma",
                  "subtype": "Melanoma"
                }
              ],
              "cancerTypes_uuid": "2de8e142-da77-46fe-86ba-0fc418df37d7",
              "diagnostic": {
                "description": "",
                "description_uuid": "4766c856-6abd-46b8-af43-6ce90057be43",
                "level": "",
                "level_uuid": "d844e2e9-c021-4a96-a0c2-651e3c05ce68",
                "short": ""
              },
              "diagnosticSummary": "",
              "diagnosticSummary_uuid": "c2e08cea-3890-4201-9371-ae0f9cfd96c8",
              "diagnostic_uuid": "0ddd0f2c-c441-4fef-826a-0da0e0f3450f",
              "prognostic": {
                "description": "",
                "description_review": {
                  "updateTime": 1493057315640
                },
                "description_uuid": "c66afca6-d18b-40ad-8106-9a0b8cdbb097",
                "level": "",
                "level_uuid": "7b648539-c028-4523-8d7e-fc2f6061e3e5",
                "short": ""
              },
              "prognosticSummary": "",
              "prognosticSummary_uuid": "c8ea539c-92bf-465b-9da0-30f4ca4f5d00",
              "prognostic_uuid": "e8043444-1116-4717-abe3-df510747296e",
              "summary": "There is promising clinical data in patients with BRAF K601E mutant melanoma treated with the FDA-approved MEK-targeted inhibitor trametinib.",
              "summary_review": {
                "updateTime": 1566490095518,
                "updatedBy": "User"
              },
              "summary_uuid": "f54dc0ea-805f-407b-acc0-878409be447b"
            },
            {
              "TIs": [
                {
                  "name": "Standard implications for sensitivity to therapy",
                  "name_uuid": "0f12f891-1148-4706-83ec-5c32650604f6",
                  "type": "SS"
                },
                {
                  "name": "Standard implications for resistance to therapy",
                  "name_uuid": "f6a590e5-d59f-49d5-9090-4fc3990ab8a1",
                  "type": "SR"
                },
                {
                  "name": "Investigational implications for sensitivity to therapy",
                  "name_uuid": "9273909d-f16e-44f0-90f6-da9b1ca34d1d",
                  "type": "IS"
                },
                {
                  "name": "Investigational implications for resistance to therapy",
                  "name_uuid": "8fb0984a-10ae-495b-813c-f582138e8fc3",
                  "type": "IR"
                }
              ],
              "cancerTypes": [
                {
                  "code": "",
                  "mainType": "Other Tumor Types",
                  "subtype": ""
                }
              ],
              "cancerTypes_uuid": "bdfd6c66-4adc-411f-ba92-ee47ee783ffb",
              "diagnostic": {
                "description": "",
                "description_uuid": "e804e526-adde-457c-885f-e9d41b746c47",
                "level": "",
                "level_uuid": "27c36a1f-0071-4116-a712-bb032ac9446f",
                "short": ""
              },
              "diagnosticSummary": "",
              "diagnosticSummary_uuid": "8cf8abad-a36c-4d10-8ad8-3f543cfd2023",
              "diagnostic_uuid": "4d2b427d-99cf-4d35-9842-8dde4e1406db",
              "prognostic": {
                "description": "",
                "description_review": {
                  "updateTime": 1493057315640
                },
                "description_uuid": "19cf04bc-7b18-40e3-abbb-83f063ab4641",
                "level": "",
                "level_uuid": "f447dffa-e466-45f6-b2b1-7631b2722f10",
                "short": ""
              },
              "prognosticSummary": "",
              "prognosticSummary_uuid": "992be879-c037-4c60-990d-4d0523b0259c",
              "prognostic_uuid": "8c549b00-7ff3-497c-bf1d-faf6da822dec",
              "summary": "While there is promising clinical data supporting the use of the MEK-targeted inhibitor trametinib in patients with BRAF K601E mutant melanoma, its clinical utility in patients with [[variant]] is unknown. BRAF class II mutations including [[gene]] [[mutation]] are insensitive to the RAF inhibitors vemurafenib and dabrafenib. Laboratory data suggest that cancer cells with oncogenic, BRAF mutations may be sensitive to novel BRAF inhibitors such as PLX8394.",
              "summary_review": {
                "updateTime": 1566490226795,
                "updatedBy": "User"
              },
              "summary_uuid": "e6703560-987d-4350-a9aa-931bdaea463b"
            },
            {
              "TIs": [
                {
                  "name": "Standard implications for sensitivity to therapy",
                  "name_uuid": "260405d8-9942-44b2-910f-1c7982d500a0",
                  "treatments_uuid": "74e722bf-d51f-47c5-81bf-ac3615d1eb70",
                  "type": "SS"
                },
                {
                  "name": "Standard implications for resistance to therapy",
                  "name_uuid": "61341a21-7bb4-4265-aff6-ad32ab0787c5",
                  "treatments_uuid": "c7a8aab9-db0f-4bed-ad53-3c7e80645dd0",
                  "type": "SR"
                },
                {
                  "name": "Investigational implications for sensitivity to therapy",
                  "name_uuid": "9868b240-b5c5-4b7a-90e8-b7dcc9357cc0",
                  "treatments": [
                    {
                      "description": "PLX8394 is an orally available, second-generation, small-molecule BRAF inhibitor that inhibits mutated, oncogenic BRAF without causing paradoxical MAPK pathway activation as is seen with first-generation BRAF inhibitors (PMID: 28659148). In a phase I clinical trial for patients with refractory or relapsed solid tumors with or without BRAF mutation, there were two (28%) partial responses of seven evaluable BRAF-mutant patients treated with PLX8394 and cobicistat, a CYP3A4 inhibitor (Abstract: Janku et al. Abstract# B176, AACR-NCI-EORTC 2017. http://mct.aacrjournals.org/content/17/1_Supplement/B176). Both responses were in patients with BRAF V600 mutations. In a phase I/IIa trial of PLX8394 for patients with BRAF-altered, advanced solid or CNS tumors (n=110; n=61, patients with class 1 mutations; n=19, patients with class 2 mutations [excluding fusions]; n=17, patients with BRAF fusions), partial response was achieved in 39% (n=9/23) of patients with MAPKi-naive, V600-mutant tumors, with a median duration of response (DoR) of 32 months, and in 18% (n=3/17) of patients with MAPKi treated, V600-mutant tumors (n=6, patients with V600-mutant glioma; n=3, patients with V600-mutant ovarian cancer; n=1, patients with V600-mutant small bowel cancer; n=1, patients with V600-mutant papillary thyroid cancer; n=1, patients with V600-mutant anaplastic thyroid cancer) (Abstract: Fuente et al. Abstract# 3006, J. Clin. Oncol. 2023, Vol 41, Suppl 16. https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.3006). Preclinical studies show that PLX8394 specifically inhibits BRAF-containing dimers and inhibits proliferation and pathway activation in BRAF-mutated colorectal cancer cell lines (PMID: 26466569, 28659148, 30559419, 28783719).",
                      "description_review": {
                        "updateTime": 1707430870906,
                        "updatedBy": "User"
                      },
                      "description_uuid": "1b376733-446c-4001-9327-25d7abc0027a",
                      "fdaLevel": "Fda3",
                      "fdaLevel_review": {
                        "updateTime": 1676490711368,
                        "updatedBy": "User"
                      },
                      "fdaLevel_uuid": "34d5b11c-58fd-4290-969b-3308838b4f61",
                      "indication": "",
                      "indication_uuid": "478cb99f-b08a-4b11-8935-cee9cdd06827",
                      "level": "4",
                      "level_review": {
                        "updateTime": 1535056926640,
                        "updatedBy": "User"
                      },
                      "level_uuid": "efd84535-ad27-4019-8263-12ba730e42b6",
                      "name": "44faeeae-ad6d-4370-8c99-97955f9e0feb",
                      "name_review": {
                        "updateTime": 1535056914139,
                        "updatedBy": "User"
                      },
                      "name_uuid": "690ed068-5612-438a-ac07-948a18228375",
                      "propagation": "4",
                      "propagationLiquid": "no",
                      "propagationLiquid_uuid": "d230fcdc-db25-11e9-a6cb-60f81dc75ed6",
                      "propagation_review": {
                        "updateTime": 1549576165995,
                        "updatedBy": "User"
                      },
                      "propagation_uuid": "df4f3cb9-6996-4d3f-adce-4c1974e15d64",
                      "short": ""
                    }
                  ],
                  "treatments_uuid": "f35d653f-a050-4818-9f25-fdbbab417681",
                  "type": "IS"
                },
                {
                  "name": "Investigational implications for resistance to therapy",
                  "name_uuid": "88d13d8a-4dd9-4db9-8066-9849e5f722da",
                  "treatments_uuid": "fb437fef-1b36-4750-bfac-2a587d00bae2",
                  "type": "IR"
                }
              ],
              "cancerTypes": [
                {
                  "code": "",
                  "mainType": "All Solid Tumors",
                  "subtype": ""
                }
              ],
              "cancerTypes_review": {
                "updateTime": 1566316221728,
                "updatedBy": "User"
              },
              "cancerTypes_uuid": "11f3ed76-44e8-4baa-a63b-d47eafb3108c",
              "diagnostic": {
                "description": "",
                "description_uuid": "83b54894-ecbc-4a75-8ad4-37f741819a43",
                "level": "",
                "level_uuid": "53f0338c-35a7-465d-a5c8-11e310309502",
                "short": ""
              },
              "diagnosticSummary": "",
              "diagnosticSummary_uuid": "b1ac745f-955d-43f5-9064-20c265350648",
              "diagnostic_uuid": "13e52146-9dd5-4db2-9d74-5126c70617ed",
              "prognostic": {
                "description": "",
                "description_uuid": "344332ba-f435-4f80-a17a-cb87b3cd9c8d",
                "level": "",
                "level_uuid": "3ac1d3e7-c654-43c0-92fc-fb9aca7e9ac5",
                "short": ""
              },
              "prognosticSummary": "",
              "prognosticSummary_uuid": "033d8d04-06cf-488c-9f6b-e9042f0fd9a6",
              "prognostic_uuid": "3b6b477b-7e3b-4c63-ad45-ec1eb732f118",
              "summary": "",
              "summary_review": {
                "updateTime": 1541708443968,
                "updatedBy": "User"
              },
              "summary_uuid": "07ece259-fca8-4e1f-b619-f6916ce99d64"
            }
          ]
        },
        {
          "mutation_effect": {
            "description": "The class II BRAF K601Q mutation is located in the kinase domain in exon 15 of the protein (PMID: 33019809). This mutation has been found in patients with cardio-facio-cutaneous syndrome (PMID: 19206169). Expression of this mutation in NIH-3T3 cells demonstrated that it is activating as measured by increased downstream pathway activation compared to wildtype BRAF, though to a lesser extent than BRAF V600E (PMID: 19206169). Preclinical studies with melanoma cells expressing BRAF K601Q demonstrated resistance to treatment with vemurafenib as measured by sustained MEK and ERK phosphorylation following treatment (PMID: 35045286).",
            "description_review": {
              "updateTime": 1678306034861,
              "updatedBy": "User"
            },
            "description_uuid": "42368832-553d-4213-92e0-3eab159a5d7a",
            "effect": "Gain-of-function",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "bf3ce630-ff39-4267-a35a-5ea53feee665",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "b3965dfe-f320-4ad5-8f89-7d2f351908f0",
            "short": ""
          },
          "mutation_effect_uuid": "a7c579f7-d314-4f58-a9d2-af2ac5d10556",
          "name": "K601Q",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "1940dfe3-ada1-493f-9b42-29f43b7b0e9d"
        },
        {
          "mutation_effect": {
            "description": "The class II BRAF L597Q mutation is located in the kinase domain in exon 15 of the protein (PMID: 28783719, 26343582). This mutation is recurrent in melanoma (PMID: 12068308, 15035987, 26643848). Biological characterization of BRAF L597Q demonstrated that it activates the downstream MAPK pathway independent of RAS and renders BRAF active as a dimer with CRAF and itself (PMID: 12068308, 15035987, 22798288, 26343582, 28783719). Preclinical studies with patient-derived colon adenocarcinoma cells expressing BRAF L597Q demonstrated sensitivity to treatment with trametinib, selumetinib, AZD8931 and trametinib plus cetuximab as measured by inhibition of tumor growth (PMID: 31704811). In a Phase I trial, a patient with lung cancer harboring BRAF L597Q was treated with BVD-523 and demonstrated partial response (PMID: 29247021). In a Phase II trial, a patient with melanoma harboring BRAF L597Q was treated with trametinib and demonstrated partial response with a 38% tumor reduction and ongoing progression-free survival of 8.3 months (PMID: 33861486). In another Phase II trial, a patient with an advanced solid tumor harboring BRAF L597Q was treated with vemurafenib and did not clinically respond to treatment (PMID: 29320312).",
            "description_review": {
              "updateTime": 1678405203189,
              "updatedBy": "User"
            },
            "description_uuid": "893ca79d-2e8d-4655-9e63-91c946c6bfa6",
            "effect": "Gain-of-function",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "1f81f2af-cf83-4764-9fe2-b5f4de735c42",
            "oncogenic": "Yes",
            "oncogenic_review": {
              "updateTime": 1529422648454,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "a4f10719-c5cb-4074-b753-acbe2a67dd47",
            "short": ""
          },
          "mutation_effect_uuid": "236204f7-c15d-4cdb-be9d-9a4407d6b23e",
          "name": "L597Q",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "ec92d846-c840-49c5-8829-1904d96e8619"
        },
        {
          "mutation_effect": {
            "description": "The class II BRAF K601N mutation is located in the kinase domain in exon 15 of the protein (PMID: 28783719, 26343582). This mutation has been identified in melanoma and multiple myeloma (PMID: 12068308, 15035987, 25178945, 23273605, 24270325). Biological characterization of BRAF K601N demonstrated that it activates the downstream MAPK pathway independently of RAS and renders BRAF active as a dimer with CRAF and itself (PMID: 26343582, 20179705). Preclinical studies with NIH3T3 and SK-MEL-239 cells expressing BRAF K601N demonstrated sensitivity to treatment with LY3009120 and PLX8394 as measured by reduced proliferation (PMID: 26732095, 30559419). In a Phase Ib trial, a patient with non-small cell lung cancer harboring BRAF K601N was treated with combination therapy of LTT462 and LXH 254 and demonstrated an unconfirmed partial response (Abstract: Wolf et al. Abstract# 1387p, Annals of Oncology 2020. https://www.annalsofoncology.org/article/S0923-7534%2820%2941697-7/fulltext). In a Phase II trial, two patients with non-small cell lung cancer harboring BRAF K601N were treated vemurafenib and did not clinically respond to treatment (PMID: 31959346).",
            "description_review": {
              "updateTime": 1678405295485,
              "updatedBy": "User"
            },
            "description_uuid": "4b930271-e34b-425b-8ae5-e30b2829610c",
            "effect": "Gain-of-function",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "99bbe560-98df-4ece-97ad-2ccf9fa0b7d8",
            "oncogenic": "Yes",
            "oncogenic_review": {
              "updateTime": 1529422541501,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "9cc4015a-8efe-4920-8520-02ef0003980b",
            "short": ""
          },
          "mutation_effect_uuid": "133c70cb-05a9-4a7d-896e-19826b4ea1cd",
          "name": "K601N",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "e66970c5-aa6a-421f-9267-4366e6db20c2"
        },
        {
          "mutation_effect": {
            "description": "The class III BRAF D594A mutation is located in the kinase domain in exon 15 of the protein (PMID: 20141835, 28783719). This mutation has been recurrently found in melanoma, lung and colorectal cancers (PMID: 20141835, 28481359). Biological characterization of the BRAF D594A mutation has demonstrated that it is RAS dependent in its activation of the MAPK pathway, signals as a dimer with CRAF, and typically co-occurs with another driver mechanism that amplifies RAS signaling (PMID: 20141835, 28783719). Thus, when BRAF D594A is observed in melanoma, it typically co-occurs with an activating RAS mutation or NF1 inactivation, whereas when observed in non-small cell lung or colorectal cancers, it is associated with receptor tyrosine kinase (RTK) hyperactivation at the protein level (PMID: 28783719, 20141835). While this mutation is sensitive to MEK inhibition by targeted inhibitors such as trametinib, it is insensitive to RAF monomer inhibitors such as vemurafenib (PMID: 28783719).",
            "description_review": {
              "updateTime": 1678135757466,
              "updatedBy": "User"
            },
            "description_uuid": "42688bd3-c1ae-48d6-84d7-e9834ffeb556",
            "effect": "Gain-of-function",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "d8ab8fe1-4049-418a-8beb-1bcf5c7c0adb",
            "oncogenic": "Yes",
            "oncogenic_review": {
              "updateTime": 1529423174284,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "f856d787-ee6c-4ece-b0b5-4bf4c20d1dbb",
            "short": ""
          },
          "mutation_effect_uuid": "bbe448da-0e25-4089-96d1-8946f29c2407",
          "name": "D594A",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "d230fe8d-70b8-4db1-9393-5d479e4604e6"
        },
        {
          "mutation_effect": {
            "description": "The class III BRAF D594E mutation is located in the kinase domain in exon 15 of the protein. This mutation has been found in non-small cell lung cancer and diffuse large B-cell lymphoma (PMID: 28947956, 32877514). In vivo studies with conditional knock-in mice expressing BRAF D594 demonstrate that the mutation activates the MAPK pathway through CRAF (PMID: 20978199). Expression of BRAF D594E in HEK293 cells demonstrated that it is activating as measured by increased downstream ERK signaling compared to wildtype BRAF (PMID: 28947956). In vitro studies have suggested that this mutation is resistant to dabrafenib, as measured by increased MAPK pathway activation upon drug treatment, but sensitive to trametinib, as measured by decreased MAPK pathway activation upon drug treatment (PMID: 28947956). As BRAF D594E is a kinase-dead mutation, it is suggested to be insensitive to treatment with vemurafenib (PMID: 28026870).",
            "description_review": {
              "updateTime": 1678135770012,
              "updatedBy": "User"
            },
            "description_uuid": "ec758764-c1f0-42b0-be9b-b52994445563",
            "effect": "Gain-of-function",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "eac9874d-79d9-454a-81b6-87c68e93307f",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "01ba7555-1f48-4cef-99a7-5bb8f0439f47",
            "short": ""
          },
          "mutation_effect_uuid": "8461a07d-e863-40df-aa68-d2badef18dac",
          "name": "D594E",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "1ac40ce5-288d-44eb-9c9b-f12920a05632"
        },
        {
          "mutation_effect": {
            "description": "The class III BRAF D594G mutation is located in the kinase domain in exon 15 of the protein (PMID: 28783719). This mutation has been found in colorectal cancer and melanomas, among others (PMID: 26498038, 28481359). Despite having hypoactive kinase activity, in vitro studies have demonstrated that this mutation is likely activating as measured by increased CRAF dimerization and downstream signaling compared to wildtype (PMID: 20141835, 26498038, 28783719). Preclinical studies with WM3670 cells expressing BRAF D594G demonstrated resistance to treatment with vemurafenib and PLX8394, as measured by persistent MEK, ERK and AKT activity, and sensitivity to treatment with SIJ1777, as measured by AKT and MAPK inhibition (PMID: 33917428). In a case report, a patient with low-grade serous ovarian cancer harboring BRAF D594G was treated with trametinib and demonstrated minimal clinical response (PMID: 35198414).",
            "description_review": {
              "updateTime": 1678135845805,
              "updatedBy": "User"
            },
            "description_uuid": "9beddad0-cffa-457e-b42a-4b4c4f0ac069",
            "effect": "Gain-of-function",
            "effect_review": {
              "updateTime": 1529423128678,
              "updatedBy": "User"
            },
            "effect_uuid": "2f4e594e-c475-49b7-a06a-dd2b1c5d4189",
            "oncogenic": "Yes",
            "oncogenic_review": {
              "updateTime": 1529423126596,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "5ea90d79-44f3-49e0-bcab-decd35590115",
            "short": ""
          },
          "mutation_effect_uuid": "cb2d7adf-654c-4d3b-88e6-571a704385fd",
          "name": "D594G",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "0a283b62-8be5-4690-ab4a-ddbfe6aab59b"
        },
        {
          "mutation_effect": {
            "description": "The class III BRAF D594N mutation occurs in the kinase domain in exon 15 of the protein (PMID: 28783719). This mutation has been found in non-small cell lung cancer and melanoma (PMID: 22798288, 23833300, 26498038, 28783719, 28947956). Biological characterization of the BRAF D594N mutation has demonstrated that it is RAS dependent in its activation of the MAPK pathway, signals as a dimer with CRAF, and typically co-occurs with another driver mechanism that amplifies RAS signaling (PMID: 28783719, 26498038). Thus, when BRAF D594N is observed in melanoma, it typically co-occurs with an activating RAS mutation or NF1 inactivation, whereas when observed in non-small cell lung or colorectal cancers, it is associated with receptor tyrosine kinase (RTK) hyperactivation at the protein level (PMID: 28783719). While this mutation is sensitive to MEK inhibition by targeted inhibitors such as trametinib, it is insensitive to RAF monomer inhibitors such as vemurafenib (PMID: 28783719). In a case report, a patient with EGFR-positive, MET-amplified non-small cell lung cancer acquired BRAF D594N as a secondary resistance mutation in response to combination treatment with osimertinib plus crizotinib (PMID: 36136993). The patient demonstrated clinical response to combination treatment with osimertinib plus trametinib (PMID: 36136993).",
            "description_review": {
              "updateTime": 1678149192517,
              "updatedBy": "User"
            },
            "description_uuid": "05597b46-bf02-452e-8a92-6ceb9be05c79",
            "effect": "Gain-of-function",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "b0ec34c2-01be-4bd8-96db-5aea6eb0706c",
            "oncogenic": "Yes",
            "oncogenic_review": {
              "updateTime": 1529423066283,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "e8e0818f-cedb-4eae-a9c1-e61cab753b74",
            "short": ""
          },
          "mutation_effect_uuid": "63e7e8e6-4fd3-41b9-9f73-920dade7efe1",
          "name": "D594N",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "ec54b583-b84d-4d58-b17f-318d688d2568"
        },
        {
          "mutation_effect": {
            "description": "The class III BRAF D594V mutation is located in the kinase domain in exon 15 of the protein (PMID: 33019809). This mutation has been found in colorectal cancer and cardio-facio-cutaneous (CFC) syndrome (PMID: 16439621, 14678966). Expression of this mutation in D04 or COS7 cells demonstrated that, despite being kinase-dead, the mutation activates the MAPK pathway through dimerization with CRAF as measured by downstream MEK and ERK phosphorylation (PMID: 15035987, 14678966). When expressed in zebrafish embryos, the BRAF D594V mutation causes the same aberrant elongation phenotype as BRAF V600E, suggesting that it is likely activating in vivo (PMID: 19376813).",
            "description_review": {
              "updateTime": 1678149262863,
              "updatedBy": "User"
            },
            "description_uuid": "5689db8e-dde3-4a4f-8f26-db019eecc642",
            "effect": "Gain-of-function",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "50b2db09-21b0-4bd8-859e-e6432d3a7483",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "d98714d2-a2af-4af6-9722-63683c1ef6b4",
            "short": ""
          },
          "mutation_effect_uuid": "3f072135-eeb5-40a9-b031-eecd440a3593",
          "name": "D594V",
          "name_comments": [
            {
              "content": "When expressed in zebrafish embryos, the D594V mutation causes the same aberrant elongation phenotype as BRAF V600E, suggesting that it is likely activating in vivo (PMID: 19376813)",
              "date": "1479468180500",
              "email": "user@gmail.com",
              "resolved": "true",
              "userName": "User"
            },
            {
              "content": "This mutation has been found in patients with cardio-facio-cutaneous syndrome, a syndrome resulting from germline activation of the MAPK pathway (PMID: 16439621).",
              "date": "1479468198004",
              "email": "user@gmail.com",
              "resolved": "true",
              "userName": "User"
            }
          ],
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "cfe94ae8-2c03-40ec-9ba2-19c349a8deff"
        },
        {
          "mutation_effect": {
            "description": "The class III BRAF D594Y mutation is located in the kinase domain in exon 15 of the protein (PMID: 30224342). This mutation has been identified in lung adenocarcinoma and ovarian cancer (PMID: 28481359, 31477716). Analysis of patients with BRAF-altered lung cancers demonstrated that BRAF D594Y has impaired kinase function (PMID: 32913992). As a BRAF class III mutation, it is suggested that BRAF D594Y is sensitive to MEK inhibition by targeted inhibitors such as trametinib and insensitive to RAF monomer inhibitors such as vemurafenib (PMID: 28783719).",
            "description_review": {
              "updateTime": 1678149299517,
              "updatedBy": "User"
            },
            "description_uuid": "ee390869-fb0f-4219-a4bb-839aa948cc12",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "4f361386-9f20-415b-ad55-2b6e73a3bc5a",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "e9ee68af-6814-4e3d-afcc-699156f2d920",
            "short": ""
          },
          "mutation_effect_uuid": "1488ec65-38a9-468c-b55f-f43d9bc3b86e",
          "name": "D594Y",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "3750ef1b-f51e-4900-8f2a-8330dd5f2da9"
        },
        {
          "mutation_effect": {
            "description": "The class II BRAF G464E mutation is located in the kinase domain in exon 11 of the protein (PMID: 28783719, 26343582). This mutation has been reported in colorectal cancer (PMID: 15150094). Biological characterization of the BRAF G464E mutation demonstrated it activates the downstream MAPK pathway independent of RAS and renders BRAF active as a dimer with CRAF (PMID: 15035987, 23680146, 15150094, 26343582, 20179705, 16364920). Preclinical studies with cancer cell lines expressing BRAF G464E demonstrate resistance to vemurafenib as measured by prolonged ERK signaling following treatment (PMID: 26343582, 28783719, 26343582). A patient with spindle cell carcinoma harboring BRAF G464E treated with trametinib resulted in stable disease with a progression-free survival of 6.9 months (PMID: 31924734).",
            "description_review": {
              "updateTime": 1678136216298,
              "updatedBy": "User"
            },
            "description_uuid": "b7da8b30-4c39-456d-8a2d-2dca47b463b5",
            "effect": "Gain-of-function",
            "effect_review": {
              "updateTime": 1529422748535,
              "updatedBy": "User"
            },
            "effect_uuid": "40f0164f-978b-4b99-87bc-392ce3f14d64",
            "oncogenic": "Yes",
            "oncogenic_review": {
              "updateTime": 1529422747368,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "c8e8b1f4-06ab-4749-b420-7a5600a95e1e",
            "short": ""
          },
          "mutation_effect_uuid": "44ac607d-b6ca-4453-8305-05f28df75d60",
          "name": "G464E",
          "name_comments": [
            {
              "content": "checked",
              "date": "1426444479718",
              "email": "user@gmail.com",
              "resolved": "true",
              "userName": "User"
            },
            {
              "content": "This publication only reports on the V mutant: 12068308",
              "date": "1438702464605",
              "email": "user@gmail.com",
              "resolved": "true",
              "userName": "User"
            },
            {
              "content": "onc: unk. no cosmic",
              "date": "1441126759607",
              "email": "user@gmail.com",
              "resolved": "true",
              "userName": "User"
            }
          ],
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "539e8df6-3099-42c1-9ba4-df874c548d21"
        },
        {
          "mutation_effect": {
            "description": "The class II BRAF G464R mutation is located in the kinase domain in exon 11 of the protein (PMID: 33019809). This mutation has been found in melanoma (PMID: 15046639). Expression of this mutation in NIH-3T3 cells demonstrated that this mutation is activating as measured by increased downstream pathway activation compared to wildtype BRAF, though to a lesser extent than BRAF V600E (PMID: 15046639). In vitro studies with Ba/F3 and MCF10A cells expressing BRAF G464R demonstrate that the mutation is activating as measured by increased cell viability and proliferation compared to wildtype (PMID: 29533785). In a case report for a patient with metastatic colorectal cancer harboring BRAF G464R and KRAS G12S, the patient was treated with bevacizumab plus FOLFIRI and then later treated with bevacizumab plus FOLFOXIRI and demonstrated recurrent disease in the sigmoid colon following both treatment regimens (PMID: 31183211).",
            "description_review": {
              "updateTime": 1678136246429,
              "updatedBy": "User"
            },
            "description_uuid": "b414c9bc-3925-4336-bd61-7b9129cb4746",
            "effect": "Gain-of-function",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "6ac26115-a639-4eee-aaac-dd0eba053dd6",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "fdb9c569-972c-4267-b851-c566fe8e0d01",
            "short": ""
          },
          "mutation_effect_uuid": "ee8097b7-9684-4727-8350-1c809e739c24",
          "name": "G464R",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "e57ff018-21ee-4ea4-b565-a8c58234bc5b"
        },
        {
          "mutation_effect": {
            "description": "The class II BRAF G464V mutation is located in the kinase domain in exon 11 of the protein (PMID: 28783719, 26343582). This mutation has been reported in melanoma, colorectal cancer and breast cancer (PMID: 15035987, 15150094, 17314276). Biological characterization of the BRAF G464V mutation demonstrated it activates the downstream MAPK pathway independent of RAS and renders BRAF active as a dimer with CRAF (PMID:  15035987, 12068308, 15150094, 26343582, 20179705). Preclinical studies with KRAS-mutant HEK293 cells expressing BRAF G464V demonstrated sensitivity to treatment with RAF inhibitor Cmpd A as measured by reduced phosphorylated ERK levels (PMID: 23680146). A patient with lung adenocarcinoma harboring BRAF G464V treated with trametinib did not respond to treatment and demonstrated progressive disease (PMID: 31924734). Two patients with advanced solid tumors harboring BRAF G464V were treated with vemurafenib and did not have an objective response to treatment (PMID: 29320312).",
            "description_review": {
              "updateTime": 1678149607725,
              "updatedBy": "User"
            },
            "description_uuid": "161b1111-36af-443d-9fcf-180a64054f5a",
            "effect": "Gain-of-function",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "532ebf53-588d-495d-92a3-fd13cb96b34b",
            "oncogenic": "Yes",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "5bab3643-9d50-43bf-be7b-307a2e48c9c4",
            "short": ""
          },
          "mutation_effect_uuid": "d3603616-755d-4486-8cc3-f24fba6f07a6",
          "name": "G464V",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "0f35fd61-6703-4960-9829-95861b411dec"
        },
        {
          "mutation_effect": {
            "description": "The class III BRAF G466A mutation is located in the kinase domain in exon 11 of the protein (PMID: 28783719, 15035987, 28783719). This mutation has been identified in melanoma and lung adenocarcinoma (PMID: 12068308, 28481359). Biological characterization of the BRAF G466A mutation has demonstrated that it is RAS dependent in its activation of the MAPK pathway, signals as a dimer with CRAF, and typically co-occurs with another driver mechanism that amplifies RAS signaling (PMID: 15035987, 28783719). Thus, when BRAF G466A is observed in melanoma, it typically co-occurs with an activating RAS mutation or NF1 inactivation, whereas when observed in non-small cell lung or colorectal cancers, it is associated with receptor tyrosine kinase (RTK) hyperactivation at the protein level (PMID: 28783719). A patient with non-small cell lung cancer harboring BRAF G466A treated with vemurafenib did not clinically respond to treatment and demonstrated progressive disease (PMID: 31959346). Patients with advanced solid tumors harboring BRAF G466A were treated with trametinib and demonstrated either progressive or stable disease (PMID: 31924734). In a case report, a patient with metastatic Bellini duct carcinoma harboring BRAF G466A treated with trametinib plus dabrafenib demonstrated 11 months of stable disease following treatment (PMID: 33669326). In a Phase Ib trial, a patient with metastatic non-small cell lung cancer harboring BRAF G466A was treated with combination therapy of the ERK1/2 inhibitor LTT462 and the BRAF/CRAF inhibitor LXH 254 and demonstrated stable disease with a 25% tumor reduction following treatment (Abstract: Wolf et al. Abstract# 1387p, Annals of Oncology 2020. https://www.annalsofoncology.org/article/S0923-7534%2820%2941697-7/fulltext).",
            "description_review": {
              "updateTime": 1678149756180,
              "updatedBy": "User"
            },
            "description_uuid": "3a9074c0-9195-4e12-8993-973d100aed3b",
            "effect": "Gain-of-function",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "855e100e-1702-43f9-ba27-bbb53498df41",
            "oncogenic": "Yes",
            "oncogenic_review": {
              "updateTime": 1529422987888,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "6ebe87c5-27e7-40a0-baa2-6ed29b00648c",
            "short": ""
          },
          "mutation_effect_uuid": "fd00e011-7b64-4a62-acc2-468acdab056f",
          "name": "G466A",
          "name_comments": [
            {
              "content": "checked, but go back and reread for grammar and fluidity",
              "date": "1426444676354",
              "email": "user@gmail.com",
              "resolved": "true",
              "userName": "User"
            }
          ],
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "fc140074-5eb2-41d8-8fbc-12cee0724239"
        },
        {
          "mutation_effect": {
            "description": "The class III BRAF G466E mutation occurs in the kinase domain in exon 11 of the protein (PMID: 15035987, 28783719). This mutation has been reported in melanoma, lung cancer, colorectal cancer and chronic myelomonocytic leukemia (PMID: 28481359, 15046639, 27790118, 24446311). Biological characterization of the BRAF G466E mutation has demonstrated that it is RAS dependent in its activation of the MAPK pathway, signals as a dimer with CRAF, and typically co-occurs with another driver mechanism that amplifies RAS signaling (PMID: 15035987, 15046639, 28783719). Thus, when BRAF G466E is observed in melanoma, it typically co-occurs with an activating RAS mutation or NF1 inactivation, whereas when observed in non-small cell lung or colorectal cancers, it is associated with receptor tyrosine kinase (RTK) hyperactivation at the protein level (PMID: 28783719). Preclinical studies with melanoma cell lines expressing BRAF G466E demonstrated sensitivity to treatment with AZ628 and TAK-632 as measured by reduced cell proliferation, and insensitivity to treatment with PLX7904, vemurafenib and dabrafenib, as measured by prolonged cell viability (PMID: 27523909). In a clinical study, two patients with metastatic colorectal cancer harboring BRAF G466E were treated with combination therapy of panitumumab and irinotecan and demonstrated partial response with a progression-free survival of 8.3 months (PMID: 31515458). In a case report, a patient with melanoma harboring BRAF G466E was treated with ipilimumab and demonstrated progressive disease (PMID: 27790118).",
            "description_review": {
              "updateTime": 1678149811909,
              "updatedBy": "User"
            },
            "description_uuid": "6f37816c-e652-4bf3-85f0-892bd84db00d",
            "effect": "Gain-of-function",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "09553532-91a2-47fb-9468-ff505476c94e",
            "oncogenic": "Yes",
            "oncogenic_review": {
              "updateTime": 1529422970543,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "3aaa447d-1aaf-41b9-b0ee-d17185ce9016",
            "short": ""
          },
          "mutation_effect_uuid": "b7dfcc5f-416e-4f9e-b358-17acae34e617",
          "name": "G466E",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "6539fc8e-7f50-4059-a0be-a1f4cc744f99"
        },
        {
          "mutation_effect": {
            "description": "The class III BRAF G466R mutation is located in the kinase domain in exon 11 of the protein (PMID: 28783719). This mutation has been identified in lung adenocarcinoma and melanoma (PMID: 24297085, 21788131). Expression of this mutation in NIH3T3 cells demonstrated that this mutation is likely activating as measured by increased downstream ERK activation (PMID: 15046639). While this mutation has kinase activity in vitro less than wildtype BRAF, it likely activates downstream ERK through dimerization with CRAF (PMID: 15035987, 16364920). A patient with stage IV lung adenocarcinoma harboring BRAF G466R was treated with selumetinib and demonstrated an overall survival of 9.1 months (PMID: 25273224). In a case report, a patient with non-small cell lung cancer harboring BRAF G466R was treated with a combination therapy of dabrafenib plus trametinib and did not clinically respond to treatment (Abstract: Citarella et al. Precis Cancer Med 2022. https://pcm.amegroups.com/article/view/6792/html#B19). Another patient with non-small cell lung cancer harboring BRAF G466R was treated with a combination therapy of nivolumab plus anlotinib and demonstrated progressive disease with a progression-free survival of two months (PMID: 32411601). In a Phase II trial, a patient with melanoma harboring BRAF G466R and NRAS Q61H was treated with a combination therapy of docetaxel plus selumetinib and demonstrated stable disease with a progression-free survival of seven months (PMID: 31839677).",
            "description_review": {
              "updateTime": 1678149893373,
              "updatedBy": "User"
            },
            "description_uuid": "93ba3c70-6481-4685-9e2a-cb11092be7b7",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "5414eff5-1ecb-4030-adf2-da44ef4b3778",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "903e2063-c368-4075-aab6-7d3f314f610a",
            "short": ""
          },
          "mutation_effect_uuid": "8d87dc2a-55c4-4cc5-8eed-a7bbac5df67c",
          "name": "G466R",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "4bc977d3-8b73-48e9-9b4c-6fd59e785c84"
        },
        {
          "mutation_effect": {
            "description": "The class III BRAF G466V missense mutation is located in the kinase domain in exon 11 of the protein (PMID: 15035987, 28783719). This mutation has been reported in melanoma, lung cancer, colorectal cancer and cardio-facio-cutaneous syndrome (PMID: 28481359, 15046639, 26498038, 16439621, 22649091). Biological characterization of the BRAF G466V mutation has demonstrated that it is RAS dependent in its activation of the MAPK pathway, signals as a dimer with CRAF, and typically co-occurs with another driver mechanism that amplifies RAS signaling (PMID: 15035987, 26498038, 22649091, 16364920, 24202393, 28783719). Thus, when BRAF G466V is observed in melanoma, it typically co-occurs with an activating RAS mutation or NF1 inactivation, whereas when observed in non-small cell lung or colorectal cancers, it is associated with receptor tyrosine kinase (RTK) hyperactivation at the protein level (PMID: 28783719). Preclinical studies with lung cancer cell lines expressing BRAF G466V demonstrated sensitivity to treatment with TAK-632, TAE226 and RMC-4550 as measured by inhibition of cell proliferation and reduced ERK phosphorylation following treatment (PMID: 26090892, 27523909, 30104724). Other preclinical studies with patient-derived xenograft colorectal cancer models expressing BRAF G466V demonstrated resistance to treatment with PLX8394 as measured by continued ERK phosphorylation and inability to suppress tumor growth, and sensitivity to treatment with cetuximab as measured by reduced tumor growth and inhibition of ERK phosphorylation (PMID: 30559419). In a Phase II trial, three patients with non-small cell lung cancer harboring BRAF G466V were treated with vemurafenib and did not clinically respond to treatment (PMID: 31959346). In another Phase II trial, a patient with lung adenocarcinoma harboring BRAF G466V was treated with trametinib and demonstrated progressive disease (PMID: 31924734). In a case report, a patient with metastatic colorectal cancer harboring BRAF G466V was treated with a combination therapy of irinotecan plus panitumumab and demonstrated a partial response with a progression-free survival of 6.1 months (PMID: 31515458).",
            "description_review": {
              "updateTime": 1678229857802,
              "updatedBy": "User"
            },
            "description_uuid": "a6f0c3d0-2313-455c-a9d5-a58c9a228afe",
            "effect": "Gain-of-function",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "4bd4a259-ff20-48b2-aa59-8d1202991f65",
            "oncogenic": "Yes",
            "oncogenic_review": {
              "updateTime": 1529422792550,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "b6105994-7ba4-42af-b463-1b0eb367d81a",
            "short": ""
          },
          "mutation_effect_uuid": "7432f4fe-2702-44e9-86a2-2ab0d45b617c",
          "name": "G466V",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "91cb3f47-ea75-4014-8ea8-ac0d2fa8b438"
        },
        {
          "mutation_effect": {
            "description": "The class II BRAF G469A mutation is located in the kinase domain in exon 11 of the protein (PMID: 28783719, 26343582). This mutation has been reported in melanoma, non-small cell lung cancer and cardio-facio-cutaneous syndrome (PMID: 12068308, 23833300, 16439621). Biological characterization of the BRAF G469A mutation demonstrated that it activates the downstream MAPK pathway independently of RAS and renders BRAF active as a dimer with CRAF and itself (PMID: 12068308, 23833300, 26343582, 20179705, 22510884). Ectopic expression of BRAF G469A in drug-sensitive EGFR-mutant cells conferred resistance to EGFR TKIs that was overcome by addition of a MEK inhibitor (PMID: 22773810). Preclinical studies with patient-derived lung adenocarcinoma cells expressing BRAF G469A demonstrated sensitivity to treatment with LXH 254, lifirafenib and dabrafenib plus trametinib, as measured by inhibition of cell growth, and resistance to treatment with LY3214996, MK-8353, ravoxertinib, ulixertinib, TAK-580, vemurafenib and dabrafenib, as measured by persistent cell growth (PMID: 32540409). In a clinical study, patients with metastatic colorectal cancer harboring BRAF G469A were treated with cetuximab plus FOLFIRI, cetuximab plus irinotecan or panitumumab plus irinotecan and each treatment group demonstrated stable disease with a progression-free survival of 4.4 months, 3.5 months and 4.0 months, respectively (PMID: 31515458). In a Phase I trial, a patient with head and neck cancer and a patient with small bowel cancer, both harboring BRAF G469A, were treated with ulixertinib and demonstrated partial response (PMID: 29247021). In a Phase II trial, a patient with lung adenocarcinoma harboring BRAF G469A was treated with trametinib and demonstrated stable disease with a progression-free survival of 20.4 months (PMID: 31924734). In another Phase II trial, two patients with advanced solid tumors harboring BRAF G469A were treated with vemurafenib and did not clinically respond to treatment (PMID: 29320312).",
            "description_review": {
              "updateTime": 1678229913774,
              "updatedBy": "User"
            },
            "description_uuid": "ae5503f3-fed6-467b-8a18-4f4a80c3910f",
            "effect": "Gain-of-function",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "ab9c04c7-415e-41da-93cd-82cbb6ce102c",
            "oncogenic": "Yes",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "acc42ebe-bf76-4b5c-9c2c-59865e0f39f6",
            "short": ""
          },
          "mutation_effect_uuid": "183fc25e-566d-43c3-86e6-a32d19c4e3ac",
          "name": "G469A",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "a49d7c7b-5b6e-45fc-8529-46dfc0469aaa"
        },
        {
          "mutation_effect": {
            "description": "The class III BRAF G469E mutation is located in the kinase domain in exon 11 of the protein (PMID: 28783719). This mutation has been reported in melanoma, lung cancer, colorectal cancer and cardio-facio-cutaneous syndrome (PMID: 26498038, 18794803, 16439621). Biological characterization of the BRAF G469E mutation has demonstrated that it is RAS dependent in its activation of the MAPK pathway, signals as a dimer with CRAF, and typically co-occurs with another driver mechanism that amplifies RAS signaling (PMID: 15035987, 28783719, 15150094, 22510884). Thus, in melanoma, the G469E variant, similar to other class III BRAF mutants, would be expected to co-occur with activating RAS mutation or NF1 inactivation, whereas in non-small cell lung or colorectal cancers, this mutation would most likely be associated with receptor tyrosine kinase (RTK) hyperactivation at the protein level (PMID: 28783719). Preclinical studies with melanoma cells expressing BRAF G469E demonstrated sensitivity to treatment with sorafenib, as measured by inhibition of growth and induced apoptosis, and resistance to treatment with U0126, as measured by persistent cell growth (PMID: 18794803). In a Phase II trial, a patient with breast ductal carcinoma harboring BRAF G469E was treated with trametinib and demonstrated partial response with a 50% tumor size reduction (PMID: 31924734).",
            "description_review": {
              "updateTime": 1678405381049,
              "updatedBy": "User"
            },
            "description_uuid": "7a0e2ecc-89bd-44aa-b6ef-afd759e6a82d",
            "effect": "Gain-of-function",
            "effect_review": {
              "updateTime": 1504815396977
            },
            "effect_uuid": "2bb6b849-bcd7-4f63-b423-6d2f5260e49c",
            "oncogenic": "Yes",
            "oncogenic_review": {
              "updateTime": 1529423027024,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "1ec9dffe-c9c5-4aa0-8439-5aca0e35730f",
            "short": ""
          },
          "mutation_effect_uuid": "bd84291a-5f68-43da-90d4-7568a1cb1008",
          "name": "G469E",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "809d33cc-d8a6-4d84-8bd9-e186fa7d3402"
        },
        {
          "mutation_effect": {
            "description": "The BRAF G469L mutation is located in the protein's kinase domain in exon 11. While this mutation has not been functionally characterized, other substitutions at this position (e.g., G469R) have been shown to be activating and oncogenic (PMID: 24920063 ). This mutation was found in a patient with non-small cell lung cancer who failed to respond to treatment with vemurafenib (PMID: 24035431).",
            "description_review": {
              "updateTime": 1493057315640
            },
            "description_uuid": "d17a1bdf-44a5-452b-a48c-a60e748c173e",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "29e7843e-2973-4cc5-9288-3a3f17757604",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "10eb50de-c687-463b-811a-6271aaef3431",
            "short": ""
          },
          "mutation_effect_uuid": "42bd253a-b50b-435d-8be5-fccf7de5e41e",
          "name": "G469L",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "af6e6e57-19ec-4c5c-9665-76c0038dd93b"
        },
        {
          "mutation_effect": {
            "description": "The class II BRAF G469R mutation is located in the kinase domain in exon 11 of the protein (PMID: 28783719, 26343582). This mutation has been reported in non-small cell lung cancer, chronic lymphocytic leukemia, melanoma and a range of other cancer types (PMID: 26498038, 24920063, 16096377, 26150740, 26619011). Biological characterization of the BRAF G469R mutation demonstrated that it activates the downstream MAPK pathway independent of RAS renders BRAF active as a dimer with CRAF and itself (PMID: 26343582, 28783719, 20179705). While sensitive to MEK inhibition by targeted inhibitors such as trametinib, this mutation is insensitive to RAF monomer inhibitors such as vemurafenib (PMID: 26343582, 28783719, 18794803, 26343582, 28783719). In a Phase II trial, a patient with melanoma harboring BRAF G469R and KIT G12V was treated with trametinib and demonstrated stable disease with a progression-free survival of 22.3 months (PMID: 33861486).",
            "description_review": {
              "updateTime": 1678303851582,
              "updatedBy": "User"
            },
            "description_uuid": "2ec0cc82-c365-499b-916d-d200af91b65c",
            "effect": "Gain-of-function",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "75cc7602-ac02-434e-89b6-5551765ba3a5",
            "oncogenic": "Yes",
            "oncogenic_review": {
              "updateTime": 1529422716158,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "f8af2c28-f6db-41e3-94d8-b1a27435331c",
            "short": ""
          },
          "mutation_effect_comments": [
            {
              "content": "deleted first sentence \"The BRAF G469R mutation is known to be oncogenic.\"",
              "date": "1479755120503",
              "email": "user@gmail.com",
              "resolved": "false",
              "userName": "User"
            }
          ],
          "mutation_effect_uuid": "a8f850c5-56e1-43b3-bb21-3945a99777a7",
          "name": "G469R",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "856f3e36-8103-448f-9242-0b339a300164"
        },
        {
          "mutation_effect": {
            "description": "The class II BRAF G469V mutation is located in the kinase domain in exon 11 of the protein (PMID: 28783719, 26343582). This mutation has been reported in non-small cell lung cancer and bladder cancer (PMID: 25870796, 27388325, 23401075). Biological characterization of the BRAF G469V mutation demonstrated that it activates the downstream MAPK pathway independently of RAS and renders BRAF active as a dimer with CRAF and itself (PMID: 26343582, 28783719, 20179705). Preclinical studies with SKBR3 cells expressing BRAF G469V demonstrated resistance to treatment with vemurafenib as measured by persistent MEK and ERK activation following treatment (PMID: 26343582). In a case report, two patients with metastatic colorectal cancer harboring BRAF G469V were treated with either panitumumab plus FOLFOX or cetuximab plus irinotecan and both treatment options demonstrated partial response with a progression-free survival of 18.9 months and 10.9 months, respectively (PMID: 31515458). In another case report, a patient with lung adenocarcinoma harboring BRAF G469V was treated with combination therapy of trametinib and dabrafenib and progressed after nine weeks of treatment (PMID: 32540409). In another case report, a patient with hepatocellular carcinoma and non-small cell lung cancer harboring BRAF G469V was treated with sorafenib and demonstrated a complete response in the lung and stability of the hepatocellular carcinoma (PMID: 27388325).",
            "description_review": {
              "updateTime": 1678405737584,
              "updatedBy": "User"
            },
            "description_uuid": "e3c85ef4-5c10-42b5-b919-1d53c79fcb1b",
            "effect": "Gain-of-function",
            "effect_review": {
              "updateTime": 1529422690583,
              "updatedBy": "User"
            },
            "effect_uuid": "94fe5461-1eb2-432a-9b78-a2e7d2e26cb7",
            "oncogenic": "Yes",
            "oncogenic_review": {
              "updateTime": 1529422687878,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "b8f3cd76-e1a5-4bd1-96c4-7a5241b5fe8b",
            "short": ""
          },
          "mutation_effect_uuid": "d9cd1b87-175f-45ac-82da-a03f5ac6aa6b",
          "name": "G469V",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "21cbf3ef-24d1-4ec4-bddb-cf301db44d78"
        },
        {
          "mutation_effect": {
            "description": "The BRAF G469del mutation is located in the kinase domain in exon 11 of the protein. This mutation has been found in non-small cell lung cancer (PMID: 23833300). Expression of this mutation in NIH-3T3 cells demonstrated that though in vitro kinase activity and in vivo downstream MEK and ERK activation were decreased compared to wildtype BRAF, colony formation was mildly increased compared to wildtype BRAF (PMID: 23833300).",
            "description_review": {
              "updateTime": 1493057315640
            },
            "description_uuid": "ae5d976d-5edf-44d5-a2ff-a3f64cf0113c",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "687e219a-c2f3-4559-b626-101529bf2bf0",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "31844270-7a3e-4505-88f9-d75959551599",
            "short": ""
          },
          "mutation_effect_uuid": "5cb3d836-affd-4c4e-aec1-bf63f162ade2",
          "name": "G469del",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "89294792-2f42-4c99-be47-28aaef2c25ee"
        },
        {
          "mutation_effect": {
            "description": "The BRAF S151A mutation is located proximal to the RAS-binding domain in exon 3 of the protein. Expression of this mutation in NHEM cells demonstrated that it is likely activating, as measured by increased binding of BRAF to NRAS (PMID: 21478863). As the S151 residue of BRAF is a suspected site of negative-regulatory phosphorylation of BRAF by ERK, mutation of this serine to alanine would be predicted to result in increased BRAF activity (PMID: 21478863).",
            "description_review": {
              "updateTime": 1493057315640
            },
            "description_uuid": "7f1eb310-91ad-4de9-bfb4-930b70a005eb",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "b67cc890-136d-4b8f-978d-643d6acd35f4",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "6877f3c4-e48a-42d4-bed6-0d55a2a9c10d",
            "short": ""
          },
          "mutation_effect_uuid": "c4f8b178-ab11-4de8-87e6-95753e7cf6f4",
          "name": "S151A",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "6094baf3-5fe9-4ddb-bb64-2c45bbbaea34"
        },
        {
          "mutation_effect": {
            "description": "The BRAF Q201H mutation is located in the RAS-binding domain in exon 4 of the protein. This mutation has been found in an ovarian cancer cell line (PMID: 18060073). While this mutation has not been functionally validated, SIFT prediction software predicted that this mutation would likely be neutral (PMID: 18060073).",
            "description_review": {
              "updateTime": 1493057315640
            },
            "description_uuid": "dc0e2d26-5e63-4a7c-9e7c-808ab9c5d4d0",
            "effect": "Inconclusive",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "9f372272-5687-477b-9727-e2ea8ae52574",
            "oncogenic": "Inconclusive",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "3bb6e5b5-4599-40e7-930e-de0be6fa52f4",
            "short": ""
          },
          "mutation_effect_uuid": "a99d2fab-4654-482d-b55c-fabf9d6ef2f4",
          "name": "Q201H",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "64d72153-68b5-4101-88e7-2dfc3e6f6dba"
        },
        {
          "mutation_effect": {
            "description": "The BRAF T241P mutation is located in the cysteine-rich domain in exon 6 of the protein. This mutation has been found in cardio-facio-cutaneous syndrome (CFC) (PMID: 19206169). Expression of this mutation in NIH-3T3 cells demonstrated that it is likely activating as measured by moderately increased activation of MEK and ERK and slightly increased colony formation compared to wildtype BRAF (PMID: 19206169).",
            "description_review": {
              "updateTime": 1562970750904,
              "updatedBy": "User"
            },
            "description_uuid": "2f9bdf6f-98a8-423e-b149-75132305c563",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "274d4c28-1e34-4982-872d-414ea59a5b73",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "d86aa3d7-afc8-4512-b4ad-03e1fcbec9fe",
            "short": ""
          },
          "mutation_effect_uuid": "3f32dcb1-c447-49c0-aac9-af0b6c5891c8",
          "name": "T241P",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "8863f254-b502-4889-9186-58c8f95b550e"
        },
        {
          "mutation_effect": {
            "description": "The BRAF A246P mutation is located in the cysteine-rich domain in exon 6 of the protein. This mutation is found in cardio-facio-cutaneous (CFC) syndrome (PMID: 16474404). Expression of BRAF A246P in NIH-3T3 cells engineered to concurrently express an ERK-dependent luciferase construct demonstrated that this mutation is activating, as measured by increased luciferase activity compared to wildtype BRAF (PMID: 16474404). Single-molecule binding assays with BRAF A246P also demonstrate that the mutation is activating as measured by increased RAS binding affinity compared to wildtype (PMID: 24409384). Preclinical studies with zebrafish embryos expressing BRAF A246P demonstrated sensitivity to treatment with MEK inhibitors CI-1040 and PD0325901 as measured by the prevention of CFC development (PMID: 19376813).",
            "description_review": {
              "updateTime": 1678135389291,
              "updatedBy": "User"
            },
            "description_uuid": "9168292b-62f9-4cdb-815b-76f0eff61cd2",
            "effect": "Gain-of-function",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "f0a7fcca-369a-4d7d-b125-ac14c41ddc57",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "de63a301-2e58-4312-abe2-cae003e0d59c",
            "short": ""
          },
          "mutation_effect_uuid": "3842ac90-4bd7-4d9d-8a100-05aec33de868",
          "name": "A246P",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "4736e881-0a19-429b-a7a4-6222992cec86"
        },
        {
          "mutation_effect": {
            "description": "The class II BRAF Q257R mutation is located in the cysteine-rich domain in exon 6 of the protein (PMID: 33019809). This mutation has been found in cardio-facio-cutaneous syndrome (PMID: 16474404, 16439621). Expression of this mutation in NIH-3T3 cells demonstrated that this mutation is activating as measured by increased transcription of downstream MAPK pathway transcriptional targets (e.g., ELK) compared to wildtype BRAF (PMID: 16474404). When expressed in zebrafish embryos, the Q257R mutation causes the same aberrant elongation phenotype as BRAF V600E, suggesting that it is likely activating in vivo (PMID: 19376813).",
            "description_review": {
              "updateTime": 1678309412838,
              "updatedBy": "User"
            },
            "description_uuid": "ddb7513f-18de-437d-b785-2f3e9f319600",
            "effect": "Gain-of-function",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "eef8ecb6-23d2-442e-927d-d5350813178d",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "d53d983d-004b-4658-896b-f9d5fd19e085",
            "short": ""
          },
          "mutation_effect_uuid": "4f612355-aae9-4974-bb100-df803dcd5692",
          "name": "Q257R",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "267ce895-2e5a-4c84-9087-4cb65957762a"
        },
        {
          "mutation_effect": {
            "description": "The BRAF E275K mutation is located in the cysteine-rich domain in exon 6 of the protein. This mutation has been found in cardio-facio-cutaneous syndrome (PMID: 19206169). Expression of this mutation in NIH-3T3 cells demonstrated that it is activating as measured by increased colony formation despite decreased MEK and ERK phosphorylation compared to wildtype BRAF (PMID: 19206169).",
            "description_review": {
              "updateTime": 1493057315640
            },
            "description_uuid": "be767ac3-a025-4db1-a6d6-e8c82aa8904c",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "0142dec9-1c86-41f8-a39e-a2c12c36d6dd",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "bcd54ffa-98df-4028-9e75-d5858ab5aed2",
            "short": ""
          },
          "mutation_effect_uuid": "82b53747-14f4-4500-8e63-1082e5441c2b",
          "name": "E275K",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "4003a5ad-221d-41bc-a3c0-d4aab09fc20a"
        },
        {
          "mutation_effect": {
            "description": "The class III BRAF D287H mutation occurs in the cysteine-rich domain in exon 6 of the protein (PMID: 28783719). Biological characterization of the BRAF D287H mutation has demonstrated that it is RAS dependent in its activation of the MAPK pathway, signals as a dimer with CRAF, and typically co-occurs with another driver mechanism that amplifies RAS signaling (PMID: 26343582, 28783719). In melanoma, the D287H variant, similar to other class III BRAF mutants, would be expected to co-occur with activating RAS mutation or NF1 inactivation, whereas in non-small cell lung or colorectal cancers, this mutation would most likely be associated with receptor tyrosine kinase (RTK) hyperactivation at the protein level (PMID: 28783719). While this mutation is sensitive to MEK inhibition by targeted inhibitors such as trametinib, it is insensitive to RAF monomer inhibitors such as vemurafenib (PMID: 28783719).",
            "description_review": {
              "updateTime": 1678135581520,
              "updatedBy": "User"
            },
            "description_uuid": "a90f2f6c-c2a4-4938-b590-1db02338540e",
            "effect": "Gain-of-function",
            "effect_review": {
              "updateTime": 1504815187060
            },
            "effect_uuid": "05840d43-e046-488f-bcd9-42517eee4a78",
            "oncogenic": "Yes",
            "oncogenic_review": {
              "updateTime": 1529422766024,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "33f20b93-a5aa-46ba-83b1-26871c2016bf",
            "short": ""
          },
          "mutation_effect_uuid": "524b639e-b13a-4414-b549-48e77c07140a",
          "name": "D287H",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "cd019401-39a1-4549-834d-2c7dda69a7e4"
        },
        {
          "mutation_effect": {
            "description": "The BRAF I326V mutation is located in the flexible hinge domain of the BRAF protein. This mutation has been found as a germline mutation in Noonan Syndrome (PMID: 17603482). In vitro studies have demonstrated that this mutation is likely neutral as measured by downstream signaling compared to wildtype (PMID: 17603482). In a clinical study, a patient with colorectal cancer harboring BRAF I326V was treated with panitumumab and irinotecan plus S-1 and demonstrated progressive disease (PMID: 30463788).",
            "description_review": {
              "updateTime": 1678304483185,
              "updatedBy": "User"
            },
            "description_uuid": "38c7aa27-a14b-45cf-ad40-39d90f37a7ea",
            "effect": "Likely Neutral",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "c81b4261-e7a5-49db-80fc-e85e54ab4055",
            "oncogenic": "Likely Neutral",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "0cb22fc2-ff96-4abc-adb1-82fcee800dd6",
            "short": ""
          },
          "mutation_effect_uuid": "852af2cc-f51b-4ab1-8be5-55568776abc3",
          "name": "I326V",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "28bf9846-db83-40ec-8b3f-473de9e96177"
        },
        {
          "mutation_effect": {
            "description": "The class III hypoactivating exon 6 BRAF V459L missense mutation occurs in the cysteine-rich domain of the protein (PMID: 28783719). This mutation has been reported in lung cancer and melanoma (PMID: 12460918). BRAF V459L signals as a dimer with CRAF, is RAS-dependent in its activation of the MAPK pathway, and, in tumors, would typically co-occur with another driver mechanism that amplifies RAS signaling (PMID: 28783719). Thus, like other class III BRAF mutants, in melanoma, the V459L variant would be expected to co-occur with activating RAS mutation or NF1 inactivation, whereas in non-small cell lung and colorectal cancers, this mutation would most likely be associated with receptor tyrosine kinase (RTK) hyperactivation at the protein level (PMID: 28783719). While this mutation is sensitive to MEK inhibition by targeted inhibitors such as trametinib, it is insensitive to RAF monomer inhibitors such as vemurafenib.",
            "description_editing": "",
            "description_review": {
              "updateTime": 1674849242769,
              "updatedBy": "User"
            },
            "description_uuid": "fa4d851c-0374-4057-9691-88a218dea418",
            "effect": "Gain-of-function",
            "effect_review": {
              "updateTime": 1504814944364
            },
            "effect_uuid": "74cb3e73-70a1-43c1-bb48-50a77184ce71",
            "oncogenic": "Yes",
            "oncogenic_review": {
              "updateTime": 1529422779361,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "7269fee4-78fd-4b9f-9589-35ff6398cb79",
            "short": ""
          },
          "mutation_effect_uuid": "dd32894d-a4d1-428c-97c0-637ac59c9758",
          "name": "V459L",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "00f0eb02-6cac-4e64-9bb3-6d2f6ec47e92"
        },
        {
          "mutation_effect": {
            "description": "The BRAF R462E mutation is located in the kinase domain of the BRAF protein. In vitro studies have demonstrated that the BRAF L597S mutation is likely activating as measured by CRAF activity and downstream signaling compared to wildtype (PMID: 25155755).",
            "description_review": {
              "updateTime": 1600636927757,
              "updatedBy": "User"
            },
            "description_uuid": "efa626c3-4230-45d3-9fc7-557e300a8088",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "612a0f55-afdf-4931-abbc-16550552dd4c",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "60619485-6bf6-456b-99bd-bf3ca8dd3286",
            "short": ""
          },
          "mutation_effect_uuid": "b8e0bca5-960e-4b17-ac9a-26265f1bccb7",
          "name": "R462E",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "2c445952-85a1-4c13-87a2-56d48f415630"
        },
        {
          "mutation_effect": {
            "description": "The class II BRAF R462I mutation is located in the kinase domain in exon 11 of the protein (PMID: 35050937). This mutation has been found in colorectal cancer (PMID: 15150094). Expression of this mutation in NIH-3T3 or IEC-6 cells demonstrated that this mutation is neutral as measured by kinase activity, foci-formation and cell proliferation comparable to wildtype BRAF (PMID: 15150094, 15035987). Additionally, expression of this mutation with HRAS G12V failed to activate the MAPK pathway either as a monomer or a dimer with CRAF, suggesting it is not activating (PMID: 15150094).",
            "description_review": {
              "updateTime": 1678309431253,
              "updatedBy": "User"
            },
            "description_uuid": "d10166f3-c441-46b0-86e6-06d5276b89fd",
            "effect": "Likely Neutral",
            "effect_review": {
              "updateTime": 1549240989790,
              "updatedBy": "User"
            },
            "effect_uuid": "89566b58-387b-4ade-bec1-847857ef762a",
            "oncogenic": "Likely Neutral",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "36c50b89-b6e6-4761-ade8-349acdcd73f1",
            "short": ""
          },
          "mutation_effect_uuid": "ccdc264d-91bc-4f83-91b3-39ed05fecedd",
          "name": "R462I",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "2337a063-ca4b-4980-ad55-daecff41af9d"
        },
        {
          "mutation_effect": {
            "description": "The class II BRAF I463S mutation is located in the kinase domain in exon 11 of the protein (PMID: 33019809). This mutation has been found in colorectal cancer (PMID: 15150094). Expression of this mutation in NIH-3T3 or IEC-6 cells demonstrated that it is likely neutral, as measured by kinase activity, foci formation, and cell proliferation comparable to wildtype BRAF (PMID: 15150094, 15035987). Additionally, expression of BRAF I463S with HRAS G12V does not lead to increased MAPK pathway activation either alone as a monomer or through dimerization with CRAF (PMID: 15150094).",
            "description_review": {
              "updateTime": 1678304524800,
              "updatedBy": "User"
            },
            "description_uuid": "251a36be-8b7c-427e-9d31-c144a733314d",
            "effect": "Likely Neutral",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "d5c4b6b2-1741-441c-ac40-b223d4060c9b",
            "oncogenic": "Likely Neutral",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "26295e28-2d03-4e12-b4c1-b70e00c7166c",
            "short": ""
          },
          "mutation_effect_uuid": "046f4440-45aa-4408-ba9c-729f414f0348",
          "name": "I463S",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "26d7494b-48af-4633-8523-d6fc9f612c8b"
        },
        {
          "mutation_effect": {
            "description": "The class III BRAF S467A mutation is located in the kinase domain in exon 11 of the protein (PMID: 35050937). This mutation has been found in cardio-facio-cutaneous syndrome (PMID: 16439621). Expression of this mutation in 293T cells demonstrated that this mutation is activating as measured by increased activation of downstream MAPK effectors compared to wildtype BRAF (PMID: 16439621). When expressed in zebrafish embryos, the BRAF S467A mutation causes the same aberrant elongation phenotype as BRAF V600E, suggesting that it is likely activating in vivo (PMID: 19376813).",
            "description_review": {
              "updateTime": 1678390521103,
              "updatedBy": "User"
            },
            "description_uuid": "9f4be1bd-7a87-4764-8bbe-dbaaf8fa4fbf",
            "effect": "Gain-of-function",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "b1f6b30a-c28b-4f4b-b0fd-04e76e8b5d9d",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "94d0f8da-898a-4f3a-9674-d2e8d7a4dec1",
            "short": ""
          },
          "mutation_effect_uuid": "c7e18196-cdb5-449c-83f2-c8c3afda74f6",
          "name": "S467A",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "5008fef8-d51e-48ce-bf53-0393f0b6673d"
        },
        {
          "mutation_effect": {
            "description": "The BRAF F468C mutation is located in the kinase domain in exon 11 of the protein. This mutation has been found in colorectal cancer (PMID: 15150094). Expression of this mutation in NIH-3T3 cells demonstrated that it is activating as measured by increased in vitro kinase activity, increased proliferation and increased foci formation compared to wildtype BRAF (PMID: 15150094).",
            "description_review": {
              "updateTime": 1493057315640
            },
            "description_uuid": "a5a07f95-8401-42b8-a7b9-894215436546",
            "effect": "Gain-of-function",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "9665e855-859a-42c2-b65e-fceb34f4b3ab",
            "oncogenic": "Yes",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "391497af-3c28-4451-8b55-b4af8b0278c5",
            "short": ""
          },
          "mutation_effect_uuid": "076544cd-be01-42fc-8d30-150074d582d4",
          "name": "F468C",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "07f03146-e998-469f-9bbe-890afd9aa6fe"
        },
        {
          "mutation_effect": {
            "description": "The class II BRAF V471F mutation is located in the kinase domain in exon 11 of the protein (PMID: 33019809). Expression of this mutation in 293T cells demonstrated that this mutation is activating as measured by increased downstream pathway activation and moderate transforming activity compared to wildtype BRAF (PMID: 25348715). Though this mutation is kinase-dead, it activates the MAPK pathway by dimerizing with CRAF (PMID: 25348715).",
            "description_review": {
              "updateTime": 1678405862010,
              "updatedBy": "User"
            },
            "description_uuid": "9d14c4c0-20ba-4f86-bcf6-24b359a6ced1",
            "effect": "Gain-of-function",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "a97a1859-463d-44b0-a455-7708ac87643d",
            "oncogenic": "Yes",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "9152f85c-59b4-4978-b42a-315ea2528a46",
            "short": ""
          },
          "mutation_effect_uuid": "e251d33d-21ee-4289-90fd-0d52a34ce816",
          "name": "V471F",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "0bca5935-6195-425b-a7bc-d4fb00bbd6bf"
        },
        {
          "mutation_effect": {
            "description": "The BRAF Y472C mutation is located in the kinase domain in exon 11 of the protein. This mutation is found in non-small cell lung cancer (PMID: 22649091). Expression of this mutation in COS7, H661, or H226 cells demonstrated that it is activating as measured by increased downstream MEK and ERK activation compared to wildtype BRAF, despite having impaired kinase activity (PMID: 22649091). Similar to other kinase-inactivating BRAF mutations, the Y472C mutant promotes downstream oncogenic signaling (via MEK/ERK pathway) by transactivating CRAF, and therefore is considered to be likely oncogenic in the clinical setting (PMID: 22649091). In a Phase II trial, a patient with non-small cell lung cancer harboring BRAF Y472C was treated with dasatinib and demonstrated a complete response (PMID: 20855820).",
            "description_review": {
              "updateTime": 1678405896317,
              "updatedBy": "User"
            },
            "description_uuid": "0f7fc335-4586-41ec-a184-cf6b0e52da54",
            "effect": "Gain-of-function",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "38abf378-98d7-47ca-b0b7-d277dfcc627f",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "f1f455b0-d3f4-4086-aee9-7af13bf507f0",
            "short": ""
          },
          "mutation_effect_uuid": "afae69e4-2bc4-467e-85cf-d8f57d17939f",
          "name": "Y472C",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "c08333f4-0699-4a87-b328-4fc9e508e5ad"
        },
        {
          "mutation_effect": {
            "description": "The BRAF G478C mutation is located in the kinase domain in exon 12 of the protein. This mutation was engineered to mimic the ARAF G331C mutation (PMID: 22926515). Expression of this mutation in COS-7 cells demonstrated that this mutation is inactivating, as shown by abolished kinase activity compared to wildtype BRAF (PMID: 22926515).",
            "description_review": {
              "updateTime": 1493057315640
            },
            "description_uuid": "9c8377c5-deb3-4548-b79d-2bfe65769bb2",
            "effect": "Loss-of-function",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "52557f96-60a6-4b41-9fba-74de217198da",
            "oncogenic": "Likely Neutral",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "290eff4d-b13d-419b-8e92-693f1f479f96",
            "short": ""
          },
          "mutation_effect_uuid": "c933c006-8e2a-42cd-bb58-f05db19624ef",
          "name": "G478C",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "737b0b24-687f-4535-bf11-c2cdb5326600"
        },
        {
          "mutation_effect": {
            "description": "The class III BRAF K483E mutation occurs in the tyrosine kinase domain of the BRAF protein (PMID: 33019809). This mutation has been identified in a patient diagnosed with pediatric poorly differentiated carcinoma (PMID: 27799065). Overexpression of this variant in 293T cells resulted in activation of MEK1/2, however, the activation was comparable to overexpression of wildtype BRAF (PMID: 27799065). Activation likely occurs via allosteric activation of BRAF or CRAF because of the lack of BRAF K483E kinase activity (PMID: 27799065). Preclinical studies with patient-derived colorectal cancer organoids expressing BRAF K483E demonstrated sensitivity to treatment with binimetinib as measured by decreased cell viability, and resistance to treatment with cetuximab as measured by no change in cell viability (PMID: 33060766).",
            "description_review": {
              "updateTime": 1678405927861,
              "updatedBy": "User"
            },
            "description_uuid": "07494578-299b-4676-a5d5-dbf790479204",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1484758354000
            },
            "effect_uuid": "0be98f82-fc8b-47a0-9ccc-7413b607a840",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "7dfeeb0c-1c68-417c-9267-78d3ccd709eb",
            "short": ""
          },
          "mutation_effect_uuid": "a1a45ad7-5586-4a76-a0e4-e66dc14a0c4f",
          "name": "K483E",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "893108b6-091a-44da-8ce0-228b0943ff45"
        },
        {
          "mutation_effect": {
            "description": "The class III BRAF K483M mutation is located in the kinase domain of the BRAF protein (PMID: 15035987). In vitro studies have demonstrated that this mutation is likely activating as measured by CRAF activation and downstream signaling compared to wildtype (PMID: 15035987, 23533272). Preclinical studies with D04 cells expressing BRAF K483M demonstrated sensitivity to treatment with sorafenib as measured by inhibition of MEK activation (PMID: 20141835).",
            "description_review": {
              "updateTime": 1678304576741,
              "updatedBy": "User"
            },
            "description_uuid": "7d766d5a-fdce-471f-b725-54a29eef9d81",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "a979f929-319b-4dad-917f-ba9414e5d0f6",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "e3a61279-8c09-41f0-83aa-2903fc667917",
            "short": ""
          },
          "mutation_effect_uuid": "bff046a8-ee5b-42f6-b7a9-57d5c7d5642d",
          "name": "K483M",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "e02171db-07d4-46e0-a898-a6ba4937dc32"
        },
        {
          "mutation_effect": {
            "description": "The class II BRAF L485F mutation is located in the kinase domain in exon 11 of the protein (PMID: 31515458). This mutation has been found in cardio-facio-cutaneous syndrome (PMID: 16474404, 16439621). Expression of this mutation in NIH-3T3 cells demonstrated that it is activating as measured by significantly increased transcription of downstream MAPK pathway transcriptional targets (e.g., ELK) compared to wildtype BRAF (PMID: 16474404). Preclinical studies with 293T cells expressing BRAF L485F demonstrated sensitivity to treatment with LY3009120, as measured by inhibition of ERK signaling, and resistance to treatment with dabrafenib, PLX8394 and vemurafenib, as measured by persistent ERK signaling (PMID: 34108213). In a clinical study, a patient with metastatic colorectal cancer harboring BRAF L485F was treated with a combination therapy of cetuximab plus irinotecan and demonstrated stable disease with a progression-free survival of 6.3 months (PMID: 31515458).",
            "description_review": {
              "updateTime": 1678307030508,
              "updatedBy": "User"
            },
            "description_uuid": "dc664875-7c76-4496-b647-4fa05f13b293",
            "effect": "Gain-of-function",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "839326e3-e318-490f-aefb-5d1cc6446c31",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "7d10414f-305b-4724-9b43-f6544d241b44",
            "short": ""
          },
          "mutation_effect_uuid": "c1c8bb08-5ec4-4134-ab32-3031b18c51df",
          "name": "L485F",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "ac68f13a-73d5-4c72-92e0-b5ddf4ae61b0"
        },
        {
          "mutation_effect": {
            "description": "The class II BRAF K499E mutation is located in the kinase domain in exon 12 of the protein (PMID: 33019809). This mutation has been found in cardio-facio-cutaneous syndrome (PMID: 16474404, 16439621). Expression of this mutation in NIH-3T3 cells demonstrated that it is activating as measured by significantly increased transcription of downstream MAPK pathway transcriptional targets (e.g., ELK) compared to wildtype BRAF (PMID: 16474404).",
            "description_review": {
              "updateTime": 1678304623776,
              "updatedBy": "User"
            },
            "description_uuid": "541ecf11-dc20-45ce-a80e-c24996a5fecc",
            "effect": "Gain-of-function",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "d46a95e1-2983-436e-9368-5485cf138059",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "cb00df9d-198b-4dad-9bf7-65978cb68d7f",
            "short": ""
          },
          "mutation_effect_uuid": "138706e4-f43e-4ecc-a6d4-b9b95c249e97",
          "name": "K499E",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "cc9e1bcd-3967-4029-8656-1d03d8c6ace7"
        },
        {
          "mutation_effect": {
            "description": "The BRAF E501G mutation is located in the kinase domain in exon 12 of the protein. This mutation has been found in cardio-facio-cutaneous (CFC) syndrome (PMID: 16439621). Expression of BRAF E501G in NIH-3T3 cells demonstrated that this mutation is slightly loss of function and therefore likely not oncogenic, as measured by MAPK pathway activation in the form of downstream ELK transcription comparable to or less than wildtype BRAF (PMID: 26065894, 16474404, 16439621).",
            "description_review": {
              "updateTime": 1549241556862,
              "updatedBy": "User"
            },
            "description_uuid": "c9fa691b-b33f-418a-8993-d0c9aad102b0",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1549241493539,
              "updatedBy": "User"
            },
            "effect_uuid": "2662435c-a398-48e3-ad80-840da9137e2b",
            "oncogenic": "Likely Neutral",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "ef03b869-b19a-406d-805f-6dc48d4c0c48",
            "short": ""
          },
          "mutation_effect_uuid": "e835debc-ea5c-40fc-9b83-a6b7a55b38bf",
          "name": "E501G",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "874c8091-960f-4ae8-a10a-ddb40bfa1df9"
        },
        {
          "mutation_effect": {
            "description": "The BRAF E501K mutation is located in the kinase domain of the BRAF protein. This mutation has been found as a germline mutation in Noonan syndrome and cardio-facio-cutaneous syndrome (PMID: 17603482, 16474404). In vitro studies have demonstrated that this mutation might be inactivating as measured by decreased BRAF kinase activity in a cell line with a second BRAF mutation compared to controls (PMID: 17603482). However, another in vitro study found increased downstream pathway output compared to wildtype (PMID: 16474404). BRAF E501K is suggested to be RAS-dependent due to enrichment of RAS regulatory genes in tumors harboring the mutation in a pan-cancer genomic data analysis (PMID: 33507258).",
            "description_review": {
              "updateTime": 1678230317900,
              "updatedBy": "User"
            },
            "description_uuid": "ca514991-8c62-4ad9-bda4-ca7f2de1e01f",
            "effect": "Inconclusive",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "ec6aaa98-f05b-4a8d-bb3c-5e1b59380208",
            "oncogenic": "Inconclusive",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "139692b6-39a3-4cc0-a9f7-1879cd870b0f",
            "short": ""
          },
          "mutation_effect_uuid": "5d3af48e-11eb-41eb-aaa5-6c5d7e93d27a",
          "name": "E501K",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "7c540aad-43fc-4593-8f38-5e483540b20d"
        },
        {
          "mutation_effect": {
            "description": "The class II BRAF L505H mutation is located in the kinase domain in exon 12 of the protein (PMID: 33019809). This mutation has been found in prostate cancer (PMID: 24283590). Expression of this mutation in 293T cells or RWPE-1 prostate cells demonstrated that it is activating as measured by increased downstream activation of MEK and ERK as well as increased colony formation in soft agar compared to wildtype BRAF (PMID: 24283590). In vitro and in vivo studies of BRAF L505H suggest that this mutation is resistant to vemurafenib as measured by the occurrence of the L505H mutation in a vemurafenib resistance screen, sustained MAPK pathway signaling upon treatment with vemurafenib in cells expressing the mutation and sustained tumor growth in a xenograft model of melanoma cells harboring this mutation (PMID: 24283590, 24112705). In one study, one patient with metastatic melanoma harboring BRAF L505H had progressive disease in response to vemurafenib treatment (PMID: 25515853). In vitro studies, however, suggest that BRAF L505H is sensitive to selumetinib as measured by decreased MAPK pathway signaling upon drug treatment (PMID: 24283590).",
            "description_review": {
              "updateTime": 1678406132046,
              "updatedBy": "User"
            },
            "description_uuid": "360b2f0e-3b17-43d4-a6b7-fd9fa2d16270",
            "effect": "Gain-of-function",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "07f22e94-4359-4e3b-a747-1a846bbf7294",
            "oncogenic": "Yes",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "dfc4709e-b7be-4ea2-9784-a5cfd49b7b6d",
            "short": ""
          },
          "mutation_effect_uuid": "8fe54443-3381-4ed3-bce4-d6eb9831afa8",
          "name": "L505H",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "8bbbfc9e-1a79-4634-9a95-902551c43cfa"
        },
        {
          "mutation_effect": {
            "description": "The BRAF R509H mutation is located in the kinase domain in exon 13 of the protein. This mutation lies along the dimer interface of the protein. Expression of this mutation in 293H cells demonstrated that it is inactivating, as shown by decreased protein dimerization and decreased downstream cell signaling (PMID: 20179705).",
            "description_review": {
              "updateTime": 1678390679972,
              "updatedBy": "User"
            },
            "description_uuid": "36b94a36-91ff-4e71-8bd7-97c98d103f0a",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1702486841334,
              "updatedBy": "User"
            },
            "effect_uuid": "5ee9e9a1-ed4b-4e83-ab9d-9c2e3969ceea",
            "oncogenic": "Likely Neutral",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "b1152f1c-13e3-4fdb-b675-1c0f378d1014",
            "short": ""
          },
          "mutation_effect_uuid": "cf77ad31-4991-4553-b905-e8538c082e77",
          "name": "R509H",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "1dbace3e-34b8-48fb-83b3-391a770dc9ed"
        },
        {
          "mutation_effect": {
            "description": "The BRAF T529I mutation is located in the kinase domain in exon 13 of the protein. This alteration is considered a gatekeeper mutation as mutations at the analogous residue in other kinases are known to cause resistance to drugs that bind in the ATP-binding pocket (PMID: 15573099). Expression of this mutation in COS7 cells demonstrated it is likely neutral as measured by kinase activity comparable to wildtype BRAF (PMID: 20538618). However, expression with BRAF V600E in COS7 cells demonstrated that this mutation confers resistance to RAF inhibitors such as vemurafenib, but maintains sensitivity to MEK inhibitors (PMID: 20538618).",
            "description_review": {
              "updateTime": 1493057315640
            },
            "description_uuid": "2672051b-de97-409e-98ae-ba37ef0407d4",
            "effect": "Likely Neutral",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "cd172ba8-907b-446b-8fa5-999d9842636d",
            "oncogenic": "Likely Neutral",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "4fcd2047-f412-4b97-880d-cf0da88a2e43",
            "short": ""
          },
          "mutation_effect_uuid": "b7cfd1fc-6c99-48ae-8126-1afae0400034",
          "name": "T529I",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "2e4c5f9e-1255-4d56-bb14-41f59414ce8e"
        },
        {
          "mutation_effect": {
            "description": "The BRAF T529M mutation is located in the kinase domain in exon 13 of the protein. This alteration is considered a gatekeeper mutation as mutations at the analogous residue in other kinases are known to cause resistance to drugs that bind in the ATP-binding pocket (PMID: 15573099). Expression of this mutation in COS7 cells demonstrated it is likely neutral as measured by kinase activity comparable to wildtype BRAF (PMID: 20538618). However, expression with BRAF V600E in COS7 cells demonstrated that this mutation confers resistance to RAF inhibitors such as vemurafenib, but maintains sensitivity to MEK inhibitors (PMID: 20538618).",
            "description_review": {
              "updateTime": 1493057315640
            },
            "description_uuid": "3a57480d-a900-4c74-9294-3f0a17151daa",
            "effect": "Likely Neutral",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "ba37133a-b86e-4e2f-9c4a-3a20bba75a12",
            "oncogenic": "Likely Neutral",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "7f29f128-5d8b-4338-bc2c-de5e0d021224",
            "short": ""
          },
          "mutation_effect_uuid": "be5325a5-eba1-4e06-a636-39454a788d48",
          "name": "T529M",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "0362905f-6d03-4fec-b8ce-66857c2675ea"
        },
        {
          "mutation_effect": {
            "description": "The BRAF T529N mutation is located in the kinase domain in exon 13 of the protein. This alteration is considered a gatekeeper mutation as mutations at the analogous residue in other kinases are known to cause resistance to drugs that bind in the ATP-binding pocket (PMID: 15573099). Expression of this mutation in COS7 cells demonstrated it is likely neutral as measured by kinase activity comparable to wildtype BRAF (PMID: 20538618). However, expression with BRAF V600E in COS7 cells demonstrated that this mutation confers resistance to RAF inhibitors such as vemurafenib, but maintains sensitivity to MEK inhibitors (PMID: 20538618).",
            "description_review": {
              "updateTime": 1493057315640
            },
            "description_uuid": "a00a0e69-c979-4361-b7f0-3374ff12b1b5",
            "effect": "Likely Neutral",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "700df84a-fd4b-4548-bc55-645b5151c41c",
            "oncogenic": "Likely Neutral",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "78859ec7-08e2-4cde-be35-dc1a8251ebe3",
            "short": "This mutation of BRAF is not activating, but will likely occur in context of a pre-existing BRAF-V600E mutation.The T529N mutation confers resistance to RAF inhibitors PLX4720, SB590885, RAF265 and sorafenib (PMID: 20538618). Cells expressing this mutant form in context of V600E mutation were still sensitive to MAPK pathway inhibition by MEK inhibitor PD184352 (PMID: 20538618)"
          },
          "mutation_effect_uuid": "b4e5bdc0-bde8-493c-9d07-1b65d0728d98",
          "name": "T529N",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "0deff888-ee47-45a8-96da-edf372483a60"
        },
        {
          "mutation_effect": {
            "description": "The BRAF W531C mutation is located in the cysteine-rich domain in exon 6 of the protein. This mutation has been found in patients with cardio-facio-cutaneous syndrome (PMID: 19206169). There is conflicting evidence on the biological and oncogenic effect of this mutation. Expression of this mutation in NIH-3T3 cells demonstrated that this mutation is likely neutral, as measured by downstream pathway activation comparable to wildtype BRAF (PMID: 19206169). However, in vitro studies with Ba/F3 and MCF10A cells and in vivo studies with drosophila expressing BRAF W531C demonstrate that the mutation is activating as measured by increased MEK and ERK signaling and cellular proliferation (PMID: 29533785, 33855281).",
            "description_review": {
              "updateTime": 1678406167785,
              "updatedBy": "User"
            },
            "description_uuid": "b9c98d03-46ad-4baf-ab6d-7cff88878b31",
            "effect": "Inconclusive",
            "effect_review": {
              "updateTime": 1678390306992,
              "updatedBy": "User"
            },
            "effect_uuid": "5ba45d26-0662-48e4-aca8-af8d9790b5fb",
            "oncogenic": "Inconclusive",
            "oncogenic_review": {
              "updateTime": 1678390306557,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "26a09bcd-4109-4a76-b3ee-47b09f771091",
            "short": ""
          },
          "mutation_effect_uuid": "08f3c228-40ef-4aa0-bd70-b51fb79692bb",
          "name": "W531C",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "ae673dc1-9e3f-4f28-b63c-f37b15ba27ac"
        },
        {
          "mutation_effect": {
            "description": "The class III BRAF N581D mutation is located in the kinase domain in exon 15 of the protein and is a statistically significant hotspot (PMID: 3010472). This mutation is found in cardio-facio-cutaneous syndrome (PMID: 16474404). Expression of this mutation in NIH-3T3 cells demonstrated that it is likely neutral as measured by transcription of downstream MAPK pathway target genes (e.g., ELK) comparable to wildtype BRAF (PMID: 16474404). Preclinical studies with patient-derived xenograft models of non-small cell lung cancer expressing BRAF N581D demonstrated sensitivity to treatment with RMC-4550 as measured by tumor growth inhibition (PMID: 30104724).",
            "description_review": {
              "updateTime": 1678406333075,
              "updatedBy": "User"
            },
            "description_uuid": "cd4b7d80-bd78-48c6-960c-ba79ab578fb3",
            "effect": "Likely Neutral",
            "effect_review": {
              "updateTime": 1676410964092,
              "updatedBy": "User"
            },
            "effect_uuid": "102f2a9d-2991-464a-984f-13df8d99e510",
            "oncogenic": "Likely Neutral",
            "oncogenic_review": {
              "updateTime": 1676411152193,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "90e25372-22a3-4004-a2f9-84f2187fbcfa",
            "short": ""
          },
          "mutation_effect_uuid": "73d3c0e7-ba04-4ffa-ad61-9aa26aa32f85",
          "name": "N581D",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "f8319652-1a11-4191-9d3e-8071ca640353"
        },
        {
          "mutation_effect": {
            "description": "The class III BRAF N581S mutation is located in the kinase domain in exon 15 of the protein (PMID:28783719). This mutation has been reported in lung cancer, colorectal cancer and melanoma (PMID: 26498038). Biological characterization of the BRAF N581S mutation has demonstrated that it is RAS dependent in its activation of the MAPK pathway, signals as a dimer with CRAF, and typically co-occurs with another driver mechanism that amplifies RAS signaling (PMID: 15035987, 28783719). Thus, in melanoma, the N581S variant, similar to other class III BRAF mutants, would be expected to co-occur with activating RAS mutation or NF1 inactivation, whereas in non-small cell lung or colorectal cancers, this mutation would most likely be associated with receptor tyrosine kinase (RTK) hyperactivation at the protein level (PMID: 28783719).  Preclinical studies with patient-derived lung adenocarcinoma cells expressing BRAF N581S demonstrated sensitivity to treatment with a combination therapy of PF-477736 plus PF3644022 as measured by increased apoptosis (PMID: 26140595). In a Phase II trial, two patients with lung adenocarcinoma and gynecologic cancer harboring BRAF N581S were treated with trametinib and demonstrated progressive disease and stable disease, respectively (PMID: 31924734). In a case report, a patient with metastatic colorectal cancer harboring BRAF N581S was treated with a combination therapy of cetuximab plus FOLFIRI and demonstrated partial response with a progression-free survival of sixteen months (PMID: 31515458). In another Phase II trial, two patients with advanced solid tumors harboring the mutation were treated with vemurafenib and did not clinically respond to treatment (PMID: 29320312).",
            "description_review": {
              "updateTime": 1678406444586,
              "updatedBy": "User"
            },
            "description_uuid": "029b1dda-1a35-4e76-9326-3291d60eaa7f",
            "effect": "Gain-of-function",
            "effect_review": {
              "updateTime": 1504813469779
            },
            "effect_uuid": "db1a6f73-d838-41b4-9004-b2b5a0684b32",
            "oncogenic": "Yes",
            "oncogenic_review": {
              "updateTime": 1529423039011,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "d51426b1-b27b-42be-b84e-20cd1d12953d",
            "short": ""
          },
          "mutation_effect_uuid": "e9dae7ed-83eb-4d6f-92f5-a4e45f24f0a6",
          "name": "N581S",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "755fef81-4367-4a40-a8fa-315a374808ed"
        },
        {
          "mutation_effect": {
            "description": "The class III BRAF N581Y mutation is located in the kinase domain of BRAF in exon 13 (PMID: 30224342). This noncanonical BRAF mutation has been identified in a screen of colorectal cell lines and in a patient with melanoma (PMID: 19474002, 26084293). In vitro studies with Ba/F3 cells expressing BRAF N581Y demonstrate that the mutation is activating as measured by increased cell viability compared to wildtype (PMID: 32540409). The HT-55 colon cancer cell line harboring this mutation was insensitive to treatment with the GDC-0879 RAF kinase inhibitor (PMID: 19276360).",
            "description_review": {
              "updateTime": 1678309249026,
              "updatedBy": "User"
            },
            "description_uuid": "4d6a06fc-60de-4050-ba38-7553806b634c",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1678309252400,
              "updatedBy": "User"
            },
            "effect_uuid": "96dc7292-f9e2-4308-ac25-83ebc2eae671",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1678309250759,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "c4f7d30f-8184-4ffb-bf52-768f6c3cb365",
            "short": ""
          },
          "mutation_effect_uuid": "b96f082d-fb60-428a-943f-de229979acc2",
          "name": "N581Y",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "8f756ab2-b2f5-4c08-b72f-b329e4dc83fd"
        },
        {
          "mutation_effect": {
            "description": "The BRAF L584F mutation is located in the kinase domain of the BRAF protein. This mutation has been found in melanoma, as well as other cancers (PMID: 23658559, 26386083). In vitro studies have demonstrated that this mutation may be activating as measured by sensitivity to RAF inhibition compared to wildtype (PMID: 23658559).",
            "description_review": {
              "updateTime": 1601869003334,
              "updatedBy": "User"
            },
            "description_uuid": "5a88ea57-81f7-49af-b002-40ad8b3e3904",
            "effect": "Inconclusive",
            "effect_review": {
              "updateTime": 1600635485347,
              "updatedBy": "User"
            },
            "effect_uuid": "31484336-b5ef-4566-9139-0889007f5784",
            "oncogenic": "Inconclusive",
            "oncogenic_review": {
              "updateTime": 1601869042952,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "1c855bc9-a6bf-48d2-b7f9-3f26397c63a3",
            "short": ""
          },
          "mutation_effect_uuid": "456602df-32e3-40eb-8c4d-31bb96d5aba1",
          "name": "L584F",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "4cb98f57-3e54-4e7d-b053-5beddc33f80f"
        },
        {
          "mutation_effect": {
            "description": "The class II BRAF E586K mutation is located in the kinase domain in exon 15 of the protein (PMID: 33019809). This mutation has been identified in lung adenocarcinoma (PMID: 31534501). Expression of this mutation in COS cells demonstrated that it is activating as measured by increased in vitro kinase activity compared to wildtype BRAF (PMID: 15035987). Preclinical studies with HEK293 cells expressing BRAF E586K demonstrated sensitivity to treatment with pan-RAF inhibitor LY3009120 as measured by inhibited phospho-MEK and -ERK activities (PMID: 26343583).",
            "description_review": {
              "updateTime": 1678230482892,
              "updatedBy": "User"
            },
            "description_uuid": "ff911fe7-e446-495f-b6f5-0f258685ba32",
            "effect": "Gain-of-function",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "2a7480c9-f5a2-4f5d-ba10-1b5d56dd2c20",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "770191ac-6644-4f4e-92fa-52bed11b6a88",
            "short": ""
          },
          "mutation_effect_uuid": "cca9ae15-47da-4e78-b255-c1a7a0818ef6",
          "name": "E586K",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "79494560-424a-418e-9dc4-67468a3f0d65"
        },
        {
          "mutation_effect": {
            "description": "The class III BRAF F595L mutation is located in the kinase domain in exon 11 of the protein (PMID: 28783719). This mutation has been reported in histiocytic sarcoma, colorectal cancer and cardio-facio-cutaneous syndrome (PMID: 26582644, 15150094, 26150740). Biological characterization of the BRAF F595L mutation has demonstrated that it is RAS dependent in its activation of the MAPK pathway, signals as a dimer with CRAF, and typically co-occurs with another driver mechanism that amplifies RAS signaling (PMID: 28783719, 15035987, 15150094). Thus, when BRAF F595L is observed in melanoma, it typically co-occurs with an activating RAS mutation or NF1 inactivation, whereas when observed in non-small cell lung or colorectal cancers, it is associated with receptor tyrosine kinase (RTK) hyperactivation at the protein level (PMID: 28783719, 20141835). While this mutation is sensitive to MEK inhibition by targeted inhibitors such as trametinib, it is insensitive to RAF monomer inhibitors such as vemurafenib (PMID: 28783719, 26582644). A patient with metastatic colorectal cancer harboring BRAF F595L was treated with a combination therapy of FOLFOX plus panitumumab and experienced partial response with a progression-free survival of 10.2 months (PMID: 31515458).",
            "description_review": {
              "updateTime": 1678230557289,
              "updatedBy": "User"
            },
            "description_uuid": "769ed8a9-a98b-4577-b6e3-5dfbca322699",
            "effect": "Gain-of-function",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "5fb6a290-f77f-4f7e-aae1-ae8e7c6eb37a",
            "oncogenic": "Yes",
            "oncogenic_review": {
              "updateTime": 1529423216928,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "4f7f3cec-7f72-4795-8bd8-0ac1ad166b47",
            "short": ""
          },
          "mutation_effect_uuid": "d798c2ce-2c42-40f8-8fa7-9690a45faa0f",
          "name": "F595L",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "6ffc245d-bfda-40b6-b07e-933f228761c1"
        },
        {
          "mutation_effect": {
            "description": "The class III BRAF G596C mutation is located in the kinase domain of the BRAF protein (PMID: 28947956). This mutation has been found in non-small cell lung cancers, among others (PMID: 28947956). In vitro experiments have demonstrated that this mutation is activating as measured by increased downstream signaling compared to wildtype controls (PMID: 28947956). The BRAF G596C mutation confers resistance to the RAF inhibitor dabrafenib, but retains sensitivity to MEK inhibitor trametinib, as measured by MAPK pathway activation (PMID: 28947956).",
            "description_review": {
              "updateTime": 1678304010592,
              "updatedBy": "User"
            },
            "description_uuid": "2e561dde-774a-4dc0-b466-0f5eec11a5a7",
            "effect": "Gain-of-function",
            "effect_review": {
              "updateTime": 1490896054000,
              "updatedBy": "User"
            },
            "effect_uuid": "7c6857fc-1772-420f-b26a-2e122ca12071",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "2f902a6a-5e44-4837-8e09-cc39f20fce39",
            "short": ""
          },
          "mutation_effect_uuid": "7bed6ed0-efcf-4395-b7df-838ba09ad33e",
          "name": "G596C",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "d66b6be0-f0fc-4e2d-87e3-ef6ff17ba4cd"
        },
        {
          "mutation_effect": {
            "description": "The class III BRAF G596R mutation is located in the kinase domain in exon 15 of the protein (PMID: 28783719). This mutation has been reported in melanoma, lung cancer and colorectal cancer (PMID: 14678966, 26498038). Biological characterization of the BRAF G596R mutation has demonstrated that it is RAS dependent in its activation of the MAPK pathway, signals as a dimer with CRAF, and typically co-occurs with another driver mechanism that amplifies RAS signaling (PMID: 15035987, 28783719, 16364920). Thus, in melanoma, the G596R variant, similar to other class III BRAF mutants, would be expected to co-occur with activating RAS mutation or NF1 inactivation, whereas in non-small cell lung or colorectal cancers, this mutation would most likely be associated with receptor tyrosine kinase (RTK) hyperactivation at the protein level (PMID: 28783719). Preclinical studies with colorectal cancer cells expressing BRAF G596R demonstrated sensitivity to treatment with PLX8394, RMC-4550 and trametinib plus dabrafenib as measured by inhibition of cellular proliferation, and resistance to treatment with vemurafenib as measured by persistent ERK and MEK activation (PMID: 30559419, 30104724,  28947956, 28783719). In a Phase II trial, a patient with non-small cell lung cancer was treated with vemurafenib and did not clinically respond to treatment (PMID: 31959346).",
            "description_review": {
              "updateTime": 1678406534127,
              "updatedBy": "User"
            },
            "description_uuid": "c0e37090-b181-4c34-bca0-cbfe67c6a0da",
            "effect": "Gain-of-function",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "4c2cce08-23cc-49a9-bb8c-3244d90f7ff2",
            "oncogenic": "Yes",
            "oncogenic_review": {
              "updateTime": 1529423256883,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "0f1e6399-024b-4bd4-9d5d-175175fce18b",
            "short": ""
          },
          "mutation_effect_uuid": "c1694281-5be6-4f32-9e4c-a2e73e5f9b6f",
          "name": "G596R",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "cbd75619-38e1-4893-901b-f4e11dbbda1f"
        },
        {
          "mutation_effect": {
            "description": "The class III BRAF G596V mutation is located in the kinase domain in exon 15 of the protein (PMID: 33198372). This mutation has been found in cardio-facio-cutaneous syndrome (PMID: 16439621). Expression of this mutant in HEK293T cells demonstrated it has impaired kinase activity and is not able to induce downstream MEK and ERK activation in this context (PMID: 16439621). However, when expressed in zebrafish embryos, the G596V mutation causes the same aberrant elongation phenotype as BRAF V600E, suggesting that it might function in a manner similar to BRAF activating mutants during development in vivo (PMID: 19376813). In a Phase II trial, a patient with non-small cell lung cancer harboring BRAF G596V was treated with vemurafenib and demonstrated a partial response (PMID: 26200454).",
            "description_review": {
              "updateTime": 1678406657089,
              "updatedBy": "User"
            },
            "description_uuid": "dbe3b4b2-63ac-4b1c-aa08-c223721c5b2e",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "86f2dcf1-34f4-426b-83d7-6336964f61fa",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "c84458f5-3f34-4136-8ab3-239bb9996d4e",
            "short": ""
          },
          "mutation_effect_uuid": "4aa96241-6778-4410-ba7e-b134988201e2",
          "name": "G596V",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "15163e0f-2d07-4a4f-8107-2e064fbaa5fe"
        },
        {
          "mutation_effect": {
            "description": "The BRAF A598T mutation is located in the kinase domain of the BRAF protein. This mutation has been identified in glioma (PMID: 32996219). In vitro experiments have demonstrated that is mutation is inactivating as measured by reduced BRAF kinase activity compared to wildtype controls (PMID: 22926515, 32059434).",
            "description_review": {
              "updateTime": 1678135488772,
              "updatedBy": "User"
            },
            "description_uuid": "1c3d39bc-47d2-423d-a3b8-27e76a53c4d3",
            "effect": "Loss-of-function",
            "effect_review": {
              "updateTime": 1488928591000,
              "updatedBy": "User"
            },
            "effect_uuid": "b0e7125c-946a-4890-b86a-9cb16ddc21bd",
            "oncogenic": "Likely Neutral",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "4fc6ccc4-22d3-4bfb-a6cd-8eead0f36523",
            "short": ""
          },
          "mutation_effect_uuid": "6735741e-6d66-4ae2-8fec-0f96221d7b25",
          "name": "A598T",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "5a60dfb7-ce12-4177-a381-a65aa2e833af"
        },
        {
          "mutation_effect": {
            "description": "The class II BRAF A598V mutation is located in the kinase domain in exon 15 of the protein (PMID: 34794740). This mutation has been found in papillary thyroid carcinoma (PMID: 19200582). In vitro studies of BRAF A598V in patient samples have demonstrated that this mutation is activating as measured by increased phosphorylated MEK and ERK levels compared to wildtype BRAF (PMID: 19200582). Preclinical studies with patient-derived circulating tumor cells expressing BRAF A598V demonstrate resistance to combination treatment with BRAF/MEK inhibitors dabrafenib and trametinib as measured by sustained detection following treatment (PMID: 33731038).",
            "description_review": {
              "updateTime": 1678135498568,
              "updatedBy": "User"
            },
            "description_uuid": "cf00ba09-f3bb-4c36-88ec-40e3500e9f5e",
            "effect": "Gain-of-function",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "4e3b29fc-7373-4ca1-a7d9-0ec1b1595842",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "094c1215-bf19-4821-8044-9d3e991acd7c",
            "short": ""
          },
          "mutation_effect_uuid": "8a3605f1-621c-4bac-84aa-737f6b07e578",
          "name": "A598V",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "5626db7e-6677-4b4a-92ae-b212b97495aa"
        },
        {
          "mutation_effect": {
            "description": "The class II BRAF T599I mutation is located in the kinase domain in exon 15 of the protein (Abstract: Severson et al. Abstract #40P, Annals of Oncology 2022. https://www.annalsofoncology.org/article/S0923-7534%2822%2900058-8/fulltext). Expression of this mutation in COS cells demonstrated that it is activating as measured by increased kinase activity and downstream ERK activation compared to wildtype BRAF (PMID: 15035987). In a case report, a patient with metastatic melanoma harboring BRAF T599I was treated with vemurafenib and demonstrated a clinical response to treatment (PMID: 29232305).",
            "description_review": {
              "updateTime": 1678406689189,
              "updatedBy": "User"
            },
            "description_uuid": "830153d5-b7ba-497e-a134-d630f83c04cb",
            "effect": "Gain-of-function",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "25bbc115-da6c-4110-c0c1-d51486913e97",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "700e3725-521c-4138-a19f-10d02ba99db4",
            "short": ""
          },
          "mutation_effect_uuid": "2d6f3ab3-b26e-4a8f-8fcf-82a984334734",
          "name": "T599I",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "84a06f9f-2d92-498e-bb82-3e32c26d982e"
        },
        {
          "mutation_effect": {
            "description": "The class II BRAF T599R mutation is located in the kinase domain in exon 15 of the protein (PMID: 33019809). This mutation has been found in cardio-facio-cutaneous syndrome and thyroid carcinoma (PMID: 19206169, 25120313). Expression of BRAF T599R in NIH3T3 cells demonstrated that it is activating as measured by increased colony formation and downstream MAPK pathway activation compared to wildtype BRAF (PMID: 19206169).",
            "description_review": {
              "updateTime": 1678390437366,
              "updatedBy": "User"
            },
            "description_uuid": "cccc610d-9261-4f2a-9e0f-c8ac7571b980",
            "effect": "Gain-of-function",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "762acae2-d84d-4f7e-9f1b-18c23afc75d4",
            "oncogenic": "Yes",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "1e49df5e-858a-4e65-a507-1d50e08e2682",
            "short": ""
          },
          "mutation_effect_uuid": "595f3397-6acc-4ca2-b752-387991b43d68",
          "name": "T599R",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "6a9392ba-c4e1-4445-a0e4-5427c42501a9"
        },
        {
          "mutation_effect": {
            "description": "The BRAF R671Q mutation is located in the kinase domain of the BRAF protein. This mutation has been found in colorectal cancers, among others (PMID: 27048246). In vitro studies have demonstrated that this mutation is likely activating as measured by increased downstream signaling compared to wildtype (PMID: 28174173).",
            "description_review": {
              "updateTime": 1601870797902,
              "updatedBy": "User"
            },
            "description_uuid": "141f7496-cc93-40eb-ac9e-b5a07d8d6bca",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "c66a2b0d-3f33-4f91-85f3-4c0cac591ad8",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "03ccaae2-8f53-4fa9-94f0-e1c098c93431",
            "short": ""
          },
          "mutation_effect_uuid": "6bd84ce8-33e0-4313-939b-e9718431f061",
          "name": "R671Q",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "98b288b6-0bc6-40dc-b814-b41f490a5988"
        },
        {
          "mutation_effect": {
            "description": "The BRAF A728V mutation is located in the C-terminal end of exon 18 of the protein. This mutation has been identified in papillary thyroid carcinoma (PMID: 19176457).  Expression of this mutation in COS cells demonstrated that it is activating as measured by increased phosphorylated ERK levels and increased kinase activity compared to wildtype BRAF (PMID: 15035987).",
            "description_review": {
              "updateTime": 1678135516236,
              "updatedBy": "User"
            },
            "description_uuid": "c0fbbaab-4d86-40db-bef6-19330facd175",
            "effect": "Gain-of-function",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "84adeb92-4025-4ce5-be2a-d0b900086110",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "4aaf8250-0888-4fb7-87f8-fd8a3648d50c",
            "short": ""
          },
          "mutation_effect_uuid": "9827fd7e-28c9-4615-98b1-571767dc2166",
          "name": "A728V",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "7c02bb18-ebfa-406f-804e-6b9f469a3d4c"
        },
        {
          "mutation_effect": {
            "description": "The class II BRAF L485_P490del mutation is located in the kinase domain in exon 11 of the protein (PMID: 36686670). Expression of this mutation in HEK293 or NIH-3T3 cells demonstrated that it is activating as measured by kinase activity and colony formation in soft agar comparable to BRAF V600E (PMID: 26732095). However, a second study in human cell lines demonstrated that this mutation has kinase activity comparable to wildtype BRAF (PMID: 26996308). This mutation is dependent on BRAF homodimer formation, as BRAF L485_P490del fails to activate downstream MAPK pathway effectors as a monomer (PMID: 26732095). Preclinical studies with NIH3T3 cells expressing BRAF L485_P490del demonstrated sensitivity to treatment with LY3009120, as measured by inhibition of MEK and ERK phosphorylation, and resistance to treatment with vemurafenib, as measured by sustained MEK and ERK signaling and proliferation (PMID: 26732095). In a case report, a patient with metastatic melanoma harboring BRAF L485_P490del and amplified PD-L1 expression was treated with a combination therapy of trametinib and dabrafenib and demonstrated partial response with a progression-free survival of 18 months (PMID: 36686670).",
            "description_review": {
              "updateTime": 1678406720711,
              "updatedBy": "User"
            },
            "description_uuid": "b4cc4a1b-8c1d-4b9e-8641-613afd88f210",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1610424819950,
              "updatedBy": "User"
            },
            "effect_uuid": "fcc850b0-b6f4-4c5e-9f3d-b1776da2b284",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1610424818740,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "c02b208b-d750-4898-957c-a9b175327513",
            "short": ""
          },
          "mutation_effect_uuid": "16de683c-70b3-446b-9a42-88757d7f3e2d",
          "name": "L485_P490del",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "973e1df8-d41b-4581-b3b1-9c3b729e412a"
        },
        {
          "mutation_effect": {
            "description": "The BRAF L485_Q494del mutation is located in the kinase domain in exon 11 of the protein. While this variant has not been functionally validated, another deletion in this amino acid range (L485_P490del) has been shown to be gain-of-function and oncogenic (PMID: 26732095). Experiments in cell lines and mouse models demonstrate that BRAF alpha-C helix indel mutants, such as L485_Q494del, are insensitive to vemurafenib and maintain activity of the MAPK pathway upon drug treatment (PMID: 26732095)",
            "description_review": {
              "updateTime": 1513629272734,
              "updatedBy": "User"
            },
            "description_uuid": "1f81d23d-f479-4871-9be0-8a3aa4dc0546",
            "effect": "Inconclusive",
            "effect_review": {
              "updateTime": 1675806600968,
              "updatedBy": "User"
            },
            "effect_uuid": "9b3aa240-60ed-4132-8cb3-b6122d96703a",
            "oncogenic": "Inconclusive",
            "oncogenic_review": {
              "updateTime": 1675806599366,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "9a46e5bd-4749-4733-afde-592265f17157",
            "short": ""
          },
          "mutation_effect_uuid": "20b5531f-59fb-4555-a831-3937eba8b931",
          "name": "L485_Q494del",
          "name_review": {
            "updateTime": 1675803206892,
            "updatedBy": "User"
          },
          "name_uuid": "dd39661b-24f1-4b00-9552-4b4e26b3a9b2"
        },
        {
          "mutation_effect": {
            "description": "The BRAF L485_P490delinsF mutation is located in the kinase domain in exon 11 of the protein. While this variant has not been functionally validated, another deletion in this amino acid range (L485_P490del) has been shown to be gain-of-function and oncogenic (PMID: 26732095). Experiments in cell lines and mouse models demonstrate that BRAF alpha-C helix indel mutants, such as L485_P490delinsF, are insensitive to vemurafenib and maintain activity of the MAPK pathway upon drug treatment (PMID: 26732095)",
            "description_review": {
              "updateTime": 1513629353663,
              "updatedBy": "User"
            },
            "description_uuid": "6f7d71eb-5bfa-4076-8bf6-3291aa35bb8b",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "2c5fe2dc-3d3c-4dd0-9342-4487716516bb",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "c3a491ee-e144-4017-9f6f-d2e809d40ccc",
            "short": ""
          },
          "mutation_effect_uuid": "444cc16d-4858-47eb-9122-70a1aee1edf1",
          "name": "L485_P490delinsF",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "858427c8-7887-4f66-8cd4-ce20275ef3ad"
        },
        {
          "mutation_effect": {
            "description": "The class II BRAF L485_P490delinsY mutation is located in the kinase domain in exon 11 of the protein (PMID: 33019809). This mutation has been identified in non-small lung cancer (PMID: 12068308). While this variant has not been functionally validated, preclinical studies with non-small lung cancer cell lines and mouse models expressing BRAF L485_P490delinsY demonstrated sensitivity to treatment with LY3009120 and trametinib as measured by inhibition of cellular proliferation, and resistance to vemurafenib as measured by sustained MEK and ERK pathway activation (PMID: 26732095).",
            "description_review": {
              "updateTime": 1678406826067,
              "updatedBy": "User"
            },
            "description_uuid": "faeec881-d98d-4b0e-bcca-5dfff57356ca",
            "effect": "Inconclusive",
            "effect_review": {
              "updateTime": 1675806700293,
              "updatedBy": "User"
            },
            "effect_uuid": "43ac21b6-f89c-4d26-9582-a4afa9412a21",
            "oncogenic": "Inconclusive",
            "oncogenic_review": {
              "updateTime": 1675806699111,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "46020abb-e172-4a09-90ee-6cedc0a7e4e7",
            "short": ""
          },
          "mutation_effect_uuid": "e53d3b63-8966-425b-9d54-e5343bd98b17",
          "name": "L485_P490delinsY",
          "name_review": {
            "updateTime": 1675803102620,
            "updatedBy": "User"
          },
          "name_uuid": "fbf49c94-2a1a-45bf-9e42-1041860d6e66"
        },
        {
          "mutation_effect": {
            "description": "The class II BRAF N486_P490del mutation is located in the kinase domain in exon 11 of the protein (PMID: 33019809). This mutation has been found in an ovarian cancer cell line and in patients with pancreatic cancer (PMID: 18060073, 26996308, 31519698). Expression of this mutation in a human cell line demonstrated that it is activating via a CRAF- and dimer-independent mechanism as measured by increased kinase activity and downstream signaling compared to wildtype (PMID: 26996308). Preclinical studies with patient-derived xenograft models of pancreatic ductal adenocarcinoma expressing BRAF N486_P490del demonstrated sensitivity to treatment with trametinib and LY3009120 alone or in combination as measured by reduced tumor growth (PMID: 34011980). A patient with pancreatic cancer harboring this mutation had a partial response to treatment with the BRAF inhibitor dabrafenib (PMID: 31519698). In a case report, two patients with Langerhans cell histiocytosis harboring BRAF N486_P490del were treated with trametinib and one patient demonstrated a complete response with a progression-free survival of over 18 months while the second patient demonstrated stable disease with a progression-free survival of over twelve months (PMID: 32991018). In another case report, a patient with metastatic pancreatic ductal adenocarcinoma harboring BRAF N486_P490del was treated with a combination therapy of dabrafenib plus trametinib and demonstrated partial response (PMID: 36505826).",
            "description_review": {
              "updateTime": 1678406942437,
              "updatedBy": "User"
            },
            "description_uuid": "d2b1c785-4d5e-407d-b5b6-7113a0c65358",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1610423105817,
              "updatedBy": "User"
            },
            "effect_uuid": "5211e083-6d72-4505-a5fe-29da60c439a0",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1610423105029,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "93be4a13-1158-4135-8c3b-062eaea0d56c",
            "short": ""
          },
          "mutation_effect_uuid": "898e987f-24dc-4580-85d3-1845b628848d",
          "name": "N486_P490del (NVTAP)",
          "name_review": {
            "updateTime": 1610422547745,
            "updatedBy": "User"
          },
          "name_uuid": "f876cba6-4d29-4ad1-9b42-0f6416e2645d"
        },
        {
          "mutation_effect": {
            "description": "The BRAF V487_P492delinsA mutation is located in the kinase domain in exon 11 of the protein. In vitro studies with BxPC-3 cells expressing BRAF V487_P492delinsA demonstrate that the mutation is activating as measured by increased pathway activation and cellular proliferation compared to wildtype (PMID: 26732095). Experiments in cell lines and mouse models demonstrate that BRAF alpha-C helix indel mutants, such as V487_P492delinsA, are insensitive to vemurafenib and maintain activity of the MAPK pathway upon drug treatment (PMID: 26732095).",
            "description_review": {
              "updateTime": 1678390374515,
              "updatedBy": "User"
            },
            "description_uuid": "7445b5fe-3a25-4da6-a601-edd8224f1d8a",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1678390377057,
              "updatedBy": "User"
            },
            "effect_uuid": "ab4e90a9-8fdf-480f-9078-717b7eae8560",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1678390376283,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "d4da6583-0755-4b4c-a0a9-88cdd924ae26",
            "short": ""
          },
          "mutation_effect_uuid": "380ea3fc-2b88-4d10-84a9-17944d933330",
          "name": "V487_P492delinsA",
          "name_review": {
            "updateTime": 1675803502440,
            "updatedBy": "User"
          },
          "name_uuid": "456504f1-e116-4098-bb64-2fba9e34d385"
        },
        {
          "mutation_effect": {
            "description": "The class II BRAF T488_P492del mutation is located in the kinase domain in exon 11 of the protein (Abstract: Severson et al. Abstract #40P, Annals of Oncology 2022. https://www.annalsofoncology.org/article/S0923-7534%2822%2900058-8/fulltext). This mutation has been found in pancreatic cancer (PMID: 26996308). Expression of this mutation in a human cell line demonstrated that it is activating as measured by increased kinase activity and downstream signaling compared to wildtype (PMID: 26996308).",
            "description_review": {
              "updateTime": 1678390478782,
              "updatedBy": "User"
            },
            "description_uuid": "0cf5d76c-945c-4520-bd73-f8232fa56d9f",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "a73f9de4-3f0a-4a19-a926-8527631caf46",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "a26d68bf-e048-4eb0-86c6-f03db77c89b7",
            "short": ""
          },
          "mutation_effect_uuid": "37d65ab5-6130-4332-b4b6-2602be6727f2",
          "name": "T488_P492del",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "8aa3b886-9ba5-445b-86a6-cc6ccece5a2e"
        },
        {
          "mutation_effect": {
            "description": "The class II BRAF P490_Q494del mutation is located in the kinase domain in exon 11 of the protein (Abstract: Severson et al. Abstract #40P, Annals of Oncology 2022. https://www.annalsofoncology.org/article/S0923-7534%2822%2900058-8/fulltext). This mutation has been found in pancreatic cancer (PMID: 26996308). Expression of this mutation in a human cell line demonstrated that it is activating as measured by increased kinase activity and downstream signaling compared to wildtype (PMID: 26996308).",
            "description_review": {
              "updateTime": 1678309387334,
              "updatedBy": "User"
            },
            "description_uuid": "0c70432c-f515-44f2-b89b-f358d3c19822",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "bdfa68e2-fbeb-4cd0-be3a-5f99c698a832",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "3b3cd9ed-bf98-4a48-8686-4462e5daffda",
            "short": ""
          },
          "mutation_effect_uuid": "a13b94df-6434-43a8-a628-1f338f31b4d0",
          "name": "P490_Q494del",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "aaf90228-362c-4e31-a830-81fa2d884656"
        },
        {
          "mutation_effect": {
            "description": "The BRAF R506_K507insVLR mutation (also referred to as BRAF V504_R506dup) is located in the kinase domain in exon 13 of the protein. This mutation has been found in pilocytic astrocytoma (PMID: 23817572). Expression of this mutation in NIH-3T3 cells demonstrated that it is activating as measured by increased downstream pathway activation compared to wildtype BRAF (PMID: 23817572). Preclinical studies with HEK293T cells expressing BRAF R506_K507insVLR demonstrated sensitivity to treatment with trametinib as measured by inhibition of ERK signaling, and resistance to treatment with PLX8394, dabrafenib, vemurafenib, LY3009120 and sorafenib as measured by sustained ERK signaling (PMID: 34108213).",
            "description_review": {
              "updateTime": 1678407078897,
              "updatedBy": "User"
            },
            "description_uuid": "54f4e345-84d4-4e7f-9d6e-fae5ba45c904",
            "effect": "Gain-of-function",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "e33ccee2-e00e-4d90-ab7c-b8dd00dc6146",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "2af03236-4075-4338-a940-501eff3ca3a6",
            "short": ""
          },
          "mutation_effect_uuid": "1805036f-60fc-4914-ad31-05a12c605522",
          "name": "R506_K507insVLR",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "9a7176ad-5e21-4699-99de-4f6abe96c536"
        },
        {
          "mutation_effect": {
            "description": "The BRAF T599dup mutation is located in the kinase domain in exon 15 of the protein. This mutation has been found in melanoma and pilocytic astrocytoma (PMID: 19363522, 21190184, 29456854). Expression of this mutation in HEK293, NIH-3T3 or MCF-10A cells demonstrated that this mutation is activating as measured by kinase activity, anchorage-independent growth and changes in contact inhibition comparable to BRAF V600E (PMID: 19363522, 21190184, 23833300). In a case report, four patients with metastatic melanoma harboring BRAF T599dup were treated with a combination therapy of dabrafenib plus trametinib and demonstrated partial response (PMID: 35319964). Another patient with metastatic melanoma harboring BRAF T599dup was treated with a combination therapy of binimetinib plus encorafenib and demonstrated a partial response and a progression-free survival of at least nine months (PMID: 35319964). Two other patients with metastatic melanoma harboring BRAF T599dup were treated with vemurafenib and demonstrated progressive disease (PMID: 35319964). In another case report, a patient with metastatic colorectal cancer was treated with a combination therapy of panitumumab plus FOLFOX and demonstrated progressive disease (PMID: 31515458).",
            "description_review": {
              "updateTime": 1678407144681,
              "updatedBy": "User"
            },
            "description_uuid": "01a91029-42e8-4e78-bab7-27db87869965",
            "effect": "Gain-of-function",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "aa40d7f6-5e58-4764-a5d0-ee4acadfd3ad",
            "oncogenic": "Yes",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "cea46944-4ddb-4879-85e5-4f5e9096b01b",
            "short": ""
          },
          "mutation_effect_uuid": "5c329804-c62e-4606-89b1-35dfeb024c31",
          "name": "T599dup",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "dad14d22-0e52-423b-ad27-5df5bb28a994"
        },
        {
          "mutation_effect": {
            "description": "The BRAF T599insTT mutation is located in the kinase domain in exon 15 of the protein. This mutation has been found in pilocytic astrocytoma (PMID: 21190184). Expression of this mutation in HEK293 cells or MCF-10A cells demonstrated that this mutation is activating as measured by kinase activity and changes in contact inhibition comparable to the BRAF V600E mutation (PMID: 21190184).",
            "description_review": {
              "updateTime": 1493057315640
            },
            "description_uuid": "dad34a66-3e3b-41b8-bdde-5e125467450e",
            "effect": "Gain-of-function",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "9d37b580-d00b-4bb8-ae07-6b3c35e024ed",
            "oncogenic": "Yes",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "9da9cbef-6692-46d3-91d5-4c2f5c0259d5",
            "short": ""
          },
          "mutation_effect_uuid": "dda94435-485e-4203-a163-1eabd26c374a",
          "name": "T599insTT",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "e72532fb-4b91-4b29-bac9-c054b2370cd7"
        },
        {
          "mutation_effect": {
            "description": "The BRAF T599_V600insV mutation is located in the kinase domain in exon 15 of the protein. This mutation has been found in papillary thyroid carcinoma (PMID: 16501605). Expression of BRAF T599_V600insV in HEK293 or NIH-3T3 cells demonstrated that it is activating and transforming as measured by increased kinase activity, increased downstream pathway activation, and increased foci formation compared to wildtype BRAF (PMID: 16501605).",
            "description_review": {
              "updateTime": 1493057315640
            },
            "description_uuid": "7ad35e18-19f8-4f11-914c-7e3abe0fd880",
            "effect": "Gain-of-function",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "666cbc41-40e1-4e09-8c5d-c452e60b3d37",
            "oncogenic": "Yes",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "0aee4a9e-61b8-4030-9b4e-dac8f285ac2a",
            "short": ""
          },
          "mutation_effect_uuid": "474b8522-bb88-4520-906f-feee386b7c22",
          "name": "T599_V600insV",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "bf2b8866-0e5d-467b-b11e-51925c96cd89"
        },
        {
          "mutation_effect": {
            "description": "The BRAF V600delinsYM mutation is located in the kinase domain in exon 15 of the protein. This mutation has been found in papillary thyroid carcinoma (PMID: 22752848). Expression of this mutation in NIH-3T3 cells demonstrated that it is activating as measured by increased kinase activity and increased cell proliferation compared to wildtype BRAF (PMID: 22752848).",
            "description_review": {
              "updateTime": 1493057315640
            },
            "description_uuid": "3a4ae9ea-534e-4ea1-99ce-3b54dbfdc67b",
            "effect": "Gain-of-function",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "228dffe7-0f4b-4554-bb4f-088824fab2ae",
            "oncogenic": "Yes",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "e28500fd-4a6d-423f-b6d3-7c78170548bd",
            "short": ""
          },
          "mutation_effect_uuid": "0f4d69c9-ffd3-413a-c095-d4612f70bd55",
          "name": "V600delinsYM",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "ca55bd30-243d-480e-8955-dac91fe2606c"
        },
        {
          "mutation_effect": {
            "description": "The BRAF V600_K601insDFGLAT alteration is located in the kinase domain in exon 15 of the protein. This mutation has been found in papillary thyroid cancer (PMID: 17297294). Expression of this mutation in NIH-3T3 cells demonstrated that it is activating as measured by increased downstream pathway activation and colony formation compared to wildtype BRAF (PMID: 17297294).",
            "description_review": {
              "updateTime": 1605664277312,
              "updatedBy": "User"
            },
            "description_uuid": "d1da1543-dec9-4bed-87f9-cd7280286ce0",
            "effect": "Gain-of-function",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "e5797c7f-7268-48b6-8ead-783fcab2d999",
            "oncogenic": "Yes",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "037bd74e-dbb8-43bf-ba1a-d3d48ba1d100",
            "short": ""
          },
          "mutation_effect_uuid": "0eccf3f8-e562-4d88-a02e-678c08d8a631",
          "name": "V600_K601insDFGLAT",
          "name_review": {
            "updateTime": 1605664271686,
            "updatedBy": "User"
          },
          "name_uuid": "c24e656a-f0db-4539-909d-a3848f941620"
        },
        {
          "mutation_effect": {
            "description": "BRAF fusions generally arise from chromosomal translocations that fuse the N-terminal end of a partner gene with the C-terminal end of BRAF (exons 9-18, containing the kinase domain), such that the fusion protein excludes the BRAF CR1 regulatory domain (PMID:15630448), thereby resulting in a constitutively active BRAF kinase. These class II hyperactivating BRAF fusions have been found in melanoma, prostate cancer, gastric cancer, and multiple other cancers (PMID: 28783719, 26343582, 24345920, 20526349, 25985019, 26324360, 18974108). Biological characterization of diverse BRAF fusion proteins demonstrate that they activate the downstream MAPK pathway independent of RAS (PMID: 24345920, 21424530, 22745804, 21424530, 18974108, 26343582), render BRAF active as a homo- or heterodimer dimer with CRAF (PMID: 26343582), and, while sensitive to MEK inhibition by targeted inhibitors such as trametinib (PMID: 24345920, 28783719, 26343582, 26314551), are insensitive to RAF monomer inhibitors such as vemurafenib and dabrafenib (PMID: 26343582, 28783719). BRAF fusions have been found across multiple studies in post-treatment samples of patients with EGFR-mutant lung cancer who progressed on osimertinib (PMID: 30257958, 30073261).",
            "description_review": {
              "updateTime": 1554788031154,
              "updatedBy": "User"
            },
            "description_uuid": "4cfbcc17-2981-4457-a985-5c7116f3901e",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1548877968452,
              "updatedBy": "User"
            },
            "effect_uuid": "896baaf7-1159-4038-9434-8a5539537581",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "ab18a9a6-b6c2-421c-b74d-08ab02c44d09",
            "short": ""
          },
          "mutation_effect_uuid": "e9b1f0f3-2a85-4df3-bdbc-cbb3eb69b88d",
          "name": "Fusions",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "4720ed7b-8593-42f9-a2bf-df33b32bc91d",
          "tumors": [
            {
              "TIs": [
                {
                  "name": "Standard implications for sensitivity to therapy",
                  "name_uuid": "fe9a7e7c-8783-4956-834e-ce5d31192004",
                  "type": "SS"
                },
                {
                  "name": "Standard implications for resistance to therapy",
                  "name_uuid": "3234ff0b-103d-4979-b20e-62ea45303104",
                  "type": "SR"
                },
                {
                  "name": "Investigational implications for sensitivity to therapy",
                  "name_uuid": "1fd6c7ad-1f07-483b-b518-c496bdb769b2",
                  "treatments": [
                    {
                      "description": "Cobimetinib and trametinib are small molecule inhibitors of the MEK1/2 kinases that are FDA-approved in combination with a RAF inhibitor for use in BRAF V600E-positive metastatic melanoma. In a study of patients with low-grade serous ovarian cancer, a patient with a CUL1-BRAF fusion who progressed on carboplatin and paclitaxel had a sustained complete response to treatment with paclitaxel and a MEK1/2 inhibitor (selumetinib) (PMID: 26324360).  Additionally, in vitro studies have demonstrated that BRAF fusions are sensitive to MEK inhibition as measured decreased downstream MAPK pathway signaling in BRAF fusion-containing cells upon treatment with trametinib (PMID: 24345920).",
                      "description_review": {
                        "updateTime": 1676490607866,
                        "updatedBy": "User"
                      },
                      "description_uuid": "69235b15-e629-4a55-91b8-1a41ab83c59b",
                      "fdaLevel": "Fda3",
                      "fdaLevel_review": {
                        "updateTime": 1676490601934,
                        "updatedBy": "User"
                      },
                      "fdaLevel_uuid": "30293618-0f85-495b-a732-564bd25433f0",
                      "indication": "",
                      "indication_uuid": "dcb86cd0-c8cb-486c-ab1d-084d14e84574",
                      "level": "3A",
                      "level_review": {
                        "updateTime": 1508185546552,
                        "updatedBy": "User"
                      },
                      "level_uuid": "e95f1081-be64-4fe4-996f-114d21d73842",
                      "name": "fb2bb01c-c0ec-4641-abf7-87f486075022, eb357145-3b18-4aca-b75a-5e18dd2bf4f9",
                      "name_review": {
                        "updateTime": 1517434826845
                      },
                      "name_uuid": "e569bfd4-15f5-421d-9d4e-31dfb7a82903",
                      "propagation": "3B",
                      "propagationLiquid": "no",
                      "propagationLiquid_uuid": "d230ee99-db25-11e9-9e0e-60f81dc75ed6",
                      "propagation_uuid": "18edbbc7-4a9e-435b-bc88-c12f900e0ab1",
                      "short": ""
                    }
                  ],
                  "type": "IS"
                },
                {
                  "name": "Investigational implications for resistance to therapy",
                  "name_uuid": "56bdd8fa-821b-4248-9a16-207f72d9dba5",
                  "type": "IR"
                }
              ],
              "cancerTypes": [
                {
                  "code": "",
                  "mainType": "Ovarian Cancer",
                  "subtype": ""
                }
              ],
              "cancerTypes_uuid": "cd8d1e6e-496f-4b6b-a998-80612a456239",
              "diagnostic": {
                "description": "",
                "description_uuid": "da40d442-797c-4663-90fe-ffcbc1a798db",
                "level": "",
                "level_uuid": "f3448e04-982c-4d17-af13-76a8eb9a5951",
                "short": ""
              },
              "diagnosticSummary": "",
              "diagnosticSummary_uuid": "b95ffd62-2501-454f-894b-44514f7d8e03",
              "diagnostic_uuid": "9bfe7289-4dfb-4c88-af6d-945f27e16513",
              "prognostic": {
                "description": "",
                "description_review": {
                  "updateTime": 1493057315640
                },
                "description_uuid": "8c438672-470e-4b8b-90b7-2c8cddbab6fd",
                "level": "",
                "level_uuid": "d60dacbf-99ce-4fde-ac01-ed25be0b24a7",
                "short": ""
              },
              "prognosticSummary": "",
              "prognosticSummary_uuid": "0fed05e3-c4d2-4138-a87a-f5b439d4ca06",
              "prognostic_uuid": "c0e6f77e-a404-4d57-a3e6-f6fb45c9cb10",
              "summary": "There is promising clinical data from a case study in a patient with BRAF fusion-positive ovarian cancer treated with the FDA-approved MEK1/2-targeted inhibitor selumetinib in combination with paclitaxel, and in patients with BRAF fusion-positive melanoma treated with the FDA-approved MEK1/2-targeted inhibitor trametinib.",
              "summary_review": {
                "updateTime": 1566848629531,
                "updatedBy": "User"
              },
              "summary_uuid": "2a6d18bb-0a61-4615-a43d-1818b7dd46ea"
            },
            {
              "TIs": [
                {
                  "name": "Standard implications for sensitivity to therapy",
                  "name_uuid": "98ec789a-c8f6-4141-a96d-2c106c049b68",
                  "type": "SS"
                },
                {
                  "name": "Standard implications for resistance to therapy",
                  "name_uuid": "fabf30e4-98c1-46a8-ab63-cc6bc793f3b1",
                  "type": "SR"
                },
                {
                  "name": "Investigational implications for sensitivity to therapy",
                  "name_uuid": "83095822-5a2a-41be-8286-7919f55370d8",
                  "treatments": [
                    {
                      "description": "Cobimetinib and trametinib are small molecule inhibitors of the MEK1/2 kinases that are FDA-approved in combination with a RAF inhibitor for use in BRAF V600E-positive metastatic melanoma. Two studies from independent groups have shown that three patients with BRAF-fusion positive metastatic melanoma experienced clinical benefit, such as improvement of ECOG status, tumor shrinkage, or stable disease upon treatment with the MEK inhibitor trametinib (PMID: 26314551, 26072686). In vitro studies have demonstrated that BRAF fusions are sensitive to MEK inhibition as measured by decreased downstream MAPK pathway signaling in BRAF fusion-containing cells upon treatment with trametinib (PMID: 24345920).",
                      "description_review": {
                        "updateTime": 1676490584210,
                        "updatedBy": "User"
                      },
                      "description_uuid": "e96e4904-704c-4c1e-9053-f12e9a0de069",
                      "fdaLevel": "Fda3",
                      "fdaLevel_review": {
                        "updateTime": 1676490581275,
                        "updatedBy": "User"
                      },
                      "fdaLevel_uuid": "bbe73a03-abc1-4255-8a15-8efe2cb6c347",
                      "indication": "",
                      "indication_uuid": "53ab094e-68f8-4d82-bd7c-f85e401f99bd",
                      "level": "3A",
                      "level_uuid": "4de282b3-1298-4cad-af00-d19e57add526",
                      "name": "fb2bb01c-c0ec-4641-abf7-87f486075022, eb357145-3b18-4aca-b75a-5e18dd2bf4f9",
                      "name_review": {
                        "updateTime": 1517434859058
                      },
                      "name_uuid": "cec96519-6479-4b9e-9d89-42e3b2a2bc94",
                      "propagation": "3B",
                      "propagationLiquid": "no",
                      "propagationLiquid_uuid": "d230ef4c-db25-11e9-80c1-60f81dc75ed6",
                      "propagation_uuid": "77036e12-2038-49bc-9767-b9e8990da5b3",
                      "short": ""
                    }
                  ],
                  "type": "IS"
                },
                {
                  "name": "Investigational implications for resistance to therapy",
                  "name_uuid": "52982679-e0c1-435b-87cf-ec59253a0fee",
                  "type": "IR"
                }
              ],
              "cancerTypes": [
                {
                  "code": "MEL",
                  "mainType": "Melanoma",
                  "subtype": "Melanoma"
                }
              ],
              "cancerTypes_uuid": "fc0e59a0-0511-4353-b0e4-ed5995daf796",
              "diagnostic": {
                "description": "",
                "description_uuid": "41476a02-7d88-4965-9089-d4436b9129d5",
                "level": "",
                "level_uuid": "0233fa3b-4433-417d-a550-e917a8276408",
                "short": ""
              },
              "diagnosticSummary": "",
              "diagnosticSummary_uuid": "754388cd-f643-45d0-a8cc-1ae98adeb07d",
              "diagnostic_uuid": "f63bfb25-01b5-4fd3-b505-c809dff0dbd4",
              "prognostic": {
                "description": "",
                "description_uuid": "94919377-aed8-44a1-b4d3-bce1cd3b4717",
                "level": "",
                "level_uuid": "0dbd2f00-ee48-49d0-a3a2-463c95cf0ee1",
                "short": ""
              },
              "prognosticSummary": "",
              "prognosticSummary_uuid": "71b303b7-60c9-400a-a0cd-7eec0817e36c",
              "prognostic_uuid": "4a7b9ddc-5e86-4da7-9d55-ce7c85d3fab8",
              "summary": "There is promising clinical data in patients with BRAF fusion-positive melanoma treated with the FDA-approved MEK1/2-targeted inhibitor trametinib.",
              "summary_review": {
                "updateTime": 1566848642310,
                "updatedBy": "User"
              },
              "summary_uuid": "4d13aa6b-fb7c-45e4-8c43-fe1223fdd53f"
            },
            {
              "TIs": [
                {
                  "name": "Standard implications for sensitivity to therapy",
                  "name_uuid": "e601ef5d-e1fa-435b-b2db-90c91bf452c8",
                  "type": "SS"
                },
                {
                  "name": "Standard implications for resistance to therapy",
                  "name_uuid": "3117b24d-2e9a-4a3b-8734-6477061a1d20",
                  "type": "SR"
                },
                {
                  "name": "Investigational implications for sensitivity to therapy",
                  "name_uuid": "6de2ce03-aa2d-4bc8-861e-54d06f8a4c99",
                  "type": "IS"
                },
                {
                  "name": "Investigational implications for resistance to therapy",
                  "name_uuid": "11579f70-9911-4634-bf4e-110858a9f299",
                  "type": "IR"
                }
              ],
              "cancerTypes": [
                {
                  "code": "",
                  "mainType": "Other Tumor Types",
                  "subtype": ""
                }
              ],
              "cancerTypes_uuid": "ac3cf6a9-ca22-4087-8deb-8e8515494523",
              "diagnostic": {
                "description": "",
                "description_uuid": "a3aef851-97dc-49ea-b6ca-73e054274cad",
                "level": "",
                "level_uuid": "61176578-feb5-467e-888e-a4789981f9f8",
                "short": ""
              },
              "diagnosticSummary": "",
              "diagnosticSummary_uuid": "352d4a59-204b-4dd9-addd-fa1a5783bb65",
              "diagnostic_uuid": "d7dc3200-8c8e-4ac7-badc-3b72d0de4057",
              "prognostic": {
                "description": "",
                "description_review": {
                  "updateTime": 1493057315640
                },
                "description_uuid": "9b1318ec-073b-43b4-ab52-902de71bc156",
                "level": "",
                "level_uuid": "a1f9be05-4c65-4172-982a-a323a41ada94",
                "short": ""
              },
              "prognosticSummary": "",
              "prognosticSummary_uuid": "c0869fc4-3999-45c9-abe4-061e63012ead",
              "prognostic_uuid": "051852c6-0c54-4be0-9c8e-91cb79073881",
              "summary": "While the MEK1/2-targeted inhibitor selumetinib is NCCN-compendium listed as a treatment option for patients with BRAF fusion-positive pilocytic astrocytoma and there is promising clinical data demonstrating the clinical utility of MEK1/2-targeted inhibitors such as the FDA-approved trametinib in patients with BRAF fusion-positive melanoma and ovarian cancer, their clinical utility in patients with [[variant]] is unknown.",
              "summary_review": {
                "updateTime": 1630025646250,
                "updatedBy": "User"
              },
              "summary_uuid": "67f8217f-063d-454f-c0a1-9ad1481afc59"
            },
            {
              "TIs": [
                {
                  "name": "Standard implications for sensitivity to therapy",
                  "name_uuid": "62c65c4e-1a8b-4848-a68f-1fc22169d64e",
                  "treatments": [
                    {
                      "description": "Selumetinib is a small molecule tyrosine kinase inhibitor of MEK1/2. In stratum one of the phase II PBTC study of selumetinib in 25 patients with pilocytic astrocytoma harboring a KIAA1549–BRAF fusion or BRAF V600E mutation, seven of eighteen patients with a KIAA1549–BRAF fusion had a partial response to treatment (PMID: 31151904). Additionally, the two year progression-free survival rate for the BRAF study population (n=25) was 70% (95% CI = 47–85) (PMID: 31151904).",
                      "description_review": {
                        "updateTime": 1676490629687,
                        "updatedBy": "User"
                      },
                      "description_uuid": "54651174-ebdb-4d7f-8a2c-f197a0f9efc3",
                      "fdaLevel": "Fda2",
                      "fdaLevel_review": {
                        "updateTime": 1676490627064,
                        "updatedBy": "User"
                      },
                      "fdaLevel_uuid": "fd0ae9c4-c58f-4553-95c6-4277e9e70b1b",
                      "indication": "",
                      "indication_uuid": "33fb66f9-e5ad-4a23-a2a6-a22213108b36",
                      "level": "2",
                      "level_review": {
                        "updateTime": 1630017304819,
                        "updatedBy": "User"
                      },
                      "level_uuid": "5a7d2cbc-2ba0-4b91-a023-b8b6953e19fb",
                      "name": "3f154145-525b-4865-8baf-12b374697b2a",
                      "name_review": {
                        "updateTime": 1630017292138,
                        "updatedBy": "User"
                      },
                      "name_uuid": "a05f8f2e-5d26-4639-9c10-019b8183fc33",
                      "propagation": "3B",
                      "propagationLiquid": "no",
                      "propagationLiquid_review": {
                        "updateTime": 1630017304817,
                        "updatedBy": "User"
                      },
                      "propagationLiquid_uuid": "e6ce9b08-9afa-4d6a-bfdc-ead1296bae42",
                      "propagation_review": {
                        "updateTime": 1630017313915,
                        "updatedBy": "User"
                      },
                      "propagation_uuid": "a47bb690-5821-42e1-84c4-642380433269",
                      "short": ""
                    }
                  ],
                  "treatments_uuid": "c33f66b3-ffed-47cb-8b76-ef62de932a12",
                  "type": "SS"
                },
                {
                  "name": "Standard implications for resistance to therapy",
                  "name_uuid": "2203256e-4463-4afc-82c1-3ec957fea4cb",
                  "treatments_uuid": "decfa780-da5f-4f16-81f4-4bf19a6ace4f",
                  "type": "SR"
                },
                {
                  "name": "Investigational implications for sensitivity to therapy",
                  "name_uuid": "8214d741-38e0-48d5-8487-d4896783ce04",
                  "treatments_uuid": "e4e0675d-3019-49f6-a89b-9d113c68c4fa",
                  "type": "IS"
                },
                {
                  "name": "Investigational implications for resistance to therapy",
                  "name_uuid": "24bdb290-7856-4e66-915a-512b2125484f",
                  "treatments_uuid": "b9222ed9-26dd-4d10-9271-b7dfe050c05c",
                  "type": "IR"
                }
              ],
              "cancerTypes": [
                {
                  "code": "PAST",
                  "mainType": "Glioma",
                  "subtype": "Pilocytic Astrocytoma"
                }
              ],
              "cancerTypes_review": {
                "updateTime": 1630017047299,
                "updatedBy": "User"
              },
              "cancerTypes_uuid": "1393c078-ecb7-495e-b9e6-fd037756396c",
              "diagnostic": {
                "description": "",
                "description_uuid": "ca4ef46b-b088-4c78-a0b9-403a40dce2e2",
                "level": "",
                "level_uuid": "72c47dc8-ddad-47e6-88dd-44a66ed95723",
                "short": ""
              },
              "diagnosticSummary": "",
              "diagnosticSummary_uuid": "e887d069-86a4-4387-aed2-4c1c4eb8a528",
              "diagnostic_uuid": "d2a75324-0a79-45c6-b454-be1a7efc27b0",
              "prognostic": {
                "description": "",
                "description_uuid": "9c5d4039-1ee8-454a-8236-755b223824da",
                "level": "",
                "level_uuid": "7b627f2d-d5a7-4ab4-9125-09ed227150f7",
                "short": ""
              },
              "prognosticSummary": "",
              "prognosticSummary_uuid": "0f4ca8f3-42c1-46d9-a0d0-cf48489dc346",
              "prognostic_uuid": "9c6360c4-2833-4a0a-9efa-375ca86e5716",
              "summary": "The MEK inhibitor selumetinib is NCCN-compendium listed as a treatment option for patients with BRAF fusion-positive pilocytic astrocytoma.",
              "summary_review": {
                "updateTime": 1630017269319,
                "updatedBy": "User"
              },
              "summary_uuid": "5306d2e7-1e09-4cfe-ae94-152e3244c7f6"
            }
          ]
        },
        {
          "mutation_effect": {
            "description": "The AGAP3-BRAF fusion protein results from an inversion on chromosome 7, joining exons 1-9 of AGAP3 with a 3' segment of the BRAF gene. The AGAP3-BRAF fusion protein contains the full BRAF kinase domain, but lacks the regulatory RAS-binding domain and the cysteine-rich (CR1) domain, which are responsible for BRAF binding to RAS and auto-inhibition. This fusion protein has been found in melanoma, colorectal cancer and ovarian serous carcinoma (PMID: 26314551, 28539463, 30279230, 34568720).  Expression of this fusion in NIH3T3 cells demonstrated that it is activating as measured by increased MAPK pathway activity and cellular growth compared to wildtype BRAF (PMID: 30279230). Expression of this fusion in cell lines demonstrated that it is sensitive to trametinib but not vemurafenib as measured by in vitro colony formation and cell proliferation (PMID: 28539463). A patient with BRAF V600E-mutated metastatic melanoma, who experienced disease relapse after an initial response to the BRAF inhibitor Vemurafenib, was subsequently treated with dabrafenib plus trametinib (RAF inhibitor plus MEK inhibitor), and had a partial response for a period of two months (PMID: 28539463).",
            "description_review": {
              "updateTime": 1634068264906,
              "updatedBy": "User"
            },
            "description_uuid": "9c8baf30-589b-4bc9-9acb-09b1a3d60a2b",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1564456374769,
              "updatedBy": "User"
            },
            "effect_uuid": "9f208268-d2d3-415b-820f-472944a8850e",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1564456373670,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "bb7f48fd-2962-44c1-a76a-08465a8aa7cf",
            "short": ""
          },
          "mutation_effect_uuid": "4cae1026-3183-446c-b2c3-c70573cbf296",
          "name": "AGAP3-BRAF Fusion",
          "name_review": {
            "updateTime": 1545146935634,
            "updatedBy": "User"
          },
          "name_uuid": "56befb06-8839-4e0e-b988-41f90ab4d744"
        },
        {
          "mutation_effect": {
            "description": "The AGK-BRAF fusion protein results from an inversion of chromosome 7, which fuses the first two exons of AGK with exons 8-18 of BRAF. The AGK-BRAF fusion protein contains the full BRAF kinase domain, but lacks the regulatory RAS-binding domain and the cysteine-rich (CR1) domain, which are responsible for BRAF binding to RAS and auto-inhibition (PMID: 23890088, 24135138). This fusion has been found in melanoma, glioma, lung cancer, ovarian serous carcinoma and pediatric post-Chernobyl thyroid cancer (PMID: 23890088, 24135138, 26314551, 34568720). Expression of AGK-BRAF in mouse fibroblasts demonstrated that this fusion is activating and transforming as measured by increased growth and colony formation in soft agar compared to GFP control (PMID: 24135138). In vitro studies of AGK-BRAF in melanoma cell lines suggest that this fusion is sensitive to sorafenib but not vemurafenib as measured by cell viability upon drug treatment (PMID: 23890088). AGK-BRAF fusion was observed in 3 of 174 EGFR-mutant lung adenocarcinoma with primary resistance to EGFR tyrosine kinase inhibitors (TKIs).  Functional studies with the induction of AGK-BRAF fusion in H1975 ( EGFR L858R + T790M), PC9 (EGFR ex19del) and HCC827 (EGFR ex19del) cell lines demonstrated that the fusion conferred resistance to growth inhibition by EGFR TKIs (PMID: 30831205).",
            "description_review": {
              "updateTime": 1634069900381,
              "updatedBy": "User"
            },
            "description_uuid": "a5190aff-dd7f-4110-a3e6-05e6728f6930",
            "effect": "Gain-of-function",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "ec17e9b0-111a-46a9-a462-3608dcfa3eac",
            "oncogenic": "Yes",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "e535c945-69cf-4a98-8ec3-6161c1706862",
            "short": "PDX model with confirmed AGK-BRAF fusion showed significant response to downstream MAPK inhibition with trametinib, a MEK inhibitor, and SCH772984, an ERK inhibitor (PMID: 30254212)"
          },
          "mutation_effect_uuid": "26405d45-2077-44aa-9f2b-72dae0333a17",
          "name": "AGK-BRAF Fusion",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "217a4b25-d43a-4e50-94a1-676998aea003"
        },
        {
          "mutation_effect": {
            "description": "The AKAP9-BRAF fusion protein results from an inversion of chromosome 7 that fuses exons 1-8 of AKAP9 and exons 9-18 of BRAF. This fusion contains the BRAF kinase domain, but excludes the BRAF CR1 domain responsible for RAS binding and auto-inhibition (PMID:15630448). Expression of AKAP9-BRAF in COS7 cells demonstrated that it is activating as measured by increased kinase activity compared to wildtype BRAF, and expression of AKAP9-BRAF in NIH-3T3 cells demonstrated that it is transforming as measured by increased foci formation compared to wildtype BRAF (PMID:15630448).",
            "description_review": {
              "updateTime": 1493057315640
            },
            "description_uuid": "77dd87dd-7daa-4b12-9b85-10529d2ded8b",
            "effect": "Gain-of-function",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "db923d23-b9a7-4aec-9c62-f8360acb48a7",
            "oncogenic": "Yes",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "60c9eb9a-dff8-4f07-a2de-5e0df3641d31",
            "short": ""
          },
          "mutation_effect_uuid": "926d0be0-6f4a-4ebe-8744-c1abea96746e",
          "name": "AKAP9-BRAF Fusion",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "a363c057-1d72-4223-9804-0f3c32a38475"
        },
        {
          "mutation_effect": {
            "description": "The CUL1-BRAF fusion protein results from an in-frame translocation of chromosome 7 that fuses exons 1-7 of CUL1 with exons 9-18 of BRAF (PMID: 26324360). The CUL1-BRAF fusion protein contains the BRAF kinase domain, but lacks the BRAF CR1 domain that is responsible for RAS-binding and auto-inhibition. This fusion has been found in low-grade serous ovarian cancer (PMID: 26324360). While this fusion has not been functionally validated, other fusions that contain the BRAF kinase domain an exclude the CR1 domain have been shown to be activating and oncogenic (PMID: 22745804, 25985019, 15630448). A patient with low-grade serious ovarian cancer harboring the CUL1-BRAF fusion achieved a sustained complete response to combination selumetinib and paclitaxel (PMID: 26324360). In a study of patients with low-grade serous ovarian cancer, a patient with a CUL1-BRAF fusion who progressed on carboplatin and paclitaxel had a sustained complete response to treatment with combined selumetinib and paclitaxel (PMID: 26324360).",
            "description_review": {
              "updateTime": 1503090539712
            },
            "description_uuid": "ade21166-9ae2-43dd-b992-baa345ff9d73",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "4a726bda-f66f-4715-b83d-a3cd788ba09d",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "1c201a83-1800-4ce4-a7d9-82e7ff1a3fd0",
            "short": ""
          },
          "mutation_effect_uuid": "8cfa290c-c9c0-4947-af59-41a5c30515c7",
          "name": "CUL1-BRAF Fusion",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "892a2ec4-a6ff-4ff8-a38b-b987864dc3dc"
        },
        {
          "mutation_effect": {
            "description": "The FAM131B-BRAF fusion is the result of a 2.5 Mb deletion on chromosome 7 which fuses the first two exons of the FAM131B gene with exons 9-18 of the BRAF gene (PMID: 21424530). This fusion contains the BRAF kinase domain, but excludes the BRAF CR1 domain responsible for RAS binding and auto-inhibition (PMID:15630448). The FAM131B-BRAF fusion has been found in pilocytic astrocytomas and pediatric low-grade gliomas (PMID: 21424530, 25040262). Expression of this mutation in NIH-3T3 cells demonstrated that it is activating, as measured by increased downstream MEK phosphorylation and decreased contact inhibition compared to wildtype BRAF (PMID: 21424530). Preclinical studies with mice and NIH3T3 cells expressing FAM131B-BRAF demonstrate sensitivity to treatment with trametinib as measured by suppressed tumor growth and anchorage-independent growth; however, acquired resistance was observed following prolonged treatment (PMID: 29156677). FAM131B-BRAF is suggested to acquire resistance against MEK inhibitors selumetinib, binimetinib and trametinib through enhancing PI3K/AKT/mTOR pathway signaling to overcome MEK inhibition (PMID: 29156677). Combination treatment of mTOR inhibitor everolimus with trametinib in mice expressing FAM131B-BRAF prolonged tumor suppression and delayed acquired resistance (PMID: 29156677).",
            "description_review": {
              "updateTime": 1678230742406,
              "updatedBy": "User"
            },
            "description_uuid": "7a08fd69-1b7e-47ba-8d72-dde18fdd89aa",
            "effect": "Gain-of-function",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "81a3f713-19b7-4236-bdad-ec27d8558e27",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "25243c5f-b3b1-4811-82e3-123c7c50193a",
            "short": "",
            "short_editing": ""
          },
          "mutation_effect_uuid": "0d10f734-a539-4d5c-9375-6aa8f7e4f91d",
          "name": "FAM131B-BRAF Fusion",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "a381fd1f-5140-4613-a716-61de3ccd4b85"
        },
        {
          "mutation_effect": {
            "description": "The GTF2I-BRAF fusion protein results from a rearrangement on chromosome 7, joining exons 1-19 of GTF21 to intron 9 BRAF, thus retaining the full kinase domain of BRAF. The GTF2I-BRAF fusion has been identified in melanoma and pilocytic astrocytoma (PMID: 26314551, 28448514). When expressed in a human embryonic kidney cell line, the fusion protein elevated basal levels of phosphorylated ERK compared to the wildtype BRAF (PMID: 28448514). The fusion was detected in a patient with pilocytic astrocytoma and immunohistochemistry confirmed elevated phospho-ERK in tumor tissue from this patient (PMID: 28448514).",
            "description_review": {
              "updateTime": 1678407213511,
              "updatedBy": "User"
            },
            "description_uuid": "e52273e1-042f-460e-8ca4-811881cf85b7",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1512002856349,
              "updatedBy": "User"
            },
            "effect_uuid": "6ef06341-1ca9-4f6c-8a4c-293b89cb6f0d",
            "oncogenic": "Yes",
            "oncogenic_review": {
              "updateTime": 1512002855529,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "71d38212-4aaa-400f-a4e5-e1b22e33a12c",
            "short": ""
          },
          "mutation_effect_uuid": "7563db83-81bb-4bc5-ad6c-e440d60b8b93",
          "name": "GTF2I-BRAF Fusion",
          "name_review": {
            "updateTime": 1512002838592,
            "updatedBy": "User"
          },
          "name_uuid": "8c693b39-8335-4fd1-a868-0657dd4d8238"
        },
        {
          "mutation_effect": {
            "description": "The KIAA1549-BRAF fusion protein results from an internal tandem duplication event on chromosome 7 that fuses exons 1-16 of KIAA1549 and exons 9-18 of BRAF. This fusion contains the BRAF kinase domain, but excludes the BRAF CR1 domain responsible for RAS binding and auto-inhibition (PMID: 18974108, 24345920). This fusion has been found in pilocytic astrocytoma (PMID: 18974108, 24345920). Expression of this fusion in NIH-3T3 cells demonstrated that it is activating as measured by constitutive kinase activity and increased anchorage independent growth in soft agar compared to wildtype BRAF (PMID: 18974108). KIAA1549-BRAF fusion protein functions as a dimer and is therefore not sensitive to RAF inhibitors such as vemurafenib in vitro (PMID: 23533272). Preclinical evidence suggests that these oncoproteins may be targeted by second-generation RAF inhibitors, which are reported to inhibit RAF dimers rather than induce their transactivation of RAF (as is the case with older inhibitors such as vemurafenib) (PMID: 23533272). In vitro studies have suggested that pediatric astrocytoma cell lines harboring the KIAA1549-BRAF fusion are resistant to treatment with first generation RAF inhibitors (PMID: 23533272, 26072686). In a Phase II clinical trial of selumetinib in 25 patients with WHO grade I pilocytic astrocytoma harboring either the KIAA1549-BRAF fusion or the BRAF V600E mutation, nine patients (36% [95% CI:18-57%]) had a sustained partial response (PMID: 31151904).",
            "description_review": {
              "updateTime": 1572225155658,
              "updatedBy": "User"
            },
            "description_uuid": "9b80938c-5428-4e54-b7f0-c715830f072f",
            "effect": "Gain-of-function",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "f98b6b73-bf97-4869-aec2-1234627962f3",
            "oncogenic": "Yes",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "55d693ef-39c8-4ddb-9623-8a864eea593b",
            "short": ""
          },
          "mutation_effect_uuid": "df12feae-5c95-4563-a6a5-3cf64c96aad4",
          "name": "KIAA1549-BRAF Fusion",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "53dd83fb-f046-470d-ac13-470cc50051a8"
        },
        {
          "mutation_effect": {
            "description": "The MKRN1-BRAF fusion results from an inversion of chromosome 7 that fuses exons 1-4 of MKRN1 and exons 11-18 of BRAF (PMID: 23817572). This fusion contains the BRAF kinase domain but excludes the BRAF cysteine-rich (CR1) domain responsible for RAS binding and auto-inhibition (PMID:15630448). This mutation has been found in pediatric pilocytic astrocytoma, colorectal cancer, head and neck cancer, and ovarian serous cancer (PMID: 23817572, 26314551, 26324360, 34568720). While this fusion has not been functionally validated, other fusions that contain exons 11-18 of BRAF (e.g., AKAP9-BRAF, KIAA1549-BRAF) have been shown to be activating and oncogenic (PMID: 15630448, 18974108, 23817572). The MKRN1-BRAF fusion was detected in a patient with low-grade serous ovarian cancer who achieved a sustained complete response to combination selumetinib and paclitaxel (PMID: 26324360, 34568720).",
            "description_review": {
              "updateTime": 1634069934255,
              "updatedBy": "User"
            },
            "description_uuid": "b2a3b4e0-73bb-4773-a372-a3198a838f31",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "621199d9-da07-472a-b38b-2674f36450af",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "89c2cc4a-b480-4509-983b-a785ba959878",
            "short": "",
            "short_editing": ""
          },
          "mutation_effect_uuid": "b7d3ab03-7928-4a1d-8c33-06bb1c65bcb5",
          "name": "MKRN1-BRAF Fusion",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "04372be5-b708-4ab3-9f0f-0705ae2e3711"
        },
        {
          "mutation_effect": {
            "description": "The PAPSS1-BRAF fusion protein results from a fusion of chromosomes 4 and 7 that fuses exons 1-5 of PAPSS1 and exons 9-18 of BRAF (PMID: 24345920). This fusion contains the BRAF kinase domain, but excludes the BRAF CR1 domain responsible for RAS binding and auto-inhibition (PMID:15630448). This fusion has been found in melanoma (PMID: 24345920). Expression of this fusion in 293H cells demonstrated that it is activating as measured by activation of downstream MEK and ERK that is comparable to BRAF V600E (PMID: 24345920). In vitro experiments have suggested that the PAPSS1-BRAF fusion is resistant to vemurafenib but sensitive to trametinib as measured by changes in MEK and ERK phosphorylation upon drug treatment (PMID: 24345920).",
            "description_review": {
              "updateTime": 1493057315640
            },
            "description_uuid": "833e3c22-02f6-4731-887a-33a2354dbc88",
            "effect": "Gain-of-function",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "aac8fa91-a07d-4eb8-b3be-b9f2132cb9b4",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "5d30335b-e959-4424-9f22-37e9577b519e",
            "short": ""
          },
          "mutation_effect_uuid": "430d25f7-cf80-4876-9139-5c666735c3b3",
          "name": "PAPSS1-BRAF Fusion",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "cdd1efde-8a6a-4675-b933-744733b33f13"
        },
        {
          "mutation_effect": {
            "description": "The PPFIBP2-BRAF fusion joins the N-terminus of PPFIBP2 with the C-terminus of BRAF resulting in a fusion protein containing the BRAF kinase domain but lacking the BRAF CR1 regulatory domain. While this fusion has not been functionally validated, other BRAF fusions lacking the BRAF CR1 regulatory domain (e.g. KIAA 1549-BRAF fusion) have been shown to be activating and oncogenic. The PPFIBP2-BRAF fusion was found in a patient with metastatic melanoma who responded to MEK inhibition with trametinib (PMID: 26072686).",
            "description_review": {
              "updateTime": 1519869185553,
              "updatedBy": "User"
            },
            "description_uuid": "b5fb9d8d-5456-4248-b9e5-47b6a51db7ad",
            "effect": "Gain-of-function",
            "effect_uuid": "935876ae-3fd7-430d-b5bd-f9f34f8f540b",
            "oncogenic": "Yes",
            "oncogenic_uuid": "0e288881-f144-4f60-b565-d607cb2c22d2",
            "short": ""
          },
          "mutation_effect_uuid": "0bbe3fef-cd16-48f8-816f-830c568fe269",
          "name": "PPFIBP2-BRAF Fusion",
          "name_review": {
            "updateTime": 1503945304076
          },
          "name_uuid": "a75c1d2b-2342-446d-b005-12621f2a01e4"
        },
        {
          "mutation_effect": {
            "description": "The SND1-BRAF fusion protein results from a rearrangement of chromosome 7 and fuses exons 1-16 of SND1 with exons 9-18 of BRAF. The SND1-BRAF fusion protein contains the BRAF kinase domain, but lacks the BRAF CR1 domain that is responsible for RAS-binding and auto-inhibition (PMID: 24345920). Expression of SND1-BRAF in a lung adenocarcinoma cell line, H1299, or a gastric cancer cell line, GTL16, demonstrated that this fusion is activating as measured by increased activation of downstream MEK and ERK signaling proteins compared to wildtype BRAF (PMID: 22745804, 25985019). Expression of SND1-BRAF in Ba/F3 cells demonstrated that this fusion is transforming as measured by IL-3-independent growth (PMID: 25266736). In vitro studies suggest that this fusion is sensitive to MEK inhibition, as measured by decreased cell viability upon treatment with trametinib (PMID: 25266736).",
            "description_review": {
              "updateTime": 1493057315640
            },
            "description_uuid": "334178e8-4fc3-4dfa-bedd-737a602bb192",
            "effect": "Gain-of-function",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "8674d546-7ec4-40ba-a4b1-0dbb0e112823",
            "oncogenic": "Yes",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "dfdf1602-37b6-40f4-a110-c0c62594f6e3",
            "short": "",
            "short_editing": ""
          },
          "mutation_effect_uuid": "067f420d-b3c5-4b4e-8cac-4e606950686c",
          "name": "SND1-BRAF Fusion",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "0fcaa00d-cd3c-4556-abd6-dc740e5922d5"
        },
        {
          "mutation_effect": {
            "description": "The TRIM24-BRAF fusion protein results from an inversion of chromosome 7 that fuses exons 1-9 of TRIM24 and exons 9-18 of BRAF (PMID: 24345920). This fusion contains the BRAF kinase domain, but excludes the BRAF CR1 domain responsible for RAS binding and auto-inhibition (PMID:15630448). This fusion has been found in melanoma (PMID: 24345920). Expression of this fusion in 293H cells demonstrated that it is activating as measured by activation of downstream MEK and ERK that is comparable to BRAF V600E (PMID: 24345920). In vitro experiments have suggested that the TRIM24-BRAF fusion is resistant to vemurafenib but sensitive to trametinib as measured by changes in MEK and ERK phosphorylation upon drug treatment (PMID: 24345920).",
            "description_review": {
              "updateTime": 1563636905453,
              "updatedBy": "User"
            },
            "description_uuid": "0e1c2cea-d58b-4f2a-b2f4-84f2bac80beb",
            "effect": "Gain-of-function",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "2ae1fb52-59a2-4a65-8fea-3fe33187dca6",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "b5a0f9dd-a623-480e-a8ce-fc163330249e",
            "short": "",
            "short_editing": ""
          },
          "mutation_effect_uuid": "0f2a2657-4ded-4bdc-b044-8a65f11c871f",
          "name": "TRIM24-BRAF Fusion",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "3e521097-f21a-470d-bda2-3a528ff981de"
        },
        {
          "mutation_effect": {
            "description": "The ZKSCAN1-BRAF fusion joins the N-terminus of ZKSCAN1 with the C-terminus of BRAF, resulting in a fusion protein containing the BRAF kinase domain but lacking the BRAF CR1 regulatory domain. While this fusion has not been functionally validated, other BRAF fusions lacking the BRAF CR1 regulatory domain (e.g. KIAA 1549-BRAF fusion) have been shown to be activating and oncogenic. The ZKSCAN1-BRAF fusion was found in a patient with spitzoid melanoma who responded to the MEK inhibitor trametinib (PMID: 26314551).",
            "description_review": {
              "updateTime": 1520284825007,
              "updatedBy": "User"
            },
            "description_uuid": "a9baa250-3c6d-4f74-b289-235b13726945",
            "effect": "Likely Gain-of-function",
            "effect_uuid": "465766c4-ccec-4657-9331-3b277c8d36eb",
            "oncogenic": "Likely",
            "oncogenic_uuid": "90c7bd08-6966-4b0b-aaf0-acf1e1625bdd",
            "short": ""
          },
          "mutation_effect_uuid": "3f6275e3-4b32-4404-aa82-b93cfceb9c73",
          "name": "ZKSCAN1-BRAF Fusion",
          "name_review": {
            "updateTime": 1503945321254
          },
          "name_uuid": "8593062e-c063-4f9b-9603-0be8c5c9d153"
        },
        {
          "mutation_effect": {
            "description": "BRAF amplification is a rare event in cancer and has been found to occur at very low frequency in melanoma and glioma (cBioPortal, MSKCC, April 2017). It has been demonstrated that amplification of wildtype BRAF in melanoma cells leads to overexpression of the protein and constitutive activation of MAPK pathway, demonstrated as a BRAF-dependent increase in ERK phosphorylation, as well as an increase in cell proliferation (PMID: 15467732). BRAF overexpression has been associated with increased proliferation in gliomas (PMID: 25618114). Amplification of BRAF V600E allele has been described as a mechanism of resistance to MEK/RAF inhibitors in melanoma via MAPK pathway hyperactivation (PMID: 22395615, 24055054, 21098728).",
            "description_review": {
              "updateTime": 1563636373516,
              "updatedBy": "User"
            },
            "description_uuid": "824ed602-c1c8-4f65-be0a-aea6478873b4",
            "effect": "Gain-of-function",
            "effect_review": {
              "updateTime": 1493475122446
            },
            "effect_uuid": "7c4682f3-b122-4160-bb8b-fd1585a3b73e",
            "oncogenic": "Yes",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "ee6a98fc-190a-40d0-8b1e-6aa8726a3a2b",
            "short": ""
          },
          "mutation_effect_uuid": "d0cc0981-b984-4119-a65b-e176b997306e",
          "name": "Amplification",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "2e04527d-6a62-459a-b21a-4ba8251a633d"
        },
        {
          "mutation_effect": {
            "description": "The class III BRAF D594H missense mutation occurs in the kinase domain in exon 15 of the protein (PMID: 28783719). This mutation has been reported in melanoma, lung and colorectal cancers (PMID: 28481359). Biological characterization of the BRAF D594H mutation has demonstrated that it is RAS dependent in its activation of the MAPK pathway, signals as a dimer with CRAF, and typically co-occurs with another driver mechanism that amplifies RAS signaling (PMID: 28783719). Thus, when BRAF D594H is observed in melanoma, it typically co-occurs with an activating RAS mutation or NF1 inactivation, whereas when observed in non-small cell lung or colorectal cancers, it is associated with receptor tyrosine kinase (RTK) hyperactivation at the protein level (PMID: 28783719, 20141835). While this mutation is sensitive to MEK inhibition by targeted inhibitors such as trametinib, it is insensitive to RAF monomer inhibitors such as vemurafenib (PMID: 28783719).",
            "description_review": {
              "updateTime": 1678135878312,
              "updatedBy": "User"
            },
            "description_uuid": "22b534dc-64d6-4131-9e6d-3eb3dee9d7c2",
            "effect": "Gain-of-function",
            "effect_uuid": "be6acfec-a41a-46ca-b9ce-e79a9b7ee84a",
            "oncogenic": "Yes",
            "oncogenic_review": {
              "updateTime": 1529423185374,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "fd6a7bec-aedd-46f3-8c87-1a3ed90ed1f5",
            "short": ""
          },
          "mutation_effect_uuid": "d49ce516-78f9-4934-c0b5-4b2eaaadf08e",
          "name": "D594H",
          "name_uuid": "f4204385-be53-4851-a4ed-667e26021ca0"
        },
        {
          "mutation_effect": {
            "description": "The class III BRAF N581I mutation is located in the kinase domain in exon 15 of the protein (PMID: 28783719). This mutation has been reported in lung cancer and vulval malignant melanoma (PMID: 22969966, 26202550, 15917418). Biochemically, it has been demonstrated that the BRAF N581I mutant signals as a dimer with CRAF, is RAS-dependent in its activation of the MAPK pathway, and, in tumors, would typically co-occur with another driver mechanism that amplifies RAS signaling (PMID: 28783719). Thus, in melanoma, the N581I variant, similar to other class III BRAF mutants, would be expected to co-occur with activating RAS mutation or NF1 inactivation, whereas in non-small cell lung or colorectal cancers, this mutation would most likely be associated with receptor tyrosine kinase (RTK) hyperactivation at the protein level (PMID: 28783719). While this mutation is sensitive to MEK inhibition by targeted inhibitors such as trametinib, it is insensitive to RAF monomer inhibitors such as vemurafenib (PMID: 28783719). In a case report, a patient with metastatic colorectal cancer harboring BRAF N581I was treated with a combination therapy of cetuximab plus irinotecan and demonstrated stable disease with a progression-free survival of 10.3 months (PMID: 31515458).",
            "description_review": {
              "updateTime": 1678407240987,
              "updatedBy": "User"
            },
            "description_uuid": "65328a0b-01d6-4c22-9084-2561ce70c601",
            "effect": "Gain-of-function",
            "effect_uuid": "0cc9d835-eac3-44d0-b116-4aaca9cf6dac",
            "oncogenic": "Yes",
            "oncogenic_review": {
              "updateTime": 1529423051338,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "08e3242b-d663-42c0-bdfe-978c4e27c4e7",
            "short": ""
          },
          "mutation_effect_uuid": "c040244e-6628-4578-ac19-45b6d9eb687d",
          "name": "N581I",
          "name_uuid": "24cf45f3-a78a-4c92-b929-821c5b383994"
        },
        {
          "mutation_effect": {
            "description": "The class III BRAF G596D mutation is located in the kinase domain in exon 15 of the protein (PMID: 28783719). This mutation has been reported in cervical adenocarcinoma and esophagogastric cancer (PMID: 17360030, 23481512). Biochemically, it has been demonstrated that the BRAF G596D mutant signals as a dimer with CRAF, is RAS-dependent in its activation of the MAPK pathway, and, in tumors, would typically co-occur with another driver mechanism that amplifies RAS signaling (PMID: 28783719). Thus, like other class III BRAF mutants, in melanoma, the G596D variant would be expected to co-occur with activating RAS mutation or NF1 inactivation, whereas in non-small cell lung and colorectal cancers, this mutation would most likely be associated with receptor tyrosine kinase (RTK) hyperactivation at the protein level (PMID: 28783719). While this mutation is sensitive to MEK inhibition by targeted inhibitors such as trametinib, it is insensitive to RAF monomer inhibitors such as vemurafenib (PMID: 28783719). Preclinical studies with SKBR3 cells expressing BRAF G596D demonstrate resistance to treatment with dabrafenib as measured by sustained ERK phosphorylation following treatment (PMID: 31158244).",
            "description_review": {
              "updateTime": 1678407315032,
              "updatedBy": "User"
            },
            "description_uuid": "ab0f4b96-9b6c-491c-92ac-066167993de1",
            "effect": "Gain-of-function",
            "effect_uuid": "49953b55-2bdb-486f-b7e4-89fe7668145b",
            "oncogenic": "Yes",
            "oncogenic_review": {
              "updateTime": 1529423241557,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "ae1e8ae2-ae37-432a-b750-d53fd88d0c79",
            "short": ""
          },
          "mutation_effect_uuid": "916904b9-4ad8-4576-b9bf-dc47119ea5cc",
          "name": "G596D",
          "name_uuid": "419dce6a-168f-4ddd-b986-3529d001cbae"
        },
        {
          "mutation_effect": {
            "description": "The BRAF P367R mutation occurs in exon 8 of the gene. A study evaluating the effects of rare somatic mutations in lung cancers showed that cells transfected with BRAF P367R mutation display a mild increase in ERK phophorylation compared to wildtype (PMID: 27478040).",
            "description_uuid": "fb8bbfe3-f294-4d50-b9e1-196ad8b18432",
            "effect": "Likely Gain-of-function",
            "effect_uuid": "31cdd5bf-1988-4e5c-9e4e-763b9e2f48cb",
            "oncogenic": "Likely",
            "oncogenic_uuid": "b43cee2e-c580-4a59-b413-2a9b73025243",
            "short": ""
          },
          "mutation_effect_uuid": "ad5fbfea-7144-4546-a0da-f412aa240e97",
          "name": "P367R",
          "name_uuid": "c57bb27e-95d9-455b-a157-f20beba303f1"
        },
        {
          "mutation_effect": {
            "description": "The BRAF H574Q mutation is located in exon 14 of the kinase domain of the protein. This mutation has been identified in glioma and melanoma (PMID: 34625582, 28972077). A study evaluating the effects of rare somatic mutations in lung cancers showed that cells transfected with BRAF H574Q mutation display a robust increase in ERK phosphorylation, comparable to BRAF V600E mutation (PMID: 27478040).",
            "description_review": {
              "updateTime": 1678407345671,
              "updatedBy": "User"
            },
            "description_uuid": "677639f4-3e1b-48e9-888c-c79e78b66fbb",
            "effect": "Likely Gain-of-function",
            "effect_uuid": "6e4e140e-18bf-423f-94d3-f0747d28683c",
            "oncogenic": "Likely",
            "oncogenic_uuid": "c12b63c0-7113-4bff-bb65-5012665295d1",
            "short": ""
          },
          "mutation_effect_uuid": "087b4e6f-11ba-4e13-986b-a865229fd944",
          "name": "H574Q",
          "name_uuid": "4aa92907-3e0c-486d-bd1b-e27cd10d1710"
        },
        {
          "mutation_effect": {
            "description": "The BRAF W450L mutation is located in the kinase domain of the BRAF protein. This mutation has been found in lung cancers, among others (PMID: 27478040). In vitro studies have demonstrated that this mutation is likely neutral as measured by downstream signaling compared to wildtype (PMID: 27478040).",
            "description_review": {
              "updateTime": 1600637656808,
              "updatedBy": "User"
            },
            "description_uuid": "340d9d91-b4b0-4554-9003-ad69bba0d26a",
            "effect": "Likely Neutral",
            "effect_uuid": "a4bddc9f-5015-46ac-bb44-29ac9c0ba4ab",
            "oncogenic": "Likely Neutral",
            "oncogenic_uuid": "81aec819-7b4c-4046-9d85-fcf61e35c5d5",
            "short": ""
          },
          "mutation_effect_uuid": "7bb06e45-4052-4c82-91f1-fbdbe8630604",
          "name": "W450L",
          "name_uuid": "4399d550-5314-4b51-944e-c3113844facf"
        },
        {
          "mutation_effect": {
            "description": "The class III BRAF S467L mutation occurs in the kinase domain in exon 11 of the protein (PMID: 28783719). This mutation has been reported in melanoma (PMID: 24710085, 25651238, 26498038, 26559571). Biochemically, it has been demonstrated that the BRAF S467L mutant signals as a dimer with CRAF, is RAS-dependent in its activation of the MAPK pathway, and, in tumors, would typically co-occur with another driver mechanism that amplifies RAS signaling (PMID: 28783719). Therefore, class III BRAF mutants like the BRAF S467L variant would be generally expected to co-occur with activating RAS mutations or NF1 inactivation in melanomas, whereas in non-small cell lung or colorectal cancers, this mutation will most likely be associated with receptor tyrosine kinase (RTK) hyperactivation at the protein level (PMID: 28783719).",
            "description_review": {
              "updateTime": 1678407375574,
              "updatedBy": "User"
            },
            "description_uuid": "dd55e4ef-24c2-47ad-a154-3c476107ff56",
            "effect": "Gain-of-function",
            "effect_uuid": "2cff07a9-00cc-46ec-b107-d2f5af04f8ba",
            "oncogenic": "Yes",
            "oncogenic_review": {
              "updateTime": 1529423010094,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "1e49a5d0-e272-4aae-9808-df8d11f19caf",
            "short": ""
          },
          "mutation_effect_uuid": "8c9735a4-b3bb-4b11-8764-00de098495ef",
          "name": "S467L",
          "name_uuid": "068cb326-d525-440c-a0a4-7bdd74ca6ab9"
        },
        {
          "mutation_effect": {
            "description": "The class II BRAF K601T mutation is located in the kinase domain in exon 15 of the protein (PMID: 28783719, 26343582). This mutation has been reported in hairy cell leukemia and multiple myeloma (PMID: 25938346, 26090869). Biochemical characterization of BRAF K601T has demonstrated that it activates the downstream MAPK pathway independent of RAS and renders BRAF active as a dimer with CRAF and itself (PMID: 26343582). While this mutation is sensitive to MEK inhibition by targeted inhibitors such as trametinib, it is insensitive to RAF monomer inhibitors such as vemurafenib (PMID: 28783719, 26343582, 22798288).",
            "description_review": {
              "updateTime": 1678407412494,
              "updatedBy": "User"
            },
            "description_uuid": "b580c360-0e81-4ace-9cb7-4936ac2d01d0",
            "effect": "Gain-of-function",
            "effect_uuid": "e34774d6-313e-4da7-824b-87c3d126c302",
            "oncogenic": "Yes",
            "oncogenic_review": {
              "updateTime": 1529422559525,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "e284c089-14e5-44d4-ad50-ab260d2d8f45",
            "short": ""
          },
          "mutation_effect_uuid": "ac5fa260-84be-4ed4-8bc8-b92569c54904",
          "name": "K601T",
          "name_uuid": "1474e63d-d911-4b46-9da4-72b2a5a308b3"
        },
        {
          "mutation_effect": {
            "description": "",
            "description_review": {
              "updateTime": 1565459377159,
              "updatedBy": "User"
            },
            "description_uuid": "e6948680-d7f8-4665-8c91-50ac63ee3fe8",
            "effect": "",
            "effect_uuid": "e052e5b4-30de-4bfd-a444-6710a9573b97",
            "oncogenic": "",
            "oncogenic_uuid": "5463fb3e-9ec3-4173-a3dd-5baec054aa4a",
            "short": ""
          },
          "mutation_effect_uuid": "2c635ebe-ea40-44a0-9366-2afb168f8bdf",
          "name": "G469A, G469V, G469R, G464 (non-V600 mutations class II )",
          "name_review": {
            "updateTime": 1678993644896,
            "updatedBy": "User"
          },
          "name_uuid": "6bfd2309-23ad-432c-9e44-e63d72acea80",
          "tumors": [
            {
              "TIs": [
                {
                  "name": "Standard implications for sensitivity to therapy",
                  "name_uuid": "6694bdc1-d799-405c-9514-48433f5b61f3",
                  "type": "SS"
                },
                {
                  "name": "Standard implications for resistance to therapy",
                  "name_uuid": "59e041b6-f693-43a8-90f4-80da4373cbe2",
                  "type": "SR"
                },
                {
                  "name": "Investigational implications for sensitivity to therapy",
                  "name_uuid": "cc372c75-219d-4db7-a372-b28e4b649f59",
                  "treatments": [
                    {
                      "description": "PLX8394 is an orally available, second-generation, small-molecule BRAF inhibitor that inhibits mutated, oncogenic BRAF without causing paradoxical MAPK pathway activation as is seen with first-generation BRAF inhibitors (PMID: 28659148). In a phase I clinical trial for patients with refractory or relapsed solid tumors with or without BRAF mutation, there were two (28%) partial responses of seven evaluable BRAF-mutant patients treated with PLX8394 and cobicistat, a CYP3A4 inhibitor (Abstract: Janku et al. Abstract# B176, AACR-NCI-EORTC 2017. http://mct.aacrjournals.org/content/17/1_Supplement/B176). Both responses were in patients with BRAF V600 mutations. In a phase I/IIa trial of PLX8394 for patients with BRAF-altered, advanced solid or CNS tumors (n=110; n=61, patients with class 1 mutations; n=19, patients with class 2 mutations [excluding fusions]; n=17, patients with BRAF fusions), partial response was achieved in 39% (n=9/23) of patients with MAPKi-naive, V600-mutant tumors, with a median duration of response (DoR) of 32 months, and in 18% (n=3/17) of patients with MAPKi treated, V600-mutant tumors (n=6, patients with V600-mutant glioma; n=3, patients with V600-mutant ovarian cancer; n=1, patients with V600-mutant small bowel cancer; n=1, patients with V600-mutant papillary thyroid cancer; n=1, patients with V600-mutant anaplastic thyroid cancer) (Abstract: Fuente et al. Abstract# 3006, J. Clin. Oncol. 2023, Vol 41, Suppl 16. https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.3006). \nPreclinical studies show that PLX8394 specifically inhibits BRAF-containing dimers and inhibits proliferation and pathway activation in BRAF-mutated colorectal cancer cell lines (PMID: 26466569, 28659148, 30559419, 28783719).",
                      "description_review": {
                        "updateTime": 1707430900015,
                        "updatedBy": "User"
                      },
                      "description_uuid": "66fe3a76-77b8-43e2-b50e-27dd8389df23",
                      "fdaLevel": "Fda3",
                      "fdaLevel_review": {
                        "updateTime": 1676490666937,
                        "updatedBy": "User"
                      },
                      "fdaLevel_uuid": "be01f6b8-ee82-4087-bfba-87c58f4530bf",
                      "indication": "",
                      "indication_uuid": "605e2606-62c5-4878-831d-be6a9ff35b4b",
                      "level": "4",
                      "level_uuid": "4b4c8f36-d252-4c65-92c6-9b9fba885d91",
                      "name": "44faeeae-ad6d-4370-8c99-97955f9e0feb",
                      "name_review": {
                        "updateTime": 1555910558541,
                        "updatedBy": "User"
                      },
                      "name_uuid": "96034660-351c-4fce-9f82-cdfe98f7a0d2",
                      "propagation": "4",
                      "propagationLiquid": "no",
                      "propagationLiquid_uuid": "d230ff0c-db25-11e9-8500-60f81dc75ed6",
                      "propagation_review": {
                        "updateTime": 1549576203165,
                        "updatedBy": "User"
                      },
                      "propagation_uuid": "1135887b-f515-46a3-a0e1-cbae63b9d407",
                      "short": ""
                    }
                  ],
                  "type": "IS"
                },
                {
                  "name": "Investigational implications for resistance to therapy",
                  "name_uuid": "d4521bb3-e3c4-47ec-afd1-b5626903c2c8",
                  "type": "IR"
                }
              ],
              "cancerTypes": [
                {
                  "code": "",
                  "mainType": "All Solid Tumors",
                  "subtype": ""
                }
              ],
              "cancerTypes_review": {
                "updateTime": 1566316199246,
                "updatedBy": "User"
              },
              "cancerTypes_uuid": "502e00e1-ac70-4500-a7fb-cb79bd35f14c",
              "diagnostic": {
                "description": "",
                "description_uuid": "0a9d5eb4-dee1-4937-abbd-37d2d3075620",
                "level": "",
                "level_uuid": "74e18a75-33c6-476f-b4a4-fb16c267a2d9",
                "short": ""
              },
              "diagnosticSummary": "",
              "diagnosticSummary_uuid": "7c7bf614-79cc-48e3-af85-a11c4069cf59",
              "diagnostic_uuid": "a6ed57a9-4dbc-4f31-b587-d14474c41b3d",
              "prognostic": {
                "description": "",
                "description_uuid": "771d1a9c-c430-49e6-9fc4-799b07a28958",
                "level": "",
                "level_uuid": "bce26569-46ad-4526-9c79-fe377e016d79",
                "short": ""
              },
              "prognosticSummary": "",
              "prognosticSummary_uuid": "42339138-e4de-46af-94d9-dc2f708eab9c",
              "prognostic_uuid": "e5a0cf0b-b8a6-45ed-bac2-66ac811c4d2b",
              "summary": "BRAF class II mutations including [[gene]] [[mutation]] are insensitive to the RAF-targeted inhibitors vemurafenib and dabrafenib. Laboratory data suggest that cancer cells with oncogenic, non-V600 BRAF mutations may be sensitive to novel BRAF inhibitors such as PLX8394.",
              "summary_review": {
                "updateTime": 1566490002045,
                "updatedBy": "User"
              },
              "summary_uuid": "522e6413-dfd4-4099-8da9-1f79b192e6e4"
            }
          ]
        },
        {
          "mutation_effect": {
            "description": "The class III BRAF F247L mutation is located in the RAS binding and kinase autoinhibitory domain of the BRAF protein (PMID: 31515458). This mutation has been found in colorectal cancers, among others (PMID: 31515458). In vitro studies have demonstrated that this mutation is activating as measured by increased downstream signaling compared to wildtype (PMID: 28512244, 29533785). A patient with metastatic colorectal cancer harboring BRAF F247L was treated with a combination therapy of FOLFIRI plus cetuximab and demonstrated a complete response with a progression-free survival of 12.6 months (PMID: 31515458).",
            "description_review": {
              "updateTime": 1678230969936,
              "updatedBy": "User"
            },
            "description_uuid": "a1ce27f1-dbc6-47ad-87cb-3dde292373fa",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1539776764297,
              "updatedBy": "User"
            },
            "effect_uuid": "6da5e4e4-ed2a-4c99-83cd-555ceb42bd76",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1539806297157,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "94ff2e7c-e9c1-490b-8f9f-0de4c1b633d1",
            "short": ""
          },
          "mutation_effect_uuid": "eac54f68-a913-4c1b-8dca-c378a3f8cb7a",
          "name": "F247L",
          "name_review": {
            "updateTime": 1539776757830,
            "updatedBy": "User"
          },
          "name_uuid": "29b444f9-5965-4301-bef8-411bbbe505f6",
          "tumors_uuid": "7127587b-5a38-47a4-a0f5-022007fd8b97"
        },
        {
          "mutation_effect": {
            "description": "The BRAF L514V mutation is located in the ATP binding pocket of the kinase domain of the protein. This mutation was found in a patient with BRAF V600E-mutant anaplastic ganglioglioma who progressed on treatment with dabrafenib (PMID: 29880583). Co-expression of this mutation in human cells with BRAF V600E in cis demonstrated that it is activating, promotes dimerization, and confers resistance to type I αC-OUT/DFG-IN BRAF inhibitors such as vemurafenib and dabrafenib (PMID: 29880583). The BRAF L514V mutation was shown to be sensitive to inhibition with RAF dimer inhibitors, such as BGB3245 (PMID: 29880583).",
            "description_review": {
              "updateTime": 1539974663111,
              "updatedBy": "User"
            },
            "description_uuid": "955be0ec-b315-421d-b05d-f95bfdc28db1",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1539972127535,
              "updatedBy": "User"
            },
            "effect_uuid": "fa20c208-4419-4084-96ea-938a2dcd9353",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1539972126640,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "06ea9f39-5cdd-4c53-9d3b-fd0740e47125",
            "short": ""
          },
          "mutation_effect_uuid": "c7856a86-8d58-45cf-b5ab-d2af13e4cfba",
          "name": "L514V",
          "name_review": {
            "updateTime": 1539971887363,
            "updatedBy": "User"
          },
          "name_uuid": "09fa1934-c2dd-4ab2-9b4e-609b7f969def",
          "tumors_uuid": "f15904e2-81d1-4d9f-93d5-aa5c7ba3a437"
        },
        {
          "mutation_effect": {
            "description": "The PCBP2-BRAF fusion results from the fusion of the 3' end of the PCBP2 gene with the 5' end of the BRAF gene. While this alteration has not been functionally characterized per se, many other BRAF fusions have been shown to be oncogenic suggesting that the PCBP2-BRAF fusion is likely oncogenic (PMID: 24345920, 21424530, 22745804, 21424530, 18974108, 26343582). In a study of patients with non-small cell lung cancer who progressed on osimertinib, one patient harbored the PCBP2-BRAF fusion (PMID: 30257958). Knockdown of BRAF in a cell line created from this patient led to a reduction of cell growth and resensitization to osimertinib (PMID: 30257958). While these cells were insensitive to the BRAF inhibitors dabrafenib and LXH245, they were sensitive to the MEK inhibitor trametinib (PMID: 30257958).",
            "description_review": {
              "updateTime": 1563639092192,
              "updatedBy": "User"
            },
            "description_uuid": "cbf7c4b5-1810-4110-9da0-b2c58c4b0172",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1549598193744,
              "updatedBy": "User"
            },
            "effect_uuid": "fc022e3e-d9df-4908-b6c7-e4881d450db2",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1549598191966,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "d76c1ca3-0fc0-4275-83e3-e01280b4e5f5",
            "short": ""
          },
          "mutation_effect_uuid": "33062162-c3dc-47b8-a8d4-64ef05994531",
          "name": "PCBP2-BRAF Fusion",
          "name_review": {
            "updateTime": 1549598135919,
            "updatedBy": "User"
          },
          "name_uuid": "65c20803-670d-4a02-a2e9-d1d1d5fe7e9b",
          "tumors_uuid": "cfcf577b-1f3f-451f-a0d6-e5cd21a3f596"
        },
        {
          "mutation_effect": {
            "description": "The BRAF N486_T491delinsK mutation is located in the kinase domain of the protein. This mutation has been found in histiocytic neoplasms (PMID: 30867592). Expression of this mutation in Ba/F3 cells demonstrates that it is activating as measured by increased downstream ERK signaling, cytokine-independent growth, and MEK1/2-inhibitor sensitivity in vitro compared to wildtype BRAF (PMID: 30867592). A patient with histiocytic disease harboring the BRAF N486_T491delinsK mutation had a complete response to treatment with the MEK1/2 inhibitor cobimetinib (PMID: 30867592).",
            "description_review": {
              "updateTime": 1553478312090,
              "updatedBy": "User"
            },
            "description_uuid": "0f21fe82-2b82-4a0a-a89b-37e351984f3e",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1552627703781,
              "updatedBy": "User"
            },
            "effect_uuid": "a4caf016-33fd-4eb9-b967-6b18c944b350",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1552627703074,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "373a848a-67c3-465e-a52e-c2d81b49eaea",
            "short": ""
          },
          "mutation_effect_uuid": "dd967b58-82fa-45a6-ab05-bca46414409f",
          "name": "N486_T491delinsK",
          "name_review": {
            "updateTime": 1552627700011,
            "updatedBy": "User"
          },
          "name_uuid": "fa6cb28b-3e00-4404-bc0a-5fd9cb047a6b",
          "tumors_uuid": "51debafa-b694-4c20-ba1c-9d5686c5b773"
        },
        {
          "mutation_effect": {
            "description": "Duplication of the BRAF kinase domain (BRAF-KDD) results from a breakpoint in intron 9 that generates a protein that is approximately 140 kDa. This alteration has been found in lung cancer (PMID: 32913992), melanoma (PMID: 27320919) and others (PMID: 26562024). Expression of this alteration in HEK293T cells demonstrated that it is activating as measured by increased downstream MAPK pathway signaling compared to control (PMID: 27320919). Knockdown of BRAF-KDD in BRAF V600E-positive cells expressing the kinase domain duplication demonstrated restored sensitivity to BRAF inhibitors such as dabrafenib (PMID: 27320919).",
            "description_review": {
              "updateTime": 1652730225032,
              "updatedBy": "User"
            },
            "description_uuid": "2eaad6a5-b28b-4a97-a9d8-51f4162a3296",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1564431292245,
              "updatedBy": "User"
            },
            "effect_uuid": "00b243ca-25a4-46b0-a189-7e9c80a3af07",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1564431291247,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "d8c54d72-0695-4cf9-aefa-e77540c5ffa0",
            "short": ""
          },
          "mutation_effect_uuid": "1e3d582f-aa18-498e-94bd-ad705ed07044",
          "name": "Kinase Domain Duplication",
          "name_review": {
            "updateTime": 1564431287111,
            "updatedBy": "User"
          },
          "name_uuid": "62feb2e4-a3eb-426b-97fa-5c5c8f1ccace",
          "tumors_uuid": "727cdb49-2079-4074-92e4-8b1568256c81"
        },
        {
          "mutation_effect": {
            "description": "The ARMC10-BRAF fusion protein combines the N-terminus of ARMC10 with the C-terminus of BRAF, preserving the kinase domain of BRAF. This fusion protein is found in patients with sporadic microsatellite instability-high colorectal cancers (PMID: 30279230). Expression of this fusion protein in NIH3T3 cells demonstrated that it was activating as shown by increased colony formation and pathway activation compared to expression of BRAF alone (PMID: 30279230). Preclinical studies with patient-derived xenograft models expressing ARMC10-BRAF demonstrated sensitivity to treatment with MEK inhibitor trametinib and ERK inhibitor SCH772984 as measured by tumor regression and decreased phosphorylated ERK following treatment (PMID: 30254212).",
            "description_review": {
              "updateTime": 1678135543472,
              "updatedBy": "User"
            },
            "description_uuid": "6e2f3792-d90e-40ae-bfbf-6c2d17e53e8e",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1564456670131,
              "updatedBy": "User"
            },
            "effect_uuid": "ee026fa7-42df-40e7-bcce-6fc7f23610f4",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1564456669140,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "b2bfc7d1-dca7-424c-aea1-f4d4f269a868",
            "short": ""
          },
          "mutation_effect_uuid": "fc1c7b9f-046b-4672-b2cf-13f94aaa6d91",
          "name": "ARMC10-BRAF Fusion",
          "name_review": {
            "updateTime": 1564456417626,
            "updatedBy": "User"
          },
          "name_uuid": "5a2aac3e-a1c2-4e5f-93f7-b1427aeaf4a8",
          "tumors_uuid": "eef44baf-6574-48c9-8aa0-b0436860e30c"
        },
        {
          "mutation_effect": {
            "description": "The BRAF N486del mutation is located in the kinase domain in exon 11 of the protein. Expression of this mutation in a human cell line demonstrated that it is likely neutral as measured by kinase activity comparable to wildtype (PMID: 26996308).",
            "description_review": {
              "updateTime": 1610424256863,
              "updatedBy": "User"
            },
            "description_uuid": "67e14d8f-60d9-472d-a34a-c7ddbf62bf1f",
            "effect": "Likely Neutral",
            "effect_review": {
              "updateTime": 1610424086444,
              "updatedBy": "User"
            },
            "effect_uuid": "8988fbbf-4d5e-4827-8715-7b7ab6fec169",
            "oncogenic": "Likely Neutral",
            "oncogenic_review": {
              "updateTime": 1610424084190,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "7fb3f203-c29f-4970-9fce-a49bbc9aaba2",
            "short": ""
          },
          "mutation_effect_uuid": "543f98dd-9b83-4838-82a6-5e61da677464",
          "name": "N486del",
          "name_review": {
            "updateTime": 1610424079199,
            "updatedBy": "User"
          },
          "name_uuid": "bdfa205f-1129-4e2b-ab6b-284415afb44b",
          "tumors_uuid": "10b9d24f-d954-48d2-bf96-1ee58cfd26ae"
        },
        {
          "mutation_effect": {
            "description": "The BRAF N486_V487del mutation is located in the kinase domain in exon 11 of the protein. Expression of this mutation in a human cell line demonstrated that it is likely activating as measured by modestly increased kinase activity compared to wildtype (PMID: 26996308).",
            "description_review": {
              "updateTime": 1610424461055,
              "updatedBy": "User"
            },
            "description_uuid": "a8451527-8636-4201-a77c-534cd6e0d05e",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1610424430924,
              "updatedBy": "User"
            },
            "effect_uuid": "efd9fd75-4a60-44c8-afaa-488fdcd9d630",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1610424429271,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "b7c09079-ec39-4eaf-a48a-29699f0561bc",
            "short": ""
          },
          "mutation_effect_uuid": "eeff9fcc-acaf-44bd-bb26-dfee8536b0ef",
          "name": "N486_V487del",
          "name_review": {
            "updateTime": 1610424327699,
            "updatedBy": "User"
          },
          "name_uuid": "b9667b29-ac3b-4eca-a8e0-ba490c7b2938",
          "tumors_uuid": "206d1dd7-6cbf-4a80-b010-82c6e4ac02a1"
        },
        {
          "mutation_effect": {
            "description": "The BRAF N486_T488del mutation is located in the kinase domain in exon 11 of the protein. This mutation has been identified in non-small cell lung cancer (PMID: 36200799). Expression of this mutation in a human cell line demonstrated that it is likely activating as measured by increased kinase activity compared to wildtype (PMID: 26996308).",
            "description_review": {
              "updateTime": 1678309198388,
              "updatedBy": "User"
            },
            "description_uuid": "68cfd242-24d8-4fe0-b89d-9762a5f0dbea",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1610424607061,
              "updatedBy": "User"
            },
            "effect_uuid": "8754dd0b-a399-4490-a974-b60c3ff0d914",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1610424605966,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "33d8da06-3401-4fe6-ab4e-f2937c13438a",
            "short": ""
          },
          "mutation_effect_uuid": "56116aad-cb95-4e3e-bcc9-b56af1760ff1",
          "name": "N486_T488del",
          "name_review": {
            "updateTime": 1610424595582,
            "updatedBy": "User"
          },
          "name_uuid": "13877568-b24a-497b-b70e-77bfd1a435cb",
          "tumors_uuid": "30d12c81-066c-4a88-baf8-0d452ddddfd3"
        },
        {
          "mutation_effect": {
            "description": "The BRAF N486_A489del mutation is located in the kinase domain in exon 11 of the protein. Expression of this mutation in a human cell line demonstrated that it is likely activating as measured by modestly increased kinase activity compared to wildtype (PMID: 26996308).",
            "description_review": {
              "updateTime": 1610424681890,
              "updatedBy": "User"
            },
            "description_uuid": "cd7b33d0-45ca-4173-96ed-e68260a0991c",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1610424692697,
              "updatedBy": "User"
            },
            "effect_uuid": "09be3075-692e-4804-bdef-15c34c209716",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1610424691004,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "65cb1cc4-f06b-4618-af23-3e11834cb4ca",
            "short": ""
          },
          "mutation_effect_uuid": "efa0df17-4768-4c8b-9f99-9c4349b88861",
          "name": "N486_A489del",
          "name_review": {
            "updateTime": 1610424651630,
            "updatedBy": "User"
          },
          "name_uuid": "4ca075b8-8624-4f5d-be52-f9a3ff6db4aa",
          "tumors_uuid": "7bbb4d82-73ab-4726-a4ba-396d232760d3"
        },
        {
          "mutation_effect": {
            "description": "The BRAF N486_T491del mutation is located in the kinase domain in exon 11 of the protein. Expression of this mutation in a human cell line demonstrated that it is likely activating as measured by modestly increased kinase activity compared to wildtype (PMID: 26996308).",
            "description_review": {
              "updateTime": 1610425641999,
              "updatedBy": "User"
            },
            "description_uuid": "2740206e-5edb-428b-c040-220552c08e45",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1610425606247,
              "updatedBy": "User"
            },
            "effect_uuid": "605adff6-663f-455d-9b22-a60cade42cfc",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1610425605175,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "f7bc56df-3d31-4f59-9949-cd88d5c8a63e",
            "short": ""
          },
          "mutation_effect_uuid": "4f14424c-991a-468a-8242-26cf90fa5985",
          "name": "N486_T491del",
          "name_review": {
            "updateTime": 1610425600953,
            "updatedBy": "User"
          },
          "name_uuid": "f3aecfaf-aa2a-4cb6-8a01-da8710acbab5",
          "tumors_uuid": "ad858391-66f9-4936-8d4d-2cf0fed712c1"
        },
        {
          "mutation_effect": {
            "description": "The BRAF P490del mutation is located in the kinase domain in exon 11 of the protein. Expression of this mutation in a human cell line demonstrated that it is likely neutral as measured by kinase activity comparable to wildtype (PMID: 26996308).",
            "description_review": {
              "updateTime": 1610425778993,
              "updatedBy": "User"
            },
            "description_uuid": "ace7d0d6-8f18-454d-85a9-cfc2abdafb8a",
            "effect": "Likely Neutral",
            "effect_review": {
              "updateTime": 1610425756197,
              "updatedBy": "User"
            },
            "effect_uuid": "beace36e-656a-43af-9044-faf7cf48039c",
            "oncogenic": "Likely Neutral",
            "oncogenic_review": {
              "updateTime": 1610425755062,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "6e00085e-9da2-492a-a8c6-a635ebebfb65",
            "short": ""
          },
          "mutation_effect_uuid": "f5d86f2b-ff75-4856-8759-aa61cead463c",
          "name": "P490del",
          "name_review": {
            "updateTime": 1610425748610,
            "updatedBy": "User"
          },
          "name_uuid": "837ba422-a90c-4718-bf2d-bdf07f46726d",
          "tumors_uuid": "73fddbc6-2fff-4552-9cc5-5ef8380150a5"
        },
        {
          "mutation_effect": {
            "description": "The BRAF A489_P490del mutation is located in the kinase domain in exon 11 of the protein. Expression of this mutation in a human cell line demonstrated that it is likely activating as measured by modestly increased kinase activity compared to wildtype (PMID: 26996308).",
            "description_review": {
              "updateTime": 1610426519414,
              "updatedBy": "User"
            },
            "description_uuid": "d23ed1e8-1d11-442c-93cb-550767689c0e",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1610426530813,
              "updatedBy": "User"
            },
            "effect_uuid": "3a2c8706-35f2-4056-a822-6cb6135aa7f8",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1610426529691,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "14e19c47-eb20-45a7-bf36-a4acc714db68",
            "short": ""
          },
          "mutation_effect_uuid": "d6789831-54c2-4249-b6fb-79ae50c99130",
          "name": "A489_P490del",
          "name_review": {
            "updateTime": 1610425818798,
            "updatedBy": "User"
          },
          "name_uuid": "25fd8536-c932-4d45-8d3a-c3697d0877ff",
          "tumors_uuid": "7c805c8c-048a-4a4e-96d0-e8a231407c29"
        },
        {
          "mutation_effect": {
            "description": "The BRAF T488_P490del mutation is located in the kinase domain in exon 11 of the protein. Expression of this mutation in a human cell line demonstrated that it is likely neutral as measured by kinase activity comparable to wildtype (PMID: 26996308).",
            "description_review": {
              "updateTime": 1610426704754,
              "updatedBy": "User"
            },
            "description_uuid": "a8eeb312-a465-4411-9024-30c25e0f6032",
            "effect": "Likely Neutral",
            "effect_review": {
              "updateTime": 1610426691942,
              "updatedBy": "User"
            },
            "effect_uuid": "93d252f6-11a4-4b50-9716-2d6603567f22",
            "oncogenic": "Likely Neutral",
            "oncogenic_review": {
              "updateTime": 1610426690565,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "6a5b6c22-8a6b-47af-b330-771367813431",
            "short": ""
          },
          "mutation_effect_uuid": "cf016510-c4ec-4bd8-98ac-2f6b76c46a0b",
          "name": "T488_P490del",
          "name_review": {
            "updateTime": 1610426669560,
            "updatedBy": "User"
          },
          "name_uuid": "b3bd86b0-9432-4b0f-a954-4f3e0d67b761",
          "tumors_uuid": "0bcd37ff-5719-4d77-a530-7f0983db2659"
        },
        {
          "mutation_effect": {
            "description": "The BRAF V487_P490del mutation is located in the kinase domain in exon 11 of the protein. Expression of this mutation in a human cell line demonstrated that it is likely activating as measured by increased kinase activity compared to wildtype (PMID: 26996308).",
            "description_review": {
              "updateTime": 1610426890908,
              "updatedBy": "User"
            },
            "description_uuid": "085138cb-ba66-4af1-9305-757e664601e8",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1610426903793,
              "updatedBy": "User"
            },
            "effect_uuid": "8fba81d3-6bfd-46b2-b3c8-be2174cf5cef",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1610426902787,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "b6c74337-4d02-4a34-b5eb-018219d39c2f",
            "short": ""
          },
          "mutation_effect_uuid": "6d9f1d04-af93-4556-9244-f6efc2fa4180",
          "name": "V487_P490del",
          "name_review": {
            "updateTime": 1610426735837,
            "updatedBy": "User"
          },
          "name_uuid": "bcf6faf4-75ac-489d-acef-f4143668082c",
          "tumors_uuid": "b323ce9c-1ed0-46a2-bf88-1437b58075d5"
        },
        {
          "mutation_effect": {
            "description": "The BRAF A598_T599insV mutation is located in the kinase domain of the protein. While this mutation has not been functionally characterized, a patient with melanoma harboring this mutation had a partial response to treatment with the combination of dabrafenib and trametinib (PMID: 28800030).",
            "description_review": {
              "updateTime": 1620262990112,
              "updatedBy": "User"
            },
            "description_uuid": "4f70acb0-8385-4686-abb7-7e4b52a973ab",
            "effect": "Inconclusive",
            "effect_review": {
              "updateTime": 1620262859093,
              "updatedBy": "User"
            },
            "effect_uuid": "5cc55276-326f-45e3-974a-fc29b92930fa",
            "oncogenic": "Inconclusive",
            "oncogenic_review": {
              "updateTime": 1620262857940,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "8e1b288e-93a8-45fa-8fad-90b6fda31633",
            "short": ""
          },
          "mutation_effect_uuid": "1b019c60-27f0-4243-bbb0-0dad95c1fe05",
          "name": "A598_T599insV",
          "name_review": {
            "updateTime": 1620262850770,
            "updatedBy": "User"
          },
          "name_uuid": "5c322e2a-aece-4acb-c07d-3c7ffd59503b",
          "tumors_uuid": "948eb59c-db7e-41ba-aec7-d969a48a9e71"
        },
        {
          "mutation_effect": {
            "description": "",
            "description_review": {
              "updateTime": 1493057315640
            },
            "description_uuid": "12bf9c4a-2cfd-45d3-894a-5a5e19a446a6",
            "effect": "",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "278b7407-ef34-422d-8655-f390e39fc77b",
            "oncogenic": "",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "875fed90-8206-49a4-b83e-bef4381257c4",
            "short": ""
          },
          "mutation_effect_uuid": "d36c069c-1ee9-47bb-be33-72f07a8805d8",
          "name": "Oncogenic Mutations",
          "name_review": {
            "updateTime": 1493057315640
          },
          "name_uuid": "9a025592-ad8a-42d1-849b-2114150e5de8",
          "tumors": [
            {
              "TIs": [
                {
                  "name": "Standard implications for sensitivity to therapy",
                  "name_uuid": "ada6bbea-93c0-43a1-a2a1-0356bff89871",
                  "type": "SS"
                },
                {
                  "name": "Standard implications for resistance to therapy",
                  "name_uuid": "1c514aab-5bd2-42d8-911d-2f6f45c14a27",
                  "type": "SR"
                },
                {
                  "name": "Investigational implications for sensitivity to therapy",
                  "name_uuid": "98566230-a614-4b12-b0e6-a164c744e3cd",
                  "type": "IS"
                },
                {
                  "name": "Investigational implications for resistance to therapy",
                  "name_uuid": "1b77c30d-9972-4ef2-b207-899b4a344c8f",
                  "type": "IR"
                }
              ],
              "cancerTypes": [
                {
                  "code": "",
                  "mainType": "Non-Small Cell Lung Cancer",
                  "subtype": ""
                }
              ],
              "cancerTypes_uuid": "462cfc56-69de-4d2b-bed4-f3c967d36ca6",
              "diagnostic": {
                "description": "",
                "description_uuid": "3fabc5cd-fdfe-47f2-9cdb-f45ba1080fd3",
                "level": "",
                "level_uuid": "4d7b2e41-b0c5-44c6-8aeb-96560a9adeb4",
                "short": ""
              },
              "diagnosticSummary": "",
              "diagnosticSummary_uuid": "2c3213a3-d1df-413b-a269-ec65b4efd2be",
              "diagnostic_uuid": "7a38bae3-307e-476b-bceb-80239703f751",
              "prognostic": {
                "description": "",
                "description_review": {
                  "updateTime": 1493057315640
                },
                "description_uuid": "637ccdff-4546-4516-9a84-cbd09b24d258",
                "level": "",
                "level_uuid": "9344f0a7-67a7-4296-9482-0689009d0f1a",
                "short": "The low prevalence of BRAF mutations in lung cancer makes it difficult to accurately estimate their prognostic significance. One study reported a similar overall survival (OS) rate between patients with wildtype BRAF and those with V600E or non-V600E BRAF mutation (PMID: 24297085). Another report suggested that the 3-year OS post-surgery of early-stage non-small cell lung cancer (NSCLC) is similar between patient tumors harboring V600 versus non-V600 mutations (67% vs. 75%; p=0.42). However, in patients with later-stage disease, the same report found that patients with V600 mutant tumors were associated with a better 3-year OS compared to patients with non-V600 BRAF mutant tumors (24% vs. 0%, p<0.001) (PMID: 25436800)."
              },
              "prognosticSummary": "",
              "prognosticSummary_uuid": "79fdc2bd-ec8b-4a41-9a3a-0f2d6950cd3a",
              "prognostic_uuid": "121903de-205d-46d8-9038-e1e1f2f054aa",
              "summary": "While the RAF-inhibitor dabrafenib in combination with the MEK-inhibitor trametinib is FDA-approved for the treatment of patients with BRAF V600E mutant non-small cell lung cancer, their clinical utility in patients with [[variant]] is unknown.",
              "summary_review": {
                "updateTime": 1511806993363,
                "updatedBy": "User"
              },
              "summary_uuid": "ec7c8254-cf2c-461a-810e-e8f8e452de0e"
            },
            {
              "TIs": [
                {
                  "name": "Standard implications for sensitivity to therapy",
                  "name_uuid": "43df17c5-63f2-4b56-8da6-12e49534d8dc",
                  "type": "SS"
                },
                {
                  "name": "Standard implications for resistance to therapy",
                  "name_uuid": "b3fb49bc-6238-4480-b2da-9b2fd92f9cdb",
                  "type": "SR"
                },
                {
                  "name": "Investigational implications for sensitivity to therapy",
                  "name_uuid": "006ae097-cf1c-4b28-913a-e22626f4f870",
                  "type": "IS"
                },
                {
                  "name": "Investigational implications for resistance to therapy",
                  "name_uuid": "dd2f361d-f811-4254-9c96-d728501f4304",
                  "type": "IR"
                }
              ],
              "cancerTypes": [
                {
                  "code": "MEL",
                  "mainType": "Melanoma",
                  "subtype": "Melanoma"
                }
              ],
              "cancerTypes_uuid": "7c073630-d624-4d9e-9367-3c83389ed06b",
              "diagnostic": {
                "description": "",
                "description_uuid": "b59aeeed-17a8-4233-bf19-cc83364e739f",
                "level": "",
                "level_uuid": "9b039377-27a1-414f-9cac-98d4da831b9a",
                "short": ""
              },
              "diagnosticSummary": "",
              "diagnosticSummary_uuid": "0c286640-cec4-4c08-afc4-06bbeb1e1e62",
              "diagnostic_uuid": "e148573d-4ef4-4bc1-aeb9-8ea7d82107d0",
              "prognostic": {
                "description": "",
                "description_review": {
                  "updateTime": 1493057315640
                },
                "description_uuid": "f8b0068f-32f4-4722-89fb-8d901b5adf3c",
                "level": "",
                "level_uuid": "47e007ee-a46a-4167-9d12-b766a2bdacfd",
                "short": ""
              },
              "prognosticSummary": "",
              "prognosticSummary_uuid": "7ec1afc5-f661-48b6-9777-53a87e4fdbed",
              "prognostic_uuid": "058c3f58-5e9e-4442-bf3e-1fe34b9e94b4",
              "summary": "While the RAF-inhibitors dabrafenib and vemurafenib, alone and in combination with the MEK-inhibitors trametinib and cobimetinib respectively, are FDA-approved for the treatment of patients with BRAF V600E and V600K mutant melanoma, their clinical utility in patients with [[variant]] is unknown.",
              "summary_review": {
                "updateTime": 1534966200139,
                "updatedBy": "User"
              },
              "summary_uuid": "68ce6de9-5658-4535-b52d-a0b574d3c573"
            },
            {
              "TIs": [
                {
                  "name": "Standard implications for sensitivity to therapy",
                  "name_uuid": "ec01d85e-b5fd-4a25-b1bb-bce2be35f5fb",
                  "type": "SS"
                },
                {
                  "name": "Standard implications for resistance to therapy",
                  "name_uuid": "b2eb68dc-2ae9-4813-a646-268e5e649261",
                  "type": "SR"
                },
                {
                  "name": "Investigational implications for sensitivity to therapy",
                  "name_uuid": "e27bdf55-9176-4419-b913-b66647a6157b",
                  "type": "IS"
                },
                {
                  "name": "Investigational implications for resistance to therapy",
                  "name_uuid": "eb437005-d7f8-4df5-a455-ff575795fc44",
                  "type": "IR"
                }
              ],
              "cancerTypes": [
                {
                  "code": "",
                  "mainType": "Other Tumor Types",
                  "subtype": ""
                }
              ],
              "cancerTypes_uuid": "0a8e9d71-dc1e-4f00-bebf-8565e39bd0db",
              "diagnostic": {
                "description": "",
                "description_uuid": "9b39cfb4-1a8d-4e07-a978-03ca9edcb7a3",
                "level": "",
                "level_uuid": "58a62463-2ff9-400e-ba26-368d9cf2d188",
                "short": ""
              },
              "diagnosticSummary": "",
              "diagnosticSummary_uuid": "67590978-2c80-4cea-aae5-361c54ff2277",
              "diagnostic_uuid": "9bebd5f7-424f-4149-8adc-0ca4a4f365ef",
              "prognostic": {
                "description": "",
                "description_review": {
                  "updateTime": 1493057315640
                },
                "description_uuid": "de24349e-c55e-4bb2-8044-99e1cf168e3f",
                "level": "",
                "level_uuid": "f842dace-6305-427e-b265-546e1a3bd3dc",
                "short": ""
              },
              "prognosticSummary": "",
              "prognosticSummary_uuid": "9b256b5b-2e78-4076-96d4-745693a57519",
              "prognostic_uuid": "3cdadde9-a8cb-4d0e-a484-2c6ba7a0041e",
              "summary": "While the RAF-inhibitor dabrafenib in combination with the MEK-inhibitor trametinib is FDA-approved for the treatment of patients with BRAF V600E mutant melanoma, non-small cell lung cancer, and anaplastic thyroid cancer, and the RAF-inhibitor vemurafenib is FDA-approved as monotherapy in BRAF V600-mutant Erdheim-Chester disease, their clinical utility in patients with [[variant]] is unknown.",
              "summary_review": {
                "updateTime": 1566490881598,
                "updatedBy": "User"
              },
              "summary_uuid": "e849d451-64e6-4dc1-ac77-0071b21a22f8"
            },
            {
              "TIs": [
                {
                  "name": "Standard implications for sensitivity to therapy",
                  "name_uuid": "7cfd6506-189f-4720-aeaa-871084f763ee",
                  "treatments_uuid": "60eb1c1d-8934-4884-92ac-51cc8917a75f",
                  "type": "SS"
                },
                {
                  "name": "Standard implications for resistance to therapy",
                  "name_uuid": "26829a00-1d90-4180-9dfd-80bad13a7321",
                  "treatments_uuid": "668c3f98-44cf-4b96-9edc-d9913735bbba",
                  "type": "SR"
                },
                {
                  "name": "Investigational implications for sensitivity to therapy",
                  "name_uuid": "b1968359-4590-423a-85f7-232803f4e568",
                  "treatments_uuid": "1a6e6e46-45bf-4d1b-8bd9-89e76547a6f2",
                  "type": "IS"
                },
                {
                  "name": "Investigational implications for resistance to therapy",
                  "name_uuid": "c8dbdc5c-fc9a-4b17-a8fb-219ad382197a",
                  "treatments_uuid": "aa104cc0-97a9-4e84-9d1f-593c7b31be5b",
                  "type": "IR"
                }
              ],
              "cancerTypes": [
                {
                  "code": "ETPLL",
                  "mainType": "T-Lymphoblastic Leukemia/Lymphoma",
                  "subtype": "Early T-Cell Precursor Lymphoblastic Leukemia"
                }
              ],
              "cancerTypes_uuid": "fda2b7d3-f6de-4b12-bb40-a29ee9cc9bd9",
              "diagnostic": {
                "description": "This assertion is supported by (PMID: 22237106).",
                "description_review": {
                  "updateTime": 1600293135309,
                  "updatedBy": "User"
                },
                "description_uuid": "3fd31e50-f76c-4e20-93c3-67dfb51a6c93",
                "level": "Dx3",
                "level_review": {
                  "updateTime": 1600293135309,
                  "updatedBy": "User"
                },
                "level_uuid": "4e906d51-752a-4626-8dea-c91ed52badad",
                "short": ""
              },
              "diagnosticSummary": "The presence of a BRAF [[mutation]] [[[mutation]]] may assist in the diagnosis of [[tumor type]].",
              "diagnosticSummary_review": {
                "updateTime": 1600293135309,
                "updatedBy": "User"
              },
              "diagnosticSummary_uuid": "614bf7fb-7926-49db-9fb0-6dd00fc3f603",
              "diagnostic_uuid": "46b031e3-4ae9-418b-8b17-3a6acfd197d8",
              "prognostic": {
                "description": "",
                "description_uuid": "1e6d46fd-a579-429d-9fd4-681ff8a59d46",
                "level": "",
                "level_uuid": "de326738-394a-4f17-81d6-5fd83070ae89",
                "short": ""
              },
              "prognosticSummary": "",
              "prognosticSummary_uuid": "3a41efdb-1e1f-45db-9108-af28ddfbf4ac",
              "prognostic_uuid": "49467e8a-098e-4345-8868-854a218474a0",
              "summary": "",
              "summary_uuid": "ce4f135d-7c8f-4ffd-8950-2bdab30e11d0"
            }
          ]
        },
        {
          "mutation_effect": {
            "description": "",
            "description_uuid": "d1a75603-df33-40ce-8d4c-710aea0ed1e8",
            "effect": "",
            "effect_uuid": "1dc30c67-c322-49f7-8e74-cd32077d672f",
            "oncogenic": "",
            "oncogenic_uuid": "7542ec73-86db-4df5-b941-28ff81964752",
            "short": ""
          },
          "mutation_effect_uuid": "5f9ac10d-35b6-4e42-970e-bc6cbef13ed6",
          "name": "Oncogenic Mutations {excluding V600}",
          "name_review": {
            "updateTime": 1634741209146,
            "updatedBy": "User"
          },
          "name_uuid": "3e608d66-9576-455a-a4cc-2e111880431c",
          "tumors": [
            {
              "TIs": [
                {
                  "name": "Standard implications for sensitivity to therapy",
                  "name_uuid": "282fdad0-12d5-4bc7-9e90-200d8fc24ae4",
                  "treatments_uuid": "e8b535ef-98fa-49eb-a263-790bc421687d",
                  "type": "SS"
                },
                {
                  "name": "Standard implications for resistance to therapy",
                  "name_uuid": "f0968332-8358-49b4-973b-855afe135acf",
                  "treatments_uuid": "d7803155-fba4-4419-ae4a-9b876c1ea226",
                  "type": "SR"
                },
                {
                  "name": "Investigational implications for sensitivity to therapy",
                  "name_uuid": "6b21d282-3a62-44ff-80e2-c64cb3f6a596",
                  "treatments": [
                    {
                      "description": "Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and both are NCCN-listed for patients with histiocytic neoplasms harboring MAPK pathway mutations. In a case study of one eighteen-year-old patient with refractory histiocytic sarcoma harboring a pathogenic variant of MAP2K1 (F53L), the patient was treated with trametinib and showed an excellent response prior to treatment interruption due to severe adverse events (PMID: 30361829).",
                      "description_review": {
                        "updateTime": 1676490864487,
                        "updatedBy": "User"
                      },
                      "description_uuid": "c08d38bc-7eb1-4bcb-9adc-2eb66225521e",
                      "fdaLevel": "Fda3",
                      "fdaLevel_review": {
                        "updateTime": 1676490860949,
                        "updatedBy": "User"
                      },
                      "fdaLevel_uuid": "5dcc978d-5b1a-47c8-b157-b835be68a0b6",
                      "indication": "",
                      "indication_uuid": "7f668efd-04f0-4655-b97c-71783b0717b9",
                      "level": "3A",
                      "level_review": {
                        "updateTime": 1634741398189,
                        "updatedBy": "User"
                      },
                      "level_uuid": "448e8d3f-d9f8-45b6-87b1-42a25028ef76",
                      "name": "eb357145-3b18-4aca-b75a-5e18dd2bf4f9, fb2bb01c-c0ec-4641-abf7-87f486075022",
                      "name_review": {
                        "updateTime": 1634741393018,
                        "updatedBy": "User"
                      },
                      "name_uuid": "658a788e-390c-41c6-8081-0376b6121bb0",
                      "propagation": "no",
                      "propagationLiquid": "no",
                      "propagationLiquid_review": {
                        "updateTime": 1634741398187,
                        "updatedBy": "User"
                      },
                      "propagationLiquid_uuid": "16ac3b04-612c-4e6e-99a0-31cbcc0ee779",
                      "propagation_review": {
                        "updateTime": 1634741398184,
                        "updatedBy": "User"
                      },
                      "propagation_uuid": "98805335-5ecf-4a91-81dd-334aa902e4be",
                      "short": ""
                    }
                  ],
                  "treatments_uuid": "42c64a97-dcc2-4195-b08d-f6d321ce3065",
                  "type": "IS"
                },
                {
                  "name": "Investigational implications for resistance to therapy",
                  "name_uuid": "f51e2d0a-1387-43a9-92e7-1606f9a1cf24",
                  "treatments_uuid": "51f16f43-d330-41cb-ac91-88e56a9c8a45",
                  "type": "IR"
                }
              ],
              "cancerTypes": [
                {
                  "code": "",
                  "mainType": "Histiocytosis",
                  "subtype": ""
                }
              ],
              "cancerTypes_review": {
                "updateTime": 1634741280284,
                "updatedBy": "User"
              },
              "cancerTypes_uuid": "a0b13f00-6bbd-4c01-a1d0-397d600de2ea",
              "diagnostic": {
                "description": "",
                "description_uuid": "1686dc2b-4601-421a-b57d-2a08b19982b7",
                "level": "",
                "level_uuid": "a8e00602-2eb0-4c8e-9803-d640f568eec4",
                "short": ""
              },
              "diagnosticSummary": "",
              "diagnosticSummary_uuid": "877fbdb9-fc4e-4a35-9ed4-eca406ca755c",
              "diagnostic_uuid": "ac925482-107b-4dc3-b0ea-21ac5868bfa5",
              "prognostic": {
                "description": "",
                "description_uuid": "9c92e93c-f064-4b6d-a187-cacbfff3547d",
                "level": "",
                "level_uuid": "99a9f1ce-85da-46e4-b3ca-8d10e3e9dd46",
                "short": ""
              },
              "prognosticSummary": "",
              "prognosticSummary_uuid": "f945e41e-a33f-4b9e-aff0-919a7bcadcde",
              "prognostic_uuid": "54e952c4-35de-45a5-8e1c-bfcd858c889d",
              "summary": "There is promising clinical data in patients with histiocytic neoplasms harboring MAPK pathway alterations treated with the MEK-targeted inhibitors cobimetinib or trametinib as monotherapy.",
              "summary_review": {
                "updateTime": 1634741288251,
                "updatedBy": "User"
              },
              "summary_uuid": "c96628e0-742b-477e-8eff-c79aa725a02d"
            },
            {
              "TIs": [
                {
                  "name": "Standard implications for sensitivity to therapy",
                  "name_uuid": "4503ba33-32ee-4bdf-93e2-1d6347c840d9",
                  "treatments": [
                    {
                      "description": "Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and both are NCCN-listed for patients with Erdheim-Chester Disease (ECD) harboring MAPK pathway mutations. In an open-label phase II trial (NCT02649972) of cobimetinib in eighteen adult patients with histiocytoses (n = twelve patients with ECD) of any mutational status, the overall response rate was 89% (90% CI: 73–100), 100% of responses were ongoing at one year, and 94% of patients remained progression-free (PMID: 30867592).",
                      "description_review": {
                        "updateTime": 1676490844721,
                        "updatedBy": "User"
                      },
                      "description_uuid": "a1b0a59c-e153-40d4-a7a5-9eb31e4eaa23",
                      "fdaLevel": "Fda3",
                      "fdaLevel_review": {
                        "updateTime": 1659103603005,
                        "updatedBy": "User"
                      },
                      "fdaLevel_uuid": "2839fe65-b0f0-4713-b70d-5ab271ec8188",
                      "indication": "",
                      "indication_uuid": "ae097583-1dc9-4d6b-c0e7-2636126b6d28",
                      "level": "2",
                      "level_review": {
                        "updateTime": 1634741537512,
                        "updatedBy": "User"
                      },
                      "level_uuid": "f327e67a-9925-4915-b10d-d7d651fe3047",
                      "name": "eb357145-3b18-4aca-b75a-5e18dd2bf4f9, fb2bb01c-c0ec-4641-abf7-87f486075022",
                      "name_review": {
                        "updateTime": 1634741533160,
                        "updatedBy": "User"
                      },
                      "name_uuid": "f85c5ffd-a7dc-4769-acdc-012ff3b7ac5d",
                      "propagation": "no",
                      "propagationLiquid": "no",
                      "propagationLiquid_review": {
                        "updateTime": 1634741537510,
                        "updatedBy": "User"
                      },
                      "propagationLiquid_uuid": "27841d07-211e-4d53-884b-4f1dead6fe60",
                      "propagation_review": {
                        "updateTime": 1634741537507,
                        "updatedBy": "User"
                      },
                      "propagation_uuid": "20e3a162-6c2d-4992-95d6-1b6cefdd3b9d",
                      "short": ""
                    }
                  ],
                  "treatments_uuid": "9dfb693f-9bea-467e-b2a2-69c65e8d618f",
                  "type": "SS"
                },
                {
                  "name": "Standard implications for resistance to therapy",
                  "name_uuid": "646b42ef-6d1c-4c48-b41a-2cbe4e3a1477",
                  "treatments_uuid": "84965d68-bb68-40c3-8892-1746a9b3868a",
                  "type": "SR"
                },
                {
                  "name": "Investigational implications for sensitivity to therapy",
                  "name_uuid": "250a6b29-e884-48c5-8371-fed03e4f2b42",
                  "treatments_uuid": "551af4a6-6dc7-41ff-a080-668d034dac06",
                  "type": "IS"
                },
                {
                  "name": "Investigational implications for resistance to therapy",
                  "name_uuid": "d92a8765-9f09-4251-9473-afa5cf34e08f",
                  "treatments_uuid": "7bdcb7d1-1dad-498a-a164-39f12da8f828",
                  "type": "IR"
                }
              ],
              "cancerTypes": [
                {
                  "code": "ECD",
                  "mainType": "Histiocytosis",
                  "subtype": "Erdheim-Chester Disease"
                }
              ],
              "cancerTypes_review": {
                "updateTime": 1634741480213,
                "updatedBy": "User"
              },
              "cancerTypes_uuid": "12e8b36a-1516-4f10-a2a6-c114e2883655",
              "diagnostic": {
                "description": "",
                "description_uuid": "5c005059-9e69-4e7a-8537-0e0af26e43f6",
                "level": "",
                "level_uuid": "20b190e8-d6d4-43c4-8372-07061de6e605",
                "short": ""
              },
              "diagnosticSummary": "",
              "diagnosticSummary_uuid": "ebe84aef-b664-4224-a7cd-f041bc74a9d0",
              "diagnostic_uuid": "6b2b0359-3101-44c9-bf7e-a088bf06253c",
              "prognostic": {
                "description": "",
                "description_uuid": "daa1cd0f-d718-4d4f-b95d-304b40c04bdd",
                "level": "",
                "level_uuid": "4ffccd63-95f9-45e9-b3dd-2c3e1c498eb0",
                "short": ""
              },
              "prognosticSummary": "",
              "prognosticSummary_uuid": "9905a331-7fb7-4567-9941-3a70713d6a12",
              "prognostic_uuid": "8ac20573-3ea2-4194-9fda-bcd67a1b0324",
              "summary": "The MEK-targeted inhibitors cobimetinib and trametinib are NCCN-listed as monotherapy for the treatment of patients with Erdheim-Chester Disease with MAPK pathway alterations, including [[gene]][[mutation]].",
              "summary_review": {
                "updateTime": 1634741503337,
                "updatedBy": "User"
              },
              "summary_uuid": "e95d9545-8b3b-480e-9222-bddc0869dba2"
            },
            {
              "TIs": [
                {
                  "name": "Standard implications for sensitivity to therapy",
                  "name_uuid": "c9a27922-f663-4d8c-9d21-160b3bcadf5e",
                  "treatments": [
                    {
                      "description": "Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and both are NCCN-listed for patients with Langerhans Cell Histiocytosis (LCH) harboring MAPK pathway mutations. In an open-label phase II trial (NCT02649972) of cobimetinib in eighteen adult patients with histiocytoses (n = two patients with LCH) of any mutational status, the overall response rate was 89% (90% CI: 73–100), 100% of responses were ongoing at one year, and 94% of patients remained progression-free (PMID: 30867592). In a study of three patients with LCH who were treated with trametinib, two patients harbored BRAF N486_P490del mutations, of which one had no reactivation and the other had a partial response, and the third patient with a MAP2K1 K57_G61del mutation had a complete response with no active disease after 22 months (PMID: 32991018).",
                      "description_review": {
                        "updateTime": 1676490879910,
                        "updatedBy": "User"
                      },
                      "description_uuid": "7bc2a848-5b81-45e1-a494-a188478b2f8e",
                      "fdaLevel": "Fda3",
                      "fdaLevel_review": {
                        "updateTime": 1659103611792,
                        "updatedBy": "User"
                      },
                      "fdaLevel_uuid": "e3f5f4fe-afff-4b5f-9a3d-281dd3059e0b",
                      "indication": "",
                      "indication_uuid": "e942ac8c-a6aa-4bc8-9b05-0f5d542a909c",
                      "level": "2",
                      "level_review": {
                        "updateTime": 1634741649147,
                        "updatedBy": "User"
                      },
                      "level_uuid": "4785be01-49eb-43c6-848b-247829d95011",
                      "name": "eb357145-3b18-4aca-b75a-5e18dd2bf4f9, fb2bb01c-c0ec-4641-abf7-87f486075022",
                      "name_review": {
                        "updateTime": 1634741643931,
                        "updatedBy": "User"
                      },
                      "name_uuid": "a7ce9682-0287-4744-895c-69df4bb7792b",
                      "propagation": "no",
                      "propagationLiquid": "no",
                      "propagationLiquid_review": {
                        "updateTime": 1634741649144,
                        "updatedBy": "User"
                      },
                      "propagationLiquid_uuid": "58654823-d7b2-46c5-9925-2486a2fee465",
                      "propagation_review": {
                        "updateTime": 1634741649141,
                        "updatedBy": "User"
                      },
                      "propagation_uuid": "89979615-ccdf-421f-92a2-2459db5f3343",
                      "short": ""
                    }
                  ],
                  "treatments_uuid": "4b45eb65-1a1d-4dc7-9608-012820536ae8",
                  "type": "SS"
                },
                {
                  "name": "Standard implications for resistance to therapy",
                  "name_uuid": "dbb226b8-c5ea-4422-bc62-2cf4e869d499",
                  "treatments_uuid": "d1a112ba-367f-43a7-ba54-465798d8e6ec",
                  "type": "SR"
                },
                {
                  "name": "Investigational implications for sensitivity to therapy",
                  "name_uuid": "49ac8cd9-c7a3-45ef-8c8f-02e62823cc80",
                  "treatments_uuid": "55b6f7f0-44bd-43a2-9c4b-f13ea93a1acf",
                  "type": "IS"
                },
                {
                  "name": "Investigational implications for resistance to therapy",
                  "name_uuid": "205ccaeb-d255-43f7-9782-866d49f16d7e",
                  "treatments_uuid": "f1471ea2-7d75-4afb-bbed-c4208bb75614",
                  "type": "IR"
                }
              ],
              "cancerTypes": [
                {
                  "code": "LCH",
                  "mainType": "Histiocytosis",
                  "subtype": "Langerhans Cell Histiocytosis"
                }
              ],
              "cancerTypes_review": {
                "updateTime": 1634741623130,
                "updatedBy": "User"
              },
              "cancerTypes_uuid": "1fdb4ff1-6f4d-4f74-a53e-82432bd2e781",
              "diagnostic": {
                "description": "",
                "description_uuid": "556bba03-c1f5-422a-9fcf-6fff28935e8b",
                "level": "",
                "level_uuid": "5d0a64b7-312c-4a2c-83cc-44b9c42148e8",
                "short": ""
              },
              "diagnosticSummary": "",
              "diagnosticSummary_uuid": "7767a131-0a58-4adb-a120-d08b77fd50bd",
              "diagnostic_uuid": "3ea3c3e6-dc20-4429-c08a-1a92d084f81a",
              "prognostic": {
                "description": "",
                "description_uuid": "65c7be1f-5e52-4425-8632-215d7328aef5",
                "level": "",
                "level_uuid": "09667bdf-d464-499d-a482-7e1905265d82",
                "short": ""
              },
              "prognosticSummary": "",
              "prognosticSummary_uuid": "d0ceffbf-1895-4153-a692-2fd1b27ce8e6",
              "prognostic_uuid": "1d0339e2-09d2-4f6c-8659-1c2c014d59a2",
              "summary": "The MEK-targeted inhibitors cobimetinib and trametinib are NCCN-listed as monotherapy for the treatment of patients with Langerhans Cell Histiocytosis with MAPK pathway alterations, including [[gene]][[mutation]].",
              "summary_review": {
                "updateTime": 1634741629656,
                "updatedBy": "User"
              },
              "summary_uuid": "7e539aa7-e805-4ac4-827e-a7a552199d1f"
            },
            {
              "TIs": [
                {
                  "name": "Standard implications for sensitivity to therapy",
                  "name_uuid": "d1b278b3-3a98-4003-9ae5-54df7e2b083d",
                  "treatments": [
                    {
                      "description": "Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and are NCCN-listed for patients with Rosai-Dorfman Disease. One adult patient with Rosai-Dorfman Disease with an activating KRAS G12R mutation was treated with cobimetinib, and a follow-up CT scan two months after treatment showed a substantial response (PMID: 29236635).",
                      "description_review": {
                        "updateTime": 1676490899501,
                        "updatedBy": "User"
                      },
                      "description_uuid": "397a718f-210a-44fd-9724-79cdacb83266",
                      "fdaLevel": "Fda3",
                      "fdaLevel_review": {
                        "updateTime": 1659103620467,
                        "updatedBy": "User"
                      },
                      "fdaLevel_uuid": "f67f0525-b183-4515-87f0-7bc9a05906ba",
                      "indication": "",
                      "indication_uuid": "413fa930-677a-42bf-a782-b9d851f3872f",
                      "level": "2",
                      "level_review": {
                        "updateTime": 1634741743056,
                        "updatedBy": "User"
                      },
                      "level_uuid": "5ce2b7bc-f70b-4b0e-b8e3-a71f1f396b20",
                      "name": "eb357145-3b18-4aca-b75a-5e18dd2bf4f9, fb2bb01c-c0ec-4641-abf7-87f486075022",
                      "name_review": {
                        "updateTime": 1634741737199,
                        "updatedBy": "User"
                      },
                      "name_uuid": "6680f049-0c87-41fb-a234-09c1a2361419",
                      "propagation": "no",
                      "propagationLiquid": "no",
                      "propagationLiquid_review": {
                        "updateTime": 1634741743054,
                        "updatedBy": "User"
                      },
                      "propagationLiquid_uuid": "6c15176f-bf60-4387-9b85-c7f1c7bd0078",
                      "propagation_review": {
                        "updateTime": 1634741743051,
                        "updatedBy": "User"
                      },
                      "propagation_uuid": "e33e1e72-1925-464a-83ec-ef6d8d07cbe9",
                      "short": ""
                    }
                  ],
                  "treatments_uuid": "ca1a86cd-3d1a-4abb-b59b-e974723d28c0",
                  "type": "SS"
                },
                {
                  "name": "Standard implications for resistance to therapy",
                  "name_uuid": "a01f1103-a725-480d-bf37-6af8e5e0682d",
                  "treatments_uuid": "3f288185-2f15-46a2-93b3-e5251c776647",
                  "type": "SR"
                },
                {
                  "name": "Investigational implications for sensitivity to therapy",
                  "name_uuid": "f522e6c4-16ff-400d-975f-c4532b8832d6",
                  "treatments_uuid": "f0c14335-8012-4287-ade1-f70533e619cd",
                  "type": "IS"
                },
                {
                  "name": "Investigational implications for resistance to therapy",
                  "name_uuid": "12c79455-ba95-43c2-984c-abc514e3eb23",
                  "treatments_uuid": "b4f7d499-4e90-4c62-8608-56dec5d46884",
                  "type": "IR"
                }
              ],
              "cancerTypes": [
                {
                  "code": "RDD",
                  "mainType": "Histiocytosis",
                  "subtype": "Rosai-Dorfman Disease"
                }
              ],
              "cancerTypes_review": {
                "updateTime": 1634741706878,
                "updatedBy": "User"
              },
              "cancerTypes_uuid": "b3571e1a-efcc-4bc2-b7a8-61d46f1bfa63",
              "diagnostic": {
                "description": "",
                "description_uuid": "96c689bf-4404-4eb3-aabd-cf504c4db492",
                "level": "",
                "level_uuid": "62dfbd07-1f0b-4f53-9b56-e7dbebac30c8",
                "short": ""
              },
              "diagnosticSummary": "",
              "diagnosticSummary_uuid": "aa32297c-8c16-40cf-9ef5-a626b5e27faa",
              "diagnostic_uuid": "cb47166a-f50a-4cb6-b277-fcbb5d13cee5",
              "prognostic": {
                "description": "",
                "description_uuid": "b510edda-0733-40d0-8e7f-f9ccef52ea7d",
                "level": "",
                "level_uuid": "8f53d090-0a16-4a78-9224-8a8e74d3865b",
                "short": ""
              },
              "prognosticSummary": "",
              "prognosticSummary_uuid": "94bf93ca-2ff9-4c66-8679-f2828e8f53aa",
              "prognostic_uuid": "3743c6e8-9326-4d3d-9bb8-6246e0f8bdac",
              "summary": "The MEK-targeted inhibitors cobimetinib and trametinib are NCCN-listed as monotherapy for the treatment of patients with Rosai-Dorfman Disease with MAPK pathway alterations, including [[gene]][[mutation]].",
              "summary_review": {
                "updateTime": 1634741723962,
                "updatedBy": "User"
              },
              "summary_uuid": "67779f76-43de-4ac6-8b31-27064c3ab215"
            }
          ],
          "tumors_uuid": "45f0ba05-48c5-4222-babc-57d85dd6e311"
        },
        {
          "mutation_effect": {
            "description": "",
            "description_uuid": "b34f4025-951f-4baa-b205-e502f09ee880",
            "effect": "",
            "effect_uuid": "96a10f1a-fa27-4a4e-974b-5b64fe9cbd76",
            "oncogenic": "",
            "oncogenic_uuid": "db68874d-5313-4b54-ac4c-543653efa8da",
            "short": ""
          },
          "mutation_effect_uuid": "52d538eb-8042-46a9-aeba-1c809ede19bd",
          "name": "V600 {excluding V600E ; V600K}",
          "name_review": {
            "updateTime": 1639687870014,
            "updatedBy": "User"
          },
          "name_uuid": "c252fd4a-da2f-41d2-81a1-8065bf5398af",
          "tumors": [
            {
              "TIs": [
                {
                  "name": "Standard implications for sensitivity to therapy",
                  "name_uuid": "0ec1912f-651c-404d-b0de-6c85009f8130",
                  "treatments": [
                    {
                      "description": "The combination of encorafenib, an inhibitor of V600E- or V600K-mutant BRAF, and binimetinib, an inhibitor of MEK1/2, is FDA-approved in combination for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. FDA approval was based on the results of the Phase III COLUMBUS trial of combined encorafenib plus binimetinib versus single agent vemurafenib in 577 patients with BRAF V600E- or V600K-mutant metastatic melanoma in which the median progression-free survival was 14.9 months (95% CI: 11.0-18.5) in the encorafenib plus binimetinib group versus 7.3 months (95% CI: 5.6-8.2) in the single agent vemurafenib group (HR= 0.54, 95% CI: 0.41-0.71; p<0·0001) (PMID: 29573941).",
                      "description_review": {
                        "updateTime": 1676491051374,
                        "updatedBy": "User"
                      },
                      "description_uuid": "16181e0a-f9a8-496e-a8c4-ce93e5adf265",
                      "fdaLevel": "Fda2",
                      "fdaLevel_review": {
                        "updateTime": 1676491048740,
                        "updatedBy": "User"
                      },
                      "fdaLevel_uuid": "7c345130-e806-4cb6-90eb-5a049e163669",
                      "indication": "",
                      "indication_uuid": "48001f48-dada-406e-9610-4223d4402f84",
                      "level": "2",
                      "level_review": {
                        "updateTime": 1637272182413,
                        "updatedBy": "User"
                      },
                      "level_uuid": "4b030ef3-4ed5-4d21-b554-ffd3df4d4a7d",
                      "name": "001e534f-3e63-432f-90a6-d1af1759e4e2 + feb9f4a3-e374-4c75-8a3b-0f1fbcdbf677",
                      "name_review": {
                        "updateTime": 1637272174474,
                        "updatedBy": "User"
                      },
                      "name_uuid": "009d1441-ac80-4048-ae01-371ac1591c33",
                      "propagation": "3B",
                      "propagationLiquid": "no",
                      "propagationLiquid_review": {
                        "updateTime": 1637272182407,
                        "updatedBy": "User"
                      },
                      "propagationLiquid_uuid": "c78bcf40-3141-40eb-8799-f423c7f881ce",
                      "propagation_review": {
                        "updateTime": 1637272187664,
                        "updatedBy": "User"
                      },
                      "propagation_uuid": "c02bf486-7cbf-4769-8d7f-8dc3ba922053",
                      "short": ""
                    },
                    {
                      "description": "Dabrafenib, an orally bioavailable RAF inhibitor, and trametinib, an orally bioavailable MEK1/2 inhibitor, are FDA-approved alone or in combination for the treatment of patients with metastatic melanoma harboring a V600E or V600K BRAF mutation. FDA approval of dabrafenib in combination with trametinib was based on results from an open-label Phase III study of combination therapy versus dabrafenib monotherapy in 247 patients with metastatic melanoma who were naive to treatment with BRAF inhibitors. Combined dabrafenib and trametinib, administered in full monotherapy doses, improved the response rate in patients with BRAF V600-mutant metastatic melanoma versus dabrafenib monotherapy (67% vs.51%; p<0.002). However, median progression-free survival improved by only two weeks (9.3 months vs 8.8 months; HR = 0.75) compared with dabrafenib monotherapy (PMID: 23020132). Combination therapy is associated with less cutaneous toxicity than monotherapy, but systemic toxicity may be increased (PMID: 25287827, 25399551). Follow-up trials have demonstrated that all clinical measures inclusive of overall and median progression-free survival as well as objective response rates, median duration of response and number of patients with complete response favored patients treated with combination dabrafenib and trametinib, administered in full monotherapy doses, compared to either dabrafenib or vemurafenib monotherapy, including patients who previously progressed on BRAF inhibitor monotherapy (PMID: 25287827, 25399551, 25265492). Additionally, patients with melanoma treated with dabrafenib and trametinib in both the neoadjuvant and adjuvant settings have improved survival over patients given standard of care (PMID: 29361468, 28991513, 28891408). Promising clinical data has also suggested that addition of an immunotherapy agent to combination RAF and MEK inhibitor treatment may improve rate of overall response and duration of response in melanoma patients (PMID: 31171876, 31171879, 31171878).",
                      "description_review": {
                        "updateTime": 1676491065713,
                        "updatedBy": "User"
                      },
                      "description_uuid": "f8d42cac-38e5-4778-9646-f18745f61d02",
                      "fdaLevel": "Fda2",
                      "fdaLevel_review": {
                        "updateTime": 1673450818704,
                        "updatedBy": "User"
                      },
                      "fdaLevel_uuid": "8a73e868-8a47-467b-85ab-fa65d59cd177",
                      "indication": "",
                      "indication_uuid": "695c1e6c-3da8-46a1-818d-8d6cc814bb57",
                      "level": "2",
                      "level_review": {
                        "updateTime": 1637272283820,
                        "updatedBy": "User"
                      },
                      "level_uuid": "0125357d-195e-4177-a2a9-fe38f7e3d77f",
                      "name": "939cd40b-b515-499d-b099-fd29027c0d17 + fb2bb01c-c0ec-4641-abf7-87f486075022",
                      "name_review": {
                        "updateTime": 1637272276956,
                        "updatedBy": "User"
                      },
                      "name_uuid": "55f1261c-2f2c-4537-aa81-92adcb798585",
                      "propagation": "3B",
                      "propagationLiquid": "no",
                      "propagationLiquid_review": {
                        "updateTime": 1637272283806,
                        "updatedBy": "User"
                      },
                      "propagationLiquid_uuid": "01d9a4f7-59a5-481a-ac19-fc411c7aade3",
                      "propagation_review": {
                        "updateTime": 1637272288782,
                        "updatedBy": "User"
                      },
                      "propagation_uuid": "702fa4a3-8290-4741-ba7d-de2be917ea1f",
                      "short": ""
                    },
                    {
                      "description": "The combination of vemurafenib, an orally available kinse inhibitor of V600-mutant BRAF, and cobimetinib, an orally available kinase inhibitor of MEK1/2, is FDA-approved for the treatment of patients with BRAF V600-mutant metastatic or unresectable locally advanced melanoma. FDA approval was based on results from the randomized Phase III coBRIM trial of combined vemurafenib and cobimetinib versus vemurafenib and placebo in 495 patients with metastatic BRAF V600-mutant melanoma that demonstrated superior clinical benefit measures in the combination versus the control arm. Specifically, median progression-free survival was 9.9 months in the combination arm versus 6.2 months in the control arm (HR = 0.51), with a complete response rate of 10% versus 4%, respectively, and interim nine-month overall survival of 81% versus 73%, respectively (PMID: 25265494). Follow-up analysis of the coBRIM trial showed two-year overall survival was 48.3% in the combination group versus 38.0% in the monotherapy group (PMID: 27480103).",
                      "description_review": {
                        "updateTime": 1676491080122,
                        "updatedBy": "User"
                      },
                      "description_uuid": "00dcd6cc-e07d-4466-9c31-85796e0d93f3",
                      "fdaLevel": "Fda2",
                      "fdaLevel_review": {
                        "updateTime": 1676491077299,
                        "updatedBy": "User"
                      },
                      "fdaLevel_uuid": "c69d4bca-387d-417f-839d-c5ae5dd1e070",
                      "indication": "",
                      "indication_uuid": "67ae0195-972a-46ff-c0d4-73fcc5473f1f",
                      "level": "2",
                      "level_review": {
                        "updateTime": 1637272386945,
                        "updatedBy": "User"
                      },
                      "level_uuid": "51d6ae20-155e-4c38-b112-dd078525cb60",
                      "name": "4e91da20-6cf0-4e07-995f-7f7db4c7c077 + eb357145-3b18-4aca-b75a-5e18dd2bf4f9",
                      "name_review": {
                        "updateTime": 1637272377215,
                        "updatedBy": "User"
                      },
                      "name_uuid": "f9aaeb93-ca4e-49cc-8424-792f49ce9006",
                      "propagation": "3B",
                      "propagationLiquid": "no",
                      "propagationLiquid_review": {
                        "updateTime": 1637272386943,
                        "updatedBy": "User"
                      },
                      "propagationLiquid_uuid": "a87f2ba1-c001-4ddc-943b-8a09c9fb80a9",
                      "propagation_review": {
                        "updateTime": 1637272390553,
                        "updatedBy": "User"
                      },
                      "propagation_uuid": "bf4dc0ee-f1d7-4203-b9a7-195dd8614112",
                      "short": ""
                    }
                  ],
                  "treatments_uuid": "04d7a8d4-30a5-4ab2-9d38-0541487d30b1",
                  "type": "SS"
                },
                {
                  "name": "Standard implications for resistance to therapy",
                  "name_uuid": "9b15717f-fb59-4473-b9e9-abf99c245d3d",
                  "treatments_uuid": "899bf2a6-1741-4baa-986d-f2125994eaaa",
                  "type": "SR"
                },
                {
                  "name": "Investigational implications for sensitivity to therapy",
                  "name_uuid": "fabe8ede-8300-4f7c-973a-f552c84e57a1",
                  "treatments_uuid": "4c3b0531-7992-44c0-a0e7-4b8fb5075926",
                  "type": "IS"
                },
                {
                  "name": "Investigational implications for resistance to therapy",
                  "name_uuid": "ed8010e4-9942-4bef-93b5-fffbb798cc90",
                  "treatments_uuid": "bba73734-e7b2-42e1-966c-862ffd092ee0",
                  "type": "IR"
                }
              ],
              "cancerTypes": [
                {
                  "code": "MEL",
                  "mainType": "Melanoma",
                  "subtype": "Melanoma"
                }
              ],
              "cancerTypes_review": {
                "updateTime": 1637271774958,
                "updatedBy": "User"
              },
              "cancerTypes_uuid": "dc47e681-776e-4452-bc38-5504f4377ef3",
              "diagnostic": {
                "description": "",
                "description_uuid": "52ed7dc3-5b83-495f-b62f-48a173d76e1b",
                "level": "",
                "level_uuid": "1a752026-72fc-453e-b074-bb4682023d62",
                "short": ""
              },
              "diagnosticSummary": "",
              "diagnosticSummary_uuid": "45923f85-26a5-4f8c-8cb2-48d38c1806d7",
              "diagnostic_uuid": "048a0b07-b884-4a91-89d6-d99f5031d214",
              "prognostic": {
                "description": "",
                "description_uuid": "db6724f3-bf1a-44d4-ba6c-6753e4c5c688",
                "level": "",
                "level_uuid": "94847365-3fa7-4b42-b55c-ad0e03f836c3",
                "short": ""
              },
              "prognosticSummary": "",
              "prognosticSummary_uuid": "b93f1983-da96-4f37-b477-b88d67958b1c",
              "prognostic_uuid": "ce202a75-13e4-4ac9-8386-0874c0329c46",
              "summary": "The RAF-targeted inhibitors encorafenib, dabrafenib and vemurafenib, alone or in combination with the MEK1/2-targeted inhibitors binimetinib, trametinib and cobimetinib respectively, are FDA-approved for the treatment of patients with BRAF V600E/K mutant melanoma and NCCN-compendium listed for the treatment of patients with BRAF V600-mutant melanoma. Additionally, the anti-PD-L1 antibody atezolizumab in combination with cobimetinib + vemurafenib is FDA-approved for the treatment of patients with unresectable or advanced BRAF V600-mutant melanoma.",
              "summary_review": {
                "updateTime": 1637272104265,
                "updatedBy": "User"
              },
              "summary_uuid": "6cbb7fd3-76a2-4d64-8332-bdb68e972b03"
            }
          ],
          "tumors_uuid": "07d5b8c0-43db-4b3e-a8a8-5f8e47f6970b"
        },
        {
          "mutation_effect": {
            "description": "The p61BRAF(V600E) mutation is the product of alternative splicing of the BRAF mRNA transcript, which contains the V600E mutation but eliminates exons 4-8 of the gene (PMID: 22113612). This mutation encodes a truncated, 16 kDa BRAF protein that has the V600E mutation but lacks the RAS binding domain and constitutively dimerizes (PMID: 22113612). This mutation has been found in melanoma (PMID: 22113612). In concordance with its ability to constitutively dimerize, in vitro studies of this mutation suggest that it is resistant to vemurafenib, as measured by persistent MAPK pathway signaling and cell proliferation upon drug treatment (PMID: 22113612). In one study, six out of nineteen patients with melanomas that were resistant to vemurafenib harbored the p61BRAF(V600E) mutation (PMID: 22113612). In a second study, BRAF splice variants were found in several patient-derived xenografts that were generated from patients who progressed on BRAF inhibitors (PMID: 27320919).",
            "description_review": {
              "updateTime": 1652729597207,
              "updatedBy": "User"
            },
            "description_uuid": "0fbbae82-0a22-460e-88d3-2f1d1303fb89",
            "effect": "Gain-of-function",
            "effect_review": {
              "updateTime": 1493057315640
            },
            "effect_uuid": "540b58a0-be50-41d4-9241-ce4d8b597398",
            "oncogenic": "Yes",
            "oncogenic_review": {
              "updateTime": 1493057315640
            },
            "oncogenic_uuid": "2d9f2a61-bb25-4bb2-ba0d-6ebe58fd7f6c",
            "short": ""
          },
          "mutation_effect_uuid": "bdfcb610-6514-4901-abd9-854f2a6d7441",
          "name": "V169_D380del [p61BRAF-V600E]",
          "name_review": {
            "updateTime": 1503087636565
          },
          "name_uuid": "01d1c08f-bd04-43f6-8d87-e5b0d0c2b064"
        },
        {
          "mutation_effect": {
            "description": "The BRAF I592_A598dup mutation is located in the kinase domain in exon 15 of the protein. This mutation has been identified in papillary thyroid carcinoma, inguinal adenopathy and primary melanoma, and is a statistically significant hotspot (PMID: 27571181, 28800030 ). This mutation has not been functionally characterized in vitro. BRAF exon 15 mutations are sensitive to treatment with combination MAPK-directed targeted therapy based on the clinical benefit of two patients with rare BRAF exon 15 insertion mutations involving the A598 residue, BRAF A598_T599insV and V600_K601delinsE (PMID: 28800030).",
            "description_review": {
              "updateTime": 1671570734352,
              "updatedBy": "User"
            },
            "description_uuid": "def51eb0-97db-438f-beb3-82a77fceb7da",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1671570741992,
              "updatedBy": "User"
            },
            "effect_uuid": "e094703b-28dd-45a1-a8c6-8f3f018fa030",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1671570737873,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "753b067a-2371-47dd-aff5-722c63c023e0",
            "short": ""
          },
          "mutation_effect_uuid": "70f3ee1b-649a-4b72-bb51-4977f483ca34",
          "name": "I592_A598dup",
          "name_review": {
            "updateTime": 1670874862854,
            "updatedBy": "User"
          },
          "name_uuid": "9a325747-602a-4188-ad73-db7164aca7aa",
          "tumors_uuid": "4a7ba7a2-3041-4971-b198-6c87c7565d27"
        },
        {
          "mutation_effect": {
            "description": "The BRAF L485W mutation is located in the kinase domain of the protein (PMID: 35117215). This mutation has been identified in bladder adenocarcinoma and is a statistically significant hotspot (PMID: 28481359). The oncogenic and biologic effect of this mutation has conflicting evidence. An in vitro study with Ba/F3 and MCF10A cells expressing BRAF L485W demonstrates the mutation is inactivating as measured by decreased cellular viability in one cell line compared to wildtype (PMID: 29533785). In contrast, BRAF L485W has been cited as an activating class II BRAF mutation and is suggested to be an atypical activating mutation due to sensitivity to MAPK targeting inhibitors (PMID: 35977349, 35117215, 31015311). Clinical studies suggest that BRAF L485W is sensitive to MAPK pathway inhibition as measured by a patient with gallbladder cancer harboring the mutation demonstrating sensitivity to the ERK1/2 kinase inhibitor ulixertinib as measured by a year-long complete response to treatment (PMID: 29247021).",
            "description_review": {
              "updateTime": 1710275347571,
              "updatedBy": "User"
            },
            "description_uuid": "b224e328-e0bf-4300-9a7b-6eaa6bc9bb59",
            "effect": "Inconclusive",
            "effect_review": {
              "updateTime": 1710253850165,
              "updatedBy": "User"
            },
            "effect_uuid": "8322f1de-86af-4e6f-8a96-b05f246d1b16",
            "oncogenic": "Inconclusive",
            "oncogenic_review": {
              "updateTime": 1710253848338,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "62fd5ccd-0491-4148-af9e-48bbc95dfd01",
            "short": ""
          },
          "mutation_effect_uuid": "5d428b3a-626b-460c-8ad6-8b92cb4f5269",
          "name": "L485W",
          "name_review": {
            "updateTime": 1674592276657,
            "updatedBy": "User"
          },
          "name_uuid": "ed087287-7ae6-4267-91d9-73d75de6f2f6",
          "tumors_uuid": "5cd4bdf5-7cf9-4b22-8467-49b7eb4d93ed"
        },
        {
          "mutation_effect": {
            "description": "The class II BRAF G469S mutation is located in the kinase domain in exon 11 of the protein (PMID: 31470866). This mutation has been identified in malignant melanoma and is a statistically significant hotspot (PMID: 16096377). In vitro studies with HEK293T cells expressing BRAF G469S demonstrate that the mutation is activating as measured by increased phosphorylated MEK and ERK levels compared to wildtype (PMID: 28947956). In a case report, a patient with metastatic melanoma harboring BRAF G469S was treated with a combination therapy of trametinib plus dabrafenib and demonstrated stable disease with a progression-free survival of three months (PMID: 31569065). In a Phase II trial, a patient with melanoma harboring BRAF G469S was treated with combination therapy of binimetinib and encorafenib and demonstrated an unconfirmed partial response (Abstract: Rose et al. Abstract# 531P, Annals of Oncology 2021. https://www.annalsofoncology.org/article/S0923-7534%2821%2903282-8/fulltext).",
            "description_review": {
              "updateTime": 1678906021959,
              "updatedBy": "User"
            },
            "description_uuid": "f7f594ff-d138-4bb6-9de7-f0bbca6d6a5e",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1675288478448,
              "updatedBy": "User"
            },
            "effect_uuid": "926f93dc-c93f-42cb-b07d-fef65da7985a",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675288477683,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "888eef19-2da3-4810-94b0-5f2e48293460",
            "short": ""
          },
          "mutation_effect_uuid": "59769101-a2d3-4486-8439-96bf94040f33",
          "name": "G469S",
          "name_review": {
            "updateTime": 1675288469670,
            "updatedBy": "User"
          },
          "name_uuid": "4b24f966-60b9-4557-b51b-5203d5b24ecc",
          "tumors_uuid": "0f2a3b93-9ca0-4208-b03b-ccb4b436db15"
        },
        {
          "mutation_effect": {
            "description": "The class III BRAF N581T mutation is located in the kinase domain of the protein (PMID: 31515458). This mutation has been identified in diffuse large B-cell lymphoma and is a statistically significant hotspot (PMID: 32187361). In vitro studies with Ba/F3 and MCF10A cells expressing BRAF N581T demonstrate that the mutation is likely neutral as measured by cell viability and proliferation comparable to wildtype (PMID: 29533785). In a case report, a patient with metastatic colorectal cancer harboring BRAF N581T was treated with a combination therapy of cetuximab plus FOLFOX and demonstrated partial response with a progression-free survival of 1.4 months (PMID: 31515458).",
            "description_review": {
              "updateTime": 1678309362397,
              "updatedBy": "User"
            },
            "description_uuid": "d5807543-7617-4176-93a7-5c61ba561702",
            "effect": "Likely Neutral",
            "effect_review": {
              "updateTime": 1675288765875,
              "updatedBy": "User"
            },
            "effect_uuid": "7d9ab560-2699-413a-9758-d8faab353cd4",
            "oncogenic": "Likely Neutral",
            "oncogenic_review": {
              "updateTime": 1675288764573,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "3c8deca4-ab8f-4724-8503-d513c1d9080b",
            "short": ""
          },
          "mutation_effect_uuid": "b6e55808-7f54-4f95-ad43-bc8007ad0ff4",
          "name": "N581T",
          "name_review": {
            "updateTime": 1675288753659,
            "updatedBy": "User"
          },
          "name_uuid": "123b070a-e042-481d-85f0-768e46f129fc",
          "tumors_uuid": "f8c056b6-09f2-4734-90bc-50fa83f81a7a"
        },
        {
          "mutation_effect": {
            "description": "The class III BRAF G596S mutation is located in the kinase domain of the protein and is a statistically significant hotspot (PMID: 33198372). In vitro studies with Ba/F3 cells expressing BRAF G596S demonstrate that the mutation is activating as measured by increased transformation ability compared to wildtype (PMID: 29533785). In silico analysis suggests that BRAF G596S is resistant to vemurafenib (PMID: 35215249).",
            "description_review": {
              "updateTime": 1678304186582,
              "updatedBy": "User"
            },
            "description_uuid": "ab89f477-46b0-45d2-a5ce-92f6cb32e9b8",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1675370387132,
              "updatedBy": "User"
            },
            "effect_uuid": "776007fd-a78b-4c5d-8aa2-4d557760ffac",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675370386593,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "19aa6810-e3ad-4768-bcd1-eb3e988abba1",
            "short": ""
          },
          "mutation_effect_uuid": "0238d778-749e-42b2-8760-4e9091ea1e24",
          "name": "G596S",
          "name_review": {
            "updateTime": 1675370382300,
            "updatedBy": "User"
          },
          "name_uuid": "4e58dc67-c895-4101-85f0-de3df3e18b95",
          "tumors_uuid": "a9dcfb42-519e-4b2c-8006-cde94751c50d"
        },
        {
          "mutation_effect": {
            "description": "The BRAF G606W mutation is located in the kinase domain of the protein. This mutation has been identified in lung adenocarcinoma (PMID: 28481359). In vitro studies with MCF10A cells expressing BRAF G606W demonstrate that the mutation is inactivating as measured by decreased transformation ability compared to wildtype (PMID: 29533785).",
            "description_review": {
              "updateTime": 1680011342414,
              "updatedBy": "User"
            },
            "description_uuid": "b76bbe14-878e-494d-b740-ac1cddf33b76",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1680011330758,
              "updatedBy": "User"
            },
            "effect_uuid": "9eefa994-e657-43db-93fb-f9ce51268979",
            "oncogenic": "Likely Neutral",
            "oncogenic_review": {
              "updateTime": 1680011329421,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "3cc907ca-954a-4ed8-89d2-4b5207ed1077",
            "short": ""
          },
          "mutation_effect_uuid": "3a0d9fc4-239f-482f-8db0-812adcd994f4",
          "name": "G606W",
          "name_review": {
            "updateTime": 1680011327209,
            "updatedBy": "User"
          },
          "name_uuid": "c07b608e-76f5-4f63-8f66-1c1b710cdecc",
          "tumors_uuid": "49386977-69c6-4006-92bb-5ca6cf69ad60"
        },
        {
          "mutation_effect": {
            "description": "The BRAF A762V mutation is located in an unknown functional domain of the protein. This mutation has been identified in colorectal cancer (PMID: 29316426). In vitro studies with Ba/F3 and MCF10A cells expressing BRAF A762V demonstrate that the mutation is likely neutral as measured by transformation and proliferation comparable to wildtype (PMID: 29533785).",
            "description_review": {
              "updateTime": 1680011370569,
              "updatedBy": "User"
            },
            "description_uuid": "4facd9bd-6aec-4f31-8b67-394606b01028",
            "effect": "Likely Neutral",
            "effect_review": {
              "updateTime": 1680011365013,
              "updatedBy": "User"
            },
            "effect_uuid": "79f3270f-b928-4965-b727-bdd74b0490eb",
            "oncogenic": "Likely Neutral",
            "oncogenic_review": {
              "updateTime": 1680011364220,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "5e9d52ed-5c92-45e2-a5d2-f09983848227",
            "short": ""
          },
          "mutation_effect_uuid": "a9bfc914-39a8-43a6-afa6-5b11e155dd4e",
          "name": "A762V",
          "name_review": {
            "updateTime": 1680011360822,
            "updatedBy": "User"
          },
          "name_uuid": "96570838-8cde-432b-b877-dad1bc8008ad",
          "tumors_uuid": "c88f622e-4100-4089-c066-5db9e8bb081d"
        },
        {
          "mutation_effect": {
            "description": "The BRAF R682W mutation is located in the kinase domain of the protein. This mutation has been identified in lung adenocarcinoma (PMID: 22980975). Preclinical studies with PC9 cells expressing BRAF R682W and EGFR exon 19 in-frame deletion mutations demonstrated that the mutation is resistant to treatment with erlotinib as measured by sustained cellular viability following treatment (PMID: 27478040).",
            "description_review": {
              "updateTime": 1680011411649,
              "updatedBy": "User"
            },
            "description_uuid": "8227dccc-4ae6-4d2b-a7a3-316ac0db351e",
            "effect": "Inconclusive",
            "effect_review": {
              "updateTime": 1680011400047,
              "updatedBy": "User"
            },
            "effect_uuid": "b4690794-43f1-4d4e-a7f1-4a916b592fe0",
            "oncogenic": "Resistance",
            "oncogenic_review": {
              "updateTime": 1680011399135,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "1229dd70-6fb5-4bbe-9d3e-a48b364433c8",
            "short": ""
          },
          "mutation_effect_uuid": "a3d63b24-98d2-4095-b410-090bf3763d06",
          "name": "R682W",
          "name_review": {
            "updateTime": 1680011394744,
            "updatedBy": "User"
          },
          "name_uuid": "e6b71e34-8eda-4c8f-a041-7d0df63067f3",
          "tumors_uuid": "35033de4-c676-476c-8e0c-86c905ca7396"
        },
        {
          "mutation_effect": {
            "description": "The BRAF P367S mutation is located in an unknown functional domain of the protein. This mutation has been identified in melanoma (PMID: 24265153). In vitro studies with Ba/F3 cells expressing BRAF P367S demonstrate that the mutation is activating as measured by increased transformation ability compared to wildtype (PMID: 29533785).",
            "description_review": {
              "updateTime": 1680011446255,
              "updatedBy": "User"
            },
            "description_uuid": "ba8771d6-1ba4-40d0-84a1-c6bf9ff19468",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1680011440841,
              "updatedBy": "User"
            },
            "effect_uuid": "91da86fe-2f02-4d1d-a26a-84d8f52f049b",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1680011439783,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "38e74d85-b24a-4938-acd7-b1c857b16a9c",
            "short": ""
          },
          "mutation_effect_uuid": "bf42520c-c429-4e0d-b917-69268f0763e4",
          "name": "P367S",
          "name_review": {
            "updateTime": 1680011436928,
            "updatedBy": "User"
          },
          "name_uuid": "6474bfeb-2d32-4c87-867c-c7810f46bdac",
          "tumors_uuid": "a02069ea-7744-413a-8896-f6e24ff0e2c4"
        },
        {
          "mutation_effect": {
            "description": "The BRAF A33T mutation is located in an unknown functional domain of the protein. This mutation has been identified in colorectal cancer (PMID: 28481359). In vitro studies with mouse embryonic fibroblasts expressing BRAF A33T demonstrate that the mutation is likely neutral as measured by ERK activation comparable to wildtype (PMID: 31515458).",
            "description_review": {
              "updateTime": 1680011480802,
              "updatedBy": "User"
            },
            "description_uuid": "86ed60fd-3075-41d9-826c-2766e69c8af8",
            "effect": "Likely Neutral",
            "effect_review": {
              "updateTime": 1680011476736,
              "updatedBy": "User"
            },
            "effect_uuid": "704334e4-f538-4143-a116-dbce48de5258",
            "oncogenic": "Likely Neutral",
            "oncogenic_review": {
              "updateTime": 1680011475832,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "23c14370-2a01-46a1-9120-a04fa88e507f",
            "short": ""
          },
          "mutation_effect_uuid": "95792c51-8628-42e2-8b63-c96027bd91e8",
          "name": "A33T",
          "name_review": {
            "updateTime": 1680011465603,
            "updatedBy": "User"
          },
          "name_uuid": "49248b00-c4ac-4aef-9063-f22ad9844522",
          "tumors_uuid": "ce6bd934-1dbe-4496-80c8-5448c7f4e46c"
        },
        {
          "mutation_effect": {
            "description": "The BRAF R271H mutation is located in the zinc-finger domain of the protein. This mutation has been identified in prostate cancer (PMID: 28825054). In vitro studies with Ba/F3 and MCF10A cells expressing BRAF R271H demonstrate that the mutation is likely neutral as measured by cellular proliferation and viability comparable to wildtype (PMID: 29533785).",
            "description_review": {
              "updateTime": 1680011508673,
              "updatedBy": "User"
            },
            "description_uuid": "9c5929cd-fbd8-47f2-8c96-192f9933b7e0",
            "effect": "Likely Neutral",
            "effect_review": {
              "updateTime": 1680011506594,
              "updatedBy": "User"
            },
            "effect_uuid": "7f946eea-0e70-4ba0-8599-1c4599a1d9f5",
            "oncogenic": "Likely Neutral",
            "oncogenic_review": {
              "updateTime": 1680011505673,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "ea70fe95-5c10-480b-9fde-1b4c0408f6db",
            "short": ""
          },
          "mutation_effect_uuid": "a94a8ba9-7fd8-408d-9bd2-25cfec206407",
          "name": "R271H",
          "name_review": {
            "updateTime": 1680011497913,
            "updatedBy": "User"
          },
          "name_uuid": "d34ad732-5a25-45ee-8c8b-775ab5de1239",
          "tumors_uuid": "8fb85a36-fa32-4cbd-a81a-adb111e9f5fe"
        },
        {
          "mutation_effect": {
            "description": "The BRAF H725Y mutation is located in an unknown functional domain of the protein. This mutation has been identified in merkel cell carcinoma (PMID: 28481359). In vitro studies with MCF10A cells expressing BRAF H725Y demonstrate that the mutation is activating as measured by increased transformation ability compared to wildtype (PMID: 29533785).",
            "description_review": {
              "updateTime": 1680011536121,
              "updatedBy": "User"
            },
            "description_uuid": "ed956086-b895-467a-8b34-7bc28ac15b19",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1680011534637,
              "updatedBy": "User"
            },
            "effect_uuid": "ea3019e5-f0bf-40b0-b577-7d467486d2b8",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1680011534086,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "b93338b9-4378-4b67-8331-97afe3c46559",
            "short": ""
          },
          "mutation_effect_uuid": "b5dcb1ca-9801-41cc-9e96-b108f68b931a",
          "name": "H725Y",
          "name_review": {
            "updateTime": 1680011527995,
            "updatedBy": "User"
          },
          "name_uuid": "c8720b4a-4d01-4757-a233-a943d33fa7fc",
          "tumors_uuid": "02786ed3-4214-4e82-8764-497bf35981da"
        },
        {
          "mutation_effect": {
            "description": "The BRAF F294L mutation is located in an unknown functional domain of the protein. This mutation has been identified in colorectal cancer (PMID: 28481359). In vitro studies with Ba/F3 and MCF10A cells expressing BRAF F294L demonstrate that the mutation is likely neutral as measured by cellular proliferation and viability comparable to wildtype (PMID: 29533785).",
            "description_review": {
              "updateTime": 1680011557508,
              "updatedBy": "User"
            },
            "description_uuid": "bebe498e-41ff-4de6-a8b6-6bf2acc665cc",
            "effect": "Likely Neutral",
            "effect_review": {
              "updateTime": 1680011552410,
              "updatedBy": "User"
            },
            "effect_uuid": "0bedcc6e-0b8d-4096-bbbf-f54063466e6f",
            "oncogenic": "Likely Neutral",
            "oncogenic_review": {
              "updateTime": 1680011551218,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "5156f3f4-6113-4df7-a5a4-c3bf3fd5e364",
            "short": ""
          },
          "mutation_effect_uuid": "295db5e3-2021-408c-b3f2-e3c60db7a504",
          "name": "F294L",
          "name_review": {
            "updateTime": 1680011548156,
            "updatedBy": "User"
          },
          "name_uuid": "d7437ca7-1950-494b-8c6f-697ab08fb6ce",
          "tumors_uuid": "8a912ebf-bec5-4299-a8b9-b36702049097"
        },
        {
          "mutation_effect": {
            "description": "The BRAF-PJA2 fusion protein results from exon 7 of PJA2 fusing with exon 11 of BRAF, retaining the BRAF kinase domain. This fusion has been identified in EGFR-mutant lung cancer (PMID: 30831205). Preclinical studies with H1975 and PC9 cells expressing BRAF-PJA2 demonstrated the fusion is resistant to treatment with osimertinib as measured by sustained cell viability following treatment (PMID: 30831205).",
            "description_review": {
              "updateTime": 1681250896728,
              "updatedBy": "User"
            },
            "description_uuid": "d0a82e6d-e895-4c65-8fd9-2580fd83e1f1",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1681250899676,
              "updatedBy": "User"
            },
            "effect_uuid": "1aff8c74-2114-4c5c-86d2-e670c01eea63",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1681250898894,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "779a250f-390d-438d-95e3-403d9832886b",
            "short": ""
          },
          "mutation_effect_uuid": "ff46185a-fc2f-4bce-ba1b-cee09ad3f04c",
          "name": "BRAF-PJA2 Fusion",
          "name_review": {
            "updateTime": 1680011596849,
            "updatedBy": "User"
          },
          "name_uuid": "56ec1fdb-0834-4a0b-9276-f28f0096e719",
          "tumors_uuid": "93fe686d-5e9c-4caf-9a15-d5db76ea8853"
        },
        {
          "mutation_effect": {
            "description": "The BRAF I572F mutation is located in the kinase domain of the protein. This mutation has been identified in lung adenocarcinoma (PMID: 28481359). Although not functionally characterized per se, a patient with lung adenocarcinoma harboring BRAF I572F and KRAS G12V was treated with nivolumab and demonstrated progressive disease (PMID: 34963703).",
            "description_review": {
              "updateTime": 1680109818395,
              "updatedBy": "User"
            },
            "description_uuid": "7bbedeb2-aee3-467d-b8a6-702cf443764a",
            "effect": "Inconclusive",
            "effect_review": {
              "updateTime": 1680109813974,
              "updatedBy": "User"
            },
            "effect_uuid": "eeefc97d-4142-4f19-af7c-26048155a361",
            "oncogenic": "Inconclusive",
            "oncogenic_review": {
              "updateTime": 1680109811485,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "b4256573-9ddb-44b0-83ff-a8d1fe2d5706",
            "short": ""
          },
          "mutation_effect_uuid": "e8315292-0331-4c86-8010-6c140949771a",
          "name": "I572F",
          "name_review": {
            "updateTime": 1680109809799,
            "updatedBy": "User"
          },
          "name_uuid": "26e6eadd-3837-42f4-9d09-e162bb3e2bc8",
          "tumors_uuid": "0ab9de87-8e65-44bc-910c-56ae13a0d503"
        },
        {
          "mutation_effect": {
            "description": "The BRAF M620I mutation is located in the kinase domain of the protein. This mutation has been identified in lung adenocarcinoma (PMID: 28481359). In silico analysis suggests that the mutation is activating and damaging (PMID: 34588906).",
            "description_review": {
              "updateTime": 1680109851158,
              "updatedBy": "User"
            },
            "description_uuid": "180c9d4b-27a0-47bd-9829-c978eb39726d",
            "effect": "Inconclusive",
            "effect_review": {
              "updateTime": 1680109846723,
              "updatedBy": "User"
            },
            "effect_uuid": "e2872a4c-bc9c-4349-979b-6b04b594df08",
            "oncogenic": "Inconclusive",
            "oncogenic_review": {
              "updateTime": 1680109845753,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "6bb9b4e8-ed04-4c42-a793-432f4ee97299",
            "short": ""
          },
          "mutation_effect_uuid": "072196c5-4649-4266-c0b0-dc35d4960a0e",
          "name": "M620I",
          "name_review": {
            "updateTime": 1680109843844,
            "updatedBy": "User"
          },
          "name_uuid": "e3336754-895e-4315-b12d-4d3a14a7695e",
          "tumors_uuid": "3569fd76-13b9-40fb-adcb-f9e1aa5187eb"
        },
        {
          "mutation_effect": {
            "description": "The BRAF P162S mutation is located in the RBD domain of the protein. This mutation has been identified in biliary tract cancer (PMID: 29360550). In vitro studies with Ba/F3 and MCF10A cells expressing BRAF P162S demonstrate that the mutation is likely neutral as measured by cellular proliferation and viability comparable to wildtype (PMID: 29533785).",
            "description_review": {
              "updateTime": 1680805382703,
              "updatedBy": "User"
            },
            "description_uuid": "bf903765-eda2-4640-9531-a19894929e98",
            "effect": "Likely Neutral",
            "effect_review": {
              "updateTime": 1680109867502,
              "updatedBy": "User"
            },
            "effect_uuid": "69cec9f1-2fa9-4d15-9fa2-3a854debe177",
            "oncogenic": "Likely Neutral",
            "oncogenic_review": {
              "updateTime": 1680109865887,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "4f26b6ee-0619-4a3e-8e4e-7a21baded348",
            "short": ""
          },
          "mutation_effect_uuid": "bd013e9e-4ab4-4f3d-acc2-ef9791a2a61b",
          "name": "P162S",
          "name_review": {
            "updateTime": 1680109860909,
            "updatedBy": "User"
          },
          "name_uuid": "7bcf2c57-992b-4eec-b73d-ea4df4e68819",
          "tumors_uuid": "1833a3a4-2695-4586-b5d7-1889cbb7de16"
        },
        {
          "mutation_effect": {
            "description": "The BRAF R239Q mutation is located in the zinc-finger domain of the protein. This mutation has been identified in melanoma (PMID: 28481359). Although not functionally characterized per se, preclinical studies with patient-derived melanoma cell lines harboring BRAF R239Q and BRAF L597S demonstrated sensitivity to treatment with binimetinib plus encorafenib, dabrafenib plus trametinib, single agent encorafenib and single agent binimetinib as measured by reduced cellular proliferation and tumor growth (PMID: 29903896).",
            "description_review": {
              "updateTime": 1680118469525,
              "updatedBy": "User"
            },
            "description_uuid": "effc2501-620a-497d-a3a3-f6df1579763d",
            "effect": "Inconclusive",
            "effect_review": {
              "updateTime": 1680118465222,
              "updatedBy": "User"
            },
            "effect_uuid": "9e1a9d85-4299-4e5d-b22b-a00933dd4196",
            "oncogenic": "Inconclusive",
            "oncogenic_review": {
              "updateTime": 1680118463959,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "86548f98-9509-40e8-9184-72020ba09c77",
            "short": ""
          },
          "mutation_effect_uuid": "7ffb2dba-487f-4d71-8873-032c799dd145",
          "name": "R239Q",
          "name_review": {
            "updateTime": 1680118458636,
            "updatedBy": "User"
          },
          "name_uuid": "45a6fd3b-d068-44b6-a1c0-e9ae68fe7673",
          "tumors_uuid": "63b73f0e-07cb-4712-9db0-99d7087fabfe"
        },
        {
          "mutation_effect": {
            "description": "The class III BRAF R558Q mutation is located in the kinase domain of the protein (PMID: 31515458). This mutation has been identified in colorectal cancer (PMID: 28481359). In vitro studies with mouse embryonic fibroblasts expressing BRAF R558Q demonstrate that the mutation is activating as measured by increased ERK signaling compared to wildtype (PMID: 31515458). In a clinical trial, a patient with metastatic colorectal cancer harboring BRAF R558Q was treated with combination cetuximab plus irinotecan and demonstrated complete response with a progression-free survival of 37.7 months (PMID: 31515458).",
            "description_review": {
              "updateTime": 1680133261412,
              "updatedBy": "User"
            },
            "description_uuid": "b58dbdc6-8ebc-4468-b022-741e19e79bc2",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1680118491795,
              "updatedBy": "User"
            },
            "effect_uuid": "40f7f0ec-543e-4254-b80a-713689ecf867",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1680118490725,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "ff3ab9a1-702c-46c8-b759-4d3a5e00947e",
            "short": ""
          },
          "mutation_effect_uuid": "3aa7cc52-53fb-411e-96c6-7623d7555ce1",
          "name": "R558Q",
          "name_review": {
            "updateTime": 1680118485485,
            "updatedBy": "User"
          },
          "name_uuid": "533253d6-9881-4929-a4f3-68c1d1e8d792",
          "tumors_uuid": "480246c7-6445-4420-a473-be745ecb914c"
        },
        {
          "mutation_effect": {
            "description": "The BRAF S363F mutation is located in an unknown functional domain of the protein. This mutation has been identified in melanoma (PMID: 28467829). Although not functionally characterized per se, preclinical studies with melanoma cell lines harboring BRAF S363F and BRAF K601E demonstrated sensitivity to treatment with binimetinib plus encorafenib, dabrafenib plus trametinib, trametinib plus vemurafenib, single agent encorafenib, single agent binimetinib, single agent trametinib and single agent cobimetinib as measured by reduced cellular proliferation (PMID: 29903896).",
            "description_review": {
              "updateTime": 1680118530278,
              "updatedBy": "User"
            },
            "description_uuid": "ff89afc2-6546-471b-895b-ac0764d15bf5",
            "effect": "Inconclusive",
            "effect_review": {
              "updateTime": 1680118526672,
              "updatedBy": "User"
            },
            "effect_uuid": "85f1e474-daa3-459e-9380-8e69a4441351",
            "oncogenic": "Inconclusive",
            "oncogenic_review": {
              "updateTime": 1680118525444,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "6f2f0aef-d53a-4ab9-bc1b-6aca75ba711e",
            "short": ""
          },
          "mutation_effect_uuid": "e74affb0-d115-4cc7-bc1c-306373d0a89e",
          "name": "S363F",
          "name_review": {
            "updateTime": 1680118515307,
            "updatedBy": "User"
          },
          "name_uuid": "bf0ca8f5-e126-4407-acd5-86cfa79d40fd",
          "tumors_uuid": "888eecef-3c7c-4a8b-ae7d-71814e40ce79"
        },
        {
          "mutation_effect": {
            "description": "The BRAF T310I mutation is located in an unknown functional domain of the protein. This mutation has been identified in glioma (PMID: 18772396). In vitro studies with SkBr3 cells expressing BRAF T310I demonstrate that the mutation is activating as measured by an increase in ERK phosphorylation compared to wildtype (PMID: 31158244). Preclinical studies with SkBr3 cells expressing this mutation demonstrate resistance to treatment with dabrafenib as measured by sustained ERK phosphorylation (PMID: 31158244).",
            "description_review": {
              "updateTime": 1680118569680,
              "updatedBy": "User"
            },
            "description_uuid": "603b94bc-7c07-4c4b-98c7-d3ee2dba8408",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1680118562509,
              "updatedBy": "User"
            },
            "effect_uuid": "aa4c01bb-ff19-4975-8d6c-2fc5047418a7",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1680118561969,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "8fa75258-b5ed-4a43-aba3-cc776ee00c5a",
            "short": ""
          },
          "mutation_effect_uuid": "93c19bee-46ab-431e-96ab-1e742b5abeaf",
          "name": "T310I",
          "name_review": {
            "updateTime": 1680118559902,
            "updatedBy": "User"
          },
          "name_uuid": "d3316937-e94f-49cf-a43c-ae90c34f4d5c",
          "tumors_uuid": "19a61b55-9241-45fe-b45b-49d67b746fb3"
        },
        {
          "mutation_effect": {
            "description": "The BRAF L485Y mutation is located in the kinase domain of the protein. In vitro studies with HT29 cells expressing BRAF L485Y demonstrated resistance to treatment with GDC0879 as measured by sustained cellular proliferation following treatment (PMID: 19276360).",
            "description_review": {
              "updateTime": 1680192155789,
              "updatedBy": "User"
            },
            "description_uuid": "6752d9db-b649-4ae9-a6e9-83f2230844f9",
            "effect": "Inconclusive",
            "effect_review": {
              "updateTime": 1680118595639,
              "updatedBy": "User"
            },
            "effect_uuid": "66e6caab-ad7f-4b9c-9a6f-cbed104e7823",
            "oncogenic": "Resistance",
            "oncogenic_review": {
              "updateTime": 1680118594586,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "b5152b18-7699-4da6-9902-f83472ec5b55",
            "short": ""
          },
          "mutation_effect_uuid": "9d945125-a0b5-4b35-b573-bd95c2c9a156",
          "name": "L485Y",
          "name_review": {
            "updateTime": 1680118592583,
            "updatedBy": "User"
          },
          "name_uuid": "5776386c-6d6a-4796-aab7-7965d1e8b4ac",
          "tumors_uuid": "c3e634eb-cf71-4c7f-b4aa-3ec56c1f54ea"
        },
        {
          "mutation_effect": {
            "description": "The BRAF L597P mutation is located in the kinase domain of the protein. This mutation has been identified in melanoma (PMID: 23890154). In vitro studies with patient-derived intrahepatic cholangiocarcinoma organoids expressing BRAF L597P demonstrated resistance to treatment with lenvatinib, temuterkib and sunitinib as measured by sustained cellular proliferation, and sensitivity to treatment with trametinib and cobimetinib, as measured by inhibition of cellular proliferation (PMID: 36867406).",
            "description_review": {
              "updateTime": 1680812852212,
              "updatedBy": "User"
            },
            "description_uuid": "cdd065aa-8dfc-436b-a141-8b7b0740f042",
            "effect": "Inconclusive",
            "effect_review": {
              "updateTime": 1680118623908,
              "updatedBy": "User"
            },
            "effect_uuid": "69394227-ec1b-4915-8c3d-a7376f871c59",
            "oncogenic": "Resistance",
            "oncogenic_review": {
              "updateTime": 1680118623313,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "65d99fa1-11e8-4693-bbbf-cea4ad0df770",
            "short": ""
          },
          "mutation_effect_uuid": "beb83c52-2042-4d32-a417-4d18a5c2ea88",
          "name": "L597P",
          "name_review": {
            "updateTime": 1680118620609,
            "updatedBy": "User"
          },
          "name_uuid": "4cd56785-f1e9-4988-b4b6-b7e700a899bd",
          "tumors_uuid": "56109518-f0d9-49ae-b85d-afa8821c71da"
        },
        {
          "mutation_effect": {
            "description": "The BRAF V600A mutation (also known as V599A) is located in the activation segment of the kinase domain of the protein. This mutation has been identified in prostate cancer (PMID: 16721785). In vitro studies with HEK293 cells expressing BRAF V600A demonstrate that the mutation is likely neutral as measured by phosphorylation comparable to wildtype (PMID: 26744778).",
            "description_review": {
              "updateTime": 1680190739743,
              "updatedBy": "User"
            },
            "description_uuid": "3ecbbd8b-6ab5-4766-9773-f96c0de40e8f",
            "effect": "Likely Neutral",
            "effect_review": {
              "updateTime": 1680118654449,
              "updatedBy": "User"
            },
            "effect_uuid": "c810a2c1-f5f4-45fb-9a9a-0251be778f03",
            "oncogenic": "Likely Neutral",
            "oncogenic_review": {
              "updateTime": 1680118653716,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "a7379224-dad4-4f69-b3d2-eee291ab022c",
            "short": ""
          },
          "mutation_effect_uuid": "58a4712d-0516-4021-89ab-479d27cd3b08",
          "name": "V600A",
          "name_review": {
            "updateTime": 1680118649169,
            "updatedBy": "User"
          },
          "name_uuid": "b58bde25-bf29-4278-952b-631bb58dcad7",
          "tumors_uuid": "ec922a68-6417-47c6-876e-561dc48e5ab2"
        },
        {
          "mutation_effect": {
            "description": "The BRAF V600L mutation (also known as V599L) is located in the activation segment of the kinase domain of the protein. This mutation has been identified in colorectal cancer (PMID: 22586484). In vitro studies with MCF10A cells expressing BRAF V600L demonstrate that the mutation is activating as measured by increased cell proliferation and viability compared to wildtype (PMID: 29533785).",
            "description_review": {
              "updateTime": 1680190734902,
              "updatedBy": "User"
            },
            "description_uuid": "5f2f74f5-d92a-4bd2-a41b-23682db0491e",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1680118673469,
              "updatedBy": "User"
            },
            "effect_uuid": "6be2d4e5-848a-456c-a5bd-951bac12dc4f",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1680118672485,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "d46d6559-30db-46b1-8f06-9f80a184f35f",
            "short": ""
          },
          "mutation_effect_uuid": "913cce09-2afe-4438-8d59-994f39827b45",
          "name": "V600L",
          "name_review": {
            "updateTime": 1680118669329,
            "updatedBy": "User"
          },
          "name_uuid": "7b1e0a7e-4a30-5000-832f-301f1202cc83",
          "tumors_uuid": "0e17fee3-84b6-4283-90fe-c52d5b995157"
        },
        {
          "mutation_effect": {
            "description": "The BRAF M117L mutation is located in an unknown functional domain of the protein. This mutation has been identified in lung adenocarcinoma (PMID: 28481359). Although not functionally characterized per se, a patient with lung adenocarcinoma harboring BRAF M117L was treated with ipilimumab plus nivolumab and demonstrated stable disease (PMID: 34963703).",
            "description_review": {
              "updateTime": 1680813033930,
              "updatedBy": "User"
            },
            "description_uuid": "847b4221-6323-46cd-a19f-4251ba87dd7b",
            "effect": "Inconclusive",
            "effect_review": {
              "updateTime": 1680191811648,
              "updatedBy": "User"
            },
            "effect_uuid": "1b15b026-9ed1-40f0-82ae-8c44c62efcdf",
            "oncogenic": "Inconclusive",
            "oncogenic_review": {
              "updateTime": 1680191810802,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "717e67f2-67aa-45b0-9201-be2a6d843eff",
            "short": ""
          },
          "mutation_effect_uuid": "c97bcec2-c4a7-4092-b253-7fa051d62aee",
          "name": "M117L",
          "name_review": {
            "updateTime": 1680191808354,
            "updatedBy": "User"
          },
          "name_uuid": "30aa4cfb-dc70-4eb4-b9bb-667ffbf1c05b",
          "tumors_uuid": "73c03696-0dca-47a3-92c2-5cad2e17f698"
        },
        {
          "mutation_effect": {
            "description": "The BRAF N412S mutation is located in an unknown functional domain of the protein. This mutation has been identified in lung adenocarcinoma (PMID: 28481359). Although not functionally characterized per se, a patient with lung adenocarcinoma harboring BRAF N412S was treated with nivolumab and demonstrated stable disease (PMID: 34963703).",
            "description_review": {
              "updateTime": 1680191851653,
              "updatedBy": "User"
            },
            "description_uuid": "68c65eba-9f69-4d41-bcd0-8a508bfe2888",
            "effect": "Inconclusive",
            "effect_review": {
              "updateTime": 1680191844734,
              "updatedBy": "User"
            },
            "effect_uuid": "1ac32a66-825d-4a32-9a45-ae8626a2d5db",
            "oncogenic": "Inconclusive",
            "oncogenic_review": {
              "updateTime": 1680191844021,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "edefd28d-d764-4fca-82d2-46649b96ff5c",
            "short": ""
          },
          "mutation_effect_uuid": "1a90937e-e08e-4063-beff-52ef1ecd89b9",
          "name": "N412S",
          "name_review": {
            "updateTime": 1680191842124,
            "updatedBy": "User"
          },
          "name_uuid": "220a4c36-de27-4354-bc8b-7598b785c45d",
          "tumors_uuid": "cf29f1ce-575d-4bf3-82ee-458c8b829763"
        },
        {
          "mutation_effect": {
            "description": "The BRAF S616Y mutation is located in the kinase domain of the protein. Although not functionally characterized per se, a patient with squamous cell carcinoma harboring BRAF S616Y was treated with nivolumab and demonstrated a complete response (PMID: 34963703).",
            "description_review": {
              "updateTime": 1680813082434,
              "updatedBy": "User"
            },
            "description_uuid": "29bf04c0-36c0-4036-b7c4-2519351c3165",
            "effect": "Inconclusive",
            "effect_review": {
              "updateTime": 1680191877429,
              "updatedBy": "User"
            },
            "effect_uuid": "ace3ae6e-78bb-4efb-9f3d-4ea4ce34dfbf",
            "oncogenic": "Inconclusive",
            "oncogenic_review": {
              "updateTime": 1680191876245,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "0a5685f6-377d-4252-9c21-ea951c58d39f",
            "short": ""
          },
          "mutation_effect_uuid": "1ed1d1df-94e4-4ef9-9d63-210a667bc747",
          "name": "S616Y",
          "name_review": {
            "updateTime": 1680191874278,
            "updatedBy": "User"
          },
          "name_uuid": "01742cd6-d493-4ee5-82d8-6873a637c5a3",
          "tumors_uuid": "22509135-9d69-407c-acfc-627efe6722d5"
        },
        {
          "mutation_effect": {
            "description": "The BRAF T274A mutation is located in the zinc finger domain of the protein. Although not functionally characterized per se, a patient with lung adenocarcinoma harboring BRAF T274A, KRAS G12D and mutant NF1 was treated with nivolumab and demonstrated progressive disease (PMID: 34963703).",
            "description_review": {
              "updateTime": 1680191915631,
              "updatedBy": "User"
            },
            "description_uuid": "7150a01f-9cfb-4a4a-a49c-9919ee6f6c55",
            "effect": "Inconclusive",
            "effect_review": {
              "updateTime": 1680191913845,
              "updatedBy": "User"
            },
            "effect_uuid": "1a45db61-f9a1-47c2-8269-b59db2ea70d2",
            "oncogenic": "Inconclusive",
            "oncogenic_review": {
              "updateTime": 1680191912849,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "5d020698-93b7-40aa-8996-48d038b97f29",
            "short": ""
          },
          "mutation_effect_uuid": "b3a2cd26-cc8f-4e04-8789-5d3a73a7c8ad",
          "name": "T274A",
          "name_review": {
            "updateTime": 1680191907711,
            "updatedBy": "User"
          },
          "name_uuid": "959da81d-db56-4098-8f0c-1e55c22bc39f",
          "tumors_uuid": "e311c4e1-3590-490f-a765-3a78382ad70c"
        },
        {
          "mutation_effect": {
            "description": "The BRAF S607F mutation is located in the kinase domain of the protein. This mutation has been identified in basal cell carcinoma (PMID: 26950094). In vitro studies with HEK293 cells expressing BRAF S607F demonstrate that the mutation is likely neutral as measured by ERK phosphorylation comparable to wildtype (PMID: 32059434).",
            "description_review": {
              "updateTime": 1680191959110,
              "updatedBy": "User"
            },
            "description_uuid": "f913da96-6007-4b14-be6a-8b9c2574b604",
            "effect": "Likely Neutral",
            "effect_review": {
              "updateTime": 1680191942310,
              "updatedBy": "User"
            },
            "effect_uuid": "a8ceb704-0924-4eba-a22f-4965fedf34a9",
            "oncogenic": "Likely Neutral",
            "oncogenic_review": {
              "updateTime": 1680191941531,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "3d789366-9270-403b-9ae9-0632cb3f21d6",
            "short": ""
          },
          "mutation_effect_uuid": "60c7cafd-af83-46fb-92cb-204bf1bf7125",
          "name": "S607F",
          "name_review": {
            "updateTime": 1680191939671,
            "updatedBy": "User"
          },
          "name_uuid": "192e6d88-99c1-4fb0-96f3-04fa62ab3d8e",
          "tumors_uuid": "6f008313-6f77-4633-95b7-1be839c03402"
        },
        {
          "mutation_effect": {
            "description": "The BRAF M517V mutation is located in the kinase domain of the protein. In silico analysis suggests that the mutation contributes to resistance against vemurafenib (PMID: 35215249).",
            "description_review": {
              "updateTime": 1680191989871,
              "updatedBy": "User"
            },
            "description_uuid": "5ae7afd0-5534-464c-b5fa-0e1133cb7e0c",
            "effect": "Inconclusive",
            "effect_review": {
              "updateTime": 1680191985485,
              "updatedBy": "User"
            },
            "effect_uuid": "892cb6e5-481c-4f59-960e-62b334192d44",
            "oncogenic": "Inconclusive",
            "oncogenic_review": {
              "updateTime": 1680191984555,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "add98c56-340e-45a8-9e9d-3e6cf140fc97",
            "short": ""
          },
          "mutation_effect_uuid": "0a3a0596-b68a-41f3-8060-42c7ffaa21d0",
          "name": "M517V",
          "name_review": {
            "updateTime": 1680191981103,
            "updatedBy": "User"
          },
          "name_uuid": "f7bfc217-c2b1-4843-b99a-aa5e4b2ca9ab",
          "tumors_uuid": "b3e0401f-b317-438d-b94b-8a9e7cd5d0ad"
        },
        {
          "mutation_effect": {
            "description": "The BRAF W604C mutation is located in the kinase domain of the protein. This mutation has been identified in melanoma (PMID: 28467829). Although not functionally characterized per se, a patient with lung adenocarcinoma harboring BRAF W604C and BRAF G469A was treated with dabrafenib plus trametinib and demonstrated stable disease with a progression-free survival of fifteen months (PMID: 30926357).",
            "description_review": {
              "updateTime": 1680814028894,
              "updatedBy": "User"
            },
            "description_uuid": "fba875cb-1107-4e7f-b6c8-ede939dd577b",
            "effect": "Inconclusive",
            "effect_review": {
              "updateTime": 1680192011109,
              "updatedBy": "User"
            },
            "effect_uuid": "2e8a7d43-8453-4d53-9337-48e395b4a216",
            "oncogenic": "Inconclusive",
            "oncogenic_review": {
              "updateTime": 1680192010319,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "59b9d7dd-aa66-4ece-8c2e-66b8fa53f7fa",
            "short": ""
          },
          "mutation_effect_uuid": "f7f26dfb-e977-4d47-9a73-d6fac338aa0c",
          "name": "W604C",
          "name_review": {
            "updateTime": 1680192007251,
            "updatedBy": "User"
          },
          "name_uuid": "8e623fef-f181-4b44-b178-f5ff50b9bdff",
          "tumors_uuid": "6c7f976d-8301-4af5-952b-5f21db8f440b"
        },
        {
          "mutation_effect": {
            "description": "The BRAF R389C mutation is located in an unknown functional domain of the protein. This mutation has been identified in colorectal cancer (PMID: 25344691). In vitro studies with Ba/F3 and MCF10A cells expressing BRAF R389C demonstrate that the mutation is likely neutral as measured by cell proliferation and viability comparable to wildtype (PMID: 29533785).",
            "description_review": {
              "updateTime": 1680192046461,
              "updatedBy": "User"
            },
            "description_uuid": "3385aa23-2df9-4c24-bbb0-45e6e43a02e9",
            "effect": "Likely Neutral",
            "effect_review": {
              "updateTime": 1680192042756,
              "updatedBy": "User"
            },
            "effect_uuid": "a7793917-0857-4385-ba53-00a84894c5cb",
            "oncogenic": "Likely Neutral",
            "oncogenic_review": {
              "updateTime": 1680192041978,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "27e36595-b7bd-4f06-a13b-2dbf005329dc",
            "short": ""
          },
          "mutation_effect_uuid": "80e790ac-2b00-48df-bd7c-54aef4d0fd2d",
          "name": "R389C",
          "name_review": {
            "updateTime": 1680192039886,
            "updatedBy": "User"
          },
          "name_uuid": "4d72d8f9-05cb-4311-91a8-5adc994a79c3",
          "tumors_uuid": "d8a444bf-5ffc-4205-9b5b-3b54e6091854"
        },
        {
          "mutation_effect": {
            "description": "The BRAF E451K mutation is located in an unknown functional domain of the protein. In vitro studies with SkBr3 cells expressing BRAF E451K demonstrate that the mutation is activating as measured by increased ERK phosphorylation compared to wildtype (PMID: 31158244). Preclinical studies with SkBr3 cells expressing this mutation demonstrate that the mutation is resistant to dabrafenib as measured by sustained ERK phosphorylation following treatment (PMID: 31158244).",
            "description_review": {
              "updateTime": 1680192072868,
              "updatedBy": "User"
            },
            "description_uuid": "8e574aa0-9f2e-498a-988f-fc5d5639aec4",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1680192069345,
              "updatedBy": "User"
            },
            "effect_uuid": "313d8c8b-8f58-47fb-882c-3ae17edb3cfb",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1680192068636,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "64ce0979-890a-451a-86c2-22a3d58f0141",
            "short": ""
          },
          "mutation_effect_uuid": "8c5ae4c7-19fd-43ee-a13d-ae666275991b",
          "name": "E451K",
          "name_review": {
            "updateTime": 1680192064375,
            "updatedBy": "User"
          },
          "name_uuid": "812142e1-51f0-4224-9260-56b42385cdd4",
          "tumors_uuid": "c5681fc6-ddaf-4ce5-9ad0-313751184f7e"
        },
        {
          "mutation_effect": {
            "description": "The BRAF S122Y mutation is located in the SBC motif of the protein. This mutation has been identified in osteosarcoma (PMID: 28481359). In vitro studies with 293T cells expressing BRAF S122Y demonstrate that the mutation is activating as measured by reduced SPOP-mediated ubiquitination and increased MAPK/ERK cascade activation compared to wildtype (PMID: 36585710).",
            "description_review": {
              "updateTime": 1680278441153,
              "updatedBy": "User"
            },
            "description_uuid": "183e79fb-2a77-4168-b455-64b97c61a64c",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1680278439208,
              "updatedBy": "User"
            },
            "effect_uuid": "97510f77-deb4-4388-b0c2-df32cea34d23",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1680278438575,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "47f68c6a-eb88-4b54-a2cf-bdcae474eceb",
            "short": ""
          },
          "mutation_effect_uuid": "1be5d11e-f6be-417c-a307-4cd2ef33df98",
          "name": "S122Y",
          "name_review": {
            "updateTime": 1680278431636,
            "updatedBy": "User"
          },
          "name_uuid": "47dc5fd3-4004-4223-9600-c6bfed1c2cf1",
          "tumors_uuid": "9194e4c3-18c1-4bc7-aac7-585c935f2196"
        },
        {
          "mutation_effect": {
            "description": "The BRAF R239L mutation is located in the zinc finger domain of the protein. Although not functionally characterized per se, a patient with lung adenocarcinoma harboring BRAF R239L and KRAS G12C was treated with nivolumab and demonstrated stable disease (PMID: 34963703).",
            "description_review": {
              "updateTime": 1680278480672,
              "updatedBy": "User"
            },
            "description_uuid": "34c7bfe2-b204-4295-92cf-6feebec1d639",
            "effect": "Inconclusive",
            "effect_review": {
              "updateTime": 1680278476624,
              "updatedBy": "User"
            },
            "effect_uuid": "92b6ade4-8ffa-4a8d-bdda-989bd7573b38",
            "oncogenic": "Inconclusive",
            "oncogenic_review": {
              "updateTime": 1680278475538,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "7cb50114-6671-44dd-8bc2-46e64960b0e7",
            "short": ""
          },
          "mutation_effect_uuid": "5e34f996-1f10-4560-a816-08778a22aa4e",
          "name": "R239L",
          "name_review": {
            "updateTime": 1680278473215,
            "updatedBy": "User"
          },
          "name_uuid": "b97fc159-176b-4e47-8c11-e3b745b3c394",
          "tumors_uuid": "a4437b09-b31c-43e8-8c28-463cc5d56e07"
        },
        {
          "mutation_effect": {
            "description": "The ZNF767-BRAF fusion results from the fusion of exon 1 of ZNF767 with exon 11 of BRAF. In vivo studies with nude mice expressing ZNF767-BRAF demonstrate that the fusion is activating as measured by rapid tumor growth compared to wildtype (PMID: 28092667). Preclinical studies with PMM cells expressing ZNF767-BRAF demonstrated sensitivity to treatment with trametinib, BKM120, LEE011, trametinib plus BKM120 and trametinib plus LEE011 as measured by inhibition of cell growth (PMID: 28092667). A patient with melanoma harboring ZNF767-BRAF was treated with vemurafenib and demonstrated resistance, with rapid progression within two weeks of treatment (PMID: 28092667).",
            "description_review": {
              "updateTime": 1680814116297,
              "updatedBy": "User"
            },
            "description_uuid": "ec60ac96-10e7-4312-9bb1-5af1936521c8",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1680278547538,
              "updatedBy": "User"
            },
            "effect_uuid": "446c9369-f5ff-4924-a94e-35ff64a2b23c",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1680278546890,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "5577f1a6-a3b2-480a-96d1-1954ba542c30",
            "short": ""
          },
          "mutation_effect_uuid": "6fce30f1-f9e6-4d28-bd9a-ec98ea41f960",
          "name": "ZNF767-BRAF Fusion",
          "name_review": {
            "updateTime": 1680278544788,
            "updatedBy": "User"
          },
          "name_uuid": "057c18a8-bbfb-4341-b8b5-f1a9dd88f8bd",
          "tumors_uuid": "29a99ad8-5ebe-4361-a4a7-5ed3282c5d4b"
        },
        {
          "mutation_effect": {
            "description": "The JHDM1D-BRAF fusion is a chromosomal rearrangement fusing exon 13 of JHDM1D and exon 4 of BRAF, resulting in the loss of part of the RAS-binding domain of RAF. In vitro studies with AZD-R cells expressing JHDM1D-BRAF demonstrate that the fusion is resistant to treatment with FGFR inhibitors AZD4547, NVP-BGJ398 and PD173074 as measured by sustained cellular proliferation following treatment (PMID: 30045926). Preclinical studies with AZD-R cells expressing this fusion demonstrated sensitivity to treatment with MEK inhibitors CH4987655, trametinib and PD0325901 as measured by decreased cell viability following treatment (PMID: 30045926).",
            "description_review": {
              "updateTime": 1680814141971,
              "updatedBy": "User"
            },
            "description_uuid": "9ca80a78-e39f-40cf-ba76-16a4d7aa3961",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1680540736548,
              "updatedBy": "User"
            },
            "effect_uuid": "d8f04f71-4c59-4b7a-b55d-5752bc0f6dbf",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1680814166148,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "c7d1f27a-b106-4f21-a877-c7c7e9eda827",
            "short": ""
          },
          "mutation_effect_uuid": "5bc46a28-95b2-4364-b843-cfc9a186cb92",
          "name": "JHDM1D-BRAF Fusion",
          "name_review": {
            "updateTime": 1680540733678,
            "updatedBy": "User"
          },
          "name_uuid": "c6b1ccca-7755-407a-bcaf-f288826bc3ab",
          "tumors_uuid": "b8f789e2-4c8e-4246-8b9c-196f5d7b2861"
        },
        {
          "mutation_effect": {
            "description": "The BRAF E46K mutation is located in the N-terminus of the protein. In vitro studies with 293FT cells expressing BRAF E46K demonstrate that the mutation is activating as measured by increased binding to HRAS compared to wildtype (PMID: 31606273).",
            "description_review": {
              "updateTime": 1680541091502,
              "updatedBy": "User"
            },
            "description_uuid": "396c1404-3a85-4ee2-9cc0-c37225fbd023",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1680541087606,
              "updatedBy": "User"
            },
            "effect_uuid": "30292363-1ec1-4b7c-873b-12cc8a629507",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1680541086842,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "35532f7e-0122-40a1-b016-cede13efc773",
            "short": ""
          },
          "mutation_effect_uuid": "2464bce2-bc43-416c-b230-67229aaa584e",
          "name": "E46K",
          "name_review": {
            "removed": true,
            "updateTime": 1717517923181,
            "updatedBy": "Test User"
          },
          "name_uuid": "3bc4a8fb-7069-498e-8792-79a3fc8a0ebc",
          "tumors_uuid": "db0bffad-cb1e-4615-8f1d-db6c2ef5b4cd"
        },
        {
          "mutation_effect": {
            "description": "The BRAF N49I mutation is located in the N-terminus of the protein. In vitro studies with Ba/F3 cells and MCF10A cells expressing BRAF N49I demonstrate that the mutation is likely neutral as measured by cell proliferation and viability comparable to wildtype (PMID: 29533785).",
            "description_review": {
              "updateTime": 1680541126552,
              "updatedBy": "User"
            },
            "description_uuid": "05d87e8b-dde7-4a08-857e-d00efb05fec2",
            "effect": "Likely Neutral",
            "effect_review": {
              "updateTime": 1680541122551,
              "updatedBy": "User"
            },
            "effect_uuid": "0120a776-b0f3-48f7-a447-adcaccb19b7d",
            "oncogenic": "Likely Neutral",
            "oncogenic_review": {
              "updateTime": 1680541121412,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "73c87c18-45b8-43fd-abf0-bfa4411653a0",
            "short": ""
          },
          "mutation_effect_uuid": "60dc28ba-966e-4816-99c3-e07f159dbef8",
          "name": "N49I",
          "name_review": {
            "updateTime": 1680541119190,
            "updatedBy": "User"
          },
          "name_uuid": "194092f4-dab1-4cd3-bfb0-80a27fdc2b56",
          "tumors_uuid": "6c784bb5-6c87-4be7-9b53-5af26ef836c1"
        },
        {
          "mutation_effect": {
            "description": "The BRAF L64I mutation is located in the N-terminus of the protein. In vitro studies with Ba/F3 cells and MCF10A cells expressing BRAF L64I demonstrate that the mutation is likely neutral as measured by cell proliferation and viability comparable to wildtype (PMID: 29533785).",
            "description_review": {
              "updateTime": 1680541143737,
              "updatedBy": "User"
            },
            "description_uuid": "5cdbeedb-6f8e-4331-a0fc-958674c170a8",
            "effect": "Likely Neutral",
            "effect_review": {
              "updateTime": 1680541140111,
              "updatedBy": "User"
            },
            "effect_uuid": "cec3efcf-1a79-40fb-9054-4a3bdee7e437",
            "oncogenic": "Likely Neutral",
            "oncogenic_review": {
              "updateTime": 1680541139502,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "a8590040-ef77-4f63-99db-a8b6e072331f",
            "short": ""
          },
          "mutation_effect_uuid": "e030e94d-94ff-45a4-88e2-9f08c996aa6d",
          "name": "L64I",
          "name_review": {
            "updateTime": 1680541136852,
            "updatedBy": "User"
          },
          "name_uuid": "4040e343-25cc-4de0-8a43-7e9a3245f7d6",
          "tumors_uuid": "89468460-046e-4cd3-af5d-2a493ff3e18c"
        },
        {
          "mutation_effect": {
            "description": "The BRAF K205Q mutation is located in the RBD domain of the protein. This mutation has been identified in colorectal cancer (PMID: 22810696). In vitro studies with Ba/F3 cells and MCF10A cells expressing BRAF K205Q demonstrate that the mutation is likely neutral as measured by cell proliferation and viability comparable to wildtype (PMID: 29533785).",
            "description_review": {
              "updateTime": 1680546139946,
              "updatedBy": "User"
            },
            "description_uuid": "c3952507-88d7-48c9-b161-8caa8ac33a47",
            "effect": "Likely Neutral",
            "effect_review": {
              "updateTime": 1680546129838,
              "updatedBy": "User"
            },
            "effect_uuid": "289de6f0-b37b-42d7-af58-539c44d08d7f",
            "oncogenic": "Likely Neutral",
            "oncogenic_review": {
              "updateTime": 1680546129059,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "5a7516da-b77e-47d8-843b-1d14136e3a33",
            "short": ""
          },
          "mutation_effect_uuid": "0e1f5753-24d8-4e57-b461-3e6e78fba8a6",
          "name": "K205Q",
          "name_review": {
            "updateTime": 1680546123894,
            "updatedBy": "User"
          },
          "name_uuid": "f9737b33-dee3-44ec-95a6-d53f38980b88",
          "tumors_uuid": "a74c2cf6-b505-402a-be1c-4947dbfb4841"
        },
        {
          "mutation_effect": {
            "description": "The BRAF E228V mutation is located in an unknown functional domain of the protein. In vitro studies with Ba/F3 cells and MCF10A cells expressing BRAF E228V demonstrate that the mutation is likely neutral as measured by cell proliferation and viability comparable to wildtype (PMID: 29533785).",
            "description_review": {
              "updateTime": 1680546165315,
              "updatedBy": "User"
            },
            "description_uuid": "83fa31b5-417e-41ee-a5cb-d27ccafef9ba",
            "effect": "Likely Neutral",
            "effect_review": {
              "updateTime": 1680546161839,
              "updatedBy": "User"
            },
            "effect_uuid": "6e81a81e-e0fe-4ed7-8647-a4f7bf5543d6",
            "oncogenic": "Likely Neutral",
            "oncogenic_review": {
              "updateTime": 1680546161011,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "04b0d077-b478-4ce1-a96e-d87b2e03cc3a",
            "short": ""
          },
          "mutation_effect_uuid": "a335eeb5-681d-4b2d-b29d-4508dfb0ac95",
          "name": "E228V",
          "name_review": {
            "updateTime": 1680546158045,
            "updatedBy": "User"
          },
          "name_uuid": "0e9ba763-7b95-41a7-bc81-dd0978b51e49",
          "tumors_uuid": "ae46872b-586f-4d71-a403-baf86f309797"
        },
        {
          "mutation_effect": {
            "description": "The BRAF L245F mutation is located in the zinc finger domain of the protein. In vitro studies with Ba/F3 cells expressing BRAF L245F demonstrate that the mutation is activating as measured by increased transformation ability compared to wildtype (PMID: 29533785).",
            "description_review": {
              "updateTime": 1680546187708,
              "updatedBy": "User"
            },
            "description_uuid": "e8cf79ee-f7b9-4a39-8a79-c0f038aef8d9",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1680546186611,
              "updatedBy": "User"
            },
            "effect_uuid": "3ae4dd07-0e7e-4e74-a3ed-caf2b539eada",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1680546185800,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "e23a602c-edf3-4f5e-a8c1-cff49d93738b",
            "short": ""
          },
          "mutation_effect_uuid": "554938ee-81de-4efa-a4a3-ee76a3b436d1",
          "name": "L245F",
          "name_review": {
            "updateTime": 1680546180469,
            "updatedBy": "User"
          },
          "name_uuid": "e1633fcf-44a1-4e8c-ae29-ee8f0654a8c4",
          "tumors_uuid": "b4ae73a8-5119-489b-882f-23945511f432"
        },
        {
          "mutation_effect": {
            "description": "The BRAF G258V mutation is located in the zinc finger domain of the protein. This mutation has been identified in glioma (PMID: 28852847). In vitro studies with Ba/F3 cells expressing BRAF G258V demonstrate that the mutation is activating as measured by increased transformation ability compared to wildtype (PMID: 29533785).",
            "description_review": {
              "updateTime": 1680546254673,
              "updatedBy": "User"
            },
            "description_uuid": "bdda9755-777e-44ab-a240-dcaa2d2d4886",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1680546251027,
              "updatedBy": "User"
            },
            "effect_uuid": "f3e01d78-f08a-4d1f-81a1-0a82077e0f5c",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1680546250432,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "18dbbedf-a3e6-46c0-9249-daeee5495f4a",
            "short": ""
          },
          "mutation_effect_uuid": "8bcdd7c8-b265-44f5-9b9d-6f1905c9e7f0",
          "name": "G258V",
          "name_review": {
            "demotedToVus": true,
            "removed": true,
            "updateTime": 1717517928319,
            "updatedBy": "Test User"
          },
          "name_uuid": "b38c0589-2d24-44fc-af43-eff4e6129b30",
          "tumors_uuid": "7f7cf80f-6b56-4de4-8c14-abc195d48f36"
        },
        {
          "mutation_effect": {
            "description": "The BRAF F259L mutation is located in the zinc finger domain of the protein. This mutation has been identified in colorectal cancer (PMID: 28002797). In vitro studies with Ba/F3 cells and MCF10A cells expressing BRAF F259L demonstrate that the mutation is likely neutral as measured by cell proliferation and viability comparable to wildtype (PMID: 29533785).",
            "description_review": {
              "updateTime": 1680546272332,
              "updatedBy": "User"
            },
            "description_uuid": "9551f2db-dba2-46af-a710-d62da35d588c",
            "effect": "Likely Neutral",
            "effect_review": {
              "updateTime": 1680546268878,
              "updatedBy": "User"
            },
            "effect_uuid": "f95c0b41-d824-4460-bcf6-f0464224b306",
            "oncogenic": "Likely Neutral",
            "oncogenic_review": {
              "updateTime": 1680546267924,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "2e3d64ae-4abf-4f68-99fa-5d91c113484e",
            "short": ""
          },
          "mutation_effect_uuid": "97d86599-4bea-4d48-aab8-239fe49438c1",
          "name": "F259L",
          "name_review": {
            "updateTime": 1680546265039,
            "updatedBy": "User"
          },
          "name_uuid": "aa5702ae-15b3-44ae-ac02-e7dfe7cf1618",
          "tumors_uuid": "81620c61-73b8-4bd7-9bcd-4cbe18cf0b61"
        },
        {
          "mutation_effect": {
            "description": "The BRAF A320T mutation is located in an unknown functional domain of the protein. In vitro studies with Ba/F3 cells and MCF10A cells expressing BRAF A320T demonstrate that the mutation is likely neutral as measured by cell proliferation and viability comparable to wildtype (PMID: 29533785).",
            "description_review": {
              "updateTime": 1680551308446,
              "updatedBy": "User"
            },
            "description_uuid": "c9c62cc8-a80f-4044-b013-c120cf7546f7",
            "effect": "Likely Neutral",
            "effect_review": {
              "updateTime": 1680551304343,
              "updatedBy": "User"
            },
            "effect_uuid": "8cb9844c-02e4-4b8b-8051-a9d340fc54a9",
            "oncogenic": "Likely Neutral",
            "oncogenic_review": {
              "updateTime": 1680551303706,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "b63943d4-3452-4128-baa7-f3d9d6afe98d",
            "short": ""
          },
          "mutation_effect_uuid": "4dc88f62-bbb5-4302-a0e4-bd12f4c41158",
          "name": "A320T",
          "name_review": {
            "updateTime": 1680551301483,
            "updatedBy": "User"
          },
          "name_uuid": "46fdbbe3-50c4-4bca-bfa4-2ddfdc808fab",
          "tumors_uuid": "77c1a234-ba85-442a-bd57-33f121d30a12"
        },
        {
          "mutation_effect": {
            "description": "The BRAF P348T mutation is located in an unknown functional domain of the protein. In vitro studies with Ba/F3 cells and MCF10A cells expressing BRAF P348T demonstrate that the mutation is likely neutral as measured by cell proliferation and viability comparable to wildtype (PMID: 29533785).",
            "description_review": {
              "updateTime": 1680551333920,
              "updatedBy": "User"
            },
            "description_uuid": "8769fc80-a5b8-4155-8e06-aa5d63332750",
            "effect": "Likely Neutral",
            "effect_review": {
              "updateTime": 1680551332581,
              "updatedBy": "User"
            },
            "effect_uuid": "2724078f-4cda-4416-b014-91590a7e45c1",
            "oncogenic": "Likely Neutral",
            "oncogenic_review": {
              "updateTime": 1680551331846,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "613d6701-bae5-4ba2-b3df-c662498abd1a",
            "short": ""
          },
          "mutation_effect_uuid": "74a6aaa4-f9bd-4777-ad5c-8925ee7f7d2b",
          "name": "P348T",
          "name_review": {
            "updateTime": 1680551327448,
            "updatedBy": "User"
          },
          "name_uuid": "b708ac07-6214-496f-8292-b4fa956962e6",
          "tumors_uuid": "d10c5bc4-1e07-4dfc-bdb9-9f84db52df93"
        },
        {
          "mutation_effect": {
            "description": "The BRAF S364L mutation is located in an unknown functional domain of the protein. In vitro studies with Ba/F3 cells and MCF10A cells expressing BRAF S364L demonstrate that the mutation is likely neutral as measured by cell proliferation and viability comparable to wildtype (PMID: 29533785).",
            "description_review": {
              "updateTime": 1680551358135,
              "updatedBy": "User"
            },
            "description_uuid": "18ec275d-907c-4177-8469-afb041420bb1",
            "effect": "Likely Neutral",
            "effect_review": {
              "updateTime": 1680551356935,
              "updatedBy": "User"
            },
            "effect_uuid": "a5671214-c40b-44b3-bbd5-9b460b4a928a",
            "oncogenic": "Likely Neutral",
            "oncogenic_review": {
              "updateTime": 1680551356075,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "a440d444-9a2c-434b-a496-b2dbc76d0c03",
            "short": ""
          },
          "mutation_effect_uuid": "dd8364ee-5e33-4e0d-a6e8-9943af0ff361",
          "name": "S364L",
          "name_review": {
            "updateTime": 1680551351676,
            "updatedBy": "User"
          },
          "name_uuid": "2533bdb0-fdf8-4c37-8ef5-48b6f3bc2e86",
          "tumors_uuid": "419354ca-cde0-4f15-93b8-82719b58e4cf"
        },
        {
          "mutation_effect": {
            "description": "The BRAF D380H mutation is located in an unknown functional domain of the protein. In vitro studies with Ba/F3 cells and MCF10A cells expressing BRAF D380H demonstrate that the mutation is likely neutral as measured by cell proliferation and viability comparable to wildtype (PMID: 29533785).",
            "description_review": {
              "updateTime": 1680551379709,
              "updatedBy": "User"
            },
            "description_uuid": "3c684f36-f2a0-44d7-bde6-d9609ea59fb7",
            "effect": "Likely Neutral",
            "effect_review": {
              "updateTime": 1680551376087,
              "updatedBy": "User"
            },
            "effect_uuid": "7100d4a2-9bc3-4e0c-8450-b02a85a7212b",
            "oncogenic": "Likely Neutral",
            "oncogenic_review": {
              "updateTime": 1680551375521,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "e8d796e0-97d4-4f49-b3e7-ca9ffaa8d2e3",
            "short": ""
          },
          "mutation_effect_uuid": "0206eb44-1496-4f38-bc67-b1def4f0cf2d",
          "name": "D380H",
          "name_review": {
            "updateTime": 1680551372977,
            "updatedBy": "User"
          },
          "name_uuid": "93f412fa-a230-425d-808c-ab2ce1e22f86",
          "tumors_uuid": "42c54842-a40e-4943-9717-3dccfab164d0"
        },
        {
          "mutation_effect": {
            "description": "The BRAF X380_splice mutation is located in an unknown functional domain of the protein. Although not functionally characterized per se, a patient with lung adenocarcinoma harboring BRAF X380_splice and KRAS G12C was treated with atezolizumab and demonstrated progressive disease (PMID: 34963703).",
            "description_review": {
              "updateTime": 1680551397310,
              "updatedBy": "User"
            },
            "description_uuid": "8cb5cfa5-aea4-4eab-b0a2-30478727013e",
            "effect": "Inconclusive",
            "effect_review": {
              "updateTime": 1680551393531,
              "updatedBy": "User"
            },
            "effect_uuid": "065529f8-03d6-49c2-a4e8-fff568778d6b",
            "oncogenic": "Inconclusive",
            "oncogenic_review": {
              "updateTime": 1680551392593,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "5ddde0ec-af7b-4206-95e1-9c9f59b50f6a",
            "short": ""
          },
          "mutation_effect_uuid": "44ea33f6-5cad-4223-8ef9-2e8c95755d4d",
          "name": "X380_splice",
          "name_review": {
            "updateTime": 1680551390373,
            "updatedBy": "User"
          },
          "name_uuid": "2598c3e5-48b7-45a2-adc5-aaaae0a2ec7a",
          "tumors_uuid": "008012f8-ac9b-4856-a254-62084afb89fb"
        },
        {
          "mutation_effect": {
            "description": "The BRAF T401I mutation is located in an unknown functional domain of the protein. In vitro studies with Ba/F3 cells and MCF10A cells expressing BRAF T401I demonstrate that the mutation is likely neutral as measured by cell proliferation and viability comparable to wildtype (PMID: 29533785).",
            "description_review": {
              "updateTime": 1680551456352,
              "updatedBy": "User"
            },
            "description_uuid": "dcd23d34-dbba-44a2-ae88-17d59d3bb3a5",
            "effect": "Likely Neutral",
            "effect_review": {
              "updateTime": 1680551455207,
              "updatedBy": "User"
            },
            "effect_uuid": "4723a368-e050-4086-8338-7ff38eb3df87",
            "oncogenic": "Likely Neutral",
            "oncogenic_review": {
              "updateTime": 1680551454232,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "4ecc4b2c-5e36-4b89-8aaa-2b1cf604caac",
            "short": ""
          },
          "mutation_effect_uuid": "e682550b-60fb-47ed-a773-e8253ee04e8a",
          "name": "T401I",
          "name_review": {
            "updateTime": 1680551449176,
            "updatedBy": "User"
          },
          "name_uuid": "c95c3301-c4bb-4f7d-9062-35527b630a58",
          "tumors_uuid": "a40a4d6f-a974-4fc4-945e-f2d679b07a75"
        },
        {
          "mutation_effect": {
            "description": "The BRAF S419Y mutation is located in an unknown functional domain of the protein. In vitro studies with Ba/F3 cells and MCF10A cells expressing BRAF S419Y demonstrate that the mutation is likely neutral as measured by cell proliferation and viability comparable to wildtype (PMID: 29533785).",
            "description_review": {
              "updateTime": 1680551475944,
              "updatedBy": "User"
            },
            "description_uuid": "7ac589bc-df40-4222-ae92-4eac79491a60",
            "effect": "Likely Neutral",
            "effect_review": {
              "updateTime": 1680551471371,
              "updatedBy": "User"
            },
            "effect_uuid": "e41fd2ef-9ae7-4528-bc2f-5f1f3ef43492",
            "oncogenic": "Likely Neutral",
            "oncogenic_review": {
              "updateTime": 1680551470531,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "917a7fc9-c634-42e1-a54e-6fdc3f15d893",
            "short": ""
          },
          "mutation_effect_uuid": "d157f4f6-d671-4e2c-9027-72913dc86a48",
          "name": "S419Y",
          "name_review": {
            "updateTime": 1680551468057,
            "updatedBy": "User"
          },
          "name_uuid": "d62533a1-c71c-47b7-bd2d-33fc67a2d2a0",
          "tumors_uuid": "5bbefbbc-8c09-4a01-829e-a1e158a62bfc"
        },
        {
          "mutation_effect": {
            "description": "The BRAF G421V mutation is located in an unknown functional domain of the protein. In vitro studies with Ba/F3 cells and MCF10A cells expressing BRAF G421V demonstrate that the mutation is likely neutral as measured by cell proliferation and viability comparable to wildtype (PMID: 29533785).",
            "description_review": {
              "updateTime": 1680551492305,
              "updatedBy": "User"
            },
            "description_uuid": "7d9fbac6-ad50-4526-8fbc-b71bae81639e",
            "effect": "Likely Neutral",
            "effect_review": {
              "updateTime": 1680551490810,
              "updatedBy": "User"
            },
            "effect_uuid": "41452405-532f-4132-9e1a-e75ffe7291ca",
            "oncogenic": "Likely Neutral",
            "oncogenic_review": {
              "updateTime": 1680551490001,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "2fab0ff2-e1c7-4ca3-aa7a-cd6e23a05f2e",
            "short": ""
          },
          "mutation_effect_uuid": "0908fe08-1a97-4d0e-b2b8-7f5fca3ae12c",
          "name": "G421V",
          "name_review": {
            "updateTime": 1680551486146,
            "updatedBy": "User"
          },
          "name_uuid": "4614090b-61d7-4859-aad1-bc7a1ac88809",
          "tumors_uuid": "73977848-d71d-4fb5-b8ef-00593c7486ff"
        },
        {
          "mutation_effect": {
            "description": "The BRAF H568D mutation is located in the kinase domain of the protein. In vitro studies with HEK293T cells expressing BRAF H568D demonstrate that the mutation is inactivating as measured by a loss of kinase activity compared to wildtype (PMID: 29666306). BRAF mutations with low kinase activity or those that are kinase-dead are Class III mutations and can possibly activate CRAF as a scaffold, resulting in increased MEK-regulated signaling (PMID: 20141835).",
            "description_review": {
              "updateTime": 1681252082691,
              "updatedBy": "User"
            },
            "description_uuid": "d578dc66-9fb9-4a3e-b8ac-7f4a95c0d50e",
            "effect": "Inconclusive",
            "effect_review": {
              "updateTime": 1681252085569,
              "updatedBy": "User"
            },
            "effect_uuid": "bf2c98d7-eb95-4ffb-be4f-fb0b87204cd2",
            "oncogenic": "Inconclusive",
            "oncogenic_review": {
              "updateTime": 1681252086273,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "b8f89baa-21b0-459c-8b48-f5bb084e0ca2",
            "short": ""
          },
          "mutation_effect_uuid": "6f162c8f-08cb-4d2e-a0ec-5773584a3b06",
          "name": "H568D",
          "name_review": {
            "updateTime": 1680555203943,
            "updatedBy": "User"
          },
          "name_uuid": "f3be5418-5e57-4904-9b80-f78166e153c7",
          "tumors_uuid": "e00a7dad-856e-4f08-b824-d89155b42eca"
        },
        {
          "mutation_effect": {
            "description": "The BRAF L613F mutation is located in the zinc finger domain of the protein. In vitro studies with MCF10A cells expressing BRAF L613F demonstrate that the mutation is activating as measured by increased transformation ability compared to wildtype (PMID: 29533785).",
            "description_review": {
              "updateTime": 1680555238834,
              "updatedBy": "User"
            },
            "description_uuid": "b4ef2b4a-2f74-4e33-b1f4-a9fafd6414e1",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1680555235252,
              "updatedBy": "User"
            },
            "effect_uuid": "add0243b-99de-41c7-b712-c8d73631f389",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1680555234776,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "f557e568-9d8a-41eb-9ef3-c6409db39b7e",
            "short": ""
          },
          "mutation_effect_uuid": "b61495d5-7559-47aa-9d73-a0efb3a3d1e4",
          "name": "L613F",
          "name_review": {
            "updateTime": 1680555232343,
            "updatedBy": "User"
          },
          "name_uuid": "0b1e3d0b-517c-4b8f-9264-223698df8227",
          "tumors_uuid": "f4204d35-aa77-4315-878f-99f7e0f6640b"
        },
        {
          "mutation_effect": {
            "description": "The BRAF V639I mutation is located in the kinase domain of the protein. In vitro studies with Ba/F3 cells and MCF10A cells expressing BRAF V639I demonstrate that the mutation is likely neutral as measured by cell proliferation and viability comparable to wildtype (PMID: 29533785).",
            "description_review": {
              "updateTime": 1680555292851,
              "updatedBy": "User"
            },
            "description_uuid": "9be709c2-fd51-4683-b4a5-f469e3cf96f2",
            "effect": "Likely Neutral",
            "effect_review": {
              "updateTime": 1680555262123,
              "updatedBy": "User"
            },
            "effect_uuid": "4964c813-f10d-499c-aa59-0eac1d608d31",
            "oncogenic": "Likely Neutral",
            "oncogenic_review": {
              "updateTime": 1680555261294,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "293674ed-e09c-44cb-b934-0aadd29bc84d",
            "short": ""
          },
          "mutation_effect_uuid": "7d93d00e-1cab-4d6f-869e-3121128160e7",
          "name": "V639I",
          "name_review": {
            "updateTime": 1680555257162,
            "updatedBy": "User"
          },
          "name_uuid": "64114cfc-41b8-4b62-87f7-9e3cb0683495",
          "tumors_uuid": "26f9aebc-fc96-4324-939b-b55a9482e3c2"
        },
        {
          "mutation_effect": {
            "description": "The BRAF E648Q mutation is located in the kinase domain of the protein. In vitro studies with MCF10A cells expressing BRAF E648Q demonstrate that the mutation is inactivating as measured by decreased cell proliferation and viability comparable to wildtype (PMID: 29533785).",
            "description_review": {
              "updateTime": 1680555287229,
              "updatedBy": "User"
            },
            "description_uuid": "d83c56c7-70b5-4fcc-a882-7aa3bf97edef",
            "effect": "Likely Neutral",
            "effect_review": {
              "updateTime": 1680555279179,
              "updatedBy": "User"
            },
            "effect_uuid": "42c85711-44fc-49b1-b1ee-4cb67df682ec",
            "oncogenic": "Likely Neutral",
            "oncogenic_review": {
              "updateTime": 1680555278559,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "8720ada2-a22c-43e5-ba96-85a693f9b919",
            "short": ""
          },
          "mutation_effect_uuid": "46147386-89d7-42db-9248-8bd94fbe7618",
          "name": "E648Q",
          "name_review": {
            "updateTime": 1680555276751,
            "updatedBy": "User"
          },
          "name_uuid": "bec646b3-cb4c-44b7-8071-8d5476d1d2d5",
          "tumors_uuid": "588d67db-e067-4a5c-a385-6e1ff9f5af9b"
        },
        {
          "mutation_effect": {
            "description": "The BRAF L678I mutation is located in the kinase domain of the protein. In vitro studies with MCF10A cells expressing BRAF L678I demonstrate that the mutation is inactivating as measured by decreased cell proliferation and viability comparable to wildtype (PMID: 29533785).",
            "description_review": {
              "updateTime": 1680555318974,
              "updatedBy": "User"
            },
            "description_uuid": "d2dddb0b-5439-420a-84af-89f8cc2aa547",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1680555317566,
              "updatedBy": "User"
            },
            "effect_uuid": "224a26ee-92a1-4522-a467-ae857e42e607",
            "oncogenic": "Likely Neutral",
            "oncogenic_review": {
              "updateTime": 1680555316760,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "bd4933d9-e9e0-4687-881b-06f4549f3aab",
            "short": ""
          },
          "mutation_effect_uuid": "3e22390f-e771-420e-8442-6279a8f3a277",
          "name": "L678I",
          "name_review": {
            "updateTime": 1680555310945,
            "updatedBy": "User"
          },
          "name_uuid": "80ef9412-aff1-4e7b-8188-499f462236c9",
          "tumors_uuid": "a286a2c6-efb0-4f31-a36e-6854e36f7134"
        },
        {
          "mutation_effect": {
            "description": "The BRAF E695K mutation is located in the kinase domain of the protein. This mutation has been identified in plasma cell myeloma (PMID: 30545397). In vitro studies with MCF10A cells expressing BRAF E695K demonstrate that the mutation is activating as measured by increased transformation ability compared to wildtype (PMID: 29533785).",
            "description_review": {
              "updateTime": 1680555343317,
              "updatedBy": "User"
            },
            "description_uuid": "23210cf5-f791-4481-abbb-044b628ac34d",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1680555339869,
              "updatedBy": "User"
            },
            "effect_uuid": "8e2dd1e0-e643-41e9-8cb6-495353cab76a",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1680555339245,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "4f8a1198-7552-4f31-a641-eb43655431a1",
            "short": ""
          },
          "mutation_effect_uuid": "e1e6d0df-5b13-4d31-8dd5-d9bb198a8840",
          "name": "E695K",
          "name_review": {
            "updateTime": 1680555336901,
            "updatedBy": "User"
          },
          "name_uuid": "ee070618-3238-41e2-bb13-d46455f59254",
          "tumors_uuid": "9d4b1a46-5185-4c60-9f1c-1531b3b8c154"
        },
        {
          "mutation_effect": {
            "description": "The BRAF K698R mutation is located in the kinase domain of the protein. In vitro studies with Ba/F3 cells and MCF10A cells expressing BRAF K698R demonstrate that the mutation is likely neutral as measured by cell proliferation and viability comparable to wildtype (PMID: 29533785).",
            "description_review": {
              "updateTime": 1680555355525,
              "updatedBy": "User"
            },
            "description_uuid": "ffe72609-3126-4dda-b522-b5261089eed9",
            "effect": "Likely Neutral",
            "effect_review": {
              "updateTime": 1680555354010,
              "updatedBy": "User"
            },
            "effect_uuid": "79b0cedd-a37f-461b-a66a-3eb1b170869a",
            "oncogenic": "Likely Neutral",
            "oncogenic_review": {
              "updateTime": 1680555353037,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "7c2ca349-5c77-4743-be79-38858be03bd7",
            "short": ""
          },
          "mutation_effect_uuid": "8fad6ef1-e803-468d-a428-f69f397caa29",
          "name": "K698R",
          "name_review": {
            "updateTime": 1680555349951,
            "updatedBy": "User"
          },
          "name_uuid": "79cef4e7-9f53-4681-bbd5-4ef3e59278d4",
          "tumors_uuid": "5d2f3a9d-0d24-4b0b-828a-cbe996ac3b6b"
        },
        {
          "mutation_effect": {
            "description": "The BRAF A712T mutation is located in the kinase domain of the protein. This mutation has been identified in colorectal cancer (PMID: 27149842). In vitro studies with Ba/F3 cells and MCF10A cells expressing BRAF A712T demonstrate that the mutation is likely neutral as measured by cell proliferation and viability comparable to wildtype (PMID: 29533785).",
            "description_review": {
              "updateTime": 1680555386865,
              "updatedBy": "User"
            },
            "description_uuid": "326c8954-6d07-4028-9c16-cbcb82744fb9",
            "effect": "Likely Neutral",
            "effect_review": {
              "updateTime": 1680555383121,
              "updatedBy": "User"
            },
            "effect_uuid": "21adc71d-5d1b-47ac-bd91-fe36d9618603",
            "oncogenic": "Likely Neutral",
            "oncogenic_review": {
              "updateTime": 1680555381780,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "c8e4c286-8009-4d83-a2cd-d6bede55fb19",
            "short": ""
          },
          "mutation_effect_uuid": "633f4342-77b6-44e7-8a8d-be2da2bb9617",
          "name": "A712T",
          "name_review": {
            "updateTime": 1680555379265,
            "updatedBy": "User"
          },
          "name_uuid": "71fe6203-6943-4ede-c0d7-92268676d818",
          "tumors_uuid": "e58f4da3-c8b4-4460-a5c1-a4e0cc525631"
        },
        {
          "mutation_effect": {
            "description": "The BRAF P731S mutation is located in an unknown functional domain of the protein. This mutation has been identified in melanoma (PMID: 22817889). In vitro studies with Ba/F3 cells expressing BRAF P731S demonstrate that the mutation is activating as measured by increased transformation ability compared to wildtype (PMID: 29533785).",
            "description_review": {
              "updateTime": 1680555408235,
              "updatedBy": "User"
            },
            "description_uuid": "da03d03d-4b97-45e7-9ddd-baeb0648edd8",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1680555403720,
              "updatedBy": "User"
            },
            "effect_uuid": "4830d21c-4512-487d-907b-10302c3890c5",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1680555402647,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "5153ddf7-c6dc-44e0-819b-3bf55f74a371",
            "short": ""
          },
          "mutation_effect_uuid": "8847d857-b632-4173-bb5e-5007f233623d",
          "name": "P731S",
          "name_review": {
            "updateTime": 1680555400382,
            "updatedBy": "User"
          },
          "name_uuid": "3361434e-72d9-494c-8f5a-9a47cc10fe2b",
          "tumors_uuid": "ac3a3c6a-e51f-4056-9c13-f0c60a5c1625"
        },
        {
          "mutation_effect": {
            "description": "The BRAF A762E mutation is located in an unknown functional domain of the protein. While this mutation has not been functionally validated per se, in vitro studies with A549 cells expressing BRAF A762E demonstrated that the mutation confers resistance to EGFR inhibitor erlotinib as measured by sustained cell viability following treatment (PMID: 27478040).",
            "description_review": {
              "updateTime": 1680635362475,
              "updatedBy": "User"
            },
            "description_uuid": "d486863e-88c6-43b2-8843-fbad69e431fd",
            "effect": "Inconclusive",
            "effect_review": {
              "updateTime": 1680635344543,
              "updatedBy": "User"
            },
            "effect_uuid": "3406a615-022d-41d0-958a-a06d1afb505a",
            "oncogenic": "Inconclusive",
            "oncogenic_review": {
              "updateTime": 1681252227387,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "3e5d66e4-deae-484d-a6aa-0f3bcc54b586",
            "short": ""
          },
          "mutation_effect_uuid": "843681b0-e83c-4ff5-859c-e85690fa92e5",
          "name": "A762E",
          "name_review": {
            "updateTime": 1680635340699,
            "updatedBy": "User"
          },
          "name_uuid": "d29bc274-b29f-4389-8519-4a68c189ea05",
          "tumors_uuid": "ea22de83-b481-4ae9-9748-b301d8912c3b"
        },
        {
          "mutation_effect": {
            "description": "The BRAF Q609H mutation is located in the kinase domain of the protein. In vitro studies with Ba/F3 cells and MCF10A cells expressing BRAF Q609H demonstrate that the mutation is likely neutral as measured by cell proliferation and viability comparable to wildtype (PMID: 29533785).",
            "description_review": {
              "updateTime": 1680635417118,
              "updatedBy": "User"
            },
            "description_uuid": "15f2354a-0694-4931-9244-99dc807a4d85",
            "effect": "Likely Neutral",
            "effect_review": {
              "updateTime": 1680635415753,
              "updatedBy": "User"
            },
            "effect_uuid": "b62c016c-0682-4d8a-97fb-8046cc52e64b",
            "oncogenic": "Likely Neutral",
            "oncogenic_review": {
              "updateTime": 1680635415076,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "8ad3ac76-7130-4524-a8a1-77e7dd030ca5",
            "short": ""
          },
          "mutation_effect_uuid": "7d53c7cb-ddde-4605-8863-9cf02ce07e78",
          "name": "Q609H",
          "name_review": {
            "updateTime": 1680635405539,
            "updatedBy": "User"
          },
          "name_uuid": "d72a229a-fd5a-4f00-b989-1fef2bfc9262",
          "tumors_uuid": "795b14ac-b45e-427c-824c-fbb30764d12b"
        },
        {
          "mutation_effect": {
            "description": "The GNAI1-BRAF fusion results from a chromosomal rearrangement fusing exon 1 of GNAI1 and exon 10 of BRAF. This fusion has been identified in pilocytic astrocytoma (PMID: 23817572). In vitro studies with NIH3T3 cells expressing GNAI1-BRAF demonstrate that the fusion is activating as measured by increased phosphorylated ERK levels compared to vector control (PMID: 29156677). Preclinical studies with NIH3T3 cells expressing the fusion demonstrated sensitivity to treatment with trametinib as measured by inhibition of colony formation (PMID: 29156677).",
            "description_review": {
              "updateTime": 1680636214111,
              "updatedBy": "User"
            },
            "description_uuid": "a773f401-fb36-4648-b825-1b1f9445f255",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1680636212829,
              "updatedBy": "User"
            },
            "effect_uuid": "036538d2-4a0f-4a70-869d-eaee537fa0e3",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1680636211576,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "d2b878af-1b7d-427c-bd5d-a9d9309b5336",
            "short": ""
          },
          "mutation_effect_uuid": "9db0a3af-4e7c-4089-9b08-ae3b9f02150c",
          "name": "GNAI1-BRAF Fusion",
          "name_review": {
            "updateTime": 1680636204955,
            "updatedBy": "User"
          },
          "name_uuid": "dc03a3a8-455e-431b-b496-1362a5a6d6e9",
          "tumors_uuid": "cbe86234-9072-4d90-8436-24227112057e"
        },
        {
          "mutation_effect": {
            "description": "The CLCN6-BRAF fusion results from a chromosomal rearrangement fusing exon 2 of CLCN6 and exon 11 of BRAF, retaining the BRAF kinase domain. This fusion has been identified in pilocytic astrocytoma (PMID: 23817572). In vitro studies with NIH3T3 cells expressing CLCN6-BRAF demonstrate that the fusion is activating as measured by increased phosphorylated ERK levels compared to vector control (PMID: 29156677). Preclinical studies with NIH3T3 cells expressing the fusion demonstrated sensitivity to treatment with trametinib as measured by inhibition of colony formation (PMID: 29156677).",
            "description_review": {
              "updateTime": 1681252278568,
              "updatedBy": "User"
            },
            "description_uuid": "4059f3e6-ad52-45ba-bd6a-da4244c1bd46",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1680636338425,
              "updatedBy": "User"
            },
            "effect_uuid": "f17ba4d6-8c93-4010-8e0b-4996e43ed556",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1680636337634,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "2d32fafb-1395-4195-b20f-24766f8449bc",
            "short": ""
          },
          "mutation_effect_uuid": "1b749da4-d4fc-425b-af30-d1df0e646ad9",
          "name": "CLCN6-BRAF Fusion",
          "name_review": {
            "updateTime": 1680636330354,
            "updatedBy": "User"
          },
          "name_uuid": "d56ac590-b968-4d32-b77c-92213095b432",
          "tumors_uuid": "f3499036-a695-4e3e-9b51-23cd6235d359"
        },
        {
          "mutation_effect": {
            "description": "The BRAF T470P mutation is located in the kinase domain of the protein. In silico analysis suggests that the mutation is damaging and activating (PMID: 24037001).",
            "description_review": {
              "updateTime": 1680636432911,
              "updatedBy": "User"
            },
            "description_uuid": "7474a188-211c-4a24-ada7-79c240a25108",
            "effect": "Inconclusive",
            "effect_review": {
              "updateTime": 1680636431462,
              "updatedBy": "User"
            },
            "effect_uuid": "3da02e00-69cb-48fd-904a-32bf20bfa6c4",
            "oncogenic": "Inconclusive",
            "oncogenic_review": {
              "updateTime": 1680636430579,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "b510f68a-e682-4207-b814-4830e295b120",
            "short": ""
          },
          "mutation_effect_uuid": "43e04871-eacc-437c-ad23-76eba270f80c",
          "name": "T470P",
          "name_review": {
            "updateTime": 1680636425828,
            "updatedBy": "User"
          },
          "name_uuid": "a6408b96-ab75-4065-b5ce-82835cdf4035",
          "tumors_uuid": "bf6a0281-77f7-4a61-a963-59635451a1cb"
        },
        {
          "mutation_effect": {
            "description": "The BRAF M517I mutation is located in the kinase domain of the protein. In vitro studies with MCF10A cells expressing BRAF M517I demonstrate that the mutation is inactivating as measured by decreased cell proliferation and viability comparable to wildtype (PMID: 29533785).",
            "description_review": {
              "updateTime": 1680636583675,
              "updatedBy": "User"
            },
            "description_uuid": "ecf3da43-b51d-479c-af0b-8752c77c7b56",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1680636582594,
              "updatedBy": "User"
            },
            "effect_uuid": "0626731d-71e8-48cd-9e0d-8ef190e46b9c",
            "oncogenic": "Likely Neutral",
            "oncogenic_review": {
              "updateTime": 1680636581238,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "92f96e90-5b2d-48ec-ae66-c3b752ff624c",
            "short": ""
          },
          "mutation_effect_uuid": "cf869eaa-c9f6-4fac-b712-5e77c00fe3e6",
          "name": "M517I",
          "name_review": {
            "updateTime": 1680636574072,
            "updatedBy": "User"
          },
          "name_uuid": "2602191a-5688-4944-a865-8a87141f7b55",
          "tumors_uuid": "0b1d4cab-1d20-4ce0-81da-562fff2e0d13"
        },
        {
          "mutation_effect": {
            "description": "The CSTF3-BRAF fusion results from a chromosomal rearrangement that retains the full kinase domain of BRAF. Although not functionally characterized per se, a patient with metastatic melanoma harboring BRAF V600E was treated with dabrafenib plus trametinib and acquired CSTF3-BRAF as a secondary resistance mutation following disease progression (PMID: 28539463).",
            "description_review": {
              "updateTime": 1680636608156,
              "updatedBy": "User"
            },
            "description_uuid": "b0fa77de-e35f-4607-b9d6-b41513d8dcbc",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1681252353717,
              "updatedBy": "User"
            },
            "effect_uuid": "1df85571-f803-4389-88c0-675a3500e905",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1681252353061,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "d2f65940-007d-407b-9d70-1320ada739d9",
            "short": ""
          },
          "mutation_effect_uuid": "42dbc373-5361-47f1-839c-2f21961831e4",
          "name": "CSTF3-BRAF Fusion",
          "name_review": {
            "updateTime": 1680636597803,
            "updatedBy": "User"
          },
          "name_uuid": "6770724b-acdb-4ef6-b3eb-b734717c4df1",
          "tumors_uuid": "34f57487-b35c-4067-972a-67f68de11d20"
        },
        {
          "mutation_effect": {
            "description": "The SEPT3-BRAF fusion results from chromosomal rearrangement fusing exon 10 of SEPT3 and exon 8 of BRAF, retaining the full kinase domain and losing the inhibitory RBD domain of BRAF. In vivo studies with patient-derived xenograft models expressing SEPT3-BRAF demonstrate that the fusion is activating as measured by increased cellular proliferation and invasion compared to wildtype (PMID: 30254212).",
            "description_review": {
              "updateTime": 1680636718962,
              "updatedBy": "User"
            },
            "description_uuid": "8551b235-bfdd-4ae9-ae1e-1b4cf13f7c37",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1680636717411,
              "updatedBy": "User"
            },
            "effect_uuid": "4fc7feb3-cbcd-4ab0-951a-f14bdbaf7b13",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1680636716835,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "ad532864-471e-4a40-92e7-f56678fed421",
            "short": ""
          },
          "mutation_effect_uuid": "38c42bcf-0c44-4a33-bf45-c7ae7f5ab3a1",
          "name": "SEPT3-BRAF Fusion",
          "name_review": {
            "updateTime": 1680636711502,
            "updatedBy": "User"
          },
          "name_uuid": "ab8049c9-80b8-4522-bcf1-91e9c352a306",
          "tumors_uuid": "39c2bc06-5b3c-44d7-ba1f-a724c37063fd"
        },
        {
          "mutation_effect": {
            "description": "The SLC45A3-BRAF fusion results from inter-chromosomal rearrangement fusing untranslated exon 1 of SLC45A3 and exon 8 of BRAF. In vivo studies with nude mice overexpressing SLC45A3-BRAF demonstrate that the fusion is activating as measured by rapid tumor growth compared to vector control (PMID: 20526349). Preclinical studies with RWPE cells expressing this fusion demonstrated sensitivity to treatment with RAF kinase inhibitor sorafenib and MEK inhibitor U0126 as measured by decreased colony growth following treatment (PMID: 20526349).",
            "description_review": {
              "updateTime": 1680638067936,
              "updatedBy": "User"
            },
            "description_uuid": "3f1243ec-3001-46b1-9dff-908b9a282272",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1680638061508,
              "updatedBy": "User"
            },
            "effect_uuid": "886fcc24-f518-44a6-ab7b-7e9a6de042b3",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1680638060837,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "8d032552-13af-43b5-8eba-5b0cb0aed0a6",
            "short": ""
          },
          "mutation_effect_uuid": "8413fef8-b0c5-4a50-8cd1-585469f26823",
          "name": "SLC45A3-BRAF Fusion",
          "name_review": {
            "updateTime": 1680638058050,
            "updatedBy": "User"
          },
          "name_uuid": "780aee42-d4b2-4ff2-a7bd-56c91cc4a729",
          "tumors_uuid": "e6f04633-c615-447d-ac92-6178a988894c"
        },
        {
          "mutation_effect": {
            "description": "The BRAF G615R mutation is located in the kinase domain of the protein. In vitro studies with MCF10A cells expressing BRAF G615R demonstrate that the mutation is inactivating as measured by decreased cell proliferation and viability comparable to wildtype (PMID: 29533785).",
            "description_review": {
              "updateTime": 1680638174563,
              "updatedBy": "User"
            },
            "description_uuid": "035c6cc3-2d74-43f8-8425-ece6550c0f30",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1680638173363,
              "updatedBy": "User"
            },
            "effect_uuid": "8743d79d-d96d-42c8-bbdc-34ca15be3433",
            "oncogenic": "Likely Neutral",
            "oncogenic_review": {
              "updateTime": 1680638172166,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "32001b24-77d3-4579-b919-138d16a18050",
            "short": ""
          },
          "mutation_effect_uuid": "9d5d6e4b-5f95-4fba-85f3-f08803dde9f4",
          "name": "G615R",
          "name_review": {
            "updateTime": 1680638158205,
            "updatedBy": "User"
          },
          "name_uuid": "b48c6ce8-d599-450c-9db8-f04054e0cac8",
          "tumors_uuid": "5e70ad43-03f7-4ec2-b6e3-191facfb10c4"
        },
        {
          "mutation_effect": {
            "description": "The BRAF L485S mutation is located in the kinase domain of the protein. Although not functionally characterized per se, in vitro studies with A375 cells expressing BRAF L485S demonstrate that the mutation confers resistance to treatment with dabrafenib as measured by sustained cell growth (PMID: 31925410).",
            "description_review": {
              "updateTime": 1680638247788,
              "updatedBy": "User"
            },
            "description_uuid": "6a39a937-0e2f-439b-bef7-194cac3d6bdf",
            "effect": "Inconclusive",
            "effect_review": {
              "updateTime": 1680638239518,
              "updatedBy": "User"
            },
            "effect_uuid": "fd514185-c401-4ece-ae58-e8368656cdfc",
            "oncogenic": "Resistance",
            "oncogenic_review": {
              "updateTime": 1680638238695,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "35fa69d8-33b3-4bdb-9d22-99baa9a53978",
            "short": ""
          },
          "mutation_effect_uuid": "851ee259-df8a-4bb5-9b98-7b07f8e9ed88",
          "name": "L485S",
          "name_review": {
            "updateTime": 1680638190409,
            "updatedBy": "User"
          },
          "name_uuid": "a575d01f-a868-4286-9a24-82699712628c",
          "tumors_uuid": "ddcca08b-b245-4a83-90c2-c1584580e7f4"
        }
      ],
      "name": "BRAF",
      "summary": "BRAF, an intracellular kinase, is frequently mutated in melanoma, thyroid and lung cancers among others. Other info",
      "summary_review": {
        "lastReviewed": "BRAF, an intracellular kinase, is frequently mutated in melanoma, thyroid and lung cancers among others.",
        "updateTime": 1717517893267,
        "updatedBy": "Test User"
      },
      "summary_uuid": "fb828c84-3a02-4f45-8721-01c20b7794d3",
      "type": {
        "ocg": "Oncogene",
        "ocg_review": {
          "updateTime": 1678229718273,
          "updatedBy": "User"
        },
        "ocg_uuid": "bacab9b9-a34d-4e6c-900d-b9f0ab6e090e",
        "tsg": "",
        "tsg_review": {
          "updateTime": 1493057315640
        },
        "tsg_uuid": "1e9ee6d5-6e05-4bfe-9044-54ac4b58bf33"
      },
      "type_uuid": "d26dfc26-6433-4849-b94f-5b0ce808c328"
    },
    "ROS1": {
      "background": "The ROS1 gene encodes a transmembrane protein with intracellular tyrosine kinase activity (PMID: 18778756). ROS1 is a member of the sevenless subfamily of tyrosine kinase insulin receptor genes (PMID: 27256160). The normal physiological role and ligand of this protein in humans is currently unknown (PMID: 23814043). ROS1 rearrangements where the kinase domain is retained (PMID: 22327623) are implicated in a range of human epithelial cancers including cholangiocarcinoma (PMID: 21253578), ovarian carcinoma (PMID: 22163003), gastric carcinoma (PMID: 23400546), angiosarcoma (PMID: 23637631) and most commonly non-small cell lung cancer (PMID: 22215748). Although ROS1 rearrangements were first discovered in a human glioblastoma cell line (PMID: 2827175), there is a paucity of ROS1 rearrangements in human gliomas (PMID: 24999209). The mechanism by which ROS1 rearrangements leads to dysregulated kinase activity is not clear, as its ligand has not yet been deciphered; however, it is hypothesized to occur through constitutive kinase activation (PMID: 18083107).",
      "background_comments": [
        {
          "content": "needs updating - more info",
          "date": "1475864840070",
          "email": "user@gmail.com",
          "resolved": "false",
          "userName": "User"
        }
      ],
      "background_review": {
        "updateTime": 1491850504608
      },
      "background_uuid": "6ab05933-cfea-46bb-a467-998f93a46f77",
      "dmp_refseq_id": "NM_002944.2",
      "dmp_refseq_id_grch38": "NM_002944.2",
      "isoform_override": "ENST00000368508",
      "isoform_override_grch38": "ENST00000368508",
      "mutations": [
        {
          "mutation_effect": {
            "description": "Fusions of ROS1 arise from chromosomal translocations that fuse the N-terminal portion of a partner protein with the C-terminal kinase-domain-containing portion of ROS1. These fusion proteins are found in a variety of cancer types and result in constitutive activation of ROS1 kinase activity. Biological characterization of specific ROS1 fusion proteins demonstrates that they are activating as shown by enhanced proliferation and colony formation and that they are sensitive to treatment with the tyrosine kinase inhibitors crizotinib and entrectinib (PMID: 23719267, 22919003, 22215748, 28465216). Preliminary clinical data suggests that lorlatinib may also be efficacious in patients with ROS1 fusion-positive non-small cell lung cancer, including those with central nervous system disease (PMID: 31669155).",
            "description_review": {
              "updateTime": 1578290033366,
              "updatedBy": "User"
            },
            "description_uuid": "44e4a3e3-4020-4791-92f2-e1eb874754b1",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1488748923000,
              "updatedBy": "User"
            },
            "effect_uuid": "e8113bd5-9371-4afc-a563-3c8db56bb3d8",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1491850504608
            },
            "oncogenic_uuid": "aeb5989e-4867-4046-8c60-d724510de642",
            "short": ""
          },
          "mutation_effect_uuid": "3541c5e8-d8b6-4c5f-9312-b8fe9fb3b4e3",
          "name": "Fusions",
          "name_uuid": "3eb598e3-66cf-489e-9969-69c9e47c5be9",
          "tumors": [
            {
              "TIs": [
                {
                  "name": "Standard implications for sensitivity to therapy",
                  "name_uuid": "7c641c70-23c9-4574-80ab-5f1a4c08a2ac",
                  "treatments": [
                    {
                      "description": "Crizotinib, an inhibitor of ALK, ROS1 and MET tyrosine kinases, is FDA-approved for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive. FDA approval is based on the results of a Phase I trial of crizotinib in 53 patients with advanced NSCLC positive for ROS1 rearrangements in which the objective response rate was 72% (95% CI= 58-84), including six complete responses, 32 partial responses (66%) and a median progression-free survival (PFS) of 19.3 months (95% CI= 15.2-39.1)(PMID: 25264305, 30980071). In a Phase II trial of crizotinib in 127 East Asian patients with ROS1-positive NSCLC, the overall response rate was 71.1% (95% CI= 63.0-79.3), including seventeen of 127 patients with complete responses (13.4%), 74 of 127 patients with partial responses (58.3%), and a median PFS of 15.9 months (95% CI= 12.9-24.0) (PMID: 29596029).",
                      "description_review": {
                        "updateTime": 1677170038518,
                        "updatedBy": "User"
                      },
                      "description_uuid": "7d959142-4c85-4522-ac3c-7e79c2486ea7",
                      "fdaLevel": "Fda2",
                      "fdaLevel_review": {
                        "updateTime": 1671647781747,
                        "updatedBy": "User"
                      },
                      "fdaLevel_uuid": "e16d704e-68de-432b-a279-64b50230077b",
                      "indication": "Crizotinib is FDA approved for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive.",
                      "indication_uuid": "bd53732a-46e8-40a9-a6c4-57254cd89252",
                      "level": "1",
                      "level_uuid": "f50d62ba-9590-4208-92ae-d762671a050f",
                      "name": "f05d12ab-6204-4a1c-803f-f3a7f6e30af2",
                      "name_comments": [
                        {
                          "content": "Crizotinib, which functions as a protein kinase inhibitor by competitive binding with target kinases (PMID: 25264305, 25087901, 23558310, 22215748, 22919003, 22617245), has shown marked anti-tumor activity in NSCLC with ROS1 rearrangements (PMID: 25264305).",
                          "date": "1457726475717",
                          "email": "user@gmail.com",
                          "resolved": "false",
                          "userName": "User"
                        }
                      ],
                      "name_review": {
                        "updateTime": 1525889131772
                      },
                      "name_uuid": "c89514ef-b096-442a-828d-6ed357e12d57",
                      "propagation": "3B",
                      "propagationLiquid": "no",
                      "propagationLiquid_uuid": "d23095b3-db25-11e9-bbf2-60f81dc75ed6",
                      "propagation_uuid": "127d606a-95c4-45a2-a7c6-f7dbb7fe245b",
                      "short": ""
                    },
                    {
                      "description": "Entrectinib is a potent, orally available, ATP-competitive tyrosine kinase inhibitor that is highly effective against NTRK1/2/3, ROS1 and ALK and is FDA-approved for patients with ROS1-fusion-positive non-small cell lung cancer (NSCLC). FDA approval was based on the results of three multicenter, single-arm clinical trials (ALKA, STARTRK-1 and STARTRK-2) in which of 51 evaluable patients with ROS1-fusion-positive NSCLC who were treated with entrectinib, the overall response rate was 78% (95% CI = 65-89) and response duration was more than one year for 55% of patients (PMID: 28183697)(Abstract: Drilon et al. Abstract# CT060, AACR 2017. https://cancerres.aacrjournals.org/content/77/13_Supplement/CT060)(Abstract: Braud et al. Abstract# 64P, ESMO 2019. https://academic.oup.com/annonc/article/30/Supplement_9/mdz420.003/5638397).",
                      "description_review": {
                        "updateTime": 1677170049504,
                        "updatedBy": "User"
                      },
                      "description_uuid": "7b74f800-c088-4859-82f6-236bc347bc7e",
                      "fdaLevel": "Fda2",
                      "fdaLevel_review": {
                        "updateTime": 1667345892418,
                        "updatedBy": "User"
                      },
                      "fdaLevel_uuid": "da358ac6-200e-44d9-9165-08ac5b792aa6",
                      "indication": "",
                      "indication_uuid": "0610e26b-6b65-44fa-972e-e2f2266d95f4",
                      "level": "1",
                      "level_review": {
                        "updateTime": 1571963724018,
                        "updatedBy": "User"
                      },
                      "level_uuid": "8feb2deb-8282-4059-b60f-34751695f7c6",
                      "name": "2371f7f5-6407-4a4b-b951-a0f786355455",
                      "name_review": {
                        "updateTime": 1571963720925,
                        "updatedBy": "User"
                      },
                      "name_uuid": "3dbaf733-ca83-47d3-b8d6-f15162c4055f",
                      "propagation": "3B",
                      "propagationLiquid": "no",
                      "propagationLiquid_review": {
                        "updateTime": 1571963724010,
                        "updatedBy": "User"
                      },
                      "propagationLiquid_uuid": "28721efe-f7fe-4f34-9cf3-7d7a138313e9",
                      "propagation_review": {
                        "updateTime": 1571963724002,
                        "updatedBy": "User"
                      },
                      "propagation_uuid": "12541af9-b57f-448a-81c6-c79d64303294",
                      "short": ""
                    },
                    {
                      "description": "Repotrectinib, an orally administered next-generation ROS1/TRK tyrosine kinase inhibitor (TKI), is FDA-approved for the treatment of patients with ROS1 fusion positive non-small cell lung cancer (NSCLC). FDA-approval is based on the results of the Phase I/II TRIDENT-1 trial of repotrectinib in patients with ROS1 fusion positive NSCLC that are ROS1-inhibitor-naive or pre-treated. ROS1-inhibitor-naive patients (n=71) demonstrated an objective response rate of 79% (95% CI=68%-88%), with a 6% complete response rate and a 73% partial response rate, and a median duration response of 34.1 months (95% CI=25.6-NE) whereas ROS1-inhibitor pre-treated patients (n=56) demonstrated an objective response rate of 38% (95% CI=25%-52%), with a 5% complete response rate and a 32% partial response rate, and a median duration response of 14.8 months (95% CI=7.6-NE) (Abstract: Cho et al. Abstract# OA03.06, J. of Thoracic Oncol. Nov. 2023. https://www.jto.org/article/S1556-0864%2823%2900837-7/fulltext).",
                      "description_review": {
                        "updateTime": 1701462617428,
                        "updatedBy": "User"
                      },
                      "description_uuid": "24aa88e2-e5ef-4cef-a902-af6f80746351",
                      "fdaLevel": "Fda2",
                      "fdaLevel_review": {
                        "updateTime": 1701197989766,
                        "updatedBy": "User"
                      },
                      "fdaLevel_uuid": "4d4df5b5-d9d2-43fd-b304-85d3b83d5117",
                      "indication": "",
                      "indication_uuid": "5a5d167e-36ff-410a-8ba7-f235699ecf15",
                      "level": "1",
                      "level_review": {
                        "updateTime": 1701197989773,
                        "updatedBy": "User"
                      },
                      "level_uuid": "c6291b47-276a-4e1a-9d91-b08d49d87ce1",
                      "name": "d28edb2a-6f51-4dd0-b1ec-aca045f50f9f",
                      "name_review": {
                        "updateTime": 1701197982383,
                        "updatedBy": "User"
                      },
                      "name_uuid": "8c2ac63c-bdc2-471f-8beb-89b57b36cf16",
                      "propagation": "3B",
                      "propagationLiquid": "no",
                      "propagationLiquid_review": {
                        "updateTime": 1701197989760,
                        "updatedBy": "User"
                      },
                      "propagationLiquid_uuid": "8504ef8e-a951-4e32-8a12-8132b9188ae9",
                      "propagation_review": {
                        "updateTime": 1701197992212,
                        "updatedBy": "User"
                      },
                      "propagation_uuid": "662a5c06-19ba-4f9d-b10d-8f55b3299402",
                      "short": ""
                    },
                    {
                      "description": "Ceritinib is a small molecule inhibitor of ALK that also binds to and inhibits ROS1 and is NCCN-listed as a category 2A treatment recommendation for patients with non-small cell lung cancer (NSCLC) who have ROS1 rearrangements. In a Phase II study of ceritinib in 32 patients with NSCLC harboring ROS1 rearrangement, the overall response rate in 28 evaluable patients was 62% (95% CI= 45 - 77) with one patient having a complete response and nineteen patients having a partial response (PMID: 28520527).",
                      "description_review": {
                        "updateTime": 1677262608694,
                        "updatedBy": "User"
                      },
                      "description_uuid": "7294f41b-8a00-41d6-9be3-0e00f0272c24",
                      "fdaLevel": "Fda2",
                      "fdaLevel_review": {
                        "updateTime": 1667345889097,
                        "updatedBy": "User"
                      },
                      "fdaLevel_uuid": "eb1a5a83-7b4a-4c83-9074-6458375eef77",
                      "indication": "",
                      "indication_uuid": "13ca1f3d-2a8c-4c40-9a4b-ca57ed56124b",
                      "level": "2",
                      "level_review": {
                        "updateTime": 1651259288336,
                        "updatedBy": "User"
                      },
                      "level_uuid": "2a149072-9cd4-4b01-a843-da49ff38be90",
                      "name": "5e9aa568-30cf-48ef-b9ce-18851af2f622",
                      "name_review": {
                        "updateTime": 1651259278588,
                        "updatedBy": "User"
                      },
                      "name_uuid": "a24c4391-adab-4b50-9df2-5d4253e243e6",
                      "propagation": "3B",
                      "propagationLiquid": "no",
                      "propagationLiquid_review": {
                        "updateTime": 1651259288312,
                        "updatedBy": "User"
                      },
                      "propagationLiquid_uuid": "21a1cd60-d896-471c-82bb-41c5f31252b8",
                      "propagation_review": {
                        "updateTime": 1651259289938,
                        "updatedBy": "User"
                      },
                      "propagation_uuid": "37871222-9157-4e0e-8bc4-60a13c41170f",
                      "short": ""
                    },
                    {
                      "description": "Lorlatinib is a third-generation small molecule inhibitor of ALK and ROS1 that is NCCN-listed as a category 2A recommended subsequent therapy option for patients with ROS1-rearrangement-positive non-small cell lung cancer (NSCLC) who progressed on entrectinib, crizotinib or ceritinib. In a phase I/II trial of lorlatinib in patients with ROS1-fusion-positive NSCLC, thirteen of 21 tyrosine kinase inhibitor-naive patients had a response to lorlatinib for an overall response rate of 62% (95% CI= 38-82), while fourteen of 40 crizotinib pre-treated patients had a response to lorlatinib with an overall response rate of 35% (95% CI= 21-52)(PMID: 31669155).",
                      "description_review": {
                        "updateTime": 1677170072499,
                        "updatedBy": "User"
                      },
                      "description_uuid": "d1443dc8-bfad-4cbf-a57d-fb3af50e5d1e",
                      "fdaLevel": "Fda2",
                      "fdaLevel_review": {
                        "updateTime": 1667345879928,
                        "updatedBy": "User"
                      },
                      "fdaLevel_uuid": "3b1f5e72-31e9-49eb-9776-fdf595d3fd3f",
                      "indication": "",
                      "indication_uuid": "8c47cb3b-28ee-42e6-b6a4-46ee1d1e1487",
                      "level": "2",
                      "level_review": {
                        "updateTime": 1651260561214,
                        "updatedBy": "User"
                      },
                      "level_uuid": "f51cc790-a448-4ae9-8a25-4cb65ac60134",
                      "name": "ed76aa01-059c-4b22-b391-94ec86320122",
                      "name_review": {
                        "updateTime": 1651259285158,
                        "updatedBy": "User"
                      },
                      "name_uuid": "88b15a8c-c63f-4b50-a0ae-b0c1e08180a9",
                      "propagation": "3B",
                      "propagationLiquid": "no",
                      "propagationLiquid_review": {
                        "updateTime": 1651260561187,
                        "updatedBy": "User"
                      },
                      "propagationLiquid_uuid": "af5a32b0-6ec1-4bc9-aea2-9fa92393baca",
                      "propagation_review": {
                        "updateTime": 1651260563097,
                        "updatedBy": "User"
                      },
                      "propagation_uuid": "63752e8a-4c9f-43b2-acb0-ac5f56ce5822",
                      "short": ""
                    }
                  ],
                  "type": "SS"
                },
                {
                  "name": "Standard implications for resistance to therapy",
                  "name_uuid": "ee14bb88-aa26-46fa-8ff5-83222896a943",
                  "type": "SR"
                },
                {
                  "name": "Investigational implications for sensitivity to therapy",
                  "name_uuid": "a57c6217-5a61-412d-a704-7bc4f2245517",
                  "type": "IS"
                },
                {
                  "name": "Investigational implications for resistance to therapy",
                  "name_uuid": "34102d33-1011-452c-9459-3000624e686a",
                  "type": "IR"
                }
              ],
              "cancerTypes": [
                {
                  "code": "",
                  "mainType": "Non-Small Cell Lung Cancer",
                  "subtype": ""
                }
              ],
              "cancerTypes_uuid": "82516cec-2494-4bfa-824b-d5ded7ef9d74",
              "diagnostic": {
                "description": "",
                "description_uuid": "6da28685-fb95-4ca7-b031-fb33dd41da2d",
                "level": "",
                "level_uuid": "ef636b4b-2b73-4a29-9ed1-0b7db2b6f5c1",
                "short": ""
              },
              "diagnosticSummary": "",
              "diagnosticSummary_uuid": "a812510c-8229-4ff5-b27e-b91bf25b860a",
              "diagnostic_uuid": "1b72bded-9e86-4ff8-9d2f-9f8d7960a71d",
              "prognostic": {
                "description": "",
                "description_review": {
                  "updateTime": 1491850504608
                },
                "description_uuid": "325520d3-65bc-4502-8051-a5dc104d3e78",
                "level": "",
                "level_uuid": "75e353b5-561b-49e6-8d46-a8ffe17cad37",
                "short": ""
              },
              "prognosticSummary": "",
              "prognosticSummary_uuid": "218db0db-bff0-4df4-a2cb-d6ab000beae3",
              "prognostic_uuid": "d919297f-2998-496d-ad2f-e9c6e847d13d",
              "summary": "The tyrosine kinase inhibitors crizotinib, entrectinib and repotrectinib are FDA-approved for the treatment of patients with ROS1 fusion positive non-small cell lung cancer.",
              "summary_review": {
                "updateTime": 1701197961707,
                "updatedBy": "User"
              },
              "summary_uuid": "3aa7655f-3fd3-41d8-a883-43bfccc6d2a2"
            },
            {
              "TIs": [
                {
                  "name": "Standard implications for sensitivity to therapy",
                  "name_uuid": "50fd2ccc-2e92-462c-806a-30ebf8b23a08",
                  "type": "SS"
                },
                {
                  "name": "Standard implications for resistance to therapy",
                  "name_uuid": "3b63f79a-f14d-4d9e-8a0a-7d66985846f8",
                  "type": "SR"
                },
                {
                  "name": "Investigational implications for sensitivity to therapy",
                  "name_uuid": "28241142-c87e-4a0e-87e1-ab8a8a09b945",
                  "type": "IS"
                },
                {
                  "name": "Investigational implications for resistance to therapy",
                  "name_uuid": "9680dd04-0f07-4f93-a109-01a872da2219",
                  "type": "IR"
                }
              ],
              "cancerTypes": [
                {
                  "code": "",
                  "mainType": "Other Tumor Types",
                  "subtype": ""
                }
              ],
              "cancerTypes_review": {
                "updateTime": 1701198078097,
                "updatedBy": "User"
              },
              "cancerTypes_uuid": "18b19820-eb94-4f03-9be2-b506f2026b1e",
              "diagnostic": {
                "description": "",
                "description_uuid": "ce9587c4-c991-40c3-864d-94fcdd6bdf21",
                "level": "",
                "level_uuid": "a900948a-116b-471e-86ab-9222c158d11b",
                "short": ""
              },
              "diagnosticSummary": "",
              "diagnosticSummary_uuid": "a95fc09f-565d-4dca-9b8c-015ad314d295",
              "diagnostic_uuid": "897af644-7e5c-445a-ab31-30748f4e29b1",
              "prognostic": {
                "description": "",
                "description_review": {
                  "updateTime": 1491850504608
                },
                "description_uuid": "5769249a-2cc9-489c-ae6c-b8dc34b6986e",
                "level": "",
                "level_uuid": "ef568b87-a239-4a7d-bd58-d4d18a5892a4",
                "short": ""
              },
              "prognosticSummary": "",
              "prognosticSummary_uuid": "484a12ca-5d02-4a0b-807b-7bef215e4c85",
              "prognostic_uuid": "0a89bf13-1907-4d27-8c42-ce2d2d5ca7ae",
              "summary": "While the tyrosine kinase inhibitors crizotinib, entrectinib and repotrectinib are FDA-approved for the treatment of patients with ROS1 fusion positive non-small cell lung cancer, their clinical utility in patients with ROS1 fusion positive [[tumor type]] is unknown.",
              "summary_review": {
                "updateTime": 1701198108446,
                "updatedBy": "User"
              },
              "summary_uuid": "25c05c7e-a64e-4eec-8206-4a198462879f"
            }
          ]
        },
        {
          "mutation_effect": {
            "description": "",
            "description_uuid": "54a15330-85d4-4171-a6c0-fae89d4ab75b",
            "effect": "",
            "effect_review": {
              "updateTime": 1491850504608
            },
            "effect_uuid": "0bc57cd0-9c87-4a32-a012-d115f4bfa4ec",
            "oncogenic": "",
            "oncogenic_review": {
              "updateTime": 1491850504608
            },
            "oncogenic_uuid": "230faf2c-ae65-4487-aa7a-37d41a53891c",
            "short": ""
          },
          "mutation_effect_uuid": "8868a91d-f0a9-446d-9472-338003a97ec7",
          "name": "Oncogenic Mutations",
          "name_uuid": "123aacc7-90df-4f96-8ac9-2278105b750b",
          "tumors": [
            {
              "TIs": [
                {
                  "name": "Standard implications for sensitivity to therapy",
                  "name_uuid": "a91ef88c-3fdd-4419-afd1-aa5007ea19f1",
                  "type": "SS"
                },
                {
                  "name": "Standard implications for resistance to therapy",
                  "name_uuid": "1467a966-601f-49d0-ab7e-751d2006eb91",
                  "type": "SR"
                },
                {
                  "name": "Investigational implications for sensitivity to therapy",
                  "name_uuid": "25e1b6bf-1fb2-4877-a493-c6f4f81ea00f",
                  "type": "IS"
                },
                {
                  "name": "Investigational implications for resistance to therapy",
                  "name_uuid": "81b04398-82a1-4842-89b0-5da49e3164dc",
                  "type": "IR"
                }
              ],
              "cancerTypes": [
                {
                  "code": "",
                  "mainType": "All Tumors",
                  "subtype": ""
                }
              ],
              "cancerTypes_uuid": "b447b58e-0720-4b8a-bbce-cfebc6dafafa",
              "diagnostic": {
                "description": "",
                "description_uuid": "167feb97-b7f1-4f23-a93f-3da575703421",
                "level": "",
                "level_uuid": "08df03ce-b4ef-4104-83ee-ff59a70c4430",
                "short": ""
              },
              "diagnosticSummary": "",
              "diagnosticSummary_uuid": "e332504c-d3b8-4a5d-a644-ad5590fdf12d",
              "diagnostic_uuid": "aed052b3-1766-423b-b076-fc234a8e843a",
              "prognostic": {
                "description": "",
                "description_review": {
                  "updateTime": 1491850504608
                },
                "description_uuid": "567ab235-5117-44b8-8851-3cb28cb22781",
                "level": "",
                "level_uuid": "b298414f-d77f-4286-a7d6-6a11837d9689",
                "short": ""
              },
              "prognosticSummary": "",
              "prognosticSummary_uuid": "08c97740-4914-405b-914b-b9c99f045b47",
              "prognostic_uuid": "af52579b-e7d8-42fb-a595-a26754f180cd",
              "summary": "While crizotinib is FDA-approved for the treatment of patients with ROS1 fusion positive non-small cell lung cancer, its clinical utility in patients with [[variant]] is unknown.",
              "summary_review": {
                "updateTime": 1566921181540,
                "updatedBy": "User"
              },
              "summary_uuid": "df602908-e466-4f95-b006-c65382ca083a"
            }
          ]
        },
        {
          "mutation_effect": {
            "description": "The FIG-ROS1 fusion is characterized by the fusion of the 3' region of ROS1 (exon 35) to the 5' region of FIG (exon 7); this fusion results from an intra-chromosomal deletion in chromosome 6 (PMID: 12661006). The FIG-ROS1 fusion results in a constitutively active ROS1 kinase (PMID: 2827175, 12661006).",
            "description_review": {
              "updateTime": 1676478955860,
              "updatedBy": "User"
            },
            "description_uuid": "15b9fb54-b26a-4c46-8f31-40e9cc22ecb9",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1676478902355,
              "updatedBy": "User"
            },
            "effect_uuid": "9151ba5c-e692-49a5-b13f-b7ee0875eb8a",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1676478900330,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "9d636c58-c0f6-40f4-9b100-d61369f2d563",
            "short": "This rearrangement was first deciphered in an endogenous human glioblastoma cell line, U118MG (PMID: 2827175)."
          },
          "mutation_effect_uuid": "6f9e2e7a-3536-4170-9bb0-409e15350c06",
          "name": "FIG-ROS1 Fusion",
          "name_uuid": "1fd92e2f-561d-4910-a183-f92233d1dd10"
        },
        {
          "mutation_effect": {
            "description": "CD74-ROS1 is a rearrangement mutation characterized by the fusion of CD74 (exon 6) and ROS1 (exon 34). This fusion generates a protein with constitutive kinase activity (PMID: 22215748, 22919003, 22327623, 18083107). CD74-ROS1 demonstrated transforming capabilities when tested in foci forming assays in vitro, and also demonstrated the ability to form subcutaneous tumors in nude mice (PMID: 22327623). A patient with non-small cell lung cancer harboring a CD74-ROS1 fusion responded to treatment with brigatinib and ceritinib after progressing on crizotinib (Abstract: Hegde et al. JCO PO, 2018. https://ascopubs.org/doi/full/10.1200/PO.18.00267).",
            "description_review": {
              "updateTime": 1558395391688,
              "updatedBy": "User"
            },
            "description_uuid": "c9a3491e-ae30-4082-bfd6-f45bb0ba85ff",
            "effect": "Gain-of-function",
            "effect_review": {
              "updateTime": 1491850504608
            },
            "effect_uuid": "bc796f57-eb77-4434-a67b-c83f986ccd53",
            "oncogenic": "Yes",
            "oncogenic_review": {
              "updateTime": 1491850504608
            },
            "oncogenic_uuid": "e866e555-f8c5-44cd-9354-67152a0b84e6",
            "short": ""
          },
          "mutation_effect_uuid": "3c910a53-7e1c-40c8-ae78-fec34eddd042",
          "name": "CD74-ROS1 Fusion",
          "name_review": {
            "updateTime": 1603290465721,
            "updatedBy": "User"
          },
          "name_uuid": "0eab9106-eb6e-4556-8193-2cf9d40eda50"
        },
        {
          "mutation_effect": {
            "description": "LRIG3-ROS1, a rearrangement mutation that results in the fusion of exon 16 of EZR with exon 35 of ROS1, results in a constitutively active protein containing the ROS1 kinase domain. This fusion demonstrated transforming capabilities when tested in foci forming assays in vitro, and also demonstrated the ability to form subcutaneous tumors in nude mice (PMID: 22327623).",
            "description_uuid": "1c8f709c-2044-40d0-9ad9-e4ece7e777f1",
            "effect": "Gain-of-function",
            "effect_review": {
              "updateTime": 1491850504608
            },
            "effect_uuid": "4192b084-39f0-4e6e-baed-2f099ebc5e3a",
            "oncogenic": "Yes",
            "oncogenic_review": {
              "updateTime": 1491850504608
            },
            "oncogenic_uuid": "b5d0a7be-8f5d-48ca-8dc7-fccc54485b44",
            "short": ""
          },
          "mutation_effect_uuid": "e1626dd3-d852-40ba-894e-6a4f3814f764",
          "name": "LRIG3-ROS1 Fusion",
          "name_uuid": "62c473c7-220b-47be-b7b5-4f4f0622617f"
        },
        {
          "mutation_effect": {
            "description": "KDELR2-ROS1, a rearrangement mutation that results in the fusion of the 5' end of KDELR2 with the 3' end of with ROS1 (PMID: 22980976). The oncogenic potential of this fusion has not been functionally tested.",
            "description_uuid": "78987ea9-f1e9-4f4b-ae1c-a299cfde1b50",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1491850504608
            },
            "effect_uuid": "47a2ab73-a141-4768-8b29-205a346d447b",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1491850504608
            },
            "oncogenic_uuid": "5c3d5d86-c7ef-4a5f-ad33-02414d7a37ba",
            "short": ""
          },
          "mutation_effect_uuid": "a378d82f-62c2-42d5-93a4-81a390719d75",
          "name": "KDELR2-ROS1 Fusion",
          "name_uuid": "25eba07f-f679-4a60-94d6-616f66ff06dd"
        },
        {
          "mutation_effect": {
            "description": "SLC34A2-ROS1 is a rearrangement mutation that results in the fusion of SLC34A2 (exon 4) and ROS1 (exon 32 and 34), creating a short and long transcript, respectively. This in-frame mutation generates a protein with constitutively active kinase activity (PMID: 22215748, 22919003). This fusion demonstrated transforming capabilities when tested in foci forming assays in vitro, and also demonstrated the ability to form subcutaneous tumors in nude mice (PMID: 22327623).",
            "description_uuid": "bcf90fcc-d219-4824-8b44-d1acbe7cfde9",
            "effect": "Gain-of-function",
            "effect_review": {
              "updateTime": 1491850504608
            },
            "effect_uuid": "19cbcfdb-7220-41f7-9db5-519c7aba7d14",
            "oncogenic": "Yes",
            "oncogenic_review": {
              "updateTime": 1491850504608
            },
            "oncogenic_uuid": "c243f6b3-8a77-488a-b446-ae6d349aebe0",
            "short": ""
          },
          "mutation_effect_uuid": "79a88182-d033-4963-90c9-83f54731a236",
          "name": "SLC34A2-ROS1 Fusion",
          "name_uuid": "880638bc-78c2-4106-b676-3d32d4f91623"
        },
        {
          "mutation_effect": {
            "description": "TPM3-ROS1, a rearrangement mutation that results in the fusion of exon 8 of TPM3 with exon 35 of ROS1, results in a constitutively active protein containing the ROS1 kinase domain (PMID: 22327623). This fusion demonstrated transforming capabilities when tested in foci forming assays in vitro, and also demonstrated the ability to form subcutaneous tumors in nude mice (PMID: 22327623).",
            "description_uuid": "130ee0a9-1490-44be-aa2a-2446c186dd7b",
            "effect": "Gain-of-function",
            "effect_review": {
              "updateTime": 1491850504608
            },
            "effect_uuid": "99fc9f8c-568d-48ea-a6a9-cd00e11509d6",
            "oncogenic": "Yes",
            "oncogenic_review": {
              "updateTime": 1491850504608
            },
            "oncogenic_uuid": "8bd71a92-568f-4a02-b316-68c6fc3f4a19",
            "short": ""
          },
          "mutation_effect_uuid": "65c39ffa-ab7d-4a9f-a5e1-9c647887e153",
          "name": "TPM3-ROS1 Fusion",
          "name_uuid": "c3798ea9-5d35-457d-a601-330c667dbb46"
        },
        {
          "mutation_effect": {
            "description": "SDC4-ROS1, a rearrangement mutation that results in the fusion of exon 2 of SDC4 with exon 33 or 34 of ROS1, results in a constitutively active protein containing the ROS1 kinase domain (PMID: 22327623). This fusion demonstrated transforming capabilities when tested in foci forming assays in vitro, and also demonstrated the ability to form subcutaneous tumors in nude mice (PMID: 22327623).",
            "description_uuid": "fb3dcaf1-8ee2-4d99-8c2a-154acc1724df",
            "effect": "Gain-of-function",
            "effect_review": {
              "updateTime": 1491850504608
            },
            "effect_uuid": "f139c10b-60e3-4a9a-98e4-8c4059ebf637",
            "oncogenic": "Yes",
            "oncogenic_review": {
              "updateTime": 1491850504608
            },
            "oncogenic_uuid": "9c1e1dea-f7b5-4819-bb0a-2c14226842cb",
            "short": ""
          },
          "mutation_effect_uuid": "4cfd4d52-2d78-46a7-9e2e-c3ddad9e947f",
          "name": "SDC4-ROS1 Fusion",
          "name_uuid": "3706ac19-2a4a-4362-93ac-de8615297a80"
        },
        {
          "mutation_effect": {
            "description": "EZR-ROS1 is a rearrangement mutation that results in the fusion of exon 10 of EZR with exon 34 of ROS1, results in a constitutively active protein containing the ROS1 kinase domain (PMID: 22327623). This fusion demonstrated transforming capabilities when tested in foci forming assays in vitro, and also demonstrated the ability to form subcutaneous tumors in nude mice (PMID: 22327623).",
            "description_uuid": "f3298aa9-1313-4ce6-a12a-cb38de952cbc",
            "effect": "Gain-of-function",
            "effect_review": {
              "updateTime": 1491850504608
            },
            "effect_uuid": "223971d5-6d75-429c-8ee6-ff87292c52ba",
            "oncogenic": "Yes",
            "oncogenic_review": {
              "updateTime": 1491850504608
            },
            "oncogenic_uuid": "4829f927-214f-4cad-8e03-f865f2388eea",
            "short": ""
          },
          "mutation_effect_uuid": "9c8914ab-635a-4b2d-9576-e87a225aa7f1",
          "name": "EZR-ROS1 Fusion",
          "name_uuid": "9ab510c6-1465-402d-b784-b6c0e4b43d90"
        },
        {
          "mutation_effect": {
            "description": "CCDC6-ROS1 is a fusion rearrangement mutation resulting in the fusion of the 3' region of ROS1 (exon 34) to the 5' region of CCDC6 (exon 6). This fusion retains the coiled-coil domain of CCDC6 and the kinase domain of ROS1 (PMID: 22975805, 25870798). The oncogenic potential of this fusion has not been functionally tested.",
            "description_uuid": "6eaed7da-aedc-4905-beb4-4e2374edea46",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1491850504608
            },
            "effect_uuid": "5bec6cce-2d4e-4d27-9435-e82c1c5afb4e",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1491850504608
            },
            "oncogenic_uuid": "e11e0f79-6dbd-4662-90e1-f511b46f1bd9",
            "short": ""
          },
          "mutation_effect_uuid": "d2d07aa4-e928-4422-b067-5b914186884d",
          "name": "CCDC6-ROS1 Fusion",
          "name_uuid": "8aa9db4b-c2ef-4369-88f7-9c8afe5f9f33"
        },
        {
          "mutation_effect": {
            "description": "The CEP85L-ROS1 fusion protein combines the N terminal of CEP85L until exon 8 with the C-terminal of ROS1 starting at exon 36 and is found in CNS tumors, angiosarcoma and glioblastoma (PMID: 23637631, 25204415, 30171048). The breakpoint preserves the coiled-coil domain of CEP85L and the tyrosine kinase domain of ROS1, and is predicted to possess transforming abilities (PMID: 23637631, 25204415, 30171048). Expression of this fusion protein in BaF3, NIH3T3, and immortalized human astrocyte cells demonstrated that it is activating as shown by IL3 independent growth, pathway activation and increased colony formation compared to ectopic expression of wildtype ROS1. Expression of this fusion in BaF3 cells also demonstrated that it is sensitive to multiple TKIs including crizotinib, foretinib, cabozantinib, ceritinib, brigatinib, AZD3463, lorlatinib, and entrectinib proliferation, pathway activation and colony formation (PMID: 30171048).",
            "description_review": {
              "updateTime": 1555912488839,
              "updatedBy": "User"
            },
            "description_uuid": "09f9348e-1edf-4ac4-b38e-00a4eb21eeb3",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1491850504608
            },
            "effect_uuid": "2efa77d7-fce2-4db2-9a47-efd2d37a8442",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1491850504608
            },
            "oncogenic_uuid": "1f433934-e5ee-4521-b22c-813311f97682",
            "short": "In angiosarcoma, the rearrangement results in the fusion of exon 12 of CEP85L with exon 35 of ROS1 (PMID: 23637631), while in glioblastoma the rearrangement results in the fusion of exon 8 of CEP85L with exon 36 of ROS1 (PMID: 25204415)."
          },
          "mutation_effect_uuid": "e438176c-d676-43d6-9ab6-26f4e8d29d4e",
          "name": "CEP85L-ROS1 Fusion",
          "name_uuid": "477f4dd7-6afa-4e10-b5a8-113608d2c62a"
        },
        {
          "mutation_effect": {
            "description": "TFG-ROS1 is a rearrangement mutation that results in the fusion of TFG (exon 4) to ROS1 (exon 36) (PMID: 24875859). The oncogenic potential of this fusion has not been functionally tested.",
            "description_uuid": "b479e26b-97f0-4c91-bd9a-d02935ac7721",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1491850504608
            },
            "effect_uuid": "189ca680-c125-47ce-a56b-8475d18ed537",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1491850504608
            },
            "oncogenic_uuid": "56ca090e-c0bb-4513-8807-d51bc9c88a9c",
            "short": ""
          },
          "mutation_effect_uuid": "cfb1da18-53e4-49f4-90ea-cd68736ff40f",
          "name": "TFG-ROS1 Fusion",
          "name_uuid": "44eb766f-2151-4160-a544-96c5246aba5f"
        },
        {
          "mutation_effect": {
            "description": "YWHAE-ROS1 is a rearrangement mutation that results in the fusion of YWHAE (exon 4) to ROS1 (exon 36) (PMID: 24875859). The oncogenic potential of this fusion has not been functionally tested.",
            "description_uuid": "69e1d600-ee3b-4ecc-80de-aca5f5656929",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1491850504608
            },
            "effect_uuid": "e877496a-b1bb-4cef-95ec-7dbf01296343",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1491850504608
            },
            "oncogenic_uuid": "8912c735-23c3-4d05-9523-eac31ed076e0",
            "short": ""
          },
          "mutation_effect_uuid": "93479ce3-b53a-4252-b021-fef6e55e9126",
          "name": "YWHAE-ROS1 Fusion",
          "name_uuid": "4ec3367c-1284-427e-858f-6862630da5f9"
        },
        {
          "mutation_effect": {
            "description": "LIMA1-ROS1 is a rearrangement mutation that results in the fusion of LIMA1 (exon 10) to ROS1 (exon 36). This novel fusion has been identified in a tumor sample from a patient with non-small cell lung cancer (NSCLC) treated with crizotinib (PMID: 25264305).",
            "description_review": {
              "updateTime": 1677262889893,
              "updatedBy": "User"
            },
            "description_uuid": "1170b86b-7e29-4603-88cf-2fbc4f4681a1",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1491850504608
            },
            "effect_uuid": "2526d944-55a3-407d-ae39-80db14f9ce98",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1491850504608
            },
            "oncogenic_uuid": "d36eed89-50ac-4f42-841c-1020fe8b559a",
            "short": ""
          },
          "mutation_effect_uuid": "3831bc72-bc4b-45df-93a6-646150823754",
          "name": "LIMA1-ROS1 Fusion",
          "name_uuid": "b9fe9c43-b07f-4b15-a807-3dd60f75992b"
        },
        {
          "mutation_effect": {
            "description": "MSN-ROS1 is a rearrangement mutation that results in the fusion of MSN (exon 9) to ROS1 (exon 34). This novel fusion has been identified in a tumor sample from a patient with non-small cell lung cancer (NSCLC) treated with crizotinib (PMID: 25264305).",
            "description_review": {
              "updateTime": 1677262899376,
              "updatedBy": "User"
            },
            "description_uuid": "12e5c364-9ad8-4f89-bba5-2af5c8fd070c",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1491850504608
            },
            "effect_uuid": "363f218b-1836-413c-bdc9-58212a6060f0",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1491850504608
            },
            "oncogenic_uuid": "42b26a42-224d-4eed-a458-c9749f402c19",
            "short": ""
          },
          "mutation_effect_uuid": "a70b8b72-2aab-477d-8b6a-3cd86f38274b",
          "name": "MSN-ROS1 Fusion",
          "name_uuid": "ec66f9e4-fadf-423d-82a4-3541de3f2225"
        },
        {
          "mutation_effect": {
            "description": "The ROS1 G2032R mutation is located in the protein's kinase domain and is associated with acquired resistance to crizotinib in ROS1-rearranged non-small cell lung cancer (PMID: 25688157, 24047073, 23724914). In vitro studies with A549 cells expressing ROS1 G2032R demonstrate that the mutation is activating as measured by increased cellular invasion and migration, increased expression of MMP-9 and TWIST1 and induced epithelial-mesenchymal transition compared to wildtype (PMID: 29477381). Preclinical studies and structural analysis of ROS1 G2023R demonstrate that the mutation confers resistance by interfering with crizotinib binding (PMID: 25351743, 23724914, 25033171). This mutation corresponds to the G1202R ALK kinase domain mutant (PMID: 23724914, 27401242). Preclinical studies of ROS1 G2023R demonstrate sensitivity to combination treatment of TWIST1 siRNA and crizotinib as measured by reduced cellular viability and invasion (PMID: 29477381).",
            "description_review": {
              "updateTime": 1697210270551,
              "updatedBy": "User"
            },
            "description_uuid": "b33bf7e8-8e46-4fcd-b870-324d36c9ca51",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1491850504608
            },
            "effect_uuid": "aa803d57-5855-4e90-a480-c4362b3b482a",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1697479185404,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "86467f41-2065-463d-9db7-c86f7d5a94ed",
            "short": ""
          },
          "mutation_effect_uuid": "ca181695-f3fb-4def-c0d3-9cb5b1bb3276",
          "name": "G2032R",
          "name_comments": [
            {
              "content": "resistance only",
              "date": "1468423512546",
              "email": "user@gmail.com",
              "resolved": "true",
              "userName": "User"
            },
            {
              "content": "23724914",
              "date": "1468425715826",
              "email": "user@gmail.com",
              "resolved": "true",
              "userName": "User"
            }
          ],
          "name_uuid": "a3c4e638-0fcf-4def-8b68-dbda0af9636f"
        },
        {
          "mutation_effect": {
            "description": "The ROS1 L1951R mutation lies in the tyrosine kinase domain of the ROS1 protein. In vitro studies in a CD74-ROS1-transformed cell line demonstrated that L1951R confers resistance to crizotinib and ceritinib as measured by cell viability and pathway activation assays. This effect is likely due to steric hindrance (PMID: 25351743).",
            "description_uuid": "11750a81-60da-43b8-bc1c-07e2f85ea684",
            "effect": "Inconclusive",
            "effect_review": {
              "updateTime": 1491850504608
            },
            "effect_uuid": "2b2b259b-8e00-4bf4-ad6d-079ad7a9cc6d",
            "oncogenic": "Resistance",
            "oncogenic_review": {
              "updateTime": 1670608349056,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "a98d8d63-c524-4fec-8aba-6e79097123f5",
            "short": ""
          },
          "mutation_effect_uuid": "d6dfdf1c-7beb-4f8e-8a16-89dadaca63c2",
          "name": "L1951R",
          "name_comments": [
            {
              "content": "needs updating",
              "date": "1467159349713",
              "email": "user@gmail.com",
              "resolved": "true",
              "userName": "User"
            }
          ],
          "name_uuid": "04af4e2a-d3cd-49cf-870d-e91ef3f1cc1f"
        },
        {
          "mutation_effect": {
            "description": "The ROS1 D2033N mutation lies in the tyrosine kinase domain of the ROS1 protein. It has been detected in a patient with CD74-ROS1-fusion positive lung cancer with acquired resistance to crizotinib. In a murine B-cell line a D2033N-mutated CD74-ROS1 construct conferred reduced sensitivity to crizotinib while cabozantinib was equally effective as against the unmutated CD74-ROS, as measured in growth and downstream signaling assays. Experiments also supported the notion that D2033N confers resistance to ceritinib, brigatinib and lorlatinib. The analogous mutation in ALK (D1203N) confers crizotinib resistance in vitro and molecular studies indicate that mutations at these residues are important due to their being located at binding surface for ATP (PMID: 26673800).",
            "description_uuid": "a04b0540-166a-4eac-8f31-dd50e45a2275",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1491850504608
            },
            "effect_uuid": "26191541-33bd-46d7-834b-288cf0f9a380",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1491850504608
            },
            "oncogenic_uuid": "9bf7d605-86c1-4fe3-b1de-700e4079c29b",
            "short": ""
          },
          "mutation_effect_uuid": "14912fc7-d149-4bec-a656-1305a4fe56fa",
          "name": "D2033N",
          "name_comments": [
            {
              "content": "corresponds to the ALK kinase domain mutant D1203N",
              "date": "1468423619505",
              "email": "user@gmail.com",
              "resolved": "true",
              "userName": "User"
            },
            {
              "content": "27401242,  26673800",
              "date": "1468425148764",
              "email": "user@gmail.com",
              "resolved": "true",
              "userName": "User"
            },
            {
              "content": "for ROS1 missense mutations, state what domain they reside in",
              "date": "1477081489709",
              "email": "user@gmail.com",
              "resolved": "true",
              "userName": "User"
            }
          ],
          "name_uuid": "aac28c9d-785d-450c-936b-48e002462646"
        },
        {
          "mutation_effect": {
            "description": "The ROS1 C2060G mutation lies in the tyrosine kinase domain of the ROS1 protein. In a murine B-cell line a C2060G-mutated FIG-ROS1 construct conferred increased resistance to crizotinib, as compared to the unmutated construct in cell-growth assays. The mutated construct showed slightly reduced sensitivity to the inhibitor foretinib (PMID: 24218589).",
            "description_uuid": "d15f94ce-074f-452f-b036-8d718b9147f5",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1491850504608
            },
            "effect_uuid": "ba413320-b38d-4bed-9dce-2cfd6c64f434",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1491850504608
            },
            "oncogenic_uuid": "5cc8c16c-c571-48dc-9448-0cb47a29623d",
            "short": ""
          },
          "mutation_effect_uuid": "4eb2cba4-0fa8-4dcf-b0e3-ff7de4ff90c2",
          "name": "C2060G",
          "name_comments": [
            {
              "content": "resistance in a fusion",
              "date": "1473873055420",
              "email": "user@gmail.com",
              "resolved": "true",
              "userName": "User"
            }
          ],
          "name_uuid": "7d4a36f6-2291-4558-b8b9-5dbf94f7f4bd"
        },
        {
          "mutation_effect": {
            "description": "The ROS1 E1935G mutation occurs in an uncharacterized region ten amino acid residues prior to the tyrosine kinase domain of the ROS1 protein. In a murine B-cell line a E1935G-mutated FIG-ROS1 construct conferred increased resistance to crizotinib, as compared to the unmutated construct in cell-growth assays. The mutated construct showed slightly reduced sensitivity to the inhibitor foretinib (PMID: 24218589).",
            "description_uuid": "8487be8d-726f-4736-a778-8ad09b23fea5",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1491850504608
            },
            "effect_uuid": "55739fa0-b5b6-4f08-a975-e1769dfdf13e",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1491850504608
            },
            "oncogenic_uuid": "990fad2a-aa8d-4650-9455-430979acdb9f",
            "short": ""
          },
          "mutation_effect_uuid": "30c3b45d-70be-4e7c-bf4a-10cc0d83090c",
          "name": "E1935G",
          "name_comments": [
            {
              "content": "resistance in a fusion",
              "date": "1473873059076",
              "email": "user@gmail.com",
              "resolved": "true",
              "userName": "User"
            },
            {
              "content": "for ROS1 missense mutations, state what domain they reside in",
              "date": "1477081504942",
              "email": "user@gmail.com",
              "resolved": "true",
              "userName": "User"
            }
          ],
          "name_uuid": "e5f49c81-0f73-4537-97a9-a4d5ea201607"
        },
        {
          "mutation_effect": {
            "description": "The ROS1 G1971E mutation lies in the tyrosine kinase domain of the ROS1 protein. In a murine B-cell line a G1971E-mutated FIG-ROS1 construct conferred increased resistance to crizotinib, as compared to the unmutated construct in cell-growth assays. The mutated construct showed slightly reduced sensitivity to the inhibitor foretinib (PMID: 24218589).",
            "description_uuid": "f9182b8f-dea3-4745-a990-1a3d75ab83b7",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1491850504608
            },
            "effect_uuid": "9ab26a40-7f6f-4ffd-b850-74576f925345",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1491850504608
            },
            "oncogenic_uuid": "21bd828d-75e5-480e-ba46-f9c44f74205d",
            "short": ""
          },
          "mutation_effect_uuid": "edb27af8-c16c-4555-9b58-eaef97db09b9",
          "name": "G1971E",
          "name_comments": [
            {
              "content": "resistance in a fusion",
              "date": "1473873062833",
              "email": "user@gmail.com",
              "resolved": "true",
              "userName": "User"
            },
            {
              "content": "for ROS1 missense mutations, state what domain they reside in",
              "date": "1477081542038",
              "email": "user@gmail.com",
              "resolved": "true",
              "userName": "User"
            }
          ],
          "name_uuid": "82cf08e5-97af-42a0-9dc9-20e953b4fa3c"
        },
        {
          "mutation_effect": {
            "description": "The ROS1 L1947R mutation occurs in the protein's kinase domain and is often identified in the context of a ROS1 fusion protein. FIG-ROS1 Ba/F3 cells expressing the L1947R mutation demonstrated increased resistance to crizotinib compared to control FIG-ROS1 Ba/F3 cells, as measured by sustained cell growth and protein activation upon drug treatment (PMID: 24218589).",
            "description_uuid": "7a760a46-4194-4af7-a13d-4a7e6bbaa037",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1491850504608
            },
            "effect_uuid": "93af185b-5b37-4c69-b631-b40c9168468d",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1491850504608
            },
            "oncogenic_uuid": "912e61e9-f663-4532-adf8-3fce18e85ac9",
            "short": ""
          },
          "mutation_effect_uuid": "ae7dcecf-be11-4171-8403-8e076575342f",
          "name": "L1947R",
          "name_comments": [
            {
              "content": "resistance in a fusion",
              "date": "1473873067108",
              "email": "user@gmail.com",
              "resolved": "true",
              "userName": "User"
            }
          ],
          "name_uuid": "218e979f-6f2f-4a00-a576-1fcdac006845"
        },
        {
          "mutation_effect": {
            "description": "The ROS1 V2098I mutation occurs in the tyrosine kinase domain of the ROS1 protein at a site implicated in inhibitor binding. In a murine B-cell line a V2098I -mutated FIG-ROS1 construct conferred increased resistance to crizotinib, as compared to the unmutated construct in cell-growth assays. The mutated construct showed slightly reduced sensitivity to the inhibitor foretinib (PMID: 24218589).",
            "description_uuid": "f84500ab-cd13-49c8-a26c-611f71413524",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1491850504608
            },
            "effect_uuid": "89a9587b-402b-409d-8c46-f4c7c83d883e",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1491850504608
            },
            "oncogenic_uuid": "890afecb-328f-42fe-9f35-0ded40d95c9e",
            "short": ""
          },
          "mutation_effect_uuid": "a363bf6b-e0c9-412e-b274-c16aa6cf5c79",
          "name": "V2098I",
          "name_comments": [
            {
              "content": "resistance in a fusion",
              "date": "1473873070528",
              "email": "user@gmail.com",
              "resolved": "true",
              "userName": "User"
            },
            {
              "content": "for ROS1 missense mutations, state what domain they reside in",
              "date": "1477081557443",
              "email": "user@gmail.com",
              "resolved": "true",
              "userName": "User"
            }
          ],
          "name_uuid": "be275641-f903-4636-be01-a60879317601"
        },
        {
          "mutation_effect": {
            "description": "The ROS1 G2101A mutation lies in the tyrosine kinase domain of the ROS1 protein. In a murine B-cell line a G2101A-mutated CD74-ROS1 construct conferred increased resistance to crizotinib, as compared to the unmutated construct in cell-growth assays. The mutated construct showed slightly reduced sensitivity to the inhibitor foretinib. The variants is analogous to the previously described ALK G1269A resistance mutation (PMID: 25688157, 24675041, 22235099).",
            "description_uuid": "cfc98830-84f9-449a-a636-2aecb6dee2ee",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1491850504608
            },
            "effect_uuid": "a05a2f36-dfef-4578-a479-e291ed0355a7",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1491850504608
            },
            "oncogenic_uuid": "278e7a1f-c695-4df6-ad75-869b8462aec0",
            "short": ""
          },
          "mutation_effect_uuid": "3767521c-c79a-4ae0-bc00-e9309400ab60",
          "name": "G2101A",
          "name_comments": [
            {
              "content": "needs curation",
              "date": "1474059091934",
              "email": "user@gmail.com",
              "resolved": "true",
              "userName": "User"
            },
            {
              "content": "Please mention in description that these are found in the context of a fusion and to be consistent with how we label things, mark as likely GOF and likely Onc.",
              "date": "1474059371161",
              "email": "user@gmail.com",
              "resolved": "true",
              "userName": "User"
            }
          ],
          "name_uuid": "abeffdb0-f0d6-4dce-84bc-9c2718140b0f"
        },
        {
          "mutation_effect": {
            "description": "The ROS1 S1986Y mutation lies in tyrosine kinase domain the of the ROS1 protein. It has been detected in a patient with ROS1-fusion positive lung cancer in concert with mutation S1986F. The two alterations at the same residue were associated with resistance to crizotinib but subsequent sensitivity to lorlatinib. In a murine B-cell line expression of individual S1986F- and S1986Y-mutated ROS1-fusion constructs were resistant to crizotinib and ceritinib but not lorlatinib, as assessed by cell viability and pathway activation assays (PMID: 27401242).",
            "description_uuid": "c50e5422-7b6d-496e-ad0b-093577885390",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1491850504608
            },
            "effect_uuid": "2e14998d-6a5e-4d9d-982d-90d7d47e51d8",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1491850504608
            },
            "oncogenic_uuid": "385c8437-b18a-4819-beab-20ae3cb25ae6",
            "short": ""
          },
          "mutation_effect_uuid": "8640888d-930b-4397-ae33-bd4882eba98a",
          "name": "S1986Y",
          "name_uuid": "4a1e7990-ff42-4e1b-b400-2c623b154f92"
        },
        {
          "mutation_effect": {
            "description": "The ROS1 S1986F mutation lies in the tyrosine kinase domain of the ROS1 protein. It has been detected in a patient with ROS1-fusion-positive lung cancer in concert with the S1986Y mutation. The two alterations at the same residue were associated with resistance to crizotinib but subsequent sensitivity to lorlatinib. In a murine B-cell line expression of individual S1986F- and S1986Y-mutated ROS1-fusion constructs were resistant to crizotinib and ceritinib but not lorlatinib, as assessed by cell viability and pathway activation assays (PMID: 27401242).",
            "description_review": {
              "updateTime": 1670452290049,
              "updatedBy": "User"
            },
            "description_uuid": "5497270d-5f33-4492-9c4f-935c77dea441",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1491850504608
            },
            "effect_uuid": "19acaaee-d519-4577-9b10-2ea228c116b3",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1491850504608
            },
            "oncogenic_uuid": "bcd08c5b-9fe6-46e6-aace-af80088b9703",
            "short": ""
          },
          "mutation_effect_uuid": "6c2ad9e8-37c5-4d56-8fb2-caa5b803e9b6",
          "name": "S1986F",
          "name_uuid": "119f7457-4d85-415c-aa71-c3a8f8431ccf"
        },
        {
          "mutation_effect": {
            "description": "Amplification of ROS1 has been shown to result in an increase in ROS1 transcript and ROS1 protein levels in cancer cell lines that is sensitive to ROS1 inhibition demonstrating that ROS1 amplification is likely activating (PMID: 25978031). Studies in cancer cell lines have demonstrated that ROS1 amplification can lead to resistance to EGFR inhibitors in cells that are otherwise sensitive to EGFR inhibition (PMID: (PMID: 25978031).",
            "description_uuid": "0ff5794d-9e81-47ce-be8b-92b57ce75e4e",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1491850504608
            },
            "effect_uuid": "58511c90-26db-438e-b897-0bdea61f61af",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1491850504608
            },
            "oncogenic_uuid": "1d70db26-7ecb-4039-c0dc-4c97bd823c89",
            "short": ""
          },
          "mutation_effect_uuid": "82196c56-2893-43e3-9539-a812e3e33972",
          "name": "Amplification",
          "name_uuid": "f958d3ca-bcf2-4572-8dda-b2b813fc0c68"
        },
        {
          "mutation_effect": {
            "description": "The GOPC-ROS1 fusion protein combines the N terminus of GOPC until exon 7 with the C-terminus of ROS1 starting at exon 35 and is found in CNS tumors (PMID: 30171048). This is the most frequent ROS1 fusion found in glioblastomas (GBMs). Expression of this fusion protein in BaF3 and immortalized human astrocyte cells demonstrated that it is activating as shown by IL3 independent growth and increased colony formation compared to ectopic expression of wildtype ROS1 (PMID: 30171048). Expression of this fusion in BaF3 cells also demonstrated that it is sensitive to multiple TKIs including crizotinib, foretinib, cabozantinib, ceritinib, brigatinib, AZD3463, lorlatinib, and entrectinib as measured by proliferation, pathway activation and colony formation with lorlatinib having the highest potency (PMID: 30171048). In a case report, a patient with ER-positive HER2-negative breast cancer harboring GOPC-ROS1 demonstrated an exceptionally response to crizotinib therapy and a subsequent modest response to cabozantinib after development of crizotinib resistance (PMID: 37487149).",
            "description_review": {
              "updateTime": 1701800193168,
              "updatedBy": "User"
            },
            "description_uuid": "ed1b93b1-8637-4acf-b21b-6bc96e0c7712",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1555912391737,
              "updatedBy": "User"
            },
            "effect_uuid": "a95bd9a0-ce83-4a4b-8782-c9cdff1175b1",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1555912390800,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "f34c6773-0f41-42b0-866d-8a7c3b3b694b",
            "short": ""
          },
          "mutation_effect_uuid": "a79c96e9-973d-4c26-98b7-47aed55b3b5e",
          "name": "GOPC-ROS1 Fusion",
          "name_review": {
            "updateTime": 1555912252820,
            "updatedBy": "User"
          },
          "name_uuid": "98d2063a-472d-417b-8e78-194b94effd8e",
          "tumors_uuid": "b8180b56-79a4-4ff4-880c-0a6e8ce8bc0f"
        },
        {
          "mutation_effect": {
            "description": "The ROS1 F2004V mutation is located in the kinase domain of the protein. This mutation was found as a secondary mutation in a patient with lung adenocarcinoma who had progressive disease in the brain and bones after treatment with crizotinib, entrectinib and brigatinib but who had a dramatic response to treatment with lorlatinib (Abstract: Dimou et al. JCO PO, 2019. https://ascopubs.org/doi/full/10.1200/PO.19.00013). This mutation may confer resistance to entrectinib and brigatinib but remains sensitive to lorlatinib. Structural studies based on homology to ALK predict that ROS1 F2004V would confer resistance to ceritinib (PMID: 27401242).",
            "description_review": {
              "updateTime": 1610601705408,
              "updatedBy": "User"
            },
            "description_uuid": "5f288894-9be0-40e2-a467-43b6080ffbe4",
            "effect": "Inconclusive",
            "effect_review": {
              "updateTime": 1570066786795,
              "updatedBy": "User"
            },
            "effect_uuid": "c74bbb3d-42fc-42f1-b262-d02131bf4837",
            "oncogenic": "Inconclusive",
            "oncogenic_review": {
              "updateTime": 1570066787661,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "21c81568-8f05-4de9-bed2-749a8b6bf283",
            "short": ""
          },
          "mutation_effect_uuid": "f25a4f24-e31f-439a-8122-1fda28e3db41",
          "name": "F2004V",
          "name_review": {
            "updateTime": 1570066579150,
            "updatedBy": "User"
          },
          "name_uuid": "5aeb52cc-4bd0-43d9-9b4f-fd359bc6c6a6",
          "tumors_uuid": "8b1c5c6f-eb11-4ff2-bca4-2d24e4920463"
        },
        {
          "mutation_effect": {
            "description": "The ROS1 F2004C mutation is located in the kinase domain of the protein. This mutation has been found in lung cancer (Abstract: Doebele et al. Abstract# LBA-28, ESMO 2019. https://www.sciencedirect.com/science/article/pii/S0923753419603777). Expression of this mutation in the context of a ROS1 fusion in Ba/F3 cells demonstrated decreased sensitivity to ROS1 inhibition (PMID: 26372962). Structural studies based on homology to ALK predict that ROS1 F2004C would confer resistance to ceritinib (PMID: 27401242). At least one patient with ROS1-fusion-positive non-small cell lung cancer acquired the ROS1 F2004C mutation upon disease progression on treatment with entrectinib (Abstract: Doebele et al. Abstract# LBA-28, ESMO 2019. https://www.sciencedirect.com/science/article/pii/S0923753419603777).",
            "description_review": {
              "updateTime": 1612327506254,
              "updatedBy": "User"
            },
            "description_uuid": "2eba78ed-6307-4690-b813-f6ab7e2bc61a",
            "effect": "Inconclusive",
            "effect_review": {
              "updateTime": 1610603842754,
              "updatedBy": "User"
            },
            "effect_uuid": "e558dfec-5cdb-431e-8f7a-9a3d30be0f41",
            "oncogenic": "Inconclusive",
            "oncogenic_review": {
              "updateTime": 1610603843301,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "fbc05162-1285-449a-a3b7-54a791068d3f",
            "short": ""
          },
          "mutation_effect_uuid": "1e8ea021-fc48-417c-aadb-997cfe4d7142",
          "name": "F2004C",
          "name_review": {
            "updateTime": 1610601652016,
            "updatedBy": "User"
          },
          "name_uuid": "fc7b0749-6563-49d1-b7d3-ecdd2982af57",
          "tumors_uuid": "f2720d24-0419-4120-97b1-378bca680662"
        }
      ],
      "name": "ROS1",
      "name_comments": [
        {
          "content": "We need to curate: 27401242",
          "date": "1468424000766",
          "email": "user@gmail.com",
          "resolved": "true",
          "userName": "User"
        },
        {
          "content": "Done.",
          "date": "1478961473947",
          "email": "user@gmail.com",
          "resolved": "false",
          "userName": "User"
        }
      ],
      "summary": "ROS1, a receptor tyrosine kinase, is altered by mutation or chromosomal rearrangement in a diverse range of cancers, including lung cancer.",
      "summary_comments": [
        {
          "content": "ROS1 encodes a receptor tyrosine kinase that is involved in cell mitogenesis. Chromosomal rearrangements of ROS1 are found in non-small cell lung and ovarian cancers, among others.",
          "date": "1464797810389",
          "email": "user@gmail.com",
          "resolved": "true",
          "userName": "User"
        }
      ],
      "summary_review": {
        "updateTime": 1491850504608
      },
      "summary_uuid": "865dbc19-355b-4142-b48c-6baa4018aae2",
      "type": {
        "ocg": "Oncogene",
        "ocg_uuid": "c9d225a1-4933-4003-95f5-62fc4fb034cf",
        "tsg": "",
        "tsg_uuid": "45784bf7-4db1-4ceb-a27c-cb0173261d94"
      },
      "type_uuid": "db8d5516-f60a-4358-a271-a5edc25f05f9"
    },
    "TP53": {
      "background": "TP53 encodes the p53 tumor suppressor protein, a transcription factor that responds to cellular stresses, including DNA damage and oncogenic activation, by inducing downstream anti-tumor responses such as DNA repair and apoptosis (PMID: 11099028). TP53 is the most commonly mutated gene in human cancers, and germline mutations occur in the cancer predisposition syndrome Li-Fraumeni (PMID: 22713868, 21765642). The p53 protein consists of an N-terminal transactivation domain, a central DNA-binding domain, an oligomerization domain and a C-terminal regulatory domain (PMID: 22713868).",
      "background_comments": [
        {
          "content": "Needs editing",
          "date": "1453303761321",
          "email": "user@gmail.com",
          "resolved": "false",
          "userName": "User"
        }
      ],
      "background_review": {
        "updateTime": 1492724745580
      },
      "background_uuid": "24a179db-26d2-45e2-80b9-71b1eb49a491",
      "dmp_refseq_id": "NM_000546.5",
      "dmp_refseq_id_grch38": "NM_000546.5",
      "isoform_override": "ENST00000269305",
      "isoform_override_grch38": "ENST00000269305",
      "mutations": [
        {
          "mutation_effect": {
            "description": "The TP53 P322R mutation is located in the oligomerization domain of the protein. In vitro studies have demonstrated that this mutation is likely neutral, as evidenced by its ability to oligomerize and transactivate downstream targets comparable to wildtype TP53 (PMID: 16007150).",
            "description_review": {
              "updateTime": 1661128060600,
              "updatedBy": "User"
            },
            "description_uuid": "7daac7a9-d6d5-4473-9bd1-d83870b34cf4",
            "effect": "Likely Neutral",
            "effect_review": {
              "updateTime": 1544636505315,
              "updatedBy": "User"
            },
            "effect_uuid": "682b6f29-3299-48fb-9d56-4449fb6aab66",
            "oncogenic": "Likely Neutral",
            "oncogenic_review": {
              "updateTime": 1544636504329,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "dd554ea2-478a-4ff5-c094-c2c74fa2032a",
            "short": ""
          },
          "mutation_effect_uuid": "6ee1a0e8-d01d-42bc-9919-6a31cb68822b",
          "name": "P322R",
          "name_review": {
            "updateTime": 1544636500573,
            "updatedBy": "User"
          },
          "name_uuid": "55268c34-2b22-4617-b806-2c2e28646722",
          "tumors_uuid": "c6c45703-a815-4b44-8875-b1823777955b"
        },
        {
          "mutation_effect": {
            "description": "The TP53 H214R mutation is located in the protein's DNA binding domain and is a known hotspot mutation (PMID: 26619011). This mutation has been found in breast cancers, among others (PMID: 20407015). In vivo studies with yeast expressing TP53 H214R demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). Other in vivo studies with yeast expressing TP53 H214R demonstrate that the mutation is also inactivating as measured by partial loss of transactivational function compared to wildtype (PMID: 11920959). In vitro studies with various human cancer cell lines expressing TP53 H214R also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644). In contrast, in vitro studies have demonstrated that this mutation is likely activating, as evidenced by increased TP53 transactivation activity compared to wildtype (PMID: 20407015).",
            "description_review": {
              "updateTime": 1683660767332,
              "updatedBy": "User"
            },
            "description_uuid": "ee71aed6-108a-43f1-ad6b-924f6b342b0e",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1683660898574,
              "updatedBy": "User"
            },
            "effect_uuid": "1d39ff8b-94cf-4c03-8a82-61886e2b9046",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1683660896815,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "cdcc69c1-9be4-4f56-a7d0-5e2c392561c9",
            "short": ""
          },
          "mutation_effect_uuid": "881b38f3-ebe2-4320-8982-cb1c0792169e",
          "name": "H214R",
          "name_comments": [
            {
              "content": "Hi Lindsay, when these are complete, just unclick the red hands - this will allow them to show up in the portal and website.",
              "date": "1477580148161",
              "email": "user@gmail.com",
              "resolved": "true",
              "userName": "User"
            },
            {
              "content": "also, make sure to remove the PMID form the top box (otherwise that is all that will show up as the description on the portal once the red hand is unclicked",
              "date": "1477580177674",
              "email": "user@gmail.com",
              "resolved": "true",
              "userName": "User"
            },
            {
              "content": "HOTSPOT!",
              "date": "1486070757551",
              "email": "user@gmail.com",
              "resolved": "false",
              "userName": "User"
            }
          ],
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "22b414db-02d1-496d-87d2-f4f9c4dcbd07"
        },
        {
          "mutation_effect": {
            "description": "The TP53 R175H mutation is located in the protein's DNA binding domain. This mutation has been found in acute myeloid leukemia (PMID: 31068365). In vitro and in vivo studies have demonstrated that this mutation is inactivating and oncogenic, as measured by the reduced ability to induce apoptosis and form colonies, as well as increased cell migration and faster progression of hematopoietic malignancy of the mutant compared to TP53 wildtype or deletion (PMID: 15781620, 25584008, 31068365). Structural studies have also shown that this mutant is defective in protein folding and DNA binding (PMID: 10713666, 21445056).",
            "description_review": {
              "updateTime": 1660096799016,
              "updatedBy": "User"
            },
            "description_uuid": "bf22c562-3225-4f80-9896-a307eb6d4bb5",
            "effect": "Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "41c4e951-4d83-4e4a-9843-3f64039400ea",
            "oncogenic": "Yes",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "10e5d16d-6ee4-4985-a46b-366b821f1ae8",
            "short": ""
          },
          "mutation_effect_uuid": "83eb8692-d466-40a5-8212-f09aade996b7",
          "name": "R175H",
          "name_comments": [
            {
              "content": "(PMID: 10713666, PMID: 22114072).",
              "date": "1477868145905",
              "email": "user@gmail.com",
              "resolved": "true",
              "userName": "User"
            }
          ],
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "294d4960-771c-4898-9cfb-e10230b479cd"
        },
        {
          "mutation_effect": {
            "description": "The TP53 S121F mutation is located in the protein's DNA binding domain. This mutation has been found in lymphoma (PMID: 22955915). In vitro studies have demonstrated that this mutation is likely activating, as evidenced by enhanced transcriptional activity, increased apoptosis and inhibition of cell cycle progression in the mutant compared to wildtype (PMID: 15781620).",
            "description_review": {
              "updateTime": 1661365279352,
              "updatedBy": "User"
            },
            "description_uuid": "e4018f41-ee7c-4906-a902-8107ab83ccf1",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "1a110d13-bfb1-4080-b89e-e1da6d04bb87",
            "oncogenic": "Likely Neutral",
            "oncogenic_review": {
              "updateTime": 1676481697874,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "afc0e256-7933-4e36-9933-50e32b8a77d5",
            "short": ""
          },
          "mutation_effect_uuid": "d3f86f11-45c2-44db-8802-9f42e33f2924",
          "name": "S121F",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "8af23907-6261-4cc2-8491-31c5f0b549b4"
        },
        {
          "mutation_effect": {
            "description": "The TP53 H214Q mutation is located in the protein's DNA binding domain and is a known hotspot mutation (PMID: 26619011). This mutation has been found in colorectal carcinoma (PMID: 11044641). In vitro studies have demonstrated that this mutation has a neutral effect, as evidenced by mutant TP53 activity similar to that of the wildtype protein, with similar transcriptional activity, increased apoptosis and inhibition of cell cycle progression (PMID: 15781620).",
            "description_review": {
              "updateTime": 1661365323614,
              "updatedBy": "User"
            },
            "description_uuid": "5145288e-52ad-4be8-bb1c-4b67becd897a",
            "effect": "Likely Neutral",
            "effect_review": {
              "updateTime": 1676479303563,
              "updatedBy": "User"
            },
            "effect_uuid": "204f9e50-8e83-45a7-a3ba-64c847535564",
            "oncogenic": "Likely Neutral",
            "oncogenic_review": {
              "updateTime": 1676479301240,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "e5eb8bf2-4c0f-4432-b6f9-f9efc1020164",
            "short": ""
          },
          "mutation_effect_uuid": "0fc80605-68b0-40a5-901f-d8c4e294d60b",
          "name": "H214Q",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "2f13e3a3-4483-4b6a-b28e-09f55d642266"
        },
        {
          "mutation_effect": {
            "description": "The TP53 K291E mutation is located in the protein's DNA binding domain and is a known hotspot mutation (PMID: 26619011). This mutation has been found in non-small cell lung cancer (PMID: 9416838). In vitro studies have demonstrated that this mutation is likely activating, as evidenced by significantly increased apoptosis, decreased cell viability and altered transcription of TP53 target genes in the mutant compared to wildtype (PMID: 15781620).",
            "description_review": {
              "updateTime": 1664464219343,
              "updatedBy": "User"
            },
            "description_uuid": "18441829-06e9-4829-b17c-8d26e278b97c",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1664464245199,
              "updatedBy": "User"
            },
            "effect_uuid": "5fc85227-bb09-490f-8adc-cbc68fa48ac1",
            "oncogenic": "Likely Neutral",
            "oncogenic_review": {
              "updateTime": 1664464504662,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "3a9cc731-75b8-4639-84d7-853aa820d2a1",
            "short": ""
          },
          "mutation_effect_uuid": "70cbda40-2364-4647-ab5b-3fb6b5d2b2f4",
          "name": "K291E",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "efaca20c-ddf2-48bf-a96a-768ce9d39d45"
        },
        {
          "mutation_effect": {
            "description": "The DNA-binding domain (DBD) of TP53 allows for contact with target DNA sequences to transactivate downstream genes. Mutations in the DBD result in conformational changes of the protein, altering contact of TP53 with its target DNA sequences and thereby altering transcriptional function (PMID: 8023157, 11900253). Given that TP53 directs the transcription of proteins that enable apoptosis, the inactivation of TP53 results in cells harboring damaged DNA and overall genomic instability (PMID: 11900253, 11900253).",
            "description_review": {
              "updateTime": 1679672162366,
              "updatedBy": "User"
            },
            "description_uuid": "1a91b692-8e95-451e-bad6-244dabd60527",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1532444062910,
              "updatedBy": "User"
            },
            "effect_uuid": "cc529222-70ea-4b5d-ab89-94e50cc9b1aa",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1532444051945,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "422a514a-a04f-49b0-adce-36facb40084d",
            "short": "There is preliminary laboratory evidence that missense mutations in the DBD can have an ‘activating’ oncogenic effect on p53 protein function, contrary to the wildtype protein’s normal function as a tumor suppressor, but this is highly dependent upon tissue context (PMID: 24651012).",
            "short_editing": ""
          },
          "mutation_effect_uuid": "b5cf9d48-f331-408c-adba-8f402c0b6db3",
          "name": "V218dup, 102_292mis [DNA binding domain missense mutations], 102_292ins [DNA binding domain insertions], 102_292del [DNA binding domain deletions]",
          "name_review": {
            "updateTime": 1646169833800,
            "updatedBy": "User"
          },
          "name_uuid": "cff5aee4-6b10-4202-93f4-53007971709e"
        },
        {
          "mutation_effect": {
            "description": "The TP53 K292T mutation is located in the protein's DNA binding domain. In vitro studies have demonstrated that this mutation is likely activating, as evidenced by significantly increased apoptosis, decreased cell viability and altered transcription of TP53 target genes in the mutant compared to wildtype (PMID: 15781620).",
            "description_review": {
              "updateTime": 1664812773920,
              "updatedBy": "User"
            },
            "description_uuid": "902c51a5-91ba-46fe-83b8-b5cbebd6b3a6",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1664812766474,
              "updatedBy": "User"
            },
            "effect_uuid": "8698b568-758c-4318-8054-28515ca884c8",
            "oncogenic": "Likely Neutral",
            "oncogenic_review": {
              "updateTime": 1664812763206,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "d1b01d13-6e1d-4aee-a800-d70b602d3247",
            "short": ""
          },
          "mutation_effect_uuid": "50569830-4378-489b-a72e-8c6882f249bf",
          "name": "K292T",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "f260376d-f89e-438e-9d0a-02f9908ce5fc"
        },
        {
          "mutation_effect": {
            "description": "The TP53 Q144R mutation is located in the protein's DNA binding domain and is a known hotspot mutation (PMID: 26619011). However, in vitro studies have demonstrated that this mutation is likely activating, as evidenced by significantly increased apoptosis, decreased cell viability and altered transcription of TP53 target genes in the mutant compared to wildtype (PMID: 15781620).",
            "description_review": {
              "updateTime": 1664812946542,
              "updatedBy": "User"
            },
            "description_uuid": "3e5a65b2-3268-4d3d-8101-00ba1f2218f4",
            "effect": "Inconclusive",
            "effect_review": {
              "updateTime": 1664812954393,
              "updatedBy": "User"
            },
            "effect_uuid": "e113fd62-9072-4307-9b2c-3f42dac5e306",
            "oncogenic": "Inconclusive",
            "oncogenic_review": {
              "updateTime": 1664812953021,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "96f664ad-8758-4b98-9a1e-7648ce877649",
            "short": ""
          },
          "mutation_effect_uuid": "5069369c-74ed-46ef-8c74-4a47ffc7c9a0",
          "name": "Q144R",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "4260aa7e-6a01-41dc-996b-d125dabe4efe"
        },
        {
          "mutation_effect": {
            "description": "The TP53 I162M mutation is located in the protein's DNA binding domain. This mutation has been found in lymphoma (PMID: 27101868). In vitro studies have demonstrated that this mutation has inconclusive effect, as evidenced by altered transcription of TP53 target genes as well as an insignificant increased apoptosis and cell cycle arrest in the mutant compared to wildtype TP53 (PMID: 15781620).",
            "description_review": {
              "updateTime": 1661136625804,
              "updatedBy": "User"
            },
            "description_uuid": "7f42fd78-f793-478e-bc71-bb0b651f7cdf",
            "effect": "Inconclusive",
            "effect_review": {
              "updateTime": 1661136519006,
              "updatedBy": "User"
            },
            "effect_uuid": "a84c15a9-c0ef-4a97-a7bd-a737fecb67c4",
            "oncogenic": "Inconclusive",
            "oncogenic_review": {
              "updateTime": 1661136517395,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "3a8903db-dc5d-47e8-8962-98d13cdf24e8",
            "short": ""
          },
          "mutation_effect_uuid": "793dcc5d-0f2e-48f8-aefd-3d5703d11e9e",
          "name": "I162M",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "8688e4f9-7e31-46c1-a6c1-4fb7d19e8153"
        },
        {
          "mutation_effect": {
            "description": "The TP53 R290G mutation is located in the protein's DNA binding domain (PMID: 26619011). In vitro studies have demonstrated that this mutation is likely activating, as evidenced by significantly increased apoptosis, decreased cell viability and altered transcription of TP53 target genes in the mutant compared to wildtype (PMID: 15781620).",
            "description_review": {
              "updateTime": 1664821689579,
              "updatedBy": "User"
            },
            "description_uuid": "c989e70d-da2a-44ed-9e4b-9120a6ce9186",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1664464263304,
              "updatedBy": "User"
            },
            "effect_uuid": "7e7a3ae5-6c0c-45a4-85c9-d3bc9042a818",
            "oncogenic": "Likely Neutral",
            "oncogenic_review": {
              "updateTime": 1664464496573,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "48f340e6-0711-4a50-996a-f0c8d403b9c4",
            "short": ""
          },
          "mutation_effect_uuid": "dcf09c4a-6a25-49de-8c2b-397e553df194",
          "name": "R290G",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "af48dea5-3774-47dd-a683-246f1b113107"
        },
        {
          "mutation_effect": {
            "description": "The TP53 L344P mutation is located in the protein's oligomerization domain. This mutation has been found in Li-Fraumeni syndromes (PMID: 9704930). In vitro and structural studies have demonstrated that this mutation is inactivating, as evidenced by the mutant's inability to oligomerize and form TP53 tetramers, leading to decreased transactivation of TP53 target genes, decreased TP53 acetylation and decreased recruitment of p300 in the mutant compared to wildtype (PMID: 19454241, 19106109, 20978130).",
            "description_review": {
              "updateTime": 1663204612145,
              "updatedBy": "User"
            },
            "description_uuid": "b8b8b3ab-f468-44ac-93ec-36be72ac57c5",
            "effect": "Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "b4f92878-cffd-4450-bfd4-7a584ef43fbc",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "8fb3a0c0-971c-445b-ab06-23c6d7b58f14",
            "short": ""
          },
          "mutation_effect_uuid": "7f217cc3-e005-4926-a809-e6b1a75735d8",
          "name": "L344P",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "6e555a7e-f2b7-4e50-a7b6-19ef272dd527"
        },
        {
          "mutation_effect": {
            "description": "The TP53 R337C mutation is located in the protein's oligomerization domain (PMID: 17311302). In vitro and structural studies have demonstrated that this mutation is inactivating, as evidenced by the mutant's ability to inhibit transcriptional activity by destabilizing the p53 tetramer, as well as its inability to oligomerize, leading to decreased transactivation of TP53 target genes, decreased TP53 acetylation and decreased recruitment of p300 in the mutant compared to wildtype (PMID: 19454241, 11753428, 16007150, 19106109).",
            "description_review": {
              "updateTime": 1663208039863,
              "updatedBy": "User"
            },
            "description_uuid": "b346e1b9-9cf1-49c2-892f-8ec52d16d37a",
            "effect": "Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "65c2d4a3-1211-4f05-9543-d8c5173e0996",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "c6d759ed-e514-4b33-9b60-28fd926b6ab1",
            "short": ""
          },
          "mutation_effect_uuid": "b8a02ca4-14a4-49b2-84fa-5100e64cba37",
          "name": "R337C",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "804d3253-c152-44d0-98ae-428b7658e3db"
        },
        {
          "mutation_effect": {
            "description": "The TP53 L330H mutation is located in the protein's oligomerization domain. In vitro and structural studies have demonstrated that this mutation is likely inactivating, as evidenced by decreased transcriptional activity, decreased protein stability and decreased p53 tetramer formation in the mutant compared to wildtype (PMID: 19454241, 20978130).",
            "description_review": {
              "updateTime": 1663205880065,
              "updatedBy": "User"
            },
            "description_uuid": "6de59b32-e63e-4660-8d26-91d7ed72c345",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "a0a3bd7b-79bd-4176-a99c-c5ea8aebdbcc",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "48b1d3a6-c7c3-45b5-a3b9-a7c1dc912f34",
            "short": ""
          },
          "mutation_effect_uuid": "0ac58296-fde8-42c0-b57b-12a8c4dc5b72",
          "name": "L330H",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "cec63456-90ee-4e96-bfc6-2be4e3b01268"
        },
        {
          "mutation_effect": {
            "description": "The TP53 L330P mutation is located in the protein's oligomerization domain. Structural studies have demonstrated that this mutation is likely inactivating, as evidenced by the mutant's inability to form p53 tetramers, which is required for TP53 DNA binding activity (PMID: 20978130).",
            "description_review": {
              "updateTime": 1663207444377,
              "updatedBy": "User"
            },
            "description_uuid": "c441008c-c2df-4851-92a4-95848bc3dd07",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "ea95c3b8-e97a-43c8-9dba-216a2853477f",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "78f23675-e3a1-4f6b-9d75-d413f954312a",
            "short": ""
          },
          "mutation_effect_uuid": "62873944-ead3-442e-aa46-0018e31a9507",
          "name": "L330P",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "37738f32-0a86-4177-8319-f16dc59a19aa"
        },
        {
          "mutation_effect": {
            "description": "The TP53 L330R mutation is located in the protein's tetramerization domain. In vitro and structural studies have demonstrated that this mutation is likely inactivating, as evidenced by the decreased transcriptional activity and protein stability in the mutant compared to wildtype, as well as by the mutant's inability to form p53 tetramers, which is required for TP53 DNA binding activity (PMID: 19454241, 20978130).",
            "description_review": {
              "updateTime": 1663208157209,
              "updatedBy": "User"
            },
            "description_uuid": "5da907b7-d75d-48e8-a3bd-3fbe06780e07",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "13f49980-7683-47d3-992e-27ce5f82dd57",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "5c990d0d-c6e1-4dc6-95f9-330aa3a1b01b",
            "short": ""
          },
          "mutation_effect_uuid": "2a026c98-ce32-404b-a024-0c9d75443ca2",
          "name": "L330R",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "5357cdef-e9c2-40ba-ab3d-3621de5a7dd0"
        },
        {
          "mutation_effect": {
            "description": "The TP53 R337P mutation is located in the protein's oligomerization domain. This mutation has been found in the germline of patients with Li-Fraumeni syndrome and adrenocortical carcinoma (PMID: 11481490). In vitro and structural studies have demonstrated that this mutation is likely inactivating, as evidenced by decreased transcriptional activity and protein stability in the mutant compared to wildtype, as well as the mutant's inability to form p53 tetramers, which is required for TP53 DNA binding activity (PMID: 19454241, 20978130).",
            "description_review": {
              "updateTime": 1663354368436,
              "updatedBy": "User"
            },
            "description_uuid": "5a53e5c0-d2b7-41e2-b582-64ba8e363ea8",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1491583480000,
              "updatedBy": "User"
            },
            "effect_uuid": "f87dbe53-d8b1-4367-95f4-6bb3dd657587",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1491583494000,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "cc8ff4ec-c683-47e6-8e65-2545188bf3bf",
            "short": "This mutation occurs within the oligomerization domain, a region rarely mutated in somatic tumors (PMID: 17311302). In structural studies, mutations at R337 were found to destabilize the p53 tetramer, inhibiting the protein’s transcriptional activity (PMID: 11753428, 16007150)."
          },
          "mutation_effect_uuid": "8b934c92-3af3-47fc-a8f6-820d5dcb8ed0",
          "name": "R337P",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "ef34652e-6e37-4dbb-b7dd-90090099dae1"
        },
        {
          "mutation_effect": {
            "description": "The TP53 R342P mutation is located in the protein's oligomerization domain. In vitro and structural studies have demonstrated that this mutation is likely inactivating, as evidenced by the decreased transcriptional activity and protein stability in the mutant compared to wildtype, as well as by the mutant's inability to form p53 tetramers, which is required for TP53 DNA binding activity (PMID: 19454241, 20978130).",
            "description_review": {
              "updateTime": 1663208208891,
              "updatedBy": "User"
            },
            "description_uuid": "d42c0cb7-feb9-4ba6-b093-47892d911b0b",
            "effect": "Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "124e09ba-4bf7-4853-98b6-b678eec9fbdc",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "9ce55e0f-9b63-4c75-9b13-11c230da8d2f",
            "short": ""
          },
          "mutation_effect_uuid": "d557146b-f9c9-49c4-aa2f-3d6129e44510",
          "name": "R342P",
          "name_comments": [
            {
              "content": "The R342P mutation of p53 is a missense mutation. It was shown that this mutation exhibits decrease in DNA binding abilities of p53 leading to a reduction in transcriptional activation (PMID: 20978130).",
              "date": "1476385067133",
              "email": "user@gmail.com",
              "resolved": "true",
              "userName": "User"
            },
            {
              "content": "This is not the primary paper demonstrating this information - it is stated in this paper with two references...",
              "date": "1476385363889",
              "email": "user@gmail.com",
              "resolved": "true",
              "userName": "User"
            }
          ],
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "04a8cfc1-7042-4fb9-afc9-ba53f7e33482"
        },
        {
          "mutation_effect": {
            "description": "The TP53 F341C mutation is located in the protein's oligomerization domain. In vitro and structural studies have demonstrated that this mutation is likely inactivating, as evidenced by the decreased transcriptional activity and protein stability in the mutant compared to wildtype, as well as by the mutant's decreased ability to form p53 tetramers, which is required for TP53 DNA binding activity (PMID: 19454241, 20978130).",
            "description_review": {
              "updateTime": 1663208311264,
              "updatedBy": "User"
            },
            "description_uuid": "f57f897f-21cb-4304-b0bb-566b9b8fe0ec",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "10cead43-d239-4486-a664-7dacc7401fdf",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "8ca0b47c-31dd-4258-8b9f-8618f4e7c3d2",
            "short": ""
          },
          "mutation_effect_uuid": "2b3b1137-b9e5-41d9-a10e-03de1fde78f6",
          "name": "F341C",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "0dd38236-1bca-4ba6-9cfb-f569c01a5a32"
        },
        {
          "mutation_effect": {
            "description": "The TP53 L344R mutation is located in the protein's oligomerization domain. In vitro and structural studies have demonstrated that this mutation is likely inactivating, as evidenced by the decreased transcriptional activity and protein stability in the mutant compared to wildtype, as well as by the mutant's decreased ability to form p53 tetramers, which is required for TP53 DNA binding activity (PMID: 19454241, 20978130).",
            "description_review": {
              "updateTime": 1663208360530,
              "updatedBy": "User"
            },
            "description_uuid": "158c4cb1-cfbb-47cf-ad50-b4895de6565b",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "97dd3cee-daea-46cc-a9e4-5a7dc823273e",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "e0150809-ab63-452f-8ab3-ee6daccfbada",
            "short": ""
          },
          "mutation_effect_uuid": "f5c98d1d-7436-45c4-9056-9f2ef90bf869",
          "name": "L344R",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "1731309a-ac58-4975-c0cb-7a57b9f4e31a"
        },
        {
          "mutation_effect": {
            "description": "The TP53 A347T mutation is located in the protein's oligomerization domain. In vitro and structural studies have demonstrated that this mutation is likely inactivating, as evidenced by the decreased transcriptional activity and protein stability in the mutant compared to wildtype, as well as by the mutant's decreased ability to form p53 tetramers, which is required for TP53 DNA binding activity (PMID: 19454241, 20978130).",
            "description_review": {
              "updateTime": 1663209224412,
              "updatedBy": "User"
            },
            "description_uuid": "416f173e-ef98-49c1-af0e-200116b98553",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "c50c6631-3785-4b6e-8d43-a6c2bed68d76",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "031ed56b-d825-4cf6-8883-3e3cf0b12bbb",
            "short": ""
          },
          "mutation_effect_uuid": "db013a41-1f09-42b0-9a5a-25bd57f8ea4b",
          "name": "A347T",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "77e5fb96-8677-4ce5-b28b-5d2d6557378d"
        },
        {
          "mutation_effect": {
            "description": "The TP53 R337H mutation is located in the protein's oligomerization domain. This mutation has been found in the germline of patients with Li-Fraumeni syndrome and adrenocortical carcinoma (PMID: 11481490). In vitro and structural studies have demonstrated that this mutation is likely inactivating, as evidenced by decreased transcriptional activity and protein stability in the mutant compared to wildtype, as well as the mutant's inability to form p53 tetramers, which is required for TP53 DNA binding activity (PMID: 19454241, 20978130).",
            "description_review": {
              "updateTime": 1663354509790,
              "updatedBy": "User"
            },
            "description_uuid": "771d97d7-5e2e-46da-a3d1-780c723c4921",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1491583549000,
              "updatedBy": "User"
            },
            "effect_uuid": "b14ddc8c-73d9-4fe1-b08c-e8fa522bd10a",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1491583554000,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "4a6fd479-7ecb-42b5-b271-7f217243a070",
            "short": "This mutation occurs within the oligomerization domain, a region rarely mutated in somatic tumors (PMID: 17311302). In structural studies, mutations at R337 were found to destabilize the p53 tetramer, inhibiting the protein’s transcriptional activity (PMID: 11753428, 16007150)."
          },
          "mutation_effect_uuid": "561d28d2-a2e8-47a2-a7f2-671f84131623",
          "name": "R337H",
          "name_comments": [
            {
              "content": "PMID: 18940924 PMID: 11481490",
              "date": "1478549129416",
              "email": "user@gmail.com",
              "resolved": "true",
              "userName": "User"
            }
          ],
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "c8a3976b-9138-47fe-9627-8e5ae80dc134"
        },
        {
          "mutation_effect": {
            "description": "The TP53 R337L mutation is located in the protein's oligomerization domain. This mutation has been found in the germlines of patients with Li-Fraumeni syndrome and adrenocortical carcinoma (PMID: 11481490). In vitro and structural studies have demonstrated that this mutation is likely inactivating, as evidenced by decreased transcriptional activity and protein stability in the mutant compared to wildtype, as well as the mutant's inability to form p53 tetramers, which is required for TP53 DNA binding activity (PMID: 19454241, 20978130).",
            "description_review": {
              "updateTime": 1663209442513,
              "updatedBy": "User"
            },
            "description_uuid": "ab5c7f50-4b5d-4e13-bbf5-f3186bb2e2ef",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1491583613000,
              "updatedBy": "User"
            },
            "effect_uuid": "a9ed758b-0cc4-4168-b1fe-f0f98d6d92e0",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1491583590000,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "46db9414-aee3-48c9-9a02-9e3e1821654a",
            "short": "This mutation occurs within the oligomerization domain, a region rarely mutated in somatic tumors (PMID: 17311302). In structural studies, mutations at R337 were found to destabilize the p53 tetramer, inhibiting the protein’s transcriptional activity (PMID: 11753428, 16007150)."
          },
          "mutation_effect_uuid": "cd6d68f2-35c3-4299-bab2-838acc2bd150",
          "name": "R337L",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "ff271326-b4d5-4e40-a4f5-bccd61682067"
        },
        {
          "mutation_effect": {
            "description": "The TP53 F338I mutation is located in the protein's oligomerization domain. In vitro and structural studies have demonstrated that this mutation is likely inactivating, as evidenced by the decreased transcriptional activity and protein stability in the mutant compared to wildtype, as well as by the mutant's inability to form p53 tetramers, which is required for TP53 DNA binding activity (PMID: 19454241, 20978130)",
            "description_review": {
              "updateTime": 1663209532269,
              "updatedBy": "User"
            },
            "description_uuid": "c192e231-511d-45ad-8010-2e16567ecf4b",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "06cd006b-82bd-4d4c-bf31-4ced5518df1a",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "55b67ba9-3f52-4ed8-ae03-2406967fe4e1",
            "short": ""
          },
          "mutation_effect_uuid": "d357dd1c-ae98-4e5a-a113-44f2a55bb4ff",
          "name": "F338I",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "f415cae5-f741-482b-940b-e91699654615"
        },
        {
          "mutation_effect": {
            "description": "The TP53 L348S mutation is located in the protein's oligomerization domain. Structural studies have demonstrated that this mutation is likely inactivating, as evidenced by the mutant's decreased ability to form TP53 tetramers compared to wildtype TP53, which likely impacts TP53 DNA binding activity (PMID: 20978130).",
            "description_review": {
              "updateTime": 1663209816755,
              "updatedBy": "User"
            },
            "description_uuid": "b28864ec-899e-4a36-a247-b40a52f434ef",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "2b5e984a-900d-4850-9dcd-cbe5d6cd0dfe",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "4da6625f-6dc7-474a-9f57-b0e74f44e1bd",
            "short": ""
          },
          "mutation_effect_uuid": "44d74cc5-8879-471f-b81d-addd81b1325a",
          "name": "L348S",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "1248c5d5-b941-4fe2-a560-83a1c6210552"
        },
        {
          "mutation_effect": {
            "description": "The TP53 P47S mutation is located in the protein's transactivation domain. This mutation has been found in the germline of patients with pediatric adrenocortical carcinoma (PMID: 25584008). In vitro studies have demonstrated that this mutation is likely neutral, as evidenced by similar levels of colony formation and TP53 transactivation activity in the mutant compared to wildtype (PMID: 25584008).",
            "description_review": {
              "updateTime": 1663354586107,
              "updatedBy": "User"
            },
            "description_uuid": "14b5b99f-8582-412a-8224-a17cb31ead2b",
            "effect": "Neutral",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "0d1f4bb9-af36-433b-8a35-3eca8f862227",
            "oncogenic": "Likely Neutral",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "d2c2e9e7-d4cf-40ab-b1c9-38182840e967",
            "short": ""
          },
          "mutation_effect_uuid": "27973f02-8484-4f98-a061-79eaec66e3da",
          "name": "P47S",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "09106a54-63fb-4d4c-aa72-dc7b855cd208"
        },
        {
          "mutation_effect": {
            "description": "The TP53 F134Y mutation is located in the protein's DNA binding domain and occurs at a known hotspot residue (PMID: 26619011). In vitro studies have demonstrated that this mutation has inconclusive effect, as evidenced by similar levels of colony formation and TP53 transactivation activity in the mutant compared to wildtype, even though its position at a hotspot residue suggests that it is likely oncogenic (PMID: 25584008, 26619011).",
            "description_review": {
              "updateTime": 1663210248123,
              "updatedBy": "User"
            },
            "description_uuid": "ba9691c1-a61e-47a8-add2-bce98117da6e",
            "effect": "Likely Neutral",
            "effect_review": {
              "updateTime": 1676479148871,
              "updatedBy": "User"
            },
            "effect_uuid": "4bc2942b-10c2-4f3f-babe-bc76bbdb2b7d",
            "oncogenic": "Likely Neutral",
            "oncogenic_review": {
              "updateTime": 1676479147509,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "2815bd4b-1619-4f67-8856-b5bfe65d1d94",
            "short": ""
          },
          "mutation_effect_uuid": "07a6277e-8c9e-41e5-996f-14e25075ed62",
          "name": "F134Y",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "b104872c-8e71-42fb-b69d-e50c2b1eb593"
        },
        {
          "mutation_effect": {
            "description": "The TP53 P152L mutation is located in the protein's DNA binding domain. In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by loss of p53-mediated transactivation and reduced colony formation in the mutant compared to wildtype (PMID: 10229196, 25584008).",
            "description_review": {
              "updateTime": 1663210605827,
              "updatedBy": "User"
            },
            "description_uuid": "3f337ae1-d4a5-40b2-9633-9c4d1e2ce86e",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "cb67c3e4-a16b-416c-a5ee-4a1a89cfcb19",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "00393141-cdd1-4ab5-9741-1bb9feb5ece8",
            "short": ""
          },
          "mutation_effect_uuid": "c7f69bea-e190-4c63-a957-99759d90c0c7",
          "name": "P152L",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "f7574f74-7069-434c-bafa-e4229b2f56d8"
        },
        {
          "mutation_effect": {
            "description": "The TP53 R158H mutation is located in the protein's DNA binding domain. In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by loss of p53-mediated transactivation, decreased ability to induce apoptosis and increased oncogenic colony transformation of the mutant compared to wildtype (PMID: 10229196, 25584008).",
            "description_review": {
              "updateTime": 1664821792332,
              "updatedBy": "User"
            },
            "description_uuid": "f36549ce-250b-43f7-a88b-9332424f903b",
            "effect": "Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "94bb01ea-f180-4306-8cd9-cab503e1bbcd",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "39b8f59b-cd28-402d-ab72-8b7e6fa4700a",
            "short": ""
          },
          "mutation_effect_uuid": "1a4c81f3-1b98-4e12-b4fa-f81604d9ce96",
          "name": "R158H",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "5a85e820-9c56-478c-89eb-81e802d4862b"
        },
        {
          "mutation_effect": {
            "description": "The TP53 R158L mutation is located in the protein's DNA binding domain. This mutation has been found in lung cancer (PMID: 31067569). In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by loss of TP53-mediated transactivation, decreased ability to reduce colony formation and aberrant transcriptional regulation in the mutant compared to wildtype (PMID: 25584008, 16861262, 31067569).",
            "description_review": {
              "updateTime": 1664825037615,
              "updatedBy": "User"
            },
            "description_uuid": "7ac41a2b-39e9-4def-8425-25997ab32071",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1664824246182,
              "updatedBy": "User"
            },
            "effect_uuid": "e833d643-3b09-43c2-ba46-3c342042ddcf",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "8536d498-deef-47ed-a102-1b94647aeb32",
            "short": ""
          },
          "mutation_effect_uuid": "c5d611c5-2322-4cf7-8983-d88f81b9112e",
          "name": "R158L",
          "name_comments": [
            {
              "content": "The R158L mutation of p53 is a missense mutation. Transactivation studies have shown reduced expression of p53-inducted genes compared to wild type p53 (PMID: 16861262).",
              "date": "1476386482024",
              "email": "user@gmail.com",
              "resolved": "true",
              "userName": "User"
            }
          ],
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "4bd884bb-adfc-4692-9ed8-c48babc8cdd6"
        },
        {
          "mutation_effect": {
            "description": "The TP53 Y163C mutation is located in the protein's DNA-binding domain. In vitro studies have demonstrated that this mutation is inactivating, as measured by increased cellular growth, decreased levels of apoptosis and decreased transactivation of downstream p53 target genes in the mutant compared to wildtype (PMID: 23246812,15077194, 25584008, 15037740).",
            "description_review": {
              "updateTime": 1663295659040,
              "updatedBy": "User"
            },
            "description_uuid": "066aec5f-67fe-4038-abd2-42ddcdd4ccc7",
            "effect": "Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "5d765c01-7b4d-40dc-a5a6-ad5f2eebeea9",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "8a3f9e27-ab57-4697-9fa4-97a1239fa9e6",
            "short": ""
          },
          "mutation_effect_uuid": "3994b8c6-4ea4-4188-befb-c2aa698fe396",
          "name": "Y163C",
          "name_comments": [
            {
              "content": "formating rules \"two\" \"\"twelve\" \"wildtype\"",
              "date": "1476890923751",
              "email": "user@gmail.com",
              "resolved": "true",
              "userName": "User"
            },
            {
              "content": "needs editing",
              "date": "1476890930293",
              "email": "user@gmail.com",
              "resolved": "true",
              "userName": "User"
            },
            {
              "content": "there is also this PMID: that you need to include: PMID: 23246812",
              "date": "1476891157782",
              "email": "user@gmail.com",
              "resolved": "true",
              "userName": "User"
            },
            {
              "content": "old description: The Y163C mutation of p53 was tested in its ability to transactivate or repress p53-regulated promoters. This mutant activated p53-regulated promoters 2 fold while wild type p53 induced its promoters by 12 fold compared to control vector. Thus, this mutant has some residual WT p53 role but not completely (PMID: 15077194).",
              "date": "1476892525191",
              "email": "user@gmail.com",
              "resolved": "true",
              "userName": "User"
            }
          ],
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "265f119a-99ff-4f20-a051-e435c9ef615a"
        },
        {
          "mutation_effect": {
            "description": "The TP53 H193P mutation is located in the protein's DNA-binding domain. This mutation has been found in Li-Fraumeni syndrome (PMID: 25584008). In vitro studies have demonstrated that this mutation is inactivating, as measured by decreased transactivation of p53 target genes and failure to suppress colony growth in a colony reduction assay in the mutant compared to wildtype (PMID: 25584008).",
            "description_review": {
              "updateTime": 1663295999954,
              "updatedBy": "User"
            },
            "description_uuid": "0cdd2495-71f7-43b6-be40-ec43e0c9adbe",
            "effect": "Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "f7616b81-3c8c-488b-bfe3-f2f41f0981b4",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "c3faae77-9204-4160-9e91-470b2541935b",
            "short": ""
          },
          "mutation_effect_uuid": "0260f050-77ec-40b5-98d4-b5d126e09e53",
          "name": "H193P",
          "name_comments": [
            {
              "content": "The H193P mutation of p53 is a missense mutation. When overexpressed in H1299 cells, luciferase assays measuring the transactivation of p53 responsive elements, determined that this mutant was unable to increase the transcriptional activity of p53 (PMID: 25584008).",
              "date": "1476387404389",
              "email": "user@gmail.com",
              "resolved": "true",
              "userName": "User"
            },
            {
              "content": "make sure all other variants in this paper are also documented",
              "date": "1476389222336",
              "email": "user@gmail.com",
              "resolved": "true",
              "userName": "User"
            }
          ],
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "24d4d700-62f3-4159-9563-d26fcddbf863"
        },
        {
          "mutation_effect": {
            "description": "The TP53 P219S mutation is located in the protein's DNA binding domain. In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by the loss of of p53-mediated transactivation, increased colony formation, decreased transactivation of genes important in cell cycle and apoptosis and decreased apoptosis compared to wildtype (PMID: 25584008, 10229196).",
            "description_review": {
              "updateTime": 1679600093572,
              "updatedBy": "User"
            },
            "description_uuid": "6d850d4f-d55a-4b60-9623-15d4ee041065",
            "effect": "Loss-of-function",
            "effect_review": {
              "updateTime": 1493755265397
            },
            "effect_uuid": "2f286414-2199-435b-be11-f12daee9f162",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "996354e0-9e2d-414a-a730-32538956157e",
            "short": ""
          },
          "mutation_effect_uuid": "3e5f1edb-9885-4f17-a543-2a1d8ab36940",
          "name": "P219S",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "9aba2dd3-1f3f-4088-8163-0e8dff02dafe"
        },
        {
          "mutation_effect": {
            "description": "The TP53 C229R mutation is located in the protein's DNA binding domain. In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by increased p53-mediated transactivation and increased colony formation in the mutant compared to wildtype (PMID: 25584008).",
            "description_review": {
              "updateTime": 1663296902713,
              "updatedBy": "User"
            },
            "description_uuid": "17d19b0b-6f41-496f-8c93-d0d299f002a7",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "2a27eee4-b03c-4090-8b70-4c063146286a",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "27d46a94-299d-4d6e-adb0-58bfe98a5149",
            "short": ""
          },
          "mutation_effect_uuid": "b9708d82-e47b-41b3-849a-04ed8a0d2616",
          "name": "C229R",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "ef53a068-d0ad-4727-a5af-13320941904f"
        },
        {
          "mutation_effect": {
            "description": "The TP53 N235D mutation is located in the protein's DNA binding domain. In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by increased p53-mediated transactivation and increased colony formation in the mutant compared to wildtype (PMID: 25584008).",
            "description_review": {
              "updateTime": 1663296894598,
              "updatedBy": "User"
            },
            "description_uuid": "bfea3e60-dcf7-4cb2-b083-793eef1560b8",
            "effect": "Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "87426af5-e84a-4ed0-a5e1-6f2a394868c9",
            "oncogenic": "Yes",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "bc631aad-1012-40e9-bc63-4a2182c94274",
            "short": ""
          },
          "mutation_effect_uuid": "21bfb765-70c8-4f32-b855-d9289c7487fd",
          "name": "N235D",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "f91cffb9-c321-4ec8-b018-264c8f2bfda2"
        },
        {
          "mutation_effect": {
            "description": "The TP53 R248W mutation is located in the protein's DNA binding domain. This mutation has been found in Li-Fraumeni syndrome (PMID: 25584008). In vitro studies have demonstrated that this mutation is inactivating, as evidenced by increased p53-mediated transactivation and failure to suppress colony growth in the mutant compared to wildtype (PMID: 18762571, 10229196, 25584008).",
            "description_review": {
              "updateTime": 1663355031481,
              "updatedBy": "User"
            },
            "description_uuid": "c7258072-d386-411b-a9e2-af9d86bde458",
            "effect": "Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "2416b4ed-b136-4f3a-9fda-8a2f17032146",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "4cd0dde0-3a2a-4e83-b1c5-fc852493ae90",
            "short": ""
          },
          "mutation_effect_uuid": "3047b48d-2954-4e7e-b646-6e4241e48d3d",
          "name": "R248W",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "266b57db-6c21-4619-9adb-6eb28303c6f5"
        },
        {
          "mutation_effect": {
            "description": "The TP53 I254T mutation is located in the protein's DNA binding domain. In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by the loss of p53-mediated transactivation and increased colony formation in the mutant compared to wildtype (PMID: 25584008).",
            "description_review": {
              "updateTime": 1663297099384,
              "updatedBy": "User"
            },
            "description_uuid": "e89a0172-0e25-4bd4-bdda-1a49023e2400",
            "effect": "Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "4afa0c35-0e9f-410e-8507-4dcc93431988",
            "oncogenic": "Yes",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "b1d7458b-5abc-4467-a834-a83dc126f0cf",
            "short": ""
          },
          "mutation_effect_uuid": "0dedc0aa-b15a-4a76-a050-1cf4b09662bb",
          "name": "I254T",
          "name_comments": [
            {
              "content": "make sure to write in description of mutation effect box - not \"short\" box",
              "date": "1476384530812",
              "email": "user@gmail.com",
              "resolved": "true",
              "userName": "User"
            }
          ],
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "b279f433-5f9c-42a6-a1e4-1cad44dfe911"
        },
        {
          "mutation_effect": {
            "description": "The TP53 R267Q mutation is located in the protein's DNA binding domain. In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by increased levels of p53-mediated transactivation (suggesting loss of negative feedback) and increased colony formation in the mutant compared to wildtype (PMID: 25584008, 10435620).",
            "description_review": {
              "updateTime": 1664404224243,
              "updatedBy": "User"
            },
            "description_uuid": "e94885e8-6f27-462f-acf9-fd46d9d7a260",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "c9ef7cfc-1216-4d66-ba5b-32c44a642b4f",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "41f37360-eee1-4f3a-bb83-76ff7f62d897",
            "short": ""
          },
          "mutation_effect_uuid": "a02d3b6f-74c9-4be2-aaec-3d4f57b90283",
          "name": "R267Q",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "c77fa114-2cf8-40e6-8444-537f3a014910"
        },
        {
          "mutation_effect": {
            "description": "The TP53 R273H mutation is located in the protein's DNA binding domain. This mutation has been found in triple-negative breast cancer and Li-Fraumeni syndrome (PMID: 31776133, 25584008). Expression of this mutant resulted in cell survival by activating AKT signaling and suppressing the expression of BCL-modifying factor (BMF) (PMID: 26181206). Expression of this mutant in TP53-null cells resulted in decreased transactivation of p53 target genes, as measured by a luciferase reporter assay (PMID: 25584008, 15037740). Expression of this mutation in osteosarcoma and breast cancer cell lines demonstrated that it is inactivating as measured by moderately increased cell proliferation and failure to suppress colony growth compared to wildtype (PMID: 25584008, 31776133).",
            "description_review": {
              "updateTime": 1664404376473,
              "updatedBy": "User"
            },
            "description_uuid": "993d500f-4bf1-4a2f-96e6-ca0f4e4d3cac",
            "effect": "Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "b54d2ced-283e-49fa-bfe2-8d3c01d34c73",
            "oncogenic": "Yes",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "94b57c4a-5bb1-44d1-9819-4b0fd48c34b6",
            "short": ""
          },
          "mutation_effect_uuid": "cf299e26-b461-41e4-9a5a-e52617f2882a",
          "name": "R273H",
          "name_comments": [
            {
              "content": "needs editing",
              "date": "1476370545309",
              "email": "user@gmail.com",
              "resolved": "true",
              "userName": "User"
            },
            {
              "content": "also, there are other papers with this variant. We need to be thorough and include all appropriate references",
              "date": "1477580279829",
              "email": "user@gmail.com",
              "resolved": "true",
              "userName": "User"
            },
            {
              "content": "PMID: 26181206  (for example) showing it is likely oncogenic",
              "date": "1477580373727",
              "email": "user@gmail.com",
              "resolved": "true",
              "userName": "User"
            },
            {
              "content": "Mutants TP53 p.R273H and p.R273C but not p.R273G Enhance Cancer Cell Malignancy",
              "date": "1477580635993",
              "email": "user@gmail.com",
              "resolved": "true",
              "userName": "User"
            }
          ],
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "29da1bf3-52c6-44d9-b0dd-1bd079dda01d"
        },
        {
          "mutation_effect": {
            "description": "The TP53 E285V mutation is located in the protein's DNA binding domain. In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by the loss of p53-mediated transactivation as well as defective growth suppression and apoptosis in the mutant compared to wildtype (PMID: 25584008, 18762572).",
            "description_review": {
              "updateTime": 1663297516904,
              "updatedBy": "User"
            },
            "description_uuid": "573281db-20b5-4f56-b96d-1ae3e2668774",
            "effect": "Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "181e1d31-6d2e-49ee-bb6c-386b07892aea",
            "oncogenic": "Yes",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "0b69cc7e-f05c-4306-9b34-f7620ad43bde",
            "short": ""
          },
          "mutation_effect_uuid": "3093b8a9-31bf-4277-82b0-fa53786a4ca1",
          "name": "E285V",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "10dc1a62-1e6a-4e81-aa1f-0563dc635955"
        },
        {
          "mutation_effect": {
            "description": "The TP53 R175L mutation is located in the protein's DNA binding domain and occurs at a hotspot residue (PMID: 26619011). In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by colony formation and reduced ability to induce apoptosis in the mutant compared to wildtype (PMID: 25584008, 15781620, 18762572).",
            "description_review": {
              "updateTime": 1663358092331,
              "updatedBy": "User"
            },
            "description_uuid": "7ad9b8be-dfcc-425d-9596-017966b3423c",
            "effect": "Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "a288827a-589c-4f83-94a1-15027bd2329d",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "10cc2308-482b-41ad-8554-2a19e84a6a03",
            "short": ""
          },
          "mutation_effect_uuid": "84377715-5240-451e-8be0-4ece59963fa5",
          "name": "R175L",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "f785a8b5-e079-424b-86f8-3869ac9dc91e"
        },
        {
          "mutation_effect": {
            "description": "The TP53 R175C mutation is located in the protein's DNA binding domain and occurs at a hotspot residue (PMID: 26619011). In vitro studies have demonstrated that this mutation has inconclusive effect, as evidenced by cell cycle arrest and apoptosis comparable to that of the wildtype (PMID: 22955915).",
            "description_review": {
              "updateTime": 1663358168085,
              "updatedBy": "User"
            },
            "description_uuid": "6792ce54-14b6-4705-889f-fca2c387e719",
            "effect": "Inconclusive",
            "effect_review": {
              "updateTime": 1663298057599,
              "updatedBy": "User"
            },
            "effect_uuid": "f1612c40-9be7-4d4b-9ee4-881ddc4dc72a",
            "oncogenic": "Inconclusive",
            "oncogenic_review": {
              "updateTime": 1663298056609,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "a2803d54-e3a5-4ae4-9f14-e290f9cfa059",
            "short": ""
          },
          "mutation_effect_uuid": "b079d067-dd1a-4dd9-8b2a-72a36f5caddd",
          "name": "R175C",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "6e7bb629-9983-4e74-bdf0-5b971436c219"
        },
        {
          "mutation_effect": {
            "description": "The TP53 R248Q mutation is located in the protein's DNA binding domain. Expression of this mutation in TP53-null cell lines resulted in aggregation of unfolded mutant proteins, likely leading to destabilization of TP53 and upregulation of heat shock proteins (PMID: 21445056). Expression of this mutation in osteosarcoma cell lines led to a reduced apoptotic response, including reduced expression of pro-apoptotic proteins (PMID: 16778209). In biochemical assays, this mutation was found to bind DNA with a lower affinity than wildtype TP53 (PMID: 24814347).",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "68df0095-ab8c-4658-958c-3b148897e4aa",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "4482b15e-4ec4-4d3b-8818-533d02e248ae",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "f67b970c-6d59-42ba-91d8-d178dc63659c",
            "short": ""
          },
          "mutation_effect_uuid": "ef787787-c0c3-4478-9fe2-98003e44d8cb",
          "name": "R248Q",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "c7d0be06-2e98-4161-97ac-08f7e269a1c0"
        },
        {
          "mutation_effect": {
            "description": "The TP53 R273C mutation is located in the protein's DNA binding domain. Expression of this mutant in TP53 null mouse embryonic fibrobalsts (MEFs) resulted in a significant increase in cell migration relative to TP53 null cells (PMID: 23612969). Structural studies demonstrated that the R273C mutation leads to a dramatic reduction in the DNA binding affinity of p53, although the protein retains wildtype stability (PMID: 23863845, 11900253). Expression of this mutation in cell lines that lack TP53 expression did not enhance TP53-mediated transcriptional activity in reporter assays, as compared to expression of wildtype TP53 (PMID: 15037740).",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "0e3bf9b5-14a7-44cb-a320-805d0cef36af",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "1795102b-8bb7-4343-999c-44e20f282c49",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "7cec6549-39de-4936-a81f-7462dc6cb172",
            "short": ""
          },
          "mutation_effect_uuid": "1c3ea501-bfc6-494a-9325-a23c854090df",
          "name": "R273C",
          "name_comments": [
            {
              "content": "PMID: 23264849",
              "date": "1479402922041",
              "email": "user@gmail.com",
              "resolved": "true",
              "userName": "User"
            },
            {
              "content": "PMID: 23612969",
              "date": "1479402933058",
              "email": "user@gmail.com",
              "resolved": "true",
              "userName": "User"
            },
            {
              "content": "This is not unknown",
              "date": "1479403049325",
              "email": "user@gmail.com",
              "resolved": "false",
              "userName": "User"
            },
            {
              "content": "and the original paper was not cited for the information",
              "date": "1479403768376",
              "email": "user@gmail.com",
              "resolved": "false",
              "userName": "User"
            },
            {
              "content": "\"Structural studies demonstrated that this mutation leads to a dramatic reduction in the DNA binding affinity of p53. However, the protein retains wildtype stability (PMID: 23863845). \" this is not the original paper",
              "date": "1479403784309",
              "email": "user@gmail.com",
              "resolved": "false",
              "userName": "User"
            },
            {
              "content": "Please add this PMID: PMID: 22198284",
              "date": "1479404420297",
              "email": "user@gmail.com",
              "resolved": "false",
              "userName": "User"
            }
          ],
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "1bc530dd-beb3-4e15-82e9-923c62aa673b"
        },
        {
          "mutation_effect": {
            "description": "The TP53 R273G mutation is located in the protein's DNA binding domain and occurs at a hotspot residue (PMID: 26619011). In vitro studies have demonstrated that this mutation has inconclusive effect, as demonstrated by similar levels of proliferation, colony formation or invasion in the mutant compared to wildtype (PMID: 24677579).",
            "description_review": {
              "updateTime": 1663298355585,
              "updatedBy": "User"
            },
            "description_uuid": "50a41285-c753-4dd2-a971-6f3768b7249b",
            "effect": "Inconclusive",
            "effect_review": {
              "updateTime": 1676479742674,
              "updatedBy": "User"
            },
            "effect_uuid": "8997fe78-40db-4812-8ead-2635615747c1",
            "oncogenic": "Inconclusive",
            "oncogenic_review": {
              "updateTime": 1676479740546,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "3a9e6f10-5522-4a50-b939-26727c5abba6",
            "short": ""
          },
          "mutation_effect_uuid": "bd1a6fa4-1eb0-49fe-bf51-7f10e4e66926",
          "name": "R273G",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "1e186cab-1f79-499f-82d0-022ef7a9b93f"
        },
        {
          "mutation_effect": {
            "description": "The TP53 R213Q mutation is located in the protein's DNA binding domain. In vitro studies have demonstrated that this mutation is inactivating, as measured by reduced ability to induce cell cycle arrest and apoptosis, as well as increased induction of MDM2 expression (PMID: 10871862).",
            "description_review": {
              "updateTime": 1663298475945,
              "updatedBy": "User"
            },
            "description_uuid": "c9704f7c-0a98-41ac-97bb-97e2f27220ac",
            "effect": "Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "ca3a45e9-ba06-4bdf-8ff8-4cb85c1eb250",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "88122f71-b84f-4681-bb49-6447aa9180cb",
            "short": ""
          },
          "mutation_effect_uuid": "f56fea0d-aaba-44f9-870f-85be7ef18d6c",
          "name": "R213Q",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "333fa347-0161-41d4-bc23-06add9c315e9"
        },
        {
          "mutation_effect": {
            "description": "The TP53 G245S mutation is located in the protein's DNA binding domain. Expression of this mutation in cell lines that lack TP53 expression did not enhance TP53-mediated transcriptional activity in reporter assays, as compared to expression of wildtype TP53 (PMID: 15037740). A mouse model harboring the TP53 G245S mutation displayed lack of p53 tumor suppressor abilities including cell cycle arrest, senescence and apoptosis. TP53 G245S-mutant mice display rapid tumor onset and accelerated death in comparison to p53-null mice (PMID: 2358418).",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "0eb2e542-e969-4c89-9271-86ef29af945b",
            "effect": "Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "25888452-3f91-4dfb-9ffa-b910ee02be2e",
            "oncogenic": "Yes",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "2798f6db-abab-48cf-af47-c72abcc3894a",
            "short": ""
          },
          "mutation_effect_uuid": "f10c4732-b524-414d-b33b-c42431ef5a13",
          "name": "G245S",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "a8aec669-ee62-4e37-b9aa-4fee3b5fcc59"
        },
        {
          "mutation_effect": {
            "description": "The TP53 G245D mutation is located in the protein's DNA binding domain. Structural studies have shown that this mutation results in differences in conformational flexibility of the DNA-binding domain of p53 (PMID: 22803791). Expression of this mutant in hepatocellular carcinoma cell lines resulted in association with the transcription factor ZBP-89 in the cytoplasm. The ZBP-89/mutant TP53 interaction abrogated induction of the cell cycle gene p21 and other apoptotic proteins, leading to reduced apoptosis (PMID: 22214764). Additionally, expression of this mutation in head and neck cancer cell lines was associated with the inability of TP53 to suppress colony growth, as compared to wildtype TP53 and is associated with reduced expression of p21 suggesting that the G245D mutation inactivates the function of p53 (PMID: 25119136).",
            "description_review": {
              "updateTime": 1495147174400
            },
            "description_uuid": "1a2ee836-82b9-4f91-a8bb-5b931588c772",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1495147174400
            },
            "effect_uuid": "b1e75857-639f-4ad4-bf91-8819ae1925c7",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "d334264d-fd19-4147-ac6c-73aed2517c29",
            "short": ""
          },
          "mutation_effect_uuid": "50af2a4a-3ac9-4c66-89f6-d57892908eca",
          "name": "G245D",
          "name_comments": [
            {
              "content": "PMID: 22214764",
              "date": "1479400919198",
              "email": "user@gmail.com",
              "resolved": "true",
              "userName": "User"
            },
            {
              "content": "there are various papers on this mutant - please look into these and curate",
              "date": "1479401000985",
              "email": "user@gmail.com",
              "resolved": "true",
              "userName": "User"
            }
          ],
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "2a00db91-e177-40dd-a158-3c163db04a7f"
        },
        {
          "mutation_effect": {
            "description": "The TP53 G245C mutation is located in the protein's DNA binding domain. In vitro and structural studies have demonstrated that this mutation has inconclusive effect, as evidenced by the similar levels of TP53-mediated transcriptional activity in the mutant compared to wildtype, even though the mutant results in differences in conformational flexibility of the DNA-binding domain of p53 (PMID: 15037740, 22803791).",
            "description_review": {
              "updateTime": 1664404552369,
              "updatedBy": "User"
            },
            "description_uuid": "a074c603-61a8-414a-8ba0-236f6064f712",
            "effect": "Inconclusive",
            "effect_review": {
              "updateTime": 1663298694973,
              "updatedBy": "User"
            },
            "effect_uuid": "13d74785-c4da-4a68-b468-5773a14a5412",
            "oncogenic": "Inconclusive",
            "oncogenic_review": {
              "updateTime": 1663298699375,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "5d65bf5b-ce94-495a-817d-ffcfe4d851fe",
            "short": ""
          },
          "mutation_effect_uuid": "81067ff3-6752-45a3-bb9a-6d6e28658a65",
          "name": "G245C",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "06b527d0-dd88-48a7-9a0e-098b280b64e8"
        },
        {
          "mutation_effect": {
            "description": "The TP53 G245A mutation is located in the protein's DNA binding domain. This mutation destabilizes p53-DNA binding. However, acetylation was shown to restore the DNA-binding ability and growth-suppressive activity of this mutation (PMID: 20589832).",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "1cc2b76c-4bd2-4b0c-963c-66a928537907",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "d26ce914-72cf-4652-905e-3f81efa3c871",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "633c047f-3593-41bd-9c66-d39f5be99226",
            "short": ""
          },
          "mutation_effect_uuid": "043e2798-8e35-4eb2-b9d4-7196cfc26bc9",
          "name": "G245A",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "3ec92369-db82-4513-97b9-7f1171bab051"
        },
        {
          "mutation_effect": {
            "description": "The TP53 Y220C mutation is located in the protein's DNA binding domain. Structural studies demonstrated that this mutation destabilizes p53 due the loss of five electrostatic interactions with key residues (PMID: 23315175). A small molecule compound, PK7088, raises the melting temperature of this mutation, triggering cell-cycle arrest and apoptosis. This compound also increases the amount of correctly folded p53 in Y220C mutant cells and increases the expression of p53 target genes such as p21 and Noxa (PMID: 23630318). Expression of this mutation in cell lines that lack TP53 expression did not enhance TP53-mediated transcriptional activity in reporter assays, as compared to expression of wildtype TP53 (PMID: 15037740).",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "d236ce48-0e73-42dc-9c06-0062e7326874",
            "effect": "Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "e4c8f539-c654-4e1b-8b94-ca11569ef178",
            "oncogenic": "Yes",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "1ed8e010-a253-402f-b9fb-72c72ebd5f7a",
            "short": ""
          },
          "mutation_effect_uuid": "579fa3aa-f793-4f00-b72b-abf8359484cc",
          "name": "Y220C",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "16210397-5073-4b18-ba3e-86b2b5f9ba33",
          "tumors": [
            {
              "TIs": [
                {
                  "name": "Standard implications for sensitivity to therapy",
                  "name_uuid": "f9a854d5-0bef-4e01-babf-b79748fec3ba",
                  "treatments_uuid": "7edcd1d5-1c73-4a2a-94fa-fc7617bf5e7b",
                  "type": "SS"
                },
                {
                  "name": "Standard implications for resistance to therapy",
                  "name_uuid": "e90cf897-5fca-4b3f-9b3b-0fabc839a238",
                  "treatments_uuid": "d3be51fa-eaf8-4020-8a5e-7848c94423ae",
                  "type": "SR"
                },
                {
                  "name": "Investigational implications for sensitivity to therapy",
                  "name_uuid": "2b04aaed-1766-498f-809a-10493b40dbba",
                  "treatments": [
                    {
                      "description": "PC14586 is an orally available, small-molecule structural corrector specific for the Y220C-mutant p53 protein. In a phase I study of PC14586 in 29 patients with advanced solid tumors harboring a TP53 Y220C mutation, one patient with small cell lung cancer and one patient with breast cancer each had a partial response to treatment (Abstract: Dumbrava et al. Abstract# 3003, ASCO 2022. https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.3003). In vivo xenograft studies with TP53 Y220C-mutant gastric cancer cell line NUGC3 and Y220C-mutant patient-derived xenografts demonstrated sensitivity to PC14586 treatment as measured by dose-dependent tumor shrinkage and conversion of TP53 Y220C to the wildtype conformation (Abstract: Dumble et al. Abstract# LB006, AACR 2021. https://aacrjournals.org/cancerres/article/81/13_Supplement/LB006/669897/Abstract-LB006-PC14586-The-first-orally).",
                      "description_review": {
                        "updateTime": 1677262113650,
                        "updatedBy": "User"
                      },
                      "description_uuid": "66c79a3e-33d8-4944-b1de-28783e75c371",
                      "fdaLevel": "Fda3",
                      "fdaLevel_review": {
                        "updateTime": 1666299095877,
                        "updatedBy": "User"
                      },
                      "fdaLevel_uuid": "24754ac4-11d8-4c33-c0f5-54e6fe3d9d79",
                      "indication": "",
                      "indication_uuid": "97b66534-7030-453e-b252-6873c46b89c3",
                      "level": "3A",
                      "level_review": {
                        "updateTime": 1666299095889,
                        "updatedBy": "User"
                      },
                      "level_uuid": "c342747b-7b60-406f-9b92-f5eb4f6d6e63",
                      "name": "89814a16-3ae4-4cf0-8d69-34c03964345f",
                      "name_review": {
                        "updateTime": 1666299092591,
                        "updatedBy": "User"
                      },
                      "name_uuid": "495ba473-e137-4343-b248-04acbea470bd",
                      "propagation": "no",
                      "propagationLiquid": "no",
                      "propagationLiquid_review": {
                        "updateTime": 1666299095864,
                        "updatedBy": "User"
                      },
                      "propagationLiquid_uuid": "e77f83e5-db1c-4d76-85a9-038b4387e459",
                      "propagation_review": {
                        "updateTime": 1666299095849,
                        "updatedBy": "User"
                      },
                      "propagation_uuid": "bb2d282e-9f90-4483-905a-119a8124fab1",
                      "short": ""
                    }
                  ],
                  "treatments_uuid": "46461976-70d0-478f-b6a0-9fdc81384abe",
                  "type": "IS"
                },
                {
                  "name": "Investigational implications for resistance to therapy",
                  "name_uuid": "566d639b-79bc-4394-a550-bcc8c9d0d4f1",
                  "treatments_uuid": "1713e719-f2e3-4883-894e-ddb6c7a9c3b8",
                  "type": "IR"
                }
              ],
              "cancerTypes": [
                {
                  "code": "",
                  "mainType": "All Solid Tumors",
                  "subtype": ""
                }
              ],
              "cancerTypes_review": {
                "updateTime": 1666298893666,
                "updatedBy": "User"
              },
              "cancerTypes_uuid": "8ffe2c4d-1ce2-418e-b329-c74835cde99a",
              "diagnostic": {
                "description": "",
                "description_uuid": "c28b5864-44ba-46b8-8625-0a96a6eba4d4",
                "level": "",
                "level_uuid": "31b61390-4151-46e6-a4e9-75f28aa2e1a6",
                "relevantCancerTypes_uuid": "2fb906e2-4259-4211-879a-869e9d7490fa",
                "short": ""
              },
              "diagnosticSummary": "",
              "diagnosticSummary_uuid": "134f7eb5-31de-4636-96e0-39e98780c9cb",
              "diagnostic_uuid": "d18b9281-4d11-42c7-bdcb-79dcbab6aa69",
              "excludedCancerTypes_uuid": "486acab0-85d7-4499-af62-fbfc929dcccb",
              "prognostic": {
                "description": "",
                "description_uuid": "d2069fce-6256-4f93-bb76-5161ecd51d15",
                "level": "",
                "level_uuid": "f9833cef-3e18-4d5b-bcd1-0c441a067924",
                "relevantCancerTypes_uuid": "5e2cc12d-82b8-451e-9a58-35c980335018",
                "short": ""
              },
              "prognosticSummary": "",
              "prognosticSummary_uuid": "b3e01328-b8d5-43bd-84df-848d829f6fe2",
              "prognostic_uuid": "c971d457-607f-4d83-8b89-8c439d7cc468",
              "relevantCancerTypes_uuid": "760dbf8f-8ed0-4c66-af92-3c6ec598ce1f",
              "summary": "There is promising clinical data in patients with TP53 Y220C-mutant solid tumors treated with the TP53 structural corrector PC14586.",
              "summary_review": {
                "updateTime": 1666298926052,
                "updatedBy": "User"
              },
              "summary_uuid": "58cfdce6-2588-49a9-8f3c-76534fd4951c"
            }
          ]
        },
        {
          "mutation_effect": {
            "description": "The TP53 Y220S mutation is located in the protein's DNA binding domain. This mutation has been identified as a germline mutation and is commonly found in patients with Li-Fraumeni syndrome (LFS). Cells expressing TP53 Y220S displayed angiogenetic properties, andibroblasts expressing this mutation exhibited resistance to doxorubicin hydrochloride (DX) (PMID: 15977174).",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "0d1567e1-c65d-42c2-a6b0-5a557ab0572e",
            "effect": "Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "bbdc7145-4b24-441d-8dbb-8100078c9759",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "5afc6808-9dfc-4408-bbb3-2175f1c98cd1",
            "short": ""
          },
          "mutation_effect_uuid": "dfb1da24-b6cb-4fde-853e-8f1cf6814fe6",
          "name": "Y220S",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "58931385-5a59-4583-bc8a-6670f8223138"
        },
        {
          "mutation_effect": {
            "description": "The TP53 R282Q mutation is located in the protein's DNA binding domain. This mutation has been identified as a statistically significant hotspot (PMID: 26619011). Structural studies have demonstrated that this mutation is likely inactivating, as evidenced by the decreased flexibility of the L1 DNA-binding loop and two novel conformations of the L3 DNA-binding loop in the mutant compared to wildtype, all of which are predicted to deactivate the tumor suppressor functions of p53 (PMID: 18453682).",
            "description_review": {
              "updateTime": 1664822070726,
              "updatedBy": "User"
            },
            "description_uuid": "ef519dc5-cc84-4622-8e0d-5586a4a7b8e8",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "42c10a9f-79bc-4300-87bb-dc024eff1ef4",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "5efbee72-241e-487a-b2e2-940bea3a256f",
            "short": ""
          },
          "mutation_effect_uuid": "5d15db29-1ba6-4d91-89a7-f8fbf8cb952e",
          "name": "R282Q",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "5cdedbcf-8390-4ee2-bb9b-9ab82333ef2f"
        },
        {
          "mutation_effect": {
            "description": "The TP53 H179R mutation is located in the protein's DNA binding domain. Expression of this mutant failed to induce expression of genes involved in apoptosis or cell cycle arrest (PMID: 17361096). Additionally, this mutation exhibited aberrant regulation of the p53 target gene, BTG2, resulting in elevated HRAS and a unique expression pattern of a cancer-related gene signature (PMID: 22427690).",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "35f84b98-c5fe-4d99-b3a5-7499828185d5",
            "effect": "Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "d37c6c5b-21b8-47b4-a98a-8fae8955f01b",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "7d717015-2e80-46dc-bcaf-5c79cdf42a67",
            "short": ""
          },
          "mutation_effect_uuid": "0f0ad22e-f4cf-44e4-8417-ad1a841cd201",
          "name": "H179R",
          "name_comments": [
            {
              "content": "need to include this PMID PMID: 17361096",
              "date": "1478547228463",
              "email": "user@gmail.com",
              "resolved": "true",
              "userName": "User"
            }
          ],
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "db87bb79-798a-4edf-948a-c34e26882239"
        },
        {
          "mutation_effect": {
            "description": "The TP53 H179Y mutation is located in the protein's DNA binding domain. In vitro studies have demonstrated that this mutation is inactivating, as evidenced by the increased G1 to S phase transition, enlarged cell size, as well as increased expression of cyclin A1 and CDK4 in the mutant compared to wildtype (PMID: 17530187).",
            "description_review": {
              "updateTime": 1663300135771,
              "updatedBy": "User"
            },
            "description_uuid": "0abbb09a-1261-496f-b452-c613c6f65842",
            "effect": "Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "4900f3b0-5437-4553-a4b8-b7a9978c107c",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "12012306-2551-40fd-ba51-4967a0101d4a",
            "short": ""
          },
          "mutation_effect_uuid": "4bd8d16a-32a2-4d14-afe5-2def4e4f948b",
          "name": "H179Y",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "8c1a04e2-8f8c-4b8f-b476-5f9d8de4d145"
        },
        {
          "mutation_effect": {
            "description": "The TP53 H179L mutation is located in the protein's DNA binding domain. In vitro studies have demonstrated that this mutation is inactivating, as evidenced by enhanced adhesion to extracellular matrix and increased growth in suspension culture in the mutant compared to wildtype (PMID: 23150443).",
            "description_review": {
              "updateTime": 1663300630854,
              "updatedBy": "User"
            },
            "description_uuid": "0997d4a1-518a-4e63-8e52-bcf32ca94ca6",
            "effect": "Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "5b08abf9-5d6f-499f-8c90-378c1a899f37",
            "oncogenic": "Yes",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "900bfaea-0b3a-4a6a-a739-3562a76d32a9",
            "short": ""
          },
          "mutation_effect_uuid": "29545a6a-4353-4178-ba66-1420ce8e1598",
          "name": "H179L",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "3d7dabaa-46dc-45cf-abcb-c137ab831040"
        },
        {
          "mutation_effect": {
            "description": "The TP53 H179Q mutation is located in the protein's DNA binding domain. In vitro studies have demonstrated that this mutation is inactivating and behaves as a dominant-negative allele, as evidenced by reduced expression of p21 and increased G1 to S phase cell cycle progression in the mutant compared to wildtype (PMID: 22540896).",
            "description_review": {
              "updateTime": 1663300794288,
              "updatedBy": "User"
            },
            "description_uuid": "388780c2-4bbf-4d2b-b654-e83cf8b2aeea",
            "effect": "Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "4ee72828-764c-4310-90a1-4719796682ca",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "bc045567-d397-42de-a75c-dda7444199e5",
            "short": ""
          },
          "mutation_effect_uuid": "5147bf16-4b07-4645-a278-6e5490d11565",
          "name": "H179Q",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "b00df1b8-b342-4c35-9f17-89c6b60ceb23"
        },
        {
          "mutation_effect": {
            "description": "The TP53 H179N mutation is located in the protein's DNA binding domain. In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by reduced DNA binding activity and similar exonuclease activity in the mutant compared to wildtype (PMID: 19462533).",
            "description_review": {
              "updateTime": 1663301094117,
              "updatedBy": "User"
            },
            "description_uuid": "cf067f09-5e5a-4e05-ba5c-651b26e44b3f",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "89391554-fcfb-436b-9903-c4982afcaf7e",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "fd6aa90a-36c5-48f7-a943-b7cb7fb0bfe9",
            "short": ""
          },
          "mutation_effect_uuid": "029e3eb0-ee7e-4d7f-80d0-3f3fb094d479",
          "name": "H179N",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "1b18323c-69b9-4a22-bb38-9b5b965d5a19"
        },
        {
          "mutation_effect": {
            "description": "The TP53 H193R mutation is located in the protein's DNA binding domain. This mutation has been found in sarcoma (PMID: 25669829). In vitro studies have demonstrated that this mutation is likely inactivating, as measured by decreased DNA binding and decreased transactivaction of TP53, likely leading to reduced p21 activation (PMID: 9627118). In a phase I clinical trial of pazopanib, a VEGF inhibitor, and vorinostat, a histone deacetylase inhibitor, eleven patients with sarcoma and colorectal cancer who harbor the TP53 H193R mutation as well as other TP53 mutations in exons 5-8 had longer median progression-free and overall survival compared to patients without TP53 mutations in response to treatment (PMID: 25669829).",
            "description_review": {
              "updateTime": 1664406242829,
              "updatedBy": "User"
            },
            "description_uuid": "ac334fc3-890a-4558-adfd-44867b2ae1b7",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "19981225-8861-4254-8a15-b38ad0176529",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "58a24041-73ee-499e-91b0-cdf0fca27d79",
            "short": ""
          },
          "mutation_effect_uuid": "31c8bd69-af53-478e-b85f-326d6983c248",
          "name": "H193R",
          "name_comments": [
            {
              "content": "there are many more references for this..is there no other functional data?",
              "date": "1478548371221",
              "email": "user@gmail.com",
              "resolved": "true",
              "userName": "User"
            }
          ],
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "3ff887d6-1839-41e8-be34-e1d40eddfd4d"
        },
        {
          "mutation_effect": {
            "description": "The TP53 H193N mutation is located in the protein's DNA binding domain. In vitro studies have suggested that this mutation is likely inactivating, as evidenced by increased exonuclease activity and significantly reduced DNA binding activity compared to the wildtype (PMID: 19462533).",
            "description_review": {
              "updateTime": 1667580373128,
              "updatedBy": "User"
            },
            "description_uuid": "74e4a908-33fb-4425-8965-9c4a08f986f3",
            "effect": "Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "a4c0defb-5dde-4e3c-86b4-514e487bbcbd",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "e0acc9c2-c214-44b1-b98e-30e699ceead2",
            "short": ""
          },
          "mutation_effect_uuid": "9bb02826-cdee-4b94-838e-e57632d796dc",
          "name": "H193N",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "6dfd3c34-733a-48d0-97f6-fcde84481612"
        },
        {
          "mutation_effect": {
            "description": "The TP53 C176F mutation is located in the protein's DNA binding domain. This mutation has been found in head and neck cancer (PMID: 22090360). In vitro studies have demonstrated that this mutation is inactivating, as evidenced by decreased transactivation of p21, decreased production of reactive oxygen species and decreased cell death when the mutant is treated with radiation compared to wildtype, suggesting an inhibition of radiation-induced senescence that results in treatment failure (PMID: 22090360).",
            "description_review": {
              "updateTime": 1667586437444,
              "updatedBy": "User"
            },
            "description_uuid": "d54b1878-158a-42de-8c63-5e277ab51722",
            "effect": "Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "d6a9728c-480b-4a9a-a8b2-48c3fd855b33",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "41f3b0e6-56b8-4f6b-84fd-181f55838535",
            "short": ""
          },
          "mutation_effect_uuid": "b5be5d49-0d2c-4f4a-a6da-08ed02f7e870",
          "name": "C176F",
          "name_comments": [
            {
              "content": "PMID: 20182602",
              "date": "1478548629171",
              "email": "user@gmail.com",
              "resolved": "false",
              "userName": "User"
            }
          ],
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "77b2b05e-5430-4813-9eb6-8ce2e994a709"
        },
        {
          "mutation_effect": {
            "description": "The TP53 C176R mutation is located in the protein's DNA binding domain. In vitro studies have suggested that this mutation is inactivating and acts as a dominant negative, as evidenced by the ability of mutant yeasts coexpressing both wild-type and C176R-mutated p53 to survive on Foa plates compared to wildtype (PMID: 8633021).",
            "description_review": {
              "updateTime": 1667587791578,
              "updatedBy": "User"
            },
            "description_uuid": "ff185803-1e1e-4aae-959b-e79822ee1ae6",
            "effect": "Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "8be2e6a2-755f-4bd6-ab7d-88b448c6171a",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "31896bf1-ca99-4d2c-b09c-964af0ee3fa6",
            "short": ""
          },
          "mutation_effect_uuid": "dc9e2ab3-6ce0-4293-a0ff-ba7cb2afb8d5",
          "name": "C176R",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "336bd1db-1238-44aa-a64a-e77e21ca6c6d"
        },
        {
          "mutation_effect": {
            "description": "The TP53 I195T mutation is located in the protein's DNA binding domain. Structural studies have suggested that this mutation is likely inactivating as evidenced by the decreased half-life time, faster aggregation and faster unfolding time at body temperature of the mutant compared to wildtype protein, suggesting that the mutant is highly destabilized and could result in loss of p53 tumor suppressor function (PMID: 12700230).",
            "description_review": {
              "updateTime": 1667593555352,
              "updatedBy": "User"
            },
            "description_uuid": "0a427e9f-f4d7-4ad1-a59c-2dcab05aa665",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "9c47ac79-0f93-4901-8709-3d2666850fcf",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "446fc820-d97c-445b-ae45-bcadb8d2331f",
            "short": ""
          },
          "mutation_effect_uuid": "515b3a40-b85b-4317-9278-bf075f61f151",
          "name": "I195T",
          "name_comments": [
            {
              "content": "is there other data for this mutation?",
              "date": "1479401181123",
              "email": "user@gmail.com",
              "resolved": "true",
              "userName": "User"
            },
            {
              "content": "anything in the DBD - include some language from that string and possibly make it likely oncogenic",
              "date": "1481659209330",
              "email": "user@gmail.com",
              "resolved": "true",
              "userName": "User"
            }
          ],
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "f80fd456-c221-4f96-b073-522b924944a5"
        },
        {
          "mutation_effect": {
            "description": "The TP53 G266E mutation is located in the protein's DNA binding domain. In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by decreased transcriptional transactivation of p53 target genes in the mutant compared to the wildtype, suggesting a loss of function to regulate transactivation of p53 target genes (PMID: 17724467).",
            "description_review": {
              "updateTime": 1667594072251,
              "updatedBy": "User"
            },
            "description_uuid": "c1ea56c3-fc24-4248-b178-9f01121523f8",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "a37213f6-cf16-40a6-b0bc-368d8530366f",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "790f5f5e-b15a-449e-a777-cc631aa83b60",
            "short": ""
          },
          "mutation_effect_uuid": "797eae71-fdab-4a8d-a825-fbf1d5292166",
          "name": "G266E",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "3d1dc835-3f4b-47a4-b191-a245bed0ea30"
        },
        {
          "mutation_effect": {
            "description": "The TP53 R249S mutation is located in the protein's DNA binding domain. Structural and in vitro studies have demonstrated that this mutation is likely inactivating as evidenced by distortion of the local binding surface and increased aggregation of the mutant proteins compared to wildtype, reduced TP53 transactivation activity as measured by luciferase reporter assays, defective cell cycle progression, and aberrant expression of apoptosis proteins in cells expressing the mutant protein compared to wildtype (PMID: 14741214, 21445056, 18996393).",
            "description_review": {
              "updateTime": 1667593647776,
              "updatedBy": "User"
            },
            "description_uuid": "7d14a126-9fa0-497d-ba23-398e4d552a60",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "9c07e707-9d36-4a29-90f3-c27a187e03da",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "343aedad-e7f2-4766-97c6-e2b1d89249f0",
            "short": ""
          },
          "mutation_effect_uuid": "6c8eba7a-1a78-4d54-b3b0-128fd1255b2f",
          "name": "R249S",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "33774f4a-2817-4dc0-bf57-58639b3e70c7"
        },
        {
          "mutation_effect": {
            "description": "The TP53 R249M mutation is located in the protein's DNA binding domain. In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by the mutant's inability to inhibit the transcriptional activity of the p21 promoter and enhance TP53-mediated transcriptional activity in reporter assays compared to wildtype (PMID: 17999388, 15037740).",
            "description_review": {
              "updateTime": 1667593109344,
              "updatedBy": "User"
            },
            "description_uuid": "d2f39c48-5928-40ef-8e02-4b0dd3b95a68",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1667592984401,
              "updatedBy": "User"
            },
            "effect_uuid": "131c7f95-88bd-4981-a4c7-727fae35bef8",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "0102b352-c961-4002-a011-30f5682ef93d",
            "short": ""
          },
          "mutation_effect_uuid": "d5a869fe-d227-401c-901b-338e98dfb0bd",
          "name": "R249M",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "bf3ed7a5-b8e9-464e-989d-57bf68478c5a"
        },
        {
          "mutation_effect": {
            "description": "The TP53 R249W mutation is located in the protein's DNA binding domain. In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by increased colony formation and greater migration in the mutant compared to wildtype (PMID: 23612969).",
            "description_review": {
              "updateTime": 1667593856237,
              "updatedBy": "User"
            },
            "description_uuid": "b4e40288-4633-4306-bd26-9a664b60423f",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1667593167806,
              "updatedBy": "User"
            },
            "effect_uuid": "ed12f229-01c9-4abd-9750-7d75ea473d06",
            "oncogenic": "Yes",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "34064c08-acba-4723-8dbb-cf91b2c70392",
            "short": ""
          },
          "mutation_effect_uuid": "b9e8526e-bca0-4362-ba8d-3bc37dbeb14a",
          "name": "R249W",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "630cad0d-6f60-4181-9e0a-5a41a1e61920"
        },
        {
          "mutation_effect": {
            "description": "The TP53 Y234C mutation is located in the protein's DNA binding domain. This mutation has been found in ovarian cancer (PMID: 26748848). In vitro studies have demonstrated that this mutation is inactivating, as evidenced by decreased transactivation of p53 target genes, increased cytoplasmic localization and increased apoptosis when treated with an amyloid aggregate TP53 inhibitor in the mutant compared to wildtype, suggesting that this mutation may cause amyloid aggregate formation that inactivates the p53 protein (PMID: 10229196, 16861262, 26748848).",
            "description_review": {
              "updateTime": 1667843346314,
              "updatedBy": "User"
            },
            "description_uuid": "033fac3a-22bc-4250-8626-db83da799ee9",
            "effect": "Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "96e2befc-af08-41f6-9e7c-1756b7ed3e47",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "6110b319-851e-494d-902a-298390b81b6d",
            "short": ""
          },
          "mutation_effect_uuid": "51fe65ee-72ee-42da-9fd6-9238a26fa917",
          "name": "Y234C",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "c4fe63a1-a50d-48b2-8a0c-ae37204c1ec7"
        },
        {
          "mutation_effect": {
            "description": "The TP53 Y234H mutation is located in the protein's DNA binding domain. In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by the reduced ability to transactivate p53 target genes of the mutant compared to wildtype (PMID: 22710932).",
            "description_review": {
              "updateTime": 1667661780744,
              "updatedBy": "User"
            },
            "description_uuid": "dfcf4c73-3b3f-42c5-bd22-1c42c04194a1",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1667661718612,
              "updatedBy": "User"
            },
            "effect_uuid": "27311c4f-ae10-4f10-b49f-113d790baa00",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "8da5c56f-54ce-4e1e-aa44-bddeecd51b9c",
            "short": ""
          },
          "mutation_effect_uuid": "942dccf3-ebfa-4a01-8825-ef6ada03542b",
          "name": "Y234H",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "8169b2c6-a770-4aa0-ab7d-19b4c9859007"
        },
        {
          "mutation_effect": {
            "description": "The TP53 C238F mutation is located in the protein's DNA binding domain. This mutation has been found in breast cancer (PMID: 20407015). In vivo and structural studies have demonstrated that this mutation is inactivating, as evidenced by the structural prediction that the mutation interferes with the histidine or cysteine side chains that are known to be involved in the coordination of the zinc ion, as well as the mutant's inability to transactivate p53 target genes compared to wildtype (PMID: 20407015).",
            "description_review": {
              "updateTime": 1667843379059,
              "updatedBy": "User"
            },
            "description_uuid": "e271bd94-3e5c-4d73-ba02-829e931e6ab2",
            "effect": "Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "f651d617-a45b-4abb-92ea-e0b8ae80cf0f",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "55add0c9-1b2d-4f4a-c019-260bcb83dd20",
            "short": ""
          },
          "mutation_effect_uuid": "f11d6cea-83e9-4971-96e3-bbf389b05853",
          "name": "C238F",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "5f68e248-71cb-4767-acc7-bda0b9ed8efd"
        },
        {
          "mutation_effect": {
            "description": "The TP53 C238S mutation is located in the protein's DNA binding domain. In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by decreased transactivation of p53 target genes in the mutant compared to wildtype (PMID: 19681600).",
            "description_review": {
              "updateTime": 1667662359923,
              "updatedBy": "User"
            },
            "description_uuid": "3e6ade8d-4ec5-42bd-9d9e-bff161a14b99",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1667662233524,
              "updatedBy": "User"
            },
            "effect_uuid": "49e1b7b9-d9d6-440c-b0a8-ac813f3a2740",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "dbc135d1-8807-4a56-ac84-a2a9563d2ff5",
            "short": ""
          },
          "mutation_effect_uuid": "fba0264b-0d80-4cb2-b7cc-9533abcada62",
          "name": "C238S",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "da32c6f2-2219-4b37-ba41-18b07357b554"
        },
        {
          "mutation_effect": {
            "description": "The TP53 V173E mutation is located in the protein's DNA binding domain. This mutation has been found in lung carcinoma  (PMID: 9472631). In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by the mutant's inability to bind to the responsive elements of p53 and transactivate p53-dependent promoters compared to wildtype (PMID: 9472631).",
            "description_review": {
              "updateTime": 1667843411317,
              "updatedBy": "User"
            },
            "description_uuid": "ad0bfe2d-8695-4e12-b1cc-8f599a3a8924",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1667662571405,
              "updatedBy": "User"
            },
            "effect_uuid": "3eec88ab-6e54-492b-8a02-36e7abed203e",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "46d61767-80b8-4aca-994a-e533fea37822",
            "short": ""
          },
          "mutation_effect_uuid": "555e5ce2-9465-436a-bec1-733a89455598",
          "name": "V173E",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "48704f12-229c-4e77-a631-ccf24cdde05f"
        },
        {
          "mutation_effect": {
            "description": "The TP53 R158C mutation is located in the protein's DNA binding domain. In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by decreased transactivation of p53 target genes in the mutant compared to wildtype (PMID: 17947339).",
            "description_review": {
              "updateTime": 1667667569484,
              "updatedBy": "User"
            },
            "description_uuid": "80a7d825-f53e-411e-b555-cf944581e4ee",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "73d09b4a-9b64-4d4c-af06-008a67646710",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "7f521adf-8df7-45d8-b9c9-c8d310f46f15",
            "short": ""
          },
          "mutation_effect_uuid": "33724a92-02e4-472a-986c-143b7ced79f2",
          "name": "R158C",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "09019ed5-e9d8-4e07-989c-94af49530102"
        },
        {
          "mutation_effect": {
            "description": "The TP53 P151S mutation is located in the protein's DNA binding domain. This mutation has been found in head and neck squamous cell carcinoma (PMID: 21903770). In vitro and in vivo studies have demonstrated that this mutation is inactivating, as evidenced by the formation of larger tumor spheroids with longer migration and invasion distances in matrigel culture compared to wildtype, as well as increased tumor growth and decreased animal survival in xenograft models (PMID: 21903770).",
            "description_review": {
              "updateTime": 1667843453572,
              "updatedBy": "User"
            },
            "description_uuid": "990421ee-0196-4410-b4cd-4ae1c9035bc8",
            "effect": "Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "1151e72c-dc3c-4a2c-ba52-c825b76238c2",
            "oncogenic": "Yes",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "d5c23995-9b5f-4448-8349-30f1642a88ab",
            "short": ""
          },
          "mutation_effect_uuid": "15f72e53-48b7-4b45-b59e-15c35bf28f4a",
          "name": "P151S",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "02e4bc79-22ec-4f2c-b478-e5b9686b7044"
        },
        {
          "mutation_effect": {
            "description": "The TP53 P151H mutation is located in the DNA binding domain of the protein. In vivo studies have demonstrated that this mutation is likely inactivating, as evidenced by decreased transactivation of p53 target genes in the mutant compared to wildtype (PMID: 22908277).",
            "description_review": {
              "updateTime": 1670454750553,
              "updatedBy": "User"
            },
            "description_uuid": "10baa664-01cd-44d0-a9df-09c39490f695",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "b88eb62c-c5da-4c01-8525-9e907028360a",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "3dbaa0fa-0c07-43a7-b18f-507cfeb27c1f",
            "short": ""
          },
          "mutation_effect_uuid": "6fcb7299-14e1-4ca2-a83c-b88583414cc7",
          "name": "P151H",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "742fcd78-088d-47a0-ad02-1c7a36bb4713"
        },
        {
          "mutation_effect": {
            "description": "The TP53 P151A mutation is located in the DNA binding domain of the protein. In vivo studies have demonstrated that this mutation is likely inactivating, as evidenced by the complete lack of transactivation of p53 target genes in the mutant compared to wildtype (PMID: 20407015).",
            "description_review": {
              "updateTime": 1670454832615,
              "updatedBy": "User"
            },
            "description_uuid": "613bf32e-cb40-4f7d-a306-1fa80a2a1dfe",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1669752775799,
              "updatedBy": "User"
            },
            "effect_uuid": "89c7e0cc-517a-4bfd-a4db-20384cc53bb0",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "cfa0a2ab-09bb-4c97-ba4a-30f701297160",
            "short": ""
          },
          "mutation_effect_uuid": "7c9a986e-aa56-4284-8a58-7ea3ac65e641",
          "name": "P151A",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "8250e298-bd35-4c01-b708-aa5012bb3a63"
        },
        {
          "mutation_effect": {
            "description": "The TP53 Y236C mutation is located in the DNA binding domain of the protein. This mutation has been found in colon cancer  (PMID: 16827139). In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by increased cytoplasmic localization of the mutant, leading to reduced transcriptional activity in the mutant compared to wildtype (PMID: 16827139).",
            "description_review": {
              "updateTime": 1670454855330,
              "updatedBy": "User"
            },
            "description_uuid": "6965946c-f475-4fd8-8bf5-3ad36098f29d",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1669753174376,
              "updatedBy": "User"
            },
            "effect_uuid": "ee2e9c0c-5c03-4700-bfd2-07ae5859bead",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "5460b591-1ea9-493e-a8ad-6cb2f5285272",
            "short": ""
          },
          "mutation_effect_uuid": "5f799add-174d-45fa-8b18-034d00ff610d",
          "name": "Y236C",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "3c055484-732e-4501-8ba6-ad1051147b99"
        },
        {
          "mutation_effect": {
            "description": "The TP53 Y236D mutation is located in the DNA binding domain of the protein. In vivo studies have demonstrated that this mutation is likely inactivating, as evidenced by the loss of binding ability of the p53 protein to its consensus sequence in the mutant compared to wildtype (PMID: 8633021).",
            "description_review": {
              "updateTime": 1670454888967,
              "updatedBy": "User"
            },
            "description_uuid": "38dde1d3-83bf-44c2-84e2-e319b2f6294b",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1669753457171,
              "updatedBy": "User"
            },
            "effect_uuid": "0d29d38e-250f-4c6c-9b79-371450932c17",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "b652862c-9b8d-4cbf-8a89-b3e3bcb0bfe4",
            "short": ""
          },
          "mutation_effect_uuid": "e3b1b043-ec8e-4bce-8014-d2170e8bdb54",
          "name": "Y236D",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "c3bab056-4798-4e46-86a4-87baa0841c46"
        },
        {
          "mutation_effect": {
            "description": "The TP53 Y236S mutation is located in the DNA binding domain of the protein. In vivo studies have demonstrated that this mutation is likely inactivating, as evidenced by the loss of transcriptional activity for p53 target genes, p21 and RGC, in the mutant compared to wildtype (PMID: 11429705).",
            "description_review": {
              "updateTime": 1670454918987,
              "updatedBy": "User"
            },
            "description_uuid": "c0a75b69-cd4e-4d2d-9cab-3d3c2353eb07",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1669754515490,
              "updatedBy": "User"
            },
            "effect_uuid": "dbc51820-a8b0-4383-b1e3-8880dfaecd8f",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "52cd1643-06bb-4ac4-9f04-e05f0f602a66",
            "short": ""
          },
          "mutation_effect_uuid": "13ef470a-3fe9-4f02-845a-171f904db2fc",
          "name": "Y236S",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "274b33cf-cb8c-4928-97ce-8eb605b676be"
        },
        {
          "mutation_effect": {
            "description": "The TP53 P278S mutation is located in the DNA binding domain of the protein. In vitro and in vivo studies have demonstrated that this mutation is inactivating, as evidenced by failure to activate the p21 promoter in the mutant compared to wildtype (PMID: 22989750).",
            "description_review": {
              "updateTime": 1670454940516,
              "updatedBy": "User"
            },
            "description_uuid": "8f9d9526-53a5-487e-c069-5afa6ce03954",
            "effect": "Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "833b1afa-c712-4d02-ae7d-2fa94464b10d",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "502cefa0-d28c-4506-a108-1035f51d8fe4",
            "short": ""
          },
          "mutation_effect_uuid": "dde19a09-9fa0-4e95-968e-38605f14792d",
          "name": "P278S",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "0047da75-56fe-4907-95f2-9c25818b19a4"
        },
        {
          "mutation_effect": {
            "description": "The TP53 P278L mutation is located in the DNA binding domain of the protein. In vivo studies have demonstrated that this mutation is likely inactivating, as evidenced by failure to transactivate p53 target genes in the mutant compared to wildtype (PMID: 16861262).",
            "description_review": {
              "updateTime": 1670454960979,
              "updatedBy": "User"
            },
            "description_uuid": "8fcdb3aa-95c6-4b7c-af4f-9a29b9df561e",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1669758496372,
              "updatedBy": "User"
            },
            "effect_uuid": "71cdbaeb-4d9a-422c-93be-3963b82b154d",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "4c4e6134-e407-43f2-9485-7b7fc2865c9e",
            "short": ""
          },
          "mutation_effect_uuid": "5e6379d6-a361-4983-a923-f15fa03bee83",
          "name": "P278L",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "5641f978-690b-4f2d-8bd9-6b267041b8a0"
        },
        {
          "mutation_effect": {
            "description": "The TP53 P278A mutation is located in the DNA binding domain of the protein. In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by failure to transactivate p53-dependent genes in the mutant compared to wildtype (PMID: 24076587).",
            "description_review": {
              "updateTime": 1670455075291,
              "updatedBy": "User"
            },
            "description_uuid": "4fdc799b-d688-469d-81ca-57658beeafd5",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "c75da0cb-1d2f-42be-9869-bfd46052d9c3",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "efbdd2eb-04d8-4744-9188-7e0541eef00f",
            "short": ""
          },
          "mutation_effect_uuid": "40575f81-df6d-443d-8a75-926dc5b2bb85",
          "name": "P278A",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "62c66c02-89b9-40c0-a682-eb0aee20a036"
        },
        {
          "mutation_effect": {
            "description": "The TP53 P278R mutation is located in the DNA binding domain of the protein. This mutation has been found in hepatocellular carcinoma (PMID: 21760996). In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by the loss of transactivation activity of p53 target genes in the mutant compared to wildtype (PMID: 21760996).",
            "description_review": {
              "updateTime": 1670455219347,
              "updatedBy": "User"
            },
            "description_uuid": "c1ebe31e-10e2-4a83-8bdd-432b4110d1eb",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1669759770552,
              "updatedBy": "User"
            },
            "effect_uuid": "f5736b95-d9c0-47d3-a5d3-bc56948d72ca",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "32202420-35e5-4bd4-b05c-99a0ec5b4654",
            "short": ""
          },
          "mutation_effect_uuid": "1a35e74a-95fa-4c87-9c38-839364fd4f05",
          "name": "P278R",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "c4fc514c-5970-4a7b-b31b-55e6ce352dbb"
        },
        {
          "mutation_effect": {
            "description": "The TP53 C135Y mutation is located in the DNA binding domain of the protein. In vitro studies with p53-null endometrial cancer cells expressing TP53 C135Y have demonstrated that this mutation is inactivating as measured by loss of miRNA expression regulation, specifically the microRNA miR-130b and miR-200c, resulting in increased epithelial to mesenchymal transition and cell invasion in the mutant compared to wildtype (PMID: 22847613). In vivo studies with yeast expressing TP53 C135Y demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 C135Y also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1671478545051,
              "updatedBy": "User"
            },
            "description_uuid": "7fb2528b-7d29-4c52-813a-fa70fe12d878",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1671047390790,
              "updatedBy": "User"
            },
            "effect_uuid": "58ac6d98-c731-4ae6-adf3-fa75457ce195",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "64951c47-fa12-4c80-82bf-0a7e60644559",
            "short": ""
          },
          "mutation_effect_uuid": "0d1c27d3-9e82-4b17-b856-d08c9e5f21ea",
          "name": "C135Y",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "691956c3-baac-437e-b49f-b7f7f1decbb6"
        },
        {
          "mutation_effect": {
            "description": "The TP53 C135R mutation is located in the DNA binding domain of the protein. This mutation has been found in non-small cell lung cancer (PMID: 17914575). Structural and in vitro studies have demonstrated that this mutation is inactivating, as evidenced by its predicted negative effect on p53-DNA interaction and the mutant protein's inability to bind to the TP53 response element from the p21 gene in an electrophoretic mobility shift assay compared to wildtype (PMID: 17914575).",
            "description_review": {
              "updateTime": 1670455335022,
              "updatedBy": "User"
            },
            "description_uuid": "91b54dc2-4382-447d-8b29-1e0ac6ebe8c0",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1574310529276,
              "updatedBy": "User"
            },
            "effect_uuid": "47bcf836-b853-4dc6-8446-91840ffe30be",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "6715ed2d-1b0b-4556-bb8d-e29a218e2d75",
            "short": ""
          },
          "mutation_effect_uuid": "458081f5-608d-4a83-ace8-d44b50449305",
          "name": "C135R",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "e61d9643-4aa4-42b3-a3fd-bfc393e4f223"
        },
        {
          "mutation_effect": {
            "description": "The TP53 C135S mutation is located in the DNA binding domain of the protein. In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by reduced binding capacity to TP53 response elements in the mutant compared to wildtype (PMID: 12034820).",
            "description_review": {
              "updateTime": 1670455364403,
              "updatedBy": "User"
            },
            "description_uuid": "6dd9c993-3813-4062-8b84-0673cfc72d1d",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "927a3833-3c85-4286-bdb9-74a8cdeef3d6",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "c611c09b-1c1b-4a04-9e2e-86211924af5f",
            "short": ""
          },
          "mutation_effect_uuid": "883347df-c916-4c25-987a-d5bc5e01a053",
          "name": "C135S",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "5a890259-adf6-40e5-9864-20f95fe8aa2e"
        },
        {
          "mutation_effect": {
            "description": "The TP53 C275S mutation is located in the DNA binding domain of the protein. Structural and in vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by decreased affinity for the Gadd45 promoter site and increased attenuation of oxidative dissociation in the mutant compared to wildtype, suggesting that this mutation affects p53's function through altering p53-DNA contact (PMID: 25584637).",
            "description_review": {
              "updateTime": 1670455404501,
              "updatedBy": "User"
            },
            "description_uuid": "5fbc06a4-c5a6-413a-a921-5bc4d578d50c",
            "effect": "Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "b19da370-891e-48e9-bf54-1b6d7b3e4bff",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "ddca5b22-8975-42c7-8261-ce9212412460",
            "short": ""
          },
          "mutation_effect_uuid": "16403a8b-08b9-48ba-9646-81085dcee078",
          "name": "C275S",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "defc6152-8e84-4cc4-bf05-8e6af7121660"
        },
        {
          "mutation_effect": {
            "description": "The TP53 M237K mutation is located in the DNA binding domain of the protein. In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by the transactivation of some p53 target genes, including bax and MDM2, but not p21 in the mutant compared to wildtype, suggesting that the mutant is partially but not fully functional (PMID: 20505364).",
            "description_review": {
              "updateTime": 1670455468046,
              "updatedBy": "User"
            },
            "description_uuid": "d380fdf5-7bce-4969-84b5-4bf4122e997c",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "f633f499-f3cc-4229-874e-ff248e29efd0",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "8932cc30-946c-4dcf-9b18-0ec6fd2f6c41",
            "short": ""
          },
          "mutation_effect_uuid": "875e1cf4-3cf1-4586-8859-a1e0b707ce54",
          "name": "M237K",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "7bf7dc0d-8821-45c4-9bed-51ac4cea7f42"
        },
        {
          "mutation_effect": {
            "description": "The TP53 S241F mutation is located in the DNA binding domain of the protein. In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by decreased co-immunoprecipitation of p53 with the tumor suppressor BARD1 and the 3' processing factor cleavage-stimulation factor 1 (CstF1), respectively, as well as decreased formation of the p53/BARD1/CstF1 complex, resulting in reduced inhibition of 3' cleavage (PMID: 21383700).",
            "description_review": {
              "updateTime": 1670455498747,
              "updatedBy": "User"
            },
            "description_uuid": "0a135df1-0dc5-4479-9bec-d3a7ab3c4502",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "dde9b7ee-3377-4b66-8840-abba2b97b783",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "52522d39-f779-465b-b75c-ae42eaf5ee0a",
            "short": ""
          },
          "mutation_effect_uuid": "89945f8f-ae4f-4ad8-95fe-88db4ebd4eb8",
          "name": "S241F",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "2e291914-a9b1-46d5-afaf-d130136362e0"
        },
        {
          "mutation_effect": {
            "description": "The TP53 S241T mutation is located in the DNA binding domain of the protein. In vitro studies have demonstrated that this mutation is inactivating and exhibits a dominant-negative phenotype, as evidenced by the lack of transcription of p53 target genes when both mutant and wildtype proteins are present, suggesting the mutant's ability to inhibit wildtype p53's transactivation ability (PMID: 11896595).",
            "description_review": {
              "updateTime": 1670455522571,
              "updatedBy": "User"
            },
            "description_uuid": "93fe15fe-ef8d-45a6-b7cf-90343ef4bfad",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1669763682275,
              "updatedBy": "User"
            },
            "effect_uuid": "4fa7669a-0569-4358-898b-6cbaac8c2d03",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "926c73a5-ef20-4e9e-b171-166a28553cf2",
            "short": ""
          },
          "mutation_effect_uuid": "0f3be281-8971-4c4f-a503-7c8a83b1a840",
          "name": "S241T",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "eafae8d7-a0d6-42b1-baaa-e7ef7b1b0923"
        },
        {
          "mutation_effect": {
            "description": "The TP53 V272M mutation is located in the DNA binding domain of the protein. This mutation has been found in esophageal cancer (PMID: 9096669). In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by the mutant's reduced reactivity with the wildtype conformation-specific antibody PAb1620, suggesting the adoption of a mutant conformation, as well as reduced accumulation in cells exposed to DNA-damaging agents and inability to rescue TP53-mediated transcriptional activity in TP53-null cells of the mutant compared to wildtype (PMID:15037740, 9096669, 11870884).",
            "description_review": {
              "updateTime": 1670455549759,
              "updatedBy": "User"
            },
            "description_uuid": "8e56731b-2713-4cff-8ba4-db92c5901f3b",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "ea2f157e-44b1-4866-a2d6-31ab37cea043",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "707351b7-2efe-4dad-9bae-38852823e1f7",
            "short": ""
          },
          "mutation_effect_uuid": "5171de43-52ec-4662-a178-aed8dfe380c6",
          "name": "V272M",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "c5588329-1e64-4081-af44-cbefdcff1c2f"
        },
        {
          "mutation_effect": {
            "description": "The TP53 V272L mutation is located in the DNA binding domain of the protein. In silico and in vitro studies have demonstrated that this mutation has inconclusive effect, as evidenced by comparable levels of p53 target gene transactivation in the mutant compared to wildtype, despite its position at a hotspot residue which suggests that it is likely oncogenic (PMID: 20407015, 26619011).",
            "description_review": {
              "updateTime": 1670455656055,
              "updatedBy": "User"
            },
            "description_uuid": "0367cd7d-575a-4bcf-a971-8567062f3b8d",
            "effect": "Inconclusive",
            "effect_review": {
              "updateTime": 1669765206050,
              "updatedBy": "User"
            },
            "effect_uuid": "bcadaf27-fa17-4978-bc4c-1efd42db3f0a",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1487884930000
            },
            "oncogenic_uuid": "348124be-1c9c-4f7f-9fde-07b0c77ac89c",
            "short": ""
          },
          "mutation_effect_uuid": "03b4cda3-8d41-45bd-9c27-b655b27dd358",
          "name": "V272L",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "48d652fb-8213-4953-b612-633c347dc3e9"
        },
        {
          "mutation_effect": {
            "description": "The TP53 V157F mutation is located in the DNA binding domain of the protein. In vitro and structural studies have demonstrated that this mutation is likely inactivating, as evidenced by the mutant protein's rearranged DNA-binding surface and reduced DNA-binding activity compared to wildtype, as well as reduced expression of pro-apoptotic proteins, reduced apoptotic response and impaired transcriptional activity in cells expressing the mutant compared to wildtype (PMID: 21561095, 16778209, 15037740).",
            "description_review": {
              "updateTime": 1670455664745,
              "updatedBy": "User"
            },
            "description_uuid": "ff12c354-83df-4e14-a802-565f311d4630",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "b771c2bb-6b11-4575-83bb-63339f53b154",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "f75ff833-43d2-4a6a-954e-de1da2b6d03c",
            "short": ""
          },
          "mutation_effect_uuid": "1ebcfddf-b516-4feb-9428-8a3e5dd53951",
          "name": "V157F",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "dfb252dd-6448-4d05-8416-511b6585c6cc"
        },
        {
          "mutation_effect": {
            "description": "The TP53 V157D mutation is located in the DNA binding domain of the protein. This mutation has been found in the germline of patients with familial cancer syndromes (PMID: 23981578). In vitro and in vivo studies have demonstrated that this mutation is inactivating, as evidenced by increased colony formation in soft agar assays and increased tumor formation in a transgenic Drosophila system expressing the mutant compared to wildtype (PMID: 23981578).",
            "description_review": {
              "updateTime": 1670455697380,
              "updatedBy": "User"
            },
            "description_uuid": "dd1206ed-8ad6-408d-9eca-ad88c27fe725",
            "effect": "Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "e139ddd4-b683-4b90-97ff-520a0e2eb969",
            "oncogenic": "Yes",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "4d5e948f-ead3-4b0b-a207-e93f30e4011e",
            "short": ""
          },
          "mutation_effect_uuid": "5457a57d-9828-4969-9d54-f493431f3fd9",
          "name": "V157D",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "9e5dfa6a-24e4-4fd1-9751-b7a19fa62d81"
        },
        {
          "mutation_effect": {
            "description": "The TP53 R280K mutation is located in the DNA binding domain of the protein. In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by decreased apoptosis and increased migration in TP53-null cells expressing the mutant compared to wildtype (PMID: 24714748).",
            "description_review": {
              "updateTime": 1670455717078,
              "updatedBy": "User"
            },
            "description_uuid": "1596ba30-dce5-40e1-933f-f16664b65c82",
            "effect": "Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "e3cc7c18-1e4e-4911-8127-79b267f757c8",
            "oncogenic": "Yes",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "2bf5a097-e62a-4e22-a62d-64cfabb6e576",
            "short": ""
          },
          "mutation_effect_uuid": "435e2f44-db10-4c02-b514-747094036a87",
          "name": "R280K",
          "name_comments": [
            {
              "content": "Is there no PMID for this?; needs a proper citation, not a link here",
              "date": "1476384655470",
              "email": "user@gmail.com",
              "resolved": "true",
              "userName": "User"
            },
            {
              "content": "refer to last slide of presentation about how to cite abstracts",
              "date": "1476888717341",
              "email": "user@gmail.com",
              "resolved": "true",
              "userName": "User"
            }
          ],
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "1d83b9e3-3e5b-40e4-99ca-a3e407adeb5a"
        },
        {
          "mutation_effect": {
            "description": "The TP53 R280T mutation is located in the DNA binding domain of the protein. This mutation has been found in glioma (PMID: 22999923). In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by increased proliferation of cells expressing the mutant compared to wildtype, as well as increased p-GSK-3 levels, reduced PTEN and Akt phosphorylation and reduced cell growth upon knockdown of the mutant protein compared to wildtype, suggesting that this mutation promotes cell growth through GSK-3beta-PTEN pathway (PMID: 22999923).",
            "description_review": {
              "updateTime": 1675288102578,
              "updatedBy": "User"
            },
            "description_uuid": "73c10b15-e57c-4db8-a7b4-91d095f3e85e",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "dc9b6b17-0643-4fb9-bd35-26ee22eb93cf",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "66bf4f84-ee70-498f-9803-abb7e70b4497",
            "short": ""
          },
          "mutation_effect_uuid": "eba82072-a35c-4038-a153-c12e5f8cc95b",
          "name": "R280T",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "efd83561-430e-49f6-b0f2-7276d6c559a3"
        },
        {
          "mutation_effect": {
            "description": "The TP53 C242F mutation is located in the protein's DNA binding domain. Structural studies have elucidated that this mutant is inactivating as it directly affects the zinc coordination sphere by substituting one of the zinc ligands and thus affects the DNA binding capabilities of p53 (PMID: 17401432).",
            "description_review": {
              "updateTime": 1678996210567,
              "updatedBy": "User"
            },
            "description_uuid": "14c32191-e469-4b48-b5c1-f67c0d0c6776",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "d43188f4-7503-42c5-a155-6a0ec1b14000",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "643a4091-2dcf-40cc-a97c-2825d661a41b",
            "short": ""
          },
          "mutation_effect_uuid": "4a75a207-8160-4f17-9a16-c84f49bd537d",
          "name": "C242F",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "7a2976b3-c2ef-4573-8f96-54310638ef0e"
        },
        {
          "mutation_effect": {
            "description": "The TP53 N239S mutation is located in the protein's DNA binding domain. This mutant has lost the wild type p53 tumor suppresive function because this mutant is unable to bind to DNA and p53 target promoters. Moreover, it fails to regulate the transcription of p21. Additionally, xenografts studies have shown that this mutant promotes tumorigenesis in p53 null MEFs (PMID: 22553460).",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "79fc0e97-9fdd-4b8a-885b-4722867c0241",
            "effect": "Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "73e866a2-4701-46a6-9f19-ba5eda7316f5",
            "oncogenic": "Yes",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "074c9875-1183-46a7-8c16-5cad43f53e90",
            "short": ""
          },
          "mutation_effect_uuid": "d2e9caa6-fce7-4f87-bd52-54ae5b52a999",
          "name": "N239S",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "5f0924a5-bbf5-4abd-a1c5-982909440050"
        },
        {
          "mutation_effect": {
            "description": "The TP53 S215C mutation is located in the protein's DNA binding domain. Expression of this mutant resulted in transactivation of p53 target genes comparable to wildtype p53, as a measured by yeast-based functional assay (PMID: 12917626). Expression of this mutation in human osteosarcoma cell lines resulted in slightly increased apoptosis, as evidenced by cell cycle progression studies, though the result was not statistically significant (PMID: 15781620). However, this mutation is a hotspot, suggesting that it is likely oncogenic (PMID: 26619011).",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "813cc573-8f32-449d-b896-6c2077e8f2d5",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "e6026de0-a248-4b16-a2b5-b46bd49f18da",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "55ee798d-973d-458c-93d1-fb0b4bd68c74",
            "short": ""
          },
          "mutation_effect_uuid": "282355b5-9b94-4db9-bc98-68685821aeea",
          "name": "S215C",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "ca3d7be4-aefe-46f6-9e6d-5ec91244f3f0"
        },
        {
          "mutation_effect": {
            "description": "The TP53 C242S mutation is located in the protein's DNA binding domain. This mutation is known to interfere with the histidine or cysteine side chains involved in coordination of the zinc ion. This structural change makes this mutant protein nonfunctional in terms of transactivation (PMID: 20407015).",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "113af2a9-f45d-4c75-bec9-7eea2f694169",
            "effect": "Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "80b18f71-f2e7-4f63-afe5-5d153f40afe2",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "3398e46b-20a4-4486-811d-eab0ddccd483",
            "short": ""
          },
          "mutation_effect_uuid": "1d8cac1e-313e-49db-8f01-f9e9d18f04bc",
          "name": "C242S",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "f6509d46-67a2-4b18-9f08-629ada94ba63"
        },
        {
          "mutation_effect": {
            "description": "The TP53 C242Y mutation is located in the protein's DNA binding domain. This mutation is known to interfere with the histidine or cysteine side chains involved in coordination of the zinc ion. This structural change makes this mutant protein nonfunctional in terms of transactivation (PMID: 20407015).",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "03063a93-e15d-4767-87b3-f6a73cf5dc09",
            "effect": "Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "eea40f25-bcab-4be0-b0aa-06a6e3d2cc78",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "a512b538-7474-49e2-9b80-ef6a9db53d95",
            "short": ""
          },
          "mutation_effect_uuid": "11afb523-ba5a-497b-8e40-9de1d1023026",
          "name": "C242Y",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "8526e94c-e17d-4d3b-a148-54372a186e5f"
        },
        {
          "mutation_effect": {
            "description": "The TP53 G244D mutation is located in the protein's DNA binding domain. When studied in a yeast model, this mutation acted as a dominant negative suggesting a loss of function mutation of p53 (PMID: 12901798).",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "d023050d-5d39-4a9b-9ca1-7d78947c32e5",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "fee8e0dc-7b6a-410e-b3ce-e2b8d5010538",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "c04bb5bd-ddf6-4414-8970-2bb58ffb8333",
            "short": ""
          },
          "mutation_effect_uuid": "50f50231-8b43-43a3-a71e-6123d7e448b0",
          "name": "G244D",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "78deecf1-cb43-44f1-8eef-294bb82278e8"
        },
        {
          "mutation_effect": {
            "description": "The TP53 G244S mutation is located in the protein's DNA binding domain. This mutation was frequently found in patients with Lii Fraumeni syndrome (LFS). Functional analysis have indicated that this mutant is unable to transactivate, does not bind to DNA and does not inhibit cell growth like wild type p53 does (PMID: 26818906).",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "a1bcd978-4741-4d9d-808a-0045e5ced890",
            "effect": "Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "06dd9563-c8d2-46b8-86f0-ccdfcea83b1c",
            "oncogenic": "Yes",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "9fc7be5a-633c-49ca-a774-dea88e50cf25",
            "short": ""
          },
          "mutation_effect_uuid": "20cd7c41-8246-451a-b841-1b1556ec7a82",
          "name": "G244S",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "cdecdd2f-7ee3-4094-b03c-2d035503b9cb"
        },
        {
          "mutation_effect": {
            "description": "The TP53 G244R mutation is located in the protein's DNA binding domain. When tested in transactivation assays, this mutant displayed lower (1.8 to 3 fold) levels than wild type p53 indicating a loss of function. Additionally, this mutant was also deficient in inhibiting cell growth in proliferation assays (PMID: 11160722).",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "e3a24b36-27a1-40b3-8727-3d1dfdc5a5d3",
            "effect": "Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "0f17d51e-970d-4457-b9da-d48614774198",
            "oncogenic": "Yes",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "595be5b5-8c99-40ca-bef1-f19323553624",
            "short": ""
          },
          "mutation_effect_uuid": "a815159b-2e1b-4bf5-ba5a-076788e1aaa5",
          "name": "G244R",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "cda3a5ad-e63a-4511-a3fe-e26c25bd331b"
        },
        {
          "mutation_effect": {
            "description": "The TP53 V274F mutation is located in the protein's DNA binding domain. In cell line studies this mutation exhibited decreased transactivation of p53 target genes and an increase in colony formation (PMID: 12782597). Additionally, overexpression of this mutant increased the resistance of prostate cells to DNA damage-induced cell death (http://www.dtic.mil/dtic/tr/fulltext/u2/a447626.pdf).",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "cbfc7703-b481-4ce3-bbe6-0e7bdbede22d",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "1a7c6f6b-efb4-4fdc-a843-4e7e56a00ac6",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "a83fc154-023e-426c-a0a3-a5b16078595b",
            "short": ""
          },
          "mutation_effect_uuid": "6ed4d8f8-03ab-4b03-8f37-575bd06a4aa4",
          "name": "V274F",
          "name_comments": [
            {
              "content": "https://ckb.jax.org/geneVariant/show?geneVariantId=4749",
              "date": "1476888619881",
              "email": "user@gmail.com",
              "resolved": "true",
              "userName": "User"
            },
            {
              "content": "Include this paper: PMID: 12782597",
              "date": "1476888636438",
              "email": "user@gmail.com",
              "resolved": "true",
              "userName": "User"
            },
            {
              "content": "fix citation",
              "date": "1478550142702",
              "email": "user@gmail.com",
              "resolved": "false",
              "userName": "User"
            }
          ],
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "0e9d8320-6c17-41dc-84b7-53a31752b9e2"
        },
        {
          "mutation_effect": {
            "description": "The TP53 S121A mutation is located in the protein's DNA binding domain. Expression of this mutation in human osteosarcoma cell lines resulted in increased apoptosis compared to wildtype TP53, as evidenced by cell cycle progression studies (PMID: 15781620).",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "3ab2b7ef-e612-4125-a405-21a7335144cf",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "6c1a04aa-198f-4254-b724-a635bce1b553",
            "oncogenic": "Likely Neutral",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "5efabdab-3081-4014-8fca-30138d16503a",
            "short": ""
          },
          "mutation_effect_uuid": "9f61b51e-32a2-479e-b7f7-eca3fdd9ff0e",
          "name": "S121A",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "d39bc7cf-f4eb-40f2-af73-378e3d574836"
        },
        {
          "mutation_effect": {
            "description": "The TP53 S121Y mutation is located in the protein's DNA binding domain. While expression of this mutation in human osteosarcoma cell lines resulted in increased apoptosis compared to wildtype TP53, (PMID: 15781620), this experimental result was not statistically significant.",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "9a7f49d3-13a0-4b71-8bb3-e3961e6adb12",
            "effect": "Inconclusive",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "16487a38-70dd-4eff-9bda-83ebd4f9b1cd",
            "oncogenic": "Inconclusive",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "eaa9c697-4f97-4644-8370-4bdac3e8c2ad",
            "short": ""
          },
          "mutation_effect_uuid": "bbb93c7b-0011-4960-bbc0-267c7f3287aa",
          "name": "S121Y",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "bcd3c3bb-c647-49c3-bac8-75b3d80dd98e"
        },
        {
          "mutation_effect": {
            "description": "The TP53 S121C mutation is located in the protein's DNA binding domain. Expression of this mutation in human osteosarcoma cell lines resulted in a significant increase in apoptotic ability compared to wildtype TP53 (PMID: 15781620).",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "89b29daf-2671-4539-bcb2-be8d8beae4eb",
            "effect": "Inconclusive",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "6e290257-712b-4c12-b00d-eb3e3c863db1",
            "oncogenic": "Inconclusive",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "7dbc66fd-09d0-4725-80b4-60466e86c744",
            "short": ""
          },
          "mutation_effect_uuid": "059b51bf-6866-4fbb-a8f6-31ddc7af5d23",
          "name": "S121C",
          "name_comments": [
            {
              "content": "Can we look into the supplemental of this table for data explaining this?",
              "date": "1479404673719",
              "email": "user@gmail.com",
              "resolved": "false",
              "userName": "User"
            }
          ],
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "183ae5e9-55df-4a43-a14e-515febe1363f"
        },
        {
          "mutation_effect": {
            "description": "The TP53 P153H mutation is located in the protein's DNA binding domain. Changes in the DNA binding domain result in altered contact of p53 with its target DNA sequences, thereby altering its transcriptional function (PMID: 8023157, 11900253). Expression of this mutation in human osteosarcoma cell lines resulted in increased apoptosis compared to wildtype TP53 (PMID: 15781620), though this experimental result was not statistically significant. TP53 P153H also had altered transcriptional activity of target genes in a luciferase assay compared to wildytype TP53 (PMID: 15781620).",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "57fe8905-f5e3-4ec5-81e2-32f3459fc30f",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "d051edb6-4619-4a26-8121-d09734c31c87",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "4108b6dd-d774-46dc-83fb-f4e4c6181123",
            "short": ""
          },
          "mutation_effect_uuid": "155baa01-bf90-4dc4-80f2-3a41a2d09ab1",
          "name": "P153H",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "b6841208-d322-4edb-8aad-d1d846ff37ea"
        },
        {
          "mutation_effect": {
            "description": "The TP53 R156C mutation is located in the protein's DNA binding domain. Changes in the DNA binding domain result in altered contact of p53 with its target DNA sequences, thereby altering its transcriptional function (PMID: 8023157, 11900253). Expression of this mutation in human osteosarcoma cell lines resulted in increased apoptosis compared to wildtype TP53 (PMID: 15781620), though this experimental result was not statistically significant. TP53 R156C also had altered transcriptional activity of target genes in a luciferase assay compared to wildytype TP53 (PMID: 15781620).",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "288668aa-fcac-4ace-9008-48e3051237b1",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "e6fe0c84-a907-4043-ae0b-3fc85008535c",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "64b2e934-78aa-444c-9abf-eeaedb929eb5",
            "short": ""
          },
          "mutation_effect_uuid": "70450f76-3b12-468f-b4e4-4e2e85d629f9",
          "name": "R156C",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "8438b87d-b852-4e84-ab1a-1ca192c3effb"
        },
        {
          "mutation_effect": {
            "description": "The TP53 F212Y mutation is located in the protein's DNA binding domain. While expression of this mutation in human osteosarcoma cell lines resulted in increased apoptosis compared to wildtype TP53, (PMID: 15781620), this experimental result was not statistically significant.",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "f0c3443e-b4a8-4e77-8490-98784d70f23b",
            "effect": "Inconclusive",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "c75e621f-6f4c-4812-844a-185ceba92676",
            "oncogenic": "Inconclusive",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "3fca7877-4ff0-4c29-a614-62a4f48062a9",
            "short": ""
          },
          "mutation_effect_uuid": "540a11bf-01f2-4a68-b9ff-2ee4ebe825b8",
          "name": "F212Y",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "73643dbe-b7f0-4e62-b4ec-4e1c85d32cb5"
        },
        {
          "mutation_effect": {
            "description": "The TP53 E221Q mutation is located in the protein's DNA binding domain. While expression of this mutation in human osteosarcoma cell lines resulted in increased apoptosis compared to wildtype TP53, (PMID: 15781620), this experimental result was not statistically significant.",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "103ad503-779c-4691-8bf6-9d95e3ed2c84",
            "effect": "Inconclusive",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "81e878e9-b8b8-41e3-a17d-3c1f4732f1ad",
            "oncogenic": "Inconclusive",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "c79e17dd-a29c-4522-9182-20d32adfbecd",
            "short": ""
          },
          "mutation_effect_uuid": "ae624a97-df89-4363-8af3-c65094bfc6ac",
          "name": "E221Q",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "96f9aa54-63b2-4477-8fd2-2242e0567faf"
        },
        {
          "mutation_effect": {
            "description": "The TP53 K291Q mutation is located in the protein's DNA binding domain. Changes in the DNA binding domain result in altered contact of p53 with its target DNA sequences, thereby altering its transcriptional function (PMID: 8023157, 11900253). Expression of this mutation in human osteosarcoma cell lines resulted in increased apoptosis compared to wildtype TP53 (PMID: 15781620), though this experimental result was not statistically significant. TP53 K291Q also had altered transcriptional activity of target genes in a luciferase assay compared to wildytype TP53 (PMID: 15781620).",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "52be9a12-2593-4213-8cce-107829c5d642",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "19f9bd96-2a87-4477-b545-a03e2a37563c",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "63631662-6129-4033-985f-ed3cb10d6021",
            "short": ""
          },
          "mutation_effect_uuid": "e5f47ce6-144b-4cd5-9619-cdb328715991",
          "name": "K291Q",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "836395cc-985e-4c20-ba8b-2a18e14053e6"
        },
        {
          "mutation_effect": {
            "description": "The TP53 K292I mutation is located in the protein's DNA binding domain. Changes in the DNA binding domain result in altered contact of p53 with its target DNA sequences, thereby altering its transcriptional function (PMID: 8023157, 11900253). Expression of this mutation in human osteosarcoma cell lines resulted in increased apoptosis compared to wildtype TP53 (PMID: 15781620), though this experimental result was not statistically significant. TP53 K292I also had altered transcriptional activity of target genes in a luciferase assay compared to wildytype TP53 (PMID: 15781620).",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "51c86328-614f-496a-9298-7694880520bd",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "39359a77-de12-40bf-a17b-557674374b58",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "1a702d75-9979-4c4f-9def-be858dac644c",
            "short": ""
          },
          "mutation_effect_uuid": "19453dba-373c-4b71-b6a2-eca0b5fdfbfe",
          "name": "K292I",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "6215d144-e550-4e34-bc56-a2b8cf9502b4"
        },
        {
          "mutation_effect": {
            "description": "The TP53 F328V mutation occurs in the protein's tetramerization domain. Expression of this mutation in human lung cancer cell lines resulted in decreased transcriptional activity and protein stability, as evidenced by a reporter assay (PMID: 19454241).",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "a9a912bd-af31-415c-967d-085231a5893d",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "f70a5690-e28a-4629-a69b-7720bcabecec",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "983ffafd-6427-4bcb-a07b-1bd4b7059780",
            "short": ""
          },
          "mutation_effect_uuid": "77ebfdc7-9899-43e2-8b3e-d452c4966c02",
          "name": "F328V",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "24159b4d-72d1-44cd-aca1-8ece01530e32"
        },
        {
          "mutation_effect": {
            "description": "The TP53 L348F mutation occurs in the protein's tetramerization domain. Expression of this mutation in human lung cancer cell lines resulted in decreased transcriptional activity and protein stability compared to wildtype TP53, as evidenced by a reporter assay (PMID: 19454241).",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "5ec400a9-785f-475e-acdb-7cafc0c67702",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "8c18e082-f43c-47c6-afcd-7c3a3c42fd73",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "8ea5737f-8374-4c12-8a4d-a7e6bac479d4",
            "short": ""
          },
          "mutation_effect_uuid": "751ad997-60ac-4e39-9c97-6fba09841c7f",
          "name": "L348F",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "7d55e0f2-dbeb-4902-ab03-0b9468e7afad"
        },
        {
          "mutation_effect": {
            "description": "The TP53 S241Y mutation is located in the protein's DNA binding domain. Expression of this mutant in TP53-null cells resulted in decreased transactivation of p53 target genes, as a measured by a luciferase report assay (PMID: 25584008). Additionally, the TP53 S241Y mutation failed to suppress colony growth in a colony reduction assay (PMID: 25584008).",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "ba550a68-f16a-4afb-93fb-69fb04785929",
            "effect": "Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "62868117-37d1-4152-b4d5-b80cf493a2f7",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "95d899f6-b753-41fc-ba17-c10354abeb60",
            "short": ""
          },
          "mutation_effect_uuid": "1ff2fa95-86a1-4dad-aec8-9d21ceed6892",
          "name": "S241Y",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "76122d3a-6655-4df7-a150-9f1359567949"
        },
        {
          "mutation_effect": {
            "description": "The TP53 R248L mutation is located in the protein's DNA binding domain. Expression of this mutant in TP53-null cells resulted in decreased transactivation of p53 target genes, as a measured by a luciferase reporter assay (PMID: 25584008). Additionally, the TP53 R248L mutation failed to suppress colony growth in a colony reduction assay compared to wildtype TP53 (PMID: 25584008). Ovarian cancer patient samples and mouse models expressing this mutation were sensitive to an amyloid aggregate TP53 inhibitor as evidenced by apoptosis assays. Some TP53 mutations have been shown to form amyloid aggregates that leads to inactivation of the TP53 protein. Responsiveness of this variant to amyloid aggregate inhibitors suggest that this is a loss-of-function mutation (PMID: 26748848).",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "ee028221-5feb-4415-a084-898c13e1eadf",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "de24f368-de4c-41f1-8c8d-9559e23bff2b",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "07a9a978-1806-4d47-b748-7c50e9dfd4be",
            "short": ""
          },
          "mutation_effect_uuid": "19e32991-74c9-4b10-886f-5309fb8c9d0f",
          "name": "R248L",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "b25840f9-4963-4202-8ed7-d1ca07c1a368"
        },
        {
          "mutation_effect": {
            "description": "The TP53 G334R mutation occurs in the protein's oligomerization domain and has been found as a germline low-penetrance founder mutation in individuals of Ashkenazi Jewish descent who have evidence of Li-Fraumeni syndrome (PMID: 32675277). Expression of this mutation in TP53-null cells did not alter TP53 transactivation in luciferase assays or colony growth as compared to expression of wildtype TP53 (PMID: 25584008). However, in a separate study, cells expressing TP53 G334R demonstrated impaired suppression ability in a colony reduction assay compared to wildtype cells. Additionally, immortalized G334R-mutant lymphoblastoid cell lines demonstrated impaired activation of a subset of TP53 target genes (including PCLO, PLTP, PLXNB3 and LCN15) following treatment with Nutlin-3A.  Further analysis showed TP53 G334R had reduced thermal stability compared to wild type cells (PMID: 32675277).",
            "description_review": {
              "updateTime": 1650300222264,
              "updatedBy": "User"
            },
            "description_uuid": "87e326f9-4d58-4a1e-90a6-343189b945a1",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1649707409062,
              "updatedBy": "User"
            },
            "effect_uuid": "bd776b5a-dfb1-4314-a8d3-5ef37e793e24",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1649707407728,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "6bda7bec-479c-42c6-bf32-97df8bb7e15b",
            "short": ""
          },
          "mutation_effect_uuid": "4869b9c4-db0d-4e9b-9071-c87e7412a7af",
          "name": "G334R",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "8db9f1d4-7ff1-4948-c0cc-2bc1296ba108"
        },
        {
          "mutation_effect": {
            "description": "The TP53 R282W mutation occurs in the protein's DNA binding domain. Expression of this mutation in TP53-null cell lines resulted in aggregation of mutant proteins, likely leading to destabilization of TP53 and upregulation of heat shock proteins (PMID: 21445056).",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "32619fce-ce29-450b-8d98-2de2b7d709b0",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "1e75a314-3d89-4e02-9292-5f3a5e1bc2f5",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "c8bbc98a-d6f3-4120-81eb-c92c3fdb212b",
            "short": ""
          },
          "mutation_effect_uuid": "7166e8ea-e2a7-460a-a705-d935356891c5",
          "name": "R282W",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "0ee1c820-2e6c-494a-9519-cf2409accffc"
        },
        {
          "mutation_effect": {
            "description": "The TP53 P250L mutation is located in the protein's DNA binding domain. Expression of this mutation in TP53-null cell lines resulted in aggregation of mutant unfolded proteins, likely leading to inactivation of TP53 and upregulation of heat shock proteins (PMID: 21445056).",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "c58d8ae2-7693-4b53-9d79-8c6b252a09c3",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "506e75cd-a2e9-42bb-b2b4-67a6966c572f",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "30e07ac9-9569-4563-ab13-29d8d7c74d59",
            "short": ""
          },
          "mutation_effect_uuid": "7b18d16f-d9cf-4a5f-a128-a7db523695d0",
          "name": "P250L",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "5a392a6a-d6b9-4fc1-8049-2a38c37aacc5"
        },
        {
          "mutation_effect": {
            "description": "The TP53 E258V mutation is located in the protein's DNA binding domain. Expression of this mutation in TP53-null cell lines resulted in aggregation of mutant unfolded proteins, likely leading to inactivation of TP53 and upregulation of heat shock proteins (PMID: 21445056).",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "bf4c1664-3c98-48a7-9724-73e0838bfb60",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "f6bc0d78-5a1d-4d01-ad6b-956b3592df46",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "e66907cb-2c8d-4177-8fa5-5384f62831c7",
            "short": ""
          },
          "mutation_effect_uuid": "4e69841d-973b-42c7-87de-e34dc1a7909e",
          "name": "E258V",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "5d92198f-1235-472f-8ad8-f8038e210b2d"
        },
        {
          "mutation_effect": {
            "description": "The TP53 R110L mutation is located in the protein's DNA binding domain. Expression of this mutation in TP53-null cell lines resulted in aggregation of mutant unfolded proteins, likely leading to inactivation of TP53 and upregulation of heat shock proteins (PMID: 21445056). Breast cancer cell lines expressing this mutation were dependent of the expression of GEF-H1, a guanidine nucleotide exchange factor (PMID: 16778209).",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "de1a2f87-3767-45a5-b3a6-35f5e907aaea",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "6e3b9ea7-4819-4573-ab6a-42897c1f12c7",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "34a8e91b-0b5f-470a-aa87-0fdc8af3b9e7",
            "short": ""
          },
          "mutation_effect_uuid": "08deda38-188d-40b1-90d7-811e80cc75b3",
          "name": "R110L",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "a5067e6d-4a42-4144-8cdb-292deeddd1cd"
        },
        {
          "mutation_effect": {
            "description": "The TP53 R110P mutation is located in the protein's DNA binding domain. Expression of this mutation in TP53-null cell lines resulted in aggregation of mutant unfolded proteins, likely leading to inactivation of TP53 and upregulation of heat shock proteins (PMID: 21445056).",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "08523f7e-e454-4a04-be1c-7b7af83133ad",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "9dbab568-5e51-425b-a92c-74e4e763b85b",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "f12818a2-8ef1-42e9-912e-5e4d8bcf2209",
            "short": ""
          },
          "mutation_effect_uuid": "388aa88f-7853-43e1-b96c-fe0be8cbf770",
          "name": "R110P",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "477f056e-b037-4948-93a7-f8fd051fbab3"
        },
        {
          "mutation_effect": {
            "description": "The TP53 H168R mutation occurs in the protein's DNA binding domain. Expression of this mutation in TP53-null lung cancer cell lines results in reduced TP53 transactivation activity, as evidenced by luciferase reporter assays. Cell lines expressing this mutation also have a defect in cell cycle progression and aberrant expression of apoptosis proteins, as compared to cells expressing wildtype TP53 (PMID: 18996393).",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "e02774cc-59e5-4844-a36d-819f4540bc30",
            "effect": "Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "57cc120f-bba4-45da-952a-c728c064e5c7",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "6d42a140-887f-4685-a040-f4f6bcd1cc39",
            "short": ""
          },
          "mutation_effect_uuid": "b0543953-e22a-471e-ba61-f6bd2bf4f9c4",
          "name": "H168R",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "9f938b5e-85ac-4f72-8332-64708d389760"
        },
        {
          "mutation_effect": {
            "description": "The TP53 T123A mutation occurs in the protein's DNA binding domain. Expression of this mutation in TP53-null lung cancer cell lines did not significantly alter TP53-induced transactivation activity, apoptosis, or cell cycle progression as compared to cells expressing wildtype TP53 (PMID: 18996393). Other reports suggest that this mutation results in a gain-of-function, leading to enhanced apoptosis (PMID: 16687402).",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "62c8a39b-99be-4c1f-a4d2-1ec6a9b0365e",
            "effect": "Likely Neutral",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "3ab614df-855d-45dc-bef9-b9940929c473",
            "oncogenic": "Likely Neutral",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "81e84053-bb4f-4799-aad0-4ec03e4a39b1",
            "short": ""
          },
          "mutation_effect_uuid": "91354f94-af32-4e65-bdca-2fc33eb1c66f",
          "name": "T123A",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "13b71a0e-9e5e-411d-9235-73d4dd6398ac"
        },
        {
          "mutation_effect": {
            "description": "The TP53 H168N mutation occurs in the protein's DNA binding domain. In biochemical assays, this mutation had DNA binding ability approximately 70% of that of wildtype P53, but no difference in exonuclease activity (PMID: 19462533). Further functional assays need to be completed to determine if this alteration is oncogenic.",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "b75caffb-0267-439d-b677-35005e2ca321",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "896cbb36-59a2-4d4c-bd85-92f94a52591c",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "473e1586-aee3-40ac-b278-ccb486b9a7ed",
            "short": ""
          },
          "mutation_effect_uuid": "dbe6a7ac-cb2a-463b-8923-a80e5c89447b",
          "name": "H168N",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "86e17508-e538-4992-bcc9-495e4b101b13"
        },
        {
          "mutation_effect": {
            "description": "The TP53 H233N mutation occurs in the protein's DNA binding domain. In biochemical assays, this mutation did not alter the DNA binding ability of TP53 compared to wildtype TP53 (PMID: 19462533). However, this mutation is a hotspot, suggesting that it is likely oncogenic (PMID: 26619011).",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "e0ca8a2a-ba2c-4dc2-b99f-7277dabb5b49",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "cec92b8a-1cb2-4db1-996e-7c896ce1d025",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1487884587000
            },
            "oncogenic_uuid": "fa2463e4-3c5e-4877-a352-6d0434cad166",
            "short": ""
          },
          "mutation_effect_uuid": "b7cc46fa-96bd-4db4-a50d-73f5e64b0d90",
          "name": "H233N",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "29283577-963d-4323-960a-b1a1927176e9"
        },
        {
          "mutation_effect": {
            "description": "The TP53 H297N mutation occurs in the protein's DNA binding domain. In biochemical assays, this mutation did not alter the DNA binding ability of TP53 (PMID: 19462533). Further functional assays need to be completed to determine if this alteration is oncogenic.",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "5b7ebc9f-cca3-417e-b578-c26c2703db1a",
            "effect": "Likely Neutral",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "3a70d2c9-cad1-447c-b723-4d37b83dcdb6",
            "oncogenic": "Likely Neutral",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "89e26112-9021-49f1-8a9b-1e4ebb985344",
            "short": ""
          },
          "mutation_effect_uuid": "11714755-0a61-46a9-a2e5-55ee98a7fc79",
          "name": "H297N",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "45f9760d-cf54-4108-b886-04f4c8645445"
        },
        {
          "mutation_effect": {
            "description": "The TP53 H214N mutation occurs in the protein's DNA binding domain. In biochemical assays, this mutant protein has reduced DNA binding activity, suggesting it is loss-of-function. Further functional assays are required to determine if this alteration is oncogenic (PMID: 19462533).",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "cea087a6-9c92-4bb7-bd8e-9b8270be9278",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "8d1e100f-e8d1-47fa-92f3-8bcbfa7341d8",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "487a1829-f2f5-430e-c070-c21914273612",
            "short": ""
          },
          "mutation_effect_uuid": "f077ddf3-b47a-4914-a922-bfd7dab0b8ba",
          "name": "H214N",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "5bea11ce-123f-4f94-96a6-8311ceca036f"
        },
        {
          "mutation_effect": {
            "description": "The TP53 H115N mutation is located in the protein's DNA binding domain. In biochemical assays, this mutation has an enhanced ability to bind DNA compared to wildtype TP53, but reduced exonuclease activity. Expression of this mutation in lung cancer cell lines results in cell cycle arrest but this mutation cannot induce TP53-mediated apoptosis (PMID: 19462533).",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "de688d7f-3c3b-43bd-a530-6a84ac593970",
            "effect": "Inconclusive",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "183c70aa-2587-44e9-923d-88efd0e1408c",
            "oncogenic": "Inconclusive",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "40665770-9057-44fc-841e-8592998a1b1f",
            "short": ""
          },
          "mutation_effect_uuid": "53c069f5-a800-4d82-9f9d-68208b44db05",
          "name": "H115N",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "40496eac-5235-41ef-b51e-f488f58a5886"
        },
        {
          "mutation_effect": {
            "description": "The TP53 A161T mutation occurs in the protein's DNA binding domain. Expression of this mutation in TP53-null cell lines suggested that this mutation is inactivating as measured by increased protein expression compared to wildtype p53, which suggests lack of negative regulation characteristic of TP53 inactivating mutations (e.g., R175H) (PMID: 21232794, 16827139).",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "db8b0f55-3643-4ad8-b23f-b2dfb3f127f9",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "cb0a7e75-bea1-4f82-b539-14d1f97a5e0a",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "c2c4b2c5-99bd-4df1-9318-540401b18d4e",
            "short": ""
          },
          "mutation_effect_uuid": "721aad27-5045-4c5c-90ed-ad41d15fab41",
          "name": "A161T",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "4eecd9a1-2fe6-42b0-ad49-47d4667c8c44"
        },
        {
          "mutation_effect": {
            "description": "The TP53 G266R mutation occurs in the protein's DNA binding domain. Expression of this mutation in TP53-null cell lines resulted in decreased TP53-induced transactivation, as evidenced by luciferase assays (PMID: 16827139).",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "81e7ba6c-51d6-450e-900a-2070cad431f6",
            "effect": "Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "85b319f4-43ac-48b5-9846-3e25c8dd0ec5",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "d92d9394-98d2-4a67-9dbf-ca95437df6a4",
            "short": ""
          },
          "mutation_effect_uuid": "c82b2236-9c04-4276-8684-b8c05e97f3f5",
          "name": "G266R",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "ace47528-16f1-4f61-a4c4-122330879f84"
        },
        {
          "mutation_effect": {
            "description": "The TP53 A161S mutation is located in the protein's DNA binding domain. Expression of this mutation in head and neck cancer cell lines results in the inability of TP53 to suppress colony growth, as compared to wildtype TP53. In addition, this alteration leads to reduced expression of p21 with implications for apoptosis (PMID: 25119136).",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "36f1030c-e4a0-4786-9764-b077dfc887cc",
            "effect": "Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "f110691a-6247-4b25-be7a-ba9c97938b7c",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "66bc592d-7d16-49d1-90dd-4141eb37b932",
            "short": ""
          },
          "mutation_effect_uuid": "14514bb1-736b-4236-8afd-50e2f2919ff7",
          "name": "A161S",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "730bb42d-0802-4df4-ae34-56277e5ac3a6"
        },
        {
          "mutation_effect": {
            "description": "The TP53 V197E mutation occurs in the protein's DNA binding domain. Expression of this mutation in TP53-null cells resulted in an increased interaction with PBF, an oncogene implicated in the regulation of TP53 target genes, such as p21 (PMID: 25408419).",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "2af242bf-8cda-4c1e-a585-9630980c0208",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "15c2897e-fc8d-4b79-8a2f-7076876796b0",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "12191136-e015-4953-8744-7c7dfa6c3c99",
            "short": ""
          },
          "mutation_effect_uuid": "27b52703-6126-41c3-bbfe-76c49aef14cf",
          "name": "V197E",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "6c835778-edf7-4fe2-a330-3b88c40d83cc"
        },
        {
          "mutation_effect": {
            "description": "The TP53 M133K mutation occurs in the protein's DNA binding domain and likely confers loss of function to the expressed p53 protein. The TP53 M133K mutation is associated with loss of p53 transcriptional activity. Moreover, expression of this mutation in TP53-null cells was associated with an aberrant increased interaction with PBF, an oncogene that interferes in p53 transcriptional activity and consequent deregulation of its target genes, such as p21 (PMID: 25408419).",
            "description_review": {
              "updateTime": 1495150569283
            },
            "description_uuid": "64012a9f-28f7-4060-acce-b2ca46646d8e",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1495150569283
            },
            "effect_uuid": "ca002c0f-42bc-4ac9-b9c9-eee83096a9e9",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "587e949b-673e-4f92-974e-e105135873ae",
            "short": ""
          },
          "mutation_effect_uuid": "d9697c5d-d98d-46a2-8884-4ba5fbaf3db5",
          "name": "M133K",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "7d4176a8-e200-4384-9704-42afd23a5637"
        },
        {
          "mutation_effect": {
            "description": "The TP53 I255F mutation occurs in the protein's DNA binding domain. Expression of this mutation in TP53-null cells resulted in an increased interaction with PBF, an oncogene implicated in the regulation of TP53 target genes, such as p21 (PMID: 25408419).",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "fd5e3bc2-82b0-43f1-bef7-541ce6c98f0b",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "2b8cee54-b7ba-4e4c-b45e-b25824b8f695",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "8339d09f-c7a8-4db0-b3f1-298a69f81ea2",
            "short": ""
          },
          "mutation_effect_uuid": "928373d5-66e3-4a22-9f4e-949f2bf58a32",
          "name": "I255F",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "e7cc97c1-46fe-43df-bf89-8f8d2b4a92d9"
        },
        {
          "mutation_effect": {
            "description": "The TP53 V197L mutation occurs in the protein's DNA binding domain. Endogenous expression of this mutation in a glioblastoma cell line resulted in decreased apoptosis and aberrant cell cycle progression, likely due to decreased TP53 transactivation (PMID: 11668476)",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "3d2cedf2-ade9-4495-86b4-510f6a4a1202",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "de75d745-2950-4466-aaa3-8dc2c2fbf549",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "ad0d09f8-70be-414a-9ee6-87e3bb76dc89",
            "short": ""
          },
          "mutation_effect_uuid": "fc6c851b-247e-49f8-8967-d34a23c74a38",
          "name": "V197L",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "8720be3c-8e15-491d-95fa-9f648db00385"
        },
        {
          "mutation_effect": {
            "description": "The TP53 M133T mutation occurs in the protein's DNA binding domain. Endogenous germline expression of this mutation in breast cancer cells results in increased expression of the anti-apoptotic gene BIRC3, likely due to alerted TP53 transcriptional activation. Expression of this mutation also unregulated the inflammatory response, including increased expression of IL-1beta (PMID: 21311097).",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "200e7b3b-e739-445f-b622-1ed4376b92f1",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "ea618d9d-5503-4381-8eb4-f3ee19b20fc2",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "334f8e20-24e5-4a30-b2d7-dca0c275cf3f",
            "short": ""
          },
          "mutation_effect_uuid": "bc50bf2e-3aed-424c-9864-f0e9d8a17cb1",
          "name": "M133T",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "26daf808-ea71-47be-aef2-51d6f46b6749"
        },
        {
          "mutation_effect": {
            "description": "The TP53 C141Y mutation occurs in the protein's DNA binding domain. Expression of this mutation in cell lines that lack TP53 expression did not enhance TP53-mediated transcriptional activity in reporter assays, as compared to expression of wildtype TP53 (PMID: 15037740).",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "df062d59-1986-4dd8-a464-abc3fc319b67",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "2b6e32cb-8db4-4dac-8bc7-110737b520fe",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "087e4522-ac70-41d1-bb2c-961fa38cb050",
            "short": ""
          },
          "mutation_effect_uuid": "55c2e081-bffd-405f-9cc0-3b9448c0bb56",
          "name": "C141Y",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "0c42ccff-945c-4c87-bb1f-87d722baf692"
        },
        {
          "mutation_effect": {
            "description": "The TP53 V173L mutation occurs in the protein's DNA binding domain. Expression of this mutation in cell lines that lack TP53 expression did not enhance TP53-mediated transcriptional activity in reporter assays, as compared to expression of wildtype TP53 (PMID: 15037740).",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "f9a53af6-70a7-499b-8190-30ea932fa22d",
            "effect": "Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "de48d259-cb71-42e1-87fe-5f46d1b47935",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "5b0c5073-9772-4497-98d8-3ce215950ab2",
            "short": ""
          },
          "mutation_effect_uuid": "3fb21050-80c2-489b-98fb-7143ecfd22f9",
          "name": "V173L",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "cfbf3881-3c17-4883-96ef-0c36d0a4eb6b"
        },
        {
          "mutation_effect": {
            "description": "The TP53 V173M mutation occurs in the protein's DNA binding domain and likely confers loss of function to the expressed p53 protein. When TP53 V173M was expressed in p53-null cells, a transient reporter gene assays demonstrated mutant p53 was impaired from binding to the promoters of its target genes and consequent lowered transcriptional activity, as compared to expression of wildtype TP53 (PMID: 15037740).",
            "description_review": {
              "updateTime": 1495149896517
            },
            "description_uuid": "8d30311b-3df3-4b81-8754-0459c4768f89",
            "effect": "Loss-of-function",
            "effect_review": {
              "updateTime": 1495149896517
            },
            "effect_uuid": "e6705b65-cad4-47ce-8106-c2ec8e4ee65f",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "e635bb54-cf10-481c-ba9a-b74a65f4174a",
            "short": ""
          },
          "mutation_effect_uuid": "8e513013-40cb-43e9-b4d5-c6a81cab0535",
          "name": "V173M",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "c3e938fd-b9f6-4712-c031-1c5b174e8d57"
        },
        {
          "mutation_effect": {
            "description": "The TP53 Y205C mutation occurs in the protein's DNA binding domain and likely confers loss of function to the expressed p53 protein. When TP53 Y205C was expressed in p53-null cells, a transient reporter gene assays demonstrated mutant p53 was impaired from binding to the promoters of its target genes and consequent lowered transcriptional activity, as compared to expression of wildtype TP53 (PMID: 15037740).",
            "description_review": {
              "updateTime": 1495149841078
            },
            "description_uuid": "cfaff3cb-cc1a-48a0-8362-3090333e451c",
            "effect": "Loss-of-function",
            "effect_review": {
              "updateTime": 1495149841078
            },
            "effect_uuid": "43d62edb-4151-466d-86cd-3c2055e93fd1",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "b2d63dac-4119-4c87-a295-cb1d5da7be27",
            "short": ""
          },
          "mutation_effect_uuid": "e9f80d3e-735d-45e2-833a-8022a8763787",
          "name": "Y205C",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "c5ade892-7176-4bef-b6b3-31eb882041a0"
        },
        {
          "mutation_effect": {
            "description": "The TP53 R273L mutation occurs in the protein's DNA binding domain (DBD). Mutations in the DBD result in altered contact of p53 with its target DNA sequences, thereby altering its transcriptional function (PMID: 8023157, 11900253). Given that p53 directs the transcription of proteins that enable apoptosis (PMID: 11900253), its inactivation results in cells harboring damaged DNA and overall genomic instability (PMID: 11900253). Expression of the R273L mutation in cell lines that lack p53 expression did not enhance p53-mediated transcriptional activity in reporter assays, as compared to expression of wildtype TP53 (PMID: 15037740).",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "5c204737-1fb7-46fb-9cfa-978a533baa33",
            "effect": "Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "cb4e3b94-9457-4208-b286-87908f41f6e8",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "868609a3-c2ff-430e-9927-676f426b3c00",
            "short": ""
          },
          "mutation_effect_uuid": "1e2dc6e0-2be5-4f5d-9bad-bbe06205e8c3",
          "name": "R273L",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "b7322e08-4d5e-4ff6-a0f3-408fa7c71fb6"
        },
        {
          "mutation_effect": {
            "description": "The TP53 E286K mutation occurs in the protein's DNA binding domain. Expression of this mutation in cell lines that lack TP53 expression did not enhance TP53-mediated transcriptional activity in reporter assays, as compared to expression of wildtype TP53 (PMID: 15037740).",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "9b2ded66-0a6b-4bfb-b41a-b2500ca3bc11",
            "effect": "Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "9b80ab13-f126-40c6-bc44-98dc7fd22a90",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "bf7eadb3-637c-47f1-9e59-cdda77d7eb0d",
            "short": ""
          },
          "mutation_effect_uuid": "ce9665c9-396b-4d0d-917b-5db4ac59f945",
          "name": "E286K",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "1569f5a4-b325-406b-8a95-7507963488ae"
        },
        {
          "mutation_effect": {
            "description": "The TP53 I251S mutation occurs in the protein's DNA binding domain. Ovarian cancer patient samples expressing this mutation were sensitive to an amyloid aggregate TP53 inhibitor, as evidenced by apoptosis assays. Some TP53 mutations have been shown to form amyloid aggregates that lead to inactivation of the TP53 protein. Responsiveness of this variant to amyloid aggregate inhibitors suggest that this is a loss-of-function mutation (PMID: 26748848).",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "fa365380-6671-4748-a5d2-9009c3ec2197",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "f64f1d16-1bb7-4a21-8321-b41b971cc019",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "e40a0483-c475-4af3-9f8b-c621def6afe8",
            "short": ""
          },
          "mutation_effect_uuid": "3b2f7725-1f7c-414c-9b52-c951ee2c08a7",
          "name": "I251S",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "0e94ff3b-4c1c-463c-add9-a5393ecc43d9"
        },
        {
          "mutation_effect": {
            "description": "The TP53 E326L mutation occurs in the protein's DNA binding domain. Ovarian cancer patient samples expressing this mutation were sensitive to an amyloid aggregate TP53 inhibitor as evidenced by apoptosis assays. Some TP53 mutations have been shown to form amyloid aggregates that lead to inactivation of the TP53 protein. Responsiveness of this variant to amyloid aggregate inhibitors suggest that this is a loss-of-function mutation (PMID: 26748848).",
            "description_review": {
              "updateTime": 1493755013385
            },
            "description_uuid": "d07acc68-c906-44ec-88de-91f8ca69c3c0",
            "effect": "Loss-of-function",
            "effect_review": {
              "updateTime": 1493755013385
            },
            "effect_uuid": "1cdf7555-cb23-4b2f-875f-0e187e1bfe89",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "bc7d3729-c0f3-46a7-a742-a3a6bf468b54",
            "short": ""
          },
          "mutation_effect_uuid": "1c8d08d7-6b62-4131-b5a8-42af03d4f6dd",
          "name": "E326L",
          "name_review": {
            "updateTime": 1493755019059
          },
          "name_uuid": "3e133af2-0b28-40d9-b095-0afb80019eda"
        },
        {
          "mutation_effect": {
            "description": "The TP53 R181C mutation occurs in the protein's DNA binding domain. Expression of this mutation in osteosarcoma cell lines that lack wildtype TP53 results in decreased transactivation of genes important for the cell cycle and apoptosis, including p21 and MDM2. Cell lines expressing this mutation exhibited decreased apoptosis and decreased DNA binding ability as compared to cell lines expressing wildtype TP53 (PMID: 10229196, 20471942).",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "c8b9602e-7a0d-4322-823c-83de0efde9ac",
            "effect": "Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "8abe3752-f25a-47dc-9e3a-450a580e2f8b",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "6701ca7c-9543-44a6-847a-084a82ccced7",
            "short": ""
          },
          "mutation_effect_uuid": "9b114045-91a5-4881-a1aa-ef3a6aa0a740",
          "name": "R181C",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "b842b4d9-6604-4adb-8143-95bb8fb411bd"
        },
        {
          "mutation_effect": {
            "description": "The TP53 R202S mutation is located in the protein's DNA binding domain. Expression of this mutation in TP53-null osteosarcoma cell lines demonstrated that TP53 R202S is inactivating as measured by decreased transactivation of genes important in cell cycle and apoptosis, including p21 and BAX, compared to cell lines that express wildtype TP53 (PMID: 10229196).",
            "description_review": {
              "updateTime": 1679672199557,
              "updatedBy": "User"
            },
            "description_uuid": "815ca0a1-db6d-4b23-8f55-56533ae57582",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "e4790ef9-3603-44bc-aa7f-d07d1c34c324",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "d9d4aa47-93cf-4d98-8451-89cc44ad7ee1",
            "short": ""
          },
          "mutation_effect_uuid": "2ee281e9-6654-4b9b-97f1-ab06afb3ceed",
          "name": "R202S",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "f1e86c3e-f094-41fd-8793-1ca229f0b8b0"
        },
        {
          "mutation_effect": {
            "description": "The TP53 T150I mutation occurs in the protein's DNA binding domain. Expression of this mutation in osteosarcoma cell lines that lack wildtype TP53 results in decreased transactivation of genes important in cell cycle and apoptosis, including p21 and Bax. Cell lines expressing this mutation have decreased apoptosis as compared to cell lines that express wildtype form of TP53 (PMID: 10229196).",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "d3d6005b-502d-4ae9-a962-3080fd5f10a7",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "31eeba79-dd25-4024-85f2-564d6f862c1e",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "8dcd4c8c-88b9-48e8-8328-0112ce40365f",
            "short": ""
          },
          "mutation_effect_uuid": "3057e38a-b5c1-4cdd-8d22-f593d158d73e",
          "name": "T150I",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "ffcdabda-d961-462b-aaea-eedc052aeb6f"
        },
        {
          "mutation_effect": {
            "description": "The TP53 S240R mutation occurs in the DNA binding domain of the protein. Expression of this mutation in osteosarcoma cell lines that lack wildtype p53 demonstrated that this mutation is likely inactivating as measured by decreased transactivation of genes important for cell cycle regulation and apoptosis, including p21 and Bax, as well as decreased apoptosis compared to cells expressing wildtype p53 (PMID: 10229196).",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "f99dfaf3-8ced-4620-836f-d80b584daa89",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1484681636000,
              "updatedBy": "User"
            },
            "effect_uuid": "f3b9ec06-6ec6-404a-8789-db95f5809e6e",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "7c310f91-960c-410d-bf87-03e8aa8d8102",
            "short": ""
          },
          "mutation_effect_uuid": "b58d0e0d-7946-4ad6-857c-d4a5802aca31",
          "name": "S240R",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "a4e9f049-1e3d-4f9b-9b13-8581fe56c593"
        },
        {
          "mutation_effect": {
            "description": "The TP53 G199R mutation occurs in the protein's DNA binding domain. Expression of this mutation in osteosarcoma cell lines that lack wildtype TP53 results in decreased transactivation of genes important in cell cycle and apoptosis, including p21 and Bax. Cell lines expressing this mutation have decreased apoptosis as compared to cell lines that express wildtype form of TP53 (PMID: 10229196).",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "b1996aac-83f9-47b6-b699-63659fdc1a5a",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "bad89955-4825-4219-803b-6f11d4d016f1",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "59d77dea-2f64-4eaf-9270-551432c9aba1",
            "short": ""
          },
          "mutation_effect_uuid": "0caa4250-75a6-42cb-a948-f434e89ad7e1",
          "name": "G199R",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "19c7b7d2-e123-4bcb-9229-384688375ea7"
        },
        {
          "mutation_effect": {
            "description": "The TP53 Q144P mutation occurs in the protein's DNA binding domain. Expression of this mutation in osteosarcoma cell lines that lack wildtype TP53 results in decreased transactivation of genes important in cell cycle and apoptosis. Cell lines expressing this mutation have decreased apoptosis and enhanced cell growth as compared to cell lines that express wildtype form of TP53 (PMID: 10229196).",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "b9c9661e-ded4-4b52-b68c-691437a9d399",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "1b3bda9d-0a5f-4721-9fe2-41d430c8e859",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "dbf32171-2b62-4a45-8ff3-ee8cbe0647f2",
            "short": ""
          },
          "mutation_effect_uuid": "bd45f6ef-3d77-4c9a-bc3a-ff2a17d9120f",
          "name": "Q144P",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "63b02f4c-e0f0-4094-bb61-c6f7750a4959"
        },
        {
          "mutation_effect": {
            "description": "The TP53 Y163N mutation occurs in the protein's DNA binding domain. Expression of this mutation in osteosarcoma cell lines that lack wildtype TP53 is associated with decreased transcriptional activation of the p53 target gene p21. Additionally, cell lines expressing this mutation have decreased apoptosis and enhanced cell growth as compared to cell lines that express wildtype form of TP53 (PMID: 10229196) suggesting that this mutation confers loss of p53 function.",
            "description_review": {
              "updateTime": 1495149404802
            },
            "description_uuid": "2b7e8d95-cd79-417e-a0cb-6c1cb5002166",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1495149404802
            },
            "effect_uuid": "d039e7b7-0731-481b-8e82-9ba69812def5",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "053f67d8-ad36-423d-b3c3-7787304d7d20",
            "short": ""
          },
          "mutation_effect_uuid": "d2af8596-7f3f-4811-a2a4-4ec46782e93f",
          "name": "Y163N",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "2b65b4d1-2fac-4a41-bf76-bae9eb69df94"
        },
        {
          "mutation_effect": {
            "description": "The TP53 H168Y mutation occurs in the protein's DNA binding domain and likely confers loss of function to the p53 protein. Expression of this mutation in osteosarcoma cell lines that lack wildtype TP53 was associated with decreased transcription of p53 target genes. Cell lines expressing this mutation have decreased apoptosis and enhanced cell growth as compared to cell lines that express wildtype form of TP53 (PMID: 10229196).",
            "description_review": {
              "updateTime": 1495150083244
            },
            "description_uuid": "ee2a2cf2-1784-4037-872b-694fc6ba6c14",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1495150083244
            },
            "effect_uuid": "17a2a1b1-4a50-4190-a8ee-4c4cc6736ca0",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "1f66b84a-d75d-489b-bec8-e6fa2652f374",
            "short": ""
          },
          "mutation_effect_uuid": "746e377b-04c3-495d-8c75-e63852628df4",
          "name": "H168Y",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "740cd985-ed39-4d76-8907-27197106acef"
        },
        {
          "mutation_effect": {
            "description": "The TP53 R181H mutation occurs in the protein's DNA binding domain. In biochemical assays, this TP53 mutant was found to have defective DNA binding activity compared to wildtype TP53. Expression of this mutation in osteosarcoma cell lines resulted in decreased transactivation of TP53 target genes and reduced apoptosis (PMID: 20471942).",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "1ddba7fe-bbd8-4ae4-ae1b-1971f7b9bd6d",
            "effect": "Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "f25a8db0-d6db-4f12-9868-3257e32db0d5",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "2fed257c-1ac2-4e09-9def-2ff0e1f3b16d",
            "short": ""
          },
          "mutation_effect_uuid": "d88a4166-3259-4554-a1bb-b7d386d8ced5",
          "name": "R181H",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "4796f185-d880-415b-bbcf-f6b392047a60"
        },
        {
          "mutation_effect": {
            "description": "The TP53 R181P mutation occurs in the protein's DNA binding domain and likely confers loss of function to the p53 protein. In biochemical assays, this TP53 mutant was found to completely lose DNA binding activity. Expression of this mutation in osteosarcoma cell lines resulted in decreased transactivation of TP53 target genes and reduced apoptosis (PMID: 20471942).",
            "description_review": {
              "updateTime": 1495150841999
            },
            "description_uuid": "20a977b7-8296-46d2-bb9f-937b36d44879",
            "effect": "Loss-of-function",
            "effect_review": {
              "updateTime": 1495150841999
            },
            "effect_uuid": "7f5362d2-5cc6-4a0b-a07d-52e0b3df046e",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "001f2b88-fb31-4d3e-a0d2-dea646391c92",
            "short": ""
          },
          "mutation_effect_uuid": "c3bf33dd-ba57-492e-9f6c-6c0b897a2265",
          "name": "R181P",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "173c2e28-56a7-4190-b08c-d79fbbe45ee0"
        },
        {
          "mutation_effect": {
            "description": "The TP53 E180K mutation occurs in the protein's DNA binding domain. In biochemical assays, this TP53 mutant was found to have defective DNA binding activity compared to wildtype TP53 (PMID: 24814347). Expression of this mutation in osteosarcoma cell lines resulted in decreased transactivation of TP53 target genes and reduced apoptosis (PMID: 20471942).",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "7837b6be-dec0-4319-81ac-75811731763c",
            "effect": "Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "e4542676-3410-4b9a-85fa-3afc44d88a05",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "564683ab-c62a-46b8-ba84-910976339f36",
            "short": ""
          },
          "mutation_effect_uuid": "a1e6b54b-4714-44aa-b045-e8084479fa42",
          "name": "E180K",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "71b74acd-3645-4476-b9f9-54121d0c5312"
        },
        {
          "mutation_effect": {
            "description": "The TP53 R181L mutation occurs in the protein's DNA binding domain. In biochemical assays, this TP53 mutant was found to have defective DNA binding activity compared to wildtype TP53. Expression of this mutation in osteosarcoma cell lines resulted in decreased transactivation of TP53 target genes and reduced apoptosis (PMID: 20471942).",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "face3d6b-e56d-4ee6-a5e2-051a0812f53c",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "9e42d6df-dbb2-49ae-be6d-f5ffd6064262",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "7ea701e7-d356-4122-b740-c18b729170d7",
            "short": ""
          },
          "mutation_effect_uuid": "b77125c5-7ec7-49fe-b357-913a908bc959",
          "name": "R181L",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "df34ca36-ece4-4fb8-89ff-88812a0cc9be"
        },
        {
          "mutation_effect": {
            "description": "The TP53 K120R mutation occurs in the protein's DNA binding domain. Expression of this mutation in lung cancer cell lines demonstrated that this mutant is defective for TP53 acetylation, compared to wildtype TP53. Loss of acetylation results in defective apoptosis, without impacting cell cycle arrest (PMID: 17189187, 7651437).",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "85b04e83-907b-41ef-b46b-4a4d111b4dd6",
            "effect": "Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "40e1aac7-b29e-44bb-a6aa-bde06b842413",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "cb05874e-484e-4f65-bde5-6f5bec6603d0",
            "short": ""
          },
          "mutation_effect_uuid": "a37f0537-8455-491c-a235-3000658e17d5",
          "name": "K120R",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "a927c274-8d3e-4679-b4b0-0584bbd4cbaf"
        },
        {
          "mutation_effect": {
            "description": "The TP53 K120M mutation occurs in the protein's DNA binding domain. Expression of this mutation in lung cancer cell lines result in decreased cell cycle arrest, compared to expression of wildtype TP53 (PMID: 17189187).",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "68a7d39b-fb06-47c7-ad91-025ff0327ab4",
            "effect": "Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "a431dbc8-2140-4cef-920c-ad433311b7c5",
            "oncogenic": "Yes",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "3fbb0295-0363-42be-abac-cb74f0269645",
            "short": ""
          },
          "mutation_effect_uuid": "0256fefb-2632-4751-bc2a-59d4dab01258",
          "name": "K120M",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "12763932-3d13-42cb-92f0-d77ece1517f9"
        },
        {
          "mutation_effect": {
            "description": "The TP53 K120E mutation occurs in the protein's DNA binding domain. Expression of this mutation in lung cancer cell lines resulted in decreased cell cycle arrest, compared to expression of wildtype TP53 (PMID: 17189187, 24814347). In colony formation assays, expression of this mutation resulted in increased cell growth compared to wildtype TP53. Expression of this mutation resulted in decreased p21 and MDM2 expression and defective cytochrome c release from the mitochondria (PMID: 18524770).",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "c0f629c7-c62d-40a4-9c16-6a16c839045e",
            "effect": "Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "3bee033c-f24a-4c07-869c-251203a4b891",
            "oncogenic": "Yes",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "3d957e82-4398-4cf4-a5b4-3615ca706728",
            "short": ""
          },
          "mutation_effect_uuid": "84882529-928a-4db1-b618-34f9b4e85e4d",
          "name": "K120E",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "0aaf111f-8181-46a0-92be-60153b22c83e"
        },
        {
          "mutation_effect": {
            "description": "The TP53 R273K mutation occurs in the protein's DNA binding domain. In biochemical assays, this TP53 mutant had a decreased ability to bind DNA compared to wildtype TP53 (PMID: 7651437).",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "b81c7dcf-5cd8-4012-be96-493663ca21a3",
            "effect": "Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "dbce0662-29d0-4b88-bf3c-49a4526b37be",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "9809454f-de0b-4cf6-b098-849358bd0f84",
            "short": ""
          },
          "mutation_effect_uuid": "e2391704-75a0-460f-90cb-6d57fbeaea84",
          "name": "R273K",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "b53b8527-512e-4fa9-b2d7-a7d16ab9f848"
        },
        {
          "mutation_effect": {
            "description": "The TP53 K120N mutation occurs in the protein's DNA binding domain. In biochemical assays, this TP53 mutant had a decreased ability to bind DNA compared to wildtype TP53 (PMID: 7651437).",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "212db923-5d91-4cec-9e69-5b59255d5bdf",
            "effect": "Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "79869457-41eb-4e30-86d6-f5ccd09dc513",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "2f740ed9-536a-4f19-be8d-bb9b5ab97f9e",
            "short": ""
          },
          "mutation_effect_uuid": "b4407657-a3ee-4efd-b6ae-a5bce5ae8be1",
          "name": "K120N",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "33be35f4-7bbf-4d0d-b82b-107a4310f2f1"
        },
        {
          "mutation_effect": {
            "description": "The TP53 C277Q mutation occurs in the protein's DNA binding domain. In biochemical assays, this TP53 mutant had a decreased ability to bind DNA compared to wildtype TP53 (PMID: 7651437).",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "3d9bfd9b-09aa-44e6-b516-2c6d162836ac",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "93b63170-5476-4728-ab27-c4617f921b46",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "d7744220-e23f-4140-a619-26514d841fda",
            "short": ""
          },
          "mutation_effect_uuid": "ead7d5c0-3bb8-4069-92b9-3f638a17651a",
          "name": "C277Q",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "0111c5e4-9e64-4e40-9ed2-daf907bc6175"
        },
        {
          "mutation_effect": {
            "description": "The TP53 C277R mutation occurs in the protein's DNA binding domain. In biochemical assays, this TP53 mutant had a decreased ability to bind DNA compared to wildtype TP53 (PMID: 7651437).",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "88b3b36d-3932-49ba-b44f-c1685f305c74",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "c331d331-6191-41ae-9730-5b0ca48ecf61",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "099645c0-c531-4b22-b6e0-f6e0a0a69630",
            "short": ""
          },
          "mutation_effect_uuid": "2a4313e3-0598-4239-bfc1-e93e8d9dba0a",
          "name": "C277R",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "d099060b-8d7b-4eaa-8193-c5d92ff50017"
        },
        {
          "mutation_effect": {
            "description": "The TP53 R248K mutation occurs in the protein's DNA binding domain. Biochemical assays have demonstrated that this TP53 mutation is inactivating as measured by decreased ability to bind DNA compared to wildtype TP53 (PMID: 7651437).",
            "description_review": {
              "updateTime": 1673642475943,
              "updatedBy": "User"
            },
            "description_uuid": "4736237f-fb7a-4620-b399-f00a140ece6a",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "a2630e1b-9300-486c-8077-f37d23f085ba",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "a4d9e08e-2675-4318-869f-696e2d2faf0b",
            "short": ""
          },
          "mutation_effect_uuid": "c5ccd3ef-712f-46ed-9206-69729d10dc98",
          "name": "R248K",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "53d2b1e2-d37f-432a-93e0-23b5dddf5627"
        },
        {
          "mutation_effect": {
            "description": "The TP53 R283Q mutation occurs in the protein's DNA binding domain. In biochemical assays, this TP53 mutant had a decreased ability to bind DNA compared to wildtype TP53 (PMID: 7651437).",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "3ec5a5ba-bc32-4556-bc0f-1ab614f49876",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "a4a9d1be-14a2-4cfe-843a-3a422b412940",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "c2d1a9ff-f41f-4896-96ef-b68381e1ea7a",
            "short": ""
          },
          "mutation_effect_uuid": "d725ac40-f012-45ff-a37f-38a9494f43e8",
          "name": "R283Q",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "7e62bcfb-a5dc-43f0-81e8-2b2cc285f1fe"
        },
        {
          "mutation_effect": {
            "description": "The TP53 H178D mutation occurs in the protein's DNA binding domain and likely confers loss of function to the p53 protein. In biochemical assays, this TP53 mutant had a decreased ability to bind DNA of apoptosis effecters Puma and p21, but not anti-apoptotic mediators such as Bcl-xl compared to wildtype TP53 (PMID: 24814347).",
            "description_review": {
              "updateTime": 1495150777727
            },
            "description_uuid": "67155d12-7d5c-4934-b79c-1fc02d9189b5",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1495150777727
            },
            "effect_uuid": "adf3b436-da78-45c0-8582-fce8b3f1a868",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "7b5e897c-ab0d-46d0-bc07-fe5b93fb2d57",
            "short": ""
          },
          "mutation_effect_uuid": "eb83d721-0725-4ba7-9588-da382f39f6b8",
          "name": "H178D",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "df032da0-784f-477b-af0d-ec1e5e46a930"
        },
        {
          "mutation_effect": {
            "description": "The TP53 D186A mutation occurs in the protein's DNA binding domain. In biochemical assays, this TP53 mutant had a decreased ability to bind DNA compared to wildtype TP53 (PMID: 24814347).",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "9d0e8398-7692-405a-a4cc-adb7f88d7022",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "38fad032-750c-4204-9578-cb2c8c76b486",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "48494947-6086-43b6-9a57-baae32aa168f",
            "short": ""
          },
          "mutation_effect_uuid": "77b6fad0-1593-46bf-b873-7ea88c9247d3",
          "name": "D186A",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "6a0e8bc2-27f1-4216-ad25-4853f3835ce7"
        },
        {
          "mutation_effect": {
            "description": "The TP53 C277W mutation occurs in the protein's DNA binding domain. In biochemical assays, this TP53 mutant had a decreased ability to bind DNA compared to wildtype TP53 (PMID: 24814347).",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "5e5d4769-326b-4832-8ad7-d886f354595b",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "a0de3084-e532-43b3-8bc1-a14d7b990697",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "9a3c3525-cce5-49c8-9d77-30e03bd577b5",
            "short": ""
          },
          "mutation_effect_uuid": "0eae7285-0ebe-4a71-83d3-021367449b6e",
          "name": "C277W",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "a095dbfe-8f14-4044-aa27-87dee976c195"
        },
        {
          "mutation_effect": {
            "description": "The TP53 K120A mutation occurs in the protein's DNA binding domain. In biochemical assays, this TP53 mutant had a decreased ability to bind DNA compared to wildtype TP53 (PMID: 24814347). Expression of this mutation in cell lines resulted in cell cycle defects and reduced apoptosis, consistent with loss of TP53 activity (PMID: 16687402).",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "5a1736f3-12fa-4525-a0d1-bd73d40655e6",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "b105cd98-386a-4031-959f-ebd8b9d9a701",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "18decb14-dbd7-4df7-8da2-d2b8836a7303",
            "short": ""
          },
          "mutation_effect_uuid": "f14f86e3-3246-4dd2-a157-cc2b21b3f8e9",
          "name": "K120A",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "55342b37-3385-4a54-b8c4-a3bd871dab56"
        },
        {
          "mutation_effect": {
            "description": "The TP53 R280A mutation occurs in the protein's DNA binding domain. Expression of this mutation in lung cancer cell lines resulted in decreased cell cycle arrest, compared to expression of wildtype TP53 (PMID: 17189187, 24814347). In colony formation assays, expression of this mutation resulted in increased cell growth compared to wildtype TP53. Expression of this mutation resulted in decreased p21 and MDM2 expression, consistent with defects in cell cycle (PMID: 18524770).",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "316d3d26-fead-4e84-8f0a-3e5a9b6b4239",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "f48417f5-975b-424d-8f8f-b77e66dab9cb",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "f8157c54-5106-4e26-869c-77fca2f5bba5",
            "short": ""
          },
          "mutation_effect_uuid": "9e406eb0-4ae7-47fb-beb1-fdc3787354e9",
          "name": "R280A",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "6e11ad84-a8f2-4b63-9ef1-2b9b5a355e21"
        },
        {
          "mutation_effect": {
            "description": "The TP53 V143A mutation occurs in the protein's DNA binding domain. Expression of this mutation in osteosarcoma TP53-null cell lines resulted in increased colony formation compared to cells expressing wildtype TP53 (PMID: 10435620).",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "199b2ee0-d709-4347-8e88-5eaf86db1213",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "5c6716f8-583a-42ec-97bf-a9c00ccd4ebc",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "c4a77df5-6243-487a-84b5-df937ddc7b4e",
            "short": ""
          },
          "mutation_effect_uuid": "d11d8b6b-e014-4723-83d5-d516969b9d4a",
          "name": "V143A",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "e9c868d3-316e-46a7-87fe-bdbe4c5f61c8"
        },
        {
          "mutation_effect": {
            "description": "The TP53 R290H mutation occurs in the protein's DNA binding domain. Expression of this mutation in osteosarcoma TP53-null cell lines resulted in increased colony formation and increased p21 transactivation compared to cells expressing wildtype TP53 (PMID: 10435620).",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "2e86e706-430b-48f3-8b1a-971bb21b2145",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "baab13ee-970b-4ef1-b408-718a71f4b577",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "0acca871-c27a-481c-a750-f3172f195b28",
            "short": ""
          },
          "mutation_effect_uuid": "ef47eeea-3125-495b-a764-050b264e536c",
          "name": "R290H",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "1b1c7213-1e62-4b30-bdfb-6273588b5a0a"
        },
        {
          "mutation_effect": {
            "description": "The TP53 R156H mutation occurs in the protein's DNA binding domain. Expression of this mutation in osteosarcoma TP53-null cell lines results in p21 transactivation compared to expression of wildtype TP53 (PMID: 10435620).",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "2bc0f25d-472b-4686-b90f-86c4a7410746",
            "effect": "Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "3dc0d794-ce11-45dd-b380-b910685fd5ad",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "41656930-7b09-48a0-8b39-dbf18ff23110",
            "short": ""
          },
          "mutation_effect_uuid": "39a3fa5f-37cf-4e6a-b536-75aee379e316",
          "name": "R156H",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "85b9b97d-7464-4fbf-8514-be8844d762be"
        },
        {
          "mutation_effect": {
            "description": "The TP53 R267P mutation occurs in the protein's DNA binding domain. Lung cancer cell lines that have endogenous expression of this mutation are sensitive to knockdown of TP53 in growth assays. Expression of this mutation in cell lines results in enhanced expression of the tyrosine kinase Axl (PMID: 22989750, 23264849).",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "efd8cce6-1d45-428d-a3b1-c3954abb6f93",
            "effect": "Likely Gain-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "8ed97575-e8de-466e-937c-44743e090b2c",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "74dec252-1b48-4ec4-acd8-156813aad0c4",
            "short": ""
          },
          "mutation_effect_uuid": "b5996c66-67f0-4d77-82d8-51e7c749baa6",
          "name": "R267P",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "046966ed-5cb2-4e91-8e87-faad39277023"
        },
        {
          "mutation_effect": {
            "description": "The TP53 Q331H mutation occurs in the protein's tetramerization domain. In biochemical assays, this TP53 mutation enhanced the formation of TP53 tetramers (PMID: 20978130). However, this mutation is a hotspot, suggesting that it is likely oncogenic (PMID: 26619011).",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "a1ece3cc-9ce7-4bef-89d0-0fa734f9062c",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "d896c2aa-a20c-46b4-a0dc-8b8dd6392e70",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1487884398000
            },
            "oncogenic_uuid": "e942a3c9-f18d-46af-a716-00acd11193b3",
            "short": ""
          },
          "mutation_effect_uuid": "945c623b-780f-4afe-997e-83b2b24b05aa",
          "name": "Q331H",
          "name_comments": [
            {
              "content": "need PMID",
              "date": "1481852025686",
              "email": "user@gmail.com",
              "resolved": "false",
              "userName": "User"
            }
          ],
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "880bc7c1-7979-4705-a124-a2827d61ffc5"
        },
        {
          "mutation_effect": {
            "description": "The TP53 T329I mutation occurs in the protein's tetramerization domain. In biochemical assays, this TP53 mutation enhanced the formation of TP53 tetramers (PMID: 20978130). Further functional data is required to determine if this mutation is indeed gain-of-function.",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "aec962dc-1270-43cf-8237-8ad2446379d9",
            "effect": "Inconclusive",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "c19b8f02-f19f-43b5-a019-4b777367ddcf",
            "oncogenic": "Inconclusive",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "b8b7d2b2-3dcc-484e-a76b-31d1f0ec49d9",
            "short": ""
          },
          "mutation_effect_uuid": "397ee707-7367-425d-b35d-bdd8139561e3",
          "name": "T329I",
          "name_comments": [
            {
              "content": "need PMID",
              "date": "1481851975208",
              "email": "user@gmail.com",
              "resolved": "false",
              "userName": "User"
            }
          ],
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "d10cca0f-0f4c-43ef-be5b-8a5fa9c19045"
        },
        {
          "mutation_effect": {
            "description": "The TP53 Q331R mutation occurs in the protein's tetramerization domain. In biochemical assays, this TP53 mutation enhanced the formation of TP53 tetramers (PMID: 20978130), which could lead to alteration of p53 function",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "5cee4464-5f09-456c-9917-03a34af4254d",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "5375dc0c-395c-43ff-be5a-598d1f79a658",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "53587bdf-fc1e-4550-bd94-880815ec8356",
            "short": ""
          },
          "mutation_effect_uuid": "28e21593-188d-471b-b2e9-195301270f31",
          "name": "Q331R",
          "name_comments": [
            {
              "content": "need PMID",
              "date": "1481852003507",
              "email": "user@gmail.com",
              "resolved": "true",
              "userName": "User"
            }
          ],
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "13b2a60a-825d-4e2f-ab4e-cbd842835fc9"
        },
        {
          "mutation_effect": {
            "description": "The TP53 G356A mutation occurs in the protein's tetramerization domain. In biochemical assays, this TP53 mutation enhanced the formation of TP53 tetramers (PMID: 20978130). Further functional data is required to determine if this mutation is indeed gain-of-function.",
            "description_review": {
              "updateTime": 1493754273398
            },
            "description_uuid": "dfdf3cf1-5965-47fd-c097-2a128e6d160a",
            "effect": "Inconclusive",
            "effect_review": {
              "updateTime": 1493754273398
            },
            "effect_uuid": "74c7493c-85e4-4ee9-c02b-b493955e323a",
            "oncogenic": "Inconclusive",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "47ec5f61-9067-43ff-89df-d8f1df0a6786",
            "short": ""
          },
          "mutation_effect_uuid": "855994d4-af9d-460b-bfaa-5af02964b31c",
          "name": "G356A",
          "name_comments": [
            {
              "content": "can we have a PMID?",
              "date": "1481851938395",
              "email": "user@gmail.com",
              "resolved": "false",
              "userName": "User"
            }
          ],
          "name_review": {
            "updateTime": 1493754269660
          },
          "name_uuid": "f8e3bcd4-4091-49d0-b47f-15344d95a7a7"
        },
        {
          "mutation_effect": {
            "description": "The TP53 P316L mutation is located in the protein's most N-terminal signal (NLS1) domain. Mutation in this domain has been shown to induce the synthesis of a cytoplasmic p53 protein, thus interfering with normal p53 protein localization (PMID: 2553699, 10618702, 20010306 ).",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "9361bc58-f3b9-45dd-b8b6-c1677cbb2d30",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "bd32563e-1c00-463e-a143-132858c5e3f1",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "063c9847-e0fd-47e5-9261-b7d6407615f1",
            "short": ""
          },
          "mutation_effect_uuid": "c076a09a-cddb-42f1-9e7f-ea7440815302",
          "name": "P316L",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "20ed9187-489c-4dd9-a330-f966d4fa2c18"
        },
        {
          "mutation_effect": {
            "description": "",
            "description_review": {
              "updateTime": 1492724745580
            },
            "description_uuid": "4bd59fa0-a43b-411e-8767-b38c2f7f690f",
            "effect": "",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "6f98de3a-2977-4ee9-98c9-6d18b80d4de2",
            "oncogenic": "",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "2910c261-26da-4123-b61b-6514637bcc67",
            "short": ""
          },
          "mutation_effect_uuid": "c73432c8-2a2d-4b5e-8343-7fcf0b62b942",
          "name": "Oncogenic Mutations",
          "name_comments": [
            {
              "content": "Need info on basal cell carcinoma",
              "date": "1433535014962",
              "email": "user@gmail.com",
              "resolved": "true",
              "userName": "User"
            }
          ],
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "95d0437f-1f1a-4789-bf03-40bb3ca68187",
          "tumors": [
            {
              "TIs": [
                {
                  "name": "Standard implications for sensitivity to therapy",
                  "name_uuid": "97ace3be-66d6-4fdd-8cfa-03fdb70b225e",
                  "type": "SS"
                },
                {
                  "name": "Standard implications for resistance to therapy",
                  "name_uuid": "439851cf-3d04-4600-8109-ebef86925e25",
                  "type": "SR"
                },
                {
                  "name": "Investigational implications for sensitivity to therapy",
                  "name_uuid": "16a39c48-75ee-4213-8789-2ad7cf820a9a",
                  "type": "IS"
                },
                {
                  "name": "Investigational implications for resistance to therapy",
                  "name_uuid": "a4879340-f5a7-48f3-a515-260f501a0f9b",
                  "type": "IR"
                }
              ],
              "cancerTypes": [
                {
                  "code": "",
                  "mainType": "Non-Small Cell Lung Cancer",
                  "subtype": ""
                }
              ],
              "cancerTypes_uuid": "41ff59d0-5ed0-4f18-90ff-bc31f9d3f117",
              "diagnostic": {
                "description": "",
                "description_uuid": "ffd40cfa-d7a4-4551-8030-5567938dff31",
                "level": "",
                "level_uuid": "fa2de82b-50cd-4fac-9d45-f24602d62a20",
                "short": ""
              },
              "diagnosticSummary": "",
              "diagnosticSummary_uuid": "412fa9aa-242e-4632-a43f-eeeff8024e29",
              "diagnostic_uuid": "922d9845-a791-46a6-9ac7-6193b83c46c1",
              "prognostic": {
                "description": "",
                "description_review": {
                  "updateTime": 1492724745580
                },
                "description_uuid": "6a936e93-35c3-4c6a-82a4-da6ada76be1a",
                "level": "",
                "level_uuid": "29b8ef7a-c161-4626-8a7a-aef716a29efd",
                "short": ""
              },
              "prognosticSummary": "",
              "prognosticSummary_uuid": "abdfacc1-ea6f-428c-94b9-16be2db9d1c8",
              "prognostic_uuid": "1dc9237d-9c64-4e35-9f76-7f909c71ab5f",
              "summary": "",
              "summary_review": {
                "updateTime": 1554239348957,
                "updatedBy": "User"
              },
              "summary_uuid": "c632d5d3-e496-4746-8fb9-1c46780ff543"
            },
            {
              "TIs": [
                {
                  "name": "Standard implications for sensitivity to therapy",
                  "name_uuid": "b7781fb4-551e-40d5-85ff-99cd9624bcde",
                  "type": "SS"
                },
                {
                  "name": "Standard implications for resistance to therapy",
                  "name_uuid": "3210d55a-be2a-401b-9640-8c2ab8e34ab0",
                  "type": "SR"
                },
                {
                  "name": "Investigational implications for sensitivity to therapy",
                  "name_uuid": "ef48e4e5-f9a9-43df-83d3-890e6174175a",
                  "type": "IS"
                },
                {
                  "name": "Investigational implications for resistance to therapy",
                  "name_uuid": "ff311a1e-aea0-497c-b8f9-3d97be0b6fc4",
                  "type": "IR"
                }
              ],
              "cancerTypes": [
                {
                  "code": "",
                  "mainType": "Colorectal Cancer",
                  "subtype": ""
                }
              ],
              "cancerTypes_uuid": "db8d9c65-e788-4319-93eb-7f236bff7e36",
              "diagnostic": {
                "description": "",
                "description_uuid": "8ce254c3-ef8c-43fe-9f63-74f96718bddc",
                "level": "",
                "level_uuid": "e8048a25-9c62-4b01-b48e-5be7837f5366",
                "short": ""
              },
              "diagnosticSummary": "",
              "diagnosticSummary_uuid": "6b0fee0b-0174-4375-a4fe-873bb80b76af",
              "diagnostic_uuid": "34c46f74-d75a-4dfe-ab9d-578d89ea0424",
              "prognostic": {
                "description": "",
                "description_review": {
                  "updateTime": 1492724745580
                },
                "description_uuid": "58e15589-5f77-46c7-89fd-e3f8125281c8",
                "level": "",
                "level_uuid": "e105cf76-5a21-4caf-9f82-6144d70f0854",
                "short": ""
              },
              "prognosticSummary": "",
              "prognosticSummary_uuid": "ef1c1b8f-a5c7-4342-a5bb-54feee07d368",
              "prognostic_uuid": "95627906-e0fb-4a45-9a76-2dc47bc1293c",
              "summary": "",
              "summary_review": {
                "updateTime": 1492724745580
              },
              "summary_uuid": "9e6460fa-c270-4d9c-c03e-7143ab29105a"
            },
            {
              "TIs": [
                {
                  "name": "Standard implications for sensitivity to therapy",
                  "name_uuid": "fb22633f-b50f-412b-8882-1622eeb43fa6",
                  "type": "SS"
                },
                {
                  "name": "Standard implications for resistance to therapy",
                  "name_uuid": "f9b9e8df-553f-428c-9107-11fd95fb6c54",
                  "type": "SR"
                },
                {
                  "name": "Investigational implications for sensitivity to therapy",
                  "name_uuid": "d77e2aa0-1384-4b1b-aa34-5d99deaf187a",
                  "type": "IS"
                },
                {
                  "name": "Investigational implications for resistance to therapy",
                  "name_uuid": "b40d0c3f-a5a7-4c97-a96f-fe5946c69983",
                  "type": "IR"
                }
              ],
              "cancerTypes": [
                {
                  "code": "",
                  "mainType": "Endometrial Cancer",
                  "subtype": ""
                }
              ],
              "cancerTypes_uuid": "aba99601-f4a7-48d2-bee6-c9890fd54fcd",
              "diagnostic": {
                "description": "",
                "description_uuid": "9d80663f-ab9f-406f-9b42-5419942aef3a",
                "level": "",
                "level_uuid": "4c34caaf-fd35-48e0-add5-9c8e24045954",
                "short": ""
              },
              "diagnosticSummary": "",
              "diagnosticSummary_uuid": "120ef4dd-ed4c-4b34-aff0-1fdd14bc670e",
              "diagnostic_uuid": "db75ec9a-64bd-4803-bbc8-c2ffc014196d",
              "prognostic": {
                "description": "",
                "description_review": {
                  "updateTime": 1492724745580
                },
                "description_uuid": "bec6cd33-f6df-4574-b32c-564b7f2d6552",
                "level": "",
                "level_uuid": "bf99d4de-9dda-4549-8fa5-d46d5d79b6d7",
                "short": ""
              },
              "prognosticSummary": "",
              "prognosticSummary_uuid": "e7b1d9d3-3707-4691-a91f-45272018b703",
              "prognostic_uuid": "5d8391fd-c9ff-4db4-a94e-ff9ac378ea21",
              "summary": "",
              "summary_review": {
                "updateTime": 1492724745580
              },
              "summary_uuid": "bddc57a0-8dc7-476f-b4ce-c4c82365c94d"
            },
            {
              "TIs": [
                {
                  "name": "Standard implications for sensitivity to therapy",
                  "name_uuid": "f2dd1aee-c972-4b8d-a5db-713129930a33",
                  "type": "SS"
                },
                {
                  "name": "Standard implications for resistance to therapy",
                  "name_uuid": "f64eb871-9d63-4f12-b456-3ae66e5f3fa2",
                  "type": "SR"
                },
                {
                  "name": "Investigational implications for sensitivity to therapy",
                  "name_uuid": "b23381f2-07ae-4f38-8b8b-e165690736e1",
                  "type": "IS"
                },
                {
                  "name": "Investigational implications for resistance to therapy",
                  "name_uuid": "ddfc7441-a42e-4062-813b-73130c6f3d3c",
                  "type": "IR"
                }
              ],
              "cancerTypes": [
                {
                  "code": "",
                  "mainType": "Head and Neck Cancer",
                  "subtype": ""
                }
              ],
              "cancerTypes_uuid": "bfdf065e-a93d-4554-bc31-44de2ff32622",
              "diagnostic": {
                "description": "",
                "description_uuid": "f55f5bdc-84f1-45a6-a0bf-232ead962444",
                "level": "",
                "level_uuid": "1378dbb7-6595-4abc-afa7-75136bcd2e21",
                "short": ""
              },
              "diagnosticSummary": "",
              "diagnosticSummary_uuid": "f8cf5eac-83be-4a87-b579-5fcb79fc0552",
              "diagnostic_uuid": "39c4a82a-967a-47fa-9751-bec55775e9be",
              "prognostic": {
                "description": "",
                "description_review": {
                  "updateTime": 1492724745580
                },
                "description_uuid": "e8dd7cea-a9ef-4eb2-8b3c-7d1381cc4306",
                "level": "",
                "level_uuid": "def9db38-8b85-44c5-8047-05e2bb8592ec",
                "short": ""
              },
              "prognosticSummary": "",
              "prognosticSummary_uuid": "fb4bccf9-6338-4e5c-9d89-e6f464c4fabd",
              "prognostic_uuid": "0d472f55-4fee-4155-b3e3-a842373786af",
              "summary": "",
              "summary_review": {
                "updateTime": 1492724745580
              },
              "summary_uuid": "f4f4a7e8-1ad9-477a-90c2-a9c97dc28b01"
            },
            {
              "TIs": [
                {
                  "name": "Standard implications for sensitivity to therapy",
                  "name_uuid": "804584a1-821f-463a-b5df-f3d0ac647ec8",
                  "type": "SS"
                },
                {
                  "name": "Standard implications for resistance to therapy",
                  "name_uuid": "fff19e47-ede2-4353-b018-9ed3dcc79814",
                  "type": "SR"
                },
                {
                  "name": "Investigational implications for sensitivity to therapy",
                  "name_uuid": "2d0218fd-d267-49d1-a1a4-81d0e75534ca",
                  "type": "IS"
                },
                {
                  "name": "Investigational implications for resistance to therapy",
                  "name_uuid": "69c0630b-aa85-4b18-9c4f-648c72703b47",
                  "type": "IR"
                }
              ],
              "cancerTypes": [
                {
                  "code": "",
                  "mainType": "Prostate Cancer",
                  "subtype": ""
                }
              ],
              "cancerTypes_uuid": "125ac8e6-6d72-4499-8da4-392cd3b6214c",
              "diagnostic": {
                "description": "",
                "description_uuid": "476712c0-3bde-46ad-a8a0-3c1147857093",
                "level": "",
                "level_uuid": "6a8fe498-3e66-4ea7-8a5d-3d5502c903cd",
                "short": ""
              },
              "diagnosticSummary": "",
              "diagnosticSummary_uuid": "2bb6a3b3-9980-4e6a-aa2e-b655a070ae01",
              "diagnostic_uuid": "1b364e12-53a3-46e4-bf1c-3ce3c5e6c404",
              "prognostic": {
                "description": "",
                "description_review": {
                  "updateTime": 1505410533876
                },
                "description_uuid": "260c8e10-122c-4f6e-af0e-b969d6013e8c",
                "level": "",
                "level_uuid": "e360bacf-ec8f-42f9-8f91-4a386628785f",
                "short": ""
              },
              "prognosticSummary": "",
              "prognosticSummary_uuid": "0c5f3baa-e1d4-4873-8b0f-79ddfe390e04",
              "prognostic_uuid": "2fc1eb99-419d-43f7-beba-484fd116068e",
              "summary": "",
              "summary_review": {
                "updateTime": 1492724745580
              },
              "summary_uuid": "b7dc16bb-991f-45e9-abe6-41fdf1bc3b06"
            },
            {
              "TIs": [
                {
                  "name": "Standard implications for sensitivity to therapy",
                  "name_uuid": "087f413a-7e1f-4e1f-930b-d17d69225608",
                  "type": "SS"
                },
                {
                  "name": "Standard implications for resistance to therapy",
                  "name_uuid": "0f7ce431-d78a-4a2d-a395-ae0ec7a776bf",
                  "type": "SR"
                },
                {
                  "name": "Investigational implications for sensitivity to therapy",
                  "name_comments": [
                    {
                      "content": "MDM2 inhibition and p53: PMID: 26459177",
                      "date": "1455319856902",
                      "email": "user@gmail.com",
                      "resolved": "false",
                      "userName": "User"
                    }
                  ],
                  "name_uuid": "ba2e3e3c-29a9-4ac2-bf2e-e4adbe66ff74",
                  "type": "IS"
                },
                {
                  "name": "Investigational implications for resistance to therapy",
                  "name_uuid": "b9af4d92-09f0-4337-8019-1d84b1636c26",
                  "type": "IR"
                }
              ],
              "cancerTypes": [
                {
                  "code": "",
                  "mainType": "All Tumors",
                  "subtype": ""
                }
              ],
              "cancerTypes_uuid": "f12cde18-0928-4512-943b-1113a9a8dc09",
              "diagnostic": {
                "description": "",
                "description_uuid": "0cdffb24-01ce-424b-8574-cc90ffa13630",
                "level": "",
                "level_uuid": "2bb01c4a-3f3b-48e2-92dd-032e496228d7",
                "short": ""
              },
              "diagnosticSummary": "",
              "diagnosticSummary_uuid": "180d3334-dae9-488b-9dd6-f36429f330e1",
              "diagnostic_uuid": "842fa371-b343-4085-9aa0-d14b14dfc312",
              "prognostic": {
                "description": "",
                "description_review": {
                  "updateTime": 1494527077323
                },
                "description_uuid": "5ea4b730-c378-4b20-9e6f-59639764ff50",
                "level": "",
                "level_uuid": "004ffc10-223c-46d6-bb31-86f88c51eefa",
                "short": ""
              },
              "prognosticSummary": "",
              "prognosticSummary_uuid": "92908370-884c-41c1-afda-444df61f475b",
              "prognostic_uuid": "b99bcf76-c60e-4531-98a4-15bf5d2005fd",
              "summary": "",
              "summary_review": {
                "updateTime": 1492724745580
              },
              "summary_uuid": "7b7b27a8-d268-4aa3-a50c-c884d734bc24"
            },
            {
              "TIs": [
                {
                  "name": "Standard implications for sensitivity to therapy",
                  "name_uuid": "369e41a5-9aca-4383-b18f-5027052dc625",
                  "treatments_uuid": "7a9a907a-f555-403b-aed7-5ed01b265128",
                  "type": "SS"
                },
                {
                  "name": "Standard implications for resistance to therapy",
                  "name_uuid": "f2644401-6561-4569-9da6-e821b5b64189",
                  "treatments_uuid": "82b7159d-2b66-498a-8b69-1ed66608d84c",
                  "type": "SR"
                },
                {
                  "name": "Investigational implications for sensitivity to therapy",
                  "name_uuid": "17773762-1c6f-4386-b8c3-40a33305058a",
                  "treatments_uuid": "1e3451a8-70ec-4a6b-9fda-ce38393e46b2",
                  "type": "IS"
                },
                {
                  "name": "Investigational implications for resistance to therapy",
                  "name_uuid": "9cdb638d-7912-4bd0-9cd1-247c9d99cf94",
                  "treatments_uuid": "c39cb431-8600-49b3-98ef-06089b98616f",
                  "type": "IR"
                }
              ],
              "cancerTypes": [
                {
                  "code": "AMLMRC",
                  "mainType": "Leukemia",
                  "subtype": "AML with Myelodysplasia-Related Changes"
                }
              ],
              "cancerTypes_uuid": "86e3d909-6ed5-432c-9f37-8a327ccd18aa",
              "diagnostic": {
                "description": "",
                "description_uuid": "fbb3c44c-ae11-43db-8542-6af6d0793ab4",
                "level": "",
                "level_uuid": "4c346553-7879-43ec-b90d-a8c8f6224da9",
                "short": ""
              },
              "diagnosticSummary": "",
              "diagnosticSummary_uuid": "65058e32-81a7-4a98-bec5-83cfa5267662",
              "diagnostic_uuid": "a6077d0c-3bed-4c56-8cfd-46b6b0d2a303",
              "prognostic": {
                "description": "This assertion is supported by (PMID: 25860933, 25412851).",
                "description_review": {
                  "updateTime": 1600293135340,
                  "updatedBy": "User"
                },
                "description_uuid": "c55e87b2-5436-40b7-a2a8-da8110c44c2f",
                "level": "Px1",
                "level_review": {
                  "updateTime": 1600293135340,
                  "updatedBy": "User"
                },
                "level_uuid": "1f7cff27-2f4a-4aba-994c-f4a48728206e",
                "short": ""
              },
              "prognosticSummary": "The WHO classification of hematologic tumors list TP53 alterations as a prognostic biomarker in [[tumor type]]. Well-powered studies find that patients with a TP53 alteration such as [[gene]] [[mutation]] have a less favorable prognosis.",
              "prognosticSummary_review": {
                "updateTime": 1600293135340,
                "updatedBy": "User"
              },
              "prognosticSummary_uuid": "507da72f-9996-47e7-935f-2477a4b97c40",
              "prognostic_uuid": "ee6b8c2d-0e7a-42bb-ab8f-ef29344cd081",
              "summary": "",
              "summary_uuid": "1847e904-d791-49dd-bfa2-ef23c9cffac2"
            },
            {
              "TIs": [
                {
                  "name": "Standard implications for sensitivity to therapy",
                  "name_uuid": "8ab6f6a8-15eb-4ce4-bb08-f8136ef2ad31",
                  "treatments_uuid": "acbb76dd-ad53-4cbb-aebd-24df72b13952",
                  "type": "SS"
                },
                {
                  "name": "Standard implications for resistance to therapy",
                  "name_uuid": "82f7694a-1474-4783-b688-a33c567113d6",
                  "treatments_uuid": "659e8649-47fd-474f-b5b4-17ecebd5d15a",
                  "type": "SR"
                },
                {
                  "name": "Investigational implications for sensitivity to therapy",
                  "name_uuid": "505edbcc-3f4b-44b7-9332-73df3e607592",
                  "treatments_uuid": "77f173f3-506c-44ea-87ec-990aa71ad169",
                  "type": "IS"
                },
                {
                  "name": "Investigational implications for resistance to therapy",
                  "name_uuid": "268c4251-22fc-44c3-94e7-c46cc754db06",
                  "treatments_uuid": "9ba933f6-7d50-42bd-9a9c-d311197f2a59",
                  "type": "IR"
                }
              ],
              "cancerTypes": [
                {
                  "code": "AML",
                  "mainType": "Leukemia",
                  "subtype": "Acute Myeloid Leukemia"
                }
              ],
              "cancerTypes_review": {
                "updateTime": 1604692725347,
                "updatedBy": "User"
              },
              "cancerTypes_uuid": "41786c95-a8c9-4767-8e82-5d64491bd495",
              "diagnostic": {
                "description": "",
                "description_uuid": "0f24de02-4722-48cb-ae31-420893fde79b",
                "level": "",
                "level_uuid": "c4d533ce-6723-4509-b529-147700044519",
                "short": ""
              },
              "diagnosticSummary": "",
              "diagnosticSummary_uuid": "a0c08e07-c583-4286-911e-58b0a1249793",
              "diagnostic_uuid": "906f87bf-8d5f-4c09-a27c-043609ad0ee4",
              "prognostic": {
                "description": "This assertion is supported by (PMID: 22186996, 18596741).",
                "description_review": {
                  "updateTime": 1600293135340,
                  "updatedBy": "User"
                },
                "description_uuid": "937d7c8a-14cb-44ce-a027-957c4081bc2f",
                "level": "Px1",
                "level_review": {
                  "updateTime": 1600293135340,
                  "updatedBy": "User"
                },
                "level_uuid": "13ec6c13-7e99-4c86-973b-2d32f56aad05",
                "short": ""
              },
              "prognosticSummary": "The NCCN guidelines list TP53 alterations as a prognostic biomarker in acute myeloid leukemia. Well-powered studies find that patients with a TP53 alteration such as [[gene]] [[mutation]] have a less favorable prognosis.",
              "prognosticSummary_review": {
                "updateTime": 1600293135340,
                "updatedBy": "User"
              },
              "prognosticSummary_uuid": "368ceece-c5c4-409b-8820-d6fad62beeb1",
              "prognostic_uuid": "e43a1d21-8fe5-454e-8200-34d72533a72e",
              "summary": "",
              "summary_uuid": "d05ed768-76d7-49e5-8ec1-f0a6d2dc78d9"
            },
            {
              "TIs": [
                {
                  "name": "Standard implications for sensitivity to therapy",
                  "name_uuid": "23b1ec08-9f72-40fe-b20a-678d90bf247e",
                  "treatments_uuid": "47dcb253-08ec-4259-a8c2-8e4a635e6949",
                  "type": "SS"
                },
                {
                  "name": "Standard implications for resistance to therapy",
                  "name_uuid": "1a1d25d1-e4f5-44af-b567-6067b7c8b43b",
                  "treatments_uuid": "0370f301-3a58-4dbf-a2d0-668c66348fa6",
                  "type": "SR"
                },
                {
                  "name": "Investigational implications for sensitivity to therapy",
                  "name_uuid": "433de53f-a874-429f-b348-a05b9e6eb800",
                  "treatments_uuid": "999c9c40-35a4-4e54-991b-0589bdfb4420",
                  "type": "IS"
                },
                {
                  "name": "Investigational implications for resistance to therapy",
                  "name_uuid": "ed31c834-0053-4f34-8153-4d539d2c610b",
                  "treatments_uuid": "b0b4be2a-e0ae-4c43-92c2-7945e80e476b",
                  "type": "IR"
                }
              ],
              "cancerTypes": [
                {
                  "code": "TMN",
                  "mainType": "Leukemia",
                  "subtype": "Therapy-Related Myeloid Neoplasms"
                }
              ],
              "cancerTypes_uuid": "5aaf23ad-ee75-4875-a6a6-a5a3e4741341",
              "diagnostic": {
                "description": "",
                "description_uuid": "bd0f8bd7-8b98-4080-b705-22fcfe0f1b95",
                "level": "",
                "level_uuid": "c21ddc70-72cb-4346-96aa-87796d33f1c4",
                "short": ""
              },
              "diagnosticSummary": "",
              "diagnosticSummary_uuid": "c5f7e3e4-08b0-42f5-92ce-412247df18b3",
              "diagnostic_uuid": "12fcf9dc-4c7a-4441-81c5-3bf0c4578f2d",
              "prognostic": {
                "description": "This assertion is supported by (PMID: 25412846, 25952993).",
                "description_review": {
                  "updateTime": 1600293135340,
                  "updatedBy": "User"
                },
                "description_uuid": "dc2018ea-8157-48cc-b3a8-d9685a307eca",
                "level": "Px1",
                "level_review": {
                  "updateTime": 1600293135340,
                  "updatedBy": "User"
                },
                "level_uuid": "5effcf9c-a171-4f7c-b01b-9a8e4c09a4f5",
                "short": ""
              },
              "prognosticSummary": "The NCCN guidelines list TP53 alterations as a prognostic biomarker in therapy-related myeloid neoplasms. Well-powered studies find that patients with a TP53 alteration such as [[gene]] [[mutation]] have a less favorable prognosis.",
              "prognosticSummary_review": {
                "updateTime": 1610046734957,
                "updatedBy": "User"
              },
              "prognosticSummary_uuid": "20ba01fb-bdf4-4de4-9c2a-afc806df84b9",
              "prognostic_uuid": "17eadd11-3a15-408a-853b-121286199008",
              "summary": "",
              "summary_uuid": "4090031c-a8ef-4a81-baed-44afcbf0d8dc"
            },
            {
              "TIs": [
                {
                  "name": "Standard implications for sensitivity to therapy",
                  "name_uuid": "fbe3c376-ffc4-4e5e-8614-50cc8618ed0b",
                  "treatments_uuid": "40f2f6a7-11d5-42c7-bf58-a5db626c3298",
                  "type": "SS"
                },
                {
                  "name": "Standard implications for resistance to therapy",
                  "name_uuid": "9e35d2f8-fb6a-4658-ad22-7ccff557d332",
                  "treatments_uuid": "acdf1fef-89db-400d-8054-3c7708cba8f7",
                  "type": "SR"
                },
                {
                  "name": "Investigational implications for sensitivity to therapy",
                  "name_uuid": "f8e86345-c26f-4c5b-99dd-0101dacf7a4f",
                  "treatments_uuid": "1a3d20ed-05ff-4538-b4e0-209ad4803b60",
                  "type": "IS"
                },
                {
                  "name": "Investigational implications for resistance to therapy",
                  "name_uuid": "c2128410-1e4f-450e-9696-07e1da296299",
                  "treatments_uuid": "b1c42fd3-48f7-4517-9861-e20cd0005560",
                  "type": "IR"
                }
              ],
              "cancerTypes": [
                {
                  "code": "CLLSLL",
                  "mainType": "Mature B-Cell Neoplasms",
                  "subtype": "Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma"
                }
              ],
              "cancerTypes_uuid": "546d6f2d-ba2c-46eb-aeeb-162eeda16f3d",
              "diagnostic": {
                "description": "",
                "description_uuid": "edb423fa-05ed-4b34-ad5f-b7f023da5200",
                "level": "",
                "level_uuid": "34a4f270-348d-45f2-91db-978568a95377",
                "short": ""
              },
              "diagnosticSummary": "",
              "diagnosticSummary_uuid": "4c4aee7a-b56d-4e24-80e9-14ddd97842be",
              "diagnostic_uuid": "a9cdb707-77f5-4828-abdd-56b7833108b0",
              "prognostic": {
                "description": "This assertion is supported by (PMID: 19188171, 20697090, 24652989, 23243274, 24004666).",
                "description_review": {
                  "updateTime": 1600293135348,
                  "updatedBy": "User"
                },
                "description_uuid": "c9249510-e897-40eb-a31c-680ae98d1392",
                "level": "Px1",
                "level_review": {
                  "updateTime": 1600293135348,
                  "updatedBy": "User"
                },
                "level_uuid": "8e89ff98-bece-43de-9941-595205a0f723",
                "short": ""
              },
              "prognosticSummary": "The NCCN guidelines list TP53 alterations as a prognostic biomarker in [[tumor type]]. Well-powered studies find that patients with a TP53 alteration such as [[gene]] [[mutation]] have a less favorable prognosis.",
              "prognosticSummary_review": {
                "updateTime": 1600293135348,
                "updatedBy": "User"
              },
              "prognosticSummary_uuid": "c384db22-b61e-4c46-b4b6-623d01adcaa2",
              "prognostic_uuid": "8d78d7c1-2bf2-4199-9d9b-8fdb688bb9be",
              "summary": "",
              "summary_uuid": "a21acb75-8dd8-4995-b210-b2462d02eade"
            },
            {
              "TIs": [
                {
                  "name": "Standard implications for sensitivity to therapy",
                  "name_uuid": "766d8d4d-86ff-4264-a27d-1ccba94d1737",
                  "treatments_uuid": "cbea73db-fb06-4657-b8b9-86d918b0c744",
                  "type": "SS"
                },
                {
                  "name": "Standard implications for resistance to therapy",
                  "name_uuid": "788db55b-6f15-4bac-a0bb-0759a48a691c",
                  "treatments_uuid": "181130be-8263-4201-b681-45593e93acd7",
                  "type": "SR"
                },
                {
                  "name": "Investigational implications for sensitivity to therapy",
                  "name_uuid": "842c3294-1fd2-466d-9717-f8c82ef1e77f",
                  "treatments_uuid": "8f6e5b63-1f07-4b8a-977b-5c44179e9add",
                  "type": "IS"
                },
                {
                  "name": "Investigational implications for resistance to therapy",
                  "name_uuid": "7696b6ed-a3fa-4b7b-9852-caf8567600bd",
                  "treatments_uuid": "abd9d283-af6d-46b0-a116-c9057c85feb0",
                  "type": "IR"
                }
              ],
              "cancerTypes": [
                {
                  "code": "PCM",
                  "mainType": "Mature B-Cell Neoplasms",
                  "subtype": "Plasma Cell Myeloma"
                }
              ],
              "cancerTypes_uuid": "19ac790c-0f15-4b88-bcab-969b480ffbbb",
              "diagnostic": {
                "description": "",
                "description_uuid": "e3df9c2c-d865-454a-8cd0-d5a2645302fb",
                "level": "",
                "level_uuid": "78948fca-54fc-44da-bb17-ff99c31e2272",
                "short": ""
              },
              "diagnosticSummary": "",
              "diagnosticSummary_uuid": "13926de0-8da5-4ab1-9d89-063d4f0abbf3",
              "diagnostic_uuid": "2fdb5619-c9ce-45a7-bfdd-5095d46a2268",
              "prognostic": {
                "description": "",
                "description_review": {
                  "updateTime": 1557356084371
                },
                "description_uuid": "1443d286-2457-4249-bed1-95a4c1a117e6",
                "level": "",
                "level_review": {
                  "updateTime": 1557356084371
                },
                "level_uuid": "79939cf5-9d0f-450c-a17c-ad5e807cfcfe",
                "short": ""
              },
              "prognosticSummary": "",
              "prognosticSummary_uuid": "2a1c7b42-c8bf-4050-a318-9afde8b753ec",
              "prognostic_uuid": "7f2fd21a-3d3e-43ff-88d6-42916c3ddc02",
              "summary": "",
              "summary_uuid": "4141195a-2e1f-4a99-a2a5-a85da0e775b3"
            },
            {
              "TIs": [
                {
                  "name": "Standard implications for sensitivity to therapy",
                  "name_uuid": "bfe6d2a9-799e-48eb-ac8f-1f5206c1d4a2",
                  "treatments_uuid": "6dee512a-3c4a-4371-8446-c957e898fbc9",
                  "type": "SS"
                },
                {
                  "name": "Standard implications for resistance to therapy",
                  "name_uuid": "c1d507ae-f6fa-4e3e-938a-f39c5a2ce267",
                  "treatments_uuid": "474cc36e-77e5-4352-842c-1da185b5ee7e",
                  "type": "SR"
                },
                {
                  "name": "Investigational implications for sensitivity to therapy",
                  "name_uuid": "b76918a7-f54a-467a-ba20-e6ad4981ac8b",
                  "treatments_uuid": "63bd6b42-fc78-4a5f-a747-341d10dfc7ea",
                  "type": "IS"
                },
                {
                  "name": "Investigational implications for resistance to therapy",
                  "name_uuid": "1cb611ad-268a-4539-ac12-c0eec510f9b9",
                  "treatments_uuid": "2825ac1c-a888-49a1-a0a3-d1582b1a43c5",
                  "type": "IR"
                }
              ],
              "cancerTypes": [
                {
                  "code": "MDS",
                  "mainType": "Myelodysplastic Syndromes",
                  "subtype": "Myelodysplastic Syndromes"
                }
              ],
              "cancerTypes_uuid": "eafb5415-6810-434e-8944-f230e2d23444",
              "diagnostic": {
                "description": "",
                "description_uuid": "0dabd7a4-2042-472b-a5b1-ee67f568c69b",
                "level": "",
                "level_uuid": "04dab7bd-54d6-46f5-acdf-f3b4452b476b",
                "short": ""
              },
              "diagnosticSummary": "",
              "diagnosticSummary_uuid": "b884ac2a-4a29-4bf9-b065-0fb2d4c76126",
              "diagnostic_uuid": "43dab662-d290-476a-8ffb-0103fa2a2a65",
              "prognostic": {
                "description": "This assertion is supported by (PMID: 24220272, 21714648, 25092778).",
                "description_review": {
                  "updateTime": 1600293135355,
                  "updatedBy": "User"
                },
                "description_uuid": "6c03a5fe-7f2c-4460-89e8-d216e8a31d11",
                "level": "Px1",
                "level_review": {
                  "updateTime": 1600293135355,
                  "updatedBy": "User"
                },
                "level_uuid": "c49ca5d0-629e-4e3d-83ef-0f00a98da51d",
                "short": ""
              },
              "prognosticSummary": "The NCCN guidelines list TP53 alterations as a prognostic biomarker in myelodysplastic syndromes. Well-powered studies find that patients with a TP53 alteration such as [[gene]] [[mutation]] have a less favorable prognosis.",
              "prognosticSummary_review": {
                "updateTime": 1600293135355,
                "updatedBy": "User"
              },
              "prognosticSummary_uuid": "a17bc9c0-d851-4c77-b257-e713827946b9",
              "prognostic_uuid": "4e8b3dca-b8a1-43bf-986a-54d18b445ceb",
              "summary": "",
              "summary_uuid": "8393bc13-09dc-4261-98c4-d4458cf9799b"
            },
            {
              "TIs": [
                {
                  "name": "Standard implications for sensitivity to therapy",
                  "name_uuid": "9f4f073c-dd42-408e-9062-6aca4446df7a",
                  "treatments_uuid": "a7822d9f-e8ec-425d-8594-e5c002682b43",
                  "type": "SS"
                },
                {
                  "name": "Standard implications for resistance to therapy",
                  "name_uuid": "5caecafa-d5bf-4f2d-b60a-fd661693eb53",
                  "treatments_uuid": "3a5098d5-922d-4829-a1b9-1071b5ec46e3",
                  "type": "SR"
                },
                {
                  "name": "Investigational implications for sensitivity to therapy",
                  "name_uuid": "5281b819-3dc7-4767-9a63-ab83eb5abbe5",
                  "treatments_uuid": "f9605419-56c8-400a-8617-88f76ce2b71a",
                  "type": "IS"
                },
                {
                  "name": "Investigational implications for resistance to therapy",
                  "name_uuid": "6c7d212f-7434-4e74-86ca-17be4d4479bf",
                  "treatments_uuid": "89f52152-6d79-4d6d-b93a-c63d8b88130f",
                  "type": "IR"
                }
              ],
              "cancerTypes": [
                {
                  "code": "ET",
                  "mainType": "Myeloproliferative Neoplasms",
                  "subtype": "Essential Thrombocythemia"
                }
              ],
              "cancerTypes_uuid": "8d43f16b-1110-4b78-916f-754858c8bbff",
              "diagnostic": {
                "description": "",
                "description_uuid": "2c242400-09aa-43ab-b09b-b87dc9c86e21",
                "level": "",
                "level_uuid": "61da2592-f610-4cd4-a834-fa9fb2b5f42b",
                "short": ""
              },
              "diagnosticSummary": "",
              "diagnosticSummary_uuid": "5c10c36a-77b4-42c6-a342-95e150e8adb7",
              "diagnostic_uuid": "87e45062-ca84-4ead-ab2b-f845be307d76",
              "prognostic": {
                "description": "This assertion is supported by (PMID: 22887079, 29296692, 24478400).",
                "description_review": {
                  "updateTime": 1600293135356,
                  "updatedBy": "User"
                },
                "description_uuid": "6491c27d-8c55-4512-895e-d57179cf77a9",
                "level": "Px1",
                "level_review": {
                  "updateTime": 1600293135356,
                  "updatedBy": "User"
                },
                "level_uuid": "b55483a4-418d-4ebf-b8d5-4e914360dd1c",
                "short": ""
              },
              "prognosticSummary": "The NCCN guidelines list TP53 alterations as a prognostic biomarker in [[tumor type]]. Well-powered studies find that patients with a TP53 alteration such as [[gene]] [[mutation]] have a less favorable prognosis.",
              "prognosticSummary_review": {
                "updateTime": 1600293135356,
                "updatedBy": "User"
              },
              "prognosticSummary_uuid": "d9fa3911-27ea-47af-bc47-e02a74df75bf",
              "prognostic_uuid": "b6f54e8b-aa53-4c55-9cd8-5edc0c81fb77",
              "summary": "",
              "summary_uuid": "517d4874-9603-4861-a317-d77cfad903b3"
            },
            {
              "TIs": [
                {
                  "name": "Standard implications for sensitivity to therapy",
                  "name_uuid": "50ff6b87-e804-41b2-8ffe-79f0391e1e69",
                  "treatments_uuid": "15a156f4-8d7d-41bc-8bcd-84890fee5a2d",
                  "type": "SS"
                },
                {
                  "name": "Standard implications for resistance to therapy",
                  "name_uuid": "dd67f130-b725-4b07-91b7-5d5b8288f22b",
                  "treatments_uuid": "e708c943-0614-41d4-acc5-9de42240c010",
                  "type": "SR"
                },
                {
                  "name": "Investigational implications for sensitivity to therapy",
                  "name_uuid": "8c134712-a90f-450d-b8b5-35fe1ff1b8f8",
                  "treatments_uuid": "e62de0a2-b6e7-4458-b342-fde4d00e3e58",
                  "type": "IS"
                },
                {
                  "name": "Investigational implications for resistance to therapy",
                  "name_uuid": "39c0ad00-e6fc-4334-845b-e96ad588bf5c",
                  "treatments_uuid": "08d96af3-a93a-40b2-b03d-1bfd8ddcc664",
                  "type": "IR"
                }
              ],
              "cancerTypes": [
                {
                  "code": "MPN",
                  "mainType": "Myeloproliferative Neoplasms",
                  "subtype": "Myeloproliferative Neoplasms"
                }
              ],
              "cancerTypes_uuid": "f5a6603e-a6a4-484b-99c5-5d694d55370c",
              "diagnostic": {
                "description": "",
                "description_uuid": "c699e651-e2a3-41ad-8a92-08052de6dfe8",
                "level": "",
                "level_uuid": "c9875cff-c4db-4b38-9956-68bc51d4ae36",
                "short": ""
              },
              "diagnosticSummary": "",
              "diagnosticSummary_uuid": "dd713910-208d-44b0-a658-b4384b2224c7",
              "diagnostic_uuid": "6e7629ba-8ace-40c0-be40-15e9f9a82c2f",
              "prognostic": {
                "description": "This assertion is supported by (PMID: 22887079, 25516983, 22052707).",
                "description_review": {
                  "updateTime": 1600293135360,
                  "updatedBy": "User"
                },
                "description_uuid": "2383980a-1114-4744-a491-ae1c4b485d14",
                "level": "Px1",
                "level_review": {
                  "updateTime": 1600293135360,
                  "updatedBy": "User"
                },
                "level_uuid": "ed33d3f1-87ea-4ea9-b67a-58c79f605473",
                "short": ""
              },
              "prognosticSummary": "The NCCN guidelines list TP53 alterations as a prognostic biomarker in primary myelofibrosis. Well-powered studies find that patients with a TP53 alteration such as [[gene]] [[mutation]] have a less favorable prognosis.",
              "prognosticSummary_review": {
                "updateTime": 1600293135360,
                "updatedBy": "User"
              },
              "prognosticSummary_uuid": "6302e148-b612-4d7f-bcfb-537512d7b0df",
              "prognostic_uuid": "b487b052-7db8-4a2c-8441-ee6b295823c6",
              "summary": "",
              "summary_uuid": "49547e47-63a8-4faa-846a-4d0681cf79ab"
            },
            {
              "TIs": [
                {
                  "name": "Standard implications for sensitivity to therapy",
                  "name_uuid": "5d5edf36-0169-4790-b29d-cd6a298e626d",
                  "treatments_uuid": "f0a5eeaa-0bb7-4f79-9bdc-03aca64dd137",
                  "type": "SS"
                },
                {
                  "name": "Standard implications for resistance to therapy",
                  "name_uuid": "ea6f9903-6526-4c52-87d9-595ca128cd4a",
                  "treatments_uuid": "0d767668-1e1b-42a9-9211-0f3decf9e416",
                  "type": "SR"
                },
                {
                  "name": "Investigational implications for sensitivity to therapy",
                  "name_uuid": "cf50f359-5b24-4c67-9cc2-9c1d2ae6a40d",
                  "treatments_uuid": "7941e0d2-e7ca-44d1-a5df-3b0e8be18c2e",
                  "type": "IS"
                },
                {
                  "name": "Investigational implications for resistance to therapy",
                  "name_uuid": "6379b32d-13c4-4f97-a029-d82caaa2e17e",
                  "treatments_uuid": "bc8b4159-ef9e-4af8-9218-d9be76310482",
                  "type": "IR"
                }
              ],
              "cancerTypes": [
                {
                  "code": "PMF",
                  "mainType": "Myeloproliferative Neoplasms",
                  "subtype": "Primary Myelofibrosis"
                }
              ],
              "cancerTypes_uuid": "bc7859d5-030a-4ed0-830e-81ff508db85d",
              "diagnostic": {
                "description": "",
                "description_uuid": "452aed40-31f0-4b95-9838-816ac67c8923",
                "level": "",
                "level_uuid": "b5b76754-aa2f-47bd-80d6-6bf4f174af7c",
                "short": ""
              },
              "diagnosticSummary": "",
              "diagnosticSummary_uuid": "ecb72a7c-2b0a-4843-9e91-982a9973a4e4",
              "diagnostic_uuid": "389c3246-5839-493e-89af-bba7f1237c9f",
              "prognostic": {
                "description": "This assertion is supported by (PMID: 22887079, 25516983, 22052707).",
                "description_review": {
                  "updateTime": 1600293135361,
                  "updatedBy": "User"
                },
                "description_uuid": "05384121-41c6-4842-9cc4-fb40600dc512",
                "level": "Px1",
                "level_review": {
                  "updateTime": 1600293135361,
                  "updatedBy": "User"
                },
                "level_uuid": "8991f1c6-6a4d-42e3-a680-67b6b701b108",
                "short": ""
              },
              "prognosticSummary": "The WHO classification of hematologic tumors list TP53 alterations as a prognostic biomarker in [[tumor type]]. Well-powered studies find that patients with a TP53 alteration such as [[gene]] [[mutation]] have a less favorable prognosis.",
              "prognosticSummary_review": {
                "updateTime": 1600293135361,
                "updatedBy": "User"
              },
              "prognosticSummary_uuid": "ee5ad677-d86e-4fb2-8324-b52072a2a559",
              "prognostic_uuid": "7940b806-79c6-4cda-a468-befdd8806bb7",
              "summary": "",
              "summary_uuid": "6231c9c4-7477-46b0-b32b-007634b94033"
            },
            {
              "TIs": [
                {
                  "name": "Standard implications for sensitivity to therapy",
                  "name_uuid": "2b13516c-ffbd-4527-9cd9-46a9fa85163e",
                  "treatments_uuid": "a5d4af96-837f-4889-9248-d9883f5b91ff",
                  "type": "SS"
                },
                {
                  "name": "Standard implications for resistance to therapy",
                  "name_uuid": "90a3dc9f-6e26-40e8-8cb9-f5d5dd01d346",
                  "treatments_uuid": "86056b33-990e-463e-bde9-01b0f37634dc",
                  "type": "SR"
                },
                {
                  "name": "Investigational implications for sensitivity to therapy",
                  "name_uuid": "14a97a3e-96ee-4034-955c-fe81b686fc57",
                  "treatments_uuid": "47be5f86-4503-46e8-821d-811c5554da5a",
                  "type": "IS"
                },
                {
                  "name": "Investigational implications for resistance to therapy",
                  "name_uuid": "cc5c14c9-59ac-491b-893f-ef236d8d82b4",
                  "treatments_uuid": "f8f04175-80e8-4950-97d8-f4d744e0f438",
                  "type": "IR"
                }
              ],
              "cancerTypes": [
                {
                  "code": "MCL",
                  "mainType": "Mature B-Cell Neoplasms",
                  "subtype": "Mantle Cell Lymphoma"
                }
              ],
              "cancerTypes_uuid": "bb62dcfd-8e27-4f67-9d93-724b86247c7f",
              "diagnostic": {
                "description": "",
                "description_uuid": "bf50eb61-0215-4595-bb6c-a9f46e5ba029",
                "level": "",
                "level_uuid": "587dfe4e-ac2e-4485-adf6-c8726c812b48",
                "short": ""
              },
              "diagnosticSummary": "",
              "diagnosticSummary_uuid": "bae78fcd-e5fe-416b-b21e-93b1b1823945",
              "diagnostic_uuid": "d7409dbf-66ab-41c8-aa54-2fb9d23b662f",
              "prognostic": {
                "description": "This assertion is supported by (PMID: 28819011, 26022239, 24684350, 8639789, 7579380).",
                "description_review": {
                  "updateTime": 1600293135377,
                  "updatedBy": "User"
                },
                "description_uuid": "cd1d6635-710a-4a33-a3f7-c6b47880f43c",
                "level": "Px3",
                "level_review": {
                  "updateTime": 1600293135377,
                  "updatedBy": "User"
                },
                "level_uuid": "34721648-0577-471b-bbc5-29ab7d315571",
                "short": ""
              },
              "prognosticSummary": "Clinical studies suggest that patients with TP53 altered [[tumor type]] have a less favorable prognosis.",
              "prognosticSummary_review": {
                "updateTime": 1600293135377,
                "updatedBy": "User"
              },
              "prognosticSummary_uuid": "6f6f4c38-43a8-4ea3-a0a7-68a3d515b009",
              "prognostic_uuid": "e05be7f2-30ba-4b12-84ab-aeba2c0e29ab",
              "summary": "",
              "summary_uuid": "0923cc5e-24ff-412f-b2c2-1a151115569a"
            }
          ]
        },
        {
          "mutation_effect": {
            "description": "The TP53 S215G mutant is located in the DNA binding domain of the protein. Mutations in the DNA binding domain are associated with altered contact of p53 with its target DNA sequences, thereby altering its transcriptional function (PMID: 8023157, 11900253). Functional studies in yeast and human cell lines suggest this mutation is temperature sensitive and inactivating, as measured by functional analysis of separated alleles in yeast (FASAY) (PMID: 17724467, 22862161). This mutation is also a hotspot, suggesting that it is likely oncogenic (PMID: 26619011).",
            "description_review": {
              "updateTime": 1674086645900,
              "updatedBy": "User"
            },
            "description_uuid": "eda49eca-ce3a-4fbd-9818-185ee4cd382e",
            "effect": "Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "a3aead6a-7ad7-4381-9b21-81c71f99515a",
            "oncogenic": "Yes",
            "oncogenic_review": {
              "updateTime": 1489883918000
            },
            "oncogenic_uuid": "62b6cb66-9135-4a95-9032-caedfa3fe453",
            "short": ""
          },
          "mutation_effect_uuid": "430f2816-e43b-4977-a325-ab6d40506521",
          "name": "S215G",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "968c2f06-a900-4ddd-b46a-129ad2113255"
        },
        {
          "mutation_effect": {
            "description": "The TP53 L145R mutation is located in the DNA-binding domain of the protein. This mutation has been identified in melanoma and is a statistically significant hotspot (PMID: 20571075). In vivo studies with yeast expressing TP53 L145R demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 L145R also demonstrated the mutation is inactivating as measured by reduced growth suppressive activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1679600067723,
              "updatedBy": "User"
            },
            "description_uuid": "b53d1cf9-e1e9-4f69-ab9b-5d8e8385cdcc",
            "effect": "Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "a65bca08-1b2c-4423-ab16-eabe9e9a14f7",
            "oncogenic": "Yes",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "daf0222b-c413-49d6-b893-eb9b1e39951e",
            "short": ""
          },
          "mutation_effect_uuid": "5eb93670-4b1d-4c0f-b96d-736de9d2e1ef",
          "name": "L145R",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "fd3bc9de-eb4a-4f31-a737-77f2a8e16684"
        },
        {
          "mutation_effect": {
            "description": "TP53 deletions are predicted to be inactivating and associated with poor prognosis (PMID: 11900253, 20697090, 21467160, 12584563). Experimental studies have revealed that deletions result in loss of TP53 tumor suppressive function, since TP53 cannot decrease cell viability in vitro (PMID: 27759562). Additionally, deletion of TP53 in the neurons of mice, while not sufficient to cause tumor development, allows the accumulation of other oncogenic mutations leading to tumorigenesis (PMID: 19477430). Further, loss of TP53 protein during 17p deletion events in leukemia/lymphoma, enhances cancer development through cooperation of linked tumor suppressive genes such as EIF5A and ALOX15B (PMID: 26982726).",
            "description_review": {
              "updateTime": 1563476801645,
              "updatedBy": "User"
            },
            "description_uuid": "ec5b0215-d71b-403f-ae36-5b08e56589fd",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724745580
            },
            "effect_uuid": "2e3b9a82-adcc-4067-9ebc-e394a9ca3081",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "2e4fa506-8016-4475-9c80-0226dc103dd0",
            "short": ""
          },
          "mutation_effect_uuid": "aca705c3-45c4-4205-9f02-db7edee8a582",
          "name": "Deletion",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "1b2069e6-6a33-46a0-8bed-494104c057a6",
          "tumors": [
            {
              "TIs": [
                {
                  "name": "Standard implications for sensitivity to therapy",
                  "name_uuid": "26101948-4ff3-45e7-98f0-5007324728ac",
                  "treatments_uuid": "4fe013ad-97e5-45bd-85c2-0abf4f9a81f4",
                  "type": "SS"
                },
                {
                  "name": "Standard implications for resistance to therapy",
                  "name_uuid": "c5e68de2-c135-4aef-8227-ef982dbf9c4d",
                  "treatments_uuid": "a6ef69f6-6616-4ce8-85d8-426e6530a4ad",
                  "type": "SR"
                },
                {
                  "name": "Investigational implications for sensitivity to therapy",
                  "name_uuid": "0895bfbc-5fda-4513-a4b3-3730aa5e1245",
                  "treatments_uuid": "b9bbe84f-2d06-4a55-9424-491e4f485d24",
                  "type": "IS"
                },
                {
                  "name": "Investigational implications for resistance to therapy",
                  "name_uuid": "1c2c82d0-3be7-444d-bc8d-a68d5b002289",
                  "treatments_uuid": "da505821-8198-416c-a670-7b4a600e3bb4",
                  "type": "IR"
                }
              ],
              "cancerTypes": [
                {
                  "code": "PCM",
                  "mainType": "Mature B-Cell Neoplasms",
                  "subtype": "Plasma Cell Myeloma"
                }
              ],
              "cancerTypes_uuid": "306b7a54-4e9a-4ae1-8e01-6bf0189d2e2d",
              "diagnostic": {
                "description": "",
                "description_uuid": "a8930703-2816-4f34-a29c-2fb8a398c6cd",
                "level": "",
                "level_uuid": "054a9b6b-f50d-43c6-8d39-c2d77ae1e972",
                "short": ""
              },
              "diagnosticSummary": "",
              "diagnosticSummary_uuid": "c0e296bd-717a-4069-a9dc-0a6ae4a46c74",
              "diagnostic_uuid": "4bf825d4-ab38-4619-bc33-776bfd4b201b",
              "prognostic": {
                "description": "This assertion is supported by (PMID: 9680348, 18337559, 17209057 Abstract: Hofste op Bruinink, D. et al. Abstract# Blood 128:3271, 2017. http://www.bloodjournal.org/content/128/22/3271?sso-checked=true; http://www.bloodjournal.org/content/122/21/1846).",
                "description_review": {
                  "updateTime": 1600293135348,
                  "updatedBy": "User"
                },
                "description_uuid": "b8d97a9d-577a-49a0-ae74-0f3373e02a01",
                "level": "Px1",
                "level_review": {
                  "updateTime": 1600293135348,
                  "updatedBy": "User"
                },
                "level_uuid": "cc35be4f-bd81-4289-b8eb-e97c87d6230a",
                "short": ""
              },
              "prognosticSummary": "The NCCN guidelines list deletion of TP53 as a prognostic biomarker in [[tumor type]]. Well-powered studies find that patients with deletion of TP53 have a less favorable prognosis.",
              "prognosticSummary_review": {
                "updateTime": 1600293135348,
                "updatedBy": "User"
              },
              "prognosticSummary_uuid": "43ecf7b6-6d53-44b7-a99e-f47d87f9b9bc",
              "prognostic_uuid": "143077a9-08b8-4800-8c52-db80dad34385",
              "summary": "",
              "summary_uuid": "1d4a0429-e290-4251-87c7-4e713409a604"
            }
          ]
        },
        {
          "mutation_effect": {
            "description": "Truncating mutations of TP53 occur throughout the gene and lead to the production of several C-terminally truncated protein forms. These alterations are predicted to be inactivating and are associated with poor prognosis (PMID: 11900253, 11753428, 16007150, 21467160, 19336573). Experimental studies have revealed that truncating mutations promote cancer cell proliferation, survival and metastasis, since ectopic expression of these mutations in melanoma cells increased cell motility and tumor formation in vivo. This was due in part to aberrant localization of truncated proteins to the mitochondria, regulating genes involved in cell survival, including CypD (PMID: 27759562).",
            "description_review": {
              "updateTime": 1497379999887
            },
            "description_uuid": "639d24fb-07c2-4e70-87a2-1aa3ba1258a5",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1486484352000,
              "updatedBy": "User"
            },
            "effect_uuid": "72ca72a6-e423-4ace-893e-b5e837f1c2c7",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724745580
            },
            "oncogenic_uuid": "74aec1d1-f984-430f-a431-fca85f5375e5",
            "short": ""
          },
          "mutation_effect_uuid": "0583b93c-2888-4839-8bf2-eaf1f06f3809",
          "name": "Truncating Mutations",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "5f591203-514f-4de0-a782-1942f9abe6f5"
        },
        {
          "mutation_effect": {
            "description": "The exon 8 TP53 E285K mutation is located in the DNA binding domain of the protein. Expression of TP53 E285K in yeast and human cancer cells demonstrated that it is likely loss of function as evidenced by decreased expression and transactivation compared to wildtype TP53 (PMID: 20407015).",
            "description_review": {
              "updateTime": 1500471732138
            },
            "description_uuid": "9246c73d-5eb3-4d63-be4d-80bf2626c7c1",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1492724419347
            },
            "effect_uuid": "c5aec539-492b-4e93-aab5-901680618a0c",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1492724357070
            },
            "oncogenic_uuid": "b459bc2f-df4e-4b37-95a1-98670b60bb2e",
            "short": ""
          },
          "mutation_effect_uuid": "80f21fb6-a333-4283-91a0-0f0d324b3daa",
          "name": "E285K",
          "name_review": {
            "updateTime": 1492724745580
          },
          "name_uuid": "da483814-d057-4ac0-b709-b4cb2aed8dbf"
        },
        {
          "mutation_effect": {
            "description": "The 3 bp in-frame deletion leading to the p53 P191del mutation arises in the DNA-binding domain of p53. Mutations in the DNA-binding domain are likely loss-of-function, associated with the loss of p53 transcriptional activity (PMID: 8023157). Additionally, this mutation was identified as a recurrent hotspot (statistically significant) in a population-scale cohort of tumor samples of various cancer types using methodology (PMID: 26619011). Lastly, immunohistochemical analysis of a stage IV adrenocortical carcinoma harboring this mutation showed absence of p53 protein (PMID: 11454518).",
            "description_review": {
              "updateTime": 1532445087148,
              "updatedBy": "User"
            },
            "description_uuid": "f0917176-cd5d-46b7-bdff-d72dc44d947d",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1532444588840,
              "updatedBy": "User"
            },
            "effect_uuid": "4bbfb245-8242-4c5f-8ec3-58d0eb2f8fb1",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1532444585504,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "f5224470-2da2-4825-a9ca-08d8a5bcb2b7",
            "short": ""
          },
          "mutation_effect_uuid": "85687085-9f14-4d81-8b17-1d9338887d86",
          "name": "P191del",
          "name_review": {
            "updateTime": 1532444579349,
            "updatedBy": "User"
          },
          "name_uuid": "c15b0d3c-fe3d-43be-be38-ec9a2f9b10be",
          "tumors_uuid": "f9ecea1c-1477-41f0-9e83-e15e24b207c6"
        },
        {
          "mutation_effect": {
            "description": "The TP53 R196G mutation arises in the p53 DNA-binding domain of the protein. Human H1299 cell transactivation studies have demonstrated that this mutation is inactivating as demonstrated by significantly decreased transcriptional activity of p53 downstream factors bax, p21 and RGC relative to wildtype p53 at two different experimental temperature conditions (32 and 37 degrees Celsius) (PMID: 22710932).",
            "description_review": {
              "updateTime": 1675286735466,
              "updatedBy": "User"
            },
            "description_uuid": "a9b4994a-7527-4a13-bb0a-21a5d5ca3eda",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1533845880281,
              "updatedBy": "User"
            },
            "effect_uuid": "0b4f34f8-aa1c-4663-b586-eca7ddd34fa1",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1533845875430,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "0efd0be7-8d9e-4660-a7cf-88d83f26739c",
            "short": ""
          },
          "mutation_effect_uuid": "84a3c795-cc3b-48fb-9dde-50330feb4235",
          "name": "R196G",
          "name_review": {
            "updateTime": 1533846048419,
            "updatedBy": "User"
          },
          "name_uuid": "503afc81-c6e7-4f77-860d-bc872d88311e",
          "tumors_uuid": "fb8a3df8-d9b0-479b-9a67-3a727b16be73"
        },
        {
          "mutation_effect": {
            "description": "The TP53 R196L mutation arises in the p53 DNA-binding domain of the protein. When this mutation is expressed in human Saos cells at different experimental temperature conditions, a difference in transactivational activity of this TP53 mutant has been observed (PMID: 14559903). However, there is no specific data demonstrating whether the mutation has decreased transactivational activity relative to wildtype p53 (PMID: 14559903). Nonetheless, an alternate mutation at this position, the TP53 R196G mutation, has been demonstrated to decrease p53 transactivation activity relative to wildtype p53 (PMID: 22710932). The R196L mutation is also a 3D hotspot mutation and therefore TP53 R196L is considered likely oncogenic (PMID: 28115009).",
            "description_review": {
              "updateTime": 1675800669441,
              "updatedBy": "User"
            },
            "description_uuid": "ace65a14-6d8d-472e-bd84-ecf92b433072",
            "effect": "Inconclusive",
            "effect_review": {
              "updateTime": 1675800649433,
              "updatedBy": "User"
            },
            "effect_uuid": "e6263878-9cbb-468a-9837-ef2294db7409",
            "oncogenic": "Inconclusive",
            "oncogenic_review": {
              "updateTime": 1675800648507,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "ebf5de87-0bf9-43f1-bd6c-f944f1bf0d49",
            "short": "",
            "short_editing": ""
          },
          "mutation_effect_uuid": "0840c0b5-b1aa-4521-8a7d-221089104b18",
          "name": "R196L",
          "name_review": {
            "updateTime": 1533846150424,
            "updatedBy": "User"
          },
          "name_uuid": "b67a343e-a548-410d-8450-fc8cf55058c7",
          "tumors_uuid": "6c9d0728-0878-4b4d-a0d2-cbba7ee6a749"
        },
        {
          "mutation_effect": {
            "description": "The tetramerization domain of TP53 is critical for the proper oligomerization and function of the p53 tumor suppressor protein. Mutations of the tetramerization domain, specifically those around G334 that affect the hinge region between the alpha helix and the beta strand, have been shown to result in structural changes that preclude proper oligomerization of the protein and therefor disrupt proper functioning (PMID: 16007150, 16460008).",
            "description_review": {
              "updateTime": 1568092879050,
              "updatedBy": "User"
            },
            "description_uuid": "ba98bd0f-9ee3-4ea3-af87-a42493808039",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1568071327168,
              "updatedBy": "User"
            },
            "effect_uuid": "7adae142-3ead-41b3-9cd2-3d2c8039ce5e",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1568071326309,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "cbc5b777-85b7-4339-b240-5c3421faa2b8",
            "short": ""
          },
          "mutation_effect_uuid": "429f4951-f9b0-4265-b232-133c632d4b3c",
          "name": "334_346del [Tetramerization domain deletions], 334_346ins [Tetramerization domain insertions]",
          "name_comments": [
            {
              "content": "11420672",
              "date": "1562731205150",
              "email": "user@gmail.com",
              "resolved": "false",
              "userName": "User"
            }
          ],
          "name_review": {
            "updateTime": 1646169874324,
            "updatedBy": "User"
          },
          "name_uuid": "65317192-d5e4-44bb-82d7-89093e594b13",
          "tumors_uuid": "96681614-6a79-4154-90a6-7e6ffbaed9bb"
        },
        {
          "mutation_effect": {
            "description": "The TP53 C124R mutation is located in the DNA binding domain of the protein. Expression of this mutation in a yeast functional assay demonstrated that it is likely inactivating (PMID: 9115587.)",
            "description_review": {
              "updateTime": 1591763690146,
              "updatedBy": "User"
            },
            "description_uuid": "1fab5311-2da0-45ee-a473-b48d715b1293",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1591763707084,
              "updatedBy": "User"
            },
            "effect_uuid": "1407e432-557d-49ce-b50d-ce74d65fb840",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1591763708546,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "16fba3bd-82c5-4dbf-be5f-b7952ed9f390",
            "short": ""
          },
          "mutation_effect_uuid": "23a2eea5-2b00-47e2-9e03-40c3eaee8068",
          "name": "C124R",
          "name_review": {
            "updateTime": 1591763576152,
            "updatedBy": "User"
          },
          "name_uuid": "338f97a9-9ef8-47ab-8ea4-15e2b76e1624",
          "tumors_uuid": "6a974304-fa72-406b-88ba-1ed49115daf0"
        },
        {
          "mutation_effect": {
            "description": "The TP53 C141W mutation is located in the DNA binding domain of the protein. Expression of this mutation in biochemical assays demonstrated that it is likely inactivating as measured by function that is moderately altered compared to wildtype (PMID: 20407015).",
            "description_review": {
              "updateTime": 1591763941271,
              "updatedBy": "User"
            },
            "description_uuid": "c631500d-b363-4ce5-a4d1-40c84f76f331",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1591763916975,
              "updatedBy": "User"
            },
            "effect_uuid": "794e66b7-6319-4180-a829-15f0b558b1b1",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1591763917651,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "8cf023da-f5e8-4ade-879d-4068589d6971",
            "short": ""
          },
          "mutation_effect_uuid": "1056fedb-e627-412b-b14a-e9b2ec475753",
          "name": "C141W",
          "name_review": {
            "updateTime": 1591763718088,
            "updatedBy": "User"
          },
          "name_uuid": "f39be152-c282-494b-aea8-da8a6eda5fd5",
          "tumors_uuid": "2aba56e4-6bc5-49df-a26a-b25f572ddb5e"
        },
        {
          "mutation_effect": {
            "description": "The TP53 C176W mutation is located in the DNA binding domain of the protein. Expression of this mutation in biochemical assays demonstrated that it is likely inactivating as measured by impaired ability to activate downstream target genes compared to wildtype (PMID: 19850740).",
            "description_review": {
              "updateTime": 1591764879208,
              "updatedBy": "User"
            },
            "description_uuid": "3c8152d3-73e2-41b6-a371-31fe27893c31",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1591764755045,
              "updatedBy": "User"
            },
            "effect_uuid": "7b23803d-83e6-4294-9bf8-8810777a0527",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1591764753255,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "0b5519b6-cde0-4060-8f6d-bfdfb69b9f46",
            "short": ""
          },
          "mutation_effect_uuid": "ecb23887-c55d-4531-b52c-98324a1088eb",
          "name": "C176W",
          "name_review": {
            "updateTime": 1591763973904,
            "updatedBy": "User"
          },
          "name_uuid": "fb1cb42c-16f2-4256-a69f-5a9762c661c1",
          "tumors_uuid": "63f00ba7-548c-4883-a231-8ccd8e7dc440"
        },
        {
          "mutation_effect": {
            "description": "The TP53 G154V mutation is located in the DNA binding domain of the protein. Biochemical experiments have suggested that this mutation is inactivating as it acts as a dominant-negative (PMID: 21289082).",
            "description_review": {
              "updateTime": 1675448756924,
              "updatedBy": "User"
            },
            "description_uuid": "9608f203-c997-4ab9-8e48-555e6335cf7e",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1591765325143,
              "updatedBy": "User"
            },
            "effect_uuid": "58fc793e-8e9e-40ee-bc2c-b1c849a283f1",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1591765323019,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "1ec44108-57ab-498c-b1c3-768bec243758",
            "short": ""
          },
          "mutation_effect_uuid": "8b9b9ca4-5c43-4744-87a2-92b6e5b24a94",
          "name": "G154V",
          "name_review": {
            "updateTime": 1591765228854,
            "updatedBy": "User"
          },
          "name_uuid": "4382d73c-30e6-41b8-aac4-b0560b5c81a3",
          "tumors_uuid": "91230b2b-18fd-4b6b-939d-e7f6c8396af8"
        },
        {
          "mutation_effect": {
            "description": "The TP53 C277Y mutation is located in the DNA-binding domain of the protein. This mutation has been identified in Ewing sarcoma and myeloproliferative neoplasms and is a statistically significant hotspot (PMID: 15192123, 35030630). In vitro studies with H1299 cells ectopically expressing TP53 C277Y demonstrated the mutation is inactivating as measured by the mutant's significant reduction in apoptosis and downregulation of p21 and BAX expression as compared to wildtype (PMID: 34282274).",
            "description_review": {
              "updateTime": 1670974223743,
              "updatedBy": "User"
            },
            "description_uuid": "96320c6a-1b03-4f4e-ae1d-6a96a12dcb90",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1670874931644,
              "updatedBy": "User"
            },
            "effect_uuid": "61d808e4-78c4-4611-b571-f87316a5c3ff",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1670874930586,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "abe217c7-44c4-4b46-aeeb-ac64fa8a71db",
            "short": ""
          },
          "mutation_effect_uuid": "102e19fc-52dc-4308-85bd-cc6360b9ac96",
          "name": "C277Y",
          "name_review": {
            "updateTime": 1670874924854,
            "updatedBy": "User"
          },
          "name_uuid": "0fb8f328-8b3c-4b99-ada2-bec0bda96471",
          "tumors_uuid": "4f876802-562b-4fe7-9be0-eeca5ebc12f8"
        },
        {
          "mutation_effect": {
            "description": "The TP53 Y236H mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer, lung cancer and basaloid pancreatic carcinoma and is a statistically significant hotspot (PMID: 20682393, 32674491, 25432630). In vivo studies with yeast expressing TP53 Y236H demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
            "description_review": {
              "updateTime": 1670974250902,
              "updatedBy": "User"
            },
            "description_uuid": "a9736895-37cd-4d2b-a3c3-5f1f104aab87",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1670874980969,
              "updatedBy": "User"
            },
            "effect_uuid": "a225696a-e751-4a12-9603-e2c980449bad",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1670874980106,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "763ff1b3-d610-4906-a9d7-e914bffd62c6",
            "short": ""
          },
          "mutation_effect_uuid": "79ff0ed0-4aa4-4a03-b74d-1f342d91c593",
          "name": "Y236H",
          "name_review": {
            "updateTime": 1670874974426,
            "updatedBy": "User"
          },
          "name_uuid": "f73198c6-9fc8-47c4-a96c-8021cbdb0873",
          "tumors_uuid": "d5b680fa-7bb4-40ee-819a-3fcf2281fe88"
        },
        {
          "mutation_effect": {
            "description": "The TP53 Y236N mutation is located in the DNA-binding domain of the protein. This mutation has been identified in B-cell precursor acute lymphoblastic leukemia, breast cancer, colon cancer and glioblastoma and is a statistically significant hotspot (PMID: 33095873, 8950983, 9301461, 10427138). In vivo studies with yeast expressing TP53 Y236N demonstrated that the mutation retains its transactivational activity as compared to wildtype (PMID: 27328919, 12826609). However, other in vitro studies with various human cancer cell lines expressing TP53 Y236N demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1670974286023,
              "updatedBy": "User"
            },
            "description_uuid": "9f0421ef-61ac-4910-85ea-6cfe6c38a1a7",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1670875036189,
              "updatedBy": "User"
            },
            "effect_uuid": "528eba0e-4a36-481e-be48-779287cec4d7",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1670875034299,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "a9aac0c1-e239-473d-98d4-437c05c03bd1",
            "short": ""
          },
          "mutation_effect_uuid": "d8a75e09-5fab-4567-93b9-3af1570523d4",
          "name": "Y236N",
          "name_review": {
            "updateTime": 1670875022152,
            "updatedBy": "User"
          },
          "name_uuid": "25d22320-7ccd-4aa5-9ad6-674c2b924a88",
          "tumors_uuid": "e171210f-af7f-4e73-af36-53f6f7df95a8"
        },
        {
          "mutation_effect": {
            "description": "The TP53 H193Q mutation is located in the DNA-binding domain of the protein.  This mutation has been identified in colorectal cancer, esophageal squamous cell carcinoma, bone sarcoma and squamous cell carcinoma and is a statistically significant hotspot (PMID: 12433709, 10414702, 1423262, 10414702). In vivo studies with yeast expressing TP53 H193Q demonstrated that mutation has partial inactivation of its transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
            "description_review": {
              "updateTime": 1670974329314,
              "updatedBy": "User"
            },
            "description_uuid": "5a282d18-c552-4562-82da-50c578652b1f",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1670875070225,
              "updatedBy": "User"
            },
            "effect_uuid": "c4462ae7-d47b-4388-88d6-8a7717109eca",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1670875068038,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "eb38de83-1cbb-472a-a5d8-17db280b3d76",
            "short": ""
          },
          "mutation_effect_uuid": "c43e00eb-e60c-439d-8a7e-85ff553e1807",
          "name": "H193Q",
          "name_review": {
            "updateTime": 1670875060105,
            "updatedBy": "User"
          },
          "name_uuid": "9f32aa27-071e-40f6-a42a-af45817e005e",
          "tumors_uuid": "5c98ff1b-6f2f-414e-9d40-e43ebbff0e6e"
        },
        {
          "mutation_effect": {
            "description": "The TP53 H193D mutation is located in the DNA-binding domain of the protein. This mutation has been identified in hepatocellular carcinoma, diffuse large B-cell lymphoma, ovarian cancer and breast cancer and is a statistically significant hotspot (PMID: 17187432, 15370252, 9665415, 12032228). In vivo studies with yeast expressing TP53 H193D demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 H193D also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1670974350480,
              "updatedBy": "User"
            },
            "description_uuid": "67aad42d-82aa-4c7a-a972-0d618c06ae71",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1670875119522,
              "updatedBy": "User"
            },
            "effect_uuid": "3b9d6c9b-7a7a-48fc-91e7-ff0723870a95",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1670875117900,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "460db1c2-76e6-428b-bb6c-b0a8f190d7a0",
            "short": ""
          },
          "mutation_effect_uuid": "e0b81bbc-8e10-43e1-a780-4d7a06027981",
          "name": "H193D",
          "name_review": {
            "updateTime": 1670875106319,
            "updatedBy": "User"
          },
          "name_uuid": "545012bf-b385-4aa0-beb9-4f063a0ed7d4",
          "tumors_uuid": "cab25340-82e4-4a1c-8f51-cfc8e45dd0fe"
        },
        {
          "mutation_effect": {
            "description": "The TP53 H193Y mutation is located in the DNA-binding domain of the protein. This mutation has been identified in glioblastoma, cholangiocarcinoma, malignant lymphoma and squamous cell carcinoma and is a statistically significant hotspot (PMID: 11504770, 10564952, 11552717, 12509970). In vivo studies with yeast expressing TP53 H193Y demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 H193Y also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1670974382437,
              "updatedBy": "User"
            },
            "description_uuid": "bffe61b9-08cb-415c-9cc9-fbb24cf497c5",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1670875146028,
              "updatedBy": "User"
            },
            "effect_uuid": "23fd0dbc-f22f-463e-b9ef-d8192ed42e58",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1670875144980,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "ac419870-741c-45ac-a246-b564122fcdc3",
            "short": ""
          },
          "mutation_effect_uuid": "f4d74a79-f448-4462-9032-f1039841c7b7",
          "name": "H193Y",
          "name_review": {
            "updateTime": 1670875139317,
            "updatedBy": "User"
          },
          "name_uuid": "95ca3597-c024-4a55-aa2c-98d200dcf444",
          "tumors_uuid": "1547890b-63b7-4b31-ba3a-d1ceabd0dbbf"
        },
        {
          "mutation_effect": {
            "description": "The TP53 H193L mutation is located in the DNA-binding domain of the protein. This mutation has been identified in diffuse large B-cell lymphoma, squamous cell carcinoma and breast cancer and is a statistically significant hotspot (PMID: 17278262, 18081876, 16818855). In vivo studies with yeast expressing TP53 H193L demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 H193L also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1670975423356,
              "updatedBy": "User"
            },
            "description_uuid": "e4861209-6d5a-4123-95fb-1b5736245b38",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1670875181327,
              "updatedBy": "User"
            },
            "effect_uuid": "ae9731c5-63f5-40ca-97ae-ffa807ee5899",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1670875179414,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "0eae3dbf-83e1-491e-bd0d-f4f12e30caa3",
            "short": ""
          },
          "mutation_effect_uuid": "85622a8d-c17b-4f3c-96f6-1cfeec689a08",
          "name": "H193L",
          "name_review": {
            "updateTime": 1670875170727,
            "updatedBy": "User"
          },
          "name_uuid": "08e640ed-3372-4110-a114-ea674ee75055",
          "tumors_uuid": "b1629e38-0ed1-481a-85c0-e1280372116f"
        },
        {
          "mutation_effect": {
            "description": "The TP53 Y163D mutation is located in the DNA-binding domain of the protein. This mutation has been identified in B-cell chronic lymphocytic leukemia, breast cancer and ovarian cancer and is a statistically significant hotspot (PMID: 11180073, 10706127, 20229506). In vivo studies with yeast expressing TP53 Y163D demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 Y163D also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1670975449126,
              "updatedBy": "User"
            },
            "description_uuid": "f4d17c96-7749-43fc-9077-daf41bf57213",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1670875216011,
              "updatedBy": "User"
            },
            "effect_uuid": "2b1eec05-a674-477c-a223-cf671c5010ea",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1670875213956,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "cb045c02-a29e-4090-aadf-deaabdf9fb40",
            "short": ""
          },
          "mutation_effect_uuid": "ab275c3c-6b2a-4f17-9bdd-03158348b85d",
          "name": "Y163D",
          "name_review": {
            "updateTime": 1670875205802,
            "updatedBy": "User"
          },
          "name_uuid": "6ad200db-489b-4317-b362-751f2fb4e909",
          "tumors_uuid": "ab563b4b-f884-4f58-8f7a-e7121894f38f"
        },
        {
          "mutation_effect": {
            "description": "The TP53 Y163H mutation is located in the DNA-binding domain of the protein. This mutation has been identified in squamous cell carcinoma, hepatocellular carcinoma, colorectal cancer and diffuse large B-cell lymphoma, and is a statistically significant hotspot (PMID: 9683822, 1327523, 9000147, 9162193). In vivo studies with yeast expressing TP53 Y163H demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 Y163H also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1670975499209,
              "updatedBy": "User"
            },
            "description_uuid": "0dd0aab5-f020-4809-97b7-efaa89a318e6",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1670875260430,
              "updatedBy": "User"
            },
            "effect_uuid": "00643e36-3d7c-4aaf-b19a-e33e2d136ef6",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1670875259405,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "8fba2def-8fa0-4a21-9ec3-0e15c555b150",
            "short": ""
          },
          "mutation_effect_uuid": "dc43622b-7bc4-44cd-84d2-20c021a4fea3",
          "name": "Y163H",
          "name_review": {
            "updateTime": 1670875251473,
            "updatedBy": "User"
          },
          "name_uuid": "2fabb556-83d4-4e10-abf6-b219b2b784c9",
          "tumors_uuid": "dba4b4fc-d160-42fb-8624-0c76b95c736c"
        },
        {
          "mutation_effect": {
            "description": "The TP53 V274A mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer, hepatocellular carcinoma and squamous cell carcinoma, and is a statistically significant hotspot (PMID: 8102535, 1330291, 8621246). In vivo studies with yeast expressing TP53 V274A demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 V274A also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1670875897884,
              "updatedBy": "User"
            },
            "description_uuid": "5d2efb0f-e21d-44ea-9e0d-2b7eef481563",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1670875902197,
              "updatedBy": "User"
            },
            "effect_uuid": "a16380c0-e780-4b6c-b5f2-e7c44f62110e",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1670875900000,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "3b5bf0b9-c452-4e5e-b252-bde150dd476a",
            "short": ""
          },
          "mutation_effect_uuid": "dd05c897-865f-4926-b14e-25be1c80c8ff",
          "name": "V274A",
          "name_review": {
            "updateTime": 1670875891039,
            "updatedBy": "User"
          },
          "name_uuid": "e8934b6b-9bd0-483c-8527-b48db4e034f0",
          "tumors_uuid": "224540ec-a7a0-4a3e-9780-733e6adb71b8"
        },
        {
          "mutation_effect": {
            "description": "The TP53 V274D mutation is located in the DNA-binding domain of the protein. This mutation has been identified in ovarian cancer, low-grade mucosa-associated lymphoid tissue lymphomas, papillary carcinoma and acute myeloid leukemia and is a statistically significant hotspot (PMID: 21720365, 8579126, 15538112, 2009369). In vivo studies with yeast expressing TP53 V274D demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 V274D also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1670976649852,
              "updatedBy": "User"
            },
            "description_uuid": "ee4315d9-d730-481e-b777-9631fa509022",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1670875930434,
              "updatedBy": "User"
            },
            "effect_uuid": "3c57f2a6-81ef-40c9-919b-ff47ff5f8711",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1670875929524,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "761b53c8-f2dd-4788-ae44-39f995a96251",
            "short": ""
          },
          "mutation_effect_uuid": "3c149e87-def5-4eab-93ed-be4359cb1563",
          "name": "V274D",
          "name_review": {
            "updateTime": 1670875921982,
            "updatedBy": "User"
          },
          "name_uuid": "3016a3d1-4fb7-4dc3-980e-1139e0c72ef6",
          "tumors_uuid": "211d6bf1-acc8-4c73-835f-40274846c63a"
        },
        {
          "mutation_effect": {
            "description": "The TP53 C277F mutation is located in the DNA-binding domain of the protein. This mutation has been identified in ovarian cancer, splenic B-cell lymphoma and non-small cell lung cancer and is a statistically significant hotspot (PMID: 9504831, 8018922, 8826941). In vivo studies with yeast expressing TP53 C277F demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 C277F also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1670976671409,
              "updatedBy": "User"
            },
            "description_uuid": "3cccf56c-aecb-42fa-955b-79059af7a8b2",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1670875953038,
              "updatedBy": "User"
            },
            "effect_uuid": "6462663b-11d0-4f85-9fb7-82c702fb89e0",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1670875952022,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "c62d1341-a69e-4eb7-9dec-e561671e6581",
            "short": ""
          },
          "mutation_effect_uuid": "1b045014-cf2f-4282-875e-d318051236aa",
          "name": "C277F",
          "name_review": {
            "updateTime": 1670875944934,
            "updatedBy": "User"
          },
          "name_uuid": "13042ae4-f20a-4c90-8a5c-2e40123e611a",
          "tumors_uuid": "385027fe-3d0b-4572-8621-d52c541100c8"
        },
        {
          "mutation_effect": {
            "description": "The TP53 V274G mutation is located in the DNA-binding domain of the protein. This mutation has been identified in colorectal cancer, ovarian cancer, breast cancer and hepatocellular carcinoma and is a statistically significant hotspot (PMID: 16721749, 21720365, 12908823, 9463584). In vivo studies with yeast expressing TP53 V274G demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 V274G also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1670976712156,
              "updatedBy": "User"
            },
            "description_uuid": "79b31a9a-a8cc-4006-af65-c867d103d3ce",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1670875979578,
              "updatedBy": "User"
            },
            "effect_uuid": "a9064cc9-2dbb-41b1-a05b-bab623816855",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1670875978326,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "c5dd5259-ccd2-482b-813c-2de0f810d26c",
            "short": ""
          },
          "mutation_effect_uuid": "ca68fa8c-33d0-491e-abe3-7eb0f8b360d6",
          "name": "V274G",
          "name_review": {
            "updateTime": 1670875972006,
            "updatedBy": "User"
          },
          "name_uuid": "6400cfc3-e52f-4030-88e0-1bf07cac1099",
          "tumors_uuid": "3a52234c-3ba1-4a3b-8e74-94330fbd89b9"
        },
        {
          "mutation_effect": {
            "description": "The TP53 V274L mutation is located in the DNA-binding domain of the protein. This mutation has been identified in ovarian cancer, glioblastoma, colorectal cancer and acute myeloid leukemia and is a statistically significant hotspot (PMID: 11329143, 15466178, 11044641, 12792784). In vivo studies with yeast expressing TP53 V274L demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 V274L also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1670976740276,
              "updatedBy": "User"
            },
            "description_uuid": "9660c833-830a-4989-ab1d-5b3c476fa4d5",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1670876017388,
              "updatedBy": "User"
            },
            "effect_uuid": "3c6acba0-e48c-4d88-8dfe-6c7ff8d884ff",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1670876016376,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "07374489-060a-4056-afb4-1f17bcd6de7d",
            "short": ""
          },
          "mutation_effect_uuid": "eb6acb5c-5392-4d6a-bbe1-2b0132d9cb60",
          "name": "V274L",
          "name_review": {
            "updateTime": 1670876009055,
            "updatedBy": "User"
          },
          "name_uuid": "cdd3f2ce-29ca-440c-9c9d-29049aae624c",
          "tumors_uuid": "70a44d22-974b-4410-85ff-afdebb4a3b80"
        },
        {
          "mutation_effect": {
            "description": "The TP53 G244A mutation is located in the DNA-binding domain of the protein. This mutation has been identified in hepatocellular carcinoma, B-cell lymphoma and prostate cancer and is a statistically significant hotspot (PMID: 14675778, 9262496, 15541116). In vivo studies with yeast expressing TP53 G244A demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 G244A also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1670976771884,
              "updatedBy": "User"
            },
            "description_uuid": "2951dfae-64ec-4287-a5e5-b0d6a5be6bf0",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1670876198071,
              "updatedBy": "User"
            },
            "effect_uuid": "82a54398-cc0a-457b-b6c7-bbb391723a2a",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1670876197010,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "4af89e61-602c-4d19-879b-cd96213ba682",
            "short": ""
          },
          "mutation_effect_uuid": "4fbcf6d3-dd97-4cad-8bc9-549891999051",
          "name": "G244A",
          "name_review": {
            "updateTime": 1670876190642,
            "updatedBy": "User"
          },
          "name_uuid": "fe22bb7a-d270-4d1f-944e-7a89403bf08e",
          "tumors_uuid": "211fc468-bc38-4cc1-a93c-8291f815f93c"
        },
        {
          "mutation_effect": {
            "description": "The TP53 G244C mutation is located in the DNA-binding domain of the protein. This mutation has been identified in squamous cell carcinoma, colorectal cancer and bladder cancer and is a statistically significant hotspot (PMID: 15305417, 14534722, 16061860). In vivo studies with yeast expressing TP53 G244C demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
            "description_review": {
              "updateTime": 1670976830888,
              "updatedBy": "User"
            },
            "description_uuid": "6511723f-86d0-4d44-8080-945a7c060847",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1670876222066,
              "updatedBy": "User"
            },
            "effect_uuid": "421495fa-6682-4408-a40d-b54fb3c422a6",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1670876220920,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "10ce96a1-df6f-415f-ac24-2b7125173c0c",
            "short": ""
          },
          "mutation_effect_uuid": "dc2c4d71-b904-4623-9c49-fe442f2aabcd",
          "name": "G244C",
          "name_review": {
            "updateTime": 1670876214478,
            "updatedBy": "User"
          },
          "name_uuid": "7b36d747-736c-4431-ae10-5a92068f7b59",
          "tumors_uuid": "b48de9ed-bfd1-40bd-afd6-b70b8fa47929"
        },
        {
          "mutation_effect": {
            "description": "The TP53 G244V mutation is located in the DNA-binding domain of the protein. This mutation has been identified in stomach adenocarcinoma, colorectal cancer and ovarian cancer, and is a statistically significant hotspot (PMID: 12796400, 11406538, 14760384). In vivo studies with yeast expressing TP53 G244V demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 G244V also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1670876254143,
              "updatedBy": "User"
            },
            "description_uuid": "d97d9a01-7ebb-4801-9579-2c9b9cd556af",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1670876257168,
              "updatedBy": "User"
            },
            "effect_uuid": "4c3b2db6-4546-4541-bc05-29c1cd6b30ef",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1670876256189,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "beb5cb1f-7d8f-4fee-874c-6550fce390d2",
            "short": ""
          },
          "mutation_effect_uuid": "c0690f3f-ab87-40d3-bea7-bceddaa2459a",
          "name": "G244V",
          "name_review": {
            "updateTime": 1670876244057,
            "updatedBy": "User"
          },
          "name_uuid": "4ee4198f-c8f6-48ab-95e9-7965922cf77a",
          "tumors_uuid": "9139468f-ae7d-43c5-8b2e-6aedce60621d"
        },
        {
          "mutation_effect": {
            "description": "The TP53 G244F mutation is located in the DNA-binding domain of the protein and is a statistically significant hotspot. In vitro studies with various human cancer cell lines expressing TP53 G244F demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1670976864895,
              "updatedBy": "User"
            },
            "description_uuid": "7e560d80-a8dd-47e7-8afe-bc9b5dd7cad0",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1670876294293,
              "updatedBy": "User"
            },
            "effect_uuid": "013358ff-b85e-4cdd-9738-064d31f647d1",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1670876293331,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "326f11db-9309-496d-a034-d73bea629d8d",
            "short": ""
          },
          "mutation_effect_uuid": "124a99b3-3afd-404d-b76b-db86f8f49e2a",
          "name": "G244F",
          "name_review": {
            "updateTime": 1670876277942,
            "updatedBy": "User"
          },
          "name_uuid": "49e6978b-af32-4764-b102-8492d6e008cf",
          "tumors_uuid": "18357041-df5a-464f-8fa5-5acae158e28d"
        },
        {
          "mutation_effect": {
            "description": "The TP53 V173A mutation is located in the DNA-binding domain of the protein. This mutation has been identified in stomach adenocarcinoma, breast cancer and ovarian cancer, and is a statistically significant hotspot (PMID: 1370612, 9569050, 9569050). In vivo studies with yeast expressing TP53 V173A demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 V173A also demonstrated the mutation is inactivating as measured by reduced growth suppressive activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1674086684796,
              "updatedBy": "User"
            },
            "description_uuid": "6b16619b-079d-4ebe-b0cb-528c9c0e8002",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1671746656069,
              "updatedBy": "User"
            },
            "effect_uuid": "27e80858-2e5c-4992-a40f-241c60acdd01",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1671746650018,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "6c4b9710-4567-449e-94ea-7e65dc9c4c64",
            "short": ""
          },
          "mutation_effect_uuid": "2af3fe11-4f7e-42ab-9a38-bd433f350156",
          "name": "V173A",
          "name_review": {
            "updateTime": 1671746642800,
            "updatedBy": "User"
          },
          "name_uuid": "d55a25a0-7504-48b7-b217-26f13352088e",
          "tumors_uuid": "3987d0f0-0353-4c3e-96ab-a7169a3972cd"
        },
        {
          "mutation_effect": {
            "description": "The TP53 V173G mutation is located in the DNA-binding domain of the protein. This mutation has been identified in stomach adenocarcinoma, breast cancer and ovarian cancer, and is a statistically significant hotspot (PMID: 1370612, 9569050, 9569050). In vivo studies with yeast expressing TP53 V173G demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 V173G also demonstrated the mutation is inactivating as measured by reduced growth suppressive activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1679600121122,
              "updatedBy": "User"
            },
            "description_uuid": "b891aa61-3aef-46b8-9d8a-c93321a91c3c",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1671746680142,
              "updatedBy": "User"
            },
            "effect_uuid": "932dbcae-ac69-4e2e-9cbc-c583d35e7d4c",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1671746678364,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "00ead91e-68e3-4975-85cd-5d3a664f5623",
            "short": ""
          },
          "mutation_effect_uuid": "0d273a85-1a7e-4ab4-9447-983b010c9006",
          "name": "V173G",
          "name_review": {
            "updateTime": 1671746674814,
            "updatedBy": "User"
          },
          "name_uuid": "04704c08-7553-4e03-8b35-c36c13547aa9",
          "tumors_uuid": "9e11b804-a515-40af-8d98-4642d6b380fb"
        },
        {
          "mutation_effect": {
            "description": "The TP53 C277G mutation is located in the DNA-binding domain of the protein. This mutation has been identified in colorectal cancer, gastric cancer and malignant peripheral nerve sheath tumor, and is a statistically significant hotspot (PMID: 9516972, 8620428, 11406645). In vivo studies with yeast expressing TP53 C277G demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 C277G also demonstrated the mutation is inactivating as measured by reduced growth suppressive activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1674086735219,
              "updatedBy": "User"
            },
            "description_uuid": "2fe1a621-1e18-4798-879d-50b7af65ed1d",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1671746699651,
              "updatedBy": "User"
            },
            "effect_uuid": "82e9c452-5ef5-4b69-89a3-2e663564a0a9",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1671746698988,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "8cd0c2f9-bd62-4d62-b7a0-752c37c0cad2",
            "short": ""
          },
          "mutation_effect_uuid": "0a8e03cf-3aa1-4d03-b3bb-fec0d210841c",
          "name": "C277G",
          "name_review": {
            "updateTime": 1671746693320,
            "updatedBy": "User"
          },
          "name_uuid": "cafca743-1a13-43a9-a384-0663fdb4927f",
          "tumors_uuid": "5259b1ca-0377-4a72-bd08-fe2abd161a07"
        },
        {
          "mutation_effect": {
            "description": "The TP53 Y205S mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer, squamous cell carcinoma and diffuse large B-cell lymphoma, and is a statistically significant hotspot (PMID: 16489069, 1324797, 15533223). In vivo studies with yeast expressing TP53 Y205S demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 Y205S also demonstrated the mutation is inactivating as measured by reduced growth suppressive activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1674086766178,
              "updatedBy": "User"
            },
            "description_uuid": "ab6bb4b6-e681-4a68-b6cc-1ce04c297196",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1671746838345,
              "updatedBy": "User"
            },
            "effect_uuid": "4e476ffa-0a02-4770-84e0-edaa870133e8",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1671746837388,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "9dfd804b-abac-4319-99cf-751331ee4636",
            "short": ""
          },
          "mutation_effect_uuid": "495f58ca-31c3-4b86-9529-1de5a91a31ef",
          "name": "Y205S",
          "name_review": {
            "updateTime": 1671746833724,
            "updatedBy": "User"
          },
          "name_uuid": "37bfa814-3864-42a7-b67e-9cad49086ec1",
          "tumors_uuid": "807a3a74-90cc-4b35-82c1-9f1052af13c6"
        },
        {
          "mutation_effect": {
            "description": "The TP53 Y205D mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer, colorectal cancer and squamous cell carcinoma, and is a statistically significant hotspot (PMID: 18725978, 15778432, 15958551). In vivo studies with yeast expressing TP53 Y205D demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 Y205D also demonstrated the mutation is inactivating as measured by reduced growth suppressive activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1674086788712,
              "updatedBy": "User"
            },
            "description_uuid": "0af39f0b-eac9-4580-ae15-d330a538cc9c",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1671746866807,
              "updatedBy": "User"
            },
            "effect_uuid": "deefda37-d4bd-418f-8ddc-0b0c61272eb6",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1671746865635,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "83ccc781-ea2b-4d81-8b7c-12f875d9c7c0",
            "short": ""
          },
          "mutation_effect_uuid": "58079e40-7454-4951-867e-c496f1464fd0",
          "name": "Y205D",
          "name_review": {
            "updateTime": 1671746861237,
            "updatedBy": "User"
          },
          "name_uuid": "e34d7c6e-1679-4d92-85e7-137414310c51",
          "tumors_uuid": "00b4b802-eec4-4289-ae4c-49a1cdffc4e3"
        },
        {
          "mutation_effect": {
            "description": "The TP53 Y205F mutation is located in the DNA-binding domain of the protein. This mutation has been identified in urothelial cancer, glioblastoma, colorectal cancer and squamous cell carcinoma, and is a statistically significant hotspot (PMID: 21413016, 15466178, 17410283, 15957194). In vivo studies with yeast expressing TP53 Y205F demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 Y205F also demonstrated the mutation is inactivating as measured by reduced growth suppressive activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1674087121263,
              "updatedBy": "User"
            },
            "description_uuid": "45bf4afe-6ee5-4cd6-9bfb-53ab540bfe60",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1671746894634,
              "updatedBy": "User"
            },
            "effect_uuid": "6508c60a-5f02-4287-b49d-7e3ed121bb84",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1671746893577,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "a346638f-1f40-48ba-a1cb-0c99db56b811",
            "short": ""
          },
          "mutation_effect_uuid": "9ed81b3b-0e6a-47ea-99fc-14951fcbd1f3",
          "name": "Y205F",
          "name_review": {
            "updateTime": 1671746890383,
            "updatedBy": "User"
          },
          "name_uuid": "f2eef519-f47a-445e-9c09-f4b464253cf4",
          "tumors_uuid": "7cefd42f-16be-48fd-908c-5daedcc1ebdc"
        },
        {
          "mutation_effect": {
            "description": "The TP53 Y205H mutation is located in the DNA-binding domain of the protein. This mutation has been identified in urothelial cancer, glioblastoma, colorectal cancer and squamous cell carcinoma, and is a statistically significant hotspot (PMID: 21413016, 15466178, 17410283, 15957194). In vivo studies with yeast expressing TP53 Y205H demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 Y205H also demonstrated the mutation is inactivating as measured by reduced growth suppressive activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1674087153617,
              "updatedBy": "User"
            },
            "description_uuid": "30cd7dbb-e34c-4511-993d-259bc6fdf222",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1671746930372,
              "updatedBy": "User"
            },
            "effect_uuid": "2a793159-c60d-4bd2-9876-86fd0b548583",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1671746929492,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "c12195bb-1d27-4d71-88fe-b11e8dfca974",
            "short": ""
          },
          "mutation_effect_uuid": "67a3f2b4-d253-40e0-9b12-10650593dab6",
          "name": "Y205H",
          "name_review": {
            "updateTime": 1671746927151,
            "updatedBy": "User"
          },
          "name_uuid": "f41891b5-8920-4fe1-848f-d55b72464da4",
          "tumors_uuid": "f9039dfe-ecc5-4b55-a7c4-9d3d239e19e8"
        },
        {
          "mutation_effect": {
            "description": "The TP53 Y205N mutation is located in the DNA-binding domain of the protein. This mutation has been identified in ovarian cancer and squamous cell carcinoma, and is a statistically significant hotspot (PMID: 7852189, 15958551). In vivo studies with yeast expressing TP53 Y205N demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 Y205N also demonstrated the mutation is inactivating as measured by reduced growth suppressive activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1674087176978,
              "updatedBy": "User"
            },
            "description_uuid": "94861a46-b3bc-436f-bfb4-485f166de30b",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1671746954088,
              "updatedBy": "User"
            },
            "effect_uuid": "93b855a6-9c16-4327-9da5-716c71cd920b",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1671746953310,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "68686269-030c-4951-9c98-574bc58e04f7",
            "short": ""
          },
          "mutation_effect_uuid": "d0b19183-2f4a-4ea4-b0c2-86b46b0a00e8",
          "name": "Y205N",
          "name_review": {
            "updateTime": 1671746950365,
            "updatedBy": "User"
          },
          "name_uuid": "9ce3731f-1f54-42c3-a179-ec396c3061a5",
          "tumors_uuid": "1366d874-de8a-4c6f-8e37-d5dcc9202515"
        },
        {
          "mutation_effect": {
            "description": "The TP53 V143E mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer, colorectal cancer and squamous cell carcinoma, and is a statistically significant hotspot (PMID: 17683074, 9052405, 7767998). In vivo studies with yeast expressing TP53 V143E demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 V143E also demonstrated the mutation is inactivating as measured by reduced growth suppressive activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1674087200955,
              "updatedBy": "User"
            },
            "description_uuid": "114ac3c9-f47c-4e5f-be58-04d25fc068e8",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1671747434923,
              "updatedBy": "User"
            },
            "effect_uuid": "56d25060-f66b-48ae-9eee-d9f34b3f9d5a",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1671747433911,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "650cb919-803d-4b78-a27a-0c279d483ec3",
            "short": ""
          },
          "mutation_effect_uuid": "97c519d8-b456-4aa3-8212-746415fbdfa7",
          "name": "V143E",
          "name_review": {
            "updateTime": 1671747422607,
            "updatedBy": "User"
          },
          "name_uuid": "2c6cee5f-debb-451e-982f-a27c52fcd81d",
          "tumors_uuid": "2e706a1c-4cac-47ff-90e6-fd2c5df88d69"
        },
        {
          "mutation_effect": {
            "description": "The TP53 C242R mutation is located in exon 6 of the protein. This mutation has been identified in pancreatic cancer, prostate cancer and squamous cell carcinoma, and is a statistically significant hotspot (PMID: 15541116, 15940643, 17456604). In vivo studies with yeast expressing TP53 C242R demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 C242R also demonstrated the mutation is inactivating as measured by reduced growth suppressive activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1674087226814,
              "updatedBy": "User"
            },
            "description_uuid": "3b077399-8791-452e-99a5-8ad237c27d8c",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1671747480948,
              "updatedBy": "User"
            },
            "effect_uuid": "9bd2e135-c776-4144-96a0-9e31da698e50",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1671747480059,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "7e07bb48-f05a-46e9-bb40-f49dbd41362c",
            "short": ""
          },
          "mutation_effect_uuid": "333cf4ce-ec25-4424-8c1b-da89659db751",
          "name": "C242R",
          "name_review": {
            "updateTime": 1671747471039,
            "updatedBy": "User"
          },
          "name_uuid": "2650470e-ecdc-490e-9fcc-ef578ca490c2",
          "tumors_uuid": "e2a2815d-b378-4916-ba12-6f541cec5a45"
        },
        {
          "mutation_effect": {
            "description": "The TP53 C242W mutation is located in exon 6 of the protein. This mutation has been identified in breast cancer, colorectal cancer and ovarian cancer, and is a statistically significant hotspot (PMID: 9815649, 8682586, 15221786). In vivo studies with yeast expressing TP53 C242W demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 C242W also demonstrated the mutation is inactivating as measured by reduced growth suppressive activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1674087306813,
              "updatedBy": "User"
            },
            "description_uuid": "53467b2b-64dc-464d-87e5-2c2ea70bdc31",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1671747492077,
              "updatedBy": "User"
            },
            "effect_uuid": "8e37c5e7-5e92-4997-bfff-e5c9545d7b2a",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1671747491159,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "6aaaacbf-8fa9-4733-b4e0-85ddbe148aeb",
            "short": ""
          },
          "mutation_effect_uuid": "d2cc50c6-8de7-45ba-b1be-ffb1f93ab6cd",
          "name": "C242W",
          "name_review": {
            "updateTime": 1671747489309,
            "updatedBy": "User"
          },
          "name_uuid": "5375009f-d1a3-4ee2-a79e-388a0351d005",
          "tumors_uuid": "b9c28f45-dccb-49f0-8721-5b0b8d859485"
        },
        {
          "mutation_effect": {
            "description": "The TP53 C242G mutation is located in exon 6 of the protein. This mutation has been identified in glioblastoma, malignant melanoma and breast cancer, and is a statistically significant hotspot (PMID: 11453385, 17260012, 7928628). In vivo studies with yeast expressing TP53 C242G demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 C242G also demonstrated the mutation is inactivating as measured by reduced growth suppressive activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1674087327057,
              "updatedBy": "User"
            },
            "description_uuid": "b0034458-9a6e-4219-9d96-cdfc44ff11f8",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1671747526687,
              "updatedBy": "User"
            },
            "effect_uuid": "de5d81eb-6375-4753-a458-2bc8adf49c3f",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1671747525844,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "aeba8487-c6f2-4fde-81e6-c7d83b0f6287",
            "short": ""
          },
          "mutation_effect_uuid": "6886e16d-c5a8-4ed2-bde2-ad40e2af964e",
          "name": "C242G",
          "name_review": {
            "updateTime": 1671747511505,
            "updatedBy": "User"
          },
          "name_uuid": "9cfbb1e4-c9e3-4ab4-af63-fadf45c0ce64",
          "tumors_uuid": "8447c547-045c-4406-b1d8-aee375c387e2"
        },
        {
          "mutation_effect": {
            "description": "The TP53 V143G mutation is located in the DNA-binding domain of the protein. This mutation has been identified in adenocarcinoma and is a statistically significant hotspot (PMID: 22551440). In vivo studies with yeast expressing TP53 V143G demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 V143G also demonstrated the mutation is inactivating as measured by reduced growth suppressive activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1674087361470,
              "updatedBy": "User"
            },
            "description_uuid": "12cca7d3-a1b0-461c-891f-58fb99f2d52d",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1673646007869,
              "updatedBy": "User"
            },
            "effect_uuid": "be7084f5-f6a3-4318-a484-9635db5720bf",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1673646006758,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "b82252b2-0d6d-402c-ace6-5cbc2620a368",
            "short": ""
          },
          "mutation_effect_uuid": "2d94b425-d4b8-4a6f-8b7c-20f189e8033b",
          "name": "V143G",
          "name_review": {
            "updateTime": 1673646000254,
            "updatedBy": "User"
          },
          "name_uuid": "9372fcec-5355-4890-85fc-866899d518c7",
          "tumors_uuid": "161e4c23-3077-4ed1-bc8f-c0c9ee619f6c"
        },
        {
          "mutation_effect": {
            "description": "The TP53 G266V mutation is located in the DNA-binding domain of the protein. This mutation has been identified in adenocarcinoma and is a statistically significant hotspot (PMID: 16143127). In vivo studies with yeast expressing TP53 G266V demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 G266V also demonstrated the mutation is inactivating as measured by reduced growth suppressive activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1674087380084,
              "updatedBy": "User"
            },
            "description_uuid": "19475e0d-c754-45f7-9618-08c10457e528",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1673646066479,
              "updatedBy": "User"
            },
            "effect_uuid": "888c47c6-58c7-4e04-81e6-1536c2bd51f4",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1673646065735,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "f3c22abd-5c1b-4b87-a9e4-b3ef361e48cc",
            "short": ""
          },
          "mutation_effect_uuid": "a97d9762-57e3-4945-a51f-7a7f9bf1e972",
          "name": "G266V",
          "name_review": {
            "updateTime": 1673646063472,
            "updatedBy": "User"
          },
          "name_uuid": "0f8074ee-1796-4cb1-8d43-60b8337fbc5e",
          "tumors_uuid": "1530ba01-8198-4b6f-93b9-cbcc56f61d57"
        },
        {
          "mutation_effect": {
            "description": "The TP53 V143M mutation is located in the DNA-binding domain of the protein. This mutation has been identified in squamous cell carcinoma and is a statistically significant hotspot (PMID: 8393371). In vivo studies with yeast expressing TP53 V143M demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 V143M also demonstrated the mutation is inactivating as measured by reduced growth suppressive activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1674087400331,
              "updatedBy": "User"
            },
            "description_uuid": "43254f38-5bef-4b43-b00b-aea85e70dad9",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1673646086897,
              "updatedBy": "User"
            },
            "effect_uuid": "8b31e7bd-936b-4c15-9afb-c14006669945",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1673646086055,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "d65ce7c9-dc14-4490-8f29-94c8b06eb46a",
            "short": ""
          },
          "mutation_effect_uuid": "698dcf7e-9466-46a8-bdde-b1695010edb6",
          "name": "V143M",
          "name_review": {
            "updateTime": 1673646083565,
            "updatedBy": "User"
          },
          "name_uuid": "fd50b6db-1860-4e89-8f09-97a669669848",
          "tumors_uuid": "726f8907-d2e3-4738-bfda-0ece2c09c24a"
        },
        {
          "mutation_effect": {
            "description": "The TP53 G266K mutation is located in the DNA-binding domain of the protein. This mutation has been identified in Merkel cell carcinoma and is a statistically significant hotspot (PMID: 26238782). In vitro studies with various human cancer cell lines expressing TP53 G266K demonstrate the mutation is inactivating as measured by reduced growth suppressive activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1674087423469,
              "updatedBy": "User"
            },
            "description_uuid": "54860447-3337-4644-95eb-e7ea1a0df268",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1673646110424,
              "updatedBy": "User"
            },
            "effect_uuid": "cf20a5e1-6648-4545-b838-3371112fad49",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1673646109598,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "fc4dfacd-c797-455d-861b-f231b35dff67",
            "short": ""
          },
          "mutation_effect_uuid": "87848e11-b55e-4d6e-a5bf-4c325cfd042f",
          "name": "G266K",
          "name_review": {
            "updateTime": 1673646107247,
            "updatedBy": "User"
          },
          "name_uuid": "158a1d57-069c-4c2d-a85c-6073bea3e383",
          "tumors_uuid": "77e39890-60c8-4dfa-9d13-6dc782b7f735"
        },
        {
          "mutation_effect": {
            "description": "The TP53 R158P mutation is located in the DNA-binding domain of the protein. This mutation has been identified in squamous cell carcinoma and is a statistically significant hotspot (PMID: 15564288). In vivo studies with yeast expressing TP53 R158P demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 R158P also demonstrated the mutation is inactivating as measured by reduced growth suppressive activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1674087440101,
              "updatedBy": "User"
            },
            "description_uuid": "d87a7c03-a563-45fc-a074-2174e97d7dc3",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1673988213287,
              "updatedBy": "User"
            },
            "effect_uuid": "8094f20d-a8f4-4245-ba06-676a2f91222f",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1673988211392,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "ab56a570-4152-4e6c-9403-909fc59e24ad",
            "short": ""
          },
          "mutation_effect_uuid": "da4eeabe-75b0-4923-98ae-8039a9b2cf34",
          "name": "R158P",
          "name_review": {
            "updateTime": 1673988206745,
            "updatedBy": "User"
          },
          "name_uuid": "87597f5b-f9ef-44c3-aaf5-1c07802731ae",
          "tumors_uuid": "0256ea49-175f-45ca-b46f-36a0ef9bcb00"
        },
        {
          "mutation_effect": {
            "description": "The TP53 R158S mutation is located in the DNA-binding domain of the protein. This mutation has been identified in clear cell carcinoma and is a statistically significant hotspot (PMID: 17581423). In vivo studies with yeast expressing TP53 R158S demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
            "description_review": {
              "updateTime": 1673988254084,
              "updatedBy": "User"
            },
            "description_uuid": "4a991dca-5e68-41ab-b08d-914068519949",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1673988249756,
              "updatedBy": "User"
            },
            "effect_uuid": "fe773070-a321-4d9a-b211-4ebef84ac21b",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1673988248934,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "446ca72f-2d19-452a-a08b-1262350e3d10",
            "short": ""
          },
          "mutation_effect_uuid": "3335cc06-3150-403a-9c67-127f08a99e9a",
          "name": "R158S",
          "name_review": {
            "updateTime": 1673988246768,
            "updatedBy": "User"
          },
          "name_uuid": "5d55bfab-3161-485e-9df5-b09758d98af1",
          "tumors_uuid": "c0fcbde0-6857-4154-9d8e-0494db93a94a"
        },
        {
          "mutation_effect": {
            "description": "The TP53 R158F mutation is located in the DNA-binding domain of the protein. This mutation has been identified in squamous cell carcinoma and is a statistically significant hotspot (PMID: 11532872). In vitro studies with various human cancer cell lines expressing TP53 R158F demonstrate the mutation is inactivating as measured by reduced growth suppressive activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1674087469703,
              "updatedBy": "User"
            },
            "description_uuid": "ecf0369e-1423-4521-93fd-399300fc7bd9",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1673988275878,
              "updatedBy": "User"
            },
            "effect_uuid": "a8c66e8b-4784-41bf-bb09-4d5e3ba46b05",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1673988274515,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "b64369a3-594d-4991-bdb9-cd26081048b6",
            "short": ""
          },
          "mutation_effect_uuid": "61fb38b7-7216-4e33-9a4e-f245f21c8b70",
          "name": "R158F",
          "name_review": {
            "updateTime": 1673988271233,
            "updatedBy": "User"
          },
          "name_uuid": "95da8bfe-77b3-40ad-92fc-cfdb2a0325e8",
          "tumors_uuid": "02bbbc71-7966-4aed-a546-7ac661cdfe2b"
        },
        {
          "mutation_effect": {
            "description": "The TP53 R158G mutation is located in the DNA-binding domain of the protein. This mutation has been identified in glioblastoma and B-cell chronic lymphocytic leukemia, and is a statistically significant hotspot (PMID: 10454262, 12149195). In vivo studies with yeast expressing TP53 R158G demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 R158G also demonstrated the mutation is inactivating as measured by reduced growth suppressive activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1674087493070,
              "updatedBy": "User"
            },
            "description_uuid": "746051ee-424b-4210-9e90-99e9142274d3",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1673988300016,
              "updatedBy": "User"
            },
            "effect_uuid": "b3447c25-a8fd-4ad1-bcb6-7a937e79e3df",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1673988299227,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "c5779258-d883-41b7-88b3-e0e4107f0176",
            "short": ""
          },
          "mutation_effect_uuid": "c405c5b5-52be-45a1-b7a9-994ea1e3d6f9",
          "name": "R158G",
          "name_review": {
            "updateTime": 1673988297220,
            "updatedBy": "User"
          },
          "name_uuid": "e36b083d-149d-4c27-a040-97e55e5c2c5c",
          "tumors_uuid": "ef7ea7e3-f404-4ab5-b28f-c4b630c3a442"
        },
        {
          "mutation_effect": {
            "description": "The TP53 E286Q mutation is located in the DNA-binding domain of the protein. This mutation has been identified in squamous cell carcinoma and adenocarcinoma and is a statistically significant hotspot (PMID: 9133458, 12509279). In vivo studies with yeast expressing TP53 E286Q demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 E286Q also demonstrated the mutation is inactivating as measured by reduced growth suppressive activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1674087522578,
              "updatedBy": "User"
            },
            "description_uuid": "128f858f-049d-42ad-871c-b213734a7765",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1673988523144,
              "updatedBy": "User"
            },
            "effect_uuid": "f163803d-8d94-4124-b0e2-9a0a13ff82b6",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1673988522460,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "0ab67089-360f-4a29-8809-a393d32ba72d",
            "short": ""
          },
          "mutation_effect_uuid": "fc096706-2772-4ddb-8fdf-6a7523f1eab6",
          "name": "E286Q",
          "name_review": {
            "updateTime": 1673988520170,
            "updatedBy": "User"
          },
          "name_uuid": "ec1c5120-1b0f-4987-a350-cc55e0a3bde1",
          "tumors_uuid": "9183ace8-dec3-469f-b484-7c95c980dd35"
        },
        {
          "mutation_effect": {
            "description": "The TP53 E286A mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and is a statistically significant hotspot (PMID: 9421363). In vivo studies with yeast expressing TP53 E286A demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 E286A also demonstrated the mutation is inactivating as measured by reduced growth suppressive activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1674088155046,
              "updatedBy": "User"
            },
            "description_uuid": "21165193-4b6f-4cf1-b471-ea313a9f79aa",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1673988542109,
              "updatedBy": "User"
            },
            "effect_uuid": "ebc95219-3398-4acb-81f0-c7180bd45e6e",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1673988541267,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "3d0afeb1-828a-41ce-b331-2c72b2ff1718",
            "short": ""
          },
          "mutation_effect_uuid": "f8e968f7-41de-4dcc-8b46-f51f0f3e34aa",
          "name": "E286A",
          "name_review": {
            "updateTime": 1673988538801,
            "updatedBy": "User"
          },
          "name_uuid": "04ea54bd-18c9-43e2-9a0f-56970cf1952d",
          "tumors_uuid": "5e9afd2f-fc8e-48d0-9084-9724e732892c"
        },
        {
          "mutation_effect": {
            "description": "The TP53 H179P mutation is located in the DNA-binding domain of the protein. This mutation has been identified in squamous cell carcinoma and is a statistically significant hotspot (PMID: 14580680). In vivo studies with yeast expressing TP53 H179P demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 H179P also demonstrated the mutation is inactivating as measured by reduced growth suppressive activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1674088576582,
              "updatedBy": "User"
            },
            "description_uuid": "54e0bbd4-7eb9-46cb-a06a-7afe4eff5ff3",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1673988633552,
              "updatedBy": "User"
            },
            "effect_uuid": "050d257d-1769-4dca-b2f7-ccf49c8fb1a1",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1673988632617,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "4f46c883-06e6-43ce-beb5-e4a357ce6a89",
            "short": ""
          },
          "mutation_effect_uuid": "9e21cdbe-0557-4dec-bca5-15eb19628f97",
          "name": "H179P",
          "name_review": {
            "updateTime": 1673988629963,
            "updatedBy": "User"
          },
          "name_uuid": "63342a80-9082-4675-8d3c-e9f6f9fa2b74",
          "tumors_uuid": "947d85c8-4f72-410d-b71d-d8067759e90e"
        },
        {
          "mutation_effect": {
            "description": "The TP53 H179D mutation is located in the DNA-binding domain of the protein. This mutation has been identified in squamous cell carcinoma and is a statistically significant hotspot (PMID: 7585600). In vivo studies with yeast expressing TP53 H179D demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 H179D also demonstrated the mutation is inactivating as measured by reduced growth suppressive activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1674088599598,
              "updatedBy": "User"
            },
            "description_uuid": "bf8d6a5d-4974-4456-8ef8-7ad6cbb82e77",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1673988655755,
              "updatedBy": "User"
            },
            "effect_uuid": "02cf3ff0-4f12-46e4-98f4-4739f5b930be",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1673988654972,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "f69b3715-81a9-48c5-b6f8-36adf31a0af6",
            "short": ""
          },
          "mutation_effect_uuid": "bddee9d4-0456-4f45-9aff-72eb116b5f6e",
          "name": "H179D",
          "name_review": {
            "updateTime": 1673988652052,
            "updatedBy": "User"
          },
          "name_uuid": "4524d681-309f-40cd-aba2-88047d0f917d",
          "tumors_uuid": "ed7237b4-a70b-4604-860c-6f2e634569c8"
        },
        {
          "mutation_effect": {
            "description": "The TP53 H168P mutation is located in the DNA-binding domain of the protein. This mutation has been identified in squamous cell carcinoma and is a statistically significant hotspot (PMID: 12649174). In vivo studies with yeast expressing TP53 H168P demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 H168P also demonstrated the mutation is inactivating as measured by reduced growth suppressive activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1674088615260,
              "updatedBy": "User"
            },
            "description_uuid": "6542ca6c-48f2-4d8f-958e-c459870fad60",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1673988683062,
              "updatedBy": "User"
            },
            "effect_uuid": "403d7ec6-9a06-42af-ac22-2df71fae1a78",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1673988681789,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "52694828-715e-446e-936e-ad16a380dc54",
            "short": ""
          },
          "mutation_effect_uuid": "6f96e970-f425-4ae6-b902-6ee8416e8971",
          "name": "H168P",
          "name_review": {
            "updateTime": 1673988727858,
            "updatedBy": "User"
          },
          "name_uuid": "6397b503-5b1f-4851-9430-9e55cc9c8426",
          "tumors_uuid": "068becdc-87c6-4c9d-8b33-6d1d09ef949c"
        },
        {
          "mutation_effect": {
            "description": "The TP53 H168L mutation is located in the DNA-binding domain of the protein. This mutation has been identified in squamous cell carcinoma and breast cancer and is a statistically significant hotspot (PMID: 1408139, 18348141). In vivo studies with yeast expressing TP53 H168L demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 H168L also demonstrated the mutation is inactivating as measured by reduced growth suppressive activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1674088901908,
              "updatedBy": "User"
            },
            "description_uuid": "99a9ae24-60e7-446a-9c78-c5b8060d178f",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1673988719701,
              "updatedBy": "User"
            },
            "effect_uuid": "ed098ad7-3177-4344-a459-47b2330de882",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1673988718545,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "7e31d293-cf1c-4273-a570-2599a8f6722c",
            "short": ""
          },
          "mutation_effect_uuid": "3013e10a-4c5a-4ce3-8ac7-ef813b104586",
          "name": "H168L",
          "name_review": {
            "updateTime": 1673988715792,
            "updatedBy": "User"
          },
          "name_uuid": "ee556d4a-1c06-4e1a-9cff-86946c792b90",
          "tumors_uuid": "77c5a0e8-8270-41e8-acf4-8cb4aeb66570"
        },
        {
          "mutation_effect": {
            "description": "The TP53 C176S mutation is located in the DNA-binding domain of the protein. This mutation has been identified in papillary serous cystadenocarcinoma and hepatocellular carcinoma and is a statistically significant hotspot (PMID: 9635683, 8407553). In vivo studies with yeast expressing TP53 C176S demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 C176S also demonstrated the mutation is inactivating as measured by reduced growth suppressive activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1674088940006,
              "updatedBy": "User"
            },
            "description_uuid": "3937b9ea-1ef2-496e-81d5-20bd20efc82a",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1673988838282,
              "updatedBy": "User"
            },
            "effect_uuid": "45ff9bcb-ef3c-4f8d-ab87-d515c640b219",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1673988837289,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "7cc87df2-9e76-4815-b34e-307024318389",
            "short": ""
          },
          "mutation_effect_uuid": "bf7f9839-fef8-4bac-8279-54c863783679",
          "name": "C176S",
          "name_review": {
            "updateTime": 1673988834936,
            "updatedBy": "User"
          },
          "name_uuid": "744aa5af-2dc9-4075-a05f-cd875268eeb4",
          "tumors_uuid": "42556737-d0a0-473c-afea-f141d3548f0d"
        },
        {
          "mutation_effect": {
            "description": "The TP53 C176G mutation is located in the DNA-binding domain of the protein. This mutation has been identified in diffuse large B-cell lymphoma and hepatocellular carcinoma, and is a statistically significant hotspot (PMID: 11113864, 8672994). In vivo studies with yeast expressing TP53 C176G demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 C176G also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1673988860422,
              "updatedBy": "User"
            },
            "description_uuid": "7d9ccece-b927-47f9-92b2-2b03fac18b88",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1673988857413,
              "updatedBy": "User"
            },
            "effect_uuid": "78e2f7ac-6c2e-46eb-8e82-f2dbfa111e29",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1673988856506,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "ba3d8ace-aa2f-47a8-9089-d93d5d000d5e",
            "short": ""
          },
          "mutation_effect_uuid": "3e6d13fd-dd8f-43b9-a9a8-3de61455d02d",
          "name": "C176G",
          "name_review": {
            "updateTime": 1673988854362,
            "updatedBy": "User"
          },
          "name_uuid": "c8b914e9-c2ab-4328-99ee-80149a001271",
          "tumors_uuid": "2b640c90-590e-4dc0-8b72-e9db3de56ad4"
        },
        {
          "mutation_effect": {
            "description": "The TP53 C176Y mutation is located in the DNA-binding domain of the protein. This mutation has been identified in squamous cell carcinoma and colorectal cancer, and is a statistically significant hotspot (PMID: 21798897, 9431782). In vivo studies with yeast expressing TP53 C176Y demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 C176Y also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1673988881260,
              "updatedBy": "User"
            },
            "description_uuid": "189ab1dd-191e-4968-a627-8599368ab0b5",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1673988877871,
              "updatedBy": "User"
            },
            "effect_uuid": "2652ccc2-d10f-4f63-b245-420e6d35a11c",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1673988877052,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "cfd13aa8-4d85-476f-91c0-1234d553cde8",
            "short": ""
          },
          "mutation_effect_uuid": "d09fae7e-2c5a-481b-9666-1c47a4084057",
          "name": "C176Y",
          "name_review": {
            "updateTime": 1673988874734,
            "updatedBy": "User"
          },
          "name_uuid": "5ac1da89-8266-49eb-a099-50d9b33a056a",
          "tumors_uuid": "78854fea-3a76-4218-b126-7315ead3ab27"
        },
        {
          "mutation_effect": {
            "description": "The TP53 C238R mutation is located in the DNA-binding domain of the protein. This mutation has been identified in squamous cell carcinoma and is a statistically significant hotspot (PMID: 10225439). In vivo studies with yeast expressing TP53 C238R demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 C238R also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1673988903066,
              "updatedBy": "User"
            },
            "description_uuid": "93d083ac-4ffe-496a-b45f-e856a78e0987",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1673988900354,
              "updatedBy": "User"
            },
            "effect_uuid": "16fa7f0a-aee7-4c27-8d100-8075b1636587",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1673988899452,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "42850a80-4674-4486-ae60-77c5f97c281e",
            "short": ""
          },
          "mutation_effect_uuid": "c77a7762-9616-423c-a1d7-25fe6a2b00fd",
          "name": "C238R",
          "name_review": {
            "updateTime": 1673988897481,
            "updatedBy": "User"
          },
          "name_uuid": "e649027c-75c3-4b0b-b539-5fbd97491758",
          "tumors_uuid": "e9316ec9-bacb-462f-8e32-6307812b8407"
        },
        {
          "mutation_effect": {
            "description": "The TP53 C238G mutation is located in the DNA-binding domain of the protein. This mutation has been identified in adenocarcinoma and is a statistically significant hotspot (PMID: 16467080). In vivo studies with yeast expressing TP53 C238G demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 C238G also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1673988929986,
              "updatedBy": "User"
            },
            "description_uuid": "26a4b32a-2849-4232-b30a-9b4429115132",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1673988925136,
              "updatedBy": "User"
            },
            "effect_uuid": "7627e773-9892-4d65-8c18-8de8cf9ad50c",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1673988922163,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "5cce95dd-793a-4fea-af99-8f3410116ab1",
            "short": ""
          },
          "mutation_effect_uuid": "b548f115-9ca6-4e9e-9d2e-6eeb89f8093c",
          "name": "C238G",
          "name_review": {
            "updateTime": 1673988920127,
            "updatedBy": "User"
          },
          "name_uuid": "aae1279b-af89-485f-918b-959749f85777",
          "tumors_uuid": "1be59ca6-59a5-46e7-ad01-d3efc9636d48"
        },
        {
          "mutation_effect": {
            "description": "The TP53 C238W mutation is located in the DNA-binding domain of the protein. This mutation has been identified in adenocarcinoma and is a statistically significant hotspot (PMID: 11710597). In vivo studies with yeast expressing TP53 C238W demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 C238W also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1673988957256,
              "updatedBy": "User"
            },
            "description_uuid": "5f62cd71-1a02-4904-849e-3410c14f91cb",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1673988953296,
              "updatedBy": "User"
            },
            "effect_uuid": "10dd559d-f9a4-4ee0-85a5-f91b47b13fd4",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1673988951778,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "d7cd8775-231e-4dca-86fb-6cc8ec905ea8",
            "short": ""
          },
          "mutation_effect_uuid": "0bc47676-e44f-4b19-8fd6-b7ae6fa08eaa",
          "name": "C238W",
          "name_review": {
            "updateTime": 1673988949302,
            "updatedBy": "User"
          },
          "name_uuid": "9a7512d8-384a-4cfc-a79d-9e357cd29dfa",
          "tumors_uuid": "fcef85ec-7563-491c-8010-010d7caaaffe"
        },
        {
          "mutation_effect": {
            "description": "The TP53 C238Y mutation is located in the DNA-binding domain of the protein. This mutation has been identified in osteosarcoma and is a statistically significant hotspot (PMID: 11596036). In vivo studies with yeast expressing TP53 C238Y demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 C238Y also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1673988983085,
              "updatedBy": "User"
            },
            "description_uuid": "d93dc550-8a9b-4800-8e6d-e050d1fed589",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1673988976812,
              "updatedBy": "User"
            },
            "effect_uuid": "e18a7835-42c3-4524-820e-0c729ca88cba",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1673988975361,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "8f0e0342-3bd5-474d-969c-253737823789",
            "short": ""
          },
          "mutation_effect_uuid": "07c45541-36a6-4535-b7a9-652e7c6a0942",
          "name": "C238Y",
          "name_review": {
            "updateTime": 1673988971688,
            "updatedBy": "User"
          },
          "name_uuid": "da20ee53-55ad-4ac9-a2d0-1e91cc5945b4",
          "tumors_uuid": "60a3abe8-6616-4dae-9304-5a9e64f3686d"
        },
        {
          "mutation_effect": {
            "description": "The TP53 E285Q mutation is located in the DNA-binding domain of the protein. This mutation has been identified in bladder cancer and is a statistically significant hotspot (PMID: 11596036). In vivo studies with yeast expressing TP53 E285Q demonstrated that the mutation is likely neutral as measured by transactivational activity comparable to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 E285Q also demonstrated the mutation likely neutral as measured by growth suppression activity comparable to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1674763554100,
              "updatedBy": "User"
            },
            "description_uuid": "b3fe202b-5dfe-4338-8a3d-0eac9b8723ba",
            "effect": "Likely Neutral",
            "effect_review": {
              "updateTime": 1673989004675,
              "updatedBy": "User"
            },
            "effect_uuid": "74d12aee-bed8-4d1b-9e7d-93d00d6aa01f",
            "oncogenic": "Likely Neutral",
            "oncogenic_review": {
              "updateTime": 1673989002102,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "0a2be534-1140-42e0-9ad1-e81dba8f0ea9",
            "short": ""
          },
          "mutation_effect_uuid": "ab824d96-a5c8-45a2-844c-815bcda12835",
          "name": "E285Q",
          "name_review": {
            "updateTime": 1673988999905,
            "updatedBy": "User"
          },
          "name_uuid": "2a06fdc7-32c1-4ae8-a03d-8b67862c1e2d",
          "tumors_uuid": "2a2e113c-5fc2-4458-9cce-d591679a219e"
        },
        {
          "mutation_effect": {
            "description": "The TP53 M237V mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and is a statistically significant hotspot (PMID: 15138567). In vivo studies with yeast expressing TP53 M237V demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 M237V also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1673989036025,
              "updatedBy": "User"
            },
            "description_uuid": "bc732a3f-a334-4ca3-a5d7-cab67ba33d55",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1673989032043,
              "updatedBy": "User"
            },
            "effect_uuid": "c0d525f6-b2d7-4b3a-9710-743575f7adce",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1673989031201,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "ba76abd6-2653-4f1e-8f18-2acbc431bf9a",
            "short": ""
          },
          "mutation_effect_uuid": "ab1d2b1e-51b5-4b49-95e6-52d9895d8680",
          "name": "M237V",
          "name_review": {
            "updateTime": 1673989026663,
            "updatedBy": "User"
          },
          "name_uuid": "1154a8b5-f699-449c-8b6d-c057643b72eb",
          "tumors_uuid": "909af5ce-347d-4a0b-bf43-23e906052550"
        },
        {
          "mutation_effect": {
            "description": "The TP53 M237I mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and colorectal cancer, and is a statistically significant hotspot (PMID: 8816892, 16696056). In vivo studies with yeast expressing TP53 M237I demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 M237I also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1673989058462,
              "updatedBy": "User"
            },
            "description_uuid": "a1d50acc-84cb-4a1c-9fdd-875a77e77d3f",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1673989054194,
              "updatedBy": "User"
            },
            "effect_uuid": "8615bc12-457f-4116-9707-9e3cd67d5781",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1673989052850,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "50baf7c6-ba89-4f15-a5d9-bfe3cc37b73e",
            "short": ""
          },
          "mutation_effect_uuid": "3c0cb8ca-35b1-4446-989e-5be14b9a6f76",
          "name": "M237I",
          "name_review": {
            "updateTime": 1673989050738,
            "updatedBy": "User"
          },
          "name_uuid": "734ed691-b4da-4c5c-b771-55a5b98f56a6",
          "tumors_uuid": "a6b1b5a6-eda1-449c-98a3-2e4adf1c19df"
        },
        {
          "mutation_effect": {
            "description": "The TP53 G154C mutation is located in the DNA-binding domain of the protein. This mutation has been identified in squamous cell carcinoma and is a statistically significant hotspot (PMID: 10709097). In vivo studies with yeast expressing TP53 G154C demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
            "description_review": {
              "updateTime": 1673989078962,
              "updatedBy": "User"
            },
            "description_uuid": "1da7d138-3ff5-4588-ade9-3e40fcd1a0d4",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1673989074543,
              "updatedBy": "User"
            },
            "effect_uuid": "5ad6c562-bd20-45df-b62d-ecc55aab2e48",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1673989073725,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "c42b3ec7-fe7d-406c-8682-1f677d5398e9",
            "short": ""
          },
          "mutation_effect_uuid": "a2bcb8df-efc3-4881-8ab9-c911145d5460",
          "name": "G154C",
          "name_review": {
            "updateTime": 1673989071588,
            "updatedBy": "User"
          },
          "name_uuid": "9212ed80-10c7-4232-9b40-46ce786de25a",
          "tumors_uuid": "7ef1edcd-b2b9-4ab3-a002-a2dc25d58f74"
        },
        {
          "mutation_effect": {
            "description": "The TP53 G154D mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and adenocarcinoma, and is a statistically significant hotspot (PMID: 15138567, 11011123). In vivo studies with yeast expressing TP53 G154D demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
            "description_review": {
              "updateTime": 1673989099134,
              "updatedBy": "User"
            },
            "description_uuid": "1b07d8b7-a11f-4c87-8884-ca2da4926b9b",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1673989096171,
              "updatedBy": "User"
            },
            "effect_uuid": "06386cec-60b5-4b2d-a61a-d65265bb498b",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1673989095120,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "dbf06d8f-7f58-46b8-b137-cb602ed15124",
            "short": ""
          },
          "mutation_effect_uuid": "d4bfa11a-2aac-4b65-98b5-027270ac2a14",
          "name": "G154D",
          "name_review": {
            "updateTime": 1673989092349,
            "updatedBy": "User"
          },
          "name_uuid": "aea38136-6000-4628-b408-e81fbd168c16",
          "tumors_uuid": "26342349-85b7-45af-bc23-81826ce4a0b0"
        },
        {
          "mutation_effect": {
            "description": "The TP53 S241P mutation is located in the DNA-binding domain of the protein. This mutation has been identified in diffuse large B-cell lymphoma and malignant melanoma, and is a statistically significant hotspot (PMID: 9002964, 11216673). In vivo studies with yeast expressing TP53 S241P demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 S241P also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1673989123137,
              "updatedBy": "User"
            },
            "description_uuid": "e9c7404a-4e3b-4e64-add6-c79bd61a7b1d",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1673989119150,
              "updatedBy": "User"
            },
            "effect_uuid": "1a2142bb-3cea-4bef-8c0a-824413de5f35",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1673989117060,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "28c9bc12-037a-4bcb-84fa-868ab04e9315",
            "short": ""
          },
          "mutation_effect_uuid": "0090dd3f-7a2e-4196-a348-b505526acfc2",
          "name": "S241P",
          "name_review": {
            "updateTime": 1673989114983,
            "updatedBy": "User"
          },
          "name_uuid": "bd4cbb1f-0064-45b5-ad0a-e661f190c3be",
          "tumors_uuid": "596e9d4c-33de-418e-8d69-56d4292d7dfc"
        },
        {
          "mutation_effect": {
            "description": "The TP53 S241A mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and is a statistically significant hotspot (PMID: 16489069). In vivo studies with yeast expressing TP53 S241A demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 S241A also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1673989145818,
              "updatedBy": "User"
            },
            "description_uuid": "bbdf5e95-b4ef-4a94-97de-337bafd2661c",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1673989141940,
              "updatedBy": "User"
            },
            "effect_uuid": "80607c3e-ed1d-4eee-9513-be9353f24587",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1673989141269,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "7a4d7dfa-8cb0-486a-9d04-b9cee79a1377",
            "short": ""
          },
          "mutation_effect_uuid": "ae89e245-9737-46f4-aa87-fe5bfa6e0de3",
          "name": "S241A",
          "name_review": {
            "updateTime": 1673989138850,
            "updatedBy": "User"
          },
          "name_uuid": "786f8914-0914-411f-8621-d40614d1c2b2",
          "tumors_uuid": "8c645337-1b7a-46be-9ebb-8265d49455c8"
        },
        {
          "mutation_effect": {
            "description": "The TP53 S241C mutation is located in the DNA-binding domain of the protein. This mutation has been identified in acute myeloid leukemia and is a statistically significant hotspot (PMID: 9854490). In vivo studies with yeast expressing TP53 S241C demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 S241C also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1673989171405,
              "updatedBy": "User"
            },
            "description_uuid": "2cb635a1-3b2d-4712-a8fe-30e2f42cc846",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1673989168348,
              "updatedBy": "User"
            },
            "effect_uuid": "70550ad9-88eb-47f4-b6c8-2652f6988fe2",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1673989167314,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "ebfbd51a-6182-4ccb-ae89-095e4550c015",
            "short": ""
          },
          "mutation_effect_uuid": "9ae9a4f5-bc58-4518-ae47-eaafc40e3470",
          "name": "S241C",
          "name_review": {
            "updateTime": 1673989165121,
            "updatedBy": "User"
          },
          "name_uuid": "37abbbcf-8af2-4e38-bf9c-1e44de56e18c",
          "tumors_uuid": "80c2eaf5-23de-4e5b-b09a-abd124aa575b"
        },
        {
          "mutation_effect": {
            "description": "The TP53 R282P mutation is located in the DNA-binding domain of the protein. This mutation has been identified in squamous cell carcinoma and is a statistically significant hotspot (PMID: 7952630). In vivo studies with yeast expressing TP53 R282P demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 R282P also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1673989603821,
              "updatedBy": "User"
            },
            "description_uuid": "22d50f12-beb4-497a-9e8c-8d86aea4a324",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1673989600558,
              "updatedBy": "User"
            },
            "effect_uuid": "8de3fd89-4727-4b43-acba-452cfbb9bdfd",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1673989599757,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "6ca4bb32-5293-4c80-96d5-5d2d851c0d4b",
            "short": ""
          },
          "mutation_effect_uuid": "c2b0e7eb-87ce-436e-b307-9445964ba6c9",
          "name": "R282P",
          "name_review": {
            "updateTime": 1673989594684,
            "updatedBy": "User"
          },
          "name_uuid": "465f666d-a22a-497d-b207-0e517e87c81a",
          "tumors_uuid": "9711e8b5-4acd-4511-a599-2452cdf00f9d"
        },
        {
          "mutation_effect": {
            "description": "The TP53 R282G mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and bladder cancer, and is a statistically significant hotspot (PMID: 17999388, 16061860). In vivo studies with yeast expressing TP53 R282G demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 R282G also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1673989624820,
              "updatedBy": "User"
            },
            "description_uuid": "01bc8758-6167-4b09-9f10-f3bf1e07ec8a",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1673989621425,
              "updatedBy": "User"
            },
            "effect_uuid": "6d0bc3ca-4d3b-4b71-8b37-022f2a14adda",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1673989620555,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "9c593844-154a-4bb1-9cc2-eb3798b03c68",
            "short": ""
          },
          "mutation_effect_uuid": "025fd314-8d37-4d38-b3ad-7ef398bda182",
          "name": "R282G",
          "name_review": {
            "updateTime": 1673989618864,
            "updatedBy": "User"
          },
          "name_uuid": "aae4d773-0bf7-4bda-92bf-e65d56fcc0d6",
          "tumors_uuid": "e8a42fe9-4be4-4103-bf57-6aed76775639"
        },
        {
          "mutation_effect": {
            "description": "The TP53 R282L mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and is a statistically significant hotspot (PMID: 12365217). In vivo studies with yeast expressing TP53 R282L demonstrated that the mutation is likely neutral as measured by transactivational activity comparable to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 R282L also demonstrated the mutation likely neutral as measured by growth suppression activity comparable to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1674763725838,
              "updatedBy": "User"
            },
            "description_uuid": "179f405b-fc0d-4cdc-8371-05f4cea08c20",
            "effect": "Likely Neutral",
            "effect_review": {
              "updateTime": 1673989641401,
              "updatedBy": "User"
            },
            "effect_uuid": "a3196366-dc81-4403-812a-5aa0581ce327",
            "oncogenic": "Likely Neutral",
            "oncogenic_review": {
              "updateTime": 1673989639394,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "91a35633-1fcb-422c-c09c-07b1c59500b9",
            "short": ""
          },
          "mutation_effect_uuid": "050c3875-dee4-4d54-9775-1d1207d5841b",
          "name": "R282L",
          "name_review": {
            "updateTime": 1673989636483,
            "updatedBy": "User"
          },
          "name_uuid": "b78b0209-7ff7-4861-953c-eece59b2a707",
          "tumors_uuid": "09a8d018-7d4d-4639-b675-2c16454520db"
        },
        {
          "mutation_effect": {
            "description": "The TP53 P250R mutation is located in the DNA-binding domain of the protein. This mutation has been identified in hepatocellular carcinoma and is a statistically significant hotspot (PMID: 31395065). In vivo studies with yeast expressing TP53 P250R demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
            "description_review": {
              "updateTime": 1673989671615,
              "updatedBy": "User"
            },
            "description_uuid": "d45e63d7-a417-4f48-a315-37155e32e2f3",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1673989668413,
              "updatedBy": "User"
            },
            "effect_uuid": "81981412-3c58-4fb6-9017-558c1aa8f49e",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1673989667109,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "9a5808a1-55a5-4519-875f-469f3388fa45",
            "short": ""
          },
          "mutation_effect_uuid": "67b3b051-33ee-478e-99e7-b3df2a18fd15",
          "name": "P250R",
          "name_review": {
            "updateTime": 1673989663333,
            "updatedBy": "User"
          },
          "name_uuid": "0ad9f868-878a-4917-91b0-acbad9a50846",
          "tumors_uuid": "6db60eec-c150-41cc-93b8-5737688382e0"
        },
        {
          "mutation_effect": {
            "description": "The TP53 E286V mutation is located in the DNA-binding domain of the protein. This mutation has been identified in hepatocellular carcinoma and is a statistically significant hotspot (PMID: 11375957). In vivo studies with yeast expressing TP53 E286V demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 E286V also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1673989689095,
              "updatedBy": "User"
            },
            "description_uuid": "0140a69b-6546-4fe8-88be-bee8008662d0",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1673989684858,
              "updatedBy": "User"
            },
            "effect_uuid": "8bae3101-5a86-4238-9e9c-e83f2900f727",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1673989683270,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "ba4961b7-1fc2-4ca4-89bc-6b7e1822d2fc",
            "short": ""
          },
          "mutation_effect_uuid": "314b5f1b-8b84-4fb5-992c-55fdfcbdfa5d",
          "name": "E286V",
          "name_review": {
            "updateTime": 1673989681432,
            "updatedBy": "User"
          },
          "name_uuid": "17df43c6-bc54-4237-b371-e5f8e10ccf1f",
          "tumors_uuid": "6033198e-60c8-4100-b183-cf28e7a500ef"
        },
        {
          "mutation_effect": {
            "description": "The TP53 N239D mutation is located in the DNA-binding domain of the protein. This mutation has been identified in squamous cell carcinoma and is a statistically significant hotspot (PMID: 16271069). In vivo studies with yeast expressing TP53 N239D demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 N239D also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1673990046383,
              "updatedBy": "User"
            },
            "description_uuid": "2c7d624f-1a01-4f2a-acc0-474bc0e37e09",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1673990043115,
              "updatedBy": "User"
            },
            "effect_uuid": "a304b726-13be-4bfe-9bf3-1cb645e8b744",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1673990042309,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "6d591281-a5f0-4975-adeb-466d5d9b6117",
            "short": ""
          },
          "mutation_effect_uuid": "68d57858-18f4-4f9e-86d4-04528a0ec0f1",
          "name": "N239D",
          "name_review": {
            "updateTime": 1673990039902,
            "updatedBy": "User"
          },
          "name_uuid": "3745cfb4-924f-4b1d-ba0c-e7c8b2b6dc93",
          "tumors_uuid": "2fe87207-145b-4d49-8770-31fda8997a5a"
        },
        {
          "mutation_effect": {
            "description": "The TP53 N239T mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and squamous cell carcinoma, and is a statistically significant hotspot (PMID: 8611423, 10225439). In vivo studies with yeast expressing TP53 N239T demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 N239T also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1673990067665,
              "updatedBy": "User"
            },
            "description_uuid": "5f5a8156-da7d-43ca-a031-b0619460240f",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1673990062911,
              "updatedBy": "User"
            },
            "effect_uuid": "3ae412f1-f80b-4baf-8982-975298ca7a61",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1673990061896,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "d277ee96-c1cd-487f-8623-204858ba652b",
            "short": ""
          },
          "mutation_effect_uuid": "d3b32865-f582-455c-a2cd-6bfe326faac6",
          "name": "N239T",
          "name_review": {
            "updateTime": 1673990059045,
            "updatedBy": "User"
          },
          "name_uuid": "f229cec3-211e-4b6f-82a5-e5dd1f2af0ef",
          "tumors_uuid": "b5b83030-6ac3-4bfb-b8e1-7636e911d64d"
        },
        {
          "mutation_effect": {
            "description": "The TP53 N239H mutation is located in the DNA-binding domain of the protein. This mutation has been identified in prostate cancer and is a statistically significant hotspot (PMID: 8978408). In vivo studies with yeast expressing TP53 N239H demonstrated that the mutation is likely neutral as measured by transactivational activity comparable to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 N239H also demonstrated the mutation likely neutral as measured by growth suppression activity comparable to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1674764590496,
              "updatedBy": "User"
            },
            "description_uuid": "b17c6264-a2b5-4fa4-8a3d-c31ceb1f9fdb",
            "effect": "Likely Neutral",
            "effect_review": {
              "updateTime": 1673990084798,
              "updatedBy": "User"
            },
            "effect_uuid": "81ddeb7d-43c6-4842-9efa-23940a64ef54",
            "oncogenic": "Likely Neutral",
            "oncogenic_review": {
              "updateTime": 1673990084204,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "70e8d6d6-145f-4a89-b57f-32ec035b9c50",
            "short": ""
          },
          "mutation_effect_uuid": "344966b6-d8ae-4c81-bbee-ce45225eb547",
          "name": "N239H",
          "name_review": {
            "updateTime": 1673990082257,
            "updatedBy": "User"
          },
          "name_uuid": "0edcc1b9-1d86-450e-98f8-4b76d42ed0e3",
          "tumors_uuid": "9c7a89b7-adbf-4b76-b26d-27fbe2dd5590"
        },
        {
          "mutation_effect": {
            "description": "The TP53 N239K mutation is located in the DNA-binding domain of the protein. This mutation has been identified in hepatocellular carcinoma and squamous cell carcinoma, and is a statistically significant hotspot (PMID: 9816044, 8407553). In vivo studies with yeast expressing TP53 N239K demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
            "description_review": {
              "updateTime": 1673990109129,
              "updatedBy": "User"
            },
            "description_uuid": "aca84bae-6fae-4367-99f0-cb3158c1537b",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1673990106235,
              "updatedBy": "User"
            },
            "effect_uuid": "97436b67-9fcc-45aa-986e-91853a8b2972",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1673990105543,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "b6a2cb2b-f4a6-4c46-9221-dc653e222bc8",
            "short": ""
          },
          "mutation_effect_uuid": "5ff757f0-94b8-4fc4-aaed-65200950d637",
          "name": "N239K",
          "name_review": {
            "updateTime": 1673990103733,
            "updatedBy": "User"
          },
          "name_uuid": "a2fa2c1d-9588-4b33-bda2-8ac92a49f97d",
          "tumors_uuid": "ddc5fd3b-d4e2-427d-8f11-45a154fa793c"
        },
        {
          "mutation_effect": {
            "description": "The TP53 E286G mutation is located in the DNA-binding domain of the protein. This mutation has been identified in colorectal cancer and squamous cell carcinoma, and is a statistically significant hotspot (PMID: 1945416, 8453641). In vivo studies with yeast expressing TP53 E286G demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 E286G also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1673990123895,
              "updatedBy": "User"
            },
            "description_uuid": "bb114ad9-ccca-45e3-8168-5712dd6f830c",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1673990121162,
              "updatedBy": "User"
            },
            "effect_uuid": "374c669b-c134-4aea-8613-ec494eff6d98",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1673990120384,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "22fd1422-1be9-4b96-9d6f-7cc20184800e",
            "short": ""
          },
          "mutation_effect_uuid": "db8321f2-3183-4680-8d65-17d7d925ee1a",
          "name": "E286G",
          "name_review": {
            "updateTime": 1673990118630,
            "updatedBy": "User"
          },
          "name_uuid": "cd7de615-cadb-4b6a-8521-158389967209",
          "tumors_uuid": "5e22e45b-89a3-466a-b988-4a091c335909"
        },
        {
          "mutation_effect": {
            "description": "The TP53 R280S mutation is located in the DNA-binding domain of the protein. This mutation has been identified in squamous cell carcinoma and is a statistically significant hotspot (PMID: 10761706). In vivo studies with yeast expressing TP53 R280S demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 R280S also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1673990151420,
              "updatedBy": "User"
            },
            "description_uuid": "a0daff06-568a-4fdd-8db3-e745b3d623a4",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1673990148183,
              "updatedBy": "User"
            },
            "effect_uuid": "bf1d10b8-d608-4207-b7a8-1f60cf29ed23",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1673990147152,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "947a5872-dba5-4662-b29c-6a56e258a5ea",
            "short": ""
          },
          "mutation_effect_uuid": "762384bc-e6f5-4013-ace4-406bc2974dac",
          "name": "R280S",
          "name_review": {
            "updateTime": 1673990145261,
            "updatedBy": "User"
          },
          "name_uuid": "7465789d-6281-45da-8312-ebcdd1ab5cad",
          "tumors_uuid": "ea85ad41-27e4-4f51-a0d3-909a735626cf"
        },
        {
          "mutation_effect": {
            "description": "The TP53 R280G mutation is located in the DNA-binding domain of the protein. This mutation has been identified in bladder cancer and is a statistically significant hotspot (PMID: 19909015). In vivo studies with yeast expressing TP53 R280G demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 R280G also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1673990171901,
              "updatedBy": "User"
            },
            "description_uuid": "5361cdb0-481c-4589-a717-e563b99df435",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1673990167239,
              "updatedBy": "User"
            },
            "effect_uuid": "7a821b22-dfa0-4037-8e80-9717c714e052",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1673990166229,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "42c02efc-a9c0-4eda-aa86-b02e969718ba",
            "short": ""
          },
          "mutation_effect_uuid": "2d69a25d-e629-40ad-822d-fac949303e87",
          "name": "R280G",
          "name_review": {
            "updateTime": 1673990164035,
            "updatedBy": "User"
          },
          "name_uuid": "19567089-ae8f-4b03-bfbf-c87a3d2c285b",
          "tumors_uuid": "317181df-182c-4ce5-99eb-e332dbaf9373"
        },
        {
          "mutation_effect": {
            "description": "The TP53 R280I mutation is located in the DNA-binding domain of the protein. This mutation has been identified in squamous cell carcinoma and is a statistically significant hotspot (PMID: 1324794). In vivo studies with yeast expressing TP53 R280I demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 R280I also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1673990193269,
              "updatedBy": "User"
            },
            "description_uuid": "49c33be1-d7b2-4c39-bb22-472e19529556",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1673990189627,
              "updatedBy": "User"
            },
            "effect_uuid": "91b5592b-31c9-4a31-b5b4-9b31489f7b22",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1673990188177,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "2d11d8aa-612f-447e-a4b3-7a049f821c21",
            "short": ""
          },
          "mutation_effect_uuid": "6c389e9d-c92f-48be-85d9-edb1c406df6d",
          "name": "R280I",
          "name_review": {
            "updateTime": 1673990186269,
            "updatedBy": "User"
          },
          "name_uuid": "ab01264d-6ce0-48f8-b8c3-5abc88a6a91f",
          "tumors_uuid": "9561aed2-51f9-4af7-aefc-81fe483ab332"
        },
        {
          "mutation_effect": {
            "description": "The TP53 P278T mutation is located in the DNA-binding domain of the protein. This mutation has been identified in renal cell carcinoma and is a statistically significant hotspot (PMID: 17133269). In vivo studies with yeast expressing TP53 P278T demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 P278T also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1674067833773,
              "updatedBy": "User"
            },
            "description_uuid": "b12be8ee-bb7f-460e-9efa-fae4a880e796",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1674067829874,
              "updatedBy": "User"
            },
            "effect_uuid": "01075238-df33-4c1e-adde-01b0f1e2d6d4",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1674067828374,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "d46bcd9c-c3ce-445f-acce-408297679691",
            "short": ""
          },
          "mutation_effect_uuid": "de0ab90e-fa9d-458c-be0b-6a22b1b8189d",
          "name": "P278T",
          "name_review": {
            "updateTime": 1674067826009,
            "updatedBy": "User"
          },
          "name_uuid": "7d00c14d-09f3-43a3-9494-d9c6ad529d34",
          "tumors_uuid": "fbb6d2af-2ce6-48ef-b70c-db722074872b"
        },
        {
          "mutation_effect": {
            "description": "The TP53 P278F mutation is located in the DNA-binding domain of the protein. This mutation has been identified in squamous cell carcinoma and is a statistically significant hotspot (PMID: 20025891). In vitro studies with various human cancer cell lines expressing TP53 P278F demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1674067856953,
              "updatedBy": "User"
            },
            "description_uuid": "6457f0e1-1311-464f-b8a1-ddcab099cf41",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1674067853120,
              "updatedBy": "User"
            },
            "effect_uuid": "54974bc2-65f2-487e-9630-f71138fd2b45",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1674067852005,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "c4157341-9d1d-4324-b160-06906cbb2c0b",
            "short": ""
          },
          "mutation_effect_uuid": "0e59a852-6d94-4766-bdf3-28307107cbe1",
          "name": "P278F",
          "name_review": {
            "updateTime": 1674067850285,
            "updatedBy": "User"
          },
          "name_uuid": "eb6da164-9866-44e5-b3df-113f9d613e30",
          "tumors_uuid": "5247877d-9a54-420b-8d9a-109cd9c18065"
        },
        {
          "mutation_effect": {
            "description": "The TP53 P278H mutation is located in the DNA-binding domain of the protein. This mutation has been identified in colorectal cancer and is a statistically significant hotspot (PMID: 9097977). In vivo studies with yeast expressing TP53 P278H demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 P278H also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1674067882438,
              "updatedBy": "User"
            },
            "description_uuid": "53a25605-35ab-45eb-92f3-d9f3bd639420",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1674067879041,
              "updatedBy": "User"
            },
            "effect_uuid": "89625149-b587-401c-a80e-67e14db09453",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1674067878212,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "39d0d7b2-16a9-461a-a723-cd84b8175eac",
            "short": ""
          },
          "mutation_effect_uuid": "107e3478-e125-4e80-a46c-026190096751",
          "name": "P278H",
          "name_review": {
            "updateTime": 1674067875261,
            "updatedBy": "User"
          },
          "name_uuid": "f934971d-a1e1-4731-8067-1fe03fc3abcc",
          "tumors_uuid": "f44e936c-a426-4701-9568-6b5511bd18b9"
        },
        {
          "mutation_effect": {
            "description": "The TP53 H178P mutation is located in the DNA-binding domain of the protein. This mutation has been identified in serous cystadenocarcinoma and is a statistically significant hotspot (PMID: 20229506). In vivo studies with yeast expressing TP53 H178P demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 H178P also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1674068338118,
              "updatedBy": "User"
            },
            "description_uuid": "c7fc2068-4fb3-4b43-bd9e-35132b7c90e0",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1674068334775,
              "updatedBy": "User"
            },
            "effect_uuid": "55b2eac5-e699-4b17-b760-11bfb897c72c",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1674068334039,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "02a31bbb-d4d9-406b-b5ea-da9abb61a369",
            "short": ""
          },
          "mutation_effect_uuid": "695301e3-cb86-4a48-aa49-ff52803a6a0e",
          "name": "H178P",
          "name_review": {
            "updateTime": 1674068332052,
            "updatedBy": "User"
          },
          "name_uuid": "f8447889-6f5e-4e13-8788-d9da81bef04a",
          "tumors_uuid": "5e80ff42-d70b-4d49-9207-baf3aab41bf2"
        },
        {
          "mutation_effect": {
            "description": "The TP53 H178Q mutation is located in the DNA-binding domain of the protein. This mutation has been identified in B-cell chronic lymphocytic leukemia and is a statistically significant hotspot (PMID: 16572201). In vivo studies with yeast expressing TP53 H178Q demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
            "description_review": {
              "updateTime": 1674068354046,
              "updatedBy": "User"
            },
            "description_uuid": "2b068cf3-efe2-4f2c-95a5-afd376657097",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1674068350769,
              "updatedBy": "User"
            },
            "effect_uuid": "10f4417b-a677-4686-8c24-c69e2500454f",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1674068349443,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "6046d1e2-de17-4f05-a5fc-39f82511577e",
            "short": ""
          },
          "mutation_effect_uuid": "214e0cae-40f3-4290-9650-b8de0ac3c296",
          "name": "H178Q",
          "name_review": {
            "updateTime": 1674068343528,
            "updatedBy": "User"
          },
          "name_uuid": "f54c99cb-19ff-479c-ae56-f007585fd947",
          "tumors_uuid": "d0741687-c7c2-4c39-b63d-2ed10df7beee"
        },
        {
          "mutation_effect": {
            "description": "The TP53 H178N mutation is located in the DNA-binding domain of the protein. This mutation has been identified in basal cell carcinoma and is a statistically significant hotspot (PMID: 10568172). In vivo studies with yeast expressing TP53 H178P demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
            "description_review": {
              "updateTime": 1674068370954,
              "updatedBy": "User"
            },
            "description_uuid": "542c76fe-88b6-43ca-bd5b-38607ebe6a2a",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1674068366967,
              "updatedBy": "User"
            },
            "effect_uuid": "63b5a81f-016e-47a4-89d3-9b736c65a320",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1674068365520,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "a6744c8b-26f5-4a24-b44b-164749e13c51",
            "short": ""
          },
          "mutation_effect_uuid": "0f01d39b-7e4f-4553-8363-fc5231e6c154",
          "name": "H178N",
          "name_review": {
            "updateTime": 1674068363552,
            "updatedBy": "User"
          },
          "name_uuid": "9fdb050e-a6e9-4356-bc9d-0c91bbee7841",
          "tumors_uuid": "e6eff7ba-f0d2-4024-b3fa-786f2097d95a"
        },
        {
          "mutation_effect": {
            "description": "The TP53 V197G mutation is located in the DNA-binding domain of the protein. This mutation has been identified in squamous cell carcinoma and is a statistically significant hotspot (PMID: 12713560). In vivo studies with yeast expressing TP53 V197G demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 V197G also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1674246673426,
              "updatedBy": "User"
            },
            "description_uuid": "485e6b46-212f-4e89-938d-b771443fd6eb",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1674246669763,
              "updatedBy": "User"
            },
            "effect_uuid": "7f9a7013-42ad-4331-b465-67f02359809c",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1674246667097,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "def3f178-df33-4a6b-b588-6c60c6a237a3",
            "short": ""
          },
          "mutation_effect_uuid": "ecc7da97-f2c8-4abc-b7f9-02d5aa1b95c6",
          "name": "V197G",
          "name_review": {
            "updateTime": 1674246664879,
            "updatedBy": "User"
          },
          "name_uuid": "4ef34812-6453-452b-8c48-087c1b5b240a",
          "tumors_uuid": "2f045d0b-569a-487d-b4fc-7540c50f2293"
        },
        {
          "mutation_effect": {
            "description": "The TP53 V197M mutation is located in the DNA-binding domain of the protein. This mutation has been identified in colorectal cancer and is a statistically significant hotspot (PMID: 11494027). In vivo studies with yeast expressing TP53 V197M demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 V197M also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1674246696705,
              "updatedBy": "User"
            },
            "description_uuid": "64ea0f45-d038-4bda-9115-8420ad30f8f1",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1674246692183,
              "updatedBy": "User"
            },
            "effect_uuid": "c2e5cb1e-8ff1-4521-b384-0468f08b5a46",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1674246691164,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "7167f4bb-5d19-4f2f-a345-b912fd3f521e",
            "short": ""
          },
          "mutation_effect_uuid": "4bfd58f6-04f0-4202-b77f-363308acdac0",
          "name": "V197M",
          "name_review": {
            "updateTime": 1674246689154,
            "updatedBy": "User"
          },
          "name_uuid": "f601612f-32cb-4759-96e6-637f53d1f27f",
          "tumors_uuid": "79c69edb-d042-4f09-8f0f-f4c843ea709e"
        },
        {
          "mutation_effect": {
            "description": "The TP53 M133R mutation is located in the DNA-binding domain of the protein. This mutation has been identified in adenocarcinoma and is a statistically significant hotspot (PMID: 12637159). In vivo studies with yeast expressing TP53 M133R demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 M133R also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1674246766379,
              "updatedBy": "User"
            },
            "description_uuid": "0d799063-6fa7-402b-afd5-a355105d7894",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1674246762442,
              "updatedBy": "User"
            },
            "effect_uuid": "4cd1b262-00fb-4833-b047-55cb9a712e77",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1674246761312,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "143ee9ac-5399-4bee-b152-c4ed6e3e9717",
            "short": ""
          },
          "mutation_effect_uuid": "6cee7f1e-a708-488a-b2c4-16650617458a",
          "name": "M133R",
          "name_review": {
            "updateTime": 1674246759263,
            "updatedBy": "User"
          },
          "name_uuid": "42540d72-93a0-46d4-85e9-504624945eb7",
          "tumors_uuid": "2d7dbe47-77e5-418f-8c1e-d5af564b44b5"
        },
        {
          "mutation_effect": {
            "description": "The TP53 M133I mutation is located in the DNA-binding domain of the protein. This mutation has been identified in squamous cell carcinoma and is a statistically significant hotspot (PMID: 9627113). In vivo studies with yeast expressing TP53 M133I demonstrated that the mutation is likely neutral as measured by transactivational activity comparable to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 M133I also demonstrated the mutation likely neutral as measured by growth suppression activity comparable to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1674764840839,
              "updatedBy": "User"
            },
            "description_uuid": "eeb32177-6720-467a-8a09-dc8fdd103fad",
            "effect": "Likely Neutral",
            "effect_review": {
              "updateTime": 1674246800660,
              "updatedBy": "User"
            },
            "effect_uuid": "18096315-2f08-4c8b-833e-9f8c72ab487f",
            "oncogenic": "Likely Neutral",
            "oncogenic_review": {
              "updateTime": 1674246799479,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "f70e61ea-8810-4de9-b2a1-06bc2501e9fe",
            "short": ""
          },
          "mutation_effect_uuid": "85539c5b-9f54-494b-a10d-69ba7f47b0b9",
          "name": "M133I",
          "name_review": {
            "updateTime": 1674246797413,
            "updatedBy": "User"
          },
          "name_uuid": "ab98ee4e-0143-4f52-c077-5b97566412e8",
          "tumors_uuid": "4d58cfb4-0640-418f-96f7-364e129fbd72"
        },
        {
          "mutation_effect": {
            "description": "The TP53 P152Q mutation is located in the DNA-binding domain of the protein. This mutation has been identified in hepatocellular carcinoma and is a statistically significant hotspot (PMID: 21567059). In vivo studies with yeast expressing TP53 P152Q demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
            "description_review": {
              "updateTime": 1674246852286,
              "updatedBy": "User"
            },
            "description_uuid": "3f7861d6-f509-4c80-8d60-5cb63185f3c9",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1674246848441,
              "updatedBy": "User"
            },
            "effect_uuid": "d6a45691-d84e-4ffa-825f-eee7cedd1736",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1674246846939,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "1cb002be-7b60-4603-8a2e-0d54e4e3324d",
            "short": ""
          },
          "mutation_effect_uuid": "bd3a684f-2f5e-4fcd-8118-6f5b7873ff7a",
          "name": "P152Q",
          "name_review": {
            "updateTime": 1674246845143,
            "updatedBy": "User"
          },
          "name_uuid": "20b1acb9-153f-4d7a-c0aa-d029e491e863",
          "tumors_uuid": "3ec68961-88ce-4c35-9dba-5ba396063aca"
        },
        {
          "mutation_effect": {
            "description": "The TP53 P152R mutation is located in the DNA-binding domain of the protein. This mutation has been identified in colorectal cancer and is a statistically significant hotspot (PMID: 11044641). In vivo studies with yeast expressing TP53 P152R demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
            "description_review": {
              "updateTime": 1674246881101,
              "updatedBy": "User"
            },
            "description_uuid": "a96b4c1c-b327-4695-ba03-ad50059ddaf9",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1674246877356,
              "updatedBy": "User"
            },
            "effect_uuid": "2c1945a4-4fdd-4cc6-8a60-d5ab1c4c921c",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1674246876358,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "cba6c559-1d91-42e4-a0b4-13897b68c6ef",
            "short": ""
          },
          "mutation_effect_uuid": "a2020832-f15c-4e95-bb4d-b3e3fa8b06a6",
          "name": "P152R",
          "name_review": {
            "updateTime": 1674246873717,
            "updatedBy": "User"
          },
          "name_uuid": "027cb5b4-9958-4676-8fe8-8131b9b0031e",
          "tumors_uuid": "85269bba-b2b1-4d53-ba30-7da66137772e"
        },
        {
          "mutation_effect": {
            "description": "The TP53 P152S mutation is located in the DNA-binding domain of the protein. This mutation has been identified in basal cell carcinoma and is a statistically significant hotspot (PMID: 15656799). In vivo studies with yeast expressing TP53 P152S demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 P152S also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1674246901491,
              "updatedBy": "User"
            },
            "description_uuid": "4406ab6a-7782-424a-b6d3-e6512b7b17d3",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1674246898094,
              "updatedBy": "User"
            },
            "effect_uuid": "e1f8468d-7d2b-4dc2-8828-80151c435c3b",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1674246897414,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "703d1f9b-992c-4cfd-bb89-051f68a30460",
            "short": ""
          },
          "mutation_effect_uuid": "c3816910-0856-42f5-b404-55c0da030452",
          "name": "P152S",
          "name_review": {
            "updateTime": 1674246895351,
            "updatedBy": "User"
          },
          "name_uuid": "b9fd7e81-9af8-4008-a62f-943e0a5dd048",
          "tumors_uuid": "51fba6d8-8389-4cc7-8505-7a415ddde633"
        },
        {
          "mutation_effect": {
            "description": "The TP53 P152T mutation is located in the DNA-binding domain of the protein. This mutation has been identified in glioblastoma and is a statistically significant hotspot (PMID: 11939587). In vivo studies with yeast expressing TP53 P152T demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
            "description_review": {
              "updateTime": 1674246937627,
              "updatedBy": "User"
            },
            "description_uuid": "d5d09d8c-c9b4-4ad0-a565-b86ab2ebc91d",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1674246933683,
              "updatedBy": "User"
            },
            "effect_uuid": "52370fa8-899b-49af-93e1-518ed06250f5",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1674246932307,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "cc308d1e-e5d4-4916-9a29-f235dd0e501d",
            "short": ""
          },
          "mutation_effect_uuid": "822217e4-883f-468d-beea-15fe32950a6a",
          "name": "P152T",
          "name_review": {
            "updateTime": 1674246930159,
            "updatedBy": "User"
          },
          "name_uuid": "0c509403-9cad-4b7a-955d-6b93ca2a4989",
          "tumors_uuid": "949b6e96-d514-4da9-919f-bc8bddf90b56"
        },
        {
          "mutation_effect": {
            "description": "The TP53 P152K mutation is located in the DNA-binding domain of the protein. This mutation has been identified in malignant melanoma and is a statistically significant hotspot (PMID: 28481359). In vitro studies with various human cancer cell lines expressing TP53 P152K demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1674246960441,
              "updatedBy": "User"
            },
            "description_uuid": "f820d43f-5f98-425a-aa12-82253574b03a",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1674246955850,
              "updatedBy": "User"
            },
            "effect_uuid": "741cb3e5-d294-47d1-a15c-74c464dfe9a5",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1674246954927,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "aca2f602-237e-4c78-ab9c-d8cdd7a3aeb7",
            "short": ""
          },
          "mutation_effect_uuid": "6d5e3475-1c10-4d92-ad05-af041fa6ffe7",
          "name": "P152K",
          "name_review": {
            "updateTime": 1674246952640,
            "updatedBy": "User"
          },
          "name_uuid": "f3a3e872-8557-4c31-be7e-bb984585c6cf",
          "tumors_uuid": "8c8118ba-2944-46a9-b5e2-4225ff9e5265"
        },
        {
          "mutation_effect": {
            "description": "The TP53 C141R mutation is located in the DNA-binding domain of the protein. This mutation has been identified in B-cell chronic lymphocytic leukemia and is a statistically significant hotspot (PMID: 12149195). In vivo studies with yeast expressing TP53 C141R demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 C141R also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1674246982571,
              "updatedBy": "User"
            },
            "description_uuid": "8099d8e4-e4ae-46e0-ba6a-42ca41994842",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1674246979105,
              "updatedBy": "User"
            },
            "effect_uuid": "e53397a1-c57c-4ce9-b54c-ae93d7fc9260",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1674246977869,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "64fa6d5d-76c3-4647-aaca-da873bc204c6",
            "short": ""
          },
          "mutation_effect_uuid": "e185854a-d503-4f21-a714-ca6bed78861d",
          "name": "C141R",
          "name_review": {
            "updateTime": 1674246974765,
            "updatedBy": "User"
          },
          "name_uuid": "fed53c85-80c5-4d6d-a4f9-8635d3191292",
          "tumors_uuid": "53d10259-9f2e-4087-be2a-6420ee64c3b5"
        },
        {
          "mutation_effect": {
            "description": "The TP53 C141S mutation is located in the DNA-binding domain of the protein. This mutation has been identified in colorectal cancer and is a statistically significant hotspot (PMID: 15316933). In vivo studies with yeast expressing TP53 C141S demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
            "description_review": {
              "updateTime": 1674247006841,
              "updatedBy": "User"
            },
            "description_uuid": "9ac488b8-1213-4036-8242-de7d2928d6f1",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1674247003803,
              "updatedBy": "User"
            },
            "effect_uuid": "1bd5d093-b333-4443-a5e4-2f5aba67434c",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1674247003037,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "494a2748-93ea-49ea-80b1-4fba8748f256",
            "short": ""
          },
          "mutation_effect_uuid": "9b6275c3-547a-4b2c-b706-60c30be46bf9",
          "name": "C141S",
          "name_review": {
            "updateTime": 1674247000980,
            "updatedBy": "User"
          },
          "name_uuid": "20acfdfa-6ef5-4697-97f7-4c7459e69c66",
          "tumors_uuid": "cdf89905-db75-460d-a4b4-ccce1f95b421"
        },
        {
          "mutation_effect": {
            "description": "The TP53 C141F mutation is located in the DNA-binding domain of the protein. This mutation has been identified in bladder cancer and is a statistically significant hotspot (PMID: 11801555). In vivo studies with yeast expressing TP53 C141F demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
            "description_review": {
              "updateTime": 1674247022380,
              "updatedBy": "User"
            },
            "description_uuid": "82a5f78c-d8da-469b-8723-b80bc6261890",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1674247019489,
              "updatedBy": "User"
            },
            "effect_uuid": "b278bb0c-6f0c-4bd3-ba0a-ed38ea6ec4a4",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1674247018632,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "7e6ff467-0a1a-4519-9c60-b77c6033ffd7",
            "short": ""
          },
          "mutation_effect_uuid": "619e8625-2b29-4c35-9dcd-5c88432582da",
          "name": "C141F",
          "name_review": {
            "updateTime": 1674247014285,
            "updatedBy": "User"
          },
          "name_uuid": "2a1e7331-cbe4-49f3-99c9-473cc28a4650",
          "tumors_uuid": "5be5d218-c778-4d96-b4e4-543e9eff79a8"
        },
        {
          "mutation_effect": {
            "description": "The TP53 C141G mutation is located in the DNA-binding domain of the protein. This mutation has been identified in squamous cell carcinoma and is a statistically significant hotspot (PMID: 15957194). In vivo studies with yeast expressing TP53 C141G demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 C141G also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1674247040646,
              "updatedBy": "User"
            },
            "description_uuid": "2f82ef8f-d2eb-425e-bcb8-337642d86129",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1674247037104,
              "updatedBy": "User"
            },
            "effect_uuid": "c31909bb-405b-4337-b0ce-327676a0496a",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1674247036417,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "146aa4dd-281b-4624-aee9-6d129ce53216",
            "short": ""
          },
          "mutation_effect_uuid": "97968b5f-41b5-41f3-a0dc-73512c4e388a",
          "name": "C141G",
          "name_review": {
            "updateTime": 1674247033668,
            "updatedBy": "User"
          },
          "name_uuid": "ba11f32c-d5c6-4dc7-9a3d-5f5e495e07b8",
          "tumors_uuid": "357f55ee-e996-499f-a5f6-9a10ac00856b"
        },
        {
          "mutation_effect": {
            "description": "The TP53 C275F mutation is located in the DNA-binding domain of the protein. This mutation has been identified in hairy cell leukemia and is a statistically significant hotspot (PMID: 10764158). In vivo studies with yeast expressing TP53 C275F demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 C275F also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1674247134395,
              "updatedBy": "User"
            },
            "description_uuid": "aa191b91-32cf-4388-b727-e7094a4ca469",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1674247123894,
              "updatedBy": "User"
            },
            "effect_uuid": "caa0493c-828d-445a-9631-522d0c15b92c",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1674247123051,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "a6d42bc7-543b-4234-b9ae-9769b0fe9e46",
            "short": ""
          },
          "mutation_effect_uuid": "68d9954e-aac0-4d8d-b9d3-f5a126e8ce56",
          "name": "C275F",
          "name_review": {
            "updateTime": 1674247120619,
            "updatedBy": "User"
          },
          "name_uuid": "a767d31b-729f-40a0-ad8e-78bbcf7ec501",
          "tumors_uuid": "d88e836d-6214-49f7-8961-e93e8ad9e4b4"
        },
        {
          "mutation_effect": {
            "description": "The TP53 C275R mutation is located in the DNA-binding domain of the protein. This mutation has been identified in squamous cell carcinoma and is a statistically significant hotspot (PMID: 10679659). In vivo studies with yeast expressing TP53 C275R demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 C275R also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1674247149478,
              "updatedBy": "User"
            },
            "description_uuid": "feca511a-8d45-4c49-b344-7b2c94093a6c",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1674247141949,
              "updatedBy": "User"
            },
            "effect_uuid": "1429cece-4ec2-4d73-8e1e-fcd4e3ba3dd3",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1674247141140,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "0d95dc0c-f514-41c4-a39e-273455796221",
            "short": ""
          },
          "mutation_effect_uuid": "2fb7ae09-5caf-40de-b7bc-138eff221f4d",
          "name": "C275R",
          "name_review": {
            "updateTime": 1674247139373,
            "updatedBy": "User"
          },
          "name_uuid": "4b9abd14-0781-4d2f-8b10-7dd85d6ef3a7",
          "tumors_uuid": "d4a55677-8207-4a4e-906b-1acc845b711d"
        },
        {
          "mutation_effect": {
            "description": "The TP53 C275W mutation is located in the DNA-binding domain of the protein. This mutation has been identified in colorectal cancer and is a statistically significant hotspot (PMID: 12921629). In vivo studies with yeast expressing TP53 C275W demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 C275W also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1674247172880,
              "updatedBy": "User"
            },
            "description_uuid": "4651ef41-8d8a-461d-b287-4adb6e96c6fd",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1674247164341,
              "updatedBy": "User"
            },
            "effect_uuid": "020e361a-5c50-4f24-af99-c12689f55001",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1674247162977,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "9a74f303-d112-4551-a854-1e51445ea4ed",
            "short": ""
          },
          "mutation_effect_uuid": "f5d90a0b-c615-4dbd-9979-78937daaaef6",
          "name": "C275W",
          "name_review": {
            "updateTime": 1674247160953,
            "updatedBy": "User"
          },
          "name_uuid": "94d6713f-6ca1-4f0a-9e44-1c97c1d79e1d",
          "tumors_uuid": "23efb35c-9e33-43ec-a086-ff6fee5a3ca0"
        },
        {
          "mutation_effect": {
            "description": "The TP53 C275G mutation is located in the DNA-binding domain of the protein. This mutation has been identified in serous cystadenocarcinoma and is a statistically significant hotspot (PMID: 9891239). In vivo studies with yeast expressing TP53 C275G demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
            "description_review": {
              "updateTime": 1674247192144,
              "updatedBy": "User"
            },
            "description_uuid": "19c7172b-a365-468b-834d-5d6dd431c78b",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1674247188670,
              "updatedBy": "User"
            },
            "effect_uuid": "2a5b28b6-82be-4b02-b220-460d72a3cb0e",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1674247187746,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "512c2091-5262-4f70-be4b-97b2b9cb842d",
            "short": ""
          },
          "mutation_effect_uuid": "1fbdde24-3010-4686-b09b-2f2a1547db87",
          "name": "C275G",
          "name_review": {
            "updateTime": 1674247182497,
            "updatedBy": "User"
          },
          "name_uuid": "195546e9-9a63-441a-8fb8-34018b6976d4",
          "tumors_uuid": "206f1ab5-2f60-4508-98f7-101d478b1544"
        },
        {
          "mutation_effect": {
            "description": "The TP53 C275Y mutation is located in the DNA-binding domain of the protein. This mutation has been identified in squamous cell carcinoma and is a statistically significant hotspot (PMID: 8761140). In vivo studies with yeast expressing TP53 C275Y demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 C275Y also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1674247209217,
              "updatedBy": "User"
            },
            "description_uuid": "6d067879-4262-4329-9ea4-d7e57b7c0a98",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1674247206076,
              "updatedBy": "User"
            },
            "effect_uuid": "186215d3-1dde-4066-a52d-0776558f0ff7",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1674247205153,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "e84a610f-87d6-4ab9-866d-0d8e7f17e443",
            "short": ""
          },
          "mutation_effect_uuid": "ea1267a0-0e0b-4407-bf2a-8e8a0eb8eaf7",
          "name": "C275Y",
          "name_review": {
            "updateTime": 1674247199088,
            "updatedBy": "User"
          },
          "name_uuid": "88b9750d-e585-42e8-b3af-92c97f42f54f",
          "tumors_uuid": "28eb4b39-f4aa-4272-ac22-92e5a357db0f"
        },
        {
          "mutation_effect": {
            "description": "The TP53 I251F mutation is located in the DNA-binding domain of the protein. This mutation has been identified in transitional cell carcinoma and is a statistically significant hotspot (PMID: 7777479). In vivo studies with yeast expressing TP53 I251F demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 I251F also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1674509300691,
              "updatedBy": "User"
            },
            "description_uuid": "910c6992-e456-45b6-982b-bce0e15cf4e7",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1674509296893,
              "updatedBy": "User"
            },
            "effect_uuid": "f1cb9c4e-f809-487c-9978-ec1eed0fe453",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1674509294994,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "e1f3bbbd-8b1f-4516-8df9-1ab57311b303",
            "short": ""
          },
          "mutation_effect_uuid": "5faeb8cc-7d95-4844-ad1b-2f32be8c61a9",
          "name": "I251F",
          "name_review": {
            "updateTime": 1674509292345,
            "updatedBy": "User"
          },
          "name_uuid": "d4f75d52-571a-439d-9737-fe35b05131d5",
          "tumors_uuid": "236f0ded-edf0-46ea-8120-6942fd19c6f4"
        },
        {
          "mutation_effect": {
            "description": "The TP53 I251M mutation is located in the DNA-binding domain of the protein. This mutation has been identified in leiomyosarcoma and is a statistically significant hotspot (PMID: 28481359). In vivo studies with yeast expressing TP53 I251M demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
            "description_review": {
              "updateTime": 1674509322617,
              "updatedBy": "User"
            },
            "description_uuid": "61113587-aa5f-4e9b-afae-ae877415f2e1",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1674509319611,
              "updatedBy": "User"
            },
            "effect_uuid": "48cd2bcd-e92a-4e15-8417-6d2af3d0c164",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1674509316626,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "b5d3a5f4-383c-4d67-8d19-a427c2a20990",
            "short": ""
          },
          "mutation_effect_uuid": "5e468841-b1b3-45db-9ed0-49697ebb86a9",
          "name": "I251M",
          "name_review": {
            "updateTime": 1674509314676,
            "updatedBy": "User"
          },
          "name_uuid": "2570d771-9cc7-4ea0-8250-8f67b0d688c2",
          "tumors_uuid": "2c3aa13f-acf0-4c21-883d-07b8376239ff"
        },
        {
          "mutation_effect": {
            "description": "The TP53 I251N mutation is located in the DNA-binding domain of the protein. This mutation has been identified in hepatocellular carcinoma and is a statistically significant hotspot (PMID: 12711820). In vivo studies with yeast expressing TP53 I251N demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 I251N also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1674509357321,
              "updatedBy": "User"
            },
            "description_uuid": "31a91434-9fc3-46ed-9172-d4d13391347e",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1674509353587,
              "updatedBy": "User"
            },
            "effect_uuid": "1a20e487-e83e-4916-a572-a0e7a2da1a37",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1674509351510,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "2f81974c-a1b6-4f33-96be-535cc280c2f7",
            "short": ""
          },
          "mutation_effect_uuid": "1dc1380f-957d-4a1b-b599-5377e843d4f5",
          "name": "I251N",
          "name_review": {
            "updateTime": 1674509348845,
            "updatedBy": "User"
          },
          "name_uuid": "a01f7cf4-13d4-49a6-9571-025ca202a3d5",
          "tumors_uuid": "8a9574f2-6156-4e74-9408-0c9fe4f5396a"
        },
        {
          "mutation_effect": {
            "description": "The TP53 E258A mutation is located in the DNA-binding domain of the protein. This mutation has been identified in glioblastoma and is a statistically significant hotspot (PMID: 16818615). In vivo studies with yeast expressing TP53 E258A demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 E258A also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1674589012070,
              "updatedBy": "User"
            },
            "description_uuid": "030d54ca-8b9d-496b-b9b9-36ddaa91997b",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1674589004111,
              "updatedBy": "User"
            },
            "effect_uuid": "42d17869-d6f0-486d-a62c-f448e4e59313",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1674589003205,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "20e50e28-b8bd-48b0-946d-cae76f115540",
            "short": ""
          },
          "mutation_effect_uuid": "1e238305-f6a1-4198-bf53-ff69e11fa596",
          "name": "E258A",
          "name_review": {
            "updateTime": 1674589000906,
            "updatedBy": "User"
          },
          "name_uuid": "7e73b049-3262-4709-8b89-716311640a73",
          "tumors_uuid": "4dd81e6e-bfff-4bbe-a95f-18f07501a717"
        },
        {
          "mutation_effect": {
            "description": "The TP53 E258Q mutation is located in the DNA-binding domain of the protein. This mutation has been identified in bladder cancer and is a statistically significant hotspot (PMID: 8339293). In vivo studies with yeast expressing TP53 E258Q demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 E258Q also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1674589030319,
              "updatedBy": "User"
            },
            "description_uuid": "c6e4f11f-6caf-4591-b349-f60f60c4b680",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1674589022804,
              "updatedBy": "User"
            },
            "effect_uuid": "7359c7c8-75c1-4d1a-a8d7-9ce4b55b18ce",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1674589021989,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "3e56e426-5c35-4a60-9134-cbcdd72e5b16",
            "short": ""
          },
          "mutation_effect_uuid": "e024192a-c4f9-438d-884e-c41b72b904d2",
          "name": "E258Q",
          "name_review": {
            "updateTime": 1674589019698,
            "updatedBy": "User"
          },
          "name_uuid": "ae87f0c5-6e3f-44c9-ab82-e89bb10b2177",
          "tumors_uuid": "022ce01a-bc89-4d50-90fa-f537ccc6c4fb"
        },
        {
          "mutation_effect": {
            "description": "The TP53 E258D mutation is located in the DNA-binding domain of the protein. This mutation has been identified in colorectal cancer and is a statistically significant hotspot (PMID: 12093899). In vivo studies with yeast expressing TP53 E258D demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 E258D also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1674589054335,
              "updatedBy": "User"
            },
            "description_uuid": "831c5bc9-e89f-434c-bf7b-73ed0d65825a",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1674589047130,
              "updatedBy": "User"
            },
            "effect_uuid": "296911f8-d9bb-4a09-a6bf-08e45bd232a4",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1674589046163,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "e33546e9-be7f-4ad1-a37a-38de7b6ef70c",
            "short": ""
          },
          "mutation_effect_uuid": "1a19e0b9-7fb7-4017-85ec-883ceff28ba0",
          "name": "E258D",
          "name_review": {
            "updateTime": 1674589043949,
            "updatedBy": "User"
          },
          "name_uuid": "274791c3-c44c-40c9-a32c-5e33b25edbb7",
          "tumors_uuid": "755c7085-7f04-453b-850f-67db1b02ab3b"
        },
        {
          "mutation_effect": {
            "description": "The TP53 E258G mutation is located in the DNA-binding domain of the protein. This mutation has been identified in hepatocellular carcinoma and is a statistically significant hotspot (PMID: 11051249). In vivo studies with yeast expressing TP53 E258G demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 E258G also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1674589078065,
              "updatedBy": "User"
            },
            "description_uuid": "9d65ad45-26c8-43f6-a307-04de44137d4e",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1674589071000,
              "updatedBy": "User"
            },
            "effect_uuid": "3a00f49c-c590-4a39-9bef-a89965edb009",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1674589070182,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "93930cca-ffe6-4d51-b585-89c9bf71a4d6",
            "short": ""
          },
          "mutation_effect_uuid": "8642a126-db9f-4cb0-8721-97b77fbd0ae1",
          "name": "E258G",
          "name_review": {
            "updateTime": 1674589067880,
            "updatedBy": "User"
          },
          "name_uuid": "02060614-88c2-453c-9fbf-fe42023efae6",
          "tumors_uuid": "6d409c08-97ea-494f-8f3e-d6647db1027b"
        },
        {
          "mutation_effect": {
            "description": "The TP53 E258K mutation is located in the DNA-binding domain of the protein. This mutation has been identified in malignant lymphoma and is a statistically significant hotspot (PMID: 8878455). In vivo studies with yeast expressing TP53 E258K demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 E258K also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1674589098602,
              "updatedBy": "User"
            },
            "description_uuid": "fdfeb117-1b17-4a31-92ef-bcfeb919eea1",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1674589090685,
              "updatedBy": "User"
            },
            "effect_uuid": "7e5472e2-33d1-437f-b139-fee9e22354b9",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1674589089773,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "dcb95978-8667-45e9-9407-c48d7280d7c1",
            "short": ""
          },
          "mutation_effect_uuid": "ff8ffd4e-db46-4fdd-af5f-27af0bc952e6",
          "name": "E258K",
          "name_review": {
            "updateTime": 1674589087530,
            "updatedBy": "User"
          },
          "name_uuid": "bff1053f-08e2-4573-9887-8984fbbe351b",
          "tumors_uuid": "4785409e-b387-4cc6-a8a4-28534f554a9f"
        },
        {
          "mutation_effect": {
            "description": "The TP53 I255S mutation is located in the DNA-binding domain of the protein. This mutation has been identified in squamous cell carcinoma and is a statistically significant hotspot (PMID: 9736425). In vivo studies with yeast expressing TP53 I255S demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 I255S also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1674589389015,
              "updatedBy": "User"
            },
            "description_uuid": "8ef2db71-650f-4bda-aeff-15a812ff6881",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1674589379644,
              "updatedBy": "User"
            },
            "effect_uuid": "bbbfa8aa-dd87-4456-b62a-c557fcf83401",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1674589378768,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "e732b84e-2160-460b-95f0-c29dcb779fc7",
            "short": ""
          },
          "mutation_effect_uuid": "66f83e71-f11f-40a3-b898-1d270bbe192b",
          "name": "I255S",
          "name_review": {
            "updateTime": 1674589376442,
            "updatedBy": "User"
          },
          "name_uuid": "d7f5cea6-0a2f-4951-9d7f-34f43d4ac9fc",
          "tumors_uuid": "03dc4c60-af89-4dd2-8f8e-e4bcdaa9e5ef"
        },
        {
          "mutation_effect": {
            "description": "The TP53 I255T mutation is located in the DNA-binding domain of the protein. This mutation has been identified in colorectal cancer and is a statistically significant hotspot (PMID: 12118339). In vivo studies with yeast expressing TP53 I255T demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 I255T also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1674589405954,
              "updatedBy": "User"
            },
            "description_uuid": "e9e1a1ce-56d2-49b9-8d60-602dc537dd3c",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1674589399094,
              "updatedBy": "User"
            },
            "effect_uuid": "8a7676f5-a723-4110-92c8-d4e4c25d3dc3",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1674589398213,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "29b9864d-a84a-4a72-97b2-cfeb8fff666b",
            "short": ""
          },
          "mutation_effect_uuid": "5bd6dc5e-49f5-4ca3-bc6c-03a63e73b4b2",
          "name": "I255T",
          "name_review": {
            "updateTime": 1674589395944,
            "updatedBy": "User"
          },
          "name_uuid": "6f42f9c3-fd03-4207-b701-2bde89032e7f",
          "tumors_uuid": "58d19d45-e452-4a40-9dd7-b563a4e1859b"
        },
        {
          "mutation_effect": {
            "description": "The TP53 I255N mutation is located in the DNA-binding domain of the protein. This mutation has been identified in adenocarcinoma and is a statistically significant hotspot (PMID: 8187092). In vivo studies with yeast expressing TP53 I255N demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 I255N also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1674589424061,
              "updatedBy": "User"
            },
            "description_uuid": "0d6b1bee-31aa-4b9b-9b81-b6c051e89ad5",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1674589420288,
              "updatedBy": "User"
            },
            "effect_uuid": "799d989f-3b74-4eac-bf02-eda4058a6bf5",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1674589419350,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "ef1bf2c7-6c3d-4284-8def-f330f174d38c",
            "short": ""
          },
          "mutation_effect_uuid": "adc942b9-e1bf-410f-b5f3-9e12b01bf0f0",
          "name": "I255N",
          "name_review": {
            "updateTime": 1674589414593,
            "updatedBy": "User"
          },
          "name_uuid": "92137b6a-ea46-4808-86c4-74403e084c92",
          "tumors_uuid": "996fcf8e-672c-49e0-b23b-a3e724d49fb7"
        },
        {
          "mutation_effect": {
            "description": "The TP53 I254S mutation is located in the DNA-binding domain of the protein. This mutation has been identified in malignant lymphoma and is a statistically significant hotspot (PMID: 9262496). In vivo studies with yeast expressing TP53 I254S demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 I254S also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1674589443353,
              "updatedBy": "User"
            },
            "description_uuid": "24688ba9-bed1-46d7-aff7-8847cb486330",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1674589436331,
              "updatedBy": "User"
            },
            "effect_uuid": "b354a9e5-9966-4eb6-b59e-d058c820c936",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1674589435499,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "ba4af5ef-67df-4456-91e6-a8497a64aba6",
            "short": ""
          },
          "mutation_effect_uuid": "2d3aed11-aa40-4cba-b68c-185b55c98c85",
          "name": "I254S",
          "name_review": {
            "updateTime": 1674589433264,
            "updatedBy": "User"
          },
          "name_uuid": "7708a224-9a51-4ced-8640-dc8a64673d5b",
          "tumors_uuid": "e5f98d55-6b49-49e7-bfb7-5210ee5e4f79"
        },
        {
          "mutation_effect": {
            "description": "The TP53 I254V mutation is located in the DNA-binding domain of the protein. This mutation has been identified in malignant lymphoma and is a statistically significant hotspot (PMID: 15370252). In vivo studies with yeast expressing TP53 I254V demonstrated that the mutation is likely neutral as measured by transactivational activity comparable to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 I254V also demonstrated the mutation likely neutral as measured by growth suppression activity comparable to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1674765176844,
              "updatedBy": "User"
            },
            "description_uuid": "da25f29c-1943-448a-9e0a-624767315a76",
            "effect": "Likely Neutral",
            "effect_review": {
              "updateTime": 1674589460611,
              "updatedBy": "User"
            },
            "effect_uuid": "42087c14-2ab6-4db9-a9dc-35d7e881d66e",
            "oncogenic": "Likely Neutral",
            "oncogenic_review": {
              "updateTime": 1674589459904,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "7d748519-325f-4637-91ec-91fc3685803a",
            "short": ""
          },
          "mutation_effect_uuid": "6e252b21-3678-4e33-9377-7a0ebd81ef65",
          "name": "I254V",
          "name_review": {
            "updateTime": 1674589457272,
            "updatedBy": "User"
          },
          "name_uuid": "189c3fe8-2a34-4c49-a794-ca8c8eecc89a",
          "tumors_uuid": "3df0b564-2f9e-45ee-9466-2aeb6b4fa943"
        },
        {
          "mutation_effect": {
            "description": "The TP53 I254F mutation is located in the DNA-binding domain of the protein. This mutation has been identified in non-small cell lung cancer and is a statistically significant hotspot (PMID: 17557246). In vivo studies with yeast expressing TP53 I254F demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
            "description_review": {
              "updateTime": 1674589493618,
              "updatedBy": "User"
            },
            "description_uuid": "b9e3ea07-2785-4fca-9bd1-7623adac5f85",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1674589485383,
              "updatedBy": "User"
            },
            "effect_uuid": "ca5454d7-7726-417b-9e7e-23e3266dbdc9",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1674589484333,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "a69be9b5-0059-4284-97f5-b438c57aa6dd",
            "short": ""
          },
          "mutation_effect_uuid": "e5cea44b-7a5b-4e5d-a39a-c644ff41c776",
          "name": "I254F",
          "name_review": {
            "updateTime": 1674589481948,
            "updatedBy": "User"
          },
          "name_uuid": "d1f05cac-972e-4564-a526-f34e63e43f1d",
          "tumors_uuid": "4e2198eb-7f92-46d2-9903-0da82c2ac368"
        },
        {
          "mutation_effect": {
            "description": "The TP53 I254L mutation is located in the DNA-binding domain of the protein. This mutation has been identified in malignant fibrous histiocytoma and is a statistically significant hotspot (PMID: 9645763). In vivo studies with yeast expressing TP53 I254L demonstrated that the mutation is likely neutral as measured by transactivational activity comparable to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 I254L also demonstrated the mutation likely neutral as measured by growth suppression activity comparable to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1674765221639,
              "updatedBy": "User"
            },
            "description_uuid": "1805d174-64d6-4b43-bbae-f6ffead49774",
            "effect": "Likely Neutral",
            "effect_review": {
              "updateTime": 1674589504816,
              "updatedBy": "User"
            },
            "effect_uuid": "d5656eb9-237f-4f99-a34e-4c77fb946894",
            "oncogenic": "Likely Neutral",
            "oncogenic_review": {
              "updateTime": 1674589504169,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "64395ac8-49d5-42f7-91f6-3193ee178584",
            "short": ""
          },
          "mutation_effect_uuid": "060fdab7-6142-41bb-b653-ce1efdbafe3e",
          "name": "I254L",
          "name_review": {
            "updateTime": 1674589502048,
            "updatedBy": "User"
          },
          "name_uuid": "860adc76-e31d-4ff1-8dbc-6659186ae7f4",
          "tumors_uuid": "27b5ec3f-59a3-4249-a2d9-c587f4d4be41"
        },
        {
          "mutation_effect": {
            "description": "The TP53 I254M mutation is located in the DNA-binding domain of the protein. This mutation has been identified in B-cell chronic lymphocytic leukemia and is a statistically significant hotspot (PMID: 18980985). In vivo studies with yeast expressing TP53 I254M demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
            "description_review": {
              "updateTime": 1674589533588,
              "updatedBy": "User"
            },
            "description_uuid": "7372f3bd-9330-4f75-884b-7f6a82d34b2f",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1674589526996,
              "updatedBy": "User"
            },
            "effect_uuid": "efeecb2d-1352-4480-bce7-44d3ba484bf0",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1674589525598,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "66d97394-5062-4abb-9069-bffe31aafb77",
            "short": ""
          },
          "mutation_effect_uuid": "42255c6c-9a7b-4e1f-9f3d-0f06a9b917f0",
          "name": "I254M",
          "name_review": {
            "updateTime": 1674589522782,
            "updatedBy": "User"
          },
          "name_uuid": "1c2b4216-6f68-4d1c-8c3d-84864aec909c",
          "tumors_uuid": "58b4d3e3-a72b-4ae4-8dd0-d1d8290d9b2c"
        },
        {
          "mutation_effect": {
            "description": "The TP53 I254N mutation is located in the DNA-binding domain of the protein. This mutation has been identified in Burkitt lymphoma and is a statistically significant hotspot (PMID: 9172810). In vivo studies with yeast expressing TP53 I254N demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 I254N also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1674589563232,
              "updatedBy": "User"
            },
            "description_uuid": "c2068fe4-07b1-4980-9c4c-e5027dc0dee9",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1674589555912,
              "updatedBy": "User"
            },
            "effect_uuid": "39ec4068-10b3-476f-b957-b874221f2a1e",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1674589554619,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "45276fc1-c8ff-4a5c-9dd0-0edf00c048dc",
            "short": ""
          },
          "mutation_effect_uuid": "24f2c26e-23f8-44c7-b834-799e340d259d",
          "name": "I254N",
          "name_review": {
            "updateTime": 1674589551334,
            "updatedBy": "User"
          },
          "name_uuid": "1fc434d4-5e08-4807-bb69-b4348467a84a",
          "tumors_uuid": "c378f2d6-d0a0-44fa-975f-ae03246872ca"
        },
        {
          "mutation_effect": {
            "description": "The TP53 V272G mutation is located in the DNA-binding domain of the protein. This mutation has been identified in bladder cancer and is a statistically significant hotspot (PMID: 10355250). In vivo studies with yeast expressing TP53 V272G demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 V272G also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1674590201559,
              "updatedBy": "User"
            },
            "description_uuid": "5d37db20-11a6-44fc-8fa8-2e90cc0fd7d2",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1674590194788,
              "updatedBy": "User"
            },
            "effect_uuid": "e5510754-9209-4205-baca-0946b6eba1fc",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1674590193299,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "bfb839e4-b32d-4321-8182-fd3aac6d601a",
            "short": ""
          },
          "mutation_effect_uuid": "b4dbf355-c681-45c3-8197-9f7865fe4081",
          "name": "V272G",
          "name_review": {
            "updateTime": 1674590191380,
            "updatedBy": "User"
          },
          "name_uuid": "d2401013-3d34-40a4-a9c3-c792a28e5480",
          "tumors_uuid": "df99ffae-1037-4f55-849d-d3b8b797a1a6"
        },
        {
          "mutation_effect": {
            "description": "The TP53 R337S mutation is located in the tetramerization motif of the protein. This mutation has been identified in biliary tract cancer and is a statistically significant hotspot (PMID: 29360550). In vivo studies with yeast expressing TP53 R337S demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
            "description_review": {
              "updateTime": 1674591282996,
              "updatedBy": "User"
            },
            "description_uuid": "9512add5-b258-46d6-a108-0741834c21c0",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1674591269973,
              "updatedBy": "User"
            },
            "effect_uuid": "c0d6f6d4-1951-4031-a46c-02c8df64edc0",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1674591267888,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "38143c1e-3a9c-48f3-b1a9-e65d13277113",
            "short": ""
          },
          "mutation_effect_uuid": "58ccd0a5-ae2d-4521-9073-144673fe68fe",
          "name": "R337S",
          "name_review": {
            "updateTime": 1674591265296,
            "updatedBy": "User"
          },
          "name_uuid": "8756a91e-d16e-4ee9-952c-9f352a7d736b",
          "tumors_uuid": "a3d448f1-c724-45f2-ade0-2cbb0949ea24"
        },
        {
          "mutation_effect": {
            "description": "The TP53 V272A mutation is located in the DNA-binding domain of the protein. This mutation has been identified in pancreatic cancer and is a statistically significant hotspot (PMID: 1630814). In vivo studies with yeast expressing TP53 V272A demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
            "description_review": {
              "updateTime": 1674591797501,
              "updatedBy": "User"
            },
            "description_uuid": "2c4ea931-f0e5-4083-a60a-243825f07e85",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1674591792819,
              "updatedBy": "User"
            },
            "effect_uuid": "72a188d1-fb9d-4dff-8ac1-8a318f873aeb",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1674591791732,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "06e146bc-daac-41d5-a743-c9ad74de9f05",
            "short": ""
          },
          "mutation_effect_uuid": "afc32a38-cd9d-4bf2-9cca-0f642d7f1588",
          "name": "V272A",
          "name_review": {
            "updateTime": 1674591790019,
            "updatedBy": "User"
          },
          "name_uuid": "5276a3fd-ba48-4d32-8271-e5bfefaea463",
          "tumors_uuid": "8fba086a-f19b-4fc2-804e-3aa510b45006"
        },
        {
          "mutation_effect": {
            "description": "The TP53 V272E mutation is located in the DNA-binding domain of the protein. This mutation has been identified in diffuse large B-cell lymphoma and is a statistically significant hotspot (PMID: 17881637). In vivo studies with yeast expressing TP53 V272E demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 V272E also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1674591816302,
              "updatedBy": "User"
            },
            "description_uuid": "1490d821-ad32-4f02-b44b-2251b2ef70a7",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1674591812316,
              "updatedBy": "User"
            },
            "effect_uuid": "15eccbf2-5330-4665-907f-c76730dcddfe",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1674591811300,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "710f3ab3-5dbc-4bda-89a4-583aed3e0f19",
            "short": ""
          },
          "mutation_effect_uuid": "445ae15b-26c7-4ad8-83f8-6da8693e92af",
          "name": "V272E",
          "name_review": {
            "updateTime": 1674591809143,
            "updatedBy": "User"
          },
          "name_uuid": "e89f3522-f425-4a33-a48e-de837db25875",
          "tumors_uuid": "faf29e67-6044-444e-b407-318af6689a87"
        },
        {
          "mutation_effect": {
            "description": "The TP53 V272K mutation is located in the DNA-binding domain of the protein. This mutation has been identified in lung adenocarcinoma and is a statistically significant hotspot (PMID: 22980975). In vitro studies with various human cancer cell lines expressing TP53 V272K demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1674591834093,
              "updatedBy": "User"
            },
            "description_uuid": "8c0c29e4-09bd-4c6f-a964-e9581cc65cda",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1674591829949,
              "updatedBy": "User"
            },
            "effect_uuid": "b90f144d-9b18-43a3-bc2d-51844b17e4f8",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1674591828896,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "1434c6ab-4456-43ec-bf1c-c93c95a0dfdb",
            "short": ""
          },
          "mutation_effect_uuid": "395a4346-e5b9-4ad8-8e03-168d74d12473",
          "name": "V272K",
          "name_review": {
            "updateTime": 1674591823867,
            "updatedBy": "User"
          },
          "name_uuid": "b1beeab3-95a9-4452-acad-0d279321d6a7",
          "tumors_uuid": "d1a6da29-08fd-4511-853e-4a1298578227"
        },
        {
          "mutation_effect": {
            "description": "The TP53 R267W mutation is located in the DNA-binding domain of the protein. This mutation has been identified in colorectal cancer and is a statistically significant hotspot (PMID: 17881637). In vivo studies with yeast expressing TP53 R267W demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 R267W also demonstrated the mutation is inactivating as measured by moderately reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1674591958653,
              "updatedBy": "User"
            },
            "description_uuid": "b9a25483-9c22-44c7-948d-f23285f7e365",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1674591954849,
              "updatedBy": "User"
            },
            "effect_uuid": "046003c6-7fc7-40c9-88f6-38b5b02c7294",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1674591953735,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "c7ebf3fa-4b02-474b-8add-b740d4008952",
            "short": ""
          },
          "mutation_effect_uuid": "8b13e6de-af98-4c6a-b3c1-1efe33d6a3e2",
          "name": "R267W",
          "name_review": {
            "updateTime": 1674591951473,
            "updatedBy": "User"
          },
          "name_uuid": "ce25b00b-044d-4807-bb1d-f458b3dd079c",
          "tumors_uuid": "8dfab4b9-2e00-461a-9486-9b93257b78a0"
        },
        {
          "mutation_effect": {
            "description": "The TP53 R267L mutation is located in the DNA-binding domain of the protein. This mutation has been identified in precursor cell lymphoblastic leukemia and is a statistically significant hotspot (PMID: 16844765). In vivo studies with yeast expressing TP53 R267L demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
            "description_review": {
              "updateTime": 1674591974395,
              "updatedBy": "User"
            },
            "description_uuid": "e37340c4-e8c8-4571-8a63-dac2c7c8572d",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1674591973099,
              "updatedBy": "User"
            },
            "effect_uuid": "3f0056f9-3dd1-43bb-aea8-98fb06612804",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1674591972345,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "df42cc7f-2f89-48eb-9ff6-d47fe5c48a8f",
            "short": ""
          },
          "mutation_effect_uuid": "2f4a93d5-99e3-4707-86c2-36cd1e683fcc",
          "name": "R267L",
          "name_review": {
            "updateTime": 1674591967098,
            "updatedBy": "User"
          },
          "name_uuid": "e109bbdf-458b-4c9f-af34-b4cc550a5aee",
          "tumors_uuid": "20a6e8e0-cb73-4d9d-a66a-2b96d5675a53"
        },
        {
          "mutation_effect": {
            "description": "The TP53 V157A mutation is located in the DNA-binding domain of the protein. This mutation has been identified in cutaneous T-cell lymphoma and is a statistically significant hotspot (PMID: 10551408). In vivo studies with yeast expressing TP53 V157A demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 V157A also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1674677211247,
              "updatedBy": "User"
            },
            "description_uuid": "890cbf03-2f9d-4408-b254-5e6b024b424d",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1674677207994,
              "updatedBy": "User"
            },
            "effect_uuid": "ece7f7bb-a624-4ce5-8da4-5896943b4160",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1674677206742,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "c5ab1822-d072-4cec-a088-5b0edaa169c9",
            "short": ""
          },
          "mutation_effect_uuid": "15ac3a86-e68b-44c1-b483-be666b2dbf7f",
          "name": "V157A",
          "name_review": {
            "updateTime": 1674677204622,
            "updatedBy": "User"
          },
          "name_uuid": "f0d159d7-410b-48ef-bcad-6d0cae193972",
          "tumors_uuid": "2d9c547f-9722-4806-8771-0bd5941d521e"
        },
        {
          "mutation_effect": {
            "description": "The TP53 V157G mutation is located in the DNA-binding domain of the protein. This mutation has been identified in ovarian cancer and is a statistically significant hotspot (PMID: 7852189). In vivo studies with yeast expressing TP53 V157G demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 V157G also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1674677230038,
              "updatedBy": "User"
            },
            "description_uuid": "70d01cd1-d41a-4c82-9c0c-4f00a7c57c7d",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1674677226233,
              "updatedBy": "User"
            },
            "effect_uuid": "31d7862d-729c-4c70-ae52-5add10a422d2",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1674677225501,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "6e0da137-96f3-4804-b72f-ab00632c74bc",
            "short": ""
          },
          "mutation_effect_uuid": "b3f3e8c8-a764-4958-8258-bef56bd530ff",
          "name": "V157G",
          "name_review": {
            "updateTime": 1674677223400,
            "updatedBy": "User"
          },
          "name_uuid": "3ead5eca-19ad-47bc-8f05-ac84d64daab3",
          "tumors_uuid": "141d760b-6f1c-4353-a81b-b1e45a186169"
        },
        {
          "mutation_effect": {
            "description": "The TP53 V157L mutation is located in the DNA-binding domain of the protein. This mutation has been identified in colorectal cancer and is a statistically significant hotspot (PMID: 7694948). In vivo studies with yeast expressing TP53 V157L demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 V157L also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1674677250788,
              "updatedBy": "User"
            },
            "description_uuid": "b7caf6e5-7599-4eed-ab9e-7502fb4149ec",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1674677247241,
              "updatedBy": "User"
            },
            "effect_uuid": "d0b12068-c8cc-4d99-87e9-fc54ce42eee6",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1674677246395,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "f97a845e-2be1-4d51-bb72-02153855edbe",
            "short": ""
          },
          "mutation_effect_uuid": "a0302270-02f1-4e30-afaf-bbd73dd052f2",
          "name": "V157L",
          "name_review": {
            "updateTime": 1674677244537,
            "updatedBy": "User"
          },
          "name_uuid": "040fafbb-830f-438e-be35-52cb215690a4",
          "tumors_uuid": "0e212285-9395-419d-b374-65e1cb3a8f4a"
        },
        {
          "mutation_effect": {
            "description": "The TP53 R110C mutation is located in the DNA-binding domain of the protein. This mutation has been identified in rectal cancer and is a statistically significant hotspot (PMID: 10884918). In vivo studies with yeast expressing TP53 R110C demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
            "description_review": {
              "updateTime": 1674677276428,
              "updatedBy": "User"
            },
            "description_uuid": "6526fb8f-1300-4580-b43e-f3c9df73e348",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1674677274854,
              "updatedBy": "User"
            },
            "effect_uuid": "9cd1932e-06c7-4386-8a8f-935b4c43394b",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1674677274088,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "2ac95d22-081e-44a1-932b-c498b3d1f357",
            "short": ""
          },
          "mutation_effect_uuid": "3733df72-3153-44dc-932c-8340ccbcb8a9",
          "name": "R110C",
          "name_review": {
            "updateTime": 1674677270074,
            "updatedBy": "User"
          },
          "name_uuid": "abb815c5-d732-491b-aeb6-34a8a3d01bc7",
          "tumors_uuid": "af05f43d-f794-451d-b005-fc356179709f"
        },
        {
          "mutation_effect": {
            "description": "The TP53 R110H mutation is located in the DNA-binding domain of the protein. This mutation has been identified in bladder cancer and is a statistically significant hotspot (PMID: 14612556). In vivo studies with yeast expressing TP53 R110H demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
            "description_review": {
              "updateTime": 1674677296283,
              "updatedBy": "User"
            },
            "description_uuid": "1ae3e165-b226-45b3-9e9f-eed4edd5c72f",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1674677295061,
              "updatedBy": "User"
            },
            "effect_uuid": "f3680fd7-29f9-4f01-b2ea-1bbcaccb0849",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1674677294315,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "1f078e45-d318-4515-8697-31a44a637053",
            "short": ""
          },
          "mutation_effect_uuid": "f174b752-863e-4bf7-9288-0aa013b49dc7",
          "name": "R110H",
          "name_review": {
            "updateTime": 1674677289931,
            "updatedBy": "User"
          },
          "name_uuid": "5436ea5c-011e-4422-9946-f95671341371",
          "tumors_uuid": "44fd0a01-a636-4f3c-a2d3-bf066f14b873"
        },
        {
          "mutation_effect": {
            "description": "The TP53 R249T mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and is a statistically significant hotspot (PMID: 14697642). In vivo studies with yeast expressing TP53 R249T demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 R249T also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675286424363,
              "updatedBy": "User"
            },
            "description_uuid": "e6b40a53-d0ae-4210-beaf-672267b29663",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675286418777,
              "updatedBy": "User"
            },
            "effect_uuid": "245b550b-772b-4077-99e6-949d96ea7b6c",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675286417641,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "b89aeac5-a0ee-4a31-8032-d3fa3ed45165",
            "short": ""
          },
          "mutation_effect_uuid": "c468547b-4987-448b-8311-988a9285b3a8",
          "name": "R249T",
          "name_review": {
            "updateTime": 1675286415850,
            "updatedBy": "User"
          },
          "name_uuid": "34992ea6-6b5d-4147-96b7-ad4e5de15ecb",
          "tumors_uuid": "4dc4af3f-2d3d-4018-a362-be130042b774"
        },
        {
          "mutation_effect": {
            "description": "The TP53 R249G mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and is a statistically significant hotspot (PMID: 8673929). In vivo studies with yeast expressing TP53 R249G demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 R249G also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675286457819,
              "updatedBy": "User"
            },
            "description_uuid": "26d74193-5cc1-4461-afb5-6cea95c5ed2c",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675286453178,
              "updatedBy": "User"
            },
            "effect_uuid": "32294a96-2e1d-4cfd-a31b-b29257426666",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675286451656,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "388e5e69-f4bb-4767-a922-6e77c5dbcfc8",
            "short": ""
          },
          "mutation_effect_uuid": "77bed699-44b2-4d70-be82-9263644b8174",
          "name": "R249G",
          "name_review": {
            "updateTime": 1675286447428,
            "updatedBy": "User"
          },
          "name_uuid": "45b98cc1-de82-4926-a23f-b42a6e3feb80",
          "tumors_uuid": "e7548eff-dac6-4fdb-b0a3-b934008e5030"
        },
        {
          "mutation_effect": {
            "description": "The TP53 R249I mutation is located in the DNA-binding domain of the protein. This mutation has been identified in small cell lung cancer and is a statistically significant hotspot (PMID: 10551408). In vitro studies with various human cancer cell lines expressing TP53 R249I demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675286486930,
              "updatedBy": "User"
            },
            "description_uuid": "8a106ffc-77e4-48df-af76-54c40de8ed7c",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675286482901,
              "updatedBy": "User"
            },
            "effect_uuid": "4279dbe0-3c2c-4b9f-b12e-d3c929007326",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675286481951,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "4fbf575b-521d-4e15-9acd-bd3d03d9f1d5",
            "short": ""
          },
          "mutation_effect_uuid": "4422ba4f-af43-473d-9118-de14d9e8749d",
          "name": "R249I",
          "name_review": {
            "updateTime": 1675286479819,
            "updatedBy": "User"
          },
          "name_uuid": "a6a2063b-afce-46a0-9bec-c6ed49350f52",
          "tumors_uuid": "bfe9100d-cfad-46b1-ab58-ca3e944258d6"
        },
        {
          "mutation_effect": {
            "description": "The TP53 R249K mutation is located in the DNA-binding domain of the protein. This mutation has been identified in colorectal cancer and is a statistically significant hotspot (PMID: 11737306). In vivo studies with yeast expressing TP53 R249K demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
            "description_review": {
              "updateTime": 1675286521518,
              "updatedBy": "User"
            },
            "description_uuid": "38a0dc68-c779-43f4-8a85-215f9573fcfc",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675286517444,
              "updatedBy": "User"
            },
            "effect_uuid": "0a6c8ee3-d351-4de9-8d22-6f879932f9b9",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675286516397,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "dbff5f06-2c96-4789-9b8b-ab997429521b",
            "short": ""
          },
          "mutation_effect_uuid": "12622ace-b86c-40a4-b9cc-825b15fb66bc",
          "name": "R249K",
          "name_review": {
            "updateTime": 1675286511789,
            "updatedBy": "User"
          },
          "name_uuid": "5329a390-0db2-4c86-9e1e-6d5b0d67592e",
          "tumors_uuid": "a61ee8e7-f03e-4282-a445-697c3d191a90"
        },
        {
          "mutation_effect": {
            "description": "The TP53 R337G mutation is located in the tetramerization motif of the protein and is a statistically significant hotspot. In vivo studies with yeast expressing TP53 R337G demonstrated that the mutation is likely neutral as measured by wildtype comparable transactivational activity (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 R337G also demonstrated the mutation likely neutral as measured by wildtype comparable growth suppression activity (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675286568948,
              "updatedBy": "User"
            },
            "description_uuid": "e829c758-286b-43cb-afa3-b35097b5fa20",
            "effect": "Likely Neutral",
            "effect_review": {
              "updateTime": 1675286561051,
              "updatedBy": "User"
            },
            "effect_uuid": "082ac28d-d3d3-48ee-867d-ea14ea7e7761",
            "oncogenic": "Likely Neutral",
            "oncogenic_review": {
              "updateTime": 1675286559522,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "8fa3286a-1b6c-4df7-9257-8234b32d8969",
            "short": ""
          },
          "mutation_effect_uuid": "4ea06746-8d26-4101-9790-56ba8ff3a1f5",
          "name": "R337G",
          "name_review": {
            "updateTime": 1675286557195,
            "updatedBy": "User"
          },
          "name_uuid": "dc6cbc83-bca4-4681-a9ac-0052eeb6fc5a",
          "tumors_uuid": "10005cf3-8821-477e-a06f-5888688d5bd9"
        },
        {
          "mutation_effect": {
            "description": "The TP53 A161P mutation is located in the DNA-binding domain of the protein. This mutation has been identified in prolymphocytic leukemia and is a statistically significant hotspot (PMID: 9058723). In vivo studies with yeast expressing TP53 A161P demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
            "description_review": {
              "updateTime": 1675287319291,
              "updatedBy": "User"
            },
            "description_uuid": "5c49a953-b07a-4049-a2d9-7b518f4f0fb1",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675287315297,
              "updatedBy": "User"
            },
            "effect_uuid": "4bd6ffda-0b3c-4d4b-a29a-709c216ea6cc",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675287313851,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "ca5291da-1dda-408f-8529-8eba0a1c290a",
            "short": ""
          },
          "mutation_effect_uuid": "9588dba8-b50c-4302-bb0c-2e775fc741cf",
          "name": "A161P",
          "name_review": {
            "updateTime": 1675287312206,
            "updatedBy": "User"
          },
          "name_uuid": "629b6f4f-bf04-46ff-8a92-2c8e42841659",
          "tumors_uuid": "b43d29cb-92c4-4c7c-a1d7-ed5d086cd9ba"
        },
        {
          "mutation_effect": {
            "description": "The TP53 A161D mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and is a statistically significant hotspot (PMID: 8522300). In vivo studies with yeast expressing TP53 A161D demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
            "description_review": {
              "updateTime": 1675287343811,
              "updatedBy": "User"
            },
            "description_uuid": "f4672dee-f7c5-4c97-b8fe-d303f4df62f9",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675287338161,
              "updatedBy": "User"
            },
            "effect_uuid": "f9f94d08-f6f3-4c8c-97be-692eda9ae9c7",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675287337275,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "aedf58d8-9ef0-49bb-9474-8c5abd9e20ea",
            "short": ""
          },
          "mutation_effect_uuid": "9ff9433f-2e4a-4428-b3a1-92dc57e12a19",
          "name": "A161D",
          "name_review": {
            "updateTime": 1675287335221,
            "updatedBy": "User"
          },
          "name_uuid": "e6c88a54-4fc8-45de-bc50-bd9e1fd1eeef",
          "tumors_uuid": "61e82959-7feb-40ae-aa12-2ccd31a1583f"
        },
        {
          "mutation_effect": {
            "description": "The TP53 A161V mutation is located in the DNA-binding domain of the protein. This mutation has been identified in Burkitt lymphoma and is a statistically significant hotspot (PMID: 12890146). In vivo studies with yeast expressing TP53 A161V demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
            "description_review": {
              "updateTime": 1675287362677,
              "updatedBy": "User"
            },
            "description_uuid": "af1f03bd-0a54-4622-9bf3-0550e54b8386",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675287361523,
              "updatedBy": "User"
            },
            "effect_uuid": "e20b4445-4b9b-49e3-9c76-569dc9c94a9e",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675287360760,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "c5b6fb1d-3044-4a97-9efe-7652edb12c99",
            "short": ""
          },
          "mutation_effect_uuid": "1e4c631c-9911-4821-8823-15c500626e9e",
          "name": "A161V",
          "name_review": {
            "updateTime": 1675287356777,
            "updatedBy": "User"
          },
          "name_uuid": "6c84f70e-93bc-4d5b-8005-a84238efb2f3",
          "tumors_uuid": "eb8d6400-88c0-4111-82e3-bc806cb74bac"
        },
        {
          "mutation_effect": {
            "description": "The TP53 R267G mutation is located in the DNA-binding domain of the protein. This mutation has been identified in bladder cancer and is a statistically significant hotspot (PMID: 7869472). In vivo studies with yeast expressing TP53 R267G demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 R267G also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675287652643,
              "updatedBy": "User"
            },
            "description_uuid": "1dfb40bf-0a12-4fea-8606-f6201bf5e839",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675287650119,
              "updatedBy": "User"
            },
            "effect_uuid": "d5c82ebf-3558-4fbb-956e-cb38a26f059b",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675287648659,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "50eaef1b-1fdc-4406-af22-e0bb9ab84efa",
            "short": ""
          },
          "mutation_effect_uuid": "48652ba3-7526-43b0-80ea-6dc81b64d043",
          "name": "R267G",
          "name_review": {
            "updateTime": 1675287638611,
            "updatedBy": "User"
          },
          "name_uuid": "ea4ea7a7-e183-4f5a-a3ec-30717b75b146",
          "tumors_uuid": "53d688a7-f334-4a07-960b-bf6d29b451fa"
        },
        {
          "mutation_effect": {
            "description": "The TP53 Y220D mutation is located in the DNA-binding domain of the protein. This mutation has been identified in esophageal squamous cell carcinoma and is a statistically significant hotspot (PMID: 9617346). In vivo studies with yeast expressing TP53 Y220D demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 Y220D also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675287673125,
              "updatedBy": "User"
            },
            "description_uuid": "72e2a1a6-0a04-4e84-b497-c5b2640bf864",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675287668996,
              "updatedBy": "User"
            },
            "effect_uuid": "9767cfd5-551e-4b61-8c2e-fff057f3f72f",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675287668222,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "0203e349-1d23-456d-bc5e-822a3fccc8a6",
            "short": ""
          },
          "mutation_effect_uuid": "268072e6-a395-4d14-8925-6e79c1c89880",
          "name": "Y220D",
          "name_review": {
            "updateTime": 1675287665106,
            "updatedBy": "User"
          },
          "name_uuid": "79f532c1-4c41-4dc4-9c90-f11f15dfb7d4",
          "tumors_uuid": "924a13f6-ef1a-499e-bc1d-7487c92eb326"
        },
        {
          "mutation_effect": {
            "description": "The TP53 Y220H mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and is a statistically significant hotspot (PMID: 17683074). In vivo studies with yeast expressing TP53 Y220H demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 Y220H also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675287689583,
              "updatedBy": "User"
            },
            "description_uuid": "9b4f9382-6220-48c7-a551-3e78dedb7c5f",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675287686652,
              "updatedBy": "User"
            },
            "effect_uuid": "5e237df7-8b5e-4697-ab51-bc2db9ea3b8d",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675287685038,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "02a04796-5a29-4073-8908-b0de455d4c18",
            "short": ""
          },
          "mutation_effect_uuid": "026abe8f-b47c-4c32-ba3a-e12cedec03b2",
          "name": "Y220H",
          "name_review": {
            "updateTime": 1675287682656,
            "updatedBy": "User"
          },
          "name_uuid": "257042eb-324a-47dc-bd11-c7cac39c3276",
          "tumors_uuid": "c8f55b3d-297a-4b8e-b5dd-293ef346fae2"
        },
        {
          "mutation_effect": {
            "description": "The TP53 Y220N mutation is located in the DNA-binding domain of the protein. This mutation has been identified in hepatocellular carcinoma and is a statistically significant hotspot (PMID: 11375957). In vivo studies with yeast expressing TP53 Y220N demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 Y220N also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675287706840,
              "updatedBy": "User"
            },
            "description_uuid": "41fd3514-4a0f-4f15-b892-224b73e93dc1",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675287705523,
              "updatedBy": "User"
            },
            "effect_uuid": "0d3ca595-7b31-4e46-9c9a-2e073439e79c",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675287704823,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "2218463b-3ccc-4ad6-b4a2-ea3dcb567fa0",
            "short": ""
          },
          "mutation_effect_uuid": "87212ad6-5e3f-4fb4-a35a-ecd9d88d6c5b",
          "name": "Y220N",
          "name_review": {
            "updateTime": 1675287699725,
            "updatedBy": "User"
          },
          "name_uuid": "d91cf67a-f564-42eb-a082-8b9f6d3464db",
          "tumors_uuid": "1725d734-2000-4fe8-a819-6b9c9fc9c763"
        },
        {
          "mutation_effect": {
            "description": "The TP53 F134C mutation is located in the DNA-binding domain of the protein. This mutation has been identified in bladder cancer and is a statistically significant hotspot (PMID: 9014203). In vivo studies with yeast expressing TP53 F134C demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 F134C also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_editing": "",
            "description_review": {
              "updateTime": 1675287725424,
              "updatedBy": "User"
            },
            "description_uuid": "6718a97d-8832-4fad-8f85-f2bd781f3faf",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675287723625,
              "updatedBy": "User"
            },
            "effect_uuid": "084c437e-b0de-46fa-9312-9a9b90caea0f",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675287722897,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "6e84e1ec-8946-454e-a1fb-7f10321c38d8",
            "short": ""
          },
          "mutation_effect_uuid": "ea691bf1-7da0-473d-a589-4a2caea5ced0",
          "name": "F134C",
          "name_review": {
            "updateTime": 1675287719075,
            "updatedBy": "User"
          },
          "name_uuid": "35491c44-2758-4f99-abdc-0fe1a52b9cf2",
          "tumors_uuid": "81a1c8e2-85e2-4c53-837f-568ecfd4dc26"
        },
        {
          "mutation_effect": {
            "description": "The TP53 R273P mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and is a statistically significant hotspot (PMID: 1734086). In vivo studies with yeast expressing TP53 R273P demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 R273P also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675287761451,
              "updatedBy": "User"
            },
            "description_uuid": "727d5052-cbf9-44a8-aeb3-193d1412f32a",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675287760220,
              "updatedBy": "User"
            },
            "effect_uuid": "1cdfd7c2-7257-46ed-a235-5c41c1bae05d",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675287759494,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "b278cb0c-0b35-447d-95bc-f5d0820ee770",
            "short": ""
          },
          "mutation_effect_uuid": "0dd7be89-8520-4165-a785-c24de0a13b4e",
          "name": "R273P",
          "name_review": {
            "updateTime": 1675287755747,
            "updatedBy": "User"
          },
          "name_uuid": "e003b29a-d6a7-412e-9045-4f029e253e3e",
          "tumors_uuid": "d4676d29-10db-437f-a6dd-dea73fa2275a"
        },
        {
          "mutation_effect": {
            "description": "The TP53 R273S mutation is located in the DNA-binding domain of the protein. This mutation has been identified in lung cancer and is a statistically significant hotspot (PMID: 7767998). In vivo studies with yeast expressing TP53 R273S demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 R273S also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675287777540,
              "updatedBy": "User"
            },
            "description_uuid": "51d919b0-b58e-487b-8a02-e91477bdd77c",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675287776137,
              "updatedBy": "User"
            },
            "effect_uuid": "b1a40a87-bf09-45f9-9e2c-e7939869f399",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675287775468,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "e5fdcc40-ceda-4592-8226-8af45e39fcac",
            "short": ""
          },
          "mutation_effect_uuid": "e03b9db0-a04b-4a1b-9265-eaf9c0dddb90",
          "name": "R273S",
          "name_review": {
            "updateTime": 1675287771992,
            "updatedBy": "User"
          },
          "name_uuid": "e8ece192-4fcf-4a12-94fc-049effaff8a6",
          "tumors_uuid": "d5914078-1528-41b1-9e06-34e1365be1d2"
        },
        {
          "mutation_effect": {
            "description": "The TP53 F134S mutation is located in the DNA-binding domain of the protein. This mutation has been identified in astrocytoma and is a statistically significant hotspot (PMID: 17917588). In vivo studies with yeast expressing TP53 F134S demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 F134S also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675287791073,
              "updatedBy": "User"
            },
            "description_uuid": "32189008-4dbc-4045-aa96-e95183402e99",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675287789641,
              "updatedBy": "User"
            },
            "effect_uuid": "416915fa-8990-4e65-972b-dd437adfd9cd",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675287788709,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "e14fc53a-b7c1-4be6-9ea9-dcfb1853bcd8",
            "short": ""
          },
          "mutation_effect_uuid": "ea13981d-b9cb-4af7-aab0-d68b8ff0a29c",
          "name": "F134S",
          "name_review": {
            "updateTime": 1675287784862,
            "updatedBy": "User"
          },
          "name_uuid": "b59020b0-b786-43cc-bbe0-16159a912faf",
          "tumors_uuid": "ebaf8206-ef60-4e61-8243-458694e51d8c"
        },
        {
          "mutation_effect": {
            "description": "The TP53 F134V mutation is located in the DNA-binding domain of the protein. This mutation has been identified in colorectal cancer and is a statistically significant hotspot (PMID: 14633673). In vivo studies with yeast expressing TP53 F134V demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 F134V also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675287915032,
              "updatedBy": "User"
            },
            "description_uuid": "b0a42a7d-2ab7-4b52-992b-aad93c5ad35c",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675287913609,
              "updatedBy": "User"
            },
            "effect_uuid": "4e6e07f3-f801-4f51-a15a-e6be1a2a48d9",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675287912905,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "1c624fa5-591a-4b8d-910e-aa7a475c64a8",
            "short": ""
          },
          "mutation_effect_uuid": "2dbfa2ec-2a39-4924-a6da-599579f32fd2",
          "name": "F134V",
          "name_review": {
            "updateTime": 1675287906915,
            "updatedBy": "User"
          },
          "name_uuid": "d836809d-6a5b-4c80-9305-b56e4adae9b2",
          "tumors_uuid": "2d48cb26-d169-41f4-8a6b-d670f505be4c"
        },
        {
          "mutation_effect": {
            "description": "The TP53 F134I mutation is located in the DNA-binding domain of the protein. This mutation has been identified in glioma and is a statistically significant hotspot (PMID: 8561860). In vivo studies with yeast expressing TP53 F134I demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 F134I also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_editing": "",
            "description_review": {
              "updateTime": 1675287929896,
              "updatedBy": "User"
            },
            "description_uuid": "11130869-d1b8-4d2c-ab48-c2113b4ddd04",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675287926828,
              "updatedBy": "User"
            },
            "effect_uuid": "9cbb3d84-44f9-4322-b0db-a648e0f9134c",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675287925987,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "b929b8c0-f570-4e5b-ac50-ea4b2dc8a3ab",
            "short": ""
          },
          "mutation_effect_uuid": "bf94d321-f23a-4dea-be20-7ed413b826d3",
          "name": "F134I",
          "name_review": {
            "updateTime": 1675287922606,
            "updatedBy": "User"
          },
          "name_uuid": "a24a7540-b57c-485a-b7b0-f57e8b195faf",
          "tumors_uuid": "10df6642-272f-4c84-a9ad-682d3d5fe67e"
        },
        {
          "mutation_effect": {
            "description": "The TP53 F134L mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and is a statistically significant hotspot (PMID: 8260732). In vivo studies with yeast expressing TP53 F134L demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 F134L also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675288181056,
              "updatedBy": "User"
            },
            "description_uuid": "41a068a8-e6a4-4112-8fea-678a7dc5d592",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675288179811,
              "updatedBy": "User"
            },
            "effect_uuid": "b48bbd6f-f3a6-4f09-8cf6-bc942a49bfb7",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675288178678,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "74235ff2-0114-4c1e-bc48-8993e2922a11",
            "short": ""
          },
          "mutation_effect_uuid": "32f82b45-feff-4092-ab7e-28e48da99df0",
          "name": "F134L",
          "name_review": {
            "updateTime": 1675288174494,
            "updatedBy": "User"
          },
          "name_uuid": "37319fef-1766-448f-a9e4-3d03fac18756",
          "tumors_uuid": "c85007ac-337a-453c-ab0f-5b5024d1899b"
        },
        {
          "mutation_effect": {
            "description": "The TP53 G245R mutation is located in the DNA-binding domain of the protein. This mutation has been identified in lung adenocarcinoma and is a statistically significant hotspot (PMID: 9627113). In vivo studies with yeast expressing TP53 G245R demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 G245R also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675288223963,
              "updatedBy": "User"
            },
            "description_uuid": "5140aa05-2e9d-45ff-8a98-6636fc177c27",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675288220688,
              "updatedBy": "User"
            },
            "effect_uuid": "ecd4a668-f550-4660-ace4-9454b1d06bc9",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675288219375,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "9a0a90c5-547d-4c73-9802-9f04900e5f11",
            "short": ""
          },
          "mutation_effect_uuid": "086a093c-8ddd-44b4-bb68-3519ded6e07b",
          "name": "G245R",
          "name_review": {
            "updateTime": 1675288216623,
            "updatedBy": "User"
          },
          "name_uuid": "1ed70cb1-880c-4903-b66d-7587a34eaf1b",
          "tumors_uuid": "3887faee-6635-4c32-92ef-e99831f81737"
        },
        {
          "mutation_effect": {
            "description": "The TP53 G245V mutation is located in the DNA-binding domain of the protein. This mutation has been identified in lung squamous cell carcinoma and is a statistically significant hotspot (PMID: 7903781). In vivo studies with yeast expressing TP53 G245V demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 G245V also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675288241736,
              "updatedBy": "User"
            },
            "description_uuid": "9561b979-73af-456a-9324-16887e07a2c8",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675288240266,
              "updatedBy": "User"
            },
            "effect_uuid": "9938a0f5-5421-4a24-90ed-c51a7b0b1e9f",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675288239361,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "c2fa718a-6009-4255-b9ea-3e7937463feb",
            "short": ""
          },
          "mutation_effect_uuid": "8ead0cc0-8e06-456c-bcc0-f0f32f69ed46",
          "name": "G245V",
          "name_review": {
            "updateTime": 1675288235761,
            "updatedBy": "User"
          },
          "name_uuid": "2af5ca09-45cf-441e-a030-64eb58c603e9",
          "tumors_uuid": "e65d4556-6aba-4278-9ecd-f4118f07f9c3"
        },
        {
          "mutation_effect": {
            "description": "The TP53 G245N mutation is located in the DNA-binding domain of the protein. This mutation has been identified in squamous cell carcinoma and is a statistically significant hotspot (PMID: 1946433). In vitro studies with various human cancer cell lines expressing TP53 G245N demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675288261416,
              "updatedBy": "User"
            },
            "description_uuid": "1aa5c748-e973-447b-949d-b553181ae256",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675288257204,
              "updatedBy": "User"
            },
            "effect_uuid": "1ecd4ec9-ea8f-4295-991a-481a7c53a1c6",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675288256291,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "1b5a1617-b23f-45e2-81f5-fbbea04025b8",
            "short": ""
          },
          "mutation_effect_uuid": "a0be82eb-2869-4b13-a3cc-338836947ecd",
          "name": "G245N",
          "name_review": {
            "updateTime": 1675288254075,
            "updatedBy": "User"
          },
          "name_uuid": "80b35c91-0626-40eb-89d9-488c56180fd1",
          "tumors_uuid": "e725b01e-e089-4635-a9b4-d65a0ee6a696"
        },
        {
          "mutation_effect": {
            "description": "The TP53 S215R mutation is located in the DNA-binding domain of the protein. This mutation has been identified in ovarian cancer and is a statistically significant hotspot (PMID: 16907706). In vivo studies with yeast expressing TP53 S215R demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 S215R also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675288543362,
              "updatedBy": "User"
            },
            "description_uuid": "47a01709-04ed-4224-b9d1-4df2046d7511",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675288540340,
              "updatedBy": "User"
            },
            "effect_uuid": "3766c612-8d4e-4c22-b23a-f1d2ccb811e6",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675288539539,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "f91185fe-c6ad-4204-8e9f-8e5a2c0ac98b",
            "short": ""
          },
          "mutation_effect_uuid": "8ae0a3ad-0050-4ca2-896a-06629e2b7b18",
          "name": "S215R",
          "name_review": {
            "updateTime": 1675288537002,
            "updatedBy": "User"
          },
          "name_uuid": "30780fda-0324-41a3-b0fb-1ae1073b1bac",
          "tumors_uuid": "6317ee3c-5c0e-48a4-9c61-490781f4e20b"
        },
        {
          "mutation_effect": {
            "description": "The TP53 S215T mutation is located in the DNA-binding domain of the protein. This mutation has been identified in giant cell glioblastoma and is a statistically significant hotspot (PMID: 9284834). In vivo studies with yeast expressing TP53 S215T demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 S215T also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675288559827,
              "updatedBy": "User"
            },
            "description_uuid": "fcd91b69-0896-4d30-bd61-5d37169101e7",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675288556656,
              "updatedBy": "User"
            },
            "effect_uuid": "b5da045b-88ca-4f07-ac9c-3e90ddb17222",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675288555916,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "138a36fc-81ca-47b0-ac78-5c07b1296d81",
            "short": ""
          },
          "mutation_effect_uuid": "7f35daf1-764b-45e2-a9cb-06fffbdd5dc3",
          "name": "S215T",
          "name_review": {
            "updateTime": 1675288553495,
            "updatedBy": "User"
          },
          "name_uuid": "36eec4f0-a8bf-4819-be2f-ae87f033948c",
          "tumors_uuid": "5d2b9369-c30f-4e5f-b2d6-aaf22dcdced4"
        },
        {
          "mutation_effect": {
            "description": "The TP53 S215I mutation is located in the DNA-binding domain of the protein. This mutation has been identified in non-small cell lung cancer and is a statistically significant hotspot (PMID: 10557071). In vivo studies with yeast expressing TP53 S215I demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 S215I also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675288577182,
              "updatedBy": "User"
            },
            "description_uuid": "59ecf17d-834e-43fa-b0e6-8814c9afa3bf",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675288573209,
              "updatedBy": "User"
            },
            "effect_uuid": "28f17009-dfe8-48d1-b7c3-d54b8cb6ac15",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675288572324,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "562dd2d0-492f-42e8-b7f9-d82a3d17bdeb",
            "short": ""
          },
          "mutation_effect_uuid": "139aa37a-6b3b-4788-b8c1-035c40f9468e",
          "name": "S215I",
          "name_review": {
            "updateTime": 1675288570638,
            "updatedBy": "User"
          },
          "name_uuid": "be208748-9c22-43ec-8eb4-1cf74b412554",
          "tumors_uuid": "bc366579-1c65-4321-9eaa-b3f7103ae84e"
        },
        {
          "mutation_effect": {
            "description": "The TP53 S215N mutation is located in the DNA-binding domain of the protein. This mutation has been identified in colorectal cancer and is a statistically significant hotspot (PMID: 10499618). In vivo studies with yeast expressing TP53 S215N demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 S215N also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675288594773,
              "updatedBy": "User"
            },
            "description_uuid": "8a4fa0f8-0e7e-4910-aa4a-6f4b7dd4ba8a",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675288591168,
              "updatedBy": "User"
            },
            "effect_uuid": "01503d51-6730-43ea-8bbd-be8753c852ec",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675288588502,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "465f18bb-d5fa-4afd-b0c0-9d0f0d3aee1a",
            "short": ""
          },
          "mutation_effect_uuid": "5df4e38c-a584-4ca2-b6c0-1314b4aec75d",
          "name": "S215N",
          "name_review": {
            "updateTime": 1675288586311,
            "updatedBy": "User"
          },
          "name_uuid": "05f295ee-3286-43f9-89d9-7b4a9820e44e",
          "tumors_uuid": "05f7d989-518c-49b1-9fbd-ff27b1f20380"
        },
        {
          "mutation_effect": {
            "description": "The TP53 Q144H mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and is a statistically significant hotspot (PMID: 10615230). In vivo studies with yeast expressing TP53 Q144H demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
            "description_review": {
              "updateTime": 1675288685749,
              "updatedBy": "User"
            },
            "description_uuid": "f362b701-827a-4bd5-9431-cf45f93812c2",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675288680455,
              "updatedBy": "User"
            },
            "effect_uuid": "1726f039-4618-47d6-ba34-1dc5db8a4259",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675288677830,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "c1acc1db-c0c7-441a-9fb9-9932a49a5028",
            "short": ""
          },
          "mutation_effect_uuid": "beeaa92b-fe62-4562-bbd6-be6f2a2fe348",
          "name": "Q144H",
          "name_review": {
            "updateTime": 1675288675996,
            "updatedBy": "User"
          },
          "name_uuid": "b335d95b-7eb6-4bbd-9cca-a1386346031a",
          "tumors_uuid": "19b71a1f-e35f-4b83-8420-014486ea038a"
        },
        {
          "mutation_effect": {
            "description": "The TP53 Q144L mutation is located in the DNA-binding domain of the protein. This mutation has been identified in colorectal cancer and is a statistically significant hotspot (PMID: 12457032). In vivo studies with yeast expressing TP53 Q144L demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
            "description_review": {
              "updateTime": 1677615446001,
              "updatedBy": "User"
            },
            "description_uuid": "0d7d6cc5-f13a-4cc9-abea-7883698cb6f1",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675288702290,
              "updatedBy": "User"
            },
            "effect_uuid": "22ee7a33-f556-475b-a579-17d1de3003c9",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675288700870,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "7c539d2d-5a5c-40fc-8349-12caca6a5bb6",
            "short": ""
          },
          "mutation_effect_uuid": "15988b96-6384-4d46-c085-13c365983ff6",
          "name": "Q144L",
          "name_review": {
            "updateTime": 1675288698833,
            "updatedBy": "User"
          },
          "name_uuid": "e5b789ff-cf5d-4f74-9f1e-4531abcd23e6",
          "tumors_uuid": "428ca58e-55f4-4e08-8ace-6eeceb336ea2"
        },
        {
          "mutation_effect": {
            "description": "The TP53 Y234S mutation is located in the DNA-binding domain of the protein. This mutation has been identified in ovarian cancer and is a statistically significant hotspot (PMID: 1923532). In vivo studies with yeast expressing TP53 Y234S demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 Y234S also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675369957986,
              "updatedBy": "User"
            },
            "description_uuid": "d09f0a2b-61e3-45c9-8f69-17cced15aff0",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675369954561,
              "updatedBy": "User"
            },
            "effect_uuid": "ba81abfe-5f89-4c70-9bbf-5a7527e1a925",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675369953695,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "27c93ca8-a87e-4ace-aa16-9f95b6824db5",
            "short": ""
          },
          "mutation_effect_uuid": "9e34267b-5183-4743-bf8a-08099346ca9f",
          "name": "Y234S",
          "name_review": {
            "updateTime": 1675369950803,
            "updatedBy": "User"
          },
          "name_uuid": "1cb83714-9e1e-4a4a-b87e-e9c3a680f602",
          "tumors_uuid": "0d7b2891-0f35-4aa6-b82b-8d591201d15e"
        },
        {
          "mutation_effect": {
            "description": "The TP53 Y234D mutation is located in the DNA-binding domain of the protein. This mutation has been identified in acute myeloid leukemia and is a statistically significant hotspot (PMID: 8824725). In vivo studies with yeast expressing TP53 Y234D demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 Y234D also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675369978524,
              "updatedBy": "User"
            },
            "description_uuid": "de0567cb-4104-4092-a2be-a9ccf22feff9",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675369974296,
              "updatedBy": "User"
            },
            "effect_uuid": "ec4aa232-55f5-4e80-91f5-a30626170c94",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675369973273,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "ce18fe6a-8600-4490-abe2-2b46f7fc6049",
            "short": ""
          },
          "mutation_effect_uuid": "c46c714a-ab0d-4316-ba1e-ad133f32c903",
          "name": "Y234D",
          "name_review": {
            "updateTime": 1675369970957,
            "updatedBy": "User"
          },
          "name_uuid": "a227968d-57a9-4ee1-a4eb-d281ca630aa6",
          "tumors_uuid": "e1b5bf61-4df0-474f-a20f-cae536cff5a9"
        },
        {
          "mutation_effect": {
            "description": "The TP53 Y234N mutation is located in the DNA-binding domain of the protein. This mutation has been identified in osteosarcoma and is a statistically significant hotspot (PMID: 9824113). In vivo studies with yeast expressing TP53 Y234N demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 Y234N also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675369999407,
              "updatedBy": "User"
            },
            "description_uuid": "a52b0e0e-22f0-4ddb-9354-809013e24d2b",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675369995409,
              "updatedBy": "User"
            },
            "effect_uuid": "3f6956dc-0b82-4a6d-82da-092feabe22bc",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675369994539,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "1d0c3c9f-b74c-4b1d-9387-cf45e770d32b",
            "short": ""
          },
          "mutation_effect_uuid": "f8a3826f-fc2a-4a30-b121-591af8473a01",
          "name": "Y234N",
          "name_review": {
            "updateTime": 1675369992871,
            "updatedBy": "User"
          },
          "name_uuid": "a6f1a96e-71bc-4990-b4d4-fcba2b8df056",
          "tumors_uuid": "a8074a20-16b5-4660-beb0-5bdb03e79fa3"
        },
        {
          "mutation_effect": {
            "description": "The TP53 R248P mutation is located in the DNA-binding domain of the protein. This mutation has been identified in Burkitt cell leukemia and is a statistically significant hotspot (PMID: 9379679). In vivo studies with yeast expressing TP53 R248P demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 R248P also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675370019650,
              "updatedBy": "User"
            },
            "description_uuid": "bc0a1b6e-47e5-4087-a172-6d3bf064111b",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675370016638,
              "updatedBy": "User"
            },
            "effect_uuid": "e5ef4964-08a3-4f4c-a293-5383562a2ca6",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675370015879,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "0b2fd09b-905e-4061-a7ba-810fb5426af8",
            "short": ""
          },
          "mutation_effect_uuid": "a75a7818-4fb3-4a06-92ec-bbff5cb182ec",
          "name": "R248P",
          "name_review": {
            "updateTime": 1675370010882,
            "updatedBy": "User"
          },
          "name_uuid": "d00e7109-9384-4622-92f2-b18e7df54626",
          "tumors_uuid": "d6513a3f-b780-456d-82af-405c6c811c0d"
        },
        {
          "mutation_effect": {
            "description": "The TP53 R248G mutation is located in the DNA-binding domain of the protein. This mutation has been identified in prostate adenocarcinoma and is a statistically significant hotspot (PMID: 8610059). In vivo studies with yeast expressing TP53 R248G demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 R248G also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_editing": "",
            "description_review": {
              "updateTime": 1675370037759,
              "updatedBy": "User"
            },
            "description_uuid": "5c1b3289-e106-4eab-87bf-b63435b39f39",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675370034279,
              "updatedBy": "User"
            },
            "effect_uuid": "ce936ea3-b7d6-460d-9a61-4ec9d59836a8",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675370033513,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "86fee14e-d26d-4a9a-84f6-059fe6a8c53e",
            "short": ""
          },
          "mutation_effect_uuid": "756ece2b-b025-4602-85fb-46e770194b94",
          "name": "R248G",
          "name_review": {
            "updateTime": 1675370030832,
            "updatedBy": "User"
          },
          "name_uuid": "e85d6a34-fe8c-475f-b78d-7e30d7fb7f87",
          "tumors_uuid": "db2ba8bb-f8ee-4910-9589-60687e2f8b12"
        },
        {
          "mutation_effect": {
            "description": "The TP53 K132Q mutation is located in the DNA-binding domain of the protein. This mutation has been identified in malignant lymphoma and is a statistically significant hotspot (PMID: 8314342). In vivo studies with yeast expressing TP53 K132Q demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 K132Q also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675370932819,
              "updatedBy": "User"
            },
            "description_uuid": "bb06859a-4b6c-4e4b-a0a0-6ed944d65106",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675370931399,
              "updatedBy": "User"
            },
            "effect_uuid": "83053575-5b65-48cd-b557-44a68cd84b5b",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675370930379,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "de69d2ed-55b9-4529-bc34-8efdade5c4b6",
            "short": ""
          },
          "mutation_effect_uuid": "0b9720ec-c43c-45b7-a8a5-d99d4e4b8a81",
          "name": "K132Q",
          "name_review": {
            "updateTime": 1675370925973,
            "updatedBy": "User"
          },
          "name_uuid": "cda880e0-d91e-4b7a-9bb0-a3e142c1c0e4",
          "tumors_uuid": "c1141856-f3af-452b-bc0f-639b8005e9f0"
        },
        {
          "mutation_effect": {
            "description": "The TP53 K132R mutation is located in the DNA-binding domain of the protein. This mutation has been identified in colorectal cancer and is a statistically significant hotspot (PMID: 17201907). In vivo studies with yeast expressing TP53 K132R demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 K132R also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675370949921,
              "updatedBy": "User"
            },
            "description_uuid": "5411ccb5-af68-4bab-9056-1365d53bda20",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675370946359,
              "updatedBy": "User"
            },
            "effect_uuid": "03219687-723f-4e61-a6fc-e6b1ba0d48c2",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675370945512,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "e77df0e2-d12d-4d5c-892d-8082703ea364",
            "short": ""
          },
          "mutation_effect_uuid": "e336fb49-c2e0-41aa-959c-cd1fb5ffb50f",
          "name": "K132R",
          "name_review": {
            "updateTime": 1675370941021,
            "updatedBy": "User"
          },
          "name_uuid": "b02825a7-f172-43e4-9424-91ea41e744b6",
          "tumors_uuid": "312e5058-3fc4-467b-93ab-9a9041433772"
        },
        {
          "mutation_effect": {
            "description": "The TP53 K132T mutation is located in the DNA-binding domain of the protein. This mutation has been identified in glioblastoma and is a statistically significant hotspot (PMID: 11221842). In vivo studies with yeast expressing TP53 K132T demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 K132T also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675370965563,
              "updatedBy": "User"
            },
            "description_uuid": "23bba056-9499-458a-b1d8-30d566041446",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675370962636,
              "updatedBy": "User"
            },
            "effect_uuid": "183c2bcc-2277-41fe-b941-66085bd03a65",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675370961897,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "ea17a4da-e3fe-4d61-8a38-1858b966807d",
            "short": ""
          },
          "mutation_effect_uuid": "b9a80023-a727-437e-b9de-907d73386279",
          "name": "K132T",
          "name_review": {
            "updateTime": 1675370960255,
            "updatedBy": "User"
          },
          "name_uuid": "b2892c5a-5a87-4172-a647-1bc7a74de5a6",
          "tumors_uuid": "b2f91bdd-db1a-4803-8e5c-68004e60de29"
        },
        {
          "mutation_effect": {
            "description": "The TP53 K132E mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and is a statistically significant hotspot (PMID: 15188009). In vivo studies with yeast expressing TP53 K132E demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 K132E also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675370987992,
              "updatedBy": "User"
            },
            "description_uuid": "25f22674-d74b-4ec5-add1-ebe4ae7e626d",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675370984485,
              "updatedBy": "User"
            },
            "effect_uuid": "97347d7b-6750-4a93-a1ad-bc0128fd2046",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675370983614,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "f728ad35-4588-496d-971a-c89e788b5553",
            "short": ""
          },
          "mutation_effect_uuid": "eccfb57e-9f75-427a-8ab9-ded71e6a7e73",
          "name": "K132E",
          "name_review": {
            "updateTime": 1675370976809,
            "updatedBy": "User"
          },
          "name_uuid": "bc856dda-41b7-4143-8d8f-b63bf6ed5a33",
          "tumors_uuid": "a1529c0c-4b7a-4a12-aa4d-7fe260271e32"
        },
        {
          "mutation_effect": {
            "description": "The TP53 K132M mutation is located in the DNA-binding domain of the protein. This mutation has been identified in Ewing sarcoma and is a statistically significant hotspot (PMID: 11295075). In vivo studies with yeast expressing TP53 K132M demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 K132M also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675371004867,
              "updatedBy": "User"
            },
            "description_uuid": "448aba27-0882-4848-b6a0-01725152291e",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675371003502,
              "updatedBy": "User"
            },
            "effect_uuid": "96b3975a-ef50-4802-8d72-e0466dd1f879",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675371002731,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "009fd9ca-841e-4e74-99fb-ecbc75b20a27",
            "short": ""
          },
          "mutation_effect_uuid": "aa3e93dc-0be9-429a-85ef-37f72f86e6a1",
          "name": "K132M",
          "name_review": {
            "updateTime": 1675370999170,
            "updatedBy": "User"
          },
          "name_uuid": "5aaddd4c-3d96-42ab-bfe8-00ecf92efd7f",
          "tumors_uuid": "eb64bcc5-cab9-495b-b8f9-64e2449d409a"
        },
        {
          "mutation_effect": {
            "description": "The TP53 K132N mutation is located in the DNA-binding domain of the protein. This mutation has been identified in non-small cell lung cancer and is a statistically significant hotspot (PMID: 17557246). In vivo studies with yeast expressing TP53 K132N demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 K132N also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675371024442,
              "updatedBy": "User"
            },
            "description_uuid": "495c02a6-9746-4d96-8e43-7d532214507e",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675371022996,
              "updatedBy": "User"
            },
            "effect_uuid": "58e13214-d535-41c0-9b6f-28d30ca8f398",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675371022101,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "99196e51-528a-46e4-b706-1c785358e7ca",
            "short": ""
          },
          "mutation_effect_uuid": "5bf5ff5e-6f20-4e1b-9818-bee806b366ae",
          "name": "K132N",
          "name_review": {
            "updateTime": 1675371016583,
            "updatedBy": "User"
          },
          "name_uuid": "44441f27-17d8-4306-84bf-50fb386a8627",
          "tumors_uuid": "6367718f-2d2e-46db-a51f-e30b7537d2af"
        },
        {
          "mutation_effect": {
            "description": "The TP53 H214L mutation is located in the DNA-binding domain of the protein. This mutation has been identified in esophageal squamous cell carcinoma and is a statistically significant hotspot (PMID: 26873401). In vivo studies with yeast expressing TP53 H214L demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 H214L also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675371041495,
              "updatedBy": "User"
            },
            "description_uuid": "ba55bb6b-17b8-4eb6-a538-3441813eb7d3",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675371039971,
              "updatedBy": "User"
            },
            "effect_uuid": "a605492e-aa49-49a8-ab3f-68fd59c8b9f9",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675371038237,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "0fe179c9-e3a3-4cd0-9212-32a640e9652b",
            "short": ""
          },
          "mutation_effect_uuid": "eb078fb7-4dba-4d3a-ab0c-cad22e4e3a8f",
          "name": "H214L",
          "name_review": {
            "updateTime": 1675371034209,
            "updatedBy": "User"
          },
          "name_uuid": "c5507de5-b1f1-4fb9-a29e-dd844d80a111",
          "tumors_uuid": "a494b5af-6ea5-4917-9ffb-ac577efcecbd"
        },
        {
          "mutation_effect": {
            "description": "The TP53 L130P mutation is located in the DNA-binding domain of the protein. This mutation has been identified in malignant lymphoma and is a statistically significant hotspot (PMID: 15875732). In vivo studies with yeast expressing TP53 L130P demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 L130P also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675371061141,
              "updatedBy": "User"
            },
            "description_uuid": "0298c531-d28e-4cd7-9355-5e077658df63",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675371058374,
              "updatedBy": "User"
            },
            "effect_uuid": "62987a47-2d20-423c-9d3f-4938f4c367cc",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675371059594,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "fe118a46-f238-41ea-b4a4-34dd9d76180c",
            "short": ""
          },
          "mutation_effect_uuid": "a2a5464c-af30-4409-872d-cfa71574d5b1",
          "name": "L130P",
          "name_review": {
            "updateTime": 1675371053067,
            "updatedBy": "User"
          },
          "name_uuid": "c2d7872b-35cd-4417-ab29-5b52e1e6a402",
          "tumors_uuid": "b0d21455-2ad9-4efe-b7fb-c373adcddac8"
        },
        {
          "mutation_effect": {
            "description": "The TP53 L130R mutation is located in the DNA-binding domain of the protein. This mutation has been identified in cholangiocarcinoma and is a statistically significant hotspot (PMID: 12210082). In vivo studies with yeast expressing TP53 L130R demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 L130R also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675371078435,
              "updatedBy": "User"
            },
            "description_uuid": "f3e2bb73-55cd-4691-ae07-9bf0f3f7e5bf",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675371075145,
              "updatedBy": "User"
            },
            "effect_uuid": "bd0c288f-590c-470f-8f61-a57ebbcbaac3",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675371074326,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "5a5155df-61ae-4459-9abd-58eca898d3bc",
            "short": ""
          },
          "mutation_effect_uuid": "69de847c-9413-4049-b262-315f360bf4b9",
          "name": "L130R",
          "name_review": {
            "updateTime": 1675371072161,
            "updatedBy": "User"
          },
          "name_uuid": "68d30a39-0440-4f4c-c08c-961908c75ba8",
          "tumors_uuid": "004d29d2-b79b-4b58-913e-e18d7d25fac6"
        },
        {
          "mutation_effect": {
            "description": "The TP53 L130V mutation is located in the DNA-binding domain of the protein. This mutation has been identified in ovarian cancer and is a statistically significant hotspot (PMID: 17171684). In vivo studies with yeast expressing TP53 L130V demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 L130V also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675371096884,
              "updatedBy": "User"
            },
            "description_uuid": "4b138d65-af2b-4420-b889-833d7d225b51",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675371092240,
              "updatedBy": "User"
            },
            "effect_uuid": "ef200fc3-095d-4b0f-c00b-6da9e50b8130",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675371091551,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "6b67fadb-1206-4e66-8251-00e98395512b",
            "short": ""
          },
          "mutation_effect_uuid": "9df431d5-8e2d-4c4f-a866-9096fdfea587",
          "name": "L130V",
          "name_review": {
            "updateTime": 1675371089575,
            "updatedBy": "User"
          },
          "name_uuid": "b811dd5a-77b0-4d75-b24a-6628183f5571",
          "tumors_uuid": "5f400c70-a391-4da2-8d0f-4a739a53d401"
        },
        {
          "mutation_effect": {
            "description": "The TP53 L130F mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and is a statistically significant hotspot (PMID: 11051239). In vivo studies with yeast expressing TP53 L130F demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 L130F also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675371121248,
              "updatedBy": "User"
            },
            "description_uuid": "880ba9e7-565c-4f9f-9225-82275a307885",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675371117611,
              "updatedBy": "User"
            },
            "effect_uuid": "e0dde03b-410b-4825-8376-609306f0a132",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675371116818,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "55785a9b-820e-4270-8396-85829e39d1f1",
            "short": ""
          },
          "mutation_effect_uuid": "947858fd-903e-471a-9d02-702b835ea83d",
          "name": "L130F",
          "name_review": {
            "updateTime": 1675371114458,
            "updatedBy": "User"
          },
          "name_uuid": "3b37275e-f39d-4102-9f0e-426696928a16",
          "tumors_uuid": "e28afb40-4db1-4d9a-8ad0-9b147e705e0f"
        },
        {
          "mutation_effect": {
            "description": "The TP53 L130H mutation is located in the DNA-binding domain of the protein. This mutation has been identified in prostate cancer and is a statistically significant hotspot (PMID: 19020536). In vivo studies with yeast expressing TP53 L130H demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 L130H also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675371143468,
              "updatedBy": "User"
            },
            "description_uuid": "2a9a311f-692f-48f3-8991-2a7b117e3ef8",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675371137373,
              "updatedBy": "User"
            },
            "effect_uuid": "854360f1-49f1-4e36-af09-54313c43f672",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675371136596,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "37705421-7861-43cc-8869-b5fb9203bd1f",
            "short": ""
          },
          "mutation_effect_uuid": "112120fd-d726-4801-b153-ffe24018dac8",
          "name": "L130H",
          "name_review": {
            "updateTime": 1675371134799,
            "updatedBy": "User"
          },
          "name_uuid": "cb6ff553-6333-475e-a50c-330405390fc6",
          "tumors_uuid": "50f7c15f-c96b-4444-9a9c-1714838dcefd"
        },
        {
          "mutation_effect": {
            "description": "The TP53 K164E mutation is located in the DNA-binding domain of the protein. This mutation has been identified in ovarian cancer and is a statistically significant hotspot (PMID: 9699640). In vivo studies with yeast expressing TP53 K164E demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 K164E also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675371159383,
              "updatedBy": "User"
            },
            "description_uuid": "323bb83b-2234-4295-88ca-2fdde20f9631",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675371157830,
              "updatedBy": "User"
            },
            "effect_uuid": "a5928c78-fc9b-4e13-bf1e-d9053d994709",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675371157037,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "b5d501d2-ed64-43e8-b225-b5f40aea3263",
            "short": ""
          },
          "mutation_effect_uuid": "2c65b317-6916-4445-8a5c-11d8f22abdda",
          "name": "K164E",
          "name_review": {
            "updateTime": 1675371153541,
            "updatedBy": "User"
          },
          "name_uuid": "87a4413d-9335-49c5-9257-855a76109664",
          "tumors_uuid": "8d5992a8-7c88-4c91-9cba-6c3bb486560d"
        },
        {
          "mutation_effect": {
            "description": "The TP53 F109S mutation is located in the DNA-binding domain of the protein. This mutation has been identified in acute lymphoblastic leukemia and is a statistically significant hotspot (PMID: 10573131). In vivo studies with yeast expressing TP53 F109S demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 F109S also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675371180168,
              "updatedBy": "User"
            },
            "description_uuid": "fa6745ba-607d-401b-912b-a4cdf03ebbd4",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675371175154,
              "updatedBy": "User"
            },
            "effect_uuid": "a9ff347b-b34a-42ee-9b43-4a151b57bc22",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675371174186,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "9dc305dc-3c89-43c1-a223-6fba3ec9772f",
            "short": ""
          },
          "mutation_effect_uuid": "5bd7e480-e121-40fe-9bde-53271b0c4eef",
          "name": "F109S",
          "name_review": {
            "updateTime": 1675371172210,
            "updatedBy": "User"
          },
          "name_uuid": "1bdd77b9-64b6-474f-b3d7-a655756161e4",
          "tumors_uuid": "bb963f09-9f81-4d08-b7e4-fa0afdf79467"
        },
        {
          "mutation_effect": {
            "description": "The TP53 F109C mutation is located in the DNA-binding domain of the protein. This mutation has been identified in ovarian cancer and is a statistically significant hotspot (PMID: 21720365). In vivo studies with yeast expressing TP53 F109C demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 F109C also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675371200946,
              "updatedBy": "User"
            },
            "description_uuid": "e896304e-05f3-4af5-be57-6e652c48268f",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675371199632,
              "updatedBy": "User"
            },
            "effect_uuid": "53c403ce-c4c8-4b7a-ad34-713319746af1",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675371198893,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "d0daea4f-4300-4794-8e0b-0e09eec91b43",
            "short": ""
          },
          "mutation_effect_uuid": "3e8fc7c4-e2da-4311-8526-f69c81fcb119",
          "name": "F109C",
          "name_review": {
            "updateTime": 1675371191657,
            "updatedBy": "User"
          },
          "name_uuid": "4ae9408e-d878-4963-8a32-31e6719ec16e",
          "tumors_uuid": "5475254a-0daa-48cd-bd3d-176ef2145c03"
        },
        {
          "mutation_effect": {
            "description": "The TP53 F109V mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and is a statistically significant hotspot (PMID: 16489069). In vivo studies with yeast expressing TP53 F109V demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 F109V also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675371221694,
              "updatedBy": "User"
            },
            "description_uuid": "c910203b-f374-4d19-b463-61c87a6ac72d",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675371220380,
              "updatedBy": "User"
            },
            "effect_uuid": "a54425dc-550c-4e09-9d02-1292718a6dd8",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675371219570,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "af277a58-8921-488a-9429-5f110517eb36",
            "short": ""
          },
          "mutation_effect_uuid": "1e28592d-855a-4a47-8777-c4bf59cb3285",
          "name": "F109V",
          "name_review": {
            "updateTime": 1675371214292,
            "updatedBy": "User"
          },
          "name_uuid": "4d26f924-93ca-4fbc-998e-041961c3fcb7",
          "tumors_uuid": "aa224c13-3145-4408-8123-cd29c95a9b82"
        },
        {
          "mutation_effect": {
            "description": "The TP53 F109I mutation is located in the DNA-binding domain of the protein. This mutation has been identified in penile squamous cell carcinoma and is a statistically significant hotspot (PMID: 26670561). In vivo studies with yeast expressing TP53 F109I demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 F109I also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675371242836,
              "updatedBy": "User"
            },
            "description_uuid": "86438986-375a-4780-aaa9-45fc53314fa1",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675371239255,
              "updatedBy": "User"
            },
            "effect_uuid": "2ba2d557-5471-415f-93bc-849a30776898",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675371238501,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "523633ac-495c-4e76-972b-8c1fc30ae83d",
            "short": ""
          },
          "mutation_effect_uuid": "9bebb526-eeab-4a70-a515-820956704b6c",
          "name": "F109I",
          "name_review": {
            "updateTime": 1675371235948,
            "updatedBy": "User"
          },
          "name_uuid": "ab704686-5e4c-43fc-96ae-6ad43bb91e0d",
          "tumors_uuid": "4e03e72c-99a3-465c-9ae0-6aab6cad9905"
        },
        {
          "mutation_effect": {
            "description": "The TP53 G105R mutation is located in the DNA-binding domain of the protein. This mutation has been identified in ovarian cancer and is a statistically significant hotspot (PMID: 9699640). In vivo studies with yeast expressing TP53 G105R demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 G105R also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675371261831,
              "updatedBy": "User"
            },
            "description_uuid": "eaad4cf7-24ea-4d4f-8762-c405b24e9e59",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675371260108,
              "updatedBy": "User"
            },
            "effect_uuid": "2e55007e-8646-44bd-bc6d-418ff4127029",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675371259281,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "09bac2c2-4a8f-4dc8-a1a8-11dd405dd692",
            "short": ""
          },
          "mutation_effect_uuid": "9c271522-133d-4cb1-8164-48d36d8f1de8",
          "name": "G105R",
          "name_review": {
            "updateTime": 1675371253735,
            "updatedBy": "User"
          },
          "name_uuid": "e8c5e462-b02b-4304-934d-438d4ac73915",
          "tumors_uuid": "a42ec8b6-a799-4f4f-939e-fd4a7dca4210"
        },
        {
          "mutation_effect": {
            "description": "The TP53 G105C mutation is located in the DNA-binding domain of the protein. This mutation has been identified in glioblastoma and is a statistically significant hotspot (PMID: 18772890). In vivo studies with yeast expressing TP53 G105C demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
            "description_review": {
              "updateTime": 1675371284085,
              "updatedBy": "User"
            },
            "description_uuid": "1665948f-30c7-484c-8795-ea378e2c1158",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675371279852,
              "updatedBy": "User"
            },
            "effect_uuid": "798b8061-c885-47bb-8729-b450f95152eb",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675371278629,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "326059a9-478c-4802-8833-35f25f05c5a8",
            "short": ""
          },
          "mutation_effect_uuid": "e0a8be64-5783-4b64-8221-2a277e4104ef",
          "name": "G105C",
          "name_review": {
            "updateTime": 1675371276714,
            "updatedBy": "User"
          },
          "name_uuid": "af4e1b4a-78d8-4308-8633-ee34420ed791",
          "tumors_uuid": "487b9d37-4dbb-4dee-b075-db805288407f"
        },
        {
          "mutation_effect": {
            "description": "The TP53 G105S mutation is located in the DNA-binding domain of the protein. This mutation has been identified in glioblastoma and is a statistically significant hotspot (PMID: 15035290). In vivo studies with yeast expressing TP53 G105S demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
            "description_review": {
              "updateTime": 1675371315051,
              "updatedBy": "User"
            },
            "description_uuid": "b025f826-26c9-4045-9cda-c4b89d4338e1",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675371309161,
              "updatedBy": "User"
            },
            "effect_uuid": "927b4ab9-b20d-462e-81f8-8df84bcbdced",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675371307790,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "75b8ee0c-7b3a-4200-95b7-05f232c7bf94",
            "short": ""
          },
          "mutation_effect_uuid": "189b6d52-3a5c-46df-bef6-5862439fa100",
          "name": "G105S",
          "name_review": {
            "updateTime": 1675371305359,
            "updatedBy": "User"
          },
          "name_uuid": "f36e9ac6-72f7-468f-a199-09d79e98ba30",
          "tumors_uuid": "f458ed45-a265-406c-b410-40b7953e42ca"
        },
        {
          "mutation_effect": {
            "description": "The TP53 G105D mutation is located in the DNA-binding domain of the protein. This mutation has been identified in glioblastoma and is a statistically significant hotspot (PMID: 15466178). In vivo studies with yeast expressing TP53 G105D demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 G105D also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675371333415,
              "updatedBy": "User"
            },
            "description_uuid": "7ac7d8e8-65b2-4fb3-9495-8d09501bde38",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675371328425,
              "updatedBy": "User"
            },
            "effect_uuid": "a8b36404-c919-4661-b5a7-477c9265199e",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675371326864,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "b51de8d6-3137-4573-a8a1-3ea365f6d8cb",
            "short": ""
          },
          "mutation_effect_uuid": "325453fe-acee-40e7-9d05-7323b2d60cde",
          "name": "G105D",
          "name_review": {
            "updateTime": 1675371325092,
            "updatedBy": "User"
          },
          "name_uuid": "c5fa81a3-a0b4-4b66-81ea-6b376d37252e",
          "tumors_uuid": "b29aea16-a1dc-485c-9166-3b25f1f668f1"
        },
        {
          "mutation_effect": {
            "description": "The TP53 G105V mutation is located in the DNA-binding domain of the protein. This mutation has been identified in ovarian cancer and is a statistically significant hotspot (PMID: 14519637). In vivo studies with yeast expressing TP53 G105V demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
            "description_review": {
              "updateTime": 1675371356103,
              "updatedBy": "User"
            },
            "description_uuid": "003089dc-b71b-4376-94e7-f697107a907b",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675371352571,
              "updatedBy": "User"
            },
            "effect_uuid": "3a8dc31c-5c99-406c-9a13-175a7e549646",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675371351031,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "61f60bc1-737b-4721-955e-4799fc3212ff",
            "short": ""
          },
          "mutation_effect_uuid": "d47b0ac6-31a2-4733-9db5-710c3ebfc69e",
          "name": "G105V",
          "name_review": {
            "updateTime": 1675371344487,
            "updatedBy": "User"
          },
          "name_uuid": "822e7afe-8e5d-4f1f-82e0-070a21976c28",
          "tumors_uuid": "bbe60460-78e0-433e-bb41-bdfbfe00a929"
        },
        {
          "mutation_effect": {
            "description": "The TP53 E271Q mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and is a statistically significant hotspot (PMID: 11929815). In vivo studies with yeast expressing TP53 E271Q demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
            "description_review": {
              "updateTime": 1675371380455,
              "updatedBy": "User"
            },
            "description_uuid": "2c74d0d3-65fe-4b36-b2b3-c3fcf132d1d8",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675371370942,
              "updatedBy": "User"
            },
            "effect_uuid": "40ecec3a-9808-4671-8f9d-6fa10aa135c6",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675371370287,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "9fb92a6f-d944-467e-a3ba-5bb3c19ff398",
            "short": ""
          },
          "mutation_effect_uuid": "604e2ccf-383b-400f-a3a0-ea83e4d171c0",
          "name": "E271Q",
          "name_review": {
            "updateTime": 1675371368203,
            "updatedBy": "User"
          },
          "name_uuid": "4e7a1017-0554-4787-9c4e-d99f9c53c998",
          "tumors_uuid": "98918bc3-c607-4dfc-98a7-26e564209aab"
        },
        {
          "mutation_effect": {
            "description": "The TP53 E271V mutation is located in the DNA-binding domain of the protein. This mutation has been identified in bladder cancer and is a statistically significant hotspot (PMID: 7628866). In vivo studies with yeast expressing TP53 E271V demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 E271V also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675371396916,
              "updatedBy": "User"
            },
            "description_uuid": "af8f4df5-7b04-4fff-9f1d-dd902977e9e1",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675371393812,
              "updatedBy": "User"
            },
            "effect_uuid": "8a8f6b3a-61d6-4929-bbd4-32b819d22fac",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675371393198,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "3acc0172-dee2-4f85-b2cb-a5b66c8b2ddf",
            "short": ""
          },
          "mutation_effect_uuid": "cf05136e-66a1-4984-912a-240c83a53db2",
          "name": "E271V",
          "name_review": {
            "updateTime": 1675371391163,
            "updatedBy": "User"
          },
          "name_uuid": "9af08c59-f826-48bf-bcaf-50b474ae4149",
          "tumors_uuid": "370dd23b-6db8-4f47-a509-594fbebb05b3"
        },
        {
          "mutation_effect": {
            "description": "The TP53 V172D mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and is a statistically significant hotspot (PMID: 7712430). In vivo studies with yeast expressing TP53 V172D demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 V172D also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675371422569,
              "updatedBy": "User"
            },
            "description_uuid": "30c3c97f-4300-4acd-818b-24b5e3f5b103",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675371418637,
              "updatedBy": "User"
            },
            "effect_uuid": "7b5883c3-3fff-450e-81bf-c2955375127b",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675371417496,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "2f34edc2-655b-4b9c-b919-d3d2124b5959",
            "short": ""
          },
          "mutation_effect_uuid": "52046bf3-58ab-4220-9368-75c1f3f711f5",
          "name": "V172D",
          "name_review": {
            "updateTime": 1675371412723,
            "updatedBy": "User"
          },
          "name_uuid": "1ec07f7b-6f05-47d4-a639-9e2014733e7f",
          "tumors_uuid": "565d0dd9-4ac8-4fa8-b1cd-49a13c8314fe"
        },
        {
          "mutation_effect": {
            "description": "The TP53 V172G mutation is located in the DNA-binding domain of the protein. This mutation has been identified in hepatocellular carcinoma and is a statistically significant hotspot (PMID: 8108145). In vivo studies with yeast expressing TP53 V172G demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 V172G also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675371444428,
              "updatedBy": "User"
            },
            "description_uuid": "5aec788b-f556-4b57-89fb-0eb1cbbd8bf8",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675371443111,
              "updatedBy": "User"
            },
            "effect_uuid": "06dd1bbd-e484-4b63-912f-dd60f0b7f257",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675371442205,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "91b64288-435a-4997-8d75-b836d8126890",
            "short": ""
          },
          "mutation_effect_uuid": "7cd8f8b9-3657-432f-a786-2e3567f83240",
          "name": "V172G",
          "name_review": {
            "updateTime": 1675371437863,
            "updatedBy": "User"
          },
          "name_uuid": "8a800462-40da-4ba9-a273-30cfdc08cac2",
          "tumors_uuid": "2148b721-a154-4b67-af1c-229776b8dfbd"
        },
        {
          "mutation_effect": {
            "description": "The TP53 T155I mutation is located in the DNA-binding domain of the protein. This mutation has been identified in lung adenocarcinoma and is a statistically significant hotspot (PMID: 11400116). In vivo studies with yeast expressing TP53 T155I demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 T155I also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675371468129,
              "updatedBy": "User"
            },
            "description_uuid": "ac3732ae-5979-4c64-9828-702f080df52c",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675371463545,
              "updatedBy": "User"
            },
            "effect_uuid": "5aee1f19-8652-466c-be94-521faa3608e6",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675371460957,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "5d4710c9-4e32-4c9a-9a87-1fb63274fe13",
            "short": ""
          },
          "mutation_effect_uuid": "a45575e9-9b6e-4061-9f9c-dfcbf98f7f03",
          "name": "T155I",
          "name_review": {
            "updateTime": 1675371458821,
            "updatedBy": "User"
          },
          "name_uuid": "9d07aacb-0b20-4090-8800-84b1af56914e",
          "tumors_uuid": "408732f3-3147-466a-ad7a-a1063e557a1b"
        },
        {
          "mutation_effect": {
            "description": "The TP53 L257P mutation is located in the DNA-binding domain of the protein. This mutation has been identified in malignant lymphoma and is a statistically significant hotspot (PMID: 1375111). In vivo studies with yeast expressing TP53 L257P demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 L257P also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675371488926,
              "updatedBy": "User"
            },
            "description_uuid": "114f83fb-114a-4e16-8e8e-c4a19e541ee0",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675371487156,
              "updatedBy": "User"
            },
            "effect_uuid": "963a78f3-0a2f-4ace-ba6b-6e79a09afa07",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675371486383,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "d675b61e-2df6-4e75-8c28-f28c077b6705",
            "short": ""
          },
          "mutation_effect_uuid": "c59eb4f1-f5db-41f9-8ccd-a688266ee4bd",
          "name": "L257P",
          "name_review": {
            "updateTime": 1675371480703,
            "updatedBy": "User"
          },
          "name_uuid": "d88ac102-f964-48bc-a858-e6958ff4c17c",
          "tumors_uuid": "6d23d0a4-1766-430e-9c7a-83692fe0fada"
        },
        {
          "mutation_effect": {
            "description": "The TP53 L257Q mutation is located in the DNA-binding domain of the protein. This mutation has been identified in ovarian cancer and is a statistically significant hotspot (PMID: 20229506). In vivo studies with yeast expressing TP53 L257Q demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 L257Q also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675371510770,
              "updatedBy": "User"
            },
            "description_uuid": "95dca8bc-5b5b-4572-91d4-740675cadfa0",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675371506988,
              "updatedBy": "User"
            },
            "effect_uuid": "c410c596-c32f-4b39-8691-c8f8c035c043",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675371506160,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "2947f759-fb3e-4c1a-bd05-9a7ce55db031",
            "short": ""
          },
          "mutation_effect_uuid": "dadeeaf4-e11c-4654-9cea-47349945fcfe",
          "name": "L257Q",
          "name_review": {
            "updateTime": 1675371503651,
            "updatedBy": "User"
          },
          "name_uuid": "28c27828-a1d9-4aa2-9025-711e7d087d77",
          "tumors_uuid": "462c38c8-0e4f-4502-8e4a-44f357a0e997"
        },
        {
          "mutation_effect": {
            "description": "The TP53 L257R mutation is located in the DNA-binding domain of the protein. This mutation has been identified in ovarian cancer and is a statistically significant hotspot (PMID: 8700537). In vivo studies with yeast expressing TP53 L257R demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 L257R also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675371533272,
              "updatedBy": "User"
            },
            "description_uuid": "987942ab-96b4-4e50-81db-2d2c35e7fa87",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675371531709,
              "updatedBy": "User"
            },
            "effect_uuid": "eaf95a60-da3e-4109-8270-a7005ab78001",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675371530828,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "c74bc26e-0ec8-4bfb-9c2d-151574046249",
            "short": ""
          },
          "mutation_effect_uuid": "968ea4d8-7fb1-4f73-94ca-e912e8a77c92",
          "name": "L257R",
          "name_review": {
            "updateTime": 1675371525939,
            "updatedBy": "User"
          },
          "name_uuid": "794af2c6-3c3b-4acf-8c2c-be4a13825e25",
          "tumors_uuid": "05009c9d-0656-48d8-91d4-3a3609c22358"
        },
        {
          "mutation_effect": {
            "description": "The TP53 L257V mutation is located in the DNA-binding domain of the protein. This mutation has been identified in glioma and is a statistically significant hotspot (PMID: 12635658). In vivo studies with yeast expressing TP53 L257V demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 L257V also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675371553186,
              "updatedBy": "User"
            },
            "description_uuid": "074f73d4-7d4a-4d04-a282-e3bd6f3dc45b",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675371549367,
              "updatedBy": "User"
            },
            "effect_uuid": "97bae24c-add8-4ad9-b793-0410baa2f451",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675371548577,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "b9b52009-122d-4cf5-941a-ec3d5791b385",
            "short": ""
          },
          "mutation_effect_uuid": "16d9d093-0a55-423d-be37-c7233918d212",
          "name": "L257V",
          "name_review": {
            "updateTime": 1675371544704,
            "updatedBy": "User"
          },
          "name_uuid": "ffa44dc5-0bc3-4957-961a-367762d5af64",
          "tumors_uuid": "64c5568f-7377-4530-af73-df923b51bb92"
        },
        {
          "mutation_effect": {
            "description": "The TP53 N131I mutation is located in the DNA-binding domain of the protein. This mutation has been identified in bladder cancer and is a statistically significant hotspot (PMID: 10492244). In vivo studies with yeast expressing TP53 N131I demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 N131I also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675371575206,
              "updatedBy": "User"
            },
            "description_uuid": "f798613b-3e48-4d69-b0db-6a3d755a8058",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675371569437,
              "updatedBy": "User"
            },
            "effect_uuid": "f90e9c7c-a7ed-45a9-b0ed-34e4d7bc6706",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675371568567,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "384bf3a8-0dbb-4723-a34f-5463e4dededc",
            "short": ""
          },
          "mutation_effect_uuid": "9aa9aa4c-1829-482f-8d70-a1cb41b8fea1",
          "name": "N131I",
          "name_review": {
            "updateTime": 1675371566419,
            "updatedBy": "User"
          },
          "name_uuid": "7f2aec9c-c80b-4fe0-bbbd-e917c154aea9",
          "tumors_uuid": "490b15dc-f185-4ff7-bc3c-2d004d2b10fc"
        },
        {
          "mutation_effect": {
            "description": "The TP53 N131K mutation is located in the DNA-binding domain of the protein. This mutation has been identified in esophageal squamous cell carcinoma and is a statistically significant hotspot (PMID: 16271069). In vivo studies with yeast expressing TP53 N131K demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
            "description_review": {
              "updateTime": 1675371597047,
              "updatedBy": "User"
            },
            "description_uuid": "f35cdac9-612c-4244-a636-40848c7e2648",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675371593055,
              "updatedBy": "User"
            },
            "effect_uuid": "f98965dd-f01e-4474-a464-c8df17f361da",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675371592091,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "a8fe2092-4636-47b6-8f95-4fd09633a1f8",
            "short": ""
          },
          "mutation_effect_uuid": "354e2888-3534-4a2a-b625-6b880108141b",
          "name": "N131K",
          "name_review": {
            "updateTime": 1675371588748,
            "updatedBy": "User"
          },
          "name_uuid": "f63c4fdf-5a5b-45b0-ace9-70c364309ae4",
          "tumors_uuid": "0779a0d2-332f-4e07-a5bf-e1164e994c88"
        },
        {
          "mutation_effect": {
            "description": "The TP53 L265P mutation is located in the DNA-binding domain of the protein. This mutation has been identified in ovarian cancer and is a statistically significant hotspot (PMID: 14760384). In vivo studies with yeast expressing TP53 L265P demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 L265P also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675371615769,
              "updatedBy": "User"
            },
            "description_uuid": "dad6da3d-1880-45e6-b9d5-2e5347d62094",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675371611222,
              "updatedBy": "User"
            },
            "effect_uuid": "15dfb079-b60c-418b-b80c-c492000af976",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675371609767,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "3c3aade7-7c32-4361-893f-25eec3101688",
            "short": ""
          },
          "mutation_effect_uuid": "92c72f48-04f4-40e3-b3f5-aa6a0810b08f",
          "name": "L265P",
          "name_review": {
            "updateTime": 1675371607457,
            "updatedBy": "User"
          },
          "name_uuid": "b47f8cde-063f-4569-a211-692be9999598",
          "tumors_uuid": "2d58314f-8746-4ed4-a05d-af15bf4a66ef"
        },
        {
          "mutation_effect": {
            "description": "The TP53 L265R mutation is located in the DNA-binding domain of the protein. This mutation has been identified in colorectal cancer and is a statistically significant hotspot (PMID: 11307149). In vivo studies with yeast expressing TP53 L265R demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 L265R also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675371804232,
              "updatedBy": "User"
            },
            "description_uuid": "6c07c5d4-7f5f-44d4-99c9-3bd0dfa18969",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675371800680,
              "updatedBy": "User"
            },
            "effect_uuid": "a0e182ae-d4a4-4b34-a4c2-167e24e1a16e",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675371799396,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "b8dee627-770b-4213-82e6-383a73f72a16",
            "short": ""
          },
          "mutation_effect_uuid": "bd4551f0-f37c-4295-8c44-20c50edbc927",
          "name": "L265R",
          "name_review": {
            "updateTime": 1675371796346,
            "updatedBy": "User"
          },
          "name_uuid": "a7a64326-0de1-4d57-8230-aa558048599c",
          "tumors_uuid": "9aa88d02-7014-4a92-9de7-405680df69cb"
        },
        {
          "mutation_effect": {
            "description": "The TP53 L265M mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and is a statistically significant hotspot (PMID: 15050734). There is conflicting evidence about the biological and oncogenic effect of the mutation. In vivo studies with yeast expressing TP53 L265M demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). However, other in vitro studies with various human cancer cell lines expressing TP53 L265M demonstrated that the mutation is likely neutral as measured by wildtype comparable growth suppression activity (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675371821120,
              "updatedBy": "User"
            },
            "description_uuid": "19bcad64-1599-48bb-89a9-ab9259295ef7",
            "effect": "Inconclusive",
            "effect_review": {
              "updateTime": 1675371817452,
              "updatedBy": "User"
            },
            "effect_uuid": "cfb2f296-d497-420e-c0ec-24e9a3deeacd",
            "oncogenic": "Inconclusive",
            "oncogenic_review": {
              "updateTime": 1675371816725,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "946a1d0f-f5d7-47f5-ae85-1e83e68449d4",
            "short": ""
          },
          "mutation_effect_uuid": "541abd36-70f5-4eb2-a129-1226adb18e8e",
          "name": "L265M",
          "name_review": {
            "updateTime": 1675371814696,
            "updatedBy": "User"
          },
          "name_uuid": "6c087e5e-db90-48d7-9978-988c22d2a64c",
          "tumors_uuid": "9dbf8473-785b-475e-ba9b-e27d754d0453"
        },
        {
          "mutation_effect": {
            "description": "The TP53 G262V mutation is located in the DNA-binding domain of the protein. This mutation has been identified in colorectal cancer and is a statistically significant hotspot (PMID: 11307149). In vivo studies with yeast expressing TP53 G262V demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 G262V also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675371842391,
              "updatedBy": "User"
            },
            "description_uuid": "7cb5cffe-ab57-49b7-8dfe-10a6c3ad8463",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675371838572,
              "updatedBy": "User"
            },
            "effect_uuid": "5aa75f46-53ed-4ff9-b3e7-ee7d1b7874a0",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675371837030,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "9ec6d731-1746-4e30-b05e-49da6c1f5028",
            "short": ""
          },
          "mutation_effect_uuid": "74ef7ad6-4aba-435f-b3e3-2f7e9d53d1ad",
          "name": "G262V",
          "name_review": {
            "updateTime": 1675371835132,
            "updatedBy": "User"
          },
          "name_uuid": "509276d0-089e-49e9-8dec-c72630657e12",
          "tumors_uuid": "1495ca9d-2bd0-474e-82d2-9bae8c8a6372"
        },
        {
          "mutation_effect": {
            "description": "The TP53 F113C mutation is located in the DNA-binding domain of the protein. This mutation has been identified in lung adenocarcinoma and is a statistically significant hotspot (PMID: 1312896). In vivo studies with yeast expressing TP53 F113C demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 F113C also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675371860819,
              "updatedBy": "User"
            },
            "description_uuid": "6b445bf0-4410-42f3-90e4-9c3e86867ab1",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675371859392,
              "updatedBy": "User"
            },
            "effect_uuid": "898ffa44-411c-4208-9881-91cd83542a76",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675371858693,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "18a5ba78-fa38-4d3c-a450-f68c57b44bcf",
            "short": ""
          },
          "mutation_effect_uuid": "cff50094-605d-4a46-a1ca-9a26d80bdf16",
          "name": "F113C",
          "name_review": {
            "updateTime": 1675371853609,
            "updatedBy": "User"
          },
          "name_uuid": "9eef746f-75a3-4753-a963-01d2c9596872",
          "tumors_uuid": "9baebcc3-412a-4136-91f2-82186fb79b84"
        },
        {
          "mutation_effect": {
            "description": "The TP53 F113S mutation is located in the DNA-binding domain of the protein. This mutation has been identified in colorectal cancer and is a statistically significant hotspot (PMID: 12242668). In vivo studies with yeast expressing TP53 F113S demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 F113S also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675371879494,
              "updatedBy": "User"
            },
            "description_uuid": "c71b7486-34f3-4e72-a735-0c1e8872cfc7",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675371875765,
              "updatedBy": "User"
            },
            "effect_uuid": "be540e00-6fa8-4778-8330-4bd8b38851fa",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675371874835,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "ee003982-469f-495e-a566-0a1ed2e775dd",
            "short": ""
          },
          "mutation_effect_uuid": "b181d139-91b7-4f74-a824-1cd24678a84d",
          "name": "F113S",
          "name_review": {
            "updateTime": 1675371872844,
            "updatedBy": "User"
          },
          "name_uuid": "d00f5fda-2a1e-49b2-b02a-e69b7262c9af",
          "tumors_uuid": "9016ef2a-f082-4fe5-b0a8-e33fe9701b61"
        },
        {
          "mutation_effect": {
            "description": "The TP53 F113V mutation is located in the DNA-binding domain of the protein. This mutation has been identified in astrocytoma and is a statistically significant hotspot (PMID: 15188009). In vivo studies with yeast expressing TP53 F113V demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 F113V also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675371897967,
              "updatedBy": "User"
            },
            "description_uuid": "97f3cc5c-58f7-42ff-bf20-a7f248bb247c",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675371892675,
              "updatedBy": "User"
            },
            "effect_uuid": "ddc53f3e-c2cf-4780-9dba-6b85f4645a8d",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675371891868,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "51db914f-e8f9-40ad-b12f-6cfa0b8a6161",
            "short": ""
          },
          "mutation_effect_uuid": "84e5f604-4d51-4ca8-9257-7a52a18b174c",
          "name": "F113V",
          "name_review": {
            "updateTime": 1675371888425,
            "updatedBy": "User"
          },
          "name_uuid": "aa2f2bda-ccf1-4696-9bde-12abc3cd4cdc",
          "tumors_uuid": "33a82fa0-e37f-4106-8a89-b67f02e12d55"
        },
        {
          "mutation_effect": {
            "description": "The TP53 F113L mutation is located in the DNA-binding domain of the protein. This mutation has been identified in bladder cancer and is a statistically significant hotspot (PMID: 16532037). There is conflicting evidence about the biological and oncogenic effect of the mutation. In vivo studies with yeast expressing TP53 F113L demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). However, other in vitro studies with various human cancer cell lines expressing TP53 F113L demonstrated that the mutation is likely neutral as measured by growth suppression activity comparable to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1677197869531,
              "updatedBy": "User"
            },
            "description_uuid": "7b6704d2-3ffa-4919-ba5e-5553cb5fadcc",
            "effect": "Inconclusive",
            "effect_review": {
              "updateTime": 1675371912864,
              "updatedBy": "User"
            },
            "effect_uuid": "a3f6813b-7927-42fb-bb7c-4c4357892c64",
            "oncogenic": "Inconclusive",
            "oncogenic_review": {
              "updateTime": 1675371911851,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "1c2b0cfd-de90-4681-866f-1aaf090f1bae",
            "short": ""
          },
          "mutation_effect_uuid": "c0c8c6a2-7a9b-4aca-8211-cc18d225c9a8",
          "name": "F113L",
          "name_review": {
            "updateTime": 1675371909441,
            "updatedBy": "User"
          },
          "name_uuid": "e11eaeba-2361-4f2c-81a5-0f6cdb7f47e5",
          "tumors_uuid": "91192c2b-2921-4d49-94ae-fff82da5d2ab"
        },
        {
          "mutation_effect": {
            "description": "The TP53 L111P mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and is a statistically significant hotspot (PMID: 16821082). In vivo studies with yeast expressing TP53 L111P demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 L111P also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675371938545,
              "updatedBy": "User"
            },
            "description_uuid": "5f8ef2a2-8a59-47fd-823a-6ef3924bb6bd",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675371937345,
              "updatedBy": "User"
            },
            "effect_uuid": "1d0c9077-7f90-4bd6-835f-109487f97226",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675371936509,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "c7c3a2f0-cf14-43c2-b32b-8c31ea9e51a6",
            "short": ""
          },
          "mutation_effect_uuid": "410df0ce-9248-45b6-afee-2a4c0cb51230",
          "name": "L111P",
          "name_review": {
            "updateTime": 1675371933030,
            "updatedBy": "User"
          },
          "name_uuid": "877e679c-9800-429c-9ee6-54b9f92d503c",
          "tumors_uuid": "1bbd0806-83d7-49b7-9064-e514e5affa59"
        },
        {
          "mutation_effect": {
            "description": "The TP53 L111Q mutation is located in the DNA-binding domain of the protein. This mutation has been identified in squamous cell carcinoma and is a statistically significant hotspot (PMID: 9400993). In vivo studies with yeast expressing TP53 L111Q demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 L111Q also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675371958450,
              "updatedBy": "User"
            },
            "description_uuid": "60a749f9-1f06-4e97-9727-9293ff578240",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675371954540,
              "updatedBy": "User"
            },
            "effect_uuid": "a1e2aa3a-ed4d-44c4-bd94-43aeb7dd18df",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675371953595,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "e4c1984a-22dc-4617-b3ce-8eb50ceb0f1b",
            "short": ""
          },
          "mutation_effect_uuid": "a95cb58d-1bc9-4319-974c-8c07fecf9ff6",
          "name": "L111Q",
          "name_review": {
            "updateTime": 1675371950707,
            "updatedBy": "User"
          },
          "name_uuid": "616e7c26-480f-4b9c-9891-84dd5140df5a",
          "tumors_uuid": "515cb84d-7809-4986-b670-2b7c6fd55a0c"
        },
        {
          "mutation_effect": {
            "description": "The TP53 L111R mutation is located in the DNA-binding domain of the protein. This mutation has been identified in hepatocellular carcinoma and is a statistically significant hotspot (PMID: 14687797). In vivo studies with yeast expressing TP53 L111R demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 L111R also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675371973377,
              "updatedBy": "User"
            },
            "description_uuid": "accc30fb-33ad-4004-bbe2-c9255a3ebeb2",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675371970384,
              "updatedBy": "User"
            },
            "effect_uuid": "e19bed62-9066-4e78-bac6-8e4697fdba39",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675371969592,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "4f86f8ad-0fad-443d-ba73-230d1ce1d673",
            "short": ""
          },
          "mutation_effect_uuid": "4f17e5de-ded9-4bf9-8153-60acdaed109d",
          "name": "L111R",
          "name_review": {
            "updateTime": 1675371967815,
            "updatedBy": "User"
          },
          "name_uuid": "f61870c4-f3fa-4c54-bd96-9016a27dd9f7",
          "tumors_uuid": "315f6675-37ff-4014-ad9f-ac705e171ea9"
        },
        {
          "mutation_effect": {
            "description": "The TP53 L111M mutation is located in the DNA-binding domain of the protein. This mutation has been identified in hepatocellular carcinoma and is a statistically significant hotspot (PMID: 15126338). There is conflicting evidence about the biological and oncogenic effect of the mutation. In vivo studies with yeast expressing TP53 L111M demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). However, other in vitro studies with various human cancer cell lines expressing TP53 L111M demonstrated that the mutation is likely neutral as measured by wildtype comparable growth suppression activity (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675371992084,
              "updatedBy": "User"
            },
            "description_uuid": "0c708958-cf0f-4312-8b9f-43014dfb72c1",
            "effect": "Inconclusive",
            "effect_review": {
              "updateTime": 1675371988772,
              "updatedBy": "User"
            },
            "effect_uuid": "1acb11dc-5b0d-4967-8274-65e77090aadc",
            "oncogenic": "Inconclusive",
            "oncogenic_review": {
              "updateTime": 1675371987668,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "f57ddce8-5774-4eeb-86f7-7d65a26efb33",
            "short": ""
          },
          "mutation_effect_uuid": "f2241b0e-bc57-4a5a-8021-3cfe48f83881",
          "name": "L111M",
          "name_review": {
            "updateTime": 1675371984170,
            "updatedBy": "User"
          },
          "name_uuid": "40521129-aeeb-42b0-8cd8-b0620c4772e3",
          "tumors_uuid": "2be2926a-1c0e-450a-aa50-f7c7cd8c7367"
        },
        {
          "mutation_effect": {
            "description": "The TP53 D259V mutation is located in the DNA-binding domain of the protein. This mutation has been identified in non-small cell lung cancer and is a statistically significant hotspot (PMID: 12209975). In vivo studies with yeast expressing TP53 D259V demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 D259V also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675372011288,
              "updatedBy": "User"
            },
            "description_uuid": "8a50fdad-68c3-48db-a4d0-7bba6ea29df2",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675372007789,
              "updatedBy": "User"
            },
            "effect_uuid": "9a1c776f-f67e-4c06-a6d2-dbfae1f194e1",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675372007119,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "41c18b1e-a95c-4ffd-b7e5-fd12b4276f77",
            "short": ""
          },
          "mutation_effect_uuid": "e9b5ca51-5f0e-47e5-a4bb-b08a4c9c4503",
          "name": "D259V",
          "name_review": {
            "updateTime": 1675372005187,
            "updatedBy": "User"
          },
          "name_uuid": "930c7ca6-bd2d-4e82-c059-268a3a60ee27",
          "tumors_uuid": "7e0293fa-e675-4b0e-911f-61369744a900"
        },
        {
          "mutation_effect": {
            "description": "The TP53 D259H mutation is located in the DNA-binding domain of the protein. This mutation has been identified in bladder cancer and is a statistically significant hotspot (PMID: 20824703). There is conflicting evidence about the biological and oncogenic effect of the mutation. In vivo studies with yeast expressing TP53 D259H demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). However, other in vitro studies with various human cancer cell lines expressing TP53 D259H demonstrated that the mutation is likely neutral as measured by growth suppression activity comparable to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1677198328791,
              "updatedBy": "User"
            },
            "description_uuid": "0a6332e6-d336-48ad-bbb4-81f8c70cb022",
            "effect": "Inconclusive",
            "effect_review": {
              "updateTime": 1675372024658,
              "updatedBy": "User"
            },
            "effect_uuid": "3fcd13c1-b177-47ac-b140-09b51c30a046",
            "oncogenic": "Inconclusive",
            "oncogenic_review": {
              "updateTime": 1675372023607,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "86bdad87-e2d6-420d-b990-b232db54968c",
            "short": ""
          },
          "mutation_effect_uuid": "002b353c-07ae-476f-b51d-3105c9f56d0e",
          "name": "D259H",
          "name_review": {
            "updateTime": 1675372021072,
            "updatedBy": "User"
          },
          "name_uuid": "a3c3eb40-e39b-452c-9174-9ae877c0bdf7",
          "tumors_uuid": "58a3249d-addd-4775-81aa-4ca81c26ccee"
        },
        {
          "mutation_effect": {
            "description": "The TP53 D259Y mutation is located in the DNA-binding domain of the protein. This mutation has been identified in ovarian cancer and is a statistically significant hotspot (PMID: 17171684). In vivo studies with yeast expressing TP53 D259Y demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 D259Y also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675372047050,
              "updatedBy": "User"
            },
            "description_uuid": "5dc1856d-4a56-4f7f-bc71-7ddba744dd01",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675372043095,
              "updatedBy": "User"
            },
            "effect_uuid": "1f3b2798-0751-446e-b403-7bea641feba1",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675372041731,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "2b5ccef5-270b-40d6-b16e-6b842e252788",
            "short": ""
          },
          "mutation_effect_uuid": "d7e2ca6e-dc71-4bd0-a973-12cca2f9d92e",
          "name": "D259Y",
          "name_review": {
            "updateTime": 1675372039885,
            "updatedBy": "User"
          },
          "name_uuid": "cad277ee-5e08-472a-98aa-d9ae6217ffa0",
          "tumors_uuid": "ad172a68-49af-4a09-a0fe-d828642dec76"
        },
        {
          "mutation_effect": {
            "description": "The TP53 D259N mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and is a statistically significant hotspot (PMID: 18348141). There is conflicting evidence about the biological and oncogenic effect of the mutation. In vivo studies with yeast expressing TP53 D259N demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). However, other in vitro studies with various human cancer cell lines expressing TP53 D259N demonstrated that the mutation is likely neutral as measured by wildtype comparable growth suppression activity (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675372062740,
              "updatedBy": "User"
            },
            "description_uuid": "1967fd07-c80e-4273-be3c-3f279ad874d0",
            "effect": "Inconclusive",
            "effect_review": {
              "updateTime": 1675372059790,
              "updatedBy": "User"
            },
            "effect_uuid": "9c7de2a0-2295-4d12-86cd-93b6c2680ae9",
            "oncogenic": "Inconclusive",
            "oncogenic_review": {
              "updateTime": 1675372059103,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "48dffcf2-7720-4e11-a93a-0668328d4ca1",
            "short": ""
          },
          "mutation_effect_uuid": "11e3128b-4e82-4bb3-b270-310e926ec47f",
          "name": "D259N",
          "name_review": {
            "updateTime": 1675372056198,
            "updatedBy": "User"
          },
          "name_uuid": "53700e38-1bec-4278-94b7-94c9294609a1",
          "tumors_uuid": "0434baf9-1039-4301-86c6-ece124d0b420"
        },
        {
          "mutation_effect": {
            "description": "The TP53 I232T mutation is located in the DNA-binding domain of the protein. This mutation has been identified in follicular lymphoma and is a statistically significant hotspot (PMID: 12217802). In vivo studies with yeast expressing TP53 I232T demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 I232T also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675372079598,
              "updatedBy": "User"
            },
            "description_uuid": "e6593126-709f-4c5d-a293-56959c95a7b3",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675372078425,
              "updatedBy": "User"
            },
            "effect_uuid": "0a8ce906-0365-45c9-8e6d-9b1bfbecae5d",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675372077701,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "0c8ae8f6-6849-4f54-87bd-c13b122350f7",
            "short": ""
          },
          "mutation_effect_uuid": "35c42422-f385-41bb-8a1f-4fd589a33d0f",
          "name": "I232T",
          "name_review": {
            "updateTime": 1675372073553,
            "updatedBy": "User"
          },
          "name_uuid": "72914e1a-b0ef-4524-8546-5634886794b8",
          "tumors_uuid": "a4c6b9bf-8f09-4798-b302-d6fad87134d4"
        },
        {
          "mutation_effect": {
            "description": "The TP53 I232N mutation is located in the DNA-binding domain of the protein. This mutation has been identified in prostate cancer and is a statistically significant hotspot (PMID: 8688333). In vivo studies with yeast expressing TP53 I232N demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 I232N also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675372095142,
              "updatedBy": "User"
            },
            "description_uuid": "e401cb2c-c391-48dd-b17d-c486bfb3b6a3",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675372091371,
              "updatedBy": "User"
            },
            "effect_uuid": "894e6d0e-c12d-4b52-91a6-7a5402eb77f6",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675372090360,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "7ed7f2b3-a71d-4b6d-ae97-c0de73aeba70",
            "short": ""
          },
          "mutation_effect_uuid": "b67aab18-d3a7-4c97-a8ea-f35843ccb8bd",
          "name": "I232N",
          "name_review": {
            "updateTime": 1675372088572,
            "updatedBy": "User"
          },
          "name_uuid": "278fb788-c53e-4633-a491-9d43eebe02dd",
          "tumors_uuid": "b75eb096-3ae0-440f-9e59-3308ed52ffca"
        },
        {
          "mutation_effect": {
            "description": "The TP53 C135F mutation is located in the DNA-binding domain of the protein. This mutation has been identified in Ewing sarcoma and is a statistically significant hotspot (PMID: 11406642). In vivo studies with yeast expressing TP53 C135F demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 C135F also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675372111880,
              "updatedBy": "User"
            },
            "description_uuid": "19f6010d-2999-4a4f-a519-5e3da7f1b08a",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675372108362,
              "updatedBy": "User"
            },
            "effect_uuid": "1d4da7e4-9d7a-4b01-9a24-150c229faa64",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675372107102,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "f863c871-c5eb-4f9b-9d9b-649844d13dfe",
            "short": ""
          },
          "mutation_effect_uuid": "2971cbd1-adc3-4be1-8cb0-5ff455a6c16b",
          "name": "C135F",
          "name_review": {
            "updateTime": 1675372105338,
            "updatedBy": "User"
          },
          "name_uuid": "1dc4cf37-5c14-4432-950e-9b60d6d08401",
          "tumors_uuid": "8a66ff06-d13e-4533-c033-e4c12b524930"
        },
        {
          "mutation_effect": {
            "description": "The TP53 H214P mutation is located in the DNA-binding domain of the protein. This mutation has been identified in astrocytoma and is a statistically significant hotspot (PMID: 7882284). There is conflicting evidence about the biological and oncogenic effect of the mutation. In vitro studies with various human cancer cell lines expressing TP53 H214P also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644). However, other in vivo studies with yeast expressing TP53 H214P demonstrated that the mutation is likely neutral as measured by wildtype comparable transactivational activity (PMID: 27328919, 12826609).",
            "description_review": {
              "updateTime": 1675372126884,
              "updatedBy": "User"
            },
            "description_uuid": "b48a7026-60f7-4e9a-848d-d7be72038925",
            "effect": "Inconclusive",
            "effect_review": {
              "updateTime": 1675372123591,
              "updatedBy": "User"
            },
            "effect_uuid": "9587a5bc-bdc2-42d2-ab32-fc70968a1f60",
            "oncogenic": "Inconclusive",
            "oncogenic_review": {
              "updateTime": 1675372122806,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "f5ca4c1e-6162-4db3-87a4-dd7ea5b95114",
            "short": ""
          },
          "mutation_effect_uuid": "8a4a4f2c-5790-4e18-8eb7-34798b7987d1",
          "name": "H214P",
          "name_review": {
            "updateTime": 1675372119894,
            "updatedBy": "User"
          },
          "name_uuid": "f1223d71-8853-4ee9-827e-20e676fd2957",
          "tumors_uuid": "fa54e02b-448b-461f-8211-84460e169f97"
        },
        {
          "mutation_effect": {
            "description": "The TP53 C135W mutation is located in the DNA-binding domain of the protein. This mutation has been identified in esophageal squamous cell carcinoma and is a statistically significant hotspot (PMID: 11309337). In vivo studies with yeast expressing TP53 C135W demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 C135W also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675372148030,
              "updatedBy": "User"
            },
            "description_uuid": "cd65128d-b606-4a20-a818-a5cd665f1b97",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675372146784,
              "updatedBy": "User"
            },
            "effect_uuid": "9d137f25-ac6e-45b4-b284-922e467f7f2d",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675372145815,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "de4a6cc4-2c4b-4a64-8b7d-165986495b24",
            "short": ""
          },
          "mutation_effect_uuid": "b904c10b-71da-4673-ace4-55983a819550",
          "name": "C135W",
          "name_review": {
            "updateTime": 1675372140525,
            "updatedBy": "User"
          },
          "name_uuid": "d0088ed8-0416-4244-8361-68f9b52e35df",
          "tumors_uuid": "49aa87ec-6c4a-4472-8658-373c297535f2"
        },
        {
          "mutation_effect": {
            "description": "The TP53 D281P mutation is located in the DNA-binding domain of the protein. This mutation has been identified in glioblastoma and is a statistically significant hotspot (PMID: 24120142). In vitro studies with various human cancer cell lines expressing TP53 D281P demonstrated that the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675372173485,
              "updatedBy": "User"
            },
            "description_uuid": "c6920b1f-1b92-4936-813c-c2150b56010a",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675372167558,
              "updatedBy": "User"
            },
            "effect_uuid": "8803add6-6bf7-4885-bc5e-bfce7dba782d",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675372166379,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "dfdf2cf0-70ff-4060-9667-dbfb2e4d35c3",
            "short": ""
          },
          "mutation_effect_uuid": "92375efb-7c05-481f-8f74-9d71ede268fc",
          "name": "D281P",
          "name_review": {
            "updateTime": 1675372158593,
            "updatedBy": "User"
          },
          "name_uuid": "7aa18bd1-209a-4ccd-8785-8f998a12e0d8",
          "tumors_uuid": "fe3541aa-4e20-4c04-98b6-744af2554a10"
        },
        {
          "mutation_effect": {
            "description": "The TP53 P151T mutation is located in the DNA-binding domain of the protein. This mutation has been identified in colorectal cancer and is a statistically significant hotspot (PMID: 15316933). In vivo studies with yeast expressing TP53 P151T demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 P151T also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675372192122,
              "updatedBy": "User"
            },
            "description_uuid": "be85b595-65f6-456d-b00c-7ea7334d5c3c",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675372190401,
              "updatedBy": "User"
            },
            "effect_uuid": "a0ade61a-1273-4816-a789-880d7f066c74",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675372189403,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "116fd63d-6a9b-4932-b425-ba040598c7fe",
            "short": ""
          },
          "mutation_effect_uuid": "104f5d48-f1e7-4abd-8d9a-b193b49adabf",
          "name": "P151T",
          "name_review": {
            "updateTime": 1675372184435,
            "updatedBy": "User"
          },
          "name_uuid": "d4ab34d3-7dee-4fec-8d8d-8472a2e8c299",
          "tumors_uuid": "53005062-bc04-4f6e-adcb-8eb8df57d502"
        },
        {
          "mutation_effect": {
            "description": "The TP53 P151F mutation is located in the DNA-binding domain of the protein. This mutation has been identified in non-small cell lung cancer and is a statistically significant hotspot (PMID: 14618621). In vitro studies with various human cancer cell lines expressing TP53 P151F demonstrated that the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675372215093,
              "updatedBy": "User"
            },
            "description_uuid": "60faf9bb-f0ac-4c3a-b11e-55119d3ed2d7",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675372210261,
              "updatedBy": "User"
            },
            "effect_uuid": "20df2fcf-6008-461e-810a-31a563311b42",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675372209053,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "8d949ed9-5cda-4cae-9fd4-7ff5ae1df088",
            "short": ""
          },
          "mutation_effect_uuid": "5e5dceff-f88c-4f19-a9b0-e879d26b24a1",
          "name": "P151F",
          "name_review": {
            "updateTime": 1675372206755,
            "updatedBy": "User"
          },
          "name_uuid": "9fd9b99e-c684-4605-c0e1-0126f8342a7f",
          "tumors_uuid": "befe183e-a933-4147-992a-c84e5485898e"
        },
        {
          "mutation_effect": {
            "description": "The TP53 P151L mutation is located in the DNA-binding domain of the protein. This mutation has been identified in NK/T-cell lymphoma and is a statistically significant hotspot (PMID: 15643509). In vivo studies with yeast expressing TP53 P151L demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
            "description_review": {
              "updateTime": 1675372237526,
              "updatedBy": "User"
            },
            "description_uuid": "86f9d5b8-7c20-45df-a572-835c9a563045",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675372233820,
              "updatedBy": "User"
            },
            "effect_uuid": "e9429b6e-ada6-4662-a455-782d894ca67f",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675372232857,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "e631ad98-eabf-4a0b-9e5b-8318375004ff",
            "short": ""
          },
          "mutation_effect_uuid": "c9eb5848-dd72-487a-904b-c7550e305019",
          "name": "P151L",
          "name_review": {
            "updateTime": 1675372230749,
            "updatedBy": "User"
          },
          "name_uuid": "9ff0220b-8728-43de-b76b-7845156a76f2",
          "tumors_uuid": "0d35b7e5-f565-4214-ac25-5824ea199091"
        },
        {
          "mutation_effect": {
            "description": "The TP53 D281A mutation is located in the DNA-binding domain of the protein. This mutation has been identified in malignant peripheral nerve sheath tumors and is a statistically significant hotspot (PMID: 20010306). There is conflicting evidence about the biological and oncogenic effect of the mutation. In vivo studies with yeast expressing TP53 D281A demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). However, other in vitro studies with various human cancer cell lines expressing TP53 D281A demonstrated that the mutation is likely neutral as measured by growth suppression activity comparable to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1677198667032,
              "updatedBy": "User"
            },
            "description_uuid": "3caf1bc7-74a8-4593-ba7b-e68abaa43d3c",
            "effect": "Inconclusive",
            "effect_review": {
              "updateTime": 1675372247892,
              "updatedBy": "User"
            },
            "effect_uuid": "cc9a3a96-431f-4a38-9bc7-0fee7434a13e",
            "oncogenic": "Inconclusive",
            "oncogenic_review": {
              "updateTime": 1675372247006,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "a3c5d9fd-1eef-4299-b589-f5461cc92094",
            "short": ""
          },
          "mutation_effect_uuid": "003a5e18-b3aa-4c6e-bcea-c6aa5f5c4a33",
          "name": "D281A",
          "name_review": {
            "updateTime": 1675372244739,
            "updatedBy": "User"
          },
          "name_uuid": "27eab5af-9a46-4aa3-92ae-720b4befa865",
          "tumors_uuid": "bdec040c-3d85-464a-9bfd-db151aa63f7e"
        },
        {
          "mutation_effect": {
            "description": "The TP53 R175G mutation is located in the DNA-binding domain of the protein. This mutation has been identified in acute T-cell lymphoblastic leukemia and is a statistically significant hotspot (PMID: 8486778). In vivo studies with yeast expressing TP53 R175G demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 R175G also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675372396423,
              "updatedBy": "User"
            },
            "description_uuid": "dce738f2-b948-416b-8955-e5f5a33efd7e",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675372393390,
              "updatedBy": "User"
            },
            "effect_uuid": "cd3b7655-6ec8-4964-b518-73ee35f26f8a",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675372392722,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "53651d7b-840a-4016-9144-99e21f93f8bc",
            "short": ""
          },
          "mutation_effect_uuid": "7796ee3d-a55a-413b-aad5-6ea8cfa8b6a1",
          "name": "R175G",
          "name_review": {
            "updateTime": 1675372390459,
            "updatedBy": "User"
          },
          "name_uuid": "3a9d655d-b052-4443-bf72-5cbd6ca6f49e",
          "tumors_uuid": "d96b3113-ae46-4e53-b775-a9ac96178c78"
        },
        {
          "mutation_effect": {
            "description": "The TP53 D281E mutation is located in the DNA-binding domain of the protein. This mutation has been identified in ovarian cancer and is a statistically significant hotspot (PMID: 11244334). There is conflicting evidence about the biological and oncogenic effect of the mutation. In vivo studies with yeast expressing TP53 D281E demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). However, other in vitro studies with various human cancer cell lines expressing TP53 D281E demonstrated that the mutation is likely neutral as measured by wildtype comparable growth suppression activity (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675372411264,
              "updatedBy": "User"
            },
            "description_uuid": "0f9f5f78-3c02-40c0-8399-e9b362a12c8c",
            "effect": "Inconclusive",
            "effect_review": {
              "updateTime": 1675372408173,
              "updatedBy": "User"
            },
            "effect_uuid": "fa55640a-c5bd-4c2b-92ec-b68dc144add7",
            "oncogenic": "Inconclusive",
            "oncogenic_review": {
              "updateTime": 1675372407442,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "6dc59b1e-6f96-4430-959b-30c233e27f03",
            "short": ""
          },
          "mutation_effect_uuid": "57985a69-755f-4695-be40-740b72a38486",
          "name": "D281E",
          "name_review": {
            "updateTime": 1675372405136,
            "updatedBy": "User"
          },
          "name_uuid": "955318c9-250b-4579-a9e5-325b74222448",
          "tumors_uuid": "24839934-567f-41b4-af44-d9892ba08d2b"
        },
        {
          "mutation_effect": {
            "description": "The TP53 D281V mutation is located in the DNA-binding domain of the protein. This mutation has been identified in Ewing sarcoma and is a statistically significant hotspot (PMID: 8168993). There is conflicting evidence about the biological and oncogenic effect of the mutation. In vivo studies with yeast expressing TP53 D281V demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). However, other in vitro studies with various human cancer cell lines expressing TP53 D281V demonstrated that the mutation is likely neutral as measured by wildtype comparable growth suppression activity (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675372568305,
              "updatedBy": "User"
            },
            "description_uuid": "d834a2cf-2f67-46a8-a84d-7d0d7a3da782",
            "effect": "Inconclusive",
            "effect_review": {
              "updateTime": 1675372564084,
              "updatedBy": "User"
            },
            "effect_uuid": "525a5306-5319-44cd-bf21-fa6ad17797cf",
            "oncogenic": "Inconclusive",
            "oncogenic_review": {
              "updateTime": 1675372563044,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "63f0a0ec-88dd-4f9d-a584-5e4f23b4e6cf",
            "short": ""
          },
          "mutation_effect_uuid": "64d0d9e2-3918-4291-beea-3298e44c9d8d",
          "name": "D281V",
          "name_review": {
            "updateTime": 1675372561230,
            "updatedBy": "User"
          },
          "name_uuid": "e0f66767-9af2-4402-a38b-92bb61d60743",
          "tumors_uuid": "d31634e1-3a55-4268-ac91-f44a71949ef3"
        },
        {
          "mutation_effect": {
            "description": "The TP53 D281G mutation is located in the DNA-binding domain of the protein. This mutation has been identified in malignant lymphoma and is a statistically significant hotspot (PMID: 8878455). There is conflicting evidence about the biological and oncogenic effect of the mutation. In vivo studies with yeast expressing TP53 D281G demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). However, other in vitro studies with various human cancer cell lines expressing TP53 D281G demonstrated that the mutation is likely neutral as measured by wildtype comparable growth suppression activity (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675372582074,
              "updatedBy": "User"
            },
            "description_uuid": "e24864a4-c618-4dbc-9122-e6bac3b6ba34",
            "effect": "Inconclusive",
            "effect_review": {
              "updateTime": 1677198808196,
              "updatedBy": "User"
            },
            "effect_uuid": "86167b42-0d99-4be1-a2cd-9e7e4b8ac132",
            "oncogenic": "Inconclusive",
            "oncogenic_review": {
              "updateTime": 1675372576572,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "6a9964a4-e846-49f2-920b-240a00cbf1a7",
            "short": ""
          },
          "mutation_effect_uuid": "a9365a83-1a13-4383-90d5-7156fee95837",
          "name": "D281G",
          "name_review": {
            "updateTime": 1675372574697,
            "updatedBy": "User"
          },
          "name_uuid": "5a71c2d1-46c9-4151-a43e-eb453400193f",
          "tumors_uuid": "d3ef5eb2-b33b-4d5b-a9c9-95ed06f7133b"
        },
        {
          "mutation_effect": {
            "description": "The TP53 D281H mutation is located in the DNA-binding domain of the protein. This mutation has been identified in clear cell renal cell carcinoma and is a statistically significant hotspot (PMID: 20137853). In vivo studies with yeast expressing TP53 D281H demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 D281H also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675372599334,
              "updatedBy": "User"
            },
            "description_uuid": "343a6358-cdf4-4920-9e28-ee0e56359c03",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675372595607,
              "updatedBy": "User"
            },
            "effect_uuid": "cf731ee9-f5cc-4e6e-b5f9-5b52f12dda77",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675372593908,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "10a87fe3-21e4-49fd-8dc5-93a58a1616c6",
            "short": ""
          },
          "mutation_effect_uuid": "624853a9-8496-417c-bf89-2a78f47789d2",
          "name": "D281H",
          "name_review": {
            "updateTime": 1675372591694,
            "updatedBy": "User"
          },
          "name_uuid": "bf6734d6-5537-460e-ac62-fe0187c051e6",
          "tumors_uuid": "6a76f524-a32c-42ad-b2fc-cd57e4a6e3d4"
        },
        {
          "mutation_effect": {
            "description": "The TP53 D281Y mutation is located in the DNA-binding domain of the protein. This mutation has been identified in follicular lymphoma and is a statistically significant hotspot (PMID: 10854221). In vivo studies with yeast expressing TP53 D281Y demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 D281Y also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675372853892,
              "updatedBy": "User"
            },
            "description_uuid": "3b369bab-3044-4a11-b522-b19f4e381d65",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675372850103,
              "updatedBy": "User"
            },
            "effect_uuid": "33f1ff16-6118-4758-9a34-340d3692efc4",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675372849323,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "733caa1a-063f-4413-a5ba-698334247f7d",
            "short": ""
          },
          "mutation_effect_uuid": "9b041a25-1d3c-44bd-a93c-84672d3828f5",
          "name": "D281Y",
          "name_review": {
            "updateTime": 1675372847071,
            "updatedBy": "User"
          },
          "name_uuid": "c9937398-c106-4247-8bc7-1c7e98e21747",
          "tumors_uuid": "d230f3c5-2b62-4bbe-bf87-3f91e21e907a"
        },
        {
          "mutation_effect": {
            "description": "The TP53 D281N mutation is located in the DNA-binding domain of the protein. This mutation has been identified in malignant lymphoma and is a statistically significant hotspot (PMID: 8916968). In vivo studies with yeast expressing TP53 D281N demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 D281N also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675372868507,
              "updatedBy": "User"
            },
            "description_uuid": "ce7a32e3-e9a8-4850-94df-d23991f2516b",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675372865418,
              "updatedBy": "User"
            },
            "effect_uuid": "18ba68ee-ff40-43c2-b093-2e4c246c12de",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675372862845,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "b3f62b84-50a5-4d24-83d6-39d8d5915f47",
            "short": ""
          },
          "mutation_effect_uuid": "bb56b65d-7f2d-4be3-974d-af372fe88157",
          "name": "D281N",
          "name_review": {
            "updateTime": 1675372861270,
            "updatedBy": "User"
          },
          "name_uuid": "8b1cc47a-8d6e-46dd-bffb-8cdd3fb6c0fc",
          "tumors_uuid": "4b934cb6-c8e2-4018-a95f-6347750fbb94"
        },
        {
          "mutation_effect": {
            "description": "The TP53 V216E mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and is a statistically significant hotspot (PMID: 7928628). In vivo studies with yeast expressing TP53 V216E demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 V216E also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675372882241,
              "updatedBy": "User"
            },
            "description_uuid": "69704ef9-6b3e-4bf9-87c0-3467cfb3194d",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675372878957,
              "updatedBy": "User"
            },
            "effect_uuid": "6bf2ce6b-961c-4e39-aca0-65a91c1a943f",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675372878091,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "01ba08ab-524c-4a73-8c73-d80f61955589",
            "short": ""
          },
          "mutation_effect_uuid": "a7d6315b-18dd-4fde-8646-1c1ef3547b4f",
          "name": "V216E",
          "name_review": {
            "updateTime": 1675372875971,
            "updatedBy": "User"
          },
          "name_uuid": "1240b14a-882f-42c1-a3e5-8990376b1c59",
          "tumors_uuid": "2bba8ff6-f6d3-4e85-a079-e34e879ae673"
        },
        {
          "mutation_effect": {
            "description": "The TP53 V216G mutation is located in the DNA-binding domain of the protein. This mutation has been identified in ovarian cancer and is a statistically significant hotspot (PMID: 16459017). In vivo studies with yeast expressing TP53 V216G demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 V216G also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675372983764,
              "updatedBy": "User"
            },
            "description_uuid": "0e6758d1-8819-42f3-b0e6-e07b4c5a4435",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675372982576,
              "updatedBy": "User"
            },
            "effect_uuid": "98d87d75-6f48-48b7-8b48-3aef97375f1c",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675372981697,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "b3e29b9d-841c-4ebb-83f7-3ec8c72799f0",
            "short": ""
          },
          "mutation_effect_uuid": "622bef66-058b-407d-84ef-b7220f1cf76e",
          "name": "V216G",
          "name_review": {
            "updateTime": 1675372976783,
            "updatedBy": "User"
          },
          "name_uuid": "94b09bb7-ded0-47aa-b201-122f9be73853",
          "tumors_uuid": "9b9bc022-efff-4908-8877-0adb20d4def5"
        },
        {
          "mutation_effect": {
            "description": "The TP53 V216L mutation is located in the DNA-binding domain of the protein. This mutation has been identified in colorectal cancer and is a statistically significant hotspot (PMID: 9516972). In vivo studies with yeast expressing TP53 V216L demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 V216L also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675373434289,
              "updatedBy": "User"
            },
            "description_uuid": "b78b3967-09d9-4ad8-82f8-69f02da29da4",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675373430744,
              "updatedBy": "User"
            },
            "effect_uuid": "16c51556-6cf3-41fa-b0df-c8723320c0e9",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675373430190,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "220d411c-edad-48f1-a8cb-c658deee8688",
            "short": ""
          },
          "mutation_effect_uuid": "760749ff-1af9-4583-b1a9-d75f8a431da1",
          "name": "V216L",
          "name_review": {
            "updateTime": 1675373427795,
            "updatedBy": "User"
          },
          "name_uuid": "c719def0-3e21-4e28-b2af-e12653b36d13",
          "tumors_uuid": "1db9a1c8-240a-4a1b-93fa-cd40771d5ab4"
        },
        {
          "mutation_effect": {
            "description": "The TP53 V216M mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and is a statistically significant hotspot (PMID: 22551440). In vivo studies with yeast expressing TP53 V216M demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 V216M also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675373516755,
              "updatedBy": "User"
            },
            "description_uuid": "63a61699-d211-443a-8ca7-a15f703a578d",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675373515276,
              "updatedBy": "User"
            },
            "effect_uuid": "f02226ef-970e-4c1d-8aae-2cd440c2dbc3",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675373514571,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "0b8dee69-81ac-4481-b462-a101899e3bca",
            "short": ""
          },
          "mutation_effect_uuid": "6a0da217-6814-475d-acd3-b05c9c083589",
          "name": "V216M",
          "name_review": {
            "updateTime": 1675373511215,
            "updatedBy": "User"
          },
          "name_uuid": "f4cebdf9-1a5a-4806-84ab-e44bb6d0193f",
          "tumors_uuid": "5f48c73e-3301-4e3f-8e03-1c921211dfb9"
        },
        {
          "mutation_effect": {
            "description": "The TP53 Y126C mutation is located in the DNA-binding domain of the protein. This mutation has been identified in ovarian cancer and is a statistically significant hotspot (PMID: 15188009). In vivo studies with yeast expressing TP53 Y126C demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 Y126C also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675373528704,
              "updatedBy": "User"
            },
            "description_uuid": "90e85aa7-d98e-495e-8dda-aeeec8fc36e7",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675373524891,
              "updatedBy": "User"
            },
            "effect_uuid": "c6a32ee8-65e0-4724-9b87-142235e14b9d",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675373524280,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "630511d2-1995-409f-8cfa-248f2583eaa1",
            "short": ""
          },
          "mutation_effect_uuid": "0b13a70c-60c2-43b3-aa85-86d045b3af9a",
          "name": "Y126C",
          "name_review": {
            "updateTime": 1675373522475,
            "updatedBy": "User"
          },
          "name_uuid": "df06e718-9cdb-4997-85b5-3800ec8b8209",
          "tumors_uuid": "c52d78aa-379d-48b5-9eb3-e733c1bde9e6"
        },
        {
          "mutation_effect": {
            "description": "The TP53 Y126S mutation is located in the DNA-binding domain of the protein. This mutation has been identified in gallbladder cancer and is a statistically significant hotspot (PMID: 15154647). In vivo studies with yeast expressing TP53 Y126S demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 Y126S also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675373541535,
              "updatedBy": "User"
            },
            "description_uuid": "51ca4223-0b1b-476b-bebc-a798102b3085",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675373536636,
              "updatedBy": "User"
            },
            "effect_uuid": "9b55570d-3118-46cb-8b0f-0a75928e06b4",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675373536084,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "aed17154-7dfe-46e1-a0bc-d826f14801fc",
            "short": ""
          },
          "mutation_effect_uuid": "10a977ef-2725-4f5d-ba98-16cadbda2f08",
          "name": "Y126S",
          "name_review": {
            "updateTime": 1675373534368,
            "updatedBy": "User"
          },
          "name_uuid": "50ee3b62-5856-4e95-97a7-a4f9fcae8584",
          "tumors_uuid": "6cd9042b-0bb2-4728-9baf-2591ed2a0e3b"
        },
        {
          "mutation_effect": {
            "description": "The TP53 Y126D mutation is located in the DNA-binding domain of the protein. This mutation has been identified in glioblastoma and is a statistically significant hotspot (PMID: 10896202). In vivo studies with yeast expressing TP53 Y126D demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 Y126D also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675373731642,
              "updatedBy": "User"
            },
            "description_uuid": "a8c51d2a-d9f3-4527-824d-54016df564f9",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675373728000,
              "updatedBy": "User"
            },
            "effect_uuid": "1e272251-a388-4c3e-b6fa-8fc02cf2014e",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675373727394,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "2c3cd489-28ad-4a8b-9326-f91333ef6353",
            "short": ""
          },
          "mutation_effect_uuid": "995afef5-e2c5-41d5-b374-480ffbe1562b",
          "name": "Y126D",
          "name_review": {
            "updateTime": 1675373725562,
            "updatedBy": "User"
          },
          "name_uuid": "ca8a4eec-eef9-46f0-9cac-e4c7e32f6e2b",
          "tumors_uuid": "6c0f2b97-9e91-4874-9e88-bd0a2c518320"
        },
        {
          "mutation_effect": {
            "description": "The TP53 Y126H mutation is located in the DNA-binding domain of the protein. This mutation has been identified in colorectal cancer and is a statistically significant hotspot (PMID: 11307149). In vivo studies with yeast expressing TP53 Y126H demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 Y126H also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675373994685,
              "updatedBy": "User"
            },
            "description_uuid": "3070c64b-a37b-4408-a02c-55004ab009c3",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675373990724,
              "updatedBy": "User"
            },
            "effect_uuid": "ebdda3ba-c34b-4b28-89b8-25edcc0ebad5",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675373989984,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "6009dab8-5c6e-4376-8cfe-285907db9069",
            "short": ""
          },
          "mutation_effect_uuid": "37607491-2689-4008-a226-08d099dcb063",
          "name": "Y126H",
          "name_review": {
            "updateTime": 1675373986319,
            "updatedBy": "User"
          },
          "name_uuid": "4afc8c96-2a52-4a2a-ae2b-bfe9a102690b",
          "tumors_uuid": "89e45dcd-af0e-4bc1-a80d-f299f3ee08ae"
        },
        {
          "mutation_effect": {
            "description": "The TP53 Y126N mutation is located in the DNA-binding domain of the protein. This mutation has been identified in glioblastoma and is a statistically significant hotspot (PMID: 16818615). In vivo studies with yeast expressing TP53 Y126N demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 Y126N also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_editing": "",
            "description_review": {
              "updateTime": 1675374007675,
              "updatedBy": "User"
            },
            "description_uuid": "69d730ec-4c6b-4aff-b162-60da86d7485d",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675374003611,
              "updatedBy": "User"
            },
            "effect_uuid": "5ab2fe4b-718d-449e-a24e-ad062c47e9bc",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675374002873,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "dc8958c2-3a4a-461a-8446-d92fe988a5f7",
            "short": ""
          },
          "mutation_effect_uuid": "dd52e54e-813e-45eb-833d-18fbad0da8c2",
          "name": "Y126N",
          "name_review": {
            "updateTime": 1675374000843,
            "updatedBy": "User"
          },
          "name_uuid": "06a4a877-8e08-4740-8452-84954e4727b3",
          "tumors_uuid": "e9c25e8a-38d0-456c-a52d-aa67766926b3"
        },
        {
          "mutation_effect": {
            "description": "The TP53 A159P mutation is located in the DNA-binding domain of the protein. This mutation has been identified in non-small cell lung cancer and is a statistically significant hotspot (PMID: 10023676). In vivo studies with yeast expressing TP53 A159P demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 A159P also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675374417841,
              "updatedBy": "User"
            },
            "description_uuid": "d7d89ac5-3c01-4ff9-aedf-2a414b6b04a2",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675374414541,
              "updatedBy": "User"
            },
            "effect_uuid": "26f46a83-e5a7-4df7-aae6-91e2c91c74b5",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675374413945,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "580e70f5-bb71-428d-90e6-976efc38e60d",
            "short": ""
          },
          "mutation_effect_uuid": "b325636a-2af1-4077-9e03-c07ef382e2dd",
          "name": "A159P",
          "name_review": {
            "updateTime": 1675374411854,
            "updatedBy": "User"
          },
          "name_uuid": "dcb6be5b-edd7-4ee3-8100-27228150b700",
          "tumors_uuid": "7b3862eb-512b-4199-89cf-1a7c22cb2b33"
        },
        {
          "mutation_effect": {
            "description": "The TP53 A159D mutation is located in the DNA-binding domain of the protein. This mutation has been identified in colorectal cancer and is a statistically significant hotspot (PMID: 7651727). There is conflicting evidence about the biological and oncogenic effect of the mutation. In vivo studies with yeast expressing TP53 A159D demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). However, other in vitro studies with various human cancer cell lines expressing TP53 A159D demonstrated that the mutation is likely neutral as measured by wildtype comparable growth suppression activity (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675374855463,
              "updatedBy": "User"
            },
            "description_uuid": "55448673-0897-4eb4-856e-cfd7d072de9f",
            "effect": "Inconclusive",
            "effect_review": {
              "updateTime": 1675374852158,
              "updatedBy": "User"
            },
            "effect_uuid": "fd759c19-416c-41db-ba73-9d0efc7186b2",
            "oncogenic": "Inconclusive",
            "oncogenic_review": {
              "updateTime": 1675374851468,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "914c65f6-e451-40cb-aff4-db054a82c131",
            "short": ""
          },
          "mutation_effect_uuid": "7333c7fa-74f0-4bc1-abeb-3a46622037e4",
          "name": "A159D",
          "name_review": {
            "updateTime": 1675374849222,
            "updatedBy": "User"
          },
          "name_uuid": "ce8ce40b-efb3-49b0-bc5f-11f71eef52e5",
          "tumors_uuid": "a6534629-3e05-4f7a-9ed6-087559eed464"
        },
        {
          "mutation_effect": {
            "description": "The TP53 A159V mutation is located in the DNA-binding domain of the protein. This mutation has been identified in astrocytoma and is a statistically significant hotspot (PMID: 8285583). In vivo studies with yeast expressing TP53 A159V demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 A159V also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675374867655,
              "updatedBy": "User"
            },
            "description_uuid": "48ecc569-b3e9-40a1-8a24-c4fed79431ad",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675374864408,
              "updatedBy": "User"
            },
            "effect_uuid": "885cbe35-bb5d-40c9-8a09-0d0ebc59f0ef",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675374863769,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "719fc285-6202-40d3-9d8c-f494199263cf",
            "short": ""
          },
          "mutation_effect_uuid": "1f71c70c-03bd-48b3-beaf-ae0bc53ab5a1",
          "name": "A159V",
          "name_review": {
            "updateTime": 1675374861118,
            "updatedBy": "User"
          },
          "name_uuid": "b73b4bb2-a390-436f-98fb-8419adff0509",
          "tumors_uuid": "6f915dab-18cc-4171-951c-b2db4f092439"
        },
        {
          "mutation_effect": {
            "description": "The TP53 L194P mutation is located in the DNA-binding domain of the protein. This mutation has been identified in glioma and is a statistically significant hotspot (PMID: 1358438). In vivo studies with yeast expressing TP53 L194P demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 L194P also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675374966605,
              "updatedBy": "User"
            },
            "description_uuid": "3fede5ff-00c1-49e1-9423-440711f12115",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675374965494,
              "updatedBy": "User"
            },
            "effect_uuid": "968b2bf2-c31a-43c3-a5f6-188c03bee3b4",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675374964763,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "5a5f7829-5ea3-44b9-a5ec-7753464e4ab0",
            "short": ""
          },
          "mutation_effect_uuid": "c2e07f82-d272-48ea-bccc-6f0d1ca5cba7",
          "name": "L194P",
          "name_review": {
            "updateTime": 1675374960972,
            "updatedBy": "User"
          },
          "name_uuid": "5f6dc75d-4b37-4174-9a83-ef97a86abe25",
          "tumors_uuid": "27ca1875-e52f-489b-b086-3c3b13a4e83a"
        },
        {
          "mutation_effect": {
            "description": "The TP53 L194R mutation is located in the DNA-binding domain of the protein. This mutation has been identified in ovarian cancer and is a statistically significant hotspot (PMID: 15221786). In vivo studies with yeast expressing TP53 L194R demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 L194R also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675375111781,
              "updatedBy": "User"
            },
            "description_uuid": "3106cda1-22f3-4d6a-8bfa-956d26b73824",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675375108112,
              "updatedBy": "User"
            },
            "effect_uuid": "f2343ddd-085a-464b-976b-0b7e7a87916e",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675375107428,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "51035597-bc2b-4ddd-9b3d-20e64f1436b5",
            "short": ""
          },
          "mutation_effect_uuid": "ce301d83-c918-4429-891f-cad2c5033094",
          "name": "L194R",
          "name_review": {
            "updateTime": 1675375105551,
            "updatedBy": "User"
          },
          "name_uuid": "dc341d2c-5419-46a9-9eb8-c83594a883ce",
          "tumors_uuid": "8dbc72a7-5fd4-491f-a87a-1baab51b4998"
        },
        {
          "mutation_effect": {
            "description": "The TP53 L194F mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and is a statistically significant hotspot (PMID: 7619219). In vivo studies with yeast expressing TP53 L194F demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 L194F also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675444787062,
              "updatedBy": "User"
            },
            "description_uuid": "2da2d558-7794-42ea-a70d-d1223e423eb7",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675444783979,
              "updatedBy": "User"
            },
            "effect_uuid": "7badfaf4-2bb6-4bfe-8455-13d6256394e8",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675444783392,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "8b579f75-5877-4d08-a810-9c21a7999717",
            "short": ""
          },
          "mutation_effect_uuid": "c31263d6-b16b-40c5-ae94-68e9a103f453",
          "name": "L194F",
          "name_review": {
            "updateTime": 1675444780166,
            "updatedBy": "User"
          },
          "name_uuid": "b1c6a4a7-e351-413f-850b-807a2c50cb54",
          "tumors_uuid": "8472fad1-8894-454a-bae1-855a8e18d69f"
        },
        {
          "mutation_effect": {
            "description": "The TP53 L194H mutation is located in the DNA-binding domain of the protein. This mutation has been identified in marginal zone B-cell lymphoma and is a statistically significant hotspot (PMID: 8541549). In vivo studies with yeast expressing TP53 L194H demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 L194H also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675445042173,
              "updatedBy": "User"
            },
            "description_uuid": "42d1f1e9-e5e0-4984-90e1-d6bd4f5197f1",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675445038798,
              "updatedBy": "User"
            },
            "effect_uuid": "14492913-e6e0-46cf-a8eb-25dce4e182f3",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675445037560,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "c323b2b7-ba86-4e3c-b3cd-93c643838107",
            "short": ""
          },
          "mutation_effect_uuid": "2adaef82-7897-468d-86d1-de50d7206cca",
          "name": "L194H",
          "name_review": {
            "updateTime": 1675445034860,
            "updatedBy": "User"
          },
          "name_uuid": "366ed801-68bb-41bd-8414-9e2741996c01",
          "tumors_uuid": "be583479-ade9-4bdd-a433-c83b9d947bea"
        },
        {
          "mutation_effect": {
            "description": "The TP53 F270S mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and is a statistically significant hotspot (PMID: 11588905). In vivo studies with yeast expressing TP53 F270S demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 F270S also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675445058115,
              "updatedBy": "User"
            },
            "description_uuid": "1f907186-5643-434c-b042-3ed474ea8428",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675445054043,
              "updatedBy": "User"
            },
            "effect_uuid": "bf5fca38-1f8f-4146-b678-23e83faed9af",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675445053294,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "8236ac91-1bec-4e79-b09c-458c39bccedd",
            "short": ""
          },
          "mutation_effect_uuid": "c921a649-9d51-4601-9749-4e64932a382c",
          "name": "F270S",
          "name_review": {
            "updateTime": 1675445051274,
            "updatedBy": "User"
          },
          "name_uuid": "2a3c1329-7dab-4d42-b124-94b697bcd0df",
          "tumors_uuid": "c01c8586-d048-4fc3-bfb3-d017e5a4ce6c"
        },
        {
          "mutation_effect": {
            "description": "The TP53 F270C mutation is located in the DNA-binding domain of the protein. This mutation has been identified in non-small cell lung cancer and is a statistically significant hotspot (PMID: 10830574). In vivo studies with yeast expressing TP53 F270C demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 F270C also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675445072888,
              "updatedBy": "User"
            },
            "description_uuid": "97521ba0-455a-44d0-9364-6dc718856625",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675445069484,
              "updatedBy": "User"
            },
            "effect_uuid": "43308441-8249-4edd-8e64-0237d15cd80f",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675445068718,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "4980d373-162a-43f7-a213-4a700a7a0cde",
            "short": ""
          },
          "mutation_effect_uuid": "0468d617-d916-4a7f-bf19-6ad83d3d7b88",
          "name": "F270C",
          "name_review": {
            "updateTime": 1675445067103,
            "updatedBy": "User"
          },
          "name_uuid": "e2335749-4d0a-410f-ad60-b95d126f33d2",
          "tumors_uuid": "629af1f9-f551-454a-8df4-0e39f986cd13"
        },
        {
          "mutation_effect": {
            "description": "The TP53 F270V mutation is located in the DNA-binding domain of the protein. This mutation has been identified in bladder cancer and is a statistically significant hotspot (PMID: 8731915). In vivo studies with yeast expressing TP53 F270V demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 F270V also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675445087062,
              "updatedBy": "User"
            },
            "description_uuid": "e2bdb72d-9e85-4310-bb77-f7a6a833029d",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675445083551,
              "updatedBy": "User"
            },
            "effect_uuid": "69277319-51a5-4773-a5a9-76a30098759c",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675445082958,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "5f49c760-8c12-47e0-bd43-ffc1069f5779",
            "short": ""
          },
          "mutation_effect_uuid": "19d8449d-0119-4cb8-9717-64878a32a932",
          "name": "F270V",
          "name_review": {
            "updateTime": 1675445081232,
            "updatedBy": "User"
          },
          "name_uuid": "c536205a-94b3-42f0-b9de-111ff86de56d",
          "tumors_uuid": "0c8cf082-64eb-4759-a3cd-54a6695e34f1"
        },
        {
          "mutation_effect": {
            "description": "The TP53 F270I mutation is located in the DNA-binding domain of the protein. This mutation has been identified in colorectal cancer and is a statistically significant hotspot (PMID: 1551126). In vivo studies with yeast expressing TP53 F270I demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 F270I also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675445099948,
              "updatedBy": "User"
            },
            "description_uuid": "763a38cf-ec0d-4707-b269-738beea2d18a",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675445095579,
              "updatedBy": "User"
            },
            "effect_uuid": "36a6e20f-5ad9-49ac-a862-5054d0792c5e",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675445094911,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "d8bf0ae8-6c4a-454f-be8f-6c06977b1c12",
            "short": ""
          },
          "mutation_effect_uuid": "96e140c0-8182-4809-96c8-9fc6a7c1a2be",
          "name": "F270I",
          "name_review": {
            "updateTime": 1675445093147,
            "updatedBy": "User"
          },
          "name_uuid": "43a94965-748e-4d06-8438-f2eb9666cd3f",
          "tumors_uuid": "e6cce1cc-f439-42f8-be1b-e2438de6bded"
        },
        {
          "mutation_effect": {
            "description": "The TP53 F270L mutation is located in the DNA-binding domain of the protein. This mutation has been identified in gallbladder cancer and is a statistically significant hotspot (PMID: 9376195). In vivo studies with yeast expressing TP53 F270L demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
            "description_review": {
              "updateTime": 1675445841833,
              "updatedBy": "User"
            },
            "description_uuid": "fa42583b-a5b7-4b87-9741-2e43f9d51446",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675445838234,
              "updatedBy": "User"
            },
            "effect_uuid": "97e3757d-94f5-41d5-b441-d0bd0de04bd3",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675445837384,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "1726fb77-736a-4d91-b73d-91572e09a92f",
            "short": ""
          },
          "mutation_effect_uuid": "64543f5b-d2e1-437a-8c38-86ebd8a30a3a",
          "name": "F270L",
          "name_review": {
            "updateTime": 1675445833800,
            "updatedBy": "User"
          },
          "name_uuid": "418cc1c8-2b7a-4cb3-9efb-0ab0a982fd95",
          "tumors_uuid": "b5dfb4a3-6625-4cfe-aa18-574f1337b5f9"
        },
        {
          "mutation_effect": {
            "description": "The TP53 M246R mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and is a statistically significant hotspot (PMID: 11929815). In vivo studies with yeast expressing TP53 M246R demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 M246R also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675445857154,
              "updatedBy": "User"
            },
            "description_uuid": "b3f62e64-9fc1-4a97-afcb-6ef846411734",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675445854065,
              "updatedBy": "User"
            },
            "effect_uuid": "b3f763db-313c-4b38-ad21-96b245214c43",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675445853377,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "785c6cd2-36dd-48fb-bc8e-a3dcbf55c140",
            "short": ""
          },
          "mutation_effect_uuid": "e7e97f20-2410-46d2-a369-9ed0a07a5c32",
          "name": "M246R",
          "name_review": {
            "updateTime": 1675445850290,
            "updatedBy": "User"
          },
          "name_uuid": "031f3031-3c97-4d06-b083-7e489bc2c7a9",
          "tumors_uuid": "55f82e96-f4ad-43e4-b6a7-c6e3ec059960"
        },
        {
          "mutation_effect": {
            "description": "The TP53 M246T mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and is a statistically significant hotspot (PMID: 9699530). In vivo studies with yeast expressing TP53 M246T demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 M246T also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675445869383,
              "updatedBy": "User"
            },
            "description_uuid": "19194c59-f66f-4c3f-8345-fd29cb390fb2",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675445868368,
              "updatedBy": "User"
            },
            "effect_uuid": "4b463a40-3237-4756-8584-3011015569c9",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675445867598,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "12a88a53-5a23-471f-9de0-ee16215cfc8b",
            "short": ""
          },
          "mutation_effect_uuid": "5c2b0f1c-977b-41ae-ab9d-5b3afcc816e2",
          "name": "M246T",
          "name_review": {
            "updateTime": 1675445863993,
            "updatedBy": "User"
          },
          "name_uuid": "26c8f4a0-bff9-4917-951d-b39322236040",
          "tumors_uuid": "1d35736a-6c56-431a-9580-879efa5c7a62"
        },
        {
          "mutation_effect": {
            "description": "The TP53 M246V mutation is located in the DNA-binding domain of the protein. This mutation has been identified in hepatocellular carcinoma and is a statistically significant hotspot (PMID: 18567082). In vivo studies with yeast expressing TP53 M246V demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 M246V also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_editing": "",
            "description_review": {
              "updateTime": 1675446152851,
              "updatedBy": "User"
            },
            "description_uuid": "90a89cda-2411-449b-bd07-e0d05da30f41",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675446148689,
              "updatedBy": "User"
            },
            "effect_uuid": "635dba92-d445-493e-8dfa-80fa1f21b0d8",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675446147781,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "05c84ffd-8dac-41a1-8a8f-f883f4b2ed3d",
            "short": ""
          },
          "mutation_effect_uuid": "ad3aa277-87ff-476f-b6ad-dfdab087685b",
          "name": "M246V",
          "name_review": {
            "updateTime": 1675446146145,
            "updatedBy": "User"
          },
          "name_uuid": "6ef84fee-f00f-411d-ad45-abc3141701d0",
          "tumors_uuid": "ccf1e7a2-133b-40c6-9099-f38c5e4b0e50"
        },
        {
          "mutation_effect": {
            "description": "The TP53 M246I mutation is located in the DNA-binding domain of the protein. This mutation has been identified in bladder cancer and is a statistically significant hotspot (PMID: 10761705). In vivo studies with yeast expressing TP53 M246I demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 F270I also demonstrated the mutation is inactivating as measured by moderately reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1677200356689,
              "updatedBy": "User"
            },
            "description_uuid": "ae97cecd-5c8c-42f0-aa47-4dccff964688",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675446598629,
              "updatedBy": "User"
            },
            "effect_uuid": "053d5f8d-ada8-41df-82c6-88d4100ac1c0",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675446597845,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "3d6191ce-50df-4bfc-8d0c-50ee9700ecb1",
            "short": ""
          },
          "mutation_effect_uuid": "0ed42f7b-6dfc-441c-b591-5d87d95acd13",
          "name": "M246I",
          "name_review": {
            "updateTime": 1675446595776,
            "updatedBy": "User"
          },
          "name_uuid": "d01c5a96-2ab2-453d-a853-b4a05bc21f4e",
          "tumors_uuid": "c20ad9f6-70ce-4b84-be5a-c6fe715c07b5"
        },
        {
          "mutation_effect": {
            "description": "The TP53 M246K mutation is located in the DNA-binding domain of the protein. This mutation has been identified in larynx squamous cell carcinoma and is a statistically significant hotspot (PMID: 8001261). In vivo studies with yeast expressing TP53 M246K demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 M246K also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675448878313,
              "updatedBy": "User"
            },
            "description_uuid": "9bc4fda0-d3ce-4fc5-94fa-4caad069a8fa",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675448873578,
              "updatedBy": "User"
            },
            "effect_uuid": "fba619a7-30dd-4295-89dc-e7da6cf903a5",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675448872752,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "d964e438-f0d2-4077-ac92-accc6102c4d2",
            "short": ""
          },
          "mutation_effect_uuid": "7a10d8ee-79b0-4c45-ad11-d2f13ca1b9a8",
          "name": "M246K",
          "name_review": {
            "updateTime": 1675448869435,
            "updatedBy": "User"
          },
          "name_uuid": "2b3f0fac-de58-4942-ac6e-a59ad9c57a5c",
          "tumors_uuid": "b75a032e-1bfa-44e5-8067-3785e1300671"
        },
        {
          "mutation_effect": {
            "description": "The TP53 M246L mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and is a statistically significant hotspot (PMID: 11304577). In vivo studies with yeast expressing TP53 M246L demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 M246L also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675448890491,
              "updatedBy": "User"
            },
            "description_uuid": "2ebb993b-cef0-48b1-9d0d-cee1df84d083",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675448887597,
              "updatedBy": "User"
            },
            "effect_uuid": "9505a0ea-defc-463e-b372-6370f42ac2b4",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675448886696,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "6e88791d-9f99-449f-ae8f-ba9116a85eb6",
            "short": ""
          },
          "mutation_effect_uuid": "7dbe5f9b-0d53-4c10-b0a0-6e7767222fc1",
          "name": "M246L",
          "name_review": {
            "updateTime": 1675448884419,
            "updatedBy": "User"
          },
          "name_uuid": "a2b1b824-bdfe-458a-bede-eb2202cb8f91",
          "tumors_uuid": "890dcef8-6cad-4acd-9040-6e331ec0de82"
        },
        {
          "mutation_effect": {
            "description": "The TP53 S127P mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and is a statistically significant hotspot (PMID: 9569050). In vivo studies with yeast expressing TP53 S127P demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 S127P also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675448901758,
              "updatedBy": "User"
            },
            "description_uuid": "cee71fb0-360e-40b2-9c59-ec9a81325f96",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675448900539,
              "updatedBy": "User"
            },
            "effect_uuid": "e13428cf-9c32-4bf0-91ea-8d57e6ea789b",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675448899822,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "6b33e8bd-ef32-4478-8ead-67723848fcbd",
            "short": ""
          },
          "mutation_effect_uuid": "f7ac3240-7dbf-418d-b047-f60aaf97e61c",
          "name": "S127P",
          "name_review": {
            "updateTime": 1675448896708,
            "updatedBy": "User"
          },
          "name_uuid": "b8cb815c-1840-4ee6-9863-d5e3781fcdee",
          "tumors_uuid": "15cec8bb-1cbe-4625-b35b-b11290b420e9"
        },
        {
          "mutation_effect": {
            "description": "The TP53 S127C mutation is located in the DNA-binding domain of the protein. This mutation has been identified in acute myeloid leukemia and is a statistically significant hotspot (PMID: 16467864). In vivo studies with yeast expressing TP53 S127C demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 S127C also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675448913744,
              "updatedBy": "User"
            },
            "description_uuid": "1aa496c1-de55-42eb-aae7-ba1a17b16a88",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675448912704,
              "updatedBy": "User"
            },
            "effect_uuid": "6e5e00c7-dc0b-4bbf-86ae-98e738b9fcac",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675448911923,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "6acb9924-3548-46db-aa26-4c8a9066cce0",
            "short": ""
          },
          "mutation_effect_uuid": "e299e60d-715d-4c14-97cc-8bd167931884",
          "name": "S127C",
          "name_review": {
            "updateTime": 1675448908606,
            "updatedBy": "User"
          },
          "name_uuid": "9afc92d2-67f4-4b46-aa0c-d4004b33fe47",
          "tumors_uuid": "9966291a-a296-4115-b4b3-833088914ea0"
        },
        {
          "mutation_effect": {
            "description": "The TP53 S127T mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and is a statistically significant hotspot (PMID: 18617062). In vivo studies with yeast expressing TP53 S127T demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 S127T also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_editing": "",
            "description_review": {
              "updateTime": 1675448931450,
              "updatedBy": "User"
            },
            "description_uuid": "43706f82-c99b-4110-ac1e-6107a3a10a1e",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675448926658,
              "updatedBy": "User"
            },
            "effect_uuid": "939d682a-d260-4ecb-bb7e-6ce9fbabc73c",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675448925981,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "cd6b9c85-b853-45ba-970e-c83c13a3c98e",
            "short": ""
          },
          "mutation_effect_uuid": "6e996502-0c55-47e7-a984-cf21b3ff6274",
          "name": "S127T",
          "name_review": {
            "updateTime": 1675448924066,
            "updatedBy": "User"
          },
          "name_uuid": "062eaf4f-d174-468a-bd36-16866650882c",
          "tumors_uuid": "a3ed3b46-c5fb-4229-961c-539f59fecc11"
        },
        {
          "mutation_effect": {
            "description": "The TP53 S127F mutation is located in the DNA-binding domain of the protein. This mutation has been identified in xeroderma pigmentosum and is a statistically significant hotspot (PMID: 9766670). In vivo studies with yeast expressing TP53 S127F demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 S127F also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675448977063,
              "updatedBy": "User"
            },
            "description_uuid": "e69b8538-94a9-48b5-96eb-38c2d08a7b78",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675448973386,
              "updatedBy": "User"
            },
            "effect_uuid": "ba1c9947-5158-42e9-b15b-0ad21debfaf7",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675448972820,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "1c192e0b-5633-45e0-8fb9-c76cf7886b2d",
            "short": ""
          },
          "mutation_effect_uuid": "b8227d86-243e-46da-c0b6-d9ba44d519ad",
          "name": "S127F",
          "name_review": {
            "updateTime": 1675448971237,
            "updatedBy": "User"
          },
          "name_uuid": "bcb18751-904d-4a87-bb5b-324b4afc234e",
          "tumors_uuid": "2dbf67cf-f79f-4dff-b4a3-3da1718b51d5"
        },
        {
          "mutation_effect": {
            "description": "The TP53 S127Y mutation is located in the DNA-binding domain of the protein. This mutation has been identified in glioblastoma and is a statistically significant hotspot (PMID: 10667596). In vivo studies with yeast expressing TP53 S127Y demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
            "description_review": {
              "updateTime": 1675448991180,
              "updatedBy": "User"
            },
            "description_uuid": "75c1971c-bb29-44e0-938b-dae65e7df05c",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675448987695,
              "updatedBy": "User"
            },
            "effect_uuid": "8b471e89-8a67-4ec7-999c-59b3686d332c",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675448986729,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "fe3315d5-5278-4ee9-bfd6-821913741eb0",
            "short": ""
          },
          "mutation_effect_uuid": "4e19dfda-5eac-4905-a2f2-da02c117b138",
          "name": "S127Y",
          "name_review": {
            "updateTime": 1675448984398,
            "updatedBy": "User"
          },
          "name_uuid": "7d16090d-947f-4726-be94-b29029bd24e5",
          "tumors_uuid": "f20cee59-70d9-4d87-9dae-2ce6b6724f02"
        },
        {
          "mutation_effect": {
            "description": "The TP53 Q136P mutation is located in the DNA-binding domain of the protein. This mutation has been identified in bladder cancer and is a statistically significant hotspot (PMID: 14678961). In vivo studies with yeast expressing TP53 Q136P demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 Q136P also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675450282090,
              "updatedBy": "User"
            },
            "description_uuid": "270cbaed-f6ab-473f-b152-95fa0ead6bd5",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675450278382,
              "updatedBy": "User"
            },
            "effect_uuid": "b995a5d3-48a2-45f5-acb9-64758d7c5c1e",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675450277604,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "ce1b2e56-9642-49fb-bf6d-9a4cd7caa7e4",
            "short": ""
          },
          "mutation_effect_uuid": "b02b2e3f-4ac6-4735-bf35-98630f9a4ffb",
          "name": "Q136P",
          "name_review": {
            "updateTime": 1675450275332,
            "updatedBy": "User"
          },
          "name_uuid": "b13df2ed-2e82-4ea8-a5ab-4deaaa35b7cb",
          "tumors_uuid": "112b456e-e87b-4d95-a2c6-e6e2f7a415cf"
        },
        {
          "mutation_effect": {
            "description": "The TP53 Q136E mutation is located in the DNA-binding domain of the protein. This mutation has been identified in bronchioloalveolar carcinoma and is a statistically significant hotspot (PMID: 9614374). In vivo studies with yeast expressing TP53 Q136E demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 Q136E also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675450293165,
              "updatedBy": "User"
            },
            "description_uuid": "c06e422f-f09d-4de1-a5ac-eaa7a56fe7d5",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675450291643,
              "updatedBy": "User"
            },
            "effect_uuid": "7800cf4c-df3c-49d2-827c-69cdaf849ce5",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675450290908,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "74381502-85c4-4685-af73-405c6792142b",
            "short": ""
          },
          "mutation_effect_uuid": "3f8b3c81-178b-4c16-8a59-ebc6fa57c54c",
          "name": "Q136E",
          "name_review": {
            "updateTime": 1675450287388,
            "updatedBy": "User"
          },
          "name_uuid": "4f36d4ef-b3f1-40d4-8485-d7eb48ccd054",
          "tumors_uuid": "06b4d808-eb2a-46ec-a170-aa962e75aea6"
        },
        {
          "mutation_effect": {
            "description": "The TP53 Q136H mutation is located in the DNA-binding domain of the protein. This mutation has been identified in acute lymphoblastic B-cell leukemia and is a statistically significant hotspot (PMID: 20575032). There is conflicting evidence about the biological and oncogenic effect of the mutation. In vivo studies with yeast expressing TP53 Q136H demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). However, other in vitro studies with various human cancer cell lines expressing TP53 Q136H demonstrated that the mutation is likely neutral as measured by growth suppression activity comparable to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1677259460408,
              "updatedBy": "User"
            },
            "description_uuid": "24adff42-c6eb-419c-8150-ac8a8f53cfb7",
            "effect": "Inconclusive",
            "effect_review": {
              "updateTime": 1675450304145,
              "updatedBy": "User"
            },
            "effect_uuid": "5f377e67-dfe4-4937-b523-6d553a466b0c",
            "oncogenic": "Inconclusive",
            "oncogenic_review": {
              "updateTime": 1675450303510,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "0bb58b04-87fc-4da6-a565-d591ae461827",
            "short": ""
          },
          "mutation_effect_uuid": "5ba12795-7e5d-4297-ab21-7da9ca7fe4d2",
          "name": "Q136H",
          "name_review": {
            "updateTime": 1675450301402,
            "updatedBy": "User"
          },
          "name_uuid": "17654327-ac3c-4d49-8cf8-e53a5b212a55",
          "tumors_uuid": "a0af5bea-c768-4c4b-951f-fd3ad81f4196"
        },
        {
          "mutation_effect": {
            "description": "The TP53 Q136L mutation is located in the DNA-binding domain of the protein. This mutation has been identified in urothelial cancer and is a statistically significant hotspot (PMID: 20575032). There is conflicting evidence about the biological and oncogenic effect of the mutation. In vivo studies with yeast expressing TP53 Q136L demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). However, other in vitro studies with various human cancer cell lines expressing TP53 Q136L demonstrated that the mutation is likely neutral as measured by growth suppression activity comparable to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1677259487874,
              "updatedBy": "User"
            },
            "description_uuid": "8b6dab6f-e149-4a8c-8f05-24a9dc758da7",
            "effect": "Inconclusive",
            "effect_review": {
              "updateTime": 1675450581923,
              "updatedBy": "User"
            },
            "effect_uuid": "15963a90-50fe-43cb-bc22-d967f9592014",
            "oncogenic": "Inconclusive",
            "oncogenic_review": {
              "updateTime": 1675450581412,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "991be246-c755-47ab-88a3-5434819b595d",
            "short": ""
          },
          "mutation_effect_uuid": "105aa68a-271e-4d4a-b51d-fbeb6e4a21b8",
          "name": "Q136L",
          "name_review": {
            "updateTime": 1675450578891,
            "updatedBy": "User"
          },
          "name_uuid": "127fe2df-e7a4-4015-bebe-cbb81c11c29b",
          "tumors_uuid": "55f3de2e-2fee-463a-9f48-56496230e8f4"
        },
        {
          "mutation_effect": {
            "description": "The TP53 T125P mutation is located in the DNA-binding domain of the protein. This mutation has been identified in non-small cell lung cancer and is a statistically significant hotspot (PMID: 15073856). In vivo studies with yeast expressing TP53 T125P demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 T125P also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675450601753,
              "updatedBy": "User"
            },
            "description_uuid": "7139cfac-4952-4e25-b29f-ad1399b89818",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675450598294,
              "updatedBy": "User"
            },
            "effect_uuid": "63d98a7c-a766-4cd0-ac39-2843e3dfc383",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675450595223,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "45e0259c-c370-453d-9674-46cf06cb9f9b",
            "short": ""
          },
          "mutation_effect_uuid": "ea190644-3ea7-4f14-85b1-5f78507fc971",
          "name": "T125P",
          "name_review": {
            "updateTime": 1675450593101,
            "updatedBy": "User"
          },
          "name_uuid": "c89ede14-7c1c-4c10-bb2c-f41b9f0eefde",
          "tumors_uuid": "6c18c4e5-e777-4411-9955-dcaaff93cfe7"
        },
        {
          "mutation_effect": {
            "description": "The TP53 T125A mutation is located in the DNA-binding domain of the protein. This mutation has been identified in NK/T-cell lymphoma and is a statistically significant hotspot (PMID: 15643509). In vivo studies with yeast expressing TP53 T125A demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
            "description_review": {
              "updateTime": 1675450614115,
              "updatedBy": "User"
            },
            "description_uuid": "e9d71686-187c-4aec-a493-5c0ac0c69b0f",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675450610354,
              "updatedBy": "User"
            },
            "effect_uuid": "adb3705e-d606-41f5-8fed-9cf58df66a59",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675450609223,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "a51ec5d9-02c0-40d9-9f92-5db8b7b0b298",
            "short": ""
          },
          "mutation_effect_uuid": "b0830ddf-4d90-42f8-9e0b-36226f2370e7",
          "name": "T125A",
          "name_review": {
            "updateTime": 1675450607171,
            "updatedBy": "User"
          },
          "name_uuid": "3603942a-8c9e-4183-9417-1502d720d482",
          "tumors_uuid": "5129f1b7-8917-42d3-a46a-0af68a016b67"
        },
        {
          "mutation_effect": {
            "description": "The TP53 T125R mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and is a statistically significant hotspot (PMID: 11229518). In vivo studies with yeast expressing TP53 T125R demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 T125R also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675450629843,
              "updatedBy": "User"
            },
            "description_uuid": "eac57f5b-6e4d-44a7-b2d6-b423d4e4d6a6",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675450623594,
              "updatedBy": "User"
            },
            "effect_uuid": "5d53b278-5c6a-4ca8-b75e-8cabb2f0c8a4",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675450622695,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "1540fa71-b49d-448c-8be4-23dd1156a546",
            "short": ""
          },
          "mutation_effect_uuid": "2a1cdb9b-fce2-4028-a0fa-0493c9a51daf",
          "name": "T125R",
          "name_review": {
            "updateTime": 1675450621035,
            "updatedBy": "User"
          },
          "name_uuid": "82172742-660e-4945-9452-e0fb73419569",
          "tumors_uuid": "1d9ea47f-c255-42fd-96cf-43842b96831c"
        },
        {
          "mutation_effect": {
            "description": "The TP53 T125K mutation is located in the DNA-binding domain of the protein. This mutation has been identified in pancreatic cancer and is a statistically significant hotspot (PMID: 18772397). There is conflicting evidence about the biological and oncogenic effect of the mutation. In vivo studies with yeast expressing TP53 T125K demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). However, other in vitro studies with various human cancer cell lines expressing TP53 T125K demonstrated that the mutation is likely neutral as measured by growth suppression activity comparable to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1677259550642,
              "updatedBy": "User"
            },
            "description_uuid": "567ee42a-8fe8-4434-827c-1c50be8fb143",
            "effect": "Inconclusive",
            "effect_review": {
              "updateTime": 1675450639883,
              "updatedBy": "User"
            },
            "effect_uuid": "bf09b51f-e32d-42cb-9374-3f0d9f6a4aa2",
            "oncogenic": "Inconclusive",
            "oncogenic_review": {
              "updateTime": 1675450638812,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "52fb3702-48c8-4df5-b125-5a309a923fc5",
            "short": ""
          },
          "mutation_effect_uuid": "89e1d4df-2ac0-4c65-9c06-076b56446b19",
          "name": "T125K",
          "name_review": {
            "updateTime": 1675450636494,
            "updatedBy": "User"
          },
          "name_uuid": "c05d64cc-acce-489f-ac09-1a4af215f138",
          "tumors_uuid": "1b56628a-c0f4-44a6-b85d-79c52253e89a"
        },
        {
          "mutation_effect": {
            "description": "The TP53 T125M mutation is located in the DNA-binding domain of the protein. This mutation has been identified in sinonasal NK/T-cell lymphoma and is a statistically significant hotspot (PMID: 15643509). There is conflicting evidence about the biological and oncogenic effect of the mutation. In vivo studies with yeast expressing TP53 T125M demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). However, other in vitro studies with various human cancer cell lines expressing TP53 T125M demonstrated that the mutation is likely neutral as measured by growth suppression activity comparable to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1677259579353,
              "updatedBy": "User"
            },
            "description_uuid": "828380c9-cfdb-4b9d-8228-fda906e9309a",
            "effect": "Inconclusive",
            "effect_review": {
              "updateTime": 1675450657053,
              "updatedBy": "User"
            },
            "effect_uuid": "bdfd89d3-5771-476b-ad05-43b0f18318b8",
            "oncogenic": "Inconclusive",
            "oncogenic_review": {
              "updateTime": 1675450655991,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "cd59f350-e019-457f-812d-1e04529ab432",
            "short": ""
          },
          "mutation_effect_uuid": "ba19a8b8-4905-4214-a98a-44f194201bbf",
          "name": "T125M",
          "name_review": {
            "updateTime": 1675450651510,
            "updatedBy": "User"
          },
          "name_uuid": "2d4fc9bc-4b51-4056-abac-07739b783435",
          "tumors_uuid": "7da230d4-7c2c-40fa-a40d-f07d0ad78bdb"
        },
        {
          "mutation_effect": {
            "description": "The TP53 E271K mutation is located in the DNA-binding domain of the protein. This mutation has been identified in bladder cancer and is a statistically significant hotspot (PMID: 15538112). In vivo studies with yeast expressing TP53 E271K demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 E271K also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675450675676,
              "updatedBy": "User"
            },
            "description_uuid": "6ab25b78-53df-452b-a25a-4feb92f74eca",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675450674441,
              "updatedBy": "User"
            },
            "effect_uuid": "b62ab704-2888-4338-93ea-f13b49e3c2c0",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675450673525,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "d0fb5975-5239-4032-bc31-7504d0bf1e4e",
            "short": ""
          },
          "mutation_effect_uuid": "41a8ea8b-4714-49ca-8e2a-b544503c39ae",
          "name": "E271K",
          "name_review": {
            "updateTime": 1675450669893,
            "updatedBy": "User"
          },
          "name_uuid": "d821a606-0789-41b9-b054-c8b4a8bfe398",
          "tumors_uuid": "42945f6e-5afa-4c02-a134-82c75bf4bf6c"
        },
        {
          "mutation_effect": {
            "description": "The TP53 V172F mutation is located in the DNA-binding domain of the protein. This mutation has been identified in ovarian cancer and is a statistically significant hotspot (PMID: 10216487). In vivo studies with yeast expressing TP53 V172F demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
            "description_editing": "",
            "description_review": {
              "updateTime": 1675450787383,
              "updatedBy": "User"
            },
            "description_uuid": "dc52f4e8-1346-4f70-86bf-b709d23461f0",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675450783625,
              "updatedBy": "User"
            },
            "effect_uuid": "3decd904-eff8-49eb-885b-b01dc7eff6ad",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675450783001,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "4c88bf6a-0ded-40cc-9ff5-3488a22bd100",
            "short": ""
          },
          "mutation_effect_uuid": "d5c4d654-6311-4187-a601-facbd7ea1663",
          "name": "V172F",
          "name_review": {
            "updateTime": 1675450780757,
            "updatedBy": "User"
          },
          "name_uuid": "0940ebd2-4329-477f-a8d2-da6bc8ffe629",
          "tumors_uuid": "aa50221e-ba7e-468a-9efe-966d87b19f4c"
        },
        {
          "mutation_effect": {
            "description": "The TP53 T155P mutation is located in the DNA-binding domain of the protein. This mutation has been identified in small-cell lung cancer and is a statistically significant hotspot (PMID: 14660794). In vivo studies with yeast expressing TP53 T155P demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 T155P also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1677259753904,
              "updatedBy": "User"
            },
            "description_uuid": "fbe616bf-df67-4793-c023-ecffd85ca7de",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675450997123,
              "updatedBy": "User"
            },
            "effect_uuid": "e6c1bf80-6bcc-4409-aa85-74fcb415a8f9",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675450996325,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "f67e9632-6c59-465c-a96b-a58020d331a6",
            "short": ""
          },
          "mutation_effect_uuid": "7e147be7-761f-4a70-ab6c-57202652ad2c",
          "name": "T155P",
          "name_review": {
            "updateTime": 1675450992463,
            "updatedBy": "User"
          },
          "name_uuid": "bfb5027f-b427-47d4-b2ff-782865a56250",
          "tumors_uuid": "3b5d05ea-e4a2-4db5-80c6-6c4184d5bbeb"
        },
        {
          "mutation_effect": {
            "description": "The TP53 T155N mutation is located in the DNA-binding domain of the protein. This mutation has been identified in colorectal cancer and is a statistically significant hotspot (PMID: 11275993). In vivo studies with yeast expressing TP53 T155N demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
            "description_review": {
              "updateTime": 1675451008547,
              "updatedBy": "User"
            },
            "description_uuid": "aae82bce-ec37-4644-be51-bdd94ad38ac6",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675451005434,
              "updatedBy": "User"
            },
            "effect_uuid": "177fb046-82ed-43e1-c0ae-3518de4c2414",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675451004832,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "626a49dc-2691-4d79-9a07-fbfaf3e4a4d7",
            "short": ""
          },
          "mutation_effect_uuid": "b9b7be5e-c3a8-4878-bb51-c9d50d1740c7",
          "name": "T155N",
          "name_review": {
            "updateTime": 1675451003361,
            "updatedBy": "User"
          },
          "name_uuid": "c075a77f-4241-43e9-a721-6973794e342c",
          "tumors_uuid": "77de7315-0072-42b1-8f79-adeb736441c4"
        },
        {
          "mutation_effect": {
            "description": "The TP53 N131S mutation is located in the DNA-binding domain of the protein. This mutation has been identified in esophageal squamous cell carcinoma and is a statistically significant hotspot (PMID: 16271069). In vivo studies with yeast expressing TP53 N131S demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
            "description_review": {
              "updateTime": 1675451021837,
              "updatedBy": "User"
            },
            "description_uuid": "410c5357-d26c-46cf-8c21-d18ad293bda2",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675451018538,
              "updatedBy": "User"
            },
            "effect_uuid": "60e562fd-d877-461d-869b-e740034061c0",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675451017772,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "e4326aa3-87d9-4d17-8af0-4176d7cd8fc3",
            "short": ""
          },
          "mutation_effect_uuid": "be08964c-02d8-4400-8fd2-5ef07293be13",
          "name": "N131S",
          "name_review": {
            "updateTime": 1675451015301,
            "updatedBy": "User"
          },
          "name_uuid": "b6d08dad-a7f7-46ce-953a-8f0c0eae9b28",
          "tumors_uuid": "88830438-741e-4556-c0f2-914ea5d881cd"
        },
        {
          "mutation_effect": {
            "description": "The TP53 F113P mutation is located in the DNA-binding domain of the protein and is a statistically significant hotspot. In vitro studies with various human cancer cell lines expressing TP53 F113P demonstrated that the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675451164586,
              "updatedBy": "User"
            },
            "description_uuid": "4fb380f0-53ce-4f33-b8fe-85f55dcce7b4",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675451160808,
              "updatedBy": "User"
            },
            "effect_uuid": "c883a618-2c0c-42b3-aeff-355c40bf37a5",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675451160120,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "7e143a9e-f655-43c8-a24e-516d6485122c",
            "short": ""
          },
          "mutation_effect_uuid": "df9e425b-d401-498e-a749-683c37eaf005",
          "name": "F113P",
          "name_review": {
            "updateTime": 1675451158108,
            "updatedBy": "User"
          },
          "name_uuid": "8fcf0d6f-e7fd-40f4-ad1e-a5bb6556de1d",
          "tumors_uuid": "97530642-62da-419b-9ee6-bab202054bcc"
        },
        {
          "mutation_effect": {
            "description": "The TP53 D208E mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and is a statistically significant hotspot (PMID: 8156519). There is conflicting evidence about the biological and oncogenic effect of the mutation. In vivo studies with yeast expressing TP53 D208E demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). However, other in vitro studies with various human cancer cell lines expressing TP53 D208E demonstrated that the mutation is likely neutral as measured by growth suppression activity comparable to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1677259814779,
              "updatedBy": "User"
            },
            "description_uuid": "c08d8010-ed49-4240-9ce8-131f9b61bdfa",
            "effect": "Inconclusive",
            "effect_review": {
              "updateTime": 1675451172904,
              "updatedBy": "User"
            },
            "effect_uuid": "04520f9d-a519-4aa3-b4f3-4f76a209545a",
            "oncogenic": "Inconclusive",
            "oncogenic_review": {
              "updateTime": 1675451172188,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "42a6a062-57d4-40ea-92f3-0b0c704b7bbd",
            "short": ""
          },
          "mutation_effect_uuid": "b875178e-88ff-4f92-b62a-cd06e7c20f36",
          "name": "D208E",
          "name_review": {
            "updateTime": 1675451170663,
            "updatedBy": "User"
          },
          "name_uuid": "85505870-6d57-4e41-ba98-3d2253d5b99f",
          "tumors_uuid": "52c4a202-781f-403c-af02-84c7d7c542f2"
        },
        {
          "mutation_effect": {
            "description": "The TP53 D208V mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and is a statistically significant hotspot (PMID: 8099903). In vivo studies with yeast expressing TP53 D208V demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 D208V also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675451192770,
              "updatedBy": "User"
            },
            "description_uuid": "01debd16-735d-471c-a92f-54644d535d5c",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675451191457,
              "updatedBy": "User"
            },
            "effect_uuid": "4fd2507a-a9db-4bbd-8fd5-2dc729b2c4a4",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675451190763,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "8831cd7b-c361-4471-ae40-7cf40380c0fc",
            "short": ""
          },
          "mutation_effect_uuid": "2889c493-12d9-44ce-87ee-26f3a08c6038",
          "name": "D208V",
          "name_review": {
            "updateTime": 1675451186367,
            "updatedBy": "User"
          },
          "name_uuid": "71361156-077f-450d-9643-169f88cc1e9c",
          "tumors_uuid": "64a24d81-4c3b-4ec6-8bfa-0bca000721fa"
        },
        {
          "mutation_effect": {
            "description": "The TP53 D208G mutation is located in the DNA-binding domain of the protein. This mutation has been identified in colorectal cancer and is a statistically significant hotspot (PMID: 9516972). In vivo studies with yeast expressing TP53 D208G demonstrated that the mutation is likely neutral as measured by transactivational activity comparable to wildtype (PMID: 27328919, 12826609).",
            "description_review": {
              "updateTime": 1677259852273,
              "updatedBy": "User"
            },
            "description_uuid": "397152a2-a8ec-4e20-9c1b-5974dce6a88c",
            "effect": "Likely Neutral",
            "effect_review": {
              "updateTime": 1675451385003,
              "updatedBy": "User"
            },
            "effect_uuid": "c6e71f6f-a9f7-4ca3-acc8-371557aa109b",
            "oncogenic": "Likely Neutral",
            "oncogenic_review": {
              "updateTime": 1675451384056,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "4ef8ed91-a16d-4a1d-9ba6-269555c01d4f",
            "short": ""
          },
          "mutation_effect_uuid": "e6568799-775a-4f07-a2e9-8f3fcac8ca22",
          "name": "D208G",
          "name_review": {
            "updateTime": 1675451381490,
            "updatedBy": "User"
          },
          "name_uuid": "02ee0fa6-d3a4-4c2e-bede-a39c0974ec06",
          "tumors_uuid": "33229b2e-87ea-48b4-9e69-361de7dad2c0"
        },
        {
          "mutation_effect": {
            "description": "The TP53 D208N mutation is located in the DNA-binding domain of the protein. This mutation has been identified in thyroid papillary carcinoma and is a statistically significant hotspot (PMID: 8768871). In vivo studies with yeast expressing TP53 D208N demonstrated that the mutation is likely neutral as measured by transactivational activity comparable to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 D208N also demonstrated the mutation likely neutral as measured by growth suppression activity comparable to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1677259983478,
              "updatedBy": "User"
            },
            "description_uuid": "3d80f5ea-fef9-4467-b50b-a1f9e553dba6",
            "effect": "Likely Neutral",
            "effect_review": {
              "updateTime": 1675451404176,
              "updatedBy": "User"
            },
            "effect_uuid": "557f4470-8fc5-4b4d-908a-65e3ab5e67b2",
            "oncogenic": "Likely Neutral",
            "oncogenic_review": {
              "updateTime": 1675451403483,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "defb094a-e6e2-4519-8910-323a17da1f35",
            "short": ""
          },
          "mutation_effect_uuid": "f567a984-39e5-43e7-9a51-ee1ac5ef8790",
          "name": "D208N",
          "name_review": {
            "updateTime": 1675451398588,
            "updatedBy": "User"
          },
          "name_uuid": "cc7526ca-278a-4a09-80aa-41960e99fcc9",
          "tumors_uuid": "e3207635-7e38-4774-8292-69cf6e9bf517"
        },
        {
          "mutation_effect": {
            "description": "The TP53 N247I mutation is located in the DNA-binding domain of the protein. This mutation has been identified in non-small cell lung cancer and is a statistically significant hotspot (PMID: 10023676). In vivo studies with yeast expressing TP53 N247I demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 N247I also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675451423498,
              "updatedBy": "User"
            },
            "description_uuid": "422d0d47-93ac-4028-b5fd-7caa5b079022",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675451419875,
              "updatedBy": "User"
            },
            "effect_uuid": "1a108a3e-dd3d-44b5-ad90-ffb307bd499e",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675451419369,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "1bb7a6af-382d-4b6f-aa5c-6d1c9a081d4e",
            "short": ""
          },
          "mutation_effect_uuid": "146cf80a-e43c-4d87-95e6-645fc5a2246d",
          "name": "N247I",
          "name_review": {
            "updateTime": 1675451417387,
            "updatedBy": "User"
          },
          "name_uuid": "d2405004-7f54-405a-a0df-79d54d43f1b5",
          "tumors_uuid": "6f0a1c3c-3ffe-450e-8807-79145004e833"
        },
        {
          "mutation_effect": {
            "description": "The TP53 Y107D mutation is located in the DNA-binding domain of the protein. This mutation has been identified in bladder cancer and is a statistically significant hotspot (PMID: 16061860). In vivo studies with yeast expressing TP53 Y107D demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 Y107D also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675451436890,
              "updatedBy": "User"
            },
            "description_uuid": "04a02850-78ca-4339-a7e7-5895631f74fb",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675451432716,
              "updatedBy": "User"
            },
            "effect_uuid": "65bf9dac-bd1f-4a55-90ad-3ad2859152fd",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675451432016,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "6ebd857d-066a-4469-9544-ee08576473a6",
            "short": ""
          },
          "mutation_effect_uuid": "5f650d17-42bc-4d8f-8df3-001d38a68f91",
          "name": "Y107D",
          "name_review": {
            "updateTime": 1675451430054,
            "updatedBy": "User"
          },
          "name_uuid": "4644e6ff-2ec9-441e-9841-29063e719bf3",
          "tumors_uuid": "7c69913e-ddf4-4531-9af4-14f77a0fe2ba"
        },
        {
          "mutation_effect": {
            "description": "The TP53 I232S mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and is a statistically significant hotspot (PMID: 1617667). In vivo studies with yeast expressing TP53 I232S demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 I232S also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_editing": "",
            "description_review": {
              "updateTime": 1675451582247,
              "updatedBy": "User"
            },
            "description_uuid": "59376817-723c-44cb-948a-b824b6546b8f",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675451578484,
              "updatedBy": "User"
            },
            "effect_uuid": "8f77f06a-8bd0-40d6-82c7-f63b292fb735",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675451577719,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "d0285f72-66b1-4b52-ae57-fed4512188d2",
            "short": ""
          },
          "mutation_effect_uuid": "bedd67bf-6c14-41ff-8b03-94bcd2e9d331",
          "name": "I232S",
          "name_review": {
            "updateTime": 1675451575451,
            "updatedBy": "User"
          },
          "name_uuid": "1e11939b-1e00-4163-8236-d28f6ee3d8c2",
          "tumors_uuid": "bfccaec2-d963-4093-aaf6-aa4a13f2e488"
        },
        {
          "mutation_effect": {
            "description": "The TP53 I232F mutation is located in the DNA-binding domain of the protein. This mutation has been identified in esophageal squamous cell carcinoma and is a statistically significant hotspot (PMID: 10753186). In vivo studies with yeast expressing TP53 I232F demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
            "description_review": {
              "updateTime": 1675451726536,
              "updatedBy": "User"
            },
            "description_uuid": "f0c3e2c3-1074-4f1f-b472-5e465701d1f0",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675451723460,
              "updatedBy": "User"
            },
            "effect_uuid": "d8939e03-2292-4989-8507-f52959238c38",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675451722413,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "cc45b460-9570-4cf7-910e-20f97e7cebdb",
            "short": ""
          },
          "mutation_effect_uuid": "0fd89c1b-3d49-4129-94aa-10e643b690fa",
          "name": "I232F",
          "name_review": {
            "updateTime": 1675451720172,
            "updatedBy": "User"
          },
          "name_uuid": "3280524d-9e1c-4a9a-8a86-dea9cf4fb4c9",
          "tumors_uuid": "717c72df-35e4-44e7-be08-054d8540baf2"
        },
        {
          "mutation_effect": {
            "description": "The TP53 P190R mutation is located in the DNA-binding domain of the protein. This mutation has been identified in ovarian cancer and is a statistically significant hotspot (PMID: 16337994). In vivo studies with yeast expressing TP53 P190R demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 P190R also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675451738987,
              "updatedBy": "User"
            },
            "description_uuid": "d7b4a047-61e9-4d12-8d35-1a5f1dc050b8",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675451735451,
              "updatedBy": "User"
            },
            "effect_uuid": "647e0a17-ec15-427c-9cbe-0481b8cea498",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675451734505,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "fd374789-14a3-437e-ab4f-98a87de04109",
            "short": ""
          },
          "mutation_effect_uuid": "c83c0d4b-e909-4710-bde3-e3110bcd461f",
          "name": "P190R",
          "name_review": {
            "updateTime": 1675451732036,
            "updatedBy": "User"
          },
          "name_uuid": "ab913378-ba3d-4a1d-8761-7e2ed1d4149e",
          "tumors_uuid": "05aeff93-9ec1-4a72-8c8e-a0a76ce8e089"
        },
        {
          "mutation_effect": {
            "description": "The TP53 P190S mutation is located in the DNA-binding domain of the protein. This mutation has been identified in ovarian cancer and is a statistically significant hotspot (PMID: 17692090). There is conflicting evidence about the biological and oncogenic effect of the mutation. In vivo studies with yeast expressing TP53 P190S demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). However, other in vitro studies with various human cancer cell lines expressing TP53 P190S demonstrated that the mutation is likely neutral as measured by growth suppression activity comparable to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1677260084902,
              "updatedBy": "User"
            },
            "description_uuid": "00552eb3-ed66-44e6-ada9-2a0cc0a3598c",
            "effect": "Inconclusive",
            "effect_review": {
              "updateTime": 1675451747569,
              "updatedBy": "User"
            },
            "effect_uuid": "db419730-f891-4cfe-95e3-b292baed66ae",
            "oncogenic": "Inconclusive",
            "oncogenic_review": {
              "updateTime": 1675451746810,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "ba64a42c-128a-4c7a-a27c-7c8f4c0c7265",
            "short": ""
          },
          "mutation_effect_uuid": "6a832884-bc95-4af0-8a0f-9bf39ef53d29",
          "name": "P190S",
          "name_review": {
            "updateTime": 1675451745154,
            "updatedBy": "User"
          },
          "name_uuid": "fe6feddb-7f67-4eaa-912e-3f84e40e297e",
          "tumors_uuid": "ead9c816-6ad6-40f4-b19a-a42a49665ebf"
        },
        {
          "mutation_effect": {
            "description": "The TP53 P190T mutation is located in the DNA-binding domain of the protein. This mutation has been identified in esophageal squamous cell carcinoma and is a statistically significant hotspot (PMID: 12713560). In vivo studies with yeast expressing TP53 P190T demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 P190T also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675452237840,
              "updatedBy": "User"
            },
            "description_uuid": "96b923af-2828-4c20-80bc-0c7eb09e643c",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675452232572,
              "updatedBy": "User"
            },
            "effect_uuid": "19b1f4cc-c835-49cc-820b-d63ae5c94bff",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675452231724,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "c86b790d-e7f0-4cd4-8e53-b4d7b2242b51",
            "short": ""
          },
          "mutation_effect_uuid": "8991f08f-3641-41ca-a054-d3f5d1c17535",
          "name": "P190T",
          "name_review": {
            "updateTime": 1675452229369,
            "updatedBy": "User"
          },
          "name_uuid": "9b5fe313-992f-4ef1-96e3-c8a661915c19",
          "tumors_uuid": "916af80b-4f18-445d-a244-840777365d8b"
        },
        {
          "mutation_effect": {
            "description": "The TP53 P190L mutation is located in the DNA-binding domain of the protein. This mutation has been identified in glioblastoma and is a statistically significant hotspot (PMID: 12124823). In vivo studies with yeast expressing TP53 P190L demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 P190L also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675452248699,
              "updatedBy": "User"
            },
            "description_uuid": "45f4be3a-0a1d-44af-92f1-aea1ff44caa5",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675452245430,
              "updatedBy": "User"
            },
            "effect_uuid": "ac798566-2677-488d-a824-29f91c3ae87a",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675452244658,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "8237bb02-95db-4afc-b3df-bdaf68c1bfdb",
            "short": ""
          },
          "mutation_effect_uuid": "a58883ec-ce48-44ed-9110-038abcc8d153",
          "name": "P190L",
          "name_review": {
            "updateTime": 1675452242482,
            "updatedBy": "User"
          },
          "name_uuid": "4ca89429-8224-4101-9aea-751d9df27dfc",
          "tumors_uuid": "b50d948b-d0df-435e-b321-f59e500211d5"
        },
        {
          "mutation_effect": {
            "description": "The TP53 V218E mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and is a statistically significant hotspot (PMID: 9569050). In vivo studies with yeast expressing TP53 V218E demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 V218E also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675452261155,
              "updatedBy": "User"
            },
            "description_uuid": "37d7a99a-c158-4a6b-af39-e0ff7668abad",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675452257710,
              "updatedBy": "User"
            },
            "effect_uuid": "c51ab0c9-9b4d-4d3b-b015-40f66ef0b308",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675452256896,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "18180fbe-e0b2-4c39-824d-78dc766fd4c9",
            "short": ""
          },
          "mutation_effect_uuid": "e6300bbf-47f2-4baa-a2e6-69cae07f62f1",
          "name": "V218E",
          "name_review": {
            "updateTime": 1675452254046,
            "updatedBy": "User"
          },
          "name_uuid": "1c951ce5-5b3a-4040-a408-df2c86038acf",
          "tumors_uuid": "ac0b7e88-8dde-4d94-bc7f-c5e2898ac15b"
        },
        {
          "mutation_effect": {
            "description": "The TP53 V218G mutation is located in the DNA-binding domain of the protein. This mutation has been identified in malignant melanoma and is a statistically significant hotspot (PMID: 8826861). There is conflicting evidence about the biological and oncogenic effect of the mutation. In vitro studies with various human cancer cell lines expressing TP53 V218G also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644). However, other in vivo studies with yeast expressing TP53 V218G demonstrated that the mutation is likely neutral as measured by transactivational activity comparable to wildtype (PMID: 27328919, 12826609).",
            "description_review": {
              "updateTime": 1677260140398,
              "updatedBy": "User"
            },
            "description_uuid": "61737701-b8be-4da2-adb3-10fcd944b8b1",
            "effect": "Inconclusive",
            "effect_review": {
              "updateTime": 1675452271154,
              "updatedBy": "User"
            },
            "effect_uuid": "f8508ea9-8b21-4599-9157-be8835c2ee62",
            "oncogenic": "Inconclusive",
            "oncogenic_review": {
              "updateTime": 1675452270068,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "933dbd39-4919-4e88-a210-3cea240dde03",
            "short": ""
          },
          "mutation_effect_uuid": "25c0b4a0-85a4-42cd-83dc-395ed0163e4b",
          "name": "V218G",
          "name_review": {
            "updateTime": 1675452267648,
            "updatedBy": "User"
          },
          "name_uuid": "fdd6a03c-4244-4d6c-add4-e3bd7b0ee346",
          "tumors_uuid": "27455abd-63f7-4893-b513-21a80f6983fe"
        },
        {
          "mutation_effect": {
            "description": "The TP53 V218L mutation is located in the DNA-binding domain of the protein. This mutation has been identified in colorectal cancer and is a statistically significant hotspot (PMID: 8556707). In vivo studies with yeast expressing TP53 V218L demonstrated that the mutation is likely neutral as measured by transactivational activity comparable to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 V218L also demonstrated the mutation is likely neutral as measured by growth suppression activity comparable to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1677260189361,
              "updatedBy": "User"
            },
            "description_uuid": "4899ad79-699c-477f-b348-46f728099b16",
            "effect": "Likely Neutral",
            "effect_review": {
              "updateTime": 1675452611627,
              "updatedBy": "User"
            },
            "effect_uuid": "51dcc022-b757-4ad0-8170-bafdd3bd2492",
            "oncogenic": "Likely Neutral",
            "oncogenic_review": {
              "updateTime": 1675452610604,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "0d0866f9-dab4-4f3c-a45a-4a5d02a52bef",
            "short": ""
          },
          "mutation_effect_uuid": "59638b7f-67c8-46af-8f5a-1c8720bd6ef3",
          "name": "V218L",
          "name_review": {
            "updateTime": 1675452606767,
            "updatedBy": "User"
          },
          "name_uuid": "fcb34461-93b6-4282-8a1c-334190b9f338",
          "tumors_uuid": "e2615af8-e7df-43d0-adfb-ad39e1aec6e7"
        },
        {
          "mutation_effect": {
            "description": "The TP53 V218M mutation is located in the DNA-binding domain of the protein. This mutation has been identified in papillary serous carcinoma and is a statistically significant hotspot (PMID: 10728699). In vivo studies with yeast expressing TP53 V218M demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
            "description_review": {
              "updateTime": 1675452644419,
              "updatedBy": "User"
            },
            "description_uuid": "8e0a1d4b-589e-41ba-accd-5815257acb7b",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675452639791,
              "updatedBy": "User"
            },
            "effect_uuid": "775ab59c-b3a0-4d5d-a6c8-9983acb18cf6",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675452638908,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "254c91ed-cf33-4bb2-a416-92bb0a057757",
            "short": ""
          },
          "mutation_effect_uuid": "f05e187b-64bb-4d35-a4cd-bbbcca1521b5",
          "name": "V218M",
          "name_review": {
            "updateTime": 1675452634289,
            "updatedBy": "User"
          },
          "name_uuid": "0a3a6643-0f92-4f80-ad0b-4b1d663e5710",
          "tumors_uuid": "7dadb9dd-7460-4363-8473-68a58d975225"
        },
        {
          "mutation_effect": {
            "description": "The TP53 N268_R273del mutation is located in the DNA-binding domain of the protein and is a statistically significant hotspot. Although not functionally characterized per se, an advanced non-small cell lung cancer patient harboring both TP53 N268_R273del and EGFR D770_N771insG treated with poziotinib demonstrated sensitivity and later acquired CDK6 amplification as a secondary resistance mutation (PMID: 35820397).",
            "description_editing": "",
            "description_review": {
              "updateTime": 1675455727666,
              "updatedBy": "User"
            },
            "description_uuid": "bcfc392d-b4e5-4806-9a91-d359aa081b2f",
            "effect": "Inconclusive",
            "effect_review": {
              "updateTime": 1675454841275,
              "updatedBy": "User"
            },
            "effect_uuid": "e28f77db-5897-4413-8593-f665b8309830",
            "oncogenic": "Inconclusive",
            "oncogenic_review": {
              "updateTime": 1677260237989,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "a6f49b52-a289-432c-9efe-da0a75438529",
            "short": ""
          },
          "mutation_effect_uuid": "931989d1-c4d8-47e1-b044-5fe401892e7d",
          "name": "N268_R273del",
          "name_review": {
            "updateTime": 1675454836347,
            "updatedBy": "User"
          },
          "name_uuid": "8239211c-4889-460d-9dfb-731b1f4bb47a",
          "tumors_uuid": "5386a215-00ae-4311-a194-d5ca8dcbac13"
        },
        {
          "mutation_effect": {
            "description": "The TP53 I195S mutation is located in the DNA-binding domain of the protein. This mutation has been identified in esophageal squamous cell carcinoma and is a statistically significant hotspot (PMID: 9133458). In vivo studies with yeast expressing TP53 I195S demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 I195S also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675712287856,
              "updatedBy": "User"
            },
            "description_uuid": "0473fe29-de2e-4b1c-ad40-13816182b439",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675712284507,
              "updatedBy": "User"
            },
            "effect_uuid": "3dd7fb97-061a-421b-89f1-341009371c7b",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675712283898,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "57036612-9792-4ca9-a5f0-eb74c77026bc",
            "short": ""
          },
          "mutation_effect_uuid": "5c07dc55-5c38-4759-8769-2ff27c5b2542",
          "name": "I195S",
          "name_review": {
            "updateTime": 1675712281529,
            "updatedBy": "User"
          },
          "name_uuid": "53811201-2971-478f-a86e-390ad9b1ddcb",
          "tumors_uuid": "5b8e010a-d930-432b-9dcc-c39f2e0c9600"
        },
        {
          "mutation_effect": {
            "description": "The TP53 I195F mutation is located in the DNA-binding domain of the protein. This mutation has been identified in ovarian cancer and is a statistically significant hotspot (PMID: 22460905). In vivo studies with yeast expressing TP53 I195F demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 I195F also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675712310379,
              "updatedBy": "User"
            },
            "description_uuid": "e452edd2-b1ce-422e-aaf0-fdd6b142f0c1",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675712306577,
              "updatedBy": "User"
            },
            "effect_uuid": "9ae310a7-f0a9-4645-bfeb-63c6dbd9ae3f",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675712305597,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "8d5534d3-2067-4b77-a8fd-941c57549700",
            "short": ""
          },
          "mutation_effect_uuid": "1adaa644-26f6-41b6-bd45-7b01ce092547",
          "name": "I195F",
          "name_review": {
            "updateTime": 1675712302866,
            "updatedBy": "User"
          },
          "name_uuid": "4ea9386a-23f3-479e-b681-30da75358dc6",
          "tumors_uuid": "adfef3de-c652-453a-9547-ebd4b2e28f6c"
        },
        {
          "mutation_effect": {
            "description": "The TP53 I195K mutation is located in the DNA-binding domain of the protein. This mutation has been identified in lung adenocarcinoma and is a statistically significant hotspot (PMID: 28481359). In vitro studies with various human cancer cell lines expressing TP53 I195K demonstrate that the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675712328021,
              "updatedBy": "User"
            },
            "description_uuid": "1946b51a-bd93-4852-b773-792678f630a6",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675712324323,
              "updatedBy": "User"
            },
            "effect_uuid": "662d0b85-cc03-428c-bd8a-d6bd90ce229c",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675712322989,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "6098083f-be56-461b-99ee-3357a5f4860e",
            "short": ""
          },
          "mutation_effect_uuid": "14c9f11c-f3d0-4a09-9a77-a5c341f88b8c",
          "name": "I195K",
          "name_review": {
            "updateTime": 1675712320297,
            "updatedBy": "User"
          },
          "name_uuid": "2cd63a19-0b03-47a9-8a6c-98f1b9f76956",
          "tumors_uuid": "7e97a7b9-6ef0-41d6-8f72-9fc9af0af57b"
        },
        {
          "mutation_effect": {
            "description": "The TP53 I195M mutation is located in the DNA-binding domain of the protein. This mutation has been identified in plasma cell myeloma and is a statistically significant hotspot (PMID: 25302557). There is conflicting evidence about the biological and oncogenic effect of the mutation. In vivo studies with yeast expressing TP53 I195M demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). However, other in vitro studies with various human cancer cell lines expressing TP53 I195M demonstrated that the mutation is likely neutral as measured by growth suppression activity comparable to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1677260312243,
              "updatedBy": "User"
            },
            "description_uuid": "0bd32678-4976-4e60-a458-03c3288c5032",
            "effect": "Inconclusive",
            "effect_review": {
              "updateTime": 1675712337399,
              "updatedBy": "User"
            },
            "effect_uuid": "0ccd7729-e3c8-494c-b2cd-5c371b007db3",
            "oncogenic": "Inconclusive",
            "oncogenic_review": {
              "updateTime": 1675712336434,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "f7e117c6-292e-4a55-8fd2-53d6f2e95813",
            "short": ""
          },
          "mutation_effect_uuid": "676a918d-11dd-4083-b49e-8a4681099f2b",
          "name": "I195M",
          "name_review": {
            "updateTime": 1675712334493,
            "updatedBy": "User"
          },
          "name_uuid": "24fc9c0e-0fe8-4cbd-a28d-c388b5d5abee",
          "tumors_uuid": "6ed5f7c1-898f-4cc7-bb49-f364e1f3cd91"
        },
        {
          "mutation_effect": {
            "description": "The TP53 I195N mutation is located in the DNA-binding domain of the protein. This mutation has been identified in ovarian cancer and is a statistically significant hotspot (PMID: 16337994). In vivo studies with yeast expressing TP53 I195N demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 I195N also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675712354390,
              "updatedBy": "User"
            },
            "description_uuid": "e1e2c161-6822-43f4-be61-401fdb0c177d",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675712350913,
              "updatedBy": "User"
            },
            "effect_uuid": "5d209b32-8275-406f-9a3f-8741f5b3eb47",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675712350148,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "469be8ee-8d28-4e39-9bdc-3a4ebf9437a7",
            "short": ""
          },
          "mutation_effect_uuid": "8cbdc341-4921-4de3-b2ec-068289b61182",
          "name": "I195N",
          "name_review": {
            "updateTime": 1675712347611,
            "updatedBy": "User"
          },
          "name_uuid": "7b560020-2d53-49cb-9ac4-cb4cbec2212b",
          "tumors_uuid": "21cd0803-65fb-4b69-9fd6-22e9098cbdc4"
        },
        {
          "mutation_effect": {
            "description": "The TP53 C135G mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and is a statistically significant hotspot (PMID: 10690522). In vivo studies with yeast expressing TP53 C135G demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 C135G also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675712371141,
              "updatedBy": "User"
            },
            "description_uuid": "18b88f1e-8116-4e64-8438-f1e92aac4e41",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675712366377,
              "updatedBy": "User"
            },
            "effect_uuid": "19b005cb-ad9d-4f99-87b4-30e729d37307",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675712365584,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "cd08472f-d535-4a87-b98a-61f6677ea879",
            "short": ""
          },
          "mutation_effect_uuid": "83cb43b1-c53a-4da5-b0ea-ba039bcc28a2",
          "name": "C135G",
          "name_review": {
            "updateTime": 1675712362745,
            "updatedBy": "User"
          },
          "name_uuid": "ad3b5d54-cf73-4004-9d85-502e829d72fe",
          "tumors_uuid": "c8b7363b-d267-4b63-bd79-d7a4d20463e1"
        },
        {
          "mutation_effect": {
            "description": "The TP53 P151R mutation is located in the DNA-binding domain of the protein. This mutation has been identified in glioblastoma and is a statistically significant hotspot (PMID: 15466178). In vivo studies with yeast expressing TP53 P151R demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 P151R also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
            "description_review": {
              "updateTime": 1675712386479,
              "updatedBy": "User"
            },
            "description_uuid": "c066ef97-a96e-44b3-a940-4554eb5310a7",
            "effect": "Likely Loss-of-function",
            "effect_review": {
              "updateTime": 1675712382382,
              "updatedBy": "User"
            },
            "effect_uuid": "35a34952-6e05-46e4-aec7-3f000d0303a5",
            "oncogenic": "Likely",
            "oncogenic_review": {
              "updateTime": 1675712381053,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "9bd83fdd-ab5a-4052-b223-d69cd2ff4957",
            "short": ""
          },
          "mutation_effect_uuid": "821014d4-dd29-4a45-ab6c-ebd086462b90",
          "name": "P151R",
          "name_review": {
            "updateTime": 1675712377311,
            "updatedBy": "User"
          },
          "name_uuid": "a654d274-bb17-41b2-a80d-0667dccefaf0",
          "tumors_uuid": "608b6d25-a426-4190-af04-f1dcf18ddebc"
        },
        {
          "mutation_effect": {
            "description": "The TP53 G360V mutation is located in the CARM1, HIPK1, HIPK2 and USP7 interacting regions of the protein. This mutation has been identified in biliary tract cancer (PMID: 34810298). There is conflicting evidence about the biological effect of this mutation. In vitro studies with H1299 cells expressing TP53 G360V demonstrate that the mutation is likely neutral as measured by colony growth comparable to wildtype (PMID: 33257846). Other in vitro studies with various human cancer cell lines expressing TP53 G360V also demonstrate that the mutation is likely neutral as measured by growth suppression activity comparable to wildtype (PMID: 29979965, 30224644). In vivo studies with yeast expressing TP53 G360V demonstrate that the mutation is likely neutral as measured by transactivational activity comparable to wildtype (PMID: 27328919, 12826609). In contrast, in vitro studies with H1299 cells expressing TP53 G360V demonstrate that the mutation is activating as measured by increased transactivational activity, increased apoptosis and decreased colony growth compared to wildtype (PMID: 27297285).",
            "description_review": {
              "updateTime": 1689113933495,
              "updatedBy": "User"
            },
            "description_uuid": "690330a9-8e7d-466b-98d3-46e0aa79e00d",
            "effect": "Inconclusive",
            "effect_review": {
              "updateTime": 1689086182788,
              "updatedBy": "User"
            },
            "effect_uuid": "b3b7f8fa-2917-468e-b3f9-d14d3b0cee6c",
            "oncogenic": "Likely Neutral",
            "oncogenic_review": {
              "updateTime": 1689113923766,
              "updatedBy": "User"
            },
            "oncogenic_uuid": "5da991e0-79f8-4a2a-a55c-953956ee76ca",
            "short": ""
          },
          "mutation_effect_uuid": "3c3f11a6-89f3-4697-8c99-8b4ecf4e73c5",
          "name": "G360V",
          "name_review": {
            "updateTime": 1689086180535,
            "updatedBy": "User"
          },
          "name_uuid": "06587d3e-ce42-414b-b5ae-6ce4b7a83d51",
          "tumors_uuid": "dcc8f8d5-a02c-4eff-ad0f-997b43744356"
        }
      ],
      "name": "TP53",
      "name_comments": [
        {
          "content": "For inactivating mutations, there is likely information about prevalence and prognostic information for a variety of cancers. Can you try to curate these?",
          "date": "1426515664704",
          "email": "user@gmail.com",
          "resolved": "false",
          "userName": "User"
        },
        {
          "content": "25958320",
          "date": "1433862886038",
          "email": "user@gmail.com",
          "resolved": "false",
          "userName": "User"
        },
        {
          "content": "For missens mutations, state what domain it is in",
          "date": "1476387946698",
          "email": "user@gmail.com",
          "resolved": "true",
          "userName": "User"
        }
      ],
      "summary": "TP53, a tumor suppressor in the DNA damage pathway, is the most frequently mutated gene in cancer.",
      "summary_comments": [
        {
          "content": "TP53, the most commonly mutated gene in cancer, encodes the p53 tumor suppressor, a transcription factor that prevents cells with damaged DNA from replicating by inducing DNA repair or apoptosis.",
          "date": "1460674582165",
          "email": "user@gmail.com",
          "resolved": "true",
          "userName": "User"
        }
      ],
      "summary_review": {
        "updateTime": 1492724745580
      },
      "summary_uuid": "1238efb3-3419-4254-a8ca-c810ff7b2696",
      "type": {
        "ocg": "",
        "ocg_review": {
          "updateTime": 1492724745580
        },
        "ocg_uuid": "ff1efac9-dcdc-45a8-92a3-d97c1f1db0d0",
        "tsg": "Tumor Suppressor",
        "tsg_review": {
          "updateTime": 1492724745580
        },
        "tsg_uuid": "9dc33bc9-af8a-4d94-80bc-fc8c97e687ef"
      },
      "type_uuid": "f6122512-16ca-48f4-83a6-cb38796e399c"
    },
    "EMPTYGENE": {
      "background": "Sample gene background",
      "background_uuid": "49cfad04-4541-4113-9f85-072c32b5c35d",
      "dmp_refseq_id": "",
      "dmp_refseq_id_grch38": "",
      "inheritanceMechanism": "",
      "inheritanceMechanism_uuid": "d6d3697f-55a6-4950-9912-16fbcf848267",
      "isoform_override": "",
      "isoform_override_grch38": "",
      "mutations_uuid": "9f541241-7fa4-40b7-be67-4c915a48e5fa",
      "name": "EMPTYGENE",
      "penetrance": "",
      "penetrance_uuid": "9a387241-a6ed-4702-91ab-f86be9bfe18a",
      "summary": "",
      "summary_uuid": "93e7f92d-5fdf-4a12-86c1-3d094649b5c9",
      "type": {
        "ocg": "",
        "ocg_uuid": "de2e592c-eddc-4cfa-aefa-78672270cc42",
        "tsg": "",
        "tsg_uuid": "780878cb-6480-4dc1-8143-979e73daf309"
      },
      "type_uuid": "aa20da52-a94f-4f1b-94e9-0e89b3e6b281"
    }
  },
  "Germline_Genes": {
    "ATM": {
      "background": "ATM is a member of the protein superfamily of phosphatidylinositol 3-kinase related serine/threonine kinases (PIKKs). ATM functions as a tumor suppressor that initiates DNA damage checkpoint signaling after accumulation of DNA double-strand breaks (DSBs) or after accumulation of other forms of cellular stress (PMID: 23219553). Activated ATM can phosphorylate hundreds of substrates in order to initiate and amplify the DNA damage response (PMID: 17525332) resulting in DNA repair, cell cycle arrest and/or apoptosis. Germline, homozygous/compound heterozygous loss-of-function mutations in ATM have been identified in the autosomal recessive disorder ataxia telangiectasia (A-T), a disorder that presents with a variety of neurologic conditions, lung and skin disorders, and immunodeficiency (PMID: 21792198). Patients with A-T are also predisposed to a wide variety of cancers, particularly childhood lymphomas and leukemia as well as breast cancer (PMID: 21792198), whereas heterozygous carriers are at increased risk for adult-onset breast (PMID: 27112364, 31171119, 33471974), pancreatic (PMID: 22585167, 34529012), prostate (PMID: 33436325), gastroesophageal junction (PMID: 35078243), and other cancers. Somatic mutations in ATM have been identified in lymphoid malignancies and a selection of solid tumors (PMID: 12400598, 27413114). ATM-mutant cancers are increasingly sensitive to DNA damaging agents due to deficits in DNA repair pathways, and ATM loss may result in better response to checkpoint inhibition in some cancers (PMID: 27413114, 29489427).\n",
      "background_review": {
        "lastReviewed": "",
        "updateTime": 1715014332560,
        "updatedBy": "User"
      },
      "background_uuid": "198b826d-807d-4411-8416-74beff2d82f7",
      "dmp_refseq_id": "",
      "dmp_refseq_id_grch38": "",
      "genomic_indicators": [
        {
          "associationVariants": [
            {
              "name": "Pathogenic Variants",
              "uuid": "Pathogenic Variants"
            }
          ],
          "associationVariants_uuid": "efe6445d-b3cb-40f8-8403-6d2f185843e6",
          "biallelic": "",
          "biallelic_uuid": "c677a13e-12f1-444d-8140-38d4c802c340",
          "description": "",
          "description_uuid": "e6f74b76-a2b5-4d73-8ab3-c8c81bfbf393",
          "monoallelic": "Monoallelic",
          "monoallelic_review": {
            "lastReviewed": "",
            "updateTime": 1715014421438,
            "updatedBy": "User"
          },
          "monoallelic_uuid": "7c180c7d-eead-4288-a3f9-08b4d1e7d7e0",
          "mosaic": "",
          "mosaic_uuid": "0c4e6b1f-f04e-4620-829a-a84e37087d11",
          "name": "ATM-associated cancer risk",
          "name_review": {
            "added": true,
            "lastReviewed": "",
            "updateTime": 1715014391799,
            "updatedBy": "User"
          },
          "name_uuid": "e3357308-7e7a-466a-98a9-6e73425b2f70"
        },
        {
          "associationVariants": [
            {
              "name": "Pathogenic Variants",
              "uuid": "Pathogenic Variants"
            }
          ],
          "associationVariants_uuid": "d882469b-dac6-4c78-a69b-303f59e83b97",
          "biallelic": "Biallelic",
          "biallelic_review": {
            "lastReviewed": "",
            "updateTime": 1715014447338,
            "updatedBy": "User"
          },
          "biallelic_uuid": "e1a5b9fd-cce4-47d2-b3ad-e81b15ab577d",
          "description": "",
          "description_uuid": "c4769285-a4a3-4bfe-9828-a565b9b21095",
          "monoallelic": "",
          "monoallelic_uuid": "f56ca3b6-4618-4ede-8ca8-f743c8b912fc",
          "mosaic": "",
          "mosaic_uuid": "33dfbf22-162d-4a87-863b-12fa524922a9",
          "name": "Ataxia telangiectasia",
          "name_review": {
            "added": true,
            "lastReviewed": "",
            "updateTime": 1715014445442,
            "updatedBy": "User"
          },
          "name_uuid": "536120d5-8824-4588-85a9-4c59a39da493"
        }
      ],
      "inheritanceMechanism": "Autosomal Dominant",
      "inheritanceMechanism_review": {
        "lastReviewed": "",
        "updateTime": 1715018738232,
        "updatedBy": "User"
      },
      "inheritanceMechanism_uuid": "0ea7d43c-e172-406e-a6f7-def68bc883aa",
      "isoform_override": "",
      "isoform_override_grch38": "",
      "mutations": [
        {
          "alterations": [
            {
              "alteration": "E2814Kfs*43",
              "comment": "",
              "consequence": "Frameshift Variant",
              "genes": [
                {
                  "entrezGeneId": 472,
                  "hgncId": "795",
                  "hugoSymbol": "ATM",
                  "id": 23657
                }
              ],
              "name": "E2814Kfs*43",
              "proteinChange": "E2814Kfs*43",
              "proteinEnd": 2814,
              "proteinStart": 2814,
              "refResidues": "E",
              "type": "PROTEIN_CHANGE",
              "varResidues": ""
            }
          ],
          "alterations_uuid": "98d51e4b-4ba0-4750-81a4-10bb9327af38",
          "mutation_effect": {
            "description": "The ATM c.8440delG variant is predicted to cause a frameshift at codon 2814 and lead to a premature termination codon 43 amino acids downstream (p.E2814Kfs*43). This alteration is predicted to lead to a truncated or absent protein, and heterozygous truncating variants in ATM are known to be pathogenic. This variant has been identified in 1/111,546 European chromosomes by the Genome Aggregation Database (gnomAD: http://gnomad.broadinstitute.org) and has been reported in a compound heterozygous patient with ataxia-telangiectasia (PMID: 25614872).",
            "description_review": {
              "lastReviewed": "",
              "updateTime": 1715018626014,
              "updatedBy": "User"
            },
            "description_uuid": "6a1d8605-003a-4a82-905a-a13ded3a9331",
            "effect": "",
            "effect_uuid": "bd543a68-5fe4-4911-861b-ea99805d7ae0",
            "germline": {
              "cancerRisk": {
                "biallelic": "",
                "biallelic_uuid": "249b399b-4fad-4a54-adb2-f33ece7525c6",
                "monoallelic": "",
                "monoallelic_uuid": "899227e6-4b23-4d9e-996a-6af724d64e93",
                "mosaic": "",
                "mosaic_uuid": "83f8921e-c772-4937-9dd5-9611e4152215"
              },
              "cancerRisk_uuid": "936e7f14-4ed4-4a53-adf8-e53eac6cdd82",
              "description": "",
              "description_uuid": "72006871-b08d-455a-a5ed-091be907e15d",
              "inheritanceMechanism": "",
              "inheritanceMechanismDescription": "",
              "inheritanceMechanismDescription_uuid": "b5f9f028-c40d-4536-8730-3003c1eaa3e9",
              "inheritanceMechanism_uuid": "b86ab918-932f-40fd-b954-8472fd0034f7",
              "pathogenic": "",
              "pathogenic_uuid": "71824340-79dd-482c-83d6-85a98d0629ef",
              "penetrance": "",
              "penetranceDescription": "",
              "penetranceDescription_uuid": "eb2d8e56-caba-4899-885c-359e73c9c563",
              "penetrance_uuid": "7b9f9204-f779-4327-9e53-ccdad13b4876"
            },
            "germline_uuid": "5cecd23b-c8ae-443c-877d-a6cdeea956e9",
            "oncogenic": "",
            "oncogenic_uuid": "c0de0983-d436-4b4a-b54b-6bf2c48d7fcb",
            "pathogenic": "Pathogenic",
            "pathogenic_review": {
              "lastReviewed": "",
              "updateTime": 1715018616767,
              "updatedBy": "User"
            },
            "pathogenic_uuid": "fa937bc0-d575-4b23-9c19-d629469e07d7",
            "short": ""
          },
          "mutation_effect_uuid": "3be7e120-c626-47a3-b2e4-96057c2beee3",
          "mutation_specific_cancer_risk": {
            "biallelic": "",
            "biallelic_uuid": "ce288ef5-80e5-4534-9adb-d6aa78fda7e7",
            "monoallelic": "",
            "monoallelic_uuid": "66858ebf-d088-4393-819d-a28c98e1b53b",
            "mosaic": "",
            "mosaic_uuid": "197f6bf5-d606-4c99-ba63-b653adee2418"
          },
          "mutation_specific_inheritance_mechanism": {
            "description": "",
            "description_uuid": "b81f2cf9-ef6e-48c2-be50-5b27333822a1",
            "inheritanceMechanism": "",
            "inheritanceMechanism_uuid": "676a4778-ed07-45c8-8dd5-390926b58dc0"
          },
          "mutation_specific_penetrance": {
            "description": "",
            "description_uuid": "9ca35353-4526-4247-88eb-cb284f44c403",
            "penetrance": "",
            "penetrance_uuid": "7e4fcb80-f569-4efe-8db0-7a7edf1b2916"
          },
          "name": "E2814Kfs*43",
          "name_review": {
            "added": true,
            "updateTime": 1715018612102,
            "updatedBy": "User"
          },
          "name_uuid": "f8861d61-a3cf-4492-a5b0-4c4c98c830f6",
          "tumors_uuid": "4fd7d7ee-f035-456d-9d90-62816bcda653"
        }
      ],
      "mutations_uuid": "33c0f2f6-00e3-407b-a511-2f27ccf98aee",
      "name": "ATM",
      "penetrance": "High",
      "penetrance_review": {
        "lastReviewed": "",
        "updateTime": 1715014479737,
        "updatedBy": "User"
      },
      "penetrance_uuid": "71a8b411-a911-46d3-86e1-932f33df8f6c",
      "summary": "Pathogenic germline mutations in ATM cause ataxia telangiectasia (biallelic) and are associated with autosomal dominant susceptibility to breast cancer (monoallelic).\n",
      "summary_review": {
        "lastReviewed": "",
        "updateTime": 1715014321221,
        "updatedBy": "User"
      },
      "summary_uuid": "c0e0c42b-385e-4910-a7bc-b1353461c1e1",
      "type": {
        "ocg": "",
        "ocg_uuid": "66876587-787e-41e8-95d7-9db49e85889b",
        "tsg": "Tumor Suppressor",
        "tsg_review": {
          "lastReviewed": "",
          "updateTime": 1715018703048,
          "updatedBy": "User"
        },
        "tsg_uuid": "951dd1c7-8742-4fd0-a21f-a789a17f09ab"
      },
      "type_uuid": "44d1bdad-d099-47b3-b0d8-cb78b7630d4f"
    },
    "BAP1": {
      "background": "BAP1 (BRCA-associated Protein-1) is a nuclear ubiquitin hydrolase that has been implicated in several cellular processes including cell proliferation, DNA repair, chromatin regulation of gene expression, and stem cell pluripotency (PMID: 19815555, 20805357, 18757409). By deubiquitinating host cell factor-1 (HCF-1), a chromatin-associated protein that helps regulate transcription, BAP1 regulates cell proliferation (PMID: 19815555). BAP1 has been shown to regulate gene expression by forming a ternary complex with HCF-1 and the YY1 transcription factor (PMID: 20805357) and to enhance cell death by increasing progression through the G1-S checkpoint (PMID: 18757409). BAP1 loss alters class I histone deacetylase (HDAC) expression, which may result in altered therapeutic response to HDAC inhibitors in BAP1-depleted cancer cells (PMID: 25970771). Germline mutations of the BAP1 tumor suppressor gene predispose to several tumors, most commonly including uveal melanoma, mesothelioma, cutaneous melanoma, and renal cell carcinoma, which suggests that BAP1 is a tumor suppressor (PMID: 21874000, 23277170, 23849051, 32690542). Somatic BAP1 mutations are also common in these tumor types, among others (PMID: 23867514, 21642991, 23277170).",
      "background_review": {
        "lastReviewed": "",
        "updateTime": 1715018821372,
        "updatedBy": "User"
      },
      "background_uuid": "6ecdab1b-c78b-4197-8d92-ef5aa0fed051",
      "dmp_refseq_id": "",
      "dmp_refseq_id_grch38": "",
      "genomic_indicators": [
        {
          "associationVariants": [
            {
              "name": "Pathogenic Variants",
              "uuid": "Pathogenic Variants"
            }
          ],
          "associationVariants_uuid": "f976afac-294f-4de2-9e59-f17fa137c758",
          "biallelic": "",
          "biallelic_uuid": "6fd8fcc7-6e4b-43b8-8819-e98c962fa92f",
          "description": "",
          "description_uuid": "0427ab53-e2ac-4ecb-bb82-2893675e5161",
          "monoallelic": "Monoallelic",
          "monoallelic_review": {
            "lastReviewed": "",
            "updateTime": 1715018851733,
            "updatedBy": "User"
          },
          "monoallelic_uuid": "9d4f54ad-845b-4989-9ec6-438980d56fa6",
          "mosaic": "",
          "mosaic_uuid": "155d62fb-fb29-47a2-924f-09f0911e770e",
          "name": "BAP1 tumor predisposition syndrome",
          "name_review": {
            "added": true,
            "lastReviewed": "",
            "updateTime": 1715018839526,
            "updatedBy": "User"
          },
          "name_uuid": "8bba4d53-fb30-4b3b-bde8-7c071d882aa5"
        }
      ],
      "inheritanceMechanism": "Autosomal Dominant",
      "inheritanceMechanism_review": {
        "lastReviewed": "",
        "updateTime": 1715018856299,
        "updatedBy": "User"
      },
      "inheritanceMechanism_uuid": "d6ba9ff8-d0c1-46d9-ae6e-61facac172ae",
      "isoform_override": "",
      "isoform_override_grch38": "",
      "mutations": [
        {
          "alterations": [
            {
              "alteration": "Q593*",
              "comment": "",
              "consequence": "Stop Gained",
              "genes": [
                {
                  "entrezGeneId": 8314,
                  "hgncId": "950",
                  "hugoSymbol": "BAP1",
                  "id": 11733
                }
              ],
              "name": "Q593*",
              "proteinChange": "Q593*",
              "proteinEnd": 593,
              "proteinStart": 593,
              "refResidues": "Q",
              "type": "PROTEIN_CHANGE",
              "varResidues": "*"
            }
          ],
          "alterations_uuid": "5ca8dd58-de91-4ab5-bd27-97a16399c4a4",
          "mutation_effect": {
            "description": "The BAP1 c.1777C>T variant is a nonsense mutation that changes a glutamine to a premature stop codon (p.Q593*) and is predicted to lead to a truncated or absent protein. Heterozygous truncating variants in BAP1 are known to be pathogenic. This variant is absent from large population databases (1000 Genomes, ESP, and Broad ExAc). It has been reported in the literature to segregate with disease in four members of a family with melanoma or dysplastic nevi (PMID: 26774355). Immunohistochemistry of the tumors in this family showed loss of BAP1 protein expression.",
            "description_review": {
              "lastReviewed": "",
              "updateTime": 1715019061670,
              "updatedBy": "User"
            },
            "description_uuid": "4505e8ad-3f46-4420-a9f6-fb1bd9d17f4b",
            "effect": "",
            "effect_uuid": "f81c2f38-f0ec-410c-921f-44530a55a523",
            "germline": {
              "cancerRisk": {
                "biallelic": "",
                "biallelic_uuid": "ce143bc6-f8a1-4bb1-bfce-7fda781644ef",
                "monoallelic": "",
                "monoallelic_uuid": "1958ba21-1c6d-406a-89d4-815a508384bc",
                "mosaic": "",
                "mosaic_uuid": "fbc44f93-d47b-4571-a5e9-d71f98c494a7"
              },
              "cancerRisk_uuid": "1ba4ca49-9204-45d9-97ce-5271ccdb85d6",
              "description": "",
              "description_uuid": "ecf5855b-9703-4136-bfc2-ba0d77fa4a08",
              "inheritanceMechanism": "",
              "inheritanceMechanismDescription": "",
              "inheritanceMechanismDescription_uuid": "6f1c04f1-4a33-449b-99d0-aea28c65842f",
              "inheritanceMechanism_uuid": "f7503bd6-f379-4249-9f2b-4c7af3fbdafb",
              "pathogenic": "",
              "pathogenic_uuid": "84840b5e-f6c1-4a54-888b-9b6145310e1e",
              "penetrance": "",
              "penetranceDescription": "",
              "penetranceDescription_uuid": "525c2cb8-7723-43a8-b20f-c19911f9e333",
              "penetrance_uuid": "a32da9e2-7a0a-424a-8f11-6004c7900be4"
            },
            "germline_uuid": "b771b432-9f08-4d4d-8aa4-92bd24573bb3",
            "oncogenic": "",
            "oncogenic_uuid": "017ba264-ca19-4a81-9d67-ed4f8cccb175",
            "pathogenic": "Pathogenic",
            "pathogenic_review": {
              "lastReviewed": "",
              "updateTime": 1715019062796,
              "updatedBy": "User"
            },
            "pathogenic_uuid": "9a4ce899-cc5b-4721-a7d4-385d72813e99",
            "short": ""
          },
          "mutation_effect_uuid": "ae79341b-05a4-4138-99b2-50f7d04c589d",
          "mutation_specific_cancer_risk": {
            "biallelic": "",
            "biallelic_uuid": "5dc4e4f8-2bc2-4dbd-acab-6ca858f3192b",
            "monoallelic": "",
            "monoallelic_uuid": "1c6bf22b-06b9-452e-a580-62a3fbfd4650",
            "mosaic": "",
            "mosaic_uuid": "13c2ba3b-bb46-45ea-8724-733421663c9b"
          },
          "mutation_specific_inheritance_mechanism": {
            "description": "",
            "description_uuid": "eb2dc38b-b1ab-4a9d-a29c-4b79ab89f5b2",
            "inheritanceMechanism": "",
            "inheritanceMechanism_uuid": "cab47c1c-d2a4-43f8-9003-1b3e5a5417ce"
          },
          "mutation_specific_penetrance": {
            "description": "",
            "description_uuid": "5ad3ed3e-a89c-452b-9f40-f0bdd114ec17",
            "penetrance": "",
            "penetrance_uuid": "3a946ad4-f758-4280-8bce-aa78a26614c5"
          },
          "name": "Q593*",
          "name_review": {
            "added": true,
            "updateTime": 1715019047177,
            "updatedBy": "User"
          },
          "name_uuid": "144c7c1a-6c0f-41bb-90db-462517f0942c",
          "tumors_uuid": "09e64e12-ef1e-4b6e-8da5-2c089e089028"
        }
      ],
      "mutations_uuid": "bd3d7d6f-80c4-4343-8cd1-8be85168e8b2",
      "name": "BAP1",
      "penetrance": "High",
      "penetrance_review": {
        "lastReviewed": "",
        "updateTime": 1715018855163,
        "updatedBy": "User"
      },
      "penetrance_uuid": "b714db45-e924-4d47-8bfc-c00b990be4a0",
      "summary": "Pathogenic germline mutations in BAP1 cause autosomal dominant BAP1 tumor predisposition syndrome and predispose to various cancer types including mesothelioma, cutaneous and uveal melanoma, renal cell carcinoma, and basal cell carcinoma.",
      "summary_review": {
        "lastReviewed": "",
        "updateTime": 1715018813167,
        "updatedBy": "User"
      },
      "summary_uuid": "d255464b-d583-4931-b817-47c1b3b28531",
      "type": {
        "ocg": "",
        "ocg_uuid": "a3aac174-6023-4a2a-b4f7-32bfb2a2aab8",
        "tsg": "Tumor Suppressor",
        "tsg_review": {
          "lastReviewed": "",
          "updateTime": 1715019226604,
          "updatedBy": "User"
        },
        "tsg_uuid": "a965b0d0-83a6-43f3-8f36-7813a0271744"
      },
      "type_uuid": "2b375577-48df-489b-8fb7-e42f0870bab1"
    },
    "MECOM": {
      "background": "",
      "background_uuid": "9e6bd672-5ad2-4a95-9279-5a723377ef74",
      "dmp_refseq_id": "",
      "dmp_refseq_id_grch38": "",
      "inheritanceMechanism": "",
      "inheritanceMechanism_uuid": "25823c10-c813-4dd5-9e71-6cadbe428e2b",
      "isoform_override": "",
      "isoform_override_grch38": "",
      "mutations_uuid": "7d6fc753-9832-4ace-ad75-794c19a255e8",
      "name": "MECOM",
      "penetrance": "",
      "penetrance_uuid": "abc51aaf-cee1-4c4d-8a90-9dddda283889",
      "summary": "",
      "summary_uuid": "db4314c8-734d-469e-ab2e-3c36a64305f9",
      "type": {
        "ocg": "",
        "ocg_uuid": "d1b87f4c-10d9-4502-812a-aae7b7928444",
        "tsg": "",
        "tsg_uuid": "2a273bd2-7eec-4386-9f88-9898da980bb2"
      },
      "type_uuid": "83f325d7-bcf9-4bf7-b276-92d8752c4feb"
    }
  },
  "Germline_Meta": {
    "ATM": {
      "lastModifiedAt": "1715018738321",
      "lastModifiedBy": "User",
      "review": {
        "0ea7d43c-e172-406e-a6f7-def68bc883aa": true,
        "198b826d-807d-4411-8416-74beff2d82f7": true,
        "536120d5-8824-4588-85a9-4c59a39da493": true,
        "6a1d8605-003a-4a82-905a-a13ded3a9331": true,
        "71a8b411-a911-46d3-86e1-932f33df8f6c": true,
        "7c180c7d-eead-4288-a3f9-08b4d1e7d7e0": true,
        "951dd1c7-8742-4fd0-a21f-a789a17f09ab": true,
        "c0e0c42b-385e-4910-a7bc-b1353461c1e1": true,
        "e1a5b9fd-cce4-47d2-b3ad-e81b15ab577d": true,
        "e3357308-7e7a-466a-98a9-6e73425b2f70": true,
        "fa937bc0-d575-4b23-9c19-d629469e07d7": true
      }
    },
    "BAP1": {
      "lastModifiedAt": "1715019226690",
      "lastModifiedBy": "User",
      "review": {
        "4505e8ad-3f46-4420-a9f6-fb1bd9d17f4b": true,
        "6ecdab1b-c78b-4197-8d92-ef5aa0fed051": true,
        "8bba4d53-fb30-4b3b-bde8-7c071d882aa5": true,
        "9a4ce899-cc5b-4721-a7d4-385d72813e99": true,
        "9d4f54ad-845b-4989-9ec6-438980d56fa6": true,
        "a965b0d0-83a6-43f3-8f36-7813a0271744": true,
        "b714db45-e924-4d47-8bfc-c00b990be4a0": true,
        "d255464b-d583-4931-b817-47c1b3b28531": true,
        "d6ba9ff8-d0c1-46d9-ae6e-61facac172ae": true
      }
    },
    "MECOM": {
      "lastModifiedAt": "1714411980727",
      "lastModifiedBy": "User"
    }
  },
  "History": {
    "BRAF": {
      "api": {
        "-LLZVv8i1Umeg3wwWoXT": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Gene Summary",
              "operation": "update",
              "uuids": "c8a6f3f5-9134-4de4-93e5-3d72157b99d6"
            },
            {
              "lastEditBy": "User",
              "location": "Gene Background",
              "operation": "update",
              "uuids": "4cf7d3b6-91bd-42ba-abdc-6b8792cec92b"
            }
          ],
          "timeStamp": 1518022762874
        },
        "-LLZVv8jH4zXjlHaLYK8": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Gene Summary",
              "operation": "update",
              "uuids": "c8a6f3f5-9134-4de4-93e5-3d72157b99d6"
            }
          ],
          "timeStamp": 1518022775626
        },
        "-LLalmCM6Ke8RxO9l9c0": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "D842V, Leukemia, Investigational implications for resistance to therapy, Sorafenib",
              "old": {
                "description": "Sorafenib is small-molecule inhibitor of different protein kinases, including PDGFRA (PMID: 22665524). A clinical study described a patient with chronic eosinophilic leukemia (CEL) positive for the disease-specific FIP1L1-PDGFRA fusion that developed resistance to imatinib due to the previously described secondary resistance mutation T674I (PMID: 19212337). Subsequently, the patient progressed on sorafenib and in the post-progression specimen, the D842V mutation had replaced T674I. Experiments in cell lines transformed with the PDGFRA fusion confirmed that the T674I mutation confers resistance to imatinib but not sorafenib, whereas D842V mediated resistance to both inhibitors as measured by cellular growth and sustained pathway activation (PMID: 19212337).",
                "description_review": {
                  "updateTime": 1502127753005
                },
                "description_uuid": "dfaaafeb-b5db-48fb-a278-e808d4e56912",
                "indication": "",
                "indication_review": {
                  "updateTime": 1493063804037
                },
                "indication_uuid": "63f20fb2-7079-4596-9504-38339ec23f95",
                "level": "R2",
                "level_review": {
                  "updateTime": 1493063804037
                },
                "level_uuid": "a9106516-cdcb-4c7d-8fa2-f0e91ce681c4",
                "name": "Sorafenib",
                "name_review": {
                  "removed": true,
                  "updateTime": 1536101343797,
                  "updatedBy": "User"
                },
                "name_uuid": "418078b0-f000-49e2-bc84-93c98a8b263e",
                "propagation_review": {
                  "updateTime": 1536101391110,
                  "updatedBy": "User"
                },
                "propagation_uuid": "0c948449-59a6-495a-b055-4cc40c9d30d3",
                "short": ""
              },
              "operation": "delete"
            }
          ],
          "timeStamp": 1536101393243
        },
        "-LNGUxPWCB9-lcrRwFGR": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600, Melanoma",
              "new": "Melanoma",
              "old": "Melanoma",
              "operation": "name change",
              "uuids": "0a0da2c0-fb6d-4561-add8-9d863bb5fd39"
            }
          ],
          "timeStamp": 1537891882677
        },
        "-LNW_6AHZK9bbO04Av81": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G469, G464, D287H, V459L, G466, S467L, N581, D594, F595L, G596 (non-V600 mutations)",
              "new": "G469, G464, D287H, V459L, G466, S467L, N581, D594, F595L, G596 (non-V600 mutations)",
              "old": "G469, G464, D287H, V459L, G466, S467L, N581, D594, F595L, G596 [non-V600 mutations]",
              "operation": "name change",
              "uuids": "6bfd2309-23ad-432c-9e44-e63d72acea80"
            }
          ],
          "timeStamp": 1538161668818
        },
        "-LP2atR4s2eok8rs12AI": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "F247L",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF F247L mutation lies within a zinc-finger region of the protein. Two separate studies have shown that this mutation is activating, as indicated by increased phosphorylation of downstream MAPK-pathway members (PMID: 28512244, 29533785).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1539806290969,
                    "updatedBy": "User"
                  },
                  "description_uuid": "a1ce27f1-dbc6-47ad-87cb-3dde292373fa",
                  "effect": "Likely Gain-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1539776764297,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "6da5e4e4-ed2a-4c99-83cd-555ceb42bd76",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1539806297157,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "94ff2e7c-e9c1-490b-8f9f-0de4c1b633d1",
                  "short": ""
                },
                "mutation_effect_uuid": "eac54f68-a913-4c1b-8dca-c378a3f8cb7a",
                "name": "F247L",
                "name_review": {
                  "added": true,
                  "updateTime": 1539776757830,
                  "updatedBy": "User"
                },
                "name_uuid": "29b444f9-5965-4301-bef8-411bbbe505f6",
                "tumors_uuid": "7127587b-5a38-47a4-a0f5-022007fd8b97"
              },
              "operation": "add",
              "uuids": "94ff2e7c-e9c1-490b-8f9f-0de4c1b633d1,6da5e4e4-ed2a-4c99-83cd-555ceb42bd76"
            }
          ],
          "timeStamp": 1539806302932
        },
        "-LP2nHyhWe5uPYHxDQS2": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600K, Melanoma, Tumor Type Summary",
              "new": "The RAF-inhibitors encorafenib, dabrafenib and vemurafenib alone or in combination with the MEK-inhibitors binimetinib, trametinib and cobimetinib, respectively, are FDA-approved for the treatment of patients with BRAF V600E/K mutant melanoma.",
              "old": "The RAF-inhibitors encorafenib, dabrafenib and vemurafenib in combination with the MEK-inhibitors binimetinib, trametinib and cobimetinib, respectively, are FDA-approved for the treatment of patients with BRAF V600E/K mutant melanoma.",
              "operation": "update",
              "uuids": "603dab24-2e01-4179-a0ac-cff1fe8c81ca"
            }
          ],
          "timeStamp": 1539809553276
        },
        "-LPRJP_TsQFANoGxCDfi": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "L514V",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF L514V mutation is located in the ATP binding pocket of the kinase domain of the protein. This mutation was found in a patient with BRAF V600E-mutant anaplastic ganglioglioma who progressed on treatment with dabrafenib (PMID: 29880583). Co-expression of this mutation in human cells with BRAF V600E in cis demonstrated that it is activating, promotes dimerization, and confers resistance to type I αC-OUT/DFG-IN BRAF inhibitors such as vemurafenib and dabrafenib (PMID: 29880583). The BRAF L514V mutation was shown to be sensitive to inhibition with RAF dimer inhibitors, such as BGB3245 (PMID: 29880583).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1539974663111,
                    "updatedBy": "User"
                  },
                  "description_uuid": "955be0ec-b315-421d-b05d-f95bfdc28db1",
                  "effect": "Likely Gain-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1539972127535,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "fa20c208-4419-4084-96ea-938a2dcd9353",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1539972126640,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "06ea9f39-5cdd-4c53-9d3b-fd0740e47125",
                  "short": ""
                },
                "mutation_effect_uuid": "c7856a86-8d58-45cf-b5ab-d2af13e4cfba",
                "name": "L514V",
                "name_review": {
                  "added": true,
                  "updateTime": 1539971887363,
                  "updatedBy": "User"
                },
                "name_uuid": "09fa1934-c2dd-4ab2-9b4e-609b7f969def",
                "tumors_uuid": "f15904e2-81d1-4d9f-93d5-aa5c7ba3a437"
              },
              "operation": "add",
              "uuids": "06ea9f39-5cdd-4c53-9d3b-fd0740e47125,fa20c208-4419-4084-96ea-938a2dcd9353"
            }
          ],
          "timeStamp": 1540220886784
        },
        "-LQnvBiMBAxsIWqsz-9W": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Colorectal Cancer",
              "old": {
                "TIs": [
                  {
                    "name": "Standard implications for sensitivity to therapy",
                    "name_uuid": "0b430558-09a2-477e-b6f7-ab4630510f36",
                    "type": "SS"
                  },
                  {
                    "name": "Standard implications for resistance to therapy",
                    "name_uuid": "07dbcc5b-f3c4-4375-9495-3caf59cc778d",
                    "type": "SR"
                  },
                  {
                    "name": "Investigational implications for sensitivity to therapy",
                    "name_uuid": "e0d7ba84-7a32-4c48-b9c0-c3c9a8345458",
                    "type": "IS"
                  },
                  {
                    "name": "Investigational implications for resistance to therapy",
                    "name_uuid": "2e652e2c-e538-4886-b51f-5da8671704d7",
                    "type": "IR"
                  }
                ],
                "cancerTypes": [
                  {
                    "code": "",
                    "mainType": "Colorectal Cancer",
                    "subtype": ""
                  }
                ],
                "cancerTypes_review": {
                  "removed": true,
                  "updateTime": 1541629735963,
                  "updatedBy": "User"
                },
                "cancerTypes_uuid": "c6adb3a2-a594-4d08-9908-86208d7c7237",
                "diagnostic": {
                  "description": "",
                  "description_uuid": "51df808d-2837-49e8-8740-ff62c99830fc",
                  "level": "",
                  "level_uuid": "5f3556ee-3042-4a61-8d4a-f1cd54ae4a1c",
                  "short": ""
                },
                "diagnostic_uuid": "d72d0bcd-f7c0-4a49-a45a-d1d29d3ba817",
                "prognostic": {
                  "description": "",
                  "description_uuid": "e0ffde22-34e2-4158-a94a-2d38a8080eff",
                  "level": "",
                  "level_uuid": "116bb337-86df-40ad-9a35-aa46b75319ba",
                  "short": ""
                },
                "prognostic_uuid": "99c174cb-9856-413c-a595-902f186f8fcd",
                "summary": "",
                "summary_review": {
                  "updateTime": 1536099668105,
                  "updatedBy": "User"
                },
                "summary_uuid": "157bf547-2083-424e-923c-bc6227ca9ba8"
              },
              "operation": "delete"
            }
          ],
          "timeStamp": 1541690678017
        },
        "-LQnvC46wm9KavpZtycp": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Oncogenic Mutations, Colorectal Cancer",
              "old": {
                "TIs": [
                  {
                    "name": "Standard implications for sensitivity to therapy",
                    "name_uuid": "959b21c6-0b02-432e-b928-6b381a1c92c6",
                    "type": "SS"
                  },
                  {
                    "name": "Standard implications for resistance to therapy",
                    "name_uuid": "a385bb62-bd05-4382-8b52-41761476fb17",
                    "type": "SR"
                  },
                  {
                    "name": "Investigational implications for sensitivity to therapy",
                    "name_comments": [
                      {
                        "content": "checked",
                        "date": "1426963479760",
                        "email": "user@gmail.com",
                        "resolved": "false",
                        "userName": "User"
                      }
                    ],
                    "name_uuid": "fe0f18b6-7a82-46b0-b19a-5a75dce62360",
                    "type": "IS"
                  },
                  {
                    "name": "Investigational implications for resistance to therapy",
                    "name_uuid": "72ac0b98-ba68-4ce2-828d-97e0b6360c1d",
                    "type": "IR"
                  }
                ],
                "cancerTypes": [
                  {
                    "code": "",
                    "mainType": "Colorectal Cancer",
                    "subtype": ""
                  }
                ],
                "cancerTypes_review": {
                  "removed": true,
                  "updateTime": 1541629769055,
                  "updatedBy": "User"
                },
                "cancerTypes_uuid": "e9ae668a-854d-4878-b589-97290034f3a6",
                "diagnostic": {
                  "description": "",
                  "description_uuid": "5e125144-6e4a-4753-b8fb-19f3d659fa5e",
                  "level": "",
                  "level_uuid": "751d7a76-f0c5-41b7-97ca-2ad9b5d4dcc9",
                  "short": ""
                },
                "diagnostic_uuid": "9a817660-38d7-4a66-bc55-e3f7e97f902c",
                "prognostic": {
                  "description": "",
                  "description_review": {
                    "updateTime": 1493057315640
                  },
                  "description_uuid": "59b768da-d3eb-4db4-919c-6319e7fb0f5a",
                  "level": "",
                  "level_uuid": "0430d084-1fd9-4792-a4b6-402424ba2834",
                  "short": ""
                },
                "prognostic_uuid": "eea2fd94-0fe4-48a1-a3d9-fd1ef946f7fd",
                "summary": "",
                "summary_review": {
                  "updateTime": 1541629757550,
                  "updatedBy": "User"
                },
                "summary_uuid": "3d2095fd-7e94-42c5-b880-77705112cbdc"
              },
              "operation": "delete"
            }
          ],
          "timeStamp": 1541690679474
        },
        "-LRO1EHxPTrcwM7ZVhAM": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Colorectal Cancer",
              "new": {
                "TIs": [
                  {
                    "name": "Standard implications for sensitivity to therapy",
                    "name_uuid": "34b4f091-f982-4bd8-864a-c25b383725a7",
                    "treatments_uuid": "a06fb981-abf2-4b3f-8b5d-0c400490e1ef",
                    "type": "SS"
                  },
                  {
                    "name": "Standard implications for resistance to therapy",
                    "name_uuid": "71e19ae9-2234-4cc0-b489-9141a5c39693",
                    "treatments_uuid": "d44ee9b4-59d6-484d-9b39-90c2cef6c975",
                    "type": "SR"
                  },
                  {
                    "name": "Investigational implications for sensitivity to therapy",
                    "name_uuid": "91e1edd2-2393-49ab-b760-d58647fa9e4f",
                    "treatments": [
                      {
                        "description": "(Abstract: Cutsem et al. Abstract# O-027, ESMO 2018. https://academic.oup.com/annonc/article/29/suppl_5/mdy149.026/5039436)(Abstract: Cutsem et al. Abstract# 627, ASCO 2018. http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.4_suppl.627)",
                        "description_review": {
                          "lastReviewed": "",
                          "updateTime": 1542309556637,
                          "updatedBy": "User"
                        },
                        "description_uuid": "8b2bebcb-a598-4b1f-bf85-c204d7c11211",
                        "indication": "",
                        "indication_uuid": "f47af581-6875-4569-87bb-229add8448d6",
                        "level": "3A",
                        "level_review": {
                          "lastReviewed": "",
                          "updateTime": 1542309553575,
                          "updatedBy": "User"
                        },
                        "level_uuid": "aea3f2f1-8fb6-4334-91a5-9c6b49040fe3",
                        "name": "Encorafenib + Binimetinib + Cetuximab",
                        "name_review": {
                          "added": true,
                          "updateTime": 1542309524262,
                          "updatedBy": "User"
                        },
                        "name_uuid": "aae49737-28a5-4bf2-97a5-920d1a71cc8e",
                        "propagation": "3B",
                        "propagation_review": {
                          "updateTime": 1542309553701,
                          "updatedBy": "User"
                        },
                        "propagation_uuid": "e7931b1c-3abf-409e-bc33-95b0b815894d",
                        "short": ""
                      }
                    ],
                    "treatments_uuid": "5d75375a-bde8-4242-a86f-3c21149f0b3e",
                    "type": "IS"
                  },
                  {
                    "name": "Investigational implications for resistance to therapy",
                    "name_uuid": "03e269f0-d249-407a-9410-df104441d76b",
                    "treatments_uuid": "b8b6f836-7a6e-4c4a-ae37-afcc1cd98bfb",
                    "type": "IR"
                  }
                ],
                "cancerTypes": [
                  {
                    "code": "",
                    "mainType": "Colorectal Cancer",
                    "subtype": ""
                  }
                ],
                "cancerTypes_review": {
                  "added": true,
                  "updateTime": 1542309512319,
                  "updatedBy": "User"
                },
                "cancerTypes_uuid": "d44183da-4fa8-4e44-bcdf-1205e4578bce",
                "diagnostic": {
                  "description": "",
                  "description_uuid": "9390cf4e-f4ee-4252-93fb-d1a06ca45000",
                  "level": "",
                  "level_uuid": "388be3d2-790d-4373-a5db-46065eebcd6d",
                  "short": ""
                },
                "diagnostic_uuid": "432336f0-9288-4589-914c-ae6f93b77b93",
                "prognostic": {
                  "description": "",
                  "description_uuid": "60e9ada5-1d33-433c-8fd1-5e1db5d52bda",
                  "level": "",
                  "level_uuid": "df685b39-0ce1-4fe7-90de-4cb467a0bdff",
                  "short": ""
                },
                "prognostic_uuid": "ae4ab53b-c637-400b-9c47-0ec6f4468978",
                "summary": "",
                "summary_review": {
                  "updateTime": 1542313195194,
                  "updatedBy": "User"
                },
                "summary_uuid": "cfcc19a6-df02-4230-85fb-992ed74d464a"
              },
              "operation": "add",
              "uuids": "aae49737-28a5-4bf2-97a5-920d1a71cc8e"
            }
          ],
          "timeStamp": 1542313276553
        },
        "-LRO1P35PSNkIC0dgaLQ": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, V600K, Colorectal Cancer",
              "old": {
                "TIs": [
                  {
                    "name": "Standard implications for sensitivity to therapy",
                    "name_uuid": "5f595899-141d-4700-b9b3-e66861636523",
                    "type": "SS"
                  },
                  {
                    "name": "Standard implications for resistance to therapy",
                    "name_uuid": "da6da8b5-fa52-4556-955a-d1823277cead",
                    "type": "SR"
                  },
                  {
                    "name": "Investigational implications for sensitivity to therapy",
                    "name_comments": [
                      {
                        "content": "ysge. r. et al. Pilot trial of combined braf and egfr inhibition in braf-mutant metastatic colorectal cancer",
                        "date": "1445306966482",
                        "email": "user@gmail.com",
                        "resolved": "false",
                        "userName": "User"
                      }
                    ],
                    "name_uuid": "a33e204b-0d74-4e80-8dbb-67b36ff7a255",
                    "type": "IS"
                  },
                  {
                    "name": "Investigational implications for resistance to therapy",
                    "name_uuid": "3e8f7b96-3245-4cb8-a36d-f730ecf6b757",
                    "type": "IR"
                  }
                ],
                "cancerTypes": [
                  {
                    "code": "",
                    "mainType": "Colorectal Cancer",
                    "subtype": ""
                  }
                ],
                "cancerTypes_review": {
                  "removed": true,
                  "updateTime": 1542309595827,
                  "updatedBy": "User"
                },
                "cancerTypes_uuid": "04c67a34-9915-42cb-bf2f-300742841db0",
                "diagnostic": {
                  "description": "",
                  "description_uuid": "06d75cab-52dd-4eac-bbbb-0b6f54676241",
                  "level": "",
                  "level_uuid": "ad4cdc29-8bd7-40e4-becc-1e9fb13931fb",
                  "short": ""
                },
                "diagnostic_uuid": "4d80e89d-2780-4f60-9d94-c0213b501e69",
                "prognostic": {
                  "description": "",
                  "description_review": {
                    "updateTime": 1493057315640
                  },
                  "description_uuid": "3f34778d-1612-4f84-b66e-e7db94542f5e",
                  "level": "",
                  "level_uuid": "67826c99-f384-420a-82ae-04d35cbc49db",
                  "short": ""
                },
                "prognostic_uuid": "4236f045-2f65-43cb-bfe9-76b4d23acd4e",
                "summary": "",
                "summary_review": {
                  "updateTime": 1542313195244,
                  "updatedBy": "User"
                },
                "summary_uuid": "1f2becc9-c818-4894-88b8-5434ae76b123"
              },
              "operation": "delete"
            }
          ],
          "timeStamp": 1542313320658
        },
        "-LRODNXqrzvGpX9m4yRR": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Colorectal Cancer, INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY, Encorafenib + Binimetinib + Cetuximab",
              "new": {
                "description": "Encorafenib is a small molecule inhibitor of RAF kinase, binimetinib is a small molecule inhibitor of MEK1/2 kinases, and cetuximab is an antibody that targets EGFR. In the Phase III BEACON study of encorafenib + binimetinib + cetuximab versus chemotherapy in 29 patients with BRAF V600E-mutant colorectal cancer, the overall response rate (complete or partial response) was 48% (14 of 29 patients), with three of fourteen patients having complete response (Abstract: Cutsem et al. Abstract# O-027, ESMO 2018. https://academic.oup.com/annonc/article/29/suppl_5/mdy149.026/5039436). Nine patients had durable stable disease (Abstract: Cutsem et al. Abstract# 627, ASCO 2018. http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.4_suppl.627). Estimated median progression-free survival was 8 months in the triplet combination arm (Abstract: Cutsem et al. Abstract# O-027, ESMO 2018. https://academic.oup.com/annonc/article/29/suppl_5/mdy149.026/5039436)."
              },
              "old": {
                "description": "Encorafenib is a small molecule inhibitor of RAF kinase, binimetinib is a small molecule inhibitor of MEK1/2 kinases, and cetuximab is an antibody that targets EGFR. In the Phase III BEACON study of encorafenib + binimetinib + cetuximab versus chemotherapy in 29 patients with BRAF V600E-mutant colorectal cancer, the overall response rate (complete or partial response) was 48% (14 of 29 patients), with three of 14 patients having complete response (Abstract: Cutsem et al. Abstract# O-027, ESMO 2018. https://academic.oup.com/annonc/article/29/suppl_5/mdy149.026/5039436). Nine patients had durable stable disease (Abstract: Cutsem et al. Abstract# 627, ASCO 2018. http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.4_suppl.627). Estimated median progression-free survival was 8 months in the triplet combination arm (Abstract: Cutsem et al. Abstract# O-027, ESMO 2018. https://academic.oup.com/annonc/article/29/suppl_5/mdy149.026/5039436)."
              },
              "operation": "update",
              "uuids": "aae49737-28a5-4bf2-97a5-920d1a71cc8e"
            }
          ],
          "timeStamp": 1542316460224
        },
        "-LROIyTf6uYXt7yUHAQO": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600, Colorectal Cancer, Tumor Type Summary",
              "new": "The FDA-approved RAF-inhibitors dabrafenib and vemurafenib have minimal activity as single agents in BRAF V600-mutant colorectal cancer (CRC). The combination of encorafenib + cetuximab + binimetinib, a RAF-inhibitor, an anti-EGFR antibody and a MEK-inhibitor respectively, has received FDA-breakthrough therapy designation based on promising clinical data in patients with BRAF V600E-mutant CRC.",
              "old": "The FDA-approved selective RAF-inhibitors dabrafenib and vemurafenib have minimal activity as single agents in BRAF V600-mutant colorectal cancer. There is promising clinical data supporting regimens that combine a RAF-inhibitor together with an anti-EGFR antibody with or without a MEK-inhibitor, such as the doublet vemurafenib plus panitumumab or the triplet dabrafenib, trametinib, plus panitumumab in patients with these tumors.",
              "operation": "update",
              "uuids": "8d714d43-7ccc-416f-99b8-4f49cc046590"
            }
          ],
          "timeStamp": 1542317926325
        },
        "-LU0voGTXGZF5Ud_28b8": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "AGAP3-BRAF Fusion",
              "new": "AGAP3-BRAF Fusion",
              "old": "AGAP3-BRAF Fusion",
              "operation": "name change",
              "uuids": "56befb06-8839-4e0e-b988-41f90ab4d744"
            }
          ],
          "timeStamp": 1545146946842
        },
        "-LXVJeeQDG2PaJuUurae": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Fusions, Mutation Effect",
              "new": {
                "effect": "Likely Gain-of-function"
              },
              "old": {
                "effect": "Gain-of-function"
              },
              "operation": "update",
              "uuids": "896baaf7-1159-4038-9434-8a5539537581"
            }
          ],
          "timeStamp": 1548878006457
        },
        "-LYY_R49LJRsq6Di4aZ9": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G469A, G469V, G469R, G464V, G464E",
              "old": {
                "mutation_effect": {
                  "description": "",
                  "description_uuid": "4b5a9880-2d23-4572-a511-1b9f46e3b0b0",
                  "effect": "",
                  "effect_uuid": "135ecea7-eb22-46c7-9b9b-34c08aa8c87c",
                  "oncogenic": "",
                  "oncogenic_uuid": "55ca648f-defa-49c6-91d2-0f9a29d733a4",
                  "short": ""
                },
                "mutation_effect_uuid": "6edc2942-37e0-43ab-bc5e-d94730068937",
                "name": "G469A, G469V, G469R, G464V, G464E",
                "name_review": {
                  "removed": true,
                  "updateTime": 1550006437906,
                  "updatedBy": "User"
                },
                "name_uuid": "1d54a305-2e34-464f-a965-a46f4e8b64ba"
              },
              "operation": "delete"
            }
          ],
          "timeStamp": 1550006469677
        },
        "-LYcBibiSMlf1dG_0Wsy": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "D594G, Colorectal Cancer",
              "old": {
                "TIs": [
                  {
                    "name": "Standard implications for sensitivity to therapy",
                    "name_uuid": "16c6eb99-b5bb-4952-b1df-148284f799a3",
                    "type": "SS"
                  },
                  {
                    "name": "Standard implications for resistance to therapy",
                    "name_uuid": "e73bfae2-01ff-40b9-97c2-e75905e61ca9",
                    "type": "SR"
                  },
                  {
                    "name": "Investigational implications for sensitivity to therapy",
                    "name_uuid": "7cdc8c19-a6dc-4a36-a354-42ad5fc72558",
                    "type": "IS"
                  },
                  {
                    "name": "Investigational implications for resistance to therapy",
                    "name_uuid": "ae31e4f7-04c5-491b-9e66-8aaca00155c7",
                    "type": "IR"
                  }
                ],
                "cancerTypes": [
                  {
                    "code": "",
                    "mainType": "Colorectal Cancer",
                    "subtype": ""
                  }
                ],
                "cancerTypes_review": {
                  "removed": true,
                  "updateTime": 1550083602623,
                  "updatedBy": "User"
                },
                "cancerTypes_uuid": "06913306-b5a8-4d5b-8fd6-9aacbead622f",
                "diagnostic": {
                  "description": "",
                  "description_uuid": "5eba5021-bfa0-4511-895e-64ec4c54a664",
                  "level": "",
                  "level_uuid": "fa0a126d-6ee0-4395-83de-2d98359c6dd2",
                  "short": ""
                },
                "diagnostic_uuid": "a6c95154-dc3f-4880-9b87-761f8111a6f8",
                "prognostic": {
                  "description": "",
                  "description_uuid": "9822de54-6a1d-4ead-c0be-32c42b19b645",
                  "level": "",
                  "level_uuid": "1d9f4928-7f8d-4a08-8770-3b6de785472c",
                  "short": ""
                },
                "prognostic_uuid": "1486c5d2-9d0c-40ed-baef-54c4a43aa64a",
                "summary": "",
                "summary_review": {
                  "updateTime": 1536099857093,
                  "updatedBy": "User"
                },
                "summary_uuid": "5e6bfa2a-d6fd-408f-bf1e-66c93ab969fc"
              },
              "operation": "delete"
            },
            {
              "lastEditBy": "User",
              "location": "G466A, Colorectal Cancer",
              "old": {
                "TIs": [
                  {
                    "name": "Standard implications for sensitivity to therapy",
                    "name_uuid": "335a216b-3951-4a41-bc4c-3e5ebb35eef6",
                    "type": "SS"
                  },
                  {
                    "name": "Standard implications for resistance to therapy",
                    "name_uuid": "cba224d7-1367-4012-969f-ccd4d4d6f5fa",
                    "type": "SR"
                  },
                  {
                    "name": "Investigational implications for sensitivity to therapy",
                    "name_uuid": "7f73584f-5c34-49f0-bf53-31199e8d3f94",
                    "type": "IS"
                  },
                  {
                    "name": "Investigational implications for resistance to therapy",
                    "name_uuid": "c2a1b061-eca2-4cbf-b5f6-6695627fe534",
                    "type": "IR"
                  }
                ],
                "cancerTypes": [
                  {
                    "code": "",
                    "mainType": "Colorectal Cancer",
                    "subtype": ""
                  }
                ],
                "cancerTypes_review": {
                  "removed": true,
                  "updateTime": 1550083580835,
                  "updatedBy": "User"
                },
                "cancerTypes_uuid": "7122c96a-fba3-4a3d-ad85-dac7ba07f2ee",
                "diagnostic": {
                  "description": "",
                  "description_uuid": "6f5becd4-3f4a-4017-8e86-903cad1618d4",
                  "level": "",
                  "level_uuid": "aeb67496-340d-4b9a-a307-28cf17696112",
                  "short": ""
                },
                "diagnostic_uuid": "cb71debe-a57e-4e88-984a-e7df07705c9c",
                "prognostic": {
                  "description": "",
                  "description_uuid": "0bc39eca-4733-4c96-ad7a-fa3b30329d00",
                  "level": "",
                  "level_uuid": "53a447c8-e8ed-4349-881f-25f0af77615e",
                  "short": ""
                },
                "prognostic_uuid": "b7ce071f-8414-4675-84f5-acf533581c75",
                "summary": "",
                "summary_review": {
                  "updateTime": 1536099895809,
                  "updatedBy": "User"
                },
                "summary_uuid": "7f57ebb3-fb58-4abf-bedf-eaba1e3fd1d9"
              },
              "operation": "delete"
            },
            {
              "lastEditBy": "User",
              "location": "G469A, Colorectal Cancer",
              "old": {
                "TIs": [
                  {
                    "name": "Standard implications for sensitivity to therapy",
                    "name_uuid": "bf2fc296-5f21-4ff9-a589-726e80cbb006",
                    "type": "SS"
                  },
                  {
                    "name": "Standard implications for resistance to therapy",
                    "name_uuid": "61913305-09a2-41a9-8a60-6ce53d067aa0",
                    "type": "SR"
                  },
                  {
                    "name": "Investigational implications for sensitivity to therapy",
                    "name_uuid": "89b33cdd-bfc8-4e54-938a-ef71d84b98e7",
                    "type": "IS"
                  },
                  {
                    "name": "Investigational implications for resistance to therapy",
                    "name_uuid": "5db4bee0-0102-479b-8a46-f8951a259827",
                    "type": "IR"
                  }
                ],
                "cancerTypes": [
                  {
                    "code": "",
                    "mainType": "Colorectal Cancer",
                    "subtype": ""
                  }
                ],
                "cancerTypes_review": {
                  "removed": true,
                  "updateTime": 1550083708719,
                  "updatedBy": "User"
                },
                "cancerTypes_uuid": "d45065a1-839f-44b0-974f-be9cf75f104e",
                "diagnostic": {
                  "description": "",
                  "description_uuid": "b29315cf-267a-42b6-bd0f-d06a707556b0",
                  "level": "",
                  "level_uuid": "29185e5f-fc07-43f7-8684-53858c0cb19c",
                  "short": ""
                },
                "diagnostic_uuid": "0dc80189-61f5-4ef8-9d73-755632f5a767",
                "prognostic": {
                  "description": "",
                  "description_uuid": "d0e1606f-bc5e-4fb9-b8c3-2aa66e019192",
                  "level": "",
                  "level_uuid": "07c896aa-e1f9-49e1-b7f9-280aa1265ab2",
                  "short": ""
                },
                "prognostic_uuid": "763e1fa1-53f7-4a2d-8a54-8453698e55bf",
                "summary": "",
                "summary_review": {
                  "updateTime": 1536099934049,
                  "updatedBy": "User"
                },
                "summary_uuid": "37ac98b1-d5ef-4296-a9a3-117c8b19d8e9"
              },
              "operation": "delete"
            },
            {
              "lastEditBy": "User",
              "location": "G469R, All Tumors",
              "old": {
                "TIs": [
                  {
                    "name": "Standard implications for sensitivity to therapy",
                    "name_uuid": "64d9d454-2ba6-400a-9a16-9ff5618208bd",
                    "type": "SS"
                  },
                  {
                    "name": "Standard implications for resistance to therapy",
                    "name_uuid": "e012d3f9-9572-4ea2-b06f-05f411a21d59",
                    "type": "SR"
                  },
                  {
                    "name": "Investigational implications for sensitivity to therapy",
                    "name_uuid": "cd3adee0-7179-406f-9617-2ee099b14f30",
                    "type": "IS"
                  },
                  {
                    "name": "Investigational implications for resistance to therapy",
                    "name_uuid": "091a38f6-5622-47a4-ada8-db3c07b048dc",
                    "type": "IR"
                  }
                ],
                "cancerTypes": [
                  {
                    "code": "",
                    "mainType": "All Tumors",
                    "subtype": ""
                  }
                ],
                "cancerTypes_review": {
                  "removed": true,
                  "updateTime": 1550083724447,
                  "updatedBy": "User"
                },
                "cancerTypes_uuid": "e6591f61-e28b-4400-b749-c9566bbabf7a",
                "diagnostic": {
                  "description": "",
                  "description_uuid": "c8f84be1-07b0-4467-b5f3-dda13914299d",
                  "level": "",
                  "level_uuid": "7e20f721-cc47-450f-9021-6e60755e74f5",
                  "short": ""
                },
                "diagnostic_uuid": "99b137e8-c727-418a-9e63-19e91718733a",
                "prognostic": {
                  "description": "",
                  "description_review": {
                    "updateTime": 1493057315640
                  },
                  "description_uuid": "41c1f09d-b9d6-49b2-a463-0be655a0dc3b",
                  "level": "",
                  "level_uuid": "12e0a54b-9436-4b9a-a798-aa873f41da7d",
                  "short": ""
                },
                "prognostic_uuid": "118c0c6b-f2b9-4af0-ae09-60a2292016e9",
                "summary": "",
                "summary_review": {
                  "updateTime": 1536099964899,
                  "updatedBy": "User"
                },
                "summary_uuid": "cd4f663a-1609-4247-80b0-75a5f68cc731"
              },
              "operation": "delete"
            },
            {
              "lastEditBy": "User",
              "location": "L505H, Melanoma",
              "old": {
                "TIs": [
                  {
                    "name": "Standard implications for sensitivity to therapy",
                    "name_uuid": "958a8b2a-8cdc-4346-bcc7-e33324a46c87",
                    "type": "SS"
                  },
                  {
                    "name": "Standard implications for resistance to therapy",
                    "name_uuid": "f6b68986-a132-4c8f-8040-be2f7eb34600",
                    "type": "SR"
                  },
                  {
                    "name": "Investigational implications for sensitivity to therapy",
                    "name_uuid": "24409fc3-43d7-4dbc-afbe-0e19fa6035dd",
                    "type": "IS"
                  },
                  {
                    "name": "Investigational implications for resistance to therapy",
                    "name_uuid": "42840cff-c1f6-40d5-8c05-25c3a289683a",
                    "type": "IR"
                  }
                ],
                "cancerTypes": [
                  {
                    "code": "MEL",
                    "mainType": "Melanoma",
                    "subtype": "Melanoma"
                  }
                ],
                "cancerTypes_review": {
                  "removed": true,
                  "updateTime": 1550083748218,
                  "updatedBy": "User"
                },
                "cancerTypes_uuid": "f7eb3c80-d0c7-45ca-9072-1160555ba75a",
                "diagnostic": {
                  "description": "",
                  "description_uuid": "e904b82c-6f0e-4cef-87be-0fbb6984817b",
                  "level": "",
                  "level_uuid": "0bcbdac7-6de6-4269-95ea-a80689447f97",
                  "short": ""
                },
                "diagnostic_uuid": "91996911-6e11-4a6c-b0c4-c5a9ec852957",
                "prognostic": {
                  "description": "",
                  "description_review": {
                    "updateTime": 1493057315640
                  },
                  "description_uuid": "a82d8192-49fd-46fb-a759-a349aa1c5c66",
                  "level": "",
                  "level_uuid": "cae842a5-1280-4d24-8223-9e5c771a6623",
                  "short": ""
                },
                "prognostic_uuid": "d7d130af-9a4d-4b05-bdf7-7000b3ecae89",
                "summary": "",
                "summary_review": {
                  "updateTime": 1536099999713,
                  "updatedBy": "User"
                },
                "summary_uuid": "ac22bc52-edb7-43f1-ab41-0f48e76004a0"
              },
              "operation": "delete"
            },
            {
              "lastEditBy": "User",
              "location": "V169_D380del [p61BRAF-V600E], Melanoma",
              "old": {
                "TIs": [
                  {
                    "name": "Standard implications for sensitivity to therapy",
                    "name_uuid": "556bd52a-f06b-4338-85f3-919a11ae59e3",
                    "type": "SS"
                  },
                  {
                    "name": "Standard implications for resistance to therapy",
                    "name_uuid": "d63edd48-2ad6-4614-b372-7753aeaa47b9",
                    "type": "SR"
                  },
                  {
                    "name": "Investigational implications for sensitivity to therapy",
                    "name_uuid": "775090f1-bd6f-412d-8822-39959c01aace",
                    "type": "IS"
                  },
                  {
                    "name": "Investigational implications for resistance to therapy",
                    "name_uuid": "dd6d0fff-6efa-41b3-88a1-eac97b7db219",
                    "type": "IR"
                  }
                ],
                "cancerTypes": [
                  {
                    "code": "MEL",
                    "mainType": "Melanoma",
                    "subtype": "Melanoma"
                  }
                ],
                "cancerTypes_review": {
                  "removed": true,
                  "updateTime": 1550083691028,
                  "updatedBy": "User"
                },
                "cancerTypes_uuid": "534bdfeb-5081-4e59-b539-6e881f1a6096",
                "diagnostic": {
                  "description": "",
                  "description_uuid": "c979f7e1-f4c4-4024-94d1-b56d8270d9ce",
                  "level": "",
                  "level_uuid": "b62f49d3-3972-4612-a913-72b65abb57fd",
                  "short": ""
                },
                "diagnostic_uuid": "34f07f85-cd09-4267-8b43-77fa6edb46e3",
                "prognostic": {
                  "description": "",
                  "description_review": {
                    "updateTime": 1493057315640
                  },
                  "description_uuid": "0be4e529-1814-44c7-accb-103a2b3db148",
                  "level": "",
                  "level_uuid": "56d4b06a-4222-400b-a24a-86ec8d76240c",
                  "short": ""
                },
                "prognostic_uuid": "1ed14454-7cd3-42ca-a86f-17de0907fe47",
                "summary": "",
                "summary_review": {
                  "updateTime": 1493057315640
                },
                "summary_uuid": "a892d63c-a5a2-4733-8588-2c68fa2260c3"
              },
              "operation": "delete"
            },
            {
              "lastEditBy": "User",
              "location": "AGAP3-BRAF Fusion, Melanoma",
              "old": {
                "TIs": [
                  {
                    "name": "Standard implications for sensitivity to therapy",
                    "name_uuid": "70ddd9d9-4e1a-4616-8043-3ab2d07e1dfd",
                    "type": "SS"
                  },
                  {
                    "name": "Standard implications for resistance to therapy",
                    "name_uuid": "65e7a5b7-d9ef-471d-b4db-071cb61eee19",
                    "type": "SR"
                  },
                  {
                    "name": "Investigational implications for sensitivity to therapy",
                    "name_uuid": "81fef3ac-0b93-4d9d-8c9c-ed15c602528e",
                    "type": "IS"
                  },
                  {
                    "name": "Investigational implications for resistance to therapy",
                    "name_uuid": "5d061752-07f3-4040-9c8f-c5761b501c68",
                    "type": "IR"
                  }
                ],
                "cancerTypes": [
                  {
                    "code": "MEL",
                    "mainType": "Melanoma",
                    "subtype": "Melanoma"
                  }
                ],
                "cancerTypes_review": {
                  "removed": true,
                  "updateTime": 1550083804450,
                  "updatedBy": "User"
                },
                "cancerTypes_uuid": "ef7c2853-d19b-4fc7-ae8b-b411af7c3a7b",
                "diagnostic": {
                  "description": "",
                  "description_uuid": "8ed67877-927b-44ce-8ca7-240865b6d612",
                  "level": "",
                  "level_uuid": "79f72153-5c22-4370-93f7-7ac5b148328c",
                  "short": ""
                },
                "diagnostic_uuid": "5017768b-46f0-48e1-8f1d-a6b29dd0df91",
                "prognostic": {
                  "description": "",
                  "description_uuid": "378288f8-7816-4411-ae01-34ca938a827d",
                  "level": "",
                  "level_uuid": "fc9ae9fa-8997-4831-a92f-cca1aba573b2",
                  "short": ""
                },
                "prognostic_uuid": "cb7d2e04-3cae-4185-bcf0-e46c85083f08",
                "summary": "",
                "summary_review": {
                  "updateTime": 1536099230797,
                  "updatedBy": "User"
                },
                "summary_uuid": "10109221-11a7-49f3-9744-ecc1a57ce96a"
              },
              "operation": "delete"
            },
            {
              "lastEditBy": "User",
              "location": "Amplification, Melanoma",
              "old": {
                "TIs": [
                  {
                    "name": "Standard implications for sensitivity to therapy",
                    "name_uuid": "5ba91f30-416c-419a-a5e1-3e26c625847a",
                    "type": "SS"
                  },
                  {
                    "name": "Standard implications for resistance to therapy",
                    "name_uuid": "ece9d41b-fdbe-45df-a396-bff694de636a",
                    "type": "SR"
                  },
                  {
                    "name": "Investigational implications for sensitivity to therapy",
                    "name_uuid": "ddafdd5c-eae6-409d-be2e-fc77c2982605",
                    "type": "IS"
                  },
                  {
                    "name": "Investigational implications for resistance to therapy",
                    "name_uuid": "ddfe574b-528c-4bdf-b092-40baa0e2042f",
                    "type": "IR"
                  }
                ],
                "cancerTypes": [
                  {
                    "code": "MEL",
                    "mainType": "Melanoma",
                    "subtype": "Melanoma"
                  }
                ],
                "cancerTypes_review": {
                  "removed": true,
                  "updateTime": 1550083656038,
                  "updatedBy": "User"
                },
                "cancerTypes_uuid": "8b4532fb-ec03-4484-9a3a-ef88f944e098",
                "diagnostic": {
                  "description": "",
                  "description_uuid": "0f60a2ed-1e2d-4028-8aaf-6a8f22a3730b",
                  "level": "",
                  "level_uuid": "c1c71dc4-cf06-49e2-bf65-34cc58d0b71a",
                  "short": ""
                },
                "diagnostic_uuid": "43c785e0-6cc4-44f5-a5e2-e02c16406cfa",
                "prognostic": {
                  "description": "",
                  "description_review": {
                    "updateTime": 1493057315640
                  },
                  "description_uuid": "3e2c0adc-a2ee-4596-b2bf-3053f8773708",
                  "level": "",
                  "level_uuid": "571dde31-378c-4030-8808-78c3cda066c8",
                  "short": ""
                },
                "prognostic_uuid": "5ea72d7d-6e9b-40aa-9942-c563af118015",
                "summary": "",
                "summary_review": {
                  "updateTime": 1536099272912,
                  "updatedBy": "User"
                },
                "summary_uuid": "ef4158f4-ab8b-4a67-8cae-8427edc7e3d5"
              },
              "operation": "delete"
            },
            {
              "lastEditBy": "User",
              "location": "Amplification, Colorectal Cancer",
              "old": {
                "TIs": [
                  {
                    "name": "Standard implications for sensitivity to therapy",
                    "name_uuid": "91f8002d-d86c-4385-a9a2-b85ab0bab19c",
                    "type": "SS"
                  },
                  {
                    "name": "Standard implications for resistance to therapy",
                    "name_uuid": "64240e44-816c-4e69-9f95-89f308e617fb",
                    "type": "SR"
                  },
                  {
                    "name": "Investigational implications for sensitivity to therapy",
                    "name_uuid": "901d786a-48e8-43ef-b1dc-f0b62e85b6af",
                    "type": "IS"
                  },
                  {
                    "name": "Investigational implications for resistance to therapy",
                    "name_uuid": "1cb47d0b-4d92-4f2d-8bff-93203425a981",
                    "type": "IR"
                  }
                ],
                "cancerTypes": [
                  {
                    "code": "",
                    "mainType": "Colorectal Cancer",
                    "subtype": ""
                  }
                ],
                "cancerTypes_review": {
                  "removed": true,
                  "updateTime": 1550083662020,
                  "updatedBy": "User"
                },
                "cancerTypes_uuid": "e46c8a9c-4182-4202-9c40-3360421a1ae2",
                "diagnostic": {
                  "description": "",
                  "description_uuid": "c7270c20-f844-40b0-bcb0-5bfd41048fdd",
                  "level": "",
                  "level_uuid": "39db8eb0-5314-40ee-99bb-18f6f1057631",
                  "short": ""
                },
                "diagnostic_uuid": "45039ee0-60d2-4308-afc6-780fa80fa4ed",
                "prognostic": {
                  "description": "",
                  "description_uuid": "3e788826-48f4-4b75-b168-ff1d3158f9ee",
                  "level": "",
                  "level_uuid": "bebc9101-6937-489d-b942-db21cafb82db",
                  "short": ""
                },
                "prognostic_uuid": "aa900d0b-cc93-4d22-858f-f6fc82556b46",
                "summary": "",
                "summary_review": {
                  "updateTime": 1536099297391,
                  "updatedBy": "User"
                },
                "summary_uuid": "43a54bc3-706b-440a-be0f-f07917873ca0"
              },
              "operation": "delete"
            }
          ],
          "timeStamp": 1550083879545
        },
        "-LZcDkNjUJIl73V82Xld": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600, Colorectal Cancer, INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY, Panitumumab + Dabrafenib + Trametinib, Panitumumab + Vemurafenib",
              "new": {
                "propagation": "no"
              },
              "operation": "update",
              "uuids": "5f98f89b-50b1-43f0-93e5-005091553c49"
            },
            {
              "lastEditBy": "User",
              "location": "L597, Melanoma, INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY, Trametinib",
              "new": {
                "propagation": "3B"
              },
              "operation": "update",
              "uuids": "af5ea563-3d74-49e1-b931-ebb6f3fdeb43"
            }
          ],
          "timeStamp": 1551158150958
        },
        "-LZfJ7w7LOUn5FQwcJ5j": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600M, Mutation Effect",
              "new": {
                "oncogenic": "Likely"
              },
              "old": {
                "oncogenic": "Inconclusive"
              },
              "operation": "update",
              "uuids": "1e543634-e853-4b7c-b61e-76537ae06c5c"
            }
          ],
          "timeStamp": 1551209889583
        },
        "-L_9UQlO_2zD49fipHdj": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600, Colorectal Cancer, INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY, Panitumumab + Dabrafenib + Trametinib, Panitumumab + Vemurafenib",
              "new": {
                "propagation": "no"
              },
              "operation": "update",
              "uuids": "5f98f89b-50b1-43f0-93e5-005091553c49"
            }
          ],
          "timeStamp": 1551732946895
        },
        "-L_9ac1riectUmKvLKFV": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "L597, All Tumors, INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY, PLX8394",
              "new": {
                "description": "PMID: 26466569 PMID: 28659148 PMID: 28783719, 30559419 (Abstract: Janku et al. Abstract# B176, AACR-NCI-EORTC 2017. http://mct.aacrjournals.org/content/17/1_Supplement/B176)."
              },
              "old": {
                "description": "PMID: 26466569 PMID: 28659148 PMID: 28783719"
              },
              "operation": "update",
              "uuids": "1fd2d2b7-b69a-4e58-b205-81ef99c8c2e9"
            }
          ],
          "timeStamp": 1551734833509
        },
        "-L_9adgL2jARBq-cwn0H": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R462I, Mutation Effect",
              "new": {
                "effect": "Likely Neutral"
              },
              "old": {
                "effect": "Neutral"
              },
              "operation": "update",
              "uuids": "89566b58-387b-4ade-bec1-847857ef762a"
            }
          ],
          "timeStamp": 1551734840260
        },
        "-L_9afOIoWwqF76Upl4Z": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "K601, All Tumors, INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY, PLX8394",
              "new": {
                "description": "PMID: 26466569 PMID: 28659148 PMID: 28783719, 30559419 (Abstract: Janku et al. Abstract# B176, AACR-NCI-EORTC 2017. http://mct.aacrjournals.org/content/17/1_Supplement/B176).",
                "propagation": "4"
              },
              "old": {
                "description": "PMID: 26466569 PMID: 28659148 PMID: 28783719"
              },
              "operation": "update",
              "uuids": "690ed068-5612-438a-ac07-948a18228375"
            }
          ],
          "timeStamp": 1551734847233
        },
        "-L_9ahEeSIjNWQ_dsHMn": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "PCBP2-BRAF Fusion",
              "new": {
                "mutation_effect": {
                  "description": "The PCBP2-BRAF fusion results from the fusion of the 3' end of the PCBP2 gene with the 5' end of the BRAF gene. While this alteration has not been functionally characterized per se, many other BRAF fusions have been shown to be oncogenic suggesting that the PCBP2-BRAF fusion is likely oncogenic (PMID: 24345920, 21424530, 22745804, 21424530, 18974108, 26343582). In a study of patients with non-small cell lung cancer who progressed on osimertinib, one patient harbored the PCBP2-BRAF fusion (PMID: 30257958). Knockdown of BRAF in a cell line created from this patient led to a reduction of cell growth and resensitization to osimertinib (PMID: 30257958). While these cells were insensitive to the BRAF inhibitors dabrafenib and LXH245, they were sensitive to the MEK inhibitor trametinib (PMID: 30257958).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1551732901690,
                    "updatedBy": "User"
                  },
                  "description_uuid": "cbf7c4b5-1810-4110-9da0-b2c58c4b0172",
                  "effect": "Likely Gain-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1549598193744,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "fc022e3e-d9df-4908-b6c7-e4881d450db2",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1549598191966,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "d76c1ca3-0fc0-4275-83e3-e01280b4e5f5",
                  "short": ""
                },
                "mutation_effect_uuid": "33062162-c3dc-47b8-a8d4-64ef05994531",
                "name": "PCBP2-BRAF Fusion",
                "name_review": {
                  "added": true,
                  "updateTime": 1549598135919,
                  "updatedBy": "User"
                },
                "name_uuid": "65c20803-670d-4a02-a2e9-d1d1d5fe7e9b",
                "tumors_uuid": "cfcf577b-1f3f-451f-a0d6-e5cd21a3f596"
              },
              "operation": "add",
              "uuids": "d76c1ca3-0fc0-4275-83e3-e01280b4e5f5,fc022e3e-d9df-4908-b6c7-e4881d450db2"
            }
          ],
          "timeStamp": 1551734854808
        },
        "-L_9aizhPW7vnjGRemb6": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G469, G464, D287H, V459L, G466, S467L, N581, D594, F595L, G596 (non-V600 mutations), All Tumors, INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY, PLX8394",
              "new": {
                "description": "PMID: 26466569 PMID: 28659148 PMID: 28783719, 30559419 (Abstract: Janku et al. Abstract# B176, AACR-NCI-EORTC 2017. http://mct.aacrjournals.org/content/17/1_Supplement/B176).",
                "propagation": "4"
              },
              "old": {
                "description": "PMID: 26466569 PMID: 28659148 PMID: 28783719"
              },
              "operation": "update",
              "uuids": "96034660-351c-4fce-9f82-cdfe98f7a0d2"
            }
          ],
          "timeStamp": 1551734861979
        },
        "-L_9akju-mHbWUF3sEGq": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "E501G, Mutation Effect",
              "new": {
                "description": "The BRAF E501G mutation is located in the kinase domain in exon 12 of the protein. This mutation has been found in cardio-facio-cutaneous (CFC) syndrome (PMID: 16439621). Expression of BRAF E501G in NIH-3T3 cells demonstrated that this mutation is slightly loss of function and therefore likely not oncogenic, as measured by MAPK pathway activation in the form of downstream ELK transcription comparable to or less than wildtype BRAF (PMID: 26065894, 16474404, 16439621).",
                "effect": "Likely Loss-of-function"
              },
              "old": {
                "description": "The BRAF E501G mutation is located in the kinase domain in exon 12 of the protein. This mutation has been found in cardio-facio-cutaneous (CFC) syndrome (PMID: 16439621). Expression of BRAF E501G in NIH-3T3 cells demonstrated that this mutation is likely neutral, as measured by MAPK pathway activation in the form of downstream ELK transcription comparable to wildtype BRAF (PMID: 16474404, 16439621).",
                "effect": "Likely Neutral"
              },
              "operation": "update",
              "uuids": "2662435c-a398-48e3-ad80-840da9137e2b"
            }
          ],
          "timeStamp": 1551734869160
        },
        "-L_F37OgamAflHUE5gsJ": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Gene Background",
              "new": "BRAF is a serine/threonine kinase that plays a key role in the regulation of the mitogen-activated protein kinase (MAPK) cascade (PMID: 15520807), which under physiologic conditions regulates the expression of genes involved in cellular functions, including proliferation (PMID: 24202393). Genetic alterations in BRAF are found in a large percentage of melanomas, thyroid cancers and histiocytic neoplasms as well as a small fraction of lung and colorectal cancers. The most common BRAF point mutation is V600E, which deregulates the protein's kinase activity leading to constitutive BRAF activation, as BRAF V600E can signal as a monomer independently of RAS or upstream activation (PMID: 20179705). Other BRAF mutations have been found that affect the protein's propensity to dimerize (PMID: 16858395, 26343582, 12068308). The product of these alterations is a BRAF kinase that can activate MAPK signaling in an unregulated manner and, in some instances, is directly responsible for cancer growth (PMID: 15520807). Inhibitors of mutant BRAF, including vemurafenib and dabrafenib, are FDA-approved for the treatment of late-stage or unresectable melanoma. Preliminary studies suggest that BRAF V600K mutant tumors may not respond to combined BRAF and MEK inhibition as well as BRAF V600E tumors due to a decreased reliance on the MAPK pathway, though further studies are needed to validate this finding (PMID: 30630828).",
              "old": "BRAF is a serine/threonine kinase that plays a key role in the regulation of the mitogen-activated protein kinase (MAPK) cascade (PMID: 15520807), which under physiologic conditions regulates the expression of genes involved in cellular functions, including proliferation (PMID: 24202393). Genetic alterations in BRAF are found in a large percentage of melanomas, thyroid cancers and histiocytic neoplasms as well as a small fraction of lung and colorectal cancers. The most common BRAF point mutation is V600E, which deregulates the protein's kinase activity leading to constitutive BRAF activation, as BRAF V600E can signal as a monomer independently of RAS or upstream activation (PMID: 20179705). Other BRAF mutations have been found that affect the protein's propensity to dimerize (PMID: 16858395, 26343582, 12068308). The product of these alterations is a BRAF kinase that can activate MAPK signaling in an unregulated manner and, in some instances, is directly responsible for cancer growth (PMID: 15520807). Inhibitors of mutant BRAF, including vemurafenib and dabrafenib, are FDA-approved for the treatment of late-stage or unresectable melanoma.",
              "operation": "update",
              "uuids": "56032b8d-22d9-4e78-97f4-6b3337c21d38"
            }
          ],
          "timeStamp": 1551826456840
        },
        "-L_FILFD-uq8bPyWa0sj": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Gene Background",
              "new": "BRAF is a serine/threonine kinase that plays a key role in the regulation of the mitogen-activated protein kinase (MAPK) cascade (PMID: 15520807), which under physiologic conditions regulates the expression of genes involved in cellular functions, including proliferation (PMID: 24202393). Genetic alterations in BRAF are found in a large percentage of melanomas, thyroid cancers and histiocytic neoplasms as well as a small fraction of lung and colorectal cancers. The most common BRAF point mutation is V600E, which deregulates the protein's kinase activity leading to constitutive BRAF activation, as BRAF V600E can signal as a monomer independently of RAS or upstream activation (PMID: 20179705). Other BRAF mutations have been found that affect the protein's propensity to dimerize (PMID: 16858395, 26343582, 12068308). The product of these alterations is a BRAF kinase that can activate MAPK signaling in an unregulated manner and, in some instances, is directly responsible for cancer growth (PMID: 15520807). Inhibitors of mutant BRAF, including vemurafenib and dabrafenib, are FDA-approved for the treatment of late-stage or unresectable melanoma. ",
              "old": "BRAF is a serine/threonine kinase that plays a key role in the regulation of the mitogen-activated protein kinase (MAPK) cascade (PMID: 15520807), which under physiologic conditions regulates the expression of genes involved in cellular functions, including proliferation (PMID: 24202393). Genetic alterations in BRAF are found in a large percentage of melanomas, thyroid cancers and histiocytic neoplasms as well as a small fraction of lung and colorectal cancers. The most common BRAF point mutation is V600E, which deregulates the protein's kinase activity leading to constitutive BRAF activation, as BRAF V600E can signal as a monomer independently of RAS or upstream activation (PMID: 20179705). Other BRAF mutations have been found that affect the protein's propensity to dimerize (PMID: 16858395, 26343582, 12068308). The product of these alterations is a BRAF kinase that can activate MAPK signaling in an unregulated manner and, in some instances, is directly responsible for cancer growth (PMID: 15520807). Inhibitors of mutant BRAF, including vemurafenib and dabrafenib, are FDA-approved for the treatment of late-stage or unresectable melanoma. Preliminary studies suggest that BRAF V600K mutant tumors may not respond to combined BRAF and MEK inhibition as well as BRAF V600E tumors due to a decreased reliance on the MAPK pathway, though further studies are needed to validate this finding (PMID: 30630828).",
              "operation": "update",
              "uuids": "56032b8d-22d9-4e78-97f4-6b3337c21d38"
            }
          ],
          "timeStamp": 1551830442181
        },
        "-L_FINPLKrBz9CD1v3wA": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600K, Mutation Effect",
              "new": {
                "description": "The class I (PMID: 28783719) activating exon 15 BRAF V600K missense mutation is located in the kinase domain of the BRAF protein. BRAF V600 alterations (predominantly V600E) are recurrent in lung (PMID: 25079552, 23833300) and thyroid (PMID: 25417114) cancers, among others. In metastatic melanoma, frequency of V600K mutation is second only to V600E, the most common BRAF alteration (PMID: 26091043). Analysis of clinicopathologic features and outcome in patients with metastatic melanoma harboring activating BRAF mutations revealed that, compared to V600E, V600K mutation was significantly associated with male sex, older age (median age, head/neck primary tumor location, shorter interval to stage IV disease, and shorter overall survival from the time of diagnosis of stage IV disease (PMID: 23922205, 22535154). Comprehensive biological characterization of BRAF V600K mutation (PMID: 15035987, 26343582) has demonstrated that this mutation activates the downstream MAPK pathway independently of RAS (PMID: 19251651, 26343582), renders BRAF constitutively activated in monomeric form (PMID: 20179705) and retains sensitivity to RAF monomer inhibitors such as vemurafenib (PMID: 26343582, 28783719, 20179705). Preliminary studies suggest that BRAF V600K mutant tumors may not respond to combined BRAF and MEK inhibition as well as BRAF V600E tumors due to a decreased reliance on the MAPK pathway, though further studies are needed to validate this finding (PMID: 30630828)."
              },
              "old": {
                "description": "The class I (PMID: 28783719) activating exon 15 BRAF V600K missense mutation is located in the kinase domain of the BRAF protein. BRAF V600 alterations (predominantly V600E) are recurrent in lung (PMID: 25079552, 23833300) and thyroid (PMID: 25417114) cancers, among others. In metastatic melanoma, frequency of V600K mutation is second only to V600E, the most common BRAF alteration (PMID: 26091043). Analysis of clinicopathologic features and outcome in patients with metastatic melanoma harboring activating BRAF mutations revealed that, compared to V600E, V600K mutation was significantly associated with male sex, older age (median age, head/neck primary tumor location, shorter interval to stage IV disease, and shorter overall survival from the time of diagnosis of stage IV disease (PMID: 23922205, 22535154). Comprehensive biological characterization of BRAF V600K mutation (PMID: 15035987, 26343582) has demonstrated that this mutation activates the downstream MAPK pathway independently of RAS (PMID: 19251651, 26343582), renders BRAF constitutively activated in monomeric form (PMID: 20179705) and retains sensitivity to RAF monomer inhibitors such as vemurafenib (PMID: 26343582, 28783719, 20179705)."
              },
              "operation": "update",
              "uuids": "7f32379e-0513-4cd5-aa97-bf5ebcb9f2fe"
            }
          ],
          "timeStamp": 1551830451021
        },
        "-LamWVqUHang8vBo9KAa": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "N486_T491delinsK",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF N486_T491delinsK mutation is located in the kinase domain of the protein. This mutation has been found in histiocytic neoplasms (PMID: 30867592). Expression of this mutation in Ba/F3 cells demonstrates that it is activating as measured by increased downstream ERK signaling, cytokine-independent growth, and MEK1/2-inhibitor sensitivity in vitro compared to wildtype BRAF (PMID: 30867592). A patient with histiocytic disease harboring the BRAF N486_T491delinsK mutation had a complete response to treatment with the MEK1/2 inhibitor cobimetinib (PMID: 30867592).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1553478312090,
                    "updatedBy": "User"
                  },
                  "description_uuid": "0f21fe82-2b82-4a0a-a89b-37e351984f3e",
                  "effect": "Likely Gain-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1552627703781,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "a4caf016-33fd-4eb9-b967-6b18c944b350",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1552627703074,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "373a848a-67c3-465e-a52e-c2d81b49eaea",
                  "short": ""
                },
                "mutation_effect_uuid": "dd967b58-82fa-45a6-ab05-bca46414409f",
                "name": "N486_T491delinsK",
                "name_review": {
                  "added": true,
                  "lastReviewed": "Y",
                  "updateTime": 1552627700011,
                  "updatedBy": "User"
                },
                "name_uuid": "fa6cb28b-3e00-4404-bc0a-5fd9cb047a6b",
                "tumors_uuid": "51debafa-b694-4c20-ba1c-9d5686c5b773"
              },
              "operation": "add",
              "uuids": "373a848a-67c3-465e-a52e-c2d81b49eaea,a4caf016-33fd-4eb9-b967-6b18c944b350"
            }
          ],
          "timeStamp": 1553478322521
        },
        "-LbvOso1iVJiPpla9aUF": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Mutation Effect",
              "new": {
                "description": "The class I activating exon 15 BRAF V600E mutation is located in the kinase domain of the BRAF protein and is highly recurrent in melanoma, lung and thyroid cancer, among others (PMID: 28783719, 26091043, 25079552, 23833300, 25417114, 28783719, 12068308). This mutation has been been comprehensively biologically characterized and has been shown to activate the downstream MAPK pathway independent of RAS (PMID: 15035987, 12068308, 19251651, 26343582), to render BRAF constitutively activated in monomeric form (PMID: 20179705), and to retain sensitivity to RAF monomer inhibitors such as vemurafenib and dabrafenib (PMID:26343582, 28783719, 20179705)."
              },
              "old": {
                "description": "The class I (PMID: 28783719) activating exon 15 BRAF V600E missense mutation is located in the kinase domain of the BRAF protein and is recurrent in melanoma (PMID: 26091043), lung (PMID: 25079552, 23833300) and thyroid (PMID: 25417114) cancers (PMID:28783719, 12068308) among others. Comprehensive biological characterization of the BRAF V600E mutation (PMID: 15035987, 12068308) has demonstrated that this mutation activates the downstream MAPK pathway independent of RAS (PMID: 19251651, 26343582), renders BRAF constitutively activated in monomeric form (PMID: 20179705), and retains sensitivity to RAF monomer inhibitors such as vemurafenib (PMID:26343582, 28783719, 20179705)."
              },
              "operation": "update",
              "uuids": "a53f5aa8-a4bb-4e65-8e30-93cf7045029e"
            }
          ],
          "timeStamp": 1554701060527
        },
        "-LbvP-Hcs_XvyF4q4BTj": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Fusions, Mutation Effect",
              "new": {
                "description": "BRAF fusions generally arise from chromosomal translocations that fuse the N-terminal end of a partner gene with the C-terminal end of BRAF (exons 9-18, containing the kinase domain), such that the fusion protein excludes the BRAF CR1 regulatory domain (PMID:15630448), thereby resulting in a constitutively active BRAF kinase. These class II hyperactivating BRAF fusions have been found in melanoma, prostate cancer, gastric cancer, and multiple other cancers (PMID: 28783719, 26343582, 24345920, 20526349, 25985019, 26324360, 18974108). Biological characterization of diverse BRAF fusion proteins demonstrate that they activate the downstream MAPK pathway independent of RAS (PMID: 24345920, 21424530, 22745804, 21424530, 18974108, 26343582), render BRAF active as a homo- or heterodimer dimer with CRAF (PMID: 26343582), and, while sensitive to MEK inhibition by targeted inhibitors such as trametinib (PMID: 24345920, 28783719, 26343582, 26314551), are insensitive to RAF monomer inhibitors such as vemurafenib and dabrafenib (PMID: 26343582, 28783719)."
              },
              "old": {
                "description": "BRAF fusions generally arise from chromosomal translocations that fuse the N-terminus of one protein with the C-terminus of BRAF (exons 9-18, containing the kinase domain), such that the fusion protein excludes the BRAF CR1 regulatory domain (PMID:15630448), thereby resulting in a constitutively active BRAF kinase. These class II (PMID: 28783719), and hyperactivating (PMID: 26343582) BRAF fusions have been reported in melanomas, prostate cancer, gastric cancer, and multiple other cancers (PMID: 24345920, 20526349, 25985019, 26324360, 18974108). Biological characterization of diverse BRAF fusion proteins demonstrated that they activate the downstream MAPK pathway independent of RAS (PMID: 24345920, 21424530, 22745804, 21424530, 18974108, 26343582), render BRAF active as a dimer with CRAF and itself (PMID: 26343582), and, while sensitive to MEK inhibition by targeted inhibitors such as trametinib (PMID: 24345920, 28783719, 26343582, 26314551), are insensitive to RAF monomer inhibitors such as vemurafenib (PMID: 26343582, 28783719)."
              },
              "operation": "update",
              "uuids": "896baaf7-1159-4038-9434-8a5539537581"
            }
          ],
          "timeStamp": 1554701091157
        },
        "-LcDuKcw53ytP0n28KYh": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Fusions, Mutation Effect",
              "new": {
                "description": "BRAF fusions generally arise from chromosomal translocations that fuse the N-terminal end of a partner gene with the C-terminal end of BRAF (exons 9-18, containing the kinase domain), such that the fusion protein excludes the BRAF CR1 regulatory domain (PMID:15630448), thereby resulting in a constitutively active BRAF kinase. These class II hyperactivating BRAF fusions have been found in melanoma, prostate cancer, gastric cancer, and multiple other cancers (PMID: 28783719, 26343582, 24345920, 20526349, 25985019, 26324360, 18974108). Biological characterization of diverse BRAF fusion proteins demonstrate that they activate the downstream MAPK pathway independent of RAS (PMID: 24345920, 21424530, 22745804, 21424530, 18974108, 26343582), render BRAF active as a homo- or heterodimer dimer with CRAF (PMID: 26343582), and, while sensitive to MEK inhibition by targeted inhibitors such as trametinib (PMID: 24345920, 28783719, 26343582, 26314551), are insensitive to RAF monomer inhibitors such as vemurafenib and dabrafenib (PMID: 26343582, 28783719). BRAF fusions have been found across multiple studies in post-treatment samples of patients with EGFR-mutant lung cancer who progressed on osimertinib (PMID: 30257958, 30073261)."
              },
              "old": {
                "description": "BRAF fusions generally arise from chromosomal translocations that fuse the N-terminal end of a partner gene with the C-terminal end of BRAF (exons 9-18, containing the kinase domain), such that the fusion protein excludes the BRAF CR1 regulatory domain (PMID:15630448), thereby resulting in a constitutively active BRAF kinase. These class II hyperactivating BRAF fusions have been found in melanoma, prostate cancer, gastric cancer, and multiple other cancers (PMID: 28783719, 26343582, 24345920, 20526349, 25985019, 26324360, 18974108). Biological characterization of diverse BRAF fusion proteins demonstrate that they activate the downstream MAPK pathway independent of RAS (PMID: 24345920, 21424530, 22745804, 21424530, 18974108, 26343582), render BRAF active as a homo- or heterodimer dimer with CRAF (PMID: 26343582), and, while sensitive to MEK inhibition by targeted inhibitors such as trametinib (PMID: 24345920, 28783719, 26343582, 26314551), are insensitive to RAF monomer inhibitors such as vemurafenib and dabrafenib (PMID: 26343582, 28783719)."
              },
              "operation": "update",
              "uuids": "896baaf7-1159-4038-9434-8a5539537581"
            }
          ],
          "timeStamp": 1555028333009
        },
        "-LeEPM8LKr9Gb0mMRrAp": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Mutation Effect",
              "new": {
                "description": "The class I activating exon 15 BRAF V600E mutation is located in the kinase domain of the BRAF protein and is highly recurrent in melanoma, lung and thyroid cancer, among others (PMID: 28783719, 26091043, 25079552, 23833300, 25417114, 28783719, 12068308). This mutation has been been comprehensively biologically characterized and has been shown to activate the downstream MAPK pathway independent of RAS (PMID: 15035987, 12068308, 19251651, 26343582), to render BRAF constitutively activated in monomeric form (PMID: 20179705), and to retain sensitivity to RAF monomer inhibitors such as vemurafenib and dabrafenib (PMID:26343582, 28783719, 20179705, 30351999)."
              },
              "old": {
                "description": "The class I activating exon 15 BRAF V600E mutation is located in the kinase domain of the BRAF protein and is highly recurrent in melanoma, lung and thyroid cancer, among others (PMID: 28783719, 26091043, 25079552, 23833300, 25417114, 28783719, 12068308). This mutation has been been comprehensively biologically characterized and has been shown to activate the downstream MAPK pathway independent of RAS (PMID: 15035987, 12068308, 19251651, 26343582), to render BRAF constitutively activated in monomeric form (PMID: 20179705), and to retain sensitivity to RAF monomer inhibitors such as vemurafenib and dabrafenib (PMID:26343582, 28783719, 20179705)."
              },
              "operation": "update",
              "uuids": "a53f5aa8-a4bb-4e65-8e30-93cf7045029e"
            }
          ],
          "timeStamp": 1557184213213
        },
        "-LeEPODJklkwVeZxtjva": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "L597S, Mutation Effect",
              "new": {
                "description": "The BRAF L597S mutation is located in the kinase domain in exon 15 of the protein. A clinicopathologic study of a cohort of 1119 Australian patients with known BRAF mutant status positive melanomas demonstrated that at 3.4% of patients, BRAF L597 mutations are one of the most commonly occuring non-BRAF V600E mutations and have distinct clinicopathologic features. This study found that L597 melanomas typically occur in older (median 66 yr) male (73.3% of L597 mutant cases) patients and were associated with chronically sun damaged skin (extremities or head and neck location - 73.3%, P = 0.001) (PMID: 26643848). Expression of this mutation in 293H cells demonstrated that it is likely activating, as measured by increased downstream MEK and ERK activation compared to vector control (PMID: 22798288). In vitro studies suggest that this mutation may be sensitive to vemurafenib and trametinib as measured by decreased MEK and ERK activation upon drug treatment similar to BRAF V600E (PMID: 22798288). A patient with melanoma harboring the BRAF L597S mutation demonstrated 33% tumor shrinkage when treated with trametinib as the first-line treatment with a partial response for 6.2 months (PMID: 24933606) and in another independent study, a patient with BRAF L597S mutant melanoma demonstrated partial radiographic response with 31% tumor shrinkage after 2 cycles treatment with allosteric MEK inhibitor (PMID: 22798288). A third study also contained a case report of a patient with melanoma harboring the BRAF L597S mutation who exhibited an objective radiographic response to dabrafenib + trametinib (PMID: 29903896)."
              },
              "old": {
                "description": "The BRAF L597S mutation is located in the kinase domain in exon 15 of the protein. A clinicopathologic study of a cohort of 1119 Australian patients with known BRAF mutant status positive melanomas demonstrated that at 3.4% of patients, BRAF L597 mutations are one of the most commonly occuring non-BRAF V600E mutations and have distinct clinicopathologic features. This study found that L597 melanomas typically occur in older (median 66 yr) male (73.3% of L597 mutant cases) patients and were associated with chronically sun damaged skin (extremities or head and neck location - 73.3%, P = 0.001) (PMID: 26643848). Expression of this mutation in 293H cells demonstrated that it is likely activating, as measured by increased downstream MEK and ERK activation compared to vector control (PMID: 22798288). In vitro studies suggest that this mutation may be sensitive to vemurafenib and trametinib as measured by decreased MEK and ERK activation upon drug treatment similar to BRAF V600E (PMID: 22798288). A patient with melanoma harboring the BRAF L597S mutation demonstrated 33% tumor shrinkage when treated with trametinib as the first-line treatment with a partial response for 6.2 months (PMID: 24933606) and in another independent study, a patient with BRAF L597S mutant melanoma demonstrated partial radiographic response with 31% tumor shrinkage after 2 cycles treatment with allosteric MEK inhibitor (PMID: 22798288)."
              },
              "operation": "update",
              "uuids": "bd08e589-0a0b-4ff9-b514-fe3fe1d84f30"
            }
          ],
          "timeStamp": 1557184221723
        },
        "-LeEPPrS7ETmuA4CxLZi": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "L597, Melanoma, INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY, Trametinib",
              "new": {
                "description": "Trametinib is a small molecule inhibitor of the MEK1/2 kinases that is FDA approved in combination with a RAF inhibitor for use in BRAF V600E-positive metastatic melanoma. In a small study of trametinib in patients with non-V600E BRAF-mutated metastatic melanoma, one patient harboring a BRAF L597Q mutation achieved partial response (6.2 months) upon treatment with trametinib (PMID: 24933606). In vitro studies of cell lines engineered to express BRAF L597R or L597S mutations demonstrated sensitivity to MEK inhibition as measured by decreased activation of downstream effector proteins upon treatment with trametinib (PMID: 22798288, 29903896)."
              },
              "old": {
                "description": "Trametinib is a small molecule inhibitor of the MEK1/2 kinases that is FDA approved in combination with a RAF inhibitor for use in BRAF V600E-positive metastatic melanoma. In a small study of trametinib in patients with non-V600E BRAF-mutated metastatic melanoma, one patient harboring a BRAF L597Q mutation achieved partial response (6.2 months) upon treatment with trametinib (PMID: 24933606). In vitro studies of cell lines engineered to express BRAF L597R or L597S mutations demonstrated sensitivity to MEK inhibition as measured by decreased activation of downstream effector proteins upon treatment with trametinib (PMID: 22798288)."
              },
              "operation": "update",
              "uuids": "af5ea563-3d74-49e1-b931-ebb6f3fdeb43"
            }
          ],
          "timeStamp": 1557184228452
        },
        "-LeEPRlXWu2Y3UBuq-Iy": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "L597, All Tumors, INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY, PLX8394",
              "new": {
                "description": "PMID: 26466569 PMID: 28659148 PMID: 28783719, 30559419,  (Abstract: Janku et al. Abstract# B176, AACR-NCI-EORTC 2017. http://mct.aacrjournals.org/content/17/1_Supplement/B176)."
              },
              "old": {
                "description": "PMID: 26466569 PMID: 28659148 PMID: 28783719, 30559419 (Abstract: Janku et al. Abstract# B176, AACR-NCI-EORTC 2017. http://mct.aacrjournals.org/content/17/1_Supplement/B176)."
              },
              "operation": "update",
              "uuids": "1fd2d2b7-b69a-4e58-b205-81ef99c8c2e9"
            }
          ],
          "timeStamp": 1557184236265
        },
        "-LeEPTZkeVB-GIV7yKt0": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "K601, Melanoma, INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY, Trametinib",
              "new": {
                "description": "Trametinib is a small molecule inhibitor of the MEK1/2 kinases that is FDA approved in combination with a RAF inhibitor for use in BRAF V600E-positive metastatic melanoma. Anecdotal evidence of clinical activity of trametinib in BRAF K601-mutant melanoma includes a patient who experienced a complete response to tratmetinib over 36 months (PMID: 28344857), and four patients in various other studies who achieved partial response or stable disease upon treatment with trametinib (PMID: 23248257, 24933606). In vitro studies of cell lines engineered to express BRAF K601E demonstrated sensitivity to MEK inhibition as measured by decreased activation of downstream effector proteins upon treatment with trametinib (PMID: 22798288, 29903896)."
              },
              "old": {
                "description": "Trametinib is a small molecule inhibitor of the MEK1/2 kinases that is FDA approved in combination with a RAF inhibitor for use in BRAF V600E-positive metastatic melanoma. Anecdotal evidence of clinical activity of trametinib in BRAF K601-mutant melanoma includes a patient who experienced a complete response to tratmetinib over 36 months (PMID: 28344857), and four patients in various other studies who achieved partial response or stable disease upon treatment with trametinib (PMID: 23248257, 24933606). In vitro studies of cell lines engineered to express BRAF K601E demonstrated sensitivity to MEK inhibition as measured by decreased activation of downstream effector proteins upon treatment with trametinib (PMID: 22798288)."
              },
              "operation": "update",
              "uuids": "b17106e4-9dd3-4157-90d2-0e791c15278b"
            }
          ],
          "timeStamp": 1557184243639
        },
        "-Lhlx5frZIvJaXY2xe76": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Colorectal Cancer, Standard implications for sensitivity to therapy, 001e534f-3e63-432f-90a6-d1af1759e4e2 + 5fce3074-e420-4c36-9603-2423daf20118 + feb9f4a3-e374-4c75-8a3b-0f1fbcdbf677, 939cd40b-b515-499d-b099-fd29027c0d17 + d7b1d12a-e942-4801-bb64-916c9bdfaaf3 + fb2bb01c-c0ec-4641-abf7-87f486075022",
              "new": {
                "description": "Encorafenib is a small molecule inhibitor of RAF kinase, binimetinib is a small molecule inhibitor of MEK1/2 kinases, and cetuximab is an antibody that targets EGFR. In the Phase III BEACON study of encorafenib + binimetinib + cetuximab versus chemotherapy in 29 patients with BRAF V600E-mutant colorectal cancer, the overall response rate (complete or partial response) was 48% (14 of 29 patients), with three of fourteen patients having complete response (Abstract: Cutsem et al. Abstract# O-027, ESMO 2018. https://academic.oup.com/annonc/article/29/suppl_5/mdy149.026/5039436). Nine patients had durable stable disease (Abstract: Cutsem et al. Abstract# 627, ASCO 2018. http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.4_suppl.627). Estimated median progression-free survival was 8 months in the triplet combination arm (Abstract: Cutsem et al. Abstract# O-027, ESMO 2018. https://academic.oup.com/annonc/article/29/suppl_5/mdy149.026/5039436). The combination of dabrafenib, trametinib and panitumumab has also shown efficacy in this population, with a response rate in one study of 26%, with an additional 57% of patients achieving stable disease (PMID: 29431699). Triplet therapy is listed as a 2A therapy in the NCCN guidlines.",
                "description_review": {
                  "lastReviewed": "Encorafenib is a small molecule inhibitor of RAF kinase, binimetinib is a small molecule inhibitor of MEK1/2 kinases, and cetuximab is an antibody that targets EGFR. In the Phase III BEACON study of encorafenib + binimetinib + cetuximab versus chemotherapy in 29 patients with BRAF V600E-mutant colorectal cancer, the overall response rate (complete or partial response) was 48% (14 of 29 patients), with three of fourteen patients having complete response (Abstract: Cutsem et al. Abstract# O-027, ESMO 2018. https://academic.oup.com/annonc/article/29/suppl_5/mdy149.026/5039436). Nine patients had durable stable disease (Abstract: Cutsem et al. Abstract# 627, ASCO 2018. http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.4_suppl.627). Estimated median progression-free survival was 8 months in the triplet combination arm (Abstract: Cutsem et al. Abstract# O-027, ESMO 2018. https://academic.oup.com/annonc/article/29/suppl_5/mdy149.026/5039436). The combination of dabrafenib, trametinib and panitumumab has also shown efficacy in this population, with a response rate in one study of 26%, with an additional 57% of patients achieving stable disease (PMID: 29431699). Triplet therapy is listed as a 2A therapy in the NCCN guidlines",
                  "updateTime": 1560984276886,
                  "updatedBy": "User"
                },
                "description_uuid": "78a9d3f6-345f-4a7f-869c-545dd7fe5f69",
                "indication": "",
                "indication_uuid": "b730f7a1-8e70-46fb-bc23-6e95bb467290",
                "level": "2A",
                "level_review": {
                  "lastReviewed": "",
                  "updateTime": 1560907093831,
                  "updatedBy": "User"
                },
                "level_uuid": "7c15b783-7b14-48d9-a040-ca77ca110d8b",
                "name": "001e534f-3e63-432f-90a6-d1af1759e4e2 + 5fce3074-e420-4c36-9603-2423daf20118 + feb9f4a3-e374-4c75-8a3b-0f1fbcdbf677, 939cd40b-b515-499d-b099-fd29027c0d17 + d7b1d12a-e942-4801-bb64-916c9bdfaaf3 + fb2bb01c-c0ec-4641-abf7-87f486075022",
                "name_review": {
                  "added": true,
                  "lastReviewed": "001e534f-3e63-432f-90a6-d1af1759e4e2 + 5fce3074-e420-4c36-9603-2423daf20118 + feb9f4a3-e374-4c75-8a3b-0f1fbcdbf677",
                  "updateTime": 1560907077540,
                  "updatedBy": "User"
                },
                "name_uuid": "d9b444f3-76b2-4f91-a919-8b8b4d853846",
                "propagation": "2B",
                "propagation_review": {
                  "updateTime": 1560907093885,
                  "updatedBy": "User"
                },
                "propagation_uuid": "143939ec-050e-416e-be4c-930f7d2e5020",
                "short": ""
              },
              "operation": "add",
              "uuids": "d9b444f3-76b2-4f91-a919-8b8b4d853846"
            },
            {
              "lastEditBy": "User",
              "location": "V600E, Colorectal Cancer, Tumor Type Summary",
              "new": "The triplet therapy combination of encorafenib + binimetinib + cetuximab, a RAF-inhibitor, a MEK-inhibitor and an anti-EGFR antibody respectively, is NCCN-compendium listed and has received FDA-breakthrough therapy designation for the treatment of patients with BRAF V600E mutant colorectal cancer.",
              "old": "",
              "operation": "update",
              "uuids": "cfcc19a6-df02-4230-85fb-992ed74d464a"
            }
          ],
          "timeStamp": 1560984972043
        },
        "-LhlxA_wZYIGTb0GyeVE": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Colorectal Cancer, Investigational implications for sensitivity to therapy, 001e534f-3e63-432f-90a6-d1af1759e4e2 + feb9f4a3-e374-4c75-8a3b-0f1fbcdbf677 + 5fce3074-e420-4c36-9603-2423daf20118",
              "old": {
                "description": "Encorafenib is a small molecule inhibitor of RAF kinase, binimetinib is a small molecule inhibitor of MEK1/2 kinases, and cetuximab is an antibody that targets EGFR. In the Phase III BEACON study of encorafenib + binimetinib + cetuximab versus chemotherapy in 29 patients with BRAF V600E-mutant colorectal cancer, the overall response rate (complete or partial response) was 48% (14 of 29 patients), with three of fourteen patients having complete response (Abstract: Cutsem et al. Abstract# O-027, ESMO 2018. https://academic.oup.com/annonc/article/29/suppl_5/mdy149.026/5039436). Nine patients had durable stable disease (Abstract: Cutsem et al. Abstract# 627, ASCO 2018. http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.4_suppl.627). Estimated median progression-free survival was 8 months in the triplet combination arm (Abstract: Cutsem et al. Abstract# O-027, ESMO 2018. https://academic.oup.com/annonc/article/29/suppl_5/mdy149.026/5039436).",
                "description_review": {
                  "updateTime": 1560979461548,
                  "updatedBy": "User"
                },
                "description_uuid": "8b2bebcb-a598-4b1f-bf85-c204d7c11211",
                "indication": "",
                "indication_uuid": "f47af581-6875-4569-87bb-229add8448d6",
                "level": "3A",
                "level_review": {
                  "updateTime": 1542309553575,
                  "updatedBy": "User"
                },
                "level_uuid": "aea3f2f1-8fb6-4334-91a5-9c6b49040fe3",
                "name": "001e534f-3e63-432f-90a6-d1af1759e4e2 + feb9f4a3-e374-4c75-8a3b-0f1fbcdbf677 + 5fce3074-e420-4c36-9603-2423daf20118",
                "name_review": {
                  "removed": true,
                  "updateTime": 1560907571482,
                  "updatedBy": "User"
                },
                "name_uuid": "aae49737-28a5-4bf2-97a5-920d1a71cc8e",
                "propagation": "3B",
                "propagation_review": {
                  "updateTime": 1542309553701,
                  "updatedBy": "User"
                },
                "propagation_uuid": "e7931b1c-3abf-409e-bc33-95b0b815894d",
                "short": ""
              },
              "operation": "delete"
            }
          ],
          "timeStamp": 1560984992145
        },
        "-LjcJJBwKbyjiUrl4J8H": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "T241P, Mutation Effect",
              "new": {
                "description": "The BRAF T241P mutation is located in the cysteine-rich domain in exon 6 of the protein. This mutation has been found in cardio-facio-cutaneous syndrome (CFC) (PMID: 19206169). Expression of this mutation in NIH-3T3 cells demonstrated that it is likely activating as measured by moderately increased activation of MEK and ERK and slightly increased colony formation compared to wildtype BRAF (PMID: 19206169)."
              },
              "old": {
                "description": "he BRAF T241P mutation is located in the cysteine-rich domain in exon 6 of the protein. This mutation has been found in cardio-facio-cutaneous syndrome (CFC) (PMID: 19206169). Expression of this mutation in NIH-3T3 cells demonstrated that it is likely activating as measured by moderately increased activation of MEK and ERK and slightly increased colony formation compared to wildtype BRAF (PMID: 19206169)."
              },
              "operation": "update",
              "uuids": "274d4c28-1e34-4982-872d-414ea59a5b73"
            }
          ],
          "timeStamp": 1562970768210
        },
        "-LkzQLOKPFGnPzhl52zH": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "T599dup, Mutation Effect",
              "new": {
                "description": "The BRAF T599dup mutation is located in the kinase domain in exon 15 of the protein. This mutation has been found in melanoma and pilocytic astrocytoma (PMID: 19363522, 21190184, 29456854). Expression of this mutation in HEK293, NIH-3T3 or MCF-10A cells demonstrated that this mutation is activating as measured by kinase activity, anchorage-independent growth and changes in contact inhibition comparable to BRAF V600E (PMID: 19363522, 21190184, 23833300)."
              },
              "old": {
                "description": "The BRAF T599dup mutation is located in the kinase domain in exon 15 of the protein. This mutation has been found in pilocytic astrocytoma (PMID: 19363522, 21190184). Expression of this mutation in HEK293, NIH-3T3 or MCF-10A cells demonstrated that this mutation is activating as measured by kinase activity, anchorage-independent growth and changes in contact inhibition comparable to BRAF V600E (PMID: 19363522, 21190184, 23833300)."
              },
              "operation": "update",
              "uuids": "aa40d7f6-5e58-4764-a5d0-ee4acadfd3ad"
            }
          ],
          "timeStamp": 1564432227113
        },
        "-LkzQacFBREGnIBa3Moe": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Kinase Domain Duplication",
              "new": {
                "mutation_effect": {
                  "description": "PMID: 27320919, 26562024",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1564431319262,
                    "updatedBy": "User"
                  },
                  "description_uuid": "2eaad6a5-b28b-4a97-a9d8-51f4162a3296",
                  "effect": "Likely Gain-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1564431292245,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "00b243ca-25a4-46b0-a189-7e9c80a3af07",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1564431291247,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "d8c54d72-0695-4cf9-aefa-e77540c5ffa0",
                  "short": ""
                },
                "mutation_effect_uuid": "1e3d582f-aa18-498e-94bd-ad705ed07044",
                "name": "Kinase Domain Duplication",
                "name_review": {
                  "added": true,
                  "updateTime": 1564431287111,
                  "updatedBy": "User"
                },
                "name_uuid": "62feb2e4-a3eb-426b-97fa-5c5c8f1ccace",
                "tumors_uuid": "727cdb49-2079-4074-92e4-8b1568256c81"
              },
              "operation": "add",
              "uuids": "d8c54d72-0695-4cf9-aefa-e77540c5ffa0,00b243ca-25a4-46b0-a189-7e9c80a3af07"
            }
          ],
          "timeStamp": 1564432293605
        },
        "-Ll0VWsJG-MICZI_lGS2": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "AGAP3-BRAF Fusion, Mutation Effect",
              "new": {
                "description": "The AGAP3-BRAF fusion protein results from an inversion on chromosome 7, joining exons 1-9 of AGAP3 to exons 9-18 of BRAF, thus retaining the full kinase domain of BRAF. This fusion protien is found in patients with sporadic microsatellite instability-high colorectal cancers (PMID: 30279230). Expression of the fusion protein in a BRAF V600E-mutated melanoma cell line elevated basal levels of phosphorylated ERK but not phosphorylated MEK. This increase was abrogated by MEK inhibition, but not BRAF inhibition. Colony formation and cell proliferation assays showed similar effects of the fusion (PMID: 28539463). Expression of this fusion protein in NIH3T3 cells demonstrated that it was activating as shown by increased colony formation and pathway activation compared to expression of BRAF alone (PMID: 30279230).",
                "oncogenic": "Likely"
              },
              "old": {
                "description": "The AGAP3-BRAF fusion protein results from an inversion on chromosome 7, joining exons 1-9 of AGAP3 to exons 9-18 of BRAF, thus retaining the full kinase domain of BRAF. Expression of the fusion protein in a BRAF V600E-mutated melanoma cell line elevated basal levels of phosphorylated ERK but not phosphorylated MEK. This increase was abrogated by MEK inhibition, but not BRAF inhibition. Colony formation and cell proliferation assays showed similar effects of the fusion (PMID: 28539463).",
                "oncogenic": "Yes"
              },
              "operation": "update",
              "uuids": "bb7f48fd-2962-44c1-a76a-08465a8aa7cf,9f208268-d2d3-415b-820f-472944a8850e"
            }
          ],
          "timeStamp": 1564467139905
        },
        "-Ll0VZlgROVZLoIax62h": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "ARMC10-BRAF Fusion",
              "new": {
                "mutation_effect": {
                  "description": "The ARMC10-BRAF fusion protein combines the N-terminus of ARMC10 with the C-terminus of BRAF, preserving the kinase domain of BRAF. This fusion protien is found in patients with sporadic microsatellite instability-high colorectal cancers (PMID: 30279230). Expression of this fusion protein in NIH3T3 cells demonstrated that it was activating as shown by increased colony formation and pathway activation compared to expression of BRAF alone (PMID: 30279230).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1564457057403,
                    "updatedBy": "User"
                  },
                  "description_uuid": "6e2f3792-d90e-40ae-bfbf-6c2d17e53e8e",
                  "effect": "Likely Gain-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1564456670131,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "ee026fa7-42df-40e7-bcce-6fc7f23610f4",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1564456669140,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "b2bfc7d1-dca7-424c-aea1-f4d4f269a868",
                  "short": ""
                },
                "mutation_effect_uuid": "fc1c7b9f-046b-4672-b2cf-13f94aaa6d91",
                "name": "ARMC10-BRAF Fusion",
                "name_review": {
                  "added": true,
                  "updateTime": 1564456417626,
                  "updatedBy": "User"
                },
                "name_uuid": "5a2aac3e-a1c2-4e5f-93f7-b1427aeaf4a8",
                "tumors_uuid": "eef44baf-6574-48c9-8aa0-b0436860e30c"
              },
              "operation": "add",
              "uuids": "b2bfc7d1-dca7-424c-aea1-f4d4f269a868,ee026fa7-42df-40e7-bcce-6fc7f23610f4"
            }
          ],
          "timeStamp": 1564467151769
        },
        "-Ll31JARNLUYSbckGs3_": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G469, G464 (non-V600 mutations, class II )",
              "new": "G469, G464 (non-V600 mutations, class II )",
              "old": "G469, G464, D287H, V459L, G466, S467L, N581, D594, F595L, G596 (non-V600 mutations)",
              "operation": "name change",
              "uuids": "6bfd2309-23ad-432c-9e44-e63d72acea80"
            }
          ],
          "timeStamp": 1564509552916
        },
        "-LlHZ6YB1E0gqU5DaeJN": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Hairy Cell Leukemia, Tumor Type Summary",
              "new": "The Raf inhibitor vemurafenib is NCCN-compendium listed for the treatment of patients with relapsed or refractory BRAF V600E-mutant hairy cell leukemia.",
              "old": "",
              "operation": "update",
              "uuids": "fe5e6dec-78e9-438d-9a22-762fcdc91ac2"
            }
          ],
          "timeStamp": 1564753299682
        },
        "-LlHZF3mw-xUxvy_MWgF": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Hairy Cell Leukemia, Standard implications for sensitivity to therapy, 4e91da20-6cf0-4e07-995f-7f7db4c7c077",
              "new": {
                "description": "Vemurafenib is an inhibitor of V600-mutant BRAF that is FDA-approved for treatment of patients with various BRAF V600-harboring tumors, including melanoma and Edheim-Chester Disease (ECD). Vemurafenib is listed as a 2A therapeutic in the NCCN guidelines for Hairy Cell Leukemia (HCL) based on data from two Phase II trials. In one study of vemurafenib in patients with BRAF V600E-mutant HCL (n=24), the overall response rate was 100%, with 42% of patients (10 of 24) having complete responses, with a response duration of 11.7 months and one year progression free and overall survival rates of 73% and 91%, repectively (PMID: 26352686). In another study of vemurafenib in patients with BRAF V600E-mutant HCL (n=26), the overall response rate was 96%, with 35% of patients (9 of 26) having complete responses (PMID: 26352686).",
                "description_review": {
                  "lastReviewed": "",
                  "updateTime": 1564680986916,
                  "updatedBy": "User"
                },
                "description_uuid": "ad710a94-191a-4f31-9c25-cf330af9d191",
                "indication": "",
                "indication_uuid": "d6bf13c9-52c1-4fc3-b63b-32f9b5958c9a",
                "level": "2A",
                "level_review": {
                  "lastReviewed": "",
                  "updateTime": 1564509443794,
                  "updatedBy": "User"
                },
                "level_uuid": "d28f3780-d246-49a5-b681-f08bba46685f",
                "name": "4e91da20-6cf0-4e07-995f-7f7db4c7c077",
                "name_review": {
                  "added": true,
                  "updateTime": 1564016553702,
                  "updatedBy": "User"
                },
                "name_uuid": "4e56b02d-394e-4397-9465-a3cc2c5026cd",
                "propagation": "2B",
                "propagation_review": {
                  "updateTime": 1564509443791,
                  "updatedBy": "User"
                },
                "propagation_uuid": "7f1fb2cd-44c7-4958-9003-21c5c4c65797",
                "short": ""
              },
              "operation": "add",
              "uuids": "4e56b02d-394e-4397-9465-a3cc2c5026cd"
            }
          ],
          "timeStamp": 1564753334600
        },
        "-LlHp68qRAJqpdJUwoTo": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G469A, G469V, G469R, G464 (non-V600 mutations, class II )",
              "new": "G469A, G469V, G469R, G464 (non-V600 mutations, class II )",
              "old": "G469, G464 (non-V600 mutations, class II )",
              "operation": "name change",
              "uuids": "6bfd2309-23ad-432c-9e44-e63d72acea80"
            }
          ],
          "timeStamp": 1564757750202
        },
        "-LlIfNcvgCxnTJLfnhhI": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Oncogenic Mutations, Histiocytosis",
              "old": {
                "TIs": [
                  {
                    "name": "Standard implications for sensitivity to therapy",
                    "name_uuid": "53e01426-f77f-47d7-90c7-25fc498afcfb",
                    "type": "SS"
                  },
                  {
                    "name": "Standard implications for resistance to therapy",
                    "name_uuid": "03a60755-9d6d-4b80-bf50-90025e040794",
                    "type": "SR"
                  },
                  {
                    "name": "Investigational implications for sensitivity to therapy",
                    "name_uuid": "0b519466-9b43-45d6-8089-d0c0b057b4fb",
                    "type": "IS"
                  },
                  {
                    "name": "Investigational implications for resistance to therapy",
                    "name_uuid": "83189f90-1810-49bc-aeee-bd732ffd8b77",
                    "type": "IR"
                  }
                ],
                "cancerTypes": [
                  {
                    "code": "",
                    "mainType": "Histiocytosis",
                    "subtype": ""
                  }
                ],
                "cancerTypes_review": {
                  "removed": true,
                  "updateTime": 1564771941370,
                  "updatedBy": "User"
                },
                "cancerTypes_uuid": "7c5a583c-bf80-41af-9f03-79f077f4a42d",
                "diagnostic": {
                  "description": "",
                  "description_uuid": "e111ad1d-ed9f-46ca-bd12-3cd30e830702",
                  "level": "",
                  "level_uuid": "2cb1f8ae-af2a-42d0-b5a6-0718d039de48",
                  "short": ""
                },
                "diagnosticSummary": "",
                "diagnosticSummary_uuid": "a768e6a3-9f20-48d7-9c6c-717774eb5b71",
                "diagnostic_uuid": "05c71c8c-28c3-4faf-b915-d338deb41d1e",
                "prognostic": {
                  "description": "",
                  "description_review": {
                    "updateTime": 1493057315640
                  },
                  "description_uuid": "b1d424af-97a6-401d-9399-f4e9d16eaff8",
                  "level": "",
                  "level_uuid": "b285a402-e202-4711-b87f-a84ec17c6acd",
                  "short": ""
                },
                "prognosticSummary": "",
                "prognosticSummary_uuid": "de58038c-bb18-435d-806b-aa968247c81d",
                "prognostic_uuid": "4636c4eb-a2f6-4b33-ace4-1c3379016d0b",
                "summary": "",
                "summary_review": {
                  "lastReviewed": "While the RAF-inhibitor vemurafenib is FDA-approved for the treatment of patients with BRAF V600-mutant histiocytic neoplasia, its clinical utility in patients with [[variant]] is unknown.",
                  "updateTime": 1564771924476,
                  "updatedBy": "User"
                },
                "summary_uuid": "2185be10-085b-4dd2-b9e3-1a278f6e37c3"
              },
              "operation": "delete"
            }
          ],
          "timeStamp": 1564771977719
        },
        "-LlIpO5nrqmH0oRkM2AI": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G469A, G469V, G469R, G464 (non-V600 mutations, class II ), All Tumors, Tumor Type Summary",
              "new": "BRAF class II mutations including [[gene]] [[mutation]] are insensitive to the RAF inhibitors vemurafenib and dabrafenib. Laboratory data suggest that cancer cells with oncogenic, non-V600 BRAF mutations may be sensitive to novel BRAF inhibitors such as PLX8394. PMID: 28783719, 30559419",
              "old": "BRAF non-V600 mutations including [[gene]] [[mutation]] are insensitive to the RAF inhibitors vemurafenib and dabrafenib. Laboratory data suggest that cancer cells with oncogenic, non-V600 BRAF mutations may be sensitive to novel BRAF inhibitors such as PLX8394.",
              "operation": "update",
              "uuids": "522e6413-dfd4-4099-8da9-1f79b192e6e4"
            }
          ],
          "timeStamp": 1564774601083
        },
        "-LlIqSbNCi61vS9KlDMM": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Oncogenic Mutations, Histiocytosis",
              "new": {
                "TIs": [
                  {
                    "name": "Standard implications for sensitivity to therapy",
                    "name_uuid": "3338130e-ea70-4d6e-b0d2-ff5ebe980dca",
                    "treatments_uuid": "02eb1410-99ef-4c0f-9462-b26104468010",
                    "type": "SS"
                  },
                  {
                    "name": "Standard implications for resistance to therapy",
                    "name_uuid": "4c69c1de-2520-4f0f-af13-b7b172bdbf32",
                    "treatments_uuid": "e6bae938-480b-4f2c-a7ac-a9733c6f8be3",
                    "type": "SR"
                  },
                  {
                    "name": "Investigational implications for sensitivity to therapy",
                    "name_uuid": "67473e7f-62b9-4cb8-8c1b-a23aa76c2f54",
                    "treatments": [
                      {
                        "description": "Cobimetinib is a small molecule inhibitor of MEK1/2 that is FDA-approved in combination with a BRAF inhibitor in BRAF V600-mutant melanoma. In a Phase II trial of cobimetinib in eighteen patients with histiocytoses, the overall response rate was 89%, with thirteen out of eighteen patients (72%) having a complete response and fifteen out of eighteen patients harboring a MAPK pathway mutation (PMID: 30867592) Six of six patients with BRAF mutations (five V600E, one non-V600E) had a partial or complete response to treatment with cobimetinib (PMID: 30867592). Small case studies have also demonstrated the clinical efficacy of MEK inhibition in patients with histiocytic neoplasms (PMID: 29236635).",
                        "description_review": {
                          "lastReviewed": "",
                          "updateTime": 1564631825363,
                          "updatedBy": "User"
                        },
                        "description_uuid": "f2002e1a-40cf-44c4-bea3-73e515082100",
                        "indication": "",
                        "indication_uuid": "d604ffa5-5f7f-4b43-b1aa-f0d04381b133",
                        "level": "3A",
                        "level_review": {
                          "lastReviewed": "",
                          "updateTime": 1564680986946,
                          "updatedBy": "User"
                        },
                        "level_uuid": "bd78225a-3aaf-454e-a3e2-68e3337f57d3",
                        "name": "eb357145-3b18-4aca-b75a-5e18dd2bf4f9",
                        "name_review": {
                          "added": true,
                          "updateTime": 1564631819537,
                          "updatedBy": "User"
                        },
                        "name_uuid": "483bc890-60e3-4c65-96e5-94f5412df6dc",
                        "propagation": "no",
                        "propagation_review": {
                          "updateTime": 1564680986938,
                          "updatedBy": "User"
                        },
                        "propagation_uuid": "62bca78f-fd37-4c92-83cf-51201564dccb",
                        "short": ""
                      }
                    ],
                    "treatments_uuid": "62057abb-52c2-4442-8f34-1586c593058f",
                    "type": "IS"
                  },
                  {
                    "name": "Investigational implications for resistance to therapy",
                    "name_uuid": "36398e6c-fc71-4d58-b4bb-7111ca386721",
                    "treatments_uuid": "4eb5542f-1cf5-49c2-859e-4f958e9361db",
                    "type": "IR"
                  }
                ],
                "cancerTypes": [
                  {
                    "code": "",
                    "mainType": "Histiocytosis",
                    "subtype": ""
                  }
                ],
                "cancerTypes_review": {
                  "added": true,
                  "lastReviewed": [
                    {
                      "code": "HDCN",
                      "mainType": "Histiocytosis",
                      "subtype": "Histiocytic and Dendritic Cell Neoplasms"
                    }
                  ],
                  "updateTime": 1564772064365,
                  "updatedBy": "User"
                },
                "cancerTypes_uuid": "0c23767d-65d7-49fe-9dbd-c5d54588f3ec",
                "diagnostic": {
                  "description": "",
                  "description_uuid": "bbbb4775-1b35-4478-960d-ef39e62e2f61",
                  "level": "",
                  "level_uuid": "3d8bd6ce-be6e-4e1b-af70-6e39dbf723de",
                  "short": ""
                },
                "diagnosticSummary": "",
                "diagnosticSummary_uuid": "71161458-5ba2-4385-bf62-3b391f726bf1",
                "diagnostic_uuid": "f0a1550e-37d5-45f7-bf88-37bc20eacffc",
                "prognostic": {
                  "description": "",
                  "description_uuid": "c215ef99-c584-4017-96e8-65f60821e74f",
                  "level": "",
                  "level_uuid": "16c01e74-5c1f-4269-b679-3dc6ccd37d4e",
                  "short": ""
                },
                "prognosticSummary": "",
                "prognosticSummary_uuid": "89a54d9f-7f16-4511-9d40-9838edc49842",
                "prognostic_uuid": "bfc84ff5-377e-42e5-941b-a2633e41f7d9",
                "summary": "While the MEK1/2 inhibitor cobimetinib has shown promising clinical activity in patients with BRAF V600E or N486_T491delinsK mutant histiocytic disease, its clinical utility in patients with [[gene]] [[mutation]] [[mutant]] histiocytic disease is unknown.",
                "summary_review": {
                  "lastReviewed": "",
                  "updateTime": 1564773502447,
                  "updatedBy": "User"
                },
                "summary_uuid": "a035a4e8-143e-4ba8-b360-8ae275fa92bd"
              },
              "operation": "add",
              "uuids": "a035a4e8-143e-4ba8-b360-8ae275fa92bd,483bc890-60e3-4c65-96e5-94f5412df6dc"
            }
          ],
          "timeStamp": 1564774881772
        },
        "-LlIqVW138IOepGlbeiB": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "N486_T491delinsK, Histiocytosis",
              "new": {
                "TIs": [
                  {
                    "name": "Standard implications for sensitivity to therapy",
                    "name_uuid": "d073cbbc-47cf-4c5a-8609-3045d0d74f2e",
                    "treatments_uuid": "17c8b8ca-6d6d-4702-982c-399b2c6f39e2",
                    "type": "SS"
                  },
                  {
                    "name": "Standard implications for resistance to therapy",
                    "name_uuid": "180c1120-3645-4397-a118-6d1378d37dbf",
                    "treatments_uuid": "bf9ef464-82cf-4a3b-9712-913dfe25a7db",
                    "type": "SR"
                  },
                  {
                    "name": "Investigational implications for sensitivity to therapy",
                    "name_uuid": "7cb6ca2a-8874-4c27-95db-85799c70cafc",
                    "treatments_uuid": "f23d580d-4c78-4ec2-8541-2fd1fbc03cde",
                    "type": "IS"
                  },
                  {
                    "name": "Investigational implications for resistance to therapy",
                    "name_uuid": "e5d90a4a-f003-4703-86aa-964df7a63230",
                    "treatments_uuid": "8a500880-7764-48a8-8377-1a17d3e0ba1a",
                    "type": "IR"
                  }
                ],
                "cancerTypes": [
                  {
                    "code": "",
                    "mainType": "Histiocytosis",
                    "subtype": ""
                  }
                ],
                "cancerTypes_review": {
                  "added": true,
                  "updateTime": 1564771688107,
                  "updatedBy": "User"
                },
                "cancerTypes_uuid": "c6f800b6-2fa1-4d51-96bf-913f06ac7079",
                "diagnostic": {
                  "description": "",
                  "description_uuid": "a76b099b-0b18-4e08-9446-de940c29d09d",
                  "level": "",
                  "level_uuid": "b7c46ed0-d4fd-462d-8ce7-edce21f2bebb",
                  "short": ""
                },
                "diagnosticSummary": "",
                "diagnosticSummary_uuid": "3ee2f20f-dce1-4318-ad26-e9791d1e0571",
                "diagnostic_uuid": "744d0935-5fb1-4142-8f01-52ff972a1db0",
                "prognostic": {
                  "description": "",
                  "description_uuid": "5e1d92be-e7d4-44d2-beec-b02814ae40a0",
                  "level": "",
                  "level_uuid": "1468368a-31f5-4757-8e73-7e481fda181a",
                  "short": ""
                },
                "prognosticSummary": "",
                "prognosticSummary_uuid": "bca16643-49b4-4547-b08a-0ced171b61b4",
                "prognostic_uuid": "c6e54649-a1c6-4e28-bd78-78fc2a366195",
                "summary": "The MEK1/2 inhibitor cobimetinib has shown promising clinical activity in a patient with BRAF N486_T491delinsK mutant Langerhans cell histiocytosis.",
                "summary_review": {
                  "lastReviewed": "",
                  "updateTime": 1564771751364,
                  "updatedBy": "User"
                },
                "summary_uuid": "3732d979-4df9-45bb-a91b-17dccba55fcb"
              },
              "operation": "add",
              "uuids": "3732d979-4df9-45bb-a91b-17dccba55fcb"
            }
          ],
          "timeStamp": 1564774893655
        },
        "-LlhMElEFWK2Nz3glYof": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600, Erdheim-Chester Disease, STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY, 4e91da20-6cf0-4e07-995f-7f7db4c7c077",
              "new": {
                "propagation": "no"
              },
              "old": {
                "propagation": "2B"
              },
              "operation": "update",
              "uuids": "729d93d7-aa18-4bf0-9c84-13b9ecce25fb"
            }
          ],
          "timeStamp": 1565202914848
        },
        "-Lm1X0guQ1L-MJL3iz8I": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "K601_S602delinsNT",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF V600_K601delinsE mutation is located in the kinase domain in exon 15 of the protein. This mutation has been found in cutaneous melanoma (PMID: 28481359). While this insertion mutation has not been functionally validated, another alteration at this position (BRAF V600_K601delinsE) is activating in NIH-3T3 cells as measured by increased kinase activity, downstream ERK activation and increased colony formation compared to wildtype BRAF (PMID: 23833300).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1565548747066,
                    "updatedBy": "User"
                  },
                  "description_uuid": "945f1b29-1d2e-4f9b-bb2f-1de43b572214",
                  "effect": "Likely Gain-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1565548749467,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "c0c8b6d2-9835-447c-97ae-ca2af2bdc09f",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1565547813819,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "39187b6d-6026-4c10-97b6-68eef0344894",
                  "short": ""
                },
                "mutation_effect_uuid": "9660c4ce-d2d0-4774-9622-378723526e7b",
                "name": "K601_S602delinsNT",
                "name_review": {
                  "added": true,
                  "updateTime": 1565547761895,
                  "updatedBy": "User"
                },
                "name_uuid": "097364ff-b225-4836-823d-db061518cdb7",
                "tumors_uuid": "e16dfeb7-031f-421a-80af-4e771876c467"
              },
              "operation": "add",
              "uuids": "39187b6d-6026-4c10-97b6-68eef0344894,c0c8b6d2-9835-447c-97ae-ca2af2bdc09f"
            }
          ],
          "timeStamp": 1565558052932
        },
        "-Lm1X5HwbIdZV-xg93F-": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "AGK-BRAF Fusion, Mutation Effect",
              "new": {
                "description": "The AGK-BRAF fusion protein results from an inversion of chromosome 7, which fuses the first two exons of AGK with exons 8-18 of BRAF. The AGK-BRAF fusion protein contains the BRAF kinase domain, but lacks the BRAF CR1 domain that is responsible for RAS-binding and auto-inhibition (PMID: 23890088, 24135138). This fusion is found in spitzoid melanoma, glioma, and post-Chernobyl patients with thyroid cancer (PMID: 23890088, PMID: 26314551). Expression of AGK-BRAF in mouse fibroblasts demonstrated that this fusion is activating and transforming as measured by increased growth and colony formation in soft agar compared to GFP control (PMID: 24135138). In vitro studies of AGK-BRAF in melanoma cell lines suggest that this fusions is sensitive to sorafenib but not vemurafenib as measured by cell viability upon drug treatment (PMID: 23890088). AGK-BRAF fusion was observed in 3 of 174 EGFR-mutant lung adenocarcinoma with primary resistance to EGFR tyrosine kinase inhibitors (TKIs).  Functional studies with the induction of AGK-BRAF fusion in H1975 (L858R + T790M), PC9 (ex19del) and HCC827 (ex19del) cell lines conferred resistance to growth inhibition by EGFR TKI (PMID: 30831205)."
              },
              "old": {
                "description": "The AGK-BRAF fusion protein results from an inversion of chromosome 7, which fuses the first two exons of AGK with exons 8-18 of BRAF. The AGK-BRAF fusion protein contains the BRAF kinase domain, but lacks the BRAF CR1 domain that is responsible for RAS-binding and auto-inhibition (PMID: 23890088, 24135138). This fusion is found in spitzoid melanoma, glioma, and post-Chernobyl patients with thyroid cancer (PMID: 23890088, PMID: 26314551). Expression of AGK-BRAF in mouse fibroblasts demonstrated that this fusion is activating and transforming as measured by increased growth and colony formation in soft agar compared to GFP control (PMID: 24135138). In vitro studies of AGK-BRAF in melanoma cell lines suggest that this fusions is sensitive to sorafenib but not vemurafenib as measured by cell viability upon drug treatment (PMID: 23890088)."
              },
              "operation": "update",
              "uuids": "ec17e9b0-111a-46a9-a462-3608dcfa3eac"
            }
          ],
          "timeStamp": 1565558071750
        },
        "-LmkUwktmTFde1g490lB": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "L597, All Solid Tumors",
              "new": "All Solid Tumors",
              "old": "All Tumors",
              "operation": "name change",
              "uuids": "d6bbd4ab-6b2b-4c26-96ff-eba923097d8f"
            }
          ],
          "timeStamp": 1566329261137
        },
        "-LmkUzlsRRePWqCdSZJX": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G469A, G469V, G469R, G464 (non-V600 mutations, class II ), All Solid Tumors",
              "new": "All Solid Tumors",
              "old": "All Tumors",
              "operation": "name change",
              "uuids": "502e00e1-ac70-4500-a7fb-cb79bd35f14c"
            }
          ],
          "timeStamp": 1566329273488
        },
        "-LmkV1g_RScfdnmX69qL": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "K601, All Solid Tumors",
              "new": "All Solid Tumors",
              "old": "All Tumors",
              "operation": "name change",
              "uuids": "11f3ed76-44e8-4baa-a63b-d47eafb3108c"
            }
          ],
          "timeStamp": 1566329285437
        },
        "-LmpUkmrBNHYG7JP2ygC": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Hairy Cell Leukemia, Tumor Type Summary",
              "new": "The RAF-inhibitor vemurafenib is NCCN-compendium listed for the treatment of patients with relapsed or refractory BRAF V600E-mutant hairy cell leukemia.",
              "old": "The Raf inhibitor vemurafenib is NCCN-compendium listed for the treatment of patients with relapsed or refractory BRAF V600E-mutant hairy cell leukemia.",
              "operation": "update",
              "uuids": "fe5e6dec-78e9-438d-9a22-762fcdc91ac2"
            }
          ],
          "timeStamp": 1566413104131
        },
        "-LmpWLMJ8cn28d5NjA7x": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Fusions, Melanoma, Tumor Type Summary",
              "new": "There is promising clinical data in patients with BRAF-fusion positive melanoma treated with the FDA-approved MEK1/2-inhibitor trametinib.",
              "old": "There is promising clinical data in patients with BRAF-fusion positive melanoma treated with the FDA-approved MEK1/2-targeted inhibitor trametinib.",
              "operation": "update",
              "uuids": "4d13aa6b-fb7c-45e4-8c43-fe1223fdd53f"
            }
          ],
          "timeStamp": 1566413520159
        },
        "-LmpX1M_eowg-jYLzaxc": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Oncogenic Mutations, Histiocytosis, Tumor Type Summary",
              "new": "While the MEK1/2-inhibitor cobimetinib has shown promising clinical activity in patients with BRAF V600E or N486_T491delinsK mutant histiocytic disease, its clinical utility in patients with [[gene]] [[mutation]] [[mutant]] histiocytic disease is unknown.",
              "old": "While the MEK1/2 inhibitor cobimetinib has shown promising clinical activity in patients with BRAF V600E or N486_T491delinsK mutant histiocytic disease, its clinical utility in patients with [[gene]] [[mutation]] [[mutant]] histiocytic disease is unknown.",
              "operation": "update",
              "uuids": "a035a4e8-143e-4ba8-b360-8ae275fa92bd"
            }
          ],
          "timeStamp": 1566413700401
        },
        "-LmpXVU3_e9FzWAB_IeD": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G469A, G469V, G469R, G464 (non-V600 mutations, class II ), All Solid Tumors, Tumor Type Summary",
              "new": "BRAF class II mutations including [[gene]] [[mutation]] are insensitive to the RAF-inhibitors vemurafenib and dabrafenib. Laboratory data suggest that cancer cells with oncogenic, non-V600 BRAF mutations may be sensitive to novel BRAF inhibitors such as PLX8394.",
              "old": "BRAF class II mutations including [[gene]] [[mutation]] are insensitive to the RAF inhibitors vemurafenib and dabrafenib. Laboratory data suggest that cancer cells with oncogenic, non-V600 BRAF mutations may be sensitive to novel BRAF inhibitors such as PLX8394. PMID: 28783719, 30559419",
              "operation": "update",
              "uuids": "522e6413-dfd4-4099-8da9-1f79b192e6e4"
            }
          ],
          "timeStamp": 1566413823760
        },
        "-Lmp_n8v5EAutaCgpNin": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "N486_T491delinsK, Histiocytosis, Tumor Type Summary",
              "new": "The MEK1/2-inhibitor cobimetinib has shown promising clinical activity in a patient with BRAF N486_T491delinsK mutant Langerhans cell histiocytosis.",
              "old": "The MEK1/2 inhibitor cobimetinib has shown promising clinical activity in a patient with BRAF N486_T491delinsK mutant Langerhans cell histiocytosis.",
              "operation": "update",
              "uuids": "3732d979-4df9-45bb-a91b-17dccba55fcb"
            }
          ],
          "timeStamp": 1566414686662
        },
        "-Lmpc6K9Zk0V9c1wWx7O": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Fusions, Other Tumor Types, Tumor Type Summary",
              "new": "While there is promising clinical data demonstrating the clinical utility of MEK1/2-inhibitors such as the FDA-approved trametinib in patients with BRAF-fusion positive melanoma and ovarian cancer, their clinical utility in patients with [[variant]] is unknown.",
              "old": "While there is promising clinical data demonstrating the clinical utility of MEK1/2-targeted inhibitors such as the FDA-approved trametinib in patients with BRAF-fusion positive melanoma and ovarian cancer, their clinical utility in patients with [[variant]] is unknown.",
              "operation": "update",
              "uuids": "67f8217f-063d-454f-c0a1-9ad1481afc59"
            }
          ],
          "timeStamp": 1566415293590
        },
        "-LmuYLpSlQ3DVrbZ58x_": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Fusions, Ovarian Cancer, Tumor Type Summary",
              "new": "There is promising clinical data from a case study in a patient with BRAF-fusion positive ovarian cancer treated with the FDA-approved MEK1/2-targeted inhibitor selumetinib in combination with paclitaxel, and in patients with BRAF-fusion positive melanoma treated with the FDA-approved MEK1/2-targeted inhibitor trametinib.",
              "old": "There is promising clinical data from a case study in a patient with BRAF-fusion positive ovarian cancer treated with the FDA-approved MEK1/2-inhibitor selumetinib in combination with paclitaxel, and in patients with BRAF-fusion positive melanoma treated with the FDA-approved MEK1/2-inhibitor trametinib.",
              "operation": "update",
              "uuids": "2a6d18bb-0a61-4615-a43d-1818b7dd46ea"
            }
          ],
          "timeStamp": 1566497938016
        },
        "-LmuYOllPWxhJxmrHEMP": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Fusions, Melanoma, Tumor Type Summary",
              "new": "There is promising clinical data in patients with BRAF-fusion positive melanoma treated with the FDA-approved MEK1/2-targeted inhibitor trametinib.",
              "old": "There is promising clinical data in patients with BRAF-fusion positive melanoma treated with the FDA-approved MEK1/2-inhibitor trametinib.",
              "operation": "update",
              "uuids": "4d13aa6b-fb7c-45e4-8c43-fe1223fdd53f"
            }
          ],
          "timeStamp": 1566497950068
        },
        "-LmuYRhjFsublGRcSDro": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Fusions, Other Tumor Types, Tumor Type Summary",
              "new": "While there is promising clinical data demonstrating the clinical utility of MEK1/2-targeted inhibitors such as the FDA-approved trametinib in patients with BRAF-fusion positive melanoma and ovarian cancer, their clinical utility in patients with [[variant]] is unknown.",
              "old": "While there is promising clinical data demonstrating the clinical utility of MEK1/2-inhibitors such as the FDA-approved trametinib in patients with BRAF-fusion positive melanoma and ovarian cancer, their clinical utility in patients with [[variant]] is unknown.",
              "operation": "update",
              "uuids": "67f8217f-063d-454f-c0a1-9ad1481afc59"
            }
          ],
          "timeStamp": 1566497962098
        },
        "-LmuYVyMg_qq_GdGAskX": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Melanoma, Tumor Type Summary",
              "new": "The RAF-targeted inhibitors encorafenib, dabrafenib and vemurafenib alone or in combination with the MEK-targeted inhibitors binimetinib, trametinib and cobimetinib, respectively, are FDA-approved for the treatment of patients with BRAF V600E/K mutant melanoma.",
              "old": "The RAF-inhibitors encorafenib, dabrafenib and vemurafenib alone or in combination with the MEK-inhibitors binimetinib, trametinib and cobimetinib, respectively, are FDA-approved for the treatment of patients with BRAF V600E/K mutant melanoma.",
              "operation": "update",
              "uuids": "814e645a-9256-493d-b2c7-6771d4328876"
            }
          ],
          "timeStamp": 1566497979545
        },
        "-LmuYZVvpvJ3vwXW4bee": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Non-Small Cell Lung Cancer, Tumor Type Summary",
              "new": "The RAF-targeted inhibitor dabrafenib in combination with the MEK1/2-targeted inhibitor trametinib is FDA-approved for the treatment of patients with BRAF V600E mutant non-small cell lung cancer.",
              "old": "The RAF-inhibitor dabrafenib in combination with the MEK1/2-inhibitor trametinib is FDA-approved for the treatment of patients with BRAF V600E mutant non-small cell lung cancer.",
              "operation": "update",
              "uuids": "dc939314-9786-4d02-942c-004c3444c33d"
            }
          ],
          "timeStamp": 1566497994046
        },
        "-LmuYbSAxiAVCxxR-mJi": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Anaplastic Thyroid Cancer, Tumor Type Summary",
              "new": "The RAF-targeted inhibitor dabrafenib in combination with the MEK1/2-targeted inhibitor trametinib is FDA-approved for the treatment of patients with BRAF V600E mutant anaplastic thyroid cancer.",
              "old": "The RAF-inhibitor dabrafenib in combination with the MEK1/2-inhibitor trametinib is FDA-approved for the treatment of patients with BRAF V600E mutant anaplastic thyroid cancer.",
              "operation": "update",
              "uuids": "a3898773-037a-4e4b-8a58-41d07b189222"
            }
          ],
          "timeStamp": 1566498006094
        },
        "-LmuYg3phi7MZe82kFgV": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Hairy Cell Leukemia, Tumor Type Summary",
              "new": "The RAF-targeted inhibitor vemurafenib is NCCN-compendium listed for the treatment of patients with relapsed or refractory BRAF V600E-mutant hairy cell leukemia.",
              "old": "The RAF-inhibitor vemurafenib is NCCN-compendium listed for the treatment of patients with relapsed or refractory BRAF V600E-mutant hairy cell leukemia.",
              "operation": "update",
              "uuids": "fe5e6dec-78e9-438d-9a22-762fcdc91ac2"
            }
          ],
          "timeStamp": 1566498025016
        },
        "-LmuYjhdzKQM6kt7hIHq": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Other Tumor Types, Tumor Type Summary",
              "new": "While the RAF-targeted inhibitor dabrafenib in combination with the MEK1/2-targeted inhibitor trametinib is FDA-approved for the treatment of patients with BRAF V600E mutant melanoma, non-small cell lung cancer and anaplastic thyroid cancer, the clinical utility of dabrafenib in combination with trametinib in patients with [[variant]] has yet to be defined.",
              "old": "While the RAF-inhibitor dabrafenib in combination with the MEK1/2-inhibitor trametinib is FDA-approved for the treatment of patients with BRAF V600E mutant melanoma, non-small cell lung cancer and anaplastic thyroid cancer, the clinical utility of dabrafenib in combination with trametinib in patients with [[variant]] has yet to be defined.",
              "operation": "update",
              "uuids": "215bd1c9-120d-4fc1-b906-5f317772b820"
            }
          ],
          "timeStamp": 1566498039916
        },
        "-LmuYv3E8a-UqSpw-XNP": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Oncogenic Mutations, Other Tumor Types, Tumor Type Summary",
              "new": "While the RAF-inhibitor dabrafenib in combination with the MEK-inhibitor trametinib is FDA-approved for the treatment of patients with BRAF V600E mutant melanoma, non-small cell lung cancer, and anaplastic thyroid cancer, and the RAF-inhibitor vemurafenib is FDA-approved as monotherapy in BRAF V600-mutant Erdheim-Chester disease, their clinical utility in patients with [[variant]] is unknown.",
              "old": "While the RAF-inhibitor dabrafenib in combination with the MEK-inhibitor trametinib is FDA-approved for the treatment of patients with BRAF V600E mutant melanoma and non-small cell lung cancer, and the RAF-inhibitor vemurafenib is FDA-approved as monotherapy in BRAF V600-mutant Erdheim-Chester disease, their clinical utility in patients with [[variant]] is unknown.",
              "operation": "update",
              "uuids": "e849d451-64e6-4dc1-ac77-0071b21a22f8"
            }
          ],
          "timeStamp": 1566498086418
        },
        "-LmuZ0K9Bl7Lh7hyX_1y": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Oncogenic Mutations, Histiocytosis, Tumor Type Summary",
              "new": "While the MEK1/2-targeted inhibitor cobimetinib has shown promising clinical activity in patients with BRAF V600E or N486_T491delinsK mutant histiocytic disease, its clinical utility in patients with [[gene]] [[mutation]] [[mutant]] histiocytic disease is unknown.",
              "old": "While the MEK1/2-inhibitor cobimetinib has shown promising clinical activity in patients with BRAF V600E or N486_T491delinsK mutant histiocytic disease, its clinical utility in patients with [[gene]] [[mutation]] [[mutant]] histiocytic disease is unknown.",
              "operation": "update",
              "uuids": "a035a4e8-143e-4ba8-b360-8ae275fa92bd"
            }
          ],
          "timeStamp": 1566498112077
        },
        "-LmuZ3tROIIYBdvZuAtu": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600, Erdheim-Chester Disease, Tumor Type Summary",
              "new": "The RAF-targeted inhibitor vemurafenib is FDA-approved for the treatment of patients with BRAF V600-mutant Erdheim-Chester disease.",
              "old": "The RAF-inhibitor vemurafenib is FDA-approved for the treatment of patients with BRAF V600-mutant Erdheim-Chester disease.",
              "operation": "update",
              "uuids": "39484c36-282c-4392-909d-cd9ab20724df"
            }
          ],
          "timeStamp": 1566498126687
        },
        "-LmuZB-tI1MxAS1buoKx": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600, Melanoma, Tumor Type Summary",
              "new": "The RAF-targeted inhibitors encorafenib, dabrafenib and vemurafenib, alone or in combination with the MEK1/2-targeted inhibitors binimetinib, trametinib and cobimetinib respectively, are FDA-approved for the treatment of patients with BRAF V600E/K mutant melanoma.",
              "old": "The RAF-inhibitors encorafenib, dabrafenib and vemurafenib, alone or in combination with the MEK1/2-inhibitors binimetinib, trametinib and cobimetinib respectively, are FDA-approved for the treatment of patients with BRAF V600E/K mutant melanoma.",
              "operation": "update",
              "uuids": "49c8da54-77d7-4480-af56-bd58072c54c0"
            }
          ],
          "timeStamp": 1566498155836
        },
        "-LmuZEb_217gkrgD9Mk5": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600, Other Tumor Types, Tumor Type Summary",
              "new": "While the RAF-targeted inhibitor dabrafenib in combination with the MEK1/2-targeted inhibitor trametinib is FDA-approved for the treatment of patients with BRAF V600E mutant melanoma, non-small cell lung cancer and anaplastic thyroid cancer, the clinical utility of dabrafenib in combination with trametinib in patients with [[variant]] has yet to be defined.",
              "old": "While the RAF-inhibitor dabrafenib in combination with the MEK1/2-inhibitor trametinib is FDA-approved for the treatment of patients with BRAF V600E mutant melanoma, non-small cell lung cancer and anaplastic thyroid cancer, the clinical utility of dabrafenib in combination with trametinib in patients with [[variant]] has yet to be defined.",
              "operation": "update",
              "uuids": "822ab686-6d4b-4605-8133-9387af0a4fbc"
            }
          ],
          "timeStamp": 1566498170600
        },
        "-LmuZHYTpP5BdBc_Rtcu": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600K, Melanoma, Tumor Type Summary",
              "new": "The RAF-targeted inhibitors encorafenib, dabrafenib and vemurafenib alone or in combination with the MEK-targeted inhibitors binimetinib, trametinib and cobimetinib, respectively, are FDA-approved for the treatment of patients with BRAF V600E/K mutant melanoma.",
              "old": "The RAF-inhibitors encorafenib, dabrafenib and vemurafenib alone or in combination with the MEK-inhibitors binimetinib, trametinib and cobimetinib, respectively, are FDA-approved for the treatment of patients with BRAF V600E/K mutant melanoma.",
              "operation": "update",
              "uuids": "603dab24-2e01-4179-a0ac-cff1fe8c81ca"
            }
          ],
          "timeStamp": 1566498182625
        },
        "-LmuZMebUTkLNsINW5_o": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600K, Other Tumor Types, Tumor Type Summary",
              "new": "While the MEK1/2-targeted inhibitor trametinib, alone or in combination with the RAF-targeted inhibitor dabrafenib, and the MEK-targeted inhibitor cobimetinib in combination with the RAF-targeted inhibitor vemurafenib are FDA-approved for the treatment of patients with BRAF V600K mutant melanoma, their clinical utility in patients with [[variant]] has yet to be defined.",
              "old": "While the MEK1/2-inhibitor trametinib, alone or in combination with the RAF-inhibitor dabrafenib, and the MEK-inhibitor cobimetinib in combination with the RAF-inhibitor vemurafenib are FDA-approved for the treatment of patients with BRAF V600K mutant melanoma, their clinical utility in patients with [[variant]] has yet to be defined.",
              "operation": "update",
              "uuids": "5719cd2c-bf51-496f-9d5f-287583907e50"
            }
          ],
          "timeStamp": 1566498203562
        },
        "-LmuZPa79w4aIHA4yTpr": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "L597, Melanoma, Tumor Type Summary",
              "new": "There is promising clinical data in patients with BRAF L597-mutant melanoma treated with the FDA-approved MEK-targeted inhibitor trametinib.",
              "old": "There is promising clinical data in patients with BRAF L597-mutant melanoma treated with the FDA-approved MEK-inhibitor trametinib.",
              "operation": "update",
              "uuids": "30a2e81e-265e-4103-ab0b-30bc2e3da638"
            }
          ],
          "timeStamp": 1566498215563
        },
        "-LmuZWG04qo9Xsqltw5u": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "K601, Melanoma, Tumor Type Summary",
              "new": "There is promising clinical data in patients with BRAF K601E mutant melanoma treated with the FDA-approved MEK-targeted inhibitor trametinib.",
              "old": "There is promising clinical data in patients with BRAF K601E mutant melanoma treated with the FDA-approved MEK-inhibitor trametinib.",
              "operation": "update",
              "uuids": "f54dc0ea-805f-407b-acc0-878409be447b"
            }
          ],
          "timeStamp": 1566498242884
        },
        "-LmuZch7EYVP8RxKu28D": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "N486_T491delinsK, Histiocytosis, Tumor Type Summary",
              "new": "The MEK1/2-targeted inhibitor cobimetinib has shown promising clinical activity in a patient with BRAF N486_T491delinsK mutant Langerhans cell histiocytosis.",
              "old": "The MEK1/2-inhibitor cobimetinib has shown promising clinical activity in a patient with BRAF N486_T491delinsK mutant Langerhans cell histiocytosis.",
              "operation": "update",
              "uuids": "3732d979-4df9-45bb-a91b-17dccba55fcb"
            }
          ],
          "timeStamp": 1566498273355
        },
        "-LmupIeKHaYVGR3wcR1p": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600, Colorectal Cancer, Tumor Type Summary",
              "new": "The FDA-approved RAF-inhibitors dabrafenib and vemurafenib have minimal activity as single agents in BRAF V600-mutant colorectal cancer (CRC). The triplet therapy combination of encorafenib + binimetinib + cetuximab, a RAF-inhibitor, a MEK-inhibitor and an anti-EGFR antibody respectively, is NCCN-compendium listed and has received FDA-breakthrough therapy designation for the treatment of patients with BRAF V600E mutant colorectal cancer.",
              "old": "The FDA-approved RAF-inhibitors dabrafenib and vemurafenib have minimal activity as single agents in BRAF V600-mutant colorectal cancer (CRC). The combination of encorafenib + cetuximab + binimetinib, a RAF-inhibitor, an anti-EGFR antibody and a MEK-inhibitor respectively, has received FDA-breakthrough therapy designation based on promising clinical data in patients with BRAF V600E-mutant CRC.",
              "operation": "update",
              "uuids": "8d714d43-7ccc-416f-99b8-4f49cc046590"
            }
          ],
          "timeStamp": 1566502632107
        },
        "-LmupPAViKVvKlX0fCU0": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "L597, Other Tumor Types, Tumor Type Summary",
              "new": "While there is promising clinical data supporting the use of the FDA-approved MEK-inhibitor trametinib in patients with BRAF L597-mutant melanoma, its clinical utility in patients with [[variant]] is unknown. BRAF class II mutations including [[gene]] [[mutation]] are insensitive to the RAF inhibitors vemurafenib and dabrafenib. Laboratory data suggest that cancer cells with oncogenic, BRAF class II mutations may be sensitive to novel BRAF inhibitors such as PLX8394.",
              "old": "While there is promising clinical data supporting the use of the FDA-approved MEK-inhibitor trametinib in patients with BRAF L597-mutant melanoma, its clinical utility in patients with [[variant]] is unknown. BRAF non-V600 mutations including [[gene]] [[mutation]] are insensitive to the RAF inhibitors vemurafenib and dabrafenib. Laboratory data suggest that cancer cells with oncogenic, non-V600 BRAF mutations may be sensitive to novel BRAF inhibitors such as PLX8394.",
              "operation": "update",
              "uuids": "9b3811aa-85b0-40d0-90fc-f5c724b37f06"
            }
          ],
          "timeStamp": 1566502658806
        },
        "-LmupX-TsZRGClO2Av_A": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "K601, Other Tumor Types, Tumor Type Summary",
              "new": "While there is promising clinical data supporting the use of the MEK-targeted inhibitor trametinib in patients with BRAF K601E mutant melanoma, its clinical utility in patients with [[variant]] is unknown. BRAF class II mutations including [[gene]] [[mutation]] are insensitive to the RAF inhibitors vemurafenib and dabrafenib. Laboratory data suggest that cancer cells with oncogenic, BRAF mutations may be sensitive to novel BRAF inhibitors such as PLX8394.",
              "old": "While there is promising clinical data supporting the use of the MEK-inhibitor trametinib in patients with BRAF K601E mutant melanoma, its clinical utility in patients with [[variant]] is unknown. BRAF non-V600 mutations including [[gene]] [[mutation]] are insensitive to the RAF inhibitors vemurafenib and dabrafenib. Laboratory data suggest that cancer cells with oncogenic, non-V600 BRAF mutations may be sensitive to novel BRAF inhibitors such as PLX8394.",
              "operation": "update",
              "uuids": "e6703560-987d-4350-a9aa-931bdaea463b"
            }
          ],
          "timeStamp": 1566502690868
        },
        "-LmupoTep1pmQCa3cStq": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G469A, G469V, G469R, G464 (non-V600 mutations, class II ), All Solid Tumors, Tumor Type Summary",
              "new": "BRAF class II mutations including [[gene]] [[mutation]] are insensitive to the RAF-targeted inhibitors vemurafenib and dabrafenib. Laboratory data suggest that cancer cells with oncogenic, non-V600 BRAF mutations may be sensitive to novel BRAF inhibitors such as PLX8394.",
              "old": "BRAF class II mutations including [[gene]] [[mutation]] are insensitive to the RAF-inhibitors vemurafenib and dabrafenib. Laboratory data suggest that cancer cells with oncogenic, non-V600 BRAF mutations may be sensitive to novel BRAF inhibitors such as PLX8394.",
              "operation": "update",
              "uuids": "522e6413-dfd4-4099-8da9-1f79b192e6e4"
            }
          ],
          "timeStamp": 1566502766528
        },
        "-Lmuq2VH58-2e_XfIPhq": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Colorectal Cancer, STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY, 001e534f-3e63-432f-90a6-d1af1759e4e2 + 5fce3074-e420-4c36-9603-2423daf20118 + feb9f4a3-e374-4c75-8a3b-0f1fbcdbf677, 939cd40b-b515-499d-b099-fd29027c0d17 + d7b1d12a-e942-4801-bb64-916c9bdfaaf3 + fb2bb01c-c0ec-4641-abf7-87f486075022",
              "new": {
                "description": "Encorafenib is a small molecule inhibitor of RAF kinase, binimetinib is a small molecule inhibitor of MEK1/2 kinases, and cetuximab is an antibody that targets EGFR. In the Phase III BEACON study of encorafenib + binimetinib + cetuximab versus doublet treatment versus chemotherapy in 665 patients with BRAF V600E-mutant colorectal cancer, the overall response rate (complete or partial response) was 26% (95% CI= 18%- 35%) in the triplet arm versus 2% (95% CI= <1%-7%) in the control arm, with median overall survival of 9.0 months in the triplet arm (95% CI= 8.0-11.4) and 5.4 months in the control arm (95% CI= 4.8-6.6) (Abstract: Kopetz et al. Abstract# LBA-006, ESMO 2019. https://academic.oup.com/annonc/article/30/Supplement_4/mdz183.004/5526665). The combination of dabrafenib, trametinib and panitumumab has also shown efficacy in this population, with a response rate in one study of 26%, with an additional 57% of patients achieving stable disease (PMID: 29431699). Triplet therapy is listed as a 2A therapy in the NCCN guidlines."
              },
              "old": {
                "description": "Encorafenib is a small molecule inhibitor of RAF kinase, binimetinib is a small molecule inhibitor of MEK1/2 kinases, and cetuximab is an antibody that targets EGFR. In the Phase III BEACON study of encorafenib + binimetinib + cetuximab versus chemotherapy in 29 patients with BRAF V600E-mutant colorectal cancer, the overall response rate (complete or partial response) was 48% (14 of 29 patients), with three of fourteen patients having complete response (Abstract: Cutsem et al. Abstract# O-027, ESMO 2018. https://academic.oup.com/annonc/article/29/suppl_5/mdy149.026/5039436). Nine patients had durable stable disease (Abstract: Cutsem et al. Abstract# 627, ASCO 2018. http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.4_suppl.627). Estimated median progression-free survival was 8 months in the triplet combination arm (Abstract: Cutsem et al. Abstract# O-027, ESMO 2018. https://academic.oup.com/annonc/article/29/suppl_5/mdy149.026/5039436). The combination of dabrafenib, trametinib and panitumumab has also shown efficacy in this population, with a response rate in one study of 26%, with an additional 57% of patients achieving stable disease (PMID: 29431699). Triplet therapy is listed as a 2A therapy in the NCCN guidlines."
              },
              "operation": "update",
              "uuids": "d9b444f3-76b2-4f91-a919-8b8b4d853846"
            }
          ],
          "timeStamp": 1566502828072
        },
        "-LnEShwPpgCi4qeStX3l": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Fusions, Ovarian Cancer, Tumor Type Summary",
              "new": "There is promising clinical data from a case study in a patient with BRAF fusion-positive ovarian cancer treated with the FDA-approved MEK1/2-targeted inhibitor selumetinib in combination with paclitaxel, and in patients with BRAF fusion-positive melanoma treated with the FDA-approved MEK1/2-targeted inhibitor trametinib.",
              "old": "There is promising clinical data from a case study in a patient with BRAF-fusion positive ovarian cancer treated with the FDA-approved MEK1/2-targeted inhibitor selumetinib in combination with paclitaxel, and in patients with BRAF-fusion positive melanoma treated with the FDA-approved MEK1/2-targeted inhibitor trametinib.",
              "operation": "update",
              "uuids": "2a6d18bb-0a61-4615-a43d-1818b7dd46ea"
            }
          ],
          "timeStamp": 1566848769666
        },
        "-LnESkroeCPqOaZilucV": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Fusions, Other Tumor Types, Tumor Type Summary",
              "new": "While there is promising clinical data demonstrating the clinical utility of MEK1/2-targeted inhibitors such as the FDA-approved trametinib in patients with BRAF fusion-positive melanoma and ovarian cancer, their clinical utility in patients with [[variant]] is unknown.",
              "old": "While there is promising clinical data demonstrating the clinical utility of MEK1/2-targeted inhibitors such as the FDA-approved trametinib in patients with BRAF-fusion positive melanoma and ovarian cancer, their clinical utility in patients with [[variant]] is unknown.",
              "operation": "update",
              "uuids": "67f8217f-063d-454f-c0a1-9ad1481afc59"
            }
          ],
          "timeStamp": 1566848781661
        },
        "-LnESnmZ9kdfVxj8YT0f": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Fusions, Melanoma, Tumor Type Summary",
              "new": "There is promising clinical data in patients with BRAF fusion-positive melanoma treated with the FDA-approved MEK1/2-targeted inhibitor trametinib.",
              "old": "There is promising clinical data in patients with BRAF-fusion positive melanoma treated with the FDA-approved MEK1/2-targeted inhibitor trametinib.",
              "operation": "update",
              "uuids": "4d13aa6b-fb7c-45e4-8c43-fe1223fdd53f"
            }
          ],
          "timeStamp": 1566848793613
        },
        "-Lp6eVZE2yjp9z_evLU2": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Oncogenic Mutations, Histiocytosis, INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY, eb357145-3b18-4aca-b75a-5e18dd2bf4f9",
              "new": {
                "description": "Cobimetinib is a small molecule inhibitor of MEK1/2 that is FDA-approved in combination with a BRAF inhibitor in BRAF V600-mutant melanoma. In a Phase II trial of cobimetinib in eighteen patients with histiocytoses, the overall response rate was 89%, with thirteen out of eighteen patients (72%) having a complete response and fifteen out of eighteen patients harboring a MAPK pathway mutation (PMID: 30867592) Six of six patients with BRAF mutations (five V600E, one non-V600E) had a partial or complete response to treatment with cobimetinib (PMID: 30867592). Small case studies and retroactive studies have also demonstrated the clinical efficacy of MEK inhibition in patients with histiocytic neoplasms (PMID: 29236635, 30718231)."
              },
              "old": {
                "description": "Cobimetinib is a small molecule inhibitor of MEK1/2 that is FDA-approved in combination with a BRAF inhibitor in BRAF V600-mutant melanoma. In a Phase II trial of cobimetinib in eighteen patients with histiocytoses, the overall response rate was 89%, with thirteen out of eighteen patients (72%) having a complete response and fifteen out of eighteen patients harboring a MAPK pathway mutation (PMID: 30867592) Six of six patients with BRAF mutations (five V600E, one non-V600E) had a partial or complete response to treatment with cobimetinib (PMID: 30867592). Small case studies have also demonstrated the clinical efficacy of MEK inhibition in patients with histiocytic neoplasms (PMID: 29236635)."
              },
              "operation": "update",
              "uuids": "483bc890-60e3-4c65-96e5-94f5412df6dc"
            }
          ],
          "timeStamp": 1568865388360
        },
        "-Lp6efwlP4RBH86EI2sy": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, V600K, Melanoma, STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY, 939cd40b-b515-499d-b099-fd29027c0d17 + fb2bb01c-c0ec-4641-abf7-87f486075022",
              "new": {
                "description": "Dabrafenib, an orally bioavailable RAF inhibitor, and trametinib, an orally bioavailable MEK1/2 inhibitor, are FDA-approved alone or in combination for the treatment of patients with metastatic melanoma harboring a V600E or V600K BRAF mutation. The FDA approved the combination of dabrafenib and trametinib based on results from an open-label Phase III study of combination therapy versus dabrafenib monotherapy in 247 patients with metastatic melanoma who were naive to treatment with BRAF inhibitors. Combined dabrafenib and trametinib, administered in full monotherapy doses, improved the response rate in patients with BRAF V600-mutant metastatic melanoma versus dabrafenib monotherapy (67% vs.51%; p<0.002). However, median progression-free survival improved by only 2 weeks (9.3 months vs 8.8 months; HR = 0.75) compared with dabrafenib monotherapy (PMID: 23020132). Combination therapy is associated with less cutaneous toxicity than monotherapy, but systemic toxicity may be increased (PMID: 25287827, 25399551). Follow-up trials have demonstrated that all clinical measures inclusive of overall and median progression-free survival as well as objective response rates, median duration of response and number of patients with complete response favored patients treated with combination dabrafenib and trametinib, administered in full monotherapy doses, compared to either dabrafenib or vemurafenib monotherapy, including patients who previously progressed on BRAF inhibitor monotherapy (PMID: 25287827, 25399551, 25265492). Additionally, patients with melanoma treated with dabrafenib and trametinib in both the neoadjuvant and adjuvant settings have improved survival over patients given standard of care (PMID: 29361468, 28991513, 28891408). Promising clinical data has also suggested that addition of an immunotherapy agent to combination RAF and MEK inhibitor treatment may improve rate of overall response and durstion of response in melanoma patients (PMID: 31171876, 31171879, 31171878)."
              },
              "old": {
                "description": "Dabrafenib, an orally bioavailable RAF inhibitor, and trametinib, an orally bioavailable MEK1/2 inhibitor, are FDA-approved alone or in combination for the treatment of patients with metastatic melanoma harboring a V600E or V600K BRAF mutation. The FDA approved the combination of dabrafenib and trametinib based on results from an open-label Phase III study of combination therapy versus dabrafenib monotherapy in 247 patients with metastatic melanoma who were naive to treatment with BRAF inhibitors. Combined dabrafenib and trametinib, administered in full monotherapy doses, improved the response rate in patients with BRAF V600-mutant metastatic melanoma versus dabrafenib monotherapy (67% vs.51%; p<0.002). However, median progression-free survival improved by only 2 weeks (9.3 months vs 8.8 months; HR = 0.75) compared with dabrafenib monotherapy (PMID: 23020132). Combination therapy is associated with less cutaneous toxicity than monotherapy, but systemic toxicity may be increased (PMID: 25287827, 25399551). Follow-up trials have demonstrated that all clinical measures inclusive of overall and median progression-free survival as well as objective response rates, median duration of response and number of patients with complete response favored patients treated with combination dabrafenib and trametinib, administered in full monotherapy doses, compared to either dabrafenib or vemurafenib monotherapy, including patients who previously progressed on BRAF inhibitor monotherapy (PMID: 25287827, 25399551, 25265492). Additionally, patients with melanoma treated with dabrafenib and trametinib in both the neoadjuvant and adjuvant settings have improved survival over patients given standard of care (PMID: 29361468, 28991513, 28891408)."
              },
              "operation": "update",
              "uuids": "bc28ec2e-60ae-4a5d-9401-524e357b5bed"
            }
          ],
          "timeStamp": 1568865434986
        },
        "-LruPMkndeuzECIGLVbN": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600, Colorectal Cancer, Investigational implications for sensitivity to therapy, d7b1d12a-e942-4801-bb64-916c9bdfaaf3 + 939cd40b-b515-499d-b099-fd29027c0d17 + fb2bb01c-c0ec-4641-abf7-87f486075022, d7b1d12a-e942-4801-bb64-916c9bdfaaf3 + 4e91da20-6cf0-4e07-995f-7f7db4c7c077",
              "old": {
                "description": "Patients with BRAF-V600E mutant colorectal cancer (CRC) do not respond to either RAF inhibitors (vemurafenib or dabrafenib) or EGFR monoclonal antibodies cetuximab or panitumumab as monotherapy (PMID: 19001320, 19884556, 20619739) (Abstract: Bendell, J et al. Abstract#3515, J Clin Oncol, 32, 2014. http://ascopubs.org/doi/abs/10.1200/jco.2014.32.15_suppl.3515) (Abstract: Kopetz, S. et al. Abstract#3534. J. Clin. Oncol. 28. 2010. http://ascopubs.org/doi/abs/10.1200/jco.2010.28.15_suppl.3534). This is thought to be due to upregulation of EGFR signaling in the setting of BRAF inhibition in CRC (PMID: 22448344). Pilot and phase II clinical trial data suggest a response rate of ~10-20% for the RAF and EGFR inhibitor combinations of vemurafenib + panitumumab (PMID: 25589621) or dabrafenib + panitumumab (http://oncologypro.esmo.org/Meeting-Resources/ESMO-2016/Efficacy-and-circulating-tumor-DNA-ctDNA-analysis-of-the-BRAF-inhibitor-dabrafenib-D-MEK-inhibitor-trametinib-T-and-anti-EGFR-antibody-panitumumab-P-in-patients-pts-with-BRAF-V600E-mutated-BRAFm-metastatic-colorectal-cancer-mCRC). More recently, a 3-arm clinical trial in 142 patients with BRAFV600E mutant metastatic colorectal cancer were treated with either dabrafenib + panitumumab, dabrafenib+trametinib + panitumumab or trametinib+panitumumab and confirmed response rates were 10%, 21%, and 0% with median progression-free survival at 3.5, 4.2 and 2.6 months respectively. Measurement of pERK in matched pre-and on-treatment biopsy samples, found that dabrafenib+trametinib + panitumumab was associated with the highest level of MAPK pathway inhibition (PMID: 29431699).",
                "description_review": {
                  "updateTime": 1531509896191,
                  "updatedBy": "User"
                },
                "description_uuid": "e6252fe2-00f7-4b39-8525-fabf9f0053e8",
                "indication": "",
                "indication_uuid": "1507d68a-9e63-46d3-8752-c3fb0c5f0523",
                "level": "3A",
                "level_review": {
                  "lastReviewedPropagation": "3B",
                  "updateTime": 1542314967060,
                  "updatedBy": "User"
                },
                "level_uuid": "9fb3e0da-ce30-4750-ac3a-9f565f9c7c02",
                "name": "d7b1d12a-e942-4801-bb64-916c9bdfaaf3 + 939cd40b-b515-499d-b099-fd29027c0d17 + fb2bb01c-c0ec-4641-abf7-87f486075022, d7b1d12a-e942-4801-bb64-916c9bdfaaf3 + 4e91da20-6cf0-4e07-995f-7f7db4c7c077",
                "name_review": {
                  "removed": true,
                  "updateTime": 1571839899274,
                  "updatedBy": "User"
                },
                "name_uuid": "5f98f89b-50b1-43f0-93e5-005091553c49",
                "propagation": "no",
                "propagationLiquid": "no",
                "propagationLiquid_uuid": "d230f6b0-db25-11e9-b783-60f81dc75ed6",
                "propagation_review": {
                  "updateTime": 1551377662801,
                  "updatedBy": "User"
                },
                "propagation_uuid": "48d50fbf-fb77-4bac-8e5b-a427d993a81f",
                "short": ""
              },
              "operation": "delete"
            }
          ],
          "timeStamp": 1571864278879
        },
        "-LsEuuiWv1J098TvZiBV": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "L597, All Solid Tumors, INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY, 44faeeae-ad6d-4370-8c99-97955f9e0feb",
              "new": {
                "description": "PLX8394 is an orally available, second-generation, small-molecule BRAF inhibitor that inhibits mutated, oncogenic BRAF without causing paradoxical MAPK pathway activation as is seen with first-generation BRAF inhibitors (PMID: 28659148). In a phase I clinical trial for patients with refractory or relapsed solid tumors with or without BRAF mutation, there were two (28%) partial responses of seven evaluable BRAF-mutant patients treated with PLX8394 and cobicistat, a CYP3A4 inhibitor (Abstract: Janku et al. Abstract# B176, AACR-NCI-EORTC 2017. http://mct.aacrjournals.org/content/17/1_Supplement/B176). Both responses were in patients with BRAF V600 mutations. Preclinical studies show that PLX8394 specifically inhibits BRAF-containing dimers and inhibits proliferation and pathway actiavtion in BRAF-mutated colorectal cancer cell lines (PMID: 26466569, 28659148, 30559419, 28783719)."
              },
              "old": {
                "description": "PMID: 26466569 PMID: 28659148 PMID: 28783719, 30559419,  (Abstract: Janku et al. Abstract# B176, AACR-NCI-EORTC 2017. http://mct.aacrjournals.org/content/17/1_Supplement/B176)."
              },
              "operation": "update",
              "uuids": "1fd2d2b7-b69a-4e58-b205-81ef99c8c2e9"
            }
          ],
          "timeStamp": 1572225133315
        },
        "-LsEuxy5Rt8krIt0a9Ro": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "K601, All Solid Tumors, INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY, 44faeeae-ad6d-4370-8c99-97955f9e0feb",
              "new": {
                "description": "PLX8394 is an orally available, second-generation, small-molecule BRAF inhibitor that inhibits mutated, oncogenic BRAF without causing paradoxical MAPK pathway activation as is seen with first-generation BRAF inhibitors (PMID: 28659148). In a phase I clinical trial for patients with refractory or relapsed solid tumors with or without BRAF mutation, there were two (28%) partial responses of seven evaluable BRAF-mutant patients treated with PLX8394 and cobicistat, a CYP3A4 inhibitor (Abstract: Janku et al. Abstract# B176, AACR-NCI-EORTC 2017. http://mct.aacrjournals.org/content/17/1_Supplement/B176). Both responses were in patients with BRAF V600 mutations. Preclinical studies show that PLX8394 specifically inhibits BRAF-containing dimers and inhibits proliferation and pathway actiavtion in BRAF-mutated colorectal cancer cell lines (PMID: 26466569, 28659148, 30559419, 28783719)."
              },
              "old": {
                "description": "PMID: 26466569 PMID: 28659148 PMID: 28783719, 30559419 (Abstract: Janku et al. Abstract# B176, AACR-NCI-EORTC 2017. http://mct.aacrjournals.org/content/17/1_Supplement/B176)."
              },
              "operation": "update",
              "uuids": "690ed068-5612-438a-ac07-948a18228375"
            }
          ],
          "timeStamp": 1572225146601
        },
        "-LsEv4X4g9wB01EFYwHR": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "KIAA1549-BRAF Fusion, Mutation Effect",
              "new": {
                "description": "The KIAA1549-BRAF fusion protein results from an internal tandem duplication event on chromosome 7 that fuses exons 1-16 of KIAA1549 and exons 9-18 of BRAF. This fusion contains the BRAF kinase domain, but excludes the BRAF CR1 domain responsible for RAS binding and auto-inhibition (PMID: 18974108, 24345920). This fusion has been found in pilocytic astrocytoma (PMID: 18974108, 24345920). Expression of this fusion in NIH-3T3 cells demonstrated that it is activating as measured by constitutive kinase activity and increased anchorage independent growth in soft agar compared to wildtype BRAF (PMID: 18974108). KIAA1549-BRAF fusion protein functions as a dimer and is therefore not sensitive to RAF inhibitors such as vemurafenib in vitro (PMID: 23533272). Preclinical evidence suggests that these oncoproteins may be targeted by second-generation RAF inhibitors, which are reported to inhibit RAF dimers rather than induce their transactivation of RAF (as is the case with older inhibitors such as vemurafenib) (PMID: 23533272). In vitro studies have suggested that pediatric astrocytoma cell lines harboring the KIAA1549-BRAF fusion are resistant to treatment with first generation RAF inhibitors (PMID: 23533272, 26072686). In a Phase II clinical trial of selumetinib in 25 patients with WHO grade I pilocytic astrocytoma harboring either the KIAA1549-BRAF fusion or the BRAF V600E mutation, nine patients (36% [95% CI:18-57%]) had a sustained partial response (PMID: 31151904)."
              },
              "old": {
                "description": "The KIAA1549-BRAF fusion protein results from an internal tandem duplication event on chromosome 7 that fuses exons 1-16 of KIAA1549 and exons 9-18 of BRAF. This fusion contains the BRAF kinase domain, but excludes the BRAF CR1 domain responsible for RAS binding and auto-inhibition (PMID: 18974108, 24345920). This fusion has been found in pilocytic astrocytoma (PMID: 18974108, 24345920). Expression of this fusion in NIH-3T3 cells demonstrated that it is activating as measured by constitutive kinase activity and increased anchorage independent growth in soft agar compared to wildtype BRAF (PMID: 18974108). KIAA1549-BRAF fusion protein functions as a dimer and is therefore not sensitive to RAF inhibitors such as vemurafenib in vitro (PMID: 23533272). Preclinical evidence suggests that these oncoproteins may be targeted by second-generation RAF inhibitors, which are reported to inhibit RAF dimers rather than induce their transactivation of RAF (as is the case with older inhibitors such as vemurafenib) (PMID: 23533272). In vitro studies have suggested that pediatric astrocytoma cell lines harboring the KIAA1549-BRAF fusion are resistant to treatment with first generation RAF inhibitors (PMID: 23533272, 26072686)."
              },
              "operation": "update",
              "uuids": "f98b6b73-bf97-4869-aec2-1234627962f3"
            }
          ],
          "timeStamp": 1572225177576
        },
        "-LsEv9VBK-AGDXQofInq": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G469A, G469V, G469R, G464 (non-V600 mutations, class II ), All Solid Tumors, INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY, 44faeeae-ad6d-4370-8c99-97955f9e0feb",
              "new": {
                "description": "PLX8394 is an orally available, second-generation, small-molecule BRAF inhibitor that inhibits mutated, oncogenic BRAF without causing paradoxical MAPK pathway activation as is seen with first-generation BRAF inhibitors (PMID: 28659148). In a phase I clinical trial for patients with refractory or relapsed solid tumors with or without BRAF mutation, there were two (28%) partial responses of seven evaluable BRAF-mutant patients treated with PLX8394 and cobicistat, a CYP3A4 inhibitor (Abstract: Janku et al. Abstract# B176, AACR-NCI-EORTC 2017. http://mct.aacrjournals.org/content/17/1_Supplement/B176). Both responses were in patients with BRAF V600 mutations. Preclinical studies show that PLX8394 specifically inhibits BRAF-containing dimers and inhibits proliferation and pathway actiavtion in BRAF-mutated colorectal cancer cell lines (PMID: 26466569, 28659148, 30559419, 28783719)."
              },
              "old": {
                "description": "PMID: 26466569 PMID: 28659148 PMID: 28783719, 30559419 (Abstract: Janku et al. Abstract# B176, AACR-NCI-EORTC 2017. http://mct.aacrjournals.org/content/17/1_Supplement/B176)."
              },
              "operation": "update",
              "uuids": "96034660-351c-4fce-9f82-cdfe98f7a0d2"
            }
          ],
          "timeStamp": 1572225197935
        },
        "-LszE9Eg5gpHuRQBxS5U": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Colorectal Cancer, STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY, 001e534f-3e63-432f-90a6-d1af1759e4e2 + 5fce3074-e420-4c36-9603-2423daf20118 + feb9f4a3-e374-4c75-8a3b-0f1fbcdbf677, 939cd40b-b515-499d-b099-fd29027c0d17 + d7b1d12a-e942-4801-bb64-916c9bdfaaf3 + fb2bb01c-c0ec-4641-abf7-87f486075022",
              "new": {
                "description": "Encorafenib is a small molecule inhibitor of RAF kinase, binimetinib is a small molecule inhibitor of MEK1/2 kinases, and cetuximab is an antibody that targets EGFR. In the Phase III BEACON study of encorafenib + binimetinib + cetuximab versus doublet treatment versus chemotherapy in 665 patients with BRAF V600E-mutant colorectal cancer, the overall response rate (complete or partial response) was 26% (95% CI= 18%- 35%) in the triplet arm versus 2% (95% CI= <1%-7%) in the control arm, with median overall survival of 9.0 months in the triplet arm (95% CI= 8.0-11.4) and 5.4 months in the control arm (95% CI= 4.8-6.6) (PMID: 31566309). The combination of dabrafenib, trametinib and panitumumab has also shown efficacy in this population, with a response rate in one study of 26%, with an additional 57% of patients achieving stable disease (PMID: 29431699). Triplet therapy is listed as a 2A therapy in the NCCN guidlines."
              },
              "old": {
                "description": "Encorafenib is a small molecule inhibitor of RAF kinase, binimetinib is a small molecule inhibitor of MEK1/2 kinases, and cetuximab is an antibody that targets EGFR. In the Phase III BEACON study of encorafenib + binimetinib + cetuximab versus doublet treatment versus chemotherapy in 665 patients with BRAF V600E-mutant colorectal cancer, the overall response rate (complete or partial response) was 26% (95% CI= 18%- 35%) in the triplet arm versus 2% (95% CI= <1%-7%) in the control arm, with median overall survival of 9.0 months in the triplet arm (95% CI= 8.0-11.4) and 5.4 months in the control arm (95% CI= 4.8-6.6) (Abstract: Kopetz et al. Abstract# LBA-006, ESMO 2019. https://academic.oup.com/annonc/article/30/Supplement_4/mdz183.004/5526665). The combination of dabrafenib, trametinib and panitumumab has also shown efficacy in this population, with a response rate in one study of 26%, with an additional 57% of patients achieving stable disease (PMID: 29431699). Triplet therapy is listed as a 2A therapy in the NCCN guidlines."
              },
              "operation": "update",
              "uuids": "d9b444f3-76b2-4f91-a919-8b8b4d853846"
            }
          ],
          "timeStamp": 1573018965047
        },
        "-LwKuLacDTtfuoWS_RYs": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600, Melanoma, Tumor Type Summary",
              "new": "The RAF-targeted inhibitors encorafenib, dabrafenib and vemurafenib, alone or in combination with the MEK1/2-targeted inhibitors binimetinib, trametinib and cobimetinib respectively, are FDA-approved for the treatment of patients with BRAF V600E/K mutant melanoma, and NCCN-compendium listed for the treatment of patients with BRAF V600-mutant melanoma.",
              "old": "The RAF-targeted inhibitors encorafenib, dabrafenib and vemurafenib, alone or in combination with the MEK1/2-targeted inhibitors binimetinib, trametinib and cobimetinib respectively, are FDA-approved for the treatment of patients with BRAF V600E/K mutant melanoma.",
              "operation": "update",
              "uuids": "49c8da54-77d7-4480-af56-bd58072c54c0"
            }
          ],
          "timeStamp": 1576620612749
        },
        "-LwKuOfQG7BOWpsk8FdO": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600, Melanoma, Standard implications for sensitivity to therapy, 4e91da20-6cf0-4e07-995f-7f7db4c7c077 + eb357145-3b18-4aca-b75a-5e18dd2bf4f9",
              "new": {
                "description": "The combination of vemurafenib, an inhibitor of V600-mutant BRAF, and cobimetinib, an inhibitor of MEK1/2, is FDA approved for the treatment of patients with BRAF V600-mutant metastatic or unresectable locally advanced melanoma. FDA-approval was based on results from the randomized Phase III coBRIM trial of combined vemurafenib and cobimetinib versus vemurafenib and placebo in 495 patients with metastatic BRAF V600-mutant melanoma that demonstrated superior clinical benefit measures in the combination versus the control arm. Specifically, median progression-free survival was 9.9 months in the combination arm versus 6.2 months in the control arm (HR = 0.51), with a complete response rate of 10% versus 4%, respectively, and interim 9-month overall survival of 81% versus 73%, respectively (PMID: 25265494). Follow-up analysis of the coBRIM trial showed two-year overall survival was 48.3% in the combination group versus 38.0% in the monotherapy group (PMID: 27480103).",
                "description_review": {
                  "lastReviewed": "",
                  "updateTime": 1576619851323,
                  "updatedBy": "User"
                },
                "description_uuid": "5c0bc8d2-dff5-4553-9e0d-b35366d24477",
                "indication": "",
                "indication_uuid": "a8dc53cf-8b65-4ba5-84a3-ae06a6cee414",
                "level": "2",
                "level_review": {
                  "lastReviewed": "",
                  "updateTime": 1576619835943,
                  "updatedBy": "User"
                },
                "level_uuid": "9f13d6a6-9649-474f-8227-b5eb866cef9b",
                "name": "4e91da20-6cf0-4e07-995f-7f7db4c7c077 + eb357145-3b18-4aca-b75a-5e18dd2bf4f9",
                "name_review": {
                  "added": true,
                  "updateTime": 1576619832635,
                  "updatedBy": "User"
                },
                "name_uuid": "04ec8bf4-289b-4dad-a110-cc3f00045e4a",
                "propagation": "3B",
                "propagationLiquid": "no",
                "propagationLiquid_review": {
                  "lastReviewed": "",
                  "updateTime": 1576619835941,
                  "updatedBy": "User"
                },
                "propagationLiquid_uuid": "fde2c9fd-d51c-40d1-aade-7031cfe40b25",
                "propagation_review": {
                  "lastReviewed": "",
                  "updateTime": 1576619835939,
                  "updatedBy": "User"
                },
                "propagation_uuid": "7ade81ad-9d19-40ad-bf04-5c9c17f1c3d3",
                "short": ""
              },
              "operation": "add",
              "uuids": "04ec8bf4-289b-4dad-a110-cc3f00045e4a"
            }
          ],
          "timeStamp": 1576620625345
        },
        "-LwKuRrq-yZIsd_rUDIy": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600, Melanoma, Standard implications for sensitivity to therapy, 939cd40b-b515-499d-b099-fd29027c0d17 + fb2bb01c-c0ec-4641-abf7-87f486075022",
              "new": {
                "description": "Dabrafenib, an orally bioavailable RAF inhibitor, and trametinib, an orally bioavailable MEK1/2 inhibitor, are FDA-approved alone or in combination for the treatment of patients with metastatic melanoma harboring a V600E or V600K BRAF mutation. The FDA approved the combination of dabrafenib and trametinib based on results from an open-label Phase III study of combination therapy versus dabrafenib monotherapy in 247 patients with metastatic melanoma who were naive to treatment with BRAF inhibitors. Combined dabrafenib and trametinib, administered in full monotherapy doses, improved the response rate in patients with BRAF V600-mutant metastatic melanoma versus dabrafenib monotherapy (67% vs.51%; p<0.002). However, median progression-free survival improved by only 2 weeks (9.3 months vs 8.8 months; HR = 0.75) compared with dabrafenib monotherapy (PMID: 23020132). Combination therapy is associated with less cutaneous toxicity than monotherapy, but systemic toxicity may be increased (PMID: 25287827, 25399551). Follow-up trials have demonstrated that all clinical measures inclusive of overall and median progression-free survival as well as objective response rates, median duration of response and number of patients with complete response favored patients treated with combination dabrafenib and trametinib, administered in full monotherapy doses, compared to either dabrafenib or vemurafenib monotherapy, including patients who previously progressed on BRAF inhibitor monotherapy (PMID: 25287827, 25399551, 25265492). Additionally, patients with melanoma treated with dabrafenib and trametinib in both the neoadjuvant and adjuvant settings have improved survival over patients given standard of care (PMID: 29361468, 28991513, 28891408). Promising clinical data has also suggested that addition of an immunotherapy agent to combination RAF and MEK inhibitor treatment may improve rate of overall response and duration of response in melanoma patients (PMID: 31171876, 31171879, 31171878).",
                "description_review": {
                  "lastReviewed": "",
                  "updateTime": 1576619770443,
                  "updatedBy": "User"
                },
                "description_uuid": "2ea521fc-5f86-4519-a12d-ab0e2fe93b0b",
                "indication": "",
                "indication_uuid": "cd44adc3-cdcc-4a53-a537-62dd6c675d09",
                "level": "2",
                "level_review": {
                  "lastReviewed": "",
                  "updateTime": 1576619761071,
                  "updatedBy": "User"
                },
                "level_uuid": "2631b490-9c48-4d93-910d-f4c4a8eafaf6",
                "name": "939cd40b-b515-499d-b099-fd29027c0d17 + fb2bb01c-c0ec-4641-abf7-87f486075022",
                "name_review": {
                  "added": true,
                  "updateTime": 1576619739704,
                  "updatedBy": "User"
                },
                "name_uuid": "cfbf8fb3-ff8b-4786-90e2-a185f3e24009",
                "propagation": "3B",
                "propagationLiquid": "no",
                "propagationLiquid_review": {
                  "lastReviewed": "",
                  "updateTime": 1576619761068,
                  "updatedBy": "User"
                },
                "propagationLiquid_uuid": "192a53fe-5fa2-4048-acb0-53631fec81bf",
                "propagation_review": {
                  "lastReviewed": "",
                  "updateTime": 1576619761065,
                  "updatedBy": "User"
                },
                "propagation_uuid": "cec11333-f85f-4fad-8275-84761897b98f",
                "short": ""
              },
              "operation": "add",
              "uuids": "cfbf8fb3-ff8b-4786-90e2-a185f3e24009"
            }
          ],
          "timeStamp": 1576620638428
        },
        "-LwKuV7rCS92zMjBHzHa": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600, Melanoma, Standard implications for sensitivity to therapy, 001e534f-3e63-432f-90a6-d1af1759e4e2 + feb9f4a3-e374-4c75-8a3b-0f1fbcdbf677",
              "new": {
                "description": "The combination of encorafenib, an inhibitor of V600E- or V600K-mutant BRAF, and binimetinib, an inhibitor of MEK1/2, is FDA approved in combination for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. FDA-approval was based on the results of the Phase III COLUMBUS trial of combined encorafenib plus binimetinib versus single agent vemurafenib in 577 patients with BRAF V600E- or V600K-mutant metastatic melanoma in which the median progression-free survival was 14.9 months (95% CI 11.0-18.5) in the encorafenib plus binimetinib group versus 7.3 months (95% CI 5.6-8.2) in the single agent vemurafenib group (HR= 0.54, 95% CI 0.41-0.71; p<0·0001) (PMID: 29573941).",
                "description_review": {
                  "lastReviewed": "",
                  "updateTime": 1576619814672,
                  "updatedBy": "User"
                },
                "description_uuid": "f76da831-1b1b-4706-8477-14eeba8893c6",
                "indication": "",
                "indication_uuid": "c705de5b-c1f8-49e2-b75f-a5f01288ef67",
                "level": "2",
                "level_review": {
                  "lastReviewed": "",
                  "updateTime": 1576619798046,
                  "updatedBy": "User"
                },
                "level_uuid": "67773473-226f-4579-b3ef-d42cec01554a",
                "name": "001e534f-3e63-432f-90a6-d1af1759e4e2 + feb9f4a3-e374-4c75-8a3b-0f1fbcdbf677",
                "name_review": {
                  "added": true,
                  "updateTime": 1576619794293,
                  "updatedBy": "User"
                },
                "name_uuid": "dc196791-41af-46c9-a295-299d1de62bb2",
                "propagation": "3B",
                "propagationLiquid": "no",
                "propagationLiquid_review": {
                  "lastReviewed": "",
                  "updateTime": 1576619798045,
                  "updatedBy": "User"
                },
                "propagationLiquid_uuid": "88d7647e-b90d-4924-92d5-c7878b427bdf",
                "propagation_review": {
                  "lastReviewed": "",
                  "updateTime": 1576619798043,
                  "updatedBy": "User"
                },
                "propagation_uuid": "540a0860-3014-4475-b36c-a1fdc58889d8",
                "short": ""
              },
              "operation": "add",
              "uuids": "dc196791-41af-46c9-a295-299d1de62bb2"
            }
          ],
          "timeStamp": 1576620651805
        },
        "-LwKudzyrXHKjMvZfU5-": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600, Anaplastic Thyroid Cancer",
              "new": {
                "TIs": [
                  {
                    "name": "Standard implications for sensitivity to therapy",
                    "name_uuid": "14ff69c9-664c-4b91-aef1-af34c5e622a8",
                    "treatments": [
                      {
                        "description": "Dabrafenib, an orally bioavailable RAF inhibitor, and trametinib, an orally bioavailable MEK1/2 inhibitor, are FDA-approved alone or in combination for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options. FDA-approval was based on results of the Phase II study of dabrafenib combined with trametinib in patients with BRAF V600E-positive ATC in which the overall response rate in sixteen evaluable patients was 69% (11/16; 95% CI= 41%-89%)(PMID: 29072975). Dabrafenib + trametinib is NCCN-compendium listed for the treatment of patients with BRAF V600-mutant ATC.",
                        "description_review": {
                          "lastReviewed": "",
                          "updateTime": 1576619586044,
                          "updatedBy": "User"
                        },
                        "description_uuid": "a9147baa-651d-4bf3-8dc0-966dbd326d3f",
                        "indication": "",
                        "indication_uuid": "87bd653e-6302-41c6-b2e4-029c1fab16ae",
                        "level": "2",
                        "level_review": {
                          "lastReviewed": "",
                          "updateTime": 1576619345596,
                          "updatedBy": "User"
                        },
                        "level_uuid": "be90e4a7-ece2-4df5-864e-007fa8b7a67d",
                        "name": "939cd40b-b515-499d-b099-fd29027c0d17 + fb2bb01c-c0ec-4641-abf7-87f486075022",
                        "name_review": {
                          "added": true,
                          "updateTime": 1576619341036,
                          "updatedBy": "User"
                        },
                        "name_uuid": "efa979c1-84eb-4c65-b291-9d395c322114",
                        "propagation": "3B",
                        "propagationLiquid": "no",
                        "propagationLiquid_review": {
                          "lastReviewed": "",
                          "updateTime": 1576619345591,
                          "updatedBy": "User"
                        },
                        "propagationLiquid_uuid": "57f805ec-3086-4992-b75a-abebeca1f718",
                        "propagation_review": {
                          "lastReviewed": "",
                          "updateTime": 1576619345585,
                          "updatedBy": "User"
                        },
                        "propagation_uuid": "c96488d8-dc81-4862-9212-97fe4d7ed9b7",
                        "short": ""
                      }
                    ],
                    "treatments_uuid": "194f9d44-baf8-4a1c-a904-4f3f171ae67e",
                    "type": "SS"
                  },
                  {
                    "name": "Standard implications for resistance to therapy",
                    "name_uuid": "a329af61-6ca3-496f-9a35-337e08f77c3f",
                    "treatments_uuid": "7874f6d2-aa61-48f3-acab-729c497a4390",
                    "type": "SR"
                  },
                  {
                    "name": "Investigational implications for sensitivity to therapy",
                    "name_uuid": "9eef4593-1bb1-4cf2-bc2f-554a8aae077a",
                    "treatments_uuid": "ad4025a5-3dd1-48a7-b29e-92249c568813",
                    "type": "IS"
                  },
                  {
                    "name": "Investigational implications for resistance to therapy",
                    "name_uuid": "456dc94c-4d6c-4993-8735-089ac0311714",
                    "treatments_uuid": "46891a9e-6bc5-4b2f-ba0c-6280db6b0f43",
                    "type": "IR"
                  }
                ],
                "cancerTypes": [
                  {
                    "code": "THAP",
                    "mainType": "Thyroid Cancer",
                    "subtype": "Anaplastic Thyroid Cancer"
                  }
                ],
                "cancerTypes_review": {
                  "added": true,
                  "updateTime": 1576619237246,
                  "updatedBy": "User"
                },
                "cancerTypes_uuid": "92c47b97-c371-494b-96dd-aa19b40dc62a",
                "diagnostic": {
                  "description": "",
                  "description_uuid": "c179c49e-8be0-49a1-bea3-1a239eb40f17",
                  "level": "",
                  "level_uuid": "a60d8e13-ae58-4d4a-9283-fd371ca9eedc",
                  "short": ""
                },
                "diagnosticSummary": "",
                "diagnosticSummary_uuid": "d67b2ac5-e72f-468b-ab52-137580698dfe",
                "diagnostic_uuid": "a153ee78-2cf9-42b7-927d-949a193965a8",
                "prognostic": {
                  "description": "",
                  "description_uuid": "59ff716e-a78b-41b1-9efe-b7c5fc645abb",
                  "level": "",
                  "level_uuid": "75ebb3e6-3ce3-4b3f-9ecc-6568a2e4f39b",
                  "short": ""
                },
                "prognosticSummary": "",
                "prognosticSummary_uuid": "8fda833a-e221-4c7f-b177-eb615b1317ef",
                "prognostic_uuid": "e2778348-64df-4188-a932-fb1e95251361",
                "summary": "The RAF-targeted inhibitor dabrafenib in combination with the MEK1/2-targeted inhibitor trametinib is FDA-approved for the treatment of patients with BRAF V600E mutant anaplastic thyroid cancer (ATC), and NCCN-compendium listed for the treatment of patients with BRAF V600-mutant ATC.",
                "summary_review": {
                  "lastReviewed": "",
                  "updateTime": 1576619252319,
                  "updatedBy": "User"
                },
                "summary_uuid": "19b9a0c7-cd5d-4202-b27c-ab3687c9efd2"
              },
              "operation": "add",
              "uuids": "19b9a0c7-cd5d-4202-b27c-ab3687c9efd2,efa979c1-84eb-4c65-b291-9d395c322114"
            }
          ],
          "timeStamp": 1576620692196
        },
        "-LwKuhI4VDMKZIaC1Vaz": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600, Anaplastic Thyroid Cancer",
              "new": {
                "TIs": [
                  {
                    "name": "Standard implications for sensitivity to therapy",
                    "name_uuid": "14ff69c9-664c-4b91-aef1-af34c5e622a8",
                    "treatments": [
                      {
                        "description": "Dabrafenib, an orally bioavailable RAF inhibitor, and trametinib, an orally bioavailable MEK1/2 inhibitor, are FDA-approved alone or in combination for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options. FDA-approval was based on results of the Phase II study of dabrafenib combined with trametinib in patients with BRAF V600E-positive ATC in which the overall response rate in sixteen evaluable patients was 69% (11/16; 95% CI= 41%-89%)(PMID: 29072975). Dabrafenib + trametinib is NCCN-compendium listed for the treatment of patients with BRAF V600-mutant ATC.",
                        "description_review": {
                          "updateTime": 1576619586044,
                          "updatedBy": "User"
                        },
                        "description_uuid": "a9147baa-651d-4bf3-8dc0-966dbd326d3f",
                        "indication": "",
                        "indication_uuid": "87bd653e-6302-41c6-b2e4-029c1fab16ae",
                        "level": "2",
                        "level_review": {
                          "updateTime": 1576619345596,
                          "updatedBy": "User"
                        },
                        "level_uuid": "be90e4a7-ece2-4df5-864e-007fa8b7a67d",
                        "name": "939cd40b-b515-499d-b099-fd29027c0d17 + fb2bb01c-c0ec-4641-abf7-87f486075022",
                        "name_review": {
                          "updateTime": 1576619341036,
                          "updatedBy": "User"
                        },
                        "name_uuid": "efa979c1-84eb-4c65-b291-9d395c322114",
                        "propagation": "3B",
                        "propagationLiquid": "no",
                        "propagationLiquid_review": {
                          "updateTime": 1576619345591,
                          "updatedBy": "User"
                        },
                        "propagationLiquid_uuid": "57f805ec-3086-4992-b75a-abebeca1f718",
                        "propagation_review": {
                          "updateTime": 1576619345585,
                          "updatedBy": "User"
                        },
                        "propagation_uuid": "c96488d8-dc81-4862-9212-97fe4d7ed9b7",
                        "short": ""
                      }
                    ],
                    "treatments_uuid": "194f9d44-baf8-4a1c-a904-4f3f171ae67e",
                    "type": "SS"
                  },
                  {
                    "name": "Standard implications for resistance to therapy",
                    "name_uuid": "a329af61-6ca3-496f-9a35-337e08f77c3f",
                    "treatments_uuid": "7874f6d2-aa61-48f3-acab-729c497a4390",
                    "type": "SR"
                  },
                  {
                    "name": "Investigational implications for sensitivity to therapy",
                    "name_uuid": "9eef4593-1bb1-4cf2-bc2f-554a8aae077a",
                    "treatments_uuid": "ad4025a5-3dd1-48a7-b29e-92249c568813",
                    "type": "IS"
                  },
                  {
                    "name": "Investigational implications for resistance to therapy",
                    "name_uuid": "456dc94c-4d6c-4993-8735-089ac0311714",
                    "treatments_uuid": "46891a9e-6bc5-4b2f-ba0c-6280db6b0f43",
                    "type": "IR"
                  }
                ],
                "cancerTypes": [
                  {
                    "code": "THAP",
                    "mainType": "Thyroid Cancer",
                    "subtype": "Anaplastic Thyroid Cancer"
                  }
                ],
                "cancerTypes_review": {
                  "updateTime": 1576619237246,
                  "updatedBy": "User"
                },
                "cancerTypes_uuid": "92c47b97-c371-494b-96dd-aa19b40dc62a",
                "diagnostic": {
                  "description": "",
                  "description_uuid": "c179c49e-8be0-49a1-bea3-1a239eb40f17",
                  "level": "",
                  "level_uuid": "a60d8e13-ae58-4d4a-9283-fd371ca9eedc",
                  "short": ""
                },
                "diagnosticSummary": "",
                "diagnosticSummary_uuid": "d67b2ac5-e72f-468b-ab52-137580698dfe",
                "diagnostic_uuid": "a153ee78-2cf9-42b7-927d-949a193965a8",
                "prognostic": {
                  "description": "",
                  "description_uuid": "59ff716e-a78b-41b1-9efe-b7c5fc645abb",
                  "level": "",
                  "level_uuid": "75ebb3e6-3ce3-4b3f-9ecc-6568a2e4f39b",
                  "short": ""
                },
                "prognosticSummary": "",
                "prognosticSummary_uuid": "8fda833a-e221-4c7f-b177-eb615b1317ef",
                "prognostic_uuid": "e2778348-64df-4188-a932-fb1e95251361",
                "summary": "The RAF-targeted inhibitor dabrafenib in combination with the MEK1/2-targeted inhibitor trametinib is FDA-approved for the treatment of patients with BRAF V600E mutant anaplastic thyroid cancer (ATC), and NCCN-compendium listed for the treatment of patients with BRAF V600-mutant ATC.",
                "summary_review": {
                  "updateTime": 1576619252319,
                  "updatedBy": "User"
                },
                "summary_uuid": "19b9a0c7-cd5d-4202-b27c-ab3687c9efd2"
              },
              "operation": "add",
              "uuids": "19b9a0c7-cd5d-4202-b27c-ab3687c9efd2,efa979c1-84eb-4c65-b291-9d395c322114"
            }
          ],
          "timeStamp": 1576620705707
        },
        "-LwKvjimufucs7-0YjoK": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600K, Non-Small Cell Lung Cancer",
              "new": {
                "TIs": [
                  {
                    "name": "Standard implications for sensitivity to therapy",
                    "name_uuid": "49e71a59-a028-4b6b-a541-5e92bf71ec17",
                    "treatments_uuid": "0821e157-a7cf-43a1-a9ad-9ab56614abcb",
                    "type": "SS"
                  },
                  {
                    "name": "Standard implications for resistance to therapy",
                    "name_uuid": "e33f11c4-5ed9-4d86-b241-16b1244d860b",
                    "treatments_uuid": "dc3fa2b7-20b8-4922-8919-ad90a4d6a457",
                    "type": "SR"
                  },
                  {
                    "name": "Investigational implications for sensitivity to therapy",
                    "name_uuid": "2814ec2e-cd50-41bd-bd15-c926b6636b1c",
                    "treatments_uuid": "f147bfc4-be90-401b-8c7c-5536b8c5c25b",
                    "type": "IS"
                  },
                  {
                    "name": "Investigational implications for resistance to therapy",
                    "name_uuid": "253f5126-5f28-46dd-9eed-e2b27269d92e",
                    "treatments_uuid": "9aa22b63-37d6-47be-b0bd-59c2d982a20d",
                    "type": "IR"
                  }
                ],
                "cancerTypes": [
                  {
                    "code": "NSCLC",
                    "mainType": "Non-Small Cell Lung Cancer",
                    "subtype": "Non-Small Cell Lung Cancer"
                  }
                ],
                "cancerTypes_review": {
                  "added": true,
                  "updateTime": 1576619943849,
                  "updatedBy": "User"
                },
                "cancerTypes_uuid": "72da4d11-d3a0-4777-9f5a-abf2a3844a55",
                "diagnostic": {
                  "description": "",
                  "description_uuid": "b0591454-9754-49a6-afec-8c434d54ab32",
                  "level": "",
                  "level_uuid": "c3956797-4b7b-44dc-b926-bd6fc9c5f3f0",
                  "short": ""
                },
                "diagnosticSummary": "",
                "diagnosticSummary_uuid": "ef391f45-5a40-4fb6-b353-02c65a44f87b",
                "diagnostic_uuid": "31cb6912-af68-4fed-a6bd-03e759963ca1",
                "prognostic": {
                  "description": "",
                  "description_uuid": "2c1fc9a5-ec8e-4280-b798-147a68c433f7",
                  "level": "",
                  "level_uuid": "d692a246-2163-42b0-abd4-c3f60f512622",
                  "short": ""
                },
                "prognosticSummary": "",
                "prognosticSummary_uuid": "3ddc76ac-4dc2-491d-86b9-5556a83d9187",
                "prognostic_uuid": "88421a7e-ba1c-44e5-be95-1650c7aa2e39",
                "summary": "While the RAF-targeted inhibitor dabrafenib in combination with the MEK1/2-targeted inhibitor trametinib is FDA-approved for the treatment of patients with BRAF V600E mutant non-small cell lung cancer (NSCLC), this combination is not specifically approved for the treatment of patients with BRAF V600K mutant NSCLC. However, laboratory data demonstrate that cells expressing BRAF V600K respond similarly to dabrafenib + trametinib as cells with BRAF V600E, and patients with BRAF V600K mutant melanoma derived similar clinical benefit to dabrafenib + trametinib as those with BRAF V600E.",
                "summary_review": {
                  "lastReviewed": "",
                  "updateTime": 1576620005051,
                  "updatedBy": "User"
                },
                "summary_uuid": "33bea22d-cd06-4a27-95d1-23125badb1f6"
              },
              "operation": "add",
              "uuids": "33bea22d-cd06-4a27-95d1-23125badb1f6"
            }
          ],
          "timeStamp": 1576620977816
        },
        "-LwKvn2mppke1y3qlUVQ": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, V600K, Melanoma, STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY, 939cd40b-b515-499d-b099-fd29027c0d17 + fb2bb01c-c0ec-4641-abf7-87f486075022",
              "new": {
                "description": "Dabrafenib, an orally bioavailable RAF inhibitor, and trametinib, an orally bioavailable MEK1/2 inhibitor, are FDA-approved alone or in combination for the treatment of patients with metastatic melanoma harboring a V600E or V600K BRAF mutation. The FDA approved the combination of dabrafenib and trametinib based on results from an open-label Phase III study of combination therapy versus dabrafenib monotherapy in 247 patients with metastatic melanoma who were naive to treatment with BRAF inhibitors. Combined dabrafenib and trametinib, administered in full monotherapy doses, improved the response rate in patients with BRAF V600-mutant metastatic melanoma versus dabrafenib monotherapy (67% vs.51%; p<0.002). However, median progression-free survival improved by only 2 weeks (9.3 months vs 8.8 months; HR = 0.75) compared with dabrafenib monotherapy (PMID: 23020132). Combination therapy is associated with less cutaneous toxicity than monotherapy, but systemic toxicity may be increased (PMID: 25287827, 25399551). Follow-up trials have demonstrated that all clinical measures inclusive of overall and median progression-free survival as well as objective response rates, median duration of response and number of patients with complete response favored patients treated with combination dabrafenib and trametinib, administered in full monotherapy doses, compared to either dabrafenib or vemurafenib monotherapy, including patients who previously progressed on BRAF inhibitor monotherapy (PMID: 25287827, 25399551, 25265492). Additionally, patients with melanoma treated with dabrafenib and trametinib in both the neoadjuvant and adjuvant settings have improved survival over patients given standard of care (PMID: 29361468, 28991513, 28891408). Promising clinical data has also suggested that addition of an immunotherapy agent to combination RAF and MEK inhibitor treatment may improve rate of overall response and duration of response in melanoma patients (PMID: 31171876, 31171879, 31171878)."
              },
              "old": {
                "description": "Dabrafenib, an orally bioavailable RAF inhibitor, and trametinib, an orally bioavailable MEK1/2 inhibitor, are FDA-approved alone or in combination for the treatment of patients with metastatic melanoma harboring a V600E or V600K BRAF mutation. The FDA approved the combination of dabrafenib and trametinib based on results from an open-label Phase III study of combination therapy versus dabrafenib monotherapy in 247 patients with metastatic melanoma who were naive to treatment with BRAF inhibitors. Combined dabrafenib and trametinib, administered in full monotherapy doses, improved the response rate in patients with BRAF V600-mutant metastatic melanoma versus dabrafenib monotherapy (67% vs.51%; p<0.002). However, median progression-free survival improved by only 2 weeks (9.3 months vs 8.8 months; HR = 0.75) compared with dabrafenib monotherapy (PMID: 23020132). Combination therapy is associated with less cutaneous toxicity than monotherapy, but systemic toxicity may be increased (PMID: 25287827, 25399551). Follow-up trials have demonstrated that all clinical measures inclusive of overall and median progression-free survival as well as objective response rates, median duration of response and number of patients with complete response favored patients treated with combination dabrafenib and trametinib, administered in full monotherapy doses, compared to either dabrafenib or vemurafenib monotherapy, including patients who previously progressed on BRAF inhibitor monotherapy (PMID: 25287827, 25399551, 25265492). Additionally, patients with melanoma treated with dabrafenib and trametinib in both the neoadjuvant and adjuvant settings have improved survival over patients given standard of care (PMID: 29361468, 28991513, 28891408). Promising clinical data has also suggested that addition of an immunotherapy agent to combination RAF and MEK inhibitor treatment may improve rate of overall response and durstion of response in melanoma patients (PMID: 31171876, 31171879, 31171878)."
              },
              "operation": "update",
              "uuids": "bc28ec2e-60ae-4a5d-9401-524e357b5bed"
            }
          ],
          "timeStamp": 1576620991448
        },
        "-LwTsp7c4p9aH665LTF6": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600, Non-Small Cell Lung Cancer",
              "new": {
                "TIs": [
                  {
                    "name": "Standard implications for sensitivity to therapy",
                    "name_uuid": "ff2992f5-7039-4d7c-ae52-f61977ead31c",
                    "treatments_uuid": "91133f71-e337-40af-9c65-7d063c31a8f2",
                    "type": "SS"
                  },
                  {
                    "name": "Standard implications for resistance to therapy",
                    "name_uuid": "36847577-6d62-4565-aeaa-ccf86d1138d4",
                    "treatments_uuid": "33021e97-bc80-4745-bb6c-40a75ed31afd",
                    "type": "SR"
                  },
                  {
                    "name": "Investigational implications for sensitivity to therapy",
                    "name_uuid": "5e0068cc-bdf2-470e-b885-fc41dba3dc05",
                    "treatments_uuid": "d95ddc97-ed56-4822-9a99-d771fba3938f",
                    "type": "IS"
                  },
                  {
                    "name": "Investigational implications for resistance to therapy",
                    "name_uuid": "c2fc65f6-4b5b-4a56-ba5a-222565b6ab94",
                    "treatments_uuid": "7eb15195-1c5d-45a9-b000-fbba562024cc",
                    "type": "IR"
                  }
                ],
                "cancerTypes": [
                  {
                    "code": "NSCLC",
                    "mainType": "Non-Small Cell Lung Cancer",
                    "subtype": "Non-Small Cell Lung Cancer"
                  }
                ],
                "cancerTypes_review": {
                  "added": true,
                  "updateTime": 1576693884298,
                  "updatedBy": "User"
                },
                "cancerTypes_uuid": "7f3f67af-cd0c-4086-b2cb-1933756b526c",
                "diagnostic": {
                  "description": "",
                  "description_uuid": "93ed1531-bcc4-4367-b17f-4e4da4cc6514",
                  "level": "",
                  "level_uuid": "0267d45e-940d-4403-8a9e-09a4c089ce5a",
                  "short": ""
                },
                "diagnosticSummary": "",
                "diagnosticSummary_uuid": "4959fb2a-5e52-4626-adc6-e4a7ba41a04f",
                "diagnostic_uuid": "4edcc727-2c00-473d-967f-5373758c1678",
                "prognostic": {
                  "description": "",
                  "description_uuid": "64c159c1-f4ea-4054-ba17-940595a28bd3",
                  "level": "",
                  "level_uuid": "2150bbab-7f6e-4e44-8877-2834ab2db1fd",
                  "short": ""
                },
                "prognosticSummary": "",
                "prognosticSummary_uuid": "09103409-4575-4f38-b7f3-d785c8e25486",
                "prognostic_uuid": "0e3eef99-9902-423c-9d4d-009c4b7c5509",
                "summary": "While the RAF-targeted inhibitor dabrafenib in combination with the MEK1/2-targeted inhibitor trametinib is FDA-approved for the treatment of patients with BRAF V600E mutant non-small cell lung cancer (NSCLC), this combination is not specifically approved for the treatment of patients with BRAF [[mutation]] mutant NSCLC.",
                "summary_review": {
                  "lastReviewed": "",
                  "updateTime": 1576693927838,
                  "updatedBy": "User"
                },
                "summary_uuid": "593f072b-2d62-4436-c06f-1d01f05298a8"
              },
              "operation": "add",
              "uuids": "593f072b-2d62-4436-c06f-1d01f05298a8"
            }
          ],
          "timeStamp": 1576771214648
        },
        "-LzdsPtQPmaGHXMoqZfH": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, V600K, Melanoma, STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY, 4e91da20-6cf0-4e07-995f-7f7db4c7c077 + eb357145-3b18-4aca-b75a-5e18dd2bf4f9",
              "new": {
                "description": "The combination of vemurafenib, an inhibitor of V600-mutant BRAF, and cobimetinib, an inhibitor of MEK1/2, is FDA approved for the treatment of patients with BRAF V600-mutant metastatic or unresectable locally advanced melanoma. FDA-approval was based on results from the randomized Phase III coBRIM trial of combined vemurafenib and cobimetinib versus vemurafenib and placebo in 495 patients with metastatic BRAF V600-mutant melanoma that demonstrated superior clinical benefit measures in the combination versus the control arm. Specifically, median progression-free survival was 9.9 months in the combination arm versus 6.2 months in the control arm (HR = 0.51), with a complete response rate of 10% versus 4%, respectively, and interim 9-month overall survival of 81% versus 73%, respectively (PMID: 25265494). Follow-up analysis of the coBRIM trial showed two-year overall survival was 48.3% in the combination group versus 38.0% in the monotherapy group (PMID: 27480103), and 5-year followup of the BRIM7 study showed a median overall survival of 31.8 months and a 5-year survival rate of 39.2% (PMID: 31732523)."
              },
              "old": {
                "description": "The combination of vemurafenib, an inhibitor of V600-mutant BRAF, and cobimetinib, an inhibitor of MEK1/2, is FDA approved for the treatment of patients with BRAF V600-mutant metastatic or unresectable locally advanced melanoma. FDA-approval was based on results from the randomized Phase III coBRIM trial of combined vemurafenib and cobimetinib versus vemurafenib and placebo in 495 patients with metastatic BRAF V600-mutant melanoma that demonstrated superior clinical benefit measures in the combination versus the control arm. Specifically, median progression-free survival was 9.9 months in the combination arm versus 6.2 months in the control arm (HR = 0.51), with a complete response rate of 10% versus 4%, respectively, and interim 9-month overall survival of 81% versus 73%, respectively (PMID: 25265494). Follow-up analysis of the coBRIM trial showed two-year overall survival was 48.3% in the combination group versus 38.0% in the monotherapy group (PMID: 27480103)."
              },
              "operation": "update",
              "uuids": "19caa107-e92a-4246-9d01-6d707b9ecd4e"
            }
          ],
          "timeStamp": 1580176879565
        },
        "-M-keIBCVkKTRg5jZyKX": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "K601_W604del",
              "new": {
                "mutation_effect": {
                  "description": "A single case-report reports that a 42-year old patient with advanced lung cancer positive for coincident BRAF V600E and K601_W604del mutations responded to treatment with combination RAF inhibitor dabrafenib and MEK inhibitor trametinib therapy (Abstract: Shimizu, J et al. JTO. Abstract# EP1.14-44.https://www.sciencedirect.com/science/article/pii/S1556086419330126?via%3Dihub). This response is may due to the presence of the mutant V600E allele alone and there is no functional evidence characterizing the K601_W604del mutation, making the impact of the indel inconclusive with this evidence alone.",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1581364016397,
                    "updatedBy": "User"
                  },
                  "description_uuid": "f79bd54f-747e-4a96-b16b-2b1f24b9389d",
                  "effect": "Inconclusive",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1581363602065,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "13dad237-c80e-4fff-89e6-818cb4608308",
                  "oncogenic": "Inconclusive",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1581363599623,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "0fbe6ead-5372-44d4-863f-ed47394b1266",
                  "short": ""
                },
                "mutation_effect_uuid": "7c53138b-86ad-4935-9049-82517200ed60",
                "name": "K601_W604del",
                "name_review": {
                  "added": true,
                  "lastReviewed": "K601_W604",
                  "updateTime": 1581363512811,
                  "updatedBy": "User"
                },
                "name_uuid": "0aba5c3c-6f70-421f-947b-8aa834e19c7c",
                "tumors_uuid": "c1a47d18-47c3-479c-af68-7ef16db5e935"
              },
              "operation": "add",
              "uuids": "0fbe6ead-5372-44d4-863f-ed47394b1266,13dad237-c80e-4fff-89e6-818cb4608308"
            }
          ],
          "timeStamp": 1581364360113
        },
        "-M58v6Jb-elpIC_h9mtb": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Colorectal Cancer, Tumor Type Summary",
              "new": "The RAF-targeted inhibitor encorafenib in combination with the anti-EGFR antibody cetuximab is FDA-approved for the treatment of patients with BRAF V600E mutant colorectal cancer.",
              "old": "The triplet therapy combination of encorafenib + binimetinib + cetuximab, a RAF-inhibitor, a MEK-inhibitor and an anti-EGFR antibody respectively, is NCCN-compendium listed and has received FDA-breakthrough therapy designation for the treatment of patients with BRAF V600E mutant colorectal cancer.",
              "operation": "update",
              "uuids": "cfcc19a6-df02-4230-85fb-992ed74d464a"
            }
          ],
          "timeStamp": 1587156907409
        },
        "-M58v9_7ydNlpgPmW6bN": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Colorectal Cancer, Tumor Type Summary",
              "new": "The RAF-targeted inhibitor encorafenib in combination with the anti-EGFR antibody cetuximab is FDA-approved for the treatment of patients with BRAF V600E mutant colorectal cancer.",
              "old": "The triplet therapy combination of encorafenib + binimetinib + cetuximab, a RAF-inhibitor, a MEK-inhibitor and an anti-EGFR antibody respectively, is NCCN-compendium listed and has received FDA-breakthrough therapy designation for the treatment of patients with BRAF V600E mutant colorectal cancer.",
              "operation": "update",
              "uuids": "cfcc19a6-df02-4230-85fb-992ed74d464a"
            }
          ],
          "timeStamp": 1587156920754
        },
        "-M58vCpDHkn3zx1rRheI": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Colorectal Cancer, STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY, 001e534f-3e63-432f-90a6-d1af1759e4e2 + d7b1d12a-e942-4801-bb64-916c9bdfaaf3",
              "new": {
                "description": "Encorafenib, a small molecule inhibitor of RAF kinase, and panitumumab, an antibody that targets EGFR, are NCCN-compendium listed as level 2A therapy for patients with BRAF V600E-positive colorectal cancer. In the Phase III BEACON study of encorafenib + cetuximab, another EGFR antibody, versus triplet treatment (including a MEK1/2 inhibitor) versus chemotherapy in 665 patients with BRAF V600E-mutant colorectal cancer, the overall response rate (complete or partial response) was 20% (95% CI= 13-29) in the doublet arm (n=220) versus 2% (95% CI= <1%-7%) in the chemotherapy arm (n=221), with median overall survival of 8.4 months in the doublet arm (95% CI= 7.5-11.0) and 5.4 months in the control arm (95% CI= 4.8-6.6) (PMID: 31566309). Panitumumab has also been used in doublet and triplet combination therapy, with a response rate in one study of 26% (PMID: 29431699)."
              },
              "old": {
                "description": "Encorafenib is a small molecule inhibitor of RAF kinase, binimetinib is a small molecule inhibitor of MEK1/2 kinases, and cetuximab is an antibody that targets EGFR. In the Phase III BEACON study of encorafenib + binimetinib + cetuximab versus doublet treatment versus chemotherapy in 665 patients with BRAF V600E-mutant colorectal cancer, the overall response rate (complete or partial response) was 26% (95% CI= 18%- 35%) in the triplet arm versus 2% (95% CI= <1%-7%) in the control arm, with median overall survival of 9.0 months in the triplet arm (95% CI= 8.0-11.4) and 5.4 months in the control arm (95% CI= 4.8-6.6) (PMID: 31566309). The combination of dabrafenib, trametinib and panitumumab has also shown efficacy in this population, with a response rate in one study of 26%, with an additional 57% of patients achieving stable disease (PMID: 29431699). Triplet therapy is listed as a 2A therapy in the NCCN guidlines."
              },
              "operation": "update",
              "uuids": "d9b444f3-76b2-4f91-a919-8b8b4d853846"
            }
          ],
          "timeStamp": 1587156934072
        },
        "-M58vG7OZ2MyBQs4ICoI": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Colorectal Cancer, Standard implications for sensitivity to therapy, 001e534f-3e63-432f-90a6-d1af1759e4e2 + 5fce3074-e420-4c36-9603-2423daf20118",
              "new": {
                "description": "Encorafenib, a small molecule inhibitor of RAF kinase, and cetuximab, an antibody that targets EGFR, are FDA-approved in combination for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation after prior therapy. FDA-approval was based on results of the Phase III BEACON study of encorafenib + cetuximab versus triplet treatment (including a MEK1/2 inhibitor) versus chemotherapy in 665 patients with BRAF V600E-mutant colorectal cancer, in which the overall response rate (complete or partial response) was 20% (95% CI= 13-29) in the doublet arm (n=220) versus 2% (95% CI= <1%-7%) in the chemotherapy arm (n=221), with median overall survival of 8.4 months in the doublet arm (95% CI= 7.5-11.0) and 5.4 months in the control arm (95% CI= 4.8-6.6) (PMID: 31566309).",
                "description_review": {
                  "lastReviewed": "",
                  "updateTime": 1587071430480,
                  "updatedBy": "User"
                },
                "description_uuid": "1db0ba8d-3f3b-4429-9e7b-00217d10437b",
                "indication": "",
                "indication_uuid": "de4360e8-e4c1-444e-bbdc-cf15e53133d1",
                "level": "1",
                "level_review": {
                  "lastReviewed": "",
                  "updateTime": 1586933580265,
                  "updatedBy": "User"
                },
                "level_uuid": "91c33ef8-6476-432b-bd47-b1434798c4d6",
                "name": "001e534f-3e63-432f-90a6-d1af1759e4e2 + 5fce3074-e420-4c36-9603-2423daf20118",
                "name_review": {
                  "added": true,
                  "updateTime": 1586933016940,
                  "updatedBy": "User"
                },
                "name_uuid": "5d3556f9-89b7-4be9-9fa8-69fee10f032b",
                "propagation": "3B",
                "propagationLiquid": "no",
                "propagationLiquid_review": {
                  "lastReviewed": "",
                  "updateTime": 1586933580257,
                  "updatedBy": "User"
                },
                "propagationLiquid_uuid": "83d371b9-ddec-428d-c052-6d2eb1d4c534",
                "propagation_review": {
                  "lastReviewed": "",
                  "updateTime": 1586933580247,
                  "updatedBy": "User"
                },
                "propagation_uuid": "2ab3f90b-29ac-4a31-b099-8f9c740691c4",
                "short": ""
              },
              "operation": "add",
              "uuids": "5d3556f9-89b7-4be9-9fa8-69fee10f032b"
            }
          ],
          "timeStamp": 1587156947587
        },
        "-M58vJSB16obGrVjeuSC": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Colorectal Cancer, Standard implications for sensitivity to therapy, 001e534f-3e63-432f-90a6-d1af1759e4e2 + 5fce3074-e420-4c36-9603-2423daf20118",
              "new": {
                "description": "Encorafenib, a small molecule inhibitor of RAF kinase, and cetuximab, an antibody that targets EGFR, are FDA-approved in combination for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation after prior therapy. FDA-approval was based on results of the Phase III BEACON study of encorafenib + cetuximab versus triplet treatment (including a MEK1/2 inhibitor) versus chemotherapy in 665 patients with BRAF V600E-mutant colorectal cancer, in which the overall response rate (complete or partial response) was 20% (95% CI= 13-29) in the doublet arm (n=220) versus 2% (95% CI= <1%-7%) in the chemotherapy arm (n=221), with median overall survival of 8.4 months in the doublet arm (95% CI= 7.5-11.0) and 5.4 months in the control arm (95% CI= 4.8-6.6) (PMID: 31566309).",
                "description_review": {
                  "lastReviewed": "",
                  "updateTime": 1587071430480,
                  "updatedBy": "User"
                },
                "description_uuid": "1db0ba8d-3f3b-4429-9e7b-00217d10437b",
                "indication": "",
                "indication_uuid": "de4360e8-e4c1-444e-bbdc-cf15e53133d1",
                "level": "1",
                "level_review": {
                  "lastReviewed": "",
                  "updateTime": 1586933580265,
                  "updatedBy": "User"
                },
                "level_uuid": "91c33ef8-6476-432b-bd47-b1434798c4d6",
                "name": "001e534f-3e63-432f-90a6-d1af1759e4e2 + 5fce3074-e420-4c36-9603-2423daf20118",
                "name_review": {
                  "added": true,
                  "updateTime": 1586933016940,
                  "updatedBy": "User"
                },
                "name_uuid": "5d3556f9-89b7-4be9-9fa8-69fee10f032b",
                "propagation": "3B",
                "propagationLiquid": "no",
                "propagationLiquid_review": {
                  "lastReviewed": "",
                  "updateTime": 1586933580257,
                  "updatedBy": "User"
                },
                "propagationLiquid_uuid": "83d371b9-ddec-428d-c052-6d2eb1d4c534",
                "propagation_review": {
                  "lastReviewed": "",
                  "updateTime": 1586933580247,
                  "updatedBy": "User"
                },
                "propagation_uuid": "2ab3f90b-29ac-4a31-b099-8f9c740691c4",
                "short": ""
              },
              "operation": "add",
              "uuids": "5d3556f9-89b7-4be9-9fa8-69fee10f032b"
            },
            {
              "lastEditBy": "User",
              "location": "V600E, Colorectal Cancer, STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY, 001e534f-3e63-432f-90a6-d1af1759e4e2 + d7b1d12a-e942-4801-bb64-916c9bdfaaf3",
              "new": {
                "description": "Encorafenib, a small molecule inhibitor of RAF kinase, and panitumumab, an antibody that targets EGFR, are NCCN-compendium listed as level 2A therapy for patients with BRAF V600E-positive colorectal cancer. In the Phase III BEACON study of encorafenib + cetuximab, another EGFR antibody, versus triplet treatment (including a MEK1/2 inhibitor) versus chemotherapy in 665 patients with BRAF V600E-mutant colorectal cancer, the overall response rate (complete or partial response) was 20% (95% CI= 13-29) in the doublet arm (n=220) versus 2% (95% CI= <1%-7%) in the chemotherapy arm (n=221), with median overall survival of 8.4 months in the doublet arm (95% CI= 7.5-11.0) and 5.4 months in the control arm (95% CI= 4.8-6.6) (PMID: 31566309). Panitumumab has also been used in doublet and triplet combination therapy, with a response rate in one study of 26% (PMID: 29431699)."
              },
              "old": {
                "description": "Encorafenib is a small molecule inhibitor of RAF kinase, binimetinib is a small molecule inhibitor of MEK1/2 kinases, and cetuximab is an antibody that targets EGFR. In the Phase III BEACON study of encorafenib + binimetinib + cetuximab versus doublet treatment versus chemotherapy in 665 patients with BRAF V600E-mutant colorectal cancer, the overall response rate (complete or partial response) was 26% (95% CI= 18%- 35%) in the triplet arm versus 2% (95% CI= <1%-7%) in the control arm, with median overall survival of 9.0 months in the triplet arm (95% CI= 8.0-11.4) and 5.4 months in the control arm (95% CI= 4.8-6.6) (PMID: 31566309). The combination of dabrafenib, trametinib and panitumumab has also shown efficacy in this population, with a response rate in one study of 26%, with an additional 57% of patients achieving stable disease (PMID: 29431699). Triplet therapy is listed as a 2A therapy in the NCCN guidlines."
              },
              "operation": "update",
              "uuids": "d9b444f3-76b2-4f91-a919-8b8b4d853846"
            }
          ],
          "timeStamp": 1587156961206
        },
        "-M6l5ggz7U-Mq_KYchPX": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Ganglioglioma, Pilocytic Astrocytoma, Pleomorphic Xanthoastrocytoma",
              "new": {
                "TIs": [
                  {
                    "name": "Standard implications for sensitivity to therapy",
                    "name_uuid": "93e82861-dd45-4d0d-b33f-39a5b162e518",
                    "treatments": [
                      {
                        "description": "The combination of a BRAF inhibitor, such as dabrafenib or vemurafenib, and a MEK1/2 inhibitor, such as trametinib and cobimetinib is FDA-approved in melanoma and is NCCN-compendium listed as recommended treatment of CNS cancers such as pilocytic astrocytoma (PA), pleomorphic xanthoastrocytoma (PXA) and ganglioglioma. The recommendation is based on several case studies and basket trials in which patients with these diseases harboring a BRAF V600E mutation (PXA: n=14, AG: n=5, PA: n=2) had a partial response or other clinical benefit following treatment with a BRAF inhibitor in combination with a MEK inhibitor (PMID: 28984141, 29380516, 26287849, 30351999, 30120137).",
                        "description_review": {
                          "lastReviewed": "",
                          "updateTime": 1588887930267,
                          "updatedBy": "User"
                        },
                        "description_uuid": "827ea474-7d3e-4802-a25e-cc67df5aa754",
                        "indication": "",
                        "indication_uuid": "63390f0a-aa80-4e26-98c6-e2ba164b7061",
                        "level": "2",
                        "level_review": {
                          "lastReviewed": "",
                          "updateTime": 1587969908339,
                          "updatedBy": "User"
                        },
                        "level_uuid": "851f2ab2-5b0f-414a-82d4-f58ef2eabf08",
                        "name": "939cd40b-b515-499d-b099-fd29027c0d17 + fb2bb01c-c0ec-4641-abf7-87f486075022, 4e91da20-6cf0-4e07-995f-7f7db4c7c077 + eb357145-3b18-4aca-b75a-5e18dd2bf4f9",
                        "name_review": {
                          "added": true,
                          "updateTime": 1587969901550,
                          "updatedBy": "User"
                        },
                        "name_uuid": "7f76d72e-ec85-4f42-91fe-b247dbe0e0e9",
                        "propagation": "3B",
                        "propagationLiquid": "no",
                        "propagationLiquid_review": {
                          "lastReviewed": "",
                          "updateTime": 1587969908334,
                          "updatedBy": "User"
                        },
                        "propagationLiquid_uuid": "76cd35f5-c87e-4065-988e-a08851d11155",
                        "propagation_review": {
                          "lastReviewed": "",
                          "updateTime": 1587969908329,
                          "updatedBy": "User"
                        },
                        "propagation_uuid": "27730433-510a-4dd9-a85b-d4a3960f666b",
                        "short": ""
                      }
                    ],
                    "treatments_uuid": "20098bb8-9fb4-4956-94f1-2c34b83ec764",
                    "type": "SS"
                  },
                  {
                    "name": "Standard implications for resistance to therapy",
                    "name_uuid": "0c311582-582d-45ed-a7c7-10cf734b5dc8",
                    "treatments_uuid": "70033d5c-ffa4-4e03-98a5-2f694c70a665",
                    "type": "SR"
                  },
                  {
                    "name": "Investigational implications for sensitivity to therapy",
                    "name_uuid": "33a99a5a-8ccf-46c4-a296-9ef6d349082e",
                    "treatments_uuid": "94a0708f-ffa2-4306-9370-9129c4e19514",
                    "type": "IS"
                  },
                  {
                    "name": "Investigational implications for resistance to therapy",
                    "name_uuid": "59ecfdb7-6879-4a03-a1db-d799c1e090af",
                    "treatments_uuid": "4602932c-c284-4b69-99ea-1574bf344cb8",
                    "type": "IR"
                  }
                ],
                "cancerTypes": [
                  {
                    "code": "PAST",
                    "mainType": "Glioma",
                    "subtype": "Pilocytic Astrocytoma"
                  },
                  {
                    "code": "PXA",
                    "mainType": "Glioma",
                    "subtype": "Pleomorphic Xanthoastrocytoma"
                  },
                  {
                    "code": "GNG",
                    "mainType": "Glioma",
                    "subtype": "Ganglioglioma"
                  }
                ],
                "cancerTypes_review": {
                  "added": true,
                  "lastReviewed": [
                    {
                      "code": "PAST",
                      "mainType": "Glioma",
                      "subtype": "Pilocytic Astrocytoma"
                    },
                    {
                      "code": "APXA",
                      "mainType": "Glioma",
                      "subtype": "Anaplastic Pleomorphic Xanthoastrocytoma"
                    },
                    {
                      "code": "AGNG",
                      "mainType": "Glioma",
                      "subtype": "Anaplastic Ganglioglioma"
                    }
                  ],
                  "updateTime": 1588887636809,
                  "updatedBy": "User"
                },
                "cancerTypes_uuid": "8a0e5008-caaa-443a-8bd6-83a79324bfd9",
                "diagnostic": {
                  "description": "",
                  "description_uuid": "a50cabb0-1c7f-4175-a8a9-0d3bc4b04492",
                  "level": "",
                  "level_uuid": "8111e079-2c3a-48c8-a8a7-edf767c6dd53",
                  "short": ""
                },
                "diagnosticSummary": "",
                "diagnosticSummary_uuid": "d2a23a0f-a886-4a23-abcc-78c383725ab6",
                "diagnostic_uuid": "490ff0ae-d940-46ed-96ce-e7da111f5ae8",
                "prognostic": {
                  "description": "",
                  "description_uuid": "2dc32a00-0d51-4e76-89c7-ee5d25bef139",
                  "level": "",
                  "level_uuid": "a92d04a7-8d0b-4cb1-afe3-ba4e5a18829b",
                  "short": ""
                },
                "prognosticSummary": "",
                "prognosticSummary_uuid": "9f6359d5-1087-4917-9210-da20882b76bb",
                "prognostic_uuid": "bd7c638c-33c2-4029-b378-009caf72b600",
                "summary": "The RAF-targeted inhibitors dabrafenib and vemurafenib in combination with the MEK-targeted inhibitors trametinib and cobimetinib, respectively, are NCCN-compendium listed for the treatment of patients with [[variant]].",
                "summary_review": {
                  "lastReviewed": "",
                  "updateTime": 1588886486654,
                  "updatedBy": "User"
                },
                "summary_uuid": "114b09bd-f15e-4f71-a3dd-048c746b20c3"
              },
              "operation": "add",
              "uuids": "114b09bd-f15e-4f71-a3dd-048c746b20c3,7f76d72e-ec85-4f42-91fe-b247dbe0e0e9"
            }
          ],
          "timeStamp": 1588887997272
        },
        "-MDlcJJALFtdkCCrTEan": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Fusions, Ovarian Cancer, INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY, fb2bb01c-c0ec-4641-abf7-87f486075022, eb357145-3b18-4aca-b75a-5e18dd2bf4f9",
              "new": {
                "description": "Cobimetinib and trametinib are small molecule inhibitors of the MEK1/2 kinases that are FDA approved in combination with a RAF inhibitor for use in BRAF V600E-positive metastatic melanoma. In a study of patients with low-grade serous ovarian cancer, a patient with a CUL1-BRAF fusion who progressed on carboplatin and paclitaxel had a sustained complete response to treatment with paclitaxel and a MEK1/2 inhibitor (selumetinib) (PMID: 26324360).  Additionally, in vitro studies have demonstrated that BRAF fusions are sensitive to MEK inhibition as measured decreased downstream MAPK pathway signaling in BRAF-fusion-containing cells upon treatment with trametinib (PMID: 24345920)."
              },
              "old": {
                "description": "Cobimetinib and trametinib are small molecule inhibitors of the MEK1/2 kinases that are FDA approved in combination with a RAF inhibitor for use in BRAF V600E-positive metastatic melanoma. In a study of patients with low-grade serous ovarian cancer, a patient with a CUL1-BRAF fusion who progressed on carboplatin and paclitaxel had a sustained complete response to treatment with paclitaxel and a MEK1/2 inhibitor (selumetinib) (PMID: 26324360). Additionally, in vitro studies have demonstrated that BRAF fusions are sensitive to MEK inhibition as measured decreased downstream MAPK pathway signaling in BRAF-fusion-containing cells upon treatment with trametinib or selumetinib (PMID: 23890088, 24345920)."
              },
              "operation": "update",
              "uuids": "e569bfd4-15f5-421d-9d4e-31dfb7a82903"
            }
          ],
          "timeStamp": 1596413003139
        },
        "-MDlcOKI-V85Cy96n-62": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Fusions, Melanoma, INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY, fb2bb01c-c0ec-4641-abf7-87f486075022, eb357145-3b18-4aca-b75a-5e18dd2bf4f9",
              "new": {
                "description": "Cobimetinib and trametinib are small molecule inhibitors of the MEK1/2 kinases that are FDA approved in combination with a RAF inhibitor for use in BRAF V600E-positive metastatic melanoma. Two studies from independent groups have shown that three patients with BRAF-fusion positive metastatic melanoma experienced clinical benefit, such as improvement of ECOG status, tumor shrinkage or stable disease, upon treatment with the MEK inhibitor trametinib (PMID: 26314551, 26072686). In vitro studies have demonstrated that BRAF fusions are sensitive to MEK inhibition as measured decreased downstream MAPK pathway signaling in BRAF-fusion-containing cells upon treatment with trametinib (PMID: 24345920)."
              },
              "old": {
                "description": "Cobimetinib and trametinib are small molecule inhibitors of the MEK1/2 kinases that are FDA approved in combination with a RAF inhibitor for use in BRAF V600E-positive metastatic melanoma. Two studies from independent groups have shown that three patients with BRAF-fusion positive metastatic melanoma experienced clinical benefit, such as improvement of ECOG status, tumor shrinkage or stable disease, upon treatment with the MEK inhibitor trametinib (PMID: 26314551, 26072686). In vitro studies have demonstrated that BRAF fusions are sensitive to MEK inhibition as measured decreased downstream MAPK pathway signaling in BRAF-fusion-containing cells upon treatment with trametinib or selumetinib (PMID: 23890088, 24345920)."
              },
              "operation": "update",
              "uuids": "cec96519-6479-4b9e-9d89-42e3b2a2bc94"
            }
          ],
          "timeStamp": 1596413023691
        },
        "-MDlcVt65ck5oy8URjOL": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Histiocytosis",
              "new": {
                "TIs": [
                  {
                    "name": "Standard implications for sensitivity to therapy",
                    "name_uuid": "b631f862-051a-4a0a-889a-4e890566b7d7",
                    "treatments_uuid": "793da244-4dc3-49eb-9dc4-39f2ca12fb4f",
                    "type": "SS"
                  },
                  {
                    "name": "Standard implications for resistance to therapy",
                    "name_uuid": "f759c5ce-7bb7-4878-adbe-f0174412418c",
                    "treatments_uuid": "d1ecaa63-6170-4555-ac8b-07fb743d807a",
                    "type": "SR"
                  },
                  {
                    "name": "Investigational implications for sensitivity to therapy",
                    "name_uuid": "7973a75d-75eb-4d63-a70d-92726be8169f",
                    "treatments_uuid": "adeb8f20-597f-4f86-b79f-f1f2de3e079d",
                    "type": "IS"
                  },
                  {
                    "name": "Investigational implications for resistance to therapy",
                    "name_uuid": "4829f582-a24e-4ff8-93db-5dee0a021fdf",
                    "treatments_uuid": "10fb3cca-9d48-4d12-9b3d-87bb68c5f1fa",
                    "type": "IR"
                  }
                ],
                "cancerTypes": [
                  {
                    "code": "",
                    "mainType": "Histiocytosis",
                    "subtype": ""
                  }
                ],
                "cancerTypes_review": {
                  "added": true,
                  "updateTime": 1588124245765,
                  "updatedBy": "User"
                },
                "cancerTypes_uuid": "e6b2a3eb-d18e-4978-974c-4f96968f8da5",
                "diagnostic": {
                  "description": "",
                  "description_uuid": "549be1e3-364a-422e-8179-73e53fad43c1",
                  "level": "",
                  "level_uuid": "0578832a-1498-4aa3-ab3e-ae5742eeeace",
                  "short": ""
                },
                "diagnosticSummary": "",
                "diagnosticSummary_uuid": "0f69f8ed-1039-47b8-b080-753fe299d9e5",
                "diagnostic_uuid": "8430d413-66d5-49d4-9349-96958414e789",
                "prognostic": {
                  "description": "",
                  "description_uuid": "58d11fc4-cf22-4d01-8ed5-1142f5acd21d",
                  "level": "",
                  "level_uuid": "dc5bfe77-54e5-4dad-a69b-5160bae26b74",
                  "short": ""
                },
                "prognosticSummary": "",
                "prognosticSummary_uuid": "197b4dcc-6b20-470d-b126-a53710bc6a52",
                "prognostic_uuid": "0c755197-2b43-4f75-b156-b878ca777cdc",
                "summary": "The MEK1/2-targeted inhibitor cobimetinib has shown promising clinical activity in patients with BRAF V600E or N486_T491delinsK mutant histiocytic disease.",
                "summary_review": {
                  "lastReviewed": "",
                  "updateTime": 1588175324404,
                  "updatedBy": "User"
                },
                "summary_uuid": "92d5ed0f-6425-4b2b-9a75-b7f673840cee"
              },
              "operation": "add",
              "uuids": "92d5ed0f-6425-4b2b-9a75-b7f673840cee"
            }
          ],
          "timeStamp": 1596413054655
        },
        "-MDlc_LvnlssrrtP1Tij": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "K601, Melanoma, INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY, fb2bb01c-c0ec-4641-abf7-87f486075022",
              "new": {
                "description": "Trametinib is a small molecule inhibitor of the MEK1/2 kinases that is FDA approved in combination with a RAF inhibitor for use in BRAF V600E-positive metastatic melanoma. Anecdotal evidence of clinical activity of trametinib in BRAF K601-mutant melanoma includes a patient who experienced a complete response to trametinib over 36 months (PMID: 28344857), and four patients in various other studies who achieved a partial response or stable disease upon treatment with trametinib (PMID: 23248257, 24933606). In vitro studies of cell lines engineered to express BRAF K601E demonstrated sensitivity to MEK inhibition as measured by decreased activation of downstream effector proteins upon treatment with trametinib (PMID: 22798288, 29903896)."
              },
              "old": {
                "description": "Trametinib is a small molecule inhibitor of the MEK1/2 kinases that is FDA approved in combination with a RAF inhibitor for use in BRAF V600E-positive metastatic melanoma. Anecdotal evidence of clinical activity of trametinib in BRAF K601-mutant melanoma includes a patient who experienced a complete response to tratmetinib over 36 months (PMID: 28344857), and four patients in various other studies who achieved partial response or stable disease upon treatment with trametinib (PMID: 23248257, 24933606). In vitro studies of cell lines engineered to express BRAF K601E demonstrated sensitivity to MEK inhibition as measured by decreased activation of downstream effector proteins upon treatment with trametinib (PMID: 22798288, 29903896)."
              },
              "operation": "update",
              "uuids": "b17106e4-9dd3-4157-90d2-0e791c15278b"
            }
          ],
          "timeStamp": 1596413072946
        },
        "-MFXGIe2eqYnLVGurVp9": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600, Melanoma, Tumor Type Summary",
              "new": "The RAF-targeted inhibitors encorafenib, dabrafenib and vemurafenib, alone or in combination with the MEK1/2-targeted inhibitors binimetinib, trametinib and cobimetinib respectively, are FDA-approved for the treatment of patients with BRAF V600E/K mutant melanoma and NCCN-compendium listed for the treatment of patients with BRAF V600-mutant melanoma. Additionally, the anti-PD-L1 antibody atezolizumab in combination with cobimetinib + vemurafenib is FDA-approved for the treatment of patients with unresectable or advanced BRAF V600-mutant melanoma.",
              "old": "The RAF-targeted inhibitors encorafenib, dabrafenib and vemurafenib, alone or in combination with the MEK1/2-targeted inhibitors binimetinib, trametinib and cobimetinib respectively, are FDA-approved for the treatment of patients with BRAF V600E/K mutant melanoma, and NCCN-compendium listed for the treatment of patients with BRAF V600-mutant melanoma.",
              "operation": "update",
              "uuids": "49c8da54-77d7-4480-af56-bd58072c54c0"
            }
          ],
          "timeStamp": 1598302796580
        },
        "-MFXGM3VqbMKbXMHFS6H": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600, Melanoma, Standard implications for sensitivity to therapy, 4e91da20-6cf0-4e07-995f-7f7db4c7c077 + 9a54c73a-15d8-41a8-8ea0-730f874831da + eb357145-3b18-4aca-b75a-5e18dd2bf4f9",
              "new": {
                "description": "The combination of vemurafenib, an inhibitor of V600-mutant BRAF, and cobimetinib, an inhibitor of MEK1/2, with atezolizumab, an immunotherapeutic PD-L1 antibody, is FDA approved for patients with BRAF V600 mutation-positive unresectable or metastatic melanoma. FDA-approval was based on the results of the Phase III double-blind, randomized, placebo-controlled IMspire150 trial of Atezolizumab + Cobimetinib + Vemurafenib versus Placebo + Cobimetinib + Vemurafenib in 514 patients with BRAF V600-mutant melanoma in which the median progression-free survival was 15.1 mos (95% CI=11.4, 18.4) in the triplet arm versus 10.6 mos (95% CI=9.3, 12.7) in the doublet + placebo arm (HR=0.78; 95% CI= 0.63, 0.97; p=0.0249) (PMID: 32534646).",
                "description_review": {
                  "lastReviewed": "",
                  "updateTime": 1598302298580,
                  "updatedBy": "User"
                },
                "description_uuid": "1ee0f4a5-318d-4143-8e47-9a32ebd8b9e8",
                "indication": "",
                "indication_uuid": "4208a33d-de35-4c52-a6dd-85a0b276eb41",
                "level": "1",
                "level_review": {
                  "lastReviewed": "",
                  "updateTime": 1596687805296,
                  "updatedBy": "User"
                },
                "level_uuid": "a4c90e67-a82b-4888-a512-1a60638a6585",
                "name": "4e91da20-6cf0-4e07-995f-7f7db4c7c077 + 9a54c73a-15d8-41a8-8ea0-730f874831da + eb357145-3b18-4aca-b75a-5e18dd2bf4f9",
                "name_review": {
                  "added": true,
                  "updateTime": 1596687800344,
                  "updatedBy": "User"
                },
                "name_uuid": "2e0a9edd-9248-4da3-b5f8-acdfe19039d6",
                "propagation": "3B",
                "propagationLiquid": "no",
                "propagationLiquid_review": {
                  "lastReviewed": "",
                  "updateTime": 1596687805291,
                  "updatedBy": "User"
                },
                "propagationLiquid_uuid": "67c961d9-3575-43d8-b653-c64dc6b85948",
                "propagation_review": {
                  "lastReviewed": "",
                  "updateTime": 1596687805286,
                  "updatedBy": "User"
                },
                "propagation_uuid": "627b61ec-51f8-453c-aa39-d9e594a4df66",
                "short": ""
              },
              "operation": "add",
              "uuids": "2e0a9edd-9248-4da3-b5f8-acdfe19039d6"
            }
          ],
          "timeStamp": 1598302810562
        },
        "-MI2mG5G9YyPEvzrSWdT": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "L597S, Mutation Effect",
              "new": {
                "description": "The BRAF L597S mutation is located in the kinase domain of the BRAF protein. This mutation has been found in melanoma, among other cancers (PMID: 26643848). In vitro studies have demonstrated that this mutation is likely activating as measured by increased downstream signaling compared to wildtype (PMID: 22798288). Drug efficacy studies in cell lines demonstrated that the BRAF L597S mutation might be sensitive to the RAF inhibitor vemurafenib and the MEK inhibitor trametinib (PMID: 22798288). The BRAF L597S mutation has also been identified in patients with positive responses to trametinib, the allosteric MEK inhibitor TAK-733, and combined dabrafenib and trametinib treatment (PMID: 24933606, 22798288, 29903896)."
              },
              "old": {
                "description": "The BRAF L597S mutation is located in the kinase domain in exon 15 of the protein. A clinicopathologic study of a cohort of 1119 Australian patients with known BRAF mutant status positive melanomas demonstrated that at 3.4% of patients, BRAF L597 mutations are one of the most commonly occuring non-BRAF V600E mutations and have distinct clinicopathologic features. This study found that L597 melanomas typically occur in older (median 66 yr) male (73.3% of L597 mutant cases) patients and were associated with chronically sun damaged skin (extremities or head and neck location - 73.3%, P = 0.001) (PMID: 26643848). Expression of this mutation in 293H cells demonstrated that it is likely activating, as measured by increased downstream MEK and ERK activation compared to vector control (PMID: 22798288). In vitro studies suggest that this mutation may be sensitive to vemurafenib and trametinib as measured by decreased MEK and ERK activation upon drug treatment similar to BRAF V600E (PMID: 22798288). A patient with melanoma harboring the BRAF L597S mutation demonstrated 33% tumor shrinkage when treated with trametinib as the first-line treatment with a partial response for 6.2 months (PMID: 24933606) and in another independent study, a patient with BRAF L597S mutant melanoma demonstrated partial radiographic response with 31% tumor shrinkage after 2 cycles treatment with allosteric MEK inhibitor (PMID: 22798288). A third study also contained a case report of a patient with melanoma harboring the BRAF L597S mutation who exhibited an objective radiographic response to dabrafenib + trametinib (PMID: 29903896)."
              },
              "operation": "update",
              "uuids": "bd08e589-0a0b-4ff9-b514-fe3fe1d84f30"
            }
          ],
          "timeStamp": 1601012568571
        },
        "-MI2mPHaaOjtg3Pq7Um0": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "L597R, Mutation Effect",
              "new": {
                "description": "The BRAF L597R mutation is located in the kinase domain of the BRAF protein. This mutation has been found in melanoma, among other cancers (PMID: 26643848). In vitro studies have demonstrated that this mutation is likely activating as measured by increased downstream signaling compared to wildtype (PMID: 22798288). Drug efficacy studies in cell lines demonstrated that the BRAF L597L mutation might be sensitive to the RAF inhibitor vemurafenib and the MEK inhibitor trametinib (PMID: 22798288). The BRAF L597L mutation has also been identified in patients with positive responses to trametinib and the allosteric MEK inhibitor TAK-733 (PMID: 24933606)."
              },
              "old": {
                "description": "The BRAF L597R mutation is located in the kinase domain in exon 15 of the protein. A clinicopathologic study of a cohort of 1119 Australian patients with known BRAF mutant status positive melanomas demonstrated that at 3.4% of patients, BRAF L597 mutations are one of the most commonly occuring non-BRAF V600E mutations and have distinct clinicopathologic features. This study found that L597 melanomas typically occur in older (median 66 yr) male (73.3% of L597 mutant cases) patients and were associated with chronically sun damaged skin (extremities or head and neck location - 73.3%, P = 0.001) (PMID: 26643848). Expression of this mutation in 293H cells demonstrated that it is likely activating, as measured by increased downstream MEK and ERK activation compared to vector control (PMID: 22798288). In vitro studies suggest that this mutation may be sensitive to vemurafenib and trametinib as measured by decreased MEK and ERK activation upon drug treatment similar to BRAF V600E (PMID: 22798288). A patient with melanoma harboring the BRAF L597S mutation demonstrated 33% tumor shrinkage when treated with trametinib as the first-line treatment with a partial response for 6.2 months (PMID: 24933606) and in another independent study, a patient with BRAF L597S mutant melanoma demonstrated partial radiographic response with 31% tumor shrinkage after 2 cycles treatment with allosteric MEK inhibitor (PMID: 22798288)."
              },
              "operation": "update",
              "uuids": "57225720-7b20-42b8-aed1-561e9d1a6922"
            }
          ],
          "timeStamp": 1601012606224
        },
        "-MI2n6BYmDUipIz6V4bQ": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "D594G, Mutation Effect",
              "new": {
                "description": "The BRAF D594G mutation is located in the kinase domain of the BRAF protein. This mutation has been found in colorectal cancer and melanomas, among others (PMID: 26498038, 28481359). Despite having hypoactive kinase activity, in vitro studies have demonstrated that this mutation is likely activating as measured by increased CRAF dimerization and downstream signaling compared to wildtype (PMID: 20141835, 26498038, 28783719). This mutation is a Class III BRAF mutation (PMID: 28783719). The BRAF D594G mutation is sensitive to the MEK inhibitor trametinib but likely insensitive to the RAF inhibitor vemurafenib (PMID: 20141835)."
              },
              "old": {
                "description": "The class III hypoactivating (PMID: 28783719) exon 15 BRAF D594G missense mutation occurs in the kinase domain of the protein and renders BRAF kinase-dead (or with “lower than wildtype kinase activity”) (PMID: 20141835, 26498038, 28783719). This mutation has been recurrently found in melanoma, lung and colorectal cancers (PMID: 26498038, 28481359). Biological characterization of the BRAF D594G mutation has demonstrated that it is RAS dependent in its activation of the MAPK pathway, signals as a dimer with CRAF (PMID: 28783719), and typically co-occurs with another driver mechanism that amplifies RAS signaling. Thus, when BRAF D594G is observed in melanoma, it typically co-occurs with an activating RAS mutation or NF1 inactivation, whereas when observed in non-small cell lung or colorectal cancers, it is associated with receptor tyrosine kinase (RTK) hyperactivation at the protein level (PMID: 28783719). While this mutation is sensitive to MEK inhibition by targeted inhibitors such as trametinib, it is insensitive to RAF monomer inhibitors such as vemurafenib."
              },
              "operation": "update",
              "uuids": "2f4e594e-c475-49b7-a06a-dd2b1c5d4189"
            }
          ],
          "timeStamp": 1601012790157
        },
        "-MI2nDHiEGv-VIODoQBr": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "I326V, Mutation Effect",
              "new": {
                "description": "The BRAF I326V mutation is located in the flexible hinge domain of the BRAF protein. This mutation has been found as a germline mutation in Noonan Syndrome (PMID: 17603482). In vitro studies have demonstrated that this mutation is likely neutral as measured by downstream signaling compared to wildtype (PMID: 17603482)."
              },
              "old": {
                "description": "The BRAF I326V mutation is located in exon 7 of the protein. Expression of this mutation in HEK293 cells demonstrated that is it neutral, as shown by similar levels of pathway activation compared to wildtype BRAF (PMID: 17603482)."
              },
              "operation": "update",
              "uuids": "c81b4261-e7a5-49db-80fc-e85e54ab4055"
            }
          ],
          "timeStamp": 1601012819224
        },
        "-MI2nH8O5TfwDTmyRl0O": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R462E, Mutation Effect",
              "new": {
                "description": "The BRAF R462E mutation is located in the kinase domain of the BRAF protein. In vitro studies have demonstrated that the BRAF L597S mutation is likely activating as measured by CRAF activity and downstream signaling compared to wildtype (PMID: 25155755)."
              },
              "old": {
                "description": "The BRAF R462E mutation occurs in the P loop of the tyrosine kinase domain of the BRAF protein. In vitro experiments show that the mutation increases CRAF activity, as indicated by phosphorylation at residue S338 (PMID: 25155755). This observation indicates that this variant, like other variants, might increase MEK activity in a CRAF-dependent manner. Its oncogenic potential has not been described."
              },
              "operation": "update",
              "uuids": "612a0f55-afdf-4931-abbc-16550552dd4c"
            }
          ],
          "timeStamp": 1601012835011
        },
        "-MI2nP_lFDRF1SIt6YQ_": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "K483M, Mutation Effect",
              "new": {
                "description": "The BRAF K483M mutation is located in the kinase domain of the BRAF protein. This mutation is a BRAF kinase-dead alteration (PMID: 15035987). However, in vitro studies have demonstrated that this mutation is likely activating as measured by CRAF activation and downstream signaling compared to wildtype (PMID: 15035987, 23533272)"
              },
              "old": {
                "description": "The BRAF K483M mutation occurs in the tyrosine kinase domain of the BRAF protein. It has been characterized as a kinase-dead mutation with no transformation ability (PMID: 15035987, 23533272). However, although initial in vitro experiments indicated an inability to induce ERK or CRAF activity, later data suggest that this variant paradoxically leads to CRAF activation and subsequent MEK activation (PMID: 27025703). The K483 mutation causes a developmental phenotype in zebrafish similaryl to BRAF V600E and is in that system sensititive to MEK inhibition (PMID: 19376813)."
              },
              "operation": "update",
              "uuids": "a979f929-319b-4dad-917f-ba9414e5d0f6"
            }
          ],
          "timeStamp": 1601012869595
        },
        "-MIqqkW5QYrIphQcOr-Q": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "L584F, Mutation Effect",
              "new": {
                "description": "The BRAF L584F mutation is located in the kinase domain of the BRAF protein. This mutation has been found in melanoma, as well as other cancers (PMID: 23658559, 26386083). In vitro studies have demonstrated that this mutation may be activating as measured by sensitivity to RAF inhibition compared to wildtype (PMID: 23658559)."
              },
              "old": {
                "description": "The BRAF L584F mutation has yet to be functionally characterized. The melanoma NZM28 cell line, which endogenously expresses BRAF G469A and L584F mutations, was sensitive to BRAF inhibition. Computational modeling predicted that the L584F mutation would alter BRAF function (PMID: 23658559)."
              },
              "operation": "update",
              "uuids": "31484336-b5ef-4566-9139-0889007f5784"
            }
          ],
          "timeStamp": 1601869383855
        },
        "-MIqt7ybIOLp1jADOoTc": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G596C, Mutation Effect",
              "new": {
                "description": "The BRAF G596C mutation is located in the kinase domain of the BRAF protein. This mutation has been found in non-small cell lung cancers, among others (PMID: 28947956). In vitro experiments have demonstrated that this mutation is activating as measured by increased downstream signaling compared to wildtype controls (PMID: 28947956). The BRAF G596C mutation confers resistance to the RAF inhibitor dabrafenib, but retains sensitivity to MEK inhibitor trametinib, as measured by MAPK pathway activation (PMID: 28947956)."
              },
              "old": {
                "description": "The BRAF exon 15 G596C mutation occurs in the kinase domain of the protein and has been found in non-small cell lung cancer. A single study has biologically characterized this BRAF mutation and in cell line experiments this study showed that BRAF G596C is activating as measured by increased downstream ERK signaling associated with the mutant compared to wildtype BRAF. Though this mutant is kinase-dead, it activates the MAPK pathway through heterodimerization with CRAF. Cell line experiments suggest that this mutation confers resistance to RAF inhibitor dabrafenib, as measured by increased MAPK pathway activation upon drug treatment, but retains sensitivity to MEK inhibitor trametinib, as measured by decreased MAPK pathway activation upon drug treatment (Abstract: Noeparast, A. et al. Abstract# 11091, ASCO 2015. http://meetinglibrary.asco.org/content/152688-156)."
              },
              "operation": "update",
              "uuids": "7c6857fc-1772-420f-b26a-2e122ca12071"
            }
          ],
          "timeStamp": 1601870008336
        },
        "-MIqw75c7gs7VNy1CW5V": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "A598T, Mutation Effect",
              "new": {
                "description": "The BRAF A598T mutation is located in the kinase domain of the BRAF protein. This mutation is predicted to be a BRAF mutational hotspot in cancer (PMID: 26619011). In vitro experiments have demonstrated that is mutation is inactivating, as shown by reduced BRAF kinase activity compared to wildtype controls (PMID: 22926515, 32059434)."
              },
              "old": {
                "description": "The BRAF exon 15 A598T mutation occurs in the BRAF kinase domain (PMID: 22926515). While this mutation is considered a BRAF hotspot (PMID: 26619011), to date it has not been found to occur in the MSK IMPACT series (Berger et al., Nature Medicine 2017) and cell line experiments demonstrate the mutation to be inactivating, as shown by abolished kinase activity compared to wildtype BRAF and inability to activate other RAF isoforms (e.g., ARAF) (PMID: 22926515)."
              },
              "operation": "update",
              "uuids": "b0e7125c-946a-4890-b86a-9cb16ddc21bd"
            }
          ],
          "timeStamp": 1601870791185
        },
        "-MIqwDBmQCDd-JYneHsH": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R671Q, Mutation Effect",
              "new": {
                "description": "The BRAF R671Q mutation is located in the kinase domain of the BRAF protein. This mutation has been found in colorectal cancers, among others (PMID: 27048246). In vitro studies have demonstrated that this mutation is likely activating as measured by increased downstream signaling compared to wildtype (PMID: 28174173)."
              },
              "old": {
                "description": "The BRAF R671Q mutation is located in the BRAF kinase domain. In vitro expression of this mutation demonstrated that it is likely activating, as shown by its resistance to FZR1 binding and FZR1-mediated degradation as compared to wildtype BRAF (PMID: 28174173)."
              },
              "operation": "update",
              "uuids": "c66a2b0d-3f33-4f91-85f3-4c0cac591ad8"
            }
          ],
          "timeStamp": 1601870816155
        },
        "-MIqwc8fb_T_jts8jrKh": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "W450L, Mutation Effect",
              "new": {
                "description": "The BRAF W450L mutation is located in the kinase domain of the BRAF protein. This mutation has been found in lung cancers, among others (PMID: 27478040). In vitro studies have demonstrated that this mutation is likely neutral as measured by downstream signaling compared to wildtype (PMID: 27478040)."
              },
              "old": {
                "description": "The BRAF W450L mutation occurs in exon 11 of the gene. A study evaluating the effects of rare somatic mutations in lung cancers showed that cells transfected with BRAF W450L mutation display similar ERK phophorylation levels than wildtype, suggesting that this mutation does not affect downstream MAPK pathway alteration (PMID: 27478040)."
              },
              "operation": "update",
              "uuids": "a4bddc9f-5015-46ac-bb44-29ac9c0ba4ab"
            }
          ],
          "timeStamp": 1601870922452
        },
        "-MIqwhIR7RZ_Pi7HfVk5": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "F247L, Mutation Effect",
              "new": {
                "description": "The BRAF F247L mutation is located in the RAS binding and kinase autoinhibitory domain of the BRAF protein. This mutation has been found in colorectal cancers, among others (PMID: 31515458). In vitro studies have demonstrated that this mutation is activating as measured by increased downstream signaling compared to wildtype (PMID: 28512244, 29533785)."
              },
              "old": {
                "description": "The BRAF F247L mutation lies within a zinc-finger region of the protein. Two separate studies have shown that this mutation is activating, as indicated by increased phosphorylation of downstream MAPK-pathway members (PMID: 28512244, 29533785)."
              },
              "operation": "update",
              "uuids": "6da5e4e4-ed2a-4c99-83cd-555ceb42bd76"
            }
          ],
          "timeStamp": 1601870943557
        },
        "-MIqxKBrvLsvgj-ZK2l0": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "E501K, Mutation Effect",
              "new": {
                "description": "The BRAF E501K mutation is located in the kinase domain of the BRAF protein. This mutation has been found as a germline mutation in Noonan syndrome and cardiofaciocutaneous syndrome (PMID: 17603482, 16474404). In vitro studies have demonstrated that this mutation might be inactivating as measured by decreased BRAF kinase activity in a cell line with a second BRAF mutation compared to controls (PMID: 17603482). However, another in vitro study found increased downstream pathway output compared to wildtype (PMID: 16474404)."
              },
              "old": {
                "description": "The BRAF E501K mutation has been identified as a germline mutation in patients with Noonan syndrome (PMID: 17603482 ) and cardio-facio-cutaneous syndrome (PMID: 16474404). This mutation, in combination with the BRAF I326V mutation, was identified in a patient with Noonan Syndrome (I326V) (PMID: 17603482). Cells expressing the double mutant (E501K and I326V) showed decreased kinase activity compared to cells expressing the single I326V mutant (I326V) or wildtype BRAF (PMID: 17603482). In a separate report, expression of the BRAF E501K in cell lines did not lead to an increase in RAS-ERK activity as measured by a luciferase reporter assay (PMID: 16474404)."
              },
              "operation": "update",
              "uuids": "ec6aaa98-f05b-4a8d-bb3c-5e1b59380208"
            }
          ],
          "timeStamp": 1601871106976
        },
        "-MK1f6rJ-0qGwx29ItNY": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "L597V, Mutation Effect",
              "new": {
                "description": "The class II (PMID: 28783719) and hyperactivating (PMID: 26343582) BRAF L597V missense mutation is located in the kinase domain in exon 15 of the BRAF protein, and is recurrent in melanoma (PMID: 12068308, 15035987, 26643848). A clinicopathologic study of a cohort of 1119 Australian patients with known BRAF mutant status positive melanomas demonstrated that, at 3.4% of patients, BRAF L597 mutations are some of the most commonly occurring BRAF non-V600E mutations. These BRAF mutations typically occur in older (median 66 yr) male (73.3% of L597 mutant cases) patients and are associated with chronically sun-damaged skin (extremities or head and neck location - 73.3%, P = 0.001) (PMID: 26643848). Biological characterization of BRAF L597V mutation has demonstrated that it activates the downstream MAPK pathway independent of RAS (PMID: 12068308, 15035987, 22798288, 26343582, 28783719), renders BRAF active as a dimer with CRAF and itself (PMID: 20179705), and while sensitive to MEK inhibition by targeted inhibitors such as trametinib (PMID: 28783719, 22798288, 18794803), is insensitive to RAF monomer inhibitors such as vemurafenib (PMID: 22798288, 28783719, 20179705)."
              },
              "old": {
                "description": "The class II (PMID: 28783719) and hyperactivating (PMID: 26343582) BRAF L597V missense mutation is located in the kinase domain in exon 15 of the BRAF protein, and is recurrent in melanoma (PMID: 12068308, 15035987, 26643848). A clinicopathologic study of a cohort of 1119 Australian patients with known BRAF mutant status positive melanomas demonstrated that, at 3.4% of patients, BRAF L597 mutations are some of the most commonly occurring BRAF non-V600E mutations. These BRAF mutations typically occur in older (median 66 yr) male (73.3% of L597 mutant cases) patients and are associated with chronically sun-damaged skin (extremities or head and neck location - 73.3%, P = 0.001) (PMID:26643848). Biological characterization of BRAF L597V mutation has demonstrated that it activates the downstream MAPK pathway independent of RAS (PMID: 12068308, 15035987, 22798288, 26343582, 28783719), renders BRAF active as a dimer with CRAF and itself (PMID: 20179705), and while sensitive to MEK inhibition by targeted inhibitors such as trametinib (PMID: 28783719, 22798288, 18794803), is insensitive to RAF monomer inhibitors such as vemurafenib (PMID: 22798288, 28783719, 20179705)."
              },
              "operation": "update",
              "uuids": "a9e6b8b3-d1fb-4685-a5ec-78811f7bb602"
            }
          ],
          "timeStamp": 1603141402284
        },
        "-MOUStobpwUI3feXwWFE": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600_K601insDFGLAT",
              "new": "V600_K601insDFGLAT",
              "old": "V600D_K601insFGLAT",
              "operation": "name change",
              "uuids": "c24e656a-f0db-4539-909d-a3848f941620"
            }
          ],
          "timeStamp": 1607919443276
        },
        "-MOUT-H8DnUhEN42vS4o": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600_K601insDFGLAT, Mutation Effect",
              "new": {
                "description": "The BRAF V600_K601insDFGLAT alteration is located in the kinase domain in exon 15 of the protein. This mutation has been found in papillary thyroid cancer (PMID: 17297294). Expression of this mutation in NIH-3T3 cells demonstrated that it is activating as measured by increased downstream pathway activation and colony formation compared to wildtype BRAF (PMID: 17297294)."
              },
              "old": {
                "description": "The BRAF V600D_K601insFGLAT alteration is located in the kinase domain in exon 15 of the protein. This mutation has been found in papillary thyroid cancer (PMID: 17297294). Expression of this mutation in NIH-3T3 cells demonstrated that it is activating as measured by increased downstream pathway activation and colony formation compared to wildtype BRAF (PMID: 17297294)."
              },
              "operation": "update",
              "uuids": "e5797c7f-7268-48b6-8ead-783fcab2d999"
            }
          ],
          "timeStamp": 1607919469742
        },
        "-MSa3qKh2_KD7XwfUgBU": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "L485_P490del, Mutation Effect",
              "new": {
                "description": "The BRAF L485_P490del mutation is located in the kinase domain in exon 11 of the protein. Expression of this mutation in HEK293 or NIH-3T3 cells demonstrated that it is activating, as measured by kinase activity and colony formation in soft agar comparable to BRAF V600E (PMID: 26732095). However, a second study in human cell lines demonstrated that this mutation has kinase activity comparable to wildtype BRAF (PMID: 26996308). This mutation is dependent on BRAF homodimer formation, as BRAF L485_P490del fails to activate downstream MAPK pathway effectors as a monomer (PMID: 26732095). In vitro studies suggest that this mutation is resistant to vemurafenib, as measured by sustained MAPK pathway signaling and proliferation upon drug treatment (PMID: 26732095).",
                "effect": "Likely Gain-of-function",
                "oncogenic": "Likely"
              },
              "old": {
                "description": "The BRAF L485_P490del mutation is located in the kinase domain in exon 11 of the protein. Expression of this mutation in HEK293 or NIH-3T3 cells demonstrated that it is activating, as measured by kinase activity and colony formation in soft agar comparable to BRAF V600E (PMID: 26732095). This mutation is dependent on BRAF homodimer formation, as BRAF L485_P490del fails to activate downstream MAPK pathway effectors as a monomer (PMID: 26732095). In vitro studies suggest that this mutation is resistant to vemurafenib, as measured by sustained MAPK pathway signaling and proliferation upon drug treatment (PMID: 26732095).",
                "effect": "Gain-of-function",
                "oncogenic": "Yes"
              },
              "operation": "update",
              "uuids": "c02b208b-d750-4898-957c-a9b175327513,fcc850b0-b6f4-4c5e-9f3d-b1776da2b284"
            }
          ],
          "timeStamp": 1612325283452
        },
        "-MSa3w7w0kGw6uoDP30i": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "N486_P490del (NVTAP)",
              "new": "N486_P490del (NVTAP)",
              "old": "N486_P490del",
              "operation": "name change",
              "uuids": "f876cba6-4d29-4ad1-9b42-0f6416e2645d"
            }
          ],
          "timeStamp": 1612325307212
        },
        "-MSa411Da9-TfWXyArrk": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "N486_P490del (NVTAP), Mutation Effect",
              "new": {
                "description": "The BRAF N486_P490del mutation is located in the kinase domain in exon 11 of the protein. This mutation has been found in an ovarian cancer cell line and in patients with pancreatic cancer (PMID: 18060073, 26996308, 31519698). Expression of this mutation in a human cell line demonstrated that it is activating via a CRAF- and dimer-independent mechanism as measured by increased kinase activity and downstream signaling compared to wildtype (PMID: 26996308). A patient with pancreatic cancer  harboring this mutation had a partial response to treatment with the BRAF inhibitor dabrafenib (PMID: 31519698)"
              },
              "old": {
                "description": "The BRAF N486_P490del mutation is located in the kinase domain in exon 11 of the protein. This mutation has been found in an ovarian cancer cell line (PMID: 18060073). While this variant has not been functionally validated, another alteration at this position (L485_P490del) has been shown to be gain-of-function and oncogenic (PMID: 26732095)."
              },
              "operation": "update",
              "uuids": "5211e083-6d72-4505-a5fe-29da60c439a0"
            }
          ],
          "timeStamp": 1612325331358
        },
        "-MSa46nGYZMQ_DPkCy1Y": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "N486_T488del",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF N486_T488del mutation is located in the kinase domain in exon 11 of the protein. Expression of this mutation in a human cell line demonstrated that it is likely activating as measured by increased kinase activity compared to wildtype (PMID: 26996308).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1610424627688,
                    "updatedBy": "User"
                  },
                  "description_uuid": "68cfd242-24d8-4fe0-b89d-9762a5f0dbea",
                  "effect": "Likely Gain-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1610424607061,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "8754dd0b-a399-4490-a974-b60c3ff0d914",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1610424605966,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "33d8da06-3401-4fe6-ab4e-f2937c13438a",
                  "short": ""
                },
                "mutation_effect_uuid": "56116aad-cb95-4e3e-bcc9-b56af1760ff1",
                "name": "N486_T488del",
                "name_review": {
                  "added": true,
                  "updateTime": 1610424595582,
                  "updatedBy": "User"
                },
                "name_uuid": "13877568-b24a-497b-b70e-77bfd1a435cb",
                "tumors_uuid": "30d12c81-066c-4a88-baf8-0d452ddddfd3"
              },
              "operation": "add",
              "uuids": "33d8da06-3401-4fe6-ab4e-f2937c13438a,8754dd0b-a399-4490-a974-b60c3ff0d914"
            }
          ],
          "timeStamp": 1612325354977
        },
        "-MSa4CdD9P538Ztk6kGL": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "N486_V487del",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF N486_V487del mutation is located in the kinase domain in exon 11 of the protein. Expression of this mutation in a human cell line demonstrated that it is likely activating as measured by modestly increased kinase activity compared to wildtype (PMID: 26996308).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1610424461055,
                    "updatedBy": "User"
                  },
                  "description_uuid": "a8451527-8636-4201-a77c-534cd6e0d05e",
                  "effect": "Likely Gain-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1610424430924,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "efd9fd75-4a60-44c8-afaa-488fdcd9d630",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1610424429271,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "b7c09079-ec39-4eaf-a48a-29699f0561bc",
                  "short": ""
                },
                "mutation_effect_uuid": "eeff9fcc-acaf-44bd-bb26-dfee8536b0ef",
                "name": "N486_V487del",
                "name_review": {
                  "added": true,
                  "updateTime": 1610424327699,
                  "updatedBy": "User"
                },
                "name_uuid": "b9667b29-ac3b-4eca-a8e0-ba490c7b2938",
                "tumors_uuid": "206d1dd7-6cbf-4a80-b010-82c6e4ac02a1"
              },
              "operation": "add",
              "uuids": "b7c09079-ec39-4eaf-a48a-29699f0561bc,efd9fd75-4a60-44c8-afaa-488fdcd9d630"
            }
          ],
          "timeStamp": 1612325378910
        },
        "-MSa4IXJQBk-NoK6DWWJ": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "N486del",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF N486del mutation is located in the kinase domain in exon 11 of the protein. Expression of this mutation in a human cell line demonstrated that it is likely neutral as measured by kinase activity comparable to wildtype (PMID: 26996308).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1610424256863,
                    "updatedBy": "User"
                  },
                  "description_uuid": "67e14d8f-60d9-472d-a34a-c7ddbf62bf1f",
                  "effect": "Likely Neutral",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1610424086444,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "8988fbbf-4d5e-4827-8715-7b7ab6fec169",
                  "oncogenic": "Likely Neutral",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1610424084190,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "7fb3f203-c29f-4970-9fce-a49bbc9aaba2",
                  "short": ""
                },
                "mutation_effect_uuid": "543f98dd-9b83-4838-82a6-5e61da677464",
                "name": "N486del",
                "name_review": {
                  "added": true,
                  "updateTime": 1610424079199,
                  "updatedBy": "User"
                },
                "name_uuid": "bdfa205f-1129-4e2b-ab6b-284415afb44b",
                "tumors_uuid": "10b9d24f-d954-48d2-bf96-1ee58cfd26ae"
              },
              "operation": "add",
              "uuids": "7fb3f203-c29f-4970-9fce-a49bbc9aaba2,8988fbbf-4d5e-4827-8715-7b7ab6fec169"
            }
          ],
          "timeStamp": 1612325403044
        },
        "-MSa4OQjCP9bpE82jK5L": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "P490_Q494del, Mutation Effect",
              "new": {
                "description": "The BRAF P490_Q494del mutation is located in the kinase domain in exon 11 of the protein. This mutation has been found in pancreatic cancer (PMID: 26996308). Expression of this mutation in a human cell line demonstrated that it is activating as measured by increased kinase activity and downstream signaling compared to wildtype (PMID: 26996308)."
              },
              "old": {
                "description": "The BRAF P490_Q494del mutation is located in the kinase domain in exon 11 of the protein. While this variant has not been functionally validated, another alteration at this position (L485_P490del) has been shown to be gain-of-function and oncogenic (PMID: 26732095)"
              },
              "operation": "update",
              "uuids": "bdfa68e2-fbeb-4cd0-be3a-5f99c698a832"
            }
          ],
          "timeStamp": 1612325427199
        },
        "-MSa4UHHUgj23Q0Iv9gm": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "T488_P492del, Mutation Effect",
              "new": {
                "description": "The BRAF T488_P492del mutation is located in the kinase domain in exon 11 of the protein. This mutation has been found in pancreatic cancer (PMID: 26996308). Expression of this mutation in a human cell line demonstrated that it is activating as measured by increased kinase activity and downstream signaling compared to wildtype (PMID: 26996308)."
              },
              "old": {
                "description": "The BRAF T488_P492del mutation is located in the kinase domain in exon 11 of the protein. While this deletion has not been functionally validated, another deletion at this position (L485_Q494del) has been shown to be gain-of-function and oncogenic (PMID: 26732095)."
              },
              "operation": "update",
              "uuids": "a73f9de4-3f0a-4a19-a926-8527631caf46"
            }
          ],
          "timeStamp": 1612325451170
        },
        "-MSa4_7e1_VG0pHVU9u3": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "T488_P490del",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF T488_P490del mutation is located in the kinase domain in exon 11 of the protein. Expression of this mutation in a human cell line demonstrated that it is likely neutral as measured by kinase activity comparable to wildtype (PMID: 26996308).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1610426704754,
                    "updatedBy": "User"
                  },
                  "description_uuid": "a8eeb312-a465-4411-9024-30c25e0f6032",
                  "effect": "Likely Neutral",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1610426691942,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "93d252f6-11a4-4b50-9716-2d6603567f22",
                  "oncogenic": "Likely Neutral",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1610426690565,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "6a5b6c22-8a6b-47af-b330-771367813431",
                  "short": ""
                },
                "mutation_effect_uuid": "cf016510-c4ec-4bd8-98ac-2f6b76c46a0b",
                "name": "T488_P490del",
                "name_review": {
                  "added": true,
                  "updateTime": 1610426669560,
                  "updatedBy": "User"
                },
                "name_uuid": "b3bd86b0-9432-4b0f-a954-4f3e0d67b761",
                "tumors_uuid": "0bcd37ff-5719-4d77-a530-7f0983db2659"
              },
              "operation": "add",
              "uuids": "6a5b6c22-8a6b-47af-b330-771367813431,93d252f6-11a4-4b50-9716-2d6603567f22"
            }
          ],
          "timeStamp": 1612325475130
        },
        "-MSa4f-laOnqclV37q-v": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "A489_P490del",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF A489_P490del mutation is located in the kinase domain in exon 11 of the protein. Expression of this mutation in a human cell line demonstrated that it is likely activating as measured by modestly increased kinase activity compared to wildtype (PMID: 26996308).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1610426519414,
                    "updatedBy": "User"
                  },
                  "description_uuid": "d23ed1e8-1d11-442c-93cb-550767689c0e",
                  "effect": "Likely Gain-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1610426530813,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "3a2c8706-35f2-4056-a822-6cb6135aa7f8",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1610426529691,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "14e19c47-eb20-45a7-bf36-a4acc714db68",
                  "short": ""
                },
                "mutation_effect_uuid": "d6789831-54c2-4249-b6fb-79ae50c99130",
                "name": "A489_P490del",
                "name_review": {
                  "added": true,
                  "updateTime": 1610425818798,
                  "updatedBy": "User"
                },
                "name_uuid": "25fd8536-c932-4d45-8d3a-c3697d0877ff",
                "tumors_uuid": "7c805c8c-048a-4a4e-96d0-e8a231407c29"
              },
              "operation": "add",
              "uuids": "14e19c47-eb20-45a7-bf36-a4acc714db68,3a2c8706-35f2-4056-a822-6cb6135aa7f8"
            }
          ],
          "timeStamp": 1612325499201
        },
        "-MSa4ksFMuurpMh2Skl9": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "P490del",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF P490del mutation is located in the kinase domain in exon 11 of the protein. Expression of this mutation in a human cell line demonstrated that it is likely neutral as measured by kinase activity comparable to wildtype (PMID: 26996308).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1610425778993,
                    "updatedBy": "User"
                  },
                  "description_uuid": "ace7d0d6-8f18-454d-85a9-cfc2abdafb8a",
                  "effect": "Likely Neutral",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1610425756197,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "beace36e-656a-43af-9044-faf7cf48039c",
                  "oncogenic": "Likely Neutral",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1610425755062,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "6e00085e-9da2-492a-a8c6-a635ebebfb65",
                  "short": ""
                },
                "mutation_effect_uuid": "f5d86f2b-ff75-4856-8759-aa61cead463c",
                "name": "P490del",
                "name_review": {
                  "added": true,
                  "updateTime": 1610425748610,
                  "updatedBy": "User"
                },
                "name_uuid": "837ba422-a90c-4718-bf2d-bdf07f46726d",
                "tumors_uuid": "73fddbc6-2fff-4552-9cc5-5ef8380150a5"
              },
              "operation": "add",
              "uuids": "6e00085e-9da2-492a-a8c6-a635ebebfb65,beace36e-656a-43af-9044-faf7cf48039c"
            }
          ],
          "timeStamp": 1612325523232
        },
        "-MSa4qhU7eWRJUxFdsRT": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "N486_T491del",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF N486_T491del mutation is located in the kinase domain in exon 11 of the protein. Expression of this mutation in a human cell line demonstrated that it is likely activating as measured by modestly increased kinase activity compared to wildtype (PMID: 26996308).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1610425641999,
                    "updatedBy": "User"
                  },
                  "description_uuid": "2740206e-5edb-428b-c040-220552c08e45",
                  "effect": "Likely Gain-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1610425606247,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "605adff6-663f-455d-9b22-a60cade42cfc",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1610425605175,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "f7bc56df-3d31-4f59-9949-cd88d5c8a63e",
                  "short": ""
                },
                "mutation_effect_uuid": "4f14424c-991a-468a-8242-26cf90fa5985",
                "name": "N486_T491del",
                "name_review": {
                  "added": true,
                  "updateTime": 1610425600953,
                  "updatedBy": "User"
                },
                "name_uuid": "f3aecfaf-aa2a-4cb6-8a01-da8710acbab5",
                "tumors_uuid": "ad858391-66f9-4936-8d4d-2cf0fed712c1"
              },
              "operation": "add",
              "uuids": "f7bc56df-3d31-4f59-9949-cd88d5c8a63e,605adff6-663f-455d-9b22-a60cade42cfc"
            }
          ],
          "timeStamp": 1612325547119
        },
        "-MSa4wYvBdavNJmAcJyD": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "N486_A489del",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF N486_A489del mutation is located in the kinase domain in exon 11 of the protein. Expression of this mutation in a human cell line demonstrated that it is likely activating as measured by modestly increased kinase activity compared to wildtype (PMID: 26996308).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1610424681890,
                    "updatedBy": "User"
                  },
                  "description_uuid": "cd7b33d0-45ca-4173-96ed-e68260a0991c",
                  "effect": "Likely Gain-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1610424692697,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "09be3075-692e-4804-bdef-15c34c209716",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1610424691004,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "65cb1cc4-f06b-4618-af23-3e11834cb4ca",
                  "short": ""
                },
                "mutation_effect_uuid": "efa0df17-4768-4c8b-9f99-9c4349b88861",
                "name": "N486_A489del",
                "name_review": {
                  "added": true,
                  "updateTime": 1610424651630,
                  "updatedBy": "User"
                },
                "name_uuid": "4ca075b8-8624-4f5d-be52-f9a3ff6db4aa",
                "tumors_uuid": "7bbb4d82-73ab-4726-a4ba-396d232760d3"
              },
              "operation": "add",
              "uuids": "65cb1cc4-f06b-4618-af23-3e11834cb4ca,09be3075-692e-4804-bdef-15c34c209716"
            }
          ],
          "timeStamp": 1612325571083
        },
        "-MSa51SV6GqebMJu6ICL": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V487_P490del",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF V487_P490del mutation is located in the kinase domain in exon 11 of the protein. Expression of this mutation in a human cell line demonstrated that it is likely activating as measured by increased kinase activity compared to wildtype (PMID: 26996308).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1610426890908,
                    "updatedBy": "User"
                  },
                  "description_uuid": "085138cb-ba66-4af1-9305-757e664601e8",
                  "effect": "Likely Gain-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1610426903793,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "8fba81d3-6bfd-46b2-b3c8-be2174cf5cef",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1610426902787,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "b6c74337-4d02-4a34-b5eb-018219d39c2f",
                  "short": ""
                },
                "mutation_effect_uuid": "6d9f1d04-af93-4556-9244-f6efc2fa4180",
                "name": "V487_P490del",
                "name_review": {
                  "added": true,
                  "updateTime": 1610426735837,
                  "updatedBy": "User"
                },
                "name_uuid": "bcf6faf4-75ac-489d-acef-f4143668082c",
                "tumors_uuid": "b323ce9c-1ed0-46a2-bf88-1437b58075d5"
              },
              "operation": "add",
              "uuids": "b6c74337-4d02-4a34-b5eb-018219d39c2f,8fba81d3-6bfd-46b2-b3c8-be2174cf5cef"
            }
          ],
          "timeStamp": 1612325595248
        },
        "-MXm0HBs5uSFpnpTCENJ": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Biliary Tract Cancer, NOS",
              "new": {
                "TIs": [
                  {
                    "name": "Standard implications for sensitivity to therapy",
                    "name_uuid": "d47a1bea-4645-4b05-831a-89687062b06b",
                    "treatments_uuid": "25440edb-536d-4bd3-8d68-fc9ffd8772d2",
                    "type": "SS"
                  },
                  {
                    "name": "Standard implications for resistance to therapy",
                    "name_uuid": "70a15af4-c6e0-4f40-9290-62c70910b5fe",
                    "treatments_uuid": "c9719120-771b-4835-94e3-4671e7ee6816",
                    "type": "SR"
                  },
                  {
                    "name": "Investigational implications for sensitivity to therapy",
                    "name_uuid": "e1ac2071-783e-4f14-b33c-799b5ebaa146",
                    "treatments": [
                      {
                        "description": "Dabrafenib, an orally bioavailable RAF inhibitor, and trametinib, an orally bioavailable MEK1/2 inhibitor, are FDA-approved alone or in combination for the treatment of patients with various solid cancers with BRAF V600E mutation. In a Phase II, single-arm basket trial of dabrafenib + trametinib in patients with BRAF V600E-mutant solid tumors, of 43 patients with biliary tract cancer, the overall response rate was 51% (22/43, 95% CI 36–67), the median progression-free survival was 9 months (95% CI 5-10), and the median overall survival was 14 months (95% CI 10-33). Of the 43 patients with biliary tract cancer, 51% of patients (22/43) had a partial response and 40% (17/43) had stable disease (PMID: 32818466).",
                        "description_review": {
                          "lastReviewed": "",
                          "updateTime": 1617760025996,
                          "updatedBy": "User"
                        },
                        "description_uuid": "937cba34-96d6-46b2-9206-c56a3643294d",
                        "indication": "",
                        "indication_uuid": "b661f91b-ffdc-4ac3-8ca3-2e9ca90ed69b",
                        "level": "3A",
                        "level_review": {
                          "lastReviewed": "",
                          "updateTime": 1617759240306,
                          "updatedBy": "User"
                        },
                        "level_uuid": "d25c6add-4534-4599-96a7-3e4fb7bb5d10",
                        "name": "939cd40b-b515-499d-b099-fd29027c0d17 + fb2bb01c-c0ec-4641-abf7-87f486075022",
                        "name_review": {
                          "added": true,
                          "updateTime": 1617759235438,
                          "updatedBy": "User"
                        },
                        "name_uuid": "445a0405-6710-464b-9f61-6adab5b10665",
                        "propagation": "3B",
                        "propagationLiquid": "no",
                        "propagationLiquid_review": {
                          "lastReviewed": "",
                          "updateTime": 1617759240303,
                          "updatedBy": "User"
                        },
                        "propagationLiquid_uuid": "0e1f27ca-b792-4c8d-a31f-3aa2406d7249",
                        "propagation_review": {
                          "lastReviewed": "",
                          "updateTime": 1617759244408,
                          "updatedBy": "User"
                        },
                        "propagation_uuid": "7fa2cb3e-2b80-47eb-888e-9e149d3fd173",
                        "short": ""
                      }
                    ],
                    "treatments_uuid": "3c7b507e-9ca9-4ae9-8add-15d36a4fe0dd",
                    "type": "IS"
                  },
                  {
                    "name": "Investigational implications for resistance to therapy",
                    "name_uuid": "e291e6bd-a676-4742-a1a6-2068382e7ae3",
                    "treatments_uuid": "cfa2981f-886c-481a-93b7-3b151f4622c3",
                    "type": "IR"
                  }
                ],
                "cancerTypes": [
                  {
                    "code": "",
                    "mainType": "Biliary Tract Cancer, NOS",
                    "subtype": ""
                  }
                ],
                "cancerTypes_review": {
                  "added": true,
                  "updateTime": 1617759167325,
                  "updatedBy": "User"
                },
                "cancerTypes_uuid": "3107dabb-5918-4f3d-9574-6afa5072a333",
                "diagnostic": {
                  "description": "",
                  "description_uuid": "16f199ae-6122-436e-bf47-54ae2117789f",
                  "level": "",
                  "level_uuid": "1173ad5b-963f-4a0c-a855-51af641768ad",
                  "short": ""
                },
                "diagnosticSummary": "",
                "diagnosticSummary_uuid": "4c85d796-2173-4fd8-8b80-03880b6347bc",
                "diagnostic_uuid": "f91f9254-43a6-4f42-86e4-3b0cc6e22bf4",
                "prognostic": {
                  "description": "",
                  "description_uuid": "99b28836-6987-463b-964c-1715559600a5",
                  "level": "",
                  "level_uuid": "6c27f9a5-76db-4efd-9c55-9950c685b190",
                  "short": ""
                },
                "prognosticSummary": "",
                "prognosticSummary_uuid": "ef868583-c4b5-44a6-ae75-ccf01c9ce2df",
                "prognostic_uuid": "9b9c33b6-94ea-4fd4-af48-eaf51582e079",
                "summary": "There is promising clinical data in patients with BRAF V600E-mutant biliary tract cancer treated with the RAF-targeted inhibitor dabrafenib in combination with the MEK1/2-targeted inhibitor trametinib.",
                "summary_review": {
                  "lastReviewed": "",
                  "updateTime": 1617894309487,
                  "updatedBy": "User"
                },
                "summary_uuid": "0cb7164f-3cca-464e-b038-857e80c8b5c2"
              },
              "operation": "add",
              "uuids": "0cb7164f-3cca-464e-b038-857e80c8b5c2,445a0405-6710-464b-9f61-6adab5b10665"
            }
          ],
          "timeStamp": 1617894385101
        },
        "-MY5UUj1E9E3ERQ65ljq": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Biliary Tract Cancer, NOS",
              "new": {
                "TIs": [
                  {
                    "name": "Standard implications for sensitivity to therapy",
                    "name_uuid": "d47a1bea-4645-4b05-831a-89687062b06b",
                    "treatments_uuid": "25440edb-536d-4bd3-8d68-fc9ffd8772d2",
                    "type": "SS"
                  },
                  {
                    "name": "Standard implications for resistance to therapy",
                    "name_uuid": "70a15af4-c6e0-4f40-9290-62c70910b5fe",
                    "treatments_uuid": "c9719120-771b-4835-94e3-4671e7ee6816",
                    "type": "SR"
                  },
                  {
                    "name": "Investigational implications for sensitivity to therapy",
                    "name_uuid": "e1ac2071-783e-4f14-b33c-799b5ebaa146",
                    "treatments": [
                      {
                        "description": "Dabrafenib, an orally bioavailable RAF inhibitor, and trametinib, an orally bioavailable MEK1/2 inhibitor, are FDA-approved alone or in combination for the treatment of patients with various solid cancers with BRAF V600E mutation. In a Phase II, single-arm basket trial of dabrafenib + trametinib in patients with BRAF V600E-mutant solid tumors, of 43 patients with biliary tract cancer, the overall response rate was 51% (22/43, 95% CI 36–67), the median progression-free survival was 9 months (95% CI 5-10), and the median overall survival was 14 months (95% CI 10-33). Of the 43 patients with biliary tract cancer, 51% of patients (22/43) had a partial response and 40% (17/43) had stable disease (PMID: 32818466).",
                        "description_review": {
                          "lastReviewed": "",
                          "updateTime": 1617760025996,
                          "updatedBy": "User"
                        },
                        "description_uuid": "937cba34-96d6-46b2-9206-c56a3643294d",
                        "indication": "",
                        "indication_uuid": "b661f91b-ffdc-4ac3-8ca3-2e9ca90ed69b",
                        "level": "3A",
                        "level_review": {
                          "lastReviewed": "",
                          "updateTime": 1617759240306,
                          "updatedBy": "User"
                        },
                        "level_uuid": "d25c6add-4534-4599-96a7-3e4fb7bb5d10",
                        "name": "939cd40b-b515-499d-b099-fd29027c0d17 + fb2bb01c-c0ec-4641-abf7-87f486075022",
                        "name_review": {
                          "added": true,
                          "updateTime": 1617759235438,
                          "updatedBy": "User"
                        },
                        "name_uuid": "445a0405-6710-464b-9f61-6adab5b10665",
                        "propagation": "3B",
                        "propagationLiquid": "no",
                        "propagationLiquid_review": {
                          "lastReviewed": "",
                          "updateTime": 1617759240303,
                          "updatedBy": "User"
                        },
                        "propagationLiquid_uuid": "0e1f27ca-b792-4c8d-a31f-3aa2406d7249",
                        "propagation_review": {
                          "lastReviewed": "",
                          "updateTime": 1617759244408,
                          "updatedBy": "User"
                        },
                        "propagation_uuid": "7fa2cb3e-2b80-47eb-888e-9e149d3fd173",
                        "short": ""
                      }
                    ],
                    "treatments_uuid": "3c7b507e-9ca9-4ae9-8add-15d36a4fe0dd",
                    "type": "IS"
                  },
                  {
                    "name": "Investigational implications for resistance to therapy",
                    "name_uuid": "e291e6bd-a676-4742-a1a6-2068382e7ae3",
                    "treatments_uuid": "cfa2981f-886c-481a-93b7-3b151f4622c3",
                    "type": "IR"
                  }
                ],
                "cancerTypes": [
                  {
                    "code": "",
                    "mainType": "Biliary Tract Cancer, NOS",
                    "subtype": ""
                  }
                ],
                "cancerTypes_review": {
                  "added": true,
                  "updateTime": 1617759167325,
                  "updatedBy": "User"
                },
                "cancerTypes_uuid": "3107dabb-5918-4f3d-9574-6afa5072a333",
                "diagnostic": {
                  "description": "",
                  "description_uuid": "16f199ae-6122-436e-bf47-54ae2117789f",
                  "level": "",
                  "level_uuid": "1173ad5b-963f-4a0c-a855-51af641768ad",
                  "short": ""
                },
                "diagnosticSummary": "",
                "diagnosticSummary_uuid": "4c85d796-2173-4fd8-8b80-03880b6347bc",
                "diagnostic_uuid": "f91f9254-43a6-4f42-86e4-3b0cc6e22bf4",
                "prognostic": {
                  "description": "",
                  "description_uuid": "99b28836-6987-463b-964c-1715559600a5",
                  "level": "",
                  "level_uuid": "6c27f9a5-76db-4efd-9c55-9950c685b190",
                  "short": ""
                },
                "prognosticSummary": "",
                "prognosticSummary_uuid": "ef868583-c4b5-44a6-ae75-ccf01c9ce2df",
                "prognostic_uuid": "9b9c33b6-94ea-4fd4-af48-eaf51582e079",
                "summary": "There is promising clinical data in patients with BRAF V600E-mutant biliary tract cancer treated with the RAF-targeted inhibitor dabrafenib in combination with the MEK1/2-targeted inhibitor trametinib.",
                "summary_review": {
                  "lastReviewed": "",
                  "updateTime": 1617894309487,
                  "updatedBy": "User"
                },
                "summary_uuid": "0cb7164f-3cca-464e-b038-857e80c8b5c2"
              },
              "operation": "add",
              "uuids": "0cb7164f-3cca-464e-b038-857e80c8b5c2,445a0405-6710-464b-9f61-6adab5b10665"
            }
          ],
          "timeStamp": 1618237853691
        },
        "-MbmpKJA2Tcg5fkbZ8Jr": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Oncogenic Mutations, Histiocytosis, INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY, eb357145-3b18-4aca-b75a-5e18dd2bf4f9",
              "new": {
                "description": "Cobimetinib is a small molecule inhibitor of MEK1/2 that is FDA-approved in combination with a BRAF inhibitor in BRAF V600-mutant melanoma. In a Phase II trial of cobimetinib in eighteen patients with histiocytoses, the overall response rate was 89%, with thirteen out of eighteen patients (72%) having a complete response and fifteen out of eighteen patients harboring a MAPK pathway mutation (PMID: 30867592). Six of six patients with BRAF mutations (five V600E, one non-V600E) had a partial or complete response to treatment with cobimetinib (PMID: 30867592). Small case studies and retroactive studies have also demonstrated the clinical efficacy of MEK inhibition in patients with histiocytic neoplasms (PMID: 29236635, 30718231)."
              },
              "old": {
                "description": "Cobimetinib is a small molecule inhibitor of MEK1/2 that is FDA-approved in combination with a BRAF inhibitor in BRAF V600-mutant melanoma. In a Phase II trial of cobimetinib in eighteen patients with histiocytoses, the overall response rate was 89%, with thirteen out of eighteen patients (72%) having a complete response and fifteen out of eighteen patients harboring a MAPK pathway mutation (PMID: 30867592) Six of six patients with BRAF mutations (five V600E, one non-V600E) had a partial or complete response to treatment with cobimetinib (PMID: 30867592). Small case studies and retroactive studies have also demonstrated the clinical efficacy of MEK inhibition in patients with histiocytic neoplasms (PMID: 29236635, 30718231)."
              },
              "operation": "update",
              "uuids": "483bc890-60e3-4c65-96e5-94f5412df6dc"
            }
          ],
          "timeStamp": 1623276737609
        },
        "-MbmpSIPAettZGSbzVHI": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600_K601delinsE, Mutation Effect",
              "new": {
                "description": "The BRAF V600_K601delinsE mutation is located in the kinase domain in exon 15 of the protein (PMID: 23833300). This mutation has been found in non-small cell lung cancer (NSCLC) (PMID: 23833300). Expression of this mutation in NIH-3T3 cells demonstrated that it is activating as measured by increased kinase activity, downstream ERK activation and increased colony formation compared to wildtype BRAF (PMID: 23833300). In a case report, a 63-year old woman with stage IV Non-small cell lung cancer harboring the V600_K601delinsE BRAF mutation had progressive disease upon treatment with vemurafenib (PMID: 26045855). In a second case report, a patient with BRAF V600_K601delinsE-mutant melanoma had a partial response to the combination of BRAF, MEK and CDK4/6 inhibition (PMID: 28800030)."
              },
              "old": {
                "description": "The BRAF V600_K601delinsE mutation is located in the kinase domain in exon 15 of the protein (PMID: 23833300). This mutation has been found in non-small cell lung cancer (NSCLC) (PMID: 23833300). Expression of this mutation in NIH-3T3 cells demonstrated that it is activating as measured by increased kinase activity, downstream ERK activation and increased colony formation compared to wildtype BRAF (PMID: 23833300). In a case report, a 63-year old woman with stage IV Non-small cell lung cancer harboring the V600_K601delinsE BRAF mutation had progressive disease upon treatment with vemurafenib (PMID: 26045855)."
              },
              "operation": "update",
              "uuids": "b6334102-f074-4b27-adbc-7ac7494a8036"
            }
          ],
          "timeStamp": 1623276770329
        },
        "-MbmpYS2wL8wf_BQZPzB": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "A598_T599insV",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF A598_T599insV mutation is located in the kinase domain of the protein. While this mutation has not been functionally characterized, a patient with melanoma harboring this mutation had a partial response to treatment with the combination of dabrafenib and trametinib (PMID: 28800030).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1620262990112,
                    "updatedBy": "User"
                  },
                  "description_uuid": "4f70acb0-8385-4686-abb7-7e4b52a973ab",
                  "effect": "Inconclusive",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1620262859093,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "5cc55276-326f-45e3-974a-fc29b92930fa",
                  "oncogenic": "Inconclusive",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1620262857940,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "8e1b288e-93a8-45fa-8fad-90b6fda31633",
                  "short": ""
                },
                "mutation_effect_uuid": "1b019c60-27f0-4243-bbb0-0dad95c1fe05",
                "name": "A598_T599insV",
                "name_review": {
                  "added": true,
                  "updateTime": 1620262850770,
                  "updatedBy": "User"
                },
                "name_uuid": "5c322e2a-aece-4acb-c07d-3c7ffd59503b",
                "tumors_uuid": "948eb59c-db7e-41ba-aec7-d969a48a9e71"
              },
              "operation": "add",
              "uuids": "8e1b288e-93a8-45fa-8fad-90b6fda31633,5cc55276-326f-45e3-974a-fc29b92930fa"
            }
          ],
          "timeStamp": 1623276795522
        },
        "-Mi45CCyZC34r-dijwfX": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Fusions, Pilocytic Astrocytoma",
              "new": {
                "TIs": [
                  {
                    "name": "Standard implications for sensitivity to therapy",
                    "name_uuid": "62c65c4e-1a8b-4848-a68f-1fc22169d64e",
                    "treatments": [
                      {
                        "description": "Selumetinib is a small molecule inhibitor of MEK1/2 kinases. In Stratum 1 of the phase 2 PBTC study of selumetinib in twenty five patients with pilocytic astrocytoma harboring a KIAA1549–BRAF fusion or BRAF V600E mutation, seven of eighteen patients with a KIAA1549–BRAF fusion had a partial response to treatment (PMID: 31151904). Additionally, the two year progression-free survival rate for the BRAF study population (n=25) was 70% (95% CI 47–85) (PMID: 31151904).",
                        "description_review": {
                          "lastReviewed": "",
                          "updateTime": 1630018309852,
                          "updatedBy": "User"
                        },
                        "description_uuid": "54651174-ebdb-4d7f-8a2c-f197a0f9efc3",
                        "indication": "",
                        "indication_uuid": "33fb66f9-e5ad-4a23-a2a6-a22213108b36",
                        "level": "2",
                        "level_review": {
                          "lastReviewed": "",
                          "updateTime": 1630017304819,
                          "updatedBy": "User"
                        },
                        "level_uuid": "5a7d2cbc-2ba0-4b91-a023-b8b6953e19fb",
                        "name": "3f154145-525b-4865-8baf-12b374697b2a",
                        "name_review": {
                          "added": true,
                          "updateTime": 1630017292138,
                          "updatedBy": "User"
                        },
                        "name_uuid": "a05f8f2e-5d26-4639-9c10-019b8183fc33",
                        "propagation": "3B",
                        "propagationLiquid": "no",
                        "propagationLiquid_review": {
                          "lastReviewed": "",
                          "updateTime": 1630017304817,
                          "updatedBy": "User"
                        },
                        "propagationLiquid_uuid": "e6ce9b08-9afa-4d6a-bfdc-ead1296bae42",
                        "propagation_review": {
                          "lastReviewed": "",
                          "updateTime": 1630017313915,
                          "updatedBy": "User"
                        },
                        "propagation_uuid": "a47bb690-5821-42e1-84c4-642380433269",
                        "short": ""
                      }
                    ],
                    "treatments_uuid": "c33f66b3-ffed-47cb-8b76-ef62de932a12",
                    "type": "SS"
                  },
                  {
                    "name": "Standard implications for resistance to therapy",
                    "name_uuid": "2203256e-4463-4afc-82c1-3ec957fea4cb",
                    "treatments_uuid": "decfa780-da5f-4f16-81f4-4bf19a6ace4f",
                    "type": "SR"
                  },
                  {
                    "name": "Investigational implications for sensitivity to therapy",
                    "name_uuid": "8214d741-38e0-48d5-8487-d4896783ce04",
                    "treatments_uuid": "e4e0675d-3019-49f6-a89b-9d113c68c4fa",
                    "type": "IS"
                  },
                  {
                    "name": "Investigational implications for resistance to therapy",
                    "name_uuid": "24bdb290-7856-4e66-915a-512b2125484f",
                    "treatments_uuid": "b9222ed9-26dd-4d10-9271-b7dfe050c05c",
                    "type": "IR"
                  }
                ],
                "cancerTypes": [
                  {
                    "code": "PAST",
                    "mainType": "Glioma",
                    "subtype": "Pilocytic Astrocytoma"
                  }
                ],
                "cancerTypes_review": {
                  "added": true,
                  "updateTime": 1630017047299,
                  "updatedBy": "User"
                },
                "cancerTypes_uuid": "1393c078-ecb7-495e-b9e6-fd037756396c",
                "diagnostic": {
                  "description": "",
                  "description_uuid": "ca4ef46b-b088-4c78-a0b9-403a40dce2e2",
                  "level": "",
                  "level_uuid": "72c47dc8-ddad-47e6-88dd-44a66ed95723",
                  "short": ""
                },
                "diagnosticSummary": "",
                "diagnosticSummary_uuid": "e887d069-86a4-4387-aed2-4c1c4eb8a528",
                "diagnostic_uuid": "d2a75324-0a79-45c6-b454-be1a7efc27b0",
                "prognostic": {
                  "description": "",
                  "description_uuid": "9c5d4039-1ee8-454a-8236-755b223824da",
                  "level": "",
                  "level_uuid": "7b627f2d-d5a7-4ab4-9125-09ed227150f7",
                  "short": ""
                },
                "prognosticSummary": "",
                "prognosticSummary_uuid": "0f4ca8f3-42c1-46d9-a0d0-cf48489dc346",
                "prognostic_uuid": "9c6360c4-2833-4a0a-9efa-375ca86e5716",
                "summary": "The MEK inhibitor selumetinib is NCCN-compendium listed as a treatment option for patients with BRAF fusion-positive pilocytic astrocytoma.",
                "summary_review": {
                  "lastReviewed": "",
                  "updateTime": 1630017269319,
                  "updatedBy": "User"
                },
                "summary_uuid": "5306d2e7-1e09-4cfe-ae94-152e3244c7f6"
              },
              "operation": "add",
              "uuids": "5306d2e7-1e09-4cfe-ae94-152e3244c7f6,a05f8f2e-5d26-4639-9c10-019b8183fc33"
            }
          ],
          "timeStamp": 1630025601927
        },
        "-Mi45WZfAuEyX_-rsIG6": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Fusions, Other Tumor Types, Tumor Type Summary",
              "new": "While the MEK1/2-targeted inhibitor selumetinib is NCCN-compendium listed as a treatment option for patients with BRAF fusion-positive pilocytic astrocytoma and there is promising clinical data demonstrating the clinical utility of MEK1/2-targeted inhibitors such as the FDA-approved trametinib in patients with BRAF fusion-positive melanoma and ovarian cancer, their clinical utility in patients with [[variant]] is unknown.",
              "old": "While there is promising clinical data demonstrating the clinical utility of MEK1/2-targeted inhibitors such as the FDA-approved trametinib in patients with BRAF fusion-positive melanoma and ovarian cancer, their clinical utility in patients with [[variant]] is unknown.",
              "operation": "update",
              "uuids": "67f8217f-063d-454f-c0a1-9ad1481afc59"
            }
          ],
          "timeStamp": 1630025685301
        },
        "-Mi46o8tPHHHH2uEM6s-": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Pilocytic Astrocytoma",
              "new": {
                "TIs": [
                  {
                    "name": "Standard implications for sensitivity to therapy",
                    "name_uuid": "8745ab87-6d3f-4f1c-a3e6-ef231a7a0881",
                    "treatments": [
                      {
                        "description": "Selumetinib is a small molecule inhibitor of MEK1/2 kinases. In Stratum 1 of the phase 2 PBTC study of selumetinib in twenty five patients with pilocytic astrocytoma harboring a KIAA1549–BRAF fusion or BRAF V600E mutation, two of seven patients with a BRAF V600E mutation had a partial response to treatment (PMID: 31151904). Additionally, the two year progression-free survival rate for the BRAF study population (n=25) was 70% (95% CI 47–85) (PMID: 31151904).",
                        "description_review": {
                          "lastReviewed": "",
                          "updateTime": 1630018662162,
                          "updatedBy": "User"
                        },
                        "description_uuid": "a4e4a347-c833-4543-94b2-cf8c89e2cd6d",
                        "indication": "",
                        "indication_uuid": "8630d57e-501d-4770-b2e4-1db8c6b6621c",
                        "level": "2",
                        "level_review": {
                          "lastReviewed": "",
                          "updateTime": 1630018614050,
                          "updatedBy": "User"
                        },
                        "level_uuid": "1cf6846a-4368-4f3c-9061-c1686e2bf2cc",
                        "name": "3f154145-525b-4865-8baf-12b374697b2a",
                        "name_review": {
                          "added": true,
                          "updateTime": 1630018608732,
                          "updatedBy": "User"
                        },
                        "name_uuid": "9ae514fa-cea6-4a01-9f6e-ae9ca1a43049",
                        "propagation": "3B",
                        "propagationLiquid": "no",
                        "propagationLiquid_review": {
                          "lastReviewed": "",
                          "updateTime": 1630018614046,
                          "updatedBy": "User"
                        },
                        "propagationLiquid_uuid": "e27e3157-11f6-4a8f-a1c7-de4679da45d1",
                        "propagation_review": {
                          "lastReviewed": "",
                          "updateTime": 1630018617395,
                          "updatedBy": "User"
                        },
                        "propagation_uuid": "626dc237-05a8-449a-82ce-22d21af5d3d0",
                        "short": ""
                      }
                    ],
                    "treatments_uuid": "5bd423ba-c62c-4359-8709-5356966af526",
                    "type": "SS"
                  },
                  {
                    "name": "Standard implications for resistance to therapy",
                    "name_uuid": "25015e60-e047-45f1-aa17-6bfe3985d12c",
                    "treatments_uuid": "af4ddc45-3c8b-483f-9006-ced1be53985f",
                    "type": "SR"
                  },
                  {
                    "name": "Investigational implications for sensitivity to therapy",
                    "name_uuid": "9fdf2d51-7214-4199-a9ea-ce397f767e5a",
                    "treatments_uuid": "77528889-b09e-45db-9e6d-ad82de971730",
                    "type": "IS"
                  },
                  {
                    "name": "Investigational implications for resistance to therapy",
                    "name_uuid": "0e9ae1b3-ac85-4c31-a267-95c32ae79525",
                    "treatments_uuid": "675c16b2-2484-42f6-8b1a-337475280573",
                    "type": "IR"
                  }
                ],
                "cancerTypes": [
                  {
                    "code": "PAST",
                    "mainType": "Glioma",
                    "subtype": "Pilocytic Astrocytoma"
                  }
                ],
                "cancerTypes_review": {
                  "added": true,
                  "updateTime": 1630018590211,
                  "updatedBy": "User"
                },
                "cancerTypes_uuid": "b7057bc7-f3cd-4a13-aac3-821a71318857",
                "diagnostic": {
                  "description": "",
                  "description_uuid": "6979c9a3-24fe-4f02-a13e-31093550ffb6",
                  "level": "",
                  "level_uuid": "9a36cff7-5832-4e6f-9177-a02a06301516",
                  "short": ""
                },
                "diagnosticSummary": "",
                "diagnosticSummary_review": {
                  "updateTime": 1630025154421,
                  "updatedBy": "User"
                },
                "diagnosticSummary_uuid": "505ee073-9229-4555-879c-8cf206efc84e",
                "diagnostic_uuid": "f99fc63c-05fe-4286-9451-025111976523",
                "prognostic": {
                  "description": "",
                  "description_uuid": "9f98b952-9425-4044-89f6-22db9e0409d5",
                  "level": "",
                  "level_uuid": "4967cb47-6189-4735-bf73-805c2db6fa1f",
                  "short": ""
                },
                "prognosticSummary": "",
                "prognosticSummary_uuid": "2232816b-6f42-4152-ab7e-c3028a4e67fc",
                "prognostic_uuid": "482b4c26-9ded-41a7-b293-1473dd721d17",
                "summary": "Combination treatment with RAF-targeted inhibitors plus MEK targeted inhibitors, including dabrafenib + trametinib, or vemurafenib + cobimetinib are NCCN-compendium listed for the treatment of patients with BRAF V600E-mutant pilocytic astrocytoma.",
                "summary_review": {
                  "lastReviewed": "",
                  "updateTime": 1630025827737,
                  "updatedBy": "User"
                },
                "summary_uuid": "06d6c080-3109-4164-9558-557d0f1d319f"
              },
              "operation": "add",
              "uuids": "06d6c080-3109-4164-9558-557d0f1d319f,9ae514fa-cea6-4a01-9f6e-ae9ca1a43049"
            }
          ],
          "timeStamp": 1630026023555
        },
        "-MkwJfz0ZF54kM_QSxap": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Oncogenic Mutations, Rosai-Dorfman Disease",
              "new": {
                "TIs": [
                  {
                    "name": "Standard implications for sensitivity to therapy",
                    "name_uuid": "3b7c5e2b-d2d2-48a8-8eab-0c2b3f196b30",
                    "treatments": [
                      {
                        "description": "PMID: 29236635",
                        "description_review": {
                          "lastReviewed": "",
                          "updateTime": 1633042643536,
                          "updatedBy": "User"
                        },
                        "description_uuid": "1a38d790-17c1-4a35-851d-4afc9e9b7bba",
                        "indication": "",
                        "indication_uuid": "a472d205-d859-4525-8c77-09b976e8cc41",
                        "level": "2",
                        "level_review": {
                          "lastReviewed": "",
                          "updateTime": 1633042626031,
                          "updatedBy": "User"
                        },
                        "level_uuid": "2963abfb-8619-4cc9-83dc-977aa49efea2",
                        "name": "eb357145-3b18-4aca-b75a-5e18dd2bf4f9, fb2bb01c-c0ec-4641-abf7-87f486075022",
                        "name_review": {
                          "added": true,
                          "updateTime": 1633042613559,
                          "updatedBy": "User"
                        },
                        "name_uuid": "3f7d891b-db8e-4024-bb95-6b0b2fcc94c0",
                        "propagation": "no",
                        "propagationLiquid": "no",
                        "propagationLiquid_review": {
                          "lastReviewed": "",
                          "updateTime": 1633042626029,
                          "updatedBy": "User"
                        },
                        "propagationLiquid_uuid": "8b8cae32-b2f5-4b1f-9e44-a1e901c5689a",
                        "propagation_review": {
                          "lastReviewed": "",
                          "updateTime": 1633042626027,
                          "updatedBy": "User"
                        },
                        "propagation_uuid": "eec0c3d8-4982-472f-a42e-ef3d1f6fff61",
                        "short": ""
                      }
                    ],
                    "treatments_uuid": "73728906-b34f-4c10-85bb-000fb740a4b9",
                    "type": "SS"
                  },
                  {
                    "name": "Standard implications for resistance to therapy",
                    "name_uuid": "3e4577c7-0b5b-4d98-ad2d-1cb86711f182",
                    "treatments_uuid": "1b0e0738-3769-4a00-9a2b-13b6d3d8d401",
                    "type": "SR"
                  },
                  {
                    "name": "Investigational implications for sensitivity to therapy",
                    "name_uuid": "e81ea76a-c04b-4c78-8602-2ab75928cd3e",
                    "treatments_uuid": "7eb5c861-9848-4d07-8d69-c4d7e73f7e63",
                    "type": "IS"
                  },
                  {
                    "name": "Investigational implications for resistance to therapy",
                    "name_uuid": "61d5f074-3506-47e0-83e4-c38bfad14d82",
                    "treatments_uuid": "ba3d7526-d9ff-4c12-91b0-b59c41d3c875",
                    "type": "IR"
                  }
                ],
                "cancerTypes": [
                  {
                    "code": "RDD",
                    "mainType": "Histiocytosis",
                    "subtype": "Rosai-Dorfman Disease"
                  }
                ],
                "cancerTypes_review": {
                  "added": true,
                  "updateTime": 1633042542483,
                  "updatedBy": "User"
                },
                "cancerTypes_uuid": "5b4a5df6-7f82-4793-9696-6278cd9f10fd",
                "diagnostic": {
                  "description": "",
                  "description_uuid": "c0c9dc93-826d-4e74-b6b4-e8922cb702eb",
                  "level": "",
                  "level_uuid": "6fac5518-4ed8-4132-8e55-645d7b4c7cc7",
                  "short": ""
                },
                "diagnosticSummary": "",
                "diagnosticSummary_uuid": "cd0aa46e-fa02-449f-c00a-5d3270407a1a",
                "diagnostic_uuid": "f8c7ed45-23a3-4588-aa85-694c11ee8132",
                "prognostic": {
                  "description": "",
                  "description_uuid": "6bc15691-00d9-47c0-a502-de940ffcce56",
                  "level": "",
                  "level_uuid": "01f338a4-20b9-461f-b42b-617b10b3605c",
                  "short": ""
                },
                "prognosticSummary": "",
                "prognosticSummary_uuid": "3378875f-1012-4a8c-8f8d-e9cb6e871205",
                "prognostic_uuid": "60d7e703-ee49-4de9-901e-701ae51564db",
                "summary": "The MEK-targeted inhibitors cobimetinib and trametinib are NCCN-listed as monotherapy for the treatment of patients with Rosai-Dorfman Disease with MAPK pathway alterations, including [[gene]][[mutation]].",
                "summary_review": {
                  "lastReviewed": "",
                  "updateTime": 1633042576508,
                  "updatedBy": "User"
                },
                "summary_uuid": "7b51745f-6c4b-4daa-9ffa-2c9c75de252a"
              },
              "operation": "add",
              "uuids": "7b51745f-6c4b-4daa-9ffa-2c9c75de252a,3f7d891b-db8e-4024-bb95-6b0b2fcc94c0"
            }
          ],
          "timeStamp": 1633099630299
        },
        "-MkwJll1EStLrgk3s_93": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Histiocytosis, Investigational implications for sensitivity to therapy, 4e91da20-6cf0-4e07-995f-7f7db4c7c077, 939cd40b-b515-499d-b099-fd29027c0d17",
              "new": {
                "description": "PMID: 25209580, 31376203, 31213430",
                "description_review": {
                  "lastReviewed": "",
                  "updateTime": 1633042828451,
                  "updatedBy": "User"
                },
                "description_uuid": "811f1a87-9e78-4e92-88c8-2f6717ed30db",
                "indication": "",
                "indication_uuid": "437d5e4a-cc7c-4474-a11a-889c92bb4468",
                "level": "3A",
                "level_review": {
                  "lastReviewed": "",
                  "updateTime": 1633042777854,
                  "updatedBy": "User"
                },
                "level_uuid": "2ffdab7f-2ede-42fc-b648-8f7883efc44f",
                "name": "4e91da20-6cf0-4e07-995f-7f7db4c7c077, 939cd40b-b515-499d-b099-fd29027c0d17",
                "name_review": {
                  "added": true,
                  "updateTime": 1633042771186,
                  "updatedBy": "User"
                },
                "name_uuid": "012aa663-c079-49fd-8e7a-f24c58b42f11",
                "propagation": "no",
                "propagationLiquid": "no",
                "propagationLiquid_review": {
                  "lastReviewed": "",
                  "updateTime": 1633042777849,
                  "updatedBy": "User"
                },
                "propagationLiquid_uuid": "6a2ab1fc-1e32-455d-b235-b87cb7f2dba3",
                "propagation_review": {
                  "lastReviewed": "",
                  "updateTime": 1633042777846,
                  "updatedBy": "User"
                },
                "propagation_uuid": "a3ab6e47-9be6-4d30-a862-6a63ff958401",
                "short": ""
              },
              "operation": "add",
              "uuids": "012aa663-c079-49fd-8e7a-f24c58b42f11"
            }
          ],
          "timeStamp": 1633099653980
        },
        "-MkwJrvP5ih_3J8eb7g7": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Oncogenic Mutations, Histiocytosis, Tumor Type Summary",
              "new": "There is promising clinical data in patients with histiocytic neoplasms harboring MAPK pathway alterations treated with the MEK-targeted inhibitors cobimetinib or trametinib as monotherapy.",
              "old": "While the MEK1/2-targeted inhibitor cobimetinib has shown promising clinical activity in patients with BRAF V600E or N486_T491delinsK mutant histiocytic disease, its clinical utility in patients with [[gene]] [[mutation]] [[mutant]] histiocytic disease is unknown.",
              "operation": "update",
              "uuids": "a035a4e8-143e-4ba8-b360-8ae275fa92bd"
            }
          ],
          "timeStamp": 1633099679220
        },
        "-MkwJxkiMS8teeECiQi6": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Oncogenic Mutations, Histiocytosis, INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY, eb357145-3b18-4aca-b75a-5e18dd2bf4f9, fb2bb01c-c0ec-4641-abf7-87f486075022",
              "new": {
                "description": "PMID: 30361829"
              },
              "old": {
                "description": "Cobimetinib is a small molecule inhibitor of MEK1/2 that is FDA-approved in combination with a BRAF inhibitor in BRAF V600-mutant melanoma. In a Phase II trial of cobimetinib in eighteen patients with histiocytoses, the overall response rate was 89%, with thirteen out of eighteen patients (72%) having a complete response and fifteen out of eighteen patients harboring a MAPK pathway mutation (PMID: 30867592). Six of six patients with BRAF mutations (five V600E, one non-V600E) had a partial or complete response to treatment with cobimetinib (PMID: 30867592). Small case studies and retroactive studies have also demonstrated the clinical efficacy of MEK inhibition in patients with histiocytic neoplasms (PMID: 29236635, 30718231)."
              },
              "operation": "update",
              "uuids": "483bc890-60e3-4c65-96e5-94f5412df6dc"
            }
          ],
          "timeStamp": 1633099703112
        },
        "-MkwK2ZmF02gCHHqiOEh": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Oncogenic Mutations, Erdheim-Chester Disease",
              "new": {
                "TIs": [
                  {
                    "name": "Standard implications for sensitivity to therapy",
                    "name_uuid": "b962c816-9f98-4aa8-a430-4abe0e063243",
                    "treatments": [
                      {
                        "description": "(PMID: 30867592)",
                        "description_review": {
                          "lastReviewed": "",
                          "updateTime": 1633041801790,
                          "updatedBy": "User"
                        },
                        "description_uuid": "3faed22d-9d4b-44a2-af45-448cda44a9c8",
                        "indication": "",
                        "indication_uuid": "92fa3d59-0dc2-4c05-87f0-b3cd668762b8",
                        "level": "2",
                        "level_review": {
                          "lastReviewed": "",
                          "updateTime": 1633041769285,
                          "updatedBy": "User"
                        },
                        "level_uuid": "cd28e919-2995-4ef5-b4e8-f21d2d0e2841",
                        "name": "eb357145-3b18-4aca-b75a-5e18dd2bf4f9, fb2bb01c-c0ec-4641-abf7-87f486075022",
                        "name_review": {
                          "added": true,
                          "updateTime": 1633041612330,
                          "updatedBy": "User"
                        },
                        "name_uuid": "4acee8ae-617b-42f8-8e80-5358048ea1aa",
                        "propagation": "no",
                        "propagationLiquid": "no",
                        "propagationLiquid_review": {
                          "lastReviewed": "",
                          "updateTime": 1633041769283,
                          "updatedBy": "User"
                        },
                        "propagationLiquid_uuid": "8068acdf-a729-4acd-999b-e2a7f731a311",
                        "propagation_review": {
                          "lastReviewed": "",
                          "updateTime": 1633041769280,
                          "updatedBy": "User"
                        },
                        "propagation_uuid": "5ab42a39-3344-42eb-b2dd-ebd8013e498f",
                        "short": ""
                      }
                    ],
                    "treatments_uuid": "eaf0ab31-f0e3-47de-9272-68e9ace7cdc2",
                    "type": "SS"
                  },
                  {
                    "name": "Standard implications for resistance to therapy",
                    "name_uuid": "deff2c0b-0e64-4ca7-87a3-1a098955f04d",
                    "treatments_uuid": "0b1ad069-97e3-44d8-9e03-999cd4e9a614",
                    "type": "SR"
                  },
                  {
                    "name": "Investigational implications for sensitivity to therapy",
                    "name_uuid": "ad5304cf-1e98-4e0c-b7d7-4066c8c9b094",
                    "treatments_uuid": "c863eb56-6395-483d-bbb7-0707e4e0e8e7",
                    "type": "IS"
                  },
                  {
                    "name": "Investigational implications for resistance to therapy",
                    "name_uuid": "cb5bccc0-6df6-4bda-8969-c354356308cc",
                    "treatments_uuid": "a17c3b6f-c447-4e48-9648-cc87745ac3e0",
                    "type": "IR"
                  }
                ],
                "cancerTypes": [
                  {
                    "code": "ECD",
                    "mainType": "Histiocytosis",
                    "subtype": "Erdheim-Chester Disease"
                  }
                ],
                "cancerTypes_review": {
                  "added": true,
                  "updateTime": 1633041570236,
                  "updatedBy": "User"
                },
                "cancerTypes_uuid": "ad8bbf0c-f44c-474b-9232-f68607aec1b4",
                "diagnostic": {
                  "description": "",
                  "description_uuid": "5e741f60-c185-42b0-81c0-39080f0883c3",
                  "level": "",
                  "level_uuid": "64d66cfe-b128-4ffe-c01d-b5c8d11b7c53",
                  "short": ""
                },
                "diagnosticSummary": "",
                "diagnosticSummary_uuid": "9f083267-2822-45de-9555-6260e6ef914d",
                "diagnostic_uuid": "c60f0786-a8b0-4e31-93f9-a8ef46a650d7",
                "prognostic": {
                  "description": "",
                  "description_uuid": "79acae59-4647-453c-bb69-f9e7c04691c2",
                  "level": "",
                  "level_uuid": "c83dd3b7-c488-4a2f-c01b-675b4c9bb1eb",
                  "short": ""
                },
                "prognosticSummary": "",
                "prognosticSummary_uuid": "1dbfafc9-754e-4079-b022-7ad65a64c0fa",
                "prognostic_uuid": "55477d5b-8fee-4a6a-87de-263d0f0d52ff",
                "summary": "The MEK-targeted inhibitors cobimetinib and trametinib are NCCN-listed as monotherapy for the treatment of patients with Erdheim-Chester Disease with MAPK pathway alterations, including [[gene]][[mutation]].",
                "summary_review": {
                  "lastReviewed": "",
                  "updateTime": 1633041758461,
                  "updatedBy": "User"
                },
                "summary_uuid": "a417de98-56a6-4211-917a-2ca0a006dfdd"
              },
              "operation": "add",
              "uuids": "a417de98-56a6-4211-917a-2ca0a006dfdd,4acee8ae-617b-42f8-8e80-5358048ea1aa"
            }
          ],
          "timeStamp": 1633099726924
        },
        "-MkwK8QsMM8lVWRAz_fh": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Oncogenic Mutations, Langerhans Cell Histiocytosis",
              "new": {
                "TIs": [
                  {
                    "name": "Standard implications for sensitivity to therapy",
                    "name_uuid": "2cdfeee4-350b-43ec-b30e-b381b2adb104",
                    "treatments": [
                      {
                        "description": "PMID: 30867592, 32991018",
                        "description_review": {
                          "lastReviewed": "",
                          "updateTime": 1633042306054,
                          "updatedBy": "User"
                        },
                        "description_uuid": "805b7af2-2939-4091-82b2-b42375df8230",
                        "indication": "",
                        "indication_uuid": "9974c4e9-a5f4-48cb-92ae-a61297a1715a",
                        "level": "2",
                        "level_review": {
                          "lastReviewed": "",
                          "updateTime": 1633042279837,
                          "updatedBy": "User"
                        },
                        "level_uuid": "40b8b711-4dc5-4f42-b62e-7e5e5df77a46",
                        "name": "eb357145-3b18-4aca-b75a-5e18dd2bf4f9, fb2bb01c-c0ec-4641-abf7-87f486075022",
                        "name_review": {
                          "added": true,
                          "updateTime": 1633042256275,
                          "updatedBy": "User"
                        },
                        "name_uuid": "cd075ddd-91ce-4499-9402-2570bb6069d1",
                        "propagation": "no",
                        "propagationLiquid": "no",
                        "propagationLiquid_review": {
                          "lastReviewed": "",
                          "updateTime": 1633042279834,
                          "updatedBy": "User"
                        },
                        "propagationLiquid_uuid": "158640f7-a390-4fb0-a837-e08ac363ee4d",
                        "propagation_review": {
                          "lastReviewed": "",
                          "updateTime": 1633042279830,
                          "updatedBy": "User"
                        },
                        "propagation_uuid": "605114d4-8085-4477-802a-2ba7d168c137",
                        "short": ""
                      }
                    ],
                    "treatments_uuid": "dc24454a-1b6c-44e1-b5ff-ae3fd1a90c36",
                    "type": "SS"
                  },
                  {
                    "name": "Standard implications for resistance to therapy",
                    "name_uuid": "8d50aacc-6d54-46cf-9576-7c852115e7d2",
                    "treatments_uuid": "0201fff6-03e0-4f85-ba18-55916f66e8a1",
                    "type": "SR"
                  },
                  {
                    "name": "Investigational implications for sensitivity to therapy",
                    "name_uuid": "5c978369-5959-4126-a6fa-e70252c98f95",
                    "treatments_uuid": "cfb290c7-7fc8-4491-a44f-70a9295fa3b2",
                    "type": "IS"
                  },
                  {
                    "name": "Investigational implications for resistance to therapy",
                    "name_uuid": "dd80fe11-3b60-4589-a431-b4ce852a5555",
                    "treatments_uuid": "7a7ed5b4-2a46-4032-9190-0cdecbe938f2",
                    "type": "IR"
                  }
                ],
                "cancerTypes": [
                  {
                    "code": "LCH",
                    "mainType": "Histiocytosis",
                    "subtype": "Langerhans Cell Histiocytosis"
                  }
                ],
                "cancerTypes_review": {
                  "added": true,
                  "updateTime": 1633042199722,
                  "updatedBy": "User"
                },
                "cancerTypes_uuid": "0f224722-a1c3-45d6-802d-89a43ccd3aef",
                "diagnostic": {
                  "description": "",
                  "description_uuid": "d50a6bac-24a0-4248-b9a3-e33339e2e453",
                  "level": "",
                  "level_uuid": "60dfedb9-028f-49ea-b152-b21b6cb2bd13",
                  "short": ""
                },
                "diagnosticSummary": "",
                "diagnosticSummary_uuid": "3f3e5af3-7098-421a-9db0-505a758f4d0a",
                "diagnostic_uuid": "52847cac-56de-45c7-bfe7-8dc174cf5b64",
                "prognostic": {
                  "description": "",
                  "description_uuid": "dcebae89-fde4-4a05-8d5c-eb76b88d74c5",
                  "level": "",
                  "level_uuid": "d3573366-b680-415c-bfbf-d70393e54086",
                  "short": ""
                },
                "prognosticSummary": "",
                "prognosticSummary_uuid": "e159aece-b521-49c6-868f-bbdff6ed30a1",
                "prognostic_uuid": "0367b814-fcbd-4b5e-9f6d-920b8b906f1f",
                "summary": "The MEK-targeted inhibitors cobimetinib and trametinib are NCCN-listed as monotherapy for the treatment of patients with Langerhans Cell Histiocytosis with MAPK pathway alterations, including [[gene]][[mutation]].",
                "summary_review": {
                  "lastReviewed": "",
                  "updateTime": 1633042229423,
                  "updatedBy": "User"
                },
                "summary_uuid": "59c90847-6e9b-4e58-bc98-9452f4bce655"
              },
              "operation": "add",
              "uuids": "59c90847-6e9b-4e58-bc98-9452f4bce655,cd075ddd-91ce-4499-9402-2570bb6069d1"
            }
          ],
          "timeStamp": 1633099750930
        },
        "-MkwKKAvTXqo05U8R91a": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Langerhans Cell Histiocytosis, Tumor Type Summary",
              "new": "The RAF-targeted inhibitors vemurafenib and dabrafenib are NCCN-listed as monotherapy for the treatment of BRAF V600E-mutant Langerhans Cell Histiocytosis and vemurafenib is FDA-approved for the treatment of BRAF V600-mutant Erdheim Chester Disease.",
              "old": "",
              "operation": "update",
              "uuids": "b1bb9c06-65cf-44a4-b7ee-0f08403b897d"
            }
          ],
          "timeStamp": 1633099799061
        },
        "-MkwKQ2V1--UIz7aqj_d": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Langerhans Cell Histiocytosis, Standard implications for sensitivity to therapy, 4e91da20-6cf0-4e07-995f-7f7db4c7c077, 939cd40b-b515-499d-b099-fd29027c0d17",
              "new": {
                "description": "PMID: 30867592",
                "description_review": {
                  "lastReviewed": "",
                  "updateTime": 1633042118604,
                  "updatedBy": "User"
                },
                "description_uuid": "8021a6df-5a15-4683-9620-bc384889062d",
                "indication": "",
                "indication_uuid": "a61ff7b9-571a-499b-814d-21df739d71c3",
                "level": "2",
                "level_review": {
                  "lastReviewed": "",
                  "updateTime": 1633042103411,
                  "updatedBy": "User"
                },
                "level_uuid": "a8d6485c-0cbe-437e-947f-b4d811fbf734",
                "name": "4e91da20-6cf0-4e07-995f-7f7db4c7c077, 939cd40b-b515-499d-b099-fd29027c0d17",
                "name_review": {
                  "added": true,
                  "updateTime": 1633042084069,
                  "updatedBy": "User"
                },
                "name_uuid": "4f3f2101-b126-486a-8cc0-b2198d338bed",
                "propagation": "no",
                "propagationLiquid": "no",
                "propagationLiquid_review": {
                  "lastReviewed": "",
                  "updateTime": 1633042103409,
                  "updatedBy": "User"
                },
                "propagationLiquid_uuid": "5fe4bb09-a186-4471-8618-f5f823e5b5c7",
                "propagation_review": {
                  "lastReviewed": "",
                  "updateTime": 1633042103406,
                  "updatedBy": "User"
                },
                "propagation_uuid": "8e460cfb-fe2e-4f44-a21e-6872ecf6a693",
                "short": ""
              },
              "operation": "add",
              "uuids": "4f3f2101-b126-486a-8cc0-b2198d338bed"
            }
          ],
          "timeStamp": 1633099823098
        },
        "-MkwKWMhJUA6bU21poxI": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Histiocytosis, Tumor Type Summary",
              "new": "The RAF-targeted inhibitor vemurafenib is FDA-approved for the treatment of patients with BRAF V600-mutant Erdheim-Chester Disease (ECD) and there is promising clinical data in patients with non-ECD BRAF V600E mutant histiocytic neoplasms treated with vemurafenib or dabrafenib as monotherapy.",
              "old": "The MEK1/2-targeted inhibitor cobimetinib has shown promising clinical activity in patients with BRAF V600E or N486_T491delinsK mutant histiocytic disease.",
              "operation": "update",
              "uuids": "92d5ed0f-6425-4b2b-9a75-b7f673840cee"
            }
          ],
          "timeStamp": 1633099848967
        },
        "-MkwRU-yeL9H7A_JmhZF": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "N486_T491delinsK, Histiocytosis",
              "old": {
                "TIs": [
                  {
                    "name": "Standard implications for sensitivity to therapy",
                    "name_uuid": "d073cbbc-47cf-4c5a-8609-3045d0d74f2e",
                    "treatments_uuid": "17c8b8ca-6d6d-4702-982c-399b2c6f39e2",
                    "type": "SS"
                  },
                  {
                    "name": "Standard implications for resistance to therapy",
                    "name_uuid": "180c1120-3645-4397-a118-6d1378d37dbf",
                    "treatments_uuid": "bf9ef464-82cf-4a3b-9712-913dfe25a7db",
                    "type": "SR"
                  },
                  {
                    "name": "Investigational implications for sensitivity to therapy",
                    "name_uuid": "7cb6ca2a-8874-4c27-95db-85799c70cafc",
                    "treatments_uuid": "f23d580d-4c78-4ec2-8541-2fd1fbc03cde",
                    "type": "IS"
                  },
                  {
                    "name": "Investigational implications for resistance to therapy",
                    "name_uuid": "e5d90a4a-f003-4703-86aa-964df7a63230",
                    "treatments_uuid": "8a500880-7764-48a8-8377-1a17d3e0ba1a",
                    "type": "IR"
                  }
                ],
                "cancerTypes": [
                  {
                    "code": "",
                    "mainType": "Histiocytosis",
                    "subtype": ""
                  }
                ],
                "cancerTypes_review": {
                  "removed": true,
                  "updateTime": 1633101632206,
                  "updatedBy": "User"
                },
                "cancerTypes_uuid": "c6f800b6-2fa1-4d51-96bf-913f06ac7079",
                "diagnostic": {
                  "description": "",
                  "description_uuid": "a76b099b-0b18-4e08-9446-de940c29d09d",
                  "level": "",
                  "level_uuid": "b7c46ed0-d4fd-462d-8ce7-edce21f2bebb",
                  "short": ""
                },
                "diagnosticSummary": "",
                "diagnosticSummary_uuid": "3ee2f20f-dce1-4318-ad26-e9791d1e0571",
                "diagnostic_uuid": "744d0935-5fb1-4142-8f01-52ff972a1db0",
                "prognostic": {
                  "description": "",
                  "description_uuid": "5e1d92be-e7d4-44d2-beec-b02814ae40a0",
                  "level": "",
                  "level_uuid": "1468368a-31f5-4757-8e73-7e481fda181a",
                  "short": ""
                },
                "prognosticSummary": "",
                "prognosticSummary_uuid": "bca16643-49b4-4547-b08a-0ced171b61b4",
                "prognostic_uuid": "c6e54649-a1c6-4e28-bd78-78fc2a366195",
                "summary": "The MEK1/2-targeted inhibitor cobimetinib has shown promising clinical activity in a patient with BRAF N486_T491delinsK mutant Langerhans cell histiocytosis.",
                "summary_review": {
                  "updateTime": 1566490031211,
                  "updatedBy": "User"
                },
                "summary_uuid": "3732d979-4df9-45bb-a91b-17dccba55fcb"
              },
              "operation": "delete"
            }
          ],
          "timeStamp": 1633101672563
        },
        "-MlLGEoXLZnNNQDFL_Pl": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Langerhans Cell Histiocytosis, Standard implications for sensitivity to therapy, 4e91da20-6cf0-4e07-995f-7f7db4c7c077, 939cd40b-b515-499d-b099-fd29027c0d17",
              "old": {
                "description": "PMID: 30867592",
                "description_review": {
                  "updateTime": 1633042118604,
                  "updatedBy": "User"
                },
                "description_uuid": "8021a6df-5a15-4683-9620-bc384889062d",
                "indication": "",
                "indication_uuid": "a61ff7b9-571a-499b-814d-21df739d71c3",
                "level": "2",
                "level_review": {
                  "updateTime": 1633042103411,
                  "updatedBy": "User"
                },
                "level_uuid": "a8d6485c-0cbe-437e-947f-b4d811fbf734",
                "name": "4e91da20-6cf0-4e07-995f-7f7db4c7c077, 939cd40b-b515-499d-b099-fd29027c0d17",
                "name_review": {
                  "removed": true,
                  "updateTime": 1633445963711,
                  "updatedBy": "User"
                },
                "name_uuid": "4f3f2101-b126-486a-8cc0-b2198d338bed",
                "propagation": "no",
                "propagationLiquid": "no",
                "propagationLiquid_review": {
                  "updateTime": 1633042103409,
                  "updatedBy": "User"
                },
                "propagationLiquid_uuid": "5fe4bb09-a186-4471-8618-f5f823e5b5c7",
                "propagation_review": {
                  "updateTime": 1633042103406,
                  "updatedBy": "User"
                },
                "propagation_uuid": "8e460cfb-fe2e-4f44-a21e-6872ecf6a693",
                "short": ""
              },
              "operation": "delete"
            },
            {
              "lastEditBy": "User",
              "location": "V600E, Histiocytosis, Investigational implications for sensitivity to therapy, 4e91da20-6cf0-4e07-995f-7f7db4c7c077, 939cd40b-b515-499d-b099-fd29027c0d17",
              "old": {
                "description": "PMID: 25209580, 31376203, 31213430",
                "description_review": {
                  "updateTime": 1633042828451,
                  "updatedBy": "User"
                },
                "description_uuid": "811f1a87-9e78-4e92-88c8-2f6717ed30db",
                "indication": "",
                "indication_uuid": "437d5e4a-cc7c-4474-a11a-889c92bb4468",
                "level": "3A",
                "level_review": {
                  "updateTime": 1633042777854,
                  "updatedBy": "User"
                },
                "level_uuid": "2ffdab7f-2ede-42fc-b648-8f7883efc44f",
                "name": "4e91da20-6cf0-4e07-995f-7f7db4c7c077, 939cd40b-b515-499d-b099-fd29027c0d17",
                "name_review": {
                  "removed": true,
                  "updateTime": 1633446247903,
                  "updatedBy": "User"
                },
                "name_uuid": "012aa663-c079-49fd-8e7a-f24c58b42f11",
                "propagation": "no",
                "propagationLiquid": "no",
                "propagationLiquid_review": {
                  "updateTime": 1633042777849,
                  "updatedBy": "User"
                },
                "propagationLiquid_uuid": "6a2ab1fc-1e32-455d-b235-b87cb7f2dba3",
                "propagation_review": {
                  "updateTime": 1633042777846,
                  "updatedBy": "User"
                },
                "propagation_uuid": "a3ab6e47-9be6-4d30-a862-6a63ff958401",
                "short": ""
              },
              "operation": "delete"
            }
          ],
          "timeStamp": 1633534933434
        },
        "-MlLGL097sb1GiI9t7zr": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Langerhans Cell Histiocytosis, Tumor Type Summary",
              "new": "",
              "old": "The RAF-targeted inhibitors vemurafenib and dabrafenib are NCCN-listed as monotherapy for the treatment of BRAF V600E-mutant Langerhans Cell Histiocytosis and vemurafenib is FDA-approved for the treatment of BRAF V600-mutant Erdheim Chester Disease.",
              "operation": "update",
              "uuids": "b1bb9c06-65cf-44a4-b7ee-0f08403b897d"
            },
            {
              "lastEditBy": "User",
              "location": "V600, Langerhans Cell Histiocytosis",
              "new": {
                "TIs": [
                  {
                    "name": "Standard implications for sensitivity to therapy",
                    "name_uuid": "a73b6c63-b131-4561-9061-8fcfb19ece73",
                    "treatments": [
                      {
                        "description": "PMID: 30867592",
                        "description_review": {
                          "lastReviewed": "",
                          "updateTime": 1633445926366,
                          "updatedBy": "User"
                        },
                        "description_uuid": "fdc4d478-90a6-490d-8fcc-0c5f780af188",
                        "indication": "",
                        "indication_uuid": "8b94d715-94bd-4a7a-a4a6-58f3e7bfb65b",
                        "level": "2",
                        "level_review": {
                          "lastReviewed": "",
                          "updateTime": 1633445920196,
                          "updatedBy": "User"
                        },
                        "level_uuid": "5fe26c83-608e-49e4-92d5-1dcdb0397ca9",
                        "name": "4e91da20-6cf0-4e07-995f-7f7db4c7c077, 939cd40b-b515-499d-b099-fd29027c0d17",
                        "name_review": {
                          "added": true,
                          "updateTime": 1633445915074,
                          "updatedBy": "User"
                        },
                        "name_uuid": "a0a7271e-c46e-43b8-8f85-7e1418192d6c",
                        "propagation": "no",
                        "propagationLiquid": "no",
                        "propagationLiquid_review": {
                          "lastReviewed": "",
                          "updateTime": 1633445920194,
                          "updatedBy": "User"
                        },
                        "propagationLiquid_uuid": "ca2ac62d-41f3-4364-afac-7ea9dfeb07b4",
                        "propagation_review": {
                          "lastReviewed": "",
                          "updateTime": 1633445920192,
                          "updatedBy": "User"
                        },
                        "propagation_uuid": "1b7b1f8d-52a9-4abf-81a6-e2480fbc86cc",
                        "short": ""
                      }
                    ],
                    "treatments_uuid": "dfe1a32d-305f-4899-a58b-14a1bb15e67a",
                    "type": "SS"
                  },
                  {
                    "name": "Standard implications for resistance to therapy",
                    "name_uuid": "c4bac879-243a-4a28-8fd8-51b4372bb31f",
                    "treatments_uuid": "a919fe48-9ff2-4ae7-937d-3d2d2ab9904d",
                    "type": "SR"
                  },
                  {
                    "name": "Investigational implications for sensitivity to therapy",
                    "name_uuid": "084b493f-e6d3-4c75-9aed-8d1e9eec2178",
                    "treatments_uuid": "4d033177-21f5-40b0-badf-ccd7eaa3b84e",
                    "type": "IS"
                  },
                  {
                    "name": "Investigational implications for resistance to therapy",
                    "name_uuid": "2d1edc97-9506-44a4-baed-396f826b1206",
                    "treatments_uuid": "7f5fc49f-6a46-4e4d-8e72-f0fad2f41a80",
                    "type": "IR"
                  }
                ],
                "cancerTypes": [
                  {
                    "code": "LCH",
                    "mainType": "Histiocytosis",
                    "subtype": "Langerhans Cell Histiocytosis"
                  }
                ],
                "cancerTypes_review": {
                  "added": true,
                  "updateTime": 1633102532080,
                  "updatedBy": "User"
                },
                "cancerTypes_uuid": "da98cd12-2999-41ad-83e0-96beb31aa593",
                "diagnostic": {
                  "description": "",
                  "description_uuid": "d6bbbde8-ec9a-415b-9066-adbe40bfcb12",
                  "level": "",
                  "level_uuid": "361dcfca-08dd-4fc9-8fea-b0ca256bf2a1",
                  "short": ""
                },
                "diagnosticSummary": "",
                "diagnosticSummary_uuid": "9d8332c4-0be6-42b0-b9c9-46e278ea4667",
                "diagnostic_uuid": "0efbfd43-b378-4591-aab5-a3a90d40c493",
                "prognostic": {
                  "description": "",
                  "description_uuid": "9bdc21c3-6715-45dc-8816-0aed17bbfcb4",
                  "level": "",
                  "level_uuid": "e5585c4f-af54-41b7-9fb6-3b0c106eecc5",
                  "short": ""
                },
                "prognosticSummary": "",
                "prognosticSummary_uuid": "494a77d8-cce8-4025-ab0f-d0798493a2d8",
                "prognostic_uuid": "fe6c4555-7fe5-4c91-9572-f9b79c64b1ab",
                "summary": "The RAF-targeted inhibitors vemurafenib and dabrafenib are NCCN-listed as monotherapy for the treatment of BRAF V600E-mutant Langerhans Cell Histiocytosis and vemurafenib is FDA-approved for the treatment of BRAF V600-mutant Erdheim Chester Disease.",
                "summary_review": {
                  "lastReviewed": "",
                  "updateTime": 1633103645994,
                  "updatedBy": "User"
                },
                "summary_uuid": "b1acc1d7-c638-4217-a6e4-986b99f66f0a"
              },
              "operation": "add",
              "uuids": "b1acc1d7-c638-4217-a6e4-986b99f66f0a,a0a7271e-c46e-43b8-8f85-7e1418192d6c"
            },
            {
              "lastEditBy": "User",
              "location": "V600, Histiocytosis",
              "new": {
                "TIs": [
                  {
                    "name": "Standard implications for sensitivity to therapy",
                    "name_uuid": "918a2cd5-d7b1-4eb6-9239-aeade97f2ced",
                    "treatments_uuid": "aab7d944-d526-4cc6-bac0-1d01a6922359",
                    "type": "SS"
                  },
                  {
                    "name": "Standard implications for resistance to therapy",
                    "name_uuid": "bbadbe7a-fd74-4a72-8a7c-72f3ee942a74",
                    "treatments_uuid": "178c37be-0163-4be0-a9bb-b22484010d04",
                    "type": "SR"
                  },
                  {
                    "name": "Investigational implications for sensitivity to therapy",
                    "name_uuid": "8887f055-f66a-4128-b70a-6736cbd3c47c",
                    "treatments": [
                      {
                        "description": "PMID: 25209580, 31376203, 31213430",
                        "description_review": {
                          "lastReviewed": "",
                          "updateTime": 1633446184639,
                          "updatedBy": "User"
                        },
                        "description_uuid": "0f239e36-effc-4881-90c1-4162eda0d41b",
                        "indication": "",
                        "indication_uuid": "ff1182b1-9535-4d2d-aecc-927aa1eaaffa",
                        "level": "3A",
                        "level_review": {
                          "lastReviewed": "",
                          "updateTime": 1633446180842,
                          "updatedBy": "User"
                        },
                        "level_uuid": "60556bec-312b-480b-ac4e-30eecb57d4e8",
                        "name": "4e91da20-6cf0-4e07-995f-7f7db4c7c077, 939cd40b-b515-499d-b099-fd29027c0d17",
                        "name_review": {
                          "added": true,
                          "updateTime": 1633446175827,
                          "updatedBy": "User"
                        },
                        "name_uuid": "ccfa69b9-f284-427a-84b5-a4ffcc5606ca",
                        "propagation": "no",
                        "propagationLiquid": "no",
                        "propagationLiquid_review": {
                          "lastReviewed": "",
                          "updateTime": 1633446180840,
                          "updatedBy": "User"
                        },
                        "propagationLiquid_uuid": "a748e972-aa30-4c60-bec0-848b48cc75b2",
                        "propagation_review": {
                          "lastReviewed": "",
                          "updateTime": 1633446180837,
                          "updatedBy": "User"
                        },
                        "propagation_uuid": "502a6c9b-46d6-4c41-8676-d1e273e2a2d6",
                        "short": ""
                      }
                    ],
                    "treatments_uuid": "0eb9da8e-c908-4128-a879-76084d0fce69",
                    "type": "IS"
                  },
                  {
                    "name": "Investigational implications for resistance to therapy",
                    "name_uuid": "f002d764-0526-4f46-b67e-98b47001d735",
                    "treatments_uuid": "6113b273-d1d2-452f-8194-7299d2a020ed",
                    "type": "IR"
                  }
                ],
                "cancerTypes": [
                  {
                    "code": "",
                    "mainType": "Histiocytosis",
                    "subtype": ""
                  }
                ],
                "cancerTypes_review": {
                  "added": true,
                  "updateTime": 1633446122726,
                  "updatedBy": "User"
                },
                "cancerTypes_uuid": "efaab408-c504-4386-acb1-c90a1091b92e",
                "diagnostic": {
                  "description": "",
                  "description_uuid": "e96ee070-a402-4e74-b61c-aaa83e26569d",
                  "level": "",
                  "level_uuid": "c9d9f220-667f-476e-a49f-80d414609320",
                  "short": ""
                },
                "diagnosticSummary": "",
                "diagnosticSummary_uuid": "b79051c6-a3a2-4118-8934-3d914389880c",
                "diagnostic_uuid": "9379c183-d004-4bdd-ac15-35deb38bb33a",
                "prognostic": {
                  "description": "",
                  "description_uuid": "d89baa01-a8d8-43c5-a127-df8c7a1bc026",
                  "level": "",
                  "level_uuid": "805c7cdf-8e79-4922-9b5a-585d202d4ad9",
                  "short": ""
                },
                "prognosticSummary": "",
                "prognosticSummary_uuid": "61f656a5-41a6-4c16-ad70-3c8ab4e0198b",
                "prognostic_uuid": "053db866-e39a-4472-b05c-5052a26e2336",
                "summary": "The RAF-targeted inhibitor vemurafenib is FDA-approved for the treatment of patients with BRAF V600-mutant Erdheim-Chester Disease (ECD) and there is promising clinical data in patients with non-ECD BRAF V600-mutant histiocytic neoplasms treated with vemurafenib or dabrafenib as monotherapy.",
                "summary_review": {
                  "lastReviewed": "",
                  "updateTime": 1633446213787,
                  "updatedBy": "User"
                },
                "summary_uuid": "86fce41b-4b83-4bff-9d45-d96ea3767cde"
              },
              "operation": "add",
              "uuids": "86fce41b-4b83-4bff-9d45-d96ea3767cde,ccfa69b9-f284-427a-84b5-a4ffcc5606ca"
            }
          ],
          "timeStamp": 1633534958818
        },
        "-MlM7T6AQQWdeXTWYMmY": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Diffuse Glioma",
              "new": {
                "TIs": [
                  {
                    "name": "Standard implications for sensitivity to therapy",
                    "name_uuid": "68a5d56f-0c08-45c3-b672-a961c710c4dd",
                    "treatments": [
                      {
                        "description": "The RAF inhibitors dabrafenib and vemurafenib in combination with the MEK inhibitors trametinib and cobimetinib, respectively, are FDA-approved for patients with melanoma, non-small cell lung cancer, and anaplastic thyroid cancer, and are NCCN-listed for patients with low-grade glioma, anaplastic glioma, and glioblastoma. Patients with various glioma subtypes harboring BRAF V600E mutations have shown responses to RAF and MEK inhibition. Three out of five patients with anaplastic astrocytoma had a response (1 PR, 2 SD) to vemurafenib monotherapy (PMID:30351999). One patient with high-grade glioma (NOS) had stable disease in response to vemurafenib monotherapy (PMID:30351999). Four out of eight patients with glioma (NOS) had a response (1 PR, 3 SD, 2 PD, 2 not evaluable) to vemurafenib monotherapy (PMID: 26287849). One patient with anaplastic oligoastrocytoma had stable disease in response to vemurafenib monotherapy (PMID: 30462564). Four of seven patients with glioblastoma multiforme had a response (1 CR, 3 SD, 1 PD, 2 not evaluable) to vemurafenib monotherapy (PMID: 30351999, 24725538). Four patients with glioblastoma (including epithelioid glioblastoma) had a response (1 “near-complete” response, 3 SD) to either dabrafenib monotherapy (n=2) or vemurafenib monotherapy (n=2) (PMID: 29621181, 29039591, 33117675, 34232949).",
                        "description_review": {
                          "lastReviewed": "",
                          "updateTime": 1633539212546,
                          "updatedBy": "User"
                        },
                        "description_uuid": "3715bed4-7f69-4a85-b288-1e362c53ecf8",
                        "indication": "",
                        "indication_uuid": "2642aeb9-4f8a-4298-9779-1b4791964931",
                        "level": "2",
                        "level_review": {
                          "lastReviewed": "",
                          "updateTime": 1633535557584,
                          "updatedBy": "User"
                        },
                        "level_uuid": "093e038e-c3f6-46eb-b850-90b588517f57",
                        "name": "939cd40b-b515-499d-b099-fd29027c0d17 + fb2bb01c-c0ec-4641-abf7-87f486075022, 4e91da20-6cf0-4e07-995f-7f7db4c7c077 + eb357145-3b18-4aca-b75a-5e18dd2bf4f9",
                        "name_review": {
                          "added": true,
                          "updateTime": 1633535507078,
                          "updatedBy": "User"
                        },
                        "name_uuid": "7b50f8a8-5662-4ad0-b63a-f2a0cf2c9fee",
                        "propagation": "3B",
                        "propagationLiquid": "no",
                        "propagationLiquid_review": {
                          "lastReviewed": "",
                          "updateTime": 1633535557580,
                          "updatedBy": "User"
                        },
                        "propagationLiquid_uuid": "70cf5068-31a8-4225-82e3-5299ca1f4a66",
                        "propagation_review": {
                          "lastReviewed": "",
                          "updateTime": 1633535560325,
                          "updatedBy": "User"
                        },
                        "propagation_uuid": "eb62aab5-f063-4ab9-bc1d-ae487aa4b503",
                        "short": ""
                      }
                    ],
                    "treatments_uuid": "0b8be57d-2717-4ff8-b4ee-20be0ae1410b",
                    "type": "SS"
                  },
                  {
                    "name": "Standard implications for resistance to therapy",
                    "name_uuid": "cadb4abd-2841-477b-bd32-d6db578b654d",
                    "treatments_uuid": "44563999-eb9e-4c5f-98d5-45acd56956ef",
                    "type": "SR"
                  },
                  {
                    "name": "Investigational implications for sensitivity to therapy",
                    "name_uuid": "a90d7f72-d04a-4756-98f2-935660f1fc08",
                    "treatments_uuid": "84cbbb29-4bed-4261-83e1-a90285030b7c",
                    "type": "IS"
                  },
                  {
                    "name": "Investigational implications for resistance to therapy",
                    "name_uuid": "402941fa-c641-4f12-9a82-754fccf97fed",
                    "treatments_uuid": "8b13699b-36f4-4ca9-a0cd-6944ab4e580f",
                    "type": "IR"
                  }
                ],
                "cancerTypes": [
                  {
                    "code": "DIFG",
                    "mainType": "Glioma",
                    "subtype": "Diffuse Glioma"
                  }
                ],
                "cancerTypes_review": {
                  "added": true,
                  "updateTime": 1633534977022,
                  "updatedBy": "User"
                },
                "cancerTypes_uuid": "c9760fd0-3926-4743-abce-afb1d3374f14",
                "diagnostic": {
                  "description": "",
                  "description_uuid": "f40e590a-591a-4501-9c28-31089bbb139c",
                  "level": "",
                  "level_uuid": "6be01097-872d-48c2-9b7a-9086b86f6b7a",
                  "short": ""
                },
                "diagnosticSummary": "",
                "diagnosticSummary_uuid": "21e89b4f-81f5-4c94-9d84-95fa49c2c1e8",
                "diagnostic_uuid": "f9d9774c-0021-49ba-a4b2-31ec7b887f68",
                "prognostic": {
                  "description": "",
                  "description_uuid": "b5061fdb-268d-49d8-81b7-cfbb7810d42a",
                  "level": "",
                  "level_uuid": "2c27d55e-672e-428b-95b6-1da8517166d3",
                  "short": ""
                },
                "prognosticSummary": "",
                "prognosticSummary_uuid": "0b544acd-6c6e-44c7-9615-fd779fefc499",
                "prognostic_uuid": "1d25d466-26e7-4fd9-bf31-6edfd3a817c1",
                "relevantCancerTypes": [
                  {
                    "code": "AOAST",
                    "mainType": "Glioma",
                    "subtype": "Anaplastic Oligoastrocytoma"
                  },
                  {
                    "code": "SCGBM",
                    "mainType": "Glioma",
                    "subtype": "Small Cell Glioblastoma"
                  },
                  {
                    "code": "HGGNOS",
                    "mainType": "Glioma",
                    "subtype": "High-Grade Glioma, NOS"
                  },
                  {
                    "code": "GB",
                    "mainType": "Glioma",
                    "subtype": "Glioblastoma"
                  },
                  {
                    "code": "OAST",
                    "mainType": "Glioma",
                    "subtype": "Oligoastrocytoma"
                  },
                  {
                    "code": "DIFG",
                    "mainType": "Glioma",
                    "subtype": "Diffuse Glioma"
                  },
                  {
                    "code": "GNOS",
                    "mainType": "Glioma",
                    "subtype": "Glioma, NOS"
                  },
                  {
                    "code": "GSARC",
                    "mainType": "Glioma",
                    "subtype": "Gliosarcoma"
                  },
                  {
                    "code": "ASTR",
                    "mainType": "Glioma",
                    "subtype": "Astrocytoma"
                  },
                  {
                    "code": "AASTR",
                    "mainType": "Glioma",
                    "subtype": "Anaplastic Astrocytoma"
                  },
                  {
                    "code": "GBM",
                    "mainType": "Glioma",
                    "subtype": "Glioblastoma Multiforme"
                  },
                  {
                    "code": "DASTR",
                    "mainType": "Glioma",
                    "subtype": "Diffuse Astrocytoma"
                  }
                ],
                "relevantCancerTypes_review": {
                  "updateTime": 1633535064482,
                  "updatedBy": "User"
                },
                "summary": "The RAF inhibitors dabrafenib and vemurafenib in combination with the MEK inhibitors trametinib and cobimetinib, respectively, are NCCN-compendium listed as a treatment option for patients with [[variant]].",
                "summary_review": {
                  "lastReviewed": "",
                  "updateTime": 1633535406440,
                  "updatedBy": "User"
                },
                "summary_uuid": "d9d2b475-f103-4960-a827-3a032f107402"
              },
              "operation": "add",
              "uuids": "d9d2b475-f103-4960-a827-3a032f107402,7b50f8a8-5662-4ad0-b63a-f2a0cf2c9fee"
            }
          ],
          "timeStamp": 1633549410771
        },
        "-MlM7ZP31pGfvz8SnblZ": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Encapsulated Glioma",
              "new": {
                "TIs": [
                  {
                    "name": "Standard implications for sensitivity to therapy",
                    "name_uuid": "108d30f1-f137-4f13-9ebc-3c4e9732a24b",
                    "treatments": [
                      {
                        "description": "The RAF inhibitors dabrafenib and vemurafenib in combination with the MEK inhibitors trametinib and cobimetinib, respectively, are FDA-approved for patients with melanoma, non-small cell lung cancer, and anaplastic thyroid cancer, and are NCCN-listed for patients with low-grade glioma, anaplastic glioma, and glioblastoma. Patients with various glioma subtypes harboring BRAF V600E mutations have shown responses to RAF and MEK inhibition. Six patients with ganglioglioma had a partial response to either vemurafenib monotherapy (n=2), vemurafenib + cobimetinib (n=1), or dabrafenib monotherapy (n=​​3)(PMID: 25524464, 31985841, 26579623, 31502039). Twelve out of thirteen patients with pleomorphic xanthoastrocytoma had a response (1 CR, 1 “near-complete” response, 6 PR, 4 SD) to either dabrafenib + trametinib (n=2) or vemurafenib monotherapy (n=11) (PMID: 28984141, 26287849, 30351999). Three patients with anaplastic pleomorphic xanthoastrocytoma had a response (1 CR, 1 “near-complete” response, 1 PR) to either vemurafenib monotherapy (n=1) or dabrafenib monotherapy (n=2)(PMID: 25092772, 29039591). One patient with low-grade glioma, NOS had a partial response to dabrafenib monotherapy (PMID: 27398937). Two patients with pilocytic astrocytoma had a response (1 PR, 1 SD) to vemurafenib monotherapy (PMID: 30351999). Three of four patients with anaplastic ganglioglioma had a response (1 PR, 1 \"significant response\", 1 SD, 1 not evaluable) to either dabrafenib + trametinib (n=1) or vemurafenib monotherapy (n=3)(PMID: 29380516, 30351999). One patient with pilomyxoid astrocytoma had a partial response to vemurafenib monotherapy (PMID: 24821190).",
                        "description_review": {
                          "lastReviewed": "",
                          "updateTime": 1633538996797,
                          "updatedBy": "User"
                        },
                        "description_uuid": "2d9907f5-c2da-426e-9b62-16b932cc5b60",
                        "indication": "",
                        "indication_uuid": "42984ca5-d663-4081-9cc2-695b6fa98c86",
                        "level": "2",
                        "level_review": {
                          "lastReviewed": "",
                          "updateTime": 1633535674388,
                          "updatedBy": "User"
                        },
                        "level_uuid": "f30a8112-563c-4ff5-96c8-6308366b8e23",
                        "name": "939cd40b-b515-499d-b099-fd29027c0d17 + fb2bb01c-c0ec-4641-abf7-87f486075022, 4e91da20-6cf0-4e07-995f-7f7db4c7c077 + eb357145-3b18-4aca-b75a-5e18dd2bf4f9",
                        "name_review": {
                          "added": true,
                          "updateTime": 1633535656959,
                          "updatedBy": "User"
                        },
                        "name_uuid": "8a864f31-163a-4868-bf67-6b1fc449a2c6",
                        "propagation": "3B",
                        "propagationLiquid": "no",
                        "propagationLiquid_review": {
                          "lastReviewed": "",
                          "updateTime": 1633535674385,
                          "updatedBy": "User"
                        },
                        "propagationLiquid_uuid": "34bf354a-8da8-401f-a337-7aa21aa8d0e8",
                        "propagation_review": {
                          "lastReviewed": "",
                          "updateTime": 1633535676841,
                          "updatedBy": "User"
                        },
                        "propagation_uuid": "10c00355-48be-40a1-8129-0383648ac05c",
                        "short": ""
                      }
                    ],
                    "treatments_uuid": "a27ea586-2f54-4ed3-a950-00be36be1b17",
                    "type": "SS"
                  },
                  {
                    "name": "Standard implications for resistance to therapy",
                    "name_uuid": "94281c9d-007c-40e8-8cf1-2e5533711409",
                    "treatments_uuid": "74748b30-818b-4825-8927-36630d51a09b",
                    "type": "SR"
                  },
                  {
                    "name": "Investigational implications for sensitivity to therapy",
                    "name_uuid": "1af37a34-fa87-4e38-8225-165e0b03c900",
                    "treatments_uuid": "28bc5e26-6c10-4ca6-b223-5ae2c4a322fb",
                    "type": "IS"
                  },
                  {
                    "name": "Investigational implications for resistance to therapy",
                    "name_uuid": "4fc45c0f-8622-437c-9a2a-128b28843b77",
                    "treatments_uuid": "2782fd2e-b751-4ab5-8a6f-17d1952e698e",
                    "type": "IR"
                  }
                ],
                "cancerTypes": [
                  {
                    "code": "ENCG",
                    "mainType": "Glioma",
                    "subtype": "Encapsulated Glioma"
                  }
                ],
                "cancerTypes_review": {
                  "added": true,
                  "updateTime": 1633535117952,
                  "updatedBy": "User"
                },
                "cancerTypes_uuid": "a809a4d9-665a-472e-83c6-259a5d9213df",
                "diagnostic": {
                  "description": "",
                  "description_uuid": "494eba06-40fb-4959-8a15-83e720ed06df",
                  "level": "",
                  "level_uuid": "6a697811-b485-48ac-a0b3-ffe4ed112b3c",
                  "short": ""
                },
                "diagnosticSummary": "",
                "diagnosticSummary_uuid": "c1ccd8d5-e488-4746-9e3f-1407affcf2fb",
                "diagnostic_uuid": "2d820c5c-ea27-4ce3-bf67-4d0a4971c05c",
                "prognostic": {
                  "description": "",
                  "description_uuid": "4a471317-6177-496d-acef-ac872d7b1af5",
                  "level": "",
                  "level_uuid": "f61f7d27-430f-4164-b82b-0a62b2da899f",
                  "short": ""
                },
                "prognosticSummary": "",
                "prognosticSummary_uuid": "f8f4a2a6-0b96-4ccf-8a53-bc603678f7d6",
                "prognostic_uuid": "678370fe-89df-4090-a07c-0018d88be5b0",
                "summary": "The RAF inhibitors dabrafenib and vemurafenib in combination with the MEK inhibitors trametinib and cobimetinib, respectively, are NCCN-compendium listed as a treatment option for patients with [[variant]].",
                "summary_review": {
                  "lastReviewed": "",
                  "updateTime": 1633535631165,
                  "updatedBy": "User"
                },
                "summary_uuid": "5be59610-1305-4ace-a94c-30ef26d7523a"
              },
              "operation": "add",
              "uuids": "5be59610-1305-4ace-a94c-30ef26d7523a,8a864f31-163a-4868-bf67-6b1fc449a2c6"
            }
          ],
          "timeStamp": 1633549436556
        },
        "-Mlq24q1AU865iinmjHC": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "AGAP3-BRAF Fusion, Mutation Effect",
              "new": {
                "description": "The AGAP3-BRAF fusion protein results from an inversion on chromosome 7, joining exons 1-9 of AGAP3 with a 3' segment of the BRAF gene, including the full kinase domain. This fusion protein has been found in melanoma, colorectal cancer and ovarian serous carcinoma (PMID: 26314551, 28539463, 30279230, 34568720).  Expression of this fusion in NIH3T3 cells demonstrated that it is activating as measured by increased MAPK pathway activity and cellular growth compared to wildtype BRAF (PMID: 30279230). Expression of this fusion in cell lines demonstrated that it is sensitive to trametinib but not vemurafenib as measured by in vitro colony formation and cell proliferation (PMID: 28539463). A patient with BRAF V600E-mutated metastatic melanoma, who experienced disease relapse after an initial response to the BRAF inhibitor Vemurafenib, was subsequently treated with dabrafenib plus trametinib (RAF inhibitor plus MEK inhibitor), and had a partial response for a period of two months (PMID: 28539463)."
              },
              "old": {
                "description": "The AGAP3-BRAF fusion protein results from an inversion on chromosome 7, joining exons 1-9 of AGAP3 to exons 9-18 of BRAF, thus retaining the full kinase domain of BRAF. This fusion protien is found in patients with sporadic microsatellite instability-high colorectal cancers (PMID: 30279230). Expression of the fusion protein in a BRAF V600E-mutated melanoma cell line elevated basal levels of phosphorylated ERK but not phosphorylated MEK. This increase was abrogated by MEK inhibition, but not BRAF inhibition. Colony formation and cell proliferation assays showed similar effects of the fusion (PMID: 28539463). Expression of this fusion protein in NIH3T3 cells demonstrated that it was activating as shown by increased colony formation and pathway activation compared to expression of BRAF alone (PMID: 30279230)."
              },
              "operation": "update",
              "uuids": "9f208268-d2d3-415b-820f-472944a8850e"
            }
          ],
          "timeStamp": 1634068094506
        },
        "-Mlq2xtZI3os7isBcA1H": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "AGAP3-BRAF Fusion, Mutation Effect",
              "new": {
                "description": "The AGAP3-BRAF fusion protein results from an inversion on chromosome 7, joining exons 1-9 of AGAP3 with a 3' segment of the BRAF gene. The AGAP3-BRAF fusion protein contains the full BRAF kinase domain, but lacks the regulatory RAS-binding domain and the cysteine-rich (CR1) domain, which are responsible for BRAF binding to RAS and auto-inhibition. This fusion protein has been found in melanoma, colorectal cancer and ovarian serous carcinoma (PMID: 26314551, 28539463, 30279230, 34568720).  Expression of this fusion in NIH3T3 cells demonstrated that it is activating as measured by increased MAPK pathway activity and cellular growth compared to wildtype BRAF (PMID: 30279230). Expression of this fusion in cell lines demonstrated that it is sensitive to trametinib but not vemurafenib as measured by in vitro colony formation and cell proliferation (PMID: 28539463). A patient with BRAF V600E-mutated metastatic melanoma, who experienced disease relapse after an initial response to the BRAF inhibitor Vemurafenib, was subsequently treated with dabrafenib plus trametinib (RAF inhibitor plus MEK inhibitor), and had a partial response for a period of two months (PMID: 28539463)."
              },
              "old": {
                "description": "The AGAP3-BRAF fusion protein results from an inversion on chromosome 7, joining exons 1-9 of AGAP3 with a 3' segment of the BRAF gene, including the full kinase domain. This fusion protein has been found in melanoma, colorectal cancer and ovarian serous carcinoma (PMID: 26314551, 28539463, 30279230, 34568720).  Expression of this fusion in NIH3T3 cells demonstrated that it is activating as measured by increased MAPK pathway activity and cellular growth compared to wildtype BRAF (PMID: 30279230). Expression of this fusion in cell lines demonstrated that it is sensitive to trametinib but not vemurafenib as measured by in vitro colony formation and cell proliferation (PMID: 28539463). A patient with BRAF V600E-mutated metastatic melanoma, who experienced disease relapse after an initial response to the BRAF inhibitor Vemurafenib, was subsequently treated with dabrafenib plus trametinib (RAF inhibitor plus MEK inhibitor), and had a partial response for a period of two months (PMID: 28539463)."
              },
              "operation": "update",
              "uuids": "9f208268-d2d3-415b-820f-472944a8850e"
            }
          ],
          "timeStamp": 1634068324108
        },
        "-Mlq94Cy5VF165OrZ9RY": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "AGK-BRAF Fusion, Mutation Effect",
              "new": {
                "description": "The AGK-BRAF fusion protein results from an inversion of chromosome 7, which fuses the first two exons of AGK with exons 8-18 of BRAF. The AGK-BRAF fusion protein contains the full BRAF kinase domain, but lacks the regulatory RAS-binding domain and the cysteine-rich (CR1) domain, which are responsible for BRAF binding to RAS and auto-inhibition (PMID: 23890088, 24135138). This fusion has been found in melanoma, glioma, lung cancer, ovarian serous carcinoma and pediatric post-Chernobyl thyroid cancer (PMID: 23890088, 24135138, 26314551, 34568720). Expression of AGK-BRAF in mouse fibroblasts demonstrated that this fusion is activating and transforming as measured by increased growth and colony formation in soft agar compared to GFP control (PMID: 24135138). In vitro studies of AGK-BRAF in melanoma cell lines suggest that this fusion is sensitive to sorafenib but not vemurafenib as measured by cell viability upon drug treatment (PMID: 23890088). AGK-BRAF fusion was observed in 3 of 174 EGFR-mutant lung adenocarcinoma with primary resistance to EGFR tyrosine kinase inhibitors (TKIs).  Functional studies with the induction of AGK-BRAF fusion in H1975 ( EGFR L858R + T790M), PC9 (EGFR ex19del) and HCC827 (EGFR ex19del) cell lines demonstrated that the fusion conferred resistance to growth inhibition by EGFR TKIs (PMID: 30831205)."
              },
              "old": {
                "description": "The AGK-BRAF fusion protein results from an inversion of chromosome 7, which fuses the first two exons of AGK with exons 8-18 of BRAF. The AGK-BRAF fusion protein contains the BRAF kinase domain, but lacks the BRAF CR1 domain that is responsible for RAS-binding and auto-inhibition (PMID: 23890088, 24135138). This fusion is found in spitzoid melanoma, glioma, and post-Chernobyl patients with thyroid cancer (PMID: 23890088, PMID: 26314551). Expression of AGK-BRAF in mouse fibroblasts demonstrated that this fusion is activating and transforming as measured by increased growth and colony formation in soft agar compared to GFP control (PMID: 24135138). In vitro studies of AGK-BRAF in melanoma cell lines suggest that this fusions is sensitive to sorafenib but not vemurafenib as measured by cell viability upon drug treatment (PMID: 23890088). AGK-BRAF fusion was observed in 3 of 174 EGFR-mutant lung adenocarcinoma with primary resistance to EGFR tyrosine kinase inhibitors (TKIs).  Functional studies with the induction of AGK-BRAF fusion in H1975 (L858R + T790M), PC9 (ex19del) and HCC827 (ex19del) cell lines conferred resistance to growth inhibition by EGFR TKI (PMID: 30831205)."
              },
              "operation": "update",
              "uuids": "ec17e9b0-111a-46a9-a462-3608dcfa3eac"
            }
          ],
          "timeStamp": 1634069926950
        },
        "-Mlq9FuX2VUeM1N91qR0": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "MKRN1-BRAF Fusion, Mutation Effect",
              "new": {
                "description": "The MKRN1-BRAF fusion results from an inversion of chromosome 7 that fuses exons 1-4 of MKRN1 and exons 11-18 of BRAF (PMID: 23817572). This fusion contains the BRAF kinase domain but excludes the BRAF cysteine-rich (CR1) domain responsible for RAS binding and auto-inhibition (PMID:15630448). This mutation has been found in pediatric pilocytic astrocytoma, colorectal cancer, head and neck cancer, and ovarian serous cancer (PMID: 23817572, 26314551, 26324360, 34568720). While this fusion has not been functionally validated, other fusions that contain exons 11-18 of BRAF (e.g., AKAP9-BRAF, KIAA1549-BRAF) have been shown to be activating and oncogenic (PMID: 15630448, 18974108, 23817572). The MKRN1-BRAF fusion was detected in a patient with low-grade serous ovarian cancer who achieved a sustained complete response to combination selumetinib and paclitaxel (PMID: 26324360, 34568720)."
              },
              "old": {
                "description": "The MKRN1-BRAF fusion results from an inversion of chromosome 7 that fuses exons 1-4 of MKRN1 and exons 11-18 of BRAF. (PMID: 23817572). This fusion contains the BRAF kinase domain, but excludes the BRAF CR1 domain responsible for RAS binding and auto-inhibition (PMID:15630448). This mutation has been found in colorectal cancer and head and neck cancer (PMID: 26314551). While this fusion has not been functionally validated, other fusions that contain exons 11-18 of BRAF (e.g., AKAP9-BRAF, KIAA1549-BRAF) have been shown to be activating and oncogenic (PMID: 15630448, 18974108). The MKRN1-BRAF fusion was detected in a patient with low-grade serous ovarian cancer who achieved a sustained complete response to combination selumetinib and paclitaxel (PMID: 26324360)."
              },
              "operation": "update",
              "uuids": "621199d9-da07-472a-b38b-2674f36450af"
            }
          ],
          "timeStamp": 1634069974858
        },
        "-MmTjwX_4ckNHIzLLruE": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Oncogenic Mutations, Histiocytosis",
              "old": {
                "TIs": [
                  {
                    "name": "Standard implications for sensitivity to therapy",
                    "name_uuid": "3338130e-ea70-4d6e-b0d2-ff5ebe980dca",
                    "treatments_uuid": "02eb1410-99ef-4c0f-9462-b26104468010",
                    "type": "SS"
                  },
                  {
                    "name": "Standard implications for resistance to therapy",
                    "name_uuid": "4c69c1de-2520-4f0f-af13-b7b172bdbf32",
                    "treatments_uuid": "e6bae938-480b-4f2c-a7ac-a9733c6f8be3",
                    "type": "SR"
                  },
                  {
                    "name": "Investigational implications for sensitivity to therapy",
                    "name_uuid": "67473e7f-62b9-4cb8-8c1b-a23aa76c2f54",
                    "treatments": [
                      {
                        "description": "PMID: 30361829",
                        "description_review": {
                          "updateTime": 1633042961555,
                          "updatedBy": "User"
                        },
                        "description_uuid": "f2002e1a-40cf-44c4-bea3-73e515082100",
                        "indication": "",
                        "indication_uuid": "d604ffa5-5f7f-4b43-b1aa-f0d04381b133",
                        "level": "3A",
                        "level_review": {
                          "updateTime": 1564680986946,
                          "updatedBy": "User"
                        },
                        "level_uuid": "bd78225a-3aaf-454e-a3e2-68e3337f57d3",
                        "name": "eb357145-3b18-4aca-b75a-5e18dd2bf4f9, fb2bb01c-c0ec-4641-abf7-87f486075022",
                        "name_review": {
                          "updateTime": 1633042903788,
                          "updatedBy": "User"
                        },
                        "name_uuid": "483bc890-60e3-4c65-96e5-94f5412df6dc",
                        "propagation": "no",
                        "propagationLiquid": "no",
                        "propagationLiquid_uuid": "d230f51e-db25-11e9-923d-60f81dc75ed6",
                        "propagation_review": {
                          "updateTime": 1564680986938,
                          "updatedBy": "User"
                        },
                        "propagation_uuid": "62bca78f-fd37-4c92-83cf-51201564dccb",
                        "short": ""
                      }
                    ],
                    "treatments_uuid": "62057abb-52c2-4442-8f34-1586c593058f",
                    "type": "IS"
                  },
                  {
                    "name": "Investigational implications for resistance to therapy",
                    "name_uuid": "36398e6c-fc71-4d58-b4bb-7111ca386721",
                    "treatments_uuid": "4eb5542f-1cf5-49c2-859e-4f958e9361db",
                    "type": "IR"
                  }
                ],
                "cancerTypes": [
                  {
                    "code": "",
                    "mainType": "Histiocytosis",
                    "subtype": ""
                  }
                ],
                "cancerTypes_review": {
                  "removed": true,
                  "updateTime": 1634741451043,
                  "updatedBy": "User"
                },
                "cancerTypes_uuid": "0c23767d-65d7-49fe-9dbd-c5d54588f3ec",
                "diagnostic": {
                  "description": "",
                  "description_uuid": "bbbb4775-1b35-4478-960d-ef39e62e2f61",
                  "level": "",
                  "level_uuid": "3d8bd6ce-be6e-4e1b-af70-6e39dbf723de",
                  "short": ""
                },
                "diagnosticSummary": "",
                "diagnosticSummary_uuid": "71161458-5ba2-4385-bf62-3b391f726bf1",
                "diagnostic_uuid": "f0a1550e-37d5-45f7-bf88-37bc20eacffc",
                "prognostic": {
                  "description": "",
                  "description_uuid": "c215ef99-c584-4017-96e8-65f60821e74f",
                  "level": "",
                  "level_uuid": "16c01e74-5c1f-4269-b679-3dc6ccd37d4e",
                  "short": ""
                },
                "prognosticSummary": "",
                "prognosticSummary_uuid": "89a54d9f-7f16-4511-9d40-9838edc49842",
                "prognostic_uuid": "bfc84ff5-377e-42e5-941b-a2633e41f7d9",
                "summary": "There is promising clinical data in patients with histiocytic neoplasms harboring MAPK pathway alterations treated with the MEK-targeted inhibitors cobimetinib or trametinib as monotherapy.",
                "summary_review": {
                  "updateTime": 1633042934434,
                  "updatedBy": "User"
                },
                "summary_uuid": "a035a4e8-143e-4ba8-b360-8ae275fa92bd"
              },
              "operation": "delete"
            },
            {
              "lastEditBy": "User",
              "location": "Oncogenic Mutations, Erdheim-Chester Disease",
              "old": {
                "TIs": [
                  {
                    "name": "Standard implications for sensitivity to therapy",
                    "name_uuid": "b962c816-9f98-4aa8-a430-4abe0e063243",
                    "treatments": [
                      {
                        "description": "(PMID: 30867592)",
                        "description_review": {
                          "updateTime": 1633041801790,
                          "updatedBy": "User"
                        },
                        "description_uuid": "3faed22d-9d4b-44a2-af45-448cda44a9c8",
                        "indication": "",
                        "indication_uuid": "92fa3d59-0dc2-4c05-87f0-b3cd668762b8",
                        "level": "2",
                        "level_review": {
                          "updateTime": 1633041769285,
                          "updatedBy": "User"
                        },
                        "level_uuid": "cd28e919-2995-4ef5-b4e8-f21d2d0e2841",
                        "name": "eb357145-3b18-4aca-b75a-5e18dd2bf4f9, fb2bb01c-c0ec-4641-abf7-87f486075022",
                        "name_review": {
                          "updateTime": 1633041612330,
                          "updatedBy": "User"
                        },
                        "name_uuid": "4acee8ae-617b-42f8-8e80-5358048ea1aa",
                        "propagation": "no",
                        "propagationLiquid": "no",
                        "propagationLiquid_review": {
                          "updateTime": 1633041769283,
                          "updatedBy": "User"
                        },
                        "propagationLiquid_uuid": "8068acdf-a729-4acd-999b-e2a7f731a311",
                        "propagation_review": {
                          "updateTime": 1633041769280,
                          "updatedBy": "User"
                        },
                        "propagation_uuid": "5ab42a39-3344-42eb-b2dd-ebd8013e498f",
                        "short": ""
                      }
                    ],
                    "treatments_uuid": "eaf0ab31-f0e3-47de-9272-68e9ace7cdc2",
                    "type": "SS"
                  },
                  {
                    "name": "Standard implications for resistance to therapy",
                    "name_uuid": "deff2c0b-0e64-4ca7-87a3-1a098955f04d",
                    "treatments_uuid": "0b1ad069-97e3-44d8-9e03-999cd4e9a614",
                    "type": "SR"
                  },
                  {
                    "name": "Investigational implications for sensitivity to therapy",
                    "name_uuid": "ad5304cf-1e98-4e0c-b7d7-4066c8c9b094",
                    "treatments_uuid": "c863eb56-6395-483d-bbb7-0707e4e0e8e7",
                    "type": "IS"
                  },
                  {
                    "name": "Investigational implications for resistance to therapy",
                    "name_uuid": "cb5bccc0-6df6-4bda-8969-c354356308cc",
                    "treatments_uuid": "a17c3b6f-c447-4e48-9648-cc87745ac3e0",
                    "type": "IR"
                  }
                ],
                "cancerTypes": [
                  {
                    "code": "ECD",
                    "mainType": "Histiocytosis",
                    "subtype": "Erdheim-Chester Disease"
                  }
                ],
                "cancerTypes_review": {
                  "removed": true,
                  "updateTime": 1634741593773,
                  "updatedBy": "User"
                },
                "cancerTypes_uuid": "ad8bbf0c-f44c-474b-9232-f68607aec1b4",
                "diagnostic": {
                  "description": "",
                  "description_uuid": "5e741f60-c185-42b0-81c0-39080f0883c3",
                  "level": "",
                  "level_uuid": "64d66cfe-b128-4ffe-c01d-b5c8d11b7c53",
                  "short": ""
                },
                "diagnosticSummary": "",
                "diagnosticSummary_uuid": "9f083267-2822-45de-9555-6260e6ef914d",
                "diagnostic_uuid": "c60f0786-a8b0-4e31-93f9-a8ef46a650d7",
                "prognostic": {
                  "description": "",
                  "description_uuid": "79acae59-4647-453c-bb69-f9e7c04691c2",
                  "level": "",
                  "level_uuid": "c83dd3b7-c488-4a2f-c01b-675b4c9bb1eb",
                  "short": ""
                },
                "prognosticSummary": "",
                "prognosticSummary_uuid": "1dbfafc9-754e-4079-b022-7ad65a64c0fa",
                "prognostic_uuid": "55477d5b-8fee-4a6a-87de-263d0f0d52ff",
                "summary": "The MEK-targeted inhibitors cobimetinib and trametinib are NCCN-listed as monotherapy for the treatment of patients with Erdheim-Chester Disease with MAPK pathway alterations, including [[gene]][[mutation]].",
                "summary_review": {
                  "updateTime": 1633041758461,
                  "updatedBy": "User"
                },
                "summary_uuid": "a417de98-56a6-4211-917a-2ca0a006dfdd"
              },
              "operation": "delete"
            },
            {
              "lastEditBy": "User",
              "location": "Oncogenic Mutations, Langerhans Cell Histiocytosis",
              "old": {
                "TIs": [
                  {
                    "name": "Standard implications for sensitivity to therapy",
                    "name_uuid": "2cdfeee4-350b-43ec-b30e-b381b2adb104",
                    "treatments": [
                      {
                        "description": "PMID: 30867592, 32991018",
                        "description_review": {
                          "updateTime": 1633042306054,
                          "updatedBy": "User"
                        },
                        "description_uuid": "805b7af2-2939-4091-82b2-b42375df8230",
                        "indication": "",
                        "indication_uuid": "9974c4e9-a5f4-48cb-92ae-a61297a1715a",
                        "level": "2",
                        "level_review": {
                          "updateTime": 1633042279837,
                          "updatedBy": "User"
                        },
                        "level_uuid": "40b8b711-4dc5-4f42-b62e-7e5e5df77a46",
                        "name": "eb357145-3b18-4aca-b75a-5e18dd2bf4f9, fb2bb01c-c0ec-4641-abf7-87f486075022",
                        "name_review": {
                          "updateTime": 1633042256275,
                          "updatedBy": "User"
                        },
                        "name_uuid": "cd075ddd-91ce-4499-9402-2570bb6069d1",
                        "propagation": "no",
                        "propagationLiquid": "no",
                        "propagationLiquid_review": {
                          "updateTime": 1633042279834,
                          "updatedBy": "User"
                        },
                        "propagationLiquid_uuid": "158640f7-a390-4fb0-a837-e08ac363ee4d",
                        "propagation_review": {
                          "updateTime": 1633042279830,
                          "updatedBy": "User"
                        },
                        "propagation_uuid": "605114d4-8085-4477-802a-2ba7d168c137",
                        "short": ""
                      }
                    ],
                    "treatments_uuid": "dc24454a-1b6c-44e1-b5ff-ae3fd1a90c36",
                    "type": "SS"
                  },
                  {
                    "name": "Standard implications for resistance to therapy",
                    "name_uuid": "8d50aacc-6d54-46cf-9576-7c852115e7d2",
                    "treatments_uuid": "0201fff6-03e0-4f85-ba18-55916f66e8a1",
                    "type": "SR"
                  },
                  {
                    "name": "Investigational implications for sensitivity to therapy",
                    "name_uuid": "5c978369-5959-4126-a6fa-e70252c98f95",
                    "treatments_uuid": "cfb290c7-7fc8-4491-a44f-70a9295fa3b2",
                    "type": "IS"
                  },
                  {
                    "name": "Investigational implications for resistance to therapy",
                    "name_uuid": "dd80fe11-3b60-4589-a431-b4ce852a5555",
                    "treatments_uuid": "7a7ed5b4-2a46-4032-9190-0cdecbe938f2",
                    "type": "IR"
                  }
                ],
                "cancerTypes": [
                  {
                    "code": "LCH",
                    "mainType": "Histiocytosis",
                    "subtype": "Langerhans Cell Histiocytosis"
                  }
                ],
                "cancerTypes_review": {
                  "removed": true,
                  "updateTime": 1634741688480,
                  "updatedBy": "User"
                },
                "cancerTypes_uuid": "0f224722-a1c3-45d6-802d-89a43ccd3aef",
                "diagnostic": {
                  "description": "",
                  "description_uuid": "d50a6bac-24a0-4248-b9a3-e33339e2e453",
                  "level": "",
                  "level_uuid": "60dfedb9-028f-49ea-b152-b21b6cb2bd13",
                  "short": ""
                },
                "diagnosticSummary": "",
                "diagnosticSummary_uuid": "3f3e5af3-7098-421a-9db0-505a758f4d0a",
                "diagnostic_uuid": "52847cac-56de-45c7-bfe7-8dc174cf5b64",
                "prognostic": {
                  "description": "",
                  "description_uuid": "dcebae89-fde4-4a05-8d5c-eb76b88d74c5",
                  "level": "",
                  "level_uuid": "d3573366-b680-415c-bfbf-d70393e54086",
                  "short": ""
                },
                "prognosticSummary": "",
                "prognosticSummary_uuid": "e159aece-b521-49c6-868f-bbdff6ed30a1",
                "prognostic_uuid": "0367b814-fcbd-4b5e-9f6d-920b8b906f1f",
                "summary": "The MEK-targeted inhibitors cobimetinib and trametinib are NCCN-listed as monotherapy for the treatment of patients with Langerhans Cell Histiocytosis with MAPK pathway alterations, including [[gene]][[mutation]].",
                "summary_review": {
                  "updateTime": 1633042229423,
                  "updatedBy": "User"
                },
                "summary_uuid": "59c90847-6e9b-4e58-bc98-9452f4bce655"
              },
              "operation": "delete"
            },
            {
              "lastEditBy": "User",
              "location": "Oncogenic Mutations, Rosai-Dorfman Disease",
              "old": {
                "TIs": [
                  {
                    "name": "Standard implications for sensitivity to therapy",
                    "name_uuid": "3b7c5e2b-d2d2-48a8-8eab-0c2b3f196b30",
                    "treatments": [
                      {
                        "description": "PMID: 29236635",
                        "description_review": {
                          "updateTime": 1633042643536,
                          "updatedBy": "User"
                        },
                        "description_uuid": "1a38d790-17c1-4a35-851d-4afc9e9b7bba",
                        "indication": "",
                        "indication_uuid": "a472d205-d859-4525-8c77-09b976e8cc41",
                        "level": "2",
                        "level_review": {
                          "updateTime": 1633042626031,
                          "updatedBy": "User"
                        },
                        "level_uuid": "2963abfb-8619-4cc9-83dc-977aa49efea2",
                        "name": "eb357145-3b18-4aca-b75a-5e18dd2bf4f9, fb2bb01c-c0ec-4641-abf7-87f486075022",
                        "name_review": {
                          "updateTime": 1633042613559,
                          "updatedBy": "User"
                        },
                        "name_uuid": "3f7d891b-db8e-4024-bb95-6b0b2fcc94c0",
                        "propagation": "no",
                        "propagationLiquid": "no",
                        "propagationLiquid_review": {
                          "updateTime": 1633042626029,
                          "updatedBy": "User"
                        },
                        "propagationLiquid_uuid": "8b8cae32-b2f5-4b1f-9e44-a1e901c5689a",
                        "propagation_review": {
                          "updateTime": 1633042626027,
                          "updatedBy": "User"
                        },
                        "propagation_uuid": "eec0c3d8-4982-472f-a42e-ef3d1f6fff61",
                        "short": ""
                      }
                    ],
                    "treatments_uuid": "73728906-b34f-4c10-85bb-000fb740a4b9",
                    "type": "SS"
                  },
                  {
                    "name": "Standard implications for resistance to therapy",
                    "name_uuid": "3e4577c7-0b5b-4d98-ad2d-1cb86711f182",
                    "treatments_uuid": "1b0e0738-3769-4a00-9a2b-13b6d3d8d401",
                    "type": "SR"
                  },
                  {
                    "name": "Investigational implications for sensitivity to therapy",
                    "name_uuid": "e81ea76a-c04b-4c78-8602-2ab75928cd3e",
                    "treatments_uuid": "7eb5c861-9848-4d07-8d69-c4d7e73f7e63",
                    "type": "IS"
                  },
                  {
                    "name": "Investigational implications for resistance to therapy",
                    "name_uuid": "61d5f074-3506-47e0-83e4-c38bfad14d82",
                    "treatments_uuid": "ba3d7526-d9ff-4c12-91b0-b59c41d3c875",
                    "type": "IR"
                  }
                ],
                "cancerTypes": [
                  {
                    "code": "RDD",
                    "mainType": "Histiocytosis",
                    "subtype": "Rosai-Dorfman Disease"
                  }
                ],
                "cancerTypes_review": {
                  "removed": true,
                  "updateTime": 1634741805769,
                  "updatedBy": "User"
                },
                "cancerTypes_uuid": "5b4a5df6-7f82-4793-9696-6278cd9f10fd",
                "diagnostic": {
                  "description": "",
                  "description_uuid": "c0c9dc93-826d-4e74-b6b4-e8922cb702eb",
                  "level": "",
                  "level_uuid": "6fac5518-4ed8-4132-8e55-645d7b4c7cc7",
                  "short": ""
                },
                "diagnosticSummary": "",
                "diagnosticSummary_uuid": "cd0aa46e-fa02-449f-c00a-5d3270407a1a",
                "diagnostic_uuid": "f8c7ed45-23a3-4588-aa85-694c11ee8132",
                "prognostic": {
                  "description": "",
                  "description_uuid": "6bc15691-00d9-47c0-a502-de940ffcce56",
                  "level": "",
                  "level_uuid": "01f338a4-20b9-461f-b42b-617b10b3605c",
                  "short": ""
                },
                "prognosticSummary": "",
                "prognosticSummary_uuid": "3378875f-1012-4a8c-8f8d-e9cb6e871205",
                "prognostic_uuid": "60d7e703-ee49-4de9-901e-701ae51564db",
                "summary": "The MEK-targeted inhibitors cobimetinib and trametinib are NCCN-listed as monotherapy for the treatment of patients with Rosai-Dorfman Disease with MAPK pathway alterations, including [[gene]][[mutation]].",
                "summary_review": {
                  "updateTime": 1633042576508,
                  "updatedBy": "User"
                },
                "summary_uuid": "7b51745f-6c4b-4daa-9ffa-2c9c75de252a"
              },
              "operation": "delete"
            }
          ],
          "timeStamp": 1634750941391
        },
        "-MmTk1mB2QOpAjZo8Jsg": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Oncogenic Mutations {excluding V600}",
              "new": {
                "mutation_effect": {
                  "description": "",
                  "description_uuid": "d1a75603-df33-40ce-8d4c-710aea0ed1e8",
                  "effect": "",
                  "effect_uuid": "1dc30c67-c322-49f7-8e74-cd32077d672f",
                  "oncogenic": "",
                  "oncogenic_uuid": "7542ec73-86db-4df5-b941-28ff81964752",
                  "short": ""
                },
                "mutation_effect_uuid": "5f9ac10d-35b6-4e42-970e-bc6cbef13ed6",
                "name": "Oncogenic Mutations {excluding V600}",
                "name_review": {
                  "added": true,
                  "updateTime": 1634741209146,
                  "updatedBy": "User"
                },
                "name_uuid": "3e608d66-9576-455a-a4cc-2e111880431c",
                "tumors": [
                  {
                    "TIs": [
                      {
                        "name": "Standard implications for sensitivity to therapy",
                        "name_uuid": "282fdad0-12d5-4bc7-9e90-200d8fc24ae4",
                        "treatments_uuid": "e8b535ef-98fa-49eb-a263-790bc421687d",
                        "type": "SS"
                      },
                      {
                        "name": "Standard implications for resistance to therapy",
                        "name_uuid": "f0968332-8358-49b4-973b-855afe135acf",
                        "treatments_uuid": "d7803155-fba4-4419-ae4a-9b876c1ea226",
                        "type": "SR"
                      },
                      {
                        "name": "Investigational implications for sensitivity to therapy",
                        "name_uuid": "6b21d282-3a62-44ff-80e2-c64cb3f6a596",
                        "treatments": [
                          {
                            "description": "PMID: 30361829",
                            "description_review": {
                              "lastReviewed": "",
                              "updateTime": 1634741409925,
                              "updatedBy": "User"
                            },
                            "description_uuid": "c08d38bc-7eb1-4bcb-9adc-2eb66225521e",
                            "indication": "",
                            "indication_uuid": "7f668efd-04f0-4655-b97c-71783b0717b9",
                            "level": "3A",
                            "level_review": {
                              "lastReviewed": "",
                              "updateTime": 1634741398189,
                              "updatedBy": "User"
                            },
                            "level_uuid": "448e8d3f-d9f8-45b6-87b1-42a25028ef76",
                            "name": "eb357145-3b18-4aca-b75a-5e18dd2bf4f9, fb2bb01c-c0ec-4641-abf7-87f486075022",
                            "name_review": {
                              "added": true,
                              "updateTime": 1634741393018,
                              "updatedBy": "User"
                            },
                            "name_uuid": "658a788e-390c-41c6-8081-0376b6121bb0",
                            "propagation": "no",
                            "propagationLiquid": "no",
                            "propagationLiquid_review": {
                              "lastReviewed": "",
                              "updateTime": 1634741398187,
                              "updatedBy": "User"
                            },
                            "propagationLiquid_uuid": "16ac3b04-612c-4e6e-99a0-31cbcc0ee779",
                            "propagation_review": {
                              "lastReviewed": "",
                              "updateTime": 1634741398184,
                              "updatedBy": "User"
                            },
                            "propagation_uuid": "98805335-5ecf-4a91-81dd-334aa902e4be",
                            "short": ""
                          }
                        ],
                        "treatments_uuid": "42c64a97-dcc2-4195-b08d-f6d321ce3065",
                        "type": "IS"
                      },
                      {
                        "name": "Investigational implications for resistance to therapy",
                        "name_uuid": "f51e2d0a-1387-43a9-92e7-1606f9a1cf24",
                        "treatments_uuid": "51f16f43-d330-41cb-ac91-88e56a9c8a45",
                        "type": "IR"
                      }
                    ],
                    "cancerTypes": [
                      {
                        "code": "",
                        "mainType": "Histiocytosis",
                        "subtype": ""
                      }
                    ],
                    "cancerTypes_review": {
                      "added": true,
                      "updateTime": 1634741280284,
                      "updatedBy": "User"
                    },
                    "cancerTypes_uuid": "a0b13f00-6bbd-4c01-a1d0-397d600de2ea",
                    "diagnostic": {
                      "description": "",
                      "description_uuid": "1686dc2b-4601-421a-b57d-2a08b19982b7",
                      "level": "",
                      "level_uuid": "a8e00602-2eb0-4c8e-9803-d640f568eec4",
                      "short": ""
                    },
                    "diagnosticSummary": "",
                    "diagnosticSummary_uuid": "877fbdb9-fc4e-4a35-9ed4-eca406ca755c",
                    "diagnostic_uuid": "ac925482-107b-4dc3-b0ea-21ac5868bfa5",
                    "prognostic": {
                      "description": "",
                      "description_uuid": "9c92e93c-f064-4b6d-a187-cacbfff3547d",
                      "level": "",
                      "level_uuid": "99a9f1ce-85da-46e4-b3ca-8d10e3e9dd46",
                      "short": ""
                    },
                    "prognosticSummary": "",
                    "prognosticSummary_uuid": "f945e41e-a33f-4b9e-aff0-919a7bcadcde",
                    "prognostic_uuid": "54e952c4-35de-45a5-8e1c-bfcd858c889d",
                    "summary": "There is promising clinical data in patients with histiocytic neoplasms harboring MAPK pathway alterations treated with the MEK-targeted inhibitors cobimetinib or trametinib as monotherapy.",
                    "summary_review": {
                      "lastReviewed": "",
                      "updateTime": 1634741288251,
                      "updatedBy": "User"
                    },
                    "summary_uuid": "c96628e0-742b-477e-8eff-c79aa725a02d"
                  },
                  {
                    "TIs": [
                      {
                        "name": "Standard implications for sensitivity to therapy",
                        "name_uuid": "4503ba33-32ee-4bdf-93e2-1d6347c840d9",
                        "treatments": [
                          {
                            "description": "(PMID: 30867592)",
                            "description_review": {
                              "lastReviewed": "",
                              "updateTime": 1634741554910,
                              "updatedBy": "User"
                            },
                            "description_uuid": "a1b0a59c-e153-40d4-a7a5-9eb31e4eaa23",
                            "indication": "",
                            "indication_uuid": "ae097583-1dc9-4d6b-c0e7-2636126b6d28",
                            "level": "2",
                            "level_review": {
                              "lastReviewed": "",
                              "updateTime": 1634741537512,
                              "updatedBy": "User"
                            },
                            "level_uuid": "f327e67a-9925-4915-b10d-d7d651fe3047",
                            "name": "eb357145-3b18-4aca-b75a-5e18dd2bf4f9, fb2bb01c-c0ec-4641-abf7-87f486075022",
                            "name_review": {
                              "added": true,
                              "updateTime": 1634741533160,
                              "updatedBy": "User"
                            },
                            "name_uuid": "f85c5ffd-a7dc-4769-acdc-012ff3b7ac5d",
                            "propagation": "no",
                            "propagationLiquid": "no",
                            "propagationLiquid_review": {
                              "lastReviewed": "",
                              "updateTime": 1634741537510,
                              "updatedBy": "User"
                            },
                            "propagationLiquid_uuid": "27841d07-211e-4d53-884b-4f1dead6fe60",
                            "propagation_review": {
                              "lastReviewed": "",
                              "updateTime": 1634741537507,
                              "updatedBy": "User"
                            },
                            "propagation_uuid": "20e3a162-6c2d-4992-95d6-1b6cefdd3b9d",
                            "short": ""
                          }
                        ],
                        "treatments_uuid": "9dfb693f-9bea-467e-b2a2-69c65e8d618f",
                        "type": "SS"
                      },
                      {
                        "name": "Standard implications for resistance to therapy",
                        "name_uuid": "646b42ef-6d1c-4c48-b41a-2cbe4e3a1477",
                        "treatments_uuid": "84965d68-bb68-40c3-8892-1746a9b3868a",
                        "type": "SR"
                      },
                      {
                        "name": "Investigational implications for sensitivity to therapy",
                        "name_uuid": "250a6b29-e884-48c5-8371-fed03e4f2b42",
                        "treatments_uuid": "551af4a6-6dc7-41ff-a080-668d034dac06",
                        "type": "IS"
                      },
                      {
                        "name": "Investigational implications for resistance to therapy",
                        "name_uuid": "d92a8765-9f09-4251-9473-afa5cf34e08f",
                        "treatments_uuid": "7bdcb7d1-1dad-498a-a164-39f12da8f828",
                        "type": "IR"
                      }
                    ],
                    "cancerTypes": [
                      {
                        "code": "ECD",
                        "mainType": "Histiocytosis",
                        "subtype": "Erdheim-Chester Disease"
                      }
                    ],
                    "cancerTypes_review": {
                      "added": true,
                      "updateTime": 1634741480213,
                      "updatedBy": "User"
                    },
                    "cancerTypes_uuid": "12e8b36a-1516-4f10-a2a6-c114e2883655",
                    "diagnostic": {
                      "description": "",
                      "description_uuid": "5c005059-9e69-4e7a-8537-0e0af26e43f6",
                      "level": "",
                      "level_uuid": "20b190e8-d6d4-43c4-8372-07061de6e605",
                      "short": ""
                    },
                    "diagnosticSummary": "",
                    "diagnosticSummary_uuid": "ebe84aef-b664-4224-a7cd-f041bc74a9d0",
                    "diagnostic_uuid": "6b2b0359-3101-44c9-bf7e-a088bf06253c",
                    "prognostic": {
                      "description": "",
                      "description_uuid": "daa1cd0f-d718-4d4f-b95d-304b40c04bdd",
                      "level": "",
                      "level_uuid": "4ffccd63-95f9-45e9-b3dd-2c3e1c498eb0",
                      "short": ""
                    },
                    "prognosticSummary": "",
                    "prognosticSummary_uuid": "9905a331-7fb7-4567-9941-3a70713d6a12",
                    "prognostic_uuid": "8ac20573-3ea2-4194-9fda-bcd67a1b0324",
                    "summary": "The MEK-targeted inhibitors cobimetinib and trametinib are NCCN-listed as monotherapy for the treatment of patients with Erdheim-Chester Disease with MAPK pathway alterations, including [[gene]][[mutation]].",
                    "summary_review": {
                      "lastReviewed": "",
                      "updateTime": 1634741503337,
                      "updatedBy": "User"
                    },
                    "summary_uuid": "e95d9545-8b3b-480e-9222-bddc0869dba2"
                  },
                  {
                    "TIs": [
                      {
                        "name": "Standard implications for sensitivity to therapy",
                        "name_uuid": "c9a27922-f663-4d8c-9d21-160b3bcadf5e",
                        "treatments": [
                          {
                            "description": "PMID: 30867592, 32991018",
                            "description_review": {
                              "lastReviewed": "",
                              "updateTime": 1634741666660,
                              "updatedBy": "User"
                            },
                            "description_uuid": "7bc2a848-5b81-45e1-a494-a188478b2f8e",
                            "indication": "",
                            "indication_uuid": "e942ac8c-a6aa-4bc8-9b05-0f5d542a909c",
                            "level": "2",
                            "level_review": {
                              "lastReviewed": "",
                              "updateTime": 1634741649147,
                              "updatedBy": "User"
                            },
                            "level_uuid": "4785be01-49eb-43c6-848b-247829d95011",
                            "name": "eb357145-3b18-4aca-b75a-5e18dd2bf4f9, fb2bb01c-c0ec-4641-abf7-87f486075022",
                            "name_review": {
                              "added": true,
                              "updateTime": 1634741643931,
                              "updatedBy": "User"
                            },
                            "name_uuid": "a7ce9682-0287-4744-895c-69df4bb7792b",
                            "propagation": "no",
                            "propagationLiquid": "no",
                            "propagationLiquid_review": {
                              "lastReviewed": "",
                              "updateTime": 1634741649144,
                              "updatedBy": "User"
                            },
                            "propagationLiquid_uuid": "58654823-d7b2-46c5-9925-2486a2fee465",
                            "propagation_review": {
                              "lastReviewed": "",
                              "updateTime": 1634741649141,
                              "updatedBy": "User"
                            },
                            "propagation_uuid": "89979615-ccdf-421f-92a2-2459db5f3343",
                            "short": ""
                          }
                        ],
                        "treatments_uuid": "4b45eb65-1a1d-4dc7-9608-012820536ae8",
                        "type": "SS"
                      },
                      {
                        "name": "Standard implications for resistance to therapy",
                        "name_uuid": "dbb226b8-c5ea-4422-bc62-2cf4e869d499",
                        "treatments_uuid": "d1a112ba-367f-43a7-ba54-465798d8e6ec",
                        "type": "SR"
                      },
                      {
                        "name": "Investigational implications for sensitivity to therapy",
                        "name_uuid": "49ac8cd9-c7a3-45ef-8c8f-02e62823cc80",
                        "treatments_uuid": "55b6f7f0-44bd-43a2-9c4b-f13ea93a1acf",
                        "type": "IS"
                      },
                      {
                        "name": "Investigational implications for resistance to therapy",
                        "name_uuid": "205ccaeb-d255-43f7-9782-866d49f16d7e",
                        "treatments_uuid": "f1471ea2-7d75-4afb-bbed-c4208bb75614",
                        "type": "IR"
                      }
                    ],
                    "cancerTypes": [
                      {
                        "code": "LCH",
                        "mainType": "Histiocytosis",
                        "subtype": "Langerhans Cell Histiocytosis"
                      }
                    ],
                    "cancerTypes_review": {
                      "added": true,
                      "updateTime": 1634741623130,
                      "updatedBy": "User"
                    },
                    "cancerTypes_uuid": "1fdb4ff1-6f4d-4f74-a53e-82432bd2e781",
                    "diagnostic": {
                      "description": "",
                      "description_uuid": "556bba03-c1f5-422a-9fcf-6fff28935e8b",
                      "level": "",
                      "level_uuid": "5d0a64b7-312c-4a2c-83cc-44b9c42148e8",
                      "short": ""
                    },
                    "diagnosticSummary": "",
                    "diagnosticSummary_uuid": "7767a131-0a58-4adb-a120-d08b77fd50bd",
                    "diagnostic_uuid": "3ea3c3e6-dc20-4429-c08a-1a92d084f81a",
                    "prognostic": {
                      "description": "",
                      "description_uuid": "65c7be1f-5e52-4425-8632-215d7328aef5",
                      "level": "",
                      "level_uuid": "09667bdf-d464-499d-a482-7e1905265d82",
                      "short": ""
                    },
                    "prognosticSummary": "",
                    "prognosticSummary_uuid": "d0ceffbf-1895-4153-a692-2fd1b27ce8e6",
                    "prognostic_uuid": "1d0339e2-09d2-4f6c-8659-1c2c014d59a2",
                    "summary": "The MEK-targeted inhibitors cobimetinib and trametinib are NCCN-listed as monotherapy for the treatment of patients with Langerhans Cell Histiocytosis with MAPK pathway alterations, including [[gene]][[mutation]].",
                    "summary_review": {
                      "lastReviewed": "",
                      "updateTime": 1634741629656,
                      "updatedBy": "User"
                    },
                    "summary_uuid": "7e539aa7-e805-4ac4-827e-a7a552199d1f"
                  },
                  {
                    "TIs": [
                      {
                        "name": "Standard implications for sensitivity to therapy",
                        "name_uuid": "d1b278b3-3a98-4003-9ae5-54df7e2b083d",
                        "treatments": [
                          {
                            "description": "PMID: 29236635",
                            "description_review": {
                              "lastReviewed": "",
                              "updateTime": 1634741761974,
                              "updatedBy": "User"
                            },
                            "description_uuid": "397a718f-210a-44fd-9724-79cdacb83266",
                            "indication": "",
                            "indication_uuid": "413fa930-677a-42bf-a782-b9d851f3872f",
                            "level": "2",
                            "level_review": {
                              "lastReviewed": "",
                              "updateTime": 1634741743056,
                              "updatedBy": "User"
                            },
                            "level_uuid": "5ce2b7bc-f70b-4b0e-b8e3-a71f1f396b20",
                            "name": "eb357145-3b18-4aca-b75a-5e18dd2bf4f9, fb2bb01c-c0ec-4641-abf7-87f486075022",
                            "name_review": {
                              "added": true,
                              "updateTime": 1634741737199,
                              "updatedBy": "User"
                            },
                            "name_uuid": "6680f049-0c87-41fb-a234-09c1a2361419",
                            "propagation": "no",
                            "propagationLiquid": "no",
                            "propagationLiquid_review": {
                              "lastReviewed": "",
                              "updateTime": 1634741743054,
                              "updatedBy": "User"
                            },
                            "propagationLiquid_uuid": "6c15176f-bf60-4387-9b85-c7f1c7bd0078",
                            "propagation_review": {
                              "lastReviewed": "",
                              "updateTime": 1634741743051,
                              "updatedBy": "User"
                            },
                            "propagation_uuid": "e33e1e72-1925-464a-83ec-ef6d8d07cbe9",
                            "short": ""
                          }
                        ],
                        "treatments_uuid": "ca1a86cd-3d1a-4abb-b59b-e974723d28c0",
                        "type": "SS"
                      },
                      {
                        "name": "Standard implications for resistance to therapy",
                        "name_uuid": "a01f1103-a725-480d-bf37-6af8e5e0682d",
                        "treatments_uuid": "3f288185-2f15-46a2-93b3-e5251c776647",
                        "type": "SR"
                      },
                      {
                        "name": "Investigational implications for sensitivity to therapy",
                        "name_uuid": "f522e6c4-16ff-400d-975f-c4532b8832d6",
                        "treatments_uuid": "f0c14335-8012-4287-ade1-f70533e619cd",
                        "type": "IS"
                      },
                      {
                        "name": "Investigational implications for resistance to therapy",
                        "name_uuid": "12c79455-ba95-43c2-984c-abc514e3eb23",
                        "treatments_uuid": "b4f7d499-4e90-4c62-8608-56dec5d46884",
                        "type": "IR"
                      }
                    ],
                    "cancerTypes": [
                      {
                        "code": "RDD",
                        "mainType": "Histiocytosis",
                        "subtype": "Rosai-Dorfman Disease"
                      }
                    ],
                    "cancerTypes_review": {
                      "added": true,
                      "updateTime": 1634741706878,
                      "updatedBy": "User"
                    },
                    "cancerTypes_uuid": "b3571e1a-efcc-4bc2-b7a8-61d46f1bfa63",
                    "diagnostic": {
                      "description": "",
                      "description_uuid": "96c689bf-4404-4eb3-aabd-cf504c4db492",
                      "level": "",
                      "level_uuid": "62dfbd07-1f0b-4f53-9b56-e7dbebac30c8",
                      "short": ""
                    },
                    "diagnosticSummary": "",
                    "diagnosticSummary_uuid": "aa32297c-8c16-40cf-9ef5-a626b5e27faa",
                    "diagnostic_uuid": "cb47166a-f50a-4cb6-b277-fcbb5d13cee5",
                    "prognostic": {
                      "description": "",
                      "description_uuid": "b510edda-0733-40d0-8e7f-f9ccef52ea7d",
                      "level": "",
                      "level_uuid": "8f53d090-0a16-4a78-9224-8a8e74d3865b",
                      "short": ""
                    },
                    "prognosticSummary": "",
                    "prognosticSummary_uuid": "94bf93ca-2ff9-4c66-8679-f2828e8f53aa",
                    "prognostic_uuid": "3743c6e8-9326-4d3d-9bb8-6246e0f8bdac",
                    "summary": "The MEK-targeted inhibitors cobimetinib and trametinib are NCCN-listed as monotherapy for the treatment of patients with Rosai-Dorfman Disease with MAPK pathway alterations, including [[gene]][[mutation]].",
                    "summary_review": {
                      "lastReviewed": "",
                      "updateTime": 1634741723962,
                      "updatedBy": "User"
                    },
                    "summary_uuid": "67779f76-43de-4ac6-8b31-27064c3ab215"
                  }
                ],
                "tumors_uuid": "45f0ba05-48c5-4222-babc-57d85dd6e311"
              },
              "operation": "add",
              "uuids": "c96628e0-742b-477e-8eff-c79aa725a02d,658a788e-390c-41c6-8081-0376b6121bb0,e95d9545-8b3b-480e-9222-bddc0869dba2,f85c5ffd-a7dc-4769-acdc-012ff3b7ac5d,7e539aa7-e805-4ac4-827e-a7a552199d1f,a7ce9682-0287-4744-895c-69df4bb7792b,67779f76-43de-4ac6-8b31-27064c3ab215,6680f049-0c87-41fb-a234-09c1a2361419"
            }
          ],
          "timeStamp": 1634750966966
        },
        "-Mo5fT7Io_8lpERzWoLK": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "K601E, Mutation Effect",
              "new": {
                "description": "The class II (PMID: 28783719) and hyperactivating (PMID: 26343582) BRAF K601E mutation is located in the kinase domain in exon 15 of the BRAF protein, and is recurrent in melanoma (PMID: 22798288, 26643848). Biological characterization of BRAF K601E mutations demonstrated that they activate the downstream MAPK pathway independently of RAS (PMID: 22798288, 26343582), render BRAF active as a dimer with CRAF and itself (PMID: 20179705, 26343582) and while sensitive to MEK inhibition by targeted inhibitors such as trametinib (PMID: 28783719, 22798288, 18794803), are insensitive to RAF monomer inhibitors such as vemurafenib (PMID: 22798288, 28783719, 20179705). A patient with metastatic BRAF K601E-mutated melanoma achieved complete response to the MEK inhibitor trametinib (PMID: 28344857)."
              },
              "old": {
                "description": "The class II (PMID: 28783719) and hyperactivating (PMID: 26343582) BRAF K601E mutation is located in the kinase domain in exon 15 of the BRAF protein, and is recurrent in melanoma (PMID: 22798288, 26643848). A clinicopathologic study of a cohort of 1119 Australian patients with known BRAF mutant status positive melanomas demonstrated that at 3.2% of patients, BRAF K601E mutations are some of the most commonly occurring BRAF non-V600E mutations. These BRAF mutations occurred predominantly in males, median age 58 years. These tumors were generally found to occur on the trunk (64%), and revealed no association with chronically sun-damaged (CSD) skin (PMID: 26643848). Biological characterization of BRAF K601E mutations demonstrated that they activate the downstream MAPK pathway independently of RAS (PMID: 22798288, 26343582), render BRAF active as a dimer with CRAF and itself (PMID: 20179705, 26343582) and while sensitive to MEK inhibition by targeted inhibitors such as trametinib (PMID: 28783719, 22798288, 18794803), are insensitive to RAF monomer inhibitors such as vemurafenib (PMID: 22798288, 28783719, 20179705)."
              },
              "operation": "update",
              "uuids": "9b64a01a-fe4a-4764-bb83-50a7dddc2093"
            }
          ],
          "timeStamp": 1636494598726
        },
        "-MopBNiHrHKKkJ11FiMR": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Oncogenic Mutations {excluding V600E}",
              "new": {
                "mutation_effect": {
                  "description": "",
                  "description_uuid": "c60d30ce-ff9d-4891-a27f-c1a87825780c",
                  "effect": "",
                  "effect_uuid": "ca3b6642-b963-45ca-b37f-411ab804e6aa",
                  "oncogenic": "",
                  "oncogenic_uuid": "89c8e52b-81cb-43f6-bd52-30ee76fb443c",
                  "short": ""
                },
                "mutation_effect_uuid": "bc5c333b-d6ee-480a-a6fd-317203c17232",
                "name": "Oncogenic Mutations {excluding V600E}",
                "name_review": {
                  "added": true,
                  "updateTime": 1637271558496,
                  "updatedBy": "User"
                },
                "name_uuid": "8abb8db3-0d1c-4b5b-b6bd-edc17c6ae14a",
                "tumors": [
                  {
                    "TIs": [
                      {
                        "name": "Standard implications for sensitivity to therapy",
                        "name_uuid": "63cc6a71-7a1e-4993-b0c7-b820bed052fe",
                        "treatments": [
                          {
                            "description": "Dabrafenib, an orally bioavailable RAF inhibitor, and trametinib, an orally bioavailable MEK1/2 inhibitor, are FDA-approved alone or in combination for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options. FDA-approval was based on results of the Phase II study of dabrafenib combined with trametinib in patients with BRAF V600E-positive ATC in which the overall response rate in sixteen evaluable patients was 69% (11/16; 95% CI= 41%-89%)(PMID: 29072975). Dabrafenib + trametinib is NCCN-compendium listed for the treatment of patients with BRAF V600-mutant ATC.",
                            "description_review": {
                              "lastReviewed": "",
                              "updateTime": 1637271701539,
                              "updatedBy": "User"
                            },
                            "description_uuid": "5ce9f90f-5634-4313-b28b-f9ad967a810d",
                            "indication": "",
                            "indication_uuid": "c0bb3f6f-69c6-4c88-a433-0a97b447bcb9",
                            "level": "2",
                            "level_review": {
                              "lastReviewed": "",
                              "updateTime": 1637271675005,
                              "updatedBy": "User"
                            },
                            "level_uuid": "eb5d69c6-65c6-40c2-abb0-df2182849e07",
                            "name": "939cd40b-b515-499d-b099-fd29027c0d17 + fb2bb01c-c0ec-4641-abf7-87f486075022",
                            "name_review": {
                              "added": true,
                              "updateTime": 1637271667456,
                              "updatedBy": "User"
                            },
                            "name_uuid": "33a3eeca-1eb7-4c2a-9c47-e33dbaa645ee",
                            "propagation": "3B",
                            "propagationLiquid": "no",
                            "propagationLiquid_review": {
                              "lastReviewed": "",
                              "updateTime": 1637271675003,
                              "updatedBy": "User"
                            },
                            "propagationLiquid_uuid": "c64b713c-9210-4694-bc85-0941df960085",
                            "propagation_review": {
                              "lastReviewed": "",
                              "updateTime": 1637271678359,
                              "updatedBy": "User"
                            },
                            "propagation_uuid": "fb10205c-96eb-4775-a2b7-32a4da4ce82c",
                            "short": ""
                          }
                        ],
                        "treatments_uuid": "e128db45-6e2c-475a-98b3-c5e7bf8b4516",
                        "type": "SS"
                      },
                      {
                        "name": "Standard implications for resistance to therapy",
                        "name_uuid": "ea34e1a4-6671-4058-c019-38411eb5694e",
                        "treatments_uuid": "08251695-e939-4f8d-a5e6-4baaabc9926d",
                        "type": "SR"
                      },
                      {
                        "name": "Investigational implications for sensitivity to therapy",
                        "name_uuid": "4bae595e-1f8d-452f-82fb-ddd4e323fdbf",
                        "treatments_uuid": "956ee588-09d0-43fb-8efc-f667632f9cd2",
                        "type": "IS"
                      },
                      {
                        "name": "Investigational implications for resistance to therapy",
                        "name_uuid": "e0304f36-082c-4153-aa58-14a55841bdc8",
                        "treatments_uuid": "c08e6b6a-004c-4420-8776-cd9ae6c62578",
                        "type": "IR"
                      }
                    ],
                    "cancerTypes": [
                      {
                        "code": "THAP",
                        "mainType": "Thyroid Cancer",
                        "subtype": "Anaplastic Thyroid Cancer"
                      }
                    ],
                    "cancerTypes_review": {
                      "added": true,
                      "updateTime": 1637271611525,
                      "updatedBy": "User"
                    },
                    "cancerTypes_uuid": "f8137d71-23e7-4498-b6d7-53e257949d28",
                    "diagnostic": {
                      "description": "",
                      "description_uuid": "b153a8b7-7759-4329-998d-3f46b408f39c",
                      "level": "",
                      "level_uuid": "2f2dd82a-0b1f-4363-90db-32623626ce9e",
                      "short": ""
                    },
                    "diagnosticSummary": "",
                    "diagnosticSummary_uuid": "a92f777b-ad12-4aed-abbe-a1ba4ea7db96",
                    "diagnostic_uuid": "9ed5bae3-789c-4b4f-8c52-157b53bf5b99",
                    "prognostic": {
                      "description": "",
                      "description_uuid": "7b722ef6-382c-4c25-86f3-ccc0b7e22a9a",
                      "level": "",
                      "level_uuid": "e0165619-bd0a-435a-90fb-5a20969e224f",
                      "short": ""
                    },
                    "prognosticSummary": "",
                    "prognosticSummary_uuid": "a4a6767f-1d32-4e5c-b389-fbf645ee50a9",
                    "prognostic_uuid": "60099ae7-5199-46e7-99e6-52df9a4f0f77",
                    "summary": "The RAF-targeted inhibitor dabrafenib in combination with the MEK1/2-targeted inhibitor trametinib is FDA-approved for the treatment of patients with BRAF V600E mutant anaplastic thyroid cancer (ATC), and NCCN-compendium listed for the treatment of patients with BRAF V600-mutant ATC.",
                    "summary_review": {
                      "lastReviewed": "",
                      "updateTime": 1637271642224,
                      "updatedBy": "User"
                    },
                    "summary_uuid": "72442100-492e-4e33-b1da-7f691ac43a3b"
                  }
                ],
                "tumors_uuid": "4d9fe6e8-8448-422c-be2b-72220524bce4"
              },
              "operation": "add",
              "uuids": "72442100-492e-4e33-b1da-7f691ac43a3b,33a3eeca-1eb7-4c2a-9c47-e33dbaa645ee"
            }
          ],
          "timeStamp": 1637274979256
        },
        "-MopD-zcG8Bqm9Ij713n": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Oncogenic Mutations {excluding V600E, V600K}",
              "new": {
                "mutation_effect": {
                  "description": "",
                  "description_uuid": "b34f4025-951f-4baa-b205-e502f09ee880",
                  "effect": "",
                  "effect_uuid": "96a10f1a-fa27-4a4e-974b-5b64fe9cbd76",
                  "oncogenic": "",
                  "oncogenic_uuid": "db68874d-5313-4b54-ac4c-543653efa8da",
                  "short": ""
                },
                "mutation_effect_uuid": "52d538eb-8042-46a9-aeba-1c809ede19bd",
                "name": "Oncogenic Mutations {excluding V600E, V600K}",
                "name_review": {
                  "added": true,
                  "updateTime": 1637271576662,
                  "updatedBy": "User"
                },
                "name_uuid": "c252fd4a-da2f-41d2-81a1-8065bf5398af",
                "tumors": [
                  {
                    "TIs": [
                      {
                        "name": "Standard implications for sensitivity to therapy",
                        "name_uuid": "0ec1912f-651c-404d-b0de-6c85009f8130",
                        "treatments": [
                          {
                            "description": "The combination of encorafenib, an inhibitor of V600E- or V600K-mutant BRAF, and binimetinib, an inhibitor of MEK1/2, is FDA approved in combination for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. FDA-approval was based on the results of the Phase III COLUMBUS trial of combined encorafenib plus binimetinib versus single agent vemurafenib in 577 patients with BRAF V600E- or V600K-mutant metastatic melanoma in which the median progression-free survival was 14.9 months (95% CI 11.0-18.5) in the encorafenib plus binimetinib group versus 7.3 months (95% CI 5.6-8.2) in the single agent vemurafenib group (HR= 0.54, 95% CI 0.41-0.71; p<0·0001) (PMID: 29573941).",
                            "description_review": {
                              "lastReviewed": "",
                              "updateTime": 1637272191882,
                              "updatedBy": "User"
                            },
                            "description_uuid": "16181e0a-f9a8-496e-a8c4-ce93e5adf265",
                            "indication": "",
                            "indication_uuid": "48001f48-dada-406e-9610-4223d4402f84",
                            "level": "2",
                            "level_review": {
                              "lastReviewed": "",
                              "updateTime": 1637272182413,
                              "updatedBy": "User"
                            },
                            "level_uuid": "4b030ef3-4ed5-4d21-b554-ffd3df4d4a7d",
                            "name": "001e534f-3e63-432f-90a6-d1af1759e4e2 + feb9f4a3-e374-4c75-8a3b-0f1fbcdbf677",
                            "name_review": {
                              "added": true,
                              "updateTime": 1637272174474,
                              "updatedBy": "User"
                            },
                            "name_uuid": "009d1441-ac80-4048-ae01-371ac1591c33",
                            "propagation": "3B",
                            "propagationLiquid": "no",
                            "propagationLiquid_review": {
                              "lastReviewed": "",
                              "updateTime": 1637272182407,
                              "updatedBy": "User"
                            },
                            "propagationLiquid_uuid": "c78bcf40-3141-40eb-8799-f423c7f881ce",
                            "propagation_review": {
                              "lastReviewed": "",
                              "updateTime": 1637272187664,
                              "updatedBy": "User"
                            },
                            "propagation_uuid": "c02bf486-7cbf-4769-8d7f-8dc3ba922053",
                            "short": ""
                          },
                          {
                            "description": "Dabrafenib, an orally bioavailable RAF inhibitor, and trametinib, an orally bioavailable MEK1/2 inhibitor, are FDA-approved alone or in combination for the treatment of patients with metastatic melanoma harboring a V600E or V600K BRAF mutation. The FDA approved the combination of dabrafenib and trametinib based on results from an open-label Phase III study of combination therapy versus dabrafenib monotherapy in 247 patients with metastatic melanoma who were naive to treatment with BRAF inhibitors. Combined dabrafenib and trametinib, administered in full monotherapy doses, improved the response rate in patients with BRAF V600-mutant metastatic melanoma versus dabrafenib monotherapy (67% vs.51%; p<0.002). However, median progression-free survival improved by only 2 weeks (9.3 months vs 8.8 months; HR = 0.75) compared with dabrafenib monotherapy (PMID: 23020132). Combination therapy is associated with less cutaneous toxicity than monotherapy, but systemic toxicity may be increased (PMID: 25287827, 25399551). Follow-up trials have demonstrated that all clinical measures inclusive of overall and median progression-free survival as well as objective response rates, median duration of response and number of patients with complete response favored patients treated with combination dabrafenib and trametinib, administered in full monotherapy doses, compared to either dabrafenib or vemurafenib monotherapy, including patients who previously progressed on BRAF inhibitor monotherapy (PMID: 25287827, 25399551, 25265492). Additionally, patients with melanoma treated with dabrafenib and trametinib in both the neoadjuvant and adjuvant settings have improved survival over patients given standard of care (PMID: 29361468, 28991513, 28891408). Promising clinical data has also suggested that addition of an immunotherapy agent to combination RAF and MEK inhibitor treatment may improve rate of overall response and duration of response in melanoma patients (PMID: 31171876, 31171879, 31171878).",
                            "description_review": {
                              "lastReviewed": "",
                              "updateTime": 1637272293030,
                              "updatedBy": "User"
                            },
                            "description_uuid": "f8d42cac-38e5-4778-9646-f18745f61d02",
                            "indication": "",
                            "indication_uuid": "695c1e6c-3da8-46a1-818d-8d6cc814bb57",
                            "level": "2",
                            "level_review": {
                              "lastReviewed": "",
                              "updateTime": 1637272283820,
                              "updatedBy": "User"
                            },
                            "level_uuid": "0125357d-195e-4177-a2a9-fe38f7e3d77f",
                            "name": "939cd40b-b515-499d-b099-fd29027c0d17 + fb2bb01c-c0ec-4641-abf7-87f486075022",
                            "name_review": {
                              "added": true,
                              "updateTime": 1637272276956,
                              "updatedBy": "User"
                            },
                            "name_uuid": "55f1261c-2f2c-4537-aa81-92adcb798585",
                            "propagation": "3B",
                            "propagationLiquid": "no",
                            "propagationLiquid_review": {
                              "lastReviewed": "",
                              "updateTime": 1637272283806,
                              "updatedBy": "User"
                            },
                            "propagationLiquid_uuid": "01d9a4f7-59a5-481a-ac19-fc411c7aade3",
                            "propagation_review": {
                              "lastReviewed": "",
                              "updateTime": 1637272288782,
                              "updatedBy": "User"
                            },
                            "propagation_uuid": "702fa4a3-8290-4741-ba7d-de2be917ea1f",
                            "short": ""
                          },
                          {
                            "description": "The combination of vemurafenib, an inhibitor of V600-mutant BRAF, and cobimetinib, an inhibitor of MEK1/2, is FDA approved for the treatment of patients with BRAF V600-mutant metastatic or unresectable locally advanced melanoma. FDA-approval was based on results from the randomized Phase III coBRIM trial of combined vemurafenib and cobimetinib versus vemurafenib and placebo in 495 patients with metastatic BRAF V600-mutant melanoma that demonstrated superior clinical benefit measures in the combination versus the control arm. Specifically, median progression-free survival was 9.9 months in the combination arm versus 6.2 months in the control arm (HR = 0.51), with a complete response rate of 10% versus 4%, respectively, and interim 9-month overall survival of 81% versus 73%, respectively (PMID: 25265494). Follow-up analysis of the coBRIM trial showed two-year overall survival was 48.3% in the combination group versus 38.0% in the monotherapy group (PMID: 27480103).",
                            "description_review": {
                              "lastReviewed": "",
                              "updateTime": 1637272394710,
                              "updatedBy": "User"
                            },
                            "description_uuid": "00dcd6cc-e07d-4466-9c31-85796e0d93f3",
                            "indication": "",
                            "indication_uuid": "67ae0195-972a-46ff-c0d4-73fcc5473f1f",
                            "level": "2",
                            "level_review": {
                              "lastReviewed": "",
                              "updateTime": 1637272386945,
                              "updatedBy": "User"
                            },
                            "level_uuid": "51d6ae20-155e-4c38-b112-dd078525cb60",
                            "name": "4e91da20-6cf0-4e07-995f-7f7db4c7c077 + eb357145-3b18-4aca-b75a-5e18dd2bf4f9",
                            "name_review": {
                              "added": true,
                              "updateTime": 1637272377215,
                              "updatedBy": "User"
                            },
                            "name_uuid": "f9aaeb93-ca4e-49cc-8424-792f49ce9006",
                            "propagation": "3B",
                            "propagationLiquid": "no",
                            "propagationLiquid_review": {
                              "lastReviewed": "",
                              "updateTime": 1637272386943,
                              "updatedBy": "User"
                            },
                            "propagationLiquid_uuid": "a87f2ba1-c001-4ddc-943b-8a09c9fb80a9",
                            "propagation_review": {
                              "lastReviewed": "",
                              "updateTime": 1637272390553,
                              "updatedBy": "User"
                            },
                            "propagation_uuid": "bf4dc0ee-f1d7-4203-b9a7-195dd8614112",
                            "short": ""
                          }
                        ],
                        "treatments_uuid": "04d7a8d4-30a5-4ab2-9d38-0541487d30b1",
                        "type": "SS"
                      },
                      {
                        "name": "Standard implications for resistance to therapy",
                        "name_uuid": "9b15717f-fb59-4473-b9e9-abf99c245d3d",
                        "treatments_uuid": "899bf2a6-1741-4baa-986d-f2125994eaaa",
                        "type": "SR"
                      },
                      {
                        "name": "Investigational implications for sensitivity to therapy",
                        "name_uuid": "fabe8ede-8300-4f7c-973a-f552c84e57a1",
                        "treatments_uuid": "4c3b0531-7992-44c0-a0e7-4b8fb5075926",
                        "type": "IS"
                      },
                      {
                        "name": "Investigational implications for resistance to therapy",
                        "name_uuid": "ed8010e4-9942-4bef-93b5-fffbb798cc90",
                        "treatments_uuid": "bba73734-e7b2-42e1-966c-862ffd092ee0",
                        "type": "IR"
                      }
                    ],
                    "cancerTypes": [
                      {
                        "code": "MEL",
                        "mainType": "Melanoma",
                        "subtype": "Melanoma"
                      }
                    ],
                    "cancerTypes_review": {
                      "added": true,
                      "updateTime": 1637271774958,
                      "updatedBy": "User"
                    },
                    "cancerTypes_uuid": "dc47e681-776e-4452-bc38-5504f4377ef3",
                    "diagnostic": {
                      "description": "",
                      "description_uuid": "52ed7dc3-5b83-495f-b62f-48a173d76e1b",
                      "level": "",
                      "level_uuid": "1a752026-72fc-453e-b074-bb4682023d62",
                      "short": ""
                    },
                    "diagnosticSummary": "",
                    "diagnosticSummary_uuid": "45923f85-26a5-4f8c-8cb2-48d38c1806d7",
                    "diagnostic_uuid": "048a0b07-b884-4a91-89d6-d99f5031d214",
                    "prognostic": {
                      "description": "",
                      "description_uuid": "db6724f3-bf1a-44d4-ba6c-6753e4c5c688",
                      "level": "",
                      "level_uuid": "94847365-3fa7-4b42-b55c-ad0e03f836c3",
                      "short": ""
                    },
                    "prognosticSummary": "",
                    "prognosticSummary_uuid": "b93f1983-da96-4f37-b477-b88d67958b1c",
                    "prognostic_uuid": "ce202a75-13e4-4ac9-8386-0874c0329c46",
                    "summary": "The RAF-targeted inhibitors encorafenib, dabrafenib and vemurafenib, alone or in combination with the MEK1/2-targeted inhibitors binimetinib, trametinib and cobimetinib respectively, are FDA-approved for the treatment of patients with BRAF V600E/K mutant melanoma and NCCN-compendium listed for the treatment of patients with BRAF V600-mutant melanoma. Additionally, the anti-PD-L1 antibody atezolizumab in combination with cobimetinib + vemurafenib is FDA-approved for the treatment of patients with unresectable or advanced BRAF V600-mutant melanoma.",
                    "summary_review": {
                      "lastReviewed": "",
                      "updateTime": 1637272104265,
                      "updatedBy": "User"
                    },
                    "summary_uuid": "6cbb7fd3-76a2-4d64-8332-bdb68e972b03"
                  }
                ],
                "tumors_uuid": "07d5b8c0-43db-4b3e-a8a8-5f8e47f6970b"
              },
              "operation": "add",
              "uuids": "6cbb7fd3-76a2-4d64-8332-bdb68e972b03,009d1441-ac80-4048-ae01-371ac1591c33,55f1261c-2f2c-4537-aa81-92adcb798585,f9aaeb93-ca4e-49cc-8424-792f49ce9006"
            }
          ],
          "timeStamp": 1637275406349
        },
        "-MopD5xmbt8YEsniLbWE": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600, Melanoma, Standard implications for sensitivity to therapy, 001e534f-3e63-432f-90a6-d1af1759e4e2 + feb9f4a3-e374-4c75-8a3b-0f1fbcdbf677",
              "old": {
                "description": "The combination of encorafenib, an inhibitor of V600E- or V600K-mutant BRAF, and binimetinib, an inhibitor of MEK1/2, is FDA approved in combination for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. FDA-approval was based on the results of the Phase III COLUMBUS trial of combined encorafenib plus binimetinib versus single agent vemurafenib in 577 patients with BRAF V600E- or V600K-mutant metastatic melanoma in which the median progression-free survival was 14.9 months (95% CI 11.0-18.5) in the encorafenib plus binimetinib group versus 7.3 months (95% CI 5.6-8.2) in the single agent vemurafenib group (HR= 0.54, 95% CI 0.41-0.71; p<0·0001) (PMID: 29573941).",
                "description_review": {
                  "updateTime": 1576619814672,
                  "updatedBy": "User"
                },
                "description_uuid": "f76da831-1b1b-4706-8477-14eeba8893c6",
                "indication": "",
                "indication_uuid": "c705de5b-c1f8-49e2-b75f-a5f01288ef67",
                "level": "2",
                "level_review": {
                  "updateTime": 1576619798046,
                  "updatedBy": "User"
                },
                "level_uuid": "67773473-226f-4579-b3ef-d42cec01554a",
                "name": "001e534f-3e63-432f-90a6-d1af1759e4e2 + feb9f4a3-e374-4c75-8a3b-0f1fbcdbf677",
                "name_review": {
                  "removed": true,
                  "updateTime": 1637272223482,
                  "updatedBy": "User"
                },
                "name_uuid": "dc196791-41af-46c9-a295-299d1de62bb2",
                "propagation": "3B",
                "propagationLiquid": "no",
                "propagationLiquid_review": {
                  "updateTime": 1576619798045,
                  "updatedBy": "User"
                },
                "propagationLiquid_uuid": "88d7647e-b90d-4924-92d5-c7878b427bdf",
                "propagation_review": {
                  "updateTime": 1576619798043,
                  "updatedBy": "User"
                },
                "propagation_uuid": "540a0860-3014-4475-b36c-a1fdc58889d8",
                "short": ""
              },
              "operation": "delete"
            }
          ],
          "timeStamp": 1637275430808
        },
        "-MopDC6g_VZdju_p_IlU": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600, Melanoma, Standard implications for sensitivity to therapy, 939cd40b-b515-499d-b099-fd29027c0d17 + fb2bb01c-c0ec-4641-abf7-87f486075022",
              "old": {
                "description": "The combination of vemurafenib, an inhibitor of V600-mutant BRAF, and cobimetinib, an inhibitor of MEK1/2, is FDA approved for the treatment of patients with BRAF V600-mutant metastatic or unresectable locally advanced melanoma. FDA-approval was based on results from the randomized Phase III coBRIM trial of combined vemurafenib and cobimetinib versus vemurafenib and placebo in 495 patients with metastatic BRAF V600-mutant melanoma that demonstrated superior clinical benefit measures in the combination versus the control arm. Specifically, median progression-free survival was 9.9 months in the combination arm versus 6.2 months in the control arm (HR = 0.51), with a complete response rate of 10% versus 4%, respectively, and interim 9-month overall survival of 81% versus 73%, respectively (PMID: 25265494). Follow-up analysis of the coBRIM trial showed two-year overall survival was 48.3% in the combination group versus 38.0% in the monotherapy group (PMID: 27480103).",
                "description_review": {
                  "updateTime": 1576619851323,
                  "updatedBy": "User"
                },
                "description_uuid": "5c0bc8d2-dff5-4553-9e0d-b35366d24477",
                "indication": "",
                "indication_uuid": "a8dc53cf-8b65-4ba5-84a3-ae06a6cee414",
                "level": "2",
                "level_review": {
                  "updateTime": 1576619835943,
                  "updatedBy": "User"
                },
                "level_uuid": "9f13d6a6-9649-474f-8227-b5eb866cef9b",
                "name": "4e91da20-6cf0-4e07-995f-7f7db4c7c077 + eb357145-3b18-4aca-b75a-5e18dd2bf4f9",
                "name_review": {
                  "removed": true,
                  "updateTime": 1637272435393,
                  "updatedBy": "User"
                },
                "name_uuid": "04ec8bf4-289b-4dad-a110-cc3f00045e4a",
                "propagation": "3B",
                "propagationLiquid": "no",
                "propagationLiquid_review": {
                  "updateTime": 1576619835941,
                  "updatedBy": "User"
                },
                "propagationLiquid_uuid": "fde2c9fd-d51c-40d1-aade-7031cfe40b25",
                "propagation_review": {
                  "updateTime": 1576619835939,
                  "updatedBy": "User"
                },
                "propagation_uuid": "7ade81ad-9d19-40ad-bf04-5c9c17f1c3d3",
                "short": ""
              },
              "operation": "delete"
            }
          ],
          "timeStamp": 1637275456018
        },
        "-MopDID6eBm0GBONEgIP": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600, Melanoma, Standard implications for sensitivity to therapy, 4e91da20-6cf0-4e07-995f-7f7db4c7c077 + eb357145-3b18-4aca-b75a-5e18dd2bf4f9",
              "old": {
                "description": "The combination of vemurafenib, an inhibitor of V600-mutant BRAF, and cobimetinib, an inhibitor of MEK1/2, with atezolizumab, an immunotherapeutic PD-L1 antibody, is FDA approved for patients with BRAF V600 mutation-positive unresectable or metastatic melanoma. FDA-approval was based on the results of the Phase III double-blind, randomized, placebo-controlled IMspire150 trial of Atezolizumab + Cobimetinib + Vemurafenib versus Placebo + Cobimetinib + Vemurafenib in 514 patients with BRAF V600-mutant melanoma in which the median progression-free survival was 15.1 mos (95% CI=11.4, 18.4) in the triplet arm versus 10.6 mos (95% CI=9.3, 12.7) in the doublet + placebo arm (HR=0.78; 95% CI= 0.63, 0.97; p=0.0249) (PMID: 32534646).",
                "description_review": {
                  "updateTime": 1598302298580,
                  "updatedBy": "User"
                },
                "description_uuid": "1ee0f4a5-318d-4143-8e47-9a32ebd8b9e8",
                "indication": "",
                "indication_uuid": "4208a33d-de35-4c52-a6dd-85a0b276eb41",
                "level": "1",
                "level_review": {
                  "updateTime": 1596687805296,
                  "updatedBy": "User"
                },
                "level_uuid": "a4c90e67-a82b-4888-a512-1a60638a6585",
                "name": "4e91da20-6cf0-4e07-995f-7f7db4c7c077 + 9a54c73a-15d8-41a8-8ea0-730f874831da + eb357145-3b18-4aca-b75a-5e18dd2bf4f9",
                "name_review": {
                  "updateTime": 1596687800344,
                  "updatedBy": "User"
                },
                "name_uuid": "2e0a9edd-9248-4da3-b5f8-acdfe19039d6",
                "propagation": "3B",
                "propagationLiquid": "no",
                "propagationLiquid_review": {
                  "updateTime": 1596687805291,
                  "updatedBy": "User"
                },
                "propagationLiquid_uuid": "67c961d9-3575-43d8-b653-c64dc6b85948",
                "propagation_review": {
                  "updateTime": 1596687805286,
                  "updatedBy": "User"
                },
                "propagation_uuid": "627b61ec-51f8-453c-aa39-d9e594a4df66",
                "short": ""
              },
              "operation": "delete"
            }
          ],
          "timeStamp": 1637275481005
        },
        "-MopDOJc7ukmJWTjBTiJ": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600, Anaplastic Thyroid Cancer",
              "old": {
                "TIs": [
                  {
                    "name": "Standard implications for sensitivity to therapy",
                    "name_uuid": "14ff69c9-664c-4b91-aef1-af34c5e622a8",
                    "treatments": [
                      {
                        "description": "Dabrafenib, an orally bioavailable RAF inhibitor, and trametinib, an orally bioavailable MEK1/2 inhibitor, are FDA-approved alone or in combination for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options. FDA-approval was based on results of the Phase II study of dabrafenib combined with trametinib in patients with BRAF V600E-positive ATC in which the overall response rate in sixteen evaluable patients was 69% (11/16; 95% CI= 41%-89%)(PMID: 29072975). Dabrafenib + trametinib is NCCN-compendium listed for the treatment of patients with BRAF V600-mutant ATC.",
                        "description_review": {
                          "updateTime": 1576619586044,
                          "updatedBy": "User"
                        },
                        "description_uuid": "a9147baa-651d-4bf3-8dc0-966dbd326d3f",
                        "indication": "",
                        "indication_uuid": "87bd653e-6302-41c6-b2e4-029c1fab16ae",
                        "level": "2",
                        "level_review": {
                          "updateTime": 1576619345596,
                          "updatedBy": "User"
                        },
                        "level_uuid": "be90e4a7-ece2-4df5-864e-007fa8b7a67d",
                        "name": "939cd40b-b515-499d-b099-fd29027c0d17 + fb2bb01c-c0ec-4641-abf7-87f486075022",
                        "name_review": {
                          "updateTime": 1576619341036,
                          "updatedBy": "User"
                        },
                        "name_uuid": "efa979c1-84eb-4c65-b291-9d395c322114",
                        "propagation": "3B",
                        "propagationLiquid": "no",
                        "propagationLiquid_review": {
                          "updateTime": 1576619345591,
                          "updatedBy": "User"
                        },
                        "propagationLiquid_uuid": "57f805ec-3086-4992-b75a-abebeca1f718",
                        "propagation_review": {
                          "updateTime": 1576619345585,
                          "updatedBy": "User"
                        },
                        "propagation_uuid": "c96488d8-dc81-4862-9212-97fe4d7ed9b7",
                        "short": ""
                      }
                    ],
                    "treatments_uuid": "194f9d44-baf8-4a1c-a904-4f3f171ae67e",
                    "type": "SS"
                  },
                  {
                    "name": "Standard implications for resistance to therapy",
                    "name_uuid": "a329af61-6ca3-496f-9a35-337e08f77c3f",
                    "treatments_uuid": "7874f6d2-aa61-48f3-acab-729c497a4390",
                    "type": "SR"
                  },
                  {
                    "name": "Investigational implications for sensitivity to therapy",
                    "name_uuid": "9eef4593-1bb1-4cf2-bc2f-554a8aae077a",
                    "treatments_uuid": "ad4025a5-3dd1-48a7-b29e-92249c568813",
                    "type": "IS"
                  },
                  {
                    "name": "Investigational implications for resistance to therapy",
                    "name_uuid": "456dc94c-4d6c-4993-8735-089ac0311714",
                    "treatments_uuid": "46891a9e-6bc5-4b2f-ba0c-6280db6b0f43",
                    "type": "IR"
                  }
                ],
                "cancerTypes": [
                  {
                    "code": "THAP",
                    "mainType": "Thyroid Cancer",
                    "subtype": "Anaplastic Thyroid Cancer"
                  }
                ],
                "cancerTypes_review": {
                  "removed": true,
                  "updateTime": 1637271479179,
                  "updatedBy": "User"
                },
                "cancerTypes_uuid": "92c47b97-c371-494b-96dd-aa19b40dc62a",
                "diagnostic": {
                  "description": "",
                  "description_uuid": "c179c49e-8be0-49a1-bea3-1a239eb40f17",
                  "level": "",
                  "level_uuid": "a60d8e13-ae58-4d4a-9283-fd371ca9eedc",
                  "short": ""
                },
                "diagnosticSummary": "",
                "diagnosticSummary_uuid": "d67b2ac5-e72f-468b-ab52-137580698dfe",
                "diagnostic_uuid": "a153ee78-2cf9-42b7-927d-949a193965a8",
                "prognostic": {
                  "description": "",
                  "description_uuid": "59ff716e-a78b-41b1-9efe-b7c5fc645abb",
                  "level": "",
                  "level_uuid": "75ebb3e6-3ce3-4b3f-9ecc-6568a2e4f39b",
                  "short": ""
                },
                "prognosticSummary": "",
                "prognosticSummary_uuid": "8fda833a-e221-4c7f-b177-eb615b1317ef",
                "prognostic_uuid": "e2778348-64df-4188-a932-fb1e95251361",
                "summary": "The RAF-targeted inhibitor dabrafenib in combination with the MEK1/2-targeted inhibitor trametinib is FDA-approved for the treatment of patients with BRAF V600E mutant anaplastic thyroid cancer (ATC), and NCCN-compendium listed for the treatment of patients with BRAF V600-mutant ATC.",
                "summary_review": {
                  "updateTime": 1576619252319,
                  "updatedBy": "User"
                },
                "summary_uuid": "19b9a0c7-cd5d-4202-b27c-ab3687c9efd2"
              },
              "operation": "delete"
            }
          ],
          "timeStamp": 1637275505998
        },
        "-MopDUPmKkFsJfINmTX3": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600, Melanoma, Standard implications for sensitivity to therapy, 939cd40b-b515-499d-b099-fd29027c0d17 + fb2bb01c-c0ec-4641-abf7-87f486075022",
              "old": {
                "description": "Dabrafenib, an orally bioavailable RAF inhibitor, and trametinib, an orally bioavailable MEK1/2 inhibitor, are FDA-approved alone or in combination for the treatment of patients with metastatic melanoma harboring a V600E or V600K BRAF mutation. The FDA approved the combination of dabrafenib and trametinib based on results from an open-label Phase III study of combination therapy versus dabrafenib monotherapy in 247 patients with metastatic melanoma who were naive to treatment with BRAF inhibitors. Combined dabrafenib and trametinib, administered in full monotherapy doses, improved the response rate in patients with BRAF V600-mutant metastatic melanoma versus dabrafenib monotherapy (67% vs.51%; p<0.002). However, median progression-free survival improved by only 2 weeks (9.3 months vs 8.8 months; HR = 0.75) compared with dabrafenib monotherapy (PMID: 23020132). Combination therapy is associated with less cutaneous toxicity than monotherapy, but systemic toxicity may be increased (PMID: 25287827, 25399551). Follow-up trials have demonstrated that all clinical measures inclusive of overall and median progression-free survival as well as objective response rates, median duration of response and number of patients with complete response favored patients treated with combination dabrafenib and trametinib, administered in full monotherapy doses, compared to either dabrafenib or vemurafenib monotherapy, including patients who previously progressed on BRAF inhibitor monotherapy (PMID: 25287827, 25399551, 25265492). Additionally, patients with melanoma treated with dabrafenib and trametinib in both the neoadjuvant and adjuvant settings have improved survival over patients given standard of care (PMID: 29361468, 28991513, 28891408). Promising clinical data has also suggested that addition of an immunotherapy agent to combination RAF and MEK inhibitor treatment may improve rate of overall response and duration of response in melanoma patients (PMID: 31171876, 31171879, 31171878).",
                "description_review": {
                  "updateTime": 1576619770443,
                  "updatedBy": "User"
                },
                "description_uuid": "2ea521fc-5f86-4519-a12d-ab0e2fe93b0b",
                "indication": "",
                "indication_uuid": "cd44adc3-cdcc-4a53-a537-62dd6c675d09",
                "level": "2",
                "level_review": {
                  "updateTime": 1576619761071,
                  "updatedBy": "User"
                },
                "level_uuid": "2631b490-9c48-4d93-910d-f4c4a8eafaf6",
                "name": "939cd40b-b515-499d-b099-fd29027c0d17 + fb2bb01c-c0ec-4641-abf7-87f486075022",
                "name_review": {
                  "removed": true,
                  "updateTime": 1637272328704,
                  "updatedBy": "User"
                },
                "name_uuid": "cfbf8fb3-ff8b-4786-90e2-a185f3e24009",
                "propagation": "3B",
                "propagationLiquid": "no",
                "propagationLiquid_review": {
                  "updateTime": 1576619761068,
                  "updatedBy": "User"
                },
                "propagationLiquid_uuid": "192a53fe-5fa2-4048-acb0-53631fec81bf",
                "propagation_review": {
                  "updateTime": 1576619761065,
                  "updatedBy": "User"
                },
                "propagation_uuid": "cec11333-f85f-4fad-8275-84761897b98f",
                "short": ""
              },
              "operation": "delete"
            }
          ],
          "timeStamp": 1637275530968
        },
        "-Mp78eludKIKcEEDCXfR": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Oncogenic Mutations {excluding V600E ; V600K}",
              "new": "Oncogenic Mutations {excluding V600E ; V600K}",
              "old": "Oncogenic Mutations {excluding V600E, V600K}",
              "operation": "name change",
              "uuids": "c252fd4a-da2f-41d2-81a1-8065bf5398af"
            }
          ],
          "timeStamp": 1637593034288
        },
        "-MpIEDpxvTvw1NZu5C-R": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Oncogenic Mutations {excluding V600E}",
              "old": {
                "mutation_effect": {
                  "description": "",
                  "description_uuid": "c60d30ce-ff9d-4891-a27f-c1a87825780c",
                  "effect": "",
                  "effect_uuid": "ca3b6642-b963-45ca-b37f-411ab804e6aa",
                  "oncogenic": "",
                  "oncogenic_uuid": "89c8e52b-81cb-43f6-bd52-30ee76fb443c",
                  "short": ""
                },
                "mutation_effect_uuid": "bc5c333b-d6ee-480a-a6fd-317203c17232",
                "name": "Oncogenic Mutations {excluding V600E}",
                "name_review": {
                  "removed": true,
                  "updateTime": 1637708723733,
                  "updatedBy": "User"
                },
                "name_uuid": "8abb8db3-0d1c-4b5b-b6bd-edc17c6ae14a",
                "tumors": [
                  {
                    "TIs": [
                      {
                        "name": "Standard implications for sensitivity to therapy",
                        "name_uuid": "63cc6a71-7a1e-4993-b0c7-b820bed052fe",
                        "treatments": [
                          {
                            "description": "Dabrafenib, an orally bioavailable RAF inhibitor, and trametinib, an orally bioavailable MEK1/2 inhibitor, are FDA-approved alone or in combination for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options. FDA-approval was based on results of the Phase II study of dabrafenib combined with trametinib in patients with BRAF V600E-positive ATC in which the overall response rate in sixteen evaluable patients was 69% (11/16; 95% CI= 41%-89%)(PMID: 29072975). Dabrafenib + trametinib is NCCN-compendium listed for the treatment of patients with BRAF V600-mutant ATC.",
                            "description_review": {
                              "updateTime": 1637271701539,
                              "updatedBy": "User"
                            },
                            "description_uuid": "5ce9f90f-5634-4313-b28b-f9ad967a810d",
                            "indication": "",
                            "indication_uuid": "c0bb3f6f-69c6-4c88-a433-0a97b447bcb9",
                            "level": "2",
                            "level_review": {
                              "updateTime": 1637271675005,
                              "updatedBy": "User"
                            },
                            "level_uuid": "eb5d69c6-65c6-40c2-abb0-df2182849e07",
                            "name": "939cd40b-b515-499d-b099-fd29027c0d17 + fb2bb01c-c0ec-4641-abf7-87f486075022",
                            "name_review": {
                              "updateTime": 1637271667456,
                              "updatedBy": "User"
                            },
                            "name_uuid": "33a3eeca-1eb7-4c2a-9c47-e33dbaa645ee",
                            "propagation": "3B",
                            "propagationLiquid": "no",
                            "propagationLiquid_review": {
                              "updateTime": 1637271675003,
                              "updatedBy": "User"
                            },
                            "propagationLiquid_uuid": "c64b713c-9210-4694-bc85-0941df960085",
                            "propagation_review": {
                              "updateTime": 1637271678359,
                              "updatedBy": "User"
                            },
                            "propagation_uuid": "fb10205c-96eb-4775-a2b7-32a4da4ce82c",
                            "short": ""
                          }
                        ],
                        "treatments_uuid": "e128db45-6e2c-475a-98b3-c5e7bf8b4516",
                        "type": "SS"
                      },
                      {
                        "name": "Standard implications for resistance to therapy",
                        "name_uuid": "ea34e1a4-6671-4058-c019-38411eb5694e",
                        "treatments_uuid": "08251695-e939-4f8d-a5e6-4baaabc9926d",
                        "type": "SR"
                      },
                      {
                        "name": "Investigational implications for sensitivity to therapy",
                        "name_uuid": "4bae595e-1f8d-452f-82fb-ddd4e323fdbf",
                        "treatments_uuid": "956ee588-09d0-43fb-8efc-f667632f9cd2",
                        "type": "IS"
                      },
                      {
                        "name": "Investigational implications for resistance to therapy",
                        "name_uuid": "e0304f36-082c-4153-aa58-14a55841bdc8",
                        "treatments_uuid": "c08e6b6a-004c-4420-8776-cd9ae6c62578",
                        "type": "IR"
                      }
                    ],
                    "cancerTypes": [
                      {
                        "code": "THAP",
                        "mainType": "Thyroid Cancer",
                        "subtype": "Anaplastic Thyroid Cancer"
                      }
                    ],
                    "cancerTypes_review": {
                      "updateTime": 1637271611525,
                      "updatedBy": "User"
                    },
                    "cancerTypes_uuid": "f8137d71-23e7-4498-b6d7-53e257949d28",
                    "diagnostic": {
                      "description": "",
                      "description_uuid": "b153a8b7-7759-4329-998d-3f46b408f39c",
                      "level": "",
                      "level_uuid": "2f2dd82a-0b1f-4363-90db-32623626ce9e",
                      "short": ""
                    },
                    "diagnosticSummary": "",
                    "diagnosticSummary_uuid": "a92f777b-ad12-4aed-abbe-a1ba4ea7db96",
                    "diagnostic_uuid": "9ed5bae3-789c-4b4f-8c52-157b53bf5b99",
                    "prognostic": {
                      "description": "",
                      "description_uuid": "7b722ef6-382c-4c25-86f3-ccc0b7e22a9a",
                      "level": "",
                      "level_uuid": "e0165619-bd0a-435a-90fb-5a20969e224f",
                      "short": ""
                    },
                    "prognosticSummary": "",
                    "prognosticSummary_uuid": "a4a6767f-1d32-4e5c-b389-fbf645ee50a9",
                    "prognostic_uuid": "60099ae7-5199-46e7-99e6-52df9a4f0f77",
                    "summary": "The RAF-targeted inhibitor dabrafenib in combination with the MEK1/2-targeted inhibitor trametinib is FDA-approved for the treatment of patients with BRAF V600E mutant anaplastic thyroid cancer (ATC), and NCCN-compendium listed for the treatment of patients with BRAF V600-mutant ATC.",
                    "summary_review": {
                      "updateTime": 1637271642224,
                      "updatedBy": "User"
                    },
                    "summary_uuid": "72442100-492e-4e33-b1da-7f691ac43a3b"
                  }
                ],
                "tumors_uuid": "4d9fe6e8-8448-422c-be2b-72220524bce4"
              },
              "operation": "delete"
            }
          ],
          "timeStamp": 1637779041644
        },
        "-MqVnq_7nZ_xwywu875X": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600, Erdheim-Chester Disease, STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY, 4e91da20-6cf0-4e07-995f-7f7db4c7c077",
              "new": {
                "description": "Vemurafenib is an inhibitor of V600-mutant BRAF that is FDA-approved for treatment of patients with Edheim-Chester Disease (ECD) harboring BRAF V600-mutations. FDA-approval was based on the open-label, nonrandomized, multicohort VE-BASKET clinical trial of vemurafenib in BRAF V600E-mutant non-melanoma cancers in which 26 evaluable patients (22 with ECD and 4 with Langerhans cell histiocytosis) achieved stable disease or better and the confirmed overall response rate in ECD was 54.5% (12/22; 95% CI, 32.2-75.6%). Median progression-free survival and overall survival were not reached at study completion with a median follow-up of 28.8 months (PMID: 29188284, 26287849)."
              },
              "old": {
                "description": "Vemurafenib is an inhibitor of V600-mutant BRAF that is FDA-approved for treatment of patients with Edheim-Chester Disease (ECD) harboring BRAF V600-mutations. FDA-approval was based on the open-label, nonrandomized, multicohort VE-BASKET clinical trial of vemurafenib in BRAF V600E-mutant non-melanoma cancers in which 26 evaluable patients (22 with ECD and 4 with Langerhans cell histiocytosis) achieved stable disease or better and the confirmed overall response rate was 61.5% (95% CI, 40.6-79.8%). Median progression-free survival and overall survival were not reached at study completion with a median follow-up of 28.8 months (PMID: 29188284, 26287849)."
              },
              "operation": "update",
              "uuids": "729d93d7-aa18-4bf0-9c84-13b9ecce25fb"
            }
          ],
          "timeStamp": 1639080487296
        },
        "-Mr40mWi2t-j_H_f11qw": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600 {excluding V600E ; V600K}",
              "new": "V600 {excluding V600E ; V600K}",
              "old": "Oncogenic Mutations {excluding V600E ; V600K}",
              "operation": "name change",
              "uuids": "c252fd4a-da2f-41d2-81a1-8065bf5398af"
            }
          ],
          "timeStamp": 1639688120534
        },
        "-Mr46iyUJ84GzRw5FEa7": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600, Langerhans Cell Histiocytosis, STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY, 4e91da20-6cf0-4e07-995f-7f7db4c7c077, 939cd40b-b515-499d-b099-fd29027c0d17",
              "new": {
                "description": "Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and both are NCCN-listed for patients with Langerhans Cell Histiocytosis (LCH). In an open-label, phase 2 trial (NCT02649972) of cobimetinib in eighteen adult patients with histiocytoses (n = two patients with LCH) of any mutational status, the overall response rate was 89% (90% CI: 73–100), 100% of responses were ongoing at one year, and 94% of patients remained progression-free (PMID: 30867592)."
              },
              "old": {
                "description": "PMID: 30867592"
              },
              "operation": "update",
              "uuids": "a0a7271e-c46e-43b8-8f85-7e1418192d6c"
            }
          ],
          "timeStamp": 1639689678803
        },
        "-Mr47CwtUTy6nDe6M_VG": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Oncogenic Mutations {excluding V600}, Erdheim-Chester Disease, STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY, eb357145-3b18-4aca-b75a-5e18dd2bf4f9, fb2bb01c-c0ec-4641-abf7-87f486075022",
              "new": {
                "description": "Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and both are NCCN-listed for patients with Erdheim-Chester Disease (ECD). In an open-label, phase 2 trial (NCT02649972) of cobimetinib in eighteen adult patients with histiocytoses (n = twelve patients with ECD) of any mutational status, the overall response rate was 89% (90% CI: 73–100), 100% of responses were ongoing at one year, and 94% of patients remained progression-free (PMID: 30867592)."
              },
              "old": {
                "description": "(PMID: 30867592)"
              },
              "operation": "update",
              "uuids": "f85c5ffd-a7dc-4769-acdc-012ff3b7ac5d"
            }
          ],
          "timeStamp": 1639689805677
        },
        "-Mr47btBp9r7H2C9_Bul": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Oncogenic Mutations {excluding V600}, Langerhans Cell Histiocytosis, STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY, eb357145-3b18-4aca-b75a-5e18dd2bf4f9, fb2bb01c-c0ec-4641-abf7-87f486075022",
              "new": {
                "description": "Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and both are NCCN-listed for patients with Langerhans Cell Histiocytosis (LCH). In an open-label, phase 2 trial (NCT02649972) of cobimetinib in eighteen adult patients with histiocytoses (n = two patients with LCH) of any mutational status, the overall response rate was 89% (90% CI: 73–100), 100% of responses were ongoing at one year, and 94% of patients remained progression-free (PMID: 30867592). In a study of three patients with LCH who were treated with trametinib, two patients harbored BRAF N486_P490del mutations, of which one had no reactivation and the other had a partial response, and the third patient with a MAP2K1 K57_G61del mutation had a complete response with no active disease after 22 months (PMID: 32991018)."
              },
              "old": {
                "description": "PMID: 30867592, 32991018"
              },
              "operation": "update",
              "uuids": "a7ce9682-0287-4744-895c-69df4bb7792b"
            }
          ],
          "timeStamp": 1639689911936
        },
        "-Mr47lk2Ls6JPNcXV8UI": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Oncogenic Mutations {excluding V600}, Rosai-Dorfman Disease, STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY, eb357145-3b18-4aca-b75a-5e18dd2bf4f9, fb2bb01c-c0ec-4641-abf7-87f486075022",
              "new": {
                "description": "Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and both are NCCN-listed for patients with Rosai-Dorfman Disease. One adult patient with Rosai-Dorfman Disease with an activating KRAS G12R mutation was treated with cobimetinib and a follow-up CT scan two months after treatment showed a substantial response (PMID: 29236635)."
              },
              "old": {
                "description": "PMID: 29236635"
              },
              "operation": "update",
              "uuids": "6680f049-0c87-41fb-a234-09c1a2361419"
            }
          ],
          "timeStamp": 1639689952311
        },
        "-Ms11v2lpiP54EJV0NLO": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600M, Mutation Effect",
              "new": {
                "description": "The BRAF V600M mutation is located in the BRAF kinase domain. This mutation has been found in melanoma (PMID: 25382067, 22536370). In vitro studies have demonstrated that this mutation, similar to other class 1 BRAF V600 mutations, activates the downstream MAPK pathway independent of RAS, as measured by increased levels of phosphorylated MEK and decreased RAS-GTP in V600E mutant cells compared to wildtype (PMID: 26343582, 28783719). The BRAF V600M mutation renders BRAF constitutively activated in monomeric form and is sensitive to inhibition by vemurafenib (PMID: 28783719, 25382067, 26343582). However, It is unknown whether the BRAF V600M mutation actually arises in cancer as noted by several studies (PMID: 22536370, 23579220, 25382067) or previous sequencing studies miscalled a V600R dinucleotide change (chromosome 7: position 140453136 AC > CT) as a single nucleotide change (chromosome 7: position 140453137 C >T).",
                "effect": "Inconclusive",
                "oncogenic": "Inconclusive"
              },
              "old": {
                "description": "It is unknown whether the BRAF V600M mutation actually arises in cancer as noted by several studies (PMID: 22536370, 23579220, 25382067) or previous sequencing studies miscalled a V600R dinucleotide change (chromosome 7: position 140453136 AC > CT) as a single nucleotide change (chromosome 7: position 140453137 C >T). Nonetheless, BRAF V600M is considered in vitro as a class I mutation located in the BRAF kinase domain and its biological characterization has demonstrated that this mutation activates the downstream MAPK pathway independent of RAS; renders BRAF constitutively activated in monomeric form (PMID: 28783719, 26343582), and retains sensitivity to vermurafenib (PMID: 28783719, 25382067, 26382582), similar to the more common variant, V600E (PMID: 28783719, 26343582, 20179705).",
                "effect": "Gain-of-function",
                "oncogenic": "Likely"
              },
              "operation": "update",
              "uuids": "1e543634-e853-4b7c-b61e-76537ae06c5c,838d4e27-f794-42e0-8f8e-d6b4955c1b4e"
            }
          ],
          "timeStamp": 1640711805993
        },
        "-MtnguzJ93C7Khh8eSMF": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600, Histiocytosis, INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY, 4e91da20-6cf0-4e07-995f-7f7db4c7c077, 939cd40b-b515-499d-b099-fd29027c0d17",
              "new": {
                "description": "Vemurafenib and dabrafenib are inhibitors of BRAF V600E that are FDA-approved for patients with unresectable or metastatic melanoma with the BRAF V600E mutation and are NCCN-listed for patients with histiocytic neoplasms. In a case study of a 40-year-old man with histiocytic sarcoma harboring a heterozygous BRAF V600E mutation, the patient was treated with vemurafenib and maintained both clinical and radiologic tumor responses for three months until disease progression (PMID: 25209580). In a separate case study of a 22-year-old woman with histiocytic sarcoma harboring a BRAF V600E mutation, the patient was treated with a combination of chemotherapy, antibiotics, steroids, and vemurafenib and remained in complete remission eighteen months after treatment initiation (PMID: 31376203). An additional case study of a 6-year-old child with BRAF V600E-mutant mixed systemic Rosai-Dorfman-Destombes disease and Langerhans cell histiocytosis reported sustained clinical and radiographic responses after treatment with dabrafenib prior to disease relapse at thirteen months (PMID: 31213430)."
              },
              "old": {
                "description": "PMID: 25209580, 31376203, 31213430"
              },
              "operation": "update",
              "uuids": "ccfa69b9-f284-427a-84b5-a4ffcc5606ca"
            }
          ],
          "timeStamp": 1642618663047
        },
        "-MtnkJ2mQqmGr5VTpzU7": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Oncogenic Mutations {excluding V600}, Histiocytosis, INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY, eb357145-3b18-4aca-b75a-5e18dd2bf4f9, fb2bb01c-c0ec-4641-abf7-87f486075022",
              "new": {
                "description": "Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and both are NCCN-listed for patients with histiocytic neoplasms. In a case study of one 18-year-old patient with refractory histiocytic sarcoma harboring a pathogenic variant of MAP2K1 (F53L), the patient was treated with trametinib and showed an excellent response prior to treatment interruption due to severe adverse events (PMID: 30361829)."
              },
              "old": {
                "description": "PMID: 30361829"
              },
              "operation": "update",
              "uuids": "658a788e-390c-41c6-8081-0376b6121bb0"
            }
          ],
          "timeStamp": 1642619552165
        },
        "-MtnueqxRvQk0--fDYlf": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600, Histiocytosis, INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY, 4e91da20-6cf0-4e07-995f-7f7db4c7c077, 939cd40b-b515-499d-b099-fd29027c0d17",
              "new": {
                "description": "Vemurafenib and dabrafenib are inhibitors of BRAF V600E that are FDA-approved for patients with unresectable or metastatic melanoma with the BRAF V600E mutation and are NCCN-listed for patients with histiocytic neoplasms harboring MAPK pathway mutations. In a case study of a 40-year-old man with histiocytic sarcoma harboring a heterozygous BRAF V600E mutation, the patient was treated with vemurafenib and maintained both clinical and radiologic tumor responses for three months until disease progression (PMID: 25209580). In a separate case study of a 22-year-old woman with histiocytic sarcoma harboring a BRAF V600E mutation, the patient was treated with a combination of chemotherapy, antibiotics, steroids, and vemurafenib and remained in complete remission eighteen months after treatment initiation (PMID: 31376203). An additional case study of a 6-year-old child with BRAF V600E-mutant mixed systemic Rosai-Dorfman-Destombes disease and Langerhans cell histiocytosis reported sustained clinical and radiographic responses after treatment with dabrafenib prior to disease relapse at thirteen months (PMID: 31213430)."
              },
              "old": {
                "description": "Vemurafenib and dabrafenib are inhibitors of BRAF V600E that are FDA-approved for patients with unresectable or metastatic melanoma with the BRAF V600E mutation and are NCCN-listed for patients with histiocytic neoplasms. In a case study of a 40-year-old man with histiocytic sarcoma harboring a heterozygous BRAF V600E mutation, the patient was treated with vemurafenib and maintained both clinical and radiologic tumor responses for three months until disease progression (PMID: 25209580). In a separate case study of a 22-year-old woman with histiocytic sarcoma harboring a BRAF V600E mutation, the patient was treated with a combination of chemotherapy, antibiotics, steroids, and vemurafenib and remained in complete remission eighteen months after treatment initiation (PMID: 31376203). An additional case study of a 6-year-old child with BRAF V600E-mutant mixed systemic Rosai-Dorfman-Destombes disease and Langerhans cell histiocytosis reported sustained clinical and radiographic responses after treatment with dabrafenib prior to disease relapse at thirteen months (PMID: 31213430)."
              },
              "operation": "update",
              "uuids": "ccfa69b9-f284-427a-84b5-a4ffcc5606ca"
            }
          ],
          "timeStamp": 1642622266992
        },
        "-Mtnux4OPxAsfOTQG8oX": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600, Histiocytosis, INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY, 4e91da20-6cf0-4e07-995f-7f7db4c7c077, 939cd40b-b515-499d-b099-fd29027c0d17",
              "new": {
                "description": "Vemurafenib and dabrafenib are inhibitors of BRAF V600E that are FDA-approved for patients with unresectable or metastatic melanoma with the BRAF V600E mutation and are NCCN-listed for patients with histiocytic neoplasms harboring BRAF V600 mutations. In a case study of a 40-year-old man with histiocytic sarcoma harboring a heterozygous BRAF V600E mutation, the patient was treated with vemurafenib and maintained both clinical and radiologic tumor responses for three months until disease progression (PMID: 25209580). In a separate case study of a 22-year-old woman with histiocytic sarcoma harboring a BRAF V600E mutation, the patient was treated with a combination of chemotherapy, antibiotics, steroids, and vemurafenib and remained in complete remission eighteen months after treatment initiation (PMID: 31376203). An additional case study of a 6-year-old child with BRAF V600E-mutant mixed systemic Rosai-Dorfman-Destombes disease and Langerhans cell histiocytosis reported sustained clinical and radiographic responses after treatment with dabrafenib prior to disease relapse at thirteen months (PMID: 31213430)."
              },
              "old": {
                "description": "Vemurafenib and dabrafenib are inhibitors of BRAF V600E that are FDA-approved for patients with unresectable or metastatic melanoma with the BRAF V600E mutation and are NCCN-listed for patients with histiocytic neoplasms harboring MAPK pathway mutations. In a case study of a 40-year-old man with histiocytic sarcoma harboring a heterozygous BRAF V600E mutation, the patient was treated with vemurafenib and maintained both clinical and radiologic tumor responses for three months until disease progression (PMID: 25209580). In a separate case study of a 22-year-old woman with histiocytic sarcoma harboring a BRAF V600E mutation, the patient was treated with a combination of chemotherapy, antibiotics, steroids, and vemurafenib and remained in complete remission eighteen months after treatment initiation (PMID: 31376203). An additional case study of a 6-year-old child with BRAF V600E-mutant mixed systemic Rosai-Dorfman-Destombes disease and Langerhans cell histiocytosis reported sustained clinical and radiographic responses after treatment with dabrafenib prior to disease relapse at thirteen months (PMID: 31213430)."
              },
              "operation": "update",
              "uuids": "ccfa69b9-f284-427a-84b5-a4ffcc5606ca"
            }
          ],
          "timeStamp": 1642622341644
        },
        "-MtoRBFuxTRzpgzTIVwg": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Oncogenic Mutations {excluding V600}, Histiocytosis, INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY, eb357145-3b18-4aca-b75a-5e18dd2bf4f9, fb2bb01c-c0ec-4641-abf7-87f486075022",
              "new": {
                "description": "Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and both are NCCN-listed for patients with histiocytic neoplasms harboring MAPK pathway mutations. In a case study of one 18-year-old patient with refractory histiocytic sarcoma harboring a pathogenic variant of MAP2K1 (F53L), the patient was treated with trametinib and showed an excellent response prior to treatment interruption due to severe adverse events (PMID: 30361829)."
              },
              "old": {
                "description": "Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and both are NCCN-listed for patients with histiocytic neoplasms. In a case study of one 18-year-old patient with refractory histiocytic sarcoma harboring a pathogenic variant of MAP2K1 (F53L), the patient was treated with trametinib and showed an excellent response prior to treatment interruption due to severe adverse events (PMID: 30361829)."
              },
              "operation": "update",
              "uuids": "658a788e-390c-41c6-8081-0376b6121bb0"
            }
          ],
          "timeStamp": 1642631054464
        },
        "-N1t7FPFeTDq6xh_c5Jb": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Ganglioglioma, Pilocytic Astrocytoma, Pleomorphic Xanthoastrocytoma, STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY, 939cd40b-b515-499d-b099-fd29027c0d17 + fb2bb01c-c0ec-4641-abf7-87f486075022, 4e91da20-6cf0-4e07-995f-7f7db4c7c077 + eb357145-3b18-4aca-b75a-5e18dd2bf4f9",
              "new": {
                "description": "The combination of a BRAF inhibitor, such as dabrafenib or vemurafenib, and a MEK1/2 inhibitor, such as trametinib and cobimetinib, is FDA-approved in melanoma and is NCCN-compendium listed as recommended treatment of CNS cancers such as pilocytic astrocytoma, pleomorphic xanthoastrocytoma (PXA) and ganglioglioma. In a case series of two patients with BRAF V600E-mutant PXA, combination treatment of dabrafenib with trametinib led to partial responses by RANO criteria in both patients (PMID: 28984141). In a case report of a 16-year-old female with BRAF V600E-mutant anaplastic ganglioglioma, dabrafenib and trametinib in combination led to a significant response that was maintained at least six months after treatment initiation (PMID: 29380516). In a separate case report of a 28-year-old man with BRAF V600E-mutant anaplastic ganglioglioma, combination treatment of vemurafenib and cobimetinib led to a complete response after three months, with no evidence of recurrence after sixteen months of treatment (PMID: 30120137)."
              },
              "old": {
                "description": "The combination of a BRAF inhibitor, such as dabrafenib or vemurafenib, and a MEK1/2 inhibitor, such as trametinib and cobimetinib is FDA-approved in melanoma and is NCCN-compendium listed as recommended treatment of CNS cancers such as pilocytic astrocytoma (PA), pleomorphic xanthoastrocytoma (PXA) and ganglioglioma. The recommendation is based on several case studies and basket trials in which patients with these diseases harboring a BRAF V600E mutation (PXA: n=14, AG: n=5, PA: n=2) had a partial response or other clinical benefit following treatment with a BRAF inhibitor in combination with a MEK inhibitor (PMID: 28984141, 29380516, 26287849, 30351999, 30120137)."
              },
              "operation": "update",
              "uuids": "7f76d72e-ec85-4f42-91fe-b247dbe0e0e9"
            }
          ],
          "timeStamp": 1652373391044
        },
        "-N2M__cSs8Dn7FJFQRTk": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Kinase Domain Duplication, Mutation Effect",
              "new": {
                "description": "Duplication of the BRAF kinase domain (BRAF-KDD) results from a breakpoint in intron 9 that generates a protein that is approximately 140 kDa. This alteration has been found in lung cancer (PMID: 32913992), melanoma (PMID: 27320919) and others (PMID: 26562024). Expression of this alteration in HEK293T cells demonstrated that it is activating as measured by increased downstream MAPK pathway signaling compared to control (PMID: 27320919). Knockdown of BRAF-KDD in BRAF V600E-positive cells expressing the kinase domain duplication demonstrated restored sensitivity to BRAF inhibitors such as dabrafenib (PMID: 27320919)."
              },
              "old": {
                "description": "PMID: 27320919, 26562024"
              },
              "operation": "update",
              "uuids": "00b243ca-25a4-46b0-a189-7e9c80a3af07"
            }
          ],
          "timeStamp": 1652884396623
        },
        "-N2m6q_mHqccO29Sreyg": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Biliary Tract Cancer, NOS, Tumor Type Summary",
              "new": "The RAF inhibitor dabrafenib in combination with the MEK1/2 inhibitor trametinib is NCCN-compendium listed for the treatment of patients with BRAF V600E-mutant biliary tract cancer.",
              "old": "There is promising clinical data in patients with BRAF V600E-mutant biliary tract cancer treated with the RAF-targeted inhibitor dabrafenib in combination with the MEK1/2-targeted inhibitor trametinib.",
              "operation": "update",
              "uuids": "0cb7164f-3cca-464e-b038-857e80c8b5c2"
            }
          ],
          "timeStamp": 1653329586333
        },
        "-N2m6wgFU2M-WMA4mS8S": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Biliary Tract Cancer, NOS, Investigational implications for sensitivity to therapy, 939cd40b-b515-499d-b099-fd29027c0d17 + fb2bb01c-c0ec-4641-abf7-87f486075022",
              "old": {
                "description": "Dabrafenib, an orally bioavailable RAF inhibitor, and trametinib, an orally bioavailable MEK1/2 inhibitor, are FDA-approved alone or in combination for the treatment of patients with various solid cancers with BRAF V600E mutation. In a Phase II, single-arm basket trial of dabrafenib + trametinib in patients with BRAF V600E-mutant solid tumors, of 43 patients with biliary tract cancer, the overall response rate was 51% (22/43, 95% CI 36–67), the median progression-free survival was nine months (95% CI 5-10), and the median overall survival was fourteen months (95% CI 10-33). Of the 43 patients with biliary tract cancer, 51% of patients (22/43) had a partial response and 40% (17/43) had stable disease (PMID: 32818466).",
                "description_review": {
                  "lastReviewed": "Dabrafenib, an orally bioavailable RAF inhibitor, and trametinib, an orally bioavailable MEK1/2 inhibitor, are FDA-approved alone or in combination for the treatment of patients with various solid cancers with BRAF V600E mutation. In a Phase II, single-arm basket trial of dabrafenib + trametinib in patients with BRAF V600E-mutant solid tumors, of 43 patients with biliary tract cancer, the overall response rate was 51% (22/43, 95% CI 36–67), the median progression-free survival was 9 months (95% CI 5-10), and the median overall survival was 14 months (95% CI 10-33). Of the 43 patients with biliary tract cancer, 51% of patients (22/43) had a partial response and 40% (17/43) had stable disease (PMID: 32818466).",
                  "updateTime": 1653328742749,
                  "updatedBy": "User"
                },
                "description_uuid": "937cba34-96d6-46b2-9206-c56a3643294d",
                "indication": "",
                "indication_uuid": "b661f91b-ffdc-4ac3-8ca3-2e9ca90ed69b",
                "level": "3A",
                "level_review": {
                  "updateTime": 1617759240306,
                  "updatedBy": "User"
                },
                "level_uuid": "d25c6add-4534-4599-96a7-3e4fb7bb5d10",
                "name": "939cd40b-b515-499d-b099-fd29027c0d17 + fb2bb01c-c0ec-4641-abf7-87f486075022",
                "name_review": {
                  "removed": true,
                  "updateTime": 1653328761678,
                  "updatedBy": "User"
                },
                "name_uuid": "445a0405-6710-464b-9f61-6adab5b10665",
                "propagation": "3B",
                "propagationLiquid": "no",
                "propagationLiquid_review": {
                  "updateTime": 1617759240303,
                  "updatedBy": "User"
                },
                "propagationLiquid_uuid": "0e1f27ca-b792-4c8d-a31f-3aa2406d7249",
                "propagation_review": {
                  "updateTime": 1617759244408,
                  "updatedBy": "User"
                },
                "propagation_uuid": "7fa2cb3e-2b80-47eb-888e-9e149d3fd173",
                "short": ""
              },
              "operation": "delete"
            }
          ],
          "timeStamp": 1653329611323
        },
        "-N2m71pYmwVdH6PG-F4A": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Biliary Tract Cancer, NOS, Standard implications for sensitivity to therapy, 939cd40b-b515-499d-b099-fd29027c0d17 + fb2bb01c-c0ec-4641-abf7-87f486075022",
              "new": {
                "description": "Dabrafenib, an orally bioavailable RAF inhibitor, and trametinib, an orally bioavailable MEK1/2 inhibitor, are FDA-approved alone or in combination for the treatment of patients with various solid cancers with BRAF V600E mutation. In a Phase II, single-arm basket trial of dabrafenib + trametinib in patients with BRAF V600E-mutant solid tumors, of 43 patients with biliary tract cancer, the overall response rate was 51% (22/43, 95% CI 36–67), the median progression-free survival was 9 months (95% CI 5-10), and the median overall survival was 14 months (95% CI 10-33). Of the 43 patients with biliary tract cancer, 51% of patients (22/43) had a partial response and 40% (17/43) had stable disease (PMID: 32818466). Additionally, in subprotocol H of the NCI-MATCH basket trial of dabrafenib + trametinib in patients with BRAF V600E-mutant solid tumors (N=4 patients with intrahepatic cholangiocarcinoma), the overall response rate was 100%, with 4/4 patients achieving a partial response (PMID: 32758030).",
                "description_review": {
                  "lastReviewed": "",
                  "updateTime": 1653328749175,
                  "updatedBy": "User"
                },
                "description_uuid": "72fdb6c0-0302-4913-8e29-77ecc1eb0b8b",
                "indication": "",
                "indication_uuid": "2db220f0-061d-4519-b74c-636a5c66c470",
                "level": "2",
                "level_review": {
                  "lastReviewed": "",
                  "updateTime": 1653328486651,
                  "updatedBy": "User"
                },
                "level_uuid": "88e3737f-4624-4312-b9f8-99768ad1e81b",
                "name": "939cd40b-b515-499d-b099-fd29027c0d17 + fb2bb01c-c0ec-4641-abf7-87f486075022",
                "name_review": {
                  "added": true,
                  "updateTime": 1653328469658,
                  "updatedBy": "User"
                },
                "name_uuid": "c0604265-c00f-4e8a-830b-49601f822f3c",
                "propagation": "3B",
                "propagationLiquid": "no",
                "propagationLiquid_review": {
                  "lastReviewed": "",
                  "updateTime": 1653328486644,
                  "updatedBy": "User"
                },
                "propagationLiquid_uuid": "3cc9c88f-8620-4365-8099-0c2fd66a6783",
                "propagation_review": {
                  "lastReviewed": "",
                  "updateTime": 1653328488784,
                  "updatedBy": "User"
                },
                "propagation_uuid": "2acb5d32-9bb1-4e41-9f29-54bf0bc928be",
                "short": ""
              },
              "operation": "add",
              "uuids": "c0604265-c00f-4e8a-830b-49601f822f3c"
            }
          ],
          "timeStamp": 1653329636493
        },
        "-N72U_0fAlIZnEQO4e8I": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Ganglioglioma, Pilocytic Astrocytoma, Pleomorphic Xanthoastrocytoma, Tumor Type Summary",
              "new": "The RAF inhibitor dabrafenib in combination with the MEK1/2 inhibitor trametinib is FDA-approved for the treatment of patients with BRAF V600E-mutant solid tumors.",
              "old": "The RAF-targeted inhibitors dabrafenib and vemurafenib in combination with the MEK-targeted inhibitors trametinib and cobimetinib, respectively, are NCCN-compendium listed for the treatment of patients with [[variant]].",
              "operation": "update",
              "uuids": "114b09bd-f15e-4f71-a3dd-048c746b20c3"
            }
          ],
          "timeStamp": 1657915985530
        },
        "-N72UfFUzhX3LqZb9xDc": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Ganglioglioma, Pilocytic Astrocytoma, Pleomorphic Xanthoastrocytoma, null, 4e91da20-6cf0-4e07-995f-7f7db4c7c077 + eb357145-3b18-4aca-b75a-5e18dd2bf4f9",
              "operation": "name change",
              "uuids": "7f76d72e-ec85-4f42-91fe-b247dbe0e0e9"
            }
          ],
          "timeStamp": 1657916011055
        },
        "-N72UlNNcRUUmdrz66_Q": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Diffuse Glioma, Tumor Type Summary",
              "new": "The RAF inhibitor dabrafenib in combination with the MEK1/2 inhibitor trametinib is FDA-approved for the treatment of patients with BRAF V600E-mutant solid tumors.",
              "old": "The RAF inhibitors dabrafenib and vemurafenib in combination with the MEK inhibitors trametinib and cobimetinib, respectively, are NCCN-compendium listed as a treatment option for patients with [[variant]].",
              "operation": "update",
              "uuids": "d9d2b475-f103-4960-a827-3a032f107402"
            }
          ],
          "timeStamp": 1657916036136
        },
        "-N72Urb5lPRYnbazPwHZ": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Biliary Tract Cancer, NOS",
              "old": {
                "TIs": [
                  {
                    "name": "Standard implications for sensitivity to therapy",
                    "name_uuid": "d47a1bea-4645-4b05-831a-89687062b06b",
                    "treatments": [
                      {
                        "description": "Dabrafenib, an orally bioavailable RAF inhibitor, and trametinib, an orally bioavailable MEK1/2 inhibitor, are FDA-approved alone or in combination for the treatment of patients with various solid cancers with BRAF V600E mutation. In a Phase II, single-arm basket trial of dabrafenib + trametinib in patients with BRAF V600E-mutant solid tumors, of 43 patients with biliary tract cancer, the overall response rate was 51% (22/43, 95% CI 36–67), the median progression-free survival was 9 months (95% CI 5-10), and the median overall survival was 14 months (95% CI 10-33). Of the 43 patients with biliary tract cancer, 51% of patients (22/43) had a partial response and 40% (17/43) had stable disease (PMID: 32818466). Additionally, in subprotocol H of the NCI-MATCH basket trial of dabrafenib + trametinib in patients with BRAF V600E-mutant solid tumors (N=4 patients with intrahepatic cholangiocarcinoma), the overall response rate was 100%, with 4/4 patients achieving a partial response (PMID: 32758030).",
                        "description_review": {
                          "updateTime": 1653328749175,
                          "updatedBy": "User"
                        },
                        "description_uuid": "72fdb6c0-0302-4913-8e29-77ecc1eb0b8b",
                        "indication": "",
                        "indication_uuid": "2db220f0-061d-4519-b74c-636a5c66c470",
                        "level": "2",
                        "level_review": {
                          "updateTime": 1653328486651,
                          "updatedBy": "User"
                        },
                        "level_uuid": "88e3737f-4624-4312-b9f8-99768ad1e81b",
                        "name": "939cd40b-b515-499d-b099-fd29027c0d17 + fb2bb01c-c0ec-4641-abf7-87f486075022",
                        "name_review": {
                          "updateTime": 1653328469658,
                          "updatedBy": "User"
                        },
                        "name_uuid": "c0604265-c00f-4e8a-830b-49601f822f3c",
                        "propagation": "3B",
                        "propagationLiquid": "no",
                        "propagationLiquid_review": {
                          "updateTime": 1653328486644,
                          "updatedBy": "User"
                        },
                        "propagationLiquid_uuid": "3cc9c88f-8620-4365-8099-0c2fd66a6783",
                        "propagation_review": {
                          "updateTime": 1653328488784,
                          "updatedBy": "User"
                        },
                        "propagation_uuid": "2acb5d32-9bb1-4e41-9f29-54bf0bc928be",
                        "short": ""
                      }
                    ],
                    "treatments_uuid": "25440edb-536d-4bd3-8d68-fc9ffd8772d2",
                    "type": "SS"
                  },
                  {
                    "name": "Standard implications for resistance to therapy",
                    "name_uuid": "70a15af4-c6e0-4f40-9290-62c70910b5fe",
                    "treatments_uuid": "c9719120-771b-4835-94e3-4671e7ee6816",
                    "type": "SR"
                  },
                  {
                    "name": "Investigational implications for sensitivity to therapy",
                    "name_uuid": "e1ac2071-783e-4f14-b33c-799b5ebaa146",
                    "treatments_uuid": "3c7b507e-9ca9-4ae9-8add-15d36a4fe0dd",
                    "type": "IS"
                  },
                  {
                    "name": "Investigational implications for resistance to therapy",
                    "name_uuid": "e291e6bd-a676-4742-a1a6-2068382e7ae3",
                    "treatments_uuid": "cfa2981f-886c-481a-93b7-3b151f4622c3",
                    "type": "IR"
                  }
                ],
                "cancerTypes": [
                  {
                    "code": "",
                    "mainType": "Biliary Tract Cancer, NOS",
                    "subtype": ""
                  }
                ],
                "cancerTypes_review": {
                  "removed": true,
                  "updateTime": 1657824898555,
                  "updatedBy": "User"
                },
                "cancerTypes_uuid": "3107dabb-5918-4f3d-9574-6afa5072a333",
                "diagnostic": {
                  "description": "",
                  "description_uuid": "16f199ae-6122-436e-bf47-54ae2117789f",
                  "level": "",
                  "level_uuid": "1173ad5b-963f-4a0c-a855-51af641768ad",
                  "short": ""
                },
                "diagnosticSummary": "",
                "diagnosticSummary_uuid": "4c85d796-2173-4fd8-8b80-03880b6347bc",
                "diagnostic_uuid": "f91f9254-43a6-4f42-86e4-3b0cc6e22bf4",
                "prognostic": {
                  "description": "",
                  "description_uuid": "99b28836-6987-463b-964c-1715559600a5",
                  "level": "",
                  "level_uuid": "6c27f9a5-76db-4efd-9c55-9950c685b190",
                  "short": ""
                },
                "prognosticSummary": "",
                "prognosticSummary_uuid": "ef868583-c4b5-44a6-ae75-ccf01c9ce2df",
                "prognostic_uuid": "9b9c33b6-94ea-4fd4-af48-eaf51582e079",
                "summary": "The RAF inhibitor dabrafenib in combination with the MEK1/2 inhibitor trametinib is NCCN-compendium listed for the treatment of patients with BRAF V600E-mutant biliary tract cancer.",
                "summary_review": {
                  "updateTime": 1653328448881,
                  "updatedBy": "User"
                },
                "summary_uuid": "0cb7164f-3cca-464e-b038-857e80c8b5c2"
              },
              "operation": "delete"
            }
          ],
          "timeStamp": 1657916061654
        },
        "-N72UxiTfsf8wfKvHNbW": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Encapsulated Glioma, Tumor Type Summary",
              "new": "The RAF inhibitor dabrafenib in combination with the MEK1/2 inhibitor trametinib is FDA-approved for the treatment of patients with BRAF V600E-mutant solid tumors.",
              "old": "The RAF inhibitors dabrafenib and vemurafenib in combination with the MEK inhibitors trametinib and cobimetinib, respectively, are NCCN-compendium listed as a treatment option for patients with [[variant]].",
              "operation": "update",
              "uuids": "5be59610-1305-4ace-a94c-30ef26d7523a"
            }
          ],
          "timeStamp": 1657916086702
        },
        "-N72V2ub8IMf2IgIgZhu": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Diffuse Glioma, null, 4e91da20-6cf0-4e07-995f-7f7db4c7c077 + eb357145-3b18-4aca-b75a-5e18dd2bf4f9",
              "operation": "name change",
              "uuids": "7b50f8a8-5662-4ad0-b63a-f2a0cf2c9fee"
            }
          ],
          "timeStamp": 1657916112055
        },
        "-N72Vi_Pr2_ZMVq2bBG4": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Diffuse Glioma, null, 4e91da20-6cf0-4e07-995f-7f7db4c7c077 + eb357145-3b18-4aca-b75a-5e18dd2bf4f9",
              "operation": "name change",
              "uuids": "7b50f8a8-5662-4ad0-b63a-f2a0cf2c9fee"
            }
          ],
          "timeStamp": 1657916286826
        },
        "-N72WTMeEmw9qANxhdFT": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Encapsulated Glioma, Tumor Type Summary",
              "new": "The RAF inhibitor dabrafenib in combination with the MEK1/2 inhibitor trametinib is FDA-approved for the treatment of patients with BRAF V600E-mutant solid tumors.",
              "old": "The RAF inhibitors dabrafenib and vemurafenib in combination with the MEK inhibitors trametinib and cobimetinib, respectively, are NCCN-compendium listed as a treatment option for patients with [[variant]].",
              "operation": "update",
              "uuids": "5be59610-1305-4ace-a94c-30ef26d7523a"
            }
          ],
          "timeStamp": 1657916482554
        },
        "-N72WZSuKfyF1Deg9l5k": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, All Solid Tumors",
              "new": {
                "TIs": [
                  {
                    "name": "Standard implications for sensitivity to therapy",
                    "name_uuid": "e133bfa7-2eb8-40ee-b76e-2a845420eef1",
                    "treatments": [
                      {
                        "description": "Dabrafenib, an orally bioavailable RAF inhibitor, and trametinib, an orally bioavailable MEK1/2 inhibitor, are FDA-approved for the treatment of patients with solid tumors other than colorectal harboring BRAF V600E mutation. FDA-approval was based on data from 131 adult patients with solid tumors treated with dabrafenib and trametinib in the BRF117019 and NCI-MATCH trials and 36 pediatric patients treated with dabrafinib and trametinib in the CTMT212X2101 study. Of the 131 adult patients treated with dabrafenib and trametinib, the overall response rate was 41% (54/131; 95% CI = 33-50) and of the 36 pediatric patients treated with dabrafenib and trametinib (low grade glioma, n=34; high grade glioma, n=2), the overall response rate was 25% (95% CI = 12-24) (PMID: 32818466, 34838156, 32758030)(Abstract: Bouffet et al. Abstract# LGG-49, Neuro-Oncology 2020. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715318/). Approval was supported by results in COMBI-d, COMBI-v and BRF113928 studies in melanoma and lung cancer (PMID: 23020132, 25399551, 27283860).",
                        "description_review": {
                          "lastReviewed": "",
                          "updateTime": 1657579742384,
                          "updatedBy": "User"
                        },
                        "description_uuid": "80e924fc-2268-4597-ba0f-67603068db13",
                        "indication": "",
                        "indication_uuid": "fa674b18-2a68-4001-a5bd-a7c29934c7a5",
                        "level": "1",
                        "level_review": {
                          "lastReviewed": "",
                          "updateTime": 1657578104900,
                          "updatedBy": "User"
                        },
                        "level_uuid": "edfc84ac-affa-4682-bed0-cd908f995684",
                        "name": "939cd40b-b515-499d-b099-fd29027c0d17 + fb2bb01c-c0ec-4641-abf7-87f486075022",
                        "name_review": {
                          "added": true,
                          "updateTime": 1657578101133,
                          "updatedBy": "User"
                        },
                        "name_uuid": "705c3359-2a48-43f2-8b96-f25fd29cd9f8",
                        "propagation": "no",
                        "propagationLiquid": "no",
                        "propagationLiquid_review": {
                          "lastReviewed": "",
                          "updateTime": 1657578104893,
                          "updatedBy": "User"
                        },
                        "propagationLiquid_uuid": "6798c048-fc1b-4239-9461-98f4bba1416f",
                        "propagation_review": {
                          "lastReviewed": "",
                          "updateTime": 1657578104884,
                          "updatedBy": "User"
                        },
                        "propagation_uuid": "f2549c03-4ef0-4690-8d40-954a35b38ced",
                        "short": ""
                      }
                    ],
                    "treatments_uuid": "0df254f0-c1c3-458a-8a9f-df5d763b3b37",
                    "type": "SS"
                  },
                  {
                    "name": "Standard implications for resistance to therapy",
                    "name_uuid": "59111cbd-39a8-468a-8308-b817529df0a0",
                    "treatments_uuid": "40b44d66-9df5-4507-b8d0-cbebe34744c1",
                    "type": "SR"
                  },
                  {
                    "name": "Investigational implications for sensitivity to therapy",
                    "name_uuid": "daeaa915-a226-4a26-b3a4-8441d754c41a",
                    "treatments_uuid": "ef9f586d-cc5b-4805-8ba3-2452046be24c",
                    "type": "IS"
                  },
                  {
                    "name": "Investigational implications for resistance to therapy",
                    "name_uuid": "f1fd5388-16cd-4f3c-8cc1-2db42ad3902d",
                    "treatments_uuid": "6409c1c6-f303-49b2-8cfa-b00863fefb2c",
                    "type": "IR"
                  }
                ],
                "cancerTypes": [
                  {
                    "code": "",
                    "mainType": "All Solid Tumors",
                    "subtype": ""
                  }
                ],
                "cancerTypes_comments": [
                  {
                    "content": "CRC is excluded because it was excluded for the approval. The other TTs are excluded only because they are already level 1 and we wanted to keep the TT specific approval and not have the solid tumor approval also show up in duplicate",
                    "date": "1657912037889",
                    "email": "user@gmail.com",
                    "resolved": "false",
                    "userName": "User"
                  }
                ],
                "cancerTypes_review": {
                  "added": true,
                  "updateTime": 1657577313406,
                  "updatedBy": "User"
                },
                "cancerTypes_uuid": "4f26dbc9-1003-4094-bae6-9e7c3a7504f2",
                "diagnostic": {
                  "description": "",
                  "description_uuid": "0b4aafc5-a1f2-49fa-a031-1790ebc1830f",
                  "level": "",
                  "level_uuid": "7e2bdfb1-3669-4788-b06c-6d686126ae17",
                  "short": ""
                },
                "diagnosticSummary": "",
                "diagnosticSummary_uuid": "f5dc7711-64b0-4198-9514-dda25a206214",
                "diagnostic_uuid": "6c8baba8-ac8d-4981-854e-512f18e9c11e",
                "prognostic": {
                  "description": "",
                  "description_uuid": "918775ea-a0e4-467d-a1e3-c75ed3e0a614",
                  "level": "",
                  "level_uuid": "c5c942fd-c1aa-4e22-9e49-01a7a95b56ca",
                  "short": ""
                },
                "prognosticSummary": "",
                "prognosticSummary_uuid": "23e8492e-3dfa-473b-b833-110a2a9491bc",
                "prognostic_uuid": "993ffe24-0c98-4acb-b719-57a67c43329a",
                "relevantCancerTypes": [
                  {
                    "code": "",
                    "mainType": "Colorectal Cancer",
                    "subtype": ""
                  },
                  {
                    "code": "THAP",
                    "mainType": "Thyroid Cancer",
                    "subtype": "Anaplastic Thyroid Cancer"
                  },
                  {
                    "code": "MEL",
                    "mainType": "Melanoma",
                    "subtype": "Melanoma"
                  },
                  {
                    "code": "NSCLC",
                    "mainType": "Non-Small Cell Lung Cancer",
                    "subtype": "Non-Small Cell Lung Cancer"
                  }
                ],
                "relevantCancerTypes_review": {
                  "updateTime": 1657911983754,
                  "updatedBy": "User"
                },
                "summary": "The RAF inhibitor dabrafenib in combination with the MEK1/2 inhibitor trametinib is FDA-approved for the treatment of patients with BRAF V600E-mutant solid tumors.",
                "summary_review": {
                  "updateTime": 1657577571167,
                  "updatedBy": "User"
                },
                "summary_uuid": "50f37a4f-8c8b-4f9e-82f4-5334cb9b436e"
              },
              "operation": "add",
              "uuids": "705c3359-2a48-43f2-8b96-f25fd29cd9f8"
            }
          ],
          "timeStamp": 1657916507530
        },
        "-N7McQEBYN7vUJNcY9Mn": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Pilocytic Astrocytoma, Tumor Type Summary",
              "new": "The RAF inhibitor dabrafenib in combination with the MEK1/2 inhibitor trametinib is FDA-approved for the treatment of patients with BRAF V600E-mutant solid tumors.",
              "old": "Combination treatment with RAF-targeted inhibitors plus MEK targeted inhibitors, including dabrafenib + trametinib, or vemurafenib + cobimetinib are NCCN-compendium listed for the treatment of patients with BRAF V600E-mutant pilocytic astrocytoma.",
              "operation": "update",
              "uuids": "06d6c080-3109-4164-9558-557d0f1d319f"
            }
          ],
          "timeStamp": 1658253849604
        },
        "-N7McWOrf4DW8vWi28s6": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Kinase Domain Duplication, Mutation Effect",
              "new": {
                "description": "Duplication of the BRAF kinase domain (BRAF-KDD) results from a breakpoint in intron 9 that generates a protein that is approximately 140 kDa. This alteration has been found in lung cancer (PMID: 32913992), melanoma (PMID: 27320919) and others (PMID: 26562024). Expression of this alteration in HEK293T cells demonstrated that it is activating as measured by increased downstream MAPK pathway signaling compared to control (PMID: 27320919). Knockdown of BRAF-KDD in BRAF V600E-positive cells expressing the kinase domain duplication demonstrated restored sensitivity to BRAF inhibitors such as dabrafenib (PMID: 27320919)."
              },
              "old": {
                "description": "PMID: 27320919, 26562024"
              },
              "operation": "update",
              "uuids": "00b243ca-25a4-46b0-a189-7e9c80a3af07"
            }
          ],
          "timeStamp": 1658253874863
        },
        "-N7McbWjW8rDP1xSnubB": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V169_D380del [p61BRAF-V600E], Mutation Effect",
              "new": {
                "description": "The p61BRAF(V600E) mutation is the product of alternative splicing of the BRAF mRNA transcript, which contains the V600E mutation but eliminates exons 4-8 of the gene (PMID: 22113612). This mutation encodes a truncated, 16 kDa BRAF protein that has the V600E mutation but lacks the RAS binding domain and constitutively dimerizes (PMID: 22113612). This mutation has been found in melanoma (PMID: 22113612). In concordance with its ability to constitutively dimerize, in vitro studies of this mutation suggest that it is resistant to vemurafenib, as measured by persistent MAPK pathway signaling and cell proliferation upon drug treatment (PMID: 22113612). In one study, six out of nineteen patients with melanomas that were resistant to vemurafenib harbored the p61BRAF(V600E) mutation (PMID: 22113612). In a second study, BRAF splice variants were found in several patient-derived xenografts that were generated from patients who progressed on BRAF inhibitors (PMID: 27320919)."
              },
              "old": {
                "description": "The p61BRAF(V600E) mutation is the product of alternative splicing of the BRAF mRNA transcript, which contains the V600E mutation but eliminates exons 4-8 of the gene (PMID: 22113612). This mutation encodes a truncated, 16 kDa BRAF protein that has the V600E mutation but lacks the RAS binding domain and constitutively dimerizes (PMID: 22113612). This mutation has been found in melanoma (PMID: 22113612). In concordance with its ability to constitutively dimerize, in vitro studies of this mutation suggest that it is resistant to vemurafenib, as measured by persistent MAPK pathway signaling and cell proliferation upon drug treatment (PMID: 22113612). In one study, six out of nineteen patients with melanomas that were resistant to vemurafenib harbored the p61BRAF(V600E) mutation (PMID: 22113612)."
              },
              "operation": "update",
              "uuids": "540b58a0-be50-41d4-9241-ce4d8b597398"
            }
          ],
          "timeStamp": 1658253899943
        },
        "-N7Y60c1-DFuKZeZPpy-": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Ganglioglioma, Pilocytic Astrocytoma, Pleomorphic Xanthoastrocytoma, Tumor Type Summary",
              "new": "The RAF inhibitors dabrafenib and vemurafenib in combination with the MEK1/2 inhibitors trametinib and cobimetinib, respectively, are NCCN-compendium listed as a treatment option for patients with [[variant]]",
              "old": "The RAF inhibitor dabrafenib in combination with the MEK1/2 inhibitor trametinib is FDA-approved for the treatment of patients with BRAF V600E-mutant solid tumors.",
              "operation": "update",
              "uuids": "114b09bd-f15e-4f71-a3dd-048c746b20c3"
            }
          ],
          "timeStamp": 1658446421115
        },
        "-N7Y66gUnsNOkyfZLf68": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Pilocytic Astrocytoma, Tumor Type Summary",
              "new": "The RAF inhibitors dabrafenib and vemurafenib in combination with the MEK1/2 inhibitors trametinib and cobimetinib, respectively, are NCCN-compendium listed as a treatment option for patients with [[variant]]",
              "old": "The RAF inhibitor dabrafenib in combination with the MEK1/2 inhibitor trametinib is FDA-approved for the treatment of patients with BRAF V600E-mutant solid tumors.",
              "operation": "update",
              "uuids": "06d6c080-3109-4164-9558-557d0f1d319f"
            }
          ],
          "timeStamp": 1658446445977
        },
        "-N7Y6Clw5p7-yr_Fq1JU": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Ganglioglioma, Pilocytic Astrocytoma, Pleomorphic Xanthoastrocytoma, null, 4e91da20-6cf0-4e07-995f-7f7db4c7c077 + eb357145-3b18-4aca-b75a-5e18dd2bf4f9, 939cd40b-b515-499d-b099-fd29027c0d17 + fb2bb01c-c0ec-4641-abf7-87f486075022",
              "operation": "name change",
              "uuids": "7f76d72e-ec85-4f42-91fe-b247dbe0e0e9"
            }
          ],
          "timeStamp": 1658446470902
        },
        "-N7Y6Ip01YyA7ZnV5VAe": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Encapsulated Glioma, Tumor Type Summary",
              "new": "The RAF inhibitors dabrafenib and vemurafenib in combination with the MEK1/2 inhibitors trametinib and cobimetinib, respectively, are NCCN-compendium listed as a treatment option for patients with [[variant]].",
              "old": "The RAF inhibitor dabrafenib in combination with the MEK1/2 inhibitor trametinib is FDA-approved for the treatment of patients with BRAF V600E-mutant solid tumors.",
              "operation": "update",
              "uuids": "5be59610-1305-4ace-a94c-30ef26d7523a"
            }
          ],
          "timeStamp": 1658446495675
        },
        "-N7Y6PKMdNvepTES80gh": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Diffuse Glioma, null, 4e91da20-6cf0-4e07-995f-7f7db4c7c077 + eb357145-3b18-4aca-b75a-5e18dd2bf4f9, 939cd40b-b515-499d-b099-fd29027c0d17 + fb2bb01c-c0ec-4641-abf7-87f486075022",
              "operation": "name change",
              "uuids": "7b50f8a8-5662-4ad0-b63a-f2a0cf2c9fee"
            }
          ],
          "timeStamp": 1658446522321
        },
        "-N7Y6UzNaQAotyqSa2KK": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Diffuse Glioma, Tumor Type Summary",
              "new": "The RAF inhibitors dabrafenib and vemurafenib in combination with the MEK1/2 inhibitors trametinib and cobimetinib, respectively, are NCCN-compendium listed as a treatment option for patients with [[variant]]",
              "old": "The RAF inhibitor dabrafenib in combination with the MEK1/2 inhibitor trametinib is FDA-approved for the treatment of patients with BRAF V600E-mutant solid tumors.",
              "operation": "update",
              "uuids": "d9d2b475-f103-4960-a827-3a032f107402"
            }
          ],
          "timeStamp": 1658446545490
        },
        "-N7Y6gBTHXphpDe1DKYu": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Encapsulated Glioma, null, 4e91da20-6cf0-4e07-995f-7f7db4c7c077 + eb357145-3b18-4aca-b75a-5e18dd2bf4f9, 939cd40b-b515-499d-b099-fd29027c0d17 + fb2bb01c-c0ec-4641-abf7-87f486075022",
              "operation": "name change",
              "uuids": "8a864f31-163a-4868-bf67-6b1fc449a2c6"
            }
          ],
          "timeStamp": 1658446595480
        },
        "-N7Y6mFDCJSkK3vBiQ57": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, All Solid Tumors",
              "old": {
                "TIs": [
                  {
                    "name": "Standard implications for sensitivity to therapy",
                    "name_uuid": "e133bfa7-2eb8-40ee-b76e-2a845420eef1",
                    "treatments": [
                      {
                        "description": "Dabrafenib, an orally bioavailable RAF inhibitor, and trametinib, an orally bioavailable MEK1/2 inhibitor, are FDA-approved for the treatment of patients with solid tumors other than colorectal harboring BRAF V600E mutation. FDA-approval was based on data from 131 adult patients with solid tumors treated with dabrafenib and trametinib in the BRF117019 and NCI-MATCH trials and 36 pediatric patients treated with dabrafinib and trametinib in the CTMT212X2101 study. Of the 131 adult patients treated with dabrafenib and trametinib, the overall response rate was 41% (54/131; 95% CI = 33-50) and of the 36 pediatric patients treated with dabrafenib and trametinib (low grade glioma, n=34; high grade glioma, n=2), the overall response rate was 25% (95% CI = 12-24) (PMID: 32818466, 34838156, 32758030)(Abstract: Bouffet et al. Abstract# LGG-49, Neuro-Oncology 2020. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715318/). Approval was supported by results in COMBI-d, COMBI-v and BRF113928 studies in melanoma and lung cancer (PMID: 23020132, 25399551, 27283860).",
                        "description_review": {
                          "updateTime": 1657579742384,
                          "updatedBy": "User"
                        },
                        "description_uuid": "80e924fc-2268-4597-ba0f-67603068db13",
                        "indication": "",
                        "indication_uuid": "fa674b18-2a68-4001-a5bd-a7c29934c7a5",
                        "level": "1",
                        "level_review": {
                          "updateTime": 1657578104900,
                          "updatedBy": "User"
                        },
                        "level_uuid": "edfc84ac-affa-4682-bed0-cd908f995684",
                        "name": "939cd40b-b515-499d-b099-fd29027c0d17 + fb2bb01c-c0ec-4641-abf7-87f486075022",
                        "name_review": {
                          "updateTime": 1657578101133,
                          "updatedBy": "User"
                        },
                        "name_uuid": "705c3359-2a48-43f2-8b96-f25fd29cd9f8",
                        "propagation": "no",
                        "propagationLiquid": "no",
                        "propagationLiquid_review": {
                          "updateTime": 1657578104893,
                          "updatedBy": "User"
                        },
                        "propagationLiquid_uuid": "6798c048-fc1b-4239-9461-98f4bba1416f",
                        "propagation_review": {
                          "updateTime": 1657578104884,
                          "updatedBy": "User"
                        },
                        "propagation_uuid": "f2549c03-4ef0-4690-8d40-954a35b38ced",
                        "short": ""
                      }
                    ],
                    "treatments_uuid": "0df254f0-c1c3-458a-8a9f-df5d763b3b37",
                    "type": "SS"
                  },
                  {
                    "name": "Standard implications for resistance to therapy",
                    "name_uuid": "59111cbd-39a8-468a-8308-b817529df0a0",
                    "treatments_uuid": "40b44d66-9df5-4507-b8d0-cbebe34744c1",
                    "type": "SR"
                  },
                  {
                    "name": "Investigational implications for sensitivity to therapy",
                    "name_uuid": "daeaa915-a226-4a26-b3a4-8441d754c41a",
                    "treatments_uuid": "ef9f586d-cc5b-4805-8ba3-2452046be24c",
                    "type": "IS"
                  },
                  {
                    "name": "Investigational implications for resistance to therapy",
                    "name_uuid": "f1fd5388-16cd-4f3c-8cc1-2db42ad3902d",
                    "treatments_uuid": "6409c1c6-f303-49b2-8cfa-b00863fefb2c",
                    "type": "IR"
                  }
                ],
                "cancerTypes": [
                  {
                    "code": "",
                    "mainType": "All Solid Tumors",
                    "subtype": ""
                  }
                ],
                "cancerTypes_comments": [
                  {
                    "content": "CRC is excluded because it was excluded for the approval. The other TTs are excluded only because they are already level 1 and we wanted to keep the TT specific approval and not have the solid tumor approval also show up in duplicate",
                    "date": "1657912037889",
                    "email": "user@gmail.com",
                    "resolved": "false",
                    "userName": "User"
                  }
                ],
                "cancerTypes_review": {
                  "removed": true,
                  "updateTime": 1658443422636,
                  "updatedBy": "User"
                },
                "cancerTypes_uuid": "4f26dbc9-1003-4094-bae6-9e7c3a7504f2",
                "diagnostic": {
                  "description": "",
                  "description_uuid": "0b4aafc5-a1f2-49fa-a031-1790ebc1830f",
                  "level": "",
                  "level_uuid": "7e2bdfb1-3669-4788-b06c-6d686126ae17",
                  "short": ""
                },
                "diagnosticSummary": "",
                "diagnosticSummary_uuid": "f5dc7711-64b0-4198-9514-dda25a206214",
                "diagnostic_uuid": "6c8baba8-ac8d-4981-854e-512f18e9c11e",
                "prognostic": {
                  "description": "",
                  "description_uuid": "918775ea-a0e4-467d-a1e3-c75ed3e0a614",
                  "level": "",
                  "level_uuid": "c5c942fd-c1aa-4e22-9e49-01a7a95b56ca",
                  "short": ""
                },
                "prognosticSummary": "",
                "prognosticSummary_uuid": "23e8492e-3dfa-473b-b833-110a2a9491bc",
                "prognostic_uuid": "993ffe24-0c98-4acb-b719-57a67c43329a",
                "relevantCancerTypes": [
                  {
                    "code": "",
                    "mainType": "Colorectal Cancer",
                    "subtype": ""
                  },
                  {
                    "code": "THAP",
                    "mainType": "Thyroid Cancer",
                    "subtype": "Anaplastic Thyroid Cancer"
                  },
                  {
                    "code": "MEL",
                    "mainType": "Melanoma",
                    "subtype": "Melanoma"
                  },
                  {
                    "code": "NSCLC",
                    "mainType": "Non-Small Cell Lung Cancer",
                    "subtype": "Non-Small Cell Lung Cancer"
                  }
                ],
                "relevantCancerTypes_review": {
                  "updateTime": 1657911983754,
                  "updatedBy": "User"
                },
                "summary": "The RAF inhibitor dabrafenib in combination with the MEK1/2 inhibitor trametinib is FDA-approved for the treatment of patients with BRAF V600E-mutant solid tumors.",
                "summary_review": {
                  "updateTime": 1657577571167,
                  "updatedBy": "User"
                },
                "summary_uuid": "50f37a4f-8c8b-4f9e-82f4-5334cb9b436e"
              },
              "operation": "delete"
            }
          ],
          "timeStamp": 1658446620296
        },
        "-N7Y7IsWYpElVl6pTOkr": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Biliary Tract Cancer, NOS",
              "old": {
                "TIs": [
                  {
                    "name": "Standard implications for sensitivity to therapy",
                    "name_uuid": "80c859e7-b4ce-431c-8a19-4c722f64e7c1",
                    "treatments": [
                      {
                        "description": "Dabrafenib, an orally bioavailable RAF inhibitor, and trametinib, an orally bioavailable MEK1/2 inhibitor, are FDA-approved alone or in combination for the treatment of patients with various solid cancers with BRAF V600E mutation. In a Phase II, single-arm basket trial of dabrafenib + trametinib in patients with BRAF V600E-mutant solid tumors, of 43 patients with biliary tract cancer, the overall response rate was 51% (22/43, 95% CI 36–67), the median progression-free survival was 9 months (95% CI 5-10), and the median overall survival was 14 months (95% CI 10-33). Of the 43 patients with biliary tract cancer, 51% of patients (22/43) had a partial response and 40% (17/43) had stable disease (PMID: 32818466). Additionally, in subprotocol H of the NCI-MATCH basket trial of dabrafenib + trametinib in patients with BRAF V600E-mutant solid tumors (N=4 patients with intrahepatic cholangiocarcinoma), the overall response rate was 100%, with 4/4 patients achieving a partial response (PMID: 32758030).",
                        "description_review": {
                          "lastReviewed": "",
                          "updateTime": 1658443531253,
                          "updatedBy": "User"
                        },
                        "description_uuid": "ccf58b9f-06bf-4fde-84c3-d779e34230a0",
                        "indication": "",
                        "indication_uuid": "af99ac0a-2904-4b3e-8f76-161cc5522a2d",
                        "level": "2",
                        "level_review": {
                          "lastReviewed": "",
                          "updateTime": 1658443523154,
                          "updatedBy": "User"
                        },
                        "level_uuid": "4717d574-296e-4907-a7a5-dcc50cb70485",
                        "name": "939cd40b-b515-499d-b099-fd29027c0d17 + fb2bb01c-c0ec-4641-abf7-87f486075022",
                        "name_review": {
                          "added": true,
                          "updateTime": 1658443518200,
                          "updatedBy": "User"
                        },
                        "name_uuid": "8198a63a-dc8a-42b5-b414-d34a4b9c397a",
                        "propagation": "3B",
                        "propagationLiquid": "no",
                        "propagationLiquid_review": {
                          "lastReviewed": "",
                          "updateTime": 1658443523108,
                          "updatedBy": "User"
                        },
                        "propagationLiquid_uuid": "e16e9e4e-4f13-437b-8686-12f32e600012",
                        "propagation_review": {
                          "lastReviewed": "",
                          "updateTime": 1658443535610,
                          "updatedBy": "User"
                        },
                        "propagation_uuid": "5265a779-9242-4427-b68e-ca83833cf2ad",
                        "short": ""
                      }
                    ],
                    "treatments_uuid": "edab0639-dffc-49c7-8b21-db01437dd780",
                    "type": "SS"
                  },
                  {
                    "name": "Standard implications for resistance to therapy",
                    "name_uuid": "e6ebb860-4339-41db-896f-1129b6a9174b",
                    "treatments_uuid": "d1b31434-54d6-4a22-b59c-1151607554e4",
                    "type": "SR"
                  },
                  {
                    "name": "Investigational implications for sensitivity to therapy",
                    "name_uuid": "d78ffe8e-9305-424b-bf3b-b55580f258e1",
                    "treatments_uuid": "9ab85e58-ad1c-435d-925b-c56e447ed701",
                    "type": "IS"
                  },
                  {
                    "name": "Investigational implications for resistance to therapy",
                    "name_uuid": "b9b3deda-2196-4d8b-8caa-e7eba40eba04",
                    "treatments_uuid": "dc148b58-15f5-43ca-80a4-a823877199df",
                    "type": "IR"
                  }
                ],
                "cancerTypes": [
                  {
                    "code": "",
                    "mainType": "Biliary Tract Cancer, NOS",
                    "subtype": ""
                  }
                ],
                "cancerTypes_review": {
                  "added": true,
                  "updateTime": 1658443492421,
                  "updatedBy": "User"
                },
                "cancerTypes_uuid": "6ff185ea-2f16-4ccf-8fb8-3a9627687d0f",
                "diagnostic": {
                  "description": "",
                  "description_uuid": "2914b030-32bc-4822-9ea5-f95897f52d56",
                  "level": "",
                  "level_uuid": "7707a55e-ec12-43e9-b423-41b99c2fb84e",
                  "short": ""
                },
                "diagnosticSummary": "",
                "diagnosticSummary_uuid": "b73d28af-80a8-4578-9b1a-f2aa98f39a0b",
                "diagnostic_uuid": "9995a07e-31c8-4d24-b172-4a21ce505e47",
                "prognostic": {
                  "description": "",
                  "description_uuid": "2ba0c125-7778-4a2f-9a72-603fa15d954e",
                  "level": "",
                  "level_uuid": "30a4e757-82d6-4f75-87ad-8efd4dc4ed43",
                  "short": ""
                },
                "prognosticSummary": "",
                "prognosticSummary_uuid": "a1aadc62-30b0-4fba-8ab0-988c00e8bb45",
                "prognostic_uuid": "1fc8e7f5-bb81-463f-b833-b83c187501c6",
                "summary": "The RAF inhibitor dabrafenib in combination with the MEK1/2 inhibitor trametinib is NCCN-compendium listed for the treatment of patients with BRAF V600E-mutant biliary tract cancer",
                "summary_review": {
                  "lastReviewed": "",
                  "updateTime": 1658443504428,
                  "updatedBy": "User"
                },
                "summary_uuid": "0e659d53-eed0-4476-8909-6fa323f1cdd2"
              },
              "operation": "delete"
            }
          ],
          "timeStamp": 1658446758043
        },
        "-N7Y7tns-tqgHgMME5AH": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Ganglioglioma, Pilocytic Astrocytoma, Pleomorphic Xanthoastrocytoma, Tumor Type Summary",
              "new": "The RAF inhibitors dabrafenib and vemurafenib in combination with the MEK1/2 inhibitors trametinib and cobimetinib, respectively, are NCCN-compendium listed as a treatment option for patients with [[variant]].",
              "old": "The RAF inhibitors dabrafenib and vemurafenib in combination with the MEK1/2 inhibitors trametinib and cobimetinib, respectively, are NCCN-compendium listed as a treatment option for patients with [[variant]]",
              "operation": "update",
              "uuids": "114b09bd-f15e-4f71-a3dd-048c746b20c3"
            }
          ],
          "timeStamp": 1658446913393
        },
        "-N7Y8-15DlZIROncuTcR": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Diffuse Glioma, Tumor Type Summary",
              "new": "The RAF inhibitors dabrafenib and vemurafenib in combination with the MEK1/2 inhibitors trametinib and cobimetinib, respectively, are NCCN-compendium listed as a treatment option for patients with [[variant]].",
              "old": "The RAF inhibitors dabrafenib and vemurafenib in combination with the MEK1/2 inhibitors trametinib and cobimetinib, respectively, are NCCN-compendium listed as a treatment option for patients with [[variant]]",
              "operation": "update",
              "uuids": "d9d2b475-f103-4960-a827-3a032f107402"
            }
          ],
          "timeStamp": 1658446938880
        },
        "-N7YBgJh1gy3mbWpPacg": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Biliary Tract Cancer, NOS",
              "new": {
                "TIs": [
                  {
                    "name": "Standard implications for sensitivity to therapy",
                    "name_uuid": "862cf5c3-011e-4fa7-83b0-235cd33635fb",
                    "treatments": [
                      {
                        "description": "Dabrafenib, an orally bioavailable RAF inhibitor, and trametinib, an orally bioavailable MEK1/2 inhibitor, are FDA-approved alone or in combination for the treatment of patients with various solid cancers with BRAF V600E mutation. In a Phase II, single-arm basket trial of dabrafenib + trametinib in patients with BRAF V600E-mutant solid tumors, of 43 patients with biliary tract cancer, the overall response rate was 51% (22/43, 95% CI 36–67), the median progression-free survival was 9 months (95% CI 5-10), and the median overall survival was 14 months (95% CI 10-33). Of the 43 patients with biliary tract cancer, 51% of patients (22/43) had a partial response and 40% (17/43) had stable disease (PMID: 32818466). Additionally, in subprotocol H of the NCI-MATCH basket trial of dabrafenib + trametinib in patients with BRAF V600E-mutant solid tumors (N=4 patients with intrahepatic cholangiocarcinoma), the overall response rate was 100%, with 4/4 patients achieving a partial response (PMID: 32758030).",
                        "description_review": {
                          "lastReviewed": "",
                          "updateTime": 1658447069677,
                          "updatedBy": "User"
                        },
                        "description_uuid": "6429f66b-751d-40ac-ae1d-134370fdb633",
                        "indication": "",
                        "indication_uuid": "e936ba53-4a42-4caf-8d6e-1907d227128a",
                        "level": "2",
                        "level_review": {
                          "lastReviewed": "",
                          "updateTime": 1658447054264,
                          "updatedBy": "User"
                        },
                        "level_uuid": "79680fa4-6219-4b5c-9b3c-45ee9174f909",
                        "name": "939cd40b-b515-499d-b099-fd29027c0d17 + fb2bb01c-c0ec-4641-abf7-87f486075022",
                        "name_review": {
                          "added": true,
                          "updateTime": 1658447048248,
                          "updatedBy": "User"
                        },
                        "name_uuid": "6d286407-4acf-4feb-9649-472fbb1b95fe",
                        "propagation": "3B",
                        "propagationLiquid": "no",
                        "propagationLiquid_review": {
                          "lastReviewed": "",
                          "updateTime": 1658447054260,
                          "updatedBy": "User"
                        },
                        "propagationLiquid_uuid": "1fb29526-28e7-4e5b-96e1-b78e5dcd3ae0",
                        "propagation_review": {
                          "lastReviewed": "",
                          "updateTime": 1658447874644,
                          "updatedBy": "User"
                        },
                        "propagation_uuid": "13f60c28-581a-4131-be5e-0c0ca02e2b93",
                        "short": ""
                      }
                    ],
                    "treatments_uuid": "904b2800-b4f0-49c0-8ca2-5b85500c67e8",
                    "type": "SS"
                  },
                  {
                    "name": "Standard implications for resistance to therapy",
                    "name_uuid": "86a82d3a-4a3c-4553-87ca-6f1d0a6bc77e",
                    "treatments_uuid": "4265240a-f3e4-4dc2-9903-1083c5e5ba38",
                    "type": "SR"
                  },
                  {
                    "name": "Investigational implications for sensitivity to therapy",
                    "name_uuid": "2823805e-c057-49ea-a356-b91388b7defc",
                    "treatments_uuid": "e3b8adb1-dbab-4a5a-a6e1-984e423cd8bf",
                    "type": "IS"
                  },
                  {
                    "name": "Investigational implications for resistance to therapy",
                    "name_uuid": "312d0743-d195-40f3-8396-6ec6f1ab81ae",
                    "treatments_uuid": "79e61da3-be3d-4513-ba89-c26a1c83f109",
                    "type": "IR"
                  }
                ],
                "cancerTypes": [
                  {
                    "code": "",
                    "mainType": "Biliary Tract Cancer, NOS",
                    "subtype": ""
                  }
                ],
                "cancerTypes_review": {
                  "added": true,
                  "updateTime": 1658446992305,
                  "updatedBy": "User"
                },
                "cancerTypes_uuid": "db15966c-0c05-42ce-c007-7b3ccf73b962",
                "diagnostic": {
                  "description": "",
                  "description_uuid": "5cffc3dd-192e-4982-8d8a-9e9b7ef1c3a1",
                  "level": "",
                  "level_uuid": "7690edd4-6650-4789-8f93-dda55bc14de3",
                  "short": ""
                },
                "diagnosticSummary": "",
                "diagnosticSummary_uuid": "205220d4-3710-4897-ae67-1701b9f68b9c",
                "diagnostic_uuid": "a5a27982-c92e-4bcd-aed6-4281094584a2",
                "prognostic": {
                  "description": "",
                  "description_uuid": "6820209b-17a7-42e5-b8c1-d624e2476cd4",
                  "level": "",
                  "level_uuid": "8cc6a095-af39-4097-acd1-a820e358e776",
                  "short": ""
                },
                "prognosticSummary": "",
                "prognosticSummary_uuid": "0b5609f7-7fb8-42a1-838f-3b4f7f741e3c",
                "prognostic_uuid": "eb91ce5e-b177-441f-9c0c-623a7fa6f942",
                "summary": "The RAF inhibitor dabrafenib in combination with the MEK1/2 inhibitor trametinib is NCCN-compendium listed for the treatment of patients with BRAF V600E-mutant biliary tract cancer.",
                "summary_review": {
                  "lastReviewed": "",
                  "updateTime": 1658447031404,
                  "updatedBy": "User"
                },
                "summary_uuid": "26d2dac0-be4d-408b-9440-14131797c627"
              },
              "operation": "add",
              "uuids": "26d2dac0-be4d-408b-9440-14131797c627,6d286407-4acf-4feb-9649-472fbb1b95fe"
            }
          ],
          "timeStamp": 1658447906569
        },
        "-NAnwoot3F9lQYTWhLjV": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600, Langerhans Cell Histiocytosis, STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY, 4e91da20-6cf0-4e07-995f-7f7db4c7c077, 939cd40b-b515-499d-b099-fd29027c0d17",
              "new": {
                "fdaLevel": "Fda3"
              },
              "old": {
                "fdaLevel": ""
              },
              "operation": "update",
              "uuids": "a0a7271e-c46e-43b8-8f85-7e1418192d6c"
            },
            {
              "lastEditBy": "User",
              "location": "Oncogenic Mutations {excluding V600}, Erdheim-Chester Disease, STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY, eb357145-3b18-4aca-b75a-5e18dd2bf4f9, fb2bb01c-c0ec-4641-abf7-87f486075022",
              "new": {
                "fdaLevel": "Fda3"
              },
              "old": {
                "fdaLevel": ""
              },
              "operation": "update",
              "uuids": "f85c5ffd-a7dc-4769-acdc-012ff3b7ac5d"
            },
            {
              "lastEditBy": "User",
              "location": "Oncogenic Mutations {excluding V600}, Langerhans Cell Histiocytosis, STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY, eb357145-3b18-4aca-b75a-5e18dd2bf4f9, fb2bb01c-c0ec-4641-abf7-87f486075022",
              "new": {
                "fdaLevel": "Fda3"
              },
              "old": {
                "fdaLevel": ""
              },
              "operation": "update",
              "uuids": "a7ce9682-0287-4744-895c-69df4bb7792b"
            },
            {
              "lastEditBy": "User",
              "location": "Oncogenic Mutations {excluding V600}, Rosai-Dorfman Disease, STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY, eb357145-3b18-4aca-b75a-5e18dd2bf4f9, fb2bb01c-c0ec-4641-abf7-87f486075022",
              "new": {
                "fdaLevel": "Fda3"
              },
              "old": {
                "fdaLevel": ""
              },
              "operation": "update",
              "uuids": "6680f049-0c87-41fb-a234-09c1a2361419"
            }
          ],
          "timeStamp": 1661950184706
        },
        "-NAoVI7gnuRla9qSEDkZ": {
          "admin": "User",
          "records": {
            "uuids": "114b09bd-f15e-4f71-a3dd-048c746b20c3"
          },
          "timeStamp": 1661959484205
        },
        "-NAoVOqPq0ZccT14BXEi": {
          "admin": "User",
          "records": {
            "uuids": "7f76d72e-ec85-4f42-91fe-b247dbe0e0e9"
          },
          "timeStamp": 1661959511708
        },
        "-NAoVVZd8VSisB5tlWhg": {
          "admin": "User",
          "records": {
            "uuids": "d9d2b475-f103-4960-a827-3a032f107402"
          },
          "timeStamp": 1661959539243
        },
        "-NAoVbH7PvyqjUmlta1Y": {
          "admin": "User",
          "records": {
            "uuids": "9ae514fa-cea6-4a01-9f6e-ae9ca1a43049"
          },
          "timeStamp": 1661959566730
        },
        "-NAoVi9e1YYRYBDJqIRN": {
          "admin": "User",
          "records": {
            "uuids": "06d6c080-3109-4164-9558-557d0f1d319f"
          },
          "timeStamp": 1661959594924
        },
        "-NAoVtt_p-eyfHX_z5Pc": {
          "admin": "User",
          "records": {
            "uuids": "7b50f8a8-5662-4ad0-b63a-f2a0cf2c9fee"
          },
          "timeStamp": 1661959642982
        },
        "-NAoW-aIrQDEzUjUUBDq": {
          "admin": "User",
          "records": {
            "uuids": "26d2dac0-be4d-408b-9440-14131797c627"
          },
          "timeStamp": 1661959670421
        },
        "-NAoW6Hj-NEIghOY0c3O": {
          "admin": "User",
          "records": {
            "uuids": "8a864f31-163a-4868-bf67-6b1fc449a2c6"
          },
          "timeStamp": 1661959697841
        },
        "-NAoWCx0UE4QN7pZBQYA": {
          "admin": "User",
          "records": {
            "uuids": "5be59610-1305-4ace-a94c-30ef26d7523a"
          },
          "timeStamp": 1661959725123
        },
        "-NAoWJgJ_tnwyttFPGdC": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, All Solid Tumors {excluding Colorectal Cancer}",
              "new": {
                "TIs": [
                  {
                    "name": "Standard implications for sensitivity to therapy",
                    "name_uuid": "cd70da53-5b64-4ff1-baa6-e1049fdcb91f",
                    "treatments": [
                      {
                        "description": "Dabrafenib, an orally bioavailable RAF inhibitor, and trametinib, an orally bioavailable MEK1/2 inhibitor, are FDA-approved for the treatment of patients with solid tumors other than colorectal harboring BRAF V600E mutation. FDA-approval was based on data from 131 adult patients with solid tumors treated with dabrafenib and trametinib in the BRF117019 and NCI-MATCH trials and 36 pediatric patients treated with dabrafinib and trametinib in the CTMT212X2101 study. Of the 131 adult patients treated with dabrafenib and trametinib, the overall response rate was 41% (54/131; 95% CI = 33-50) and of the 36 pediatric patients treated with dabrafenib and trametinib (low grade glioma, n=34; high grade glioma, n=2), the overall response rate was 25% (95% CI = 12-24) (PMID: 32818466, 34838156, 32758030)(Abstract: Bouffet et al. Abstract# LGG-49, Neuro-Oncology 2020. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715318/). Approval was supported by results in COMBI-d, COMBI-v and BRF113928 studies in melanoma and lung cancer (PMID: 23020132, 25399551, 27283860).",
                        "description_review": {
                          "lastReviewed": "",
                          "updateTime": 1661884606104,
                          "updatedBy": "User"
                        },
                        "description_uuid": "6f0f3c4b-5619-4639-bb62-7bbd86a5c5c9",
                        "fdaLevel": "Fda2",
                        "fdaLevel_review": {
                          "lastReviewed": "",
                          "updateTime": 1661884588802,
                          "updatedBy": "User"
                        },
                        "fdaLevel_uuid": "1d99c83f-16e0-4a59-a6a4-0a9f001de619",
                        "indication": "",
                        "indication_uuid": "7a2749de-22d0-4564-88c4-58c144ab48f8",
                        "level": "1",
                        "level_review": {
                          "lastReviewed": "",
                          "updateTime": 1661884588805,
                          "updatedBy": "User"
                        },
                        "level_uuid": "d9ced8ba-b6ac-4d80-a3f5-3ef90f083522",
                        "name": "939cd40b-b515-499d-b099-fd29027c0d17 + fb2bb01c-c0ec-4641-abf7-87f486075022",
                        "name_review": {
                          "added": true,
                          "updateTime": 1661884582287,
                          "updatedBy": "User"
                        },
                        "name_uuid": "6d039136-d681-4915-a342-16e424f5e42c",
                        "propagation": "3B",
                        "propagationLiquid": "no",
                        "propagationLiquid_review": {
                          "lastReviewed": "",
                          "updateTime": 1661884588799,
                          "updatedBy": "User"
                        },
                        "propagationLiquid_uuid": "6f49d954-d18d-4bae-9a99-b1a8095249ed",
                        "propagation_review": {
                          "lastReviewed": "",
                          "updateTime": 1661884593019,
                          "updatedBy": "User"
                        },
                        "propagation_uuid": "0251f011-cf44-44ce-84c0-9e8c56f6e3f5",
                        "short": ""
                      }
                    ],
                    "treatments_uuid": "286cbb6c-2828-43ec-a8b7-2427e4a522dd",
                    "type": "SS"
                  },
                  {
                    "name": "Standard implications for resistance to therapy",
                    "name_uuid": "f58e1286-d1b5-41b2-c0e8-274f020f738f",
                    "treatments_uuid": "1260ee7a-730f-4fb8-b6cb-b0a9e2e8fc4b",
                    "type": "SR"
                  },
                  {
                    "name": "Investigational implications for sensitivity to therapy",
                    "name_uuid": "543ab6de-03f0-400f-9a5f-d88c7a556b68",
                    "treatments_uuid": "fd953b99-aa3e-4d40-b82c-78a8a8d53a2b",
                    "type": "IS"
                  },
                  {
                    "name": "Investigational implications for resistance to therapy",
                    "name_uuid": "0b6ca1a1-bbc7-4acd-a5ab-62ebc433ed14",
                    "treatments_uuid": "0f6fcefb-fa22-4d58-a07f-bbe093025326",
                    "type": "IR"
                  }
                ],
                "cancerTypes": [
                  {
                    "code": "",
                    "mainType": "All Solid Tumors",
                    "subtype": ""
                  }
                ],
                "cancerTypes_review": {
                  "added": true,
                  "updateTime": 1661884507325,
                  "updatedBy": "User"
                },
                "cancerTypes_uuid": "26f46af9-c07e-41b1-a13c-55707762c5b1",
                "diagnostic": {
                  "description": "",
                  "description_uuid": "5e731fd4-4445-44ad-b820-16b476417b13",
                  "level": "",
                  "level_uuid": "0e1cecb7-0e3d-4ffa-93ec-b2dd5d8e68e8",
                  "relevantCancerTypes_uuid": "f03b746a-9227-4c82-b731-dae41ba4f742",
                  "short": ""
                },
                "diagnosticSummary": "",
                "diagnosticSummary_uuid": "65360119-3191-4a8d-a812-c4b9c50477d3",
                "diagnostic_uuid": "8dacb284-3a51-4ff0-b3fd-74ac642d9250",
                "excludedCancerTypes": [
                  {
                    "code": "",
                    "mainType": "Colorectal Cancer",
                    "subtype": ""
                  }
                ],
                "excludedCancerTypes_review": {
                  "updateTime": 1661884549038,
                  "updatedBy": "User"
                },
                "excludedCancerTypes_uuid": "6ffe69ce-3132-4b72-b805-5ee26fcb8c2d",
                "prognostic": {
                  "description": "",
                  "description_uuid": "ccffcae9-60ca-405f-b11f-3f61ebd6153a",
                  "level": "",
                  "level_uuid": "51749cca-f2b3-41d2-a973-2f7832ae5a8e",
                  "relevantCancerTypes_uuid": "b96406b9-a404-4201-a558-d6849b82f4d2",
                  "short": ""
                },
                "prognosticSummary": "",
                "prognosticSummary_uuid": "358966b6-a4c4-43c9-96c9-063f8c9533d6",
                "prognostic_uuid": "432077a6-4c52-48b2-91c7-7c098a6a2dd5",
                "relevantCancerTypes_uuid": "68519313-dc7c-4810-a299-6bc8b4fbf3e6",
                "summary": "The RAF inhibitor dabrafenib in combination with the MEK1/2 inhibitor trametinib is FDA-approved for the treatment of patients with BRAF V600E-mutant solid tumors.",
                "summary_review": {
                  "lastReviewed": "",
                  "updateTime": 1661884563863,
                  "updatedBy": "User"
                },
                "summary_uuid": "a1317432-a427-476c-86f1-84c15b50d5c5"
              },
              "operation": "add",
              "uuids": "a1317432-a427-476c-86f1-84c15b50d5c5,6d039136-d681-4915-a342-16e424f5e42c"
            }
          ],
          "timeStamp": 1661959752726
        },
        "-NAoWQLRMEESTxPSdSzp": {
          "admin": "User",
          "records": {
            "uuids": "6d286407-4acf-4feb-9649-472fbb1b95fe"
          },
          "timeStamp": 1661959779998
        },
        "-NAoYvnIdXTtamhWxW-S": {
          "admin": "User",
          "records": {
            "uuids": "215bd1c9-120d-4fc1-b906-5f317772b820"
          },
          "timeStamp": 1661960437003
        },
        "-NAoZKSVkPqrl5-hw1JM": {
          "admin": "User",
          "records": {
            "uuids": "6d286407-4acf-4feb-9649-472fbb1b95fe"
          },
          "timeStamp": 1661960542105
        },
        "-NAo_N5OOnEMZx3pqZR0": {
          "admin": "User",
          "records": {
            "uuids": "6d039136-d681-4915-a342-16e424f5e42c"
          },
          "timeStamp": 1661960815058
        },
        "-ND-8MrfwZi_ISDQm0ao": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600, Langerhans Cell Histiocytosis, STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY, 4e91da20-6cf0-4e07-995f-7f7db4c7c077, 939cd40b-b515-499d-b099-fd29027c0d17",
              "new": {
                "description": "Vemurafenib and Dabrafenib, inhibitors of BRAF V600E that are FDA-approved for patients with BRAF V600E or V600K mutant positive melanoma, are NCCN-listed for patients with Langerhans Cell Histiocytosis (LCH). NCCN recommendation is based on the Phase II VE BASKET study of vemurafenib in patients with BRAF V600E-mutant cancer in which four of four patients with LCH harboring BRAF V600E mutations had partial response to vemurafenib treatment (PMID: 29188284)."
              },
              "old": {
                "description": "Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and both are NCCN-listed for patients with Langerhans Cell Histiocytosis (LCH). In an open-label, phase 2 trial (NCT02649972) of cobimetinib in eighteen adult patients with histiocytoses (n = two patients with LCH) of any mutational status, the overall response rate was 89% (90% CI: 73–100), 100% of responses were ongoing at one year, and 94% of patients remained progression-free (PMID: 30867592)."
              },
              "operation": "update",
              "uuids": "a0a7271e-c46e-43b8-8f85-7e1418192d6c"
            }
          ],
          "timeStamp": 1664302284414
        },
        "-NEmUwpL5yT0YnBucWqO": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Mutation Effect",
              "new": {
                "description": "The class I activating exon 15 BRAF V600E mutation is located in the kinase domain of the BRAF protein and is highly recurrent in melanoma, lung and thyroid cancer, among others (PMID: 28783719, 26091043, 25079552, 23833300, 25417114, 28783719, 12068308). This mutation has been comprehensively biologically characterized and has been shown to activate the downstream MAPK pathway independent of RAS (PMID: 15035987, 12068308, 19251651, 26343582), to render BRAF constitutively activated in monomeric form (PMID: 20179705), and to retain sensitivity to RAF monomer inhibitors such as vemurafenib and dabrafenib (PMID:26343582, 28783719, 20179705, 30351999)."
              },
              "old": {
                "description": "The class I activating exon 15 BRAF V600E mutation is located in the kinase domain of the BRAF protein and is highly recurrent in melanoma, lung and thyroid cancer, among others (PMID: 28783719, 26091043, 25079552, 23833300, 25417114, 28783719, 12068308). This mutation has been been comprehensively biologically characterized and has been shown to activate the downstream MAPK pathway independent of RAS (PMID: 15035987, 12068308, 19251651, 26343582), to render BRAF constitutively activated in monomeric form (PMID: 20179705), and to retain sensitivity to RAF monomer inhibitors such as vemurafenib and dabrafenib (PMID:26343582, 28783719, 20179705, 30351999)."
              },
              "operation": "update",
              "uuids": "a53f5aa8-a4bb-4e65-8e30-93cf7045029e"
            }
          ],
          "timeStamp": 1666220805402
        },
        "-NEmV2aRoXDBzjAgSiLV": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600, Histiocytosis, INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY, 4e91da20-6cf0-4e07-995f-7f7db4c7c077, 939cd40b-b515-499d-b099-fd29027c0d17",
              "operation": "update",
              "uuids": "ccfa69b9-f284-427a-84b5-a4ffcc5606ca"
            }
          ],
          "timeStamp": 1666220833120
        },
        "-NEmV9Ii4YCNlAzlz5ut": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Colorectal Cancer, STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY, 001e534f-3e63-432f-90a6-d1af1759e4e2 + d7b1d12a-e942-4801-bb64-916c9bdfaaf3",
              "operation": "update",
              "uuids": "d9b444f3-76b2-4f91-a919-8b8b4d853846"
            }
          ],
          "timeStamp": 1666220860594
        },
        "-NEmVG1L3zi8vTvPwcuj": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Colorectal Cancer, STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY, 001e534f-3e63-432f-90a6-d1af1759e4e2 + 5fce3074-e420-4c36-9603-2423daf20118",
              "operation": "update",
              "uuids": "5d3556f9-89b7-4be9-9fa8-69fee10f032b"
            }
          ],
          "timeStamp": 1666220888154
        },
        "-NEmVMkiAQ_3bqU6Z6qN": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Melanoma, STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY, 939cd40b-b515-499d-b099-fd29027c0d17",
              "operation": "update",
              "uuids": "86887f5d-62df-429b-9968-7b73c31a9504"
            }
          ],
          "timeStamp": 1666220915698
        },
        "-NF9ZvSC6BfA34ZHJCDz": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Melanoma, STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY, 939cd40b-b515-499d-b099-fd29027c0d17",
              "operation": "update",
              "uuids": "86887f5d-62df-429b-9968-7b73c31a9504"
            }
          ],
          "timeStamp": 1666624762356
        },
        "-NF9_1C_J1MP5LTvTp9Q": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600, Histiocytosis, INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY, 4e91da20-6cf0-4e07-995f-7f7db4c7c077, 939cd40b-b515-499d-b099-fd29027c0d17",
              "operation": "update",
              "uuids": "ccfa69b9-f284-427a-84b5-a4ffcc5606ca"
            }
          ],
          "timeStamp": 1666624790028
        },
        "-NF9_80ExtUmAV_cOMPV": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Colorectal Cancer, STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY, 001e534f-3e63-432f-90a6-d1af1759e4e2 + d7b1d12a-e942-4801-bb64-916c9bdfaaf3",
              "operation": "update",
              "uuids": "d9b444f3-76b2-4f91-a919-8b8b4d853846"
            }
          ],
          "timeStamp": 1666624817910
        },
        "-NF9_ElXXNFLWU0nfLEM": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Colorectal Cancer, STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY, 001e534f-3e63-432f-90a6-d1af1759e4e2 + 5fce3074-e420-4c36-9603-2423daf20118",
              "operation": "update",
              "uuids": "5d3556f9-89b7-4be9-9fa8-69fee10f032b"
            }
          ],
          "timeStamp": 1666624845577
        },
        "-NHWMTcMT_QwFAmOchIp": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Non-Small Cell Lung Cancer, STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY, 939cd40b-b515-499d-b099-fd29027c0d17 + fb2bb01c-c0ec-4641-abf7-87f486075022",
              "operation": "update",
              "uuids": "c63b34cb-c1fa-4784-c031-98566ad048bb"
            }
          ],
          "timeStamp": 1669154597411
        },
        "-NHWM_MuMf7wqbwTbfo-": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "K601, Melanoma, INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY, fb2bb01c-c0ec-4641-abf7-87f486075022",
              "operation": "update",
              "uuids": "b17106e4-9dd3-4157-90d2-0e791c15278b"
            }
          ],
          "timeStamp": 1669154625030
        },
        "-NIj2IwV5upbCBx2Gzqo": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, V600K, Melanoma, STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY, 001e534f-3e63-432f-90a6-d1af1759e4e2 + feb9f4a3-e374-4c75-8a3b-0f1fbcdbf677",
              "new": {
                "description": "The combination of encorafenib, an inhibitor of V600E- or V600K-mutant BRAF, and binimetinib, an inhibitor of MEK1/2, is FDA approved in combination for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. FDA approval was based on the results of the Phase III COLUMBUS trial of combined encorafenib plus binimetinib versus single-agent vemurafenib in 577 patients with BRAF V600E- or V600K-mutant metastatic melanoma in which the median progression-free survival was 14.9 months (95% CI 11.0-18.5) in the encorafenib plus binimetinib group versus 7.3 months (95% CI 5.6-8.2) in the single agent vemurafenib group (HR= 0.54, 95% CI 0.41-0.71; p<0·0001) (PMID: 29573941). In the five-year update of the Phase III COLUMBUS trial, the progression-free survival and overall survival were 23% and 35% respectively in the encorafenib plus binimetinib group (n=192) versus 10% and 21% respectively in the single agent vemurafenib group (n=191), and the median duration of response and disease control rate were 18.6 months and 92.2% in the encorafenib plus binimetinib group versus 12.3 months and 81.2% in the single-agent vemurafenib group (PMID: 35862871)."
              },
              "old": {
                "description": "The combination of encorafenib, an inhibitor of V600E- or V600K-mutant BRAF, and binimetinib, an inhibitor of MEK1/2, is FDA approved in combination for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. FDA-approval was based on the results of the Phase III COLUMBUS trial of combined encorafenib plus binimetinib versus single agent vemurafenib in 577 patients with BRAF V600E- or V600K-mutant metastatic melanoma in which the median progression-free survival was 14.9 months (95% CI 11.0-18.5) in the encorafenib plus binimetinib group versus 7.3 months (95% CI 5.6-8.2) in the single agent vemurafenib group (HR= 0.54, 95% CI 0.41-0.71; p<0·0001) (PMID: 29573941)."
              },
              "operation": "update",
              "uuids": "b76c8407-558c-49e9-ab3c-90a181df0044"
            }
          ],
          "timeStamp": 1670457933498
        },
        "-NIj2RWKgV8zhQxNYJIZ": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "K601, Melanoma, INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY, fb2bb01c-c0ec-4641-abf7-87f486075022",
              "operation": "update",
              "uuids": "b17106e4-9dd3-4157-90d2-0e791c15278b"
            }
          ],
          "timeStamp": 1670457968623
        },
        "-NJ7bTNqLom5kciyPE0l": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "K601, Melanoma, INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY, fb2bb01c-c0ec-4641-abf7-87f486075022",
              "operation": "update",
              "uuids": "b17106e4-9dd3-4157-90d2-0e791c15278b"
            }
          ],
          "timeStamp": 1670886843974
        },
        "-NJH9mqrdkLdO1vAHKh9": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "K601, Melanoma, INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY, fb2bb01c-c0ec-4641-abf7-87f486075022",
              "operation": "update",
              "uuids": "b17106e4-9dd3-4157-90d2-0e791c15278b"
            }
          ],
          "timeStamp": 1671047097772
        },
        "-NJlNn_AQnH_-wRvZwNI": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "I592_A598dup",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF I592_A598dup mutation is located in the kinase domain in exon 15 of the protein. This mutation has been identified in papillary thyroid carcinoma, inguinal adenopathy and primary melanoma, and is a statistically significant hotspot (PMID: 27571181, 28800030 ). This mutation has not been functionally characterized in vitro. BRAF exon 15 mutations are sensitive to treatment with combination MAPK-directed targeted therapy based on the clinical benefit of two patients with rare BRAF exon 15 insertion mutations involving the A598 residue, BRAF A598_T599insV and V600_K601delinsE (PMID: 28800030).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1671570734352,
                    "updatedBy": "User"
                  },
                  "description_uuid": "def51eb0-97db-438f-beb3-82a77fceb7da",
                  "effect": "Likely Gain-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1671570741992,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "e094703b-28dd-45a1-a8c6-8f3f018fa030",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1671570737873,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "753b067a-2371-47dd-aff5-722c63c023e0",
                  "short": ""
                },
                "mutation_effect_uuid": "70f3ee1b-649a-4b72-bb51-4977f483ca34",
                "name": "I592_A598dup",
                "name_review": {
                  "added": true,
                  "updateTime": 1670874862854,
                  "updatedBy": "User"
                },
                "name_uuid": "9a325747-602a-4188-ad73-db7164aca7aa",
                "tumors_uuid": "4a7ba7a2-3041-4971-b198-6c87c7565d27"
              },
              "operation": "add",
              "uuids": "753b067a-2371-47dd-aff5-722c63c023e0,e094703b-28dd-45a1-a8c6-8f3f018fa030"
            }
          ],
          "timeStamp": 1671570864562
        },
        "-NLbjpr4hRb4P4Uz_wkF": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, V600K, Melanoma, STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY, 939cd40b-b515-499d-b099-fd29027c0d17 + fb2bb01c-c0ec-4641-abf7-87f486075022",
              "operation": "update",
              "uuids": "bc28ec2e-60ae-4a5d-9401-524e357b5bed"
            }
          ],
          "timeStamp": 1673556614411
        },
        "-NLbjwlXBzK2w7bXdF_P": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600 {excluding V600E ; V600K}, Melanoma, STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY, 939cd40b-b515-499d-b099-fd29027c0d17 + fb2bb01c-c0ec-4641-abf7-87f486075022",
              "operation": "update",
              "uuids": "55f1261c-2f2c-4537-aa81-92adcb798585"
            }
          ],
          "timeStamp": 1673556642728
        },
        "-NM616ngVKPPOaizWNv6": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, All Solid Tumors {excluding Colorectal Cancer}, STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY, 939cd40b-b515-499d-b099-fd29027c0d17 + fb2bb01c-c0ec-4641-abf7-87f486075022",
              "new": {
                "description": "Dabrafenib, an orally bioavailable RAF inhibitor, and trametinib, an orally bioavailable MEK1/2 inhibitor, are FDA-approved for the treatment of patients with solid tumors other than colorectal harboring BRAF V600E mutation. FDA approval was based on data from 131 adult patients with solid tumors treated with dabrafenib and trametinib in the BRF117019 and NCI-MATCH trials and 36 pediatric patients treated with dabrafenib and trametinib in the CTMT212X2101 study. Of the 131 adult patients treated with dabrafenib and trametinib, the overall response rate was 41% (54/131; 95% CI = 33-50) and of the 36 pediatric patients treated with dabrafenib and trametinib (low-grade glioma, n=34; high-grade glioma, n=2), the overall response rate was 25% (95% CI = 12-24) (PMID: 32818466, 34838156, 32758030)(Abstract: Bouffet et al. Abstract# LGG-49, Neuro-Oncology 2020. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715318/). The results from the randomized, Phase II study of dabrafenib and trametinib in 110 patients with BRAF V600–mutant pediatric low-grade glioma (dabrafenib + trametinib treatment, n=37; carboplatin + vincristine treatment, n=37), the overall response rate was 47% (95% CI, 35%-59%) with dabrafenib and trametinib and 11% (95% CI, 3%-25%) with carboplatin and vincristine, and the progression-free survival was 20.1 months (95% CI, 12.8 mo-not estimable) with dabrafenib and trametinib and 7.4 months (95% CI, 3.6-11.8 mo) with carboplatin and vincristine (Abstract: Bouffet et al. Abstract# LBA2002, ASCO 2022. https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.17_suppl.LBA2002). Approval was supported by results in COMBI-d, COMBI-v and BRF113928 studies in melanoma and lung cancer (PMID: 23020132, 25399551, 27283860)."
              },
              "old": {
                "description": "Dabrafenib, an orally bioavailable RAF inhibitor, and trametinib, an orally bioavailable MEK1/2 inhibitor, are FDA-approved for the treatment of patients with solid tumors other than colorectal harboring BRAF V600E mutation. FDA-approval was based on data from 131 adult patients with solid tumors treated with dabrafenib and trametinib in the BRF117019 and NCI-MATCH trials and 36 pediatric patients treated with dabrafenib and trametinib in the CTMT212X2101 study. Of the 131 adult patients treated with dabrafenib and trametinib, the overall response rate was 41% (54/131; 95% CI = 33-50) and of the 36 pediatric patients treated with dabrafenib and trametinib (low grade glioma, n=34; high grade glioma, n=2), the overall response rate was 25% (95% CI = 12-24) (PMID: 32818466, 34838156, 32758030)(Abstract: Bouffet et al. Abstract# LGG-49, Neuro-Oncology 2020. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715318/). Approval was supported by results in COMBI-d, COMBI-v and BRF113928 studies in melanoma and lung cancer (PMID: 23020132, 25399551, 27283860)."
              },
              "operation": "update",
              "uuids": "6d039136-d681-4915-a342-16e424f5e42c"
            }
          ],
          "timeStamp": 1674081500257
        },
        "-NMf2Yrz-DjfRzDCa5IS": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "L485W",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF L485W mutation is located in the kinase domain of the protein. This mutation has been identified in bladder adenocarcinoma and is a statistically significant hotspot (PMID: 28481359). In vitro studies with Ba/F3 and MCF10A cells expressing BRAF L485W demonstrate the mutation is activating as measured by increased transformation ability compared to wildtype (PMID: 29533785). BRAF L485W is suggested to be sensitive to ERK1/2 kinase inhibitor ulixertinib as measured by a gallbladder cancer patient harboring the mutation having a year-long complete response to treatment (PMID: 29247021).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674685817352,
                    "updatedBy": "User"
                  },
                  "description_uuid": "b224e328-e0bf-4300-9a7b-6eaa6bc9bb59",
                  "effect": "Likely Gain-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1674592280312,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "8322f1de-86af-4e6f-8a96-b05f246d1b16",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1674592279629,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "62fd5ccd-0491-4148-af9e-48bbc95dfd01",
                  "short": ""
                },
                "mutation_effect_uuid": "5d428b3a-626b-460c-8ad6-8b92cb4f5269",
                "name": "L485W",
                "name_review": {
                  "added": true,
                  "updateTime": 1674592276657,
                  "updatedBy": "User"
                },
                "name_uuid": "ed087287-7ae6-4267-91d9-73d75de6f2f6",
                "tumors_uuid": "5cd4bdf5-7cf9-4b22-8467-49b7eb4d93ed"
              },
              "operation": "add",
              "uuids": "62fd5ccd-0491-4148-af9e-48bbc95dfd01,8322f1de-86af-4e6f-8a96-b05f246d1b16"
            }
          ],
          "timeStamp": 1674685857229
        },
        "-NMocGcrF0Uf6_SQDYTp": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "D594A, Mutation Effect",
              "new": {
                "description": "The class III hypoactivating exon 15 BRAF D594A missense mutation occurs in the kinase domain of the protein and renders BRAF kinase-dead (or with “lower than wildtype kinase activity”) (PMID: 20141835, 28783719). This mutation has been recurrently found in melanoma, lung and colorectal cancers (PMID: 20141835, 28481359). Biological characterization of the BRAF D594A mutation has demonstrated that it is RAS dependent in its activation of the MAPK pathway, signals as a dimer with CRAF, and typically co-occurs with another driver mechanism that amplifies RAS signaling (PMID: 20141835, 28783719). Thus, when BRAF D594A is observed in melanoma, it typically co-occurs with an activating RAS mutation or NF1 inactivation, whereas when observed in non-small cell lung or colorectal cancers, it is associated with receptor tyrosine kinase (RTK) hyperactivation at the protein level (PMID: 28783719, 20141835). While this mutation is sensitive to MEK inhibition by targeted inhibitors such as trametinib, it is insensitive to RAF monomer inhibitors such as vemurafenib."
              },
              "old": {
                "description": "The class III hypoactivating (PMID: 28783719) exon 15 BRAF D594A missense mutation occurs in the kinase domain of the protein and renders BRAF kinase-dead (or with “lower than wildtype kinase activity”) (PMID: 20141835, 28783719). This mutation has been recurrently found in melanoma, lung and colorectal cancers (PMID: 20141835, 28481359). Biological characterization of the BRAF D594A mutation has demonstrated that it is RAS dependent in its activation of the MAPK pathway, signals as a dimer with CRAF, and typically co-occurs with another driver mechanism that amplifies RAS signaling (PMID: 20141835, 28783719). Thus, when BRAF D594A is observed in melanoma, it typically co-occurs with an activating RAS mutation or NF1 inactivation, whereas when observed in non-small cell lung or colorectal cancers, it is associated with receptor tyrosine kinase (RTK) hyperactivation at the protein level (PMID: 28783719, 20141835). While this mutation is sensitive to MEK inhibition by targeted inhibitors such as trametinib, it is insensitive to RAF monomer inhibitors such as vemurafenib."
              },
              "operation": "update",
              "uuids": "d8ab8fe1-4049-418a-8beb-1bcf5c7c0adb"
            }
          ],
          "timeStamp": 1674846476765
        },
        "-NMocNR6m6NzNTmYzH-3": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G466V, Mutation Effect",
              "new": {
                "description": "The class III hypoactivating exon 11 BRAF G466V missense mutation occurs in the kinase domain of the protein and renders BRAF kinase-dead (or with “lower than wildtype kinase activity”) (PMID: 15035987, 28783719). This mutation has been reported in melanomas, lung and colorectal cancers, and in cardio-facio-cutaneous syndrome (PMID: 28481359, 15046639, 26498038, 16439621, 22649091). Biological characterization of the BRAF G466V mutation has demonstrated that it is RAS dependent in its activation of the MAPK pathway, signals as a dimer with CRAF, and typically co-occurs with another driver mechanism that amplifies RAS signaling (PMID: 15035987, 26498038, 22649091, 16364920, 24202393, 28783719). Thus, when BRAF G466V is observed in melanoma, it typically co-occurs with an activating RAS mutation or NF1 inactivation, whereas when observed in non-small cell lung or colorectal cancers, it is associated with receptor tyrosine kinase (RTK) hyperactivation at the protein level (PMID: 28783719). While this mutation is sensitive to MEK inhibition by targeted inhibitors such as trametinib, it is insensitive to RAF monomer inhibitors such as vemurafenib."
              },
              "old": {
                "description": "The class III hypoactivating (PMID: 28783719) exon 11 BRAF G466V missense mutation occurs in the kinase domain of the protein and renders BRAF kinase-dead (or with “lower than wildtype kinase activity”) (PMID: 15035987, 28783719). This mutation has been reported in melanomas, lung and colorectal cancers, and in cardio-facio-cutaneous syndrome (PMID: 28481359, 15046639, 26498038, 16439621, 22649091). Biological characterization of the BRAF G466V mutation has demonstrated that it is RAS dependent in its activation of the MAPK pathway, signals as a dimer with CRAF, and typically co-occurs with another driver mechanism that amplifies RAS signaling (PMID: 15035987, 26498038, 22649091, 16364920, 24202393, 28783719). Thus, when BRAF G466V is observed in melanoma, it typically co-occurs with an activating RAS mutation or NF1 inactivation, whereas when observed in non-small cell lung or colorectal cancers, it is associated with receptor tyrosine kinase (RTK) hyperactivation at the protein level (PMID: 28783719). While this mutation is sensitive to MEK inhibition by targeted inhibitors such as trametinib, it is insensitive to RAF monomer inhibitors such as vemurafenib."
              },
              "operation": "update",
              "uuids": "4bd4a259-ff20-48b2-aa59-8d1202991f65"
            }
          ],
          "timeStamp": 1674846504621
        },
        "-NMocUELa9NTbh4xB7b-": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G466E, Mutation Effect",
              "new": {
                "description": "The class III hypoactivating exon 11 BRAF G466E missense mutation occurs in the kinase domain of the protein and renders BRAF kinase-dead (or with “lower than wildtype kinase activity”) (PMID: 15035987, 28783719). This mutation has been reported in melanomas, lung and colorectal cancers, and in chronic myelomonocytic leukemia (PMID: 28481359, 15046639, 27790118, 24446311). Biological characterization of the BRAF G466E mutation has demonstrated that it is RAS dependent in its activation of the MAPK pathway, signals as a dimer with CRAF, and typically co-occurs with another driver mechanism that amplifies RAS signaling (PMID: 15035987, 15046639, 28783719). Thus, when BRAF G466E is observed in melanoma, it typically co-occurs with an activating RAS mutation or NF1 inactivation, whereas when observed in non-small cell lung or colorectal cancers, it is associated with receptor tyrosine kinase (RTK) hyperactivation at the protein level (PMID: 28783719). While this mutation is sensitive to MEK inhibition by targeted inhibitors such as trametinib, it is insensitive to RAF monomer inhibitors such as vemurafenib."
              },
              "old": {
                "description": "The class III hypoactivating (PMID: 28783719) exon 11 BRAF G466E missense mutation occurs in the kinase domain of the protein and renders BRAF kinase-dead (or with “lower than wildtype kinase activity”) (PMID: 15035987, 28783719). This mutation has been reported in melanomas, lung and colorectal cancers, and in chronic myelomonocytic leukemia (PMID: 28481359, 15046639, 27790118, 24446311). Biological characterization of the BRAF G466E mutation has demonstrated that it is RAS dependent in its activation of the MAPK pathway, signals as a dimer with CRAF, and typically co-occurs with another driver mechanism that amplifies RAS signaling (PMID: 15035987, 15046639, 28783719). Thus, when BRAF G466E is observed in melanoma, it typically co-occurs with an activating RAS mutation or NF1 inactivation, whereas when observed in non-small cell lung or colorectal cancers, it is associated with receptor tyrosine kinase (RTK) hyperactivation at the protein level (PMID: 28783719). While this mutation is sensitive to MEK inhibition by targeted inhibitors such as trametinib, it is insensitive to RAF monomer inhibitors such as vemurafenib."
              },
              "operation": "update",
              "uuids": "09553532-91a2-47fb-9468-ff505476c94e"
            }
          ],
          "timeStamp": 1674846532476
        },
        "-NMoca1IMns39e2qLLzX": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "D594N, Mutation Effect",
              "new": {
                "description": "The class III hypoactivating exon 15 BRAF D594N missense mutation occurs in the kinase domain of the BRAF protein and renders BRAF kinase-dead (or with “lower than wildtype kinase activity”) (PMID: 28783719). This mutation has been found in non-small cell lung cancer and melanoma (PMID: 22798288, 23833300, 26498038, 28783719) (Abstract: Noeparast et al. Abstract# 11091, ASCO 2015. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/11091). Biological characterization of the BRAF D594N mutation has demonstrated that it is RAS dependent in its activation of the MAPK pathway, signals as a dimer with CRAF, and typically co-occurs with another driver mechanism that amplifies RAS signaling (PMID: 28783719, 26498038). Thus, when BRAF D594N is observed in melanoma, it typically co-occurs with an activating RAS mutation or NF1 inactivation, whereas when observed in non-small cell lung or colorectal cancers, it is associated with receptor tyrosine kinase (RTK) hyperactivation at the protein level (PMID: 28783719). While this mutation is sensitive to MEK inhibition by targeted inhibitors such as trametinib, it is insensitive to RAF monomer inhibitors such as vemurafenib (PMID: 28783719)."
              },
              "old": {
                "description": "The class III hypoactivating (PMID: 28783719) exon 15 BRAF D594N missense mutation occurs in the kinase domain of the BRAF protein and renders BRAF kinase-dead (or with “lower than wildtype kinase activity”) (PMID: 28783719). This mutation has been found in non-small cell lung cancer and melanoma (PMID: 22798288, 23833300, 26498038, 28783719) (Abstract: Noeparast et al. Abstract# 11091, ASCO 2015. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/11091). Biological characterization of the BRAF D594N mutation has demonstrated that it is RAS dependent in its activation of the MAPK pathway, signals as a dimer with CRAF, and typically co-occurs with another driver mechanism that amplifies RAS signaling (PMID: 28783719, 26498038). Thus, when BRAF D594N is observed in melanoma, it typically co-occurs with an activating RAS mutation or NF1 inactivation, whereas when observed in non-small cell lung or colorectal cancers, it is associated with receptor tyrosine kinase (RTK) hyperactivation at the protein level (PMID: 28783719). While this mutation is sensitive to MEK inhibition by targeted inhibitors such as trametinib, it is insensitive to RAF monomer inhibitors such as vemurafenib (PMID: 28783719)."
              },
              "operation": "update",
              "uuids": "b0ec34c2-01be-4bd8-96db-5aea6eb0706c"
            }
          ],
          "timeStamp": 1674846560313
        },
        "-NMocgo2YkYyN1faAYX3": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "D594H, Mutation Effect",
              "new": {
                "description": "The class III and hypoactivating BRAF D594H missense mutation occurs in the kinase domain in exon 15 of the protein and renders BRAF kinase-dead (or with “lower than wildtype kinase activity”) (PMID: 28783719). Substitutions at the D594 position in the BRAF protein kinase has been reported in melanoma, lung and colorectal cancers (PMID: 28481359). Biological characterization of the BRAF D594H mutation has demonstrated that it is RAS dependent in its activation of the MAPK pathway, signals as a dimer with CRAF, and typically co-occurs with another driver mechanism that amplifies RAS signaling (PMID: 28783719). While this mutation is sensitive to MEK inhibition by targeted inhibitors such as trametinib, it is insensitive to RAF monomer inhibitors such as vemurafenib. Thus, when BRAF D594H is observed in melanoma, it typically co-occurs with an activating RAS mutation or NF1 inactivation, whereas when observed in non-small cell lung or colorectal cancers, it is associated with receptor tyrosine kinase (RTK) hyperactivation at the protein level (PMID: 28783719)."
              },
              "old": {
                "description": "The class III and hypoactivating (PMID: 28783719)BRAF D594H missense mutation occurs in the kinase domain in exon 15 of the protein and renders BRAF kinase-dead (or with “lower than wildtype kinase activity”) (PMID: 28783719). Substitutions at the D594 position in the BRAF protein kinase has been reported in melanoma, lung and colorectal cancers (PMID: 28481359). Biological characterization of the BRAF D594H mutation has demonstrated that it is RAS dependent in its activation of the MAPK pathway, signals as a dimer with CRAF, and typically co-occurs with another driver mechanism that amplifies RAS signaling (PMID: 28783719). While this mutation is sensitive to MEK inhibition by targeted inhibitors such as trametinib, it is insensitive to RAF monomer inhibitors such as vemurafenib. Thus, when BRAF D594H is observed in melanoma, it typically co-occurs with an activating RAS mutation or NF1 inactivation, whereas when observed in non-small cell lung or colorectal cancers, it is associated with receptor tyrosine kinase (RTK) hyperactivation at the protein level (PMID: 28783719)."
              },
              "operation": "update",
              "uuids": "be6acfec-a41a-46ca-b9ce-e79a9b7ee84a"
            }
          ],
          "timeStamp": 1674846588073
        },
        "-NMocnoNrVbkD3uhJAwC": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G469V, Mutation Effect",
              "new": {
                "description": "The class II (PMID: 28783719) hyperactivating (PMID: 26343582) exon 11 BRAF G469V missense mutation is located in the kinase domain (G loop) of the BRAF protein, and has been reported in non-small cell lung cancer (NSCLC) (PMID: 25870796, 27388325) and in bladder cancer (PMID: 23401075). Biological characterization of the BRAF G469V mutation demonstrated that it activates the downstream MAPK pathway independently of RAS (PMID: 26343582, 28783719), renders BRAF active as a dimer with CRAF and itself (PMID: 20179705, 26343582) and while sensitive to MEK inhibition by targeted inhibitors such as trametinib (PMID: 28783719, 18794803), is insensitive to RAF monomer inhibitors such as vemurafenib (PMID: 28783719, 26343582, 20179705)."
              },
              "old": {
                "description": "The class II (PMID: 28783719) hyperactivating (PMID: 26343582) exon 11 BRAF G469V missense mutation is located in the kinase domain (G loop) of the BRAF protein, and has been reported in non small cell lung cancer (NSCLC) (PMID: 25870796, 27388325) and in bladder cancer (PMID: 23401075). Biological characterization of the BRAF G469V mutation demonstrated that it activates the downstream MAPK pathway independently of RAS (PMID: 26343582, 28783719), renders BRAF active as a dimer with CRAF and itself (PMID: 20179705, 26343582) and while sensitive to MEK inhibition by targeted inhibitors such as trametinib (PMID: 28783719, 18794803), is insensitive to RAF monomer inhibitors such as vemurafenib (PMID: 28783719, 26343582, 20179705)."
              },
              "operation": "update",
              "uuids": "94fe5461-1eb2-432a-9b78-a2e7d2e26cb7"
            }
          ],
          "timeStamp": 1674846616766
        },
        "-NMocucsgNd-bt4FeVaP": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G469R, Mutation Effect",
              "new": {
                "description": "The class II (PMID: 28783719) hyperactivating (PMID: 26343582) exon 11 BRAF G469R missense mutation is located in the kinase domain (G loop) of the BRAF protein, and has been reported in non-small cell lung cancer (NSCLC) (PMID: 26498038), chronic lymphocytic leukemia (CLL) (PMID: 24920063), melanoma, and a range of other cancer types (PMID: 16096377, 26150740, 26619011). Biological characterization of the BRAF G469R mutation demonstrated that it activates the downstream MAPK pathway independent of RAS (PMID: 26343582, 28783719), renders BRAF active as a dimer with CRAF and itself (PMID: 26343582, 20179705) and while sensitive to MEK inhibition by targeted inhibitors such as trametinib (PMID: 26343582, 28783719, 18794803), is insensitive to RAF monomer inhibitors such as vemurafenib (PMID: 26343582, 28783719)."
              },
              "old": {
                "description": "The class II (PMID: 28783719) hyperactivating (PMID: 26343582) exon 11 BRAF G469R missense mutation is located in the kinase domain (G loop) of the BRAF protein, and has been reported in non small cell lung cancer (NSCLC) (PMID: 26498038), chronic lymphocytic leukemia (CLL) (PMID: 24920063), melanoma, and a range of other cancer types (PMID: 16096377, 26150740, 26619011). Biological characterization of the BRAF G469R mutation demonstrated that it activates the downstream MAPK pathway independent of RAS (PMID: 26343582, 28783719), renders BRAF active as a dimer with CRAF and itself (PMID: 26343582, 20179705) and while sensitive to MEK inhibition by targeted inhibitors such as trametinib (PMID: 26343582, 28783719, 18794803), is insensitive to RAF monomer inhibitors such as vemurafenib (PMID: 26343582, 28783719)."
              },
              "operation": "update",
              "uuids": "75cc7602-ac02-434e-89b6-5551765ba3a5"
            }
          ],
          "timeStamp": 1674846644702
        },
        "-NMod0VkJ6qOH-sFQLpV": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G469A, Mutation Effect",
              "new": {
                "description": "The class II (PMID: 28783719) hyperactivating (PMID: 26343582) exon 11 BRAF G469A missense mutation is located in the kinase domain (G loop) of the BRAF protein, and has been reported in melanoma (PMID: 12068308), non-small cell lung cancer (NSCLC) (PMID: 23833300), as well as in cardio-facio-cutaneous syndrome (CFC) (PMID: 16439621). Biological characterization of BRAF G469A mutation demonstrated that it activates downstream MAPK pathway independently of RAS (PMID: 12068308, 23833300, 26343582), renders BRAF active as a dimer with CRAF and itself (PMID: 20179705, 22510884), and while sensitive to MEK inhibition by targeted inhibitors such as trametinib (PMID: 28783719, 26343582, 18794803), is insensitive to RAF monomer inhibitors such as vemurafenib (PMID: 28783719, 26343582, 20179705). Ectopic expression of BRAF G469A in drug-sensitive EGFR-mutant cells conferred resistance to EGFR TKIs that was overcome by addition of a MEK inhibitor (PMID: 22773810)."
              },
              "old": {
                "description": "The class II (PMID: 28783719) hyperactivating (PMID: 26343582) exon 11 BRAF G469A missense mutation is located in the kinase domain (G loop) of the BRAF protein, and has been reported in melanoma (PMID: 12068308), non small cell lung cancer (NSCLC) (PMID: 23833300), as well as in cardio-facio-cutaneous syndrome (CFC) (PMID: 16439621). Biological characterization of BRAF G469A mutation demonstrated that it activates downstream MAPK pathway independently of RAS (PMID: 12068308, 23833300, 26343582), renders BRAF active as a dimer with CRAF and itself (PMID: 20179705, 22510884), and while sensitive to MEK inhibition by targeted inhibitors such as trametinib (PMID: 28783719, 26343582, 18794803), is insensitive to RAF monomer inhibitors such as vemurafenib (PMID: 28783719, 26343582, 20179705). Ectopic expression of BRAF G469A in drug-sensitive EGFR-mutant cells conferred resistance to EGFR TKIs that was overcome by addition of a MEK inhibitor (PMID: 22773810)."
              },
              "operation": "update",
              "uuids": "ab9c04c7-415e-41da-93cd-82cbb6ce102c"
            }
          ],
          "timeStamp": 1674846672854
        },
        "-NN3COdaIfIr4PKxfSEi": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V459L, Mutation Effect",
              "new": {
                "description": "The class III hypoactivating exon 6 BRAF V459L missense mutation occurs in the cysteine-rich domain of the protein (PMID: 28783719). This mutation has been reported in lung cancer and melanoma (PMID: 12460918). BRAF V459L signals as a dimer with CRAF, is RAS-dependent in its activation of the MAPK pathway, and, in tumors, would typically co-occur with another driver mechanism that amplifies RAS signaling (PMID: 28783719). Thus, like other class III BRAF mutants, in melanoma, the V459L variant would be expected to co-occur with activating RAS mutation or NF1 inactivation, whereas in non-small cell lung and colorectal cancers, this mutation would most likely be associated with receptor tyrosine kinase (RTK) hyperactivation at the protein level (PMID: 28783719). While this mutation is sensitive to MEK inhibition by targeted inhibitors such as trametinib, it is insensitive to RAF monomer inhibitors such as vemurafenib."
              },
              "old": {
                "description": "The class III hypoactivating (PMID: 28783719) exon 6 BRAF V459L missense mutation occurs in the cysteine-rich domain of the protein, and it has been reported in lung cancer and melanoma (PMID: 12460918). BRAF V459L signals as a dimer with CRAF, is RAS-dependent in its activation of the MAPK pathway, and, in tumors, would typically co-occur with another driver mechanism that amplifies RAS signaling (PMID: 28783719). Thus, like other class III BRAF mutants, in melanoma, the V459L variant would be expected to co-occur with activating RAS mutation or NF1 inactivation, whereas in non-small cell lung and colorectal cancers, this mutation would most likely be associated with receptor tyrosine kinase (RTK) hyperactivation at the protein level (PMID: 28783719). While this mutation is sensitive to MEK inhibition by targeted inhibitors such as trametinib, it is insensitive to RAF monomer inhibitors such as vemurafenib."
              },
              "operation": "update",
              "uuids": "74cb3e73-70a1-43c1-bb48-50a77184ce71"
            }
          ],
          "timeStamp": 1675107866881
        },
        "-NNhpDzutCnObox3sZBV": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "T599_V600insEAT",
              "old": {
                "mutation_effect": {
                  "description": "The BRAF T599_V600insEAT mutation is located in the kinase domain in exon 15 of the protein. While this insertion mutation has not been functionally validated, another alteration at this position (T599_V600insV) has been shown to be gain-of-function and oncogenic (PMID: 16501605).",
                  "description_review": {
                    "updateTime": 1493057315640
                  },
                  "description_uuid": "182765f1-c415-40d7-aacf-053f85531ba2",
                  "effect": "Likely Gain-of-function",
                  "effect_review": {
                    "updateTime": 1493057315640
                  },
                  "effect_uuid": "eb665f4d-eb21-47b9-99bb-f34f4e95a3f3",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "updateTime": 1493057315640
                  },
                  "oncogenic_uuid": "f9d077c9-7ad4-4189-b87a-8f4ea00cb0a8",
                  "short": ""
                },
                "mutation_effect_uuid": "18fa6404-db47-4215-b459-d925e8572b3d",
                "name": "T599_V600insEAT",
                "name_review": {
                  "removed": true,
                  "updateTime": 1675803288075,
                  "updatedBy": "User"
                },
                "name_uuid": "06b16ea8-70a1-4040-afbb-05e81812d2c0"
              },
              "operation": "delete"
            }
          ],
          "timeStamp": 1675806174953
        },
        "-NNhpKruCwVAhdBa3Ps_": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "K601_S602delinsNT",
              "old": {
                "mutation_effect": {
                  "description": "A single case-report reports that a 42-year old patient with advanced lung cancer positive for coincident BRAF V600E and K601_W604del mutations responded to treatment with combination RAF inhibitor dabrafenib and MEK inhibitor trametinib therapy (Abstract: Shimizu, J et al. JTO. Abstract# EP1.14-44.https://www.sciencedirect.com/science/article/pii/S1556086419330126?via%3Dihub). This response is may due to the presence of the mutant V600E allele alone and there is no functional evidence characterizing the K601_W604del mutation, making the impact of the indel inconclusive with this evidence alone.",
                  "description_review": {
                    "updateTime": 1581364016397,
                    "updatedBy": "User"
                  },
                  "description_uuid": "f79bd54f-747e-4a96-b16b-2b1f24b9389d",
                  "effect": "Inconclusive",
                  "effect_review": {
                    "updateTime": 1581363602065,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "13dad237-c80e-4fff-89e6-818cb4608308",
                  "oncogenic": "Inconclusive",
                  "oncogenic_review": {
                    "updateTime": 1581363599623,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "0fbe6ead-5372-44d4-863f-ed47394b1266",
                  "short": ""
                },
                "mutation_effect_uuid": "7c53138b-86ad-4935-9049-82517200ed60",
                "name": "K601_W604del",
                "name_review": {
                  "updateTime": 1581363512811,
                  "updatedBy": "User"
                },
                "name_uuid": "0aba5c3c-6f70-421f-947b-8aa834e19c7c",
                "tumors_uuid": "c1a47d18-47c3-479c-af68-7ef16db5e935"
              },
              "operation": "delete"
            }
          ],
          "timeStamp": 1675806203113
        },
        "-NNhpRayiigcLlZEGez0": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "T599_V600insETT",
              "old": {
                "mutation_effect": {
                  "description": "The BRAF V600_K601delinsE mutation is located in the kinase domain in exon 15 of the protein (PMID: 23833300). This mutation has been found in non-small cell lung cancer (NSCLC) (PMID: 23833300). Expression of this mutation in NIH-3T3 cells demonstrated that it is activating as measured by increased kinase activity, downstream ERK activation and increased colony formation compared to wildtype BRAF (PMID: 23833300). In a case report, a 63-year old woman with stage IV Non-small cell lung cancer harboring the V600_K601delinsE BRAF mutation had progressive disease upon treatment with vemurafenib (PMID: 26045855). In a second case report, a patient with BRAF V600_K601delinsE-mutant melanoma had a partial response to the combination of BRAF, MEK and CDK4/6 inhibition (PMID: 28800030).",
                  "description_review": {
                    "updateTime": 1620262820505,
                    "updatedBy": "User"
                  },
                  "description_uuid": "e28ef383-10de-4240-b5100-8ed20e1f0e3d",
                  "effect": "Gain-of-function",
                  "effect_review": {
                    "updateTime": 1493057315640
                  },
                  "effect_uuid": "b6334102-f074-4b27-adbc-7ac7494a8036",
                  "oncogenic": "Yes",
                  "oncogenic_review": {
                    "updateTime": 1493057315640
                  },
                  "oncogenic_uuid": "f0714f3e-fb74-426c-9bbb-950e5ebc6250",
                  "short": ""
                },
                "mutation_effect_uuid": "b3e93428-895d-403b-92b5-c64c9a9a9580",
                "name": "V600_K601delinsE",
                "name_review": {
                  "updateTime": 1493057315640
                },
                "name_uuid": "d792d671-b0af-478e-8de3-97c0eec70442"
              },
              "operation": "delete"
            }
          ],
          "timeStamp": 1675806230701
        },
        "-NNhpcLhaHgLpf7Ejim-": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "N581Y, Mutation Effect",
              "new": {
                "description": "The BRAF N581Y mutation is located in the kinase domain of BRAF in exon 13. This noncanonical BRAF mutation has been identified in a screen of colorectal cell lines and in a patient with melanoma (PMID: 19474002, 26084293). While this mutation has not been functionally characterized, another substitution at this position (e.g., N581S) has been shown to be likely activating and likely oncogenic (PMID: 15035987). The HT-55 colon cancer cell line harboring this mutation was insensitive to treatment with the GDC-0879 RAF kinase inhibitor (PMID: 19276360).",
                "effect": "Inconclusive",
                "oncogenic": "Inconclusive"
              },
              "old": {
                "description": "The BRAF N581Y mutation is located in the kinase domain of BRAF in exon 13. This noncanonical BRAF mutation was identified in a screen of colorectal cell lines (PMID: 19474002), and has also been identified in a patient with melanoma (PMID: 26084293). While this mutation has not been functionally characterized, another substitution at this position (e.g., N581S) has been shown to be likely activating and likely oncogenic (PMID: 15035987). The HT-55 colon cancer cell line harboring this mutation was insensitive to treatment with the GDC-0879 RAF kinase inhibitor (PMID: 19276360).",
                "effect": "Likely Gain-of-function",
                "oncogenic": "Likely"
              },
              "operation": "update",
              "uuids": "c4f7d30f-8184-4ffb-bf52-768f6c3cb365,96dc7292-f9e2-4308-ac25-83ebc2eae671"
            }
          ],
          "timeStamp": 1675806278812
        },
        "-NNhuAWRRX7JOcxdG6Ci": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "L485_Q494del, Mutation Effect",
              "new": {
                "effect": "Inconclusive",
                "oncogenic": "Inconclusive"
              },
              "old": {
                "effect": "Likely Gain-of-function",
                "oncogenic": "Likely"
              },
              "operation": "update",
              "uuids": "9a46e5bd-4749-4733-afde-592265f17157,9b3aa240-60ed-4132-8cb3-b6122d96703a"
            }
          ],
          "timeStamp": 1675807471438
        },
        "-NNhuHpEYb7oskAjoSof": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V487_P492delinsA, Mutation Effect",
              "new": {
                "effect": "Inconclusive",
                "oncogenic": "Inconclusive"
              },
              "old": {
                "effect": "Likely Gain-of-function",
                "oncogenic": "Likely"
              },
              "operation": "update",
              "uuids": "d4da6583-0755-4b4c-a0a9-88cdd924ae26,ab4e90a9-8fdf-480f-9078-717b7eae8560"
            }
          ],
          "timeStamp": 1675807501377
        },
        "-NNhuPB3DVyjULa1Te57": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "L485_P490delinsY, Mutation Effect",
              "new": {
                "effect": "Inconclusive",
                "oncogenic": "Inconclusive"
              },
              "old": {
                "effect": "Likely Gain-of-function",
                "oncogenic": "Likely"
              },
              "operation": "update",
              "uuids": "46020abb-e172-4a09-90ee-6cedc0a7e4e7,43ac21b6-f89c-4d26-9582-a4afa9412a21"
            }
          ],
          "timeStamp": 1675807531510
        },
        "-NNsNl4TGHiSZX-BUi6c": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "T599_V600insETT",
              "old": {
                "mutation_effect": {
                  "description": "The BRAF T599_V600insETT mutation is located in the kinase domain in exon 15 of the protein. While this insertion mutation has not been functionally validated, another insertion at this position (T599_V600insV) has been shown to be gain-of-function and oncogenic (PMID: 16501605).",
                  "description_review": {
                    "updateTime": 1493057315640
                  },
                  "description_uuid": "66aa58de-4a92-4f83-917d-cb907e573bb0",
                  "effect": "Likely Gain-of-function",
                  "effect_review": {
                    "updateTime": 1493057315640
                  },
                  "effect_uuid": "647de2e0-f50d-4ef3-ac83-e88937c385c5",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "updateTime": 1493057315640
                  },
                  "oncogenic_uuid": "08b12c70-9b2c-4225-9940-7cb6fb61b75a",
                  "short": ""
                },
                "mutation_effect_uuid": "5465ef7a-6b3f-4212-8908-81ce37546fff",
                "name": "T599_V600insETT",
                "name_review": {
                  "removed": true,
                  "updateTime": 1675861209352,
                  "updatedBy": "User"
                },
                "name_uuid": "5d97e03d-57de-47f5-a74f-4fa7a54bac92"
              },
              "operation": "delete"
            }
          ],
          "timeStamp": 1675983261950
        },
        "-NNsNptH-cldjimY-Zv9": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "K601_S602delinsNT",
              "old": {
                "mutation_effect": {
                  "description": "The BRAF V600_K601delinsE mutation is located in the kinase domain in exon 15 of the protein. This mutation has been found in cutaneous melanoma (PMID: 28481359). While this insertion mutation has not been functionally validated, another alteration at this position (BRAF V600_K601delinsE) is activating in NIH-3T3 cells as measured by increased kinase activity, downstream ERK activation and increased colony formation compared to wildtype BRAF (PMID: 23833300).",
                  "description_review": {
                    "updateTime": 1565548747066,
                    "updatedBy": "User"
                  },
                  "description_uuid": "945f1b29-1d2e-4f9b-bb2f-1de43b572214",
                  "effect": "Likely Gain-of-function",
                  "effect_review": {
                    "updateTime": 1565548749467,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "c0c8b6d2-9835-447c-97ae-ca2af2bdc09f",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "updateTime": 1565547813819,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "39187b6d-6026-4c10-97b6-68eef0344894",
                  "short": ""
                },
                "mutation_effect_uuid": "9660c4ce-d2d0-4774-9622-378723526e7b",
                "name": "K601_S602delinsNT",
                "name_review": {
                  "removed": true,
                  "updateTime": 1675861238340,
                  "updatedBy": "User"
                },
                "name_uuid": "097364ff-b225-4836-823d-db061518cdb7",
                "tumors_uuid": "e16dfeb7-031f-421a-80af-4e771876c467"
              },
              "operation": "delete"
            }
          ],
          "timeStamp": 1675983281651
        },
        "-NNsOL1pC6A6gzE1QqgP": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "N581T",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF N581T mutation is located in the kinase domain of the protein. This mutation has been identified in diffuse large B-cell lymphoma and is a statistically significant hotspot (PMID: 32187361). In vitro studies with Ba/F3 and MCF10A cells expressing BRAF N581T demonstrate that the mutation is likely neutral as measured by cell viability and proliferation comparable to wildtype (PMID: 29533785).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675806333088,
                    "updatedBy": "User"
                  },
                  "description_uuid": "d5807543-7617-4176-93a7-5c61ba561702",
                  "effect": "Likely Neutral",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675288765875,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "7d9ab560-2699-413a-9758-d8faab353cd4",
                  "oncogenic": "Likely Neutral",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675288764573,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "3c8deca4-ab8f-4724-8503-d513c1d9080b",
                  "short": ""
                },
                "mutation_effect_uuid": "b6e55808-7f54-4f95-ad43-bc8007ad0ff4",
                "name": "N581T",
                "name_review": {
                  "added": true,
                  "updateTime": 1675288753659,
                  "updatedBy": "User"
                },
                "name_uuid": "123b070a-e042-481d-85f0-768e46f129fc",
                "tumors_uuid": "f8c056b6-09f2-4734-90bc-50fa83f81a7a"
              },
              "operation": "add",
              "uuids": "3c8deca4-ab8f-4724-8503-d513c1d9080b,7d9ab560-2699-413a-9758-d8faab353cd4"
            }
          ],
          "timeStamp": 1675983413334
        },
        "-NNsOSbqJE96IMZjFYmP": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G596S",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF G596S mutation is located in the kinase domain of the protein and is a statistically significant hotspot. In vitro studies with Ba/F3 cells expressing BRAF G596S demonstrate that the mutation is activating as measured by increased transformation ability compared to wildtype (PMID: 29533785).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675983399630,
                    "updatedBy": "User"
                  },
                  "description_uuid": "ab89f477-46b0-45d2-a5ce-92f6cb32e9b8",
                  "effect": "Likely Gain-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675370387132,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "776007fd-a78b-4c5d-8aa2-4d557760ffac",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675370386593,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "19aa6810-e3ad-4768-bcd1-eb3e988abba1",
                  "short": ""
                },
                "mutation_effect_uuid": "0238d778-749e-42b2-8760-4e9091ea1e24",
                "name": "G596S",
                "name_review": {
                  "added": true,
                  "updateTime": 1675370382300,
                  "updatedBy": "User"
                },
                "name_uuid": "4e58dc67-c895-4101-85f0-de3df3e18b95",
                "tumors_uuid": "a9dcfb42-519e-4b2c-8006-cde94751c50d"
              },
              "operation": "add",
              "uuids": "19aa6810-e3ad-4768-bcd1-eb3e988abba1,776007fd-a78b-4c5d-8aa2-4d557760ffac"
            }
          ],
          "timeStamp": 1675983444375
        },
        "-NOL7XHAgoA0hsuWSWtP": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "N581D, Mutation Effect",
              "new": {
                "effect": "Likely Neutral",
                "oncogenic": "Likely Neutral"
              },
              "old": {
                "effect": "Likely Gain-of-function",
                "oncogenic": "Likely"
              },
              "operation": "update",
              "uuids": "90e25372-22a3-4004-a2f9-84f2187fbcfa,102f2a9d-2991-464a-984f-13df8d99e510"
            }
          ],
          "timeStamp": 1676482323606
        },
        "-NOL7ddaMvq06Ma6776O": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G469S",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF G469S mutation is located in the kinase domain of the protein. This mutation has been identified in malignant melanoma and is a statistically significant hotspot (PMID: 16096377). In vitro studies with HEK293T cells expressing BRAF G469S demonstrate that the mutation is activating as measured by increased phosphorylated MEK and ERK levels compared to wildtype (PMID: 28947956).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675288479713,
                    "updatedBy": "User"
                  },
                  "description_uuid": "f7f594ff-d138-4bb6-9de7-f0bbca6d6a5e",
                  "effect": "Likely Gain-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675288478448,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "926f93dc-c93f-42cb-b07d-fef65da7985a",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675288477683,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "888eef19-2da3-4810-94b0-5f2e48293460",
                  "short": ""
                },
                "mutation_effect_uuid": "59769101-a2d3-4486-8439-96bf94040f33",
                "name": "G469S",
                "name_review": {
                  "added": true,
                  "updateTime": 1675288469670,
                  "updatedBy": "User"
                },
                "name_uuid": "4b24f966-60b9-4557-b51b-5203d5b24ecc",
                "tumors_uuid": "0f2a3b93-9ca0-4208-b03b-ccb4b436db15"
              },
              "operation": "add",
              "uuids": "888eef19-2da3-4810-94b0-5f2e48293460,926f93dc-c93f-42cb-b07d-fef65da7985a"
            }
          ],
          "timeStamp": 1676482353777
        },
        "-NOv7iHZAmEVLPcCGuxA": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Melanoma, STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY, 939cd40b-b515-499d-b099-fd29027c0d17",
              "new": {
                "description": "Dabrafenib is an orally bioavailable RAF inhibitor that is FDA-approved for use in patients with BRAF V600E- and V600K-mutant metastatic melanoma. FDA approval is based on the randomized Phase III trial in which dabrafenib (150 mg orally twice daily) was compared with dacarbazine (1000 mg/m2 intravenously every three weeks) in 250 patients with BRAF V600E-mutated metastatic melanoma. Dabrafenib was associated with improved progression-free survival (median 5.1 months vs. 2.7 months with dacarbazine; hazard ratio = 0.30, p<0.0001) (PMID: 22735384). Dabrafenib may also be effective against brain metastases, as demonstrated by a Phase II trial in which approximately 40% of previously untreated and 30% of previously treated patients experienced an overall intracranial response and a separate trial in which nine out of ten patients had a reduction in the size of their brain metastases (PMID: 23051966, 22608338)."
              },
              "old": {
                "description": "Dabrafenib is an orally bioavailable RAF inhibitor that is FDA-approved for use in patients with BRAF V600E/K-mutant metastatic melanoma. FDA-approval is based on the randomized Phase III trial in which dabrafenib (150 mg orally twice daily) was compared with dacarbazine (1000 mg/m2 intravenously every 3 weeks) in 250 patients with BRAF V600E-mutated metastatic melanoma. Dabrafenib was associated with improved progression-free survival (median 5.1 months vs. 2.7 months with dacarbazine; hazard ratio = 0.30, p<0.0001) (PMID: 22735384). Dabrafenib may also be effective against brain metastases, as demonstrated by a Phase II trial in which approximately 40% of previously untreated and 30% of previously treated patients experienced an overall intracranial response and a separate trial in which nine out of ten patients had a reduction in the size of their brain metastases (PMID: 23051966, 22608338)."
              },
              "operation": "update",
              "uuids": "86887f5d-62df-429b-9968-7b73c31a9504"
            }
          ],
          "timeStamp": 1677103129550
        },
        "-NOv7p4dvLAjyauYLHPc": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Colorectal Cancer, STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY, 001e534f-3e63-432f-90a6-d1af1759e4e2 + 5fce3074-e420-4c36-9603-2423daf20118",
              "new": {
                "description": "Encorafenib, a small molecule inhibitor of RAF kinase, and cetuximab, an antibody that targets EGFR, are FDA-approved in combination for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation after prior therapy. FDA approval was based on results of the Phase III BEACON study of encorafenib + cetuximab versus triplet treatment (including a MEK1/2 inhibitor) versus chemotherapy in 665 patients with BRAF V600E-mutant colorectal cancer, in which the overall response rate (complete or partial response) was 20% (95% CI= 13-29) in the doublet arm (n=220) versus 2% (95% CI= <1%-7%) in the chemotherapy arm (n=221), with median overall survival of 8.4 months in the doublet arm (95% CI= 7.5-11.0) and 5.4 months in the control arm (95% CI= 4.8-6.6) (PMID: 31566309)."
              },
              "old": {
                "description": "Encorafenib, a small molecule inhibitor of RAF kinase, and cetuximab, an antibody that targets EGFR, are FDA-approved in combination for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation after prior therapy. FDA-approval was based on results of the Phase III BEACON study of encorafenib + cetuximab versus triplet treatment (including a MEK1/2 inhibitor) versus chemotherapy in 665 patients with BRAF V600E-mutant colorectal cancer, in which the overall response rate (complete or partial response) was 20% (95% CI= 13-29) in the doublet arm (n=220) versus 2% (95% CI= <1%-7%) in the chemotherapy arm (n=221), with median overall survival of 8.4 months in the doublet arm (95% CI= 7.5-11.0) and 5.4 months in the control arm (95% CI= 4.8-6.6) (PMID: 31566309)."
              },
              "operation": "update",
              "uuids": "5d3556f9-89b7-4be9-9fa8-69fee10f032b"
            }
          ],
          "timeStamp": 1677103157395
        },
        "-NOv7vtMJancYtQw8TVr": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Anaplastic Thyroid Cancer, STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY, 939cd40b-b515-499d-b099-fd29027c0d17 + fb2bb01c-c0ec-4641-abf7-87f486075022",
              "new": {
                "description": "Dabrafenib, an orally bioavailable RAF inhibitor, and trametinib, an orally bioavailable MEK1/2 inhibitor, are FDA-approved alone or in combination for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options. FDA approval was based on results of the Phase II study of dabrafenib combined with trametinib in patients with BRAF V600E-positive ATC in which the overall response rate in sixteen evaluable patients was 69% (11/16; 95% CI= 41%-89%)(PMID: 29072975)."
              },
              "old": {
                "description": "Dabrafenib, an orally bioavailable RAF inhibitor, and trametinib, an orally bioavailable MEK1/2 inhibitor, are FDA-approved alone or in combination for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options. FDA-approval was based on results of the Phase II study of dabrafenib combined with trametinib in patients with BRAF V600E-positive ATC in which the overall response rate in sixteen evaluable patients was 69% (11/16; 95% CI= 41%-89%)(PMID: 29072975)."
              },
              "operation": "update",
              "uuids": "87b2f23f-8d71-4664-b259-c2384202937b"
            }
          ],
          "timeStamp": 1677103185281
        },
        "-NOv81o_9-twY-VFvYYG": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Non-Small Cell Lung Cancer, STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY, 939cd40b-b515-499d-b099-fd29027c0d17 + fb2bb01c-c0ec-4641-abf7-87f486075022",
              "new": {
                "description": "Dabrafenib, an orally bioavailable RAF inhibitor, and trametinib, an orally bioavailable MEK1/2 inhibitor, are FDA-approved alone or in combination for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation. FDA approval was based on a Phase II, multicenter, non-randomized, open-label study of dabrafenib in combination with trametinib in patients with chemotherapy-pretreated, metastatic, stage IV BRAF(V600E)-mutant non-small cell lung cancer, in which 36 of 57 patients (63%) achieved overall tumor response, with two patients experiencing durable complete responses and 34 patients having durable partial responses (PMID: 27283860). In the third arm of that study, which included patients with untreated, metastatic, stage IV BRAF(V600E)-mutant non-small cell lung cancer, 23 of 26 patients (64%, 95% CI 46-79) had an overall response, with two patients (6%) having durable complete response and 21 (58%) having partial response (PMID: 28919011)."
              },
              "old": {
                "description": "Dabrafenib, an orally bioavailable RAF inhibitor, and trametinib, an orally bioavailable MEK1/2 inhibitor, are FDA-approved alone or in combination for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation. FDA-approval was based on a Phase II, multicenter, non-randomized, open-label study of dabrafenib in combination with trametinib in patients with chemotherapy-pretreated, metastatic, stage IV BRAF(V600E)-mutant non-small cell lung cancer, in which 36 of 57 patients (63%) achieved overall tumor response, with two patients experiencing durable complete responses and 34 patients having durable partial responses (PMID: 27283860). In the third arm of that study, which included patients with untreated, metastatic, stage IV BRAF(V600E)-mutant non-small cell lung cancer, 23 of 26 patients (64%, 95% CI 46-79) had an overall response, with two patients (6%) having durable complete response and 21 (58%) having partial response (PMID: 28919011)."
              },
              "operation": "update",
              "uuids": "c63b34cb-c1fa-4784-c031-98566ad048bb"
            }
          ],
          "timeStamp": 1677103213647
        },
        "-NOv88eG2skpjDW8-6kL": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Melanoma, STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY, 4e91da20-6cf0-4e07-995f-7f7db4c7c077",
              "new": {
                "description": "Vemurafenib is an orally available kinse inhibitor of V600-mutant BRAF that is FDA-approved for treatment of patients with unresectable or metastatic melanoma with the BRAF V600E mutation. Vemurafenib has been shown to have nearly equivalent activity against melanomas with BRAF V600E and V600K mutations (PMID: 24508103). In a randomized Phase III trial comparing vemurafenib (960 mg orally twice daily) with dacarbazine (1000 mg/m2 i.v. every 3 weeks) for treatment-naive, metastatic, BRAF V600E-mutant melanoma, vemurafenib was associated with better overall survival (median survival 13.6 months vs. 9.7 months; hazard ratio 0.70, p=.0008) and longer median progression-free survival (6.9 months vs. 1.6 months) (PMID: 24508103). Final overall survival data from the BRIM-3 study showed that the survival advantage of vemurafenib over dacarbazine persisted through the 4-year landmark, with survival rates for vemurafenib and dacarbazine at the 4-year landmark being 17.0% and 15.6%, respectively (PMID: 28961848). However, a trial evaluating clinical outcomes in patients with melanoma treated with either combination therapy of dabrafenib and trametinib compared to those treated with vemurafenib monotherapy demonstrated improved survival outcomes in the combination-therapy group compared to the vemurafenib group (PMID: 25399551)."
              },
              "old": {
                "description": "Vemurafenib is an inhibitor of V600-mutant BRAF that is FDA-approved for treatment of patients with unresectable or metastatic melanoma with the BRAF V600E mutation. Vemurafenib has been shown to have nearly equivalent activity against melanomas with BRAF V600E and V600K mutations (PMID: 24508103). In a randomized Phase III trial comparing vemurafenib (960 mg orally twice daily) with dacarbazine (1000 mg/m2 i.v. every 3 weeks) for treatment-naive, metastatic, BRAF V600E-mutant melanoma, vemurafenib was associated with better overall survival (median survival 13.6 months vs. 9.7 months; hazard ratio 0.70 p=.0008) and longer median progression-free survival (6.9 months vs. 1.6 months) (PMID: 24508103). Final overall survival data from the BRIM-3 study showed that the survival advantage of vemurafenib over dacarbazine persisted through the 4-year landmark, with survival rates for vemurafenib and dacarbazine at the 4-year landmark being 17.0% and 15.6%, respectively (PMID: 28961848). However, a trial evaluating clinical outcomes in patients with melanoma treated with either combination therapy of dabrafenib and trametinib compared to those treated with vemurafenib monotherapy demonstrated improved survival outcomes in the combination-therapy group compared to the vemurafenib group (PMID: 25399551)."
              },
              "operation": "update",
              "uuids": "09c8f359-ae07-4746-a2b1-2cc3d948b09f"
            }
          ],
          "timeStamp": 1677103241659
        },
        "-NOv8FWICwyvEq16iCne": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Diffuse Glioma, STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY, 4e91da20-6cf0-4e07-995f-7f7db4c7c077 + eb357145-3b18-4aca-b75a-5e18dd2bf4f9",
              "new": {
                "description": "The RAF inhibitor vemurafenib in combination with the MEK inhibitor cobimetinib is FDA-approved for patients with BRAF V600E-positive melanoma, non-small cell lung cancer, and anaplastic thyroid cancer, and is NCCN-listed for patients with low-grade glioma, anaplastic glioma, and glioblastoma. Patients with various glioma subtypes harboring BRAF V600E mutations have shown responses to RAF and MEK inhibition. Three out of five patients with anaplastic astrocytoma had a response (one partial response, two stable disease) to vemurafenib monotherapy (PMID: 30351999). One patient with high-grade glioma (NOS) had stable disease in response to vemurafenib monotherapy (PMID:30351999). Four out of eight patients with glioma (NOS) had a response (one partial response, three stable disease, two progressive disease, two not evaluable) to vemurafenib monotherapy (PMID: 26287849). One patient with anaplastic oligoastrocytoma had stable disease in response to vemurafenib monotherapy (PMID: 30462564). Four of seven patients with glioblastoma multiforme had a response (one complete response, three stable disease, one progressive disease, two not evaluable) to vemurafenib monotherapy (PMID: 30351999, 24725538). Four patients with glioblastoma (including epithelioid glioblastoma) had a response (one “near-complete” response, three stable disease) to either dabrafenib monotherapy (n=2) or vemurafenib monotherapy (n=2) (PMID: 29621181, 29039591, 33117675, 34232949)."
              },
              "old": {
                "description": "The RAF inhibitor vemurafenib in combination with the MEK inhibitor cobimetinib is FDA-approved for patients with BRAF V600E-positive melanoma, non-small cell lung cancer, and anaplastic thyroid cancer, and is NCCN-listed for patients with low-grade glioma, anaplastic glioma, and glioblastoma. Patients with various glioma subtypes harboring BRAF V600E mutations have shown responses to RAF and MEK inhibition. Three out of five patients with anaplastic astrocytoma had a response (1 PR, 2 SD) to vemurafenib monotherapy (PMID:30351999). One patient with high-grade glioma (NOS) had stable disease in response to vemurafenib monotherapy (PMID:30351999). Four out of eight patients with glioma (NOS) had a response (1 PR, 3 SD, 2 PD, 2 not evaluable) to vemurafenib monotherapy (PMID: 26287849). One patient with anaplastic oligoastrocytoma had stable disease in response to vemurafenib monotherapy (PMID: 30462564). Four of seven patients with glioblastoma multiforme had a response (1 CR, 3 SD, 1 PD, 2 not evaluable) to vemurafenib monotherapy (PMID: 30351999, 24725538). Four patients with glioblastoma (including epithelioid glioblastoma) had a response (1 “near-complete” response, 3 SD) to either dabrafenib monotherapy (n=2) or vemurafenib monotherapy (n=2) (PMID: 29621181, 29039591, 33117675, 34232949)."
              },
              "operation": "update",
              "uuids": "7b50f8a8-5662-4ad0-b63a-f2a0cf2c9fee"
            }
          ],
          "timeStamp": 1677103269757
        },
        "-NOv8MIrZSPtdIEaPet1": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Pilocytic Astrocytoma, STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY, 3f154145-525b-4865-8baf-12b374697b2a",
              "new": {
                "description": "Selumetinib is a small molecule tyrosine kinase inhibitor of MEK1/2. In stratum one of the phase II PBTC study of selumetinib in 25 patients with pilocytic astrocytoma harboring a KIAA1549–BRAF fusion or BRAF V600E mutation, seven of eighteen patients with a KIAA1549–BRAF fusion had a partial response to treatment (PMID: 31151904). Additionally, the two year progression-free survival rate for the BRAF study population (n=25) was 70% (95% CI = 47–85) (PMID: 31151904)."
              },
              "old": {
                "description": "Selumetinib is a small molecule inhibitor of MEK1/2 kinases. In Stratum 1 of the phase 2 PBTC study of selumetinib in twenty five patients with pilocytic astrocytoma harboring a KIAA1549–BRAF fusion or BRAF V600E mutation, two of seven patients with a BRAF V600E mutation had a partial response to treatment (PMID: 31151904). Additionally, the two year progression-free survival rate for the BRAF study population (n=25) was 70% (95% CI 47–85) (PMID: 31151904)."
              },
              "operation": "update",
              "uuids": "9ae514fa-cea6-4a01-9f6e-ae9ca1a43049"
            }
          ],
          "timeStamp": 1677103297569
        },
        "-NOv8T8Qgbib1o-VfF84": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Ganglioglioma, Pilocytic Astrocytoma, Pleomorphic Xanthoastrocytoma, STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY, 4e91da20-6cf0-4e07-995f-7f7db4c7c077 + eb357145-3b18-4aca-b75a-5e18dd2bf4f9",
              "new": {
                "description": "The RAF inhibitor vemurafenib in combination with the MEK inhibitor cobimetinib is FDA-approved for patients with melanoma, non-small cell lung cancer, and anaplastic thyroid cancer, and is NCCN-compendium listed as recommended treatment of central nervous system cancers such as pilocytic astrocytoma, pleomorphic xanthoastrocytoma (PXA) and ganglioglioma. In a case series of two patients with BRAF V600E-mutant PXA, combination treatment of dabrafenib with trametinib led to partial responses by RANO criteria in both patients (PMID: 28984141). In a case report of a sixteen-year-old female with BRAF V600E-mutant anaplastic ganglioglioma, dabrafenib and trametinib in combination led to a significant response that was maintained at least six months after treatment initiation (PMID: 29380516). In a separate case report of a 28-year-old man with BRAF V600E-mutant anaplastic ganglioglioma, combination treatment of vemurafenib and cobimetinib led to a complete response after three months, with no evidence of recurrence after sixteen months of treatment (PMID: 30120137)."
              },
              "old": {
                "description": "The combination of a BRAF inhibitor, such as vemurafenib, and a MEK1/2 inhibitor, such as cobimetinib, is FDA-approved in melanoma and is NCCN-compendium listed as recommended treatment of CNS cancers such as pilocytic astrocytoma, pleomorphic xanthoastrocytoma (PXA) and ganglioglioma. In a case series of two patients with BRAF V600E-mutant PXA, combination treatment of dabrafenib with trametinib led to partial responses by RANO criteria in both patients (PMID: 28984141). In a case report of a 16-year-old female with BRAF V600E-mutant anaplastic ganglioglioma, dabrafenib and trametinib in combination led to a significant response that was maintained at least six months after treatment initiation (PMID: 29380516). In a separate case report of a 28-year-old man with BRAF V600E-mutant anaplastic ganglioglioma, combination treatment of vemurafenib and cobimetinib led to a complete response after three months, with no evidence of recurrence after sixteen months of treatment (PMID: 30120137)."
              },
              "operation": "update",
              "uuids": "7f76d72e-ec85-4f42-91fe-b247dbe0e0e9"
            }
          ],
          "timeStamp": 1677103325573
        },
        "-NOv8ZyA1ua0o_nKQ-DB": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Hairy Cell Leukemia, STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY, 4e91da20-6cf0-4e07-995f-7f7db4c7c077",
              "new": {
                "description": "Vemurafenib is an orally available kinse inhibitor of V600-mutant BRAF that is FDA-approved for treatment of patients with various BRAF V600-harboring tumors, including melanoma and Edheim-Chester Disease (ECD). Vemurafenib is listed as a 2A therapeutic in the NCCN guidelines for Hairy Cell Leukemia (HCL) based on data from two Phase II trials. In one study of vemurafenib in patients with BRAF V600E-mutant HCL (n=24), the overall response rate was 100%, with 42% of patients (10 of 24) having complete responses, with a response duration of 11.7 months and one year progression free and overall survival rates of 73% and 91%, repectively (PMID: 26352686). In another study of vemurafenib in patients with BRAF V600E-mutant HCL (n=26), the overall response rate was 96%, with 35% of patients (9 of 26) having complete responses (PMID: 26352686)."
              },
              "old": {
                "description": "Vemurafenib is an inhibitor of V600-mutant BRAF that is FDA-approved for treatment of patients with various BRAF V600-harboring tumors, including melanoma and Edheim-Chester Disease (ECD). Vemurafenib is listed as a 2A therapeutic in the NCCN guidelines for Hairy Cell Leukemia (HCL) based on data from two Phase II trials. In one study of vemurafenib in patients with BRAF V600E-mutant HCL (n=24), the overall response rate was 100%, with 42% of patients (10 of 24) having complete responses, with a response duration of 11.7 months and one year progression free and overall survival rates of 73% and 91%, repectively (PMID: 26352686). In another study of vemurafenib in patients with BRAF V600E-mutant HCL (n=26), the overall response rate was 96%, with 35% of patients (9 of 26) having complete responses (PMID: 26352686)."
              },
              "operation": "update",
              "uuids": "4e56b02d-394e-4397-9465-a3cc2c5026cd"
            }
          ],
          "timeStamp": 1677103353525
        },
        "-NOv8fpVfivL-IS4xRNK": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Colorectal Cancer, STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY, 001e534f-3e63-432f-90a6-d1af1759e4e2 + d7b1d12a-e942-4801-bb64-916c9bdfaaf3",
              "new": {
                "description": "Encorafenib, a small molecule inhibitor of RAF kinase, and panitumumab, an antibody that targets EGFR, are NCCN-compendium listed in combination as level 2A therapy for patients with BRAF V600E-positive colorectal cancer. In the Phase III BEACON study of encorafenib + cetuximab, another EGFR antibody, versus triplet treatment (including a MEK1/2 inhibitor) versus chemotherapy in 665 patients with BRAF V600E-mutant colorectal cancer, the overall response rate (complete or partial response) was 20% (95% CI= 13-29) in the doublet arm (n=220) versus 2% (95% CI= <1%-7%) in the chemotherapy arm (n=221), with median overall survival of 8.4 months in the doublet arm (95% CI= 7.5-11.0) and 5.4 months in the control arm (95% CI= 4.8-6.6) (PMID: 31566309). Panitumumab has also been used in doublet and triplet combination therapy, with a response rate in one study of 26% (PMID: 29431699)."
              },
              "old": {
                "description": "Encorafenib, a small molecule inhibitor of RAF kinase, and panitumumab, an antibody that targets EGFR, are NCCN-compendium listed as level 2A therapy for patients with BRAF V600E-positive colorectal cancer. In the Phase III BEACON study of encorafenib + cetuximab, another EGFR antibody, versus triplet treatment (including a MEK1/2 inhibitor) versus chemotherapy in 665 patients with BRAF V600E-mutant colorectal cancer, the overall response rate (complete or partial response) was 20% (95% CI= 13-29) in the doublet arm (n=220) versus 2% (95% CI= <1%-7%) in the chemotherapy arm (n=221), with median overall survival of 8.4 months in the doublet arm (95% CI= 7.5-11.0) and 5.4 months in the control arm (95% CI= 4.8-6.6) (PMID: 31566309). Panitumumab has also been used in doublet and triplet combination therapy, with a response rate in one study of 26% (PMID: 29431699)."
              },
              "operation": "update",
              "uuids": "d9b444f3-76b2-4f91-a919-8b8b4d853846"
            }
          ],
          "timeStamp": 1677103381642
        },
        "-NOv8nA-TGLhtJy9SQri": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600, Melanoma, STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY, 4e91da20-6cf0-4e07-995f-7f7db4c7c077 + 9a54c73a-15d8-41a8-8ea0-730f874831da + eb357145-3b18-4aca-b75a-5e18dd2bf4f9",
              "new": {
                "description": "The combination of vemurafenib, an inhibitor of V600-mutant BRAF, and cobimetinib, an inhibitor of MEK1/2, with atezolizumab, an immunotherapeutic PD-L1 antibody, is FDA-approved for patients with BRAF V600 mutation-positive unresectable or metastatic melanoma. FDA approval was based on the results of the Phase III double-blind, randomized, placebo-controlled IMspire150 trial of Atezolizumab + Cobimetinib + Vemurafenib versus Placebo + Cobimetinib + Vemurafenib in 514 patients with BRAF V600-mutant melanoma in which the median progression-free survival was 15.1 mos (95% CI=11.4,18.4) in the triplet arm versus 10.6 mos (95% CI=9.3,12.7) in the doublet + placebo arm (HR=0.78; 95% CI= 0.63, 0.97; p=0.0249) (PMID: 32534646)."
              },
              "old": {
                "description": "The combination of vemurafenib, an inhibitor of V600-mutant BRAF, and cobimetinib, an inhibitor of MEK1/2, with atezolizumab, an immunotherapeutic PD-L1 antibody, is FDA approved for patients with BRAF V600 mutation-positive unresectable or metastatic melanoma. FDA-approval was based on the results of the Phase III double-blind, randomized, placebo-controlled IMspire150 trial of Atezolizumab + Cobimetinib + Vemurafenib versus Placebo + Cobimetinib + Vemurafenib in 514 patients with BRAF V600-mutant melanoma in which the median progression-free survival was 15.1 mos (95% CI=11.4, 18.4) in the triplet arm versus 10.6 mos (95% CI=9.3, 12.7) in the doublet + placebo arm (HR=0.78; 95% CI= 0.63, 0.97; p=0.0249) (PMID: 32534646)."
              },
              "operation": "update",
              "uuids": "2e0a9edd-9248-4da3-b5f8-acdfe19039d6"
            }
          ],
          "timeStamp": 1677103411690
        },
        "-NOv8u1y2UrcUaTTWVjx": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600, Langerhans Cell Histiocytosis, STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY, 4e91da20-6cf0-4e07-995f-7f7db4c7c077, 939cd40b-b515-499d-b099-fd29027c0d17",
              "new": {
                "description": "Vemurafenib and dabrafenib, inhibitors of BRAF V600E that are FDA-approved for patients with BRAF V600E or V600K mutant positive melanoma, are NCCN-listed for patients with Langerhans Cell Histiocytosis (LCH) harboring BRAF V600E mutations. NCCN recommendation is based on the Phase II VE BASKET study of vemurafenib in patients with BRAF V600E-mutant cancer in which four of four patients with LCH harboring BRAF V600E mutations had partial response to vemurafenib treatment (PMID: 29188284)."
              },
              "old": {
                "description": "Vemurafenib and Dabrafenib, inhibitors of BRAF V600E that are FDA-approved for patients with BRAF V600E or V600K mutant positive melanoma, are NCCN-listed for patients with Langerhans Cell Histiocytosis (LCH). NCCN recommendation is based on the Phase II VE BASKET study of vemurafenib in patients with BRAF V600E-mutant cancer in which four of four patients with LCH harboring BRAF V600E mutations had partial response to vemurafenib treatment (PMID: 29188284)."
              },
              "operation": "update",
              "uuids": "a0a7271e-c46e-43b8-8f85-7e1418192d6c"
            }
          ],
          "timeStamp": 1677103439848
        },
        "-NOv9-qGW-AxZGPEfWAQ": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600, Erdheim-Chester Disease, STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY, 4e91da20-6cf0-4e07-995f-7f7db4c7c077",
              "new": {
                "description": "Vemurafenib is an orally available kinse inhibitor of V600-mutant BRAF that is FDA-approved for treatment of patients with Edheim-Chester Disease (ECD) harboring BRAF V600-mutations. FDA approval was based on the open-label, nonrandomized, multicohort VE-BASKET clinical trial of vemurafenib in BRAF V600E-mutant non-melanoma cancers in which 26 evaluable patients (ECD, n=22; LCH, n=4 ) achieved stable disease or better, and the confirmed overall response rate in ECD was 54.5% (12/22; 95% CI= 32.2-75.6%). Median progression-free survival and overall survival were not reached at study completion with a median follow-up of 28.8 months (PMID: 29188284, 26287849)."
              },
              "old": {
                "description": "Vemurafenib is an inhibitor of V600-mutant BRAF that is FDA-approved for treatment of patients with Edheim-Chester Disease (ECD) harboring BRAF V600-mutations. FDA-approval was based on the open-label, nonrandomized, multicohort VE-BASKET clinical trial of vemurafenib in BRAF V600E-mutant non-melanoma cancers in which 26 evaluable patients (22 with ECD and 4 with Langerhans cell histiocytosis) achieved stable disease or better and the confirmed overall response rate in ECD was 54.5% (12/22; 95% CI, 32.2-75.6%). Median progression-free survival and overall survival were not reached at study completion with a median follow-up of 28.8 months (PMID: 29188284, 26287849)."
              },
              "operation": "update",
              "uuids": "729d93d7-aa18-4bf0-9c84-13b9ecce25fb"
            }
          ],
          "timeStamp": 1677103467707
        },
        "-NOv96dLPQNV9TBLKL77": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Biliary Tract Cancer, NOS, STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY, 939cd40b-b515-499d-b099-fd29027c0d17 + fb2bb01c-c0ec-4641-abf7-87f486075022",
              "new": {
                "description": "Dabrafenib, an orally bioavailable RAF inhibitor, and trametinib, an orally bioavailable MEK1/2 inhibitor, are FDA-approved in combination for the treatment of patients with solid tumors other than colorectal harboring BRAF V600E mutation. FDA approval was based on data from 131 adult patients with solid tumors treated with dabrafenib and trametinib in the BRF117019 and NCI-MATCH trials and 36 pediatric patients treated with dabrafenib and trametinib in the CTMT212X2101 study. Of the 131 adult patients treated with dabrafenib and trametinib, the overall response rate was 41% (54/131; 95% CI = 33-50) and of the 36 pediatric patients treated with dabrafenib and trametinib (low grade glioma, n=34; high grade glioma, n=2), the overall response rate was 25% (95% CI = 12-24) (PMID: 32818466, 34838156, 32758030)(Abstract: Bouffet et al. Abstract# LGG-49, Neuro-Oncology 2020. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715318/). Approval was supported by results in COMBI-d, COMBI-v and BRF113928 studies in melanoma and lung cancer (PMID: 23020132, 25399551, 27283860). In a Phase II, single-arm basket trial of dabrafenib + trametinib in patients with BRAF V600E-mutant solid tumors, of 43 patients with biliary tract cancer, the overall response rate was 51% (22/43, 95% CI = 36–67), the median progression-free survival was nine months (95% CI = 5-10), and the median overall survival was fourteen months (95% CI = 10-33). Of the 43 patients with biliary tract cancer, 51% of patients (22/43) had a partial response and 40% (17/43) had stable disease (PMID: 32818466). Additionally, in subprotocol H of the NCI-MATCH basket trial of dabrafenib + trametinib in patients with BRAF V600E-mutant solid tumors (N=4 patients with intrahepatic cholangiocarcinoma), the overall response rate was 100%, with 4/4 patients achieving a partial response (PMID: 32758030)."
              },
              "old": {
                "description": "Dabrafenib, an orally bioavailable RAF inhibitor, and trametinib, an orally bioavailable MEK1/2 inhibitor, are FDA-approved for the treatment of patients with solid tumors other than colorectal harboring BRAF V600E mutation. FDA-approval was based on data from 131 adult patients with solid tumors treated with dabrafenib and trametinib in the BRF117019 and NCI-MATCH trials and 36 pediatric patients treated with dabrafenib and trametinib in the CTMT212X2101 study. Of the 131 adult patients treated with dabrafenib and trametinib, the overall response rate was 41% (54/131; 95% CI = 33-50) and of the 36 pediatric patients treated with dabrafenib and trametinib (low grade glioma, n=34; high grade glioma, n=2), the overall response rate was 25% (95% CI = 12-24) (PMID: 32818466, 34838156, 32758030)(Abstract: Bouffet et al. Abstract# LGG-49, Neuro-Oncology 2020. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715318/). Approval was supported by results in COMBI-d, COMBI-v and BRF113928 studies in melanoma and lung cancer (PMID: 23020132, 25399551, 27283860). In a Phase II, single-arm basket trial of dabrafenib + trametinib in patients with BRAF V600E-mutant solid tumors, of 43 patients with biliary tract cancer, the overall response rate was 51% (22/43, 95% CI 36–67), the median progression-free survival was 9 months (95% CI 5-10), and the median overall survival was 14 months (95% CI 10-33). Of the 43 patients with biliary tract cancer, 51% of patients (22/43) had a partial response and 40% (17/43) had stable disease (PMID: 32818466). Additionally, in subprotocol H of the NCI-MATCH basket trial of dabrafenib + trametinib in patients with BRAF V600E-mutant solid tumors (N=4 patients with intrahepatic cholangiocarcinoma), the overall response rate was 100%, with 4/4 patients achieving a partial response (PMID: 32758030)."
              },
              "operation": "update",
              "uuids": "6d286407-4acf-4feb-9649-472fbb1b95fe"
            }
          ],
          "timeStamp": 1677103495552
        },
        "-NOv9DUkVnOEQ-mfQ_XM": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Encapsulated Glioma, STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY, 4e91da20-6cf0-4e07-995f-7f7db4c7c077 + eb357145-3b18-4aca-b75a-5e18dd2bf4f9",
              "new": {
                "description": "The RAF inhibitor vemurafenib in combination with the MEK inhibitor cobimetinib is FDA-approved for patients with melanoma, non-small cell lung cancer, and anaplastic thyroid cancer, and is NCCN-listed for patients with low-grade glioma, anaplastic glioma, and glioblastoma. Patients with various glioma subtypes harboring BRAF V600E mutations have shown responses to RAF and MEK inhibition. Six patients with ganglioglioma had a partial response to either vemurafenib monotherapy (n=2), vemurafenib + cobimetinib (n=1), or dabrafenib monotherapy (n=​​3)(PMID: 25524464, 31985841, 26579623, 31502039). Twelve out of thirteen patients with pleomorphic xanthoastrocytoma had a response (one complete response, one “near-complete” response, six partial response, four stable disease) to either dabrafenib + trametinib (n=2) or vemurafenib monotherapy (n=11) (PMID: 28984141, 26287849, 30351999). Three patients with anaplastic pleomorphic xanthoastrocytoma had a response (one complete response, one “near-complete” response, one partial response) to either vemurafenib monotherapy (n=1) or dabrafenib monotherapy (n=2)(PMID: 25092772, 29039591). One patient with low-grade glioma, NOS had a partial response to dabrafenib monotherapy (PMID: 27398937). Two patients with pilocytic astrocytoma had a response (one partial response, one stable disease) to vemurafenib monotherapy (PMID: 30351999). Three of four patients with anaplastic ganglioglioma had a response (one partial response, one \"significant response\", one stable disease, one not evaluable) to either dabrafenib + trametinib (n=1) or vemurafenib monotherapy (n=3)(PMID: 29380516, 30351999). One patient with pilomyxoid astrocytoma had a partial response to vemurafenib monotherapy (PMID: 24821190)."
              },
              "old": {
                "description": "The RAF inhibitor vemurafenib in combination with the MEK inhibitors cobimetinib is FDA-approved for patients with melanoma, non-small cell lung cancer, and anaplastic thyroid cancer, and is NCCN-listed for patients with low-grade glioma, anaplastic glioma, and glioblastoma. Patients with various glioma subtypes harboring BRAF V600E mutations have shown responses to RAF and MEK inhibition. Six patients with ganglioglioma had a partial response to either vemurafenib monotherapy (n=2), vemurafenib + cobimetinib (n=1), or dabrafenib monotherapy (n=​​3)(PMID: 25524464, 31985841, 26579623, 31502039). Twelve out of thirteen patients with pleomorphic xanthoastrocytoma had a response (1 CR, 1 “near-complete” response, 6 PR, 4 SD) to either dabrafenib + trametinib (n=2) or vemurafenib monotherapy (n=11) (PMID: 28984141, 26287849, 30351999). Three patients with anaplastic pleomorphic xanthoastrocytoma had a response (1 CR, 1 “near-complete” response, 1 PR) to either vemurafenib monotherapy (n=1) or dabrafenib monotherapy (n=2)(PMID: 25092772, 29039591). One patient with low-grade glioma, NOS had a partial response to dabrafenib monotherapy (PMID: 27398937). Two patients with pilocytic astrocytoma had a response (1 PR, 1 SD) to vemurafenib monotherapy (PMID: 30351999). Three of four patients with anaplastic ganglioglioma had a response (1 PR, 1 \"significant response\", 1 SD, 1 not evaluable) to either dabrafenib + trametinib (n=1) or vemurafenib monotherapy (n=3)(PMID: 29380516, 30351999). One patient with pilomyxoid astrocytoma had a partial response to vemurafenib monotherapy (PMID: 24821190)."
              },
              "operation": "update",
              "uuids": "8a864f31-163a-4868-bf67-6b1fc449a2c6"
            }
          ],
          "timeStamp": 1677103523610
        },
        "-NOv9KHumYPRxoys5wgK": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, V600K, Melanoma, STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY, 001e534f-3e63-432f-90a6-d1af1759e4e2 + feb9f4a3-e374-4c75-8a3b-0f1fbcdbf677",
              "new": {
                "description": "The combination of encorafenib, an inhibitor of V600E- or V600K-mutant BRAF, and binimetinib, an inhibitor of MEK1/2, is FDA-approved in combination for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. FDA approval was based on the results of the Phase III COLUMBUS trial of combined encorafenib plus binimetinib versus single-agent vemurafenib in 577 patients with BRAF V600E- or V600K-mutant metastatic melanoma in which the median progression-free survival was 14.9 months (95% CI = 11.0-18.5) in the encorafenib plus binimetinib group versus 7.3 months (95% CI = 5.6-8.2) in the single agent vemurafenib group (HR= 0.54, 95% CI = 0.41-0.71; p<0·0001) (PMID: 29573941). In the five-year update of the Phase III COLUMBUS trial, the progression-free survival and overall survival were 23% and 35% respectively in the encorafenib plus binimetinib group (n=192) versus 10% and 21% respectively in the single agent vemurafenib group (n=191), and the median duration of response and disease control rate were 18.6 months and 92.2% in the encorafenib plus binimetinib group versus 12.3 months and 81.2% in the single-agent vemurafenib group (PMID: 35862871)."
              },
              "old": {
                "description": "The combination of encorafenib, an inhibitor of V600E- or V600K-mutant BRAF, and binimetinib, an inhibitor of MEK1/2, is FDA approved in combination for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. FDA approval was based on the results of the Phase III COLUMBUS trial of combined encorafenib plus binimetinib versus single-agent vemurafenib in 577 patients with BRAF V600E- or V600K-mutant metastatic melanoma in which the median progression-free survival was 14.9 months (95% CI 11.0-18.5) in the encorafenib plus binimetinib group versus 7.3 months (95% CI 5.6-8.2) in the single agent vemurafenib group (HR= 0.54, 95% CI 0.41-0.71; p<0·0001) (PMID: 29573941). In the five-year update of the Phase III COLUMBUS trial, the progression-free survival and overall survival were 23% and 35% respectively in the encorafenib plus binimetinib group (n=192) versus 10% and 21% respectively in the single agent vemurafenib group (n=191), and the median duration of response and disease control rate were 18.6 months and 92.2% in the encorafenib plus binimetinib group versus 12.3 months and 81.2% in the single-agent vemurafenib group (PMID: 35862871)."
              },
              "operation": "update",
              "uuids": "b76c8407-558c-49e9-ab3c-90a181df0044"
            }
          ],
          "timeStamp": 1677103551460
        },
        "-NOv9RBBy0zA7IHUdjkT": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, V600K, Melanoma, STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY, 4e91da20-6cf0-4e07-995f-7f7db4c7c077 + eb357145-3b18-4aca-b75a-5e18dd2bf4f9",
              "new": {
                "description": "The RAF inhibitor vemurafenib in combination with the MEK inhibitor cobimetinib is FDA-approved for the treatment of patients with BRAF V600-mutant metastatic or unresectable locally advanced melanoma. FDA approval was based on results from the randomized Phase III coBRIM trial of combined vemurafenib and cobimetinib versus vemurafenib and placebo in 495 patients with metastatic BRAF V600-mutant melanoma that demonstrated superior clinical benefit measures in the combination versus the control arm. Specifically, median progression-free survival was 9.9 months in the combination arm versus 6.2 months in the control arm (HR = 0.51), with a complete response rate of 10% versus 4%, respectively, and interim nine-month overall survival of 81% versus 73%, respectively (PMID: 25265494). Follow-up analysis of the coBRIM trial showed two-year overall survival was 48.3% in the combination group versus 38.0% in the monotherapy group (PMID: 27480103), and five-year followup of the BRIM7 study showed a median overall survival of 31.8 months and a five-year survival rate of 39.2% (PMID: 31732523)."
              },
              "old": {
                "description": "The combination of vemurafenib, an inhibitor of V600-mutant BRAF, and cobimetinib, an inhibitor of MEK1/2, is FDA approved for the treatment of patients with BRAF V600-mutant metastatic or unresectable locally advanced melanoma. FDA-approval was based on results from the randomized Phase III coBRIM trial of combined vemurafenib and cobimetinib versus vemurafenib and placebo in 495 patients with metastatic BRAF V600-mutant melanoma that demonstrated superior clinical benefit measures in the combination versus the control arm. Specifically, median progression-free survival was 9.9 months in the combination arm versus 6.2 months in the control arm (HR = 0.51), with a complete response rate of 10% versus 4%, respectively, and interim 9-month overall survival of 81% versus 73%, respectively (PMID: 25265494). Follow-up analysis of the coBRIM trial showed two-year overall survival was 48.3% in the combination group versus 38.0% in the monotherapy group (PMID: 27480103), and 5-year followup of the BRIM7 study showed a median overall survival of 31.8 months and a 5-year survival rate of 39.2% (PMID: 31732523)."
              },
              "operation": "update",
              "uuids": "19caa107-e92a-4246-9d01-6d707b9ecd4e"
            }
          ],
          "timeStamp": 1677103579702
        },
        "-NOv9Y-2dygcqe_d5EZI": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, V600K, Melanoma, STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY, fb2bb01c-c0ec-4641-abf7-87f486075022",
              "new": {
                "description": "Trametinib is an oral small molecule inhibitor of MEK1/2 that is FDA-approved alone or with dabrafenib for the treatment of patients with metastatic melanoma harboring a V600E or V600K BRAF mutation. In an open-label, randomized Phase III trial, patients with BRAF V600E/K-mutated unresectable, metastatic melanoma received oral trametinib (2 mg once daily) or an intravenous regimen of either dacarbazine (1000 mg/m2) or paclitaxel (175 mg/m2) every three weeks. Trametinib demonstrated improved progression-free survival (HR for disease progression or death = 0.45) and six-month overall survival (81% vs. 67%; death HR = 0.54; p=0.01) (PMID: 22663011). However, like other MEK inhibitors, the benefit of trametinib is limited by adverse reactions, most notably grade three or four rash and diarrhea (PMID: 22663011). Trametinib is not typically used as monotherapy for patients with BRAF V600K melanoma given its lower response rate compared to BRAF inhibitors and combined BRAF and MEK inhibitors. Patients previously treated with a RAF inhibitor appear to be less likely than untreated patients to respond to trametinib treatment (PMID: 22663011), and FDA guidelines state that trametinib as a monotherapy is not indicated for these patients. Dabrafenib and trametinib are FDA-approved as a combination therapy, which has superior clinical outcomes compared to dabrafenib or trametinib monotherapy (PMID: 25399551, 25265492). Additionally, patients with melanoma treated with dabrafenib and trametinib in both the neoadjuvant and adjuvant settings had improved survival over patients given standard of care (PMID: 29361468)."
              },
              "old": {
                "description": "Trametinib is an oral small molecule inhibitor of MEK1/2 that is FDA-approved alone or with dabrafenib for the treatment of patients with metastatic melanoma harboring a V600E or V600K BRAF mutation. In an open-label, randomized, Phase III trial, patients with BRAF V600E/K-mutated unresectable, metastatic melanoma received oral trametinib (2 mg once daily) or an intravenous regimen of either dacarbazine (1000 mg/m2) or paclitaxel (175 mg/m2) every three weeks. Trametinib demonstrated improved progression-free survival (HR for disease progression or death = 0.45) and six-month overall survival (81% vs. 67%; death HR = 0.54; p=0.01) (PMID: 22663011). However, like other MEK inhibitors, the benefit of trametinib is limited by adverse reactions, most notably grade 3 or 4 rash and diarrhea (PMID: 22663011). Trametinib is not typically used as monotherapy for patients with BRAF V600K melanoma given its lower response rate compared to BRAF inhibitors and combined BRAF and MEK inhibitors. Patients previously treated with a RAF inhibitor appear to be less likely than untreated patients to respond to trametinib treatment (PMID: 22663011), and FDA guidelines state that trametinib as a monotherapy is not indicated for these patients. Dabrafenib and trametinib are FDA-approved as a combination therapy, which has superior clinical outcomes compared to dabrafenib or trametinib monotherapy (PMID: 25399551, 25265492). Additionally, patients with melanoma treated with dabrafenib and trametinib in both the neoadjuvant and adjuvant settings had improved survival over patients given standard of care (PMID: 29361468)."
              },
              "operation": "update",
              "uuids": "873eaae0-4bf1-4d6d-a312-f8ff9770f393"
            }
          ],
          "timeStamp": 1677103607597
        },
        "-NOv9dqCSwKA5-4yklc-": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, V600K, Melanoma, STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY, 939cd40b-b515-499d-b099-fd29027c0d17 + fb2bb01c-c0ec-4641-abf7-87f486075022",
              "new": {
                "description": "Dabrafenib, an orally bioavailable RAF inhibitor, and trametinib, an orally bioavailable MEK1/2 inhibitor, are FDA-approved alone or in combination for the treatment of patients with metastatic melanoma harboring a V600E or V600K BRAF mutation. FDA approval of dabrafenib in combination with trametinib was based on results from an open-label Phase III study of combination therapy versus dabrafenib monotherapy in 247 patients with metastatic melanoma who were naive to treatment with BRAF inhibitors. Combined dabrafenib and trametinib, administered in full monotherapy doses, improved the response rate in patients with BRAF V600-mutant metastatic melanoma versus dabrafenib monotherapy (67% vs.51%; p<0.002). However, median progression-free survival improved by only 2 weeks (9.3 months vs 8.8 months; HR = 0.75) compared with dabrafenib monotherapy (PMID: 23020132). Combination therapy is associated with less cutaneous toxicity than monotherapy, but systemic toxicity may be increased (PMID: 25287827, 25399551). Follow-up trials have demonstrated that all clinical measures inclusive of overall and median progression-free survival as well as objective response rates, median duration of response and number of patients with complete response favored patients treated with combination dabrafenib and trametinib, administered in full monotherapy doses, compared to either dabrafenib or vemurafenib monotherapy, including patients who previously progressed on BRAF inhibitor monotherapy (PMID: 25287827, 25399551, 25265492). Additionally, patients with melanoma treated with dabrafenib and trametinib in both the neoadjuvant and adjuvant settings have improved survival over patients given standard of care (PMID: 29361468, 28991513, 28891408). Promising clinical data has also suggested that addition of an immunotherapy agent to combination RAF and MEK inhibitor treatment may improve rate of overall response and duration of response in melanoma patients (PMID: 31171876, 31171879, 31171878)."
              },
              "old": {
                "description": "Dabrafenib, an orally bioavailable RAF inhibitor, and trametinib, an orally bioavailable MEK1/2 inhibitor, are FDA-approved alone or in combination for the treatment of patients with metastatic melanoma harboring a V600E or V600K BRAF mutation. The FDA approved the combination of dabrafenib and trametinib based on results from an open-label Phase III study of combination therapy versus dabrafenib monotherapy in 247 patients with metastatic melanoma who were naive to treatment with BRAF inhibitors. Combined dabrafenib and trametinib, administered in full monotherapy doses, improved the response rate in patients with BRAF V600-mutant metastatic melanoma versus dabrafenib monotherapy (67% vs.51%; p<0.002). However, median progression-free survival improved by only 2 weeks (9.3 months vs 8.8 months; HR = 0.75) compared with dabrafenib monotherapy (PMID: 23020132). Combination therapy is associated with less cutaneous toxicity than monotherapy, but systemic toxicity may be increased (PMID: 25287827, 25399551). Follow-up trials have demonstrated that all clinical measures inclusive of overall and median progression-free survival as well as objective response rates, median duration of response and number of patients with complete response favored patients treated with combination dabrafenib and trametinib, administered in full monotherapy doses, compared to either dabrafenib or vemurafenib monotherapy, including patients who previously progressed on BRAF inhibitor monotherapy (PMID: 25287827, 25399551, 25265492). Additionally, patients with melanoma treated with dabrafenib and trametinib in both the neoadjuvant and adjuvant settings have improved survival over patients given standard of care (PMID: 29361468, 28991513, 28891408). Promising clinical data has also suggested that addition of an immunotherapy agent to combination RAF and MEK inhibitor treatment may improve rate of overall response and duration of response in melanoma patients (PMID: 31171876, 31171879, 31171878)."
              },
              "operation": "update",
              "uuids": "bc28ec2e-60ae-4a5d-9401-524e357b5bed"
            }
          ],
          "timeStamp": 1677103635639
        },
        "-NOv9kgTiZI4ELW3Y-GT": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600, Histiocytosis, INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY, 4e91da20-6cf0-4e07-995f-7f7db4c7c077, 939cd40b-b515-499d-b099-fd29027c0d17",
              "new": {
                "description": "Vemurafenib and dabrafenib are orally available kinse inhibitors of V600-mutant BRAF that are FDA-approved for patients with unresectable or metastatic melanoma with the BRAF V600E mutation, and are NCCN-listed for patients with histiocytic neoplasms harboring BRAF V600 mutations. In a case study of a 40-year-old man with histiocytic sarcoma harboring a heterozygous BRAF V600E mutation, the patient was treated with vemurafenib and maintained both clinical and radiologic tumor responses for three months until disease progression (PMID: 25209580). In a separate case study of a 22-year-old woman with histiocytic sarcoma harboring a BRAF V600E mutation, the patient was treated with a combination of chemotherapy, antibiotics, steroids, and vemurafenib, and remained in complete remission eighteen months after treatment initiation (PMID: 31376203). An additional case study of a six-year-old child with BRAF V600E-mutant mixed systemic Rosai-Dorfman-Destombes disease and Langerhans cell histiocytosis reported sustained clinical and radiographic responses after treatment with dabrafenib prior to disease relapse at thirteen months (PMID: 31213430)."
              },
              "old": {
                "description": "Vemurafenib and dabrafenib are inhibitors of BRAF V600E that are FDA-approved for patients with unresectable or metastatic melanoma with the BRAF V600E mutation and are NCCN-listed for patients with histiocytic neoplasms harboring BRAF V600 mutations. In a case study of a 40-year-old man with histiocytic sarcoma harboring a heterozygous BRAF V600E mutation, the patient was treated with vemurafenib and maintained both clinical and radiologic tumor responses for three months until disease progression (PMID: 25209580). In a separate case study of a 22-year-old woman with histiocytic sarcoma harboring a BRAF V600E mutation, the patient was treated with a combination of chemotherapy, antibiotics, steroids, and vemurafenib and remained in complete remission eighteen months after treatment initiation (PMID: 31376203). An additional case study of a 6-year-old child with BRAF V600E-mutant mixed systemic Rosai-Dorfman-Destombes disease and Langerhans cell histiocytosis reported sustained clinical and radiographic responses after treatment with dabrafenib prior to disease relapse at thirteen months (PMID: 31213430)."
              },
              "operation": "update",
              "uuids": "ccfa69b9-f284-427a-84b5-a4ffcc5606ca"
            }
          ],
          "timeStamp": 1677103663688
        },
        "-NOv9rVLfdO5TRyCX5ai": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Fusions, Ovarian Cancer, INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY, fb2bb01c-c0ec-4641-abf7-87f486075022, eb357145-3b18-4aca-b75a-5e18dd2bf4f9",
              "new": {
                "description": "Cobimetinib and trametinib are small molecule inhibitors of the MEK1/2 kinases that are FDA-approved in combination with a RAF inhibitor for use in BRAF V600E-positive metastatic melanoma. In a study of patients with low-grade serous ovarian cancer, a patient with a CUL1-BRAF fusion who progressed on carboplatin and paclitaxel had a sustained complete response to treatment with paclitaxel and a MEK1/2 inhibitor (selumetinib) (PMID: 26324360).  Additionally, in vitro studies have demonstrated that BRAF fusions are sensitive to MEK inhibition as measured decreased downstream MAPK pathway signaling in BRAF fusion-containing cells upon treatment with trametinib (PMID: 24345920)."
              },
              "old": {
                "description": "Cobimetinib and trametinib are small molecule inhibitors of the MEK1/2 kinases that are FDA approved in combination with a RAF inhibitor for use in BRAF V600E-positive metastatic melanoma. In a study of patients with low-grade serous ovarian cancer, a patient with a CUL1-BRAF fusion who progressed on carboplatin and paclitaxel had a sustained complete response to treatment with paclitaxel and a MEK1/2 inhibitor (selumetinib) (PMID: 26324360).  Additionally, in vitro studies have demonstrated that BRAF fusions are sensitive to MEK inhibition as measured decreased downstream MAPK pathway signaling in BRAF-fusion-containing cells upon treatment with trametinib (PMID: 24345920)."
              },
              "operation": "update",
              "uuids": "e569bfd4-15f5-421d-9d4e-31dfb7a82903"
            }
          ],
          "timeStamp": 1677103691584
        },
        "-NOv9yRWW7XC2RkKCdrs": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "K601, All Solid Tumors, INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY, 44faeeae-ad6d-4370-8c99-97955f9e0feb",
              "operation": "update",
              "uuids": "690ed068-5612-438a-ac07-948a18228375"
            }
          ],
          "timeStamp": 1677103720011
        },
        "-NOvA4EdnTHgdPW6nqdc": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "K601, Melanoma, INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY, fb2bb01c-c0ec-4641-abf7-87f486075022",
              "new": {
                "description": "Trametinib is a small molecule inhibitor of the MEK1/2 kinases that is FDA-approved in combination with a RAF inhibitor for use in BRAF V600E-positive metastatic melanoma. Anecdotal evidence of clinical activity of trametinib in BRAF K601-mutant melanoma includes a patient who experienced a complete response to trametinib over 36 months (PMID: 28344857), and four patients in various other studies who achieved a partial response or stable disease upon treatment with trametinib (PMID: 23248257, 24933606). In vitro studies of cell lines engineered to express BRAF K601E demonstrated sensitivity to MEK inhibition as measured by decreased activation of downstream effector proteins upon treatment with trametinib (PMID: 22798288, 29903896)."
              },
              "old": {
                "description": "Trametinib is a small molecule inhibitor of the MEK1/2 kinases that is FDA approved in combination with a RAF inhibitor for use in BRAF V600E-positive metastatic melanoma. Anecdotal evidence of clinical activity of trametinib in BRAF K601-mutant melanoma includes a patient who experienced a complete response to trametinib over 36 months (PMID: 28344857), and four patients in various other studies who achieved a partial response or stable disease upon treatment with trametinib (PMID: 23248257, 24933606). In vitro studies of cell lines engineered to express BRAF K601E demonstrated sensitivity to MEK inhibition as measured by decreased activation of downstream effector proteins upon treatment with trametinib (PMID: 22798288, 29903896)."
              },
              "operation": "update",
              "uuids": "b17106e4-9dd3-4157-90d2-0e791c15278b"
            }
          ],
          "timeStamp": 1677103747859
        },
        "-NOvAB3W96HdgeU0DUa8": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "L597, All Solid Tumors, INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY, 44faeeae-ad6d-4370-8c99-97955f9e0feb",
              "operation": "update",
              "uuids": "1fd2d2b7-b69a-4e58-b205-81ef99c8c2e9"
            }
          ],
          "timeStamp": 1677103775819
        },
        "-NOvAHwWYJKV-A0s24XY": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "L597, Melanoma, INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY, fb2bb01c-c0ec-4641-abf7-87f486075022",
              "new": {
                "description": "Trametinib is a small molecule inhibitor of the MEK1/2 kinases that is FDA-approved in combination with a RAF inhibitor for use in BRAF V600E-positive metastatic melanoma. In a small study of trametinib in patients with non-V600E BRAF-mutated metastatic melanoma, one patient harboring a BRAF L597Q mutation achieved partial response (6.2 months) upon treatment with trametinib (PMID: 24933606). In vitro studies of cell lines engineered to express BRAF L597R or L597S mutations demonstrated sensitivity to MEK inhibition as measured by decreased activation of downstream effector proteins upon treatment with trametinib (PMID: 22798288, 29903896)."
              },
              "old": {
                "description": "Trametinib is a small molecule inhibitor of the MEK1/2 kinases that is FDA approved in combination with a RAF inhibitor for use in BRAF V600E-positive metastatic melanoma. In a small study of trametinib in patients with non-V600E BRAF-mutated metastatic melanoma, one patient harboring a BRAF L597Q mutation achieved partial response (6.2 months) upon treatment with trametinib (PMID: 24933606). In vitro studies of cell lines engineered to express BRAF L597R or L597S mutations demonstrated sensitivity to MEK inhibition as measured by decreased activation of downstream effector proteins upon treatment with trametinib (PMID: 22798288, 29903896)."
              },
              "operation": "update",
              "uuids": "af5ea563-3d74-49e1-b931-ebb6f3fdeb43"
            }
          ],
          "timeStamp": 1677103803979
        },
        "-NOvAOo3d3FYNQAGkoOZ": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Oncogenic Mutations {excluding V600}, Erdheim-Chester Disease, STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY, eb357145-3b18-4aca-b75a-5e18dd2bf4f9, fb2bb01c-c0ec-4641-abf7-87f486075022",
              "new": {
                "description": "Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and both are NCCN-listed for patients with Erdheim-Chester Disease (ECD) harboring MAPK pathway mutations. In an open-label phase II trial (NCT02649972) of cobimetinib in eighteen adult patients with histiocytoses (n = twelve patients with ECD) of any mutational status, the overall response rate was 89% (90% CI: 73–100), 100% of responses were ongoing at one year, and 94% of patients remained progression-free (PMID: 30867592)."
              },
              "old": {
                "description": "Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and both are NCCN-listed for patients with Erdheim-Chester Disease (ECD). In an open-label, phase 2 trial (NCT02649972) of cobimetinib in eighteen adult patients with histiocytoses (n = twelve patients with ECD) of any mutational status, the overall response rate was 89% (90% CI: 73–100), 100% of responses were ongoing at one year, and 94% of patients remained progression-free (PMID: 30867592)."
              },
              "operation": "update",
              "uuids": "f85c5ffd-a7dc-4769-acdc-012ff3b7ac5d"
            }
          ],
          "timeStamp": 1677103832110
        },
        "-NOvAVfTv1A5hrMpIj7V": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Oncogenic Mutations {excluding V600}, Histiocytosis, INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY, eb357145-3b18-4aca-b75a-5e18dd2bf4f9, fb2bb01c-c0ec-4641-abf7-87f486075022",
              "new": {
                "description": "Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and both are NCCN-listed for patients with histiocytic neoplasms harboring MAPK pathway mutations. In a case study of one eighteen-year-old patient with refractory histiocytic sarcoma harboring a pathogenic variant of MAP2K1 (F53L), the patient was treated with trametinib and showed an excellent response prior to treatment interruption due to severe adverse events (PMID: 30361829)."
              },
              "old": {
                "description": "Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and both are NCCN-listed for patients with histiocytic neoplasms harboring MAPK pathway mutations. In a case study of one 18-year-old patient with refractory histiocytic sarcoma harboring a pathogenic variant of MAP2K1 (F53L), the patient was treated with trametinib and showed an excellent response prior to treatment interruption due to severe adverse events (PMID: 30361829)."
              },
              "operation": "update",
              "uuids": "658a788e-390c-41c6-8081-0376b6121bb0"
            }
          ],
          "timeStamp": 1677103860232
        },
        "-NOzA4zxoOOW5KoHxXFA": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, All Solid Tumors {excluding Colorectal Cancer}, STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY, 939cd40b-b515-499d-b099-fd29027c0d17 + fb2bb01c-c0ec-4641-abf7-87f486075022",
              "new": {
                "description": "Dabrafenib, an orally bioavailable RAF inhibitor, and trametinib, an orally bioavailable MEK1/2 inhibitor, are FDA-approved in combination for the treatment of patients with solid tumors other than colorectal harboring BRAF V600E mutation. FDA approval was based on data from 131 adult patients with solid tumors treated with dabrafenib and trametinib in the BRF117019 and NCI-MATCH trials and 36 pediatric patients treated with dabrafenib and trametinib in the CTMT212X2101 study. Of the 131 adult patients treated with dabrafenib and trametinib, the overall response rate was 41% (54/131; 95% CI = 33-50) and of the 36 pediatric patients treated with dabrafenib and trametinib (low-grade glioma, n=34; high-grade glioma, n=2), the overall response rate was 25% (95% CI = 12-24) (PMID: 32818466, 34838156, 32758030)(Abstract: Bouffet et al. Abstract# LGG-49, Neuro-Oncology 2020. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715318/). In the randomized, Phase II study of dabrafenib and trametinib in 110 patients with BRAF V600–mutant pediatric low-grade glioma (dabrafenib + trametinib treatment, n=37; carboplatin + vincristine treatment, n=37), the overall response rate was 47% (95% CI= 35%-59%) with dabrafenib and trametinib and 11% (95% CI= 3%-25%) with carboplatin and vincristine, and the progression-free survival was 20.1 months (95% CI= 12.8 mo-not estimable) with dabrafenib and trametinib and 7.4 months (95% CI= 3.6-11.8 mo) with carboplatin and vincristine (Abstract: Bouffet et al. Abstract# LBA2002, ASCO 2022. https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.17_suppl.LBA2002). FDA approval was supported by results in COMBI-d, COMBI-v and BRF113928 studies in melanoma and lung cancer (PMID: 23020132, 25399551, 27283860)."
              },
              "old": {
                "description": "Dabrafenib, an orally bioavailable RAF inhibitor, and trametinib, an orally bioavailable MEK1/2 inhibitor, are FDA-approved for the treatment of patients with solid tumors other than colorectal harboring BRAF V600E mutation. FDA approval was based on data from 131 adult patients with solid tumors treated with dabrafenib and trametinib in the BRF117019 and NCI-MATCH trials and 36 pediatric patients treated with dabrafenib and trametinib in the CTMT212X2101 study. Of the 131 adult patients treated with dabrafenib and trametinib, the overall response rate was 41% (54/131; 95% CI = 33-50) and of the 36 pediatric patients treated with dabrafenib and trametinib (low-grade glioma, n=34; high-grade glioma, n=2), the overall response rate was 25% (95% CI = 12-24) (PMID: 32818466, 34838156, 32758030)(Abstract: Bouffet et al. Abstract# LGG-49, Neuro-Oncology 2020. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715318/). The results from the randomized, Phase II study of dabrafenib and trametinib in 110 patients with BRAF V600–mutant pediatric low-grade glioma (dabrafenib + trametinib treatment, n=37; carboplatin + vincristine treatment, n=37), the overall response rate was 47% (95% CI, 35%-59%) with dabrafenib and trametinib and 11% (95% CI, 3%-25%) with carboplatin and vincristine, and the progression-free survival was 20.1 months (95% CI, 12.8 mo-not estimable) with dabrafenib and trametinib and 7.4 months (95% CI, 3.6-11.8 mo) with carboplatin and vincristine (Abstract: Bouffet et al. Abstract# LBA2002, ASCO 2022. https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.17_suppl.LBA2002). Approval was supported by results in COMBI-d, COMBI-v and BRF113928 studies in melanoma and lung cancer (PMID: 23020132, 25399551, 27283860)."
              },
              "operation": "update",
              "uuids": "6d039136-d681-4915-a342-16e424f5e42c"
            }
          ],
          "timeStamp": 1677170860075
        },
        "-NOzABnGUkjTgLhGPPNd": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Oncogenic Mutations {excluding V600}, Langerhans Cell Histiocytosis, STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY, eb357145-3b18-4aca-b75a-5e18dd2bf4f9, fb2bb01c-c0ec-4641-abf7-87f486075022",
              "new": {
                "description": "Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and both are NCCN-listed for patients with Langerhans Cell Histiocytosis (LCH) harboring MAPK pathway mutations. In an open-label phase II trial (NCT02649972) of cobimetinib in eighteen adult patients with histiocytoses (n = two patients with LCH) of any mutational status, the overall response rate was 89% (90% CI: 73–100), 100% of responses were ongoing at one year, and 94% of patients remained progression-free (PMID: 30867592). In a study of three patients with LCH who were treated with trametinib, two patients harbored BRAF N486_P490del mutations, of which one had no reactivation and the other had a partial response, and the third patient with a MAP2K1 K57_G61del mutation had a complete response with no active disease after 22 months (PMID: 32991018)."
              },
              "old": {
                "description": "Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and both are NCCN-listed for patients with Langerhans Cell Histiocytosis (LCH). In an open-label, phase 2 trial (NCT02649972) of cobimetinib in eighteen adult patients with histiocytoses (n = two patients with LCH) of any mutational status, the overall response rate was 89% (90% CI: 73–100), 100% of responses were ongoing at one year, and 94% of patients remained progression-free (PMID: 30867592). In a study of three patients with LCH who were treated with trametinib, two patients harbored BRAF N486_P490del mutations, of which one had no reactivation and the other had a partial response, and the third patient with a MAP2K1 K57_G61del mutation had a complete response with no active disease after 22 months (PMID: 32991018)."
              },
              "operation": "update",
              "uuids": "a7ce9682-0287-4744-895c-69df4bb7792b"
            }
          ],
          "timeStamp": 1677170887935
        },
        "-NOzAIaMPyu9trQArz6s": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Oncogenic Mutations {excluding V600}, Histiocytosis, INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY, eb357145-3b18-4aca-b75a-5e18dd2bf4f9, fb2bb01c-c0ec-4641-abf7-87f486075022",
              "new": {
                "description": "Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and both are NCCN-listed for patients with histiocytic neoplasms harboring MAPK pathway mutations. In a case study of one eighteen-year-old patient with refractory histiocytic sarcoma harboring a pathogenic variant of MAP2K1 (F53L), the patient was treated with trametinib and showed an excellent response prior to treatment interruption due to severe adverse events (PMID: 30361829)."
              },
              "old": {
                "description": "Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and both are NCCN-listed for patients with histiocytic neoplasms harboring MAPK pathway mutations. In a case study of one 18-year-old patient with refractory histiocytic sarcoma harboring a pathogenic variant of MAP2K1 (F53L), the patient was treated with trametinib and showed an excellent response prior to treatment interruption due to severe adverse events (PMID: 30361829)."
              },
              "operation": "update",
              "uuids": "658a788e-390c-41c6-8081-0376b6121bb0"
            }
          ],
          "timeStamp": 1677170915781
        },
        "-NOzAc83IvRfA75U4q8t": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600 {excluding V600E ; V600K}, Melanoma, STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY, 939cd40b-b515-499d-b099-fd29027c0d17 + fb2bb01c-c0ec-4641-abf7-87f486075022",
              "new": {
                "description": "Dabrafenib, an orally bioavailable RAF inhibitor, and trametinib, an orally bioavailable MEK1/2 inhibitor, are FDA-approved alone or in combination for the treatment of patients with metastatic melanoma harboring a V600E or V600K BRAF mutation. FDA approval of dabrafenib in combination with trametinib was based on results from an open-label Phase III study of combination therapy versus dabrafenib monotherapy in 247 patients with metastatic melanoma who were naive to treatment with BRAF inhibitors. Combined dabrafenib and trametinib, administered in full monotherapy doses, improved the response rate in patients with BRAF V600-mutant metastatic melanoma versus dabrafenib monotherapy (67% vs.51%; p<0.002). However, median progression-free survival improved by only two weeks (9.3 months vs 8.8 months; HR = 0.75) compared with dabrafenib monotherapy (PMID: 23020132). Combination therapy is associated with less cutaneous toxicity than monotherapy, but systemic toxicity may be increased (PMID: 25287827, 25399551). Follow-up trials have demonstrated that all clinical measures inclusive of overall and median progression-free survival as well as objective response rates, median duration of response and number of patients with complete response favored patients treated with combination dabrafenib and trametinib, administered in full monotherapy doses, compared to either dabrafenib or vemurafenib monotherapy, including patients who previously progressed on BRAF inhibitor monotherapy (PMID: 25287827, 25399551, 25265492). Additionally, patients with melanoma treated with dabrafenib and trametinib in both the neoadjuvant and adjuvant settings have improved survival over patients given standard of care (PMID: 29361468, 28991513, 28891408). Promising clinical data has also suggested that addition of an immunotherapy agent to combination RAF and MEK inhibitor treatment may improve rate of overall response and duration of response in melanoma patients (PMID: 31171876, 31171879, 31171878)."
              },
              "old": {
                "description": "Dabrafenib, an orally bioavailable RAF inhibitor, and trametinib, an orally bioavailable MEK1/2 inhibitor, are FDA-approved alone or in combination for the treatment of patients with metastatic melanoma harboring a V600E or V600K BRAF mutation. The FDA approved the combination of dabrafenib and trametinib based on results from an open-label Phase III study of combination therapy versus dabrafenib monotherapy in 247 patients with metastatic melanoma who were naive to treatment with BRAF inhibitors. Combined dabrafenib and trametinib, administered in full monotherapy doses, improved the response rate in patients with BRAF V600-mutant metastatic melanoma versus dabrafenib monotherapy (67% vs.51%; p<0.002). However, median progression-free survival improved by only 2 weeks (9.3 months vs 8.8 months; HR = 0.75) compared with dabrafenib monotherapy (PMID: 23020132). Combination therapy is associated with less cutaneous toxicity than monotherapy, but systemic toxicity may be increased (PMID: 25287827, 25399551). Follow-up trials have demonstrated that all clinical measures inclusive of overall and median progression-free survival as well as objective response rates, median duration of response and number of patients with complete response favored patients treated with combination dabrafenib and trametinib, administered in full monotherapy doses, compared to either dabrafenib or vemurafenib monotherapy, including patients who previously progressed on BRAF inhibitor monotherapy (PMID: 25287827, 25399551, 25265492). Additionally, patients with melanoma treated with dabrafenib and trametinib in both the neoadjuvant and adjuvant settings have improved survival over patients given standard of care (PMID: 29361468, 28991513, 28891408). Promising clinical data has also suggested that addition of an immunotherapy agent to combination RAF and MEK inhibitor treatment may improve rate of overall response and duration of response in melanoma patients (PMID: 31171876, 31171879, 31171878)."
              },
              "operation": "update",
              "uuids": "55f1261c-2f2c-4537-aa81-92adcb798585"
            }
          ],
          "timeStamp": 1677170999832
        },
        "-NOzAiz33Edj8HrsbQsf": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600 {excluding V600E ; V600K}, Melanoma, STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY, 001e534f-3e63-432f-90a6-d1af1759e4e2 + feb9f4a3-e374-4c75-8a3b-0f1fbcdbf677",
              "new": {
                "description": "The combination of encorafenib, an inhibitor of V600E- or V600K-mutant BRAF, and binimetinib, an inhibitor of MEK1/2, is FDA-approved in combination for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. FDA approval was based on the results of the Phase III COLUMBUS trial of combined encorafenib plus binimetinib versus single agent vemurafenib in 577 patients with BRAF V600E- or V600K-mutant metastatic melanoma in which the median progression-free survival was 14.9 months (95% CI: 11.0-18.5) in the encorafenib plus binimetinib group versus 7.3 months (95% CI: 5.6-8.2) in the single agent vemurafenib group (HR= 0.54, 95% CI: 0.41-0.71; p<0·0001) (PMID: 29573941)."
              },
              "old": {
                "description": "The combination of encorafenib, an inhibitor of V600E- or V600K-mutant BRAF, and binimetinib, an inhibitor of MEK1/2, is FDA approved in combination for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation. FDA-approval was based on the results of the Phase III COLUMBUS trial of combined encorafenib plus binimetinib versus single agent vemurafenib in 577 patients with BRAF V600E- or V600K-mutant metastatic melanoma in which the median progression-free survival was 14.9 months (95% CI 11.0-18.5) in the encorafenib plus binimetinib group versus 7.3 months (95% CI 5.6-8.2) in the single agent vemurafenib group (HR= 0.54, 95% CI 0.41-0.71; p<0·0001) (PMID: 29573941)."
              },
              "operation": "update",
              "uuids": "009d1441-ac80-4048-ae01-371ac1591c33"
            }
          ],
          "timeStamp": 1677171027864
        },
        "-NOzApr8aYXUzUmrP5ro": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Oncogenic Mutations {excluding V600}, Rosai-Dorfman Disease, STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY, eb357145-3b18-4aca-b75a-5e18dd2bf4f9, fb2bb01c-c0ec-4641-abf7-87f486075022",
              "new": {
                "description": "Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and are NCCN-listed for patients with Rosai-Dorfman Disease. One adult patient with Rosai-Dorfman Disease with an activating KRAS G12R mutation was treated with cobimetinib, and a follow-up CT scan two months after treatment showed a substantial response (PMID: 29236635)."
              },
              "old": {
                "description": "Trametinib and cobimetinib are MEK1/2 kinase inhibitors that are FDA-approved for patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations and both are NCCN-listed for patients with Rosai-Dorfman Disease. One adult patient with Rosai-Dorfman Disease with an activating KRAS G12R mutation was treated with cobimetinib and a follow-up CT scan two months after treatment showed a substantial response (PMID: 29236635)."
              },
              "operation": "update",
              "uuids": "6680f049-0c87-41fb-a234-09c1a2361419"
            }
          ],
          "timeStamp": 1677171056029
        },
        "-NOzAwmO7WaMRfS4uGH_": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Fusions, Pilocytic Astrocytoma, STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY, 3f154145-525b-4865-8baf-12b374697b2a",
              "new": {
                "description": "Selumetinib is a small molecule tyrosine kinase inhibitor of MEK1/2. In stratum one of the phase II PBTC study of selumetinib in 25 patients with pilocytic astrocytoma harboring a KIAA1549–BRAF fusion or BRAF V600E mutation, seven of eighteen patients with a KIAA1549–BRAF fusion had a partial response to treatment (PMID: 31151904). Additionally, the two year progression-free survival rate for the BRAF study population (n=25) was 70% (95% CI = 47–85) (PMID: 31151904)."
              },
              "old": {
                "description": "Selumetinib is a small molecule inhibitor of MEK1/2 kinases. In Stratum 1 of the phase 2 PBTC study of selumetinib in twenty five patients with pilocytic astrocytoma harboring a KIAA1549–BRAF fusion or BRAF V600E mutation, seven of eighteen patients with a KIAA1549–BRAF fusion had a partial response to treatment (PMID: 31151904). Additionally, the two year progression-free survival rate for the BRAF study population (n=25) was 70% (95% CI 47–85) (PMID: 31151904)."
              },
              "operation": "update",
              "uuids": "a05f8f2e-5d26-4639-9c10-019b8183fc33"
            }
          ],
          "timeStamp": 1677171084397
        },
        "-NOzB2nr7rE_H_gB5bO2": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Fusions, Melanoma, INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY, fb2bb01c-c0ec-4641-abf7-87f486075022, eb357145-3b18-4aca-b75a-5e18dd2bf4f9",
              "new": {
                "description": "Cobimetinib and trametinib are small molecule inhibitors of the MEK1/2 kinases that are FDA-approved in combination with a RAF inhibitor for use in BRAF V600E-positive metastatic melanoma. Two studies from independent groups have shown that three patients with BRAF-fusion positive metastatic melanoma experienced clinical benefit, such as improvement of ECOG status, tumor shrinkage, or stable disease upon treatment with the MEK inhibitor trametinib (PMID: 26314551, 26072686). In vitro studies have demonstrated that BRAF fusions are sensitive to MEK inhibition as measured by decreased downstream MAPK pathway signaling in BRAF fusion-containing cells upon treatment with trametinib (PMID: 24345920)."
              },
              "old": {
                "description": "Cobimetinib and trametinib are small molecule inhibitors of the MEK1/2 kinases that are FDA approved in combination with a RAF inhibitor for use in BRAF V600E-positive metastatic melanoma. Two studies from independent groups have shown that three patients with BRAF-fusion positive metastatic melanoma experienced clinical benefit, such as improvement of ECOG status, tumor shrinkage or stable disease, upon treatment with the MEK inhibitor trametinib (PMID: 26314551, 26072686). In vitro studies have demonstrated that BRAF fusions are sensitive to MEK inhibition as measured decreased downstream MAPK pathway signaling in BRAF-fusion-containing cells upon treatment with trametinib (PMID: 24345920)."
              },
              "operation": "update",
              "uuids": "cec96519-6479-4b9e-9d89-42e3b2a2bc94"
            }
          ],
          "timeStamp": 1677171113163
        },
        "-NOzBa9PSXkLcPrpHRi4": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600 {excluding V600E ; V600K}, Melanoma, STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY, 4e91da20-6cf0-4e07-995f-7f7db4c7c077 + eb357145-3b18-4aca-b75a-5e18dd2bf4f9",
              "new": {
                "description": "The combination of vemurafenib, an orally available kinse inhibitor of V600-mutant BRAF, and cobimetinib, an orally available kinase inhibitor of MEK1/2, is FDA-approved for the treatment of patients with BRAF V600-mutant metastatic or unresectable locally advanced melanoma. FDA approval was based on results from the randomized Phase III coBRIM trial of combined vemurafenib and cobimetinib versus vemurafenib and placebo in 495 patients with metastatic BRAF V600-mutant melanoma that demonstrated superior clinical benefit measures in the combination versus the control arm. Specifically, median progression-free survival was 9.9 months in the combination arm versus 6.2 months in the control arm (HR = 0.51), with a complete response rate of 10% versus 4%, respectively, and interim nine-month overall survival of 81% versus 73%, respectively (PMID: 25265494). Follow-up analysis of the coBRIM trial showed two-year overall survival was 48.3% in the combination group versus 38.0% in the monotherapy group (PMID: 27480103)."
              },
              "old": {
                "description": "The combination of vemurafenib, an inhibitor of V600-mutant BRAF, and cobimetinib, an inhibitor of MEK1/2, is FDA approved for the treatment of patients with BRAF V600-mutant metastatic or unresectable locally advanced melanoma. FDA-approval was based on results from the randomized Phase III coBRIM trial of combined vemurafenib and cobimetinib versus vemurafenib and placebo in 495 patients with metastatic BRAF V600-mutant melanoma that demonstrated superior clinical benefit measures in the combination versus the control arm. Specifically, median progression-free survival was 9.9 months in the combination arm versus 6.2 months in the control arm (HR = 0.51), with a complete response rate of 10% versus 4%, respectively, and interim 9-month overall survival of 81% versus 73%, respectively (PMID: 25265494). Follow-up analysis of the coBRIM trial showed two-year overall survival was 48.3% in the combination group versus 38.0% in the monotherapy group (PMID: 27480103)."
              },
              "operation": "update",
              "uuids": "f9aaeb93-ca4e-49cc-8424-792f49ce9006"
            }
          ],
          "timeStamp": 1677171253870
        },
        "-NPtTtUknbG_ZIwvzVP5": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "D594A, Mutation Effect",
              "new": {
                "description": "The class III BRAF D594A mutation is located in the kinase domain in exon 15 of the protein (PMID: 20141835, 28783719). This mutation has been recurrently found in melanoma, lung and colorectal cancers (PMID: 20141835, 28481359). Biological characterization of the BRAF D594A mutation has demonstrated that it is RAS dependent in its activation of the MAPK pathway, signals as a dimer with CRAF, and typically co-occurs with another driver mechanism that amplifies RAS signaling (PMID: 20141835, 28783719). Thus, when BRAF D594A is observed in melanoma, it typically co-occurs with an activating RAS mutation or NF1 inactivation, whereas when observed in non-small cell lung or colorectal cancers, it is associated with receptor tyrosine kinase (RTK) hyperactivation at the protein level (PMID: 28783719, 20141835). While this mutation is sensitive to MEK inhibition by targeted inhibitors such as trametinib, it is insensitive to RAF monomer inhibitors such as vemurafenib (PMID: 28783719)."
              },
              "old": {
                "description": "The class III hypoactivating exon 15 BRAF D594A missense mutation occurs in the kinase domain of the protein and renders BRAF kinase-dead (or with “lower than wildtype kinase activity”) (PMID: 20141835, 28783719). This mutation has been recurrently found in melanoma, lung and colorectal cancers (PMID: 20141835, 28481359). Biological characterization of the BRAF D594A mutation has demonstrated that it is RAS dependent in its activation of the MAPK pathway, signals as a dimer with CRAF, and typically co-occurs with another driver mechanism that amplifies RAS signaling (PMID: 20141835, 28783719). Thus, when BRAF D594A is observed in melanoma, it typically co-occurs with an activating RAS mutation or NF1 inactivation, whereas when observed in non-small cell lung or colorectal cancers, it is associated with receptor tyrosine kinase (RTK) hyperactivation at the protein level (PMID: 28783719, 20141835). While this mutation is sensitive to MEK inhibition by targeted inhibitors such as trametinib, it is insensitive to RAF monomer inhibitors such as vemurafenib."
              },
              "operation": "update",
              "uuids": "d8ab8fe1-4049-418a-8beb-1bcf5c7c0adb"
            }
          ],
          "timeStamp": 1678149130226
        },
        "-NPtU-ZXrMv3vllocZ_-": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "D594E, Mutation Effect",
              "new": {
                "description": "The class III BRAF D594E mutation is located in the kinase domain in exon 15 of the protein. This mutation has been found in non-small cell lung cancer and diffuse large B-cell lymphoma (PMID: 28947956, 32877514). In vivo studies with conditional knock-in mice expressing BRAF D594 demonstrate that the mutation activates the MAPK pathway through CRAF (PMID: 20978199). Expression of BRAF D594E in HEK293 cells demonstrated that it is activating as measured by increased downstream ERK signaling compared to wildtype BRAF (PMID: 28947956). In vitro studies have suggested that this mutation is resistant to dabrafenib, as measured by increased MAPK pathway activation upon drug treatment, but sensitive to trametinib, as measured by decreased MAPK pathway activation upon drug treatment (PMID: 28947956). As BRAF D594E is a kinase-dead mutation, it is suggested to be insensitive to treatment with vemurafenib (PMID: 28026870)."
              },
              "old": {
                "description": "The BRAF D594E mutation is located in the kinase domain in exon 15 of the protein. This mutation has been found in non-small cell lung cancer (Abstract: Noeparast et al. Abstract# 11091, ASCO 2015. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/11091). Mutation of BRAF at D594 has been shown to activate the MAPK pathway (PMID: 20978199). Expression of BRAF D594E in HEK293 cells demonstrated that it is activating as measured by increased downstream ERK signaling compared to wildtype BRAF (Abstract: Noeparast, A. et al. Abstract# 11091, ASCO 2015. http://meetinglibrary.asco.org/content/152688-156). Though this mutant is kinase-dead, it activates the MAPK pathway through CRAF (Abstract: Noeparast, A. et al. Abstract# 11091, ASCO 2015. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/11091). In vitro studies have suggested that this mutation is resistant to dabrafenib, as measured by increased MAPK pathway activation upon drug treatment, but sensitive to trametinib, as measured by decreased MAPK pathway activation upon drug treatment (Abstract: Noeparast, A. et al. Abstract# 11091, ASCO 2015. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/11091)."
              },
              "operation": "update",
              "uuids": "eac9874d-79d9-454a-81b6-87c68e93307f"
            }
          ],
          "timeStamp": 1678149159204
        },
        "-NPtU6TbnwRZcmiWTUhf": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "D594G, Mutation Effect",
              "new": {
                "description": "The class III BRAF D594G mutation is located in the kinase domain in exon 15 of the protein (PMID: 28783719). This mutation has been found in colorectal cancer and melanomas, among others (PMID: 26498038, 28481359). Despite having hypoactive kinase activity, in vitro studies have demonstrated that this mutation is likely activating as measured by increased CRAF dimerization and downstream signaling compared to wildtype (PMID: 20141835, 26498038, 28783719). Preclinical studies with WM3670 cells expressing BRAF D594G demonstrated resistance to treatment with vemurafenib and PLX8394, as measured by persistent MEK, ERK and AKT activity, and sensitivity to treatment with SIJ1777, as measured by AKT and MAPK inhibition (PMID: 33917428). In a case report, a patient with low-grade serous ovarian cancer harboring BRAF D594G was treated with trametinib and demonstrated minimal clinical response (PMID: 35198414)."
              },
              "old": {
                "description": "The BRAF D594G mutation is located in the kinase domain of the BRAF protein. This mutation has been found in colorectal cancer and melanomas, among others (PMID: 26498038, 28481359). Despite having hypoactive kinase activity, in vitro studies have demonstrated that this mutation is likely activating as measured by increased CRAF dimerization and downstream signaling compared to wildtype (PMID: 20141835, 26498038, 28783719). This mutation is a Class III BRAF mutation (PMID: 28783719). The BRAF D594G mutation is sensitive to the MEK inhibitor trametinib but likely insensitive to the RAF inhibitor vemurafenib (PMID: 20141835)."
              },
              "operation": "update",
              "uuids": "2f4e594e-c475-49b7-a06a-dd2b1c5d4189"
            }
          ],
          "timeStamp": 1678149187497
        },
        "-NPtUNbv8cCj0nehnanQ": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "D594N, Mutation Effect",
              "new": {
                "description": "The class III BRAF D594N mutation occurs in the kinase domain in exon 15 of the protein (PMID: 28783719). This mutation has been found in non-small cell lung cancer and melanoma (PMID: 22798288, 23833300, 26498038, 28783719, 28947956). Biological characterization of the BRAF D594N mutation has demonstrated that it is RAS dependent in its activation of the MAPK pathway, signals as a dimer with CRAF, and typically co-occurs with another driver mechanism that amplifies RAS signaling (PMID: 28783719, 26498038). Thus, when BRAF D594N is observed in melanoma, it typically co-occurs with an activating RAS mutation or NF1 inactivation, whereas when observed in non-small cell lung or colorectal cancers, it is associated with receptor tyrosine kinase (RTK) hyperactivation at the protein level (PMID: 28783719). While this mutation is sensitive to MEK inhibition by targeted inhibitors such as trametinib, it is insensitive to RAF monomer inhibitors such as vemurafenib (PMID: 28783719). In a case report, a patient with EGFR-positive, MET-amplified non-small cell lung cancer acquired BRAF D594N as a secondary resistance mutation in response to combination treatment with osimertinib plus crizotinib (PMID: 36136993). The patient demonstrated clinical response to combination treatment with osimertinib plus trametinib (PMID: 36136993)."
              },
              "old": {
                "description": "The class III hypoactivating exon 15 BRAF D594N missense mutation occurs in the kinase domain of the BRAF protein and renders BRAF kinase-dead (or with “lower than wildtype kinase activity”) (PMID: 28783719). This mutation has been found in non-small cell lung cancer and melanoma (PMID: 22798288, 23833300, 26498038, 28783719) (Abstract: Noeparast et al. Abstract# 11091, ASCO 2015. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/11091). Biological characterization of the BRAF D594N mutation has demonstrated that it is RAS dependent in its activation of the MAPK pathway, signals as a dimer with CRAF, and typically co-occurs with another driver mechanism that amplifies RAS signaling (PMID: 28783719, 26498038). Thus, when BRAF D594N is observed in melanoma, it typically co-occurs with an activating RAS mutation or NF1 inactivation, whereas when observed in non-small cell lung or colorectal cancers, it is associated with receptor tyrosine kinase (RTK) hyperactivation at the protein level (PMID: 28783719). While this mutation is sensitive to MEK inhibition by targeted inhibitors such as trametinib, it is insensitive to RAF monomer inhibitors such as vemurafenib (PMID: 28783719)."
              },
              "operation": "update",
              "uuids": "b0ec34c2-01be-4bd8-96db-5aea6eb0706c"
            }
          ],
          "timeStamp": 1678149257725
        },
        "-NPtUXS2Rv4rA_xQUrny": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "D594V, Mutation Effect",
              "new": {
                "description": "The class III BRAF D594V mutation is located in the kinase domain in exon 15 of the protein (PMID: 33019809). This mutation has been found in colorectal cancer and cardio-facio-cutaneous (CFC) syndrome (PMID: 16439621, 14678966). Expression of this mutation in D04 or COS7 cells demonstrated that, despite being kinase-dead, the mutation activates the MAPK pathway through dimerization with CRAF as measured by downstream MEK and ERK phosphorylation (PMID: 15035987, 14678966). When expressed in zebrafish embryos, the BRAF D594V mutation causes the same aberrant elongation phenotype as BRAF V600E, suggesting that it is likely activating in vivo (PMID: 19376813)."
              },
              "old": {
                "description": "The BRAF D594V mutation is located in the kinase domain in exon 15 of the protein. This mutation has been found in colorectal cancer and cardio-facio-cutaneous (CFC) syndrome (PMID: 16439621, 14678966). Expression of this mutation in D04 or COS7 cells demonstrated that though this mutation abolishes kinase activity of the protein, it activates the MAPK pathway, as measured by downstream MEK and ERK phosphorylation, through dimerization with CRAF (PMID: 15035987, 14678966). When expressed in zebrafish embryos, the D594V mutation causes the same aberrant elongation phenotype as BRAF V600E, suggesting that it is likely activating in vivo (PMID: 19376813)."
              },
              "operation": "update",
              "uuids": "50b2db09-21b0-4bd8-859e-e6432d3a7483"
            }
          ],
          "timeStamp": 1678149297988
        },
        "-NPtUgIVrZmIYniX1shV": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "D594Y, Mutation Effect",
              "new": {
                "description": "The class III BRAF D594Y mutation is located in the kinase domain in exon 15 of the protein (PMID: 30224342). This mutation has been identified in lung adenocarcinoma and ovarian cancer (PMID: 28481359, 31477716). Analysis of patients with BRAF-altered lung cancers demonstrated that BRAF D594Y has impaired kinase function (PMID: 32913992). As a BRAF class III mutation, it is suggested that BRAF D594Y is sensitive to MEK inhibition by targeted inhibitors such as trametinib and insensitive to RAF monomer inhibitors such as vemurafenib (PMID: 28783719)."
              },
              "old": {
                "description": "The BRAF D594Y mutation is located in the kinase domain in exon 15 of the protein. This mutation has been observed in a single case study of a patient with cardio-facio-cutaneous (CFC) syndrome (GfH-Jahrestagung Abstract P-ClinG-053).While this mutation has not been been functionally characterized, other amino acid substitutions at this position (e.g., D594V, D594A) have been shown to be activating through dimerization with CRAF despite loss of BRAF kinase activity (PMID: 23833300, 16439621, 20141835)."
              },
              "operation": "update",
              "uuids": "4f361386-9f20-415b-ad55-2b6e73a3bc5a"
            }
          ],
          "timeStamp": 1678149338338
        },
        "-NPtV-Uk8bEn6d-j835q": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G464E, Mutation Effect",
              "new": {
                "description": "The class II BRAF G464E mutation is located in the kinase domain in exon 11 of the protein (PMID: 28783719, 26343582). This mutation has been reported in colorectal cancer (PMID: 15150094). Biological characterization of the BRAF G464E mutation demonstrated it activates the downstream MAPK pathway independent of RAS and renders BRAF active as a dimer with CRAF (PMID: 15035987, 23680146, 15150094, 26343582, 20179705, 16364920). Preclinical studies with cancer cell lines expressing BRAF G464E demonstrate resistance to vemurafenib as measured by prolonged ERK signaling following treatment (PMID: 26343582, 28783719, 26343582). A patient with spindle cell carcinoma harboring BRAF G464E treated with trametinib resulted in stable disease with a progression-free survival of 6.9 months (PMID: 31924734)."
              },
              "old": {
                "description": "The class II (PMID: 28783719) hyperactivating (PMID: 26343582) exon 11 BRAF G464E missense mutation is located in the kinase domain (G loop) of the BRAF protein, and has been reported in colorectal cancer (PMID: 15150094). Biological characterization of the BRAF G464E mutation demonstrated it activates the downstream MAPK pathway independent of RAS (PMID: 15035987, 23680146, 15150094, 26343582), renders BRAF active as a dimer with CRAF and itself (PMID: 20179705, 16364920), and, while sensitive to MEK inhibition by targeted inhibitors such as trametinib (PMID: 26343582, 28783719, 18794803), is insensitive to RAF monomer inhibitors such as vemurafenib (PMID: 26343582, 28783719)."
              },
              "operation": "update",
              "uuids": "40f0164f-978b-4b99-87bc-392ce3f14d64"
            }
          ],
          "timeStamp": 1678149421042
        },
        "-NPtVdc2iJ746REaTJLX": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G464R, Mutation Effect",
              "new": {
                "description": "The class II BRAF G464R mutation is located in the kinase domain in exon 11 of the protein (PMID: 33019809). This mutation has been found in melanoma (PMID: 15046639). Expression of this mutation in NIH-3T3 cells demonstrated that this mutation is activating as measured by increased downstream pathway activation compared to wildtype BRAF, though to a lesser extent than BRAF V600E (PMID: 15046639). In vitro studies with Ba/F3 and MCF10A cells expressing BRAF G464R demonstrate that the mutation is activating as measured by increased cell viability and proliferation compared to wildtype (PMID: 29533785). In a case report for a patient with metastatic colorectal cancer harboring BRAF G464R and KRAS G12S, the patient was treated with bevacizumab plus FOLFIRI and then later treated with bevacizumab plus FOLFOXIRI and demonstrated recurrent disease in the sigmoid colon following both treatment regimens (PMID: 31183211)."
              },
              "old": {
                "description": "The BRAF G464R mutation is located in the kinase domain in exon 11 of the protein. This mutation has been found in melanoma (PMID: 15046639). Expression of this mutation in NIH-3T3 cells demonstrated that this mutation is activating as measured by increased downstream pathway activation compared to wildtype BRAF, though to a lesser extent than BRAF V600E (PMID: 15046639)."
              },
              "operation": "update",
              "uuids": "6ac26115-a639-4eee-aaac-dd0eba053dd6"
            }
          ],
          "timeStamp": 1678149589509
        },
        "-NPtVr-sJ80Qy9Ir2vQy": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G464V, Mutation Effect",
              "new": {
                "description": "The class II BRAF G464V mutation is located in the kinase domain in exon 11 of the protein (PMID: 28783719, 26343582). This mutation has been reported in melanoma, colorectal cancer and breast cancer (PMID: 15035987, 15150094, 17314276). Biological characterization of the BRAF G464V mutation demonstrated it activates the downstream MAPK pathway independent of RAS and renders BRAF active as a dimer with CRAF (PMID:  15035987, 12068308, 15150094, 26343582, 20179705). Preclinical studies with KRAS-mutant HEK293 cells expressing BRAF G464V demonstrated sensitivity to treatment with RAF inhibitor Cmpd A as measured by reduced phosphorylated ERK levels (PMID: 23680146). A patient with lung adenocarcinoma harboring BRAF G464V treated with trametinib did not respond to treatment and demonstrated progressive disease (PMID: 31924734). Two patients with advanced solid tumors harboring BRAF G464V were treated with vemurafenib and did not have an objective response to treatment (PMID: 29320312)."
              },
              "old": {
                "description": "The class II (PMID: 28783719) hyperactivating (PMID: 26343582) exon 11 BRAF G464V missense mutation is located in the kinase domain (G loop) of the BRAF protein, and has been reported in melanoma (PMID: 15035987), and in colorectal cancer (PMID: 15150094), and in breast cancer cell line (PMID: 17314276). Biological characterization of the BRAF G464V mutation demonstrated that it activates the downstream MAPK pathway independently of RAS (PMID: 15035987, 12068308, 15150094, 26343582), renders BRAF active as a dimer with CRAF and itself (PMID: 20179705), and, while sensitive to MEK inhibition by targeted inhibitors such as trametinib (PMID: 26343582, 28783719, 18794803), is insensitive to RAF monomer inhibitors such as vemurafenib (PMID: 26343582, 28783719)."
              },
              "operation": "update",
              "uuids": "532ebf53-588d-495d-92a3-fd13cb96b34b"
            }
          ],
          "timeStamp": 1678149644346
        },
        "-NPtWP926HgW2SnJ3vF_": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G466A, Mutation Effect",
              "new": {
                "description": "The class III BRAF G466A mutation is located in the kinase domain in exon 11 of the protein (PMID: 28783719, 15035987, 28783719). This mutation has been identified in melanoma and lung adenocarcinoma (PMID: 12068308, 28481359). Biological characterization of the BRAF G466A mutation has demonstrated that it is RAS dependent in its activation of the MAPK pathway, signals as a dimer with CRAF, and typically co-occurs with another driver mechanism that amplifies RAS signaling (PMID: 15035987, 28783719). Thus, when BRAF G466A is observed in melanoma, it typically co-occurs with an activating RAS mutation or NF1 inactivation, whereas when observed in non-small cell lung or colorectal cancers, it is associated with receptor tyrosine kinase (RTK) hyperactivation at the protein level (PMID: 28783719). A patient with non-small cell lung cancer harboring BRAF G466A treated with vemurafenib did not clinically respond to treatment and demonstrated progressive disease (PMID: 31959346). Patients with advanced solid tumors harboring BRAF G466A were treated with trametinib and demonstrated either progressive or stable disease (PMID: 31924734). In a case report, a patient with metastatic Bellini duct carcinoma harboring BRAF G466A treated with trametinib plus dabrafenib demonstrated 11 months of stable disease following treatment (PMID: 33669326). In a Phase Ib trial, a patient with metastatic non-small cell lung cancer harboring BRAF G466A was treated with combination therapy of the ERK1/2 inhibitor LTT462 and the BRAF/CRAF inhibitor LXH 254 and demonstrated stable disease with a 25% tumor reduction following treatment (Abstract: Wolf et al. Abstract# 1387p, Annals of Oncology 2020. https://www.annalsofoncology.org/article/S0923-7534%2820%2941697-7/fulltext)."
              },
              "old": {
                "description": "The class III hypoactivating (PMID: 28783719) exon 11 BRAF G466A missense mutation occurs in the kinase domain of the protein and renders BRAF kinase-dead (or with “lower than wildtype kinase activity”) (PMID: 15035987, 28783719). This class of mutations has been recurrently found in melanoma, lung and colorectal cancers (PMID: 28481359). Biological characterization of the BRAF G466A mutation has demonstrated that it is RAS dependent in its activation of the MAPK pathway, signals as a dimer with CRAF, and typically co-occurs with another driver mechanism that amplifies RAS signaling (PMID: 15035987, 28783719). Thus, when BRAF G466A is observed in melanoma, it typically co-occurs with an activating RAS mutation or NF1 inactivation, whereas when observed in non-small cell lung or colorectal cancers, it is associated with receptor tyrosine kinase (RTK) hyperactivation at the protein level (PMID: 28783719). While this mutation is sensitive to MEK inhibition by targeted inhibitors such as trametinib, it is insensitive to RAF monomer inhibitors such as vemurafenib."
              },
              "operation": "update",
              "uuids": "855e100e-1702-43f9-ba27-bbb53498df41"
            }
          ],
          "timeStamp": 1678149788293
        },
        "-NPtWeKMBS9pn1_cXnez": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G466E, Mutation Effect",
              "new": {
                "description": "The class III BRAF G466E mutation occurs in the kinase domain in exon 11 of the protein (PMID: 15035987, 28783719). This mutation has been reported in melanoma, lung cancer, colorectal cancer and chronic myelomonocytic leukemia (PMID: 28481359, 15046639, 27790118, 24446311). Biological characterization of the BRAF G466E mutation has demonstrated that it is RAS dependent in its activation of the MAPK pathway, signals as a dimer with CRAF, and typically co-occurs with another driver mechanism that amplifies RAS signaling (PMID: 15035987, 15046639, 28783719). Thus, when BRAF G466E is observed in melanoma, it typically co-occurs with an activating RAS mutation or NF1 inactivation, whereas when observed in non-small cell lung or colorectal cancers, it is associated with receptor tyrosine kinase (RTK) hyperactivation at the protein level (PMID: 28783719). Preclinical studies with melanoma cell lines expressing BRAF G466E demonstrated sensitivity to treatment with AZ628 and TAK-632 as measured by reduced cell proliferation, and insensitivity to treatment with PLX7904, vemurafenib and dabrafenib, as measured by prolonged cell viability (PMID: 27523909). In a clinical study, two patients with metastatic colorectal cancer harboring BRAF G466E were treated with combination therapy of panitumumab and irinotecan and demonstrated partial response with a progression-free survival of 8.3 months (PMID: 31515458). In a case report, a patient with melanoma harboring BRAF G466E was treated with ipilimumab and demonstrated progressive disease (PMID: 27790118)."
              },
              "old": {
                "description": "The class III hypoactivating exon 11 BRAF G466E missense mutation occurs in the kinase domain of the protein and renders BRAF kinase-dead (or with “lower than wildtype kinase activity”) (PMID: 15035987, 28783719). This mutation has been reported in melanomas, lung and colorectal cancers, and in chronic myelomonocytic leukemia (PMID: 28481359, 15046639, 27790118, 24446311). Biological characterization of the BRAF G466E mutation has demonstrated that it is RAS dependent in its activation of the MAPK pathway, signals as a dimer with CRAF, and typically co-occurs with another driver mechanism that amplifies RAS signaling (PMID: 15035987, 15046639, 28783719). Thus, when BRAF G466E is observed in melanoma, it typically co-occurs with an activating RAS mutation or NF1 inactivation, whereas when observed in non-small cell lung or colorectal cancers, it is associated with receptor tyrosine kinase (RTK) hyperactivation at the protein level (PMID: 28783719). While this mutation is sensitive to MEK inhibition by targeted inhibitors such as trametinib, it is insensitive to RAF monomer inhibitors such as vemurafenib."
              },
              "operation": "update",
              "uuids": "09553532-91a2-47fb-9468-ff505476c94e"
            }
          ],
          "timeStamp": 1678149854553
        },
        "-NPtWvH3ZyQwEL4uKQGW": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G466R, Mutation Effect",
              "new": {
                "description": "The class III BRAF G466R mutation is located in the kinase domain in exon 11 of the protein (PMID: 28783719). This mutation has been identified in lung adenocarcinoma and melanoma (PMID: 24297085, 21788131). Expression of this mutation in NIH3T3 cells demonstrated that this mutation is likely activating as measured by increased downstream ERK activation (PMID: 15046639). While this mutation has kinase activity in vitro less than wildtype BRAF, it likely activates downstream ERK through dimerization with CRAF (PMID: 15035987, 16364920). A patient with stage IV lung adenocarcinoma harboring BRAF G466R was treated with selumetinib and demonstrated an overall survival of 9.1 months (PMID: 25273224). In a case report, a patient with non-small cell lung cancer harboring BRAF G466R was treated with a combination therapy of dabrafenib plus trametinib and did not clinically respond to treatment (Abstract: Citarella et al. Precis Cancer Med 2022. https://pcm.amegroups.com/article/view/6792/html#B19). Another patient with non-small cell lung cancer harboring BRAF G466R was treated with a combination therapy of nivolumab plus anlotinib and demonstrated progressive disease with a progression-free survival of two months (PMID: 32411601). In a Phase II trial, a patient with melanoma harboring BRAF G466R and NRAS Q61H was treated with a combination therapy of docetaxel plus selumetinib and demonstrated stable disease with a progression-free survival of seven months (PMID: 31839677)."
              },
              "old": {
                "description": "The BRAF G466R mutation is located in the kinase domain in exon 11 of the protein. Expression of this mutation in NIH-3T3 cells demonstrated that this mutation is likely activating as measured by increased downstream ERK activation (PMID: 15046639). While this mutation has kinase activity in vitro less than wildtype BRAF, it likely activates downstream ERK through dimerization with CRAF (PMID: 15035987, 16364920)."
              },
              "operation": "update",
              "uuids": "5414eff5-1ecb-4030-adf2-da44ef4b3778"
            }
          ],
          "timeStamp": 1678149923974
        },
        "-NPyI119MjkT6x0-9g3h": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G466V, Mutation Effect",
              "new": {
                "description": "The class III BRAF G466V missense mutation is located in the kinase domain in exon 11 of the protein (PMID: 15035987, 28783719). This mutation has been reported in melanoma, lung cancer, colorectal cancer and cardio-facio-cutaneous syndrome (PMID: 28481359, 15046639, 26498038, 16439621, 22649091). Biological characterization of the BRAF G466V mutation has demonstrated that it is RAS dependent in its activation of the MAPK pathway, signals as a dimer with CRAF, and typically co-occurs with another driver mechanism that amplifies RAS signaling (PMID: 15035987, 26498038, 22649091, 16364920, 24202393, 28783719). Thus, when BRAF G466V is observed in melanoma, it typically co-occurs with an activating RAS mutation or NF1 inactivation, whereas when observed in non-small cell lung or colorectal cancers, it is associated with receptor tyrosine kinase (RTK) hyperactivation at the protein level (PMID: 28783719). Preclinical studies with lung cancer cell lines expressing BRAF G466V demonstrated sensitivity to treatment with TAK-632, TAE226 and RMC-4550 as measured by inhibition of cell proliferation and reduced ERK phosphorylation following treatment (PMID: 26090892, 27523909, 30104724). Other preclinical studies with patient-derived xenograft colorectal cancer models expressing BRAF G466V demonstrated resistance to treatment with PLX8394 as measured by continued ERK phosphorylation and inability to suppress tumor growth, and sensitivity to treatment with cetuximab as measured by reduced tumor growth and inhibition of ERK phosphorylation (PMID: 30559419). In a Phase II trial, three patients with non-small cell lung cancer harboring BRAF G466V were treated with vemurafenib and did not clinically respond to treatment (PMID: 31959346). In another Phase II trial, a patient with lung adenocarcinoma harboring BRAF G466V was treated with trametinib and demonstrated progressive disease (PMID: 31924734). In a case report, a patient with metastatic colorectal cancer harboring BRAF G466V was treated with a combination therapy of irinotecan plus panitumumab and demonstrated a partial response with a progression-free survival of 6.1 months (PMID: 31515458)."
              },
              "old": {
                "description": "The class III hypoactivating exon 11 BRAF G466V missense mutation occurs in the kinase domain of the protein and renders BRAF kinase-dead (or with “lower than wildtype kinase activity”) (PMID: 15035987, 28783719). This mutation has been reported in melanomas, lung and colorectal cancers, and in cardio-facio-cutaneous syndrome (PMID: 28481359, 15046639, 26498038, 16439621, 22649091). Biological characterization of the BRAF G466V mutation has demonstrated that it is RAS dependent in its activation of the MAPK pathway, signals as a dimer with CRAF, and typically co-occurs with another driver mechanism that amplifies RAS signaling (PMID: 15035987, 26498038, 22649091, 16364920, 24202393, 28783719). Thus, when BRAF G466V is observed in melanoma, it typically co-occurs with an activating RAS mutation or NF1 inactivation, whereas when observed in non-small cell lung or colorectal cancers, it is associated with receptor tyrosine kinase (RTK) hyperactivation at the protein level (PMID: 28783719). While this mutation is sensitive to MEK inhibition by targeted inhibitors such as trametinib, it is insensitive to RAF monomer inhibitors such as vemurafenib."
              },
              "operation": "update",
              "uuids": "4bd4a259-ff20-48b2-aa59-8d1202991f65"
            }
          ],
          "timeStamp": 1678229905575
        },
        "-NPyIlnQitCkSMMWJ8yQ": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G469A, Mutation Effect",
              "new": {
                "description": "The class II BRAF G469A mutation is located in the kinase domain in exon 11 of the protein (PMID: 28783719, 26343582). This mutation has been reported in melanoma, non-small cell lung cancer and cardio-facio-cutaneous syndrome (PMID: 12068308, 23833300, 16439621). Biological characterization of the BRAF G469A mutation demonstrated that it activates the downstream MAPK pathway independently of RAS and renders BRAF active as a dimer with CRAF and itself (PMID: 12068308, 23833300, 26343582, 20179705, 22510884). Ectopic expression of BRAF G469A in drug-sensitive EGFR-mutant cells conferred resistance to EGFR TKIs that was overcome by addition of a MEK inhibitor (PMID: 22773810). Preclinical studies with patient-derived lung adenocarcinoma cells expressing BRAF G469A demonstrated sensitivity to treatment with LXH 254, lifirafenib and dabrafenib plus trametinib, as measured by inhibition of cell growth, and resistance to treatment with LY3214996, MK-8353, ravoxertinib, ulixertinib, TAK-580, vemurafenib and dabrafenib, as measured by persistent cell growth (PMID: 32540409). In a clinical study, patients with metastatic colorectal cancer harboring BRAF G469A were treated with cetuximab plus FOLFIRI, cetuximab plus irinotecan or panitumumab plus irinotecan and each treatment group demonstrated stable disease with a progression-free survival of 4.4 months, 3.5 months and 4.0 months, respectively (PMID: 31515458). In a Phase I trial, a patient with head and neck cancer and a patient with small bowel cancer, both harboring BRAF G469A, were treated with ulixertinib and demonstrated partial response (PMID: 29247021). In a Phase II trial, a patient with lung adenocarcinoma harboring BRAF G469A was treated with trametinib and demonstrated stable disease with a progression-free survival of 20.4 months (PMID: 31924734). In another Phase II trial, two patients with advanced solid tumors harboring BRAF G469A were treated with vemurafenib and did not clinically respond to treatment (PMID: 29320312)."
              },
              "old": {
                "description": "The class II (PMID: 28783719) hyperactivating (PMID: 26343582) exon 11 BRAF G469A missense mutation is located in the kinase domain (G loop) of the BRAF protein, and has been reported in melanoma (PMID: 12068308), non-small cell lung cancer (NSCLC) (PMID: 23833300), as well as in cardio-facio-cutaneous syndrome (CFC) (PMID: 16439621). Biological characterization of BRAF G469A mutation demonstrated that it activates downstream MAPK pathway independently of RAS (PMID: 12068308, 23833300, 26343582), renders BRAF active as a dimer with CRAF and itself (PMID: 20179705, 22510884), and while sensitive to MEK inhibition by targeted inhibitors such as trametinib (PMID: 28783719, 26343582, 18794803), is insensitive to RAF monomer inhibitors such as vemurafenib (PMID: 28783719, 26343582, 20179705). Ectopic expression of BRAF G469A in drug-sensitive EGFR-mutant cells conferred resistance to EGFR TKIs that was overcome by addition of a MEK inhibitor (PMID: 22773810)."
              },
              "operation": "update",
              "uuids": "ab9c04c7-415e-41da-93cd-82cbb6ce102c"
            }
          ],
          "timeStamp": 1678230101240
        },
        "-NPyIsuEJZQlYHfU1KWC": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "A246P, Mutation Effect",
              "new": {
                "description": "The BRAF A246P mutation is located in the cysteine-rich domain in exon 6 of the protein. This mutation is found in cardio-facio-cutaneous (CFC) syndrome (PMID: 16474404). Expression of BRAF A246P in NIH-3T3 cells engineered to concurrently express an ERK-dependent luciferase construct demonstrated that this mutation is activating, as measured by increased luciferase activity compared to wildtype BRAF (PMID: 16474404). Single-molecule binding assays with BRAF A246P also demonstrate that the mutation is activating as measured by increased RAS binding affinity compared to wildtype (PMID: 24409384). Preclinical studies with zebrafish embryos expressing BRAF A246P demonstrated sensitivity to treatment with MEK inhibitors CI-1040 and PD0325901 as measured by the prevention of CFC development (PMID: 19376813)."
              },
              "old": {
                "description": "The BRAF A246P mutation is located in the cysteine-rich domain in exon 6 of the protein. This mutation is found in cardio-facio-cutaneous (CFC) syndrome (PMID: 16474404). Expression of BRAF A246P in NIH-3T3 cells engineered to concurrently express an ERK-dependent luciferase construct demonstrated that this mutation is activating, as measured by increased luciferase activity compared to wildtype BRAF (PMID: 16474404)."
              },
              "operation": "update",
              "uuids": "f0a7fcca-369a-4d7d-b125-ac14c41ddc57"
            }
          ],
          "timeStamp": 1678230130348
        },
        "-NPyJdrXM73TtSSkUu5c": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "D287H, Mutation Effect",
              "new": {
                "description": "The class III BRAF D287H mutation occurs in the cysteine-rich domain in exon 6 of the protein (PMID: 28783719). Biological characterization of the BRAF D287H mutation has demonstrated that it is RAS dependent in its activation of the MAPK pathway, signals as a dimer with CRAF, and typically co-occurs with another driver mechanism that amplifies RAS signaling (PMID: 26343582, 28783719). In melanoma, the D287H variant, similar to other class III BRAF mutants, would be expected to co-occur with activating RAS mutation or NF1 inactivation, whereas in non-small cell lung or colorectal cancers, this mutation would most likely be associated with receptor tyrosine kinase (RTK) hyperactivation at the protein level (PMID: 28783719). While this mutation is sensitive to MEK inhibition by targeted inhibitors such as trametinib, it is insensitive to RAF monomer inhibitors such as vemurafenib (PMID: 28783719)."
              },
              "old": {
                "description": "The class III hypoactivating (PMID: 28783719) exon 6 BRAF D287H missense mutation occurs in the cysteine-rich domain of the protein. Biological characterization of the BRAF D287H mutation has demonstrated that it is RAS dependent in its activation of the MAPK pathway, signals as a dimer with CRAF, and typically co-occurs with another driver mechanism that amplifies RAS signaling (PMID: 26343582, 28783719). In melanoma, the D287H variant, similar to other class III BRAF mutants, would be expected to co-occur with activating RAS mutation or NF1 inactivation, whereas in non-small cell lung or colorectal cancers, this mutation would most likely be associated with receptor tyrosine kinase (RTK) hyperactivation at the protein level (PMID: 28783719). While this mutation is sensitive to MEK inhibition by targeted inhibitors such as trametinib, it is insensitive to RAF monomer inhibitors such as vemurafenib."
              },
              "operation": "update",
              "uuids": "05840d43-e046-488f-bcd9-42517eee4a78"
            }
          ],
          "timeStamp": 1678230330879
        },
        "-NPyJohMcZL7NJMdg49A": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "E501K, Mutation Effect",
              "new": {
                "description": "The BRAF E501K mutation is located in the kinase domain of the BRAF protein. This mutation has been found as a germline mutation in Noonan syndrome and cardio-facio-cutaneous syndrome (PMID: 17603482, 16474404). In vitro studies have demonstrated that this mutation might be inactivating as measured by decreased BRAF kinase activity in a cell line with a second BRAF mutation compared to controls (PMID: 17603482). However, another in vitro study found increased downstream pathway output compared to wildtype (PMID: 16474404). BRAF E501K is suggested to be RAS-dependent due to enrichment of RAS regulatory genes in tumors harboring the mutation in a pan-cancer genomic data analysis (PMID: 33507258)."
              },
              "old": {
                "description": "The BRAF E501K mutation is located in the kinase domain of the BRAF protein. This mutation has been found as a germline mutation in Noonan syndrome and cardiofaciocutaneous syndrome (PMID: 17603482, 16474404). In vitro studies have demonstrated that this mutation might be inactivating as measured by decreased BRAF kinase activity in a cell line with a second BRAF mutation compared to controls (PMID: 17603482). However, another in vitro study found increased downstream pathway output compared to wildtype (PMID: 16474404)."
              },
              "operation": "update",
              "uuids": "ec6aaa98-f05b-4a8d-bb3c-5e1b59380208"
            }
          ],
          "timeStamp": 1678230375284
        },
        "-NPyKMIs-lAPeaTW4P7g": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "E586K, Mutation Effect",
              "new": {
                "description": "The class II BRAF E586K mutation is located in the kinase domain in exon 15 of the protein (PMID: 33019809). This mutation has been identified in lung adenocarcinoma (PMID: 31534501). Expression of this mutation in COS cells demonstrated that it is activating as measured by increased in vitro kinase activity compared to wildtype BRAF (PMID: 15035987). Preclinical studies with HEK293 cells expressing BRAF E586K demonstrated sensitivity to treatment with pan-RAF inhibitor LY3009120 as measured by inhibited phospho-MEK and -ERK activities (PMID: 26343583)."
              },
              "old": {
                "description": "The BRAF E586K mutation is located in the kinase domain in exon 15 of the protein. Expression of this mutation in COS cells demonstrated that it is activating as measured by increased in vitro kinase activity compared to wildtype BRAF (PMID: 15035987)."
              },
              "operation": "update",
              "uuids": "2a7480c9-f5a2-4f5d-ba10-1b5d56dd2c20"
            }
          ],
          "timeStamp": 1678230517013
        },
        "-NPyKw96KYcNnTfBZRg0": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "F595L, Mutation Effect",
              "new": {
                "description": "The class III BRAF F595L mutation is located in the kinase domain in exon 11 of the protein (PMID: 28783719). This mutation has been reported in histiocytic sarcoma, colorectal cancer and cardio-facio-cutaneous syndrome (PMID: 26582644, 15150094, 26150740). Biological characterization of the BRAF F595L mutation has demonstrated that it is RAS dependent in its activation of the MAPK pathway, signals as a dimer with CRAF, and typically co-occurs with another driver mechanism that amplifies RAS signaling (PMID: 28783719, 15035987, 15150094). Thus, when BRAF F595L is observed in melanoma, it typically co-occurs with an activating RAS mutation or NF1 inactivation, whereas when observed in non-small cell lung or colorectal cancers, it is associated with receptor tyrosine kinase (RTK) hyperactivation at the protein level (PMID: 28783719, 20141835). While this mutation is sensitive to MEK inhibition by targeted inhibitors such as trametinib, it is insensitive to RAF monomer inhibitors such as vemurafenib (PMID: 28783719, 26582644). A patient with metastatic colorectal cancer harboring BRAF F595L was treated with a combination therapy of FOLFOX plus panitumumab and experienced partial response with a progression-free survival of 10.2 months (PMID: 31515458)."
              },
              "old": {
                "description": "The class III hypoactivating (PMID: 28783719) exon 11 BRAF F595L mutation occurs in the kinase domain of the BRAF protein and has been reported in histiocytic sarcoma (PMID: 26582644), colorectal cancer, as well as cardio-facio-cutaneous syndrome (PMID: 15150094, 26150740). Biochemically, it has been demonstrated that the BRAF F595L mutant signals as a dimer with CRAF, is RAS-dependent in its activation of the MAPK pathway, and, in tumors, would typically co-occur with another driver mechanism that amplifies RAS signaling (PMID: 28783719, 15035987, 15150094). Thus, like other class III BRAF mutants, in melanoma, the F595L variant would be expected to co-occur with activating RAS mutation or NF1 inactivation, whereas in non-small cell lung and colorectal cancers, this mutation would most likely be associated with receptor tyrosine kinase (RTK) hyperactivation at the protein level (PMID: 28783719). While this mutation is sensitive to MEK inhibition by targeted inhibitors such as trametinib, it is insensitive to RAF monomer inhibitors such as vemurafenib."
              },
              "operation": "update",
              "uuids": "5fb6a290-f77f-4f7e-aae1-ae8e7c6eb37a"
            }
          ],
          "timeStamp": 1678230667940
        },
        "-NPyL2M5McJFt7-4yEwS": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "A598T, Mutation Effect",
              "new": {
                "description": "The BRAF A598T mutation is located in the kinase domain of the BRAF protein. This mutation has been identified in glioma (PMID: 32996219). In vitro experiments have demonstrated that is mutation is inactivating as measured by reduced BRAF kinase activity compared to wildtype controls (PMID: 22926515, 32059434)."
              },
              "old": {
                "description": "The BRAF A598T mutation is located in the kinase domain of the BRAF protein. This mutation is predicted to be a BRAF mutational hotspot in cancer (PMID: 26619011). In vitro experiments have demonstrated that is mutation is inactivating, as shown by reduced BRAF kinase activity compared to wildtype controls (PMID: 22926515, 32059434)."
              },
              "operation": "update",
              "uuids": "b0e7125c-946a-4890-b86a-9cb16ddc21bd"
            }
          ],
          "timeStamp": 1678230697443
        },
        "-NPyL9V7rM4Jzh_wspwd": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "A598V, Mutation Effect",
              "new": {
                "description": "The class II BRAF A598V mutation is located in the kinase domain in exon 15 of the protein (PMID: 34794740). This mutation has been found in papillary thyroid carcinoma (PMID: 19200582). In vitro studies of BRAF A598V in patient samples have demonstrated that this mutation is activating as measured by increased phosphorylated MEK and ERK levels compared to wildtype BRAF (PMID: 19200582). Preclinical studies with patient-derived circulating tumor cells expressing BRAF A598V demonstrate resistance to combination treatment with BRAF/MEK inhibitors dabrafenib and trametinib as measured by sustained detection following treatment (PMID: 33731038)."
              },
              "old": {
                "description": "The BRAF A598V mutation is located in the kinase domain in exon 15 of the protein. This mutation has been found in papillary thyroid carcinoma (PMID: 19200582). In vitro studies of BRAF A598V in patient samples have demonstrated that this mutation is activating, as demonstrated by increased phosphorylated MEK and ERK levels compared to wildtype BRAF (PMID: 19200582)."
              },
              "operation": "update",
              "uuids": "4e3b29fc-7373-4ca1-a7d9-0ec1b1595842"
            }
          ],
          "timeStamp": 1678230726693
        },
        "-NPyLGPYf1r3g34odppQ": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "A728V, Mutation Effect",
              "new": {
                "description": "The BRAF A728V mutation is located in the C-terminal end of exon 18 of the protein. This mutation has been identified in papillary thyroid carcinoma (PMID: 19176457).  Expression of this mutation in COS cells demonstrated that it is activating as measured by increased phosphorylated ERK levels and increased kinase activity compared to wildtype BRAF (PMID: 15035987)."
              },
              "old": {
                "description": "The BRAF A728V mutation is located in the C-terminal end of exon 18 of the protein. Expression of this mutation in COS cells demonstrated that it is activating as measured by increased phosphorylated ERK levels and increased kinase activity compared to wildtype BRAF (PMID: 15035987)."
              },
              "operation": "update",
              "uuids": "84adeb92-4025-4ce5-be2a-d0b900086110"
            }
          ],
          "timeStamp": 1678230755008
        },
        "-NPyLiHJV2QehmxKtkHK": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "FAM131B-BRAF Fusion, Mutation Effect",
              "new": {
                "description": "The FAM131B-BRAF fusion is the result of a 2.5 Mb deletion on chromosome 7 which fuses the first two exons of the FAM131B gene with exons 9-18 of the BRAF gene (PMID: 21424530). This fusion contains the BRAF kinase domain, but excludes the BRAF CR1 domain responsible for RAS binding and auto-inhibition (PMID:15630448). The FAM131B-BRAF fusion has been found in pilocytic astrocytomas and pediatric low-grade gliomas (PMID: 21424530, 25040262). Expression of this mutation in NIH-3T3 cells demonstrated that it is activating, as measured by increased downstream MEK phosphorylation and decreased contact inhibition compared to wildtype BRAF (PMID: 21424530). Preclinical studies with mice and NIH3T3 cells expressing FAM131B-BRAF demonstrate sensitivity to treatment with trametinib as measured by suppressed tumor growth and anchorage-independent growth; however, acquired resistance was observed following prolonged treatment (PMID: 29156677). FAM131B-BRAF is suggested to acquire resistance against MEK inhibitors selumetinib, binimetinib and trametinib through enhancing PI3K/AKT/mTOR pathway signaling to overcome MEK inhibition (PMID: 29156677). Combination treatment of mTOR inhibitor everolimus with trametinib in mice expressing FAM131B-BRAF prolonged tumor suppression and delayed acquired resistance (PMID: 29156677)."
              },
              "old": {
                "description": "The FAM131B-BRAF fusion is the result of a 2.5 Mb deletion on chromosome 7, which fuses the first two exons of the FAM131B gene with exons 9-18 of the BRAF gene (PMID: 21424530). This fusion contains the BRAF kinase domain, but excludes the BRAF CR1 domain responsible for RAS binding and auto-inhibition (PMID:15630448). This FAM131B-BRAF fusion has been found in pilocytic astrocytomas and pediatric low-grade gliomas (PMID: 21424530, 25040262). Expression of this mutation in NIH-3T3 cells demonstrated that it is activating, as measured by increased downstream MEK phosphorylation and decreased contact inhibition compared to wildtype BRAF (PMID: 21424530)."
              },
              "operation": "update",
              "uuids": "81a3f713-19b7-4236-bdad-ec27d8558e27"
            }
          ],
          "timeStamp": 1678230873265
        },
        "-NPyLy7cRT2KG01CrHJd": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "D594H, Mutation Effect",
              "new": {
                "description": "The class III BRAF D594H missense mutation occurs in the kinase domain in exon 15 of the protein (PMID: 28783719). This mutation has been reported in melanoma, lung and colorectal cancers (PMID: 28481359). Biological characterization of the BRAF D594H mutation has demonstrated that it is RAS dependent in its activation of the MAPK pathway, signals as a dimer with CRAF, and typically co-occurs with another driver mechanism that amplifies RAS signaling (PMID: 28783719). Thus, when BRAF D594H is observed in melanoma, it typically co-occurs with an activating RAS mutation or NF1 inactivation, whereas when observed in non-small cell lung or colorectal cancers, it is associated with receptor tyrosine kinase (RTK) hyperactivation at the protein level (PMID: 28783719, 20141835). While this mutation is sensitive to MEK inhibition by targeted inhibitors such as trametinib, it is insensitive to RAF monomer inhibitors such as vemurafenib (PMID: 28783719)."
              },
              "old": {
                "description": "The class III and hypoactivating BRAF D594H missense mutation occurs in the kinase domain in exon 15 of the protein and renders BRAF kinase-dead (or with “lower than wildtype kinase activity”) (PMID: 28783719). Substitutions at the D594 position in the BRAF protein kinase has been reported in melanoma, lung and colorectal cancers (PMID: 28481359). Biological characterization of the BRAF D594H mutation has demonstrated that it is RAS dependent in its activation of the MAPK pathway, signals as a dimer with CRAF, and typically co-occurs with another driver mechanism that amplifies RAS signaling (PMID: 28783719). While this mutation is sensitive to MEK inhibition by targeted inhibitors such as trametinib, it is insensitive to RAF monomer inhibitors such as vemurafenib. Thus, when BRAF D594H is observed in melanoma, it typically co-occurs with an activating RAS mutation or NF1 inactivation, whereas when observed in non-small cell lung or colorectal cancers, it is associated with receptor tyrosine kinase (RTK) hyperactivation at the protein level (PMID: 28783719)."
              },
              "operation": "update",
              "uuids": "be6acfec-a41a-46ca-b9ce-e79a9b7ee84a"
            }
          ],
          "timeStamp": 1678230938181
        },
        "-NPyMCyzVAhtwjnbqHzR": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "F247L, Mutation Effect",
              "new": {
                "description": "The class III BRAF F247L mutation is located in the RAS binding and kinase autoinhibitory domain of the BRAF protein (PMID: 31515458). This mutation has been found in colorectal cancers, among others (PMID: 31515458). In vitro studies have demonstrated that this mutation is activating as measured by increased downstream signaling compared to wildtype (PMID: 28512244, 29533785). A patient with metastatic colorectal cancer harboring BRAF F247L was treated with a combination therapy of FOLFIRI plus cetuximab and demonstrated a complete response with a progression-free survival of 12.6 months (PMID: 31515458)."
              },
              "old": {
                "description": "The BRAF F247L mutation is located in the RAS binding and kinase autoinhibitory domain of the BRAF protein. This mutation has been found in colorectal cancers, among others (PMID: 31515458). In vitro studies have demonstrated that this mutation is activating as measured by increased downstream signaling compared to wildtype (PMID: 28512244, 29533785)."
              },
              "operation": "update",
              "uuids": "6da5e4e4-ed2a-4c99-83cd-555ceb42bd76"
            }
          ],
          "timeStamp": 1678231003100
        },
        "-NPyMVfsTrF6xJg-ufIe": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "ARMC10-BRAF Fusion, Mutation Effect",
              "new": {
                "description": "The ARMC10-BRAF fusion protein combines the N-terminus of ARMC10 with the C-terminus of BRAF, preserving the kinase domain of BRAF. This fusion protein is found in patients with sporadic microsatellite instability-high colorectal cancers (PMID: 30279230). Expression of this fusion protein in NIH3T3 cells demonstrated that it was activating as shown by increased colony formation and pathway activation compared to expression of BRAF alone (PMID: 30279230). Preclinical studies with patient-derived xenograft models expressing ARMC10-BRAF demonstrated sensitivity to treatment with MEK inhibitor trametinib and ERK inhibitor SCH772984 as measured by tumor regression and decreased phosphorylated ERK following treatment (PMID: 30254212)."
              },
              "old": {
                "description": "The ARMC10-BRAF fusion protein combines the N-terminus of ARMC10 with the C-terminus of BRAF, preserving the kinase domain of BRAF. This fusion protien is found in patients with sporadic microsatellite instability-high colorectal cancers (PMID: 30279230). Expression of this fusion protein in NIH3T3 cells demonstrated that it was activating as shown by increased colony formation and pathway activation compared to expression of BRAF alone (PMID: 30279230)."
              },
              "operation": "update",
              "uuids": "ee026fa7-42df-40e7-bcce-6fc7f23610f4"
            }
          ],
          "timeStamp": 1678231079701
        },
        "-NQ7h0cqnbQg9rnmrpHo": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "L597S, Mutation Effect",
              "new": {
                "description": "The class II BRAF L597S mutation is located in the kinase domain of the protein (PMID: 33019809). This mutation has been found in melanoma, among other cancers (PMID: 26643848). In vitro studies have demonstrated that this mutation is likely activating as measured by increased downstream signaling compared to wildtype (PMID: 22798288). Drug efficacy studies in cell lines demonstrated that the BRAF L597S mutation might be sensitive to the RAF inhibitor vemurafenib and the MEK inhibitor trametinib (PMID: 22798288). The BRAF L597S mutation has also been identified in patients with positive responses to trametinib, the allosteric MEK inhibitor TAK-733 and combined dabrafenib and trametinib treatment (PMID: 24933606, 22798288, 29903896)."
              },
              "old": {
                "description": "The BRAF L597S mutation is located in the kinase domain of the BRAF protein. This mutation has been found in melanoma, among other cancers (PMID: 26643848). In vitro studies have demonstrated that this mutation is likely activating as measured by increased downstream signaling compared to wildtype (PMID: 22798288). Drug efficacy studies in cell lines demonstrated that the BRAF L597S mutation might be sensitive to the RAF inhibitor vemurafenib and the MEK inhibitor trametinib (PMID: 22798288). The BRAF L597S mutation has also been identified in patients with positive responses to trametinib, the allosteric MEK inhibitor TAK-733, and combined dabrafenib and trametinib treatment (PMID: 24933606, 22798288, 29903896)."
              },
              "operation": "update",
              "uuids": "bd08e589-0a0b-4ff9-b514-fe3fe1d84f30"
            }
          ],
          "timeStamp": 1678404491753
        },
        "-NQ7hVJWGybfKSVX4KVz": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "K601E, Mutation Effect",
              "new": {
                "description": "The class II BRAF K601E mutation is located in the kinase domain in exon 15 of the protein (PMID: 28783719, 26343582). This mutation is recurrent in melanoma (PMID: 22798288, 26643848). Biological characterization of BRAF K601E mutations demonstrated that they activate the downstream MAPK pathway independently of RAS and render BRAF active as a dimer with CRAF and itself (PMID: 22798288, 20179705, 26343582). Preclinical studies with patient-derived xenograft models of colorectal cancer expressing BRAF K601E demonstrated sensitivity to treatment with PLX8394 with or without cetuximab as measured by reduced tumor growth, and resistance to treatment with cetuximab and vemurafenib as measured by no reduction in tumor growth upon treatment (PMID: 30559419, 31515458). A patient with metastatic BRAF K601E-mutated melanoma achieved a complete response to the MEK inhibitor trametinib (PMID: 28344857). In a case report, a patient with lung adenocarcinoma harboring BRAF K601E was treated with a combination therapy of dabrafenib plus trametinib and demonstrated partial response with a progression-free survival of nine months (PMID: 34590045). In another case report, a patient with papillary thyroid carcinoma harboring BRAF K601E was treated with a combination therapy of sorafenib plus denosumab and demonstrated a complete response (PMID: 35630083). In a Phase II trial, a patient with melanoma harboring BRAF K601E was treated with trametinib and demonstrated partial response with a progression-free survival of 32 weeks (PMID: 23248257). In another Phase II trial, six patients with advanced solid tumors harboring BRAF K601E were treated with vemurafenib and did not clinically respond to treatment (PMID: 29320312). In a Phase I trial, two patients with melanoma harboring BRAF K601E were treated with dabrafenib and did not clinically respond to treatment (PMID: 22608338)."
              },
              "old": {
                "description": "The class II (PMID: 28783719) and hyperactivating (PMID: 26343582) BRAF K601E mutation is located in the kinase domain in exon 15 of the BRAF protein, and is recurrent in melanoma (PMID: 22798288, 26643848). Biological characterization of BRAF K601E mutations demonstrated that they activate the downstream MAPK pathway independently of RAS (PMID: 22798288, 26343582), render BRAF active as a dimer with CRAF and itself (PMID: 20179705, 26343582) and while sensitive to MEK inhibition by targeted inhibitors such as trametinib (PMID: 28783719, 22798288, 18794803), are insensitive to RAF monomer inhibitors such as vemurafenib (PMID: 22798288, 28783719, 20179705). A patient with metastatic BRAF K601E-mutated melanoma achieved complete response to the MEK inhibitor trametinib (PMID: 28344857)."
              },
              "operation": "update",
              "uuids": "9b64a01a-fe4a-4764-bb83-50a7dddc2093"
            }
          ],
          "timeStamp": 1678404617428
        },
        "-NQ7i3XlYkHsdIGyaOrf": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600D, Mutation Effect",
              "new": {
                "description": "The class I activating exon 15 BRAF V600D mutation is located in the kinase domain of the protein (PMID: 28783719). This mutation is recurrent in melanoma (PMID: 26091043, 23579220, 22614978). Comprehensive biological characterization of the BRAF V600D mutation has demonstrated that this mutation activates the downstream MAPK pathway independently of RAS and renders BRAF constitutively activated in monomeric form (PMID: 15035987, 12068308, 19251651, 26343582, 20179705). Preclinical studies with melanoma cells expressing BRAF V600D demonstrate sensitivity to treatment with CCT196969, CCT241161, AZ628, TAK-632, PLX7904, vemurafenib, dabrafenib, ASTX029 and cobimetinib plus HM95573 as measured by inhibition of MEK and ERK phosphorylation and cellular proliferation (PMID: 25500121, 17210691, 27523909, 33953400, 34330842). In a case report, a patient with pilocytic astrocytoma harboring BRAF V600D was treated with single-agent dabrafenib then subsequently treated with combination therapy of dabrafenib plus trametinib and demonstrated stable disease (PMID: 28784858). In a Phase II trial, a patient with non-small cell lung cancer harboring BRAF V600D was treated with vemurafenib and demonstrated partial response with a progression-free survival of 3.8 months (PMID: 31959346)."
              },
              "old": {
                "description": "The class I (PMID: 28783719) activating exon 15 BRAF V600D missense mutation is located in the kinase domain of the BRAF protein. BRAF V600D mutation is recurrent in melanoma (PMID: 26091043, 23579220, 22614978), although the more common V600E variant is also frequently found in lung (PMID: 25079552, 23833300) and thyroid (PMID: 25417114) cancers, among others. Comprehensive biological characterization of the BRAF V600D mutation (PMID: 15035987, 12068308) has demonstrated that this mutation activates the downstream MAPK pathway independently of RAS (PMID: 19251651, 26343582), renders BRAF constitutively activated in monomeric form (PMID: 20179705) and retains sensitivity to RAF monomer inhibitors such as vemurafenib (PMID: 26343582, 28783719, 20179705)."
              },
              "operation": "update",
              "uuids": "2d9f29be-c010-4fd7-8bf1-724be975d211"
            }
          ],
          "timeStamp": 1678404765796
        },
        "-NQ7iOT0fpEgKlJFNdHX": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600R, Mutation Effect",
              "new": {
                "description": "The class I activating exon 15 BRAF V600R missense mutation is located in the kinase domain of the BRAF protein (PMID: 28783719). BRAF V600R is the third most common mutation occurring in 5-7% of patients with BRAF-mutant melanoma (PMID: 22536370, 23237741, 22614978). Comprehensive biological characterization of the BRAF V600R mutation has demonstrated that this mutation activates the downstream MAPK pathway independently of RAS and renders BRAF constitutively activated in monomeric form (PMID: 15035987, 28783719, 26343582, 20179705). Preclinical studies with melanoma cells expressing BRAF V600R demonstrate sensitivity to treatment with AZ628, TAK-632, PLX7904, vemurafenib and dabrafenib as measured by inhibition of cellular proliferation (PMID: 27523909). In a case report, a patient with melanoma harboring BRAF V600R was treated with a combination therapy of dabrafenib plus trametinib and demonstrated partial response with a progression-free survival of 52.2 months (PMID: 36039514). In another case report, a patient with melanoma harboring BRAF V600R was treated with dabrafenib and demonstrated partial response with lesion reduction and progression-free survival of seven months (PMID: 27255157)."
              },
              "old": {
                "description": "The class I (PMID: 28783719) activating exon 15 BRAF V600R missense mutation is located in the kinase domain of the BRAF protein. BRAF V600R is the third most common mutation occurring in 5-7% of patients with BRAF-mutant melanoma (PMID: 22536370, 23237741, 22614978), although the more common V600E variant is also frequently found in lung (PMID: 25079552, 23833300) and thyroid (PMID: 25417114) cancers, among others. Comprehensive biological characterization of the BRAF V600R mutation (PMID: 15035987) has demonstrated that this mutation activates the downstream MAPK pathway independently of RAS (PMID: 28783719, 26343582), and similar to V600E, renders BRAF constitutively activated in monomeric form (PMID: 20179705). Like other class I BRAF mutants, V600R is sensitive to vemurafenib (PMID: 26343582, 28783719, 20179705), which has been reported to be very effective in treating melanoma brain metastases in patients harboring BRAF V600R mutation (PMID: 23237741, 23490649, 23473613)."
              },
              "operation": "update",
              "uuids": "12d0ecbc-50f2-4179-b883-236acf79ec53"
            }
          ],
          "timeStamp": 1678404851508
        },
        "-NQ7ijL1nhbxZ_JSrEvF": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "L597R, Mutation Effect",
              "new": {
                "description": "The class II BRAF L597R mutation is located in the kinase domain of the protein (PMID: 33019809). This mutation has been found in melanoma, among other cancers (PMID: 26643848). In vitro studies have demonstrated that this mutation is likely activating as measured by increased downstream signaling compared to wildtype (PMID: 22798288). Drug efficacy studies in cell lines demonstrated that the BRAF L597R mutation might be sensitive to the RAF inhibitor vemurafenib and the MEK inhibitor trametinib (PMID: 22798288). The BRAF L597R mutation has also been identified in patients with positive responses to trametinib and the allosteric MEK inhibitor TAK-733 (PMID: 24933606). In a case report, a patient with melanoma harboring BRAF L597R was treated with vemurafenib and demonstrated partial response with 30% growth inhibition of skin and lung nodules (PMID: 23715574). In another case report, a patient with lung adenocarcinoma harboring BRAF L597R was treated with a combination therapy of dabrafenib and trametinib and demonstrated partial response with a progression-free survival of twelve months (PMID: 32540409). In another case report, a patient with colorectal cancer harboring BRAF L597R was treated with a combination therapy of panitumumab plus FOLFIRI and demonstrated stable disease with a progression-free survival of 16.5 months (PMID: 31515458)."
              },
              "old": {
                "description": "The BRAF L597R mutation is located in the kinase domain of the BRAF protein. This mutation has been found in melanoma, among other cancers (PMID: 26643848). In vitro studies have demonstrated that this mutation is likely activating as measured by increased downstream signaling compared to wildtype (PMID: 22798288). Drug efficacy studies in cell lines demonstrated that the BRAF L597L mutation might be sensitive to the RAF inhibitor vemurafenib and the MEK inhibitor trametinib (PMID: 22798288). The BRAF L597L mutation has also been identified in patients with positive responses to trametinib and the allosteric MEK inhibitor TAK-733 (PMID: 24933606)."
              },
              "operation": "update",
              "uuids": "57225720-7b20-42b8-aed1-561e9d1a6922"
            }
          ],
          "timeStamp": 1678404941109
        },
        "-NQ7iy54FGZ2yt-LV24z": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "L597V, Mutation Effect",
              "new": {
                "description": "The class II BRAF L597V mutation is located in the kinase domain in exon 15 of the protein (PMID: 28783719, 26343582). This mutation is recurrent in melanoma (PMID: 12068308, 15035987, 26643848). Biological characterization of BRAF L597V mutation demonstrated that it activates the downstream MAPK pathway independent of RAS and renders BRAF active as a dimer with CRAF and itself (PMID: 12068308, 15035987, 22798288, 26343582, 28783719, 20179705). Preclinical studies with patient-derived lung adenocarcinoma cells expressing BRAF L597V demonstrated sensitivity to treatment with dabrafenib plus trametinib, trametinib, BGB-283 and LXH 254, as measured by cellular proliferation inhibition, and resistance to treatment with dabrafenib, encorafenib, vemurafenib,TAK-580, LY3214996, MK-8353, GDC-0994 and BVD-523, as measured by sustained cellular proliferation upon drug treatment (PMID: 32540409). In a Phase II trial, a patient with endometrial adenocarcinoma harboring BRAF L597V was treated with trametinib and demonstrated stable disease with a progression-free survival of 7.9 months (PMID: 31924734)."
              },
              "old": {
                "description": "The class II (PMID: 28783719) and hyperactivating (PMID: 26343582) BRAF L597V missense mutation is located in the kinase domain in exon 15 of the BRAF protein, and is recurrent in melanoma (PMID: 12068308, 15035987, 26643848). A clinicopathologic study of a cohort of 1119 Australian patients with known BRAF mutant status positive melanomas demonstrated that, at 3.4% of patients, BRAF L597 mutations are some of the most commonly occurring BRAF non-V600E mutations. These BRAF mutations typically occur in older (median 66 yr) male (73.3% of L597 mutant cases) patients and are associated with chronically sun-damaged skin (extremities or head and neck location - 73.3%, P = 0.001) (PMID: 26643848). Biological characterization of BRAF L597V mutation has demonstrated that it activates the downstream MAPK pathway independent of RAS (PMID: 12068308, 15035987, 22798288, 26343582, 28783719), renders BRAF active as a dimer with CRAF and itself (PMID: 20179705), and while sensitive to MEK inhibition by targeted inhibitors such as trametinib (PMID: 28783719, 22798288, 18794803), is insensitive to RAF monomer inhibitors such as vemurafenib (PMID: 22798288, 28783719, 20179705)."
              },
              "operation": "update",
              "uuids": "a9e6b8b3-d1fb-4685-a5ec-78811f7bb602"
            }
          ],
          "timeStamp": 1678405001528
        },
        "-NQ7j6uUY_bl6kikqrKF": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "K601Q, Mutation Effect",
              "new": {
                "description": "The class II BRAF K601Q mutation is located in the kinase domain in exon 15 of the protein (PMID: 33019809). This mutation has been found in patients with cardio-facio-cutaneous syndrome (PMID: 19206169). Expression of this mutation in NIH-3T3 cells demonstrated that it is activating as measured by increased downstream pathway activation compared to wildtype BRAF, though to a lesser extent than BRAF V600E (PMID: 19206169). Preclinical studies with melanoma cells expressing BRAF K601Q demonstrated resistance to treatment with vemurafenib as measured by sustained MEK and ERK phosphorylation following treatment (PMID: 35045286)."
              },
              "old": {
                "description": "The BRAF K601Q mutation is located in the kinase domain in exon 15 of the protein. This mutation has been found in patients with cardio-facio-cutaneous syndrome (CFC) (PMID: 19206169). Expression of this mutation in NIH-3T3 cells demonstrated that it is activating as measured by increased downstream pathway activation compared to wildtype BRAF, though to a lesser extent than BRAF V600E (PMID: 19206169)."
              },
              "operation": "update",
              "uuids": "bf3ce630-ff39-4267-a35a-5ea53feee665"
            }
          ],
          "timeStamp": 1678405041746
        },
        "-NQ7jsKIClQHLS_JFQVH": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "L597Q, Mutation Effect",
              "new": {
                "description": "The class II BRAF L597Q mutation is located in the kinase domain in exon 15 of the protein (PMID: 28783719, 26343582). This mutation is recurrent in melanoma (PMID: 12068308, 15035987, 26643848). Biological characterization of BRAF L597Q demonstrated that it activates the downstream MAPK pathway independent of RAS and renders BRAF active as a dimer with CRAF and itself (PMID: 12068308, 15035987, 22798288, 26343582, 28783719). Preclinical studies with patient-derived colon adenocarcinoma cells expressing BRAF L597Q demonstrated sensitivity to treatment with trametinib, selumetinib, AZD8931 and trametinib plus cetuximab as measured by inhibition of tumor growth (PMID: 31704811). In a Phase I trial, a patient with lung cancer harboring BRAF L597Q was treated with BVD-523 and demonstrated partial response (PMID: 29247021). In a Phase II trial, a patient with melanoma harboring BRAF L597Q was treated with trametinib and demonstrated partial response with a 38% tumor reduction and ongoing progression-free survival of 8.3 months (PMID: 33861486). In another Phase II trial, a patient with an advanced solid tumor harboring BRAF L597Q was treated with vemurafenib and did not clinically respond to treatment (PMID: 29320312)."
              },
              "old": {
                "description": "The class II (PMID: 28783719) hyperactivating (PMID: 26343582) exon 15 BRAF L597Q missense mutation is located in the kinase domain of the BRAF protein, and is recurrent in melanoma (PMID: 12068308, 15035987, 26643848). A clinicopathologic study of a cohort of 1119 Australian patients with known BRAF mutant status positive melanomas demonstrated that at 3.4% of patients, BRAF L597 mutations are some of the most commonly occurring BRAF non-V600E mutations. These BRAF mutations typically occur in older (median age 66 yr) male (73.3% of L597 mutant cases) patients and are associated with chronically sun-damaged skin (extremities or head and neck location - 73.3%, P = 0.001) (PMID:26643848). Biological characterization of BRAF L597Q mutation demonstrated that it activates the downstream MAPK pathway independent of RAS (PMID: 12068308, 15035987, 22798288, 26343582), renders BRAF active as a dimer with CRAF and itself (PMID: 26343582, 28783719), and while sensitive to MEK inhibition by targeted inhibitors such as trametinib (PMID: 28783719, 22798288, 18794803, 24933606), is insensitive to RAF monomer inhibitors such as vemurafenib (PMID: 22798288, 28783719, 20179705, 26343582)."
              },
              "operation": "update",
              "uuids": "1f81f2af-cf83-4764-9fe2-b5f4de735c42"
            }
          ],
          "timeStamp": 1678405240070
        },
        "-NQ7kEuv06cBM0gPky0A": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "K601N, Mutation Effect",
              "new": {
                "description": "The class II BRAF K601N mutation is located in the kinase domain in exon 15 of the protein (PMID: 28783719, 26343582). This mutation has been identified in melanoma and multiple myeloma (PMID: 12068308, 15035987, 25178945, 23273605, 24270325). Biological characterization of BRAF K601N demonstrated that it activates the downstream MAPK pathway independently of RAS and renders BRAF active as a dimer with CRAF and itself (PMID: 26343582, 20179705). Preclinical studies with NIH3T3 and SK-MEL-239 cells expressing BRAF K601N demonstrated sensitivity to treatment with LY3009120 and PLX8394 as measured by reduced proliferation (PMID: 26732095, 30559419). In a Phase Ib trial, a patient with non-small cell lung cancer harboring BRAF K601N was treated with combination therapy of LTT462 and LXH 254 and demonstrated an unconfirmed partial response (Abstract: Wolf et al. Abstract# 1387p, Annals of Oncology 2020. https://www.annalsofoncology.org/article/S0923-7534%2820%2941697-7/fulltext). In a Phase II trial, two patients with non-small cell lung cancer harboring BRAF K601N were treated vemurafenib and did not clinically respond to treatment (PMID: 31959346)."
              },
              "old": {
                "description": "The class II (PMID: 28783719) hyperactivating (PMID: 26343582)exon 15 BRAF K601N missense mutation is located in the kinase domain of the BRAF protein. It is recurrent in melanoma (PMID: 12068308, 15035987, 25178945, 23273605) and has also been reported in multiple myeloma cell lines (PMID: 24270325). Biological characterization of BRAF K601N mutation demonstrated that it activates the downstream MAPK pathway independently of RAS (PMID: 26343582), renders BRAF active as a dimer with CRAF and itself (PMID: 20179705) and while sensitive to MEK inhibition by targeted inhibitors such as trametinib (PMID: 28783719, 28783719, 18794803), is insensitive to RAF monomer inhibitors such as vemurafenib (PMID: 22798288, 28783719, 20179705)."
              },
              "operation": "update",
              "uuids": "99bbe560-98df-4ece-97ad-2ccf9fa0b7d8"
            }
          ],
          "timeStamp": 1678405336686
        },
        "-NQ7kXGFKHNYKPK9Satj": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G469E, Mutation Effect",
              "new": {
                "description": "The class III BRAF G469E mutation is located in the kinase domain in exon 11 of the protein (PMID: 28783719). This mutation has been reported in melanoma, lung cancer, colorectal cancer and cardio-facio-cutaneous syndrome (PMID: 26498038, 18794803, 16439621). Biological characterization of the BRAF G469E mutation has demonstrated that it is RAS dependent in its activation of the MAPK pathway, signals as a dimer with CRAF, and typically co-occurs with another driver mechanism that amplifies RAS signaling (PMID: 15035987, 28783719, 15150094, 22510884). Thus, in melanoma, the G469E variant, similar to other class III BRAF mutants, would be expected to co-occur with activating RAS mutation or NF1 inactivation, whereas in non-small cell lung or colorectal cancers, this mutation would most likely be associated with receptor tyrosine kinase (RTK) hyperactivation at the protein level (PMID: 28783719). Preclinical studies with melanoma cells expressing BRAF G469E demonstrated sensitivity to treatment with sorafenib, as measured by inhibition of growth and induced apoptosis, and resistance to treatment with U0126, as measured by persistent cell growth (PMID: 18794803). In a Phase II trial, a patient with breast ductal carcinoma harboring BRAF G469E was treated with trametinib and demonstrated partial response with a 50% tumor size reduction (PMID: 31924734)."
              },
              "old": {
                "description": "The class III hypoactivating (PMID: 28783719) exon 11 BRAF G469E missense mutation occurs in the kinase domain of the BRAF protein, and it has been reported in melanomas, lung and colorectal cancers (PMID: 26498038, 18794803), as well as in cardio-facio-cutaneous syndrome (CFC) (PMID: 16439621). Biological characterization of the BRAF G469E mutation has demonstrated that it is RAS dependent in its activation of the MAPK pathway, signals as a dimer with CRAF, and typically co-occurs with another driver mechanism that amplifies RAS signaling (PMID: 15035987, 28783719, 15150094, 22510884). Thus, in melanoma, the G469E variant, similar to other class III BRAF mutants, would be expected to co-occur with activating RAS mutation or NF1 inactivation, whereas in non-small cell lung or colorectal cancers, this mutation would most likely be associated with receptor tyrosine kinase (RTK) hyperactivation at the protein level (PMID: 28783719). While this mutation is sensitive to MEK inhibition by targeted inhibitors such as trametinib, it is insensitive to RAF monomer inhibitors such as vemurafenib."
              },
              "operation": "update",
              "uuids": "2bb6b849-bcd7-4f63-b423-6d2f5260e49c"
            }
          ],
          "timeStamp": 1678405411843
        },
        "-NQ7kehftOYu6PLnJLlH": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G469R, Mutation Effect",
              "new": {
                "description": "The class II BRAF G469R mutation is located in the kinase domain in exon 11 of the protein (PMID: 28783719, 26343582). This mutation has been reported in non-small cell lung cancer, chronic lymphocytic leukemia, melanoma and a range of other cancer types (PMID: 26498038, 24920063, 16096377, 26150740, 26619011). Biological characterization of the BRAF G469R mutation demonstrated that it activates the downstream MAPK pathway independent of RAS renders BRAF active as a dimer with CRAF and itself (PMID: 26343582, 28783719, 20179705). While sensitive to MEK inhibition by targeted inhibitors such as trametinib, this mutation is insensitive to RAF monomer inhibitors such as vemurafenib (PMID: 26343582, 28783719, 18794803, 26343582, 28783719). In a Phase II trial, a patient with melanoma harboring BRAF G469R and KIT G12V was treated with trametinib and demonstrated stable disease with a progression-free survival of 22.3 months (PMID: 33861486)."
              },
              "old": {
                "description": "The class II (PMID: 28783719) hyperactivating (PMID: 26343582) exon 11 BRAF G469R missense mutation is located in the kinase domain (G loop) of the BRAF protein, and has been reported in non-small cell lung cancer (NSCLC) (PMID: 26498038), chronic lymphocytic leukemia (CLL) (PMID: 24920063), melanoma, and a range of other cancer types (PMID: 16096377, 26150740, 26619011). Biological characterization of the BRAF G469R mutation demonstrated that it activates the downstream MAPK pathway independent of RAS (PMID: 26343582, 28783719), renders BRAF active as a dimer with CRAF and itself (PMID: 26343582, 20179705) and while sensitive to MEK inhibition by targeted inhibitors such as trametinib (PMID: 26343582, 28783719, 18794803), is insensitive to RAF monomer inhibitors such as vemurafenib (PMID: 26343582, 28783719)."
              },
              "operation": "update",
              "uuids": "75cc7602-ac02-434e-89b6-5551765ba3a5"
            }
          ],
          "timeStamp": 1678405446430
        },
        "-NQ7ltaAK9Bluiypjavp": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G469V, Mutation Effect",
              "new": {
                "description": "The class II BRAF G469V mutation is located in the kinase domain in exon 11 of the protein (PMID: 28783719, 26343582). This mutation has been reported in non-small cell lung cancer and bladder cancer (PMID: 25870796, 27388325, 23401075). Biological characterization of the BRAF G469V mutation demonstrated that it activates the downstream MAPK pathway independently of RAS and renders BRAF active as a dimer with CRAF and itself (PMID: 26343582, 28783719, 20179705). Preclinical studies with SKBR3 cells expressing BRAF G469V demonstrated resistance to treatment with vemurafenib as measured by persistent MEK and ERK activation following treatment (PMID: 26343582). In a case report, two patients with metastatic colorectal cancer harboring BRAF G469V were treated with either panitumumab plus FOLFOX or cetuximab plus irinotecan and both treatment options demonstrated partial response with a progression-free survival of 18.9 months and 10.9 months, respectively (PMID: 31515458). In another case report, a patient with lung adenocarcinoma harboring BRAF G469V was treated with combination therapy of trametinib and dabrafenib and progressed after nine weeks of treatment (PMID: 32540409). In another case report, a patient with hepatocellular carcinoma and non-small cell lung cancer harboring BRAF G469V was treated with sorafenib and demonstrated a complete response in the lung and stability of the hepatocellular carcinoma (PMID: 27388325)."
              },
              "old": {
                "description": "The class II (PMID: 28783719) hyperactivating (PMID: 26343582) exon 11 BRAF G469V missense mutation is located in the kinase domain (G loop) of the BRAF protein, and has been reported in non-small cell lung cancer (NSCLC) (PMID: 25870796, 27388325) and in bladder cancer (PMID: 23401075). Biological characterization of the BRAF G469V mutation demonstrated that it activates the downstream MAPK pathway independently of RAS (PMID: 26343582, 28783719), renders BRAF active as a dimer with CRAF and itself (PMID: 20179705, 26343582) and while sensitive to MEK inhibition by targeted inhibitors such as trametinib (PMID: 28783719, 18794803), is insensitive to RAF monomer inhibitors such as vemurafenib (PMID: 28783719, 26343582, 20179705)."
              },
              "operation": "update",
              "uuids": "94fe5461-1eb2-432a-9b78-a2e7d2e26cb7"
            }
          ],
          "timeStamp": 1678405769534
        },
        "-NQ7m-VZLBJDiwirLD6a": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Q257R, Mutation Effect",
              "new": {
                "description": "The class II BRAF Q257R mutation is located in the cysteine-rich domain in exon 6 of the protein (PMID: 33019809). This mutation has been found in cardio-facio-cutaneous syndrome (PMID: 16474404, 16439621). Expression of this mutation in NIH-3T3 cells demonstrated that this mutation is activating as measured by increased transcription of downstream MAPK pathway transcriptional targets (e.g., ELK) compared to wildtype BRAF (PMID: 16474404). When expressed in zebrafish embryos, the Q257R mutation causes the same aberrant elongation phenotype as BRAF V600E, suggesting that it is likely activating in vivo (PMID: 19376813)."
              },
              "old": {
                "description": "The BRAF Q257R mutation is located in the cysteine-rich domain in exon 6 of the protein. This mutation has been found in cardio-facio-cutaneous syndrome (CFC) (PMID: 16474404, 16439621). Expression of this mutation in NIH-3T3 cells demonstrated that this mutation is activating as measured by increased transcription of downstream MAPK pathway transcriptional targets (e.g., ELK) compared to wildtype BRAF (PMID: 16474404). When expressed in zebrafish embryos, the Q257R mutation causes the same aberrant elongation phenotype as BRAF V600E, suggesting that it is likely activating in vivo (PMID: 19376813)."
              },
              "operation": "update",
              "uuids": "eef8ecb6-23d2-442e-927d-d5350813178d"
            }
          ],
          "timeStamp": 1678405797847
        },
        "-NQ7m6Rfh4y601ALiuwU": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "I326V, Mutation Effect",
              "new": {
                "description": "The BRAF I326V mutation is located in the flexible hinge domain of the BRAF protein. This mutation has been found as a germline mutation in Noonan Syndrome (PMID: 17603482). In vitro studies have demonstrated that this mutation is likely neutral as measured by downstream signaling compared to wildtype (PMID: 17603482). In a clinical study, a patient with colorectal cancer harboring BRAF I326V was treated with panitumumab and irinotecan plus S-1 and demonstrated progressive disease (PMID: 30463788)."
              },
              "old": {
                "description": "The BRAF I326V mutation is located in the flexible hinge domain of the BRAF protein. This mutation has been found as a germline mutation in Noonan Syndrome (PMID: 17603482). In vitro studies have demonstrated that this mutation is likely neutral as measured by downstream signaling compared to wildtype (PMID: 17603482)."
              },
              "operation": "update",
              "uuids": "c81b4261-e7a5-49db-80fc-e85e54ab4055"
            }
          ],
          "timeStamp": 1678405826270
        },
        "-NQ7mDMbpC40tD7TUUDg": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "I463S, Mutation Effect",
              "new": {
                "description": "The class II BRAF I463S mutation is located in the kinase domain in exon 11 of the protein (PMID: 33019809). This mutation has been found in colorectal cancer (PMID: 15150094). Expression of this mutation in NIH-3T3 or IEC-6 cells demonstrated that it is likely neutral, as measured by kinase activity, foci formation, and cell proliferation comparable to wildtype BRAF (PMID: 15150094, 15035987). Additionally, expression of BRAF I463S with HRAS G12V does not lead to increased MAPK pathway activation either alone as a monomer or through dimerization with CRAF (PMID: 15150094)."
              },
              "old": {
                "description": "The BRAF I463S mutation is located in the kinase domain in exon 11 of the protein. This mutation has been found in colorectal cancer (PMID: 15150094). Expression of this mutation in NIH-3T3 or IEC-6 cells demonstrated that it is likely neutral, as measured by kinase activity, foci formation, and cell proliferation comparable to wildtype BRAF (PMID: 15150094, 15035987). Additionally, expression of BRAF I463S with HRAS G12V does not lead to increased MAPK pathway activation either alone as a monomer or through dimerization with CRAF (PMID: 15150094)."
              },
              "operation": "update",
              "uuids": "d5c4b6b2-1741-441c-ac40-b223d4060c9b"
            }
          ],
          "timeStamp": 1678405854618
        },
        "-NQ7mKL71Y9_V3IJgMql": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R462I, Mutation Effect",
              "new": {
                "description": "The class II BRAF R462I mutation is located in the kinase domain in exon 11 of the protein (PMID: 35050937). This mutation has been found in colorectal cancer (PMID: 15150094). Expression of this mutation in NIH-3T3 or IEC-6 cells demonstrated that this mutation is neutral as measured by kinase activity, foci-formation and cell proliferation comparable to wildtype BRAF (PMID: 15150094, 15035987). Additionally, expression of this mutation with HRAS G12V failed to activate the MAPK pathway either as a monomer or a dimer with CRAF, suggesting it is not activating (PMID: 15150094)."
              },
              "old": {
                "description": "The BRAF R462I mutation is located in the kinase domain in exon 11 of the protein. This mutation has been found in colorectal cancer (PMID: 15150094). Expression of this mutation in NIH-3T3 or IEC-6 cells demonstrated that this mutation is neutral as measured by kinase activity, foci-formation and cell proliferation comparable to wildtype BRAF (PMID: 15150094, 15035987). Additionally, expression of this mutation with HRAS G12V failed to activate the MAPK pathway either as a monomer or a dimer with CRAF, suggesting it is not activating (PMID: 15150094)."
              },
              "operation": "update",
              "uuids": "89566b58-387b-4ade-bec1-847857ef762a"
            }
          ],
          "timeStamp": 1678405883195
        },
        "-NQ7mRAjAOTceYxUQlfF": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V471F, Mutation Effect",
              "new": {
                "description": "The class II BRAF V471F mutation is located in the kinase domain in exon 11 of the protein (PMID: 33019809). Expression of this mutation in 293T cells demonstrated that this mutation is activating as measured by increased downstream pathway activation and moderate transforming activity compared to wildtype BRAF (PMID: 25348715). Though this mutation is kinase-dead, it activates the MAPK pathway by dimerizing with CRAF (PMID: 25348715)."
              },
              "old": {
                "description": "The BRAF V471F mutation is located in the kinase domain in exon 11 of the protein. Expression of this mutation in 293T cells demonstrated that this mutation is activating as measured by increased downstream pathway activation and moderate transforming activity compared to wildtype BRAF (PMID: 25348715). Though this mutation is kinase dead, it activates the MAPK pathway by dimerizing with CRAF (PMID: 25348715)."
              },
              "operation": "update",
              "uuids": "a97a1859-463d-44b0-a455-7708ac87643d"
            }
          ],
          "timeStamp": 1678405911202
        },
        "-NQ7mY5QP2Cpav1EdUb1": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "S467A, Mutation Effect",
              "new": {
                "description": "The class III BRAF S467A mutation is located in the kinase domain in exon 11 of the protein (PMID: 35050937). This mutation has been found in cardio-facio-cutaneous syndrome (PMID: 16439621). Expression of this mutation in 293T cells demonstrated that this mutation is activating as measured by increased activation of downstream MAPK effectors compared to wildtype BRAF (PMID: 16439621). When expressed in zebrafish embryos, the BRAF S467A mutation causes the same aberrant elongation phenotype as BRAF V600E, suggesting that it is likely activating in vivo (PMID: 19376813)."
              },
              "old": {
                "description": "The BRAF S467A mutation is located in the kinase domain in exon 11 of the protein. This mutation has been found in cardio-facio-cutaneous syndrome (CFC) (PMID: 16439621). Expression of this mutation in 293T cells demonstrated that this mutation is activating as measured by increased activation of downstream MAPK effectors compared to wildtype BRAF (PMID: 16439621). When expressed in zebrafish embryos, the BRAF S467A mutation causes the same aberrant elongation phenotype as BRAF V600E, suggesting that it is likely activating in vivo (PMID: 19376813)."
              },
              "operation": "update",
              "uuids": "b1f6b30a-c28b-4f4b-b0fd-04e76e8b5d9d"
            }
          ],
          "timeStamp": 1678405939534
        },
        "-NQ7me3WtI2IUt0W1YBy": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "K483E, Mutation Effect",
              "new": {
                "description": "The class III BRAF K483E mutation occurs in the tyrosine kinase domain of the BRAF protein (PMID: 33019809). This mutation has been identified in a patient diagnosed with pediatric poorly differentiated carcinoma (PMID: 27799065). Overexpression of this variant in 293T cells resulted in activation of MEK1/2, however, the activation was comparable to overexpression of wildtype BRAF (PMID: 27799065). Activation likely occurs via allosteric activation of BRAF or CRAF because of the lack of BRAF K483E kinase activity (PMID: 27799065). Preclinical studies with patient-derived colorectal cancer organoids expressing BRAF K483E demonstrated sensitivity to treatment with binimetinib as measured by decreased cell viability, and resistance to treatment with cetuximab as measured by no change in cell viability (PMID: 33060766)."
              },
              "old": {
                "description": "The BRAF K483E mutation occurs in the tyrosine kinase domain of the BRAF protein. This residue is characterized as a kinase-dead mutation with no transformation ability (PMID: 15035987, 23533272). This mutation has been identified in a patient diagnosed with pediatric poorly differentiated carcinoma (PMID: 27799065). Overexpression of this variant in 293T cells resulted in activation of MEK1/2, however, the activation was comparable to overexpression of wildtype BRAF (PMID: 27799065). Activation likely occurs via allosteric activation of BRAF or CRAF because of the lack of BRAF K483E kinase activity."
              },
              "operation": "update",
              "uuids": "0be98f82-fc8b-47a0-9ccc-7413b607a840"
            }
          ],
          "timeStamp": 1678405968084
        },
        "-NQ7mkzK1mXa_GyN-ppJ": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Y472C, Mutation Effect",
              "new": {
                "description": "The BRAF Y472C mutation is located in the kinase domain in exon 11 of the protein. This mutation is found in non-small cell lung cancer (PMID: 22649091). Expression of this mutation in COS7, H661, or H226 cells demonstrated that it is activating as measured by increased downstream MEK and ERK activation compared to wildtype BRAF, despite having impaired kinase activity (PMID: 22649091). Similar to other kinase-inactivating BRAF mutations, the Y472C mutant promotes downstream oncogenic signaling (via MEK/ERK pathway) by transactivating CRAF, and therefore is considered to be likely oncogenic in the clinical setting (PMID: 22649091). In a Phase II trial, a patient with non-small cell lung cancer harboring BRAF Y472C was treated with dasatinib and demonstrated a complete response (PMID: 20855820)."
              },
              "old": {
                "description": "The BRAF Y472C mutation is located in the kinase domain in exon 11 of the protein. This mutation is found in non-small cell lung cancer (PMID: 22649091). Expression of this mutation in COS7, H661, or H226 cells demonstrated that it is activating as measured by increased downstream MEK and ERK activation compared to wildtype BRAF, despite having impaired kinase activity (PMID: 22649091). Similar to other kinase-inactivating BRAF mutations, the Y472C mutant promotes downstream oncogenic signaling (via MEK/ERK pathway) by transactivating CRAF, and therefore is considered to be likely oncogenic in the clinical setting (PMID: 22649091)."
              },
              "operation": "update",
              "uuids": "38abf378-98d7-47ca-b0b7-d277dfcc627f"
            }
          ],
          "timeStamp": 1678405996424
        },
        "-NQ7mrsoztxtAXJRq82S": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "K499E, Mutation Effect",
              "new": {
                "description": "The class II BRAF K499E mutation is located in the kinase domain in exon 12 of the protein (PMID: 33019809). This mutation has been found in cardio-facio-cutaneous syndrome (PMID: 16474404, 16439621). Expression of this mutation in NIH-3T3 cells demonstrated that it is activating as measured by significantly increased transcription of downstream MAPK pathway transcriptional targets (e.g., ELK) compared to wildtype BRAF (PMID: 16474404)."
              },
              "old": {
                "description": "The BRAF K499E mutation is located in the kinase domain in exon 12 of the protein. This mutation has been found in cardio-facio-cutaneous syndrome (CFC) (PMID: 16474404, 16439621). Expression of this mutation in NIH-3T3 cells demonstrated that it is activating as measured by significantly increased transcription of downstream MAPK pathway transcriptional targets (e.g., ELK) compared to wildtype BRAF (PMID: 16474404)."
              },
              "operation": "update",
              "uuids": "d46a95e1-2983-436e-9368-5485cf138059"
            }
          ],
          "timeStamp": 1678406024679
        },
        "-NQ7myuLCw_Lm1vJ9ZQc": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "L485F, Mutation Effect",
              "new": {
                "description": "The class II BRAF L485F mutation is located in the kinase domain in exon 11 of the protein (PMID: 31515458). This mutation has been found in cardio-facio-cutaneous syndrome (PMID: 16474404, 16439621). Expression of this mutation in NIH-3T3 cells demonstrated that it is activating as measured by significantly increased transcription of downstream MAPK pathway transcriptional targets (e.g., ELK) compared to wildtype BRAF (PMID: 16474404). Preclinical studies with 293T cells expressing BRAF L485F demonstrated sensitivity to treatment with LY3009120, as measured by inhibition of ERK signaling, and resistance to treatment with dabrafenib, PLX8394 and vemurafenib, as measured by persistent ERK signaling (PMID: 34108213). In a clinical study, a patient with metastatic colorectal cancer harboring BRAF L485F was treated with a combination therapy of cetuximab plus irinotecan and demonstrated stable disease with a progression-free survival of 6.3 months (PMID: 31515458)."
              },
              "old": {
                "description": "The BRAF L485F mutation is located in the kinase domain in exon 11 of the protein. This mutation has been found in cardio-facio-cutaneous syndrome (CFC) (PMID: 16474404, 16439621). Expression of this mutation in NIH-3T3 cells demonstrated that it is activating as measured by significantly increased transcription of downstream MAPK pathway transcriptional targets (e.g., ELK) compared to wildtype BRAF (PMID: 16474404)."
              },
              "operation": "update",
              "uuids": "839326e3-e318-490f-aefb-5d1cc6446c31"
            }
          ],
          "timeStamp": 1678406053449
        },
        "-NQ7n4ln-iYV650DL_21": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "K483M, Mutation Effect",
              "new": {
                "description": "The class III BRAF K483M mutation is located in the kinase domain of the BRAF protein (PMID: 15035987). In vitro studies have demonstrated that this mutation is likely activating as measured by CRAF activation and downstream signaling compared to wildtype (PMID: 15035987, 23533272). Preclinical studies with D04 cells expressing BRAF K483M demonstrated sensitivity to treatment with sorafenib as measured by inhibition of MEK activation (PMID: 20141835)."
              },
              "old": {
                "description": "The BRAF K483M mutation is located in the kinase domain of the BRAF protein. This mutation is a BRAF kinase-dead alteration (PMID: 15035987). However, in vitro studies have demonstrated that this mutation is likely activating as measured by CRAF activation and downstream signaling compared to wildtype (PMID: 15035987, 23533272)"
              },
              "operation": "update",
              "uuids": "a979f929-319b-4dad-917f-ba9414e5d0f6"
            }
          ],
          "timeStamp": 1678406081574
        },
        "-NQ7nTE6JdyBsrP1jrRY": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "L505H, Mutation Effect",
              "new": {
                "description": "The class II BRAF L505H mutation is located in the kinase domain in exon 12 of the protein (PMID: 33019809). This mutation has been found in prostate cancer (PMID: 24283590). Expression of this mutation in 293T cells or RWPE-1 prostate cells demonstrated that it is activating as measured by increased downstream activation of MEK and ERK as well as increased colony formation in soft agar compared to wildtype BRAF (PMID: 24283590). In vitro and in vivo studies of BRAF L505H suggest that this mutation is resistant to vemurafenib as measured by the occurrence of the L505H mutation in a vemurafenib resistance screen, sustained MAPK pathway signaling upon treatment with vemurafenib in cells expressing the mutation and sustained tumor growth in a xenograft model of melanoma cells harboring this mutation (PMID: 24283590, 24112705). In one study, one patient with metastatic melanoma harboring BRAF L505H had progressive disease in response to vemurafenib treatment (PMID: 25515853). In vitro studies, however, suggest that BRAF L505H is sensitive to selumetinib as measured by decreased MAPK pathway signaling upon drug treatment (PMID: 24283590)."
              },
              "old": {
                "description": "The BRAF L505H mutation is located in the kinase domain in exon 12 of the protein. This mutation has been found in prostate cancer (PMID: 24283590). Expression of this mutation in 293T cells or RWPE-1 prostate cells demonstrated that it is activating, as measured by increased downstream activation of MEK and ERK as well as increased colony formation in soft agar compared to wildtype BRAF (PMID: 24283590). In vitro and in vivo studies of BRAF L505H suggest that this mutation is resistant to vemurafenib as measured by occurrence of the L505H mutation in a vemurafenib resistance screen, sustained MAPK pathway signaling upon treatment with vemurafenib in cells expressing the mutation and sustained tumor growth in a xenograft model of melanoma cells harboring this mutation (PMID: 24283590, 24112705). In one study, one patient with metastatic melanoma harboring BRAF L505H had progressive disease in response to vemurafenib treatment (PMID: 25515853). In vitro studies, however, suggest that BRAF L505H is sensitive to selumetinib as measured by decreased MAPK pathway signaling upon drug treatment (PMID: 24283590)."
              },
              "operation": "update",
              "uuids": "07f22e94-4359-4e3b-a747-1a846bbf7294"
            }
          ],
          "timeStamp": 1678406181754
        },
        "-NQ7nf-p4RsNVtFOXGD_": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "W531C, Mutation Effect",
              "new": {
                "description": "The BRAF W531C mutation is located in the cysteine-rich domain in exon 6 of the protein. This mutation has been found in patients with cardio-facio-cutaneous syndrome (PMID: 19206169). There is conflicting evidence on the biological and oncogenic effect of this mutation. Expression of this mutation in NIH-3T3 cells demonstrated that this mutation is likely neutral, as measured by downstream pathway activation comparable to wildtype BRAF (PMID: 19206169). However, in vitro studies with Ba/F3 and MCF10A cells and in vivo studies with drosophila expressing BRAF W531C demonstrate that the mutation is activating as measured by increased MEK and ERK signaling and cellular proliferation (PMID: 29533785, 33855281).",
                "effect": "Inconclusive",
                "oncogenic": "Inconclusive"
              },
              "old": {
                "description": "The BRAF W531C mutation is located in the cysteine-rich domain in exon 6 of the protein. This mutation has been found in patients with cardiofaciocutaneous syndrome (PMID: 19206169). Expression of this mutation in NIH-3T3 cells demonstrated that this mutation is likely neutral, as measured by downstream pathway activation comparable to wildtype BRAF (PMID: 19206169).",
                "effect": "Likely Neutral",
                "oncogenic": "Likely Neutral"
              },
              "operation": "update",
              "uuids": "26a09bcd-4109-4a76-b3ee-47b09f771091,5ba45d26-0662-48e4-aca8-af8d9790b5fb"
            }
          ],
          "timeStamp": 1678406234088
        },
        "-NQ7nlxQjWkZxXZx_HwK": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "N581D, Mutation Effect",
              "new": {
                "description": "The class III BRAF N581D mutation is located in the kinase domain in exon 15 of the protein and is a statistically significant hotspot (PMID: 3010472). This mutation is found in cardio-facio-cutaneous syndrome (PMID: 16474404). While expression of this mutation in NIH-3T3 cells demonstrated that it is likely neutral, as measured by transcription of downstream MAPK pathway target genes (e.g., ELK) comparable to wildtype BRAF (PMID: 16474404). Preclinical studies with patient-derived xenograft models of non-small cell lung cancer expressing BRAF N581D demonstrated sensitivity to treatment with RMC-4550 as measured by tumor growth inhibition (PMID: 30104724)."
              },
              "old": {
                "description": "The BRAF N581D mutation is located in the kinase domain in exon 15 of the protein. This mutation is found in cardio-facio-cutaneous (CFC) syndrome (PMID: 16474404). While expression of this mutation in NIH-3T3 cells demonstrated that it is likely neutral, as measured by transcription of downstream MAPK pathway target genes (e.g., ELK) comparable to wildtype BRAF (PMID: 16474404). However, this mutation is a hotspot suggesting that it is likely oncogenic."
              },
              "operation": "update",
              "uuids": "102f2a9d-2991-464a-984f-13df8d99e510"
            }
          ],
          "timeStamp": 1678406262542
        },
        "-NQ7oHqGJKz7fA-VlQMt": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "N581D, Mutation Effect",
              "new": {
                "description": "The class III BRAF N581D mutation is located in the kinase domain in exon 15 of the protein and is a statistically significant hotspot (PMID: 3010472). This mutation is found in cardio-facio-cutaneous syndrome (PMID: 16474404). Expression of this mutation in NIH-3T3 cells demonstrated that it is likely neutral as measured by transcription of downstream MAPK pathway target genes (e.g., ELK) comparable to wildtype BRAF (PMID: 16474404). Preclinical studies with patient-derived xenograft models of non-small cell lung cancer expressing BRAF N581D demonstrated sensitivity to treatment with RMC-4550 as measured by tumor growth inhibition (PMID: 30104724)."
              },
              "old": {
                "description": "The class III BRAF N581D mutation is located in the kinase domain in exon 15 of the protein and is a statistically significant hotspot (PMID: 3010472). This mutation is found in cardio-facio-cutaneous syndrome (PMID: 16474404). While expression of this mutation in NIH-3T3 cells demonstrated that it is likely neutral as measured by transcription of downstream MAPK pathway target genes (e.g., ELK) comparable to wildtype BRAF (PMID: 16474404). Preclinical studies with patient-derived xenograft models of non-small cell lung cancer expressing BRAF N581D demonstrated sensitivity to treatment with RMC-4550 as measured by tumor growth inhibition (PMID: 30104724)."
              },
              "operation": "update",
              "uuids": "102f2a9d-2991-464a-984f-13df8d99e510"
            }
          ],
          "timeStamp": 1678406397252
        },
        "-NQ7oNjeytWraL4xL0Xv": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "N581D, Mutation Effect",
              "new": {
                "description": "The class III BRAF N581D mutation is located in the kinase domain in exon 15 of the protein and is a statistically significant hotspot (PMID: 3010472). This mutation is found in cardio-facio-cutaneous syndrome (PMID: 16474404). Expression of this mutation in NIH-3T3 cells demonstrated that it is likely neutral as measured by transcription of downstream MAPK pathway target genes (e.g., ELK) comparable to wildtype BRAF (PMID: 16474404). Preclinical studies with patient-derived xenograft models of non-small cell lung cancer expressing BRAF N581D demonstrated sensitivity to treatment with RMC-4550 as measured by tumor growth inhibition (PMID: 30104724)."
              },
              "old": {
                "description": "The class III BRAF N581D mutation is located in the kinase domain in exon 15 of the protein and is a statistically significant hotspot (PMID: 3010472). This mutation is found in cardio-facio-cutaneous syndrome (PMID: 16474404). While expression of this mutation in NIH-3T3 cells demonstrated that it is likely neutral as measured by transcription of downstream MAPK pathway target genes (e.g., ELK) comparable to wildtype BRAF (PMID: 16474404). Preclinical studies with patient-derived xenograft models of non-small cell lung cancer expressing BRAF N581D demonstrated sensitivity to treatment with RMC-4550 as measured by tumor growth inhibition (PMID: 30104724)."
              },
              "operation": "update",
              "uuids": "102f2a9d-2991-464a-984f-13df8d99e510"
            }
          ],
          "timeStamp": 1678406421405
        },
        "-NQ7oamNWNV13QMHZ_ca": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "N581S, Mutation Effect",
              "new": {
                "description": "The class III BRAF N581S mutation is located in the kinase domain in exon 15 of the protein (PMID:28783719). This mutation has been reported in lung cancer, colorectal cancer and melanoma (PMID: 26498038). Biological characterization of the BRAF N581S mutation has demonstrated that it is RAS dependent in its activation of the MAPK pathway, signals as a dimer with CRAF, and typically co-occurs with another driver mechanism that amplifies RAS signaling (PMID: 15035987, 28783719). Thus, in melanoma, the N581S variant, similar to other class III BRAF mutants, would be expected to co-occur with activating RAS mutation or NF1 inactivation, whereas in non-small cell lung or colorectal cancers, this mutation would most likely be associated with receptor tyrosine kinase (RTK) hyperactivation at the protein level (PMID: 28783719).  Preclinical studies with patient-derived lung adenocarcinoma cells expressing BRAF N581S demonstrated sensitivity to treatment with a combination therapy of PF-477736 plus PF3644022 as measured by increased apoptosis (PMID: 26140595). In a Phase II trial, two patients with lung adenocarcinoma and gynecologic cancer harboring BRAF N581S were treated with trametinib and demonstrated progressive disease and stable disease, respectively (PMID: 31924734). In a case report, a patient with metastatic colorectal cancer harboring BRAF N581S was treated with a combination therapy of cetuximab plus FOLFIRI and demonstrated partial response with a progression-free survival of sixteen months (PMID: 31515458). In another Phase II trial, two patients with advanced solid tumors harboring the mutation were treated with vemurafenib and did not clinically respond to treatment (PMID: 29320312)."
              },
              "old": {
                "description": "The class III hypoactivating (PMID:28783719) exon 15 BRAF N581S missense mutation occurs in the kinase domain of the protein, and it has been reported in lung, colorectal cancers and in melanoma (PMID: 26498038). Biological characterization of the BRAF N581S mutation has demonstrated that it is RAS dependent in its activation of the MAPK pathway, signals as a dimer with CRAF, and typically co-occurs with another driver mechanism that amplifies RAS signaling (PMID: 15035987, 28783719). Thus, in melanoma, the N581S variant, similar to other class III BRAF mutants, would be expected to co-occur with activating RAS mutation or NF1 inactivation, whereas in non-small cell lung or colorectal cancers, this mutation would most likely be associated with receptor tyrosine kinase (RTK) hyperactivation at the protein level (PMID: 28783719). While this mutation is sensitive to MEK inhibition by targeted inhibitors such as trametinib, it is insensitive to RAF monomer inhibitors such as vemurafenib."
              },
              "operation": "update",
              "uuids": "db1a6f73-d838-41b4-9004-b2b5a0684b32"
            }
          ],
          "timeStamp": 1678406478923
        },
        "-NQ7oiVj0m_PIB8obCz5": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "N581Y, Mutation Effect",
              "new": {
                "description": "The class III BRAF N581Y mutation is located in the kinase domain of BRAF in exon 13 (PMID: 30224342). This noncanonical BRAF mutation has been identified in a screen of colorectal cell lines and in a patient with melanoma (PMID: 19474002, 26084293). In vitro studies with Ba/F3 cells expressing BRAF N581Y demonstrate that the mutation is activating as measured by increased cell viability compared to wildtype (PMID: 32540409). The HT-55 colon cancer cell line harboring this mutation was insensitive to treatment with the GDC-0879 RAF kinase inhibitor (PMID: 19276360).",
                "effect": "Likely Gain-of-function",
                "oncogenic": "Likely"
              },
              "old": {
                "description": "The BRAF N581Y mutation is located in the kinase domain of BRAF in exon 13. This noncanonical BRAF mutation has been identified in a screen of colorectal cell lines and in a patient with melanoma (PMID: 19474002, 26084293). While this mutation has not been functionally characterized, another substitution at this position (e.g., N581S) has been shown to be likely activating and likely oncogenic (PMID: 15035987). The HT-55 colon cancer cell line harboring this mutation was insensitive to treatment with the GDC-0879 RAF kinase inhibitor (PMID: 19276360).",
                "effect": "Inconclusive",
                "oncogenic": "Inconclusive"
              },
              "operation": "update",
              "uuids": "c4f7d30f-8184-4ffb-bf52-768f6c3cb365,96dc7292-f9e2-4308-ac25-83ebc2eae671"
            }
          ],
          "timeStamp": 1678406510562
        },
        "-NQ7oph2cipw0JWdBLPQ": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G596C, Mutation Effect",
              "new": {
                "description": "The class III BRAF G596C mutation is located in the kinase domain of the BRAF protein (PMID: 28947956). This mutation has been found in non-small cell lung cancers, among others (PMID: 28947956). In vitro experiments have demonstrated that this mutation is activating as measured by increased downstream signaling compared to wildtype controls (PMID: 28947956). The BRAF G596C mutation confers resistance to the RAF inhibitor dabrafenib, but retains sensitivity to MEK inhibitor trametinib, as measured by MAPK pathway activation (PMID: 28947956)."
              },
              "old": {
                "description": "The BRAF G596C mutation is located in the kinase domain of the BRAF protein. This mutation has been found in non-small cell lung cancers, among others (PMID: 28947956). In vitro experiments have demonstrated that this mutation is activating as measured by increased downstream signaling compared to wildtype controls (PMID: 28947956). The BRAF G596C mutation confers resistance to the RAF inhibitor dabrafenib, but retains sensitivity to MEK inhibitor trametinib, as measured by MAPK pathway activation (PMID: 28947956)."
              },
              "operation": "update",
              "uuids": "7c6857fc-1772-420f-b26a-2e122ca12071"
            }
          ],
          "timeStamp": 1678406540022
        },
        "-NQ7owcdXoQAK-rSWsjP": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G596R, Mutation Effect",
              "new": {
                "description": "The class III BRAF G596R mutation is located in the kinase domain in exon 15 of the protein (PMID: 28783719). This mutation has been reported in melanoma, lung cancer and colorectal cancer (PMID: 14678966, 26498038). Biological characterization of the BRAF G596R mutation has demonstrated that it is RAS dependent in its activation of the MAPK pathway, signals as a dimer with CRAF, and typically co-occurs with another driver mechanism that amplifies RAS signaling (PMID: 15035987, 28783719, 16364920). Thus, in melanoma, the G596R variant, similar to other class III BRAF mutants, would be expected to co-occur with activating RAS mutation or NF1 inactivation, whereas in non-small cell lung or colorectal cancers, this mutation would most likely be associated with receptor tyrosine kinase (RTK) hyperactivation at the protein level (PMID: 28783719). Preclinical studies with colorectal cancer cells expressing BRAF G596R demonstrated sensitivity to treatment with PLX8394, RMC-4550 and trametinib plus dabrafenib as measured by inhibition of cellular proliferation, and resistance to treatment with vemurafenib as measured by persistent ERK and MEK activation (PMID: 30559419, 30104724,  28947956, 28783719). In a Phase II trial, a patient with non-small cell lung cancer was treated with vemurafenib and did not clinically respond to treatment (PMID: 31959346)."
              },
              "old": {
                "description": "The class III hypoactivating (PMID:28783719) exon 15 BRAF G596R missense mutation occurs in the kinase domain of the protein and has been reported in melanoma, lung and colorectal cancers (PMID: 14678966, 26498038). Biological characterization of the BRAF G596R mutation has demonstrated that it is RAS dependent in its activation of the MAPK pathway, signals as a dimer with CRAF, and typically co-occurs with another driver mechanism that amplifies RAS signaling (PMID: 15035987, 28783719, 16364920). Thus, in melanoma, the G596R variant, similar to other class III BRAF mutants, would be expected to co-occur with activating RAS mutation or NF1 inactivation, whereas in non-small cell lung or colorectal cancers, this mutation would most likely be associated with receptor tyrosine kinase (RTK) hyperactivation at the protein level (PMID: 28783719). While this mutation is sensitive to MEK inhibition by targeted inhibitors such as trametinib, it is insensitive to RAF monomer inhibitors such as vemurafenib."
              },
              "operation": "update",
              "uuids": "4c2cce08-23cc-49a9-bb8c-3244d90f7ff2"
            }
          ],
          "timeStamp": 1678406568412
        },
        "-NQ7pOzHMa0hdEAb1H5q": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G596V, Mutation Effect",
              "new": {
                "description": "The class III BRAF G596V mutation is located in the kinase domain in exon 15 of the protein (PMID: 33198372). This mutation has been found in cardio-facio-cutaneous syndrome (PMID: 16439621). Expression of this mutant in HEK293T cells demonstrated it has impaired kinase activity and is not able to induce downstream MEK and ERK activation in this context (PMID: 16439621). However, when expressed in zebrafish embryos, the G596V mutation causes the same aberrant elongation phenotype as BRAF V600E, suggesting that it might function in a manner similar to BRAF activating mutants during development in vivo (PMID: 19376813). In a Phase II trial, a patient with non-small cell lung cancer harboring BRAF G596V was treated with vemurafenib and demonstrated a partial response (PMID: 26200454)."
              },
              "old": {
                "description": "The BRAF G596V mutation is located in the kinase domain in exon 15 of the protein. This mutation has been found in cardio-facio-cutaneous syndrome (CFC) (PMID: 16439621). Expression of this mutant in HEK293T cells demonstrated it has impaired kinase activity and is not able to induce downstream MEK and ERK activation in this context (PMID: 16439621). However, when expressed in zebrafish embryos, the G596V mutation causes the same aberrant elongation phenotype as BRAF V600E, suggesting that it might function in a manner similar to BRAF activating mutants during development in vivo (PMID: 19376813)."
              },
              "operation": "update",
              "uuids": "86f2dcf1-34f4-426b-83d7-6336964f61fa"
            }
          ],
          "timeStamp": 1678406688645
        },
        "-NQ7pWe-2brckHjT9JNy": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "T599I, Mutation Effect",
              "new": {
                "description": "The class II BRAF T599I mutation is located in the kinase domain in exon 15 of the protein (Abstract: Severson et al. Abstract #40P, Annals of Oncology 2022. https://www.annalsofoncology.org/article/S0923-7534%2822%2900058-8/fulltext). Expression of this mutation in COS cells demonstrated that it is activating as measured by increased kinase activity and downstream ERK activation compared to wildtype BRAF (PMID: 15035987). In a case report, a patient with metastatic melanoma harboring BRAF T599I was treated with vemurafenib and demonstrated a clinical response to treatment (PMID: 29232305)."
              },
              "old": {
                "description": "The BRAF T599I mutation is located in the kinase domain in exon 15 of the protein. Expression of this mutation in COS cells demonstrated that it is activating as measured by increased kinase activity and downstream ERK activation compared to wildtype BRAF (PMID: 15035987)."
              },
              "operation": "update",
              "uuids": "25bbc115-da6c-4110-c0c1-d51486913e97"
            }
          ],
          "timeStamp": 1678406720051
        },
        "-NQ7pccmNfI7HDuQ2TfL": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "T599R, Mutation Effect",
              "new": {
                "description": "The class II BRAF T599R mutation is located in the kinase domain in exon 15 of the protein (PMID: 33019809). This mutation has been found in cardio-facio-cutaneous syndrome and thyroid carcinoma (PMID: 19206169, 25120313). Expression of BRAF T599R in NIH3T3 cells demonstrated that it is activating as measured by increased colony formation and downstream MAPK pathway activation compared to wildtype BRAF (PMID: 19206169)."
              },
              "old": {
                "description": "The BRAF T599R mutation is located in the kinase domain in exon 15 of the protein. This mutation has been found in cardio-facio-cutaneous syndrome (CFC) and thyroid carcinomas (PMID: 19206169, 25120313). Expression of BRAF T599R in NIH3T3 cells demonstrated that it is activating as measured by increased colony formation and downstream MAPK pathway activation compared to wildtype BRAF (PMID: 19206169)."
              },
              "operation": "update",
              "uuids": "762acae2-d84d-4f7e-9f1b-18c23afc75d4"
            }
          ],
          "timeStamp": 1678406748645
        },
        "-NQ7pllrLLv4QEZJpSri": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "L485_P490del, Mutation Effect",
              "new": {
                "description": "The class II BRAF L485_P490del mutation is located in the kinase domain in exon 11 of the protein (PMID: 36686670). Expression of this mutation in HEK293 or NIH-3T3 cells demonstrated that it is activating as measured by kinase activity and colony formation in soft agar comparable to BRAF V600E (PMID: 26732095). However, a second study in human cell lines demonstrated that this mutation has kinase activity comparable to wildtype BRAF (PMID: 26996308). This mutation is dependent on BRAF homodimer formation, as BRAF L485_P490del fails to activate downstream MAPK pathway effectors as a monomer (PMID: 26732095). Preclinical studies with NIH3T3 cells expressing BRAF L485_P490del demonstrated sensitivity to treatment with LY3009120, as measured by inhibition of MEK and ERK phosphorylation, and resistance to treatment with vemurafenib, as measured by sustained MEK and ERK signaling and proliferation (PMID: 26732095). In a case report, a patient with metastatic melanoma harboring BRAF L485_P490del and amplified PD-L1 expression was treated with a combination therapy of trametinib and dabrafenib and demonstrated partial response with a progression-free survival of 18 months (PMID: 36686670)."
              },
              "old": {
                "description": "The BRAF L485_P490del mutation is located in the kinase domain in exon 11 of the protein. Expression of this mutation in HEK293 or NIH-3T3 cells demonstrated that it is activating, as measured by kinase activity and colony formation in soft agar comparable to BRAF V600E (PMID: 26732095). However, a second study in human cell lines demonstrated that this mutation has kinase activity comparable to wildtype BRAF (PMID: 26996308). This mutation is dependent on BRAF homodimer formation, as BRAF L485_P490del fails to activate downstream MAPK pathway effectors as a monomer (PMID: 26732095). In vitro studies suggest that this mutation is resistant to vemurafenib, as measured by sustained MAPK pathway signaling and proliferation upon drug treatment (PMID: 26732095)."
              },
              "operation": "update",
              "uuids": "fcc850b0-b6f4-4c5e-9f3d-b1776da2b284"
            }
          ],
          "timeStamp": 1678406786090
        },
        "-NQ7q3AaXA1tMIQ1stUi": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "L485_P490delinsY, Mutation Effect",
              "new": {
                "description": "The class II BRAF L485_P490delinsY mutation is located in the kinase domain in exon 11 of the protein (PMID: 33019809). This mutation has been identified in non-small lung cancer (PMID: 12068308). While this variant has not been functionally validated, preclinical studies with non-small lung cancer cell lines and mouse models expressing BRAF L485_P490delinsY demonstrated sensitivity to treatment with LY3009120 and trametinib as measured by inhibition of cellular proliferation, and resistance to vemurafenib as measured by sustained MEK and ERK pathway activation (PMID: 26732095)."
              },
              "old": {
                "description": "The BRAF L485_P490delinsY mutation is located in the kinase domain in exon 11 of the protein. While this variant has not been functionally validated, another deletion in this amino acid range (L485_P490del) has been shown to be gain-of-function and oncogenic (PMID: 26732095). Experiments in cell lines and mouse models demonstrate that BRAF alpha-C helix indel mutants, such as L485_P490delinsY, are insensitive to vemurafenib and maintain activity of the MAPK pathway upon drug treatment (PMID: 26732095)."
              },
              "operation": "update",
              "uuids": "43ac21b6-f89c-4d26-9582-a4afa9412a21"
            }
          ],
          "timeStamp": 1678406861464
        },
        "-NQ7r17UvCHDvjdHzEcO": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "N486_P490del (NVTAP), Mutation Effect",
              "new": {
                "description": "The class II BRAF N486_P490del mutation is located in the kinase domain in exon 11 of the protein (PMID: 33019809). This mutation has been found in an ovarian cancer cell line and in patients with pancreatic cancer (PMID: 18060073, 26996308, 31519698). Expression of this mutation in a human cell line demonstrated that it is activating via a CRAF- and dimer-independent mechanism as measured by increased kinase activity and downstream signaling compared to wildtype (PMID: 26996308). Preclinical studies with patient-derived xenograft models of pancreatic ductal adenocarcinoma expressing BRAF N486_P490del demonstrated sensitivity to treatment with trametinib and LY3009120 alone or in combination as measured by reduced tumor growth (PMID: 34011980). A patient with pancreatic cancer harboring this mutation had a partial response to treatment with the BRAF inhibitor dabrafenib (PMID: 31519698). In a case report, two patients with Langerhans cell histiocytosis harboring BRAF N486_P490del were treated with trametinib and one patient demonstrated a complete response with a progression-free survival of over 18 months while the second patient demonstrated stable disease with a progression-free survival of over twelve months (PMID: 32991018). In another case report, a patient with metastatic pancreatic ductal adenocarcinoma harboring BRAF N486_P490del was treated with a combination therapy of dabrafenib plus trametinib and demonstrated partial response (PMID: 36505826)."
              },
              "old": {
                "description": "The BRAF N486_P490del mutation is located in the kinase domain in exon 11 of the protein. This mutation has been found in an ovarian cancer cell line and in patients with pancreatic cancer (PMID: 18060073, 26996308, 31519698). Expression of this mutation in a human cell line demonstrated that it is activating via a CRAF- and dimer-independent mechanism as measured by increased kinase activity and downstream signaling compared to wildtype (PMID: 26996308). A patient with pancreatic cancer  harboring this mutation had a partial response to treatment with the BRAF inhibitor dabrafenib (PMID: 31519698)"
              },
              "operation": "update",
              "uuids": "5211e083-6d72-4505-a5fe-29da60c439a0"
            }
          ],
          "timeStamp": 1678407115218
        },
        "-NQ7r8Xok0Jnc8IfjlJ4": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R506_K507insVLR, Mutation Effect",
              "new": {
                "description": "The BRAF R506_K507insVLR mutation (also referred to as BRAF V504_R506dup) is located in the kinase domain in exon 13 of the protein. This mutation has been found in pilocytic astrocytoma (PMID: 23817572). Expression of this mutation in NIH-3T3 cells demonstrated that it is activating as measured by increased downstream pathway activation compared to wildtype BRAF (PMID: 23817572). Preclinical studies with HEK293T cells expressing BRAF R506_K507insVLR demonstrated sensitivity to treatment with trametinib as measured by inhibition of ERK signaling, and resistance to treatment with PLX8394, dabrafenib, vemurafenib, LY3009120 and sorafenib as measured by sustained ERK signaling (PMID: 34108213)."
              },
              "old": {
                "description": "The BRAF R506_K507insVLR mutation is located in the kinase domain in exon 13 of the protein. This mutation has been found in pilocytic astrocytoma (PMID: 23817572). Expression of this mutation in NIH-3T3 cells demonstrated that it is activating as measured by increased downstream pathway activation compared to wildtype BRAF (PMID: 23817572)."
              },
              "operation": "update",
              "uuids": "e33ccee2-e00e-4d90-ab7c-b8dd00dc6146"
            }
          ],
          "timeStamp": 1678407145575
        },
        "-NQ7rFzrazzgza0D79TM": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "P490_Q494del, Mutation Effect",
              "new": {
                "description": "The class II BRAF P490_Q494del mutation is located in the kinase domain in exon 11 of the protein (Abstract: Severson et al. Abstract #40P, Annals of Oncology 2022. https://www.annalsofoncology.org/article/S0923-7534%2822%2900058-8/fulltext). This mutation has been found in pancreatic cancer (PMID: 26996308). Expression of this mutation in a human cell line demonstrated that it is activating as measured by increased kinase activity and downstream signaling compared to wildtype (PMID: 26996308)."
              },
              "old": {
                "description": "The BRAF P490_Q494del mutation is located in the kinase domain in exon 11 of the protein. This mutation has been found in pancreatic cancer (PMID: 26996308). Expression of this mutation in a human cell line demonstrated that it is activating as measured by increased kinase activity and downstream signaling compared to wildtype (PMID: 26996308)."
              },
              "operation": "update",
              "uuids": "bdfa68e2-fbeb-4cd0-be3a-5f99c698a832"
            }
          ],
          "timeStamp": 1678407176106
        },
        "-NQ7rNYYoKw-ydwfyUoE": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "T488_P492del, Mutation Effect",
              "new": {
                "description": "The class II BRAF T488_P492del mutation is located in the kinase domain in exon 11 of the protein (Abstract: Severson et al. Abstract #40P, Annals of Oncology 2022. https://www.annalsofoncology.org/article/S0923-7534%2822%2900058-8/fulltext). This mutation has been found in pancreatic cancer (PMID: 26996308). Expression of this mutation in a human cell line demonstrated that it is activating as measured by increased kinase activity and downstream signaling compared to wildtype (PMID: 26996308)."
              },
              "old": {
                "description": "The BRAF T488_P492del mutation is located in the kinase domain in exon 11 of the protein. This mutation has been found in pancreatic cancer (PMID: 26996308). Expression of this mutation in a human cell line demonstrated that it is activating as measured by increased kinase activity and downstream signaling compared to wildtype (PMID: 26996308)."
              },
              "operation": "update",
              "uuids": "a73f9de4-3f0a-4a19-a926-8527631caf46"
            }
          ],
          "timeStamp": 1678407207062
        },
        "-NQ7rWaJrYvM-7qXYpQO": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V487_P492delinsA, Mutation Effect",
              "new": {
                "description": "The BRAF V487_P492delinsA mutation is located in the kinase domain in exon 11 of the protein. In vitro studies with BxPC-3 cells expressing BRAF V487_P492delinsA demonstrate that the mutation is activating as measured by increased pathway activation and cellular proliferation compared to wildtype (PMID: 26732095). Experiments in cell lines and mouse models demonstrate that BRAF alpha-C helix indel mutants, such as V487_P492delinsA, are insensitive to vemurafenib and maintain activity of the MAPK pathway upon drug treatment (PMID: 26732095).",
                "effect": "Likely Gain-of-function",
                "oncogenic": "Likely"
              },
              "old": {
                "description": "The BRAF V487_P492delinsA mutation is located in the kinase domain in exon 11 of the protein. While this deletion mutation has not been functionally validated, another deletion at this position (L485_Q494del) has been shown to be gain-of-function and oncogenic (PMID: 26732095). Experiments in cell lines and mouse models demonstrate that BRAF alpha-C helix indel mutants, such as V487_P492delinsA, are insensitive to vemurafenib and maintain activity of the MAPK pathway upon drug treatment (PMID: 26732095).",
                "effect": "Inconclusive",
                "oncogenic": "Inconclusive"
              },
              "operation": "update",
              "uuids": "d4da6583-0755-4b4c-a0a9-88cdd924ae26,ab4e90a9-8fdf-480f-9078-717b7eae8560"
            }
          ],
          "timeStamp": 1678407244103
        },
        "-NQ7rdJc34zLcl1i_CA2": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "GTF2I-BRAF Fusion, Mutation Effect",
              "new": {
                "description": "The GTF2I-BRAF fusion protein results from a rearrangement on chromosome 7, joining exons 1-19 of GTF21 to intron 9 BRAF, thus retaining the full kinase domain of BRAF. The GTF2I-BRAF fusion has been identified in melanoma and pilocytic astrocytoma (PMID: 26314551, 28448514). When expressed in a human embryonic kidney cell line, the fusion protein elevated basal levels of phosphorylated ERK compared to the wildtype BRAF (PMID: 28448514). The fusion was detected in a patient with pilocytic astrocytoma and immunohistochemistry confirmed elevated phospho-ERK in tumor tissue from this patient (PMID: 28448514)."
              },
              "old": {
                "description": "The GTF2I-BRAF fusion protein results from a rearrangement on chromosome 7, joining exons 1-19 of GTF21 to intron 9 BRAF, thus retaining the full kinase domain of BRAF. The GTF2I-BRAF fusion has been identified in a patient with melanoma and pilocytic astrocytoma (PMID: 26314551, 28448514). When expressed in a human embryonic kidney cell line, the fusion protein elevated basal levels of phosphorylated ERK (pERK), compared to the wildtype BRAF. The fusion was detected in a patient with pilocytic astrocytoma and immunohistochemistry confirmed elevated pERK in tumor tissue from this patient (PMID: 28448514)."
              },
              "operation": "update",
              "uuids": "6ef06341-1ca9-4f6c-8a4c-293b89cb6f0d"
            }
          ],
          "timeStamp": 1678407275739
        },
        "-NQ7rkxJsE0kc8_xY8K8": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "T599dup, Mutation Effect",
              "new": {
                "description": "The BRAF T599dup mutation is located in the kinase domain in exon 15 of the protein. This mutation has been found in melanoma and pilocytic astrocytoma (PMID: 19363522, 21190184, 29456854). Expression of this mutation in HEK293, NIH-3T3 or MCF-10A cells demonstrated that this mutation is activating as measured by kinase activity, anchorage-independent growth and changes in contact inhibition comparable to BRAF V600E (PMID: 19363522, 21190184, 23833300). In a case report, four patients with metastatic melanoma harboring BRAF T599dup were treated with a combination therapy of dabrafenib plus trametinib and demonstrated partial response (PMID: 35319964). Another patient with metastatic melanoma harboring BRAF T599dup was treated with a combination therapy of binimetinib plus encorafenib and demonstrated a partial response and a progression-free survival of at least nine months (PMID: 35319964). Two other patients with metastatic melanoma harboring BRAF T599dup were treated with vemurafenib and demonstrated progressive disease (PMID: 35319964). In another case report, a patient with metastatic colorectal cancer was treated with a combination therapy of panitumumab plus FOLFOX and demonstrated progressive disease (PMID: 31515458)."
              },
              "old": {
                "description": "The BRAF T599dup mutation is located in the kinase domain in exon 15 of the protein. This mutation has been found in melanoma and pilocytic astrocytoma (PMID: 19363522, 21190184, 29456854). Expression of this mutation in HEK293, NIH-3T3 or MCF-10A cells demonstrated that this mutation is activating as measured by kinase activity, anchorage-independent growth and changes in contact inhibition comparable to BRAF V600E (PMID: 19363522, 21190184, 23833300)."
              },
              "operation": "update",
              "uuids": "aa40d7f6-5e58-4764-a5d0-ee4acadfd3ad"
            }
          ],
          "timeStamp": 1678407307015
        },
        "-NQ7rsPbjbD_u6OxMvgL": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "N581I, Mutation Effect",
              "new": {
                "description": "The class III BRAF N581I mutation is located in the kinase domain in exon 15 of the protein (PMID: 28783719). This mutation has been reported in lung cancer and vulval malignant melanoma (PMID: 22969966, 26202550, 15917418). Biochemically, it has been demonstrated that the BRAF N581I mutant signals as a dimer with CRAF, is RAS-dependent in its activation of the MAPK pathway, and, in tumors, would typically co-occur with another driver mechanism that amplifies RAS signaling (PMID: 28783719). Thus, in melanoma, the N581I variant, similar to other class III BRAF mutants, would be expected to co-occur with activating RAS mutation or NF1 inactivation, whereas in non-small cell lung or colorectal cancers, this mutation would most likely be associated with receptor tyrosine kinase (RTK) hyperactivation at the protein level (PMID: 28783719). While this mutation is sensitive to MEK inhibition by targeted inhibitors such as trametinib, it is insensitive to RAF monomer inhibitors such as vemurafenib (PMID: 28783719). In a case report, a patient with metastatic colorectal cancer harboring BRAF N581I was treated with a combination therapy of cetuximab plus irinotecan and demonstrated stable disease with a progression-free survival of 10.3 months (PMID: 31515458)."
              },
              "old": {
                "description": "The class III and hypoactivating (PMID: 28783719) BRAF N581I missense mutation occurs in the kinase domain in exon 15 of the protein, and it has been reported in lung cancers (PMID: 22969966, 26202550) and in vulval malignant melanoma (PMID: 15917418). Biochemically, it has been demonstrated that the BRAF N581I mutant signals as a dimer with CRAF, is RAS-dependent in its activation of the MAPK pathway, and, in tumors, would typically co-occur with another driver mechanism that amplifies RAS signaling (PMID: 28783719). While this mutation is sensitive to MEK inhibition by targeted inhibitors such as trametinib, it is insensitive to RAF monomer inhibitors such as vemurafenib. Thus, in melanoma, the N581I variant, similar to other class III BRAF mutants, would be expected to co-occur with activating RAS mutation or NF1 inactivation, whereas in non-small cell lung or colorectal cancers, this mutation would most likely be associated with receptor tyrosine kinase (RTK) hyperactivation at the protein level (PMID: 28783719)."
              },
              "operation": "update",
              "uuids": "0cc9d835-eac3-44d0-b116-4aaca9cf6dac"
            }
          ],
          "timeStamp": 1678407337562
        },
        "-NQ7s-EB9D2SGAsEBHwK": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G596D, Mutation Effect",
              "new": {
                "description": "The class III BRAF G596D mutation is located in the kinase domain in exon 15 of the protein (PMID: 28783719). This mutation has been reported in cervical adenocarcinoma and esophagogastric cancer (PMID: 17360030, 23481512). Biochemically, it has been demonstrated that the BRAF G596D mutant signals as a dimer with CRAF, is RAS-dependent in its activation of the MAPK pathway, and, in tumors, would typically co-occur with another driver mechanism that amplifies RAS signaling (PMID: 28783719). Thus, like other class III BRAF mutants, in melanoma, the G596D variant would be expected to co-occur with activating RAS mutation or NF1 inactivation, whereas in non-small cell lung and colorectal cancers, this mutation would most likely be associated with receptor tyrosine kinase (RTK) hyperactivation at the protein level (PMID: 28783719). While this mutation is sensitive to MEK inhibition by targeted inhibitors such as trametinib, it is insensitive to RAF monomer inhibitors such as vemurafenib (PMID: 28783719). Preclinical studies with SKBR3 cells expressing BRAF G596D demonstrate resistance to treatment with dabrafenib as measured by sustained ERK phosphorylation following treatment (PMID: 31158244)."
              },
              "old": {
                "description": "The class III and hypoactivating (PMID: 28783719) BRAF G596D missense mutation occurs in the kinase domain in exon 15 of the protein, and it has been reported in cervical adenocarcinoma (PMID: 17360030) and esophagogastric cancer (PMID: 23481512). Biochemically, it has been demonstrated that the BRAF G596D mutant signals as a dimer with CRAF, is RAS-dependent in its activation of the MAPK pathway, and, in tumors, would typically co-occur with another driver mechanism that amplifies RAS signaling (PMID: 28783719). While this mutation is sensitive to MEK inhibition by targeted inhibitors such as trametinib, it is insensitive to RAF monomer inhibitors such as vemurafenib. Thus, like other class III BRAF mutants, in melanoma, the G596D variant would be expected to co-occur with activating RAS mutation or NF1 inactivation, whereas in non-small cell lung and colorectal cancers, this mutation would most likely be associated with receptor tyrosine kinase(RTK) hyperactivation at the protein level (PMID: 28783719)."
              },
              "operation": "update",
              "uuids": "49953b55-2bdb-486f-b7e4-89fe7668145b"
            }
          ],
          "timeStamp": 1678407369599
        },
        "-NQ7s6lyJSN8l6EFR32w": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "H574Q, Mutation Effect",
              "new": {
                "description": "The BRAF H574Q mutation is located in exon 14 of the kinase domain of the protein. This mutation has been identified in glioma and melanoma (PMID: 34625582, 28972077). A study evaluating the effects of rare somatic mutations in lung cancers showed that cells transfected with BRAF H574Q mutation display a robust increase in ERK phosphorylation, comparable to BRAF V600E mutation (PMID: 27478040)."
              },
              "old": {
                "description": "The BRAF H574Q mutation occurs in exon 14 of the kinase domain of the protein. A study evaluating the effects of rare somatic mutations in lung cancers showed that cells transfected with BRAF H574Q mutation display a robust increase in ERK phophorylation, comparable to BRAF V600E mutation (PMID: 27478040)."
              },
              "operation": "update",
              "uuids": "6e4e140e-18bf-423f-94d3-f0747d28683c"
            }
          ],
          "timeStamp": 1678407400497
        },
        "-NQ7sEBGcWS59vMRWCeA": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "S467L, Mutation Effect",
              "new": {
                "description": "The class III BRAF S467L mutation occurs in the kinase domain in exon 11 of the protein (PMID: 28783719). This mutation has been reported in melanoma (PMID: 24710085, 25651238, 26498038, 26559571). Biochemically, it has been demonstrated that the BRAF S467L mutant signals as a dimer with CRAF, is RAS-dependent in its activation of the MAPK pathway, and, in tumors, would typically co-occur with another driver mechanism that amplifies RAS signaling (PMID: 28783719). Therefore, class III BRAF mutants like the BRAF S467L variant would be generally expected to co-occur with activating RAS mutations or NF1 inactivation in melanomas, whereas in non-small cell lung or colorectal cancers, this mutation will most likely be associated with receptor tyrosine kinase (RTK) hyperactivation at the protein level (PMID: 28783719)."
              },
              "old": {
                "description": "The class III and hypoactivating (PMID: 28783719) BRAF S467L missense mutation occurs in the kinase domain in exon 11 of the BRAF protein, and this mutation has been reported in melanomas (PMID: 24710085, 25651238, 26498038, 26559571). Biochemically, it has been demonstrated that the BRAF S467L mutant signals as a dimer with CRAF, is RAS-dependent in its activation of the MAPK pathway, and, in tumors, would typically co-occur with another driver mechanism that amplifies RAS signaling (PMID: 28783719). Therefore, class III BRAF mutants like the BRAF S467L variant would be generally expected to co-occur with activating RAS mutations or NF1 inactivation in melanomas, whereas in non-small cell lung or colorectal cancers, this mutation will most likely be associated with receptor tyrosine kinase (RTK) hyperactivation at the protein level (PMID: 28783719)."
              },
              "operation": "update",
              "uuids": "2cff07a9-00cc-46ec-b107-d2f5af04f8ba"
            }
          ],
          "timeStamp": 1678407430852
        },
        "-NQ7sLmBk4yw43EwacGG": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "K601T, Mutation Effect",
              "new": {
                "description": "The class II BRAF K601T mutation is located in the kinase domain in exon 15 of the protein (PMID: 28783719, 26343582). This mutation has been reported in hairy cell leukemia and multiple myeloma (PMID: 25938346, 26090869). Biochemical characterization of BRAF K601T has demonstrated that it activates the downstream MAPK pathway independent of RAS and renders BRAF active as a dimer with CRAF and itself (PMID: 26343582). While this mutation is sensitive to MEK inhibition by targeted inhibitors such as trametinib, it is insensitive to RAF monomer inhibitors such as vemurafenib (PMID: 28783719, 26343582, 22798288)."
              },
              "old": {
                "description": "The class II (PMID: 28783719) and hyperactivating (PMID: 26343582) BRAF K601T missense mutation is located in the kinase domain in exon 15 of the BRAF protein. This mutation has been reported in hairy cell leukemia (PMID: 25938346) and in multiple myeloma (PMID: 26090869). Biochemical characterization of BRAF K601T mutation has demonstrated that it activates the downstream MAPK pathway independent of RAS (PMID: 26343582); renders BRAF active as a dimer with CRAF and itself; and while sensitive to MEK inhibition by targeted inhibitors such as trametinib (PMID: 28783719, 26343582, 22798288), is insensitive to RAF monomer inhibitors such as vemurafenib (PMID: 28783719, 26343582)."
              },
              "operation": "update",
              "uuids": "e34774d6-313e-4da7-824b-87c3d126c302"
            }
          ],
          "timeStamp": 1678407461951
        },
        "-NQaa9wiTQwzFwkBMn7K": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "N486_T488del, Mutation Effect",
              "new": {
                "description": "The BRAF N486_T488del mutation is located in the kinase domain in exon 11 of the protein. This mutation has been identified in non-small cell lung cancer (PMID: 36200799). Expression of this mutation in a human cell line demonstrated that it is likely activating as measured by increased kinase activity compared to wildtype (PMID: 26996308)."
              },
              "old": {
                "description": "The BRAF N486_T488del mutation is located in the kinase domain in exon 11 of the protein. Expression of this mutation in a human cell line demonstrated that it is likely activating as measured by increased kinase activity compared to wildtype (PMID: 26996308)."
              },
              "operation": "update",
              "uuids": "8754dd0b-a399-4490-a974-b60c3ff0d914"
            }
          ],
          "timeStamp": 1678906011304
        },
        "-NQaaHLQE27DdN6y_vnD": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "L485W, Mutation Effect",
              "new": {
                "description": "The class II BRAF L485W mutation is located in the kinase domain of the protein (PMID: 35117215). This mutation has been identified in bladder adenocarcinoma and is a statistically significant hotspot (PMID: 28481359). In vitro studies with Ba/F3 and MCF10A cells expressing BRAF L485W demonstrate the mutation is activating as measured by increased transformation ability compared to wildtype (PMID: 29533785). BRAF L485W is suggested to be sensitive to ERK1/2 kinase inhibitor ulixertinib as measured by a gallbladder cancer patient harboring the mutation having a year-long complete response to treatment (PMID: 29247021)."
              },
              "old": {
                "description": "The BRAF L485W mutation is located in the kinase domain of the protein. This mutation has been identified in bladder adenocarcinoma and is a statistically significant hotspot (PMID: 28481359). In vitro studies with Ba/F3 and MCF10A cells expressing BRAF L485W demonstrate the mutation is activating as measured by increased transformation ability compared to wildtype (PMID: 29533785). BRAF L485W is suggested to be sensitive to ERK1/2 kinase inhibitor ulixertinib as measured by a gallbladder cancer patient harboring the mutation having a year-long complete response to treatment (PMID: 29247021)."
              },
              "operation": "update",
              "uuids": "8322f1de-86af-4e6f-8a96-b05f246d1b16"
            }
          ],
          "timeStamp": 1678906041621
        },
        "-NQaaOaXULkjMF1_syLE": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G469S, Mutation Effect",
              "new": {
                "description": "The class II BRAF G469S mutation is located in the kinase domain in exon 11 of the protein (PMID: 31470866). This mutation has been identified in malignant melanoma and is a statistically significant hotspot (PMID: 16096377). In vitro studies with HEK293T cells expressing BRAF G469S demonstrate that the mutation is activating as measured by increased phosphorylated MEK and ERK levels compared to wildtype (PMID: 28947956). In a case report, a patient with metastatic melanoma harboring BRAF G469S was treated with a combination therapy of trametinib plus dabrafenib and demonstrated stable disease with a progression-free survival of three months (PMID: 31569065). In a Phase II trial, a patient with melanoma harboring BRAF G469S was treated with combination therapy of binimetinib and encorafenib and demonstrated an unconfirmed partial response (Abstract: Rose et al. Abstract# 531P, Annals of Oncology 2021. https://www.annalsofoncology.org/article/S0923-7534%2821%2903282-8/fulltext)."
              },
              "old": {
                "description": "The BRAF G469S mutation is located in the kinase domain of the protein. This mutation has been identified in malignant melanoma and is a statistically significant hotspot (PMID: 16096377). In vitro studies with HEK293T cells expressing BRAF G469S demonstrate that the mutation is activating as measured by increased phosphorylated MEK and ERK levels compared to wildtype (PMID: 28947956)."
              },
              "operation": "update",
              "uuids": "926f93dc-c93f-42cb-b07d-fef65da7985a"
            }
          ],
          "timeStamp": 1678906071324
        },
        "-NQaaW-nzvAeMZDnXvfS": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G596S, Mutation Effect",
              "new": {
                "description": "The class III BRAF G596S mutation is located in the kinase domain of the protein and is a statistically significant hotspot (PMID: 33198372). In vitro studies with Ba/F3 cells expressing BRAF G596S demonstrate that the mutation is activating as measured by increased transformation ability compared to wildtype (PMID: 29533785). In silico analysis suggests that BRAF G596S is resistant to vemurafenib (PMID: 35215249)."
              },
              "old": {
                "description": "The BRAF G596S mutation is located in the kinase domain of the protein and is a statistically significant hotspot. In vitro studies with Ba/F3 cells expressing BRAF G596S demonstrate that the mutation is activating as measured by increased transformation ability compared to wildtype (PMID: 29533785)."
              },
              "operation": "update",
              "uuids": "776007fd-a78b-4c5d-8aa2-4d557760ffac"
            }
          ],
          "timeStamp": 1678906101677
        },
        "-NQaacKREyMj8cM1Yrvl": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "N581T, Mutation Effect",
              "new": {
                "description": "The class III BRAF N581T mutation is located in the kinase domain of the protein (PMID: 31515458). This mutation has been identified in diffuse large B-cell lymphoma and is a statistically significant hotspot (PMID: 32187361). In vitro studies with Ba/F3 and MCF10A cells expressing BRAF N581T demonstrate that the mutation is likely neutral as measured by cell viability and proliferation comparable to wildtype (PMID: 29533785). In a case report, a patient with metastatic colorectal cancer harboring BRAF N581T was treated with a combination therapy of cetuximab plus FOLFOX and demonstrated partial response with a progression-free survival of 1.4 months (PMID: 31515458)."
              },
              "old": {
                "description": "The BRAF N581T mutation is located in the kinase domain of the protein. This mutation has been identified in diffuse large B-cell lymphoma and is a statistically significant hotspot (PMID: 32187361). In vitro studies with Ba/F3 and MCF10A cells expressing BRAF N581T demonstrate that the mutation is likely neutral as measured by cell viability and proliferation comparable to wildtype (PMID: 29533785)."
              },
              "operation": "update",
              "uuids": "7d9ab560-2699-413a-9758-d8faab353cd4"
            }
          ],
          "timeStamp": 1678906131670
        },
        "-NQfocgt7gjlXqXi0sCu": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G469A, G469V, G469R, G464 (non-V600 mutations class II )",
              "new": "G469A, G469V, G469R, G464 (non-V600 mutations class II )",
              "old": "G469A, G469V, G469R, G464 (non-V600 mutations, class II )",
              "operation": "name change",
              "uuids": "6bfd2309-23ad-432c-9e44-e63d72acea80"
            }
          ],
          "timeStamp": 1678993689312
        },
        "-NQfopuUJ1R5AZ-OVEKi": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G469A, G469V, G469R, G464 (non-V600 mutations class II ), All Solid Tumors, INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY, 44faeeae-ad6d-4370-8c99-97955f9e0feb",
              "new": {
                "description": "PLX8394 is an orally available, second-generation, small-molecule BRAF inhibitor that inhibits mutated, oncogenic BRAF without causing paradoxical MAPK pathway activation as is seen with first-generation BRAF inhibitors (PMID: 28659148). In a phase I clinical trial for patients with refractory or relapsed solid tumors with or without BRAF mutation, there were two (28%) partial responses of seven evaluable BRAF-mutant patients treated with PLX8394 and cobicistat, a CYP3A4 inhibitor (Abstract: Janku et al. Abstract# B176, AACR-NCI-EORTC 2017. http://mct.aacrjournals.org/content/17/1_Supplement/B176). Both responses were in patients with BRAF V600 mutations. Preclinical studies show that PLX8394 specifically inhibits BRAF-containing dimers and inhibits proliferation and pathway activation in BRAF-mutated colorectal cancer cell lines (PMID: 26466569, 28659148, 30559419, 28783719)."
              },
              "old": {
                "description": "PLX8394 is an orally available, second-generation, small-molecule BRAF inhibitor that inhibits mutated, oncogenic BRAF without causing paradoxical MAPK pathway activation as is seen with first-generation BRAF inhibitors (PMID: 28659148). In a phase I clinical trial for patients with refractory or relapsed solid tumors with or without BRAF mutation, there were two (28%) partial responses of seven evaluable BRAF-mutant patients treated with PLX8394 and cobicistat, a CYP3A4 inhibitor (Abstract: Janku et al. Abstract# B176, AACR-NCI-EORTC 2017. http://mct.aacrjournals.org/content/17/1_Supplement/B176). Both responses were in patients with BRAF V600 mutations. Preclinical studies show that PLX8394 specifically inhibits BRAF-containing dimers and inhibits proliferation and pathway actiavtion in BRAF-mutated colorectal cancer cell lines (PMID: 26466569, 28659148, 30559419, 28783719)."
              },
              "operation": "update",
              "uuids": "96034660-351c-4fce-9f82-cdfe98f7a0d2"
            }
          ],
          "timeStamp": 1678993743430
        },
        "-NSMRgQEFaqQJG9QvqLX": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Low-Grade Glioma, NOS",
              "new": {
                "TIs": [
                  {
                    "name": "Standard implications for sensitivity to therapy",
                    "name_uuid": "038fb404-c879-4740-970a-fa29f4f69ec0",
                    "treatments_uuid": "a4378b1c-a6a2-417e-bab4-6f42a5d0be62",
                    "type": "SS"
                  },
                  {
                    "name": "Standard implications for resistance to therapy",
                    "name_uuid": "130dcbd6-b910-4097-aba5-79f650a90a26",
                    "treatments_uuid": "c541b7fc-147c-478b-8f68-bbf156cd3804",
                    "type": "SR"
                  },
                  {
                    "name": "Investigational implications for sensitivity to therapy",
                    "name_uuid": "dc728279-3828-4013-a7d6-32997607b7c8",
                    "treatments_uuid": "150bb5ff-962d-4f5a-a973-d34410503148",
                    "type": "IS"
                  },
                  {
                    "name": "Investigational implications for resistance to therapy",
                    "name_uuid": "9122b006-67a4-4cda-8a4e-80cd192c6186",
                    "treatments_uuid": "4f095b57-58c1-488c-beed-8a24134165ac",
                    "type": "IR"
                  }
                ],
                "cancerTypes": [
                  {
                    "code": "LGGNOS",
                    "mainType": "Glioma",
                    "subtype": "Low-Grade Glioma, NOS"
                  }
                ],
                "cancerTypes_review": {
                  "added": true,
                  "updateTime": 1680793147980,
                  "updatedBy": "User"
                },
                "cancerTypes_uuid": "91390944-50a1-4320-b7be-1f35f7160adc",
                "diagnostic": {
                  "description": "",
                  "description_uuid": "295428ed-378b-4cf8-84f4-8790215c993f",
                  "level": "",
                  "level_uuid": "f966f738-09ee-446a-bfdc-31e84ef0058e",
                  "relevantCancerTypes_uuid": "ec1695cc-a423-46fe-8d3f-ff86e823c056",
                  "short": ""
                },
                "diagnosticSummary": "",
                "diagnosticSummary_uuid": "8fa7279f-fe50-4d31-8844-b0b5d0610992",
                "diagnostic_uuid": "738a0ae3-af28-4532-823b-20514874c009",
                "excludedCancerTypes_uuid": "60358747-30fd-4029-9427-5e6026da6776",
                "prognostic": {
                  "description": "",
                  "description_uuid": "8644dfcc-80e8-42c2-b3dd-a80b1705a826",
                  "level": "",
                  "level_uuid": "f680c9d6-0950-419d-abaf-5fdeedf40a59",
                  "relevantCancerTypes_uuid": "164dcdfd-53ee-4704-a894-e96c22b245df",
                  "short": ""
                },
                "prognosticSummary": "",
                "prognosticSummary_uuid": "46b6736f-de66-4a31-8d04-c5994ef39505",
                "prognostic_uuid": "a768e2a7-3c39-4bae-aa2e-e50ae1eaca86",
                "relevantCancerTypes_uuid": "057ffd81-d90c-404e-8fe8-5afc2ce25bb7",
                "summary": "The RAF inhibitor dabrafenib in combination with the MEK1/2 inhibitor trametinib is FDA-approved for the treatment of pediatric patients 1 year of age and older with low-grade glioma.",
                "summary_review": {
                  "lastReviewed": "",
                  "updateTime": 1680793154766,
                  "updatedBy": "User"
                },
                "summary_uuid": "65384f19-67f6-4187-a4e9-b0e67c0d2d44"
              },
              "operation": "add",
              "uuids": "65384f19-67f6-4187-a4e9-b0e67c0d2d44"
            }
          ],
          "timeStamp": 1680799352371
        },
        "-NSMS0LZzYB8UTJmqWYh": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G606W",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF G606W mutation is located in the kinase domain of the protein. This mutation has been identified in lung adenocarcinoma (PMID: 28481359). In vitro studies with MCF10A cells expressing BRAF G606W demonstrate that the mutation is inactivating as measured by decreased transformation ability compared to wildtype (PMID: 29533785).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1680011342414,
                    "updatedBy": "User"
                  },
                  "description_uuid": "b76bbe14-878e-494d-b740-ac1cddf33b76",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1680011330758,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "9eefa994-e657-43db-93fb-f9ce51268979",
                  "oncogenic": "Likely Neutral",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1680011329421,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "3cc907ca-954a-4ed8-89d2-4b5207ed1077",
                  "short": ""
                },
                "mutation_effect_uuid": "3a0d9fc4-239f-482f-8db0-812adcd994f4",
                "name": "G606W",
                "name_review": {
                  "added": true,
                  "updateTime": 1680011327209,
                  "updatedBy": "User"
                },
                "name_uuid": "c07b608e-76f5-4f63-8f66-1c1b710cdecc",
                "tumors_uuid": "49386977-69c6-4006-92bb-5ca6cf69ad60"
              },
              "operation": "add",
              "uuids": "3cc907ca-954a-4ed8-89d2-4b5207ed1077,9eefa994-e657-43db-93fb-f9ce51268979"
            }
          ],
          "timeStamp": 1680799438088
        },
        "-NSMS8k-ArDgLTJjp0Mb": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "A762V",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF A762V mutation is located in an unknown functional domain of the protein. This mutation has been identified in colorectal cancer (PMID: 29316426). In vitro studies with Ba/F3 and MCF10A cells expressing BRAF A762V demonstrate that the mutation is likely neutral as measured by transformation and proliferation comparable to wildtype (PMID: 29533785).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1680011370569,
                    "updatedBy": "User"
                  },
                  "description_uuid": "4facd9bd-6aec-4f31-8b67-394606b01028",
                  "effect": "Likely Neutral",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1680011365013,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "79f3270f-b928-4965-b727-bdd74b0490eb",
                  "oncogenic": "Likely Neutral",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1680011364220,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "5e9d52ed-5c92-45e2-a5d2-f09983848227",
                  "short": ""
                },
                "mutation_effect_uuid": "a9bfc914-39a8-43a6-afa6-5b11e155dd4e",
                "name": "A762V",
                "name_review": {
                  "added": true,
                  "updateTime": 1680011360822,
                  "updatedBy": "User"
                },
                "name_uuid": "96570838-8cde-432b-b877-dad1bc8008ad",
                "tumors_uuid": "c88f622e-4100-4089-c066-5db9e8bb081d"
              },
              "operation": "add",
              "uuids": "5e9d52ed-5c92-45e2-a5d2-f09983848227,79f3270f-b928-4965-b727-bdd74b0490eb"
            }
          ],
          "timeStamp": 1680799472484
        },
        "-NSMSItoIpD3pF6WEgXJ": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R682W",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF R682W mutation is located in the kinase domain of the protein. This mutation has been identified in lung adenocarcinoma (PMID: 22980975). Preclinical studies with PC9 cells expressing BRAF R682W and EGFR exon 19 in-frame deletion mutations demonstrated that the mutation is resistant to treatment with erlotinib as measured by sustained cellular viability following treatment (PMID: 27478040).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1680011411649,
                    "updatedBy": "User"
                  },
                  "description_uuid": "8227dccc-4ae6-4d2b-a7a3-316ac0db351e",
                  "effect": "Inconclusive",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1680011400047,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "b4690794-43f1-4d4e-a7f1-4a916b592fe0",
                  "oncogenic": "Resistance",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1680011399135,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "1229dd70-6fb5-4bbe-9d3e-a48b364433c8",
                  "short": ""
                },
                "mutation_effect_uuid": "a3d63b24-98d2-4095-b410-090bf3763d06",
                "name": "R682W",
                "name_review": {
                  "added": true,
                  "updateTime": 1680011394744,
                  "updatedBy": "User"
                },
                "name_uuid": "e6b71e34-8eda-4c8f-a041-7d0df63067f3",
                "tumors_uuid": "35033de4-c676-476c-8e0c-86c905ca7396"
              },
              "operation": "add",
              "uuids": "1229dd70-6fb5-4bbe-9d3e-a48b364433c8,b4690794-43f1-4d4e-a7f1-4a916b592fe0"
            }
          ],
          "timeStamp": 1680799514072
        },
        "-NSMSR7Ti56qrBjMd2bh": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "A33T",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF A33T mutation is located in an unknown functional domain of the protein. This mutation has been identified in colorectal cancer (PMID: 28481359). In vitro studies with mouse embryonic fibroblasts expressing BRAF A33T demonstrate that the mutation is likely neutral as measured by ERK activation comparable to wildtype (PMID: 31515458).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1680011480802,
                    "updatedBy": "User"
                  },
                  "description_uuid": "86ed60fd-3075-41d9-826c-2766e69c8af8",
                  "effect": "Likely Neutral",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1680011476736,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "704334e4-f538-4143-a116-dbce48de5258",
                  "oncogenic": "Likely Neutral",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1680011475832,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "23c14370-2a01-46a1-9120-a04fa88e507f",
                  "short": ""
                },
                "mutation_effect_uuid": "95792c51-8628-42e2-8b63-c96027bd91e8",
                "name": "A33T",
                "name_review": {
                  "added": true,
                  "updateTime": 1680011465603,
                  "updatedBy": "User"
                },
                "name_uuid": "49248b00-c4ac-4aef-9063-f22ad9844522",
                "tumors_uuid": "ce6bd934-1dbe-4496-80c8-5448c7f4e46c"
              },
              "operation": "add",
              "uuids": "23c14370-2a01-46a1-9120-a04fa88e507f,704334e4-f538-4143-a116-dbce48de5258"
            }
          ],
          "timeStamp": 1680799547778
        },
        "-NSMSZRcXO73LO5Mso8F": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "P367S",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF P367S mutation is located in an unknown functional domain of the protein. This mutation has been identified in melanoma (PMID: 24265153). In vitro studies with Ba/F3 cells expressing BRAF P367S demonstrate that the mutation is activating as measured by increased transformation ability compared to wildtype (PMID: 29533785).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1680011446255,
                    "updatedBy": "User"
                  },
                  "description_uuid": "ba8771d6-1ba4-40d0-84a1-c6bf9ff19468",
                  "effect": "Likely Gain-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1680011440841,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "91da86fe-2f02-4d1d-a26a-84d8f52f049b",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1680011439783,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "38e74d85-b24a-4938-acd7-b1c857b16a9c",
                  "short": ""
                },
                "mutation_effect_uuid": "bf42520c-c429-4e0d-b917-69268f0763e4",
                "name": "P367S",
                "name_review": {
                  "added": true,
                  "updateTime": 1680011436928,
                  "updatedBy": "User"
                },
                "name_uuid": "6474bfeb-2d32-4c87-867c-c7810f46bdac",
                "tumors_uuid": "a02069ea-7744-413a-8896-f6e24ff0e2c4"
              },
              "operation": "add",
              "uuids": "38e74d85-b24a-4938-acd7-b1c857b16a9c,91da86fe-2f02-4d1d-a26a-84d8f52f049b"
            }
          ],
          "timeStamp": 1680799581836
        },
        "-NSMSghfUONnzWCcwk9N": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "H725Y",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF H725Y mutation is located in an unknown functional domain of the protein. This mutation has been identified in merkel cell carcinoma (PMID: 28481359). In vitro studies with MCF10A cells expressing BRAF H725Y demonstrate that the mutation is activating as measured by increased transformation ability compared to wildtype (PMID: 29533785).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1680011536121,
                    "updatedBy": "User"
                  },
                  "description_uuid": "ed956086-b895-467a-8b34-7bc28ac15b19",
                  "effect": "Likely Gain-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1680011534637,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "ea3019e5-f0bf-40b0-b577-7d467486d2b8",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1680011534086,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "b93338b9-4378-4b67-8331-97afe3c46559",
                  "short": ""
                },
                "mutation_effect_uuid": "b5dcb1ca-9801-41cc-9e96-b108f68b931a",
                "name": "H725Y",
                "name_review": {
                  "added": true,
                  "updateTime": 1680011527995,
                  "updatedBy": "User"
                },
                "name_uuid": "c8720b4a-4d01-4757-a233-a943d33fa7fc",
                "tumors_uuid": "02786ed3-4214-4e82-8764-497bf35981da"
              },
              "operation": "add",
              "uuids": "b93338b9-4378-4b67-8331-97afe3c46559,ea3019e5-f0bf-40b0-b577-7d467486d2b8"
            }
          ],
          "timeStamp": 1680799615695
        },
        "-NSMSpo9ELr6eyvBHzkZ": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R271H",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF R271H mutation is located in the zinc-finger domain of the protein. This mutation has been identified in prostate cancer (PMID: 28825054). In vitro studies with Ba/F3 and MCF10A cells expressing BRAF R271H demonstrate that the mutation is likely neutral as measured by cellular proliferation and viability comparable to wildtype (PMID: 29533785).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1680011508673,
                    "updatedBy": "User"
                  },
                  "description_uuid": "9c5929cd-fbd8-47f2-8c96-192f9933b7e0",
                  "effect": "Likely Neutral",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1680011506594,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "7f946eea-0e70-4ba0-8599-1c4599a1d9f5",
                  "oncogenic": "Likely Neutral",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1680011505673,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "ea70fe95-5c10-480b-9fde-1b4c0408f6db",
                  "short": ""
                },
                "mutation_effect_uuid": "a94a8ba9-7fd8-408d-9bd2-25cfec206407",
                "name": "R271H",
                "name_review": {
                  "added": true,
                  "updateTime": 1680011497913,
                  "updatedBy": "User"
                },
                "name_uuid": "d34ad732-5a25-45ee-8c8b-775ab5de1239",
                "tumors_uuid": "8fb85a36-fa32-4cbd-a81a-adb111e9f5fe"
              },
              "operation": "add",
              "uuids": "ea70fe95-5c10-480b-9fde-1b4c0408f6db,7f946eea-0e70-4ba0-8599-1c4599a1d9f5"
            }
          ],
          "timeStamp": 1680799652974
        },
        "-NSMT4sreFw6sH5hI5R7": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "F294L",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF F294L mutation is located in an unknown functional domain of the protein. This mutation has been identified in colorectal cancer (PMID: 28481359). In vitro studies with Ba/F3 and MCF10A cells expressing BRAF F294L demonstrate that the mutation is likely neutral as measured by cellular proliferation and viability comparable to wildtype (PMID: 29533785).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1680011557508,
                    "updatedBy": "User"
                  },
                  "description_uuid": "bebe498e-41ff-4de6-a8b6-6bf2acc665cc",
                  "effect": "Likely Neutral",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1680011552410,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "0bedcc6e-0b8d-4096-bbbf-f54063466e6f",
                  "oncogenic": "Likely Neutral",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1680011551218,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "5156f3f4-6113-4df7-a5a4-c3bf3fd5e364",
                  "short": ""
                },
                "mutation_effect_uuid": "295db5e3-2021-408c-b3f2-e3c60db7a504",
                "name": "F294L",
                "name_review": {
                  "added": true,
                  "updateTime": 1680011548156,
                  "updatedBy": "User"
                },
                "name_uuid": "d7437ca7-1950-494b-8c6f-697ab08fb6ce",
                "tumors_uuid": "8a912ebf-bec5-4299-a8b9-b36702049097"
              },
              "operation": "add",
              "uuids": "5156f3f4-6113-4df7-a5a4-c3bf3fd5e364,0bedcc6e-0b8d-4096-bbbf-f54063466e6f"
            }
          ],
          "timeStamp": 1680799718811
        },
        "-NSMniopH5xjFP1C4gBy": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "I572F",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF I572F mutation is located in the kinase domain of the protein. This mutation has been identified in lung adenocarcinoma (PMID: 28481359). Although not functionally characterized per se, a patient with lung adenocarcinoma harboring BRAF I572F and KRAS G12V was treated with nivolumab and demonstrated progressive disease (PMID: 34963703).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1680109818395,
                    "updatedBy": "User"
                  },
                  "description_uuid": "7bbedeb2-aee3-467d-b8a6-702cf443764a",
                  "effect": "Inconclusive",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1680109813974,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "eeefc97d-4142-4f19-af7c-26048155a361",
                  "oncogenic": "Inconclusive",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1680109811485,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "b4256573-9ddb-44b0-83ff-a8d1fe2d5706",
                  "short": ""
                },
                "mutation_effect_uuid": "e8315292-0331-4c86-8010-6c140949771a",
                "name": "I572F",
                "name_review": {
                  "added": true,
                  "updateTime": 1680109809799,
                  "updatedBy": "User"
                },
                "name_uuid": "26e6eadd-3837-42f4-9d09-e162bb3e2bc8",
                "tumors_uuid": "0ab9de87-8e65-44bc-910c-56ae13a0d503"
              },
              "operation": "add",
              "uuids": "b4256573-9ddb-44b0-83ff-a8d1fe2d5706,eeefc97d-4142-4f19-af7c-26048155a361"
            }
          ],
          "timeStamp": 1680805391576
        },
        "-NSMnqxP5Qn6vEGR_MRx": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "P162S",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF P162S mutation is located in the RBD domain of the protein. This mutation has been identified in biliary tract cancer (PMID: 29360550). In vitro studies with Ba/F3 and MCF10A cells expressing BRAF P162S demonstrate that the mutation is likely neutral as measured by cellular proliferation and viability comparable to wildtype (PMID: 29533785).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1680805382703,
                    "updatedBy": "User"
                  },
                  "description_uuid": "bf903765-eda2-4640-9531-a19894929e98",
                  "effect": "Likely Neutral",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1680109867502,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "69cec9f1-2fa9-4d15-9fa2-3a854debe177",
                  "oncogenic": "Likely Neutral",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1680109865887,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "4f26b6ee-0619-4a3e-8e4e-7a21baded348",
                  "short": ""
                },
                "mutation_effect_uuid": "bd013e9e-4ab4-4f3d-acc2-ef9791a2a61b",
                "name": "P162S",
                "name_review": {
                  "added": true,
                  "updateTime": 1680109860909,
                  "updatedBy": "User"
                },
                "name_uuid": "7bcf2c57-992b-4eec-b73d-ea4df4e68819",
                "tumors_uuid": "1833a3a4-2695-4586-b5d7-1889cbb7de16"
              },
              "operation": "add",
              "uuids": "4f26b6ee-0619-4a3e-8e4e-7a21baded348,69cec9f1-2fa9-4d15-9fa2-3a854debe177"
            }
          ],
          "timeStamp": 1680805424893
        },
        "-NSMnzRNCnIsP7B2TSvb": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "M620I",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF M620I mutation is located in the kinase domain of the protein. This mutation has been identified in lung adenocarcinoma (PMID: 28481359). In silico analysis suggests that the mutation is activating and damaging (PMID: 34588906).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1680109851158,
                    "updatedBy": "User"
                  },
                  "description_uuid": "180c9d4b-27a0-47bd-9829-c978eb39726d",
                  "effect": "Inconclusive",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1680109846723,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "e2872a4c-bc9c-4349-979b-6b04b594df08",
                  "oncogenic": "Inconclusive",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1680109845753,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "6bb9b4e8-ed04-4c42-a793-432f4ee97299",
                  "short": ""
                },
                "mutation_effect_uuid": "072196c5-4649-4266-c0b0-dc35d4960a0e",
                "name": "M620I",
                "name_review": {
                  "added": true,
                  "updateTime": 1680109843844,
                  "updatedBy": "User"
                },
                "name_uuid": "e3336754-895e-4315-b12d-4d3a14a7695e",
                "tumors_uuid": "3569fd76-13b9-40fb-adcb-f9e1aa5187eb"
              },
              "operation": "add",
              "uuids": "6bb9b4e8-ed04-4c42-a793-432f4ee97299,e2872a4c-bc9c-4349-979b-6b04b594df08"
            }
          ],
          "timeStamp": 1680805459643
        },
        "-NSModmNQ20j2mzK8sad": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R239Q",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF R239Q mutation is located in the zinc-finger domain of the protein. This mutation has been identified in melanoma (PMID: 28481359). Although not functionally characterized per se, preclinical studies with patient-derived melanoma cell lines harboring BRAF R239Q and BRAF L597S demonstrated sensitivity to treatment with binimetinib plus encorafenib, dabrafenib plus trametinib, single agent encorafenib and single agent binimetinib as measured by reduced cellular proliferation and tumor growth (PMID: 29903896).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1680118469525,
                    "updatedBy": "User"
                  },
                  "description_uuid": "effc2501-620a-497d-a3a3-f6df1579763d",
                  "effect": "Inconclusive",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1680118465222,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "9e1a9d85-4299-4e5d-b22b-a00933dd4196",
                  "oncogenic": "Inconclusive",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1680118463959,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "86548f98-9509-40e8-9184-72020ba09c77",
                  "short": ""
                },
                "mutation_effect_uuid": "7ffb2dba-487f-4d71-8873-032c799dd145",
                "name": "R239Q",
                "name_review": {
                  "added": true,
                  "updateTime": 1680118458636,
                  "updatedBy": "User"
                },
                "name_uuid": "45a6fd3b-d068-44b6-a1c0-e9ae68fe7673",
                "tumors_uuid": "63b73f0e-07cb-4712-9db0-99d7087fabfe"
              },
              "operation": "add",
              "uuids": "86548f98-9509-40e8-9184-72020ba09c77,9e1a9d85-4299-4e5d-b22b-a00933dd4196"
            }
          ],
          "timeStamp": 1680805633083
        },
        "-NSMom7htj9OawR-NxrH": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R558Q",
              "new": {
                "mutation_effect": {
                  "description": "The class III BRAF R558Q mutation is located in the kinase domain of the protein (PMID: 31515458). This mutation has been identified in colorectal cancer (PMID: 28481359). In vitro studies with mouse embryonic fibroblasts expressing BRAF R558Q demonstrate that the mutation is activating as measured by increased ERK signaling compared to wildtype (PMID: 31515458). In a clinical trial, a patient with metastatic colorectal cancer harboring BRAF R558Q was treated with combination cetuximab plus irinotecan and demonstrated complete response with a progression-free survival of 37.7 months (PMID: 31515458).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1680133261412,
                    "updatedBy": "User"
                  },
                  "description_uuid": "b58dbdc6-8ebc-4468-b022-741e19e79bc2",
                  "effect": "Likely Gain-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1680118491795,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "40f7f0ec-543e-4254-b80a-713689ecf867",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1680118490725,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "ff3ab9a1-702c-46c8-b759-4d3a5e00947e",
                  "short": ""
                },
                "mutation_effect_uuid": "3aa7cc52-53fb-411e-96c6-7623d7555ce1",
                "name": "R558Q",
                "name_review": {
                  "added": true,
                  "updateTime": 1680118485485,
                  "updatedBy": "User"
                },
                "name_uuid": "533253d6-9881-4929-a4f3-68c1d1e8d792",
                "tumors_uuid": "480246c7-6445-4420-a473-be745ecb914c"
              },
              "operation": "add",
              "uuids": "ff3ab9a1-702c-46c8-b759-4d3a5e00947e,40f7f0ec-543e-4254-b80a-713689ecf867"
            }
          ],
          "timeStamp": 1680805667280
        },
        "-NSNEkXEDvS-Zy5-72Bo": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "S363F",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF S363F mutation is located in an unknown functional domain of the protein. This mutation has been identified in melanoma (PMID: 28467829). Although not functionally characterized per se, preclinical studies with melanoma cell lines harboring BRAF S363F and BRAF K601E demonstrated sensitivity to treatment with binimetinib plus encorafenib, dabrafenib plus trametinib, trametinib plus vemurafenib, single agent encorafenib, single agent binimetinib, single agent trametinib and single agent cobimetinib as measured by reduced cellular proliferation (PMID: 29903896).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1680118530278,
                    "updatedBy": "User"
                  },
                  "description_uuid": "ff89afc2-6546-471b-895b-ac0764d15bf5",
                  "effect": "Inconclusive",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1680118526672,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "85f1e474-daa3-459e-9380-8e69a4441351",
                  "oncogenic": "Inconclusive",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1680118525444,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "6f2f0aef-d53a-4ab9-bc1b-6aca75ba711e",
                  "short": ""
                },
                "mutation_effect_uuid": "e74affb0-d115-4cc7-bc1c-306373d0a89e",
                "name": "S363F",
                "name_review": {
                  "added": true,
                  "updateTime": 1680118515307,
                  "updatedBy": "User"
                },
                "name_uuid": "bf0ca8f5-e126-4407-acd5-86cfa79d40fd",
                "tumors_uuid": "888eecef-3c7c-4a8b-ae7d-71814e40ce79"
              },
              "operation": "add",
              "uuids": "6f2f0aef-d53a-4ab9-bc1b-6aca75ba711e,85f1e474-daa3-459e-9380-8e69a4441351"
            }
          ],
          "timeStamp": 1680812738575
        },
        "-NSNEsqzapu2ag1QwPa1": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "T310I",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF T310I mutation is located in an unknown functional domain of the protein. This mutation has been identified in glioma (PMID: 18772396). In vitro studies with SkBr3 cells expressing BRAF T310I demonstrate that the mutation is activating as measured by an increase in ERK phosphorylation compared to wildtype (PMID: 31158244). Preclinical studies with SkBr3 cells expressing this mutation demonstrate resistance to treatment with dabrafenib as measured by sustained ERK phosphorylation (PMID: 31158244).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1680118569680,
                    "updatedBy": "User"
                  },
                  "description_uuid": "603b94bc-7c07-4c4b-98c7-d3ee2dba8408",
                  "effect": "Likely Gain-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1680118562509,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "aa4c01bb-ff19-4975-8d6c-2fc5047418a7",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1680118561969,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "8fa75258-b5ed-4a43-aba3-cc776ee00c5a",
                  "short": ""
                },
                "mutation_effect_uuid": "93c19bee-46ab-431e-96ab-1e742b5abeaf",
                "name": "T310I",
                "name_review": {
                  "added": true,
                  "updateTime": 1680118559902,
                  "updatedBy": "User"
                },
                "name_uuid": "d3316937-e94f-49cf-a43c-ae90c34f4d5c",
                "tumors_uuid": "19a61b55-9241-45fe-b45b-49d67b746fb3"
              },
              "operation": "add",
              "uuids": "8fa75258-b5ed-4a43-aba3-cc776ee00c5a,aa4c01bb-ff19-4975-8d6c-2fc5047418a7"
            }
          ],
          "timeStamp": 1680812772671
        },
        "-NSNF0Dr81DOSuJiN9jJ": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "L485Y",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF L485Y mutation is located in the kinase domain of the protein. In vitro studies with HT29 cells expressing BRAF L485Y demonstrated resistance to treatment with GDC0879 as measured by sustained cellular proliferation following treatment (PMID: 19276360).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1680192155789,
                    "updatedBy": "User"
                  },
                  "description_uuid": "6752d9db-b649-4ae9-a6e9-83f2230844f9",
                  "effect": "Inconclusive",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1680118595639,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "66e6caab-ad7f-4b9c-9a6f-cbed104e7823",
                  "oncogenic": "Resistance",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1680118594586,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "b5152b18-7699-4da6-9902-f83472ec5b55",
                  "short": ""
                },
                "mutation_effect_uuid": "9d945125-a0b5-4b35-b573-bd95c2c9a156",
                "name": "L485Y",
                "name_review": {
                  "added": true,
                  "updateTime": 1680118592583,
                  "updatedBy": "User"
                },
                "name_uuid": "5776386c-6d6a-4796-aab7-7965d1e8b4ac",
                "tumors_uuid": "c3e634eb-cf71-4c7f-b4aa-3ec56c1f54ea"
              },
              "operation": "add",
              "uuids": "b5152b18-7699-4da6-9902-f83472ec5b55,66e6caab-ad7f-4b9c-9a6f-cbed104e7823"
            }
          ],
          "timeStamp": 1680812806967
        },
        "-NSNFK5Wlr40wgIvHy2D": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "L597P",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF L597P mutation is located in the kinase domain of the protein. This mutation has been identified in melanoma (PMID: 23890154). In vitro studies with patient-derived intrahepatic cholangiocarcinoma organoids expressing BRAF L597P demonstrated resistance to treatment with lenvatinib, temuterkib and sunitinib as measured by sustained cellular proliferation, and sensitivity to treatment with trametinib and cobimetinib, as measured by inhibition of cellular proliferation (PMID: 36867406).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1680812852212,
                    "updatedBy": "User"
                  },
                  "description_uuid": "cdd065aa-8dfc-436b-a141-8b7b0740f042",
                  "effect": "Inconclusive",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1680118623908,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "69394227-ec1b-4915-8c3d-a7376f871c59",
                  "oncogenic": "Resistance",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1680118623313,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "65d99fa1-11e8-4693-bbbf-cea4ad0df770",
                  "short": ""
                },
                "mutation_effect_uuid": "beb83c52-2042-4d32-a417-4d18a5c2ea88",
                "name": "L597P",
                "name_review": {
                  "added": true,
                  "updateTime": 1680118620609,
                  "updatedBy": "User"
                },
                "name_uuid": "4cd56785-f1e9-4988-b4b6-b7e700a899bd",
                "tumors_uuid": "56109518-f0d9-49ae-b85d-afa8821c71da"
              },
              "operation": "add",
              "uuids": "65d99fa1-11e8-4693-bbbf-cea4ad0df770,69394227-ec1b-4915-8c3d-a7376f871c59"
            }
          ],
          "timeStamp": 1680812888353
        },
        "-NSNFSVTg3iB6IcIobDw": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600L",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF V600L mutation (also known as V599L) is located in the activation segment of the kinase domain of the protein. This mutation has been identified in colorectal cancer (PMID: 22586484). In vitro studies with MCF10A cells expressing BRAF V600L demonstrate that the mutation is activating as measured by increased cell proliferation and viability compared to wildtype (PMID: 29533785).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1680190734902,
                    "updatedBy": "User"
                  },
                  "description_uuid": "5f2f74f5-d92a-4bd2-a41b-23682db0491e",
                  "effect": "Likely Gain-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1680118673469,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "6be2d4e5-848a-456c-a5bd-951bac12dc4f",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1680118672485,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "d46d6559-30db-46b1-8f06-9f80a184f35f",
                  "short": ""
                },
                "mutation_effect_uuid": "913cce09-2afe-4438-8d59-994f39827b45",
                "name": "V600L",
                "name_review": {
                  "added": true,
                  "updateTime": 1680118669329,
                  "updatedBy": "User"
                },
                "name_uuid": "7b1e0a7e-4a30-5000-832f-301f1202cc83",
                "tumors_uuid": "0e17fee3-84b6-4283-90fe-c52d5b995157"
              },
              "operation": "add",
              "uuids": "d46d6559-30db-46b1-8f06-9f80a184f35f,6be2d4e5-848a-456c-a5bd-951bac12dc4f"
            }
          ],
          "timeStamp": 1680812922782
        },
        "-NSNFaTtWDd2ghDXgDN_": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600A",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF V600A mutation (also known as V599A) is located in the activation segment of the kinase domain of the protein. This mutation has been identified in prostate cancer (PMID: 16721785). In vitro studies with HEK293 cells expressing BRAF V600A demonstrate that the mutation is likely neutral as measured by phosphorylation comparable to wildtype (PMID: 26744778).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1680190739743,
                    "updatedBy": "User"
                  },
                  "description_uuid": "3ecbbd8b-6ab5-4766-9773-f96c0de40e8f",
                  "effect": "Likely Neutral",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1680118654449,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "c810a2c1-f5f4-45fb-9a9a-0251be778f03",
                  "oncogenic": "Likely Neutral",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1680118653716,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "a7379224-dad4-4f69-b3d2-eee291ab022c",
                  "short": ""
                },
                "mutation_effect_uuid": "58a4712d-0516-4021-89ab-479d27cd3b08",
                "name": "V600A",
                "name_review": {
                  "added": true,
                  "updateTime": 1680118649169,
                  "updatedBy": "User"
                },
                "name_uuid": "b58bde25-bf29-4278-952b-631bb58dcad7",
                "tumors_uuid": "ec922a68-6417-47c6-876e-561dc48e5ab2"
              },
              "operation": "add",
              "uuids": "a7379224-dad4-4f69-b3d2-eee291ab022c,c810a2c1-f5f4-45fb-9a9a-0251be778f03"
            }
          ],
          "timeStamp": 1680812959544
        },
        "-NSNFojuJ2zv1YM2XN_U": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600A",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF V600A mutation (also known as V599A) is located in the activation segment of the kinase domain of the protein. This mutation has been identified in prostate cancer (PMID: 16721785). In vitro studies with HEK293 cells expressing BRAF V600A demonstrate that the mutation is likely neutral as measured by phosphorylation comparable to wildtype (PMID: 26744778).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1680190739743,
                    "updatedBy": "User"
                  },
                  "description_uuid": "3ecbbd8b-6ab5-4766-9773-f96c0de40e8f",
                  "effect": "Likely Neutral",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1680118654449,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "c810a2c1-f5f4-45fb-9a9a-0251be778f03",
                  "oncogenic": "Likely Neutral",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1680118653716,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "a7379224-dad4-4f69-b3d2-eee291ab022c",
                  "short": ""
                },
                "mutation_effect_uuid": "58a4712d-0516-4021-89ab-479d27cd3b08",
                "name": "V600A",
                "name_review": {
                  "added": true,
                  "updateTime": 1680118649169,
                  "updatedBy": "User"
                },
                "name_uuid": "b58bde25-bf29-4278-952b-631bb58dcad7",
                "tumors_uuid": "ec922a68-6417-47c6-876e-561dc48e5ab2"
              },
              "operation": "add"
            }
          ],
          "timeStamp": 1680813017975
        },
        "-NSNG4tg-L4DywBcZ0xl": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "M117L",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF M117L mutation is located in an unknown functional domain of the protein. This mutation has been identified in lung adenocarcinoma (PMID: 28481359). Although not functionally characterized per se, a patient with lung adenocarcinoma harboring BRAF M117L was treated with ipilimumab plus nivolumab and demonstrated stable disease (PMID: 34963703).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1680813033930,
                    "updatedBy": "User"
                  },
                  "description_uuid": "847b4221-6323-46cd-a19f-4251ba87dd7b",
                  "effect": "Inconclusive",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1680191811648,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "1b15b026-9ed1-40f0-82ae-8c44c62efcdf",
                  "oncogenic": "Inconclusive",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1680191810802,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "717e67f2-67aa-45b0-9201-be2a6d843eff",
                  "short": ""
                },
                "mutation_effect_uuid": "c97bcec2-c4a7-4092-b253-7fa051d62aee",
                "name": "M117L",
                "name_review": {
                  "added": true,
                  "updateTime": 1680191808354,
                  "updatedBy": "User"
                },
                "name_uuid": "30aa4cfb-dc70-4eb4-b9bb-667ffbf1c05b",
                "tumors_uuid": "73c03696-0dca-47a3-92c2-5cad2e17f698"
              },
              "operation": "add",
              "uuids": "717e67f2-67aa-45b0-9201-be2a6d843eff,1b15b026-9ed1-40f0-82ae-8c44c62efcdf"
            }
          ],
          "timeStamp": 1680813088232
        },
        "-NSNGDJrtPpUyOv9CAXu": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "S616Y",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF S616Y mutation is located in the kinase domain of the protein. Although not functionally characterized per se, a patient with squamous cell carcinoma harboring BRAF S616Y was treated with nivolumab and demonstrated a complete response (PMID: 34963703).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1680813082434,
                    "updatedBy": "User"
                  },
                  "description_uuid": "29bf04c0-36c0-4036-b7c4-2519351c3165",
                  "effect": "Inconclusive",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1680191877429,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "ace3ae6e-78bb-4efb-9f3d-4ea4ce34dfbf",
                  "oncogenic": "Inconclusive",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1680191876245,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "0a5685f6-377d-4252-9c21-ea951c58d39f",
                  "short": ""
                },
                "mutation_effect_uuid": "1ed1d1df-94e4-4ef9-9d63-210a667bc747",
                "name": "S616Y",
                "name_review": {
                  "added": true,
                  "updateTime": 1680191874278,
                  "updatedBy": "User"
                },
                "name_uuid": "01742cd6-d493-4ee5-82d8-6873a637c5a3",
                "tumors_uuid": "22509135-9d69-407c-acfc-627efe6722d5"
              },
              "operation": "add",
              "uuids": "0a5685f6-377d-4252-9c21-ea951c58d39f,ace3ae6e-78bb-4efb-9f3d-4ea4ce34dfbf"
            }
          ],
          "timeStamp": 1680813122740
        },
        "-NSNGLdvf99bQkoUFmM3": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "N412S",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF N412S mutation is located in an unknown functional domain of the protein. This mutation has been identified in lung adenocarcinoma (PMID: 28481359). Although not functionally characterized per se, a patient with lung adenocarcinoma harboring BRAF N412S was treated with nivolumab and demonstrated stable disease (PMID: 34963703).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1680191851653,
                    "updatedBy": "User"
                  },
                  "description_uuid": "68c65eba-9f69-4d41-bcd0-8a508bfe2888",
                  "effect": "Inconclusive",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1680191844734,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "1ac32a66-825d-4a32-9a45-ae8626a2d5db",
                  "oncogenic": "Inconclusive",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1680191844021,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "edefd28d-d764-4fca-82d2-46649b96ff5c",
                  "short": ""
                },
                "mutation_effect_uuid": "1a90937e-e08e-4063-beff-52ef1ecd89b9",
                "name": "N412S",
                "name_review": {
                  "added": true,
                  "updateTime": 1680191842124,
                  "updatedBy": "User"
                },
                "name_uuid": "220a4c36-de27-4354-bc8b-7598b785c45d",
                "tumors_uuid": "cf29f1ce-575d-4bf3-82ee-458c8b829763"
              },
              "operation": "add",
              "uuids": "edefd28d-d764-4fca-82d2-46649b96ff5c,1ac32a66-825d-4a32-9a45-ae8626a2d5db"
            }
          ],
          "timeStamp": 1680813156856
        },
        "-NSNGUP-c0kYMKqlxYRL": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "M517V",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF M517V mutation is located in the kinase domain of the protein. In silico analysis suggests that the mutation contributes to resistance against vemurafenib (PMID: 35215249).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1680191989871,
                    "updatedBy": "User"
                  },
                  "description_uuid": "5ae7afd0-5534-464c-b5fa-0e1133cb7e0c",
                  "effect": "Inconclusive",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1680191985485,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "892cb6e5-481c-4f59-960e-62b334192d44",
                  "oncogenic": "Inconclusive",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1680191984555,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "add98c56-340e-45a8-9e9d-3e6cf140fc97",
                  "short": ""
                },
                "mutation_effect_uuid": "0a3a0596-b68a-41f3-8060-42c7ffaa21d0",
                "name": "M517V",
                "name_review": {
                  "added": true,
                  "updateTime": 1680191981103,
                  "updatedBy": "User"
                },
                "name_uuid": "f7bfc217-c2b1-4843-b99a-aa5e4b2ca9ab",
                "tumors_uuid": "b3e0401f-b317-438d-b94b-8a9e7cd5d0ad"
              },
              "operation": "add",
              "uuids": "add98c56-340e-45a8-9e9d-3e6cf140fc97,892cb6e5-481c-4f59-960e-62b334192d44"
            }
          ],
          "timeStamp": 1680813192701
        },
        "-NSNGbloUFGX0eTqkt2l": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "S607F",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF S607F mutation is located in the kinase domain of the protein. This mutation has been identified in basal cell carcinoma (PMID: 26950094). In vitro studies with HEK293 cells expressing BRAF S607F demonstrate that the mutation is likely neutral as measured by ERK phosphorylation comparable to wildtype (PMID: 32059434).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1680191959110,
                    "updatedBy": "User"
                  },
                  "description_uuid": "f913da96-6007-4b14-be6a-8b9c2574b604",
                  "effect": "Likely Neutral",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1680191942310,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "a8ceb704-0924-4eba-a22f-4965fedf34a9",
                  "oncogenic": "Likely Neutral",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1680191941531,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "3d789366-9270-403b-9ae9-0632cb3f21d6",
                  "short": ""
                },
                "mutation_effect_uuid": "60c7cafd-af83-46fb-92cb-204bf1bf7125",
                "name": "S607F",
                "name_review": {
                  "added": true,
                  "updateTime": 1680191939671,
                  "updatedBy": "User"
                },
                "name_uuid": "192e6d88-99c1-4fb0-96f3-04fa62ab3d8e",
                "tumors_uuid": "6f008313-6f77-4633-95b7-1be839c03402"
              },
              "operation": "add",
              "uuids": "3d789366-9270-403b-9ae9-0632cb3f21d6,a8ceb704-0924-4eba-a22f-4965fedf34a9"
            }
          ],
          "timeStamp": 1680813226993
        },
        "-NSNGkLueG7t971l2UB3": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "T274A",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF T274A mutation is located in the zinc finger domain of the protein. Although not functionally characterized per se, a patient with lung adenocarcinoma harboring BRAF T274A, KRAS G12D and mutant NF1 was treated with nivolumab and demonstrated progressive disease (PMID: 34963703).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1680191915631,
                    "updatedBy": "User"
                  },
                  "description_uuid": "7150a01f-9cfb-4a4a-a49c-9919ee6f6c55",
                  "effect": "Inconclusive",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1680191913845,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "1a45db61-f9a1-47c2-8269-b59db2ea70d2",
                  "oncogenic": "Inconclusive",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1680191912849,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "5d020698-93b7-40aa-8996-48d038b97f29",
                  "short": ""
                },
                "mutation_effect_uuid": "b3a2cd26-cc8f-4e04-8789-5d3a73a7c8ad",
                "name": "T274A",
                "name_review": {
                  "added": true,
                  "updateTime": 1680191907711,
                  "updatedBy": "User"
                },
                "name_uuid": "959da81d-db56-4098-8f0c-1e55c22bc39f",
                "tumors_uuid": "e311c4e1-3590-490f-a765-3a78382ad70c"
              },
              "operation": "add",
              "uuids": "5d020698-93b7-40aa-8996-48d038b97f29,1a45db61-f9a1-47c2-8269-b59db2ea70d2"
            }
          ],
          "timeStamp": 1680813262135
        },
        "-NSNJogPkqyzXPZGZwoS": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "W604C",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF W604C mutation is located in the kinase domain of the protein. This mutation has been identified in melanoma (PMID: 28467829). Although not functionally characterized per se, a patient with lung adenocarcinoma harboring BRAF W604C and BRAF G469A was treated with dabrafenib plus trametinib and demonstrated stable disease with a progression-free survival of fifteen months (PMID: 30926357).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1680814028894,
                    "updatedBy": "User"
                  },
                  "description_uuid": "fba875cb-1107-4e7f-b6c8-ede939dd577b",
                  "effect": "Inconclusive",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1680192011109,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "2e8a7d43-8453-4d53-9337-48e395b4a216",
                  "oncogenic": "Inconclusive",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1680192010319,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "59b9d7dd-aa66-4ece-8c2e-66b8fa53f7fa",
                  "short": ""
                },
                "mutation_effect_uuid": "f7f26dfb-e977-4d47-9a73-d6fac338aa0c",
                "name": "W604C",
                "name_review": {
                  "added": true,
                  "updateTime": 1680192007251,
                  "updatedBy": "User"
                },
                "name_uuid": "8e623fef-f181-4b44-b178-f5ff50b9bdff",
                "tumors_uuid": "6c7f976d-8301-4af5-952b-5f21db8f440b"
              },
              "operation": "add",
              "uuids": "59b9d7dd-aa66-4ece-8c2e-66b8fa53f7fa,2e8a7d43-8453-4d53-9337-48e395b4a216"
            }
          ],
          "timeStamp": 1680814066327
        },
        "-NSNJxE8hWZWv97EVxa8": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "E451K",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF E451K mutation is located in an unknown functional domain of the protein. In vitro studies with SkBr3 cells expressing BRAF E451K demonstrate that the mutation is activating as measured by increased ERK phosphorylation compared to wildtype (PMID: 31158244). Preclinical studies with SkBr3 cells expressing this mutation demonstrate that the mutation is resistant to dabrafenib as measured by sustained ERK phosphorylation following treatment (PMID: 31158244).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1680192072868,
                    "updatedBy": "User"
                  },
                  "description_uuid": "8e574aa0-9f2e-498a-988f-fc5d5639aec4",
                  "effect": "Likely Gain-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1680192069345,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "313d8c8b-8f58-47fb-882c-3ae17edb3cfb",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1680192068636,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "64ce0979-890a-451a-86c2-22a3d58f0141",
                  "short": ""
                },
                "mutation_effect_uuid": "8c5ae4c7-19fd-43ee-a13d-ae666275991b",
                "name": "E451K",
                "name_review": {
                  "added": true,
                  "updateTime": 1680192064375,
                  "updatedBy": "User"
                },
                "name_uuid": "812142e1-51f0-4224-9260-56b42385cdd4",
                "tumors_uuid": "c5681fc6-ddaf-4ce5-9ad0-313751184f7e"
              },
              "operation": "add",
              "uuids": "64ce0979-890a-451a-86c2-22a3d58f0141,313d8c8b-8f58-47fb-882c-3ae17edb3cfb"
            }
          ],
          "timeStamp": 1680814101318
        },
        "-NSNK4fULUTYMBj3sWYH": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R389C",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF R389C mutation is located in an unknown functional domain of the protein. This mutation has been identified in colorectal cancer (PMID: 25344691). In vitro studies with Ba/F3 and MCF10A cells expressing BRAF R389C demonstrate that the mutation is likely neutral as measured by cell proliferation and viability comparable to wildtype (PMID: 29533785).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1680192046461,
                    "updatedBy": "User"
                  },
                  "description_uuid": "3385aa23-2df9-4c24-bbb0-45e6e43a02e9",
                  "effect": "Likely Neutral",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1680192042756,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "a7793917-0857-4385-ba53-00a84894c5cb",
                  "oncogenic": "Likely Neutral",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1680192041978,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "27e36595-b7bd-4f06-a13b-2dbf005329dc",
                  "short": ""
                },
                "mutation_effect_uuid": "80e790ac-2b00-48df-bd7c-54aef4d0fd2d",
                "name": "R389C",
                "name_review": {
                  "added": true,
                  "updateTime": 1680192039886,
                  "updatedBy": "User"
                },
                "name_uuid": "4d72d8f9-05cb-4311-91a8-5adc994a79c3",
                "tumors_uuid": "d8a444bf-5ffc-4205-9b5b-3b54e6091854"
              },
              "operation": "add",
              "uuids": "27e36595-b7bd-4f06-a13b-2dbf005329dc,a7793917-0857-4385-ba53-00a84894c5cb"
            }
          ],
          "timeStamp": 1680814135900
        },
        "-NSNKDLg2LUeDzuQYOC1": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "ZNF767-BRAF Fusion",
              "new": {
                "mutation_effect": {
                  "description": "The ZNF767-BRAF fusion results from the fusion of exon 1 of ZNF767 with exon 11 of BRAF. In vivo studies with nude mice expressing ZNF767-BRAF demonstrate that the fusion is activating as measured by rapid tumor growth compared to wildtype (PMID: 28092667). Preclinical studies with PMM cells expressing ZNF767-BRAF demonstrated sensitivity to treatment with trametinib, BKM120, LEE011, trametinib plus BKM120 and trametinib plus LEE011 as measured by inhibition of cell growth (PMID: 28092667). A patient with melanoma harboring ZNF767-BRAF was treated with vemurafenib and demonstrated resistance, with rapid progression within two weeks of treatment (PMID: 28092667).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1680814116297,
                    "updatedBy": "User"
                  },
                  "description_uuid": "ec60ac96-10e7-4312-9bb1-5af1936521c8",
                  "effect": "Likely Gain-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1680278547538,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "446c9369-f5ff-4924-a94e-35ff64a2b23c",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1680278546890,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "5577f1a6-a3b2-480a-96d1-1954ba542c30",
                  "short": ""
                },
                "mutation_effect_uuid": "6fce30f1-f9e6-4d28-bd9a-ec98ea41f960",
                "name": "ZNF767-BRAF Fusion",
                "name_review": {
                  "added": true,
                  "updateTime": 1680278544788,
                  "updatedBy": "User"
                },
                "name_uuid": "057c18a8-bbfb-4341-b8b5-f1a9dd88f8bd",
                "tumors_uuid": "29a99ad8-5ebe-4361-a4a7-5ed3282c5d4b"
              },
              "operation": "add",
              "uuids": "5577f1a6-a3b2-480a-96d1-1954ba542c30,446c9369-f5ff-4924-a94e-35ff64a2b23c"
            }
          ],
          "timeStamp": 1680814171433
        },
        "-NSNKLvYz9XfKkXbIWXq": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R239L",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF R239L mutation is located in the zinc finger domain of the protein. Although not functionally characterized per se, a patient with lung adenocarcinoma harboring BRAF R239L and KRAS G12C was treated with nivolumab and demonstrated stable disease (PMID: 34963703).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1680278480672,
                    "updatedBy": "User"
                  },
                  "description_uuid": "34c7bfe2-b204-4295-92cf-6feebec1d639",
                  "effect": "Inconclusive",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1680278476624,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "92b6ade4-8ffa-4a8d-bdda-989bd7573b38",
                  "oncogenic": "Inconclusive",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1680278475538,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "7cb50114-6671-44dd-8bc2-46e64960b0e7",
                  "short": ""
                },
                "mutation_effect_uuid": "5e34f996-1f10-4560-a816-08778a22aa4e",
                "name": "R239L",
                "name_review": {
                  "added": true,
                  "updateTime": 1680278473215,
                  "updatedBy": "User"
                },
                "name_uuid": "b97fc159-176b-4e47-8c11-e3b745b3c394",
                "tumors_uuid": "a4437b09-b31c-43e8-8c28-463cc5d56e07"
              },
              "operation": "add",
              "uuids": "7cb50114-6671-44dd-8bc2-46e64960b0e7,92b6ade4-8ffa-4a8d-bdda-989bd7573b38"
            }
          ],
          "timeStamp": 1680814206560
        },
        "-NSNKUimrjNu_lSheW3A": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "S122Y",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF S122Y mutation is located in the SBC motif of the protein. This mutation has been identified in osteosarcoma (PMID: 28481359). In vitro studies with 293T cells expressing BRAF S122Y demonstrate that the mutation is activating as measured by reduced SPOP-mediated ubiquitination and increased MAPK/ERK cascade activation compared to wildtype (PMID: 36585710).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1680278441153,
                    "updatedBy": "User"
                  },
                  "description_uuid": "183e79fb-2a77-4168-b455-64b97c61a64c",
                  "effect": "Likely Gain-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1680278439208,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "97510f77-deb4-4388-b0c2-df32cea34d23",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1680278438575,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "47f68c6a-eb88-4b54-a2cf-bdcae474eceb",
                  "short": ""
                },
                "mutation_effect_uuid": "1be5d11e-f6be-417c-a307-4cd2ef33df98",
                "name": "S122Y",
                "name_review": {
                  "added": true,
                  "updateTime": 1680278431636,
                  "updatedBy": "User"
                },
                "name_uuid": "47dc5fd3-4004-4223-9600-c6bfed1c2cf1",
                "tumors_uuid": "9194e4c3-18c1-4bc7-aac7-585c935f2196"
              },
              "operation": "add",
              "uuids": "47f68c6a-eb88-4b54-a2cf-bdcae474eceb,97510f77-deb4-4388-b0c2-df32cea34d23"
            }
          ],
          "timeStamp": 1680814242607
        },
        "-NSmMLZz4JLhcU5_Zno6": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "BRAF-PJA2 Fusion",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF-PJA2 fusion protein results from exon 7 of PJA2 fusing with exon 11 of BRAF, retaining the BRAF kinase domain. This fusion has been identified in EGFR-mutant lung cancer (PMID: 30831205). Preclinical studies with H1975 and PC9 cells expressing BRAF-PJA2 demonstrated the fusion is resistant to treatment with osimertinib as measured by sustained cell viability following treatment (PMID: 30831205).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1681250896728,
                    "updatedBy": "User"
                  },
                  "description_uuid": "d0a82e6d-e895-4c65-8fd9-2580fd83e1f1",
                  "effect": "Likely Gain-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1681250899676,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "1aff8c74-2114-4c5c-86d2-e670c01eea63",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1681250898894,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "779a250f-390d-438d-95e3-403d9832886b",
                  "short": ""
                },
                "mutation_effect_uuid": "ff46185a-fc2f-4bce-ba1b-cee09ad3f04c",
                "name": "BRAF-PJA2 Fusion",
                "name_review": {
                  "added": true,
                  "updateTime": 1680011596849,
                  "updatedBy": "User"
                },
                "name_uuid": "56ec1fdb-0834-4a0b-9276-f28f0096e719",
                "tumors_uuid": "93fe686d-5e9c-4caf-9a15-d5db76ea8853"
              },
              "operation": "add",
              "uuids": "779a250f-390d-438d-95e3-403d9832886b,1aff8c74-2114-4c5c-86d2-e670c01eea63"
            }
          ],
          "timeStamp": 1681250938639
        },
        "-NSmMTahpvDQsHO74A7l": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "JHDM1D-BRAF Fusion",
              "new": {
                "mutation_effect": {
                  "description": "The JHDM1D-BRAF fusion is a chromosomal rearrangement fusing exon 13 of JHDM1D and exon 4 of BRAF, resulting in the loss of part of the RAS-binding domain of RAF. In vitro studies with AZD-R cells expressing JHDM1D-BRAF demonstrate that the fusion is resistant to treatment with FGFR inhibitors AZD4547, NVP-BGJ398 and PD173074 as measured by sustained cellular proliferation following treatment (PMID: 30045926). Preclinical studies with AZD-R cells expressing this fusion demonstrated sensitivity to treatment with MEK inhibitors CH4987655, trametinib and PD0325901 as measured by decreased cell viability following treatment (PMID: 30045926).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1680814141971,
                    "updatedBy": "User"
                  },
                  "description_uuid": "9ca80a78-e39f-40cf-ba76-16a4d7aa3961",
                  "effect": "Likely Gain-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1680540736548,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "d8f04f71-4c59-4b7a-b55d-5752bc0f6dbf",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1680814166148,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "c7d1f27a-b106-4f21-a877-c7c7e9eda827",
                  "short": ""
                },
                "mutation_effect_uuid": "5bc46a28-95b2-4364-b843-cfc9a186cb92",
                "name": "JHDM1D-BRAF Fusion",
                "name_review": {
                  "added": true,
                  "updateTime": 1680540733678,
                  "updatedBy": "User"
                },
                "name_uuid": "c6b1ccca-7755-407a-bcaf-f288826bc3ab",
                "tumors_uuid": "b8f789e2-4c8e-4246-8b9c-196f5d7b2861"
              },
              "operation": "add",
              "uuids": "c7d1f27a-b106-4f21-a877-c7c7e9eda827,d8f04f71-4c59-4b7a-b55d-5752bc0f6dbf"
            }
          ],
          "timeStamp": 1681250971517
        },
        "-NSmNFv092v6bh1aM8Kj": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "E46K",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF E46K mutation is located in the N-terminus of the protein. In vitro studies with 293FT cells expressing BRAF E46K demonstrate that the mutation is activating as measured by increased binding to HRAS compared to wildtype (PMID: 31606273).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1680541091502,
                    "updatedBy": "User"
                  },
                  "description_uuid": "396c1404-3a85-4ee2-9cc0-c37225fbd023",
                  "effect": "Likely Gain-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1680541087606,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "30292363-1ec1-4b7c-873b-12cc8a629507",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1680541086842,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "35532f7e-0122-40a1-b016-cede13efc773",
                  "short": ""
                },
                "mutation_effect_uuid": "2464bce2-bc43-416c-b230-67229aaa584e",
                "name": "E46K",
                "name_review": {
                  "added": true,
                  "updateTime": 1680541084235,
                  "updatedBy": "User"
                },
                "name_uuid": "3bc4a8fb-7069-498e-8792-79a3fc8a0ebc",
                "tumors_uuid": "db0bffad-cb1e-4615-8f1d-db6c2ef5b4cd"
              },
              "operation": "add",
              "uuids": "35532f7e-0122-40a1-b016-cede13efc773,30292363-1ec1-4b7c-873b-12cc8a629507"
            }
          ],
          "timeStamp": 1681251177617
        },
        "-NSmNNr8op2wiC9beaEX": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "L64I",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF L64I mutation is located in the N-terminus of the protein. In vitro studies with Ba/F3 cells and MCF10A cells expressing BRAF L64I demonstrate that the mutation is likely neutral as measured by cell proliferation and viability comparable to wildtype (PMID: 29533785).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1680541143737,
                    "updatedBy": "User"
                  },
                  "description_uuid": "5cdbeedb-6f8e-4331-a0fc-958674c170a8",
                  "effect": "Likely Neutral",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1680541140111,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "cec3efcf-1a79-40fb-9054-4a3bdee7e437",
                  "oncogenic": "Likely Neutral",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1680541139502,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "a8590040-ef77-4f63-99db-a8b6e072331f",
                  "short": ""
                },
                "mutation_effect_uuid": "e030e94d-94ff-45a4-88e2-9f08c996aa6d",
                "name": "L64I",
                "name_review": {
                  "added": true,
                  "updateTime": 1680541136852,
                  "updatedBy": "User"
                },
                "name_uuid": "4040e343-25cc-4de0-8a43-7e9a3245f7d6",
                "tumors_uuid": "89468460-046e-4cd3-af5d-2a493ff3e18c"
              },
              "operation": "add",
              "uuids": "a8590040-ef77-4f63-99db-a8b6e072331f,cec3efcf-1a79-40fb-9054-4a3bdee7e437"
            }
          ],
          "timeStamp": 1681251210137
        },
        "-NSmNVpbOzWkh4oiHHPx": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "N49I",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF N49I mutation is located in the N-terminus of the protein. In vitro studies with Ba/F3 cells and MCF10A cells expressing BRAF N49I demonstrate that the mutation is likely neutral as measured by cell proliferation and viability comparable to wildtype (PMID: 29533785).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1680541126552,
                    "updatedBy": "User"
                  },
                  "description_uuid": "05d87e8b-dde7-4a08-857e-d00efb05fec2",
                  "effect": "Likely Neutral",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1680541122551,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "0120a776-b0f3-48f7-a447-adcaccb19b7d",
                  "oncogenic": "Likely Neutral",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1680541121412,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "73c87c18-45b8-43fd-abf0-bfa4411653a0",
                  "short": ""
                },
                "mutation_effect_uuid": "60dc28ba-966e-4816-99c3-e07f159dbef8",
                "name": "N49I",
                "name_review": {
                  "added": true,
                  "updateTime": 1680541119190,
                  "updatedBy": "User"
                },
                "name_uuid": "194092f4-dab1-4cd3-bfb0-80a27fdc2b56",
                "tumors_uuid": "6c784bb5-6c87-4be7-9b53-5af26ef836c1"
              },
              "operation": "add",
              "uuids": "73c87c18-45b8-43fd-abf0-bfa4411653a0,0120a776-b0f3-48f7-a447-adcaccb19b7d"
            }
          ],
          "timeStamp": 1681251242807
        },
        "-NSmNcu-WqGbv21DvF__": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "F259L",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF F259L mutation is located in the zinc finger domain of the protein. This mutation has been identified in colorectal cancer (PMID: 28002797). In vitro studies with Ba/F3 cells and MCF10A cells expressing BRAF F259L demonstrate that the mutation is likely neutral as measured by cell proliferation and viability comparable to wildtype (PMID: 29533785).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1680546272332,
                    "updatedBy": "User"
                  },
                  "description_uuid": "9551f2db-dba2-46af-a710-d62da35d588c",
                  "effect": "Likely Neutral",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1680546268878,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "f95c0b41-d824-4460-bcf6-f0464224b306",
                  "oncogenic": "Likely Neutral",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1680546267924,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "2e3d64ae-4abf-4f68-99fa-5d91c113484e",
                  "short": ""
                },
                "mutation_effect_uuid": "97d86599-4bea-4d48-aab8-239fe49438c1",
                "name": "F259L",
                "name_review": {
                  "added": true,
                  "updateTime": 1680546265039,
                  "updatedBy": "User"
                },
                "name_uuid": "aa5702ae-15b3-44ae-ac02-e7dfe7cf1618",
                "tumors_uuid": "81620c61-73b8-4bd7-9bcd-4cbe18cf0b61"
              },
              "operation": "add",
              "uuids": "2e3d64ae-4abf-4f68-99fa-5d91c113484e,f95c0b41-d824-4460-bcf6-f0464224b306"
            }
          ],
          "timeStamp": 1681251275856
        },
        "-NSmNkzvLlg3yTI602RE": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G258V",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF G258V mutation is located in the zinc finger domain of the protein. This mutation has been identified in glioma (PMID: 28852847). In vitro studies with Ba/F3 cells expressing BRAF G258V demonstrate that the mutation is activating as measured by increased transformation ability compared to wildtype (PMID: 29533785).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1680546254673,
                    "updatedBy": "User"
                  },
                  "description_uuid": "bdda9755-777e-44ab-a240-dcaa2d2d4886",
                  "effect": "Likely Gain-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1680546251027,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "f3e01d78-f08a-4d1f-81a1-0a82077e0f5c",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1680546250432,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "18dbbedf-a3e6-46c0-9249-daeee5495f4a",
                  "short": ""
                },
                "mutation_effect_uuid": "8bcdd7c8-b265-44f5-9b9d-6f1905c9e7f0",
                "name": "G258V",
                "name_review": {
                  "added": true,
                  "updateTime": 1680546248164,
                  "updatedBy": "User"
                },
                "name_uuid": "b38c0589-2d24-44fc-af43-eff4e6129b30",
                "tumors_uuid": "7f7cf80f-6b56-4de4-8c14-abc195d48f36"
              },
              "operation": "add",
              "uuids": "18dbbedf-a3e6-46c0-9249-daeee5495f4a,f3e01d78-f08a-4d1f-81a1-0a82077e0f5c"
            }
          ],
          "timeStamp": 1681251309003
        },
        "-NSmNswNgxZUEK3rGsCG": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "L245F",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF L245F mutation is located in the zinc finger domain of the protein. In vitro studies with Ba/F3 cells expressing BRAF L245F demonstrate that the mutation is activating as measured by increased transformation ability compared to wildtype (PMID: 29533785).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1680546187708,
                    "updatedBy": "User"
                  },
                  "description_uuid": "e8cf79ee-f7b9-4a39-8a79-c0f038aef8d9",
                  "effect": "Likely Gain-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1680546186611,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "3ae4dd07-0e7e-4e74-a3ed-caf2b539eada",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1680546185800,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "e23a602c-edf3-4f5e-a8c1-cff49d93738b",
                  "short": ""
                },
                "mutation_effect_uuid": "554938ee-81de-4efa-a4a3-ee76a3b436d1",
                "name": "L245F",
                "name_review": {
                  "added": true,
                  "updateTime": 1680546180469,
                  "updatedBy": "User"
                },
                "name_uuid": "e1633fcf-44a1-4e8c-ae29-ee8f0654a8c4",
                "tumors_uuid": "b4ae73a8-5119-489b-882f-23945511f432"
              },
              "operation": "add",
              "uuids": "e23a602c-edf3-4f5e-a8c1-cff49d93738b,3ae4dd07-0e7e-4e74-a3ed-caf2b539eada"
            }
          ],
          "timeStamp": 1681251341544
        },
        "-NSmO-svmWsVWgBOicqh": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "E228V",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF E228V mutation is located in an unknown functional domain of the protein. In vitro studies with Ba/F3 cells and MCF10A cells expressing BRAF E228V demonstrate that the mutation is likely neutral as measured by cell proliferation and viability comparable to wildtype (PMID: 29533785).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1680546165315,
                    "updatedBy": "User"
                  },
                  "description_uuid": "83fa31b5-417e-41ee-a5cb-d27ccafef9ba",
                  "effect": "Likely Neutral",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1680546161839,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "6e81a81e-e0fe-4ed7-8647-a4f7bf5543d6",
                  "oncogenic": "Likely Neutral",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1680546161011,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "04b0d077-b478-4ce1-a96e-d87b2e03cc3a",
                  "short": ""
                },
                "mutation_effect_uuid": "a335eeb5-681d-4b2d-b29d-4508dfb0ac95",
                "name": "E228V",
                "name_review": {
                  "added": true,
                  "updateTime": 1680546158045,
                  "updatedBy": "User"
                },
                "name_uuid": "0e9ba763-7b95-41a7-bc81-dd0978b51e49",
                "tumors_uuid": "ae46872b-586f-4d71-a403-baf86f309797"
              },
              "operation": "add",
              "uuids": "04b0d077-b478-4ce1-a96e-d87b2e03cc3a,6e81a81e-e0fe-4ed7-8647-a4f7bf5543d6"
            }
          ],
          "timeStamp": 1681251374090
        },
        "-NSmO7xrQF013uFRHW_2": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "K205Q",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF K205Q mutation is located in the RBD domain of the protein. This mutation has been identified in colorectal cancer (PMID: 22810696). In vitro studies with Ba/F3 cells and MCF10A cells expressing BRAF K205Q demonstrate that the mutation is likely neutral as measured by cell proliferation and viability comparable to wildtype (PMID: 29533785).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1680546139946,
                    "updatedBy": "User"
                  },
                  "description_uuid": "c3952507-88d7-48c9-b161-8caa8ac33a47",
                  "effect": "Likely Neutral",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1680546129838,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "289de6f0-b37b-42d7-af58-539c44d08d7f",
                  "oncogenic": "Likely Neutral",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1680546129059,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "5a7516da-b77e-47d8-843b-1d14136e3a33",
                  "short": ""
                },
                "mutation_effect_uuid": "0e1f5753-24d8-4e57-b461-3e6e78fba8a6",
                "name": "K205Q",
                "name_review": {
                  "added": true,
                  "updateTime": 1680546123894,
                  "updatedBy": "User"
                },
                "name_uuid": "f9737b33-dee3-44ec-95a6-d53f38980b88",
                "tumors_uuid": "a74c2cf6-b505-402a-be1c-4947dbfb4841"
              },
              "operation": "add",
              "uuids": "5a7516da-b77e-47d8-843b-1d14136e3a33,289de6f0-b37b-42d7-af58-539c44d08d7f"
            }
          ],
          "timeStamp": 1681251407175
        },
        "-NSmOFztRxo5EMFLR6Og": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "S364L",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF S364L mutation is located in an unknown functional domain of the protein. In vitro studies with Ba/F3 cells and MCF10A cells expressing BRAF S364L demonstrate that the mutation is likely neutral as measured by cell proliferation and viability comparable to wildtype (PMID: 29533785).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1680551358135,
                    "updatedBy": "User"
                  },
                  "description_uuid": "18ec275d-907c-4177-8469-afb041420bb1",
                  "effect": "Likely Neutral",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1680551356935,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "a5671214-c40b-44b3-bbd5-9b460b4a928a",
                  "oncogenic": "Likely Neutral",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1680551356075,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "a440d444-9a2c-434b-a496-b2dbc76d0c03",
                  "short": ""
                },
                "mutation_effect_uuid": "dd8364ee-5e33-4e0d-a6e8-9943af0ff361",
                "name": "S364L",
                "name_review": {
                  "added": true,
                  "updateTime": 1680551351676,
                  "updatedBy": "User"
                },
                "name_uuid": "2533bdb0-fdf8-4c37-8ef5-48b6f3bc2e86",
                "tumors_uuid": "419354ca-cde0-4f15-93b8-82719b58e4cf"
              },
              "operation": "add",
              "uuids": "a440d444-9a2c-434b-a496-b2dbc76d0c03,a5671214-c40b-44b3-bbd5-9b460b4a928a"
            }
          ],
          "timeStamp": 1681251440073
        },
        "-NSmOO2soiTJHu46QW6c": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "P348T",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF P348T mutation is located in an unknown functional domain of the protein. In vitro studies with Ba/F3 cells and MCF10A cells expressing BRAF P348T demonstrate that the mutation is likely neutral as measured by cell proliferation and viability comparable to wildtype (PMID: 29533785).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1680551333920,
                    "updatedBy": "User"
                  },
                  "description_uuid": "8769fc80-a5b8-4155-8e06-aa5d63332750",
                  "effect": "Likely Neutral",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1680551332581,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "2724078f-4cda-4416-b014-91590a7e45c1",
                  "oncogenic": "Likely Neutral",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1680551331846,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "613d6701-bae5-4ba2-b3df-c662498abd1a",
                  "short": ""
                },
                "mutation_effect_uuid": "74a6aaa4-f9bd-4777-ad5c-8925ee7f7d2b",
                "name": "P348T",
                "name_review": {
                  "added": true,
                  "updateTime": 1680551327448,
                  "updatedBy": "User"
                },
                "name_uuid": "b708ac07-6214-496f-8292-b4fa956962e6",
                "tumors_uuid": "d10c5bc4-1e07-4dfc-bdb9-9f84db52df93"
              },
              "operation": "add",
              "uuids": "613d6701-bae5-4ba2-b3df-c662498abd1a,2724078f-4cda-4416-b014-91590a7e45c1"
            }
          ],
          "timeStamp": 1681251473096
        },
        "-NSmOWA-GLsR5rhyZSZh": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "A320T",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF A320T mutation is located in an unknown functional domain of the protein. In vitro studies with Ba/F3 cells and MCF10A cells expressing BRAF A320T demonstrate that the mutation is likely neutral as measured by cell proliferation and viability comparable to wildtype (PMID: 29533785).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1680551308446,
                    "updatedBy": "User"
                  },
                  "description_uuid": "c9c62cc8-a80f-4044-b013-c120cf7546f7",
                  "effect": "Likely Neutral",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1680551304343,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "8cb9844c-02e4-4b8b-8051-a9d340fc54a9",
                  "oncogenic": "Likely Neutral",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1680551303706,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "b63943d4-3452-4128-baa7-f3d9d6afe98d",
                  "short": ""
                },
                "mutation_effect_uuid": "4dc88f62-bbb5-4302-a0e4-bd12f4c41158",
                "name": "A320T",
                "name_review": {
                  "added": true,
                  "updateTime": 1680551301483,
                  "updatedBy": "User"
                },
                "name_uuid": "46fdbbe3-50c4-4bca-bfa4-2ddfdc808fab",
                "tumors_uuid": "77c1a234-ba85-442a-bd57-33f121d30a12"
              },
              "operation": "add",
              "uuids": "b63943d4-3452-4128-baa7-f3d9d6afe98d,8cb9844c-02e4-4b8b-8051-a9d340fc54a9"
            }
          ],
          "timeStamp": 1681251506320
        },
        "-NSmP61hTSp4FLLAepRx": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "D380H",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF D380H mutation is located in an unknown functional domain of the protein. In vitro studies with Ba/F3 cells and MCF10A cells expressing BRAF D380H demonstrate that the mutation is likely neutral as measured by cell proliferation and viability comparable to wildtype (PMID: 29533785).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1680551379709,
                    "updatedBy": "User"
                  },
                  "description_uuid": "3c684f36-f2a0-44d7-bde6-d9609ea59fb7",
                  "effect": "Likely Neutral",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1680551376087,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "7100d4a2-9bc3-4e0c-8450-b02a85a7212b",
                  "oncogenic": "Likely Neutral",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1680551375521,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "e8d796e0-97d4-4f49-b3e7-ca9ffaa8d2e3",
                  "short": ""
                },
                "mutation_effect_uuid": "0206eb44-1496-4f38-bc67-b1def4f0cf2d",
                "name": "D380H",
                "name_review": {
                  "added": true,
                  "updateTime": 1680551372977,
                  "updatedBy": "User"
                },
                "name_uuid": "93f412fa-a230-425d-808c-ab2ce1e22f86",
                "tumors_uuid": "42c54842-a40e-4943-9717-3dccfab164d0"
              },
              "operation": "add",
              "uuids": "e8d796e0-97d4-4f49-b3e7-ca9ffaa8d2e3,7100d4a2-9bc3-4e0c-8450-b02a85a7212b"
            }
          ],
          "timeStamp": 1681251661437
        },
        "-NSmPEAdTc7wHFTryZnc": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "T401I",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF T401I mutation is located in an unknown functional domain of the protein. In vitro studies with Ba/F3 cells and MCF10A cells expressing BRAF T401I demonstrate that the mutation is likely neutral as measured by cell proliferation and viability comparable to wildtype (PMID: 29533785).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1680551456352,
                    "updatedBy": "User"
                  },
                  "description_uuid": "dcd23d34-dbba-44a2-ae88-17d59d3bb3a5",
                  "effect": "Likely Neutral",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1680551455207,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "4723a368-e050-4086-8338-7ff38eb3df87",
                  "oncogenic": "Likely Neutral",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1680551454232,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "4ecc4b2c-5e36-4b89-8aaa-2b1cf604caac",
                  "short": ""
                },
                "mutation_effect_uuid": "e682550b-60fb-47ed-a773-e8253ee04e8a",
                "name": "T401I",
                "name_review": {
                  "added": true,
                  "updateTime": 1680551449176,
                  "updatedBy": "User"
                },
                "name_uuid": "c95c3301-c4bb-4f7d-9062-35527b630a58",
                "tumors_uuid": "a40a4d6f-a974-4fc4-945e-f2d679b07a75"
              },
              "operation": "add",
              "uuids": "4ecc4b2c-5e36-4b89-8aaa-2b1cf604caac,4723a368-e050-4086-8338-7ff38eb3df87"
            }
          ],
          "timeStamp": 1681251694777
        },
        "-NSmPMJzOEA3bXV4HfK3": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "X380_splice",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF X380_splice mutation is located in an unknown functional domain of the protein. Although not functionally characterized per se, a patient with lung adenocarcinoma harboring BRAF X380_splice and KRAS G12C was treated with atezolizumab and demonstrated progressive disease (PMID: 34963703).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1680551397310,
                    "updatedBy": "User"
                  },
                  "description_uuid": "8cb5cfa5-aea4-4eab-b0a2-30478727013e",
                  "effect": "Inconclusive",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1680551393531,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "065529f8-03d6-49c2-a4e8-fff568778d6b",
                  "oncogenic": "Inconclusive",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1680551392593,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "5ddde0ec-af7b-4206-95e1-9c9f59b50f6a",
                  "short": ""
                },
                "mutation_effect_uuid": "44ea33f6-5cad-4223-8ef9-2e8c95755d4d",
                "name": "X380_splice",
                "name_review": {
                  "added": true,
                  "updateTime": 1680551390373,
                  "updatedBy": "User"
                },
                "name_uuid": "2598c3e5-48b7-45a2-adc5-aaaae0a2ec7a",
                "tumors_uuid": "008012f8-ac9b-4856-a254-62084afb89fb"
              },
              "operation": "add",
              "uuids": "5ddde0ec-af7b-4206-95e1-9c9f59b50f6a,065529f8-03d6-49c2-a4e8-fff568778d6b"
            }
          ],
          "timeStamp": 1681251728143
        },
        "-NSmPxrCKjUj7KyPdirp": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "S419Y",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF S419Y mutation is located in an unknown functional domain of the protein. In vitro studies with Ba/F3 cells and MCF10A cells expressing BRAF S419Y demonstrate that the mutation is likely neutral as measured by cell proliferation and viability comparable to wildtype (PMID: 29533785).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1680551475944,
                    "updatedBy": "User"
                  },
                  "description_uuid": "7ac589bc-df40-4222-ae92-4eac79491a60",
                  "effect": "Likely Neutral",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1680551471371,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "e41fd2ef-9ae7-4528-bc2f-5f1f3ef43492",
                  "oncogenic": "Likely Neutral",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1680551470531,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "917a7fc9-c634-42e1-a54e-6fdc3f15d893",
                  "short": ""
                },
                "mutation_effect_uuid": "d157f4f6-d671-4e2c-9027-72913dc86a48",
                "name": "S419Y",
                "name_review": {
                  "added": true,
                  "updateTime": 1680551468057,
                  "updatedBy": "User"
                },
                "name_uuid": "d62533a1-c71c-47b7-bd2d-33fc67a2d2a0",
                "tumors_uuid": "5bbefbbc-8c09-4a01-829e-a1e158a62bfc"
              },
              "operation": "add",
              "uuids": "917a7fc9-c634-42e1-a54e-6fdc3f15d893,e41fd2ef-9ae7-4528-bc2f-5f1f3ef43492"
            }
          ],
          "timeStamp": 1681251885981
        },
        "-NSmQ4w-R7MFf7Myzj1k": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G421V",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF G421V mutation is located in an unknown functional domain of the protein. In vitro studies with Ba/F3 cells and MCF10A cells expressing BRAF G421V demonstrate that the mutation is likely neutral as measured by cell proliferation and viability comparable to wildtype (PMID: 29533785).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1680551492305,
                    "updatedBy": "User"
                  },
                  "description_uuid": "7d9fbac6-ad50-4526-8fbc-b71bae81639e",
                  "effect": "Likely Neutral",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1680551490810,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "41452405-532f-4132-9e1a-e75ffe7291ca",
                  "oncogenic": "Likely Neutral",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1680551490001,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "2fab0ff2-e1c7-4ca3-aa7a-cd6e23a05f2e",
                  "short": ""
                },
                "mutation_effect_uuid": "0908fe08-1a97-4d0e-b2b8-7f5fca3ae12c",
                "name": "G421V",
                "name_review": {
                  "added": true,
                  "updateTime": 1680551486146,
                  "updatedBy": "User"
                },
                "name_uuid": "4614090b-61d7-4859-aad1-bc7a1ac88809",
                "tumors_uuid": "73977848-d71d-4fb5-b8ef-00593c7486ff"
              },
              "operation": "add",
              "uuids": "2fab0ff2-e1c7-4ca3-aa7a-cd6e23a05f2e,41452405-532f-4132-9e1a-e75ffe7291ca"
            }
          ],
          "timeStamp": 1681251919056
        },
        "-NSmQrVs44n_aLiZdhO-": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "H568D",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF H568D mutation is located in the kinase domain of the protein. In vitro studies with HEK293T cells expressing BRAF H568D demonstrate that the mutation is inactivating as measured by a loss of kinase activity compared to wildtype (PMID: 29666306). BRAF mutations with low kinase activity or those that are kinase-dead are Class III mutations and can possibly activate CRAF as a scaffold, resulting in increased MEK-regulated signaling (PMID: 20141835).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1681252082691,
                    "updatedBy": "User"
                  },
                  "description_uuid": "d578dc66-9fb9-4a3e-b8ac-7f4a95c0d50e",
                  "effect": "Inconclusive",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1681252085569,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "bf2c98d7-eb95-4ffb-be4f-fb0b87204cd2",
                  "oncogenic": "Inconclusive",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1681252086273,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "b8f89baa-21b0-459c-8b48-f5bb084e0ca2",
                  "short": ""
                },
                "mutation_effect_uuid": "6f162c8f-08cb-4d2e-a0ec-5773584a3b06",
                "name": "H568D",
                "name_review": {
                  "added": true,
                  "updateTime": 1680555203943,
                  "updatedBy": "User"
                },
                "name_uuid": "f3be5418-5e57-4904-9b80-f78166e153c7",
                "tumors_uuid": "e00a7dad-856e-4f08-b824-d89155b42eca"
              },
              "operation": "add",
              "uuids": "b8f89baa-21b0-459c-8b48-f5bb084e0ca2,bf2c98d7-eb95-4ffb-be4f-fb0b87204cd2"
            }
          ],
          "timeStamp": 1681252122120
        },
        "-NSmQzbE9TT929zRgxSf": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V639I",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF V639I mutation is located in the kinase domain of the protein. In vitro studies with Ba/F3 cells and MCF10A cells expressing BRAF V639I demonstrate that the mutation is likely neutral as measured by cell proliferation and viability comparable to wildtype (PMID: 29533785).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1680555292851,
                    "updatedBy": "User"
                  },
                  "description_uuid": "9be709c2-fd51-4683-b4a5-f469e3cf96f2",
                  "effect": "Likely Neutral",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1680555262123,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "4964c813-f10d-499c-aa59-0eac1d608d31",
                  "oncogenic": "Likely Neutral",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1680555261294,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "293674ed-e09c-44cb-b934-0aadd29bc84d",
                  "short": ""
                },
                "mutation_effect_uuid": "7d93d00e-1cab-4d6f-869e-3121128160e7",
                "name": "V639I",
                "name_review": {
                  "added": true,
                  "updateTime": 1680555257162,
                  "updatedBy": "User"
                },
                "name_uuid": "64114cfc-41b8-4b62-87f7-9e3cb0683495",
                "tumors_uuid": "26f9aebc-fc96-4324-939b-b55a9482e3c2"
              },
              "operation": "add",
              "uuids": "293674ed-e09c-44cb-b934-0aadd29bc84d,4964c813-f10d-499c-aa59-0eac1d608d31"
            }
          ],
          "timeStamp": 1681252155295
        },
        "-NSmR6mQ_8o7wTs1jMbq": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "L613F",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF L613F mutation is located in the zinc finger domain of the protein. In vitro studies with MCF10A cells expressing BRAF L613F demonstrate that the mutation is activating as measured by increased transformation ability compared to wildtype (PMID: 29533785).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1680555238834,
                    "updatedBy": "User"
                  },
                  "description_uuid": "b4ef2b4a-2f74-4e33-b1f4-a9fafd6414e1",
                  "effect": "Likely Gain-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1680555235252,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "add0243b-99de-41c7-b712-c8d73631f389",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1680555234776,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "f557e568-9d8a-41eb-9ef3-c6409db39b7e",
                  "short": ""
                },
                "mutation_effect_uuid": "b61495d5-7559-47aa-9d73-a0efb3a3d1e4",
                "name": "L613F",
                "name_review": {
                  "added": true,
                  "updateTime": 1680555232343,
                  "updatedBy": "User"
                },
                "name_uuid": "0b1e3d0b-517c-4b8f-9264-223698df8227",
                "tumors_uuid": "f4204d35-aa77-4315-878f-99f7e0f6640b"
              },
              "operation": "add",
              "uuids": "f557e568-9d8a-41eb-9ef3-c6409db39b7e,add0243b-99de-41c7-b712-c8d73631f389"
            }
          ],
          "timeStamp": 1681252188779
        },
        "-NSmREz8ZBfoa4BmMwTW": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "A712T",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF A712T mutation is located in the kinase domain of the protein. This mutation has been identified in colorectal cancer (PMID: 27149842). In vitro studies with Ba/F3 cells and MCF10A cells expressing BRAF A712T demonstrate that the mutation is likely neutral as measured by cell proliferation and viability comparable to wildtype (PMID: 29533785).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1680555386865,
                    "updatedBy": "User"
                  },
                  "description_uuid": "326c8954-6d07-4028-9c16-cbcb82744fb9",
                  "effect": "Likely Neutral",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1680555383121,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "21adc71d-5d1b-47ac-bd91-fe36d9618603",
                  "oncogenic": "Likely Neutral",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1680555381780,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "c8e4c286-8009-4d83-a2cd-d6bede55fb19",
                  "short": ""
                },
                "mutation_effect_uuid": "633f4342-77b6-44e7-8a8d-be2da2bb9617",
                "name": "A712T",
                "name_review": {
                  "added": true,
                  "updateTime": 1680555379265,
                  "updatedBy": "User"
                },
                "name_uuid": "71fe6203-6943-4ede-c0d7-92268676d818",
                "tumors_uuid": "e58f4da3-c8b4-4460-a5c1-a4e0cc525631"
              },
              "operation": "add",
              "uuids": "c8e4c286-8009-4d83-a2cd-d6bede55fb19,21adc71d-5d1b-47ac-bd91-fe36d9618603"
            }
          ],
          "timeStamp": 1681252222361
        },
        "-NSmRNEGdyWFUZ4ahwWS": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "K698R",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF K698R mutation is located in the kinase domain of the protein. In vitro studies with Ba/F3 cells and MCF10A cells expressing BRAF K698R demonstrate that the mutation is likely neutral as measured by cell proliferation and viability comparable to wildtype (PMID: 29533785).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1680555355525,
                    "updatedBy": "User"
                  },
                  "description_uuid": "ffe72609-3126-4dda-b522-b5261089eed9",
                  "effect": "Likely Neutral",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1680555354010,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "79b0cedd-a37f-461b-a66a-3eb1b170869a",
                  "oncogenic": "Likely Neutral",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1680555353037,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "7c2ca349-5c77-4743-be79-38858be03bd7",
                  "short": ""
                },
                "mutation_effect_uuid": "8fad6ef1-e803-468d-a428-f69f397caa29",
                "name": "K698R",
                "name_review": {
                  "added": true,
                  "updateTime": 1680555349951,
                  "updatedBy": "User"
                },
                "name_uuid": "79cef4e7-9f53-4681-bbd5-4ef3e59278d4",
                "tumors_uuid": "5d2f3a9d-0d24-4b0b-828a-cbe996ac3b6b"
              },
              "operation": "add",
              "uuids": "7c2ca349-5c77-4743-be79-38858be03bd7,79b0cedd-a37f-461b-a66a-3eb1b170869a"
            }
          ],
          "timeStamp": 1681252256161
        },
        "-NSmRVOmoqm46bHFnWhc": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "E695K",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF E695K mutation is located in the kinase domain of the protein. This mutation has been identified in plasma cell myeloma (PMID: 30545397). In vitro studies with MCF10A cells expressing BRAF E695K demonstrate that the mutation is activating as measured by increased transformation ability compared to wildtype (PMID: 29533785).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1680555343317,
                    "updatedBy": "User"
                  },
                  "description_uuid": "23210cf5-f791-4481-abbb-044b628ac34d",
                  "effect": "Likely Gain-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1680555339869,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "8e2dd1e0-e643-41e9-8cb6-495353cab76a",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1680555339245,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "4f8a1198-7552-4f31-a641-eb43655431a1",
                  "short": ""
                },
                "mutation_effect_uuid": "e1e6d0df-5b13-4d31-8dd5-d9bb198a8840",
                "name": "E695K",
                "name_review": {
                  "added": true,
                  "updateTime": 1680555336901,
                  "updatedBy": "User"
                },
                "name_uuid": "ee070618-3238-41e2-bb13-d46455f59254",
                "tumors_uuid": "9d4b1a46-5185-4c60-9f1c-1531b3b8c154"
              },
              "operation": "add",
              "uuids": "4f8a1198-7552-4f31-a641-eb43655431a1,8e2dd1e0-e643-41e9-8cb6-495353cab76a"
            }
          ],
          "timeStamp": 1681252289602
        },
        "-NSmRc_jikQdIk1UXuyt": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "L678I",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF L678I mutation is located in the kinase domain of the protein. In vitro studies with MCF10A cells expressing BRAF L678I demonstrate that the mutation is inactivating as measured by decreased cell proliferation and viability comparable to wildtype (PMID: 29533785).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1680555318974,
                    "updatedBy": "User"
                  },
                  "description_uuid": "d2dddb0b-5439-420a-84af-89f8cc2aa547",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1680555317566,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "224a26ee-92a1-4522-a467-ae857e42e607",
                  "oncogenic": "Likely Neutral",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1680555316760,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "bd4933d9-e9e0-4687-881b-06f4549f3aab",
                  "short": ""
                },
                "mutation_effect_uuid": "3e22390f-e771-420e-8442-6279a8f3a277",
                "name": "L678I",
                "name_review": {
                  "added": true,
                  "updateTime": 1680555310945,
                  "updatedBy": "User"
                },
                "name_uuid": "80ef9412-aff1-4e7b-8188-499f462236c9",
                "tumors_uuid": "a286a2c6-efb0-4f31-a36e-6854e36f7134"
              },
              "operation": "add",
              "uuids": "bd4933d9-e9e0-4687-881b-06f4549f3aab,224a26ee-92a1-4522-a467-ae857e42e607"
            }
          ],
          "timeStamp": 1681252323135
        },
        "-NSmRklaRvqNw02O5c4b": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "E648Q",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF E648Q mutation is located in the kinase domain of the protein. In vitro studies with MCF10A cells expressing BRAF E648Q demonstrate that the mutation is inactivating as measured by decreased cell proliferation and viability comparable to wildtype (PMID: 29533785).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1680555287229,
                    "updatedBy": "User"
                  },
                  "description_uuid": "d83c56c7-70b5-4fcc-a882-7aa3bf97edef",
                  "effect": "Likely Neutral",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1680555279179,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "42c85711-44fc-49b1-b1ee-4cb67df682ec",
                  "oncogenic": "Likely Neutral",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1680555278559,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "8720ada2-a22c-43e5-ba96-85a693f9b919",
                  "short": ""
                },
                "mutation_effect_uuid": "46147386-89d7-42db-9248-8bd94fbe7618",
                "name": "E648Q",
                "name_review": {
                  "added": true,
                  "updateTime": 1680555276751,
                  "updatedBy": "User"
                },
                "name_uuid": "bec646b3-cb4c-44b7-8071-8d5476d1d2d5",
                "tumors_uuid": "588d67db-e067-4a5c-a385-6e1ff9f5af9b"
              },
              "operation": "add",
              "uuids": "8720ada2-a22c-43e5-ba96-85a693f9b919,42c85711-44fc-49b1-b1ee-4cb67df682ec"
            }
          ],
          "timeStamp": 1681252356662
        },
        "-NSmRswFXjStY-sIwnbU": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "CLCN6-BRAF Fusion",
              "new": {
                "mutation_effect": {
                  "description": "The CLCN6-BRAF fusion results from a chromosomal rearrangement fusing exon 2 of CLCN6 and exon 11 of BRAF, retaining the BRAF kinase domain. This fusion has been identified in pilocytic astrocytoma (PMID: 23817572). In vitro studies with NIH3T3 cells expressing CLCN6-BRAF demonstrate that the fusion is activating as measured by increased phosphorylated ERK levels compared to vector control (PMID: 29156677). Preclinical studies with NIH3T3 cells expressing the fusion demonstrated sensitivity to treatment with trametinib as measured by inhibition of colony formation (PMID: 29156677).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1681252278568,
                    "updatedBy": "User"
                  },
                  "description_uuid": "4059f3e6-ad52-45ba-bd6a-da4244c1bd46",
                  "effect": "Likely Gain-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1680636338425,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "f17ba4d6-8c93-4010-8e0b-4996e43ed556",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1680636337634,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "2d32fafb-1395-4195-b20f-24766f8449bc",
                  "short": ""
                },
                "mutation_effect_uuid": "1b749da4-d4fc-425b-af30-d1df0e646ad9",
                "name": "CLCN6-BRAF Fusion",
                "name_review": {
                  "added": true,
                  "updateTime": 1680636330354,
                  "updatedBy": "User"
                },
                "name_uuid": "d56ac590-b968-4d32-b77c-92213095b432",
                "tumors_uuid": "f3499036-a695-4e3e-9b51-23cd6235d359"
              },
              "operation": "add",
              "uuids": "2d32fafb-1395-4195-b20f-24766f8449bc,f17ba4d6-8c93-4010-8e0b-4996e43ed556"
            }
          ],
          "timeStamp": 1681252390112
        },
        "-NSmS09H2qvedceBrkUo": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "GNAI1-BRAF Fusion",
              "new": {
                "mutation_effect": {
                  "description": "The GNAI1-BRAF fusion results from a chromosomal rearrangement fusing exon 1 of GNAI1 and exon 10 of BRAF. This fusion has been identified in pilocytic astrocytoma (PMID: 23817572). In vitro studies with NIH3T3 cells expressing GNAI1-BRAF demonstrate that the fusion is activating as measured by increased phosphorylated ERK levels compared to vector control (PMID: 29156677). Preclinical studies with NIH3T3 cells expressing the fusion demonstrated sensitivity to treatment with trametinib as measured by inhibition of colony formation (PMID: 29156677).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1680636214111,
                    "updatedBy": "User"
                  },
                  "description_uuid": "a773f401-fb36-4648-b825-1b1f9445f255",
                  "effect": "Likely Gain-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1680636212829,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "036538d2-4a0f-4a70-869d-eaee537fa0e3",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1680636211576,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "d2b878af-1b7d-427c-bd5d-a9d9309b5336",
                  "short": ""
                },
                "mutation_effect_uuid": "9db0a3af-4e7c-4089-9b08-ae3b9f02150c",
                "name": "GNAI1-BRAF Fusion",
                "name_review": {
                  "added": true,
                  "updateTime": 1680636204955,
                  "updatedBy": "User"
                },
                "name_uuid": "dc03a3a8-455e-431b-b496-1362a5a6d6e9",
                "tumors_uuid": "cbe86234-9072-4d90-8436-24227112057e"
              },
              "operation": "add",
              "uuids": "d2b878af-1b7d-427c-bd5d-a9d9309b5336,036538d2-4a0f-4a70-869d-eaee537fa0e3"
            }
          ],
          "timeStamp": 1681252423778
        },
        "-NSmS8PMQ54EojIR9Lr5": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Q609H",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF Q609H mutation is located in the kinase domain of the protein. In vitro studies with Ba/F3 cells and MCF10A cells expressing BRAF Q609H demonstrate that the mutation is likely neutral as measured by cell proliferation and viability comparable to wildtype (PMID: 29533785).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1680635417118,
                    "updatedBy": "User"
                  },
                  "description_uuid": "15f2354a-0694-4931-9244-99dc807a4d85",
                  "effect": "Likely Neutral",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1680635415753,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "b62c016c-0682-4d8a-97fb-8046cc52e64b",
                  "oncogenic": "Likely Neutral",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1680635415076,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "8ad3ac76-7130-4524-a8a1-77e7dd030ca5",
                  "short": ""
                },
                "mutation_effect_uuid": "7d53c7cb-ddde-4605-8863-9cf02ce07e78",
                "name": "Q609H",
                "name_review": {
                  "added": true,
                  "updateTime": 1680635405539,
                  "updatedBy": "User"
                },
                "name_uuid": "d72a229a-fd5a-4f00-b989-1fef2bfc9262",
                "tumors_uuid": "795b14ac-b45e-427c-824c-fbb30764d12b"
              },
              "operation": "add",
              "uuids": "8ad3ac76-7130-4524-a8a1-77e7dd030ca5,b62c016c-0682-4d8a-97fb-8046cc52e64b"
            }
          ],
          "timeStamp": 1681252457575
        },
        "-NSmSGg-U3y2LUxciKmc": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "A762E",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF A762E mutation is located in an unknown functional domain of the protein. While this mutation has not been functionally validated per se, in vitro studies with A549 cells expressing BRAF A762E demonstrated that the mutation confers resistance to EGFR inhibitor erlotinib as measured by sustained cell viability following treatment (PMID: 27478040).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1680635362475,
                    "updatedBy": "User"
                  },
                  "description_uuid": "d486863e-88c6-43b2-8843-fbad69e431fd",
                  "effect": "Inconclusive",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1680635344543,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "3406a615-022d-41d0-958a-a06d1afb505a",
                  "oncogenic": "Inconclusive",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1681252227387,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "3e5d66e4-deae-484d-a6aa-0f3bcc54b586",
                  "short": ""
                },
                "mutation_effect_uuid": "843681b0-e83c-4ff5-859c-e85690fa92e5",
                "name": "A762E",
                "name_review": {
                  "added": true,
                  "updateTime": 1680635340699,
                  "updatedBy": "User"
                },
                "name_uuid": "d29bc274-b29f-4389-8519-4a68c189ea05",
                "tumors_uuid": "ea22de83-b481-4ae9-9748-b301d8912c3b"
              },
              "operation": "add",
              "uuids": "3e5d66e4-deae-484d-a6aa-0f3bcc54b586,3406a615-022d-41d0-958a-a06d1afb505a"
            }
          ],
          "timeStamp": 1681252491472
        },
        "-NSmSP-wBca9uFK_wkc-": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "P731S",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF P731S mutation is located in an unknown functional domain of the protein. This mutation has been identified in melanoma (PMID: 22817889). In vitro studies with Ba/F3 cells expressing BRAF P731S demonstrate that the mutation is activating as measured by increased transformation ability compared to wildtype (PMID: 29533785).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1680555408235,
                    "updatedBy": "User"
                  },
                  "description_uuid": "da03d03d-4b97-45e7-9ddd-baeb0648edd8",
                  "effect": "Likely Gain-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1680555403720,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "4830d21c-4512-487d-907b-10302c3890c5",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1680555402647,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "5153ddf7-c6dc-44e0-819b-3bf55f74a371",
                  "short": ""
                },
                "mutation_effect_uuid": "8847d857-b632-4173-bb5e-5007f233623d",
                "name": "P731S",
                "name_review": {
                  "added": true,
                  "updateTime": 1680555400382,
                  "updatedBy": "User"
                },
                "name_uuid": "3361434e-72d9-494c-8f5a-9a47cc10fe2b",
                "tumors_uuid": "ac3a3c6a-e51f-4056-9c13-f0c60a5c1625"
              },
              "operation": "add",
              "uuids": "5153ddf7-c6dc-44e0-819b-3bf55f74a371,4830d21c-4512-487d-907b-10302c3890c5"
            }
          ],
          "timeStamp": 1681252525580
        },
        "-NSmSXEgiUcUedgt2_hR": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "SLC45A3-BRAF Fusion",
              "new": {
                "mutation_effect": {
                  "description": "The SLC45A3-BRAF fusion results from inter-chromosomal rearrangement fusing untranslated exon 1 of SLC45A3 and exon 8 of BRAF. In vivo studies with nude mice overexpressing SLC45A3-BRAF demonstrate that the fusion is activating as measured by rapid tumor growth compared to vector control (PMID: 20526349). Preclinical studies with RWPE cells expressing this fusion demonstrated sensitivity to treatment with RAF kinase inhibitor sorafenib and MEK inhibitor U0126 as measured by decreased colony growth following treatment (PMID: 20526349).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1680638067936,
                    "updatedBy": "User"
                  },
                  "description_uuid": "3f1243ec-3001-46b1-9dff-908b9a282272",
                  "effect": "Likely Gain-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1680638061508,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "886fcc24-f518-44a6-ab7b-7e9a6de042b3",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1680638060837,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "8d032552-13af-43b5-8eba-5b0cb0aed0a6",
                  "short": ""
                },
                "mutation_effect_uuid": "8413fef8-b0c5-4a50-8cd1-585469f26823",
                "name": "SLC45A3-BRAF Fusion",
                "name_review": {
                  "added": true,
                  "updateTime": 1680638058050,
                  "updatedBy": "User"
                },
                "name_uuid": "780aee42-d4b2-4ff2-a7bd-56c91cc4a729",
                "tumors_uuid": "e6f04633-c615-447d-ac92-6178a988894c"
              },
              "operation": "add",
              "uuids": "8d032552-13af-43b5-8eba-5b0cb0aed0a6,886fcc24-f518-44a6-ab7b-7e9a6de042b3"
            }
          ],
          "timeStamp": 1681252559292
        },
        "-NSmSeXaP8BxsR3C03LT": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "SEPT3-BRAF Fusion",
              "new": {
                "mutation_effect": {
                  "description": "The SEPT3-BRAF fusion results from chromosomal rearrangement fusing exon 10 of SEPT3 and exon 8 of BRAF, retaining the full kinase domain and losing the inhibitory RBD domain of BRAF. In vivo studies with patient-derived xenograft models expressing SEPT3-BRAF demonstrate that the fusion is activating as measured by increased cellular proliferation and invasion compared to wildtype (PMID: 30254212).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1680636718962,
                    "updatedBy": "User"
                  },
                  "description_uuid": "8551b235-bfdd-4ae9-ae1e-1b4cf13f7c37",
                  "effect": "Likely Gain-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1680636717411,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "4fc7feb3-cbcd-4ab0-951a-f14bdbaf7b13",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1680636716835,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "ad532864-471e-4a40-92e7-f56678fed421",
                  "short": ""
                },
                "mutation_effect_uuid": "38c42bcf-0c44-4a33-bf45-c7ae7f5ab3a1",
                "name": "SEPT3-BRAF Fusion",
                "name_review": {
                  "added": true,
                  "updateTime": 1680636711502,
                  "updatedBy": "User"
                },
                "name_uuid": "ab8049c9-80b8-4522-bcf1-91e9c352a306",
                "tumors_uuid": "39c2bc06-5b3c-44d7-ba1f-a724c37063fd"
              },
              "operation": "add",
              "uuids": "ad532864-471e-4a40-92e7-f56678fed421,4fc7feb3-cbcd-4ab0-951a-f14bdbaf7b13"
            }
          ],
          "timeStamp": 1681252593270
        },
        "-NSmSmoQWiRNNvtlKxGD": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "CSTF3-BRAF Fusion",
              "new": {
                "mutation_effect": {
                  "description": "The CSTF3-BRAF fusion results from a chromosomal rearrangement that retains the full kinase domain of BRAF. Although not functionally characterized per se, a patient with metastatic melanoma harboring BRAF V600E was treated with dabrafenib plus trametinib and acquired CSTF3-BRAF as a secondary resistance mutation following disease progression (PMID: 28539463).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1680636608156,
                    "updatedBy": "User"
                  },
                  "description_uuid": "b0fa77de-e35f-4607-b9d6-b41513d8dcbc",
                  "effect": "Likely Gain-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1681252353717,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "1df85571-f803-4389-88c0-675a3500e905",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1681252353061,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "d2f65940-007d-407b-9d70-1320ada739d9",
                  "short": ""
                },
                "mutation_effect_uuid": "42dbc373-5361-47f1-839c-2f21961831e4",
                "name": "CSTF3-BRAF Fusion",
                "name_review": {
                  "added": true,
                  "updateTime": 1680636597803,
                  "updatedBy": "User"
                },
                "name_uuid": "6770724b-acdb-4ef6-b3eb-b734717c4df1",
                "tumors_uuid": "34f57487-b35c-4067-972a-67f68de11d20"
              },
              "operation": "add",
              "uuids": "d2f65940-007d-407b-9d70-1320ada739d9,1df85571-f803-4389-88c0-675a3500e905"
            }
          ],
          "timeStamp": 1681252627179
        },
        "-NSmSv293tlUQRy-ytQg": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "M517I",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF M517I mutation is located in the kinase domain of the protein. In vitro studies with MCF10A cells expressing BRAF M517I demonstrate that the mutation is inactivating as measured by decreased cell proliferation and viability comparable to wildtype (PMID: 29533785).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1680636583675,
                    "updatedBy": "User"
                  },
                  "description_uuid": "ecf3da43-b51d-479c-af0b-8752c77c7b56",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1680636582594,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "0626731d-71e8-48cd-9e0d-8ef190e46b9c",
                  "oncogenic": "Likely Neutral",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1680636581238,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "92f96e90-5b2d-48ec-ae66-c3b752ff624c",
                  "short": ""
                },
                "mutation_effect_uuid": "cf869eaa-c9f6-4fac-b712-5e77c00fe3e6",
                "name": "M517I",
                "name_review": {
                  "added": true,
                  "updateTime": 1680636574072,
                  "updatedBy": "User"
                },
                "name_uuid": "2602191a-5688-4944-a865-8a87141f7b55",
                "tumors_uuid": "0b1d4cab-1d20-4ce0-81da-562fff2e0d13"
              },
              "operation": "add",
              "uuids": "92f96e90-5b2d-48ec-ae66-c3b752ff624c,0626731d-71e8-48cd-9e0d-8ef190e46b9c"
            }
          ],
          "timeStamp": 1681252660890
        },
        "-NSmT2_zAjOkbe452kSI": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "T470P",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF T470P mutation is located in the kinase domain of the protein. In silico analysis suggests that the mutation is damaging and activating (PMID: 24037001).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1680636432911,
                    "updatedBy": "User"
                  },
                  "description_uuid": "7474a188-211c-4a24-ada7-79c240a25108",
                  "effect": "Inconclusive",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1680636431462,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "3da02e00-69cb-48fd-904a-32bf20bfa6c4",
                  "oncogenic": "Inconclusive",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1680636430579,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "b510f68a-e682-4207-b814-4830e295b120",
                  "short": ""
                },
                "mutation_effect_uuid": "43e04871-eacc-437c-ad23-76eba270f80c",
                "name": "T470P",
                "name_review": {
                  "added": true,
                  "updateTime": 1680636425828,
                  "updatedBy": "User"
                },
                "name_uuid": "a6408b96-ab75-4065-b5ce-82835cdf4035",
                "tumors_uuid": "bf6a0281-77f7-4a61-a963-59635451a1cb"
              },
              "operation": "add",
              "uuids": "b510f68a-e682-4207-b814-4830e295b120,3da02e00-69cb-48fd-904a-32bf20bfa6c4"
            }
          ],
          "timeStamp": 1681252695887
        },
        "-NSmTApkoy_qx_ey7VhP": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "L485S",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF L485S mutation is located in the kinase domain of the protein. Although not functionally characterized per se, in vitro studies with A375 cells expressing BRAF L485S demonstrate that the mutation confers resistance to treatment with dabrafenib as measured by sustained cell growth (PMID: 31925410).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1680638247788,
                    "updatedBy": "User"
                  },
                  "description_uuid": "6a39a937-0e2f-439b-bef7-194cac3d6bdf",
                  "effect": "Inconclusive",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1680638239518,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "fd514185-c401-4ece-ae58-e8368656cdfc",
                  "oncogenic": "Resistance",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1680638238695,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "35fa69d8-33b3-4bdb-9d22-99baa9a53978",
                  "short": ""
                },
                "mutation_effect_uuid": "851ee259-df8a-4bb5-9b98-7b07f8e9ed88",
                "name": "L485S",
                "name_review": {
                  "added": true,
                  "updateTime": 1680638190409,
                  "updatedBy": "User"
                },
                "name_uuid": "a575d01f-a868-4286-9a24-82699712628c",
                "tumors_uuid": "ddcca08b-b245-4a83-90c2-c1584580e7f4"
              },
              "operation": "add",
              "uuids": "35fa69d8-33b3-4bdb-9d22-99baa9a53978,fd514185-c401-4ece-ae58-e8368656cdfc"
            }
          ],
          "timeStamp": 1681252729664
        },
        "-NSmTJ9tiiEdeUBERpel": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G615R",
              "new": {
                "mutation_effect": {
                  "description": "The BRAF G615R mutation is located in the kinase domain of the protein. In vitro studies with MCF10A cells expressing BRAF G615R demonstrate that the mutation is inactivating as measured by decreased cell proliferation and viability comparable to wildtype (PMID: 29533785).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1680638174563,
                    "updatedBy": "User"
                  },
                  "description_uuid": "035c6cc3-2d74-43f8-8425-ece6550c0f30",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1680638173363,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "8743d79d-d96d-42c8-bbdc-34ca15be3433",
                  "oncogenic": "Likely Neutral",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1680638172166,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "32001b24-77d3-4579-b919-138d16a18050",
                  "short": ""
                },
                "mutation_effect_uuid": "9d5d6e4b-5f95-4fba-85f3-f08803dde9f4",
                "name": "G615R",
                "name_review": {
                  "added": true,
                  "updateTime": 1680638158205,
                  "updatedBy": "User"
                },
                "name_uuid": "b48c6ce8-d599-450c-9db8-f04054e0cac8",
                "tumors_uuid": "5e70ad43-03f7-4ec2-b6e3-191facfb10c4"
              },
              "operation": "add",
              "uuids": "32001b24-77d3-4579-b919-138d16a18050,8743d79d-d96d-42c8-bbdc-34ca15be3433"
            }
          ],
          "timeStamp": 1681252763785
        },
        "-NW9jHE8Loz3InbnGto_": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Biliary Tract Cancer, NOS, STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY, 939cd40b-b515-499d-b099-fd29027c0d17 + fb2bb01c-c0ec-4641-abf7-87f486075022",
              "new": {
                "description": "Dabrafenib, an orally bioavailable RAF inhibitor, and trametinib, an orally bioavailable MEK1/2 inhibitor, are FDA-approved in combination for the treatment of patients with solid tumors other than colorectal harboring BRAF V600E mutation. FDA approval was based on data from 131 adult patients with solid tumors treated with dabrafenib and trametinib in the BRF117019 and NCI-MATCH trials and 36 pediatric patients treated with dabrafenib and trametinib in the CTMT212X2101 study. Of the 131 adult patients treated with dabrafenib and trametinib, the overall response rate was 41% (54/131; 95% CI = 33-50) and of the 36 pediatric patients treated with dabrafenib and trametinib (low-grade glioma, n=34; high-grade glioma, n=2), the overall response rate was 25% (95% CI = 12-24) (PMID: 32818466, 34838156, 32758030)(Abstract: Bouffet et al. Abstract# LGG-49, Neuro-Oncology 2020. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715318/). Approval was supported by results in COMBI-d, COMBI-v and BRF113928 studies in melanoma and lung cancer (PMID: 23020132, 25399551, 27283860). In the Phase II ROAR basket trial of dabrafenib + trametinib in patients with BRAF V600E-mutated rare cancers (biliary tract cancer, n=43), the overall response rate was 53%, the median progression-free survival was nine months (95% CI = 5.5, 9.4) and the median overall survival was 13.5 months (95% CI = 10.4, 17.6) (PMID: 37059834). Of the 43 patients with biliary tract cancer, 53% of patients (23/43) had a partial response and 37% (16/43) had stable disease (PMID: 37059834). Additionally, in subprotocol H of the NCI-MATCH basket trial of dabrafenib + trametinib in patients with BRAF V600E-mutant solid tumors (n=4 patients with intrahepatic cholangiocarcinoma), the overall response rate was 100%, with 4/4 patients achieving a partial response (PMID: 32758030)."
              },
              "old": {
                "description": "Dabrafenib, an orally bioavailable RAF inhibitor, and trametinib, an orally bioavailable MEK1/2 inhibitor, are FDA-approved in combination for the treatment of patients with solid tumors other than colorectal harboring BRAF V600E mutation. FDA approval was based on data from 131 adult patients with solid tumors treated with dabrafenib and trametinib in the BRF117019 and NCI-MATCH trials and 36 pediatric patients treated with dabrafenib and trametinib in the CTMT212X2101 study. Of the 131 adult patients treated with dabrafenib and trametinib, the overall response rate was 41% (54/131; 95% CI = 33-50) and of the 36 pediatric patients treated with dabrafenib and trametinib (low grade glioma, n=34; high grade glioma, n=2), the overall response rate was 25% (95% CI = 12-24) (PMID: 32818466, 34838156, 32758030)(Abstract: Bouffet et al. Abstract# LGG-49, Neuro-Oncology 2020. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715318/). Approval was supported by results in COMBI-d, COMBI-v and BRF113928 studies in melanoma and lung cancer (PMID: 23020132, 25399551, 27283860). In a Phase II, single-arm basket trial of dabrafenib + trametinib in patients with BRAF V600E-mutant solid tumors, of 43 patients with biliary tract cancer, the overall response rate was 51% (22/43, 95% CI = 36–67), the median progression-free survival was nine months (95% CI = 5-10), and the median overall survival was fourteen months (95% CI = 10-33). Of the 43 patients with biliary tract cancer, 51% of patients (22/43) had a partial response and 40% (17/43) had stable disease (PMID: 32818466). Additionally, in subprotocol H of the NCI-MATCH basket trial of dabrafenib + trametinib in patients with BRAF V600E-mutant solid tumors (N=4 patients with intrahepatic cholangiocarcinoma), the overall response rate was 100%, with 4/4 patients achieving a partial response (PMID: 32758030)."
              },
              "operation": "update",
              "uuids": "6d286407-4acf-4feb-9649-472fbb1b95fe"
            }
          ],
          "timeStamp": 1684881089474
        },
        "-Nh3QWOYZ7GeDvq6-wAw": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Non-Small Cell Lung Cancer, Tumor Type Summary",
              "new": "The RAF-targeted inhibitors dabrafenib and encorafenib in combination with the MEK1/2-targeted inhibitors trametinib and binimetinib, respectively, are FDA-approved for the treatment of patients with BRAF V600E mutant non-small cell lung cancer.",
              "old": "The RAF-targeted inhibitor dabrafenib in combination with the MEK1/2-targeted inhibitor trametinib is FDA-approved for the treatment of patients with BRAF V600E mutant non-small cell lung cancer.",
              "operation": "update",
              "uuids": "dc939314-9786-4d02-942c-004c3444c33d"
            }
          ],
          "timeStamp": 1697660147519
        },
        "-Nh3QfCN362_oCQRgW4v": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V600E, Non-Small Cell Lung Cancer, Standard implications for sensitivity to therapy, 001e534f-3e63-432f-90a6-d1af1759e4e2 + feb9f4a3-e374-4c75-8a3b-0f1fbcdbf677",
              "new": {
                "description": "Encorafenib, a small molecule inhibitor of RAF kinases, and binimetinib, a small molecule inhibitor of MEK1/2 kinases, are FDA-approved in combination for the treatment of patients with BRAF V600E mutant non-small cell lung cancer (NSCLC). FDA approval was based on the Phase II, open-label, multicenter, single-arm PHAROS study of encorafenib in combination with binimetinib in treatment-naïve (n=59) and previously treated (n=39) patients with BRAF V600E-mutant metastatic NSCLC (PMID: 37270692). In the Phase II PHAROS study, the objective response rate and duration of response for treatment-naïve patients were 72% (95% CI=62, 85) and 44 months (95% CI=23.1, NE), with 15% experiencing a complete response and 59% experiencing a partial response, compared to 46% (95% CI=30, 63) and 18 months (95% CI=7.4, NE) in previously treated patients, with 10% experiencing a complete response and 36% experiencing a partial response (PMID: 37270692).",
                "description_review": {
                  "lastReviewed": "",
                  "updateTime": 1697648683213,
                  "updatedBy": "User"
                },
                "description_uuid": "37fae80e-3989-46c9-bb82-9bbfcc0b8eae",
                "fdaLevel": "Fda2",
                "fdaLevel_review": {
                  "lastReviewed": "",
                  "updateTime": 1697580288235,
                  "updatedBy": "User"
                },
                "fdaLevel_uuid": "dcb476b2-f7ec-4dbc-9a03-d036b059e355",
                "indication": "Encorafenib and binimetinib are FDA-approved for use in combination in the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation",
                "indication_review": {
                  "lastReviewed": "",
                  "updateTime": 1697637517180,
                  "updatedBy": "User"
                },
                "indication_uuid": "40645fd7-8e21-4007-af8b-e8eff67607f7",
                "level": "1",
                "level_review": {
                  "lastReviewed": "",
                  "updateTime": 1697580288244,
                  "updatedBy": "User"
                },
                "level_uuid": "48669f54-a123-4b96-8170-51087557b7d0",
                "name": "001e534f-3e63-432f-90a6-d1af1759e4e2 + feb9f4a3-e374-4c75-8a3b-0f1fbcdbf677",
                "name_review": {
                  "added": true,
                  "updateTime": 1697580272446,
                  "updatedBy": "User"
                },
                "name_uuid": "f9d7a2ff-3395-49ac-b86f-a141d0337167",
                "propagation": "3B",
                "propagationLiquid": "no",
                "propagationLiquid_review": {
                  "lastReviewed": "",
                  "updateTime": 1697580288224,
                  "updatedBy": "User"
                },
                "propagationLiquid_uuid": "54f9cf2a-40d5-47c4-b3be-5b12bc30bec0",
                "propagation_review": {
                  "lastReviewed": "",
                  "updateTime": 1697580329269,
                  "updatedBy": "User"
                },
                "propagation_uuid": "34d9a44b-564b-4306-a8f3-83f190fc0508",
                "short": ""
              },
              "operation": "add",
              "uuids": "f9d7a2ff-3395-49ac-b86f-a141d0337167"
            }
          ],
          "timeStamp": 1697660187701
        },
        "-Nm25HQtWCxFrycD94TR": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R509H, Mutation Effect",
              "new": {
                "effect": "Likely Loss-of-function"
              },
              "old": {
                "effect": "Loss-of-function"
              },
              "operation": "update",
              "uuids": "5ee9e9a1-ed4b-4e83-ab9d-9c2e3969ceea"
            }
          ],
          "timeStamp": 1703006512948
        },
        "-NsQNW41X3i7KdNtTm2F": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "K601, All Solid Tumors, INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY, 44faeeae-ad6d-4370-8c99-97955f9e0feb",
              "new": {
                "description": "PLX8394 is an orally available, second-generation, small-molecule BRAF inhibitor that inhibits mutated, oncogenic BRAF without causing paradoxical MAPK pathway activation as is seen with first-generation BRAF inhibitors (PMID: 28659148). In a phase I clinical trial for patients with refractory or relapsed solid tumors with or without BRAF mutation, there were two (28%) partial responses of seven evaluable BRAF-mutant patients treated with PLX8394 and cobicistat, a CYP3A4 inhibitor (Abstract: Janku et al. Abstract# B176, AACR-NCI-EORTC 2017. http://mct.aacrjournals.org/content/17/1_Supplement/B176). Both responses were in patients with BRAF V600 mutations. In a phase I/IIa trial of PLX8394 for patients with BRAF-altered, advanced solid or CNS tumors (n=110; n=61, patients with class 1 mutations; n=19, patients with class 2 mutations [excluding fusions]; n=17, patients with BRAF fusions), partial response was achieved in 39% (n=9/23) of patients with MAPKi-naive, V600-mutant tumors, with a median duration of response (DoR) of 32 months, and in 18% (n=3/17) of patients with MAPKi treated, V600-mutant tumors (n=6, patients with V600-mutant glioma; n=3, patients with V600-mutant ovarian cancer; n=1, patients with V600-mutant small bowel cancer; n=1, patients with V600-mutant papillary thyroid cancer; n=1, patients with V600-mutant anaplastic thyroid cancer) (Abstract: Fuente et al. Abstract# 3006, J. Clin. Oncol. 2023, Vol 41, Suppl 16. https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.3006). Preclinical studies show that PLX8394 specifically inhibits BRAF-containing dimers and inhibits proliferation and pathway activation in BRAF-mutated colorectal cancer cell lines (PMID: 26466569, 28659148, 30559419, 28783719)."
              },
              "old": {
                "description": "PLX8394 is an orally available, second-generation, small-molecule BRAF inhibitor that inhibits mutated, oncogenic BRAF without causing paradoxical MAPK pathway activation as is seen with first-generation BRAF inhibitors (PMID: 28659148). In a phase I clinical trial for patients with refractory or relapsed solid tumors with or without BRAF mutation, there were two (28%) partial responses of seven evaluable BRAF-mutant patients treated with PLX8394 and cobicistat, a CYP3A4 inhibitor (Abstract: Janku et al. Abstract# B176, AACR-NCI-EORTC 2017. http://mct.aacrjournals.org/content/17/1_Supplement/B176). Both responses were in patients with BRAF V600 mutations. Preclinical studies show that PLX8394 specifically inhibits BRAF-containing dimers and inhibits proliferation and pathway actiavtion in BRAF-mutated colorectal cancer cell lines (PMID: 26466569, 28659148, 30559419, 28783719)."
              },
              "operation": "update",
              "uuids": "690ed068-5612-438a-ac07-948a18228375"
            }
          ],
          "timeStamp": 1709856395519
        },
        "-NsQNjGrreMQhtBjW1gg": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G469A, G469V, G469R, G464 (non-V600 mutations class II ), All Solid Tumors, INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY, 44faeeae-ad6d-4370-8c99-97955f9e0feb",
              "new": {
                "description": "PLX8394 is an orally available, second-generation, small-molecule BRAF inhibitor that inhibits mutated, oncogenic BRAF without causing paradoxical MAPK pathway activation as is seen with first-generation BRAF inhibitors (PMID: 28659148). In a phase I clinical trial for patients with refractory or relapsed solid tumors with or without BRAF mutation, there were two (28%) partial responses of seven evaluable BRAF-mutant patients treated with PLX8394 and cobicistat, a CYP3A4 inhibitor (Abstract: Janku et al. Abstract# B176, AACR-NCI-EORTC 2017. http://mct.aacrjournals.org/content/17/1_Supplement/B176). Both responses were in patients with BRAF V600 mutations. In a phase I/IIa trial of PLX8394 for patients with BRAF-altered, advanced solid or CNS tumors (n=110; n=61, patients with class 1 mutations; n=19, patients with class 2 mutations [excluding fusions]; n=17, patients with BRAF fusions), partial response was achieved in 39% (n=9/23) of patients with MAPKi-naive, V600-mutant tumors, with a median duration of response (DoR) of 32 months, and in 18% (n=3/17) of patients with MAPKi treated, V600-mutant tumors (n=6, patients with V600-mutant glioma; n=3, patients with V600-mutant ovarian cancer; n=1, patients with V600-mutant small bowel cancer; n=1, patients with V600-mutant papillary thyroid cancer; n=1, patients with V600-mutant anaplastic thyroid cancer) (Abstract: Fuente et al. Abstract# 3006, J. Clin. Oncol. 2023, Vol 41, Suppl 16. https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.3006). \nPreclinical studies show that PLX8394 specifically inhibits BRAF-containing dimers and inhibits proliferation and pathway activation in BRAF-mutated colorectal cancer cell lines (PMID: 26466569, 28659148, 30559419, 28783719)."
              },
              "old": {
                "description": "PLX8394 is an orally available, second-generation, small-molecule BRAF inhibitor that inhibits mutated, oncogenic BRAF without causing paradoxical MAPK pathway activation as is seen with first-generation BRAF inhibitors (PMID: 28659148). In a phase I clinical trial for patients with refractory or relapsed solid tumors with or without BRAF mutation, there were two (28%) partial responses of seven evaluable BRAF-mutant patients treated with PLX8394 and cobicistat, a CYP3A4 inhibitor (Abstract: Janku et al. Abstract# B176, AACR-NCI-EORTC 2017. http://mct.aacrjournals.org/content/17/1_Supplement/B176). Both responses were in patients with BRAF V600 mutations. Preclinical studies show that PLX8394 specifically inhibits BRAF-containing dimers and inhibits proliferation and pathway activation in BRAF-mutated colorectal cancer cell lines (PMID: 26466569, 28659148, 30559419, 28783719)."
              },
              "operation": "update",
              "uuids": "96034660-351c-4fce-9f82-cdfe98f7a0d2"
            }
          ],
          "timeStamp": 1709856453684
        },
        "-NsoLpJQVUt_Jzpmu0XA": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "L485W, Mutation Effect",
              "new": {
                "description": "The BRAF L485W mutation is located in the kinase domain of the protein (PMID: 35117215). This mutation has been identified in bladder adenocarcinoma and is a statistically significant hotspot (PMID: 28481359). The oncogenic and biologic effect of this mutation has conflicting evidence. An in vitro study with Ba/F3 and MCF10A cells expressing BRAF L485W demonstrates the mutation is inactivating as measured by decreased cellular viability in one cell line compared to wildtype (PMID: 29533785). In contrast, BRAF L485W has been cited as an activating class II BRAF mutation and is suggested to be an atypical activating mutation due to sensitivity to MAPK targeting inhibitors (PMID: 35977349, 35117215, 31015311). Clinical studies suggest that BRAF L485W is sensitive to MAPK pathway inhibition as measured by a patient with gallbladder cancer harboring the mutation demonstrating sensitivity to the ERK1/2 kinase inhibitor ulixertinib as measured by a year-long complete response to treatment (PMID: 29247021).",
                "effect": "Inconclusive",
                "oncogenic": "Inconclusive"
              },
              "old": {
                "description": "The BRAF L485W mutation is located in the kinase domain of the protein (PMID: 35117215). This mutation has been identified in bladder adenocarcinoma and is a statistically significant hotspot (PMID: 28481359). The oncogenic and biologic effect of this mutation has conflicting evidence. An in vitro study with Ba/F3 and MCF10A cells expressing BRAF L485W demonstrates the mutation is inactivating as measured by decreased cellular viability in one cell line compared to wildtype (PMID: 29533785). BRAF L485W has been cited as an activating class II BRAF mutation and is suggested to be an atypical activating mutation due to sensitivity to MAPK targeting (PMID: 35977349, 35117215, 31015311). Clinical studies suggest that BRAF L485W is sensitive to MAPK targeting as measured by a patient with gallbladder cancer harboring the mutation demonstrating sensitivity to the ERK1/2 kinase inhibitor ulixertinib as measured by a year-long complete response to treatment (PMID: 29247021).",
                "effect": "Likely Gain-of-function",
                "oncogenic": "Likely"
              },
              "operation": "update",
              "uuids": "62fd5ccd-0491-4148-af9e-48bbc95dfd01,8322f1de-86af-4e6f-8a96-b05f246d1b16"
            }
          ],
          "timeStamp": 1710275384552
        }
      }
    },
    "ROS1": {
      "api": {
        "-LLZVv8i1Umeg3wwWoXT": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Gene Summary",
              "operation": "update",
              "uuids": "c8a6f3f5-9134-4de4-93e5-3d72157b99d6"
            },
            {
              "lastEditBy": "User",
              "location": "Gene Background",
              "operation": "update",
              "uuids": "4cf7d3b6-91bd-42ba-abdc-6b8792cec92b"
            }
          ],
          "timeStamp": 1518022762874
        },
        "-LLZVv8jH4zXjlHaLYK8": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Gene Summary",
              "operation": "update",
              "uuids": "c8a6f3f5-9134-4de4-93e5-3d72157b99d6"
            }
          ],
          "timeStamp": 1518022775626
        },
        "-LLalmCM6Ke8RxO9l9c0": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "D842V, Leukemia, Investigational implications for resistance to therapy, Sorafenib",
              "old": {
                "description": "Sorafenib is small-molecule inhibitor of different protein kinases, including PDGFRA (PMID: 22665524). A clinical study described a patient with chronic eosinophilic leukemia (CEL) positive for the disease-specific FIP1L1-PDGFRA fusion that developed resistance to imatinib due to the previously described secondary resistance mutation T674I (PMID: 19212337). Subsequently, the patient progressed on sorafenib and in the post-progression specimen, the D842V mutation had replaced T674I. Experiments in cell lines transformed with the PDGFRA fusion confirmed that the T674I mutation confers resistance to imatinib but not sorafenib, whereas D842V mediated resistance to both inhibitors as measured by cellular growth and sustained pathway activation (PMID: 19212337).",
                "description_review": {
                  "updateTime": 1502127753005
                },
                "description_uuid": "dfaaafeb-b5db-48fb-a278-e808d4e56912",
                "indication": "",
                "indication_review": {
                  "updateTime": 1493063804037
                },
                "indication_uuid": "63f20fb2-7079-4596-9504-38339ec23f95",
                "level": "R2",
                "level_review": {
                  "updateTime": 1493063804037
                },
                "level_uuid": "a9106516-cdcb-4c7d-8fa2-f0e91ce681c4",
                "name": "Sorafenib",
                "name_review": {
                  "removed": true,
                  "updateTime": 1536101343797,
                  "updatedBy": "User"
                },
                "name_uuid": "418078b0-f000-49e2-bc84-93c98a8b263e",
                "propagation_review": {
                  "updateTime": 1536101391110,
                  "updatedBy": "User"
                },
                "propagation_uuid": "0c948449-59a6-495a-b055-4cc40c9d30d3",
                "short": ""
              },
              "operation": "delete"
            }
          ],
          "timeStamp": 1536101393243
        },
        "-LNLv9VmcK2NvacrxVtU": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G2032R, All Solid Tumors, INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_RESISTANCE, Ceritinib",
              "operation": "update",
              "uuids": "e7e91d11-1c7b-4594-afac-fd6e85f52edd"
            },
            {
              "lastEditBy": "User",
              "location": "G2032R, All Solid Tumors, INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_RESISTANCE, AP26113",
              "operation": "update",
              "uuids": "505bc449-27af-4ba7-9e60-1ad41582d8b8"
            },
            {
              "lastEditBy": "User",
              "location": "G2032R, All Solid Tumors, INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_RESISTANCE, ASP3026",
              "operation": "update",
              "uuids": "4144e7f0-6575-4ad1-9ecb-891982989dde"
            },
            {
              "lastEditBy": "User",
              "location": "L1951R, All Solid Tumors, INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_RESISTANCE, Crizotinib",
              "operation": "update",
              "uuids": "f276b522-22b1-4f09-be02-e0232b9fb632"
            },
            {
              "lastEditBy": "User",
              "location": "S1986Y, All Solid Tumors, INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_RESISTANCE, Ceritinib",
              "operation": "update",
              "uuids": "d4192d7d-9822-481d-b29a-af3dbc2c61ac"
            },
            {
              "lastEditBy": "User",
              "location": "S1986F, All Solid Tumors, INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_RESISTANCE, Ceritinib",
              "operation": "update",
              "uuids": "ecc90907-c844-4339-a463-3a24e815562c"
            }
          ],
          "timeStamp": 1537982897981
        },
        "-LYc5bz4vtg4y3DJndsV": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G2032R, All Solid Tumors",
              "old": {
                "TIs": [
                  {
                    "name": "Standard implications for sensitivity to therapy",
                    "name_uuid": "687eaa38-87cb-4fdc-9f40-f70a0dda83be",
                    "type": "SS"
                  },
                  {
                    "name": "Standard implications for resistance to therapy",
                    "name_uuid": "a852155d-7525-4186-8f80-b470dc6386d6",
                    "type": "SR"
                  },
                  {
                    "name": "Investigational implications for sensitivity to therapy",
                    "name_uuid": "cd30633d-b4cf-4405-9104-9918e088d8bd",
                    "type": "IS"
                  },
                  {
                    "name": "Investigational implications for resistance to therapy",
                    "name_uuid": "554f78a2-34c6-4eaa-aa31-03ab891b2ac6",
                    "type": "IR"
                  }
                ],
                "cancerTypes": [
                  {
                    "code": "",
                    "mainType": "All Solid Tumors",
                    "subtype": ""
                  }
                ],
                "cancerTypes_review": {
                  "removed": true,
                  "updateTime": 1550082214436,
                  "updatedBy": "User"
                },
                "cancerTypes_uuid": "a3983ca9-7647-4d27-ac54-c5f61719222e",
                "diagnostic": {
                  "description": "",
                  "description_uuid": "a32ac796-56b9-4e18-8ffe-5522a2008b9b",
                  "level": "",
                  "level_uuid": "3076d13b-4681-4947-8e93-1ed42c691453",
                  "short": ""
                },
                "diagnostic_uuid": "609e71bb-ebb8-489f-9013-90de11218939",
                "prognostic": {
                  "description": "",
                  "description_review": {
                    "updateTime": 1491850504608
                  },
                  "description_uuid": "8041f867-2ae8-48a4-871d-778668cb6dd2",
                  "level": "",
                  "level_uuid": "49cf1b52-a7da-43e6-ad01-1f4ccaec620c",
                  "short": ""
                },
                "prognostic_uuid": "edf3d5de-afcc-42e6-8611-5d943ea2edea",
                "summary": "",
                "summary_review": {
                  "updateTime": 1550082210850,
                  "updatedBy": "User"
                },
                "summary_uuid": "4edaeeb9-cdee-4037-a2cb-aa8ece215572"
              },
              "operation": "delete"
            },
            {
              "lastEditBy": "User",
              "location": "G2032R, Non-Small Cell Lung Cancer",
              "old": {
                "TIs": [
                  {
                    "name": "Standard implications for sensitivity to therapy",
                    "name_uuid": "b818dd3b-ba0f-4944-bd35-499b42567f5e",
                    "type": "SS"
                  },
                  {
                    "name": "Standard implications for resistance to therapy",
                    "name_uuid": "06f7ae50-c262-41a3-9616-520de9389aa5",
                    "type": "SR"
                  },
                  {
                    "name": "Investigational implications for sensitivity to therapy",
                    "name_uuid": "51e62af6-05e5-4e84-830e-80718f620926",
                    "type": "IS"
                  },
                  {
                    "name": "Investigational implications for resistance to therapy",
                    "name_uuid": "a4ffe904-d309-4523-b9e8-7408cbbdb347",
                    "type": "IR"
                  }
                ],
                "cancerTypes": [
                  {
                    "code": "",
                    "mainType": "Non-Small Cell Lung Cancer",
                    "subtype": ""
                  }
                ],
                "cancerTypes_review": {
                  "removed": true,
                  "updateTime": 1550082224522,
                  "updatedBy": "User"
                },
                "cancerTypes_uuid": "f61de384-dc39-4906-8d69-01eb3bbf51da",
                "diagnostic": {
                  "description": "",
                  "description_uuid": "7cb1031a-181d-47ce-a5c3-84eb054d104f",
                  "level": "",
                  "level_uuid": "52e01240-b4d9-4585-b007-98e4ef4e91c8",
                  "short": ""
                },
                "diagnostic_uuid": "1f8ddf0f-8081-43f8-c098-cf6168d3f283",
                "prognostic": {
                  "description": "",
                  "description_uuid": "016ffde2-0b91-40ed-ba1a-02ffb8175b9a",
                  "level": "",
                  "level_uuid": "e2009e7e-9e46-4031-a5c6-c161fc25a6db",
                  "short": ""
                },
                "prognostic_uuid": "aca60139-2865-49cb-8f9b-1c5f50a252f0",
                "summary": "",
                "summary_review": {
                  "updateTime": 1550082218037,
                  "updatedBy": "User"
                },
                "summary_uuid": "b3265f0b-c162-4715-b1e4-0c3dd1c88711"
              },
              "operation": "delete"
            },
            {
              "lastEditBy": "User",
              "location": "L1951R, All Solid Tumors",
              "old": {
                "TIs": [
                  {
                    "name": "Standard implications for sensitivity to therapy",
                    "name_uuid": "4d4eb9f0-be21-47f1-9c5e-1b4d6ef1bbfe",
                    "type": "SS"
                  },
                  {
                    "name": "Standard implications for resistance to therapy",
                    "name_uuid": "028229b3-8235-4036-9cb3-0bdc24f16548",
                    "type": "SR"
                  },
                  {
                    "name": "Investigational implications for sensitivity to therapy",
                    "name_uuid": "706412f4-e8fa-499a-9d7c-8b5264f92312",
                    "type": "IS"
                  },
                  {
                    "name": "Investigational implications for resistance to therapy",
                    "name_uuid": "d8cac55e-3ebb-404e-b986-6fcbab292e39",
                    "type": "IR"
                  }
                ],
                "cancerTypes": [
                  {
                    "code": "",
                    "mainType": "All Solid Tumors",
                    "subtype": ""
                  }
                ],
                "cancerTypes_review": {
                  "removed": true,
                  "updateTime": 1550082177427,
                  "updatedBy": "User"
                },
                "cancerTypes_uuid": "caf3099f-5ee8-43d3-ad8c-88c90cee5656",
                "diagnostic": {
                  "description": "",
                  "description_uuid": "69267f6d-02e0-4e01-ab86-6d49f441837a",
                  "level": "",
                  "level_uuid": "6c1b321a-77e7-4383-b270-d45cf713f554",
                  "short": ""
                },
                "diagnostic_uuid": "e7498e6c-b4dd-4ed0-b496-4a23e64c1756",
                "prognostic": {
                  "description": "",
                  "description_review": {
                    "updateTime": 1491850504608
                  },
                  "description_uuid": "6b01681e-d8c6-4db3-8626-37203287e60a",
                  "level": "",
                  "level_uuid": "45229592-472a-445d-9e5f-33bdc675e367",
                  "short": ""
                },
                "prognostic_uuid": "dc67a30d-07d4-4e13-8ff9-c01ff1ada4cb",
                "summary": "",
                "summary_review": {
                  "updateTime": 1550082173719,
                  "updatedBy": "User"
                },
                "summary_uuid": "46eccee3-e708-452d-83d2-0323973e8805"
              },
              "operation": "delete"
            },
            {
              "lastEditBy": "User",
              "location": "D2033N, Non-Small Cell Lung Cancer",
              "old": {
                "TIs": [
                  {
                    "name": "Standard implications for sensitivity to therapy",
                    "name_uuid": "f3252ee0-9610-46e9-b9dc-a56a2a60f90f",
                    "type": "SS"
                  },
                  {
                    "name": "Standard implications for resistance to therapy",
                    "name_uuid": "fb1fbdd0-8eea-438c-8ee2-69e265e94e2b",
                    "type": "SR"
                  },
                  {
                    "name": "Investigational implications for sensitivity to therapy",
                    "name_uuid": "00170142-1769-4e97-a00a-e480975d25e8",
                    "type": "IS"
                  },
                  {
                    "name": "Investigational implications for resistance to therapy",
                    "name_uuid": "04ce55ce-1825-467e-8ab6-1c9964772fd6",
                    "type": "IR"
                  }
                ],
                "cancerTypes": [
                  {
                    "code": "",
                    "mainType": "Non-Small Cell Lung Cancer",
                    "subtype": ""
                  }
                ],
                "cancerTypes_review": {
                  "removed": true,
                  "updateTime": 1550082263342,
                  "updatedBy": "User"
                },
                "cancerTypes_uuid": "5bfd83a3-6b74-496c-9ccd-90586cb4dc38",
                "diagnostic": {
                  "description": "",
                  "description_uuid": "91440b50-6e96-481a-b4d8-43bed0f38a9f",
                  "level": "",
                  "level_uuid": "f814470f-c441-4d5e-a2ec-79bba7168e2d",
                  "short": ""
                },
                "diagnostic_uuid": "920f875a-20f7-42d2-985f-accc603cecbf",
                "prognostic": {
                  "description": "",
                  "description_review": {
                    "updateTime": 1491850504608
                  },
                  "description_uuid": "3f0152be-6207-4b99-b63c-315429d9041e",
                  "level": "",
                  "level_uuid": "3d20f754-af17-4fa8-890a-5d098fad8ed1",
                  "short": ""
                },
                "prognostic_uuid": "1eebedf7-18eb-4e12-b801-2716baea24cb",
                "summary": "",
                "summary_review": {
                  "updateTime": 1550082259007,
                  "updatedBy": "User"
                },
                "summary_uuid": "c9c2f982-347c-4d03-bfa2-debf8cf906d4"
              },
              "operation": "delete"
            },
            {
              "lastEditBy": "User",
              "location": "C2060G, All Solid Tumors",
              "old": {
                "TIs": [
                  {
                    "name": "Standard implications for sensitivity to therapy",
                    "name_uuid": "0bf57f64-6db6-4e8c-9144-a96e761243aa",
                    "type": "SS"
                  },
                  {
                    "name": "Standard implications for resistance to therapy",
                    "name_uuid": "031ac7b0-e7ec-4f4b-ac43-9c1a0a576aa9",
                    "type": "SR"
                  },
                  {
                    "name": "Investigational implications for sensitivity to therapy",
                    "name_uuid": "c6b948ac-42e8-485e-b483-132c43558d5b",
                    "type": "IS"
                  },
                  {
                    "name": "Investigational implications for resistance to therapy",
                    "name_uuid": "7e7b37f3-c45d-47ea-9240-f72678be24b0",
                    "type": "IR"
                  }
                ],
                "cancerTypes": [
                  {
                    "code": "",
                    "mainType": "All Solid Tumors",
                    "subtype": ""
                  }
                ],
                "cancerTypes_review": {
                  "removed": true,
                  "updateTime": 1550082247262,
                  "updatedBy": "User"
                },
                "cancerTypes_uuid": "64c0efea-97b8-4e2a-8b37-8a501f0a8a97",
                "diagnostic": {
                  "description": "",
                  "description_uuid": "5e6e915a-13df-47c6-b059-fcfd66b5b37a",
                  "level": "",
                  "level_uuid": "baedc53f-2274-4047-8697-773935ff71ec",
                  "short": ""
                },
                "diagnostic_uuid": "6607e961-39b5-46db-a2e8-4a35ee8db5bb",
                "prognostic": {
                  "description": "",
                  "description_review": {
                    "updateTime": 1491850504608
                  },
                  "description_uuid": "d062dc33-67fd-4d43-96bd-5f7a6643001b",
                  "level": "",
                  "level_uuid": "5eb53f5e-a8aa-4305-b73a-0e0400ded8b0",
                  "short": ""
                },
                "prognostic_uuid": "d1d50c41-d7c8-4d18-a58a-ea47807280e3",
                "summary": "",
                "summary_review": {
                  "updateTime": 1550082243583,
                  "updatedBy": "User"
                },
                "summary_uuid": "db9cd947-1a5e-40cf-be59-cfe7616432fc"
              },
              "operation": "delete"
            },
            {
              "lastEditBy": "User",
              "location": "E1935G, All Solid Tumors",
              "old": {
                "TIs": [
                  {
                    "name": "Standard implications for sensitivity to therapy",
                    "name_uuid": "bbadaf03-9366-4757-acdd-30d7f454c611",
                    "type": "SS"
                  },
                  {
                    "name": "Standard implications for resistance to therapy",
                    "name_uuid": "48af0356-587c-4d5e-981c-41c181403a6d",
                    "type": "SR"
                  },
                  {
                    "name": "Investigational implications for sensitivity to therapy",
                    "name_uuid": "5506057a-a8df-4efa-a4a9-e646ea8db20f",
                    "type": "IS"
                  },
                  {
                    "name": "Investigational implications for resistance to therapy",
                    "name_uuid": "c4cfbfa2-1fa9-47bd-adc2-4c6b763228a7",
                    "type": "IR"
                  }
                ],
                "cancerTypes": [
                  {
                    "code": "",
                    "mainType": "All Solid Tumors",
                    "subtype": ""
                  }
                ],
                "cancerTypes_review": {
                  "removed": true,
                  "updateTime": 1550082139593,
                  "updatedBy": "User"
                },
                "cancerTypes_uuid": "e76a606a-5752-43bc-9f7d-eeadd998e0a6",
                "diagnostic": {
                  "description": "",
                  "description_uuid": "b4385c1c-1133-4c2c-a55b-0026cdf2e54a",
                  "level": "",
                  "level_uuid": "0c09a979-b200-4e69-b04f-d24fe204f586",
                  "short": ""
                },
                "diagnostic_uuid": "342e2568-c030-40af-b3fa-660ff864532b",
                "prognostic": {
                  "description": "",
                  "description_review": {
                    "updateTime": 1491850504608
                  },
                  "description_uuid": "1b8eac6a-ab1e-4585-aa28-297ef5a2ebec",
                  "level": "",
                  "level_uuid": "f14cead9-5d33-497c-c0eb-93971af73cbf",
                  "short": ""
                },
                "prognostic_uuid": "998db2a0-e2de-4cd0-c031-dcfbb7b15120",
                "summary": "",
                "summary_review": {
                  "updateTime": 1550082135973,
                  "updatedBy": "User"
                },
                "summary_uuid": "0d43ab9b-c4b3-4810-a69c-0c4ce7ece375"
              },
              "operation": "delete"
            },
            {
              "lastEditBy": "User",
              "location": "G1971E, All Solid Tumors",
              "old": {
                "TIs": [
                  {
                    "name": "Standard implications for sensitivity to therapy",
                    "name_uuid": "20f75fc5-b521-4a85-b724-41ff46460dab",
                    "type": "SS"
                  },
                  {
                    "name": "Standard implications for resistance to therapy",
                    "name_uuid": "810d28a5-e44a-4bff-aaf8-7875c76b75dc",
                    "type": "SR"
                  },
                  {
                    "name": "Investigational implications for sensitivity to therapy",
                    "name_uuid": "2b215bc0-c8ca-43ae-af5c-d35cd295c429",
                    "type": "IS"
                  },
                  {
                    "name": "Investigational implications for resistance to therapy",
                    "name_uuid": "c7a27b28-823f-4aea-b5ab-8de86de1033e",
                    "type": "IR"
                  }
                ],
                "cancerTypes": [
                  {
                    "code": "",
                    "mainType": "All Solid Tumors",
                    "subtype": ""
                  }
                ],
                "cancerTypes_review": {
                  "removed": true,
                  "updateTime": 1550082158163,
                  "updatedBy": "User"
                },
                "cancerTypes_uuid": "24e26e5b-5349-4284-addc-6cb0f372a730",
                "diagnostic": {
                  "description": "",
                  "description_uuid": "3b4a971d-32f9-488c-83e3-c617755f5c82",
                  "level": "",
                  "level_uuid": "cddda637-d6ed-4623-82ad-b43ab74131b2",
                  "short": ""
                },
                "diagnostic_uuid": "4d5f9a55-2cbc-46b0-8973-25ac69517fa9",
                "prognostic": {
                  "description": "",
                  "description_review": {
                    "updateTime": 1491850504608
                  },
                  "description_uuid": "b64096a7-f4e7-486e-8174-37be39d01442",
                  "level": "",
                  "level_uuid": "063d159f-0d40-4b54-9657-6330eda8431a",
                  "short": ""
                },
                "prognostic_uuid": "25788c65-2204-4d6e-86f0-1319474a9374",
                "summary": "",
                "summary_review": {
                  "updateTime": 1550082153898,
                  "updatedBy": "User"
                },
                "summary_uuid": "126c3ac4-5137-4da2-9b31-fa61725a3c93"
              },
              "operation": "delete"
            },
            {
              "lastEditBy": "User",
              "location": "G2101A, All Solid Tumors",
              "old": {
                "TIs": [
                  {
                    "name": "Standard implications for sensitivity to therapy",
                    "name_uuid": "4f158d6d-f0b5-472a-a22e-92b295e3f82d",
                    "type": "SS"
                  },
                  {
                    "name": "Standard implications for resistance to therapy",
                    "name_uuid": "4858af5c-3a88-4ea1-b478-c50cf1967668",
                    "type": "SR"
                  },
                  {
                    "name": "Investigational implications for sensitivity to therapy",
                    "name_uuid": "8e89ff9b-fff4-4ea4-a5dd-a6f87fa3f06e",
                    "type": "IS"
                  },
                  {
                    "name": "Investigational implications for resistance to therapy",
                    "name_uuid": "ad7ea1b2-98f2-4e46-a87e-f532f7ec618f",
                    "type": "IR"
                  }
                ],
                "cancerTypes": [
                  {
                    "code": "",
                    "mainType": "All Solid Tumors",
                    "subtype": ""
                  }
                ],
                "cancerTypes_review": {
                  "removed": true,
                  "updateTime": 1550082048995,
                  "updatedBy": "User"
                },
                "cancerTypes_uuid": "815a81fc-8821-4401-8e8b-ff7e1466a90d",
                "diagnostic": {
                  "description": "",
                  "description_uuid": "7a520496-e721-4bbe-b8f7-5832f76ef1a4",
                  "level": "",
                  "level_uuid": "c77a48d5-2479-437f-a480-7e31acfae39d",
                  "short": ""
                },
                "diagnostic_uuid": "1a2d57cd-f1bf-4aaa-9398-ec070f156a78",
                "prognostic": {
                  "description": "",
                  "description_review": {
                    "updateTime": 1491850504608
                  },
                  "description_uuid": "9b30c1fc-af82-486e-b76c-482d0aa7392f",
                  "level": "",
                  "level_uuid": "c751134a-48de-48b8-bb57-4da73ff61cd7",
                  "short": ""
                },
                "prognostic_uuid": "969e46c1-52bd-4c78-9687-415a2e638008",
                "summary": "",
                "summary_review": {
                  "updateTime": 1491850504608
                },
                "summary_uuid": "978b4852-66f8-4800-a43d-78e8b16e1d38"
              },
              "operation": "delete"
            },
            {
              "lastEditBy": "User",
              "location": "S1986Y, All Solid Tumors",
              "old": {
                "TIs": [
                  {
                    "name": "Standard implications for sensitivity to therapy",
                    "name_uuid": "75ed7d8c-08f2-4dc5-b753-05ccbd76ba90",
                    "type": "SS"
                  },
                  {
                    "name": "Standard implications for resistance to therapy",
                    "name_uuid": "49c7596b-4079-4b04-871c-963b49e98fb8",
                    "type": "SR"
                  },
                  {
                    "name": "Investigational implications for sensitivity to therapy",
                    "name_uuid": "1134f3c6-93fb-49e9-a31b-448550b583b1",
                    "type": "IS"
                  },
                  {
                    "name": "Investigational implications for resistance to therapy",
                    "name_uuid": "12ccec06-dd32-4399-96b4-03968a7b63ec",
                    "type": "IR"
                  }
                ],
                "cancerTypes": [
                  {
                    "code": "",
                    "mainType": "All Solid Tumors",
                    "subtype": ""
                  }
                ],
                "cancerTypes_review": {
                  "removed": true,
                  "updateTime": 1550082066080,
                  "updatedBy": "User"
                },
                "cancerTypes_uuid": "f77fadc1-6cc6-4cf9-89a0-a76665b9a224",
                "diagnostic": {
                  "description": "",
                  "description_uuid": "3b00e95c-c5bf-497a-b87a-ad47da874097",
                  "level": "",
                  "level_uuid": "12b99214-43c2-4b16-b045-2be7cf7a295c",
                  "short": ""
                },
                "diagnostic_uuid": "df9800f0-2859-4c26-a148-936a1b4bec54",
                "prognostic": {
                  "description": "",
                  "description_review": {
                    "updateTime": 1491850504608
                  },
                  "description_uuid": "beb7e2fa-fd6f-4ef3-8767-a8f27101ccbe",
                  "level": "",
                  "level_uuid": "3c449ef1-4bb5-4a1f-8644-ac8f4b6e867d",
                  "short": ""
                },
                "prognostic_uuid": "3dcc2d4a-bc74-4450-8335-4f92dcecf83a",
                "summary": "",
                "summary_review": {
                  "updateTime": 1550082061635,
                  "updatedBy": "User"
                },
                "summary_uuid": "96763795-268a-4c43-9706-603ba26aa879"
              },
              "operation": "delete"
            },
            {
              "lastEditBy": "User",
              "location": "S1986Y, Non-Small Cell Lung Cancer",
              "old": {
                "TIs": [
                  {
                    "name": "Standard implications for sensitivity to therapy",
                    "name_uuid": "0828b68c-c166-4131-8bb8-5d8526ee6609",
                    "type": "SS"
                  },
                  {
                    "name": "Standard implications for resistance to therapy",
                    "name_uuid": "cc4dc109-b615-4234-b169-019f89ae79bf",
                    "type": "SR"
                  },
                  {
                    "name": "Investigational implications for sensitivity to therapy",
                    "name_uuid": "a7ba184b-f528-49f1-bcb2-72e12b4937f5",
                    "type": "IS"
                  },
                  {
                    "name": "Investigational implications for resistance to therapy",
                    "name_uuid": "c7be4168-4073-4f34-bba9-68c412e56ab7",
                    "type": "IR"
                  }
                ],
                "cancerTypes": [
                  {
                    "code": "",
                    "mainType": "Non-Small Cell Lung Cancer",
                    "subtype": ""
                  }
                ],
                "cancerTypes_review": {
                  "removed": true,
                  "updateTime": 1550082076245,
                  "updatedBy": "User"
                },
                "cancerTypes_uuid": "8348e718-e3cd-477f-8934-08a50645b683",
                "diagnostic": {
                  "description": "",
                  "description_uuid": "86c7c91b-8c8a-482a-8b02-c8dacf0f17d3",
                  "level": "",
                  "level_uuid": "f3d0013d-1c48-4086-a180-d5021cdd3e43",
                  "short": ""
                },
                "diagnostic_uuid": "1385a587-fbac-4abc-97c1-ca5d322d2152",
                "prognostic": {
                  "description": "",
                  "description_uuid": "ed789450-34e5-4cf7-96c3-b796cf46a5d7",
                  "level": "",
                  "level_uuid": "56613fb1-91d4-4193-a809-19ded6345612",
                  "short": ""
                },
                "prognostic_uuid": "0d1980a7-e011-4c8e-b194-3898950d6cc1",
                "summary": "",
                "summary_review": {
                  "updateTime": 1550082069408,
                  "updatedBy": "User"
                },
                "summary_uuid": "60dde67a-90e9-4149-9934-5d1b2a6ab3e4"
              },
              "operation": "delete"
            },
            {
              "lastEditBy": "User",
              "location": "S1986F, All Solid Tumors",
              "old": {
                "TIs": [
                  {
                    "name": "Standard implications for sensitivity to therapy",
                    "name_uuid": "9659a4d3-824d-45b2-8a56-146b0ca19644",
                    "type": "SS"
                  },
                  {
                    "name": "Standard implications for resistance to therapy",
                    "name_uuid": "4b5733f0-cf9a-4c1f-b10f-d4dfe2d59e47",
                    "type": "SR"
                  },
                  {
                    "name": "Investigational implications for sensitivity to therapy",
                    "name_uuid": "54d10ac8-9f07-41f6-8ad0-b6f17964da2e",
                    "type": "IS"
                  },
                  {
                    "name": "Investigational implications for resistance to therapy",
                    "name_uuid": "610b80b5-b59d-47be-8204-49f10205dc58",
                    "type": "IR"
                  }
                ],
                "cancerTypes": [
                  {
                    "code": "",
                    "mainType": "All Solid Tumors",
                    "subtype": ""
                  }
                ],
                "cancerTypes_review": {
                  "removed": true,
                  "updateTime": 1550082090557,
                  "updatedBy": "User"
                },
                "cancerTypes_uuid": "321b2a46-aaba-4e72-93b5-6034cbc5de91",
                "diagnostic": {
                  "description": "",
                  "description_uuid": "beb4f636-a335-4d08-aa70-a677ceeb5dc1",
                  "level": "",
                  "level_uuid": "e9c86306-a013-4e47-baf4-46215a0563b1",
                  "short": ""
                },
                "diagnostic_uuid": "676e442d-bb82-4c7c-810f-6d9cb49befaf",
                "prognostic": {
                  "description": "",
                  "description_review": {
                    "updateTime": 1491850504608
                  },
                  "description_uuid": "2e5994a8-4617-448e-9573-bf3b62ac80c9",
                  "level": "",
                  "level_uuid": "4eec09d1-216c-4d99-b02b-9eaee0ff2c5d",
                  "short": ""
                },
                "prognostic_uuid": "ae8f40bb-2b43-400a-9a84-6e9f3d50b253",
                "summary": "",
                "summary_review": {
                  "updateTime": 1550082086684,
                  "updatedBy": "User"
                },
                "summary_uuid": "617361ce-4c85-4113-a67d-fd95ef668576"
              },
              "operation": "delete"
            },
            {
              "lastEditBy": "User",
              "location": "S1986F, Non-Small Cell Lung Cancer",
              "old": {
                "TIs": [
                  {
                    "name": "Standard implications for sensitivity to therapy",
                    "name_uuid": "a8ee986b-61c6-4a05-9cba-541ed89352ee",
                    "type": "SS"
                  },
                  {
                    "name": "Standard implications for resistance to therapy",
                    "name_uuid": "57c49362-8f0f-41bc-8633-06df2872edbb",
                    "type": "SR"
                  },
                  {
                    "name": "Investigational implications for sensitivity to therapy",
                    "name_uuid": "2dd751f2-d1c9-437a-96a4-f8fb2f96febc",
                    "type": "IS"
                  },
                  {
                    "name": "Investigational implications for resistance to therapy",
                    "name_uuid": "69ad0c1e-37bb-471e-ae5d-6df536ad5ba3",
                    "type": "IR"
                  }
                ],
                "cancerTypes": [
                  {
                    "code": "",
                    "mainType": "Non-Small Cell Lung Cancer",
                    "subtype": ""
                  }
                ],
                "cancerTypes_review": {
                  "removed": true,
                  "updateTime": 1550082114751,
                  "updatedBy": "User"
                },
                "cancerTypes_uuid": "6aef8acb-b542-471c-8741-0e2eee638ef5",
                "diagnostic": {
                  "description": "",
                  "description_uuid": "0d3b4f02-f555-45f7-a460-d7015ca1dc4f",
                  "level": "",
                  "level_uuid": "9434c9d7-9796-4b86-9292-8da1160b9e05",
                  "short": ""
                },
                "diagnostic_uuid": "2912976e-f65e-4ecf-8473-ce4f90ca672d",
                "prognostic": {
                  "description": "",
                  "description_uuid": "fda6e02c-2490-4d76-b0de-a770b0172e54",
                  "level": "",
                  "level_uuid": "52060850-3c36-41d8-b13f-f35968315cb7",
                  "short": ""
                },
                "prognostic_uuid": "2fbb0ef6-a3b0-4161-a136-9ac0b80152a9",
                "summary": "",
                "summary_review": {
                  "updateTime": 1550082093421,
                  "updatedBy": "User"
                },
                "summary_uuid": "2186c5f1-1ab5-44f3-a976-c30aa2635829"
              },
              "operation": "delete"
            }
          ],
          "timeStamp": 1550082279504
        },
        "-LbvPMeRJc02QHTgIEY8": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Fusions, Mutation Effect",
              "new": {
                "description": "Fusions of ROS1 arise from chromosomal translocations that fuse the N-terminal portion of a partner protein with the C-terminal kinase-domain-containing portion of ROS1. These fusion proteins are found in a variety of cancer types and result in constitutive activation of ROS1 kinase activity. Biological characterization of specific ROS1 fusion proteins demonstrates that they are activating as shown by enhanced proliferation and colony formation and that they are sensitive to treatment with the tyrosine kinase inhibitor crizotinib (PMID: 23719267, 22919003, 22215748, 28465216)."
              },
              "old": {
                "description": "Fusion alterations involving ROS1 have been detected in a variety of human cancers and involve the translocation of a heterogenous group of genes (PMID: 23719267). This leads to constitutively activated ROS1 resulting in enhanced cell proliferation and anchorage-independent growth in soft agar (PMID: 23719267). Furthermore, experimental studies demonstrate that ROS1 fusions are particularly sensitive to treatment with crizotinib (PMID: 22919003, 22215748)."
              },
              "operation": "update",
              "uuids": "e8113bd5-9371-4afc-a563-3c8db56bb3d8"
            }
          ],
          "timeStamp": 1554701186889
        },
        "-LeFb6FqI5jcY2mikitb": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "CEP85L-ROS1 Fusion, Mutation Effect",
              "new": {
                "description": "The CEP85L-ROS1 fusion protein combines the N terminal of CEP85L until exon 8 with the C-terminal of ROS1 starting at exon 36 and is found in CNS tumors, angiosarcoma and glioblastoma (PMID: 23637631, 25204415, 30171048). The breakpoint preserves the coiled-coil domain of CEP85L and the tyrosine kinase domain of ROS1, and is predicted to possess transforming abilities (PMID: 23637631, 25204415, 30171048). Expression of this fusion protein in BaF3, NIH3T3, and immortalized human astrocyte cells demonstrated that it is activating as shown by IL3 independent growth, pathway activation and increased colony formation compared to ectopic expression of wildtype ROS1. Expression of this fusion in BaF3 cells also demonstrated that it is sensitive to multiple TKIs including crizotinib, foretinib, cabozantinib, ceritinib, brigatinib, AZD3463, lorlatinib, and entrectinib proliferation, pathway activation and colony formation (PMID: 30171048)."
              },
              "old": {
                "description": "CEP85L-ROS1 is a rearrangement mutation identified in angiosarcoma and glioblastoma (PMID: 23637631, 25204415). The breakpoint preserves the coiled-coil domain of CEP85L and the tyrosine kinase domain of ROS1, and is predicted to possess transforming abilities (PMID: 23637631, 25204415)."
              },
              "operation": "update",
              "uuids": "2efa77d7-fce2-4db2-9a47-efd2d37a8442"
            }
          ],
          "timeStamp": 1557204333706
        },
        "-LeFbHVJauUxk_eI7P2Y": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "GOPC-ROS1 Fusion",
              "new": {
                "mutation_effect": {
                  "description": "The GOPC-ROS1 fusion protein combines the N terminus of GOPC until exon 7 with the C-terminus of ROS1 starting at exon 35 and is found in CNS tumors (PMID: 30171048). This is the most frequent ROS1 fusion found in GBMs. Expression of this fusion protein in BaF3 and immortalized human astrocyte cells demonstrated that it is activating as shown by IL3 independent growth and increased colony formation compared to ectopic expression of wildtype ROS1 (PMID: 30171048). Expression of this fusion in BaF3 cells also demonstrated that it is sensitive to multiple TKIs including crizotinib, foretinib, cabozantinib, ceritinib, brigatinib, AZD3463, lorlatinib, and entrectinib as measured by proliferation, pathway activation and colony formation with lorlatinib having the highest potency (PMID: 30171048).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1557204355768,
                    "updatedBy": "User"
                  },
                  "description_uuid": "ed1b93b1-8637-4acf-b21b-6bc96e0c7712",
                  "effect": "Likely Gain-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1555912391737,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "a95bd9a0-ce83-4a4b-8782-c9cdff1175b1",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1555912390800,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "f34c6773-0f41-42b0-866d-8a7c3b3b694b",
                  "short": ""
                },
                "mutation_effect_uuid": "a79c96e9-973d-4c26-98b7-47aed55b3b5e",
                "name": "GOPC-ROS1 Fusion",
                "name_review": {
                  "added": true,
                  "updateTime": 1555912252820,
                  "updatedBy": "User"
                },
                "name_uuid": "98d2063a-472d-417b-8e78-194b94effd8e",
                "tumors_uuid": "b8180b56-79a4-4ff4-880c-0a6e8ce8bc0f"
              },
              "operation": "add",
              "uuids": "f34c6773-0f41-42b0-866d-8a7c3b3b694b,a95bd9a0-ce83-4a4b-8782-c9cdff1175b1"
            }
          ],
          "timeStamp": 1557204379752
        },
        "-LhgN1jbMgfvcD_awaCZ": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "CD74-ROS1 Fusion, ROS1-CD74 Fusion, Mutation Effect",
              "new": {
                "description": "CD74-ROS1 is a rearrangement mutation characterized by the fusion of CD74 (exon 6) and ROS1 (exon 34). This fusion generates a protein with constitutive kinase activity (PMID: 22215748, 22919003, 22327623, 18083107). CD74-ROS1 demonstrated transforming capabilities when tested in foci forming assays in vitro, and also demonstrated the ability to form subcutaneous tumors in nude mice (PMID: 22327623). A patient with non-small cell lung cancer harboring a CD74-ROS1 fusion responded to treatment with brigatinib and ceritinib after progressing on crizotinib (Abstract: Hegde et al. JCO PO, 2018. https://ascopubs.org/doi/full/10.1200/PO.18.00267)."
              },
              "old": {
                "description": "CD74-ROS1 is a rearrangement mutation characterized by the fusion of CD74 (exon 6) and ROS1 (exon 34). This fusion generates a protein with constitutive kinase activity (PMID: 22215748, 22919003, 22327623, 18083107). CD74-ROS1 demonstrated transforming capabilities when tested in foci forming assays in vitro, and also demonstrated the ability to form subcutaneous tumors in nude mice (PMID: 22327623)."
              },
              "operation": "update",
              "uuids": "bc796f57-eb77-4434-a67b-c83f986ccd53"
            }
          ],
          "timeStamp": 1560891369882
        },
        "-LnFLDiloEF3608YskZl": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Fusions, Non-Small Cell Lung Cancer, STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY, f05d12ab-6204-4a1c-803f-f3a7f6e30af2",
              "new": {
                "description": "Crizotinib, an inhibitor of ALK, ROS1 and MET tyrosine kinases, is FDA approved for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive. FDA-approval is based on the results of a Phase I trial of crizotinib in 53 patients with advanced NSCLC positive for ROS1 rearrangements in which the objective response rate was 72% (95% CI 58-84), including six complete responses, 32 partial responses (66%) and a median progression-free survival (PFS) of 19.3 months (95% CI 15.2-39.1)(PMID: 25264305, 30980071). In a Phase II trial of crizotinib in 127 East Asian patients with ROS1-positive NSCLC, the overall response rate was 71.1% (95% CI 63.0-79.3), including seventeen of 127 patients with complete responses (13.4%), 74 of 127 patients with partial responses (58.3%), and a median PFS of 15.9 months (95% CI 12.9-24.0) (PMID: 29596029)."
              },
              "old": {
                "description": "Crizotinib, an inhibitor of ALK, ROS1 and MET tyrosine kinases, is FDA approved for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive. FDA-approval is based on the results of a Phase I trial of crizotinib in 50 patients with advanced NSCLC positive for ROS1 rearrangements in which the objective response rate was 72% (95% CI 58-84), including three complete responses (6%), 33 partial responses (66%) and a median progression-free survival (PFS) of 19.2 months (95% CI 14.4-not reached)(PMID: 25264305). In a more recent Phase II trial of crizotinib in 127 East Asian patients with ROS1-positive NSCLC, the overall response rate was 71.1% (95% CI 63.0-79.3), including seventeen of 127 patients with complete responses (13.4%), 74 of 127 patients with partial responses (58.3%), and a median PFS of 15.9 months (95% CI 12.9-24.0) (PMID: 29596029)."
              },
              "operation": "update",
              "uuids": "c89514ef-b096-442a-828d-6ed357e12d57"
            }
          ],
          "timeStamp": 1566863585548
        },
        "-LnIlywS4saKpqIJ3VOq": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Fusions, Non-Small Cell Lung Cancer, Tumor Type Summary",
              "new": "Crizotinib is FDA-approved for the treatment of patients with ROS1 fusion positive non-small cell lung cancer.",
              "old": "Crizotinib is FDA-approved for the treatment of patients with ROS1-fusion positive non-small cell lung cancer.",
              "operation": "update",
              "uuids": "3aa7655f-3fd3-41d8-a883-43bfccc6d2a2"
            }
          ],
          "timeStamp": 1566921195646
        },
        "-LnIm-I_k73JC5yx9y6e": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Fusions, Other Tumor Types, Tumor Type Summary",
              "new": "While crizotinib is FDA-approved for the treatment of patients with ROS1 fusion positive non-small cell lung cancer, its clinical utility in patients with ROS1 fusion positive [[tumor type]] is unknown.",
              "old": "While crizotinib is FDA-approved for the treatment of patients with ROS1-fusion positive non-small cell lung cancer, its clinical utility in patients with ROS1-fusion positive [[tumor type]] is unknown.",
              "operation": "update",
              "uuids": "25c05c7e-a64e-4eec-8206-4a198462879f"
            }
          ],
          "timeStamp": 1566921201223
        },
        "-LnIm0-rSwpIcQeyqrlg": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Oncogenic Mutations, All Tumors, Tumor Type Summary",
              "new": "While crizotinib is FDA-approved for the treatment of patients with ROS1 fusion positive non-small cell lung cancer, its clinical utility in patients with [[variant]] is unknown.",
              "old": "While crizotinib is FDA-approved for the treatment of patients with ROS1-fusion positive non-small cell lung cancer, its clinical utility in patients with [[variant]] is unknown.",
              "operation": "update",
              "uuids": "df602908-e466-4f95-b006-c65382ca083a"
            }
          ],
          "timeStamp": 1566921204121
        },
        "-LsEsioVrNfvUe-B5lzh": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Fusions, Non-Small Cell Lung Cancer, Standard implications for sensitivity to therapy, 2371f7f5-6407-4a4b-b951-a0f786355455",
              "new": {
                "description": "Entrectinib is a potent, orally available, ATP-competitive tyrosine kinase inhibitor that is highly effective against NTRK1/2/3, ROS1 and ALK and is FDA-approved for patients with ROS1-fusion-positive non-small cell lung cancer (NSCLC). FDA-approval was based on the results of three multicenter, single-arm clinical trials (ALKA, STARTRK-1 and STARTRK-2) in which of 51 evaluable patients with ROS1-fusion-positive NSCLC who were treated with entrectinib, the overall response rate was 78% (95% CI = 65-89) and response duration was more than one year for 55% of patients (PMID: 28183697)(Abstract: Drilon et al. Abstract# CT060, AACR 2017. https://cancerres.aacrjournals.org/content/77/13_Supplement/CT060).",
                "description_review": {
                  "lastReviewed": "",
                  "updateTime": 1572224543743,
                  "updatedBy": "User"
                },
                "description_uuid": "7b74f800-c088-4859-82f6-236bc347bc7e",
                "indication": "",
                "indication_uuid": "0610e26b-6b65-44fa-972e-e2f2266d95f4",
                "level": "1",
                "level_review": {
                  "lastReviewed": "",
                  "updateTime": 1571963724018,
                  "updatedBy": "User"
                },
                "level_uuid": "8feb2deb-8282-4059-b60f-34751695f7c6",
                "name": "2371f7f5-6407-4a4b-b951-a0f786355455",
                "name_review": {
                  "added": true,
                  "updateTime": 1571963720925,
                  "updatedBy": "User"
                },
                "name_uuid": "3dbaf733-ca83-47d3-b8d6-f15162c4055f",
                "propagation": "2B",
                "propagationLiquid": "no",
                "propagationLiquid_review": {
                  "lastReviewed": "",
                  "updateTime": 1571963724010,
                  "updatedBy": "User"
                },
                "propagationLiquid_uuid": "28721efe-f7fe-4f34-9cf3-7d7a138313e9",
                "propagation_review": {
                  "lastReviewed": "",
                  "updateTime": 1571963724002,
                  "updatedBy": "User"
                },
                "propagation_uuid": "12541af9-b57f-448a-81c6-c79d64303294",
                "short": ""
              },
              "operation": "add",
              "uuids": "3dbaf733-ca83-47d3-b8d6-f15162c4055f"
            }
          ],
          "timeStamp": 1572224560259
        },
        "-LsEskuyv4aqe5eWwSpg": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Fusions, Non-Small Cell Lung Cancer, Tumor Type Summary",
              "new": "Crizotinib and entrectinib are FDA-approved for the treatment of patients with ROS1 fusion positive non-small cell lung cancer.",
              "old": "Crizotinib is FDA-approved for the treatment of patients with ROS1 fusion positive non-small cell lung cancer.",
              "operation": "update",
              "uuids": "3aa7655f-3fd3-41d8-a883-43bfccc6d2a2"
            }
          ],
          "timeStamp": 1572224568865
        },
        "-LsEspXalS7tkLFHt_Gq": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Fusions, Other Tumor Types, Tumor Type Summary",
              "new": "While crizotinib and entrectinib are FDA-approved for the treatment of patients with ROS1 fusion positive non-small cell lung cancer, their clinical utility in patients with ROS1 fusion positive [[tumor type]] is unknown.",
              "old": "While crizotinib is FDA-approved for the treatment of patients with ROS1 fusion positive non-small cell lung cancer, its clinical utility in patients with ROS1 fusion positive [[tumor type]] is unknown.",
              "operation": "update",
              "uuids": "25c05c7e-a64e-4eec-8206-4a198462879f"
            }
          ],
          "timeStamp": 1572224587785
        },
        "-LsEsvBWFHRiBunGKoGj": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "F2004V",
              "new": {
                "mutation_effect": {
                  "description": "The ROS1 F2004V mutation is located in the kinase domain of the protein. This mutation was found as a secondary mutation in a patient with lung adenocarcinoma who had progressive disease in the brain and bones after treatment with crizotinib, entrectinib and brigatinib but who had a dramatic response to treatment with lorlatinib (Abstract: Dimou et al. JCO PO, 2019. https://ascopubs.org/doi/full/10.1200/PO.19.00013). This mutation may confer resistance to entrectinib and brigatinib but remains sensitive to lorlatinib.",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1570066784758,
                    "updatedBy": "User"
                  },
                  "description_uuid": "5f288894-9be0-40e2-a467-43b6080ffbe4",
                  "effect": "Inconclusive",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1570066786795,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "c74bbb3d-42fc-42f1-b262-d02131bf4837",
                  "oncogenic": "Inconclusive",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1570066787661,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "21c81568-8f05-4de9-bed2-749a8b6bf283",
                  "short": ""
                },
                "mutation_effect_uuid": "f25a4f24-e31f-439a-8122-1fda28e3db41",
                "name": "F2004V",
                "name_review": {
                  "added": true,
                  "updateTime": 1570066579150,
                  "updatedBy": "User"
                },
                "name_uuid": "5aeb52cc-4bd0-43d9-9b4f-fd359bc6c6a6",
                "tumors_uuid": "8b1c5c6f-eb11-4ff2-bca4-2d24e4920463"
              },
              "operation": "add",
              "uuids": "21c81568-8f05-4de9-bed2-749a8b6bf283,c74bbb3d-42fc-42f1-b262-d02131bf4837"
            }
          ],
          "timeStamp": 1572224610948
        },
        "-LzeaBHWsEBVNnRn3cKW": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Fusions, Mutation Effect",
              "new": {
                "description": "Fusions of ROS1 arise from chromosomal translocations that fuse the N-terminal portion of a partner protein with the C-terminal kinase-domain-containing portion of ROS1. These fusion proteins are found in a variety of cancer types and result in constitutive activation of ROS1 kinase activity. Biological characterization of specific ROS1 fusion proteins demonstrates that they are activating as shown by enhanced proliferation and colony formation and that they are sensitive to treatment with the tyrosine kinase inhibitors crizotinib and entrectinib (PMID: 23719267, 22919003, 22215748, 28465216). Preliminary clinical data suggests that lorlatinib may also be efficacious in patients with ROS1 fusion-positive non-small cell lung cancer, including those with central nervous system disease (PMID: 31669155)."
              },
              "old": {
                "description": "Fusions of ROS1 arise from chromosomal translocations that fuse the N-terminal portion of a partner protein with the C-terminal kinase-domain-containing portion of ROS1. These fusion proteins are found in a variety of cancer types and result in constitutive activation of ROS1 kinase activity. Biological characterization of specific ROS1 fusion proteins demonstrates that they are activating as shown by enhanced proliferation and colony formation and that they are sensitive to treatment with the tyrosine kinase inhibitor crizotinib (PMID: 23719267, 22919003, 22215748, 28465216)."
              },
              "operation": "update",
              "uuids": "e8113bd5-9371-4afc-a563-3c8db56bb3d8"
            }
          ],
          "timeStamp": 1580188877985
        },
        "-LzeaE5inMTsaN300dJm": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Fusions, Non-Small Cell Lung Cancer, STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY, 2371f7f5-6407-4a4b-b951-a0f786355455",
              "new": {
                "description": "Entrectinib is a potent, orally available, ATP-competitive tyrosine kinase inhibitor that is highly effective against NTRK1/2/3, ROS1 and ALK and is FDA-approved for patients with ROS1-fusion-positive non-small cell lung cancer (NSCLC). FDA-approval was based on the results of three multicenter, single-arm clinical trials (ALKA, STARTRK-1 and STARTRK-2) in which of 51 evaluable patients with ROS1-fusion-positive NSCLC who were treated with entrectinib, the overall response rate was 78% (95% CI = 65-89) and response duration was more than one year for 55% of patients (PMID: 28183697)(Abstract: Drilon et al. Abstract# CT060, AACR 2017. https://cancerres.aacrjournals.org/content/77/13_Supplement/CT060)(Abstract: Braud et al. Abstract# 64P, ESMO 2019. https://academic.oup.com/annonc/article/30/Supplement_9/mdz420.003/5638397)."
              },
              "old": {
                "description": "Entrectinib is a potent, orally available, ATP-competitive tyrosine kinase inhibitor that is highly effective against NTRK1/2/3, ROS1 and ALK and is FDA-approved for patients with ROS1-fusion-positive non-small cell lung cancer (NSCLC). FDA-approval was based on the results of three multicenter, single-arm clinical trials (ALKA, STARTRK-1 and STARTRK-2) in which of 51 evaluable patients with ROS1-fusion-positive NSCLC who were treated with entrectinib, the overall response rate was 78% (95% CI = 65-89) and response duration was more than one year for 55% of patients (PMID: 28183697)(Abstract: Drilon et al. Abstract# CT060, AACR 2017. https://cancerres.aacrjournals.org/content/77/13_Supplement/CT060)."
              },
              "operation": "update",
              "uuids": "3dbaf733-ca83-47d3-b8d6-f15162c4055f"
            }
          ],
          "timeStamp": 1580188889518
        },
        "-M4ZYfpabXA47SENlaYm": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G2032R, Mutation Effect",
              "new": {
                "description": "The ROS1 G2032R mutation is located in the protein's kinase domain and is associated with acquired resistance to crizotinib in ROS1-rearranged non-small cell lung cancer (PMID: 25688157, 24047072, 24047073, 23724914). In vitro studies demonstrated that G2032R confers resistance by interfering with crizotinib binding (PMID: 25351743). This mutation corresponds to the G1202R ALK kinase domain mutant (PMID: 24047072, 27401242)."
              },
              "old": {
                "description": "The ROS1 G2032R mutation is located in the protein's kinase domain and is associated with acquired resistance to crizotinib in ROS1-rearranged non-small cell lung cancer (PMID: 25688157, 24047072, 24047073, 23724914). In vitro studies demonstrated that G2032R confers resistance by interfering with crizotinib binding (PMID: 25351743). This mutation corresponds to the G1202R ALK kinase domain mutant (PMID: 24047072 , 27401242)."
              },
              "operation": "update",
              "uuids": "aa803d57-5855-4e90-a480-c4362b3b482a"
            }
          ],
          "timeStamp": 1586530008445
        },
        "-MKDSe_bgvH-Dvdgy65J": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "CD74-ROS1 Fusion",
              "new": "CD74-ROS1 Fusion",
              "old": "CD74-ROS1 Fusion, ROS1-CD74 Fusion",
              "operation": "name change",
              "uuids": "0eab9106-eb6e-4556-8193-2cf9d40eda50"
            }
          ],
          "timeStamp": 1603339201058
        },
        "-MSaCHUfNPzSe0mLSH2T": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "F2004V, Mutation Effect",
              "new": {
                "description": "The ROS1 F2004V mutation is located in the kinase domain of the protein. This mutation was found as a secondary mutation in a patient with lung adenocarcinoma who had progressive disease in the brain and bones after treatment with crizotinib, entrectinib and brigatinib but who had a dramatic response to treatment with lorlatinib (Abstract: Dimou et al. JCO PO, 2019. https://ascopubs.org/doi/full/10.1200/PO.19.00013). This mutation may confer resistance to entrectinib and brigatinib but remains sensitive to lorlatinib. Structural studies based on homology to ALK predict that ROS1 F2004V would confer resistance to ceritinib (PMID: 27401242)."
              },
              "old": {
                "description": "The ROS1 F2004V mutation is located in the kinase domain of the protein. This mutation was found as a secondary mutation in a patient with lung adenocarcinoma who had progressive disease in the brain and bones after treatment with crizotinib, entrectinib and brigatinib but who had a dramatic response to treatment with lorlatinib (Abstract: Dimou et al. JCO PO, 2019. https://ascopubs.org/doi/full/10.1200/PO.19.00013). This mutation may confer resistance to entrectinib and brigatinib but remains sensitive to lorlatinib."
              },
              "operation": "update",
              "uuids": "c74bbb3d-42fc-42f1-b262-d02131bf4837"
            }
          ],
          "timeStamp": 1612327495931
        },
        "-MSaCQS0C72BQK5mNlgK": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "F2004C",
              "new": {
                "mutation_effect": {
                  "description": "The ROS1 F2004C mutation is located in the kinase domain of the protein. This mutation has been found in lung cancer (Abstract: Doebele et al. Abstract# LBA-28, ESMO 2019. https://www.sciencedirect.com/science/article/pii/S0923753419603777). Expression of this mutation in the context of a ROS1 fusion in Ba/F3 cells demonstrated decreased sensitivity to ROS1 inhibition (PMID: 26372962). Structural studies based on homology to ALK predict that ROS1 F2004C would confer resistance to ceritinib (PMID: 27401242). At least one patient with ROS1-fusion-positive non-small cell lung cancer acquired the ROS1 F2004C mutation upon disease progression on treatment with entrectinib (Abstract: Doebele et al. Abstract# LBA-28, ESMO 2019. https://www.sciencedirect.com/science/article/pii/S0923753419603777).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1612327506254,
                    "updatedBy": "User"
                  },
                  "description_uuid": "2eba78ed-6307-4690-b813-f6ab7e2bc61a",
                  "effect": "Inconclusive",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1610603842754,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "e558dfec-5cdb-431e-8f7a-9a3d30be0f41",
                  "oncogenic": "Inconclusive",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1610603843301,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "fbc05162-1285-449a-a3b7-54a791068d3f",
                  "short": ""
                },
                "mutation_effect_uuid": "1e8ea021-fc48-417c-aadb-997cfe4d7142",
                "name": "F2004C",
                "name_review": {
                  "added": true,
                  "updateTime": 1610601652016,
                  "updatedBy": "User"
                },
                "name_uuid": "fc7b0749-6563-49d1-b7d3-ecdd2982af57",
                "tumors_uuid": "f2720d24-0419-4120-97b1-378bca680662"
              },
              "operation": "add",
              "uuids": "fbc05162-1285-449a-a3b7-54a791068d3f,e558dfec-5cdb-431e-8f7a-9a3d30be0f41"
            }
          ],
          "timeStamp": 1612327532625
        },
        "-N0rAfeRkn9CLvOO6gbq": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Fusions, Non-Small Cell Lung Cancer, Standard implications for sensitivity to therapy, 5e9aa568-30cf-48ef-b9ce-18851af2f622",
              "new": {
                "description": "Ceritinib is a small molecule inhibitor of ALK that also binds to and inhibits ROS1. In a Phase II study of ceritinib in 32 patients with non-small cell lung cancer harboring ROS1 rearrangement, the overall response rate in 28 evaluable patients was 62% (95% CI, 45 - 77) with one patient having a complete response and nineteen patients having partial response (PMID: 28520527).",
                "description_review": {
                  "lastReviewed": "",
                  "updateTime": 1651260550766,
                  "updatedBy": "User"
                },
                "description_uuid": "7294f41b-8a00-41d6-9be3-0e00f0272c24",
                "indication": "",
                "indication_uuid": "13ca1f3d-2a8c-4c40-9a4b-ca57ed56124b",
                "level": "2",
                "level_review": {
                  "lastReviewed": "",
                  "updateTime": 1651259288336,
                  "updatedBy": "User"
                },
                "level_uuid": "2a149072-9cd4-4b01-a843-da49ff38be90",
                "name": "5e9aa568-30cf-48ef-b9ce-18851af2f622",
                "name_review": {
                  "added": true,
                  "updateTime": 1651259278588,
                  "updatedBy": "User"
                },
                "name_uuid": "a24c4391-adab-4b50-9df2-5d4253e243e6",
                "propagation": "3B",
                "propagationLiquid": "no",
                "propagationLiquid_review": {
                  "lastReviewed": "",
                  "updateTime": 1651259288312,
                  "updatedBy": "User"
                },
                "propagationLiquid_uuid": "21a1cd60-d896-471c-82bb-41c5f31252b8",
                "propagation_review": {
                  "lastReviewed": "",
                  "updateTime": 1651259289938,
                  "updatedBy": "User"
                },
                "propagation_uuid": "37871222-9157-4e0e-8bc4-60a13c41170f",
                "short": ""
              },
              "operation": "add",
              "uuids": "a24c4391-adab-4b50-9df2-5d4253e243e6"
            },
            {
              "lastEditBy": "User",
              "location": "Fusions, Non-Small Cell Lung Cancer, Standard implications for sensitivity to therapy, ed76aa01-059c-4b22-b391-94ec86320122",
              "new": {
                "description": "Lorlatinib is a small molecule inhibitor of ALK and ROS1. In a phase I/II trial of lorlatinib in patients with ROS1-fusion-positive non-small cell lung cancer, thirteen of 21 tyrosine kinase inhibitor naive patients had a response to lorlatinib for an overall response rate of 62% (95% CI 38 - 82), while fourteen of 40 crizotinib pre-treated patients had a response to lorlatinib with an overall response rate of 35% (95% CI 21 - 52)(PMID: 31669155).",
                "description_review": {
                  "lastReviewed": "",
                  "updateTime": 1651262140489,
                  "updatedBy": "User"
                },
                "description_uuid": "d1443dc8-bfad-4cbf-a57d-fb3af50e5d1e",
                "indication": "",
                "indication_uuid": "8c47cb3b-28ee-42e6-b6a4-46ee1d1e1487",
                "level": "2",
                "level_review": {
                  "lastReviewed": "",
                  "updateTime": 1651260561214,
                  "updatedBy": "User"
                },
                "level_uuid": "f51cc790-a448-4ae9-8a25-4cb65ac60134",
                "name": "ed76aa01-059c-4b22-b391-94ec86320122",
                "name_review": {
                  "added": true,
                  "updateTime": 1651259285158,
                  "updatedBy": "User"
                },
                "name_uuid": "88b15a8c-c63f-4b50-a0ae-b0c1e08180a9",
                "propagation": "3B",
                "propagationLiquid": "no",
                "propagationLiquid_review": {
                  "lastReviewed": "",
                  "updateTime": 1651260561187,
                  "updatedBy": "User"
                },
                "propagationLiquid_uuid": "af5a32b0-6ec1-4bc9-aea2-9fa92393baca",
                "propagation_review": {
                  "lastReviewed": "",
                  "updateTime": 1651260563097,
                  "updatedBy": "User"
                },
                "propagation_uuid": "63752e8a-4c9f-43b2-acb0-ac5f56ce5822",
                "short": ""
              },
              "operation": "add",
              "uuids": "88b15a8c-c63f-4b50-a0ae-b0c1e08180a9"
            }
          ],
          "timeStamp": 1651266992820
        },
        "-N3Q6l0KHUMZqfpG8_It": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Fusions, Non-Small Cell Lung Cancer, Investigational implications for sensitivity to therapy, d28edb2a-6f51-4dd0-b1ec-aca045f50f9f",
              "new": {
                "description": "(Abstract: Cho, B.C. et al. Abstract# MA11.07, J. Thoracic Oncol. 2021. https://www.jto.org/article/S1556-0864%2821%2900293-8/fulltext)",
                "description_review": {
                  "lastReviewed": "",
                  "updateTime": 1653666166903,
                  "updatedBy": "User"
                },
                "description_uuid": "436d1cb3-76c9-48b6-b5ea-1713c4c35d15",
                "indication": "",
                "indication_uuid": "d6be1365-fe17-409b-b25d-4a3a1403c9e5",
                "level": "3A",
                "level_review": {
                  "lastReviewed": "",
                  "updateTime": 1653665987331,
                  "updatedBy": "User"
                },
                "level_uuid": "79f6f99b-740c-4f5b-8a5b-87e4296744ec",
                "name": "d28edb2a-6f51-4dd0-b1ec-aca045f50f9f",
                "name_review": {
                  "added": true,
                  "updateTime": 1653665922725,
                  "updatedBy": "User"
                },
                "name_uuid": "f9b2722c-dbb9-4884-b18f-673b34e3304c",
                "propagation": "3B",
                "propagationLiquid": "no",
                "propagationLiquid_review": {
                  "lastReviewed": "",
                  "updateTime": 1653665987325,
                  "updatedBy": "User"
                },
                "propagationLiquid_uuid": "e47e2d13-5c48-41d3-bded-0e2ddabfe03a",
                "propagation_review": {
                  "lastReviewed": "",
                  "updateTime": 1653666176218,
                  "updatedBy": "User"
                },
                "propagation_uuid": "3038c225-2d6f-4600-84eb-bd82741c2d95",
                "short": ""
              },
              "operation": "add",
              "uuids": "f9b2722c-dbb9-4884-b18f-673b34e3304c"
            }
          ],
          "timeStamp": 1654017429718
        },
        "-N3Q8T22z9osWUdqIkf_": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Fusions, Non-Small Cell Lung Cancer, INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY, d28edb2a-6f51-4dd0-b1ec-aca045f50f9f",
              "new": {
                "description": "(Abstract: Cho et al. Abstract# MA11.07, IASLC 2021. https://www.jto.org/article/S1556-0864%2821%2900293-8/fulltext#relatedArticles)"
              },
              "old": {
                "description": "(Abstract: Cho, B.C. et al. Abstract# MA11.07, J. Thoracic Oncol. 2021. https://www.jto.org/article/S1556-0864%2821%2900293-8/fulltext)"
              },
              "operation": "update",
              "uuids": "f9b2722c-dbb9-4884-b18f-673b34e3304c"
            }
          ],
          "timeStamp": 1654017876292
        },
        "-NG3NLpkZ6Kh1q76yc-s": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Fusions, Non-Small Cell Lung Cancer, STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY, 2371f7f5-6407-4a4b-b951-a0f786355455",
              "operation": "update",
              "uuids": "3dbaf733-ca83-47d3-b8d6-f15162c4055f"
            }
          ],
          "timeStamp": 1667594546548
        },
        "-NG3NNDA-kV-7Vf22sbb": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Fusions, Non-Small Cell Lung Cancer, STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY, ed76aa01-059c-4b22-b391-94ec86320122",
              "operation": "update",
              "uuids": "88b15a8c-c63f-4b50-a0ae-b0c1e08180a9"
            }
          ],
          "timeStamp": 1667594552207
        },
        "-NG3NOa948E-fxqn3gIS": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Fusions, Non-Small Cell Lung Cancer, STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY, 5e9aa568-30cf-48ef-b9ce-18851af2f622",
              "operation": "update",
              "uuids": "a24c4391-adab-4b50-9df2-5d4253e243e6"
            }
          ],
          "timeStamp": 1667594557838
        },
        "-NHRIfnxV-PXbEIQ78uk": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Fusions, Non-Small Cell Lung Cancer, INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY, d28edb2a-6f51-4dd0-b1ec-aca045f50f9f",
              "new": {
                "description": "Repotrectinib is an orally bioavailable tyrosine kinase inhibitor. In the Phase I/II TRIDENT-1 study of repotrectinib in 171 patients with ROS1 fusion-positive non-small lung cancer, an overall objective response rate of 79% was found in patients who had not previously received a ROS1 tyrosine kinase inhibitor treatment. For patients previously treated with a ROS1 tyrosine kinase inhibitor, overall response rates were 38% if the patient did not previously receive chemotherapy, 42% if the patient did previously receive chemotherapy and 28% if the patient previously received two different ROS1 tyrosine kinase inhibitors (Abstract: Cho et al. Abstract# 2LBA, EJC 2022. https://www.ejcancer.com/article/S0959-8049(22)00812-7/fulltext)."
              },
              "old": {
                "description": "(Abstract: Cho et al. Abstract# MA11.07, IASLC 2021. https://www.jto.org/article/S1556-0864%2821%2900293-8/fulltext#relatedArticles)"
              },
              "operation": "update",
              "uuids": "f9b2722c-dbb9-4884-b18f-673b34e3304c"
            }
          ],
          "timeStamp": 1669069716585
        },
        "-NIihfZEQxU6nnwoHqOc": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G2032R, Mutation Effect",
              "new": {
                "description": "The ROS1 G2032R mutation is located in the protein's kinase domain and is associated with acquired resistance to crizotinib in ROS1-rearranged non-small cell lung cancer (PMID: 25688157, 24047073, 23724914). In vitro studies demonstrated that G2032R confers resistance by interfering with crizotinib binding (PMID: 25351743). This mutation corresponds to the G1202R ALK kinase domain mutant (PMID: 23724914, 27401242)."
              },
              "old": {
                "description": "The ROS1 G2032R mutation is located in the protein's kinase domain and is associated with acquired resistance to crizotinib in ROS1-rearranged non-small cell lung cancer (PMID: 25688157, 24047072, 24047073, 23724914). In vitro studies demonstrated that G2032R confers resistance by interfering with crizotinib binding (PMID: 25351743). This mutation corresponds to the G1202R ALK kinase domain mutant (PMID: 24047072, 27401242)."
              },
              "operation": "update",
              "uuids": "aa803d57-5855-4e90-a480-c4362b3b482a"
            }
          ],
          "timeStamp": 1670452263097
        },
        "-NIihr8n2tTMQcQGY77Q": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "S1986F, Mutation Effect",
              "new": {
                "description": "The ROS1 S1986F mutation lies in the tyrosine kinase domain of the ROS1 protein. It has been detected in a patient with ROS1-fusion-positive lung cancer in concert with the S1986Y mutation. The two alterations at the same residue were associated with resistance to crizotinib but subsequent sensitivity to lorlatinib. In a murine B-cell line expression of individual S1986F- and S1986Y-mutated ROS1-fusion constructs were resistant to crizotinib and ceritinib but not lorlatinib, as assessed by cell viability and pathway activation assays (PMID: 27401242)."
              },
              "old": {
                "description": "The ROS1 S1986F mutation lies in tyrosine kinase domain the of the ROS1 protein. It has been detected in a patient with ROS1-fusion positive lung cancer in concert with mutation S1986F. The two alterations at the same residue were associated with resistance to crizotinib but subsequent sensitivity to lorlatinib. In a murine B-cell line expression of individual S1986F- and S1986Y-mutated ROS1-fusion constructs were resistant to crizotinib and ceritinib but not lorlatinib, as assessed by cell viability and pathway activation assays (PMID: 27401242)."
              },
              "operation": "update",
              "uuids": "19acaaee-d519-4577-9b10-2ea228c116b3"
            }
          ],
          "timeStamp": 1670452310557
        },
        "-NJH38W2GSBeObZXMc_j": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "L1951R, Mutation Effect",
              "new": {
                "oncogenic": "Resistance"
              },
              "old": {
                "oncogenic": "Yes"
              },
              "operation": "update",
              "uuids": "a98d8d63-c524-4fec-8aba-6e79097123f5"
            }
          ],
          "timeStamp": 1671045355576
        },
        "-NJqul4ykGx1LOBmLnTx": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Fusions, Non-Small Cell Lung Cancer, STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY, f05d12ab-6204-4a1c-803f-f3a7f6e30af2",
              "operation": "update",
              "uuids": "c89514ef-b096-442a-828d-6ed357e12d57"
            }
          ],
          "timeStamp": 1671663653195
        },
        "-NP3d0FIGz_8nE4t9m8d": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Fusions, Non-Small Cell Lung Cancer, STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY, f05d12ab-6204-4a1c-803f-f3a7f6e30af2",
              "new": {
                "description": "Crizotinib, an inhibitor of ALK, ROS1 and MET tyrosine kinases, is FDA-approved for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive. FDA approval is based on the results of a Phase I trial of crizotinib in 53 patients with advanced NSCLC positive for ROS1 rearrangements in which the objective response rate was 72% (95% CI= 58-84), including six complete responses, 32 partial responses (66%) and a median progression-free survival (PFS) of 19.3 months (95% CI= 15.2-39.1)(PMID: 25264305, 30980071). In a Phase II trial of crizotinib in 127 East Asian patients with ROS1-positive NSCLC, the overall response rate was 71.1% (95% CI= 63.0-79.3), including seventeen of 127 patients with complete responses (13.4%), 74 of 127 patients with partial responses (58.3%), and a median PFS of 15.9 months (95% CI= 12.9-24.0) (PMID: 29596029)."
              },
              "old": {
                "description": "Crizotinib, an inhibitor of ALK, ROS1 and MET tyrosine kinases, is FDA approved for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive. FDA-approval is based on the results of a Phase I trial of crizotinib in 53 patients with advanced NSCLC positive for ROS1 rearrangements in which the objective response rate was 72% (95% CI 58-84), including six complete responses, 32 partial responses (66%) and a median progression-free survival (PFS) of 19.3 months (95% CI 15.2-39.1)(PMID: 25264305, 30980071). In a Phase II trial of crizotinib in 127 East Asian patients with ROS1-positive NSCLC, the overall response rate was 71.1% (95% CI 63.0-79.3), including seventeen of 127 patients with complete responses (13.4%), 74 of 127 patients with partial responses (58.3%), and a median PFS of 15.9 months (95% CI 12.9-24.0) (PMID: 29596029)."
              },
              "operation": "update",
              "uuids": "c89514ef-b096-442a-828d-6ed357e12d57"
            }
          ],
          "timeStamp": 1677262590800
        },
        "-NP3d2q_KmpzmwxLmxgf": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Fusions, Non-Small Cell Lung Cancer, STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY, 2371f7f5-6407-4a4b-b951-a0f786355455",
              "new": {
                "description": "Entrectinib is a potent, orally available, ATP-competitive tyrosine kinase inhibitor that is highly effective against NTRK1/2/3, ROS1 and ALK and is FDA-approved for patients with ROS1-fusion-positive non-small cell lung cancer (NSCLC). FDA approval was based on the results of three multicenter, single-arm clinical trials (ALKA, STARTRK-1 and STARTRK-2) in which of 51 evaluable patients with ROS1-fusion-positive NSCLC who were treated with entrectinib, the overall response rate was 78% (95% CI = 65-89) and response duration was more than one year for 55% of patients (PMID: 28183697)(Abstract: Drilon et al. Abstract# CT060, AACR 2017. https://cancerres.aacrjournals.org/content/77/13_Supplement/CT060)(Abstract: Braud et al. Abstract# 64P, ESMO 2019. https://academic.oup.com/annonc/article/30/Supplement_9/mdz420.003/5638397)."
              },
              "old": {
                "description": "Entrectinib is a potent, orally available, ATP-competitive tyrosine kinase inhibitor that is highly effective against NTRK1/2/3, ROS1 and ALK and is FDA-approved for patients with ROS1-fusion-positive non-small cell lung cancer (NSCLC). FDA-approval was based on the results of three multicenter, single-arm clinical trials (ALKA, STARTRK-1 and STARTRK-2) in which of 51 evaluable patients with ROS1-fusion-positive NSCLC who were treated with entrectinib, the overall response rate was 78% (95% CI = 65-89) and response duration was more than one year for 55% of patients (PMID: 28183697)(Abstract: Drilon et al. Abstract# CT060, AACR 2017. https://cancerres.aacrjournals.org/content/77/13_Supplement/CT060)(Abstract: Braud et al. Abstract# 64P, ESMO 2019. https://academic.oup.com/annonc/article/30/Supplement_9/mdz420.003/5638397)."
              },
              "operation": "update",
              "uuids": "3dbaf733-ca83-47d3-b8d6-f15162c4055f"
            }
          ],
          "timeStamp": 1677262601442
        },
        "-NP3d6YwnMUKRPzMARDH": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Fusions, Non-Small Cell Lung Cancer, STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY, 5e9aa568-30cf-48ef-b9ce-18851af2f622",
              "new": {
                "description": "Ceritinib is a small molecule inhibitor of ALK that also binds to and inhibits ROS1 and is NCCN-listed as a category 2A treatment recommendation for patients with non-small cell lung cancer (NSCLC) who have ROS1 rearrangements. In a Phase II study of ceritinib in 32 patients with NSCLC harboring ROS1 rearrangement, the overall response rate in 28 evaluable patients was 62% (95% CI= 45 - 77) with one patient having a complete response and nineteen patients having a partial response (PMID: 28520527)."
              },
              "old": {
                "description": "Ceritinib is a small molecule inhibitor of ALK that also binds to and inhibits ROS1. In a Phase II study of ceritinib in 32 patients with non-small cell lung cancer harboring ROS1 rearrangement, the overall response rate in 28 evaluable patients was 62% (95% CI, 45 - 77) with one patient having a complete response and nineteen patients having partial response (PMID: 28520527)."
              },
              "operation": "update",
              "uuids": "a24c4391-adab-4b50-9df2-5d4253e243e6"
            }
          ],
          "timeStamp": 1677262616633
        },
        "-NP3d9XESVEKXKVGg7fZ": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Fusions, Non-Small Cell Lung Cancer, STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY, ed76aa01-059c-4b22-b391-94ec86320122",
              "new": {
                "description": "Lorlatinib is a third-generation small molecule inhibitor of ALK and ROS1 that is NCCN-listed as a category 2A recommended subsequent therapy option for patients with ROS1-rearrangement-positive non-small cell lung cancer (NSCLC) who progressed on entrectinib, crizotinib or ceritinib. In a phase I/II trial of lorlatinib in patients with ROS1-fusion-positive NSCLC, thirteen of 21 tyrosine kinase inhibitor-naive patients had a response to lorlatinib for an overall response rate of 62% (95% CI= 38-82), while fourteen of 40 crizotinib pre-treated patients had a response to lorlatinib with an overall response rate of 35% (95% CI= 21-52)(PMID: 31669155)."
              },
              "old": {
                "description": "Lorlatinib is a small molecule inhibitor of ALK and ROS1. In a phase I/II trial of lorlatinib in patients with ROS1-fusion-positive non-small cell lung cancer, thirteen of 21 tyrosine kinase inhibitor naive patients had a response to lorlatinib for an overall response rate of 62% (95% CI 38 - 82), while fourteen of 40 crizotinib pre-treated patients had a response to lorlatinib with an overall response rate of 35% (95% CI 21 - 52)(PMID: 31669155)."
              },
              "operation": "update",
              "uuids": "88b15a8c-c63f-4b50-a0ae-b0c1e08180a9"
            }
          ],
          "timeStamp": 1677262628812
        },
        "-NP3dAz2UkeC4MzgwbT5": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Fusions, Non-Small Cell Lung Cancer, INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY, d28edb2a-6f51-4dd0-b1ec-aca045f50f9f",
              "new": {
                "description": "Repotrectinib is an orally bioavailable tyrosine kinase inhibitor that targets ROS1. In the Phase I/II TRIDENT-1 study of repotrectinib in 171 patients with ROS1-fusion-positive non-small lung cancer (NSCLC), an overall objective response rate of 79% was found in patients who had not previously received a ROS1 tyrosine kinase inhibitor treatment. For patients previously treated with a ROS1 tyrosine kinase inhibitor, overall response rates were 38% if the patient did not previously receive chemotherapy, 42% if the patient did previously receive chemotherapy and 28% if the patient previously received two different ROS1 tyrosine kinase inhibitors (Abstract: Cho et al. Abstract# 2LBA, EJC 2022. https://www.ejcancer.com/article/S0959-8049(22)00812-7/fulltext)."
              },
              "old": {
                "description": "Repotrectinib is an orally bioavailable tyrosine kinase inhibitor. In the Phase I/II TRIDENT-1 study of repotrectinib in 171 patients with ROS1 fusion-positive non-small lung cancer, an overall objective response rate of 79% was found in patients who had not previously received a ROS1 tyrosine kinase inhibitor treatment. For patients previously treated with a ROS1 tyrosine kinase inhibitor, overall response rates were 38% if the patient did not previously receive chemotherapy, 42% if the patient did previously receive chemotherapy and 28% if the patient previously received two different ROS1 tyrosine kinase inhibitors (Abstract: Cho et al. Abstract# 2LBA, EJC 2022. https://www.ejcancer.com/article/S0959-8049(22)00812-7/fulltext)."
              },
              "operation": "update",
              "uuids": "f9b2722c-dbb9-4884-b18f-673b34e3304c"
            }
          ],
          "timeStamp": 1677262634752
        },
        "-NP3dM8_28LvMUGrdcgD": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "FIG-ROS1 Fusion, Mutation Effect",
              "new": {
                "description": "The FIG-ROS1 fusion is characterized by the fusion of the 3' region of ROS1 (exon 35) to the 5' region of FIG (exon 7); this fusion results from an intra-chromosomal deletion in chromosome 6 (PMID: 12661006). The FIG-ROS1 fusion results in a constitutively active ROS1 kinase (PMID: 2827175, 12661006).",
                "effect": "Likely Gain-of-function",
                "oncogenic": "Likely"
              },
              "old": {
                "description": "FIG-ROS1 is characterized by the fusion of the 3' region of ROS1 (exon 35) to the 5' region of FIG (exon 7); this fusion results from an intra-chromosomal deletion in chromosome 6 (PMID: 12661006). The FIG-ROS1 fusion results in a constitutively active ROS1 kinase (PMID: 2827175, 12661006).",
                "effect": "Gain-of-function",
                "oncogenic": "Yes"
              },
              "operation": "update",
              "uuids": "9d636c58-c0f6-40f4-9b100-d61369f2d563,9151ba5c-e692-49a5-b13f-b7ee0875eb8a"
            }
          ],
          "timeStamp": 1677262680482
        },
        "-NP3eBM4t-ZqCqOv4Duo": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "LIMA1-ROS1 Fusion, Mutation Effect",
              "new": {
                "description": "LIMA1-ROS1 is a rearrangement mutation that results in the fusion of LIMA1 (exon 10) to ROS1 (exon 36). This novel fusion has been identified in a tumor sample from a patient with non-small cell lung cancer (NSCLC) treated with crizotinib (PMID: 25264305)."
              },
              "old": {
                "description": "LIMA1-ROS1 is a rearrangement mutation that results in the fusion of LIMA1 (exon 10) to ROS1 (exon 36). This novel fusion has recently been identified in a tumor sample from a patient with non small cell lung cancer (NSCLC) treated with crizotinib (PMID: 25264305)."
              },
              "operation": "update",
              "uuids": "2526d944-55a3-407d-ae39-80db14f9ce98"
            }
          ],
          "timeStamp": 1677262898425
        },
        "-NP3eDptZxYDwELalZCr": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "MSN-ROS1 Fusion, Mutation Effect",
              "new": {
                "description": "MSN-ROS1 is a rearrangement mutation that results in the fusion of MSN (exon 9) to ROS1 (exon 34). This novel fusion has been identified in a tumor sample from a patient with non-small cell lung cancer (NSCLC) treated with crizotinib (PMID: 25264305)."
              },
              "old": {
                "description": "MSN-ROS1 is a rearrangement mutation that results in the fusion of MSN (exon 9) to ROS1 (exon 34). This novel fusion has recently been identified in a tumor sample from a patient with non small cell lung cancer (NSCLC) treated with crizotinib (PMID: 25264305)."
              },
              "operation": "update",
              "uuids": "363f218b-1836-413c-bdc9-58212a6060f0"
            }
          ],
          "timeStamp": 1677262908589
        },
        "-NP3eIl7Ih3uD11nIDJX": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "GOPC-ROS1 Fusion, Mutation Effect",
              "new": {
                "description": "The GOPC-ROS1 fusion protein combines the N terminus of GOPC until exon 7 with the C-terminus of ROS1 starting at exon 35 and is found in CNS tumors (PMID: 30171048). This is the most frequent ROS1 fusion found in glioblastomas (GBMs). Expression of this fusion protein in BaF3 and immortalized human astrocyte cells demonstrated that it is activating as shown by IL3 independent growth and increased colony formation compared to ectopic expression of wildtype ROS1 (PMID: 30171048). Expression of this fusion in BaF3 cells also demonstrated that it is sensitive to multiple TKIs including crizotinib, foretinib, cabozantinib, ceritinib, brigatinib, AZD3463, lorlatinib, and entrectinib as measured by proliferation, pathway activation and colony formation with lorlatinib having the highest potency (PMID: 30171048)."
              },
              "old": {
                "description": "The GOPC-ROS1 fusion protein combines the N terminus of GOPC until exon 7 with the C-terminus of ROS1 starting at exon 35 and is found in CNS tumors (PMID: 30171048). This is the most frequent ROS1 fusion found in GBMs. Expression of this fusion protein in BaF3 and immortalized human astrocyte cells demonstrated that it is activating as shown by IL3 independent growth and increased colony formation compared to ectopic expression of wildtype ROS1 (PMID: 30171048). Expression of this fusion in BaF3 cells also demonstrated that it is sensitive to multiple TKIs including crizotinib, foretinib, cabozantinib, ceritinib, brigatinib, AZD3463, lorlatinib, and entrectinib as measured by proliferation, pathway activation and colony formation with lorlatinib having the highest potency (PMID: 30171048)."
              },
              "operation": "update",
              "uuids": "a95bd9a0-ce83-4a4b-8782-c9cdff1175b1"
            }
          ],
          "timeStamp": 1677262928764
        },
        "-NgtdJ6vacp-9FdUH31Y": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G2032R, Mutation Effect",
              "new": {
                "description": "The ROS1 G2032R mutation is located in the protein's kinase domain and is associated with acquired resistance to crizotinib in ROS1-rearranged non-small cell lung cancer (PMID: 25688157, 24047073, 23724914). In vitro studies with A549 cells expressing ROS1 G2032R demonstrate that the mutation is activating as measured by increased cellular invasion and migration, increased expression of MMP-9 and TWIST1 and induced epithelial-mesenchymal transition compared to wildtype (PMID: 29477381). Preclinical studies and structural analysis of ROS1 G2023R demonstrate that the mutation confers resistance by interfering with crizotinib binding (PMID: 25351743, 23724914, 25033171). This mutation corresponds to the G1202R ALK kinase domain mutant (PMID: 23724914, 27401242). Preclinical studies of ROS1 G2023R demonstrate sensitivity to combination treatment of TWIST1 siRNA and crizotinib as measured by reduced cellular viability and invasion (PMID: 29477381)."
              },
              "old": {
                "description": "The ROS1 G2032R mutation is located in the protein's kinase domain and is associated with acquired resistance to crizotinib in ROS1-rearranged non-small cell lung cancer (PMID: 25688157, 24047073, 23724914). In vitro studies demonstrated that G2032R confers resistance by interfering with crizotinib binding (PMID: 25351743). This mutation corresponds to the G1202R ALK kinase domain mutant (PMID: 23724914, 27401242)."
              },
              "operation": "update",
              "uuids": "aa803d57-5855-4e90-a480-c4362b3b482a"
            }
          ],
          "timeStamp": 1697479213569
        },
        "-NkWhwoTAgVYASgV8Eqx": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Fusions, Non-Small Cell Lung Cancer, Tumor Type Summary",
              "new": "The tyrosine kinase inhibitors crizotinib, entrectinib and repotrectinib are FDA-approved for the treatment of patients with ROS1 fusion positive non-small cell lung cancer.",
              "old": "Crizotinib and entrectinib are FDA-approved for the treatment of patients with ROS1 fusion positive non-small cell lung cancer.",
              "operation": "update",
              "uuids": "3aa7655f-3fd3-41d8-a883-43bfccc6d2a2"
            }
          ],
          "timeStamp": 1701372742932
        },
        "-NkWhy36q3AERWeDHgsu": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Fusions, Non-Small Cell Lung Cancer, Standard implications for sensitivity to therapy, d28edb2a-6f51-4dd0-b1ec-aca045f50f9f",
              "new": {
                "description": "Repotrectinib, an orally administered next-generation ROS1/TRK tyrosine kinase inhibitor (TKI), is FDA-approved for the treatment of patients with ROS1 fusion positive non-small cell lung cancer (NSCLC). FDA-approval is based on the results of the Phase I/II TRIDENT-1 trial of repotrectinib in patients with ROS1 fusion positive NSCLC that are ROS1-inhibitor-naive or pre-treated. ROS1-inhibitor-naive patients (n=71) demonstrated an objective response rate of 79% (95% CI=68%-88%), with a 6% complete response rate and a 73% partial response rate, and a median duration response of 34.1 months (95% CI=25.6-NE) whereas ROS1-inhibitor pre-treated patients (n=56) demonstrated an objective response rate of 38% (95% CI=25%-52%), with a 5% complete response rate and a 32% partial response rate, and a median duration response of 14.8 months (95% CI=7.6-NE) (Abstract: Cho et al. Abstract# OA03.06, J. of Thoracic Oncol. Nov. 2023. https://www.jto.org/article/S1556-0864%2823%2900837-7/fulltext).",
                "description_review": {
                  "lastReviewed": "",
                  "updateTime": 1701200987459,
                  "updatedBy": "User"
                },
                "description_uuid": "24aa88e2-e5ef-4cef-a902-af6f80746351",
                "fdaLevel": "Fda2",
                "fdaLevel_review": {
                  "lastReviewed": "",
                  "updateTime": 1701197989766,
                  "updatedBy": "User"
                },
                "fdaLevel_uuid": "4d4df5b5-d9d2-43fd-b304-85d3b83d5117",
                "indication": "",
                "indication_uuid": "5a5d167e-36ff-410a-8ba7-f235699ecf15",
                "level": "1",
                "level_review": {
                  "lastReviewed": "",
                  "updateTime": 1701197989773,
                  "updatedBy": "User"
                },
                "level_uuid": "c6291b47-276a-4e1a-9d91-b08d49d87ce1",
                "name": "d28edb2a-6f51-4dd0-b1ec-aca045f50f9f",
                "name_review": {
                  "added": true,
                  "updateTime": 1701197982383,
                  "updatedBy": "User"
                },
                "name_uuid": "8c2ac63c-bdc2-471f-8beb-89b57b36cf16",
                "propagation": "3B",
                "propagationLiquid": "no",
                "propagationLiquid_review": {
                  "lastReviewed": "",
                  "updateTime": 1701197989760,
                  "updatedBy": "User"
                },
                "propagationLiquid_uuid": "8504ef8e-a951-4e32-8a12-8132b9188ae9",
                "propagation_review": {
                  "lastReviewed": "",
                  "updateTime": 1701197992212,
                  "updatedBy": "User"
                },
                "propagation_uuid": "662a5c06-19ba-4f9d-b10d-8f55b3299402",
                "short": ""
              },
              "operation": "add",
              "uuids": "8c2ac63c-bdc2-471f-8beb-89b57b36cf16"
            }
          ],
          "timeStamp": 1701372748029
        },
        "-NkWi-c0xar3azWcV9tX": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Fusions, Other Tumor Types, Tumor Type Summary",
              "new": "While the tyrosine kinase inhibitors crizotinib, entrectinib and repotrectinib are FDA-approved for the treatment of patients with ROS1 fusion positive non-small cell lung cancer, their clinical utility in patients with ROS1 fusion positive [[tumor type]] is unknown.",
              "old": "While crizotinib and entrectinib are FDA-approved for the treatment of patients with ROS1 fusion positive non-small cell lung cancer, their clinical utility in patients with ROS1 fusion positive [[tumor type]] is unknown.",
              "operation": "update",
              "uuids": "25c05c7e-a64e-4eec-8206-4a198462879f"
            }
          ],
          "timeStamp": 1701372758519
        },
        "-Nkb7CAD0dwHMlaRXxS-": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Fusions, Non-Small Cell Lung Cancer, STANDARD_THERAPEUTIC_IMPLICATIONS_FOR_DRUG_SENSITIVITY, d28edb2a-6f51-4dd0-b1ec-aca045f50f9f",
              "new": {
                "description": "Repotrectinib, an orally administered next-generation ROS1/TRK tyrosine kinase inhibitor (TKI), is FDA-approved for the treatment of patients with ROS1 fusion positive non-small cell lung cancer (NSCLC). FDA-approval is based on the results of the Phase I/II TRIDENT-1 trial of repotrectinib in patients with ROS1 fusion positive NSCLC that are ROS1-inhibitor-naive or pre-treated. ROS1-inhibitor-naive patients (n=71) demonstrated an objective response rate of 79% (95% CI=68%-88%), with a 6% complete response rate and a 73% partial response rate, and a median duration response of 34.1 months (95% CI=25.6-NE) whereas ROS1-inhibitor pre-treated patients (n=56) demonstrated an objective response rate of 38% (95% CI=25%-52%), with a 5% complete response rate and a 32% partial response rate, and a median duration response of 14.8 months (95% CI=7.6-NE) (Abstract: Cho et al. Abstract# OA03.06, J. of Thoracic Oncol. Nov. 2023. https://www.jto.org/article/S1556-0864%2823%2900837-7/fulltext)."
              },
              "old": {
                "description": "Repotrectinib, an orally administered next-generation ROS1/TRK tyrosine kinase inhibitor (TKI), is FDA-approved for the treatment of patients with ROS1 fusion positive non-small cell lung cancer (NSCLC). FDA-approval is based on the results of the Phase I/II TRIDENT-1 trial of repotrectinib in patients with ROS1 fusion positive NSCLC that are ROS1-inhibitor-naive or pre-treated. ROS1-inhibitor-naive patients (n=71) demonstrated an objective response rate of 79% (95% CI=68%-88%), with a 6% complete response rate and a 73% partial response rate, and a median duration response of 34.1 months (95% CI=25.6-NE) whereas ROS1-inhibitor pre-treated patients (n=56) demonstrated an objective response rate of 38% (95% CI=25%-52%), with a 5% complete response rate and a 32% partial response rate, and a median duration response of 14.8 months (95% CI=7.6-NE) (Abstract: Cho et al. Abstract# OA03.06, J. of Thoracic Oncol. Nov. 2023. https://www.jto.org/article/S1556-0864%2823%2900837-7/fulltext)."
              },
              "operation": "update",
              "uuids": "8c2ac63c-bdc2-471f-8beb-89b57b36cf16"
            }
          ],
          "timeStamp": 1701463511804
        },
        "-Nkb7DlUwGNJs-hlU5SR": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Fusions, Non-Small Cell Lung Cancer, Investigational implications for sensitivity to therapy, d28edb2a-6f51-4dd0-b1ec-aca045f50f9f",
              "old": {
                "description": "Repotrectinib is an orally bioavailable tyrosine kinase inhibitor that targets ROS1. In the Phase I/II TRIDENT-1 study of repotrectinib in 171 patients with ROS1-fusion-positive non-small lung cancer (NSCLC), an overall objective response rate of 79% was found in patients who had not previously received a ROS1 tyrosine kinase inhibitor treatment. For patients previously treated with a ROS1 tyrosine kinase inhibitor, overall response rates were 38% if the patient did not previously receive chemotherapy, 42% if the patient did previously receive chemotherapy and 28% if the patient previously received two different ROS1 tyrosine kinase inhibitors (Abstract: Cho et al. Abstract# 2LBA, EJC 2022. https://www.ejcancer.com/article/S0959-8049(22)00812-7/fulltext).",
                "description_review": {
                  "updateTime": 1677170101145,
                  "updatedBy": "User"
                },
                "description_uuid": "436d1cb3-76c9-48b6-b5ea-1713c4c35d15",
                "fdaLevel": "Fda3",
                "fdaLevel_review": {
                  "updateTime": 1668791453597,
                  "updatedBy": "User"
                },
                "fdaLevel_uuid": "b23f7253-0a5f-4745-ad85-aa1dd28528bd",
                "indication": "",
                "indication_uuid": "d6be1365-fe17-409b-b25d-4a3a1403c9e5",
                "level": "3A",
                "level_review": {
                  "updateTime": 1653665987331,
                  "updatedBy": "User"
                },
                "level_uuid": "79f6f99b-740c-4f5b-8a5b-87e4296744ec",
                "name": "d28edb2a-6f51-4dd0-b1ec-aca045f50f9f",
                "name_review": {
                  "removed": true,
                  "updateTime": 1701452132958,
                  "updatedBy": "User"
                },
                "name_uuid": "f9b2722c-dbb9-4884-b18f-673b34e3304c",
                "propagation": "3B",
                "propagationLiquid": "no",
                "propagationLiquid_review": {
                  "updateTime": 1653665987325,
                  "updatedBy": "User"
                },
                "propagationLiquid_uuid": "e47e2d13-5c48-41d3-bded-0e2ddabfe03a",
                "propagation_review": {
                  "updateTime": 1653666176218,
                  "updatedBy": "User"
                },
                "propagation_uuid": "3038c225-2d6f-4600-84eb-bd82741c2d95",
                "short": ""
              },
              "operation": "delete"
            }
          ],
          "timeStamp": 1701463518349
        },
        "-NlTsf-K0FwbhFLq_F7l": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "GOPC-ROS1 Fusion, Mutation Effect",
              "new": {
                "description": "The GOPC-ROS1 fusion protein combines the N terminus of GOPC until exon 7 with the C-terminus of ROS1 starting at exon 35 and is found in CNS tumors (PMID: 30171048). This is the most frequent ROS1 fusion found in glioblastomas (GBMs). Expression of this fusion protein in BaF3 and immortalized human astrocyte cells demonstrated that it is activating as shown by IL3 independent growth and increased colony formation compared to ectopic expression of wildtype ROS1 (PMID: 30171048). Expression of this fusion in BaF3 cells also demonstrated that it is sensitive to multiple TKIs including crizotinib, foretinib, cabozantinib, ceritinib, brigatinib, AZD3463, lorlatinib, and entrectinib as measured by proliferation, pathway activation and colony formation with lorlatinib having the highest potency (PMID: 30171048). In a case report, a patient with ER-positive HER2-negative breast cancer harboring GOPC-ROS1 demonstrated an exceptionally response to crizotinib therapy and a subsequent modest response to cabozantinib after development of crizotinib resistance (PMID: 37487149)."
              },
              "old": {
                "description": "The GOPC-ROS1 fusion protein combines the N terminus of GOPC until exon 7 with the C-terminus of ROS1 starting at exon 35 and is found in CNS tumors (PMID: 30171048). This is the most frequent ROS1 fusion found in glioblastomas (GBMs). Expression of this fusion protein in BaF3 and immortalized human astrocyte cells demonstrated that it is activating as shown by IL3 independent growth and increased colony formation compared to ectopic expression of wildtype ROS1 (PMID: 30171048). Expression of this fusion in BaF3 cells also demonstrated that it is sensitive to multiple TKIs including crizotinib, foretinib, cabozantinib, ceritinib, brigatinib, AZD3463, lorlatinib, and entrectinib as measured by proliferation, pathway activation and colony formation with lorlatinib having the highest potency (PMID: 30171048)."
              },
              "operation": "update",
              "uuids": "a95bd9a0-ce83-4a4b-8782-c9cdff1175b1"
            }
          ],
          "timeStamp": 1702398964387
        }
      }
    },
    "TP53": {
      "api": {
        "-LLZVvCrAUcKWEAMamkH": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Internal tandem duplication",
              "operation": "name change",
              "uuids": "83691dc9-a434-4e2e-9996-969912f142a7"
            }
          ],
          "timeStamp": 1533664255083
        },
        "-LTcHKlq9xZouOTcBD79": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "P322R",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 P322R mutation is located in the oligomerization domain of the protein (PMID: 16007150). Oligomerization studies of the mutation showed that it was able to oligomerize and transactivate downstream targets comparable to wildtype TP53 (PMID: 16007150).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1544636703617,
                    "updatedBy": "User"
                  },
                  "description_uuid": "7daac7a9-d6d5-4473-9bd1-d83870b34cf4",
                  "effect": "Likely Neutral",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1544636505315,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "682b6f29-3299-48fb-9d56-4449fb6aab66",
                  "oncogenic": "Likely Neutral",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1544636504329,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "dd554ea2-478a-4ff5-c094-c2c74fa2032a",
                  "short": ""
                },
                "mutation_effect_uuid": "6ee1a0e8-d01d-42bc-9919-6a31cb68822b",
                "name": "P322R",
                "name_review": {
                  "added": true,
                  "updateTime": 1544636500573,
                  "updatedBy": "User"
                },
                "name_uuid": "55268c34-2b22-4617-b806-2c2e28646722",
                "tumors_uuid": "c6c45703-a815-4b44-8875-b1823777955b"
              },
              "operation": "add",
              "uuids": "dd554ea2-478a-4ff5-c094-c2c74fa2032a,682b6f29-3299-48fb-9d56-4449fb6aab66"
            }
          ],
          "timeStamp": 1544716638238
        },
        "-LbOfGkPp20Z_844JE_f": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Deletion, Mutation Effect",
              "new": {
                "description": "TP53 deletions are predicted to be inactivating and associated with poor prognosis (PMID: 11900253, 20697090, 21467160, 12584563). Experimental studies have revealed that deletions result in loss of TP53 tumor suppressive function, since TP53 cannot decrease cell viability in vitro (PMID: 27759562). Additionally, deletion of TP53 in the neurons of mice, while not sufficient to cause tumor development, allows the accumulation of other oncogenic mutations leading to tumorigenesis (PMID: 19477430). Further, loss of TP53 protein during 17p deletion events in leukemia/lymphoma, enhances cancer development through cooperation of linked tumor suppressive genes such as EIF5A and ALOX15B (PMID: 26982726)."
              },
              "old": {
                "description": "TP53 deletions are predicted to be inactivating and associated with poor prognosis (PMID: 11900253, 20697090 21467160, 12584563). Experimental studies have revealed that deletions result in loss of TP53 tumor suppressive function, since TP53 cannot decrease cell viability in vitro (PMID: 27759562). Additionally, deletion of TP53 in the neurons of mice, while not sufficient to cause tumor development, allows the accumulation of other oncogenic mutations leading to tumorigenesis (PMID: 19477430). Further, loss of TP53 protein during 17p deletion events in leukemia/lymphoma, enhances cancer development through cooperation of linked tumor suppressive genes such as EIF5A and ALOX15B (PMID: 26982726)."
              },
              "operation": "update",
              "uuids": "2e3b9a82-adcc-4067-9ebc-e394a9ca3081"
            }
          ],
          "timeStamp": 1554135194689
        },
        "-LsFu7zywEON-ymD8n4s": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R175H, Mutation Effect",
              "new": {
                "description": "The TP53 R175H mutation is located in the protein's DNA binding domain. This mutation has been found in acute myeloid leukemia (PMID: 31068365). Overexpression of this mutation in Saos-2 cells resulted in a reduced ability to induce apoptosis compared to wildtype TP53 (PMID: 15781620). Additionally, cells expressing the R175H mutation exhibited enhanced cell migration (PMID: 22114072). Structural studies have also shown that this mutant is defective in protein folding and DNA binding (PMID: 10713666, 21445056). Expression of this mutation in human lung cancer cell lines resulted in reduced growth as shown by colony formation assays (PMID: 25584008).  In vivo expression of this mutation using a hematopoietic-specific promoter resulted in hematopoetic malignancy with signficantly faster disease progression than mice with TP53 deletion (PMID: 31068365)."
              },
              "old": {
                "description": "The TP53 R175H mutation is located in the protein's DNA binding domain. Overexpression of this mutation in Saos-2 cells resulted in a reduced ability to induce apoptosis compared to wildtype TP53 (PMID: 15781620). Additionally, cells expressing the R175H mutation exhibited enhanced cell migration (PMID: 22114072). Structural studies have also shown that this mutant is defective in protein folding and DNA binding (PMID: 10713666, 21445056). Expression of this mutation in human lung cancer cell lines resulted in reduced growth as shown by colony formation assays (PMID: 25584008)."
              },
              "operation": "update",
              "uuids": "41c4e951-4d83-4e4a-9843-3f64039400ea"
            }
          ],
          "timeStamp": 1572241707134
        },
        "-LsFuG_QrVLcixLVOmCj": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G334_E346del [Tetramerization domain deletions], G334_E346ins [Tetramerization domain insertions]",
              "new": {
                "mutation_effect": {
                  "description": "The tetramerization domain of TP53 is critical for the proper oligomerization and function of the p53 tumor suppressor protein. Mutations of the tetramerization domain, specifically those around G334 that affect the hinge region between the alpha helix and the beta strand, have been shown to result in structural changes that preclude proper oligomerization of the protein and therefor disrupt proper functioning (PMID: 16007150, 16460008).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1568092879050,
                    "updatedBy": "User"
                  },
                  "description_uuid": "ba98bd0f-9ee3-4ea3-af87-a42493808039",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1568071327168,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "7adae142-3ead-41b3-9cd2-3d2c8039ce5e",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1568071326309,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "cbc5b777-85b7-4339-b240-5c3421faa2b8",
                  "short": ""
                },
                "mutation_effect_uuid": "429f4951-f9b0-4265-b232-133c632d4b3c",
                "name": "G334_E346del [Tetramerization domain deletions], G334_E346ins [Tetramerization domain insertions]",
                "name_comments": [
                  {
                    "content": "11420672",
                    "date": "1562731205150",
                    "email": "user@gmail.com",
                    "resolved": "false",
                    "userName": "User"
                  }
                ],
                "name_review": {
                  "added": true,
                  "lastReviewed": "Tetramerization domain indels",
                  "updateTime": 1568339651464,
                  "updatedBy": "User"
                },
                "name_uuid": "65317192-d5e4-44bb-82d7-89093e594b13",
                "tumors_uuid": "96681614-6a79-4154-90a6-7e6ffbaed9bb"
              },
              "operation": "add",
              "uuids": "cbc5b777-85b7-4339-b240-5c3421faa2b8,7adae142-3ead-41b3-9cd2-3d2c8039ce5e"
            }
          ],
          "timeStamp": 1572241742299
        },
        "-LuGWdQ-K3Xmt28EVBd3": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "C135Y, Mutation Effect",
              "new": {
                "effect": "Likely Loss-of-function"
              },
              "old": {
                "effect": "Switch-of-function"
              },
              "operation": "update",
              "uuids": "58ac6d98-c731-4ae6-adf3-fa75457ce195"
            }
          ],
          "timeStamp": 1574399545918
        },
        "-LuGWgCkd7jbUuU7wz6J": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "C135R, Mutation Effect",
              "new": {
                "effect": "Likely Loss-of-function"
              },
              "old": {
                "effect": "Loss-of-function"
              },
              "operation": "update",
              "uuids": "47bcf836-b853-4dc6-8446-91840ffe30be"
            }
          ],
          "timeStamp": 1574399557358
        },
        "-M3wkz6gGF9jp_hedK7Z": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V218dup, 102_292mis [DNA binding domain missense mutation], 102_292ins [DNA binding domain insertion], 102_292del [DNA binding domain deletion]",
              "new": "V218dup, 102_292mis [DNA binding domain missense mutation], 102_292ins [DNA binding domain insertion], 102_292del [DNA binding domain deletion]",
              "old": "V218dup, 102_292mis [DNA binding domain missense mutations], 102_292ins [DNA binding domain insertions], 102_292del [DNA binding domain deletions]",
              "operation": "name change",
              "uuids": "cff5aee4-6b10-4202-93f4-53007971709e"
            }
          ],
          "timeStamp": 1585862407047
        },
        "-M3wl5E-cZw5KZip8cQF": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G334_E346del [Tetramerization domain deletion], G334_E346ins [Tetramerization domain insertion]",
              "new": "G334_E346del [Tetramerization domain deletion], G334_E346ins [Tetramerization domain insertion]",
              "old": "G334_E346del [Tetramerization domain deletions], G334_E346ins [Tetramerization domain insertions]",
              "operation": "name change",
              "uuids": "65317192-d5e4-44bb-82d7-89093e594b13"
            }
          ],
          "timeStamp": 1585862436187
        },
        "-MBbWEqD0c1anXSxsKwC": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "C124R",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 C124R mutation is located in the DNA binding domain of the protein. Expression of this mutation in a yeast functional assay demonstrated that it is likely inactivating (PMID: 9115587.)",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1591763690146,
                    "updatedBy": "User"
                  },
                  "description_uuid": "1fab5311-2da0-45ee-a473-b48d715b1293",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1591763707084,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "1407e432-557d-49ce-b50d-ce74d65fb840",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1591763708546,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "16fba3bd-82c5-4dbf-be5f-b7952ed9f390",
                  "short": ""
                },
                "mutation_effect_uuid": "23a2eea5-2b00-47e2-9e03-40c3eaee8068",
                "name": "C124R",
                "name_review": {
                  "added": true,
                  "updateTime": 1591763576152,
                  "updatedBy": "User"
                },
                "name_uuid": "338f97a9-9ef8-47ab-8ea4-15e2b76e1624",
                "tumors_uuid": "6a974304-fa72-406b-88ba-1ed49115daf0"
              },
              "operation": "add",
              "uuids": "16fba3bd-82c5-4dbf-be5f-b7952ed9f390,1407e432-557d-49ce-b50d-ce74d65fb840"
            }
          ],
          "timeStamp": 1594095894124
        },
        "-MBbWHl8-JDlzQMoHa92": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "C141W",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 C141W mutation is located in the DNA binding domain of the protein. Expression of this mutation in biochemical assays demonstrated that it is likely inactivating as measured by function that is moderately altered compared to wildtype (PMID: 20407015).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1591763941271,
                    "updatedBy": "User"
                  },
                  "description_uuid": "c631500d-b363-4ce5-a4d1-40c84f76f331",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1591763916975,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "794e66b7-6319-4180-a829-15f0b558b1b1",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1591763917651,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "8cf023da-f5e8-4ade-879d-4068589d6971",
                  "short": ""
                },
                "mutation_effect_uuid": "1056fedb-e627-412b-b14a-e9b2ec475753",
                "name": "C141W",
                "name_review": {
                  "added": true,
                  "updateTime": 1591763718088,
                  "updatedBy": "User"
                },
                "name_uuid": "f39be152-c282-494b-aea8-da8a6eda5fd5",
                "tumors_uuid": "2aba56e4-6bc5-49df-a26a-b25f572ddb5e"
              },
              "operation": "add",
              "uuids": "8cf023da-f5e8-4ade-879d-4068589d6971,794e66b7-6319-4180-a829-15f0b558b1b1"
            }
          ],
          "timeStamp": 1594095906087
        },
        "-MBbWKi3bIA0vfCVNxhA": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "C176W",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 C176W mutation is located in the DNA binding domain of the protein. Expression of this mutation in biochemical assays demonstrated that it is likely inactivating as measured by impaired ability to activate downstream target genes compared to wildtype (PMID: 19850740).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1591764879208,
                    "updatedBy": "User"
                  },
                  "description_uuid": "3c8152d3-73e2-41b6-a371-31fe27893c31",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1591764755045,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "7b23803d-83e6-4294-9bf8-8810777a0527",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1591764753255,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "0b5519b6-cde0-4060-8f6d-bfdfb69b9f46",
                  "short": ""
                },
                "mutation_effect_uuid": "ecb23887-c55d-4531-b52c-98324a1088eb",
                "name": "C176W",
                "name_review": {
                  "added": true,
                  "updateTime": 1591763973904,
                  "updatedBy": "User"
                },
                "name_uuid": "fb1cb42c-16f2-4256-a69f-5a9762c661c1",
                "tumors_uuid": "63f00ba7-548c-4883-a231-8ccd8e7dc440"
              },
              "operation": "add",
              "uuids": "0b5519b6-cde0-4060-8f6d-bfdfb69b9f46,7b23803d-83e6-4294-9bf8-8810777a0527"
            }
          ],
          "timeStamp": 1594095918178
        },
        "-MBbWNf6gBkXeJ3LYxxs": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G154V",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 G154V mutation is located in the DNA binding domain of the protein. Biochemical experiments have suggested that this mutation acts as a dominant-negative  (PMID: 21289082).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1594095909604,
                    "updatedBy": "User"
                  },
                  "description_uuid": "9608f203-c997-4ab9-8e48-555e6335cf7e",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1591765325143,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "58fc793e-8e9e-40ee-bc2c-b1c849a283f1",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1591765323019,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "1ec44108-57ab-498c-b1c3-768bec243758",
                  "short": ""
                },
                "mutation_effect_uuid": "8b9b9ca4-5c43-4744-87a2-92b6e5b24a94",
                "name": "G154V",
                "name_review": {
                  "added": true,
                  "updateTime": 1591765228854,
                  "updatedBy": "User"
                },
                "name_uuid": "4382d73c-30e6-41b8-aac4-b0560b5c81a3",
                "tumors_uuid": "91230b2b-18fd-4b6b-939d-e7f6c8396af8"
              },
              "operation": "add",
              "uuids": "1ec44108-57ab-498c-b1c3-768bec243758,58fc793e-8e9e-40ee-bc2c-b1c849a283f1"
            }
          ],
          "timeStamp": 1594095930277
        },
        "-MFTrSHFrEjN1xy30yt1": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R273H, Mutation Effect",
              "new": {
                "description": "The TP53 R273H mutation is located in the protein's DNA binding domain. The TP53 R273H mutation was found in triple-negative breast cancer and 20% of pedigrees of families diagnosed with the Li-Fraumeni syndrome (LFS) (PMID: 31776133 , 25584008). Expression of this mutant resulted in cell survival by activating AKT signaling and suppressing the expression of BCL-modifying factor (BMF) (PMID: 26181206). Expression of this mutant in TP53-null cells resulted in decreased transactivation of p53 target genes, as measured by a luciferase reporter assay (PMID: 25584008, 15037740). Expression of this mutation in osteosarcoma and breast cancer cell lines demonstrated that it is inactivating as measured by moderately increased cell proliferation and failure to suppress colony growth compared to wildtype (PMID: 25584008, 31776133). In vitro studies demonstrate that this mutation confers sensitivity to the combination of chemotherapy with the PARP inhibitor talazoparib when expressed in a breast cancer cell line as measured by decreased cell metabolic activity upon drug treatment (PMID: 31776133)."
              },
              "old": {
                "description": "The TP53 R273H mutation is located in the protein's DNA binding domain. The TP53 R273H mutation was found in 20% of pedigrees of families diagnosed with the Li-Fraumeni syndrome (LFS) (PMID: 25584008). Expression of this mutant resulted in cell survival by activating AKT signaling and suppressing the expression of BCL-modifying factor (BMF) (PMID: 26181206). Expression of this mutant in TP53-null cells resulted in decreased transactivation of p53 target genes, as a measured by a luciferase reporter assay (PMID: 25584008, 15037740). Additionally, the TP53 R273H mutation failed to suppress colony growth in a colony reduction assay as compared to wildtype TP53 (PMID: 25584008)."
              },
              "operation": "update",
              "uuids": "b54d2ced-283e-49fa-bfe2-8d3c01d34c73"
            }
          ],
          "timeStamp": 1598245688781
        },
        "-MHEVHAPvllPIpUyTAws": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R273H, Mutation Effect",
              "new": {
                "description": "The TP53 R273H mutation is located in the protein's DNA binding domain. The TP53 R273H mutation was found in triple-negative breast cancer and 20% of pedigrees of families diagnosed with the Li-Fraumeni syndrome (LFS) (PMID: 31776133, 25584008). Expression of this mutant resulted in cell survival by activating AKT signaling and suppressing the expression of BCL-modifying factor (BMF) (PMID: 26181206). Expression of this mutant in TP53-null cells resulted in decreased transactivation of p53 target genes, as measured by a luciferase reporter assay (PMID: 25584008, 15037740). Expression of this mutation in osteosarcoma and breast cancer cell lines demonstrated that it is inactivating as measured by moderately increased cell proliferation and failure to suppress colony growth compared to wildtype (PMID: 25584008, 31776133). In vitro studies demonstrate that this mutation confers sensitivity to the combination of chemotherapy with the PARP inhibitor talazoparib when expressed in a breast cancer cell line as measured by decreased cell metabolic activity upon drug treatment (PMID: 31776133)."
              },
              "old": {
                "description": "The TP53 R273H mutation is located in the protein's DNA binding domain. The TP53 R273H mutation was found in triple-negative breast cancer and 20% of pedigrees of families diagnosed with the Li-Fraumeni syndrome (LFS) (PMID: 31776133 , 25584008). Expression of this mutant resulted in cell survival by activating AKT signaling and suppressing the expression of BCL-modifying factor (BMF) (PMID: 26181206). Expression of this mutant in TP53-null cells resulted in decreased transactivation of p53 target genes, as measured by a luciferase reporter assay (PMID: 25584008, 15037740). Expression of this mutation in osteosarcoma and breast cancer cell lines demonstrated that it is inactivating as measured by moderately increased cell proliferation and failure to suppress colony growth compared to wildtype (PMID: 25584008, 31776133). In vitro studies demonstrate that this mutation confers sensitivity to the combination of chemotherapy with the PARP inhibitor talazoparib when expressed in a breast cancer cell line as measured by decreased cell metabolic activity upon drug treatment (PMID: 31776133)."
              },
              "operation": "update",
              "uuids": "b54d2ced-283e-49fa-bfe2-8d3c01d34c73"
            }
          ],
          "timeStamp": 1600135439251
        },
        "-MLU80uGLGV8dzsGRnen": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Oncogenic Mutations, Acute Myeloid Leukemia",
              "new": "Acute Myeloid Leukemia",
              "old": "AML, NOS",
              "operation": "name change",
              "uuids": "41786c95-a8c9-4767-8e82-5d64491bd495"
            }
          ],
          "timeStamp": 1604692745898
        },
        "-MRzc39B-hC7Cjky7_Pi": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Oncogenic Mutations, Therapy-Related Myeloid Neoplasms, Prognostic Summary",
              "new": "The NCCN guidelines list TP53 alterations as a prognostic biomarker in therapy-related myeloid neoplasms. Well-powered studies find that patients with a TP53 alteration such as [[gene]] [[mutation]] have a less favorable prognosis.",
              "old": "The NCCN guidelines list TP53 alterations as a prognostic biomarker in acute myeloid leukemia. Well-powered studies find that patients with a TP53 alteration such as [[gene]] [[mutation]] have a less favorable prognosis.",
              "operation": "update",
              "uuids": "20ba01fb-bdf4-4de4-9c2a-afc806df84b9"
            }
          ],
          "timeStamp": 1611680203453
        },
        "-Mx6N_byF8PBa9qWah6r": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V218dup, 102_292mis [DNA binding domain missense mutations], 102_292ins [DNA binding domain insertions], 102_292del [DNA binding domain deletions]",
              "new": "V218dup, 102_292mis [DNA binding domain missense mutations], 102_292ins [DNA binding domain insertions], 102_292del [DNA binding domain deletions]",
              "old": "V218dup, 102_292mis [DNA binding domain missense mutation], 102_292ins [DNA binding domain insertion], 102_292del [DNA binding domain deletion]",
              "operation": "name change",
              "uuids": "cff5aee4-6b10-4202-93f4-53007971709e"
            }
          ],
          "timeStamp": 1646170101235
        },
        "-Mx6NexdeDv3J7EoHv04": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "334_346del [Tetramerization domain deletions], 334_346ins [Tetramerization domain insertions]",
              "new": "334_346del [Tetramerization domain deletions], 334_346ins [Tetramerization domain insertions]",
              "old": "G334_E346del [Tetramerization domain deletion], G334_E346ins [Tetramerization domain insertion]",
              "operation": "name change",
              "uuids": "65317192-d5e4-44bb-82d7-89093e594b13"
            }
          ],
          "timeStamp": 1646170123102
        },
        "-N0Hw60HaQ9186aRMSgg": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G334R, Mutation Effect",
              "new": {
                "description": "The TP53 G334R mutation occurs in the protein's oligomerization domain and has been found as a germline low-penetrance founder mutation in individuals of Ashkenazi Jewish descent who have evidence of Li-Fraumeni syndrome (PMID: 32675277). Expression of this mutation in TP53-null cells did not alter TP53 transactivation in luciferase assays or colony growth as compared to expression of wildtype TP53 (PMID: 25584008). However, in a separate study, cells expressing TP53 G334R demonstrated impaired suppression ability in a colony reduction assay compared to wildtype cells. Additionally, immortalized G334R-mutant lymphoblastoid cell lines demonstrated impaired activation of a subset of TP53 target genes (including PCLO, PLTP, PLXNB3 and LCN15) following treatment with Nutlin-3A.  Further analysis showed TP53 G334R had reduced thermal stability compared to wild type cells (PMID: 32675277).",
                "effect": "Likely Gain-of-function",
                "oncogenic": "Likely"
              },
              "old": {
                "description": "The TP53 G334R mutation occurs in the protein's oligomerization domain. Expression of this mutation in TP53-null cells did not alter TP53 transactivation in luciferase assays or colony growth as compared to expression of wildtype TP53 (PMID: 25584008).",
                "effect": "Neutral",
                "oncogenic": "Likely Neutral"
              },
              "operation": "update",
              "uuids": "6bda7bec-479c-42c6-bf32-97df8bb7e15b,bd776b5a-dfb1-4314-a8d3-5ef37e793e24"
            }
          ],
          "timeStamp": 1650658931193
        },
        "-N9YSUFTobNQuKPuvI1T": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R175H, Mutation Effect",
              "new": {
                "description": "The TP53 R175H mutation is located in the protein's DNA binding domain. This mutation has been found in acute myeloid leukemia (PMID: 31068365). In vitro and in vivo studies have demonstrated that this mutation is inactivating and oncogenic, as measured by the reduced ability to induce apoptosis and form colonies, as well as increased cell migration and faster progression of hematopoietic malignancy of the mutant compared to TP53 wildtype or deletion (PMID: 15781620, 25584008, 31068365). Structural studies have also shown that this mutant is defective in protein folding and DNA binding (PMID: 10713666, 21445056)."
              },
              "old": {
                "description": "The TP53 R175H mutation is located in the protein's DNA binding domain. This mutation has been found in acute myeloid leukemia (PMID: 31068365). Overexpression of this mutation in Saos-2 cells resulted in a reduced ability to induce apoptosis compared to wildtype TP53 (PMID: 15781620). Additionally, cells expressing the R175H mutation exhibited enhanced cell migration (PMID: 22114072). Structural studies have also shown that this mutant is defective in protein folding and DNA binding (PMID: 10713666, 21445056). Expression of this mutation in human lung cancer cell lines resulted in reduced growth as shown by colony formation assays (PMID: 25584008).  In vivo expression of this mutation using a hematopoietic-specific promoter resulted in hematopoetic malignancy with signficantly faster disease progression than mice with TP53 deletion (PMID: 31068365)."
              },
              "operation": "update",
              "uuids": "41c4e951-4d83-4e4a-9843-3f64039400ea"
            }
          ],
          "timeStamp": 1660599793511
        },
        "-NAG4YvYmrSpRebxPCU1": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "P322R, Mutation Effect",
              "new": {
                "description": "The TP53 P322R mutation is located in the oligomerization domain of the protein. In vitro studies have demonstrated that this mutation is likely neutral, as evidenced by its ability to oligomerize and transactivate downstream targets comparable to wildtype TP53 (PMID: 16007150)."
              },
              "old": {
                "description": "The TP53 P322R mutation is located in the oligomerization domain of the protein (PMID: 16007150). Oligomerization studies of the mutation showed that it was able to oligomerize and transactivate downstream targets comparable to wildtype TP53 (PMID: 16007150)."
              },
              "operation": "update",
              "uuids": "682b6f29-3299-48fb-9d56-4449fb6aab66"
            }
          ],
          "timeStamp": 1661365272363
        },
        "-NAG4d5WE7ocSO4k2qoU": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "H214R, Mutation Effect",
              "new": {
                "description": "The TP53 H214R mutation is located in the protein's DNA binding domain and is a known hotspot mutation (PMID: 26619011). This mutation has been found in breast cancers, among others (PMID: 20407015). In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by increased TP53 transactivation activity compared to wildtype (PMID: 20407015)."
              },
              "old": {
                "description": "The TP53 H214R mutation is located in the protein's DNA binding domain. While this variant has not yet been characterized in mammalian systems, expression of this variant in yeast assays results in increased TP53 transactivation activity, which may suggest loss of function and loss of feedback regulation (PMID: 20407015). However, this mutation is a hotspot, suggesting that it is likely oncogenic (PMID: 26619011)."
              },
              "operation": "update",
              "uuids": "1d39ff8b-94cf-4c03-8a82-61886e2b9046"
            }
          ],
          "timeStamp": 1661365293546
        },
        "-NAG4m5PfBlKJIU6436p": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "S121F, Mutation Effect",
              "new": {
                "description": "The TP53 S121F mutation is located in the protein's DNA binding domain. This mutation has been found in lymphoma (PMID: 22955915). In vitro studies have demonstrated that this mutation is likely activating, as evidenced by enhanced transcriptional activity, increased apoptosis and inhibition of cell cycle progression in the mutant compared to wildtype (PMID: 15781620)."
              },
              "old": {
                "description": "The TP53 S121F mutation is located in the protein's DNA binding domain. Expression of this mutation in human osteosarcoma cell lines resulted in increased TP53 activity, as evidenced by enhanced transcriptional activity, increased apoptosis and inhibition of cell cycle progression (PMID: 15781620)."
              },
              "operation": "update",
              "uuids": "1a110d13-bfb1-4080-b89e-e1da6d04bb87"
            }
          ],
          "timeStamp": 1661365330403
        },
        "-NAG5tvpU7UWwgnV1t37": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "H214Q, Mutation Effect",
              "new": {
                "description": "The TP53 H214Q mutation is located in the protein's DNA binding domain and is a known hotspot mutation (PMID: 26619011). This mutation has been found in colorectal carcinoma (PMID: 11044641). In vitro studies have demonstrated that this mutation has a neutral effect, as evidenced by mutant TP53 activity similar to that of the wildtype protein, with similar transcriptional activity, increased apoptosis and inhibition of cell cycle progression (PMID: 15781620)."
              },
              "old": {
                "description": "While the TP53 H214Q mutation is located in the protein's DNA binding domain and is a known hotspot mutation (PMID: 26619011), a single study demonstrated that expression of this mutant in osteosarcoma cells was associated with TP53 activity similar to that of the wildtype protein, with similar transcriptional activity, increased apoptosis and inhibition of cell cycle progression attributed to potential lack of feedback regulation (PMID: 15781620)."
              },
              "operation": "update",
              "uuids": "204f9e50-8e83-45a7-a3ba-64c847535564"
            }
          ],
          "timeStamp": 1661365624638
        },
        "-NAG6-c6HUmeKBkk595a": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "K291E, Mutation Effect",
              "new": {
                "description": "The TP53 K291E mutation is located in the protein's DNA binding domain and is a known hotspot mutation (PMID: 26619011). This mutation has been found in non-small cell lung cancer (PMID: 9416838). In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by significantly increased apoptosis, decreased cell viability and altered transcription of target genes in the mutant compared to wildtype (PMID: 15781620)."
              },
              "old": {
                "description": "The TP53 K291E mutation is located in the protein's DNA binding domain. Changes in the DNA binding domain result in altered contact of p53 with its target DNA sequences, thereby altering its transcriptional function (PMID: 8023157, 11900253). Expression of this mutation in human osteosarcoma cell lines resulted in significantly increased apoptosis and decreased cell viability compared to wildtype TP53 (PMID: 15781620). TP53 K291E also had altered transcriptional activity of target genes in a luciferase assay compared to wildytype TP53 (PMID: 15781620). However, this mutation is a hotspot, suggesting that it is likely oncogenic (PMID: 26619011)."
              },
              "operation": "update",
              "uuids": "5fc85227-bb09-490f-8adc-cbc68fa48ac1"
            }
          ],
          "timeStamp": 1661365652048
        },
        "-NAG668lYIsHFFGunXSu": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "K292T, Mutation Effect",
              "new": {
                "description": "The TP53 K292T mutation is located in the protein's DNA binding domain and is a known hotspot mutation (PMID: 26619011). In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by significantly increased apoptosis, decreased cell viability and altered transcription of target genes in the mutant compared to wildtype (PMID: 15781620)."
              },
              "old": {
                "description": "The TP53 K292T mutation is located in the protein's DNA binding domain. Changes in the DNA binding domain result in altered contact of p53 with its target DNA sequences, thereby altering its transcriptional function (PMID: 8023157, 11900253). Expression of this mutation in human osteosarcoma cell lines resulted in significantly increased apoptosis and decreased cell viability compared to wildtype TP53 (PMID: 15781620). TP53 K292T also had altered transcriptional activity of target genes in a luciferase assay compared to wildytype TP53 (PMID: 15781620). However, this mutation is a hotspot, suggesting that it is likely oncogenic (PMID: 26619011)."
              },
              "operation": "update",
              "uuids": "8698b568-758c-4318-8054-28515ca884c8"
            }
          ],
          "timeStamp": 1661365678778
        },
        "-NAG6BTXdNeJSBrnLcoJ": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Q144R, Mutation Effect",
              "new": {
                "description": "The TP53 Q144R mutation is located in the protein's DNA binding domain and is a known hotspot mutation (PMID: 26619011). In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by significantly increased apoptosis, decreased cell viability and altered transcription of target genes in the mutant compared to wildtype (PMID: 15781620)."
              },
              "old": {
                "description": "The TP53 Q144R mutation is located in the protein's DNA binding domain. Changes in the DNA binding domain result in altered contact of p53 with its target DNA sequences, thereby altering its transcriptional function (PMID: 8023157, 11900253). Expression of this mutation in human osteosarcoma cell lines resulted in significantly increased apoptosis and decreased cell viability compared to wildtype TP53 (PMID: 15781620). TP53 Q144R also had altered transcriptional activity of target genes in a luciferase assay compared to wildytype TP53 (PMID: 15781620). However, this mutation is a hotspot, suggesting that it is likely oncogenic (PMID: 26619011)."
              },
              "operation": "update",
              "uuids": "e113fd62-9072-4307-9b2c-3f42dac5e306"
            }
          ],
          "timeStamp": 1661365700587
        },
        "-NAG6Klrr_KdySmWHyqE": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "I162M, Mutation Effect",
              "new": {
                "description": "The TP53 I162M mutation is located in the protein's DNA binding domain. This mutation has been found in lymphoma (PMID: 27101868). In vitro studies have demonstrated that this mutation has inconclusive effect, as evidenced by altered transcription of TP53 target genes as well as an insignificant increased apoptosis and cell cycle arrest in the mutant compared to wildtype TP53 (PMID: 15781620).",
                "effect": "Inconclusive",
                "oncogenic": "Inconclusive"
              },
              "old": {
                "description": "The TP53 I162M mutation is located in the protein's DNA binding domain. Changes in the DNA binding domain result in altered contact of p53 with its target DNA sequences, thereby altering its transcriptional function (PMID: 8023157, 11900253). Expression of this mutation in human osteosarcoma cell lines resulted in increased apoptosis and cell cycle arrest compared to wildtype TP53 (PMID: 15781620), though this experimental result was not statistically significant. TP53 I162M also had altered transcriptional activity of target genes in a luciferase assay compared to wildytype TP53 (PMID: 15781620).",
                "effect": "Likely Loss-of-function",
                "oncogenic": "Likely"
              },
              "operation": "update",
              "uuids": "3a8903db-dc5d-47e8-8962-98d13cdf24e8,a84c15a9-c0ef-4a97-a7bd-a737fecb67c4"
            }
          ],
          "timeStamp": 1661365738688
        },
        "-NAG6Q0jd2gxm5bqRjEA": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R290G, Mutation Effect",
              "new": {
                "description": "The TP53 R290G mutation is located in the protein's DNA binding domain and is a known hotspot mutation (PMID: 26619011). In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by significantly increased apoptosis, decreased cell viability and altered transcription of target genes in the mutant compared to wildtype (PMID: 15781620)."
              },
              "old": {
                "description": "The TP53 R290G mutation is located in the protein's DNA binding domain. Changes in the DNA binding domain result in altered contact of p53 with its target DNA sequences, thereby altering its transcriptional function (PMID: 8023157, 11900253). Expression of this mutation in human osteosarcoma cell lines resulted in significantly increased apoptosis and decreased cell viability compared to wildtype TP53 (PMID: 15781620). TP53 R290G also had altered transcriptional activity of target genes in a luciferase assay compared to wildytype TP53 (PMID: 15781620). However, this mutation is a hotspot, suggesting that it is likely oncogenic (PMID: 26619011)."
              },
              "operation": "update",
              "uuids": "7e7a3ae5-6c0c-45a4-85c9-d3bc9042a818"
            }
          ],
          "timeStamp": 1661365760184
        },
        "-NAG8heeEWQpB6PEH8F1": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "H214R, Mutation Effect",
              "new": {
                "description": "The TP53 H214R mutation is located in the protein's DNA binding domain and is a known hotspot mutation (PMID: 26619011). This mutation has been found in breast cancers, among others (PMID: 20407015). In vitro studies have demonstrated that this mutation is likely activating, as evidenced by increased TP53 transactivation activity compared to wildtype (PMID: 20407015).",
                "effect": "Inconclusive",
                "oncogenic": "Inconclusive"
              },
              "old": {
                "description": "The TP53 H214R mutation is located in the protein's DNA binding domain and is a known hotspot mutation (PMID: 26619011). This mutation has been found in breast cancers, among others (PMID: 20407015). In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by increased TP53 transactivation activity compared to wildtype (PMID: 20407015).",
                "effect": "Likely Loss-of-function",
                "oncogenic": "Likely"
              },
              "operation": "update",
              "uuids": "cdcc69c1-9be4-4f56-a7d0-5e2c392561c9,1d39ff8b-94cf-4c03-8a82-61886e2b9046"
            }
          ],
          "timeStamp": 1661366360819
        },
        "-NC6bnvWSRhRn-RrI6k-": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "L344P, Mutation Effect",
              "new": {
                "description": "The TP53 L344P mutation is located in the protein's oligomerization domain. This mutation has been found in Li-Fraumeni syndromes (PMID: 9704930). In vitro and structural studies have demonstrated that this mutation is inactivating, as evidenced by the mutant's inability to oligomerize and form TP53 tetramers, leading to decreased transactivation of TP53 target genes, decreased TP53 acetylation and decreased recruitment of p300 in the mutant compared to wildtype (PMID: 19454241, 19106109, 20978130)."
              },
              "old": {
                "description": "The TP53 L344P mutation is located in the protein's oligomerization domain. Expression of this mutation in human lung cancer cell lines resulted in the inability of TP53 to oligomerize, leading to decreased transactivation of TP53 target genes such as p21 (PMID: 19454241). This TP53 mutation resulted in decreased TP53 acetylation and therefore decreased recruitment of p300, a transcription factor required for the assembly of appropriate TP53 regulatory transcriptional complexes (PMID: 19106109). Structural studies confirm that TP53 L344P is unable to form TP53 tetramers (PMID: 20978130)."
              },
              "operation": "update",
              "uuids": "b4f92878-cffd-4450-bfd4-7a584ef43fbc"
            }
          ],
          "timeStamp": 1663353962259
        },
        "-NC6btkAUwL0ssWQ-3ta": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R337C, Mutation Effect",
              "new": {
                "description": "The TP53 R337C mutation is located in the protein's oligomerization domain (PMID: 17311302). In vitro and structural studies have demonstrated that this mutation is inactivating, as evidenced by the mutant's ability to inhibit transcriptional activity by destabilizing the p53 tetramer, as well as its inability to oligomerize, leading to decreased transactivation of TP53 target genes, decreased TP53 acetylation and decreased recruitment of p300 in the mutant compared to wildtype (PMID: 19454241, 11753428, 16007150, 19106109)."
              },
              "old": {
                "description": "The TP53 R337C mutation is located in the protein's oligomerization domain (PMID: 17311302). Expression of this mutation in human lung cancer cell lines resulted in the inability of TP53 to oligomerize, leading to decreased transactivation of TP53 target genes such as p21. This TP53 mutation resulted in decreased TP53 acetylation and therefore decreased recruitment of p300, a transcription factor required for the assembly of appropriate TP53 regulatory transcriptional complexes (PMID: 19106109). In structural and reporter studies, mutations at R337 were found to destabilize the p53 tetramer, inhibiting the protein’s transcriptional activity (PMID: 19454241, 11753428, 16007150)."
              },
              "operation": "update",
              "uuids": "65c2d4a3-1211-4f05-9543-d8c5173e0996"
            }
          ],
          "timeStamp": 1663353986109
        },
        "-NC6dH0aKVQLaOORasv6": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "L330H, Mutation Effect",
              "new": {
                "description": "The TP53 L330H mutation is located in the protein's oligomerization domain. In vitro and structural studies have demonstrated that this mutation is likely inactivating, as evidenced by decreased transcriptional activity, decreased protein stability and decreased p53 tetramer formation in the mutant compared to wildtype (PMID: 19454241, 20978130)."
              },
              "old": {
                "description": "The TP53 L330H mutation is located in the protein's oligomerization domain. Expression of this mutation in human lung cancer cell lines resulted in decreased transcriptional activity and protein stability, as evidenced by a reporter assay (PMID: 19454241). Structural studies demonstrated that this mutation results in decreased TP53 tetramer formation compared to wildtype TP53, likely impacting TP53 DNA binding activity (PMID: 20978130)."
              },
              "operation": "update",
              "uuids": "a0a3bd7b-79bd-4176-a99c-c5ea8aebdbcc"
            }
          ],
          "timeStamp": 1663354347672
        },
        "-NC6dMl7RbSUQf9a9aGe": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "L330P, Mutation Effect",
              "new": {
                "description": "The TP53 L330P mutation is located in the protein's oligomerization domain. Structural studies have demonstrated that this mutation is likely inactivating, as evidenced by the mutant's inability to form p53 tetramers, which is required for TP53 DNA binding activity (PMID: 20978130)."
              },
              "old": {
                "description": "The TP53 L330P mutation is located in the protein's oligomerization domain. Structural studies demonstrate that the TP53 L330P mutation is unable to form TP53 tetramers, and tetramerization is required for TP53 DNA binding activity (PMID: 20978130)."
              },
              "operation": "update",
              "uuids": "ea95c3b8-e97a-43c8-9dba-216a2853477f"
            }
          ],
          "timeStamp": 1663354371194
        },
        "-NC6dSc7g2uYL7HrwM2N": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "L330R, Mutation Effect",
              "new": {
                "description": "The TP53 L330R mutation is located in the protein's tetramerization domain. In vitro and structural studies have demonstrated that this mutation is likely inactivating, as evidenced by the decreased transcriptional activity and protein stability in the mutant compared to wildtype, as well as by the mutant's inability to form p53 tetramers, which is required for TP53 DNA binding activity (PMID: 19454241, 20978130)."
              },
              "old": {
                "description": "The TP53 L330R mutation is located in the protein's tetramerization domain. Expression of this mutation in human lung cancer cell lines resulted in decreased transcriptional activity and protein stability compared to wildtype TP53, as evidenced by a reporter assay (PMID: 19454241). Structural studies demonstrate that the TP53 L330R mutation is unable to form TP53 tetramers, and tetramerization is required for TP53 DNA binding activity (PMID: 20978130)."
              },
              "operation": "update",
              "uuids": "13f49980-7683-47d3-992e-27ce5f82dd57"
            }
          ],
          "timeStamp": 1663354395194
        },
        "-NC6dYMf_JmvVlarzfZW": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R337P, Mutation Effect",
              "new": {
                "description": "The TP53 R337P mutation is located in the protein's oligomerization domain. This mutation has been found in the germline of patients with Li-Fraumeni syndrome and adrenocortical carcinoma (PMID: 11481490). In vitro and structural studies have demonstrated that this mutation is likely inactivating, as evidenced by decreased transcriptional activity and protein stability in the mutant compared to wildtype, as well as the mutant's inability to form p53 tetramers, which is required for TP53 DNA binding activity (PMID: 19454241, 20978130)."
              },
              "old": {
                "description": "The TP53 R337P mutation is located in the protein's DNA binding domain. Missense mutations at codon R337 constitute approximately 10% of all germline mutations in TP53 present in Li-Fraumeni syndrome (p53.iarc.fr/TP53GermlineMutations.aspx) and were initially reported in Brazilian families with pediatric cases of adrenocortical carcinoma (PMID: 11481490). Expression of this mutation in human lung cancer cell lines resulted in decreased transcriptional activity and protein stability compared to wildtype TP53, as evidenced by a reporter assay (PMID: 19454241). Structural studies demonstrate that the TP53 R337P mutation is unable to form TP53 tetramers, and tetramerization is required for TP53 DNA binding activity (PMID: 20978130)."
              },
              "operation": "update",
              "uuids": "f87dbe53-d8b1-4367-95f4-6bb3dd657587"
            }
          ],
          "timeStamp": 1663354418717
        },
        "-NC6dd7Sw7eaYl3EAf8E": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "F341C, Mutation Effect",
              "new": {
                "description": "The TP53 F341C mutation is located in the protein's oligomerization domain. In vitro and structural studies have demonstrated that this mutation is likely inactivating, as evidenced by the decreased transcriptional activity and protein stability in the mutant compared to wildtype, as well as by the mutant's decreased ability to form p53 tetramers, which is required for TP53 DNA binding activity (PMID: 19454241, 20978130)."
              },
              "old": {
                "description": "The TP53 F341C mutation is located in the protein's oligomerization domain. Expression of this mutation in human lung cancer cell lines resulted in decreased transcriptional activity and protein stability compared to wildtype TP53, as evidenced by a reporter assay (PMID: 19454241). Structural studies demonstrate that the TP53 F341C mutation has a decreased ability to form TP53 tetramers compared to wildtype TP53, likely impacting TP53 DNA binding activity (PMID: 20978130)."
              },
              "operation": "update",
              "uuids": "10cead43-d239-4486-a664-7dacc7401fdf"
            }
          ],
          "timeStamp": 1663354442319
        },
        "-NC6diwOf6krnqn0T4cp": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R342P, Mutation Effect",
              "new": {
                "description": "The TP53 R342P mutation is located in the protein's oligomerization domain. In vitro and structural studies have demonstrated that this mutation is likely inactivating, as evidenced by the decreased transcriptional activity and protein stability in the mutant compared to wildtype, as well as by the mutant's inability to form p53 tetramers, which is required for TP53 DNA binding activity (PMID: 19454241, 20978130)."
              },
              "old": {
                "description": "The TP53 R342P mutation is located in the protein's oligomerization domain. Expression of this mutation in human lung cancer cell lines resulted in decreased transcriptional activity and protein stability compared to wildtype TP53, as evidenced by a reporter assay (PMID: 19454241). Structural studies demonstrate that the TP53 R342P mutation is unable to form TP53 tetramers, and tetramerization is required for TP53 DNA binding activity (PMID: 20978130)."
              },
              "operation": "update",
              "uuids": "124e09ba-4bf7-4853-98b6-b678eec9fbdc"
            }
          ],
          "timeStamp": 1663354466123
        },
        "-NC6dofOD9DX2AfoI5NM": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "L344R, Mutation Effect",
              "new": {
                "description": "The TP53 L344R mutation is located in the protein's oligomerization domain. In vitro and structural studies have demonstrated that this mutation is likely inactivating, as evidenced by the decreased transcriptional activity and protein stability in the mutant compared to wildtype, as well as by the mutant's decreased ability to form p53 tetramers, which is required for TP53 DNA binding activity (PMID: 19454241, 20978130)."
              },
              "old": {
                "description": "The TP53 L344R mutation is located in the protein's oligomerization domain. Expression of this mutation in human lung cancer cell lines resulted in decreased transcriptional activity and protein stability compared to wildtype TP53, as evidenced by a reporter assay (PMID: 19454241). Structural studies demonstrate that the TP53 L344R mutation has a decreased ability to form TP53 tetramers compared to wildtype TP53, likely impacting TP53 DNA binding activity (PMID: 20978130)."
              },
              "operation": "update",
              "uuids": "97dd3cee-daea-46cc-a9e4-5a7dc823273e"
            }
          ],
          "timeStamp": 1663354489611
        },
        "-NC6duTWGCFpaTzvRKWw": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "A347T, Mutation Effect",
              "new": {
                "description": "The TP53 A347T mutation is located in the protein's oligomerization domain. In vitro and structural studies have demonstrated that this mutation is likely inactivating, as evidenced by the decreased transcriptional activity and protein stability in the mutant compared to wildtype, as well as by the mutant's decreased ability to form p53 tetramers, which is required for TP53 DNA binding activity (PMID: 19454241, 20978130)."
              },
              "old": {
                "description": "The TP53 A347T mutation is located in the protein's oligomerization domain. Expression of this mutation in human lung cancer cell lines resulted in decreased transcriptional activity and protein stability compared to wildtype TP53, as evidenced by a reporter assay (PMID: 19454241). tructural studies demonstrate that the TP53 A347T mutation has a decreased ability to form TP53 tetramers compared to wildtype TP53, likely impacting TP53 DNA binding activity (PMID: 20978130)."
              },
              "operation": "update",
              "uuids": "c50c6631-3785-4b6e-8d43-a6c2bed68d76"
            }
          ],
          "timeStamp": 1663354513363
        },
        "-NC6e0UKh-wnBQOAkw4K": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R337H, Mutation Effect",
              "new": {
                "description": "The TP53 R337H mutation is located in the protein's oligomerization domain. This mutation has been found in the germline of patients with Li-Fraumeni syndrome and adrenocortical carcinoma (PMID: 11481490). In vitro and structural studies have demonstrated that this mutation is likely inactivating, as evidenced by decreased transcriptional activity and protein stability in the mutant compared to wildtype, as well as the mutant's inability to form p53 tetramers, which is required for TP53 DNA binding activity (PMID: 19454241, 20978130)."
              },
              "old": {
                "description": "The TP53 R337H mutation is located in the protein's oliogmerization domain. Missense mutations at codon R337 constitute approximately 10% of all germline mutations in TP53 present in Li-Fraumeni syndrome (p53.iarc.fr/TP53GermlineMutations.aspx) and were initially reported in Brazilian families with pediatric cases of adrenocortical carcinoma (PMID: 11481490). Expression of this mutation in human lung cancer cell lines resulted in decreased transcriptional activity and protein stability compared to wildtype TP53, as evidenced by a reporter assay (PMID: 19454241). However, expression of this mutation in TP53-null cells resulted in a suppression in colony growth comparable to wildtype TP53 (PMID: 25584008). Mutant TP53 R337H has been found to abnormally accumulate in the nuclei in cell lines lacking wildtype TP53 (PMID: 11481490)."
              },
              "operation": "update",
              "uuids": "b14ddc8c-73d9-4fe1-b08c-e8fa522bd10a"
            }
          ],
          "timeStamp": 1663354542087
        },
        "-NC6e6GbIjmea-Wj_8lP": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R337L, Mutation Effect",
              "new": {
                "description": "The TP53 R337L mutation is located in the protein's oligomerization domain. This mutation has been found in the germlines of patients with Li-Fraumeni syndrome and adrenocortical carcinoma (PMID: 11481490). In vitro and structural studies have demonstrated that this mutation is likely inactivating, as evidenced by decreased transcriptional activity and protein stability in the mutant compared to wildtype, as well as the mutant's inability to form p53 tetramers, which is required for TP53 DNA binding activity (PMID: 19454241, 20978130)."
              },
              "old": {
                "description": "The TP53 R337L mutation is located in the protein's oligomerization domain. Missense mutations at codon R337 constitute approximately 10% of all germline mutations in TP53 present in Li-Fraumeni syndrome (p53.iarc.fr/TP53GermlineMutations.aspx) and were initially reported in Brazilian families with pediatric cases of adrenocortical carcinoma (PMID: 11481490).Expression of this mutation in human lung cancer cell lines resulted in decreased transcriptional activity and protein stability compared to wildtype TP53, as evidenced by a reporter assay (PMID: 19454241). Structural studies demonstrate that the TP53 R337L mutation has a decreased ability to form TP53 tetramers compared to wildtype TP53, likely impacting TP53 DNA binding activity (PMID: 20978130)."
              },
              "operation": "update",
              "uuids": "a9ed758b-0cc4-4168-b1fe-f0f98d6d92e0"
            }
          ],
          "timeStamp": 1663354565785
        },
        "-NC6eC74GaZhnGCIu3X5": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "F338I, Mutation Effect",
              "new": {
                "description": "The TP53 F338I mutation is located in the protein's oligomerization domain. In vitro and structural studies have demonstrated that this mutation is likely inactivating, as evidenced by the decreased transcriptional activity and protein stability in the mutant compared to wildtype, as well as by the mutant's inability to form p53 tetramers, which is required for TP53 DNA binding activity (PMID: 19454241, 20978130)"
              },
              "old": {
                "description": "The F338I mutation is located in the protein's oligomerization domain. Expression of this mutation in human lung cancer cell lines resulted in decreased transcriptional activity and protein stability compared to wildtype TP53, as evidenced by a reporter assay (PMID: 19454241). Structural studies demonstrate that the TP53 F338I mutation has a decreased ability to form TP53 tetramers compared to wildtype TP53, likely impacting TP53 DNA binding activity (PMID: 20978130)."
              },
              "operation": "update",
              "uuids": "06cd006b-82bd-4d4c-bf31-4ced5518df1a"
            }
          ],
          "timeStamp": 1663354589751
        },
        "-NC6eHnGSS7tUgH6V6qA": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "L348S, Mutation Effect",
              "new": {
                "description": "The TP53 L348S mutation is located in the protein's oligomerization domain. Structural studies have demonstrated that this mutation is likely inactivating, as evidenced by the mutant's decreased ability to form TP53 tetramers compared to wildtype TP53, which likely impacts TP53 DNA binding activity (PMID: 20978130)."
              },
              "old": {
                "description": "The TP53 L348S mutation is located in the protein's oligomerization domain. Structural studies demonstrate that the TP53 L348S mutation has a decreased ability to form TP53 tetramers compared to wildtype TP53, likely impacting TP53 DNA binding activity (PMID: 20978130)."
              },
              "operation": "update",
              "uuids": "2b5e984a-900d-4850-9dcd-cbe5d6cd0dfe"
            }
          ],
          "timeStamp": 1663354612995
        },
        "-NC6eNYlKqz9dRYwPatB": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "P47S, Mutation Effect",
              "new": {
                "description": "The TP53 P47S mutation is located in the protein's transactivation domain. This mutation has been found in the germline of patients with pediatric adrenocortical carcinoma (PMID: 25584008). In vitro studies have demonstrated that this mutation is likely neutral, as evidenced by similar levels of colony formation and TP53 transactivation activity in the mutant compared to wildtype (PMID: 25584008)."
              },
              "old": {
                "description": "The TP53 P47S mutation is located in the protein's transactivation domain. The TP53 P47S mutation has been previously identified as a germline polymorphism in pediatric adrenocortical carcinoma. Expression of this mutation in lung cancer cell lines resulted in colony formation and TP53 transactivation activity comparable to wildtype TP53 (PMID: 25584008)."
              },
              "operation": "update",
              "uuids": "0d1f4bb9-af36-433b-8a35-3eca8f862227"
            }
          ],
          "timeStamp": 1663354636579
        },
        "-NC6eTLdeieim0ax_Xxr": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "F134Y, Mutation Effect",
              "new": {
                "description": "The TP53 F134Y mutation is located in the protein's DNA binding domain and occurs at a known hotspot residue (PMID: 26619011). In vitro studies have demonstrated that this mutation has inconclusive effect, as evidenced by similar levels of colony formation and TP53 transactivation activity in the mutant compared to wildtype, even though its position at a hotspot residue suggests that it is likely oncogenic (PMID: 25584008, 26619011).",
                "effect": "Inconclusive",
                "oncogenic": "Inconclusive"
              },
              "old": {
                "description": "The TP53 F134Y mutation is located in the protein's DNA binding domain. Expression of this mutation in lung cancer cell lines resulted in colony formation and TP53 transactivation activity comparable to wildtype TP53 (PMID: 25584008). However, this mutation is a hotspot, suggesting that it is likely oncogenic (PMID: 26619011).",
                "effect": "Likely Loss-of-function",
                "oncogenic": "Likely"
              },
              "operation": "update",
              "uuids": "2815bd4b-1619-4f67-8856-b5bfe65d1d94,4bc2942b-10c2-4f3f-babe-bc76bbdb2b7d"
            }
          ],
          "timeStamp": 1663354660315
        },
        "-NC6eZ5YqnU0hWed9I9n": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "P152L, Mutation Effect",
              "new": {
                "description": "The TP53 P152L mutation is located in the protein's DNA binding domain. In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by loss of p53-mediated transactivation and reduced colony formation in the mutant compared to wildtype (PMID: 10229196, 25584008)."
              },
              "old": {
                "description": "The TP53 P152L mutation is located in the protein's DNA binding domain. Expression of this mutation in human lung cancer cell lines results in a loss of p53-mediated transactivation as detected by luciferase reporter assays (PMID: 25584008). Additionally, expression of the P152L mutation resulted in reduced growth as evidenced by colony formation assays (PMID: 25584008)."
              },
              "operation": "update",
              "uuids": "cb67c3e4-a16b-416c-a5ee-4a1a89cfcb19"
            }
          ],
          "timeStamp": 1663354683860
        },
        "-NC6fagqyCyNmFskJjzH": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R158H, Mutation Effect",
              "new": {
                "description": "The TP53 R158H mutation is located in the protein's DNA binding domain. In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by loss of p53-mediated transactivation and reduced colony formation in the mutant compared to wildtype (PMID: 10229196, 25584008)."
              },
              "old": {
                "description": "The TP53 R158H mutation is located in the protein's DNA binding domain. Expression of this mutation in human lung cancer cell lines results in loss of p53-mediated transactivation as detected by luciferase reporter assays (PMID: 25584008, 10229196). Additionally, expression of this mutant resulted in reduced growth as shown by colony formation assays (PMID: 25584008)."
              },
              "operation": "update",
              "uuids": "94bb01ea-f180-4306-8cd9-cab503e1bbcd"
            }
          ],
          "timeStamp": 1663354956648
        },
        "-NC6fiZvLIxLMz8WNgoL": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Y163C, Mutation Effect",
              "new": {
                "description": "The TP53 Y163C mutation is located in the protein's DNA-binding domain. In vitro studies have demonstrated that this mutation is inactivating, as measured by increased cellular growth, decreased levels of apoptosis and decreased transactivation of downstream p53 target genes in the mutant compared to wildtype (PMID: 23246812,15077194, 25584008, 15037740)."
              },
              "old": {
                "description": "The TP53 Y163C mutation is located in the protein's DNA-binding domain (DBD). Mutations in this domain often lead to conformational changes of the p53 protein, resulting in altered contact of p53 with its target DNA sequences, and thus altering its transcriptional function (PMID: 8023157, 11900253). Expression of the TP53 Y163C mutant in TP53-null cells resulted in an increased rate of cellular growth, decreased levels of apoptosis and decreased transactivation of downstream p53 target genes compared to cells expressing wildtype p53 (PMID: 23246812,15077194, 25584008, 15037740)."
              },
              "operation": "update",
              "uuids": "5d765c01-7b4d-40dc-a5a6-ad5f2eebeea9"
            }
          ],
          "timeStamp": 1663354988909
        },
        "-NC6foIEOccIE8cZiTkn": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "H193P, Mutation Effect",
              "new": {
                "description": "The TP53 H193P mutation is located in the protein's DNA-binding domain. This mutation has been found in Li-Fraumeni syndrome (PMID: 25584008). In vitro studies have demonstrated that this mutation is inactivating, as measured by decreased transactivation of p53 target genes and failure to suppress colony growth in a colony reduction assay in the mutant compared to wildtype (PMID: 25584008)."
              },
              "old": {
                "description": "The TP53 H193P mutation is located in the protein's DNA-binding domain and was identified in a patient with a Li-Fraumeni syndrome (LFS)-component tumor. Expression of this mutant in TP53-null cells resulted in decreased transactivation of p53 target genes, as a measured by a luciferase report assay (PMID: 25584008). Additionally, the TP53 H193P mutation failed to suppress colony growth in a colony reduction assay (PMID: 25584008)."
              },
              "operation": "update",
              "uuids": "f7616b81-3c8c-488b-bfe3-f2f41f0981b4"
            }
          ],
          "timeStamp": 1663355012353
        },
        "-NC6fu0f0zKbTwLJ9Gtj": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "C229R, Mutation Effect",
              "new": {
                "description": "The TP53 C229R mutation is located in the protein's DNA binding domain. In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by increased p53-mediated transactivation and increased colony formation in the mutant compared to wildtype (PMID: 25584008)."
              },
              "old": {
                "description": "The TP53 C229R mutation is located in the protein's DNA binding domain. Expression of this mutation in human lung cancer cell lines results in increased p53-mediated transactivation as detected by luciferase reporter assays, suggesting it is a loss-of-function allele and has lost negative feedback (PMID: 25584008). Expression of this mutant resulted in formation of more colonies in soft agar in comparison to wild type p53 as shown by colony formation assays (PMID: 25584008)."
              },
              "operation": "update",
              "uuids": "2a27eee4-b03c-4090-8b70-4c063146286a"
            }
          ],
          "timeStamp": 1663355035805
        },
        "-NC6fzlAGcWd-IhaT9Hm": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "P219S, Mutation Effect",
              "new": {
                "description": "The TP53 R219S mutation is located in the protein's DNA binding domain. In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by the loss of of p53-mediated transactivation, increased colony formation, decreased transactivation of genes important in cell cycle and apoptosis, and decreased apoptosis in the mutant compared to wildtype (PMID: 25584008, 10229196)."
              },
              "old": {
                "description": "The TP53 R219S mutation is located in the protein's DNA binding domain. Expression of this mutation in human lung cancer cell lines results in a loss of p53-mediated transactivation as detected by luciferase reporter assays (PMID: 25584008). Additionally expression of this mutant resulted in colony formation as shown by colony formation assays (PMID: 25584008). Expression of this mutation in osteosarcoma cell lines that lack wildtype TP53 results in decreased transactivation of genes important in cell cycle and apoptosis, including p21 and Bax. Cell lines expressing this mutation have decreased apoptosis as compared to cell lines that express wildtype form of TP53 (PMID: 10229196)."
              },
              "operation": "update",
              "uuids": "2f286414-2199-435b-be11-f12daee9f162"
            }
          ],
          "timeStamp": 1663355059325
        },
        "-NC6g4YPvx6kY-qisXkD": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "N235D, Mutation Effect",
              "new": {
                "description": "The TP53 N235D mutation is located in the protein's DNA binding domain. In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by increased p53-mediated transactivation and increased colony formation in the mutant compared to wildtype (PMID: 25584008)."
              },
              "old": {
                "description": "The TP53 N235D mutation is located in the protein's DNA binding domain. Expression of this mutation in human lung cancer cell lines results in a loss of p53-mediated transactivation as detected by luciferase reporter assays (PMID: 25584008). Additionally expression of this mutant resulted in colony formation as shown by colony formation assays (PMID: 25584008)."
              },
              "operation": "update",
              "uuids": "87426af5-e84a-4ed0-a5e1-6f2a394868c9"
            }
          ],
          "timeStamp": 1663355083020
        },
        "-NC6hLnNdWZjSnzR4US4": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R248W, Mutation Effect",
              "new": {
                "description": "The TP53 R248W mutation is located in the protein's DNA binding domain. This mutation has been found in Li-Fraumeni syndrome (PMID: 25584008). In vitro studies have demonstrated that this mutation is inactivating, as evidenced by increased p53-mediated transactivation and failure to suppress colony growth in the mutant compared to wildtype (PMID: 18762571, 10229196, 25584008)."
              },
              "old": {
                "description": "The TP53 R248W mutation is located in the protein's DNA binding domain. This mutation was found to occur in 20% of pedigrees of families with Li-Fraumeni syndrome (LFS) (PMID: 25584008). Expression of TP53 R248W in TP53-null cells resulted in decreased transactivation of p53 target genes, as a measured by a luciferase reporter assay (PMID: 18762571, 10229196). Additionally, the TP53 R248W mutation failed to suppress colony growth in a colony reduction assay (PMID: 25584008)."
              },
              "operation": "update",
              "uuids": "2416b4ed-b136-4f3a-9fda-8a2f17032146"
            }
          ],
          "timeStamp": 1663355415817
        },
        "-NC6hRdZnqs8Aq_-ztfJ": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "I254T, Mutation Effect",
              "new": {
                "description": "The TP53 I254T mutation is located in the protein's DNA binding domain. In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by the loss of p53-mediated transactivation and increased colony formation in the mutant compared to wildtype (PMID: 25584008)."
              },
              "old": {
                "description": "The TP53 I254T mutation is located in the protein's DNA binding domain. Expression of this mutation in human lung cancer cell lines results in a loss of p53-mediated transactivation as detected by luciferase reporter assays (PMID: 25584008). Additionally expression of this mutant resulted in colony formation as shown by colony formation assays (PMID: 25584008)."
              },
              "operation": "update",
              "uuids": "4afa0c35-0e9f-410e-8507-4dcc93431988"
            }
          ],
          "timeStamp": 1663355439766
        },
        "-NC6rTLodwQkpONn-cdb": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "E285V, Mutation Effect",
              "new": {
                "description": "The TP53 E285V mutation is located in the protein's DNA binding domain. In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by the loss of p53-mediated transactivation as well as defective growth suppression and apoptosis in the mutant compared to wildtype (PMID: 25584008, 18762572)."
              },
              "old": {
                "description": "The TP53 E285V mutation is located in the protein's DNA binding domain. Expression of this mutation in human lung cancer cell lines results in a loss of p53-mediated transactivation and acted as a dominant negative as detected by luciferase reporter assays. Additionally, this mutant was defective growth suppression and apoptosis as shown by colony formation assays (PMID: 25584008, 18762572)."
              },
              "operation": "update",
              "uuids": "181e1d31-6d2e-49ee-bb6c-386b07892aea"
            }
          ],
          "timeStamp": 1663358068130
        },
        "-NC6rgVqJ12upJdNfCMC": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R175L, Mutation Effect",
              "new": {
                "description": "The TP53 R175L mutation is located in the protein's DNA binding domain and occurs at a hotspot residue (PMID: 26619011). In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by colony formation and reduced ability to induce apoptosis in the mutant compared to wildtype (PMID: 25584008, 15781620, 18762572)."
              },
              "old": {
                "description": "The TP53 R175L mutation is located in the protein's DNA binding domain. Expression of this mutation in human lung cancer cell lines resulted in reduced growth as evidenced by colony formation assays (PMID: 25584008). When overexpressed in Saos-2 cells, this mutation had a reduced ability to induce apoptosis than wildtype p53, indicating that it is a loss of function\\ p53 mutation (PMID: 15781620, 18762572)."
              },
              "operation": "update",
              "uuids": "a288827a-589c-4f83-94a1-15027bd2329d"
            }
          ],
          "timeStamp": 1663358126116
        },
        "-NC6s03DfN2xu_lXpNwf": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R175C, Mutation Effect",
              "new": {
                "description": "The TP53 R175C mutation is located in the protein's DNA binding domain and occurs at a hotspot residue (PMID: 26619011). In vitro studies have demonstrated that this mutation has inconclusive effect, as evidenced by cell cycle arrest and apoptosis comparable to that of the wildtype (PMID: 22955915).",
                "effect": "Inconclusive",
                "oncogenic": "Inconclusive"
              },
              "old": {
                "description": "The TP53 R175C mutation is located in the protein's DNA binding domain. The R175C mutant retained wildtype cell cycle arrest and proapoptotic function when transfected into p53-null human tumor Saos-2 cells (PMID: 9632751). The ability of this mutation to retain wildtype p53 apoptotic function was confirmed in other studies (PMID: 22955915). However, this mutation is a hotspot, suggesting that it is likely oncogenic (PMID: 26619011).",
                "effect": "Likely Loss-of-function",
                "oncogenic": "Likely"
              },
              "operation": "update",
              "uuids": "a2803d54-e3a5-4ae4-9f14-e290f9cfa059,f1612c40-9be7-4d4b-9ee4-881ddc4dc72a"
            }
          ],
          "timeStamp": 1663358210300
        },
        "-ND5Ca2j-uGA_p6OG4uh": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "K291E, Mutation Effect",
              "new": {
                "description": "The TP53 K291E mutation is located in the protein's DNA binding domain and is a known hotspot mutation (PMID: 26619011). This mutation has been found in non-small cell lung cancer (PMID: 9416838). In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by significantly increased apoptosis, decreased cell viability and altered transcription of TP53 target genes in the mutant compared to wildtype (PMID: 15781620)."
              },
              "old": {
                "description": "The TP53 K291E mutation is located in the protein's DNA binding domain and is a known hotspot mutation (PMID: 26619011). This mutation has been found in non-small cell lung cancer (PMID: 9416838). In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by significantly increased apoptosis, decreased cell viability and altered transcription of target genes in the mutant compared to wildtype (PMID: 15781620)."
              },
              "operation": "update",
              "uuids": "5fc85227-bb09-490f-8adc-cbc68fa48ac1"
            }
          ],
          "timeStamp": 1664404054111
        },
        "-ND5DNFPkZbyYLR6c01U": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R267Q, Mutation Effect",
              "new": {
                "description": "The TP53 R267Q mutation is located in the protein's DNA binding domain. In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by increased levels of p53-mediated transactivation (suggesting loss of negative feedback) and increased colony formation in the mutant compared to wildtype (PMID: 25584008, 10435620)."
              },
              "old": {
                "description": "The TP53 R267Q mutation is located in the protein's DNA binding domain. Expression of this mutation in human lung cancer cell lines results in increased p53-mediated transactivation as detected by luciferase reporter assays, suggesting loss of negative feedback and thus suggesting that this mutation is loss-of-function (PMID: 25584008). Additionally, expression of this mutant resulted in moderately enhanced colony formation compared to wildtype TP53 (PMID: 25584008, 10435620)."
              },
              "operation": "update",
              "uuids": "c9ef7cfc-1216-4d66-ba5b-32c44a642b4f"
            }
          ],
          "timeStamp": 1664404259722
        },
        "-ND5Duxdjh4inzbyxMqh": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R273H, Mutation Effect",
              "new": {
                "description": "The TP53 R273H mutation is located in the protein's DNA binding domain. This mutation has been found in triple-negative breast cancer and Li-Fraumeni syndrome (PMID: 31776133, 25584008). Expression of this mutant resulted in cell survival by activating AKT signaling and suppressing the expression of BCL-modifying factor (BMF) (PMID: 26181206). Expression of this mutant in TP53-null cells resulted in decreased transactivation of p53 target genes, as measured by a luciferase reporter assay (PMID: 25584008, 15037740). Expression of this mutation in osteosarcoma and breast cancer cell lines demonstrated that it is inactivating as measured by moderately increased cell proliferation and failure to suppress colony growth compared to wildtype (PMID: 25584008, 31776133)."
              },
              "old": {
                "description": "The TP53 R273H mutation is located in the protein's DNA binding domain. The TP53 R273H mutation was found in triple-negative breast cancer and 20% of pedigrees of families diagnosed with the Li-Fraumeni syndrome (LFS) (PMID: 31776133, 25584008). Expression of this mutant resulted in cell survival by activating AKT signaling and suppressing the expression of BCL-modifying factor (BMF) (PMID: 26181206). Expression of this mutant in TP53-null cells resulted in decreased transactivation of p53 target genes, as measured by a luciferase reporter assay (PMID: 25584008, 15037740). Expression of this mutation in osteosarcoma and breast cancer cell lines demonstrated that it is inactivating as measured by moderately increased cell proliferation and failure to suppress colony growth compared to wildtype (PMID: 25584008, 31776133). In vitro studies demonstrate that this mutation confers sensitivity to the combination of chemotherapy with the PARP inhibitor talazoparib when expressed in a breast cancer cell line as measured by decreased cell metabolic activity upon drug treatment (PMID: 31776133)."
              },
              "operation": "update",
              "uuids": "b54d2ced-283e-49fa-bfe2-8d3c01d34c73"
            }
          ],
          "timeStamp": 1664404401881
        },
        "-ND5ENN86K001Q_DZIhu": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R273G, Mutation Effect",
              "new": {
                "description": "The TP53 R273G mutation is located in the protein's DNA binding domain and occurs at a hotspot residue (PMID: 26619011). In vitro studies have demonstrated that this mutation has inconclusive effect, as demonstrated by similar levels of proliferation, colony formation or invasion in the mutant compared to wildtype (PMID: 24677579)."
              },
              "old": {
                "description": "The TP53 R273G mutation is located in the protein's DNA binding domain. Expression of this mutation in cells did not enhance proliferation, colony formation or invasion compared to wildtype TP53 (PMID: 24677579). However, this mutation is a hotspot, suggesting that it is likely oncogenic (PMID: 26619011)."
              },
              "operation": "update",
              "uuids": "8997fe78-40db-4812-8ead-2635615747c1"
            }
          ],
          "timeStamp": 1664404522361
        },
        "-ND5ET6Dmnf3YRMZAE92": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R213Q, Mutation Effect",
              "new": {
                "description": "The TP53 R213Q mutation is located in the protein's DNA binding domain. In vitro studies have demonstrated that this mutation is inactivating, as measured by reduced ability to induce cell cycle arrest and apoptosis, as well as increased induction of MDM2 expression (PMID: 10871862)."
              },
              "old": {
                "description": "The TP53 R213Q mutation is located in the protein's DNA binding domain. This mutation displays a reduced ability to induce cell cycle arrest and apoptosis. Additionally, TP53 R213Q has been shown to induce expression of the growth-promoting molecule, MDM2 (PMID: 10871862)."
              },
              "operation": "update",
              "uuids": "ca3a45e9-ba06-4bdf-8ff8-4cb85c1eb250"
            }
          ],
          "timeStamp": 1664404545854
        },
        "-ND5EbIlJADIkB2LDze4": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G245C, Mutation Effect",
              "new": {
                "description": "The TP53 G245C mutation is located in the protein's DNA binding domain. In vitro and structural studies have demonstrated that this mutation has inconclusive effect, as evidenced by the similar levels of TP53-mediated transcriptional activity in the mutant compared to wildtype, even though the mutant results in differences in conformational flexibility of the DNA-binding domain of p53 (PMID: 15037740, 22803791).",
                "effect": "Inconclusive",
                "oncogenic": "Inconclusive"
              },
              "old": {
                "description": "The TP53 G245C mutation is located in the protein's DNA binding domain. Structural studies have shown that this mutation results in differences of conformational flexibility of the DNA-binding domain of p53 (PMID: 22803791). Expression of this mutation in cell lines that lack TP53 expression did not enhance TP53-mediated transcriptional activity in reporter assays, as compared to expression of wildtype TP53 (PMID: 15037740).",
                "effect": "Likely Loss-of-function",
                "oncogenic": "Likely"
              },
              "operation": "update",
              "uuids": "5d65bf5b-ce94-495a-817d-ffcfe4d851fe,13d74785-c4da-4a68-b468-5773a14a5412"
            }
          ],
          "timeStamp": 1664404583521
        },
        "-ND5Ga4SaGDwdMO5McvC": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "H179Y, Mutation Effect",
              "new": {
                "description": "The TP53 H179Y mutation is located in the protein's DNA binding domain. In vitro studies have demonstrated that this mutation is inactivating, as evidenced by the increased G1 to S phase transition, enlarged cell size, as well as increased expression of cyclin A1 and CDK4 in the mutant compared to wildtype (PMID: 17530187)."
              },
              "old": {
                "description": "The TP53 H179Y mutation is located in the protein's DNA binding domain. Overexpression of this mutant in HELF cells promoted G1 to S phase transition and caused enlarged cell size. Moreover, it induced increased expression of cyclin A1 and CDK4 (PMID: 17530187)."
              },
              "operation": "update",
              "uuids": "4900f3b0-5437-4553-a4b8-b7a9978c107c"
            }
          ],
          "timeStamp": 1664405102797
        },
        "-ND5GfnNNQXHuNEdjhRc": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "H179L, Mutation Effect",
              "new": {
                "description": "The TP53 H179L mutation is located in the protein's DNA binding domain. In vitro studies have demonstrated that this mutation is inactivating, as evidenced by enhanced adhesion to extracellular matrix and increased growth in suspension culture in the mutant compared to wildtype (PMID: 23150443)."
              },
              "old": {
                "description": "The TP53 H179L mutation is located in the protein's DNA binding domain. Overexpression of this mutant into NIH3T3 fibroblast resulted in enhanced adhesion to extracellular matrix and was sufficient to allow anchorage-independent growth in soft agar assays compared to controls (PMID: 23150443)."
              },
              "operation": "update",
              "uuids": "5b08abf9-5d6f-499f-8c90-378c1a899f37"
            }
          ],
          "timeStamp": 1664405126216
        },
        "-ND5IRvuJP63VWAQEcem": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "H179Q, Mutation Effect",
              "new": {
                "description": "The TP53 H179Q mutation is located in the protein's DNA binding domain. In vitro studies have demonstrated that this mutation is inactivating and behaves as a dominant-negative allele, as evidenced by reduced expression of p21 and increased G1 to S phase cell cycle progression in the mutant compared to wildtype (PMID: 22540896)."
              },
              "old": {
                "description": "The TP53 H179Q mutation is located in the protein's DNA binding domain. This mutation behaves as a dominant-negative allele. Expression of TP53 H179Q in the SK-Mel173 melanoma cell line reduced the expression of p21, a negative regulator of cell cycle, and resulted in increased G1 to S phase cell cycle progression (PMID: 22540896)."
              },
              "operation": "update",
              "uuids": "4ee72828-764c-4310-90a1-4719796682ca"
            }
          ],
          "timeStamp": 1664405589610
        },
        "-ND5KsP4Tl7_Jmrp9jDa": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "H179N, Mutation Effect",
              "new": {
                "description": "The TP53 H179N mutation is located in the protein's DNA binding domain. In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by reduced DNA binding activity and similar exonuclease activity in the mutant compared to wildtype (PMID: 19462533)."
              },
              "old": {
                "description": "The TP53 H179N mutation is located in the protein's DNA binding domain. This mutation did not change the exonuclease activity of p53 in comparison to the wildtype protein. However, this mutant exhibits significantly reduced DNA binding activity, as measured by sequence-specific DNA binding activity assays (PMID: 19462533)."
              },
              "operation": "update",
              "uuids": "89391554-fcfb-436b-9903-c4982afcaf7e"
            }
          ],
          "timeStamp": 1664406226421
        },
        "-ND5L2AsNmhuXIPA_9QU": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "H193R, Mutation Effect",
              "new": {
                "description": "The TP53 H193R mutation is located in the protein's DNA binding domain. This mutation has been found in sarcoma (PMID: 25669829). In vitro studies have demonstrated that this mutation is likely inactivating, as measured by decreased DNA binding and decreased transactivaction of TP53, likely leading to reduced p21 activation (PMID: 9627118). In a phase I clinical trial of pazopanib, a VEGF inhibitor, and vorinostat, a histone deacetylase inhibitor, eleven patients with sarcoma and colorectal cancer who harbor the TP53 H193R mutation as well as other TP53 mutations in exons 5-8 had longer median progression-free and overall survival compared to patients without TP53 mutations in response to treatment (PMID: 25669829)."
              },
              "old": {
                "description": "The TP53 H193R mutation is located in the protein's DNA binding domain. In biochemical assays, expression of this TP53 mutant resulted in decreased DNA binding and decreased transaction of TP53, likely leading to reduced p21 activation (PMID: 9627118)."
              },
              "operation": "update",
              "uuids": "19981225-8861-4254-8a15-b38ad0176529"
            }
          ],
          "timeStamp": 1664406270568
        },
        "-NDTUkPsKVUQf9JTp_Fc": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "K291E, Mutation Effect",
              "new": {
                "description": "The TP53 K291E mutation is located in the protein's DNA binding domain and is a known hotspot mutation (PMID: 26619011). This mutation has been found in non-small cell lung cancer (PMID: 9416838). In vitro studies have demonstrated that this mutation is likely activating, as evidenced by significantly increased apoptosis, decreased cell viability and altered transcription of TP53 target genes in the mutant compared to wildtype (PMID: 15781620).",
                "effect": "Likely Gain-of-function",
                "oncogenic": "Likely Neutral"
              },
              "old": {
                "description": "The TP53 K291E mutation is located in the protein's DNA binding domain and is a known hotspot mutation (PMID: 26619011). This mutation has been found in non-small cell lung cancer (PMID: 9416838). In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by significantly increased apoptosis, decreased cell viability and altered transcription of TP53 target genes in the mutant compared to wildtype (PMID: 15781620).",
                "effect": "Likely Loss-of-function",
                "oncogenic": "Likely"
              },
              "operation": "update",
              "uuids": "3a9cc731-75b8-4639-84d7-853aa820d2a1,5fc85227-bb09-490f-8adc-cbc68fa48ac1"
            }
          ],
          "timeStamp": 1664811468485
        },
        "-NDT_BeaEIwL3pIClmwj": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "K292T, Mutation Effect",
              "new": {
                "description": "The TP53 K292T mutation is located in the protein's DNA binding domain. In vitro studies have demonstrated that this mutation is likely activating, as evidenced by significantly increased apoptosis, decreased cell viability and altered transcription of TP53 target genes in the mutant compared to wildtype (PMID: 15781620).",
                "effect": "Likely Gain-of-function",
                "oncogenic": "Likely Neutral"
              },
              "old": {
                "description": "The TP53 K292T mutation is located in the protein's DNA binding domain and is a known hotspot mutation (PMID: 26619011). In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by significantly increased apoptosis, decreased cell viability and altered transcription of target genes in the mutant compared to wildtype (PMID: 15781620).",
                "effect": "Likely Loss-of-function",
                "oncogenic": "Likely"
              },
              "operation": "update",
              "uuids": "d1b01d13-6e1d-4aee-a800-d70b602d3247,8698b568-758c-4318-8054-28515ca884c8"
            }
          ],
          "timeStamp": 1664812894902
        },
        "-NDT_kQEEj-JBghw0CwK": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Q144R, Mutation Effect",
              "new": {
                "description": "The TP53 Q144R mutation is located in the protein's DNA binding domain and is a known hotspot mutation (PMID: 26619011). However, in vitro studies have demonstrated that this mutation is likely activating, as evidenced by significantly increased apoptosis, decreased cell viability and altered transcription of TP53 target genes in the mutant compared to wildtype (PMID: 15781620).",
                "effect": "Inconclusive",
                "oncogenic": "Inconclusive"
              },
              "old": {
                "description": "The TP53 Q144R mutation is located in the protein's DNA binding domain and is a known hotspot mutation (PMID: 26619011). In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by significantly increased apoptosis, decreased cell viability and altered transcription of target genes in the mutant compared to wildtype (PMID: 15781620).",
                "effect": "Likely Loss-of-function",
                "oncogenic": "Likely"
              },
              "operation": "update",
              "uuids": "96f664ad-8758-4b98-9a1e-7648ce877649,e113fd62-9072-4307-9b2c-3f42dac5e306"
            }
          ],
          "timeStamp": 1664813041375
        },
        "-NDU63NGDMCDuZwtPwrX": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R290G, Mutation Effect",
              "new": {
                "description": "The TP53 R290G mutation is located in the protein's DNA binding domain (PMID: 26619011). In vitro studies have demonstrated that this mutation is likely activating, as evidenced by significantly increased apoptosis, decreased cell viability and altered transcription of TP53 target genes in the mutant compared to wildtype (PMID: 15781620).",
                "effect": "Likely Gain-of-function",
                "oncogenic": "Likely Neutral"
              },
              "old": {
                "description": "The TP53 R290G mutation is located in the protein's DNA binding domain and is a known hotspot mutation (PMID: 26619011). In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by significantly increased apoptosis, decreased cell viability and altered transcription of target genes in the mutant compared to wildtype (PMID: 15781620).",
                "effect": "Likely Loss-of-function",
                "oncogenic": "Likely"
              },
              "operation": "update",
              "uuids": "48f340e6-0711-4a50-996a-f0c8d403b9c4,7e7a3ae5-6c0c-45a4-85c9-d3bc9042a818"
            }
          ],
          "timeStamp": 1664821773977
        },
        "-NDU6SJFFrTXTqRY-ZaW": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R158H, Mutation Effect",
              "new": {
                "description": "The TP53 R158H mutation is located in the protein's DNA binding domain. In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by loss of p53-mediated transactivation, decreased ability to induce apoptosis and increased oncogenic colony transformation of the mutant compared to wildtype (PMID: 10229196, 25584008)."
              },
              "old": {
                "description": "The TP53 R158H mutation is located in the protein's DNA binding domain. In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by loss of p53-mediated transactivation and reduced colony formation in the mutant compared to wildtype (PMID: 10229196, 25584008)."
              },
              "operation": "update",
              "uuids": "94bb01ea-f180-4306-8cd9-cab503e1bbcd"
            }
          ],
          "timeStamp": 1664821876120
        },
        "-NDU7K_qzOV9gV7e0yf-": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R282Q, Mutation Effect",
              "new": {
                "description": "The TP53 R282Q mutation is located in the protein's DNA binding domain. This mutation has been identified as a statistically significant hotspot (PMID: 26619011). Structural studies have demonstrated that this mutation is likely inactivating, as evidenced by the decreased flexibility of the L1 DNA-binding loop and two novel conformations of the L3 DNA-binding loop in the mutant compared to wildtype, all of which are predicted to deactivate the tumor suppressor functions of p53 (PMID: 18453682)."
              },
              "old": {
                "description": "The TP53 R282Q mutation is located in the protein's DNA binding domain. Structural studies showed that this mutation has a significant impact on the flexibility of two DNA-binding loops (L1 and L3) of p53, which is predicted to deactivate the tumor suppressor functions of p53 (PMID: 18453682)."
              },
              "operation": "update",
              "uuids": "42c10a9f-79bc-4300-87bb-dc024eff1ef4"
            }
          ],
          "timeStamp": 1664822106622
        },
        "-NDUJvoXBRzbrp6-UkJc": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R158L, Mutation Effect",
              "new": {
                "description": "The TP53 R158L mutation is located in the protein's DNA binding domain. This mutation has been found in lung cancer (PMID: 31067569). In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by loss of TP53-mediated transactivation, decreased ability to reduce colony formation and aberrant transcriptional regulation in the mutant compared to wildtype (PMID: 25584008, 16861262, 31067569).",
                "effect": "Likely Loss-of-function"
              },
              "old": {
                "description": "The TP53 R158L mutation is located in the protein's DNA binding domain. Expression of this mutation in human lung cancer cell lines results in loss of p53-mediated transactivation as detected by luciferase reporter assays (PMID: 25584008, 15037740). Additionally, expression of this mutant resulted in reduced growth as shown by colony formation assays (PMID: 25584008). However, this mutation does not interfere with wildtype p53, as measured by a mammalian reporter gene assay (PMID: 16861262).",
                "effect": "Loss-of-function"
              },
              "operation": "update",
              "uuids": "e833d643-3b09-43c2-ba46-3c342042ddcf"
            }
          ],
          "timeStamp": 1664825408810
        },
        "-NErBNg6o9GMk21qA6f2": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Y220C, All Solid Tumors",
              "new": {
                "TIs": [
                  {
                    "name": "Standard implications for sensitivity to therapy",
                    "name_uuid": "f9a854d5-0bef-4e01-babf-b79748fec3ba",
                    "treatments_uuid": "7edcd1d5-1c73-4a2a-94fa-fc7617bf5e7b",
                    "type": "SS"
                  },
                  {
                    "name": "Standard implications for resistance to therapy",
                    "name_uuid": "e90cf897-5fca-4b3f-9b3b-0fabc839a238",
                    "treatments_uuid": "d3be51fa-eaf8-4020-8a5e-7848c94423ae",
                    "type": "SR"
                  },
                  {
                    "name": "Investigational implications for sensitivity to therapy",
                    "name_uuid": "2b04aaed-1766-498f-809a-10493b40dbba",
                    "treatments": [
                      {
                        "description": "(Abstract: Dumbrava et al. Abstract# 3003, ASCO 2022. https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.3003)(Abstract: Dumble et al. Abstract# LB006, AACR 2021. https://aacrjournals.org/cancerres/article/81/13_Supplement/LB006/669897/Abstract-LB006-PC14586-The-first-orally)",
                        "description_review": {
                          "lastReviewed": "",
                          "updateTime": 1666299255424,
                          "updatedBy": "User"
                        },
                        "description_uuid": "66c79a3e-33d8-4944-b1de-28783e75c371",
                        "fdaLevel": "Fda3",
                        "fdaLevel_review": {
                          "lastReviewed": "",
                          "updateTime": 1666299095877,
                          "updatedBy": "User"
                        },
                        "fdaLevel_uuid": "24754ac4-11d8-4c33-c0f5-54e6fe3d9d79",
                        "indication": "",
                        "indication_uuid": "97b66534-7030-453e-b252-6873c46b89c3",
                        "level": "3A",
                        "level_review": {
                          "lastReviewed": "",
                          "updateTime": 1666299095889,
                          "updatedBy": "User"
                        },
                        "level_uuid": "c342747b-7b60-406f-9b92-f5eb4f6d6e63",
                        "name": "89814a16-3ae4-4cf0-8d69-34c03964345f",
                        "name_review": {
                          "added": true,
                          "updateTime": 1666299092591,
                          "updatedBy": "User"
                        },
                        "name_uuid": "495ba473-e137-4343-b248-04acbea470bd",
                        "propagation": "no",
                        "propagationLiquid": "no",
                        "propagationLiquid_review": {
                          "lastReviewed": "",
                          "updateTime": 1666299095864,
                          "updatedBy": "User"
                        },
                        "propagationLiquid_uuid": "e77f83e5-db1c-4d76-85a9-038b4387e459",
                        "propagation_review": {
                          "lastReviewed": "",
                          "updateTime": 1666299095849,
                          "updatedBy": "User"
                        },
                        "propagation_uuid": "bb2d282e-9f90-4483-905a-119a8124fab1",
                        "short": ""
                      }
                    ],
                    "treatments_uuid": "46461976-70d0-478f-b6a0-9fdc81384abe",
                    "type": "IS"
                  },
                  {
                    "name": "Investigational implications for resistance to therapy",
                    "name_uuid": "566d639b-79bc-4394-a550-bcc8c9d0d4f1",
                    "treatments_uuid": "1713e719-f2e3-4883-894e-ddb6c7a9c3b8",
                    "type": "IR"
                  }
                ],
                "cancerTypes": [
                  {
                    "code": "",
                    "mainType": "All Solid Tumors",
                    "subtype": ""
                  }
                ],
                "cancerTypes_review": {
                  "added": true,
                  "updateTime": 1666298893666,
                  "updatedBy": "User"
                },
                "cancerTypes_uuid": "8ffe2c4d-1ce2-418e-b329-c74835cde99a",
                "diagnostic": {
                  "description": "",
                  "description_uuid": "c28b5864-44ba-46b8-8625-0a96a6eba4d4",
                  "level": "",
                  "level_uuid": "31b61390-4151-46e6-a4e9-75f28aa2e1a6",
                  "relevantCancerTypes_uuid": "2fb906e2-4259-4211-879a-869e9d7490fa",
                  "short": ""
                },
                "diagnosticSummary": "",
                "diagnosticSummary_uuid": "134f7eb5-31de-4636-96e0-39e98780c9cb",
                "diagnostic_uuid": "d18b9281-4d11-42c7-bdcb-79dcbab6aa69",
                "excludedCancerTypes_uuid": "486acab0-85d7-4499-af62-fbfc929dcccb",
                "prognostic": {
                  "description": "",
                  "description_uuid": "d2069fce-6256-4f93-bb76-5161ecd51d15",
                  "level": "",
                  "level_uuid": "f9833cef-3e18-4d5b-bcd1-0c441a067924",
                  "relevantCancerTypes_uuid": "5e2cc12d-82b8-451e-9a58-35c980335018",
                  "short": ""
                },
                "prognosticSummary": "",
                "prognosticSummary_uuid": "b3e01328-b8d5-43bd-84df-848d829f6fe2",
                "prognostic_uuid": "c971d457-607f-4d83-8b89-8c439d7cc468",
                "relevantCancerTypes_uuid": "760dbf8f-8ed0-4c66-af92-3c6ec598ce1f",
                "summary": "There is promising clinical data in patients with TP53 Y220C-mutant solid tumors treated with the TP53 structural corrector PC14586.",
                "summary_review": {
                  "lastReviewed": "",
                  "updateTime": 1666298926052,
                  "updatedBy": "User"
                },
                "summary_uuid": "58cfdce6-2588-49a9-8f3c-76534fd4951c"
              },
              "operation": "add",
              "uuids": "58cfdce6-2588-49a9-8f3c-76534fd4951c,495ba473-e137-4343-b248-04acbea470bd"
            }
          ],
          "timeStamp": 1666299562450
        },
        "-NG2XOGmHnCTRVPDzX5V": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "H193N, Mutation Effect",
              "new": {
                "description": "The TP53 H193N mutation is located in the protein's DNA binding domain. In vitro studies have suggested that this mutation is likely inactivating, as evidenced by increased exonuclease activity and significantly reduced DNA binding activity compared to the wildtype (PMID: 19462533)."
              },
              "old": {
                "description": "The TP53 H193N mutation is located in the protein's DNA binding domain. This mutation exhibited increased exonuclease activity and displayed significantly reduced DNA binding activity compared to the wildtype protein, suggesting a loss of tumor suppressor function (PMID: 19462533)."
              },
              "operation": "update",
              "uuids": "a4c0defb-5dde-4e3c-86b4-514e487bbcbd"
            }
          ],
          "timeStamp": 1667580400763
        },
        "-NG3JXwuuBb2h0KXXrtE": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "C176F, Mutation Effect",
              "new": {
                "description": "The TP53 C176F mutation is located in the protein's DNA binding domain. This mutation has been found in head and neck cancer (PMID: 22090360). In vitro studies have demonstrated that this mutation is inactivating, as evidenced by decreased transactivation of p21, decreased production of reactive oxygen species and decreased cell death when the mutant is treated with radiation compared to wildtype, suggesting an inhibition of radiation-induced senescence that results in treatment failure (PMID: 22090360)."
              },
              "old": {
                "description": "The TP53 C176F mutation is located in the protein's DNA binding domain. Expression of this mutant resulted in decreased transactivation of thee p53 target gene, p21, that is known to inhibit the cell cycle progression. Additionally, the TP53 C176F mutant led to treatment failure of head and neck cancers through inhibition of radiation-induced senescence (PMID: 22090360)."
              },
              "operation": "update",
              "uuids": "d6a9728c-480b-4a9a-a8b2-48c3fd855b33"
            }
          ],
          "timeStamp": 1667593547581
        },
        "-NG3Jchc1Cfyc7kjRush": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "C176R, Mutation Effect",
              "new": {
                "description": "The TP53 C176R mutation is located in the protein's DNA binding domain. In vitro studies have suggested that this mutation is inactivating and acts as a dominant negative, as evidenced by the ability of mutant yeasts coexpressing both wild-type and C176R-mutated p53 to survive on Foa plates compared to wildtype (PMID: 8633021)."
              },
              "old": {
                "description": "The TP53 C176R mutation is located in the protein's DNA binding domain. Expression of this mutant acted as a dominant negative and inhibited the tumor suppressor abilities of wild type p53 (PMID: 8633021)."
              },
              "operation": "update",
              "uuids": "8be2e6a2-755f-4bd6-ab7d-88b448c6171a"
            }
          ],
          "timeStamp": 1667593571180
        },
        "-NG3Jiv1wB1VI0lLyZKF": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "I195T, Mutation Effect",
              "new": {
                "description": "The TP53 I195T mutation is located in the protein's DNA binding domain. Structural studies have suggested that this mutation is likely inactivating as evidenced by the decreased half-life time, faster aggregation and faster unfolding time at body temperature of the mutant compared to wildtype protein, suggesting that the mutant is highly destabilized and could result in loss of p53 tumor suppressor function (PMID: 12700230)."
              },
              "old": {
                "description": "The TP53 I195T mutation is located in the protein's DNA binding domain. Based on structural studies, the TP53 I195T mutant is a highly destabilized mutant that has not folded properly; this may suggest loss of p53 tumor suppressor function (PMID: 12700230). Alterations in the DNA binding domain result in altered contact of p53 with its target DNA sequences, thereby altering its transcriptional function (PMID: 8023157, 11900253)."
              },
              "operation": "update",
              "uuids": "9c47ac79-0f93-4901-8709-3d2666850fcf"
            }
          ],
          "timeStamp": 1667593596614
        },
        "-NG3JodISCcQDgYihRnM": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G266E, Mutation Effect",
              "new": {
                "description": "The TP53 G266E mutation is located in the protein's DNA binding domain. In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by decreased transcriptional transactivation in the mutant compared to the wildtype, suggesting a loss of function to regulate transactivation of p53 target genes (PMID: 17724467)."
              },
              "old": {
                "description": "The TP53 G266E mutation is located in the protein's DNA binding domain. Assessment of transcriptional transactivation by p53 in yeast, has shown that this mutant has relative weak activity in comparison to that of the wild type p53, suggesting a loss of function to regulate transactivation of p53 target genes (PMID: 17724467)."
              },
              "operation": "update",
              "uuids": "a37213f6-cf16-40a6-b0bc-368d8530366f"
            }
          ],
          "timeStamp": 1667593620055
        },
        "-NG3K1327UDmM_rmACMf": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R249S, Mutation Effect",
              "new": {
                "description": "The TP53 R249S mutation is located in the protein's DNA binding domain. Structural and in vitro studies have demonstrated that this mutation is likely inactivating as evidenced by distortion of the local binding surface and increased aggregation of the mutant proteins compared to wildtype, reduced TP53 transactivation activity as measured by luciferase reporter assays, defective cell cycle progression, and aberrant expression of apoptosis proteins in cells expressing the mutant protein compared to wildtype (PMID: 14741214, 21445056, 18996393)."
              },
              "old": {
                "description": "The TP53 R249S mutation is located in the protein's DNA binding domain. Structural studies have shown distortion of p53 throughout the DNA binding surface. The peptide FL-CDB3 has been design to rescue this mutation to revert the chemical shifts back to that of the wild type (PMID: 14741214). Expression of this mutation in TP53-null cell lines resulted in aggregation of mutant proteins, likely leading to destabilization of TP53 and upregulation of heat shock proteins (PMID: 21445056). Expression of this mutation in TP53-null lung cancer cell lines results in reduced TP53 transactivation activity, as evidenced by luciferase reporter assays. Cell lines expressing this mutation also have a defect in cell cycle progression and aberrant expression of apoptosis proteins, as compared to cells expressing wildtype TP53 (PMID: 18996393)."
              },
              "operation": "update",
              "uuids": "9c07e707-9d36-4a29-90f3-c27a187e03da"
            }
          ],
          "timeStamp": 1667593675015
        },
        "-NG3K6tyiGIh_zDLGoT-": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R249M, Mutation Effect",
              "new": {
                "description": "The TP53 R249M mutation is located in the protein's DNA binding domain. In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by the mutant's inability to inhibit the transcriptional activity of the p21 promoter and enhance TP53-mediated transcriptional activity in reporter assays compared to wildtype (PMID: 17999388, 15037740).",
                "effect": "Likely Loss-of-function"
              },
              "old": {
                "description": "The TP53 R249M mutation is located in the protein's DNA binding domain. When expressed in cells it failed to inhibit the transcriptional activity of FAK promoter or p21 promoter, suggesting that it fails to activate/repress p53 target genes (PMID: 17999388). Expression of this mutation in cell lines that lack TP53 expression did not enhance TP53-mediated transcriptional activity in reporter assays, as compared to expression of wildtype TP53 (PMID: 15037740).",
                "effect": "Loss-of-function"
              },
              "operation": "update",
              "uuids": "131c7f95-88bd-4981-a4c7-727fae35bef8"
            }
          ],
          "timeStamp": 1667593698946
        },
        "-NGICAGNNV3viKkzJwtC": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Y220C, All Solid Tumors, INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY, 89814a16-3ae4-4cf0-8d69-34c03964345f",
              "new": {
                "description": "PC14586 is an orally available, small molecule structural corrector specific for the p53 Y220C mutant protein. In a phase I study of PC14586 in 29 patients with advanced solid tumors harboring a TP53 Y220C mutation, one patient with small cell lung cancer and one patient with breast cancer each had a partial response to treatment (Abstract: Dumbrava et al. Abstract# 3003, ASCO 2022. https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.3003). In vivo xenograft studies with TP53 Y220C mutant gastric cancer cell line NUGC3 and Y220C-mutant patient derived xenografts demonstrated sensitivity to PC14586 treatment as measured by dose-dependent tumor shrinkage and conversion of TP53 Y220C to the wildtype conformation (Abstract: Dumble et al. Abstract# LB006, AACR 2021. https://aacrjournals.org/cancerres/article/81/13_Supplement/LB006/669897/Abstract-LB006-PC14586-The-first-orally)."
              },
              "old": {
                "description": "(Abstract: Dumbrava et al. Abstract# 3003, ASCO 2022. https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.3003)(Abstract: Dumble et al. Abstract# LB006, AACR 2021. https://aacrjournals.org/cancerres/article/81/13_Supplement/LB006/669897/Abstract-LB006-PC14586-The-first-orally)"
              },
              "operation": "update",
              "uuids": "495ba473-e137-4343-b248-04acbea470bd"
            }
          ],
          "timeStamp": 1667843273490
        },
        "-NGICG11cR1t_up6t1Nq": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G266E, Mutation Effect",
              "new": {
                "description": "The TP53 G266E mutation is located in the protein's DNA binding domain. In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by decreased transcriptional transactivation of p53 target genes in the mutant compared to the wildtype, suggesting a loss of function to regulate transactivation of p53 target genes (PMID: 17724467)."
              },
              "old": {
                "description": "The TP53 G266E mutation is located in the protein's DNA binding domain. In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by decreased transcriptional transactivation in the mutant compared to the wildtype, suggesting a loss of function to regulate transactivation of p53 target genes (PMID: 17724467)."
              },
              "operation": "update",
              "uuids": "a37213f6-cf16-40a6-b0bc-368d8530366f"
            }
          ],
          "timeStamp": 1667843297084
        },
        "-NGICRCQ1buawzTFj-aX": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R249M, Mutation Effect",
              "new": {
                "description": "The TP53 R249M mutation is located in the protein's DNA binding domain. In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by the mutant's inability to inhibit the transcriptional activity of the p21 promoter and enhance TP53-mediated transcriptional activity in reporter assays compared to wildtype (PMID: 17999388, 15037740).",
                "effect": "Likely Loss-of-function"
              },
              "old": {
                "description": "The TP53 R249M mutation is located in the protein's DNA binding domain. When expressed in cells it failed to inhibit the transcriptional activity of FAK promoter or p21 promoter, suggesting that it fails to activate/repress p53 target genes (PMID: 17999388). Expression of this mutation in cell lines that lack TP53 expression did not enhance TP53-mediated transcriptional activity in reporter assays, as compared to expression of wildtype TP53 (PMID: 15037740).",
                "effect": "Loss-of-function"
              },
              "operation": "update",
              "uuids": "131c7f95-88bd-4981-a4c7-727fae35bef8"
            }
          ],
          "timeStamp": 1667843342869
        },
        "-NGICWwR3s8yKsFRboiI": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R249W, Mutation Effect",
              "new": {
                "description": "The TP53 R249W mutation is located in the protein's DNA binding domain. In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by increased colony formation and greater migration in the mutant compared to wildtype (PMID: 23612969).",
                "effect": "Likely Loss-of-function"
              },
              "old": {
                "description": "The TP53 R248W mutation is located in the protein's DNA binding domain. Expression of this mutant in p53 null cells leads to robust colony formation ability and greater migration relative to wild type p53 as measured by colony formation assays (PMID: 23612969).",
                "effect": "Loss-of-function"
              },
              "operation": "update",
              "uuids": "ed12f229-01c9-4abd-9750-7d75ea473d06"
            }
          ],
          "timeStamp": 1667843366358
        },
        "-NGICbcxaMw9V1QBDa1Q": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Y234H, Mutation Effect",
              "new": {
                "description": "The TP53 Y234H mutation is located in the protein's DNA binding domain. In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by the reduced ability to transactivate p53 target genes of the mutant compared to wildtype (PMID: 22710932).",
                "effect": "Likely Loss-of-function"
              },
              "old": {
                "description": "The TP53 Y234H mutation is located in the protein's DNA binding domain. Transactivation studies have shown that this mutant can weakly transactivate p53 target genes in comparison to that of the wild type p53 (PMID: 22710932).",
                "effect": "Loss-of-function"
              },
              "operation": "update",
              "uuids": "27311c4f-ae10-4f10-b49f-113d790baa00"
            }
          ],
          "timeStamp": 1667843389687
        },
        "-NGIChPXrDdEexL9-RKE": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Y234C, Mutation Effect",
              "new": {
                "description": "The TP53 Y234C mutation is located in the protein's DNA binding domain. This mutation has been found in ovarian cancer (PMID: 26748848). In vitro studies have demonstrated that this mutation is inactivating, as evidenced by decreased transactivation of p53 target genes, increased cytoplasmic localization and increased apoptosis when treated with an amyloid aggregate TP53 inhibitor in the mutant compared to wildtype, suggesting that this mutation may cause amyloid aggregate formation that inactivates the p53 protein (PMID: 10229196, 16861262, 26748848)."
              },
              "old": {
                "description": "The TP53 Y234C mutation is located in the protein's DNA binding domain. Expression of this mutant resulted in decreased transactivation of p53 target genes, as a measured by a luciferase reporter assay (PMID: 10229196). This was because this mutant was predominantly localized in the cytoplasm and not in the nucleus (PMID: 16861262). Ovarian cancer patient samples expressing this mutation were sensitive to an amyloid aggregate TP53 inhibitor as evidenced by apoptosis assays. Some TP53 mutations have been shown to form amyloid aggregates that leads to inactivation of the TP53 protein. Responsiveness of this variant to amyloid aggregate inhibitors suggest that this is a loss-of-function mutation (PMID: 26748848)."
              },
              "operation": "update",
              "uuids": "96e2befc-af08-41f6-9e7c-1756b7ed3e47"
            }
          ],
          "timeStamp": 1667843413340
        },
        "-NGICn4sJojYfhDSu36R": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "C238S, Mutation Effect",
              "new": {
                "description": "The TP53 C238S mutation is located in the protein's DNA binding domain. In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by decreased transactivation of p53 target genes in the mutant compared to wildtype (PMID: 19681600).",
                "effect": "Likely Loss-of-function"
              },
              "old": {
                "description": "The TP53 C238S mutation is located in the protein's DNA binding domain. Expression of this mutant resulted in decreased transactivation of p53 target genes, as a measured by a luciferase reporter assay (PMID: 19681600).",
                "effect": "Loss-of-function"
              },
              "operation": "update",
              "uuids": "49e1b7b9-d9d6-440c-b0a8-ac813f3a2740"
            }
          ],
          "timeStamp": 1667843436594
        },
        "-NGICsmy7NtJi_85C3rd": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "C238F, Mutation Effect",
              "new": {
                "description": "The TP53 C238F mutation is located in the protein's DNA binding domain. This mutation has been found in breast cancer (PMID: 20407015). In vivo and structural studies have demonstrated that this mutation is inactivating, as evidenced by the structural prediction that the mutation interferes with the histidine or cysteine side chains that are known to be involved in the coordination of the zinc ion, as well as the mutant's inability to transactivate p53 target genes compared to wildtype (PMID: 20407015)."
              },
              "old": {
                "description": "The TP53 C238F mutation is located in the protein's DNA binding domain. This mutation interferes with the histidine or cysteine site chains that are known to be involved in coordination of the zinc ion. This makes the protein dysfunctional in terms of transcriptional activation (PMID: 20407015)."
              },
              "operation": "update",
              "uuids": "f651d617-a45b-4abb-92ea-e0b8ae80cf0f"
            }
          ],
          "timeStamp": 1667843459960
        },
        "-NGICydRrjo6i5tlDNTf": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "P151S, Mutation Effect",
              "new": {
                "description": "The TP53 P151S mutation is located in the protein's DNA binding domain. This mutation has been found in head and neck squamous cell carcinoma (PMID: 21903770). In vitro and in vivo studies have demonstrated that this mutation is inactivating, as evidenced by the formation of larger tumor spheroids with longer migration and invasion distances in matrigel culture compared to wildtype, as well as increased tumor growth and decreased animal survival in xenograft models (PMID: 21903770)."
              },
              "old": {
                "description": "The TP53 P151S mutation is located in the protein's DNA binding domain. Overexpression of this mutant in HNSCC cells promoted the formation of larger tumor spheroids with longer migration and invasion distances in matrigel culture in comparison with control vectors. Moreover, this mutant led to increased tumor growth and decreased animal survival in xenograft models (PMID: 2857548)."
              },
              "operation": "update",
              "uuids": "1151e72c-dc3c-4a2c-ba52-c825b76238c2"
            }
          ],
          "timeStamp": 1667843483926
        },
        "-NGID3L_bAUZzJeohKqj": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R158C, Mutation Effect",
              "new": {
                "description": "The TP53 R158C mutation is located in the protein's DNA binding domain. In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by decreased transactivation of p53 target genes in the mutant compared to wildtype (PMID: 17947339)."
              },
              "old": {
                "description": "The TP53 R158C mutation is located in the protein's DNA binding domain. Expression of this mutant resulted in decreased transactivation of p53 target genes, as a measured by a luciferase reporter assay (PMID: 17947339)."
              },
              "operation": "update",
              "uuids": "73d09b4a-9b64-4d4c-af06-008a67646710"
            }
          ],
          "timeStamp": 1667843507295
        },
        "-NGID966il7dpVei1G5E": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V173E, Mutation Effect",
              "new": {
                "description": "The TP53 V173E mutation is located in the protein's DNA binding domain. This mutation has been found in lung carcinoma  (PMID: 9472631). In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by the mutant's inability to bind to the responsive elements of p53 and transactivate p53-dependent promoters compared to wildtype (PMID: 9472631).",
                "effect": "Likely Loss-of-function"
              },
              "old": {
                "description": "The TP53 V173E mutation is located in the protein's DNA binding domain. This mutation failed to bind to the responsive elements of p53 and also failed to transactivate p53-dependent promoters, as measured by luciferase reporter assays (PMID: 9472631).",
                "effect": "Loss-of-function"
              },
              "operation": "update",
              "uuids": "3eec88ab-6e54-492b-8a02-36e7abed203e"
            }
          ],
          "timeStamp": 1667843530881
        },
        "-NGIDEpX0VdZG4kfCvqo": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "P151H, Mutation Effect",
              "new": {
                "description": "The TP53 P151H mutation is located in the protein's DNA binding domain. Alterations in the DNA binding domain result in altered contact of p53 with its target DNA sequences, thereby altering its transcriptional function (PMID: 8023157, 11900253). Expression of this mutant in yeast resulted in decreased transactivation of p53 target genes in the absence of galactose, as measured by a luciferase reporter assay (PMID: 22908277)."
              },
              "old": {
                "description": "The TP53 P151H mutation is located in the protein's DNA binding domain. Alterations in the DNA binding domain result in altered contact of p53 with its target DNA sequences, thereby altering its transcriptional function (PMID: 8023157, 11900253).Expression of this mutant in yeast resulted in decreased transactivation of p53 target genes in the absence of galactose, as a measured by a luciferase reporter assay (PMID: 22908277)."
              },
              "operation": "update",
              "uuids": "b88eb62c-c5da-4c01-8525-9e907028360a"
            }
          ],
          "timeStamp": 1667843554331
        },
        "-NIirHJ1mwy3oZN4gysa": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "P151H, Mutation Effect",
              "new": {
                "description": "The TP53 P151H mutation is located in the DNA binding domain of the protein. In vivo studies have demonstrated that this mutation is likely inactivating, as evidenced by decreased transactivation of p53 target genes in the mutant compared to wildtype (PMID: 22908277)."
              },
              "old": {
                "description": "The TP53 P151H mutation is located in the protein's DNA binding domain. Alterations in the DNA binding domain result in altered contact of p53 with its target DNA sequences, thereby altering its transcriptional function (PMID: 8023157, 11900253). Expression of this mutant in yeast resulted in decreased transactivation of p53 target genes in the absence of galactose, as measured by a luciferase reporter assay (PMID: 22908277)."
              },
              "operation": "update",
              "uuids": "b88eb62c-c5da-4c01-8525-9e907028360a"
            }
          ],
          "timeStamp": 1670454781100
        },
        "-NIiralx7zwBRdWYeQlC": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "P151A, Mutation Effect",
              "new": {
                "description": "The TP53 P151A mutation is located in the DNA binding domain of the protein. In vivo studies have demonstrated that this mutation is likely inactivating, as evidenced by the complete lack of transactivation of p53 target genes in the mutant compared to wildtype (PMID: 20407015).",
                "effect": "Likely Loss-of-function"
              },
              "old": {
                "description": "The TP53 P151A mutation is located in the protein's DNA binding domain. Expression of this mutant showed complete lack of transactivation of p53 target genes, by luciferase reporter assays (PMID: 20407015).",
                "effect": "Loss-of-function"
              },
              "operation": "update",
              "uuids": "89c7e0cc-517a-4bfd-a4db-20384cc53bb0"
            }
          ],
          "timeStamp": 1670454864935
        },
        "-NIirhDWtyNCcvruBxYY": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Y236C, Mutation Effect",
              "new": {
                "description": "The TP53 Y236C mutation is located in the DNA binding domain of the protein. This mutation has been found in colon cancer  (PMID: 16827139). In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by increased cytoplasmic localization of the mutant, leading to reduced transcriptional activity in the mutant compared to wildtype (PMID: 16827139).",
                "effect": "Likely Loss-of-function"
              },
              "old": {
                "description": "The TP53 Y236C mutation is located in the protein's DNA binding domain. Expression of this mutation leads to cytoplasmic localization of p53 leading to a reduction in transcriptional activity of p53 (PMID: 16827139).",
                "effect": "Loss-of-function"
              },
              "operation": "update",
              "uuids": "ee2e9c0c-5c03-4700-bfd2-07ae5859bead"
            }
          ],
          "timeStamp": 1670454891339
        },
        "-NIirr0ueIbY6qyr8hID": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Y236D, Mutation Effect",
              "new": {
                "description": "The TP53 Y236D mutation is located in the DNA binding domain of the protein. In vivo studies have demonstrated that this mutation is likely inactivating, as evidenced by the loss of binding ability of the p53 protein to its consensus sequence in the mutant compared to wildtype (PMID: 8633021).",
                "effect": "Likely Loss-of-function"
              },
              "old": {
                "description": "The TP53 Y236D mutation is located in the protein's DNA binding domain. For this mutant there is a dominant loss of binding ability of p53 to its consensus sequence in yeast cells (PMID: 8633021).",
                "effect": "Loss-of-function"
              },
              "operation": "update",
              "uuids": "0d29d38e-250f-4c6c-9b79-371450932c17"
            }
          ],
          "timeStamp": 1670454931492
        },
        "-NIirwxAjgCOcEJeRB-m": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Y236S, Mutation Effect",
              "new": {
                "description": "The TP53 Y236S mutation is located in the DNA binding domain of the protein. In vivo studies have demonstrated that this mutation is likely inactivating, as evidenced by the loss of transcriptional activity for p53 target genes, p21 and RGC, in the mutant compared to wildtype (PMID: 11429705).",
                "effect": "Likely Loss-of-function"
              },
              "old": {
                "description": "The TP53 Y236S mutation is located in the protein's DNA binding domain. Expression of this mutant in human cell lines induced loss of transcriptional activity for p53 target genes, p21 and RGC (PMID: 11429705).",
                "effect": "Loss-of-function"
              },
              "operation": "update",
              "uuids": "dbc51820-a8b0-4383-b1e3-8880dfaecd8f"
            }
          ],
          "timeStamp": 1670454955765
        },
        "-NIis1omg1XWe9T90gSM": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "P278S, Mutation Effect",
              "new": {
                "description": "The TP53 P278S mutation is located in the DNA binding domain of the protein. In vitro and in vivo studies have demonstrated that this mutation is inactivating, as evidenced by failure to activate the p21 promoter in the mutant compared to wildtype (PMID: 22989750)."
              },
              "old": {
                "description": "The TP53 P278S mutation is located in the protein's DNA binding domain. In p53 reporter assays, this mutant failed to activate the p21 promoter (PMID: 22989750)."
              },
              "operation": "update",
              "uuids": "833b1afa-c712-4d02-ae7d-2fa94464b10d"
            }
          ],
          "timeStamp": 1670454979804
        },
        "-NIisRUYFBigl6u7mhPH": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "P278L, Mutation Effect",
              "new": {
                "description": "The TP53 P278L mutation is located in the DNA binding domain of the protein. In vivo studies have demonstrated that this mutation is likely inactivating, as evidenced by failure to transactivate p53 target genes in the mutant compared to wildtype (PMID: 16861262).",
                "effect": "Likely Loss-of-function"
              },
              "old": {
                "description": "The TP53 P278L mutation is located in the protein's DNA binding domain. In p53 reporter assays, this mutant failed to transactivate p53 target genes, as measured by reporter assays (PMID: 16861262).",
                "effect": "Loss-of-function"
              },
              "operation": "update",
              "uuids": "71cdbaeb-4d9a-422c-93be-3963b82b154d"
            }
          ],
          "timeStamp": 1670455084941
        },
        "-NIisiW_mV9z1shMF9dv": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "P278A, Mutation Effect",
              "new": {
                "description": "The TP53 P278A mutation is located in the DNA binding domain of the protein. In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by failure to transactivate p53-dependent genes in the mutant compared to wildtype (PMID: 24076587)."
              },
              "old": {
                "description": "The TP53 P278A mutation is located in the protein's DNA binding domain. In a p53 reporter assays, this mutant failed to transactivate p53 dependent genes (PMID: 24076587)."
              },
              "operation": "update",
              "uuids": "c75da0cb-1d2f-42be-9869-bfd46052d9c3"
            }
          ],
          "timeStamp": 1670455158799
        },
        "-NIit2o0u8PH2Ag_r-FP": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "P278R, Mutation Effect",
              "new": {
                "description": "The TP53 P278R mutation is located in the DNA binding domain of the protein. This mutation has been found in hepatocellular carcinoma (PMID: 21760996). In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by the loss of transactivation activity of p53 target genes in the mutant compared to wildtype (PMID: 21760996).",
                "effect": "Likely Loss-of-function"
              },
              "old": {
                "description": "The TP53 P278R mutation is located in the protein's DNA binding domain. In p53 reporter assays, this mutant shows loss of transactivation activity of p53 target genes (PMID: 21760996).",
                "effect": "Loss-of-function"
              },
              "operation": "update",
              "uuids": "f5736b95-d9c0-47d3-a5d3-bc56948d72ca"
            }
          ],
          "timeStamp": 1670455245995
        },
        "-NIitYq5HtPPgtqXFocV": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "C135R, Mutation Effect",
              "new": {
                "description": "The TP53 C135R mutation is located in the DNA binding domain of the protein. This mutation has been found in non-small cell lung cancer (PMID: 17914575). Structural and in vitro studies have demonstrated that this mutation is inactivating, as evidenced by its predicted negative effect on p53-DNA interaction and the mutant protein's inability to bind to the TP53 response element from the p21 gene in an electrophoretic mobility shift assay compared to wildtype (PMID: 17914575)."
              },
              "old": {
                "description": "The TP53 C135R mutation is located in the protein's DNA binding domain. Expression of this mutant induces loss of p53-DNA interaction and it directly affects p53's role as a transcription factor and as a tumor suppressor (PMID: 17914575)."
              },
              "operation": "update",
              "uuids": "47bcf836-b853-4dc6-8446-91840ffe30be"
            }
          ],
          "timeStamp": 1670455377200
        },
        "-NIitePyt126SWHGzCsB": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "C135S, Mutation Effect",
              "new": {
                "description": "The TP53 C135S mutation is located in the DNA binding domain of the protein. In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by reduced binding capacity to TP53 response elements in the mutant compared to wildtype (PMID: 12034820)."
              },
              "old": {
                "description": "The TP53 C135S mutation is located in the protein's DNA binding domain (DBD). Mutations in the DBD lead to conformational changes of the p53 protein. These changes result in altered contact of p53 with its target DNA sequences, thereby altering its transcriptional function (PMID: 8023157, 11900253). Given that p53 directs the transcription of proteins that enable apoptosis (PMID: 11900253), its inactivation results in cells harboring damaged DNA and overall genomic instability (PMID: 11900253). SaOS-2 cells expressing the TP53 C135S mutation retain low binding capacity to DNA compared to wildtype p53, suggesting a loss of function of p53 (PMID: 17914575)."
              },
              "operation": "update",
              "uuids": "927a3833-3c85-4286-bdb9-74a8cdeef3d6"
            }
          ],
          "timeStamp": 1670455404136
        },
        "-NIitlb69SW4kKuMnRs3": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "C275S, Mutation Effect",
              "new": {
                "description": "The TP53 C275S mutation is located in the DNA binding domain of the protein. Structural and in vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by decreased affinity for the Gadd45 promoter site and increased attenuation of oxidative dissociation in the mutant compared to wildtype, suggesting that this mutation affects p53's function through altering p53-DNA contact (PMID: 25584637)."
              },
              "old": {
                "description": "The TP53 C275S mutation is located in the protein's DNA binding domain. This mutant showed decreased affinity for the Gadd45 promoter site and resulted in substantial attenuation of oxidative dissociation (PMID: 25584637)."
              },
              "operation": "update",
              "uuids": "b19da370-891e-48e9-bf54-1b6d7b3e4bff"
            }
          ],
          "timeStamp": 1670455433585
        },
        "-NIitxQa7Y-xvFRPU7Oc": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "M237K, Mutation Effect",
              "new": {
                "description": "The TP53 M237K mutation is located in the DNA binding domain. In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by the transactivation of some p53 target genes, including bax and MDM2, but not p21 in the mutant compared to wildtype, suggesting that the mutant is partially but not fully functional (PMID: 20505364)."
              },
              "old": {
                "description": "The TP53 M237K mutation is located in the protein's DNA binding domain. Expression of this mutant in H1299 cells does not produce any p21 protein but produces expression of bax and MDM2, other p53 target genes, suggesting the mutation is partially but not fully functional (PMID: 20505364)."
              },
              "operation": "update",
              "uuids": "f633f499-f3cc-4229-874e-ff248e29efd0"
            }
          ],
          "timeStamp": 1670455482000
        },
        "-NIiu7jjoeC59hQwrLwp": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "S241F, Mutation Effect",
              "new": {
                "description": "The TP53 S241F mutation is located in the DNA binding domain of the protein. In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by decreased co-immunoprecipitation of p53 with the tumor suppressor BARD1 and the 3' processing factor cleavage-stimulation factor 1 (CstF1), respectively, as well as decreased formation of the p53/BARD1/CstF1 complex, resulting in reduced inhibition of 3' cleavage (PMID: 21383700)."
              },
              "old": {
                "description": "The TP53 S241F mutation is located in the protein's DNA binding domain. The S241F mutation of p53 is known to disrupt the interaction of p53 with BARD1, CstF and also to decrease the inhibitory effects of p53 on 3' cleavage (PMID: 21383700)."
              },
              "operation": "update",
              "uuids": "dde9b7ee-3377-4b66-8840-abba2b97b783"
            }
          ],
          "timeStamp": 1670455528345
        },
        "-NIiuFyNHWHi5zBeZ7Nq": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "S241T, Mutation Effect",
              "new": {
                "description": "The TP53 S241T mutation is located in the DNA binding domain of the protein. In vitro studies have demonstrated that this mutation is inactivating and exhibits a dominant-negative phenotype, as evidenced by the lack of transcription of p53 target genes when both mutant and wildtype proteins are present, suggesting the mutant's ability to inhibit wildtype p53's transactivation ability (PMID: 11896595).",
                "effect": "Likely Loss-of-function"
              },
              "old": {
                "description": "The TP53 S241T mutation is located in the protein's DNA binding domain. When expressed into cells, it shows a dominant effect and inhibits wild type p53 as measured by yeast transcriptional assays (PMID: 11896595).",
                "effect": "Loss-of-function"
              },
              "operation": "update",
              "uuids": "4fa7669a-0569-4358-898b-6cbaac8c2d03"
            }
          ],
          "timeStamp": 1670455562050
        },
        "-NIiuW9yVegxVvuZ-wmU": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V272M, Mutation Effect",
              "new": {
                "description": "The TP53 V272M mutation is located in the DNA binding domain of the protein. This mutation has been found in esophageal cancer (PMID: 9096669). In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by the mutant's reduced reactivity with the wildtype conformation-specific antibody PAb1620, suggesting the adoption of a mutant conformation, as well as reduced accumulation in cells exposed to DNA-damaging agents and inability to rescue TP53-mediated transcriptional activity in TP53-null cells of the mutant compared to wildtype (PMID:15037740, 9096669, 11870884)."
              },
              "old": {
                "description": "The TP53 V272M mutation is located in the protein's DNA binding domain. This mutant does not bind specifically to DNA and it does not get activated in response to DNA-damaging treatments like wild type p53 does (PMID: 11870884). Expression of this mutation in cell lines that lack TP53 expression did not enhance TP53-mediated transcriptional activity in reporter assays, as compared to expression of wildtype TP53 (PMID: 15037740)."
              },
              "operation": "update",
              "uuids": "ea2f157e-44b1-4866-a2d6-31ab37cea043"
            }
          ],
          "timeStamp": 1670455628392
        },
        "-NIiueRgD7pZS4J2d1et": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V272L, Mutation Effect",
              "new": {
                "description": "The TP53 V272L mutation is located in the protein's DNA binding domain. In silico and in vitro studies have demonstrated that this mutation has inconclusive effect, as evidenced by comparable levels of p53 target gene transactivation in the mutant compared to wildtype, despite its position at a hotspot residue which suggests that it is likely oncogenic (PMID: 20407015, 26619011).",
                "effect": "Inconclusive"
              },
              "old": {
                "description": "The TP53 V272L mutation is located in the protein's DNA binding domain. Expression of this mutant resulted in transactivation of p53 target genes comparable to wildtype p53, as a measured by a luciferase reporter assay (PMID: 20407015). However, this mutation is a hotspot, suggesting that it is likely oncogenic (PMID: 26619011).",
                "effect": "Likely Loss-of-function"
              },
              "operation": "update",
              "uuids": "bcadaf27-fa17-4978-bc4c-1efd42db3f0a"
            }
          ],
          "timeStamp": 1670455666390
        },
        "-NIiuoJKYAJR4dbqyfNV": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V157F, Mutation Effect",
              "new": {
                "description": "The TP53 V157F mutation is located in the DNA binding domain of the protein. In vitro and structural studies have demonstrated that this mutation is likely inactivating, as evidenced by the mutant protein's rearranged DNA-binding surface and reduced DNA-binding activity compared to wildtype, as well as reduced expression of pro-apoptotic proteins, reduced apoptotic response and impaired transcriptional activity in cells expressing the mutant compared to wildtype (PMID: 21561095, 16778209, 15037740)."
              },
              "old": {
                "description": "The TP53 V157F mutation is located in the protein's DNA binding domain. Expression of this mutation in osteosarcoma cell lines led to a reduced apoptotic response, including reduced expression of pro-apoptotic proteins (PMID: 16778209). Structural studies have shown that this mutation causes rearrangement of the DNA-binding surface and reduced DNA-binding activity of p53 (PMID: 21561095). In addition, expression of this mutation in TP53-null cells results in a lack of transcriptional activity as evidenced in reporter assays (PMID: 15037740)."
              },
              "operation": "update",
              "uuids": "b771c2bb-6b11-4575-83bb-63339f53b154"
            }
          ],
          "timeStamp": 1670455706815
        },
        "-NIiuuUlPjdv1FN1vzGg": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V157D, Mutation Effect",
              "new": {
                "description": "The TP53 V157D mutation is located in the DNA binding domain of the protein. This mutation has been found in the germline of patients with familial cancer syndromes (PMID: 23981578). In vitro and in vivo studies have demonstrated that this mutation is inactivating, as evidenced by increased colony formation in soft agar assays and increased tumor formation in a transgenic Drosophila system expressing the mutant compared to wildtype (PMID: 23981578)."
              },
              "old": {
                "description": "The TP53 V157D mutation is located in the protein's DNA binding domain. This mutant is capable of promoting formation in soft agar as well as tumor formation in transgenic drosophila system (PMID: 23981578)."
              },
              "operation": "update",
              "uuids": "e139ddd4-b683-4b90-97ff-520a0e2eb969"
            }
          ],
          "timeStamp": 1670455732123
        },
        "-NIiv32WVDJEivunObDy": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R280K, Mutation Effect",
              "new": {
                "description": "The TP53 R280K mutation is located in the DNA binding domain of the protein. In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by decreased apoptosis and increased migration in TP53-null cells expressing the mutant compared to wildtype (PMID: 24714748)."
              },
              "old": {
                "description": "The TP53 R280K mutation is located in the protein's DNA binding domain. Expression of the R280K mutant in MDA-MB-231 cells decreased apoptosis compared to expression of wildtype TP53 which induced apoptosis. The TP53 R280K mutant also induces migration in TP53-null lung cancer cell lines, independent of TGFβ-mediated stimulus (PMID: 24714748)."
              },
              "operation": "update",
              "uuids": "e3cc7c18-1e4e-4911-8127-79b267f757c8"
            }
          ],
          "timeStamp": 1670455771275
        },
        "-NIivA5Fpv_YBUiZI3pd": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R280T, Mutation Effect",
              "new": {
                "description": "The TP53 R280T mutation is located in the DNA binding domain of the protein. This mutation has been found in glioma (PMID: 22999923) In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by increased proliferation of cells expressing the mutant compared to wildtype, as well as increased p-GSK-3 levels, reduced PTEN and Akt phosphorylation and reduced cell growth upon knockdown of the mutant protein compared to wildtype, suggesting that this mutation promotes cell growth through GSK-3beta-PTEN pathway (PMID: 22999923)."
              },
              "old": {
                "description": "The TP53 R280T mutation is located in the protein's DNA binding domain. Expression of this mutant promotes the proliferation of human glioma cells and knockdown of this mutation reduces the growth of glioma cells. Additionally, the TP53 R280T mutation promotes cell growth through GSK-3beta-PTEN pathway (PMID: 22999923)."
              },
              "operation": "update",
              "uuids": "dc9b6b17-0643-4fb9-bd35-26ee22eb93cf"
            }
          ],
          "timeStamp": 1670455800122
        },
        "-NJCoxf_CMLPdMgLGV0i": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "C277Y",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 C277Y mutation is located in the DNA-binding domain of the protein. This mutation has been identified in Ewing sarcoma and myeloproliferative neoplasms and is a statistically significant hotspot (PMID: 15192123, 35030630). In vitro studies with H1299 cells ectopically expressing TP53 C277Y demonstrated the mutation is inactivating as measured by the mutant's significant reduction in apoptosis and downregulation of p21 and BAX expression as compared to wildtype (PMID: 34282274).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1670974223743,
                    "updatedBy": "User"
                  },
                  "description_uuid": "96320c6a-1b03-4f4e-ae1d-6a96a12dcb90",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1670874931644,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "61d808e4-78c4-4611-b571-f87316a5c3ff",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1670874930586,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "abe217c7-44c4-4b46-aeeb-ac64fa8a71db",
                  "short": ""
                },
                "mutation_effect_uuid": "102e19fc-52dc-4308-85bd-cc6360b9ac96",
                "name": "C277Y",
                "name_review": {
                  "added": true,
                  "updateTime": 1670874924854,
                  "updatedBy": "User"
                },
                "name_uuid": "0fb8f328-8b3c-4b99-ada2-bec0bda96471",
                "tumors_uuid": "4f876802-562b-4fe7-9be0-eeca5ebc12f8"
              },
              "operation": "add",
              "uuids": "abe217c7-44c4-4b46-aeeb-ac64fa8a71db,61d808e4-78c4-4611-b571-f87316a5c3ff"
            }
          ],
          "timeStamp": 1670974265972
        },
        "-NJCp36zw5w0b2BDnMQf": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Y236H",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 Y236H mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer, lung cancer and basaloid pancreatic carcinoma and is a statistically significant hotspot (PMID: 20682393, 32674491, 25432630). In vivo studies with yeast expressing TP53 Y236H demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1670974250902,
                    "updatedBy": "User"
                  },
                  "description_uuid": "a9736895-37cd-4d2b-a3c3-5f1f104aab87",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1670874980969,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "a225696a-e751-4a12-9603-e2c980449bad",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1670874980106,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "763ff1b3-d610-4906-a9d7-e914bffd62c6",
                  "short": ""
                },
                "mutation_effect_uuid": "79ff0ed0-4aa4-4a03-b74d-1f342d91c593",
                "name": "Y236H",
                "name_review": {
                  "added": true,
                  "updateTime": 1670874974426,
                  "updatedBy": "User"
                },
                "name_uuid": "f73198c6-9fc8-47c4-a96c-8021cbdb0873",
                "tumors_uuid": "d5b680fa-7bb4-40ee-819a-3fcf2281fe88"
              },
              "operation": "add",
              "uuids": "763ff1b3-d610-4906-a9d7-e914bffd62c6,a225696a-e751-4a12-9603-e2c980449bad"
            }
          ],
          "timeStamp": 1670974292366
        },
        "-NJCpDqjMdXu77kwIC5E": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Y236N",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 Y236N mutation is located in the DNA-binding domain of the protein. This mutation has been identified in B-cell precursor acute lymphoblastic leukemia, breast cancer, colon cancer and glioblastoma and is a statistically significant hotspot (PMID: 33095873, 8950983, 9301461, 10427138). In vivo studies with yeast expressing TP53 Y236N demonstrated that the mutation retains its transactivational activity as compared to wildtype (PMID: 27328919, 12826609). However, other in vitro studies with various human cancer cell lines expressing TP53 Y236N demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1670974286023,
                    "updatedBy": "User"
                  },
                  "description_uuid": "9f0421ef-61ac-4910-85ea-6cfe6c38a1a7",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1670875036189,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "528eba0e-4a36-481e-be48-779287cec4d7",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1670875034299,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "a9aac0c1-e239-473d-98d4-437c05c03bd1",
                  "short": ""
                },
                "mutation_effect_uuid": "d8a75e09-5fab-4567-93b9-3af1570523d4",
                "name": "Y236N",
                "name_review": {
                  "added": true,
                  "updateTime": 1670875022152,
                  "updatedBy": "User"
                },
                "name_uuid": "25d22320-7ccd-4aa5-9ad6-674c2b924a88",
                "tumors_uuid": "e171210f-af7f-4e73-af36-53f6f7df95a8"
              },
              "operation": "add",
              "uuids": "a9aac0c1-e239-473d-98d4-437c05c03bd1,528eba0e-4a36-481e-be48-779287cec4d7"
            }
          ],
          "timeStamp": 1670974336318
        },
        "-NJCpL92VojrGKj6Bmv-": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "H193Q",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 H193Q mutation is located in the DNA-binding domain of the protein.  This mutation has been identified in colorectal cancer, esophageal squamous cell carcinoma, bone sarcoma and squamous cell carcinoma and is a statistically significant hotspot (PMID: 12433709, 10414702, 1423262, 10414702). In vivo studies with yeast expressing TP53 H193Q demonstrated that mutation has partial inactivation of its transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1670974329314,
                    "updatedBy": "User"
                  },
                  "description_uuid": "5a282d18-c552-4562-82da-50c578652b1f",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1670875070225,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "c4462ae7-d47b-4388-88d6-8a7717109eca",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1670875068038,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "eb38de83-1cbb-472a-a5d8-17db280b3d76",
                  "short": ""
                },
                "mutation_effect_uuid": "c43e00eb-e60c-439d-8a7e-85ff553e1807",
                "name": "H193Q",
                "name_review": {
                  "added": true,
                  "updateTime": 1670875060105,
                  "updatedBy": "User"
                },
                "name_uuid": "9f32aa27-071e-40f6-a42a-af45817e005e",
                "tumors_uuid": "5c98ff1b-6f2f-414e-9d40-e43ebbff0e6e"
              },
              "operation": "add",
              "uuids": "eb38de83-1cbb-472a-a5d8-17db280b3d76,c4462ae7-d47b-4388-88d6-8a7717109eca"
            }
          ],
          "timeStamp": 1670974366226
        },
        "-NJCpS5pPTmw3qYP83Yj": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "H193D",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 H193D mutation is located in the DNA-binding domain of the protein. This mutation has been identified in hepatocellular carcinoma, diffuse large B-cell lymphoma, ovarian cancer and breast cancer and is a statistically significant hotspot (PMID: 17187432, 15370252, 9665415, 12032228). In vivo studies with yeast expressing TP53 H193D demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 H193D also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1670974350480,
                    "updatedBy": "User"
                  },
                  "description_uuid": "67aad42d-82aa-4c7a-a972-0d618c06ae71",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1670875119522,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "3b9d6c9b-7a7a-48fc-91e7-ff0723870a95",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1670875117900,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "460db1c2-76e6-428b-bb6c-b0a8f190d7a0",
                  "short": ""
                },
                "mutation_effect_uuid": "e0b81bbc-8e10-43e1-a780-4d7a06027981",
                "name": "H193D",
                "name_review": {
                  "added": true,
                  "updateTime": 1670875106319,
                  "updatedBy": "User"
                },
                "name_uuid": "545012bf-b385-4aa0-beb9-4f063a0ed7d4",
                "tumors_uuid": "cab25340-82e4-4a1c-8f51-cfc8e45dd0fe"
              },
              "operation": "add",
              "uuids": "460db1c2-76e6-428b-bb6c-b0a8f190d7a0,3b9d6c9b-7a7a-48fc-91e7-ff0723870a95"
            }
          ],
          "timeStamp": 1670974394692
        },
        "-NJCpZngdmrCqQuHhltu": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "H193Y",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 H193Y mutation is located in the DNA-binding domain of the protein. This mutation has been identified in glioblastoma, cholangiocarcinoma, malignant lymphoma and squamous cell carcinoma and is a statistically significant hotspot (PMID: 11504770, 10564952, 11552717, 12509970). In vivo studies with yeast expressing TP53 H193Y demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 H193Y also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1670974382437,
                    "updatedBy": "User"
                  },
                  "description_uuid": "bffe61b9-08cb-415c-9cc9-fbb24cf497c5",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1670875146028,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "23fd0dbc-f22f-463e-b9ef-d8192ed42e58",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1670875144980,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "ac419870-741c-45ac-a246-b564122fcdc3",
                  "short": ""
                },
                "mutation_effect_uuid": "f4d74a79-f448-4462-9032-f1039841c7b7",
                "name": "H193Y",
                "name_review": {
                  "added": true,
                  "updateTime": 1670875139317,
                  "updatedBy": "User"
                },
                "name_uuid": "95ca3597-c024-4a55-aa2c-98d200dcf444",
                "tumors_uuid": "1547890b-63b7-4b31-ba3a-d1ceabd0dbbf"
              },
              "operation": "add",
              "uuids": "ac419870-741c-45ac-a246-b564122fcdc3,23fd0dbc-f22f-463e-b9ef-d8192ed42e58"
            }
          ],
          "timeStamp": 1670974426235
        },
        "-NJCtXzJzrHU4iCEftxX": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "H193L",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 H193L mutation is located in the DNA-binding domain of the protein. This mutation has been identified in diffuse large B-cell lymphoma, squamous cell carcinoma and breast cancer and is a statistically significant hotspot (PMID: 17278262, 18081876, 16818855). In vivo studies with yeast expressing TP53 H193L demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 H193L also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1670975423356,
                    "updatedBy": "User"
                  },
                  "description_uuid": "e4861209-6d5a-4123-95fb-1b5736245b38",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1670875181327,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "ae9731c5-63f5-40ca-97ae-ffa807ee5899",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1670875179414,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "0eae3dbf-83e1-491e-bd0d-f4f12e30caa3",
                  "short": ""
                },
                "mutation_effect_uuid": "85622a8d-c17b-4f3c-96f6-1cfeec689a08",
                "name": "H193L",
                "name_review": {
                  "added": true,
                  "updateTime": 1670875170727,
                  "updatedBy": "User"
                },
                "name_uuid": "08e640ed-3372-4110-a114-ea674ee75055",
                "tumors_uuid": "b1629e38-0ed1-481a-85c0-e1280372116f"
              },
              "operation": "add",
              "uuids": "0eae3dbf-83e1-491e-bd0d-f4f12e30caa3,ae9731c5-63f5-40ca-97ae-ffa807ee5899"
            }
          ],
          "timeStamp": 1670975467363
        },
        "-NJCtdzErho1-Sx7uqcC": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Y163D",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 Y163D mutation is located in the DNA-binding domain of the protein. This mutation has been identified in B-cell chronic lymphocytic leukemia, breast cancer and ovarian cancer and is a statistically significant hotspot (PMID: 11180073, 10706127, 20229506). In vivo studies with yeast expressing TP53 Y163D demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 Y163D also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1670975449126,
                    "updatedBy": "User"
                  },
                  "description_uuid": "f4d17c96-7749-43fc-9077-daf41bf57213",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1670875216011,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "2b1eec05-a674-477c-a223-cf671c5010ea",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1670875213956,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "cb045c02-a29e-4090-aadf-deaabdf9fb40",
                  "short": ""
                },
                "mutation_effect_uuid": "ab275c3c-6b2a-4f17-9bdd-03158348b85d",
                "name": "Y163D",
                "name_review": {
                  "added": true,
                  "updateTime": 1670875205802,
                  "updatedBy": "User"
                },
                "name_uuid": "6ad200db-489b-4317-b362-751f2fb4e909",
                "tumors_uuid": "ab563b4b-f884-4f58-8f7a-e7121894f38f"
              },
              "operation": "add",
              "uuids": "cb045c02-a29e-4090-aadf-deaabdf9fb40,2b1eec05-a674-477c-a223-cf671c5010ea"
            }
          ],
          "timeStamp": 1670975496030
        },
        "-NJCtm-_cF7uvfeTjt23": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Y163H",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 Y163H mutation is located in the DNA-binding domain of the protein. This mutation has been identified in squamous cell carcinoma, hepatocellular carcinoma, colorectal cancer and diffuse large B-cell lymphoma, and is a statistically significant hotspot (PMID: 9683822, 1327523, 9000147, 9162193). In vivo studies with yeast expressing TP53 Y163H demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 Y163H also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1670975499209,
                    "updatedBy": "User"
                  },
                  "description_uuid": "0dd0aab5-f020-4809-97b7-efaa89a318e6",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1670875260430,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "00643e36-3d7c-4aaf-b19a-e33e2d136ef6",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1670875259405,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "8fba2def-8fa0-4a21-9ec3-0e15c555b150",
                  "short": ""
                },
                "mutation_effect_uuid": "dc43622b-7bc4-44cd-84d2-20c021a4fea3",
                "name": "Y163H",
                "name_review": {
                  "added": true,
                  "updateTime": 1670875251473,
                  "updatedBy": "User"
                },
                "name_uuid": "2fabb556-83d4-4e10-abf6-b219b2b784c9",
                "tumors_uuid": "dba4b4fc-d160-42fb-8624-0c76b95c736c"
              },
              "operation": "add",
              "uuids": "8fba2def-8fa0-4a21-9ec3-0e15c555b150,00643e36-3d7c-4aaf-b19a-e33e2d136ef6"
            }
          ],
          "timeStamp": 1670975528884
        },
        "-NJCy-uJpgcS_a6kMUBj": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V274A",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 V274A mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer, hepatocellular carcinoma and squamous cell carcinoma, and is a statistically significant hotspot (PMID: 8102535, 1330291, 8621246). In vivo studies with yeast expressing TP53 V274A demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 V274A also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1670875897884,
                    "updatedBy": "User"
                  },
                  "description_uuid": "5d2efb0f-e21d-44ea-9e0d-2b7eef481563",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1670875902197,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "a16380c0-e780-4b6c-b5f2-e7c44f62110e",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1670875900000,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "3b5bf0b9-c452-4e5e-b252-bde150dd476a",
                  "short": ""
                },
                "mutation_effect_uuid": "dd05c897-865f-4926-b14e-25be1c80c8ff",
                "name": "V274A",
                "name_review": {
                  "added": true,
                  "updateTime": 1670875891039,
                  "updatedBy": "User"
                },
                "name_uuid": "e8934b6b-9bd0-483c-8527-b48db4e034f0",
                "tumors_uuid": "224540ec-a7a0-4a3e-9780-733e6adb71b8"
              },
              "operation": "add",
              "uuids": "3b5bf0b9-c452-4e5e-b252-bde150dd476a,a16380c0-e780-4b6c-b5f2-e7c44f62110e"
            }
          ],
          "timeStamp": 1670976638499
        },
        "-NJCy7rTHCzPOa3Xs08V": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V274D",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 V274D mutation is located in the DNA-binding domain of the protein. This mutation has been identified in ovarian cancer, low-grade mucosa-associated lymphoid tissue lymphomas, papillary carcinoma and acute myeloid leukemia and is a statistically significant hotspot (PMID: 21720365, 8579126, 15538112, 2009369). In vivo studies with yeast expressing TP53 V274D demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 V274D also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1670976649852,
                    "updatedBy": "User"
                  },
                  "description_uuid": "ee4315d9-d730-481e-b777-9631fa509022",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1670875930434,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "3c57f2a6-81ef-40c9-919b-ff47ff5f8711",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1670875929524,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "761b53c8-f2dd-4788-ae44-39f995a96251",
                  "short": ""
                },
                "mutation_effect_uuid": "3c149e87-def5-4eab-93ed-be4359cb1563",
                "name": "V274D",
                "name_review": {
                  "added": true,
                  "updateTime": 1670875921982,
                  "updatedBy": "User"
                },
                "name_uuid": "3016a3d1-4fb7-4dc3-980e-1139e0c72ef6",
                "tumors_uuid": "211d6bf1-acc8-4c73-835f-40274846c63a"
              },
              "operation": "add",
              "uuids": "761b53c8-f2dd-4788-ae44-39f995a96251,3c57f2a6-81ef-40c9-919b-ff47ff5f8711"
            }
          ],
          "timeStamp": 1670976671085
        },
        "-NJCyJZuwgLoNirEu_HY": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "C277F",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 C277F mutation is located in the DNA-binding domain of the protein. This mutation has been identified in ovarian cancer, splenic B-cell lymphoma and non-small cell lung cancer and is a statistically significant hotspot (PMID: 9504831, 8018922, 8826941). In vivo studies with yeast expressing TP53 C277F demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 C277F also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1670976671409,
                    "updatedBy": "User"
                  },
                  "description_uuid": "3cccf56c-aecb-42fa-955b-79059af7a8b2",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1670875953038,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "6462663b-11d0-4f85-9fb7-82c702fb89e0",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1670875952022,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "c62d1341-a69e-4eb7-9dec-e561671e6581",
                  "short": ""
                },
                "mutation_effect_uuid": "1b045014-cf2f-4282-875e-d318051236aa",
                "name": "C277F",
                "name_review": {
                  "added": true,
                  "updateTime": 1670875944934,
                  "updatedBy": "User"
                },
                "name_uuid": "13042ae4-f20a-4c90-8a5c-2e40123e611a",
                "tumors_uuid": "385027fe-3d0b-4572-8621-d52c541100c8"
              },
              "operation": "add",
              "uuids": "c62d1341-a69e-4eb7-9dec-e561671e6581,6462663b-11d0-4f85-9fb7-82c702fb89e0"
            }
          ],
          "timeStamp": 1670976719049
        },
        "-NJCySUoHIII0h7Lr9sC": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V274G",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 V274G mutation is located in the DNA-binding domain of the protein. This mutation has been identified in colorectal cancer, ovarian cancer, breast cancer and hepatocellular carcinoma and is a statistically significant hotspot (PMID: 16721749, 21720365, 12908823, 9463584). In vivo studies with yeast expressing TP53 V274G demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 V274G also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1670976712156,
                    "updatedBy": "User"
                  },
                  "description_uuid": "79b31a9a-a8cc-4006-af65-c867d103d3ce",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1670875979578,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "a9064cc9-2dbb-41b1-a05b-bab623816855",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1670875978326,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "c5dd5259-ccd2-482b-813c-2de0f810d26c",
                  "short": ""
                },
                "mutation_effect_uuid": "ca68fa8c-33d0-491e-abe3-7eb0f8b360d6",
                "name": "V274G",
                "name_review": {
                  "added": true,
                  "updateTime": 1670875972006,
                  "updatedBy": "User"
                },
                "name_uuid": "6400cfc3-e52f-4030-88e0-1bf07cac1099",
                "tumors_uuid": "3a52234c-3ba1-4a3b-8e74-94330fbd89b9"
              },
              "operation": "add",
              "uuids": "c5dd5259-ccd2-482b-813c-2de0f810d26c,a9064cc9-2dbb-41b1-a05b-bab623816855"
            }
          ],
          "timeStamp": 1670976755587
        },
        "-NJCy_8M7KSv5Tu0WSg-": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V274L",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 V274L mutation is located in the DNA-binding domain of the protein. This mutation has been identified in ovarian cancer, glioblastoma, colorectal cancer and acute myeloid leukemia and is a statistically significant hotspot (PMID: 11329143, 15466178, 11044641, 12792784). In vivo studies with yeast expressing TP53 V274L demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 V274L also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1670976740276,
                    "updatedBy": "User"
                  },
                  "description_uuid": "9660c833-830a-4989-ab1d-5b3c476fa4d5",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1670876017388,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "3c6acba0-e48c-4d88-8dfe-6c7ff8d884ff",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1670876016376,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "07374489-060a-4056-afb4-1f17bcd6de7d",
                  "short": ""
                },
                "mutation_effect_uuid": "eb6acb5c-5392-4d6a-bbe1-2b0132d9cb60",
                "name": "V274L",
                "name_review": {
                  "added": true,
                  "updateTime": 1670876009055,
                  "updatedBy": "User"
                },
                "name_uuid": "cdd3f2ce-29ca-440c-9c9d-29049aae624c",
                "tumors_uuid": "70a44d22-974b-4410-85ff-afdebb4a3b80"
              },
              "operation": "add",
              "uuids": "07374489-060a-4056-afb4-1f17bcd6de7d,3c6acba0-e48c-4d88-8dfe-6c7ff8d884ff"
            }
          ],
          "timeStamp": 1670976786918
        },
        "-NJCymr_eSSH6hBJOu6l": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G244A",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 G244A mutation is located in the DNA-binding domain of the protein. This mutation has been identified in hepatocellular carcinoma, B-cell lymphoma and prostate cancer and is a statistically significant hotspot (PMID: 14675778, 9262496, 15541116). In vivo studies with yeast expressing TP53 G244A demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 G244A also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1670976771884,
                    "updatedBy": "User"
                  },
                  "description_uuid": "2951dfae-64ec-4287-a5e5-b0d6a5be6bf0",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1670876198071,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "82a54398-cc0a-457b-b6c7-bbb391723a2a",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1670876197010,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "4af89e61-602c-4d19-879b-cd96213ba682",
                  "short": ""
                },
                "mutation_effect_uuid": "4fbcf6d3-dd97-4cad-8bc9-549891999051",
                "name": "G244A",
                "name_review": {
                  "added": true,
                  "updateTime": 1670876190642,
                  "updatedBy": "User"
                },
                "name_uuid": "fe22bb7a-d270-4d1f-944e-7a89403bf08e",
                "tumors_uuid": "211fc468-bc38-4cc1-a93c-8291f815f93c"
              },
              "operation": "add",
              "uuids": "4af89e61-602c-4d19-879b-cd96213ba682,82a54398-cc0a-457b-b6c7-bbb391723a2a"
            }
          ],
          "timeStamp": 1670976843124
        },
        "-NJCyu2qeAa8NGy3XIxt": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G244C",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 G244C mutation is located in the DNA-binding domain of the protein. This mutation has been identified in squamous cell carcinoma, colorectal cancer and bladder cancer and is a statistically significant hotspot (PMID: 15305417, 14534722, 16061860). In vivo studies with yeast expressing TP53 G244C demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1670976830888,
                    "updatedBy": "User"
                  },
                  "description_uuid": "6511723f-86d0-4d44-8080-945a7c060847",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1670876222066,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "421495fa-6682-4408-a40d-b54fb3c422a6",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1670876220920,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "10ce96a1-df6f-415f-ac24-2b7125173c0c",
                  "short": ""
                },
                "mutation_effect_uuid": "dc2c4d71-b904-4623-9c49-fe442f2aabcd",
                "name": "G244C",
                "name_review": {
                  "added": true,
                  "updateTime": 1670876214478,
                  "updatedBy": "User"
                },
                "name_uuid": "7b36d747-736c-4431-ae10-5a92068f7b59",
                "tumors_uuid": "b48de9ed-bfd1-40bd-afd6-b70b8fa47929"
              },
              "operation": "add",
              "uuids": "10ce96a1-df6f-415f-ac24-2b7125173c0c,421495fa-6682-4408-a40d-b54fb3c422a6"
            }
          ],
          "timeStamp": 1670976872581
        },
        "-NJCz-jmVejmtA9vGqRx": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G244V",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 G244V mutation is located in the DNA-binding domain of the protein. This mutation has been identified in stomach adenocarcinoma, colorectal cancer and ovarian cancer, and is a statistically significant hotspot (PMID: 12796400, 11406538, 14760384). In vivo studies with yeast expressing TP53 G244V demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 G244V also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1670876254143,
                    "updatedBy": "User"
                  },
                  "description_uuid": "d97d9a01-7ebb-4801-9579-2c9b9cd556af",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1670876257168,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "4c3b2db6-4546-4541-bc05-29c1cd6b30ef",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1670876256189,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "beb5cb1f-7d8f-4fee-874c-6550fce390d2",
                  "short": ""
                },
                "mutation_effect_uuid": "c0690f3f-ab87-40d3-bea7-bceddaa2459a",
                "name": "G244V",
                "name_review": {
                  "added": true,
                  "updateTime": 1670876244057,
                  "updatedBy": "User"
                },
                "name_uuid": "4ee4198f-c8f6-48ab-95e9-7965922cf77a",
                "tumors_uuid": "9139468f-ae7d-43c5-8b2e-6aedce60621d"
              },
              "operation": "add",
              "uuids": "beb5cb1f-7d8f-4fee-874c-6550fce390d2,4c3b2db6-4546-4541-bc05-29c1cd6b30ef"
            }
          ],
          "timeStamp": 1670976899969
        },
        "-NJCz6RVBcfxGRGT3YMo": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G244F",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 G244F mutation is located in the DNA-binding domain of the protein and is a statistically significant hotspot. In vitro studies with various human cancer cell lines expressing TP53 G244F demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1670976864895,
                    "updatedBy": "User"
                  },
                  "description_uuid": "7e560d80-a8dd-47e7-8afe-bc9b5dd7cad0",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1670876294293,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "013358ff-b85e-4cdd-9738-064d31f647d1",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1670876293331,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "326f11db-9309-496d-a034-d73bea629d8d",
                  "short": ""
                },
                "mutation_effect_uuid": "124a99b3-3afd-404d-b76b-db86f8f49e2a",
                "name": "G244F",
                "name_review": {
                  "added": true,
                  "updateTime": 1670876277942,
                  "updatedBy": "User"
                },
                "name_uuid": "49e6978b-af32-4764-b102-8492d6e008cf",
                "tumors_uuid": "18357041-df5a-464f-8fa5-5acae158e28d"
              },
              "operation": "add",
              "uuids": "326f11db-9309-496d-a034-d73bea629d8d,013358ff-b85e-4cdd-9738-064d31f647d1"
            }
          ],
          "timeStamp": 1670976927407
        },
        "-NJfso0t3voLwZ6dRTfT": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "C135Y, Mutation Effect",
              "new": {
                "description": "The TP53 C135Y mutation is located in the DNA binding domain of the protein. In vitro studies with p53-null endometrial cancer cells expressing TP53 C135Y have demonstrated that this mutation is inactivating as measured by loss of miRNA expression regulation, specifically the microRNA miR-130b and miR-200c, resulting in increased epithelial to mesenchymal transition and cell invasion in the mutant compared to wildtype (PMID: 22847613). In vivo studies with yeast expressing TP53 C135Y demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 C135Y also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644)."
              },
              "old": {
                "description": "The TP53 C135Y mutation is located in the protein's DNA binding domain. Expression of this mutant has been shown to bind and transrepress the promoter of the microRNA miR-130b ad miR-200c. Downregulation of these microRNAs induces epithelial to mesenchymal transition and cell invasion (PMID: 22847613)."
              },
              "operation": "update",
              "uuids": "58ac6d98-c731-4ae6-adf3-fa75457ce195"
            }
          ],
          "timeStamp": 1671478590584
        },
        "-NM6KlMM6Ng8kf9niYGK": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R248K, Mutation Effect",
              "new": {
                "description": "The TP53 R248K mutation occurs in the protein's DNA binding domain. Biochemical assays have demonstrated that this TP53 mutation is inactivating as measured by decreased ability to bind DNA compared to wildtype TP53 (PMID: 7651437)."
              },
              "old": {
                "description": "The TP53 R248K mutation occurs in the protein's DNA binding domain. In biochemical assays, this TP53 mutant had a decreased ability to bind DNA compared to wildtype TP53 (PMID: 7651437)."
              },
              "operation": "update",
              "uuids": "a2630e1b-9300-486c-8077-f37d23f085ba"
            }
          ],
          "timeStamp": 1674086651211
        },
        "-NM6KqCIHr6zadeBllZI": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "S215G, Mutation Effect",
              "new": {
                "description": "The TP53 S215G mutant is located in the DNA binding domain. Mutations in the DNA binding domain are associated with altered contact of p53 with its target DNA sequences, thereby altering its transcriptional function (PMID: 8023157, 11900253). Functional studies in yeast and human cell lines suggest this mutation is temperature sensitive and inactivating, as measured by functional analysis of separated alleles in yeast (FASAY) (PMID: 17724467, 22862161). This mutation is also a hotspot, suggesting that it is likely oncogenic (PMID: 26619011)."
              },
              "old": {
                "description": "The TP53 S215G mutant is located in the DNA binding domain. Mutations in the DNA binding domain are associated with altered contact of p53 with its target DNA sequences, thereby altering its transcriptional function (PMID: 8023157, 11900253). Functional studies in yeast and human cell lines suggest this mutation is temperature sensitive and inactivating, as measured by Functional analysis of separated alleles in yeast (FASAY) (PMID: 17724467, 22862161). This mutation is also a hotspot, suggesting that it is likely oncogenic (PMID: 26619011)."
              },
              "operation": "update",
              "uuids": "a3aead6a-7ad7-4381-9b21-81c71f99515a"
            }
          ],
          "timeStamp": 1674086671048
        },
        "-NM6L0U9G5SRusvnuAui": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V173A",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 V173A mutation is located in the DNA-binding domain of the protein. This mutation has been identified in stomach adenocarcinoma, breast cancer and ovarian cancer, and is a statistically significant hotspot (PMID: 1370612, 9569050, 9569050). In vivo studies with yeast expressing TP53 V173A demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 V173A also demonstrated the mutation is inactivating as measured by reduced growth suppressive activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674086684796,
                    "updatedBy": "User"
                  },
                  "description_uuid": "6b16619b-079d-4ebe-b0cb-528c9c0e8002",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1671746656069,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "27e80858-2e5c-4992-a40f-241c60acdd01",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1671746650018,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "6c4b9710-4567-449e-94ea-7e65dc9c4c64",
                  "short": ""
                },
                "mutation_effect_uuid": "2af3fe11-4f7e-42ab-9a38-bd433f350156",
                "name": "V173A",
                "name_review": {
                  "added": true,
                  "updateTime": 1671746642800,
                  "updatedBy": "User"
                },
                "name_uuid": "d55a25a0-7504-48b7-b217-26f13352088e",
                "tumors_uuid": "3987d0f0-0353-4c3e-96ab-a7169a3972cd"
              },
              "operation": "add",
              "uuids": "6c4b9710-4567-449e-94ea-7e65dc9c4c64,27e80858-2e5c-4992-a40f-241c60acdd01"
            }
          ],
          "timeStamp": 1674086717247
        },
        "-NM6L72BqC3qNotOpJqB": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V173G",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 V173A mutation is located in the DNA-binding domain of the protein. This mutation has been identified in stomach adenocarcinoma, breast cancer and ovarian cancer, and is a statistically significant hotspot (PMID: 1370612, 9569050, 9569050). In vivo studies with yeast expressing TP53 V173A demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 V173A also demonstrated the mutation is inactivating as measured by reduced growth suppressive activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674086711730,
                    "updatedBy": "User"
                  },
                  "description_uuid": "b891aa61-3aef-46b8-9d8a-c93321a91c3c",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1671746680142,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "932dbcae-ac69-4e2e-9cbc-c583d35e7d4c",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1671746678364,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "00ead91e-68e3-4975-85cd-5d3a664f5623",
                  "short": ""
                },
                "mutation_effect_uuid": "0d273a85-1a7e-4ab4-9447-983b010c9006",
                "name": "V173G",
                "name_review": {
                  "added": true,
                  "updateTime": 1671746674814,
                  "updatedBy": "User"
                },
                "name_uuid": "04704c08-7553-4e03-8b35-c36c13547aa9",
                "tumors_uuid": "9e11b804-a515-40af-8d98-4642d6b380fb"
              },
              "operation": "add",
              "uuids": "00ead91e-68e3-4975-85cd-5d3a664f5623,932dbcae-ac69-4e2e-9cbc-c583d35e7d4c"
            }
          ],
          "timeStamp": 1674086744129
        },
        "-NM6LDdWw8hP-g3KuD3O": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "C277G",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 C277G mutation is located in the DNA-binding domain of the protein. This mutation has been identified in colorectal cancer, gastric cancer and malignant peripheral nerve sheath tumor, and is a statistically significant hotspot (PMID: 9516972, 8620428, 11406645). In vivo studies with yeast expressing TP53 C277G demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 C277G also demonstrated the mutation is inactivating as measured by reduced growth suppressive activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674086735219,
                    "updatedBy": "User"
                  },
                  "description_uuid": "2fe1a621-1e18-4798-879d-50b7af65ed1d",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1671746699651,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "82e9c452-5ef5-4b69-89a3-2e663564a0a9",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1671746698988,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "8cd0c2f9-bd62-4d62-b7a0-752c37c0cad2",
                  "short": ""
                },
                "mutation_effect_uuid": "0a8e03cf-3aa1-4d03-b3bb-fec0d210841c",
                "name": "C277G",
                "name_review": {
                  "added": true,
                  "updateTime": 1671746693320,
                  "updatedBy": "User"
                },
                "name_uuid": "cafca743-1a13-43a9-a384-0663fdb4927f",
                "tumors_uuid": "5259b1ca-0377-4a72-bd08-fe2abd161a07"
              },
              "operation": "add",
              "uuids": "8cd0c2f9-bd62-4d62-b7a0-752c37c0cad2,82e9c452-5ef5-4b69-89a3-2e663564a0a9"
            }
          ],
          "timeStamp": 1674086771158
        },
        "-NM6LKDM0nSMB8jaoGiW": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Y205S",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 Y205S mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer, squamous cell carcinoma and diffuse large B-cell lymphoma, and is a statistically significant hotspot (PMID: 16489069, 1324797, 15533223). In vivo studies with yeast expressing TP53 Y205S demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 Y205S also demonstrated the mutation is inactivating as measured by reduced growth suppressive activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674086766178,
                    "updatedBy": "User"
                  },
                  "description_uuid": "ab6bb4b6-e681-4a68-b6cc-1ce04c297196",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1671746838345,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "4e476ffa-0a02-4770-84e0-edaa870133e8",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1671746837388,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "9dfd804b-abac-4319-99cf-751331ee4636",
                  "short": ""
                },
                "mutation_effect_uuid": "495f58ca-31c3-4b86-9529-1de5a91a31ef",
                "name": "Y205S",
                "name_review": {
                  "added": true,
                  "updateTime": 1671746833724,
                  "updatedBy": "User"
                },
                "name_uuid": "37bfa814-3864-42a7-b67e-9cad49086ec1",
                "tumors_uuid": "807a3a74-90cc-4b35-82c1-9f1052af13c6"
              },
              "operation": "add",
              "uuids": "9dfd804b-abac-4319-99cf-751331ee4636,4e476ffa-0a02-4770-84e0-edaa870133e8"
            }
          ],
          "timeStamp": 1674086798092
        },
        "-NM6Ma4rzxXaF1CxQOAT": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Y205D",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 Y205D mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer, colorectal cancer and squamous cell carcinoma, and is a statistically significant hotspot (PMID: 18725978, 15778432, 15958551). In vivo studies with yeast expressing TP53 Y205D demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 Y205D also demonstrated the mutation is inactivating as measured by reduced growth suppressive activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674086788712,
                    "updatedBy": "User"
                  },
                  "description_uuid": "0af39f0b-eac9-4580-ae15-d330a538cc9c",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1671746866807,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "deefda37-d4bd-418f-8ddc-0b0c61272eb6",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1671746865635,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "83ccc781-ea2b-4d81-8b7c-12f875d9c7c0",
                  "short": ""
                },
                "mutation_effect_uuid": "58079e40-7454-4951-867e-c496f1464fd0",
                "name": "Y205D",
                "name_review": {
                  "added": true,
                  "lastReviewed": "y205d",
                  "updateTime": 1671746861237,
                  "updatedBy": "User"
                },
                "name_uuid": "e34d7c6e-1679-4d92-85e7-137414310c51",
                "tumors_uuid": "00b4b802-eec4-4289-ae4c-49a1cdffc4e3"
              },
              "operation": "add",
              "uuids": "83ccc781-ea2b-4d81-8b7c-12f875d9c7c0,deefda37-d4bd-418f-8ddc-0b0c61272eb6"
            }
          ],
          "timeStamp": 1674087129324
        },
        "-NM6MgnzG59-IMcBZFMo": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Y205F",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 Y205F mutation is located in the DNA-binding domain of the protein. This mutation has been identified in urothelial cancer, glioblastoma, colorectal cancer and squamous cell carcinoma, and is a statistically significant hotspot (PMID: 21413016, 15466178, 17410283, 15957194). In vivo studies with yeast expressing TP53 Y205F demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 Y205F also demonstrated the mutation is inactivating as measured by reduced growth suppressive activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674087121263,
                    "updatedBy": "User"
                  },
                  "description_uuid": "45bf4afe-6ee5-4cd6-9bfb-53ab540bfe60",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1671746894634,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "6508c60a-5f02-4287-b49d-7e3ed121bb84",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1671746893577,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "a346638f-1f40-48ba-a1cb-0c99db56b811",
                  "short": ""
                },
                "mutation_effect_uuid": "9ed81b3b-0e6a-47ea-99fc-14951fcbd1f3",
                "name": "Y205F",
                "name_review": {
                  "added": true,
                  "updateTime": 1671746890383,
                  "updatedBy": "User"
                },
                "name_uuid": "f2eef519-f47a-445e-9c09-f4b464253cf4",
                "tumors_uuid": "7cefd42f-16be-48fd-908c-5daedcc1ebdc"
              },
              "operation": "add",
              "uuids": "a346638f-1f40-48ba-a1cb-0c99db56b811,6508c60a-5f02-4287-b49d-7e3ed121bb84"
            }
          ],
          "timeStamp": 1674087156852
        },
        "-NM6MndwsphI3jmJLvyg": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Y205H",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 Y205H mutation is located in the DNA-binding domain of the protein. This mutation has been identified in urothelial cancer, glioblastoma, colorectal cancer and squamous cell carcinoma, and is a statistically significant hotspot (PMID: 21413016, 15466178, 17410283, 15957194). In vivo studies with yeast expressing TP53 Y205H demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 Y205H also demonstrated the mutation is inactivating as measured by reduced growth suppressive activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674087153617,
                    "updatedBy": "User"
                  },
                  "description_uuid": "30cd7dbb-e34c-4511-993d-259bc6fdf222",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1671746930372,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "2a793159-c60d-4bd2-9876-86fd0b548583",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1671746929492,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "c12195bb-1d27-4d71-88fe-b11e8dfca974",
                  "short": ""
                },
                "mutation_effect_uuid": "67a3f2b4-d253-40e0-9b12-10650593dab6",
                "name": "Y205H",
                "name_review": {
                  "added": true,
                  "updateTime": 1671746927151,
                  "updatedBy": "User"
                },
                "name_uuid": "f41891b5-8920-4fe1-848f-d55b72464da4",
                "tumors_uuid": "f9039dfe-ecc5-4b55-a7c4-9d3d239e19e8"
              },
              "operation": "add",
              "uuids": "c12195bb-1d27-4d71-88fe-b11e8dfca974,2a793159-c60d-4bd2-9876-86fd0b548583"
            }
          ],
          "timeStamp": 1674087184881
        },
        "-NM6MuKBHy8Hz3_oRA5P": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Y205N",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 Y205N mutation is located in the DNA-binding domain of the protein. This mutation has been identified in ovarian cancer and squamous cell carcinoma, and is a statistically significant hotspot (PMID: 7852189, 15958551). In vivo studies with yeast expressing TP53 Y205N demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 Y205N also demonstrated the mutation is inactivating as measured by reduced growth suppressive activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674087176978,
                    "updatedBy": "User"
                  },
                  "description_uuid": "94861a46-b3bc-436f-bfb4-485f166de30b",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1671746954088,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "93b855a6-9c16-4327-9da5-716c71cd920b",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1671746953310,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "68686269-030c-4951-9c98-574bc58e04f7",
                  "short": ""
                },
                "mutation_effect_uuid": "d0b19183-2f4a-4ea4-b0c2-86b46b0a00e8",
                "name": "Y205N",
                "name_review": {
                  "added": true,
                  "updateTime": 1671746950365,
                  "updatedBy": "User"
                },
                "name_uuid": "9ce3731f-1f54-42c3-a179-ec396c3061a5",
                "tumors_uuid": "1366d874-de8a-4c6f-8e37-d5dcc9202515"
              },
              "operation": "add",
              "uuids": "68686269-030c-4951-9c98-574bc58e04f7,93b855a6-9c16-4327-9da5-716c71cd920b"
            }
          ],
          "timeStamp": 1674087212225
        },
        "-NM6N04Tw5yHW--AR_oR": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V143E",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 V143E mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer, colorectal cancer and squamous cell carcinoma, and is a statistically significant hotspot (PMID: 17683074, 9052405, 7767998). In vivo studies with yeast expressing TP53 V143E demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 V143E also demonstrated the mutation is inactivating as measured by reduced growth suppressive activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674087200955,
                    "updatedBy": "User"
                  },
                  "description_uuid": "114ac3c9-f47c-4e5f-be58-04d25fc068e8",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1671747434923,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "56d25060-f66b-48ae-9eee-d9f34b3f9d5a",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1671747433911,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "650cb919-803d-4b78-a27a-0c279d483ec3",
                  "short": ""
                },
                "mutation_effect_uuid": "97c519d8-b456-4aa3-8212-746415fbdfa7",
                "name": "V143E",
                "name_review": {
                  "added": true,
                  "updateTime": 1671747422607,
                  "updatedBy": "User"
                },
                "name_uuid": "2c6cee5f-debb-451e-982f-a27c52fcd81d",
                "tumors_uuid": "2e706a1c-4cac-47ff-90e6-fd2c5df88d69"
              },
              "operation": "add",
              "uuids": "650cb919-803d-4b78-a27a-0c279d483ec3,56d25060-f66b-48ae-9eee-d9f34b3f9d5a"
            }
          ],
          "timeStamp": 1674087239890
        },
        "-NM6N6p9vxkFpMHijRiS": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "C242R",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 C242R mutation is located in exon 6 of the protein. This mutation has been identified in pancreatic cancer, prostate cancer and squamous cell carcinoma, and is a statistically significant hotspot (PMID: 15541116, 15940643, 17456604). In vivo studies with yeast expressing TP53 C242R demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 C242R also demonstrated the mutation is inactivating as measured by reduced growth suppressive activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674087226814,
                    "updatedBy": "User"
                  },
                  "description_uuid": "3b077399-8791-452e-99a5-8ad237c27d8c",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1671747480948,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "9bd2e135-c776-4144-96a0-9e31da698e50",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1671747480059,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "7e07bb48-f05a-46e9-bb40-f49dbd41362c",
                  "short": ""
                },
                "mutation_effect_uuid": "333cf4ce-ec25-4424-8c1b-da89659db751",
                "name": "C242R",
                "name_review": {
                  "added": true,
                  "updateTime": 1671747471039,
                  "updatedBy": "User"
                },
                "name_uuid": "2650470e-ecdc-490e-9fcc-ef578ca490c2",
                "tumors_uuid": "e2a2815d-b378-4916-ba12-6f541cec5a45"
              },
              "operation": "add",
              "uuids": "7e07bb48-f05a-46e9-bb40-f49dbd41362c,9bd2e135-c776-4144-96a0-9e31da698e50"
            }
          ],
          "timeStamp": 1674087267519
        },
        "-NM6NO49x7ExG_NeoGjD": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "C242W",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 C242W mutation is located in exon 6 of the protein. This mutation has been identified in breast cancer, colorectal cancer and ovarian cancer, and is a statistically significant hotspot (PMID: 9815649, 8682586, 15221786). In vivo studies with yeast expressing TP53 C242W demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 C242W also demonstrated the mutation is inactivating as measured by reduced growth suppressive activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674087306813,
                    "updatedBy": "User"
                  },
                  "description_uuid": "53467b2b-64dc-464d-87e5-2c2ea70bdc31",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1671747492077,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "8e37c5e7-5e92-4997-bfff-e5c9545d7b2a",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1671747491159,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "6aaaacbf-8fa9-4733-b4e0-85ddbe148aeb",
                  "short": ""
                },
                "mutation_effect_uuid": "d2cc50c6-8de7-45ba-b1be-ffb1f93ab6cd",
                "name": "C242W",
                "name_review": {
                  "added": true,
                  "updateTime": 1671747489309,
                  "updatedBy": "User"
                },
                "name_uuid": "5375009f-d1a3-4ee2-a79e-388a0351d005",
                "tumors_uuid": "b9c28f45-dccb-49f0-8721-5b0b8d859485"
              },
              "operation": "add",
              "uuids": "6aaaacbf-8fa9-4733-b4e0-85ddbe148aeb,8e37c5e7-5e92-4997-bfff-e5c9545d7b2a"
            }
          ],
          "timeStamp": 1674087338175
        },
        "-NM6NUypBlRW5q7hrQiD": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "C242G",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 C242G mutation is located in exon 6 of the protein. This mutation has been identified in glioblastoma, malignant melanoma and breast cancer, and is a statistically significant hotspot (PMID: 11453385, 17260012, 7928628). In vivo studies with yeast expressing TP53 C242G demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 C242G also demonstrated the mutation is inactivating as measured by reduced growth suppressive activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674087327057,
                    "updatedBy": "User"
                  },
                  "description_uuid": "b0034458-9a6e-4219-9d96-cdfc44ff11f8",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1671747526687,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "de5d81eb-6375-4753-a458-2bc8adf49c3f",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1671747525844,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "aeba8487-c6f2-4fde-81e6-c7d83b0f6287",
                  "short": ""
                },
                "mutation_effect_uuid": "6886e16d-c5a8-4ed2-bde2-ad40e2af964e",
                "name": "C242G",
                "name_review": {
                  "added": true,
                  "updateTime": 1671747511505,
                  "updatedBy": "User"
                },
                "name_uuid": "9cfbb1e4-c9e3-4ab4-af63-fadf45c0ce64",
                "tumors_uuid": "8447c547-045c-4406-b1d8-aee375c387e2"
              },
              "operation": "add",
              "uuids": "aeba8487-c6f2-4fde-81e6-c7d83b0f6287,de5d81eb-6375-4753-a458-2bc8adf49c3f"
            }
          ],
          "timeStamp": 1674087366442
        },
        "-NM6Nao_rJhigbP5blQv": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V143G",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 V143G mutation is located in the DNA-binding domain of the protein. This mutation has been identified in adenocarcinoma and is a statistically significant hotspot (PMID: 22551440). In vivo studies with yeast expressing TP53 V143G demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 V143G also demonstrated the mutation is inactivating as measured by reduced growth suppressive activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674087361470,
                    "updatedBy": "User"
                  },
                  "description_uuid": "12cca7d3-a1b0-461c-891f-58fb99f2d52d",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1673646007869,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "be7084f5-f6a3-4318-a484-9635db5720bf",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1673646006758,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "b82252b2-0d6d-402c-ace6-5cbc2620a368",
                  "short": ""
                },
                "mutation_effect_uuid": "2d94b425-d4b8-4a6f-8b7c-20f189e8033b",
                "name": "V143G",
                "name_review": {
                  "added": true,
                  "updateTime": 1673646000254,
                  "updatedBy": "User"
                },
                "name_uuid": "9372fcec-5355-4890-85fc-866899d518c7",
                "tumors_uuid": "161e4c23-3077-4ed1-bc8f-c0c9ee619f6c"
              },
              "operation": "add",
              "uuids": "b82252b2-0d6d-402c-ace6-5cbc2620a368,be7084f5-f6a3-4318-a484-9635db5720bf"
            }
          ],
          "timeStamp": 1674087394458
        },
        "-NM6NhY1FUaip6vd6VlA": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G266V",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 G266V mutation is located in the DNA-binding domain of the protein. This mutation has been identified in adenocarcinoma and is a statistically significant hotspot (PMID: 16143127). In vivo studies with yeast expressing TP53 G266V demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 G266V also demonstrated the mutation is inactivating as measured by reduced growth suppressive activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674087380084,
                    "updatedBy": "User"
                  },
                  "description_uuid": "19475e0d-c754-45f7-9618-08c10457e528",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1673646066479,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "888c47c6-58c7-4e04-81e6-1536c2bd51f4",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1673646065735,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "f3c22abd-5c1b-4b87-a9e4-b3ef361e48cc",
                  "short": ""
                },
                "mutation_effect_uuid": "a97d9762-57e3-4945-a51f-7a7f9bf1e972",
                "name": "G266V",
                "name_review": {
                  "added": true,
                  "updateTime": 1673646063472,
                  "updatedBy": "User"
                },
                "name_uuid": "0f8074ee-1796-4cb1-8d43-60b8337fbc5e",
                "tumors_uuid": "1530ba01-8198-4b6f-93b9-cbcc56f61d57"
              },
              "operation": "add",
              "uuids": "f3c22abd-5c1b-4b87-a9e4-b3ef361e48cc,888c47c6-58c7-4e04-81e6-1536c2bd51f4"
            }
          ],
          "timeStamp": 1674087422007
        },
        "-NM6NoMmULaaeEiIDsPT": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V143M",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 V143M mutation is located in the DNA-binding domain of the protein. This mutation has been identified in squamous cell carcinoma and is a statistically significant hotspot (PMID: 8393371). In vivo studies with yeast expressing TP53 V143M demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 V143M also demonstrated the mutation is inactivating as measured by reduced growth suppressive activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674087400331,
                    "updatedBy": "User"
                  },
                  "description_uuid": "43254f38-5bef-4b43-b00b-aea85e70dad9",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1673646086897,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "8b31e7bd-936b-4c15-9afb-c14006669945",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1673646086055,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "d65ce7c9-dc14-4490-8f29-94c8b06eb46a",
                  "short": ""
                },
                "mutation_effect_uuid": "698dcf7e-9466-46a8-bdde-b1695010edb6",
                "name": "V143M",
                "name_review": {
                  "added": true,
                  "updateTime": 1673646083565,
                  "updatedBy": "User"
                },
                "name_uuid": "fd50b6db-1860-4e89-8f09-97a669669848",
                "tumors_uuid": "726f8907-d2e3-4738-bfda-0ece2c09c24a"
              },
              "operation": "add",
              "uuids": "d65ce7c9-dc14-4490-8f29-94c8b06eb46a,8b31e7bd-936b-4c15-9afb-c14006669945"
            }
          ],
          "timeStamp": 1674087449959
        },
        "-NM6NvIse4IAaykEcM_4": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R158P",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 R158P mutation is located in the DNA-binding domain of the protein. This mutation has been identified in squamous cell carcinoma and is a statistically significant hotspot (PMID: 15564288). In vivo studies with yeast expressing TP53 R158P demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 R158P also demonstrated the mutation is inactivating as measured by reduced growth suppressive activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674087440101,
                    "updatedBy": "User"
                  },
                  "description_uuid": "d87a7c03-a563-45fc-a074-2174e97d7dc3",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1673988213287,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "8094f20d-a8f4-4245-ba06-676a2f91222f",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1673988211392,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "ab56a570-4152-4e6c-9403-909fc59e24ad",
                  "short": ""
                },
                "mutation_effect_uuid": "da4eeabe-75b0-4923-98ae-8039a9b2cf34",
                "name": "R158P",
                "name_review": {
                  "added": true,
                  "updateTime": 1673988206745,
                  "updatedBy": "User"
                },
                "name_uuid": "87597f5b-f9ef-44c3-aaf5-1c07802731ae",
                "tumors_uuid": "0256ea49-175f-45ca-b46f-36a0ef9bcb00"
              },
              "operation": "add",
              "uuids": "ab56a570-4152-4e6c-9403-909fc59e24ad,8094f20d-a8f4-4245-ba06-676a2f91222f"
            }
          ],
          "timeStamp": 1674087478381
        },
        "-NM6O153F12uqR2Bp7fk": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G266K",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 G266K mutation is located in the DNA-binding domain of the protein. This mutation has been identified in Merkel cell carcinoma and is a statistically significant hotspot (PMID: 26238782). In vitro studies with various human cancer cell lines expressing TP53 G266K demonstrate the mutation is inactivating as measured by reduced growth suppressive activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674087423469,
                    "updatedBy": "User"
                  },
                  "description_uuid": "54860447-3337-4644-95eb-e7ea1a0df268",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1673646110424,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "cf20a5e1-6648-4545-b838-3371112fad49",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1673646109598,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "fc4dfacd-c797-455d-861b-f231b35dff67",
                  "short": ""
                },
                "mutation_effect_uuid": "87848e11-b55e-4d6e-a5bf-4c325cfd042f",
                "name": "G266K",
                "name_review": {
                  "added": true,
                  "updateTime": 1673646107247,
                  "updatedBy": "User"
                },
                "name_uuid": "158a1d57-069c-4c2d-a85c-6073bea3e383",
                "tumors_uuid": "77e39890-60c8-4dfa-9d13-6dc782b7f735"
              },
              "operation": "add",
              "uuids": "fc4dfacd-c797-455d-861b-f231b35dff67,cf20a5e1-6648-4545-b838-3371112fad49"
            }
          ],
          "timeStamp": 1674087506169
        },
        "-NM6O7vR0zlXpLnNqTHO": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R158G",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 R158G mutation is located in the DNA-binding domain of the protein. This mutation has been identified in glioblastoma and B-cell chronic lymphocytic leukemia, and is a statistically significant hotspot (PMID: 10454262, 12149195). In vivo studies with yeast expressing TP53 R158G demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 R158G also demonstrated the mutation is inactivating as measured by reduced growth suppressive activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674087493070,
                    "updatedBy": "User"
                  },
                  "description_uuid": "746051ee-424b-4210-9e90-99e9142274d3",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1673988300016,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "b3447c25-a8fd-4ad1-bcb6-7a937e79e3df",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1673988299227,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "c5779258-d883-41b7-88b3-e0e4107f0176",
                  "short": ""
                },
                "mutation_effect_uuid": "c405c5b5-52be-45a1-b7a9-994ea1e3d6f9",
                "name": "R158G",
                "name_review": {
                  "added": true,
                  "updateTime": 1673988297220,
                  "updatedBy": "User"
                },
                "name_uuid": "e36b083d-149d-4c27-a040-97e55e5c2c5c",
                "tumors_uuid": "ef7ea7e3-f404-4ab5-b28f-c4b630c3a442"
              },
              "operation": "add",
              "uuids": "c5779258-d883-41b7-88b3-e0e4107f0176,b3447c25-a8fd-4ad1-bcb6-7a937e79e3df"
            }
          ],
          "timeStamp": 1674087534161
        },
        "-NM6OEm4GukgwDQ1pZnW": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R158F",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 R158F mutation is located in the DNA-binding domain of the protein. This mutation has been identified in squamous cell carcinoma and is a statistically significant hotspot (PMID: 11532872). In vitro studies with various human cancer cell lines expressing TP53 R158F demonstrate the mutation is inactivating as measured by reduced growth suppressive activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674087469703,
                    "updatedBy": "User"
                  },
                  "description_uuid": "ecf0369e-1423-4521-93fd-399300fc7bd9",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1673988275878,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "a8c66e8b-4784-41bf-bb09-4d5e3ba46b05",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1673988274515,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "b64369a3-594d-4991-bdb9-cd26081048b6",
                  "short": ""
                },
                "mutation_effect_uuid": "61fb38b7-7216-4e33-9a4e-f245f21c8b70",
                "name": "R158F",
                "name_review": {
                  "added": true,
                  "updateTime": 1673988271233,
                  "updatedBy": "User"
                },
                "name_uuid": "95da8bfe-77b3-40ad-92fc-cfdb2a0325e8",
                "tumors_uuid": "02bbbc71-7966-4aed-a546-7ac661cdfe2b"
              },
              "operation": "add",
              "uuids": "b64369a3-594d-4991-bdb9-cd26081048b6,a8c66e8b-4784-41bf-bb09-4d5e3ba46b05"
            }
          ],
          "timeStamp": 1674087562234
        },
        "-NM6OLbz9LlEv5c3ocrt": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R158S",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 R158S mutation is located in the DNA-binding domain of the protein. This mutation has been identified in clear cell carcinoma and is a statistically significant hotspot (PMID: 17581423). In vivo studies with yeast expressing TP53 R158S demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1673988254084,
                    "updatedBy": "User"
                  },
                  "description_uuid": "4a991dca-5e68-41ab-b08d-914068519949",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1673988249756,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "fe773070-a321-4d9a-b211-4ebef84ac21b",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1673988248934,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "446ca72f-2d19-452a-a08b-1262350e3d10",
                  "short": ""
                },
                "mutation_effect_uuid": "3335cc06-3150-403a-9c67-127f08a99e9a",
                "name": "R158S",
                "name_review": {
                  "added": true,
                  "updateTime": 1673988246768,
                  "updatedBy": "User"
                },
                "name_uuid": "5d55bfab-3161-485e-9df5-b09758d98af1",
                "tumors_uuid": "c0fcbde0-6857-4154-9d8e-0494db93a94a"
              },
              "operation": "add",
              "uuids": "446ca72f-2d19-452a-a08b-1262350e3d10,fe773070-a321-4d9a-b211-4ebef84ac21b"
            }
          ],
          "timeStamp": 1674087590260
        },
        "-NM6OSTtRKvMbTvb7a4G": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "E286Q",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 E286Q mutation is located in the DNA-binding domain of the protein. This mutation has been identified in squamous cell carcinoma and adenocarcinoma and is a statistically significant hotspot (PMID: 9133458, 12509279). In vivo studies with yeast expressing TP53 E286Q demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 E286Q also demonstrated the mutation is inactivating as measured by reduced growth suppressive activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674087522578,
                    "updatedBy": "User"
                  },
                  "description_uuid": "128f858f-049d-42ad-871c-b213734a7765",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1673988523144,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "f163803d-8d94-4124-b0e2-9a0a13ff82b6",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1673988522460,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "0ab67089-360f-4a29-8809-a393d32ba72d",
                  "short": ""
                },
                "mutation_effect_uuid": "fc096706-2772-4ddb-8fdf-6a7523f1eab6",
                "name": "E286Q",
                "name_review": {
                  "added": true,
                  "updateTime": 1673988520170,
                  "updatedBy": "User"
                },
                "name_uuid": "ec1c5120-1b0f-4987-a350-cc55e0a3bde1",
                "tumors_uuid": "9183ace8-dec3-469f-b484-7c95c980dd35"
              },
              "operation": "add",
              "uuids": "0ab67089-360f-4a29-8809-a393d32ba72d,f163803d-8d94-4124-b0e2-9a0a13ff82b6"
            }
          ],
          "timeStamp": 1674087618350
        },
        "-NM6S2ZbMvUIiIl1VMEM": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "E286A",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 E286A mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and is a statistically significant hotspot (PMID: 9421363). In vivo studies with yeast expressing TP53 E286A demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 E286A also demonstrated the mutation is inactivating as measured by reduced growth suppressive activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674088155046,
                    "updatedBy": "User"
                  },
                  "description_uuid": "21165193-4b6f-4cf1-b471-ea313a9f79aa",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1673988542109,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "ebc95219-3398-4acb-81f0-c7180bd45e6e",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1673988541267,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "3d0afeb1-828a-41ce-b331-2c72b2ff1718",
                  "short": ""
                },
                "mutation_effect_uuid": "f8e968f7-41de-4dcc-8b46-f51f0f3e34aa",
                "name": "E286A",
                "name_review": {
                  "added": true,
                  "updateTime": 1673988538801,
                  "updatedBy": "User"
                },
                "name_uuid": "04ea54bd-18c9-43e2-9a0f-56970cf1952d",
                "tumors_uuid": "5e9afd2f-fc8e-48d0-9084-9724e732892c"
              },
              "operation": "add",
              "uuids": "3d0afeb1-828a-41ce-b331-2c72b2ff1718,ebc95219-3398-4acb-81f0-c7180bd45e6e"
            }
          ],
          "timeStamp": 1674088560796
        },
        "-NM6SEgkc3e7mFYAi0_F": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "H179P",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 H179P mutation is located in the DNA-binding domain of the protein. This mutation has been identified in squamous cell carcinoma and is a statistically significant hotspot (PMID: 14580680). In vivo studies with yeast expressing TP53 H179P demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 H179P also demonstrated the mutation is inactivating as measured by reduced growth suppressive activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674088576582,
                    "updatedBy": "User"
                  },
                  "description_uuid": "54e0bbd4-7eb9-46cb-a06a-7afe4eff5ff3",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1673988633552,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "050d257d-1769-4dca-b2f7-ccf49c8fb1a1",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1673988632617,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "4f46c883-06e6-43ce-beb5-e4a357ce6a89",
                  "short": ""
                },
                "mutation_effect_uuid": "9e21cdbe-0557-4dec-bca5-15eb19628f97",
                "name": "H179P",
                "name_review": {
                  "added": true,
                  "updateTime": 1673988629963,
                  "updatedBy": "User"
                },
                "name_uuid": "63342a80-9082-4675-8d3c-e9f6f9fa2b74",
                "tumors_uuid": "947d85c8-4f72-410d-b71d-d8067759e90e"
              },
              "operation": "add",
              "uuids": "4f46c883-06e6-43ce-beb5-e4a357ce6a89,050d257d-1769-4dca-b2f7-ccf49c8fb1a1"
            }
          ],
          "timeStamp": 1674088610469
        },
        "-NM6SLaW1fYeOuYNjO9o": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "H179D",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 H179D mutation is located in the DNA-binding domain of the protein. This mutation has been identified in squamous cell carcinoma and is a statistically significant hotspot (PMID: 7585600). In vivo studies with yeast expressing TP53 H179D demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 H179D also demonstrated the mutation is inactivating as measured by reduced growth suppressive activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674088599598,
                    "updatedBy": "User"
                  },
                  "description_uuid": "bf8d6a5d-4974-4456-8ef8-7ad6cbb82e77",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1673988655755,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "02cf3ff0-4f12-46e4-98f4-4739f5b930be",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1673988654972,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "f69b3715-81a9-48c5-b6f8-36adf31a0af6",
                  "short": ""
                },
                "mutation_effect_uuid": "bddee9d4-0456-4f45-9aff-72eb116b5f6e",
                "name": "H179D",
                "name_review": {
                  "added": true,
                  "updateTime": 1673988652052,
                  "updatedBy": "User"
                },
                "name_uuid": "4524d681-309f-40cd-aba2-88047d0f917d",
                "tumors_uuid": "ed7237b4-a70b-4604-860c-6f2e634569c8"
              },
              "operation": "add",
              "uuids": "f69b3715-81a9-48c5-b6f8-36adf31a0af6,02cf3ff0-4f12-46e4-98f4-4739f5b930be"
            }
          ],
          "timeStamp": 1674088638742
        },
        "-NM6SS_mP7JPVfxc-21o": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "H168P",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 H168P mutation is located in the DNA-binding domain of the protein. This mutation has been identified in squamous cell carcinoma and is a statistically significant hotspot (PMID: 12649174). In vivo studies with yeast expressing TP53 H168P demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 H168P also demonstrated the mutation is inactivating as measured by reduced growth suppressive activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674088615260,
                    "updatedBy": "User"
                  },
                  "description_uuid": "6542ca6c-48f2-4d8f-958e-c459870fad60",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1673988683062,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "403d7ec6-9a06-42af-ac22-2df71fae1a78",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1673988681789,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "52694828-715e-446e-936e-ad16a380dc54",
                  "short": ""
                },
                "mutation_effect_uuid": "6f96e970-f425-4ae6-b902-6ee8416e8971",
                "name": "H168P",
                "name_review": {
                  "added": true,
                  "lastReviewed": "H169P",
                  "updateTime": 1673988727858,
                  "updatedBy": "User"
                },
                "name_uuid": "6397b503-5b1f-4851-9430-9e55cc9c8426",
                "tumors_uuid": "068becdc-87c6-4c9d-8b33-6d1d09ef949c"
              },
              "operation": "add",
              "uuids": "52694828-715e-446e-936e-ad16a380dc54,403d7ec6-9a06-42af-ac22-2df71fae1a78"
            }
          ],
          "timeStamp": 1674088667367
        },
        "-NM6TUlPETvpdIQtw4m9": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "H168L",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 H168L mutation is located in the DNA-binding domain of the protein. This mutation has been identified in squamous cell carcinoma and breast cancer and is a statistically significant hotspot (PMID: 1408139, 18348141). In vivo studies with yeast expressing TP53 H168L demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 H168L also demonstrated the mutation is inactivating as measured by reduced growth suppressive activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674088901908,
                    "updatedBy": "User"
                  },
                  "description_uuid": "99a9ae24-60e7-446a-9c78-c5b8060d178f",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1673988719701,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "ed098ad7-3177-4344-a459-47b2330de882",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1673988718545,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "7e31d293-cf1c-4273-a570-2599a8f6722c",
                  "short": ""
                },
                "mutation_effect_uuid": "3013e10a-4c5a-4ce3-8ac7-ef813b104586",
                "name": "H168L",
                "name_review": {
                  "added": true,
                  "updateTime": 1673988715792,
                  "updatedBy": "User"
                },
                "name_uuid": "ee556d4a-1c06-4e1a-9cff-86946c792b90",
                "tumors_uuid": "77c5a0e8-8270-41e8-acf4-8cb4aeb66570"
              },
              "operation": "add",
              "uuids": "7e31d293-cf1c-4273-a570-2599a8f6722c,ed098ad7-3177-4344-a459-47b2330de882"
            }
          ],
          "timeStamp": 1674088938447
        },
        "-NM6TcN7t-UpkhGR5Cpl": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "C176S",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 C176S mutation is located in the DNA-binding domain of the protein. This mutation has been identified in papillary serous cystadenocarcinoma and hepatocellular carcinoma and is a statistically significant hotspot (PMID: 9635683, 8407553). In vivo studies with yeast expressing TP53 C176S demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 C176S also demonstrated the mutation is inactivating as measured by reduced growth suppressive activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674088940006,
                    "updatedBy": "User"
                  },
                  "description_uuid": "3937b9ea-1ef2-496e-81d5-20bd20efc82a",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1673988838282,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "45ff9bcb-ef3c-4f8d-ab87-d515c640b219",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1673988837289,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "7cc87df2-9e76-4815-b34e-307024318389",
                  "short": ""
                },
                "mutation_effect_uuid": "bf7f9839-fef8-4bac-8279-54c863783679",
                "name": "C176S",
                "name_review": {
                  "added": true,
                  "updateTime": 1673988834936,
                  "updatedBy": "User"
                },
                "name_uuid": "744aa5af-2dc9-4075-a05f-cd875268eeb4",
                "tumors_uuid": "42556737-d0a0-473c-afea-f141d3548f0d"
              },
              "operation": "add",
              "uuids": "7cc87df2-9e76-4815-b34e-307024318389,45ff9bcb-ef3c-4f8d-ab87-d515c640b219"
            }
          ],
          "timeStamp": 1674088973693
        },
        "-NMjfdg5nKA9-gp-Lxpj": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "C176G",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 C176G mutation is located in the DNA-binding domain of the protein. This mutation has been identified in diffuse large B-cell lymphoma and hepatocellular carcinoma, and is a statistically significant hotspot (PMID: 11113864, 8672994). In vivo studies with yeast expressing TP53 C176G demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 C176G also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1673988860422,
                    "updatedBy": "User"
                  },
                  "description_uuid": "7d9ccece-b927-47f9-92b2-2b03fac18b88",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1673988857413,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "78e2f7ac-6c2e-46eb-8e82-f2dbfa111e29",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1673988856506,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "ba3d8ace-aa2f-47a8-9089-d93d5d000d5e",
                  "short": ""
                },
                "mutation_effect_uuid": "3e6d13fd-dd8f-43b9-a9a8-3de61455d02d",
                "name": "C176G",
                "name_review": {
                  "added": true,
                  "updateTime": 1673988854362,
                  "updatedBy": "User"
                },
                "name_uuid": "c8b914e9-c2ab-4328-99ee-80149a001271",
                "tumors_uuid": "2b640c90-590e-4dc0-8b72-e9db3de56ad4"
              },
              "operation": "add",
              "uuids": "ba3d8ace-aa2f-47a8-9089-d93d5d000d5e,78e2f7ac-6c2e-46eb-8e82-f2dbfa111e29"
            }
          ],
          "timeStamp": 1674763475731
        },
        "-NMjfgArJBO0SiPBLKuZ": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "C238R",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 C238R mutation is located in the DNA-binding domain of the protein. This mutation has been identified in squamous cell carcinoma and is a statistically significant hotspot (PMID: 10225439). In vivo studies with yeast expressing TP53 C238R demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 C238R also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1673988903066,
                    "updatedBy": "User"
                  },
                  "description_uuid": "93d083ac-4ffe-496a-b45f-e856a78e0987",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1673988900354,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "16fa7f0a-aee7-4c27-8d100-8075b1636587",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1673988899452,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "42850a80-4674-4486-ae60-77c5f97c281e",
                  "short": ""
                },
                "mutation_effect_uuid": "c77a7762-9616-423c-a1d7-25fe6a2b00fd",
                "name": "C238R",
                "name_review": {
                  "added": true,
                  "updateTime": 1673988897481,
                  "updatedBy": "User"
                },
                "name_uuid": "e649027c-75c3-4b0b-b539-5fbd97491758",
                "tumors_uuid": "e9316ec9-bacb-462f-8e32-6307812b8407"
              },
              "operation": "add",
              "uuids": "42850a80-4674-4486-ae60-77c5f97c281e,16fa7f0a-aee7-4c27-8d100-8075b1636587"
            }
          ],
          "timeStamp": 1674763486478
        },
        "-NMjfmsncPqSjE4z7p1Q": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "C176Y",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 C176Y mutation is located in the DNA-binding domain of the protein. This mutation has been identified in squamous cell carcinoma and colorectal cancer, and is a statistically significant hotspot (PMID: 21798897, 9431782). In vivo studies with yeast expressing TP53 C176Y demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 C176Y also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1673988881260,
                    "updatedBy": "User"
                  },
                  "description_uuid": "189ab1dd-191e-4968-a627-8599368ab0b5",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1673988877871,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "2652ccc2-d10f-4f63-b245-420e6d35a11c",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1673988877052,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "cfd13aa8-4d85-476f-91c0-1234d553cde8",
                  "short": ""
                },
                "mutation_effect_uuid": "d09fae7e-2c5a-481b-9666-1c47a4084057",
                "name": "C176Y",
                "name_review": {
                  "added": true,
                  "updateTime": 1673988874734,
                  "updatedBy": "User"
                },
                "name_uuid": "5ac1da89-8266-49eb-a099-50d9b33a056a",
                "tumors_uuid": "78854fea-3a76-4218-b126-7315ead3ab27"
              },
              "operation": "add",
              "uuids": "cfd13aa8-4d85-476f-91c0-1234d553cde8,2652ccc2-d10f-4f63-b245-420e6d35a11c"
            }
          ],
          "timeStamp": 1674763513930
        },
        "-NMjftQ_uNIuacUS8ZFY": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "C238Y",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 C238Y mutation is located in the DNA-binding domain of the protein. This mutation has been identified in osteosarcoma and is a statistically significant hotspot (PMID: 11596036). In vivo studies with yeast expressing TP53 C238Y demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 C238Y also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1673988983085,
                    "updatedBy": "User"
                  },
                  "description_uuid": "d93dc550-8a9b-4800-8e6d-e050d1fed589",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1673988976812,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "e18a7835-42c3-4524-820e-0c729ca88cba",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1673988975361,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "8f0e0342-3bd5-474d-969c-253737823789",
                  "short": ""
                },
                "mutation_effect_uuid": "07c45541-36a6-4535-b7a9-652e7c6a0942",
                "name": "C238Y",
                "name_review": {
                  "added": true,
                  "updateTime": 1673988971688,
                  "updatedBy": "User"
                },
                "name_uuid": "da20ee53-55ad-4ac9-a2d0-1e91cc5945b4",
                "tumors_uuid": "60a3abe8-6616-4dae-9304-5a9e64f3686d"
              },
              "operation": "add",
              "uuids": "8f0e0342-3bd5-474d-969c-253737823789,e18a7835-42c3-4524-820e-0c729ca88cba"
            }
          ],
          "timeStamp": 1674763540732
        },
        "-NMjfztERX-LeSRc7GEI": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "C238W",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 C238W mutation is located in the DNA-binding domain of the protein. This mutation has been identified in adenocarcinoma and is a statistically significant hotspot (PMID: 11710597). In vivo studies with yeast expressing TP53 C238W demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 C238W also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1673988957256,
                    "updatedBy": "User"
                  },
                  "description_uuid": "5f62cd71-1a02-4904-849e-3410c14f91cb",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1673988953296,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "10dd559d-f9a4-4ee0-85a5-f91b47b13fd4",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1673988951778,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "d7cd8775-231e-4dca-86fb-6cc8ec905ea8",
                  "short": ""
                },
                "mutation_effect_uuid": "0bc47676-e44f-4b19-8fd6-b7ae6fa08eaa",
                "name": "C238W",
                "name_review": {
                  "added": true,
                  "updateTime": 1673988949302,
                  "updatedBy": "User"
                },
                "name_uuid": "9a7512d8-384a-4cfc-a79d-9e357cd29dfa",
                "tumors_uuid": "fcef85ec-7563-491c-8010-010d7caaaffe"
              },
              "operation": "add",
              "uuids": "d7cd8775-231e-4dca-86fb-6cc8ec905ea8,10dd559d-f9a4-4ee0-85a5-f91b47b13fd4"
            }
          ],
          "timeStamp": 1674763567206
        },
        "-NMjg5W0sIFliGGqpb_U": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "C238G",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 C238G mutation is located in the DNA-binding domain of the protein. This mutation has been identified in adenocarcinoma and is a statistically significant hotspot (PMID: 16467080). In vivo studies with yeast expressing TP53 C238G demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 C238G also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1673988929986,
                    "updatedBy": "User"
                  },
                  "description_uuid": "26a4b32a-2849-4232-b30a-9b4429115132",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1673988925136,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "7627e773-9892-4d65-8c18-8de8cf9ad50c",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1673988922163,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "5cce95dd-793a-4fea-af99-8f3410116ab1",
                  "short": ""
                },
                "mutation_effect_uuid": "b548f115-9ca6-4e9e-9d2e-6eeb89f8093c",
                "name": "C238G",
                "name_review": {
                  "added": true,
                  "updateTime": 1673988920127,
                  "updatedBy": "User"
                },
                "name_uuid": "aae1279b-af89-485f-918b-959749f85777",
                "tumors_uuid": "1be59ca6-59a5-46e7-ad01-d3efc9636d48"
              },
              "operation": "add",
              "uuids": "5cce95dd-793a-4fea-af99-8f3410116ab1,7627e773-9892-4d65-8c18-8de8cf9ad50c"
            }
          ],
          "timeStamp": 1674763594328
        },
        "-NMjgCLFd-vrKu90nscz": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "M237I",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 M237I mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and colorectal cancer, and is a statistically significant hotspot (PMID: 8816892, 16696056). In vivo studies with yeast expressing TP53 M237I demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 M237I also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1673989058462,
                    "updatedBy": "User"
                  },
                  "description_uuid": "a1d50acc-84cb-4a1c-9fdd-875a77e77d3f",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1673989054194,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "8615bc12-457f-4116-9707-9e3cd67d5781",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1673989052850,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "50baf7c6-ba89-4f15-a5d9-bfe3cc37b73e",
                  "short": ""
                },
                "mutation_effect_uuid": "3c0cb8ca-35b1-4446-989e-5be14b9a6f76",
                "name": "M237I",
                "name_review": {
                  "added": true,
                  "updateTime": 1673989050738,
                  "updatedBy": "User"
                },
                "name_uuid": "734ed691-b4da-4c5c-b771-55a5b98f56a6",
                "tumors_uuid": "a6b1b5a6-eda1-449c-98a3-2e4adf1c19df"
              },
              "operation": "add",
              "uuids": "50baf7c6-ba89-4f15-a5d9-bfe3cc37b73e,8615bc12-457f-4116-9707-9e3cd67d5781"
            }
          ],
          "timeStamp": 1674763622311
        },
        "-NMjgIpws36crFq9_04-": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "M237V",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 M237V mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and is a statistically significant hotspot (PMID: 15138567). In vivo studies with yeast expressing TP53 M237V demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 M237V also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1673989036025,
                    "updatedBy": "User"
                  },
                  "description_uuid": "bc732a3f-a334-4ca3-a5d7-cab67ba33d55",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1673989032043,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "c0d525f6-b2d7-4b3a-9710-743575f7adce",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1673989031201,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "ba76abd6-2653-4f1e-8f18-2acbc431bf9a",
                  "short": ""
                },
                "mutation_effect_uuid": "ab1d2b1e-51b5-4b49-95e6-52d9895d8680",
                "name": "M237V",
                "name_review": {
                  "added": true,
                  "updateTime": 1673989026663,
                  "updatedBy": "User"
                },
                "name_uuid": "1154a8b5-f699-449c-8b6d-c057643b72eb",
                "tumors_uuid": "909af5ce-347d-4a0b-bf43-23e906052550"
              },
              "operation": "add",
              "uuids": "ba76abd6-2653-4f1e-8f18-2acbc431bf9a,c0d525f6-b2d7-4b3a-9710-743575f7adce"
            }
          ],
          "timeStamp": 1674763648915
        },
        "-NMjgPSQNQkHBmzwGd24": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "E285Q",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 E285Q mutation is located in the DNA-binding domain of the protein. This mutation has been identified in bladder cancer and is a statistically significant hotspot (PMID: 11596036). In vivo studies with yeast expressing TP53 E285Q demonstrated that the mutation is likely neutral as measured by transactivational activity comparable to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 E285Q also demonstrated the mutation likely neutral as measured by growth suppression activity comparable to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674763554100,
                    "updatedBy": "User"
                  },
                  "description_uuid": "b3fe202b-5dfe-4338-8a3d-0eac9b8723ba",
                  "effect": "Likely Neutral",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1673989004675,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "74d12aee-bed8-4d1b-9e7d-93d00d6aa01f",
                  "oncogenic": "Likely Neutral",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1673989002102,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "0a2be534-1140-42e0-9ad1-e81dba8f0ea9",
                  "short": ""
                },
                "mutation_effect_uuid": "ab824d96-a5c8-45a2-844c-815bcda12835",
                "name": "E285Q",
                "name_review": {
                  "added": true,
                  "updateTime": 1673988999905,
                  "updatedBy": "User"
                },
                "name_uuid": "2a06fdc7-32c1-4ae8-a03d-8b67862c1e2d",
                "tumors_uuid": "2a2e113c-5fc2-4458-9cce-d591679a219e"
              },
              "operation": "add",
              "uuids": "0a2be534-1140-42e0-9ad1-e81dba8f0ea9,74d12aee-bed8-4d1b-9e7d-93d00d6aa01f"
            }
          ],
          "timeStamp": 1674763676018
        },
        "-NMjgW5555r_9-Cs6hcn": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "S241C",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 S241C mutation is located in the DNA-binding domain of the protein. This mutation has been identified in acute myeloid leukemia and is a statistically significant hotspot (PMID: 9854490). In vivo studies with yeast expressing TP53 S241C demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 S241C also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1673989171405,
                    "updatedBy": "User"
                  },
                  "description_uuid": "2cb635a1-3b2d-4712-a8fe-30e2f42cc846",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1673989168348,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "70550ad9-88eb-47f4-b6c8-2652f6988fe2",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1673989167314,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "ebfbd51a-6182-4ccb-ae89-095e4550c015",
                  "short": ""
                },
                "mutation_effect_uuid": "9ae9a4f5-bc58-4518-ae47-eaafc40e3470",
                "name": "S241C",
                "name_review": {
                  "added": true,
                  "updateTime": 1673989165121,
                  "updatedBy": "User"
                },
                "name_uuid": "37abbbcf-8af2-4e38-bf9c-1e44de56e18c",
                "tumors_uuid": "80c2eaf5-23de-4e5b-b09a-abd124aa575b"
              },
              "operation": "add",
              "uuids": "ebfbd51a-6182-4ccb-ae89-095e4550c015,70550ad9-88eb-47f4-b6c8-2652f6988fe2"
            }
          ],
          "timeStamp": 1674763703197
        },
        "-NMjgbU6Nw7ZHOchccHI": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "S241A",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 S241A mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and is a statistically significant hotspot (PMID: 16489069). In vivo studies with yeast expressing TP53 S241A demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 S241A also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1673989145818,
                    "updatedBy": "User"
                  },
                  "description_uuid": "bbdf5e95-b4ef-4a94-97de-337bafd2661c",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1673989141940,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "80607c3e-ed1d-4eee-9513-be9353f24587",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1673989141269,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "7a4d7dfa-8cb0-486a-9d04-b9cee79a1377",
                  "short": ""
                },
                "mutation_effect_uuid": "ae89e245-9737-46f4-aa87-fe5bfa6e0de3",
                "name": "S241A",
                "name_review": {
                  "added": true,
                  "updateTime": 1673989138850,
                  "updatedBy": "User"
                },
                "name_uuid": "786f8914-0914-411f-8621-d40614d1c2b2",
                "tumors_uuid": "8c645337-1b7a-46be-9ebb-8265d49455c8"
              },
              "operation": "add",
              "uuids": "7a4d7dfa-8cb0-486a-9d04-b9cee79a1377,80607c3e-ed1d-4eee-9513-be9353f24587"
            }
          ],
          "timeStamp": 1674763729374
        },
        "-NMjgi6o9v2b0ip8C4qX": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "S241P",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 S241P mutation is located in the DNA-binding domain of the protein. This mutation has been identified in diffuse large B-cell lymphoma and malignant melanoma, and is a statistically significant hotspot (PMID: 9002964, 11216673). In vivo studies with yeast expressing TP53 S241P demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 S241P also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1673989123137,
                    "updatedBy": "User"
                  },
                  "description_uuid": "e9c7404a-4e3b-4e64-add6-c79bd61a7b1d",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1673989119150,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "1a2142bb-3cea-4bef-8c0a-824413de5f35",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1673989117060,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "28c9bc12-037a-4bcb-84fa-868ab04e9315",
                  "short": ""
                },
                "mutation_effect_uuid": "0090dd3f-7a2e-4196-a348-b505526acfc2",
                "name": "S241P",
                "name_review": {
                  "added": true,
                  "updateTime": 1673989114983,
                  "updatedBy": "User"
                },
                "name_uuid": "bd4cbb1f-0064-45b5-ad0a-e661f190c3be",
                "tumors_uuid": "596e9d4c-33de-418e-8d69-56d4292d7dfc"
              },
              "operation": "add",
              "uuids": "28c9bc12-037a-4bcb-84fa-868ab04e9315,1a2142bb-3cea-4bef-8c0a-824413de5f35"
            }
          ],
          "timeStamp": 1674763756555
        },
        "-NMjgopNPnlSujIOvrTk": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G154D",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 G154D mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and adenocarcinoma, and is a statistically significant hotspot (PMID: 15138567, 11011123). In vivo studies with yeast expressing TP53 G154D demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1673989099134,
                    "updatedBy": "User"
                  },
                  "description_uuid": "1b07d8b7-a11f-4c87-8884-ca2da4926b9b",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1673989096171,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "06386cec-60b5-4b2d-a61a-d65265bb498b",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1673989095120,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "dbf06d8f-7f58-46b8-b137-cb602ed15124",
                  "short": ""
                },
                "mutation_effect_uuid": "d4bfa11a-2aac-4b65-98b5-027270ac2a14",
                "name": "G154D",
                "name_review": {
                  "added": true,
                  "updateTime": 1673989092349,
                  "updatedBy": "User"
                },
                "name_uuid": "aea38136-6000-4628-b408-e81fbd168c16",
                "tumors_uuid": "26342349-85b7-45af-bc23-81826ce4a0b0"
              },
              "operation": "add",
              "uuids": "dbf06d8f-7f58-46b8-b137-cb602ed15124,06386cec-60b5-4b2d-a61a-d65265bb498b"
            }
          ],
          "timeStamp": 1674763784047
        },
        "-NMjgvbrsMLveEOAv2sX": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G154C",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 G154C mutation is located in the DNA-binding domain of the protein. This mutation has been identified in squamous cell carcinoma and is a statistically significant hotspot (PMID: 10709097). In vivo studies with yeast expressing TP53 G154C demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1673989078962,
                    "updatedBy": "User"
                  },
                  "description_uuid": "1da7d138-3ff5-4588-ade9-3e40fcd1a0d4",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1673989074543,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "5ad6c562-bd20-45df-b62d-ecc55aab2e48",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1673989073725,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "c42b3ec7-fe7d-406c-8682-1f677d5398e9",
                  "short": ""
                },
                "mutation_effect_uuid": "a2bcb8df-efc3-4881-8ab9-c911145d5460",
                "name": "G154C",
                "name_review": {
                  "added": true,
                  "updateTime": 1673989071588,
                  "updatedBy": "User"
                },
                "name_uuid": "9212ed80-10c7-4232-9b40-46ce786de25a",
                "tumors_uuid": "7ef1edcd-b2b9-4ab3-a002-a2dc25d58f74"
              },
              "operation": "add",
              "uuids": "c42b3ec7-fe7d-406c-8682-1f677d5398e9,5ad6c562-bd20-45df-b62d-ecc55aab2e48"
            }
          ],
          "timeStamp": 1674763811854
        },
        "-NMjh1OpCVdjC5hKenDq": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "E286V",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 E286V mutation is located in the DNA-binding domain of the protein. This mutation has been identified in hepatocellular carcinoma and is a statistically significant hotspot (PMID: 11375957). In vivo studies with yeast expressing TP53 E286V demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 E286V also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1673989689095,
                    "updatedBy": "User"
                  },
                  "description_uuid": "0140a69b-6546-4fe8-88be-bee8008662d0",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1673989684858,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "8bae3101-5a86-4238-9e9c-e83f2900f727",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1673989683270,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "ba4961b7-1fc2-4ca4-89bc-6b7e1822d2fc",
                  "short": ""
                },
                "mutation_effect_uuid": "314b5f1b-8b84-4fb5-992c-55fdfcbdfa5d",
                "name": "E286V",
                "name_review": {
                  "added": true,
                  "updateTime": 1673989681432,
                  "updatedBy": "User"
                },
                "name_uuid": "17df43c6-bc54-4237-b371-e5f8e10ccf1f",
                "tumors_uuid": "6033198e-60c8-4100-b183-cf28e7a500ef"
              },
              "operation": "add",
              "uuids": "ba4961b7-1fc2-4ca4-89bc-6b7e1822d2fc,8bae3101-5a86-4238-9e9c-e83f2900f727"
            }
          ],
          "timeStamp": 1674763839628
        },
        "-NMjh85KgahCA4cELY-A": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "P250R",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 P250R mutation is located in the DNA-binding domain of the protein. This mutation has been identified in hepatocellular carcinoma and is a statistically significant hotspot (PMID: 31395065). In vivo studies with yeast expressing TP53 P250R demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1673989671615,
                    "updatedBy": "User"
                  },
                  "description_uuid": "d45e63d7-a417-4f48-a315-37155e32e2f3",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1673989668413,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "81981412-3c58-4fb6-9017-558c1aa8f49e",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1673989667109,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "9a5808a1-55a5-4519-875f-469f3388fa45",
                  "short": ""
                },
                "mutation_effect_uuid": "67b3b051-33ee-478e-99e7-b3df2a18fd15",
                "name": "P250R",
                "name_review": {
                  "added": true,
                  "updateTime": 1673989663333,
                  "updatedBy": "User"
                },
                "name_uuid": "0ad9f868-878a-4917-91b0-acbad9a50846",
                "tumors_uuid": "6db60eec-c150-41cc-93b8-5737688382e0"
              },
              "operation": "add",
              "uuids": "9a5808a1-55a5-4519-875f-469f3388fa45,81981412-3c58-4fb6-9017-558c1aa8f49e"
            }
          ],
          "timeStamp": 1674763867052
        },
        "-NMjhEvPxBS8uKqLq8kV": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R282L",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 R282L mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and is a statistically significant hotspot (PMID: 12365217). In vivo studies with yeast expressing TP53 R282L demonstrated that the mutation is likely neutral as measured by transactivational activity comparable to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 R282L also demonstrated the mutation likely neutral as measured by growth suppression activity comparable to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674763725838,
                    "updatedBy": "User"
                  },
                  "description_uuid": "179f405b-fc0d-4cdc-8371-05f4cea08c20",
                  "effect": "Likely Neutral",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1673989641401,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "a3196366-dc81-4403-812a-5aa0581ce327",
                  "oncogenic": "Likely Neutral",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1673989639394,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "91a35633-1fcb-422c-c09c-07b1c59500b9",
                  "short": ""
                },
                "mutation_effect_uuid": "050c3875-dee4-4d54-9775-1d1207d5841b",
                "name": "R282L",
                "name_review": {
                  "added": true,
                  "updateTime": 1673989636483,
                  "updatedBy": "User"
                },
                "name_uuid": "b78b0209-7ff7-4861-953c-eece59b2a707",
                "tumors_uuid": "09a8d018-7d4d-4639-b675-2c16454520db"
              },
              "operation": "add",
              "uuids": "91a35633-1fcb-422c-c09c-07b1c59500b9,a3196366-dc81-4403-812a-5aa0581ce327"
            }
          ],
          "timeStamp": 1674763895025
        },
        "-NMjhLu2f0gI8H9_3e8N": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R282G",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 R282G mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and bladder cancer, and is a statistically significant hotspot (PMID: 17999388, 16061860). In vivo studies with yeast expressing TP53 R282G demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 R282G also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1673989624820,
                    "updatedBy": "User"
                  },
                  "description_uuid": "01bc8758-6167-4b09-9f10-f3bf1e07ec8a",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1673989621425,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "6d0bc3ca-4d3b-4b71-8b37-022f2a14adda",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1673989620555,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "9c593844-154a-4bb1-9cc2-eb3798b03c68",
                  "short": ""
                },
                "mutation_effect_uuid": "025fd314-8d37-4d38-b3ad-7ef398bda182",
                "name": "R282G",
                "name_review": {
                  "added": true,
                  "updateTime": 1673989618864,
                  "updatedBy": "User"
                },
                "name_uuid": "aae4d773-0bf7-4bda-92bf-e65d56fcc0d6",
                "tumors_uuid": "e8a42fe9-4be4-4103-bf57-6aed76775639"
              },
              "operation": "add",
              "uuids": "9c593844-154a-4bb1-9cc2-eb3798b03c68,6d0bc3ca-4d3b-4b71-8b37-022f2a14adda"
            }
          ],
          "timeStamp": 1674763923610
        },
        "-NMjhSXzNlvsls6qIdQd": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R282P",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 R282P mutation is located in the DNA-binding domain of the protein. This mutation has been identified in squamous cell carcinoma and is a statistically significant hotspot (PMID: 7952630). In vivo studies with yeast expressing TP53 R282P demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 R282P also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1673989603821,
                    "updatedBy": "User"
                  },
                  "description_uuid": "22d50f12-beb4-497a-9e8c-8d86aea4a324",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1673989600558,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "8de3fd89-4727-4b43-acba-452cfbb9bdfd",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1673989599757,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "6ca4bb32-5293-4c80-96d5-5d2d851c0d4b",
                  "short": ""
                },
                "mutation_effect_uuid": "c2b0e7eb-87ce-436e-b307-9445964ba6c9",
                "name": "R282P",
                "name_review": {
                  "added": true,
                  "updateTime": 1673989594684,
                  "updatedBy": "User"
                },
                "name_uuid": "465f666d-a22a-497d-b207-0e517e87c81a",
                "tumors_uuid": "9711e8b5-4acd-4511-a599-2452cdf00f9d"
              },
              "operation": "add",
              "uuids": "6ca4bb32-5293-4c80-96d5-5d2d851c0d4b,8de3fd89-4727-4b43-acba-452cfbb9bdfd"
            }
          ],
          "timeStamp": 1674763950806
        },
        "-NMjhZFgInrzJBULzY1z": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "N239T",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 N239T mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and squamous cell carcinoma, and is a statistically significant hotspot (PMID: 8611423, 10225439). In vivo studies with yeast expressing TP53 N239T demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 N239T also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1673990067665,
                    "updatedBy": "User"
                  },
                  "description_uuid": "5f5a8156-da7d-43ca-a031-b0619460240f",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1673990062911,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "3ae412f1-f80b-4baf-8982-975298ca7a61",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1673990061896,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "d277ee96-c1cd-487f-8623-204858ba652b",
                  "short": ""
                },
                "mutation_effect_uuid": "d3b32865-f582-455c-a2cd-6bfe326faac6",
                "name": "N239T",
                "name_review": {
                  "added": true,
                  "updateTime": 1673990059045,
                  "updatedBy": "User"
                },
                "name_uuid": "f229cec3-211e-4b6f-82a5-e5dd1f2af0ef",
                "tumors_uuid": "b5b83030-6ac3-4bfb-b8e1-7636e911d64d"
              },
              "operation": "add",
              "uuids": "d277ee96-c1cd-487f-8623-204858ba652b,3ae412f1-f80b-4baf-8982-975298ca7a61"
            }
          ],
          "timeStamp": 1674763978307
        },
        "-NMjhfLY_A_HWwmwXyJa": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "N239D",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 N239D mutation is located in the DNA-binding domain of the protein. This mutation has been identified in squamous cell carcinoma and is a statistically significant hotspot (PMID: 16271069). In vivo studies with yeast expressing TP53 N239D demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 N239D also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1673990046383,
                    "updatedBy": "User"
                  },
                  "description_uuid": "2c7d624f-1a01-4f2a-acc0-474bc0e37e09",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1673990043115,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "a304b726-13be-4bfe-9bf3-1cb645e8b744",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1673990042309,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "6d591281-a5f0-4975-adeb-466d5d9b6117",
                  "short": ""
                },
                "mutation_effect_uuid": "68d57858-18f4-4f9e-86d4-04528a0ec0f1",
                "name": "N239D",
                "name_review": {
                  "added": true,
                  "updateTime": 1673990039902,
                  "updatedBy": "User"
                },
                "name_uuid": "3745cfb4-924f-4b1d-ba0c-e7c8b2b6dc93",
                "tumors_uuid": "2fe87207-145b-4d49-8770-31fda8997a5a"
              },
              "operation": "add",
              "uuids": "6d591281-a5f0-4975-adeb-466d5d9b6117,a304b726-13be-4bfe-9bf3-1cb645e8b744"
            }
          ],
          "timeStamp": 1674764007354
        },
        "-NMjk2A1mjPZ6dTeklxS": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "N239H",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 N239H mutation is located in the DNA-binding domain of the protein. This mutation has been identified in prostate cancer and is a statistically significant hotspot (PMID: 8978408). In vivo studies with yeast expressing TP53 N239H demonstrated that the mutation is likely neutral as measured by transactivational activity comparable to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 N239H also demonstrated the mutation likely neutral as measured by growth suppression activity comparable to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674764590496,
                    "updatedBy": "User"
                  },
                  "description_uuid": "b17c6264-a2b5-4fa4-8a3d-c31ceb1f9fdb",
                  "effect": "Likely Neutral",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1673990084798,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "81ddeb7d-43c6-4842-9efa-23940a64ef54",
                  "oncogenic": "Likely Neutral",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1673990084204,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "70e8d6d6-145f-4a89-b57f-32ec035b9c50",
                  "short": ""
                },
                "mutation_effect_uuid": "344966b6-d8ae-4c81-bbee-ce45225eb547",
                "name": "N239H",
                "name_review": {
                  "added": true,
                  "updateTime": 1673990082257,
                  "updatedBy": "User"
                },
                "name_uuid": "0edcc1b9-1d86-450e-98f8-4b76d42ed0e3",
                "tumors_uuid": "9c7a89b7-adbf-4b76-b26d-27fbe2dd5590"
              },
              "operation": "add",
              "uuids": "70e8d6d6-145f-4a89-b57f-32ec035b9c50,81ddeb7d-43c6-4842-9efa-23940a64ef54"
            }
          ],
          "timeStamp": 1674764629209
        },
        "-NMjk9JgMR_l4-8feRlE": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "N239K",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 N239K mutation is located in the DNA-binding domain of the protein. This mutation has been identified in hepatocellular carcinoma and squamous cell carcinoma, and is a statistically significant hotspot (PMID: 9816044, 8407553). In vivo studies with yeast expressing TP53 N239K demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1673990109129,
                    "updatedBy": "User"
                  },
                  "description_uuid": "aca84bae-6fae-4367-99f0-cb3158c1537b",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1673990106235,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "97436b67-9fcc-45aa-986e-91853a8b2972",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1673990105543,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "b6a2cb2b-f4a6-4c46-9221-dc653e222bc8",
                  "short": ""
                },
                "mutation_effect_uuid": "5ff757f0-94b8-4fc4-aaed-65200950d637",
                "name": "N239K",
                "name_review": {
                  "added": true,
                  "updateTime": 1673990103733,
                  "updatedBy": "User"
                },
                "name_uuid": "a2fa2c1d-9588-4b33-bda2-8ac92a49f97d",
                "tumors_uuid": "ddc5fd3b-d4e2-427d-8f11-45a154fa793c"
              },
              "operation": "add",
              "uuids": "b6a2cb2b-f4a6-4c46-9221-dc653e222bc8,97436b67-9fcc-45aa-986e-91853a8b2972"
            }
          ],
          "timeStamp": 1674764658499
        },
        "-NMjkGAVwnDcn_ZX3iFc": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R280S",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 R280S mutation is located in the DNA-binding domain of the protein. This mutation has been identified in squamous cell carcinoma and is a statistically significant hotspot (PMID: 10761706). In vivo studies with yeast expressing TP53 R280S demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 R280S also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1673990151420,
                    "updatedBy": "User"
                  },
                  "description_uuid": "a0daff06-568a-4fdd-8db3-e745b3d623a4",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1673990148183,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "bf1d10b8-d608-4207-b7a8-1f60cf29ed23",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1673990147152,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "947a5872-dba5-4662-b29c-6a56e258a5ea",
                  "short": ""
                },
                "mutation_effect_uuid": "762384bc-e6f5-4013-ace4-406bc2974dac",
                "name": "R280S",
                "name_review": {
                  "added": true,
                  "updateTime": 1673990145261,
                  "updatedBy": "User"
                },
                "name_uuid": "7465789d-6281-45da-8312-ebcdd1ab5cad",
                "tumors_uuid": "ea85ad41-27e4-4f51-a0d3-909a735626cf"
              },
              "operation": "add",
              "uuids": "947a5872-dba5-4662-b29c-6a56e258a5ea,bf1d10b8-d608-4207-b7a8-1f60cf29ed23"
            }
          ],
          "timeStamp": 1674764686583
        },
        "-NMjkMvCAkEn868BRV5C": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "E286G",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 E286G mutation is located in the DNA-binding domain of the protein. This mutation has been identified in colorectal cancer and squamous cell carcinoma, and is a statistically significant hotspot (PMID: 1945416, 8453641). In vivo studies with yeast expressing TP53 E286G demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 E286G also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1673990123895,
                    "updatedBy": "User"
                  },
                  "description_uuid": "bb114ad9-ccca-45e3-8168-5712dd6f830c",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1673990121162,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "374c669b-c134-4aea-8613-ec494eff6d98",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1673990120384,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "22fd1422-1be9-4b96-9d6f-7cc20184800e",
                  "short": ""
                },
                "mutation_effect_uuid": "db8321f2-3183-4680-8d65-17d7d925ee1a",
                "name": "E286G",
                "name_review": {
                  "added": true,
                  "updateTime": 1673990118630,
                  "updatedBy": "User"
                },
                "name_uuid": "cd7de615-cadb-4b6a-8521-158389967209",
                "tumors_uuid": "5e22e45b-89a3-466a-b988-4a091c335909"
              },
              "operation": "add",
              "uuids": "22fd1422-1be9-4b96-9d6f-7cc20184800e,374c669b-c134-4aea-8613-ec494eff6d98"
            }
          ],
          "timeStamp": 1674764714212
        },
        "-NMjkTrl688b5xsEt4ns": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "P278T",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 P278T mutation is located in the DNA-binding domain of the protein. This mutation has been identified in renal cell carcinoma and is a statistically significant hotspot (PMID: 17133269). In vivo studies with yeast expressing TP53 P278T demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 P278T also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674067833773,
                    "updatedBy": "User"
                  },
                  "description_uuid": "b12be8ee-bb7f-460e-9efa-fae4a880e796",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1674067829874,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "01075238-df33-4c1e-adde-01b0f1e2d6d4",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1674067828374,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "d46bcd9c-c3ce-445f-acce-408297679691",
                  "short": ""
                },
                "mutation_effect_uuid": "de0ab90e-fa9d-458c-be0b-6a22b1b8189d",
                "name": "P278T",
                "name_review": {
                  "added": true,
                  "updateTime": 1674067826009,
                  "updatedBy": "User"
                },
                "name_uuid": "7d00c14d-09f3-43a3-9494-d9c6ad529d34",
                "tumors_uuid": "fbb6d2af-2ce6-48ef-b70c-db722074872b"
              },
              "operation": "add",
              "uuids": "d46bcd9c-c3ce-445f-acce-408297679691,01075238-df33-4c1e-adde-01b0f1e2d6d4"
            }
          ],
          "timeStamp": 1674764742664
        },
        "-NMjk_vdPCn3HJe5Jg1_": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R280I",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 R280I mutation is located in the DNA-binding domain of the protein. This mutation has been identified in squamous cell carcinoma and is a statistically significant hotspot (PMID: 1324794). In vivo studies with yeast expressing TP53 R280I demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 R280I also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1673990193269,
                    "updatedBy": "User"
                  },
                  "description_uuid": "49c33be1-d7b2-4c39-bb22-472e19529556",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1673990189627,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "91b5592b-31c9-4a31-b5b4-9b31489f7b22",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1673990188177,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "2d11d8aa-612f-447e-a4b3-7a049f821c21",
                  "short": ""
                },
                "mutation_effect_uuid": "6c389e9d-c92f-48be-85d9-edb1c406df6d",
                "name": "R280I",
                "name_review": {
                  "added": true,
                  "updateTime": 1673990186269,
                  "updatedBy": "User"
                },
                "name_uuid": "ab01264d-6ce0-48f8-b8c3-5abc88a6a91f",
                "tumors_uuid": "9561aed2-51f9-4af7-aefc-81fe483ab332"
              },
              "operation": "add",
              "uuids": "2d11d8aa-612f-447e-a4b3-7a049f821c21,91b5592b-31c9-4a31-b5b4-9b31489f7b22"
            }
          ],
          "timeStamp": 1674764771584
        },
        "-NMjkgvUMUQeeKblfO2L": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R280G",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 R280G mutation is located in the DNA-binding domain of the protein. This mutation has been identified in bladder cancer and is a statistically significant hotspot (PMID: 19909015). In vivo studies with yeast expressing TP53 R280G demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 R280G also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1673990171901,
                    "updatedBy": "User"
                  },
                  "description_uuid": "5361cdb0-481c-4589-a717-e563b99df435",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1673990167239,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "7a821b22-dfa0-4037-8e80-9717c714e052",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1673990166229,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "42c02efc-a9c0-4eda-aa86-b02e969718ba",
                  "short": ""
                },
                "mutation_effect_uuid": "2d69a25d-e629-40ad-822d-fac949303e87",
                "name": "R280G",
                "name_review": {
                  "added": true,
                  "updateTime": 1673990164035,
                  "updatedBy": "User"
                },
                "name_uuid": "19567089-ae8f-4b03-bfbf-c87a3d2c285b",
                "tumors_uuid": "317181df-182c-4ce5-99eb-e332dbaf9373"
              },
              "operation": "add",
              "uuids": "42c02efc-a9c0-4eda-aa86-b02e969718ba,7a821b22-dfa0-4037-8e80-9717c714e052"
            }
          ],
          "timeStamp": 1674764800246
        },
        "-NMjko2SiRtoi4LAOqz8": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "H178N",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 H178N mutation is located in the DNA-binding domain of the protein. This mutation has been identified in basal cell carcinoma and is a statistically significant hotspot (PMID: 10568172). In vivo studies with yeast expressing TP53 H178P demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674068370954,
                    "updatedBy": "User"
                  },
                  "description_uuid": "542c76fe-88b6-43ca-bd5b-38607ebe6a2a",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1674068366967,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "63b5a81f-016e-47a4-89d3-9b736c65a320",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1674068365520,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "a6744c8b-26f5-4a24-b44b-164749e13c51",
                  "short": ""
                },
                "mutation_effect_uuid": "0f01d39b-7e4f-4553-8363-fc5231e6c154",
                "name": "H178N",
                "name_review": {
                  "added": true,
                  "updateTime": 1674068363552,
                  "updatedBy": "User"
                },
                "name_uuid": "9fdb050e-a6e9-4356-bc9d-0c91bbee7841",
                "tumors_uuid": "e6eff7ba-f0d2-4024-b3fa-786f2097d95a"
              },
              "operation": "add",
              "uuids": "a6744c8b-26f5-4a24-b44b-164749e13c51,63b5a81f-016e-47a4-89d3-9b736c65a320"
            }
          ],
          "timeStamp": 1674764829428
        },
        "-NMjkuzb2-y2wvS4b73N": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "H178Q",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 H178Q mutation is located in the DNA-binding domain of the protein. This mutation has been identified in B-cell chronic lymphocytic leukemia and is a statistically significant hotspot (PMID: 16572201). In vivo studies with yeast expressing TP53 H178Q demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674068354046,
                    "updatedBy": "User"
                  },
                  "description_uuid": "2b068cf3-efe2-4f2c-95a5-afd376657097",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1674068350769,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "10f4417b-a677-4686-8c24-c69e2500454f",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1674068349443,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "6046d1e2-de17-4f05-a5fc-39f82511577e",
                  "short": ""
                },
                "mutation_effect_uuid": "214e0cae-40f3-4290-9650-b8de0ac3c296",
                "name": "H178Q",
                "name_review": {
                  "added": true,
                  "updateTime": 1674068343528,
                  "updatedBy": "User"
                },
                "name_uuid": "f54c99cb-19ff-479c-ae56-f007585fd947",
                "tumors_uuid": "d0741687-c7c2-4c39-b63d-2ed10df7beee"
              },
              "operation": "add",
              "uuids": "6046d1e2-de17-4f05-a5fc-39f82511577e,10f4417b-a677-4686-8c24-c69e2500454f"
            }
          ],
          "timeStamp": 1674764857854
        },
        "-NMjl0j_VgDIRgXQo_OT": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "H178P",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 H178P mutation is located in the DNA-binding domain of the protein. This mutation has been identified in serous cystadenocarcinoma and is a statistically significant hotspot (PMID: 20229506). In vivo studies with yeast expressing TP53 H178P demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 H178P also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674068338118,
                    "updatedBy": "User"
                  },
                  "description_uuid": "c7fc2068-4fb3-4b43-bd9e-35132b7c90e0",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1674068334775,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "55b2eac5-e699-4b17-b760-11bfb897c72c",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1674068334039,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "02a31bbb-d4d9-406b-b5ea-da9abb61a369",
                  "short": ""
                },
                "mutation_effect_uuid": "695301e3-cb86-4a48-aa49-ff52803a6a0e",
                "name": "H178P",
                "name_review": {
                  "added": true,
                  "updateTime": 1674068332052,
                  "updatedBy": "User"
                },
                "name_uuid": "f8447889-6f5e-4e13-8788-d9da81bef04a",
                "tumors_uuid": "5e80ff42-d70b-4d49-9207-baf3aab41bf2"
              },
              "operation": "add",
              "uuids": "02a31bbb-d4d9-406b-b5ea-da9abb61a369,55b2eac5-e699-4b17-b760-11bfb897c72c"
            }
          ],
          "timeStamp": 1674764885500
        },
        "-NMjl7rUrn-OZwZyW11A": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "P278H",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 P278H mutation is located in the DNA-binding domain of the protein. This mutation has been identified in colorectal cancer and is a statistically significant hotspot (PMID: 9097977). In vivo studies with yeast expressing TP53 P278H demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 P278H also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674067882438,
                    "updatedBy": "User"
                  },
                  "description_uuid": "53a25605-35ab-45eb-92f3-d9f3bd639420",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1674067879041,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "89625149-b587-401c-a80e-67e14db09453",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1674067878212,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "39d0d7b2-16a9-461a-a723-cd84b8175eac",
                  "short": ""
                },
                "mutation_effect_uuid": "107e3478-e125-4e80-a46c-026190096751",
                "name": "P278H",
                "name_review": {
                  "added": true,
                  "updateTime": 1674067875261,
                  "updatedBy": "User"
                },
                "name_uuid": "f934971d-a1e1-4731-8067-1fe03fc3abcc",
                "tumors_uuid": "f44e936c-a426-4701-9568-6b5511bd18b9"
              },
              "operation": "add",
              "uuids": "39d0d7b2-16a9-461a-a723-cd84b8175eac,89625149-b587-401c-a80e-67e14db09453"
            }
          ],
          "timeStamp": 1674764914678
        },
        "-NMjlEpEYv_sm_OQS_mu": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "P278F",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 P278F mutation is located in the DNA-binding domain of the protein. This mutation has been identified in squamous cell carcinoma and is a statistically significant hotspot (PMID: 20025891). In vitro studies with various human cancer cell lines expressing TP53 P278F demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674067856953,
                    "updatedBy": "User"
                  },
                  "description_uuid": "6457f0e1-1311-464f-b8a1-ddcab099cf41",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1674067853120,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "54974bc2-65f2-487e-9630-f71138fd2b45",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1674067852005,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "c4157341-9d1d-4324-b160-06906cbb2c0b",
                  "short": ""
                },
                "mutation_effect_uuid": "0e59a852-6d94-4766-bdf3-28307107cbe1",
                "name": "P278F",
                "name_review": {
                  "added": true,
                  "updateTime": 1674067850285,
                  "updatedBy": "User"
                },
                "name_uuid": "eb6da164-9866-44e5-b3df-113f9d613e30",
                "tumors_uuid": "5247877d-9a54-420b-8d9a-109cd9c18065"
              },
              "operation": "add",
              "uuids": "c4157341-9d1d-4324-b160-06906cbb2c0b,54974bc2-65f2-487e-9630-f71138fd2b45"
            }
          ],
          "timeStamp": 1674764943206
        },
        "-NMjlLewAxEkiaNBKRso": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "P152Q",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 P152Q mutation is located in the DNA-binding domain of the protein. This mutation has been identified in hepatocellular carcinoma and is a statistically significant hotspot (PMID: 21567059). In vivo studies with yeast expressing TP53 P152Q demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674246852286,
                    "updatedBy": "User"
                  },
                  "description_uuid": "3f7861d6-f509-4c80-8d60-5cb63185f3c9",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1674246848441,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "d6a45691-d84e-4ffa-825f-eee7cedd1736",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1674246846939,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "1cb002be-7b60-4603-8a2e-0d54e4e3324d",
                  "short": ""
                },
                "mutation_effect_uuid": "bd3a684f-2f5e-4fcd-8118-6f5b7873ff7a",
                "name": "P152Q",
                "name_review": {
                  "added": true,
                  "updateTime": 1674246845143,
                  "updatedBy": "User"
                },
                "name_uuid": "20b1acb9-153f-4d7a-c0aa-d029e491e863",
                "tumors_uuid": "3ec68961-88ce-4c35-9dba-5ba396063aca"
              },
              "operation": "add",
              "uuids": "1cb002be-7b60-4603-8a2e-0d54e4e3324d,d6a45691-d84e-4ffa-825f-eee7cedd1736"
            }
          ],
          "timeStamp": 1674764971219
        },
        "-NMjlSrRKyML6PXjFNp6": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "M133I",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 M133I mutation is located in the DNA-binding domain of the protein. This mutation has been identified in squamous cell carcinoma and is a statistically significant hotspot (PMID: 9627113). In vivo studies with yeast expressing TP53 M133I demonstrated that the mutation is likely neutral as measured by transactivational activity comparable to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 M133I also demonstrated the mutation likely neutral as measured by growth suppression activity comparable to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674764840839,
                    "updatedBy": "User"
                  },
                  "description_uuid": "eeb32177-6720-467a-8a09-dc8fdd103fad",
                  "effect": "Likely Neutral",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1674246800660,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "18096315-2f08-4c8b-833e-9f8c72ab487f",
                  "oncogenic": "Likely Neutral",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1674246799479,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "f70e61ea-8810-4de9-b2a1-06bc2501e9fe",
                  "short": ""
                },
                "mutation_effect_uuid": "85539c5b-9f54-494b-a10d-69ba7f47b0b9",
                "name": "M133I",
                "name_review": {
                  "added": true,
                  "updateTime": 1674246797413,
                  "updatedBy": "User"
                },
                "name_uuid": "ab98ee4e-0143-4f52-c077-5b97566412e8",
                "tumors_uuid": "4d58cfb4-0640-418f-96f7-364e129fbd72"
              },
              "operation": "add",
              "uuids": "f70e61ea-8810-4de9-b2a1-06bc2501e9fe,18096315-2f08-4c8b-833e-9f8c72ab487f"
            }
          ],
          "timeStamp": 1674765000691
        },
        "-NMjl_1MWyZ9EGp_RN7X": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "M133R",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 M133R mutation is located in the DNA-binding domain of the protein. This mutation has been identified in adenocarcinoma and is a statistically significant hotspot (PMID: 12637159). In vivo studies with yeast expressing TP53 M133R demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 M133R also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674246766379,
                    "updatedBy": "User"
                  },
                  "description_uuid": "0d799063-6fa7-402b-afd5-a355105d7894",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1674246762442,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "4cd1b262-00fb-4833-b047-55cb9a712e77",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1674246761312,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "143ee9ac-5399-4bee-b152-c4ed6e3e9717",
                  "short": ""
                },
                "mutation_effect_uuid": "6cee7f1e-a708-488a-b2c4-16650617458a",
                "name": "M133R",
                "name_review": {
                  "added": true,
                  "updateTime": 1674246759263,
                  "updatedBy": "User"
                },
                "name_uuid": "42540d72-93a0-46d4-85e9-504624945eb7",
                "tumors_uuid": "2d7dbe47-77e5-418f-8c1e-d5af564b44b5"
              },
              "operation": "add",
              "uuids": "143ee9ac-5399-4bee-b152-c4ed6e3e9717,4cd1b262-00fb-4833-b047-55cb9a712e77"
            }
          ],
          "timeStamp": 1674765030062
        },
        "-NMjlfzlhV0l_LjAWimU": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V197M",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 V197M mutation is located in the DNA-binding domain of the protein. This mutation has been identified in colorectal cancer and is a statistically significant hotspot (PMID: 11494027). In vivo studies with yeast expressing TP53 V197M demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 V197M also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674246696705,
                    "updatedBy": "User"
                  },
                  "description_uuid": "64ea0f45-d038-4bda-9115-8420ad30f8f1",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1674246692183,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "c2e5cb1e-8ff1-4521-b384-0468f08b5a46",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1674246691164,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "7167f4bb-5d19-4f2f-a345-b912fd3f521e",
                  "short": ""
                },
                "mutation_effect_uuid": "4bfd58f6-04f0-4202-b77f-363308acdac0",
                "name": "V197M",
                "name_review": {
                  "added": true,
                  "updateTime": 1674246689154,
                  "updatedBy": "User"
                },
                "name_uuid": "f601612f-32cb-4759-96e6-637f53d1f27f",
                "tumors_uuid": "79c69edb-d042-4f09-8f0f-f4c843ea709e"
              },
              "operation": "add",
              "uuids": "7167f4bb-5d19-4f2f-a345-b912fd3f521e,c2e5cb1e-8ff1-4521-b384-0468f08b5a46"
            }
          ],
          "timeStamp": 1674765058568
        },
        "-NMjlnJUBbY1BLEfsNp3": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V197G",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 V197G mutation is located in the DNA-binding domain of the protein. This mutation has been identified in squamous cell carcinoma and is a statistically significant hotspot (PMID: 12713560). In vivo studies with yeast expressing TP53 V197G demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 V197G also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674246673426,
                    "updatedBy": "User"
                  },
                  "description_uuid": "485e6b46-212f-4e89-938d-b771443fd6eb",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1674246669763,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "7f9a7013-42ad-4331-b465-67f02359809c",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1674246667097,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "def3f178-df33-4a6b-b588-6c60c6a237a3",
                  "short": ""
                },
                "mutation_effect_uuid": "ecc7da97-f2c8-4abc-b7f9-02d5aa1b95c6",
                "name": "V197G",
                "name_review": {
                  "added": true,
                  "updateTime": 1674246664879,
                  "updatedBy": "User"
                },
                "name_uuid": "4ef34812-6453-452b-8c48-087c1b5b240a",
                "tumors_uuid": "2f045d0b-569a-487d-b4fc-7540c50f2293"
              },
              "operation": "add",
              "uuids": "def3f178-df33-4a6b-b588-6c60c6a237a3,7f9a7013-42ad-4331-b465-67f02359809c"
            }
          ],
          "timeStamp": 1674765088566
        },
        "-NMjlu3TXqA6ShwQ7JKg": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "C141R",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 C141R mutation is located in the DNA-binding domain of the protein. This mutation has been identified in B-cell chronic lymphocytic leukemia and is a statistically significant hotspot (PMID: 12149195). In vivo studies with yeast expressing TP53 C141R demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 C141R also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674246982571,
                    "updatedBy": "User"
                  },
                  "description_uuid": "8099d8e4-e4ae-46e0-ba6a-42ca41994842",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1674246979105,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "e53397a1-c57c-4ce9-b54c-ae93d7fc9260",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1674246977869,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "64fa6d5d-76c3-4647-aaca-da873bc204c6",
                  "short": ""
                },
                "mutation_effect_uuid": "e185854a-d503-4f21-a714-ca6bed78861d",
                "name": "C141R",
                "name_review": {
                  "added": true,
                  "updateTime": 1674246974765,
                  "updatedBy": "User"
                },
                "name_uuid": "fed53c85-80c5-4d6d-a4f9-8635d3191292",
                "tumors_uuid": "53d10259-9f2e-4087-be2a-6420ee64c3b5"
              },
              "operation": "add",
              "uuids": "64fa6d5d-76c3-4647-aaca-da873bc204c6,e53397a1-c57c-4ce9-b54c-ae93d7fc9260"
            }
          ],
          "timeStamp": 1674765116213
        },
        "-NMjm-nLC4Ezau2f_SV6": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "P152K",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 P152K mutation is located in the DNA-binding domain of the protein. This mutation has been identified in malignant melanoma and is a statistically significant hotspot (PMID: 28481359). In vitro studies with various human cancer cell lines expressing TP53 P152K demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674246960441,
                    "updatedBy": "User"
                  },
                  "description_uuid": "f820d43f-5f98-425a-aa12-82253574b03a",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1674246955850,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "741cb3e5-d294-47d1-a15c-74c464dfe9a5",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1674246954927,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "aca2f602-237e-4c78-ab9c-d8cdd7a3aeb7",
                  "short": ""
                },
                "mutation_effect_uuid": "6d5e3475-1c10-4d92-ad05-af041fa6ffe7",
                "name": "P152K",
                "name_review": {
                  "added": true,
                  "updateTime": 1674246952640,
                  "updatedBy": "User"
                },
                "name_uuid": "f3a3e872-8557-4c31-be7e-bb984585c6cf",
                "tumors_uuid": "8c8118ba-2944-46a9-b5e2-4225ff9e5265"
              },
              "operation": "add",
              "uuids": "aca2f602-237e-4c78-ab9c-d8cdd7a3aeb7,741cb3e5-d294-47d1-a15c-74c464dfe9a5"
            }
          ],
          "timeStamp": 1674765143789
        },
        "-NMjm72i303l9RgYerR0": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "P152T",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 P152T mutation is located in the DNA-binding domain of the protein. This mutation has been identified in glioblastoma and is a statistically significant hotspot (PMID: 11939587). In vivo studies with yeast expressing TP53 P152T demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674246937627,
                    "updatedBy": "User"
                  },
                  "description_uuid": "d5d09d8c-c9b4-4ad0-a565-b86ab2ebc91d",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1674246933683,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "52370fa8-899b-49af-93e1-518ed06250f5",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1674246932307,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "cc308d1e-e5d4-4916-9a29-f235dd0e501d",
                  "short": ""
                },
                "mutation_effect_uuid": "822217e4-883f-468d-beea-15fe32950a6a",
                "name": "P152T",
                "name_review": {
                  "added": true,
                  "updateTime": 1674246930159,
                  "updatedBy": "User"
                },
                "name_uuid": "0c509403-9cad-4b7a-955d-6b93ca2a4989",
                "tumors_uuid": "949b6e96-d514-4da9-919f-bc8bddf90b56"
              },
              "operation": "add",
              "uuids": "cc308d1e-e5d4-4916-9a29-f235dd0e501d,52370fa8-899b-49af-93e1-518ed06250f5"
            }
          ],
          "timeStamp": 1674765173509
        },
        "-NMjmE5UcHEveSAP7uhg": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "P152S",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 P152S mutation is located in the DNA-binding domain of the protein. This mutation has been identified in basal cell carcinoma and is a statistically significant hotspot (PMID: 15656799). In vivo studies with yeast expressing TP53 P152S demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 P152S also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674246901491,
                    "updatedBy": "User"
                  },
                  "description_uuid": "4406ab6a-7782-424a-b6d3-e6512b7b17d3",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1674246898094,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "e1f8468d-7d2b-4dc2-8828-80151c435c3b",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1674246897414,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "703d1f9b-992c-4cfd-bb89-051f68a30460",
                  "short": ""
                },
                "mutation_effect_uuid": "c3816910-0856-42f5-b404-55c0da030452",
                "name": "P152S",
                "name_review": {
                  "added": true,
                  "updateTime": 1674246895351,
                  "updatedBy": "User"
                },
                "name_uuid": "b9fd7e81-9af8-4008-a62f-943e0a5dd048",
                "tumors_uuid": "51fba6d8-8389-4cc7-8505-7a415ddde633"
              },
              "operation": "add",
              "uuids": "703d1f9b-992c-4cfd-bb89-051f68a30460,e1f8468d-7d2b-4dc2-8828-80151c435c3b"
            }
          ],
          "timeStamp": 1674765202358
        },
        "-NMjmKy5ZQBhYGbz52MF": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "P152R",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 P152R mutation is located in the DNA-binding domain of the protein. This mutation has been identified in colorectal cancer and is a statistically significant hotspot (PMID: 11044641). In vivo studies with yeast expressing TP53 P152R demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674246881101,
                    "updatedBy": "User"
                  },
                  "description_uuid": "a96b4c1c-b327-4695-ba03-ad50059ddaf9",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1674246877356,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "2c1945a4-4fdd-4cc6-8a60-d5ab1c4c921c",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1674246876358,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "cba6c559-1d91-42e4-a0b4-13897b68c6ef",
                  "short": ""
                },
                "mutation_effect_uuid": "a2020832-f15c-4e95-bb4d-b3e3fa8b06a6",
                "name": "P152R",
                "name_review": {
                  "added": true,
                  "updateTime": 1674246873717,
                  "updatedBy": "User"
                },
                "name_uuid": "027cb5b4-9958-4676-8fe8-8131b9b0031e",
                "tumors_uuid": "85269bba-b2b1-4d53-ba30-7da66137772e"
              },
              "operation": "add",
              "uuids": "cba6c559-1d91-42e4-a0b4-13897b68c6ef,2c1945a4-4fdd-4cc6-8a60-d5ab1c4c921c"
            }
          ],
          "timeStamp": 1674765230493
        },
        "-NMjmSA6sXmAAWUMeSkN": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "C275R",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 C275R mutation is located in the DNA-binding domain of the protein. This mutation has been identified in squamous cell carcinoma and is a statistically significant hotspot (PMID: 10679659). In vivo studies with yeast expressing TP53 C275R demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 C275R also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674247149478,
                    "updatedBy": "User"
                  },
                  "description_uuid": "feca511a-8d45-4c49-b344-7b2c94093a6c",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1674247141949,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "1429cece-4ec2-4d73-8e1e-fcd4e3ba3dd3",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1674247141140,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "0d95dc0c-f514-41c4-a39e-273455796221",
                  "short": ""
                },
                "mutation_effect_uuid": "2fb7ae09-5caf-40de-b7bc-138eff221f4d",
                "name": "C275R",
                "name_review": {
                  "added": true,
                  "updateTime": 1674247139373,
                  "updatedBy": "User"
                },
                "name_uuid": "4b9abd14-0781-4d2f-8b10-7dd85d6ef3a7",
                "tumors_uuid": "d4a55677-8207-4a4e-906b-1acc845b711d"
              },
              "operation": "add",
              "uuids": "0d95dc0c-f514-41c4-a39e-273455796221,1429cece-4ec2-4d73-8e1e-fcd4e3ba3dd3"
            }
          ],
          "timeStamp": 1674765259998
        },
        "-NMjmZ8KvOKc0ItcN94v": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "C275F",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 C275F mutation is located in the DNA-binding domain of the protein. This mutation has been identified in hairy cell leukemia and is a statistically significant hotspot (PMID: 10764158). In vivo studies with yeast expressing TP53 C275F demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 C275F also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674247134395,
                    "updatedBy": "User"
                  },
                  "description_uuid": "aa191b91-32cf-4388-b727-e7094a4ca469",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1674247123894,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "caa0493c-828d-445a-9631-522d0c15b92c",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1674247123051,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "a6d42bc7-543b-4234-b9ae-9769b0fe9e46",
                  "short": ""
                },
                "mutation_effect_uuid": "68d9954e-aac0-4d8d-b9d3-f5a126e8ce56",
                "name": "C275F",
                "name_review": {
                  "added": true,
                  "updateTime": 1674247120619,
                  "updatedBy": "User"
                },
                "name_uuid": "a767d31b-729f-40a0-ad8e-78bbcf7ec501",
                "tumors_uuid": "d88e836d-6214-49f7-8961-e93e8ad9e4b4"
              },
              "operation": "add",
              "uuids": "a6d42bc7-543b-4234-b9ae-9769b0fe9e46,caa0493c-828d-445a-9631-522d0c15b92c"
            }
          ],
          "timeStamp": 1674765288556
        },
        "-NMjmfChEkGBQDrjsKUv": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "C141G",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 C141G mutation is located in the DNA-binding domain of the protein. This mutation has been identified in squamous cell carcinoma and is a statistically significant hotspot (PMID: 15957194). In vivo studies with yeast expressing TP53 C141G demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 C141G also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674247040646,
                    "updatedBy": "User"
                  },
                  "description_uuid": "2f82ef8f-d2eb-425e-bcb8-337642d86129",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1674247037104,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "c31909bb-405b-4337-b0ce-327676a0496a",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1674247036417,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "146aa4dd-281b-4624-aee9-6d129ce53216",
                  "short": ""
                },
                "mutation_effect_uuid": "97968b5f-41b5-41f3-a0dc-73512c4e388a",
                "name": "C141G",
                "name_review": {
                  "added": true,
                  "updateTime": 1674247033668,
                  "updatedBy": "User"
                },
                "name_uuid": "ba11f32c-d5c6-4dc7-9a3d-5f5e495e07b8",
                "tumors_uuid": "357f55ee-e996-499f-a5f6-9a10ac00856b"
              },
              "operation": "add",
              "uuids": "146aa4dd-281b-4624-aee9-6d129ce53216,c31909bb-405b-4337-b0ce-327676a0496a"
            }
          ],
          "timeStamp": 1674765317508
        },
        "-NMjmmksgm_vtBJaOYXL": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "C141F",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 C141F mutation is located in the DNA-binding domain of the protein. This mutation has been identified in bladder cancer and is a statistically significant hotspot (PMID: 11801555). In vivo studies with yeast expressing TP53 C141F demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674247022380,
                    "updatedBy": "User"
                  },
                  "description_uuid": "82a5f78c-d8da-469b-8723-b80bc6261890",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1674247019489,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "b278bb0c-6f0c-4bd3-ba0a-ed38ea6ec4a4",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1674247018632,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "7e6ff467-0a1a-4519-9c60-b77c6033ffd7",
                  "short": ""
                },
                "mutation_effect_uuid": "619e8625-2b29-4c35-9dcd-5c88432582da",
                "name": "C141F",
                "name_review": {
                  "added": true,
                  "updateTime": 1674247014285,
                  "updatedBy": "User"
                },
                "name_uuid": "2a1e7331-cbe4-49f3-99c9-473cc28a4650",
                "tumors_uuid": "5be5d218-c778-4d96-b4e4-543e9eff79a8"
              },
              "operation": "add",
              "uuids": "7e6ff467-0a1a-4519-9c60-b77c6033ffd7,b278bb0c-6f0c-4bd3-ba0a-ed38ea6ec4a4"
            }
          ],
          "timeStamp": 1674765348431
        },
        "-NMjmuJQ4gXHarfzwceU": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "C141S",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 C141S mutation is located in the DNA-binding domain of the protein. This mutation has been identified in colorectal cancer and is a statistically significant hotspot (PMID: 15316933). In vivo studies with yeast expressing TP53 C141S demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674247006841,
                    "updatedBy": "User"
                  },
                  "description_uuid": "9ac488b8-1213-4036-8242-de7d2928d6f1",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1674247003803,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "1bd5d093-b333-4443-a5e4-2f5aba67434c",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1674247003037,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "494a2748-93ea-49ea-80b1-4fba8748f256",
                  "short": ""
                },
                "mutation_effect_uuid": "9b6275c3-547a-4b2c-b706-60c30be46bf9",
                "name": "C141S",
                "name_review": {
                  "added": true,
                  "updateTime": 1674247000980,
                  "updatedBy": "User"
                },
                "name_uuid": "20acfdfa-6ef5-4697-97f7-4c7459e69c66",
                "tumors_uuid": "cdf89905-db75-460d-a4b4-ccce1f95b421"
              },
              "operation": "add",
              "uuids": "494a2748-93ea-49ea-80b1-4fba8748f256,1bd5d093-b333-4443-a5e4-2f5aba67434c"
            }
          ],
          "timeStamp": 1674765379378
        },
        "-NMjn0G7rL5MyCxtLU9n": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "I251M",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 I251M mutation is located in the DNA-binding domain of the protein. This mutation has been identified in leiomyosarcoma and is a statistically significant hotspot (PMID: 28481359). In vivo studies with yeast expressing TP53 I251M demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674509322617,
                    "updatedBy": "User"
                  },
                  "description_uuid": "61113587-aa5f-4e9b-afae-ae877415f2e1",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1674509319611,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "48cd2bcd-e92a-4e15-8417-6d2af3d0c164",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1674509316626,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "b5d3a5f4-383c-4d67-8d19-a427c2a20990",
                  "short": ""
                },
                "mutation_effect_uuid": "5e468841-b1b3-45db-9ed0-49697ebb86a9",
                "name": "I251M",
                "name_review": {
                  "added": true,
                  "updateTime": 1674509314676,
                  "updatedBy": "User"
                },
                "name_uuid": "2570d771-9cc7-4ea0-8250-8f67b0d688c2",
                "tumors_uuid": "2c3aa13f-acf0-4c21-883d-07b8376239ff"
              },
              "operation": "add",
              "uuids": "b5d3a5f4-383c-4d67-8d19-a427c2a20990,48cd2bcd-e92a-4e15-8417-6d2af3d0c164"
            }
          ],
          "timeStamp": 1674765407839
        },
        "-NMjn7JUm3U02kHxQ2eS": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "I251F",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 I251F mutation is located in the DNA-binding domain of the protein. This mutation has been identified in transitional cell carcinoma and is a statistically significant hotspot (PMID: 7777479). In vivo studies with yeast expressing TP53 I251F demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 I251F also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674509300691,
                    "updatedBy": "User"
                  },
                  "description_uuid": "910c6992-e456-45b6-982b-bce0e15cf4e7",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1674509296893,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "f1cb9c4e-f809-487c-9978-ec1eed0fe453",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1674509294994,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "e1f3bbbd-8b1f-4516-8df9-1ab57311b303",
                  "short": ""
                },
                "mutation_effect_uuid": "5faeb8cc-7d95-4844-ad1b-2f32be8c61a9",
                "name": "I251F",
                "name_review": {
                  "added": true,
                  "updateTime": 1674509292345,
                  "updatedBy": "User"
                },
                "name_uuid": "d4f75d52-571a-439d-9737-fe35b05131d5",
                "tumors_uuid": "236f0ded-edf0-46ea-8120-6942fd19c6f4"
              },
              "operation": "add",
              "uuids": "e1f3bbbd-8b1f-4516-8df9-1ab57311b303,f1cb9c4e-f809-487c-9978-ec1eed0fe453"
            }
          ],
          "timeStamp": 1674765436726
        },
        "-NMjnEdO9yjVuqYPH1Lv": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "C275Y",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 C275Y mutation is located in the DNA-binding domain of the protein. This mutation has been identified in squamous cell carcinoma and is a statistically significant hotspot (PMID: 8761140). In vivo studies with yeast expressing TP53 C275Y demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 C275Y also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674247209217,
                    "updatedBy": "User"
                  },
                  "description_uuid": "6d067879-4262-4329-9ea4-d7e57b7c0a98",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1674247206076,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "186215d3-1dde-4066-a52d-0776558f0ff7",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1674247205153,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "e84a610f-87d6-4ab9-866d-0d8e7f17e443",
                  "short": ""
                },
                "mutation_effect_uuid": "ea1267a0-0e0b-4407-bf2a-8e8a0eb8eaf7",
                "name": "C275Y",
                "name_review": {
                  "added": true,
                  "updateTime": 1674247199088,
                  "updatedBy": "User"
                },
                "name_uuid": "88b9750d-e585-42e8-b3af-92c97f42f54f",
                "tumors_uuid": "28eb4b39-f4aa-4272-ac22-92e5a357db0f"
              },
              "operation": "add",
              "uuids": "e84a610f-87d6-4ab9-866d-0d8e7f17e443,186215d3-1dde-4066-a52d-0776558f0ff7"
            }
          ],
          "timeStamp": 1674765466736
        },
        "-NMjnLleWGIAlHQwCWPB": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "C275G",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 C275G mutation is located in the DNA-binding domain of the protein. This mutation has been identified in serous cystadenocarcinoma and is a statistically significant hotspot (PMID: 9891239). In vivo studies with yeast expressing TP53 C275G demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674247192144,
                    "updatedBy": "User"
                  },
                  "description_uuid": "19c7172b-a365-468b-834d-5d6dd431c78b",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1674247188670,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "2a5b28b6-82be-4b02-b220-460d72a3cb0e",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1674247187746,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "512c2091-5262-4f70-be4b-97b2b9cb842d",
                  "short": ""
                },
                "mutation_effect_uuid": "1fbdde24-3010-4686-b09b-2f2a1547db87",
                "name": "C275G",
                "name_review": {
                  "added": true,
                  "updateTime": 1674247182497,
                  "updatedBy": "User"
                },
                "name_uuid": "195546e9-9a63-441a-8fb8-34018b6976d4",
                "tumors_uuid": "206f1ab5-2f60-4508-98f7-101d478b1544"
              },
              "operation": "add",
              "uuids": "512c2091-5262-4f70-be4b-97b2b9cb842d,2a5b28b6-82be-4b02-b220-460d72a3cb0e"
            }
          ],
          "timeStamp": 1674765495937
        },
        "-NMjnSmNN2dg3D88F9C0": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "C275W",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 C275W mutation is located in the DNA-binding domain of the protein. This mutation has been identified in colorectal cancer and is a statistically significant hotspot (PMID: 12921629). In vivo studies with yeast expressing TP53 C275W demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 C275W also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674247172880,
                    "updatedBy": "User"
                  },
                  "description_uuid": "4651ef41-8d8a-461d-b287-4adb6e96c6fd",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1674247164341,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "020e361a-5c50-4f24-af99-c12689f55001",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1674247162977,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "9a74f303-d112-4551-a854-1e51445ea4ed",
                  "short": ""
                },
                "mutation_effect_uuid": "f5d90a0b-c615-4dbd-9979-78937daaaef6",
                "name": "C275W",
                "name_review": {
                  "added": true,
                  "updateTime": 1674247160953,
                  "updatedBy": "User"
                },
                "name_uuid": "94d6713f-6ca1-4f0a-9e44-1c97c1d79e1d",
                "tumors_uuid": "23efb35c-9e33-43ec-a086-ff6fee5a3ca0"
              },
              "operation": "add",
              "uuids": "9a74f303-d112-4551-a854-1e51445ea4ed,020e361a-5c50-4f24-af99-c12689f55001"
            }
          ],
          "timeStamp": 1674765524655
        },
        "-NMjn_44eR6N52rWjfM-": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "E258G",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 E258G mutation is located in the DNA-binding domain of the protein. This mutation has been identified in hepatocellular carcinoma and is a statistically significant hotspot (PMID: 11051249). In vivo studies with yeast expressing TP53 E258G demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 E258G also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674589078065,
                    "updatedBy": "User"
                  },
                  "description_uuid": "9d65ad45-26c8-43f6-a307-04de44137d4e",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1674589071000,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "3a00f49c-c590-4a39-9bef-a89965edb009",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1674589070182,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "93930cca-ffe6-4d51-b585-89c9bf71a4d6",
                  "short": ""
                },
                "mutation_effect_uuid": "8642a126-db9f-4cb0-8721-97b77fbd0ae1",
                "name": "E258G",
                "name_review": {
                  "added": true,
                  "updateTime": 1674589067880,
                  "updatedBy": "User"
                },
                "name_uuid": "02060614-88c2-453c-9fbf-fe42023efae6",
                "tumors_uuid": "6d409c08-97ea-494f-8f3e-d6647db1027b"
              },
              "operation": "add",
              "uuids": "93930cca-ffe6-4d51-b585-89c9bf71a4d6,3a00f49c-c590-4a39-9bef-a89965edb009"
            }
          ],
          "timeStamp": 1674765554524
        },
        "-NMjngQ9XWMC9kaUbMr2": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "E258D",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 E258D mutation is located in the DNA-binding domain of the protein. This mutation has been identified in colorectal cancer and is a statistically significant hotspot (PMID: 12093899). In vivo studies with yeast expressing TP53 E258D demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 E258D also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674589054335,
                    "updatedBy": "User"
                  },
                  "description_uuid": "831c5bc9-e89f-434c-bf7b-73ed0d65825a",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1674589047130,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "296911f8-d9bb-4a09-a6bf-08e45bd232a4",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1674589046163,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "e33546e9-be7f-4ad1-a37a-38de7b6ef70c",
                  "short": ""
                },
                "mutation_effect_uuid": "1a19e0b9-7fb7-4017-85ec-883ceff28ba0",
                "name": "E258D",
                "name_review": {
                  "added": true,
                  "updateTime": 1674589043949,
                  "updatedBy": "User"
                },
                "name_uuid": "274791c3-c44c-40c9-a32c-5e33b25edbb7",
                "tumors_uuid": "755c7085-7f04-453b-850f-67db1b02ab3b"
              },
              "operation": "add",
              "uuids": "e33546e9-be7f-4ad1-a37a-38de7b6ef70c,296911f8-d9bb-4a09-a6bf-08e45bd232a4"
            }
          ],
          "timeStamp": 1674765584609
        },
        "-NMjnnt1FVIo1fQLFdiC": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "E258Q",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 E258Q mutation is located in the DNA-binding domain of the protein. This mutation has been identified in bladder cancer and is a statistically significant hotspot (PMID: 8339293). In vivo studies with yeast expressing TP53 E258Q demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 E258Q also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674589030319,
                    "updatedBy": "User"
                  },
                  "description_uuid": "c6e4f11f-6caf-4591-b349-f60f60c4b680",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1674589022804,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "7359c7c8-75c1-4d1a-a8d7-9ce4b55b18ce",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1674589021989,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "3e56e426-5c35-4a60-9134-cbcdd72e5b16",
                  "short": ""
                },
                "mutation_effect_uuid": "e024192a-c4f9-438d-884e-c41b72b904d2",
                "name": "E258Q",
                "name_review": {
                  "added": true,
                  "updateTime": 1674589019698,
                  "updatedBy": "User"
                },
                "name_uuid": "ae87f0c5-6e3f-44c9-ab82-e89bb10b2177",
                "tumors_uuid": "022ce01a-bc89-4d50-90fa-f537ccc6c4fb"
              },
              "operation": "add",
              "uuids": "3e56e426-5c35-4a60-9134-cbcdd72e5b16,7359c7c8-75c1-4d1a-a8d7-9ce4b55b18ce"
            }
          ],
          "timeStamp": 1674765615193
        },
        "-NMjnvHKxBJTpsi_jioR": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "E258A",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 E258A mutation is located in the DNA-binding domain of the protein. This mutation has been identified in glioblastoma and is a statistically significant hotspot (PMID: 16818615). In vivo studies with yeast expressing TP53 E258A demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 E258A also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674589012070,
                    "updatedBy": "User"
                  },
                  "description_uuid": "030d54ca-8b9d-496b-b9b9-36ddaa91997b",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1674589004111,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "42d17869-d6f0-486d-a62c-f448e4e59313",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1674589003205,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "20e50e28-b8bd-48b0-946d-cae76f115540",
                  "short": ""
                },
                "mutation_effect_uuid": "1e238305-f6a1-4198-bf53-ff69e11fa596",
                "name": "E258A",
                "name_review": {
                  "added": true,
                  "updateTime": 1674589000906,
                  "updatedBy": "User"
                },
                "name_uuid": "7e73b049-3262-4709-8b89-716311640a73",
                "tumors_uuid": "4dd81e6e-bfff-4bbe-a95f-18f07501a717"
              },
              "operation": "add",
              "uuids": "20e50e28-b8bd-48b0-946d-cae76f115540,42d17869-d6f0-486d-a62c-f448e4e59313"
            }
          ],
          "timeStamp": 1674765645484
        },
        "-NMjo1VGK9CXU1wFOkpz": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "I251N",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 I251N mutation is located in the DNA-binding domain of the protein. This mutation has been identified in hepatocellular carcinoma and is a statistically significant hotspot (PMID: 12711820). In vivo studies with yeast expressing TP53 I251N demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 I251N also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674509357321,
                    "updatedBy": "User"
                  },
                  "description_uuid": "31a91434-9fc3-46ed-9172-d4d13391347e",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1674509353587,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "1a20e487-e83e-4916-a572-a0e7a2da1a37",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1674509351510,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "2f81974c-a1b6-4f33-96be-535cc280c2f7",
                  "short": ""
                },
                "mutation_effect_uuid": "1dc1380f-957d-4a1b-b599-5377e843d4f5",
                "name": "I251N",
                "name_review": {
                  "added": true,
                  "updateTime": 1674509348845,
                  "updatedBy": "User"
                },
                "name_uuid": "a01f7cf4-13d4-49a6-9571-025ca202a3d5",
                "tumors_uuid": "8a9574f2-6156-4e74-9408-0c9fe4f5396a"
              },
              "operation": "add",
              "uuids": "2f81974c-a1b6-4f33-96be-535cc280c2f7,1a20e487-e83e-4916-a572-a0e7a2da1a37"
            }
          ],
          "timeStamp": 1674765675048
        },
        "-NMjo8mArQfLYPYbOoPt": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "I254S",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 I254S mutation is located in the DNA-binding domain of the protein. This mutation has been identified in malignant lymphoma and is a statistically significant hotspot (PMID: 9262496). In vivo studies with yeast expressing TP53 I254S demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 I254S also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674589443353,
                    "updatedBy": "User"
                  },
                  "description_uuid": "24688ba9-bed1-46d7-aff7-8847cb486330",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1674589436331,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "b354a9e5-9966-4eb6-b59e-d058c820c936",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1674589435499,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "ba4af5ef-67df-4456-91e6-a8497a64aba6",
                  "short": ""
                },
                "mutation_effect_uuid": "2d3aed11-aa40-4cba-b68c-185b55c98c85",
                "name": "I254S",
                "name_review": {
                  "added": true,
                  "updateTime": 1674589433264,
                  "updatedBy": "User"
                },
                "name_uuid": "7708a224-9a51-4ced-8640-dc8a64673d5b",
                "tumors_uuid": "e5f98d55-6b49-49e7-bfb7-5210ee5e4f79"
              },
              "operation": "add",
              "uuids": "ba4af5ef-67df-4456-91e6-a8497a64aba6,b354a9e5-9966-4eb6-b59e-d058c820c936"
            }
          ],
          "timeStamp": 1674765704866
        },
        "-NMjoGNgliXxFyQqfOx2": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "I255N",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 I255N mutation is located in the DNA-binding domain of the protein. This mutation has been identified in adenocarcinoma and is a statistically significant hotspot (PMID: 8187092). In vivo studies with yeast expressing TP53 I255N demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 I255N also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674589424061,
                    "updatedBy": "User"
                  },
                  "description_uuid": "0d6b1bee-31aa-4b9b-9b81-b6c051e89ad5",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1674589420288,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "799d989f-3b74-4eac-bf02-eda4058a6bf5",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1674589419350,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "ef1bf2c7-6c3d-4284-8def-f330f174d38c",
                  "short": ""
                },
                "mutation_effect_uuid": "adc942b9-e1bf-410f-b5f3-9e12b01bf0f0",
                "name": "I255N",
                "name_review": {
                  "added": true,
                  "updateTime": 1674589414593,
                  "updatedBy": "User"
                },
                "name_uuid": "92137b6a-ea46-4808-86c4-74403e084c92",
                "tumors_uuid": "996fcf8e-672c-49e0-b23b-a3e724d49fb7"
              },
              "operation": "add",
              "uuids": "ef1bf2c7-6c3d-4284-8def-f330f174d38c,799d989f-3b74-4eac-bf02-eda4058a6bf5"
            }
          ],
          "timeStamp": 1674765736003
        },
        "-NMjoNjD1jAmO6PQ1Z0p": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "I255T",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 I255T mutation is located in the DNA-binding domain of the protein. This mutation has been identified in colorectal cancer and is a statistically significant hotspot (PMID: 12118339). In vivo studies with yeast expressing TP53 I255T demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 I255T also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674589405954,
                    "updatedBy": "User"
                  },
                  "description_uuid": "e9e1a1ce-56d2-49b9-8d60-602dc537dd3c",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1674589399094,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "8a7676f5-a723-4110-92c8-d4e4c25d3dc3",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1674589398213,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "29b9864d-a84a-4a72-97b2-cfeb8fff666b",
                  "short": ""
                },
                "mutation_effect_uuid": "5bd6dc5e-49f5-4ca3-bc6c-03a63e73b4b2",
                "name": "I255T",
                "name_review": {
                  "added": true,
                  "updateTime": 1674589395944,
                  "updatedBy": "User"
                },
                "name_uuid": "6f42f9c3-fd03-4207-b701-2bde89032e7f",
                "tumors_uuid": "58d19d45-e452-4a40-9dd7-b563a4e1859b"
              },
              "operation": "add",
              "uuids": "29b9864d-a84a-4a72-97b2-cfeb8fff666b,8a7676f5-a723-4110-92c8-d4e4c25d3dc3"
            }
          ],
          "timeStamp": 1674765766117
        },
        "-NMjoV66SPp8gSp6vtjq": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "I255S",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 I255S mutation is located in the DNA-binding domain of the protein. This mutation has been identified in squamous cell carcinoma and is a statistically significant hotspot (PMID: 9736425). In vivo studies with yeast expressing TP53 I255S demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 I255S also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674589389015,
                    "updatedBy": "User"
                  },
                  "description_uuid": "8ef2db71-650f-4bda-aeff-15a812ff6881",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1674589379644,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "bbbfa8aa-dd87-4456-b62a-c557fcf83401",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1674589378768,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "e732b84e-2160-460b-95f0-c29dcb779fc7",
                  "short": ""
                },
                "mutation_effect_uuid": "66f83e71-f11f-40a3-b898-1d270bbe192b",
                "name": "I255S",
                "name_review": {
                  "added": true,
                  "updateTime": 1674589376442,
                  "updatedBy": "User"
                },
                "name_uuid": "d7f5cea6-0a2f-4951-9d7f-34f43d4ac9fc",
                "tumors_uuid": "03dc4c60-af89-4dd2-8f8e-e4bcdaa9e5ef"
              },
              "operation": "add",
              "uuids": "e732b84e-2160-460b-95f0-c29dcb779fc7,bbbfa8aa-dd87-4456-b62a-c557fcf83401"
            }
          ],
          "timeStamp": 1674765796318
        },
        "-NMjobVlpHzmXPX4JmRv": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "E258K",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 E258K mutation is located in the DNA-binding domain of the protein. This mutation has been identified in malignant lymphoma and is a statistically significant hotspot (PMID: 8878455). In vivo studies with yeast expressing TP53 E258K demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 E258K also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674589098602,
                    "updatedBy": "User"
                  },
                  "description_uuid": "fdfeb117-1b17-4a31-92ef-bcfeb919eea1",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1674589090685,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "7e5472e2-33d1-437f-b139-fee9e22354b9",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1674589089773,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "dcb95978-8667-45e9-9407-c48d7280d7c1",
                  "short": ""
                },
                "mutation_effect_uuid": "ff8ffd4e-db46-4fdd-af5f-27af0bc952e6",
                "name": "E258K",
                "name_review": {
                  "added": true,
                  "updateTime": 1674589087530,
                  "updatedBy": "User"
                },
                "name_uuid": "bff1053f-08e2-4573-9887-8984fbbe351b",
                "tumors_uuid": "4785409e-b387-4cc6-a8a4-28534f554a9f"
              },
              "operation": "add",
              "uuids": "dcb95978-8667-45e9-9407-c48d7280d7c1,7e5472e2-33d1-437f-b139-fee9e22354b9"
            }
          ],
          "timeStamp": 1674765826632
        },
        "-NMjoicwGIUAqmC7f3t3": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "I254N",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 I254N mutation is located in the DNA-binding domain of the protein. This mutation has been identified in Burkitt lymphoma and is a statistically significant hotspot (PMID: 9172810). In vivo studies with yeast expressing TP53 I254N demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 I254N also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674589563232,
                    "updatedBy": "User"
                  },
                  "description_uuid": "c2068fe4-07b1-4980-9c4c-e5027dc0dee9",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1674589555912,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "39ec4068-10b3-476f-b957-b874221f2a1e",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1674589554619,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "45276fc1-c8ff-4a5c-9dd0-0edf00c048dc",
                  "short": ""
                },
                "mutation_effect_uuid": "24f2c26e-23f8-44c7-b834-799e340d259d",
                "name": "I254N",
                "name_review": {
                  "added": true,
                  "updateTime": 1674589551334,
                  "updatedBy": "User"
                },
                "name_uuid": "1fc434d4-5e08-4807-bb69-b4348467a84a",
                "tumors_uuid": "c378f2d6-d0a0-44fa-975f-ae03246872ca"
              },
              "operation": "add",
              "uuids": "45276fc1-c8ff-4a5c-9dd0-0edf00c048dc,39ec4068-10b3-476f-b957-b874221f2a1e"
            }
          ],
          "timeStamp": 1674765855827
        },
        "-NMjoq7hsqxnGN9gB2hf": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "I254M",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 I254M mutation is located in the DNA-binding domain of the protein. This mutation has been identified in B-cell chronic lymphocytic leukemia and is a statistically significant hotspot (PMID: 18980985). In vivo studies with yeast expressing TP53 I254M demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674589533588,
                    "updatedBy": "User"
                  },
                  "description_uuid": "7372f3bd-9330-4f75-884b-7f6a82d34b2f",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1674589526996,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "efeecb2d-1352-4480-bce7-44d3ba484bf0",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1674589525598,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "66d97394-5062-4abb-9069-bffe31aafb77",
                  "short": ""
                },
                "mutation_effect_uuid": "42255c6c-9a7b-4e1f-9f3d-0f06a9b917f0",
                "name": "I254M",
                "name_review": {
                  "added": true,
                  "updateTime": 1674589522782,
                  "updatedBy": "User"
                },
                "name_uuid": "1c2b4216-6f68-4d1c-8c3d-84864aec909c",
                "tumors_uuid": "58b4d3e3-a72b-4ae4-8dd0-d1d8290d9b2c"
              },
              "operation": "add",
              "uuids": "66d97394-5062-4abb-9069-bffe31aafb77,efeecb2d-1352-4480-bce7-44d3ba484bf0"
            }
          ],
          "timeStamp": 1674765886532
        },
        "-NMjoxXOrC7EIwvzW3AT": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "I254L",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 I254L mutation is located in the DNA-binding domain of the protein. This mutation has been identified in malignant fibrous histiocytoma and is a statistically significant hotspot (PMID: 9645763). In vivo studies with yeast expressing TP53 I254L demonstrated that the mutation is likely neutral as measured by transactivational activity comparable to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 I254L also demonstrated the mutation likely neutral as measured by growth suppression activity comparable to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674765221639,
                    "updatedBy": "User"
                  },
                  "description_uuid": "1805d174-64d6-4b43-bbae-f6ffead49774",
                  "effect": "Likely Neutral",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1674589504816,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "d5656eb9-237f-4f99-a34e-4c77fb946894",
                  "oncogenic": "Likely Neutral",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1674589504169,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "64395ac8-49d5-42f7-91f6-3193ee178584",
                  "short": ""
                },
                "mutation_effect_uuid": "060fdab7-6142-41bb-b653-ce1efdbafe3e",
                "name": "I254L",
                "name_review": {
                  "added": true,
                  "updateTime": 1674589502048,
                  "updatedBy": "User"
                },
                "name_uuid": "860adc76-e31d-4ff1-8dbc-6659186ae7f4",
                "tumors_uuid": "27b5ec3f-59a3-4249-a2d9-c587f4d4be41"
              },
              "operation": "add",
              "uuids": "64395ac8-49d5-42f7-91f6-3193ee178584,d5656eb9-237f-4f99-a34e-4c77fb946894"
            }
          ],
          "timeStamp": 1674765916848
        },
        "-NMjp3z5zjTTk7fpnBiR": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "I254F",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 I254F mutation is located in the DNA-binding domain of the protein. This mutation has been identified in non-small cell lung cancer and is a statistically significant hotspot (PMID: 17557246). In vivo studies with yeast expressing TP53 I254F demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674589493618,
                    "updatedBy": "User"
                  },
                  "description_uuid": "b9e3ea07-2785-4fca-9bd1-7623adac5f85",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1674589485383,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "ca5454d7-7726-417b-9e7e-23e3266dbdc9",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1674589484333,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "a69be9b5-0059-4284-97f5-b438c57aa6dd",
                  "short": ""
                },
                "mutation_effect_uuid": "e5cea44b-7a5b-4e5d-a39a-c644ff41c776",
                "name": "I254F",
                "name_review": {
                  "added": true,
                  "updateTime": 1674589481948,
                  "updatedBy": "User"
                },
                "name_uuid": "d1f05cac-972e-4564-a526-f34e63e43f1d",
                "tumors_uuid": "4e2198eb-7f92-46d2-9903-0da82c2ac368"
              },
              "operation": "add",
              "uuids": "a69be9b5-0059-4284-97f5-b438c57aa6dd,ca5454d7-7726-417b-9e7e-23e3266dbdc9"
            }
          ],
          "timeStamp": 1674765947357
        },
        "-NMjpBKXLkkIKyRI0hWv": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "I254V",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 I254V mutation is located in the DNA-binding domain of the protein. This mutation has been identified in malignant lymphoma and is a statistically significant hotspot (PMID: 15370252). In vivo studies with yeast expressing TP53 I254V demonstrated that the mutation is likely neutral as measured by transactivational activity comparable to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 I254V also demonstrated the mutation likely neutral as measured by growth suppression activity comparable to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674765176844,
                    "updatedBy": "User"
                  },
                  "description_uuid": "da25f29c-1943-448a-9e0a-624767315a76",
                  "effect": "Likely Neutral",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1674589460611,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "42087c14-2ab6-4db9-a9dc-35d7e881d66e",
                  "oncogenic": "Likely Neutral",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1674589459904,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "7d748519-325f-4637-91ec-91fc3685803a",
                  "short": ""
                },
                "mutation_effect_uuid": "6e252b21-3678-4e33-9377-7a0ebd81ef65",
                "name": "I254V",
                "name_review": {
                  "added": true,
                  "updateTime": 1674589457272,
                  "updatedBy": "User"
                },
                "name_uuid": "189c3fe8-2a34-4c49-a794-ca8c8eecc89a",
                "tumors_uuid": "3df0b564-2f9e-45ee-9466-2aeb6b4fa943"
              },
              "operation": "add",
              "uuids": "7d748519-325f-4637-91ec-91fc3685803a,42087c14-2ab6-4db9-a9dc-35d7e881d66e"
            }
          ],
          "timeStamp": 1674765977465
        },
        "-NMjpJ-K4Up0XLOdHOH6": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V272K",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 V272K mutation is located in the DNA-binding domain of the protein. This mutation has been identified in lung adenocarcinoma and is a statistically significant hotspot (PMID: 22980975). In vitro studies with various human cancer cell lines expressing TP53 V272K demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674591834093,
                    "updatedBy": "User"
                  },
                  "description_uuid": "8c0c29e4-09bd-4c6f-a964-e9581cc65cda",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1674591829949,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "b90f144d-9b18-43a3-bc2d-51844b17e4f8",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1674591828896,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "1434c6ab-4456-43ec-bf1c-c93c95a0dfdb",
                  "short": ""
                },
                "mutation_effect_uuid": "395a4346-e5b9-4ad8-8e03-168d74d12473",
                "name": "V272K",
                "name_review": {
                  "added": true,
                  "updateTime": 1674591823867,
                  "updatedBy": "User"
                },
                "name_uuid": "b1beeab3-95a9-4452-acad-0d279321d6a7",
                "tumors_uuid": "d1a6da29-08fd-4511-853e-4a1298578227"
              },
              "operation": "add",
              "uuids": "1434c6ab-4456-43ec-bf1c-c93c95a0dfdb,b90f144d-9b18-43a3-bc2d-51844b17e4f8"
            }
          ],
          "timeStamp": 1674766008876
        },
        "-NMjpQKTIqu1ptBkN6Zu": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V272E",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 V272E mutation is located in the DNA-binding domain of the protein. This mutation has been identified in diffuse large B-cell lymphoma and is a statistically significant hotspot (PMID: 17881637). In vivo studies with yeast expressing TP53 V272E demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 V272E also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674591816302,
                    "updatedBy": "User"
                  },
                  "description_uuid": "1490d821-ad32-4f02-b44b-2251b2ef70a7",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1674591812316,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "15eccbf2-5330-4665-907f-c76730dcddfe",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1674591811300,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "710f3ab3-5dbc-4bda-89a4-583aed3e0f19",
                  "short": ""
                },
                "mutation_effect_uuid": "445ae15b-26c7-4ad8-83f8-6da8693e92af",
                "name": "V272E",
                "name_review": {
                  "added": true,
                  "updateTime": 1674591809143,
                  "updatedBy": "User"
                },
                "name_uuid": "e89f3522-f425-4a33-a48e-de837db25875",
                "tumors_uuid": "faf29e67-6044-444e-b407-318af6689a87"
              },
              "operation": "add",
              "uuids": "710f3ab3-5dbc-4bda-89a4-583aed3e0f19,15eccbf2-5330-4665-907f-c76730dcddfe"
            }
          ],
          "timeStamp": 1674766038901
        },
        "-NMjpXy-2_Cv8-iSP7Qc": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V272A",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 V272A mutation is located in the DNA-binding domain of the protein. This mutation has been identified in pancreatic cancer and is a statistically significant hotspot (PMID: 1630814). In vivo studies with yeast expressing TP53 V272A demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674591797501,
                    "updatedBy": "User"
                  },
                  "description_uuid": "2c4ea931-f0e5-4083-a60a-243825f07e85",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1674591792819,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "72a188d1-fb9d-4dff-8ac1-8a318f873aeb",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1674591791732,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "06e146bc-daac-41d5-a743-c9ad74de9f05",
                  "short": ""
                },
                "mutation_effect_uuid": "afc32a38-cd9d-4bf2-9cca-0f642d7f1588",
                "name": "V272A",
                "name_review": {
                  "added": true,
                  "updateTime": 1674591790019,
                  "updatedBy": "User"
                },
                "name_uuid": "5276a3fd-ba48-4d32-8271-e5bfefaea463",
                "tumors_uuid": "8fba086a-f19b-4fc2-804e-3aa510b45006"
              },
              "operation": "add",
              "uuids": "06e146bc-daac-41d5-a743-c9ad74de9f05,72a188d1-fb9d-4dff-8ac1-8a318f873aeb"
            }
          ],
          "timeStamp": 1674766070167
        },
        "-NMjpe_Flfob9Ed_nf9d": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R337S",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 R337S mutation is located in the tetramerization motif of the protein. This mutation has been identified in biliary tract cancer and is a statistically significant hotspot (PMID: 29360550). In vivo studies with yeast expressing TP53 R337S demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674591282996,
                    "updatedBy": "User"
                  },
                  "description_uuid": "9512add5-b258-46d6-a108-0741834c21c0",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1674591269973,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "c0d6f6d4-1951-4031-a46c-02c8df64edc0",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1674591267888,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "38143c1e-3a9c-48f3-b1a9-e65d13277113",
                  "short": ""
                },
                "mutation_effect_uuid": "58ccd0a5-ae2d-4521-9073-144673fe68fe",
                "name": "R337S",
                "name_review": {
                  "added": true,
                  "updateTime": 1674591265296,
                  "updatedBy": "User"
                },
                "name_uuid": "8756a91e-d16e-4ee9-952c-9f352a7d736b",
                "tumors_uuid": "a3d448f1-c724-45f2-ade0-2cbb0949ea24"
              },
              "operation": "add",
              "uuids": "38143c1e-3a9c-48f3-b1a9-e65d13277113,c0d6f6d4-1951-4031-a46c-02c8df64edc0"
            }
          ],
          "timeStamp": 1674766101351
        },
        "-NMjplzJDyuYLZ-3KBoj": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V272G",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 V272G mutation is located in the DNA-binding domain of the protein. This mutation has been identified in bladder cancer and is a statistically significant hotspot (PMID: 10355250). In vivo studies with yeast expressing TP53 V272G demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 V272G also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674590201559,
                    "updatedBy": "User"
                  },
                  "description_uuid": "5d37db20-11a6-44fc-8fa8-2e90cc0fd7d2",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1674590194788,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "e5510754-9209-4205-baca-0946b6eba1fc",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1674590193299,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "bfb839e4-b32d-4321-8182-fd3aac6d601a",
                  "short": ""
                },
                "mutation_effect_uuid": "b4dbf355-c681-45c3-8197-9f7865fe4081",
                "name": "V272G",
                "name_review": {
                  "added": true,
                  "updateTime": 1674590191380,
                  "updatedBy": "User"
                },
                "name_uuid": "d2401013-3d34-40a4-a9c3-c792a28e5480",
                "tumors_uuid": "df99ffae-1037-4f55-849d-d3b8b797a1a6"
              },
              "operation": "add",
              "uuids": "bfb839e4-b32d-4321-8182-fd3aac6d601a,e5510754-9209-4205-baca-0946b6eba1fc"
            }
          ],
          "timeStamp": 1674766131691
        },
        "-NMjptPKFJKXL5M_z2P6": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V157L",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 V157L mutation is located in the DNA-binding domain of the protein. This mutation has been identified in colorectal cancer and is a statistically significant hotspot (PMID: 7694948). In vivo studies with yeast expressing TP53 V157L demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 V157L also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674677250788,
                    "updatedBy": "User"
                  },
                  "description_uuid": "b7caf6e5-7599-4eed-ab9e-7502fb4149ec",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1674677247241,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "d0b12068-c8cc-4d99-87e9-fc54ce42eee6",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1674677246395,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "f97a845e-2be1-4d51-bb72-02153855edbe",
                  "short": ""
                },
                "mutation_effect_uuid": "a0302270-02f1-4e30-afaf-bbd73dd052f2",
                "name": "V157L",
                "name_review": {
                  "added": true,
                  "updateTime": 1674677244537,
                  "updatedBy": "User"
                },
                "name_uuid": "040fafbb-830f-438e-be35-52cb215690a4",
                "tumors_uuid": "0e212285-9395-419d-b374-65e1cb3a8f4a"
              },
              "operation": "add",
              "uuids": "f97a845e-2be1-4d51-bb72-02153855edbe,d0b12068-c8cc-4d99-87e9-fc54ce42eee6"
            }
          ],
          "timeStamp": 1674766162092
        },
        "-NMjq05iSCH3BeJCHVg6": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V157G",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 V157G mutation is located in the DNA-binding domain of the protein. This mutation has been identified in ovarian cancer and is a statistically significant hotspot (PMID: 7852189). In vivo studies with yeast expressing TP53 V157G demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 V157G also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674677230038,
                    "updatedBy": "User"
                  },
                  "description_uuid": "70d01cd1-d41a-4c82-9c0c-4f00a7c57c7d",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1674677226233,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "31d7862d-729c-4c70-ae52-5add10a422d2",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1674677225501,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "6e0da137-96f3-4804-b72f-ab00632c74bc",
                  "short": ""
                },
                "mutation_effect_uuid": "b3f3e8c8-a764-4958-8258-bef56bd530ff",
                "name": "V157G",
                "name_review": {
                  "added": true,
                  "updateTime": 1674677223400,
                  "updatedBy": "User"
                },
                "name_uuid": "3ead5eca-19ad-47bc-8f05-ac84d64daab3",
                "tumors_uuid": "141d760b-6f1c-4353-a81b-b1e45a186169"
              },
              "operation": "add",
              "uuids": "6e0da137-96f3-4804-b72f-ab00632c74bc,31d7862d-729c-4c70-ae52-5add10a422d2"
            }
          ],
          "timeStamp": 1674766193605
        },
        "-NMjq7SXlRt2Xjw10RQk": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V157A",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 V157A mutation is located in the DNA-binding domain of the protein. This mutation has been identified in cutaneous T-cell lymphoma and is a statistically significant hotspot (PMID: 10551408). In vivo studies with yeast expressing TP53 V157A demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 V157A also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674677211247,
                    "updatedBy": "User"
                  },
                  "description_uuid": "890cbf03-2f9d-4408-b254-5e6b024b424d",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1674677207994,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "ece7f7bb-a624-4ce5-8da4-5896943b4160",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1674677206742,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "c5ab1822-d072-4cec-a088-5b0edaa169c9",
                  "short": ""
                },
                "mutation_effect_uuid": "15ac3a86-e68b-44c1-b483-be666b2dbf7f",
                "name": "V157A",
                "name_review": {
                  "added": true,
                  "updateTime": 1674677204622,
                  "updatedBy": "User"
                },
                "name_uuid": "f0d159d7-410b-48ef-bcad-6d0cae193972",
                "tumors_uuid": "2d9c547f-9722-4806-8771-0bd5941d521e"
              },
              "operation": "add",
              "uuids": "c5ab1822-d072-4cec-a088-5b0edaa169c9,ece7f7bb-a624-4ce5-8da4-5896943b4160"
            }
          ],
          "timeStamp": 1674766223737
        },
        "-NMjqErDTRMH0UhUddtC": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R267L",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 R267L mutation is located in the DNA-binding domain of the protein. This mutation has been identified in precursor cell lymphoblastic leukemia and is a statistically significant hotspot (PMID: 16844765). In vivo studies with yeast expressing TP53 R267L demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674591974395,
                    "updatedBy": "User"
                  },
                  "description_uuid": "e37340c4-e8c8-4571-8a63-dac2c7c8572d",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1674591973099,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "3f0056f9-3dd1-43bb-aea8-98fb06612804",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1674591972345,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "df42cc7f-2f89-48eb-9ff6-d47fe5c48a8f",
                  "short": ""
                },
                "mutation_effect_uuid": "2f4a93d5-99e3-4707-86c2-36cd1e683fcc",
                "name": "R267L",
                "name_review": {
                  "added": true,
                  "updateTime": 1674591967098,
                  "updatedBy": "User"
                },
                "name_uuid": "e109bbdf-458b-4c9f-af34-b4cc550a5aee",
                "tumors_uuid": "20a6e8e0-cb73-4d9d-a66a-2b96d5675a53"
              },
              "operation": "add",
              "uuids": "df42cc7f-2f89-48eb-9ff6-d47fe5c48a8f,3f0056f9-3dd1-43bb-aea8-98fb06612804"
            }
          ],
          "timeStamp": 1674766254053
        },
        "-NMjqMKYFJiUchOZfvro": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R267W",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 R267W mutation is located in the DNA-binding domain of the protein. This mutation has been identified in colorectal cancer and is a statistically significant hotspot (PMID: 17881637). In vivo studies with yeast expressing TP53 R267W demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 R267W also demonstrated the mutation is inactivating as measured by moderately reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674591958653,
                    "updatedBy": "User"
                  },
                  "description_uuid": "b9a25483-9c22-44c7-948d-f23285f7e365",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1674591954849,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "046003c6-7fc7-40c9-88f6-38b5b02c7294",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1674591953735,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "c7ebf3fa-4b02-474b-8add-b740d4008952",
                  "short": ""
                },
                "mutation_effect_uuid": "8b13e6de-af98-4c6a-b3c1-1efe33d6a3e2",
                "name": "R267W",
                "name_review": {
                  "added": true,
                  "updateTime": 1674591951473,
                  "updatedBy": "User"
                },
                "name_uuid": "ce25b00b-044d-4807-bb1d-f458b3dd079c",
                "tumors_uuid": "8dfab4b9-2e00-461a-9486-9b93257b78a0"
              },
              "operation": "add",
              "uuids": "c7ebf3fa-4b02-474b-8add-b740d4008952,046003c6-7fc7-40c9-88f6-38b5b02c7294"
            }
          ],
          "timeStamp": 1674766284666
        },
        "-NMjqTgJmPsS03Sya-2k": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R110H",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 R110H mutation is located in the DNA-binding domain of the protein. This mutation has been identified in bladder cancer and is a statistically significant hotspot (PMID: 14612556). In vivo studies with yeast expressing TP53 R110H demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674677296283,
                    "updatedBy": "User"
                  },
                  "description_uuid": "1ae3e165-b226-45b3-9e9f-eed4edd5c72f",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1674677295061,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "f3680fd7-29f9-4f01-b2ea-1bbcaccb0849",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1674677294315,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "1f078e45-d318-4515-8697-31a44a637053",
                  "short": ""
                },
                "mutation_effect_uuid": "f174b752-863e-4bf7-9288-0aa013b49dc7",
                "name": "R110H",
                "name_review": {
                  "added": true,
                  "updateTime": 1674677289931,
                  "updatedBy": "User"
                },
                "name_uuid": "5436ea5c-011e-4422-9946-f95671341371",
                "tumors_uuid": "44fd0a01-a636-4f3c-a2d3-bf066f14b873"
              },
              "operation": "add",
              "uuids": "1f078e45-d318-4515-8697-31a44a637053,f3680fd7-29f9-4f01-b2ea-1bbcaccb0849"
            }
          ],
          "timeStamp": 1674766314795
        },
        "-NMjqa7W3xznATzqDRTo": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R110C",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 R110C mutation is located in the DNA-binding domain of the protein. This mutation has been identified in rectal cancer and is a statistically significant hotspot (PMID: 10884918). In vivo studies with yeast expressing TP53 R110C demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1674677276428,
                    "updatedBy": "User"
                  },
                  "description_uuid": "6526fb8f-1300-4580-b43e-f3c9df73e348",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1674677274854,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "9cd1932e-06c7-4386-8a8f-935b4c43394b",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1674677274088,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "2ac95d22-081e-44a1-932b-c498b3d1f357",
                  "short": ""
                },
                "mutation_effect_uuid": "3733df72-3153-44dc-932c-8340ccbcb8a9",
                "name": "R110C",
                "name_review": {
                  "added": true,
                  "updateTime": 1674677270074,
                  "updatedBy": "User"
                },
                "name_uuid": "abb815c5-d732-491b-aeb6-34a8a3d01bc7",
                "tumors_uuid": "af05f43d-f794-451d-b005-fc356179709f"
              },
              "operation": "add",
              "uuids": "2ac95d22-081e-44a1-932b-c498b3d1f357,9cd1932e-06c7-4386-8a8f-935b4c43394b"
            }
          ],
          "timeStamp": 1674766345272
        },
        "-NP-VJqEGm_XeuZJNGGq": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "S121F, Mutation Effect",
              "new": {
                "oncogenic": "Likely Neutral"
              },
              "old": {
                "oncogenic": "Likely"
              },
              "operation": "update",
              "uuids": "afc0e256-7933-4e36-9933-50e32b8a77d5"
            }
          ],
          "timeStamp": 1677193203060
        },
        "-NP-WBHqUhzKJOAbU-_j": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R249T",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 R249T mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and is a statistically significant hotspot (PMID: 14697642). In vivo studies with yeast expressing TP53 R249T demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 R249T also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675286424363,
                    "updatedBy": "User"
                  },
                  "description_uuid": "e6b40a53-d0ae-4210-beaf-672267b29663",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675286418777,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "245b550b-772b-4077-99e6-949d96ea7b6c",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675286417641,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "b89aeac5-a0ee-4a31-8032-d3fa3ed45165",
                  "short": ""
                },
                "mutation_effect_uuid": "c468547b-4987-448b-8311-988a9285b3a8",
                "name": "R249T",
                "name_review": {
                  "added": true,
                  "updateTime": 1675286415850,
                  "updatedBy": "User"
                },
                "name_uuid": "34992ea6-6b5d-4147-96b7-ad4e5de15ecb",
                "tumors_uuid": "4dc4af3f-2d3d-4018-a362-be130042b774"
              },
              "operation": "add",
              "uuids": "b89aeac5-a0ee-4a31-8032-d3fa3ed45165,245b550b-772b-4077-99e6-949d96ea7b6c"
            }
          ],
          "timeStamp": 1677193430171
        },
        "-NP-WBVDsI5CARzvVhye": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G154V, Mutation Effect",
              "new": {
                "description": "The TP53 G154V mutation is located in the DNA binding domain of the protein. Biochemical experiments have suggested that this mutation is inactivating as it acts as a dominant-negative (PMID: 21289082)."
              },
              "old": {
                "description": "The TP53 G154V mutation is located in the DNA binding domain of the protein. Biochemical experiments have suggested that this mutation acts as a dominant-negative  (PMID: 21289082)."
              },
              "operation": "update",
              "uuids": "58fc793e-8e9e-40ee-bc2c-b1c849a283f1"
            }
          ],
          "timeStamp": 1677193431027
        },
        "-NP-WC-wwC1n4T1TEhZ1": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R196L, Mutation Effect",
              "new": {
                "description": "The TP53 R196L mutation arises in the p53 DNA-binding domain of the protein. When this mutation is expressed in human Saos cells at different experimental temperature conditions, a difference in transactivational activity of this TP53 mutant has been observed (PMID: 14559903). However, there is no specific data demonstrating whether the mutation has decreased transactivational activity relative to wildtype p53 (PMID: 14559903). Nonetheless, an alternate mutation at this position, the TP53 R196G mutation, has been demonstrated to decrease p53 transactivation activity relative to wildtype p53 (PMID: 22710932). The R196L mutation is also a 3D hotspot mutation and therefore TP53 R196L is considered likely oncogenic (PMID: 28115009).",
                "effect": "Inconclusive",
                "oncogenic": "Inconclusive"
              },
              "old": {
                "description": "This TP53 mutation arises in the p53 DNA-binding domain and when expressed in human Saos cells at different experimental temperature conditions, a difference in transactivational activity of this TP53 mutant has been observed (PMID: 14559903). However, there is no specific data demonstrating whether the mutation has decreased transactivational activity relative to wildtype p53 (PMID: 14559903). Nonetheless, an alternate mutation at this position, the TP53 R196G mutation, has been demonstrated to decrease p53 transactivation activity relative to wildtype p53 (PMID: 22710932), the R196L mutation is also is a 3D hotspot mutation (PMID: 28115009) and therefore TP53 R196L is considered likely oncogenic",
                "effect": "Likely Loss-of-function",
                "oncogenic": "Likely"
              },
              "operation": "update",
              "uuids": "ebf5de87-0bf9-43f1-bd6c-f944f1bf0d49,e6263878-9cbb-468a-9837-ef2294db7409"
            }
          ],
          "timeStamp": 1677193433121
        },
        "-NP-WC7JWI8cpj-tWvMI": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R196G, Mutation Effect",
              "new": {
                "description": "The TP53 R196G mutation arises in the p53 DNA-binding domain of the protein. Human H1299 cell transactivation studies have demonstrated that this mutation is inactivating as demonstrated by significantly decreased transcriptional activity of p53 downstream factors bax, p21 and RGC relative to wildtype p53 at two different experimental temperature conditions (32 and 37 degrees Celsius) (PMID: 22710932)."
              },
              "old": {
                "description": "This TP53 mutation arises in the p53 DNA-binding domain and has been shown in human H1299 cell transactivation studies, to have significantly decreased transcriptional activity of p53 downstream factors bax, p21 and RGC relative to wildtype p53 at two different experimental temperature conditions (32 and 37 degrees celsius) (PMID: 22710932)."
              },
              "operation": "update",
              "uuids": "0b4f34f8-aa1c-4663-b586-eca7ddd34fa1"
            }
          ],
          "timeStamp": 1677193433593
        },
        "-NP-WCEm6PwS1V3JMkEU": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R280T, Mutation Effect",
              "new": {
                "description": "The TP53 R280T mutation is located in the DNA binding domain of the protein. This mutation has been found in glioma (PMID: 22999923). In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by increased proliferation of cells expressing the mutant compared to wildtype, as well as increased p-GSK-3 levels, reduced PTEN and Akt phosphorylation and reduced cell growth upon knockdown of the mutant protein compared to wildtype, suggesting that this mutation promotes cell growth through GSK-3beta-PTEN pathway (PMID: 22999923)."
              },
              "old": {
                "description": "The TP53 R280T mutation is located in the DNA binding domain of the protein. This mutation has been found in glioma (PMID: 22999923) In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by increased proliferation of cells expressing the mutant compared to wildtype, as well as increased p-GSK-3 levels, reduced PTEN and Akt phosphorylation and reduced cell growth upon knockdown of the mutant protein compared to wildtype, suggesting that this mutation promotes cell growth through GSK-3beta-PTEN pathway (PMID: 22999923)."
              },
              "operation": "update",
              "uuids": "dc9b6b17-0643-4fb9-bd35-26ee22eb93cf"
            }
          ],
          "timeStamp": 1677193434071
        },
        "-NP-WCdgskBs49o2lV2J": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R249K",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 R249K mutation is located in the DNA-binding domain of the protein. This mutation has been identified in colorectal cancer and is a statistically significant hotspot (PMID: 11737306). In vivo studies with yeast expressing TP53 R249K demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675286521518,
                    "updatedBy": "User"
                  },
                  "description_uuid": "38a0dc68-c779-43f4-8a85-215f9573fcfc",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675286517444,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "0a6c8ee3-d351-4de9-8d22-6f879932f9b9",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675286516397,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "dbff5f06-2c96-4789-9b8b-ab997429521b",
                  "short": ""
                },
                "mutation_effect_uuid": "12622ace-b86c-40a4-b9cc-825b15fb66bc",
                "name": "R249K",
                "name_review": {
                  "added": true,
                  "updateTime": 1675286511789,
                  "updatedBy": "User"
                },
                "name_uuid": "5329a390-0db2-4c86-9e1e-6d5b0d67592e",
                "tumors_uuid": "a61ee8e7-f03e-4282-a445-697c3d191a90"
              },
              "operation": "add",
              "uuids": "dbff5f06-2c96-4789-9b8b-ab997429521b,0a6c8ee3-d351-4de9-8d22-6f879932f9b9"
            }
          ],
          "timeStamp": 1677193435729
        },
        "-NP-WClc6v6mpWSbvJzZ": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "H214Q, Mutation Effect",
              "new": {
                "effect": "Likely Neutral",
                "oncogenic": "Likely Neutral"
              },
              "old": {
                "effect": "Inconclusive",
                "oncogenic": "Inconclusive"
              },
              "operation": "update",
              "uuids": "e5eb8bf2-4c0f-4432-b6f9-f9efc1020164,204f9e50-8e83-45a7-a3ba-64c847535564"
            }
          ],
          "timeStamp": 1677193436237
        },
        "-NP-WDGcvV2XMlVcWfDd": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "F134Y, Mutation Effect",
              "new": {
                "effect": "Likely Neutral",
                "oncogenic": "Likely Neutral"
              },
              "old": {
                "effect": "Inconclusive",
                "oncogenic": "Inconclusive"
              },
              "operation": "update",
              "uuids": "2815bd4b-1619-4f67-8856-b5bfe65d1d94,4bc2942b-10c2-4f3f-babe-bc76bbdb2b7d"
            }
          ],
          "timeStamp": 1677193438285
        },
        "-NP-WDO9kChSKkbxpzGX": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R273G, Mutation Effect",
              "new": {
                "effect": "Inconclusive",
                "oncogenic": "Inconclusive"
              },
              "old": {
                "effect": "Likely Loss-of-function",
                "oncogenic": "Likely"
              },
              "operation": "update",
              "uuids": "3a9e6f10-5522-4a50-b939-26727c5abba6,8997fe78-40db-4812-8ead-2635615747c1"
            }
          ],
          "timeStamp": 1677193438767
        },
        "-NP-WDoB_ggEmW2tl7l7": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R337G",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 R337G mutation is located in the tetramerization motif of the protein and is a statistically significant hotspot. In vivo studies with yeast expressing TP53 R337G demonstrated that the mutation is likely neutral as measured by transactivational activity comparable to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 R337G also demonstrated the mutation likely neutral as measured by growth suppression activity comparable to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1677193247125,
                    "updatedBy": "User"
                  },
                  "description_uuid": "e829c758-286b-43cb-afa3-b35097b5fa20",
                  "effect": "Likely Neutral",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675286561051,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "082ac28d-d3d3-48ee-867d-ea14ea7e7761",
                  "oncogenic": "Likely Neutral",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675286559522,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "8fa3286a-1b6c-4df7-9257-8234b32d8969",
                  "short": ""
                },
                "mutation_effect_uuid": "4ea06746-8d26-4101-9790-56ba8ff3a1f5",
                "name": "R337G",
                "name_review": {
                  "added": true,
                  "updateTime": 1675286557195,
                  "updatedBy": "User"
                },
                "name_uuid": "dc6cbc83-bca4-4681-a9ac-0052eeb6fc5a",
                "tumors_uuid": "10005cf3-8821-477e-a06f-5888688d5bd9"
              },
              "operation": "add",
              "uuids": "8fa3286a-1b6c-4df7-9257-8234b32d8969,082ac28d-d3d3-48ee-867d-ea14ea7e7761"
            }
          ],
          "timeStamp": 1677193440497
        },
        "-NP-WE7QkpCtmpLLYrg2": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "A161P",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 A161P mutation is located in the DNA-binding domain of the protein. This mutation has been identified in prolymphocytic leukemia and is a statistically significant hotspot (PMID: 9058723). In vivo studies with yeast expressing TP53 A161P demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675287319291,
                    "updatedBy": "User"
                  },
                  "description_uuid": "5c49a953-b07a-4049-a2d9-7b518f4f0fb1",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675287315297,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "4bd6ffda-0b3c-4d4b-a29a-709c216ea6cc",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675287313851,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "ca5291da-1dda-408f-8529-8eba0a1c290a",
                  "short": ""
                },
                "mutation_effect_uuid": "9588dba8-b50c-4302-bb0c-2e775fc741cf",
                "name": "A161P",
                "name_review": {
                  "added": true,
                  "updateTime": 1675287312206,
                  "updatedBy": "User"
                },
                "name_uuid": "629b6f4f-bf04-46ff-8a92-2c8e42841659",
                "tumors_uuid": "b43d29cb-92c4-4c7c-a1d7-ed5d086cd9ba"
              },
              "operation": "add",
              "uuids": "ca5291da-1dda-408f-8529-8eba0a1c290a,4bd6ffda-0b3c-4d4b-a29a-709c216ea6cc"
            }
          ],
          "timeStamp": 1677193441792
        },
        "-NP-WEfKUHY2pR7KrSpN": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R249I",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 R249I mutation is located in the DNA-binding domain of the protein. This mutation has been identified in small cell lung cancer and is a statistically significant hotspot (PMID: 10551408). In vitro studies with various human cancer cell lines expressing TP53 R249I demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675286486930,
                    "updatedBy": "User"
                  },
                  "description_uuid": "8a106ffc-77e4-48df-af76-54c40de8ed7c",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675286482901,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "4279dbe0-3c2c-4b9f-b12e-d3c929007326",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675286481951,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "4fbf575b-521d-4e15-9acd-bd3d03d9f1d5",
                  "short": ""
                },
                "mutation_effect_uuid": "4422ba4f-af43-473d-9118-de14d9e8749d",
                "name": "R249I",
                "name_review": {
                  "added": true,
                  "updateTime": 1675286479819,
                  "updatedBy": "User"
                },
                "name_uuid": "a6a2063b-afce-46a0-9bec-c6ed49350f52",
                "tumors_uuid": "bfe9100d-cfad-46b1-ab58-ca3e944258d6"
              },
              "operation": "add",
              "uuids": "4fbf575b-521d-4e15-9acd-bd3d03d9f1d5,4279dbe0-3c2c-4b9f-b12e-d3c929007326"
            }
          ],
          "timeStamp": 1677193444026
        },
        "-NP-WLe4unNg2D0RIAbk": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R249G",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 R249G mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and is a statistically significant hotspot (PMID: 8673929). In vivo studies with yeast expressing TP53 R249G demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 R249G also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675286457819,
                    "updatedBy": "User"
                  },
                  "description_uuid": "26d74193-5cc1-4461-afb5-6cea95c5ed2c",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675286453178,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "32294a96-2e1d-4cfd-a31b-b29257426666",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675286451656,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "388e5e69-f4bb-4767-a922-6e77c5dbcfc8",
                  "short": ""
                },
                "mutation_effect_uuid": "77bed699-44b2-4d70-be82-9263644b8174",
                "name": "R249G",
                "name_review": {
                  "added": true,
                  "updateTime": 1675286447428,
                  "updatedBy": "User"
                },
                "name_uuid": "45b98cc1-de82-4926-a23f-b42a6e3feb80",
                "tumors_uuid": "e7548eff-dac6-4fdb-b0a3-b934008e5030"
              },
              "operation": "add",
              "uuids": "388e5e69-f4bb-4767-a922-6e77c5dbcfc8,32294a96-2e1d-4cfd-a31b-b29257426666"
            }
          ],
          "timeStamp": 1677193474401
        },
        "-NP-WT4_cXgg5cLcVN8O": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Y220H",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 Y220H mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and is a statistically significant hotspot (PMID: 17683074). In vivo studies with yeast expressing TP53 Y220H demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 Y220H also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675287689583,
                    "updatedBy": "User"
                  },
                  "description_uuid": "9b4f9382-6220-48c7-a551-3e78dedb7c5f",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675287686652,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "5e237df7-8b5e-4697-ab51-bc2db9ea3b8d",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675287685038,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "02a04796-5a29-4073-8908-b0de455d4c18",
                  "short": ""
                },
                "mutation_effect_uuid": "026abe8f-b47c-4c32-ba3a-e12cedec03b2",
                "name": "Y220H",
                "name_review": {
                  "added": true,
                  "updateTime": 1675287682656,
                  "updatedBy": "User"
                },
                "name_uuid": "257042eb-324a-47dc-bd11-c7cac39c3276",
                "tumors_uuid": "c8f55b3d-297a-4b8e-b5dd-293ef346fae2"
              },
              "operation": "add",
              "uuids": "02a04796-5a29-4073-8908-b0de455d4c18,5e237df7-8b5e-4697-ab51-bc2db9ea3b8d"
            }
          ],
          "timeStamp": 1677193504833
        },
        "-NP-W_adP0A27UQsaeDF": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Y220D",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 Y220D mutation is located in the DNA-binding domain of the protein. This mutation has been identified in esophageal squamous cell carcinoma and is a statistically significant hotspot (PMID: 9617346). In vivo studies with yeast expressing TP53 Y220D demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 Y220D also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675287673125,
                    "updatedBy": "User"
                  },
                  "description_uuid": "72e2a1a6-0a04-4e84-b497-c5b2640bf864",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675287668996,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "9767cfd5-551e-4b61-8c2e-fff057f3f72f",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675287668222,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "0203e349-1d23-456d-bc5e-822a3fccc8a6",
                  "short": ""
                },
                "mutation_effect_uuid": "268072e6-a395-4d14-8925-6e79c1c89880",
                "name": "Y220D",
                "name_review": {
                  "added": true,
                  "updateTime": 1675287665106,
                  "updatedBy": "User"
                },
                "name_uuid": "79f532c1-4c41-4dc4-9c90-f11f15dfb7d4",
                "tumors_uuid": "924a13f6-ef1a-499e-bc1d-7487c92eb326"
              },
              "operation": "add",
              "uuids": "0203e349-1d23-456d-bc5e-822a3fccc8a6,9767cfd5-551e-4b61-8c2e-fff057f3f72f"
            }
          ],
          "timeStamp": 1677193535621
        },
        "-NP-Wh8rjAnNXfZuVlxE": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R267G",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 R267G mutation is located in the DNA-binding domain of the protein. This mutation has been identified in bladder cancer and is a statistically significant hotspot (PMID: 7869472). In vivo studies with yeast expressing TP53 R267G demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 R267G also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675287652643,
                    "updatedBy": "User"
                  },
                  "description_uuid": "1dfb40bf-0a12-4fea-8606-f6201bf5e839",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675287650119,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "d5c82ebf-3558-4fbb-956e-cb38a26f059b",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675287648659,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "50eaef1b-1fdc-4406-af22-e0bb9ab84efa",
                  "short": ""
                },
                "mutation_effect_uuid": "48652ba3-7526-43b0-80ea-6dc81b64d043",
                "name": "R267G",
                "name_review": {
                  "added": true,
                  "updateTime": 1675287638611,
                  "updatedBy": "User"
                },
                "name_uuid": "ea4ea7a7-e183-4f5a-a3ec-30717b75b146",
                "tumors_uuid": "53d688a7-f334-4a07-960b-bf6d29b451fa"
              },
              "operation": "add",
              "uuids": "50eaef1b-1fdc-4406-af22-e0bb9ab84efa,d5c82ebf-3558-4fbb-956e-cb38a26f059b"
            }
          ],
          "timeStamp": 1677193566547
        },
        "-NP-Wod8du33TpTkKsEF": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "A161V",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 A161V mutation is located in the DNA-binding domain of the protein. This mutation has been identified in Burkitt lymphoma and is a statistically significant hotspot (PMID: 12890146). In vivo studies with yeast expressing TP53 A161V demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675287362677,
                    "updatedBy": "User"
                  },
                  "description_uuid": "af1f03bd-0a54-4622-9bf3-0550e54b8386",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675287361523,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "e20b4445-4b9b-49e3-9c76-569dc9c94a9e",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675287360760,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "c5b6fb1d-3044-4a97-9efe-7652edb12c99",
                  "short": ""
                },
                "mutation_effect_uuid": "1e4c631c-9911-4821-8823-15c500626e9e",
                "name": "A161V",
                "name_review": {
                  "added": true,
                  "updateTime": 1675287356777,
                  "updatedBy": "User"
                },
                "name_uuid": "6c84f70e-93bc-4d5b-8005-a84238efb2f3",
                "tumors_uuid": "eb8d6400-88c0-4111-82e3-bc806cb74bac"
              },
              "operation": "add",
              "uuids": "c5b6fb1d-3044-4a97-9efe-7652edb12c99,e20b4445-4b9b-49e3-9c76-569dc9c94a9e"
            }
          ],
          "timeStamp": 1677193597221
        },
        "-NP-Ww31OPlThfTHK7kg": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "A161D",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 A161D mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and is a statistically significant hotspot (PMID: 8522300). In vivo studies with yeast expressing TP53 A161D demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675287343811,
                    "updatedBy": "User"
                  },
                  "description_uuid": "f4672dee-f7c5-4c97-b8fe-d303f4df62f9",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675287338161,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "f9f94d08-f6f3-4c8c-97be-692eda9ae9c7",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675287337275,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "aedf58d8-9ef0-49bb-9474-8c5abd9e20ea",
                  "short": ""
                },
                "mutation_effect_uuid": "9ff9433f-2e4a-4428-b3a1-92dc57e12a19",
                "name": "A161D",
                "name_review": {
                  "added": true,
                  "updateTime": 1675287335221,
                  "updatedBy": "User"
                },
                "name_uuid": "e6c88a54-4fc8-45de-bc50-bd9e1fd1eeef",
                "tumors_uuid": "61e82959-7feb-40ae-aa12-2ccd31a1583f"
              },
              "operation": "add",
              "uuids": "aedf58d8-9ef0-49bb-9474-8c5abd9e20ea,f9f94d08-f6f3-4c8c-97be-692eda9ae9c7"
            }
          ],
          "timeStamp": 1677193627614
        },
        "-NP-X2U68ZflrFdQKYI_": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "F134S",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 F134S mutation is located in the DNA-binding domain of the protein. This mutation has been identified in astrocytoma and is a statistically significant hotspot (PMID: 17917588). In vivo studies with yeast expressing TP53 F134S demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 F134S also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675287791073,
                    "updatedBy": "User"
                  },
                  "description_uuid": "32189008-4dbc-4045-aa96-e95183402e99",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675287789641,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "416915fa-8990-4e65-972b-dd437adfd9cd",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675287788709,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "e14fc53a-b7c1-4be6-9ea9-dcfb1853bcd8",
                  "short": ""
                },
                "mutation_effect_uuid": "ea13981d-b9cb-4af7-aab0-d68b8ff0a29c",
                "name": "F134S",
                "name_review": {
                  "added": true,
                  "updateTime": 1675287784862,
                  "updatedBy": "User"
                },
                "name_uuid": "b59020b0-b786-43cc-bbe0-16159a912faf",
                "tumors_uuid": "ebaf8206-ef60-4e61-8243-458694e51d8c"
              },
              "operation": "add",
              "uuids": "e14fc53a-b7c1-4be6-9ea9-dcfb1853bcd8,416915fa-8990-4e65-972b-dd437adfd9cd"
            }
          ],
          "timeStamp": 1677193658019
        },
        "-NP-XABRclRBkeOMJymg": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R273S",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 R273S mutation is located in the DNA-binding domain of the protein. This mutation has been identified in lung cancer and is a statistically significant hotspot (PMID: 7767998). In vivo studies with yeast expressing TP53 R273S demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 R273S also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675287777540,
                    "updatedBy": "User"
                  },
                  "description_uuid": "51d919b0-b58e-487b-8a02-e91477bdd77c",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675287776137,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "b1a40a87-bf09-45f9-9e2c-e7939869f399",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675287775468,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "e5fdcc40-ceda-4592-8226-8af45e39fcac",
                  "short": ""
                },
                "mutation_effect_uuid": "e03b9db0-a04b-4a1b-9265-eaf9c0dddb90",
                "name": "R273S",
                "name_review": {
                  "added": true,
                  "updateTime": 1675287771992,
                  "updatedBy": "User"
                },
                "name_uuid": "e8ece192-4fcf-4a12-94fc-049effaff8a6",
                "tumors_uuid": "d5914078-1528-41b1-9e06-34e1365be1d2"
              },
              "operation": "add",
              "uuids": "e5fdcc40-ceda-4592-8226-8af45e39fcac,b1a40a87-bf09-45f9-9e2c-e7939869f399"
            }
          ],
          "timeStamp": 1677193689592
        },
        "-NP-XHfAcdUCmgUcDCBE": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R273P",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 R273P mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and is a statistically significant hotspot (PMID: 1734086). In vivo studies with yeast expressing TP53 R273P demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 R273P also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675287761451,
                    "updatedBy": "User"
                  },
                  "description_uuid": "727d5052-cbf9-44a8-aeb3-193d1412f32a",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675287760220,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "1cdfd7c2-7257-46ed-a235-5c41c1bae05d",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675287759494,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "b278cb0c-0b35-447d-95bc-f5d0820ee770",
                  "short": ""
                },
                "mutation_effect_uuid": "0dd7be89-8520-4165-a785-c24de0a13b4e",
                "name": "R273P",
                "name_review": {
                  "added": true,
                  "updateTime": 1675287755747,
                  "updatedBy": "User"
                },
                "name_uuid": "e003b29a-d6a7-412e-9045-4f029e253e3e",
                "tumors_uuid": "d4676d29-10db-437f-a6dd-dea73fa2275a"
              },
              "operation": "add",
              "uuids": "b278cb0c-0b35-447d-95bc-f5d0820ee770,1cdfd7c2-7257-46ed-a235-5c41c1bae05d"
            }
          ],
          "timeStamp": 1677193720231
        },
        "-NP-XPD6arPnaXmpdqpW": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "F134C",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 F134C mutation is located in the DNA-binding domain of the protein. This mutation has been identified in bladder cancer and is a statistically significant hotspot (PMID: 9014203). In vivo studies with yeast expressing TP53 F134C demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 F134C also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_editing": "",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675287725424,
                    "updatedBy": "User"
                  },
                  "description_uuid": "6718a97d-8832-4fad-8f85-f2bd781f3faf",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675287723625,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "084c437e-b0de-46fa-9312-9a9b90caea0f",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675287722897,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "6e84e1ec-8946-454e-a1fb-7f10321c38d8",
                  "short": ""
                },
                "mutation_effect_uuid": "ea691bf1-7da0-473d-a589-4a2caea5ced0",
                "name": "F134C",
                "name_review": {
                  "added": true,
                  "updateTime": 1675287719075,
                  "updatedBy": "User"
                },
                "name_uuid": "35491c44-2758-4f99-abdc-0fe1a52b9cf2",
                "tumors_uuid": "81a1c8e2-85e2-4c53-837f-568ecfd4dc26"
              },
              "operation": "add",
              "uuids": "6e84e1ec-8946-454e-a1fb-7f10321c38d8,084c437e-b0de-46fa-9312-9a9b90caea0f"
            }
          ],
          "timeStamp": 1677193751139
        },
        "-NP-XWrTANpoZYsdltJw": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Y220N",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 Y220N mutation is located in the DNA-binding domain of the protein. This mutation has been identified in hepatocellular carcinoma and is a statistically significant hotspot (PMID: 11375957). In vivo studies with yeast expressing TP53 Y220N demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 Y220N also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675287706840,
                    "updatedBy": "User"
                  },
                  "description_uuid": "41fd3514-4a0f-4f15-b892-224b73e93dc1",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675287705523,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "0d3ca595-7b31-4e46-9c9a-2e073439e79c",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675287704823,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "2218463b-3ccc-4ad6-b4a2-ea3dcb567fa0",
                  "short": ""
                },
                "mutation_effect_uuid": "87212ad6-5e3f-4fb4-a35a-ecd9d88d6c5b",
                "name": "Y220N",
                "name_review": {
                  "added": true,
                  "updateTime": 1675287699725,
                  "updatedBy": "User"
                },
                "name_uuid": "d91cf67a-f564-42eb-a082-8b9f6d3464db",
                "tumors_uuid": "1725d734-2000-4fe8-a819-6b9c9fc9c763"
              },
              "operation": "add",
              "uuids": "2218463b-3ccc-4ad6-b4a2-ea3dcb567fa0,0d3ca595-7b31-4e46-9c9a-2e073439e79c"
            }
          ],
          "timeStamp": 1677193782458
        },
        "-NP-XdMp4rnGcf5rIdp9": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "F134L",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 F134L mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and is a statistically significant hotspot (PMID: 8260732). In vivo studies with yeast expressing TP53 F134L demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 F134L also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675288181056,
                    "updatedBy": "User"
                  },
                  "description_uuid": "41a068a8-e6a4-4112-8fea-678a7dc5d592",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675288179811,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "b48bbd6f-f3a6-4f09-8cf6-bc942a49bfb7",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675288178678,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "74235ff2-0114-4c1e-bc48-8993e2922a11",
                  "short": ""
                },
                "mutation_effect_uuid": "32f82b45-feff-4092-ab7e-28e48da99df0",
                "name": "F134L",
                "name_review": {
                  "added": true,
                  "updateTime": 1675288174494,
                  "updatedBy": "User"
                },
                "name_uuid": "37319fef-1766-448f-a9e4-3d03fac18756",
                "tumors_uuid": "c85007ac-337a-453c-ab0f-5b5024d1899b"
              },
              "operation": "add",
              "uuids": "74235ff2-0114-4c1e-bc48-8993e2922a11,b48bbd6f-f3a6-4f09-8cf6-bc942a49bfb7"
            }
          ],
          "timeStamp": 1677193813201
        },
        "-NP-XkvktgYqAy31aUAa": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "F134I",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 F134I mutation is located in the DNA-binding domain of the protein. This mutation has been identified in glioma and is a statistically significant hotspot (PMID: 8561860). In vivo studies with yeast expressing TP53 F134I demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 F134I also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_editing": "",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675287929896,
                    "updatedBy": "User"
                  },
                  "description_uuid": "11130869-d1b8-4d2c-ab48-c2113b4ddd04",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675287926828,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "9cbb3d84-44f9-4322-b0db-a648e0f9134c",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675287925987,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "b929b8c0-f570-4e5b-ac50-ea4b2dc8a3ab",
                  "short": ""
                },
                "mutation_effect_uuid": "bf94d321-f23a-4dea-be20-7ed413b826d3",
                "name": "F134I",
                "name_review": {
                  "added": true,
                  "updateTime": 1675287922606,
                  "updatedBy": "User"
                },
                "name_uuid": "a24a7540-b57c-485a-b7b0-f57e8b195faf",
                "tumors_uuid": "10df6642-272f-4c84-a9ad-682d3d5fe67e"
              },
              "operation": "add",
              "uuids": "b929b8c0-f570-4e5b-ac50-ea4b2dc8a3ab,9cbb3d84-44f9-4322-b0db-a648e0f9134c"
            }
          ],
          "timeStamp": 1677193844172
        },
        "-NP-XsgUDmTkX0bDGPl0": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "F134V",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 F134V mutation is located in the DNA-binding domain of the protein. This mutation has been identified in colorectal cancer and is a statistically significant hotspot (PMID: 14633673). In vivo studies with yeast expressing TP53 F134V demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 F134V also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675287915032,
                    "updatedBy": "User"
                  },
                  "description_uuid": "b0a42a7d-2ab7-4b52-992b-aad93c5ad35c",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675287913609,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "4e6e07f3-f801-4f51-a15a-e6be1a2a48d9",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675287912905,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "1c624fa5-591a-4b8d-910e-aa7a475c64a8",
                  "short": ""
                },
                "mutation_effect_uuid": "2dbfa2ec-2a39-4924-a6da-599579f32fd2",
                "name": "F134V",
                "name_review": {
                  "added": true,
                  "updateTime": 1675287906915,
                  "updatedBy": "User"
                },
                "name_uuid": "d836809d-6a5b-4c80-9305-b56e4adae9b2",
                "tumors_uuid": "2d48cb26-d169-41f4-8a6b-d670f505be4c"
              },
              "operation": "add",
              "uuids": "1c624fa5-591a-4b8d-910e-aa7a475c64a8,4e6e07f3-f801-4f51-a15a-e6be1a2a48d9"
            }
          ],
          "timeStamp": 1677193875963
        },
        "-NP-Z2Tl-_-WBNfyF62k": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G245R",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 G245R mutation is located in the DNA-binding domain of the protein. This mutation has been identified in lung adenocarcinoma and is a statistically significant hotspot (PMID: 9627113). In vivo studies with yeast expressing TP53 G245R demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 G245R also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675288223963,
                    "updatedBy": "User"
                  },
                  "description_uuid": "5140aa05-2e9d-45ff-8a98-6636fc177c27",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675288220688,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "ecd4a668-f550-4660-ace4-9454b1d06bc9",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675288219375,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "9a0a90c5-547d-4c73-9802-9f04900e5f11",
                  "short": ""
                },
                "mutation_effect_uuid": "086a093c-8ddd-44b4-bb68-3519ded6e07b",
                "name": "G245R",
                "name_review": {
                  "added": true,
                  "updateTime": 1675288216623,
                  "updatedBy": "User"
                },
                "name_uuid": "1ed70cb1-880c-4903-b66d-7587a34eaf1b",
                "tumors_uuid": "3887faee-6635-4c32-92ef-e99831f81737"
              },
              "operation": "add",
              "uuids": "9a0a90c5-547d-4c73-9802-9f04900e5f11,ecd4a668-f550-4660-ace4-9454b1d06bc9"
            }
          ],
          "timeStamp": 1677194182285
        },
        "-NP-ZB00bxh7CpXNQ2MM": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G245V",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 G245V mutation is located in the DNA-binding domain of the protein. This mutation has been identified in lung squamous cell carcinoma and is a statistically significant hotspot (PMID: 7903781). In vivo studies with yeast expressing TP53 G245V demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 G245V also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675288241736,
                    "updatedBy": "User"
                  },
                  "description_uuid": "9561b979-73af-456a-9324-16887e07a2c8",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675288240266,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "9938a0f5-5421-4a24-90ed-c51a7b0b1e9f",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675288239361,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "c2fa718a-6009-4255-b9ea-3e7937463feb",
                  "short": ""
                },
                "mutation_effect_uuid": "8ead0cc0-8e06-456c-bcc0-f0f32f69ed46",
                "name": "G245V",
                "name_review": {
                  "added": true,
                  "updateTime": 1675288235761,
                  "updatedBy": "User"
                },
                "name_uuid": "2af5ca09-45cf-441e-a030-64eb58c603e9",
                "tumors_uuid": "e65d4556-6aba-4278-9ecd-f4118f07f9c3"
              },
              "operation": "add",
              "uuids": "c2fa718a-6009-4255-b9ea-3e7937463feb,9938a0f5-5421-4a24-90ed-c51a7b0b1e9f"
            }
          ],
          "timeStamp": 1677194217245
        },
        "-NP-ZIO76KrEvGzaNKSF": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G245N",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 G245N mutation is located in the DNA-binding domain of the protein. This mutation has been identified in squamous cell carcinoma and is a statistically significant hotspot (PMID: 1946433). In vitro studies with various human cancer cell lines expressing TP53 G245N demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675288261416,
                    "updatedBy": "User"
                  },
                  "description_uuid": "1aa5c748-e973-447b-949d-b553181ae256",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675288257204,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "1ecd4ec9-ea8f-4295-991a-481a7c53a1c6",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675288256291,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "1b5a1617-b23f-45e2-81f5-fbbea04025b8",
                  "short": ""
                },
                "mutation_effect_uuid": "a0be82eb-2869-4b13-a3cc-338836947ecd",
                "name": "G245N",
                "name_review": {
                  "added": true,
                  "updateTime": 1675288254075,
                  "updatedBy": "User"
                },
                "name_uuid": "80b35c91-0626-40eb-89d9-488c56180fd1",
                "tumors_uuid": "e725b01e-e089-4635-a9b4-d65a0ee6a696"
              },
              "operation": "add",
              "uuids": "1b5a1617-b23f-45e2-81f5-fbbea04025b8,1ecd4ec9-ea8f-4295-991a-481a7c53a1c6"
            }
          ],
          "timeStamp": 1677194247460
        },
        "-NP-ZQ1d5IT6FXasIj_X": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "S215T",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 S215T mutation is located in the DNA-binding domain of the protein. This mutation has been identified in giant cell glioblastoma and is a statistically significant hotspot (PMID: 9284834). In vivo studies with yeast expressing TP53 S215T demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 S215T also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675288559827,
                    "updatedBy": "User"
                  },
                  "description_uuid": "fcd91b69-0896-4d30-bd61-5d37169101e7",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675288556656,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "b5da045b-88ca-4f07-ac9c-3e90ddb17222",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675288555916,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "138a36fc-81ca-47b0-ac78-5c07b1296d81",
                  "short": ""
                },
                "mutation_effect_uuid": "7f35daf1-764b-45e2-a9cb-06fffbdd5dc3",
                "name": "S215T",
                "name_review": {
                  "added": true,
                  "updateTime": 1675288553495,
                  "updatedBy": "User"
                },
                "name_uuid": "36eec4f0-a8bf-4819-be2f-ae87f033948c",
                "tumors_uuid": "5d2b9369-c30f-4e5f-b2d6-aaf22dcdced4"
              },
              "operation": "add",
              "uuids": "138a36fc-81ca-47b0-ac78-5c07b1296d81,b5da045b-88ca-4f07-ac9c-3e90ddb17222"
            }
          ],
          "timeStamp": 1677194278789
        },
        "-NP-ZXbltvyeQTxGNGNn": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "S215R",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 S215R mutation is located in the DNA-binding domain of the protein. This mutation has been identified in ovarian cancer and is a statistically significant hotspot (PMID: 16907706). In vivo studies with yeast expressing TP53 S215R demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 S215R also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675288543362,
                    "updatedBy": "User"
                  },
                  "description_uuid": "47a01709-04ed-4224-b9d1-4df2046d7511",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675288540340,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "3766c612-8d4e-4c22-b23a-f1d2ccb811e6",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675288539539,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "f91185fe-c6ad-4204-8e9f-8e5a2c0ac98b",
                  "short": ""
                },
                "mutation_effect_uuid": "8ae0a3ad-0050-4ca2-896a-06629e2b7b18",
                "name": "S215R",
                "name_review": {
                  "added": true,
                  "updateTime": 1675288537002,
                  "updatedBy": "User"
                },
                "name_uuid": "30780fda-0324-41a3-b0fb-1ae1073b1bac",
                "tumors_uuid": "6317ee3c-5c0e-48a4-9c61-490781f4e20b"
              },
              "operation": "add",
              "uuids": "f91185fe-c6ad-4204-8e9f-8e5a2c0ac98b,3766c612-8d4e-4c22-b23a-f1d2ccb811e6"
            }
          ],
          "timeStamp": 1677194309837
        },
        "-NP-ZeLGYCw_HGWilD2X": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "S215I",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 S215I mutation is located in the DNA-binding domain of the protein. This mutation has been identified in non-small cell lung cancer and is a statistically significant hotspot (PMID: 10557071). In vivo studies with yeast expressing TP53 S215I demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 S215I also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675288577182,
                    "updatedBy": "User"
                  },
                  "description_uuid": "59ecf17d-834e-43fa-b0e6-8814c9afa3bf",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675288573209,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "28f17009-dfe8-48d1-b7c3-d54b8cb6ac15",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675288572324,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "562dd2d0-492f-42e8-b7f9-d82a3d17bdeb",
                  "short": ""
                },
                "mutation_effect_uuid": "139aa37a-6b3b-4788-b8c1-035c40f9468e",
                "name": "S215I",
                "name_review": {
                  "added": true,
                  "updateTime": 1675288570638,
                  "updatedBy": "User"
                },
                "name_uuid": "be208748-9c22-43ec-8eb4-1cf74b412554",
                "tumors_uuid": "bc366579-1c65-4321-9eaa-b3f7103ae84e"
              },
              "operation": "add",
              "uuids": "562dd2d0-492f-42e8-b7f9-d82a3d17bdeb,28f17009-dfe8-48d1-b7c3-d54b8cb6ac15"
            }
          ],
          "timeStamp": 1677194341485
        },
        "-NP-b0yd1FdHuJj0L3O5": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "S215N",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 S215N mutation is located in the DNA-binding domain of the protein. This mutation has been identified in colorectal cancer and is a statistically significant hotspot (PMID: 10499618). In vivo studies with yeast expressing TP53 S215N demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 S215N also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675288594773,
                    "updatedBy": "User"
                  },
                  "description_uuid": "8a4fa0f8-0e7e-4910-aa4a-6f4b7dd4ba8a",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675288591168,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "01503d51-6730-43ea-8bbd-be8753c852ec",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675288588502,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "465f18bb-d5fa-4afd-b0c0-9d0f0d3aee1a",
                  "short": ""
                },
                "mutation_effect_uuid": "5df4e38c-a584-4ca2-b6c0-1314b4aec75d",
                "name": "S215N",
                "name_review": {
                  "added": true,
                  "updateTime": 1675288586311,
                  "updatedBy": "User"
                },
                "name_uuid": "05f295ee-3286-43f9-89d9-7b4a9820e44e",
                "tumors_uuid": "05f7d989-518c-49b1-9fbd-ff27b1f20380"
              },
              "operation": "add",
              "uuids": "465f18bb-d5fa-4afd-b0c0-9d0f0d3aee1a,01503d51-6730-43ea-8bbd-be8753c852ec"
            }
          ],
          "timeStamp": 1677194962565
        },
        "-NP-b8f3z8rl2Buoj8rE": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Q144H",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 Q144H mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and is a statistically significant hotspot (PMID: 10615230). In vivo studies with yeast expressing TP53 Q144H demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675288685749,
                    "updatedBy": "User"
                  },
                  "description_uuid": "f362b701-827a-4bd5-9431-cf45f93812c2",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675288680455,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "1726f039-4618-47d6-ba34-1dc5db8a4259",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675288677830,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "c1acc1db-c0c7-441a-9fb9-9932a49a5028",
                  "short": ""
                },
                "mutation_effect_uuid": "beeaa92b-fe62-4562-bbd6-be6f2a2fe348",
                "name": "Q144H",
                "name_review": {
                  "added": true,
                  "updateTime": 1675288675996,
                  "updatedBy": "User"
                },
                "name_uuid": "b335d95b-7eb6-4bbd-9cca-a1386346031a",
                "tumors_uuid": "19b71a1f-e35f-4b83-8420-014486ea038a"
              },
              "operation": "add",
              "uuids": "c1acc1db-c0c7-441a-9fb9-9932a49a5028,1726f039-4618-47d6-ba34-1dc5db8a4259"
            }
          ],
          "timeStamp": 1677194994080
        },
        "-NP-bGEjziCVn_iI1KEH": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Y234D",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 Y234D mutation is located in the DNA-binding domain of the protein. This mutation has been identified in acute myeloid leukemia and is a statistically significant hotspot (PMID: 8824725). In vivo studies with yeast expressing TP53 Y234D demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 Y234D also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675369978524,
                    "updatedBy": "User"
                  },
                  "description_uuid": "de0567cb-4104-4092-a2be-a9ccf22feff9",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675369974296,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "ec4aa232-55f5-4e80-91f5-a30626170c94",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675369973273,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "ce18fe6a-8600-4490-abe2-2b46f7fc6049",
                  "short": ""
                },
                "mutation_effect_uuid": "c46c714a-ab0d-4316-ba1e-ad133f32c903",
                "name": "Y234D",
                "name_review": {
                  "added": true,
                  "updateTime": 1675369970957,
                  "updatedBy": "User"
                },
                "name_uuid": "a227968d-57a9-4ee1-a4eb-d281ca630aa6",
                "tumors_uuid": "e1b5bf61-4df0-474f-a20f-cae536cff5a9"
              },
              "operation": "add",
              "uuids": "ce18fe6a-8600-4490-abe2-2b46f7fc6049,ec4aa232-55f5-4e80-91f5-a30626170c94"
            }
          ],
          "timeStamp": 1677195025099
        },
        "-NP-bNmlbhJBizW_Y1FE": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Y234S",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 Y234S mutation is located in the DNA-binding domain of the protein. This mutation has been identified in ovarian cancer and is a statistically significant hotspot (PMID: 1923532). In vivo studies with yeast expressing TP53 Y234S demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 Y234S also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675369957986,
                    "updatedBy": "User"
                  },
                  "description_uuid": "d09f0a2b-61e3-45c9-8f69-17cced15aff0",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675369954561,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "ba81abfe-5f89-4c70-9bbf-5a7527e1a925",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675369953695,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "27c93ca8-a87e-4ace-aa16-9f95b6824db5",
                  "short": ""
                },
                "mutation_effect_uuid": "9e34267b-5183-4743-bf8a-08099346ca9f",
                "name": "Y234S",
                "name_review": {
                  "added": true,
                  "updateTime": 1675369950803,
                  "updatedBy": "User"
                },
                "name_uuid": "1cb83714-9e1e-4a4a-b87e-e9c3a680f602",
                "tumors_uuid": "0d7b2891-0f35-4aa6-b82b-8d591201d15e"
              },
              "operation": "add",
              "uuids": "27c93ca8-a87e-4ace-aa16-9f95b6824db5,ba81abfe-5f89-4c70-9bbf-5a7527e1a925"
            }
          ],
          "timeStamp": 1677195056013
        },
        "-NP-bVa9L53Oy_ZZXldk": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R248P",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 R248P mutation is located in the DNA-binding domain of the protein. This mutation has been identified in Burkitt cell leukemia and is a statistically significant hotspot (PMID: 9379679). In vivo studies with yeast expressing TP53 R248P demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 R248P also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675370019650,
                    "updatedBy": "User"
                  },
                  "description_uuid": "bc0a1b6e-47e5-4087-a172-6d3bf064111b",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675370016638,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "e5ef4964-08a3-4f4c-a293-5383562a2ca6",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675370015879,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "0b2fd09b-905e-4061-a7ba-810fb5426af8",
                  "short": ""
                },
                "mutation_effect_uuid": "a75a7818-4fb3-4a06-92ec-bbff5cb182ec",
                "name": "R248P",
                "name_review": {
                  "added": true,
                  "updateTime": 1675370010882,
                  "updatedBy": "User"
                },
                "name_uuid": "d00e7109-9384-4622-92f2-b18e7df54626",
                "tumors_uuid": "d6513a3f-b780-456d-82af-405c6c811c0d"
              },
              "operation": "add",
              "uuids": "0b2fd09b-905e-4061-a7ba-810fb5426af8,e5ef4964-08a3-4f4c-a293-5383562a2ca6"
            }
          ],
          "timeStamp": 1677195087974
        },
        "-NP-bcJeCkFaqEc4NUQT": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Y234N",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 Y234N mutation is located in the DNA-binding domain of the protein. This mutation has been identified in osteosarcoma and is a statistically significant hotspot (PMID: 9824113). In vivo studies with yeast expressing TP53 Y234N demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 Y234N also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675369999407,
                    "updatedBy": "User"
                  },
                  "description_uuid": "a52b0e0e-22f0-4ddb-9354-809013e24d2b",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675369995409,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "3f6956dc-0b82-4a6d-82da-092feabe22bc",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675369994539,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "1d0c3c9f-b74c-4b1d-9387-cf45e770d32b",
                  "short": ""
                },
                "mutation_effect_uuid": "f8a3826f-fc2a-4a30-b121-591af8473a01",
                "name": "Y234N",
                "name_review": {
                  "added": true,
                  "updateTime": 1675369992871,
                  "updatedBy": "User"
                },
                "name_uuid": "a6f1a96e-71bc-4990-b4d4-fcba2b8df056",
                "tumors_uuid": "a8074a20-16b5-4660-beb0-5bdb03e79fa3"
              },
              "operation": "add",
              "uuids": "1d0c3c9f-b74c-4b1d-9387-cf45e770d32b,3f6956dc-0b82-4a6d-82da-092feabe22bc"
            }
          ],
          "timeStamp": 1677195119622
        },
        "-NP-bjwVs_81kesW_Day": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "K132Q",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 K132Q mutation is located in the DNA-binding domain of the protein. This mutation has been identified in malignant lymphoma and is a statistically significant hotspot (PMID: 8314342). In vivo studies with yeast expressing TP53 K132Q demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 K132Q also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675370932819,
                    "updatedBy": "User"
                  },
                  "description_uuid": "bb06859a-4b6c-4e4b-a0a0-6ed944d65106",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675370931399,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "83053575-5b65-48cd-b557-44a68cd84b5b",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675370930379,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "de69d2ed-55b9-4529-bc34-8efdade5c4b6",
                  "short": ""
                },
                "mutation_effect_uuid": "0b9720ec-c43c-45b7-a8a5-d99d4e4b8a81",
                "name": "K132Q",
                "name_review": {
                  "added": true,
                  "updateTime": 1675370925973,
                  "updatedBy": "User"
                },
                "name_uuid": "cda880e0-d91e-4b7a-9bb0-a3e142c1c0e4",
                "tumors_uuid": "c1141856-f3af-452b-bc0f-639b8005e9f0"
              },
              "operation": "add",
              "uuids": "de69d2ed-55b9-4529-bc34-8efdade5c4b6,83053575-5b65-48cd-b557-44a68cd84b5b"
            }
          ],
          "timeStamp": 1677195150844
        },
        "-NP-brj8nuEF1ch7-Ypr": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R248G",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 R248G mutation is located in the DNA-binding domain of the protein. This mutation has been identified in prostate adenocarcinoma and is a statistically significant hotspot (PMID: 8610059). In vivo studies with yeast expressing TP53 R248G demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 R248G also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_editing": "",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675370037759,
                    "updatedBy": "User"
                  },
                  "description_uuid": "5c1b3289-e106-4eab-87bf-b63435b39f39",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675370034279,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "ce936ea3-b7d6-460d-9a61-4ec9d59836a8",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675370033513,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "86fee14e-d26d-4a9a-84f6-059fe6a8c53e",
                  "short": ""
                },
                "mutation_effect_uuid": "756ece2b-b025-4602-85fb-46e770194b94",
                "name": "R248G",
                "name_review": {
                  "added": true,
                  "updateTime": 1675370030832,
                  "updatedBy": "User"
                },
                "name_uuid": "e85d6a34-fe8c-475f-b78d-7e30d7fb7f87",
                "tumors_uuid": "db2ba8bb-f8ee-4910-9589-60687e2f8b12"
              },
              "operation": "add",
              "uuids": "86fee14e-d26d-4a9a-84f6-059fe6a8c53e,ce936ea3-b7d6-460d-9a61-4ec9d59836a8"
            }
          ],
          "timeStamp": 1677195182757
        },
        "-NP-cUcLy0Eh9XQOzIjQ": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "K132R",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 K132R mutation is located in the DNA-binding domain of the protein. This mutation has been identified in colorectal cancer and is a statistically significant hotspot (PMID: 17201907). In vivo studies with yeast expressing TP53 K132R demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 K132R also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675370949921,
                    "updatedBy": "User"
                  },
                  "description_uuid": "5411ccb5-af68-4bab-9056-1365d53bda20",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675370946359,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "03219687-723f-4e61-a6fc-e6b1ba0d48c2",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675370945512,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "e77df0e2-d12d-4d5c-892d-8082703ea364",
                  "short": ""
                },
                "mutation_effect_uuid": "e336fb49-c2e0-41aa-959c-cd1fb5ffb50f",
                "name": "K132R",
                "name_review": {
                  "added": true,
                  "updateTime": 1675370941021,
                  "updatedBy": "User"
                },
                "name_uuid": "b02825a7-f172-43e4-9424-91ea41e744b6",
                "tumors_uuid": "312e5058-3fc4-467b-93ab-9a9041433772"
              },
              "operation": "add",
              "uuids": "e77df0e2-d12d-4d5c-892d-8082703ea364,03219687-723f-4e61-a6fc-e6b1ba0d48c2"
            }
          ],
          "timeStamp": 1677195346162
        },
        "-NP-cbQ1gmHCb8BpWQRT": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "K132T",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 K132T mutation is located in the DNA-binding domain of the protein. This mutation has been identified in glioblastoma and is a statistically significant hotspot (PMID: 11221842). In vivo studies with yeast expressing TP53 K132T demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 K132T also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675370965563,
                    "updatedBy": "User"
                  },
                  "description_uuid": "23bba056-9499-458a-b1d8-30d566041446",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675370962636,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "183c2bcc-2277-41fe-b941-66085bd03a65",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675370961897,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "ea17a4da-e3fe-4d61-8a38-1858b966807d",
                  "short": ""
                },
                "mutation_effect_uuid": "b9a80023-a727-437e-b9de-907d73386279",
                "name": "K132T",
                "name_review": {
                  "added": true,
                  "updateTime": 1675370960255,
                  "updatedBy": "User"
                },
                "name_uuid": "b2892c5a-5a87-4172-a647-1bc7a74de5a6",
                "tumors_uuid": "b2f91bdd-db1a-4803-8e5c-68004e60de29"
              },
              "operation": "add",
              "uuids": "ea17a4da-e3fe-4d61-8a38-1858b966807d,183c2bcc-2277-41fe-b941-66085bd03a65"
            }
          ],
          "timeStamp": 1677195378078
        },
        "-NP-d--OBdVn4RMIHiB-": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "K132E",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 K132E mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and is a statistically significant hotspot (PMID: 15188009). In vivo studies with yeast expressing TP53 K132E demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 K132E also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675370987992,
                    "updatedBy": "User"
                  },
                  "description_uuid": "25f22674-d74b-4ec5-add1-ebe4ae7e626d",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675370984485,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "97347d7b-6750-4a93-a1ad-bc0128fd2046",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675370983614,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "f728ad35-4588-496d-971a-c89e788b5553",
                  "short": ""
                },
                "mutation_effect_uuid": "eccfb57e-9f75-427a-8ab9-ded71e6a7e73",
                "name": "K132E",
                "name_review": {
                  "added": true,
                  "updateTime": 1675370976809,
                  "updatedBy": "User"
                },
                "name_uuid": "bc856dda-41b7-4143-8d8f-b63bf6ed5a33",
                "tumors_uuid": "a1529c0c-4b7a-4a12-aa4d-7fe260271e32"
              },
              "operation": "add",
              "uuids": "f728ad35-4588-496d-971a-c89e788b5553,97347d7b-6750-4a93-a1ad-bc0128fd2046"
            }
          ],
          "timeStamp": 1677195478773
        },
        "-NP-d6okIC9R0SUfWoxy": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "K132M",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 K132M mutation is located in the DNA-binding domain of the protein. This mutation has been identified in Ewing sarcoma and is a statistically significant hotspot (PMID: 11295075). In vivo studies with yeast expressing TP53 K132M demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 K132M also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371004867,
                    "updatedBy": "User"
                  },
                  "description_uuid": "448aba27-0882-4848-b6a0-01725152291e",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371003502,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "96b3975a-ef50-4802-8d72-e0466dd1f879",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371002731,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "009fd9ca-841e-4e74-99fb-ecbc75b20a27",
                  "short": ""
                },
                "mutation_effect_uuid": "aa3e93dc-0be9-429a-85ef-37f72f86e6a1",
                "name": "K132M",
                "name_review": {
                  "added": true,
                  "updateTime": 1675370999170,
                  "updatedBy": "User"
                },
                "name_uuid": "5aaddd4c-3d96-42ab-bfe8-00ecf92efd7f",
                "tumors_uuid": "eb64bcc5-cab9-495b-b8f9-64e2449d409a"
              },
              "operation": "add",
              "uuids": "009fd9ca-841e-4e74-99fb-ecbc75b20a27,96b3975a-ef50-4802-8d72-e0466dd1f879"
            }
          ],
          "timeStamp": 1677195510796
        },
        "-NP-dEU8-YhArVFp_Lb-": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "K132N",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 K132N mutation is located in the DNA-binding domain of the protein. This mutation has been identified in non-small cell lung cancer and is a statistically significant hotspot (PMID: 17557246). In vivo studies with yeast expressing TP53 K132N demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 K132N also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371024442,
                    "updatedBy": "User"
                  },
                  "description_uuid": "495c02a6-9746-4d96-8e43-7d532214507e",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371022996,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "58e13214-d535-41c0-9b6f-28d30ca8f398",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371022101,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "99196e51-528a-46e4-b706-1c785358e7ca",
                  "short": ""
                },
                "mutation_effect_uuid": "5bf5ff5e-6f20-4e1b-9818-bee806b366ae",
                "name": "K132N",
                "name_review": {
                  "added": true,
                  "updateTime": 1675371016583,
                  "updatedBy": "User"
                },
                "name_uuid": "44441f27-17d8-4306-84bf-50fb386a8627",
                "tumors_uuid": "6367718f-2d2e-46db-a51f-e30b7537d2af"
              },
              "operation": "add",
              "uuids": "99196e51-528a-46e4-b706-1c785358e7ca,58e13214-d535-41c0-9b6f-28d30ca8f398"
            }
          ],
          "timeStamp": 1677195542181
        },
        "-NP-g5NgnQYRLlhPvAll": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "H214L",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 H214L mutation is located in the DNA-binding domain of the protein. This mutation has been identified in esophageal squamous cell carcinoma and is a statistically significant hotspot (PMID: 26873401). In vivo studies with yeast expressing TP53 H214L demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 H214L also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371041495,
                    "updatedBy": "User"
                  },
                  "description_uuid": "ba55bb6b-17b8-4eb6-a538-3441813eb7d3",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371039971,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "a605492e-aa49-49a8-ab3f-68fd59c8b9f9",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371038237,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "0fe179c9-e3a3-4cd0-9212-32a640e9652b",
                  "short": ""
                },
                "mutation_effect_uuid": "eb078fb7-4dba-4d3a-ab0c-cad22e4e3a8f",
                "name": "H214L",
                "name_review": {
                  "added": true,
                  "updateTime": 1675371034209,
                  "updatedBy": "User"
                },
                "name_uuid": "c5507de5-b1f1-4fb9-a29e-dd844d80a111",
                "tumors_uuid": "a494b5af-6ea5-4917-9ffb-ac577efcecbd"
              },
              "operation": "add",
              "uuids": "0fe179c9-e3a3-4cd0-9212-32a640e9652b,a605492e-aa49-49a8-ab3f-68fd59c8b9f9"
            }
          ],
          "timeStamp": 1677196291336
        },
        "-NP-gDFeDHqw0wDwzw1W": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "L130P",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 L130P mutation is located in the DNA-binding domain of the protein. This mutation has been identified in malignant lymphoma and is a statistically significant hotspot (PMID: 15875732). In vivo studies with yeast expressing TP53 L130P demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 L130P also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371061141,
                    "updatedBy": "User"
                  },
                  "description_uuid": "0298c531-d28e-4cd7-9355-5e077658df63",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371058374,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "62987a47-2d20-423c-9d3f-4938f4c367cc",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371059594,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "fe118a46-f238-41ea-b4a4-34dd9d76180c",
                  "short": ""
                },
                "mutation_effect_uuid": "a2a5464c-af30-4409-872d-cfa71574d5b1",
                "name": "L130P",
                "name_review": {
                  "added": true,
                  "updateTime": 1675371053067,
                  "updatedBy": "User"
                },
                "name_uuid": "c2d7872b-35cd-4417-ab29-5b52e1e6a402",
                "tumors_uuid": "b0d21455-2ad9-4efe-b7fb-c373adcddac8"
              },
              "operation": "add",
              "uuids": "fe118a46-f238-41ea-b4a4-34dd9d76180c,62987a47-2d20-423c-9d3f-4938f4c367cc"
            }
          ],
          "timeStamp": 1677196323590
        },
        "-NP-gZiocmMGGVNQ25lG": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "L130R",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 L130R mutation is located in the DNA-binding domain of the protein. This mutation has been identified in cholangiocarcinoma and is a statistically significant hotspot (PMID: 12210082). In vivo studies with yeast expressing TP53 L130R demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 L130R also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371078435,
                    "updatedBy": "User"
                  },
                  "description_uuid": "f3e2bb73-55cd-4691-ae07-9bf0f3f7e5bf",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371075145,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "bd0c288f-590c-470f-8f61-a57ebbcbaac3",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371074326,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "5a5155df-61ae-4459-9abd-58eca898d3bc",
                  "short": ""
                },
                "mutation_effect_uuid": "69de847c-9413-4049-b262-315f360bf4b9",
                "name": "L130R",
                "name_review": {
                  "added": true,
                  "updateTime": 1675371072161,
                  "updatedBy": "User"
                },
                "name_uuid": "68d30a39-0440-4f4c-c08c-961908c75ba8",
                "tumors_uuid": "004d29d2-b79b-4b58-913e-e18d7d25fac6"
              },
              "operation": "add",
              "uuids": "5a5155df-61ae-4459-9abd-58eca898d3bc,bd0c288f-590c-470f-8f61-a57ebbcbaac3"
            }
          ],
          "timeStamp": 1677196415632
        },
        "-NP-gmmtgkFcyZzJDHFc": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "L130V",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 L130V mutation is located in the DNA-binding domain of the protein. This mutation has been identified in ovarian cancer and is a statistically significant hotspot (PMID: 17171684). In vivo studies with yeast expressing TP53 L130V demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 L130V also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371096884,
                    "updatedBy": "User"
                  },
                  "description_uuid": "4b138d65-af2b-4420-b889-833d7d225b51",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371092240,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "ef200fc3-095d-4b0f-c00b-6da9e50b8130",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371091551,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "6b67fadb-1206-4e66-8251-00e98395512b",
                  "short": ""
                },
                "mutation_effect_uuid": "9df431d5-8e2d-4c4f-a866-9096fdfea587",
                "name": "L130V",
                "name_review": {
                  "added": true,
                  "updateTime": 1675371089575,
                  "updatedBy": "User"
                },
                "name_uuid": "b811dd5a-77b0-4d75-b24a-6628183f5571",
                "tumors_uuid": "5f400c70-a391-4da2-8d0f-4a739a53d401"
              },
              "operation": "add",
              "uuids": "6b67fadb-1206-4e66-8251-00e98395512b,ef200fc3-095d-4b0f-c00b-6da9e50b8130"
            }
          ],
          "timeStamp": 1677196473237
        },
        "-NP-guYOJsGIuH6UppTv": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "L130F",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 L130F mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and is a statistically significant hotspot (PMID: 11051239). In vivo studies with yeast expressing TP53 L130F demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 L130F also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371121248,
                    "updatedBy": "User"
                  },
                  "description_uuid": "880ba9e7-565c-4f9f-9225-82275a307885",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371117611,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "e0dde03b-410b-4825-8376-609306f0a132",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371116818,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "55785a9b-820e-4270-8396-85829e39d1f1",
                  "short": ""
                },
                "mutation_effect_uuid": "947858fd-903e-471a-9d02-702b835ea83d",
                "name": "L130F",
                "name_review": {
                  "added": true,
                  "updateTime": 1675371114458,
                  "updatedBy": "User"
                },
                "name_uuid": "3b37275e-f39d-4102-9f0e-426696928a16",
                "tumors_uuid": "e28afb40-4db1-4d9a-8ad0-9b147e705e0f"
              },
              "operation": "add",
              "uuids": "55785a9b-820e-4270-8396-85829e39d1f1,e0dde03b-410b-4825-8376-609306f0a132"
            }
          ],
          "timeStamp": 1677196505013
        },
        "-NP-h1FKEqW3xs62pV_0": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "L130H",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 L130H mutation is located in the DNA-binding domain of the protein. This mutation has been identified in prostate cancer and is a statistically significant hotspot (PMID: 19020536). In vivo studies with yeast expressing TP53 L130H demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 L130H also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371143468,
                    "updatedBy": "User"
                  },
                  "description_uuid": "2a9a311f-692f-48f3-8991-2a7b117e3ef8",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371137373,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "854360f1-49f1-4e36-af09-54313c43f672",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371136596,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "37705421-7861-43cc-8869-b5fb9203bd1f",
                  "short": ""
                },
                "mutation_effect_uuid": "112120fd-d726-4801-b153-ffe24018dac8",
                "name": "L130H",
                "name_review": {
                  "added": true,
                  "updateTime": 1675371134799,
                  "updatedBy": "User"
                },
                "name_uuid": "cb6ff553-6333-475e-a50c-330405390fc6",
                "tumors_uuid": "50f7c15f-c96b-4444-9a9c-1714838dcefd"
              },
              "operation": "add",
              "uuids": "37705421-7861-43cc-8869-b5fb9203bd1f,854360f1-49f1-4e36-af09-54313c43f672"
            }
          ],
          "timeStamp": 1677196536561
        },
        "-NP-hGzpl8eiWQ2fQ4qh": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "K164E",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 K164E mutation is located in the DNA-binding domain of the protein. This mutation has been identified in ovarian cancer and is a statistically significant hotspot (PMID: 9699640). In vivo studies with yeast expressing TP53 K164E demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 K164E also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371159383,
                    "updatedBy": "User"
                  },
                  "description_uuid": "323bb83b-2234-4295-88ca-2fdde20f9631",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371157830,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "a5928c78-fc9b-4e13-bf1e-d9053d994709",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371157037,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "b5d501d2-ed64-43e8-b225-b5f40aea3263",
                  "short": ""
                },
                "mutation_effect_uuid": "2c65b317-6916-4445-8a5c-11d8f22abdda",
                "name": "K164E",
                "name_review": {
                  "added": true,
                  "updateTime": 1675371153541,
                  "updatedBy": "User"
                },
                "name_uuid": "87a4413d-9335-49c5-9257-855a76109664",
                "tumors_uuid": "8d5992a8-7c88-4c91-9cba-6c3bb486560d"
              },
              "operation": "add",
              "uuids": "b5d501d2-ed64-43e8-b225-b5f40aea3263,a5928c78-fc9b-4e13-bf1e-d9053d994709"
            }
          ],
          "timeStamp": 1677196601041
        },
        "-NP-hOxAmk5ya4709xji": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "F109S",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 F109S mutation is located in the DNA-binding domain of the protein. This mutation has been identified in acute lymphoblastic leukemia and is a statistically significant hotspot (PMID: 10573131). In vivo studies with yeast expressing TP53 F109S demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 F109S also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371180168,
                    "updatedBy": "User"
                  },
                  "description_uuid": "fa6745ba-607d-401b-912b-a4cdf03ebbd4",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371175154,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "a9ff347b-b34a-42ee-9b43-4a151b57bc22",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371174186,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "9dc305dc-3c89-43c1-a223-6fba3ec9772f",
                  "short": ""
                },
                "mutation_effect_uuid": "5bd7e480-e121-40fe-9bde-53271b0c4eef",
                "name": "F109S",
                "name_review": {
                  "added": true,
                  "updateTime": 1675371172210,
                  "updatedBy": "User"
                },
                "name_uuid": "1bdd77b9-64b6-474f-b3d7-a655756161e4",
                "tumors_uuid": "bb963f09-9f81-4d08-b7e4-fa0afdf79467"
              },
              "operation": "add",
              "uuids": "9dc305dc-3c89-43c1-a223-6fba3ec9772f,a9ff347b-b34a-42ee-9b43-4a151b57bc22"
            }
          ],
          "timeStamp": 1677196633639
        },
        "-NP-hWfc-iSr_95L43sB": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "F109V",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 F109V mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and is a statistically significant hotspot (PMID: 16489069). In vivo studies with yeast expressing TP53 F109V demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 F109V also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371221694,
                    "updatedBy": "User"
                  },
                  "description_uuid": "c910203b-f374-4d19-b463-61c87a6ac72d",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371220380,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "a54425dc-550c-4e09-9d02-1292718a6dd8",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371219570,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "af277a58-8921-488a-9429-5f110517eb36",
                  "short": ""
                },
                "mutation_effect_uuid": "1e28592d-855a-4a47-8777-c4bf59cb3285",
                "name": "F109V",
                "name_review": {
                  "added": true,
                  "updateTime": 1675371214292,
                  "updatedBy": "User"
                },
                "name_uuid": "4d26f924-93ca-4fbc-998e-041961c3fcb7",
                "tumors_uuid": "aa224c13-3145-4408-8123-cd29c95a9b82"
              },
              "operation": "add",
              "uuids": "af277a58-8921-488a-9429-5f110517eb36,a54425dc-550c-4e09-9d02-1292718a6dd8"
            }
          ],
          "timeStamp": 1677196665284
        },
        "-NP-hdTL2ceOEe9yHmeJ": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "F109C",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 F109C mutation is located in the DNA-binding domain of the protein. This mutation has been identified in ovarian cancer and is a statistically significant hotspot (PMID: 21720365). In vivo studies with yeast expressing TP53 F109C demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 F109C also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371200946,
                    "updatedBy": "User"
                  },
                  "description_uuid": "e896304e-05f3-4af5-be57-6e652c48268f",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371199632,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "53c403ce-c4c8-4b7a-ad34-713319746af1",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371198893,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "d0daea4f-4300-4794-8e0b-0e09eec91b43",
                  "short": ""
                },
                "mutation_effect_uuid": "3e8fc7c4-e2da-4311-8526-f69c81fcb119",
                "name": "F109C",
                "name_review": {
                  "added": true,
                  "updateTime": 1675371191657,
                  "updatedBy": "User"
                },
                "name_uuid": "4ae9408e-d878-4963-8a32-31e6719ec16e",
                "tumors_uuid": "5475254a-0daa-48cd-bd3d-176ef2145c03"
              },
              "operation": "add",
              "uuids": "d0daea4f-4300-4794-8e0b-0e09eec91b43,53c403ce-c4c8-4b7a-ad34-713319746af1"
            }
          ],
          "timeStamp": 1677196697202
        },
        "-NP-hlF1RK2CwWAzwU7s": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "F109I",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 F109I mutation is located in the DNA-binding domain of the protein. This mutation has been identified in penile squamous cell carcinoma and is a statistically significant hotspot (PMID: 26670561). In vivo studies with yeast expressing TP53 F109I demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 F109I also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371242836,
                    "updatedBy": "User"
                  },
                  "description_uuid": "86438986-375a-4780-aaa9-45fc53314fa1",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371239255,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "2ba2d557-5471-415f-93bc-849a30776898",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371238501,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "523633ac-495c-4e76-972b-8c1fc30ae83d",
                  "short": ""
                },
                "mutation_effect_uuid": "9bebb526-eeab-4a70-a515-820956704b6c",
                "name": "F109I",
                "name_review": {
                  "added": true,
                  "updateTime": 1675371235948,
                  "updatedBy": "User"
                },
                "name_uuid": "ab704686-5e4c-43fc-96ae-6ad43bb91e0d",
                "tumors_uuid": "4e03e72c-99a3-465c-9ae0-6aab6cad9905"
              },
              "operation": "add",
              "uuids": "523633ac-495c-4e76-972b-8c1fc30ae83d,2ba2d557-5471-415f-93bc-849a30776898"
            }
          ],
          "timeStamp": 1677196729054
        },
        "-NP-hwgcJBLJzlz473d0": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G105R",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 G105R mutation is located in the DNA-binding domain of the protein. This mutation has been identified in ovarian cancer and is a statistically significant hotspot (PMID: 9699640). In vivo studies with yeast expressing TP53 G105R demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 G105R also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371261831,
                    "updatedBy": "User"
                  },
                  "description_uuid": "eaad4cf7-24ea-4d4f-8762-c405b24e9e59",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371260108,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "2e55007e-8646-44bd-bc6d-418ff4127029",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371259281,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "09bac2c2-4a8f-4dc8-a1a8-11dd405dd692",
                  "short": ""
                },
                "mutation_effect_uuid": "9c271522-133d-4cb1-8164-48d36d8f1de8",
                "name": "G105R",
                "name_review": {
                  "added": true,
                  "updateTime": 1675371253735,
                  "updatedBy": "User"
                },
                "name_uuid": "e8c5e462-b02b-4304-934d-438d4ac73915",
                "tumors_uuid": "a42ec8b6-a799-4f4f-939e-fd4a7dca4210"
              },
              "operation": "add",
              "uuids": "09bac2c2-4a8f-4dc8-a1a8-11dd405dd692,2e55007e-8646-44bd-bc6d-418ff4127029"
            }
          ],
          "timeStamp": 1677196775940
        },
        "-NP-i3y8D7CMH9cK4vwi": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G105S",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 G105S mutation is located in the DNA-binding domain of the protein. This mutation has been identified in glioblastoma and is a statistically significant hotspot (PMID: 15035290). In vivo studies with yeast expressing TP53 G105S demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371315051,
                    "updatedBy": "User"
                  },
                  "description_uuid": "b025f826-26c9-4045-9cda-c4b89d4338e1",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371309161,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "927b4ab9-b20d-462e-81f8-8df84bcbdced",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371307790,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "75b8ee0c-7b3a-4200-95b7-05f232c7bf94",
                  "short": ""
                },
                "mutation_effect_uuid": "189b6d52-3a5c-46df-bef6-5862439fa100",
                "name": "G105S",
                "name_review": {
                  "added": true,
                  "updateTime": 1675371305359,
                  "updatedBy": "User"
                },
                "name_uuid": "f36e9ac6-72f7-468f-a199-09d79e98ba30",
                "tumors_uuid": "f458ed45-a265-406c-b410-40b7953e42ca"
              },
              "operation": "add",
              "uuids": "75b8ee0c-7b3a-4200-95b7-05f232c7bf94,927b4ab9-b20d-462e-81f8-8df84bcbdced"
            }
          ],
          "timeStamp": 1677196809829
        },
        "-NP-iBoGS4eqq8iLOe2E": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G105C",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 G105C mutation is located in the DNA-binding domain of the protein. This mutation has been identified in glioblastoma and is a statistically significant hotspot (PMID: 18772890). In vivo studies with yeast expressing TP53 G105C demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371284085,
                    "updatedBy": "User"
                  },
                  "description_uuid": "1665948f-30c7-484c-8795-ea378e2c1158",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371279852,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "798b8061-c885-47bb-8729-b450f95152eb",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371278629,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "326059a9-478c-4802-8833-35f25f05c5a8",
                  "short": ""
                },
                "mutation_effect_uuid": "e0a8be64-5783-4b64-8221-2a277e4104ef",
                "name": "G105C",
                "name_review": {
                  "added": true,
                  "updateTime": 1675371276714,
                  "updatedBy": "User"
                },
                "name_uuid": "af4e1b4a-78d8-4308-8633-ee34420ed791",
                "tumors_uuid": "487b9d37-4dbb-4dee-b075-db805288407f"
              },
              "operation": "add",
              "uuids": "326059a9-478c-4802-8833-35f25f05c5a8,798b8061-c885-47bb-8729-b450f95152eb"
            }
          ],
          "timeStamp": 1677196841965
        },
        "-NP-j6bGq2weagA0Z4gw": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G105D",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 G105D mutation is located in the DNA-binding domain of the protein. This mutation has been identified in glioblastoma and is a statistically significant hotspot (PMID: 15466178). In vivo studies with yeast expressing TP53 G105D demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 G105D also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371333415,
                    "updatedBy": "User"
                  },
                  "description_uuid": "7ac7d8e8-65b2-4fb3-9495-8d09501bde38",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371328425,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "a8b36404-c919-4661-b5a7-477c9265199e",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371326864,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "b51de8d6-3137-4573-a8a1-3ea365f6d8cb",
                  "short": ""
                },
                "mutation_effect_uuid": "325453fe-acee-40e7-9d05-7323b2d60cde",
                "name": "G105D",
                "name_review": {
                  "added": true,
                  "updateTime": 1675371325092,
                  "updatedBy": "User"
                },
                "name_uuid": "c5fa81a3-a0b4-4b66-81ea-6b376d37252e",
                "tumors_uuid": "b29aea16-a1dc-485c-9166-3b25f1f668f1"
              },
              "operation": "add",
              "uuids": "b51de8d6-3137-4573-a8a1-3ea365f6d8cb,a8b36404-c919-4661-b5a7-477c9265199e"
            }
          ],
          "timeStamp": 1677197082797
        },
        "-NP-jEs5G2_fLb53b5Jf": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "E271Q",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 E271Q mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and is a statistically significant hotspot (PMID: 11929815). In vivo studies with yeast expressing TP53 E271Q demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371380455,
                    "updatedBy": "User"
                  },
                  "description_uuid": "2c74d0d3-65fe-4b36-b2b3-c3fcf132d1d8",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371370942,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "40ecec3a-9808-4671-8f9d-6fa10aa135c6",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371370287,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "9fb92a6f-d944-467e-a3ba-5bb3c19ff398",
                  "short": ""
                },
                "mutation_effect_uuid": "604e2ccf-383b-400f-a3a0-ea83e4d171c0",
                "name": "E271Q",
                "name_review": {
                  "added": true,
                  "updateTime": 1675371368203,
                  "updatedBy": "User"
                },
                "name_uuid": "4e7a1017-0554-4787-9c4e-d99f9c53c998",
                "tumors_uuid": "98918bc3-c607-4dfc-98a7-26e564209aab"
              },
              "operation": "add",
              "uuids": "9fb92a6f-d944-467e-a3ba-5bb3c19ff398,40ecec3a-9808-4671-8f9d-6fa10aa135c6"
            }
          ],
          "timeStamp": 1677197116642
        },
        "-NP-jMxlKT449aM1IELY": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G105V",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 G105V mutation is located in the DNA-binding domain of the protein. This mutation has been identified in ovarian cancer and is a statistically significant hotspot (PMID: 14519637). In vivo studies with yeast expressing TP53 G105V demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371356103,
                    "updatedBy": "User"
                  },
                  "description_uuid": "003089dc-b71b-4376-94e7-f697107a907b",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371352571,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "3a8dc31c-5c99-406c-9a13-175a7e549646",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371351031,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "61f60bc1-737b-4721-955e-4799fc3212ff",
                  "short": ""
                },
                "mutation_effect_uuid": "d47b0ac6-31a2-4733-9db5-710c3ebfc69e",
                "name": "G105V",
                "name_review": {
                  "added": true,
                  "updateTime": 1675371344487,
                  "updatedBy": "User"
                },
                "name_uuid": "822e7afe-8e5d-4f1f-82e0-070a21976c28",
                "tumors_uuid": "bbe60460-78e0-433e-bb41-bdfbfe00a929"
              },
              "operation": "add",
              "uuids": "61f60bc1-737b-4721-955e-4799fc3212ff,3a8dc31c-5c99-406c-9a13-175a7e549646"
            }
          ],
          "timeStamp": 1677197149773
        },
        "-NP-jUsQlkXcP9WNV2lX": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "E271V",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 E271V mutation is located in the DNA-binding domain of the protein. This mutation has been identified in bladder cancer and is a statistically significant hotspot (PMID: 7628866). In vivo studies with yeast expressing TP53 E271V demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 E271V also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371396916,
                    "updatedBy": "User"
                  },
                  "description_uuid": "af8f4df5-7b04-4fff-9f1d-dd902977e9e1",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371393812,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "8a8f6b3a-61d6-4929-bbd4-32b819d22fac",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371393198,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "3acc0172-dee2-4f85-b2cb-a5b66c8b2ddf",
                  "short": ""
                },
                "mutation_effect_uuid": "cf05136e-66a1-4984-912a-240c83a53db2",
                "name": "E271V",
                "name_review": {
                  "added": true,
                  "updateTime": 1675371391163,
                  "updatedBy": "User"
                },
                "name_uuid": "9af08c59-f826-48bf-bcaf-50b474ae4149",
                "tumors_uuid": "370dd23b-6db8-4f47-a509-594fbebb05b3"
              },
              "operation": "add",
              "uuids": "3acc0172-dee2-4f85-b2cb-a5b66c8b2ddf,8a8f6b3a-61d6-4929-bbd4-32b819d22fac"
            }
          ],
          "timeStamp": 1677197182199
        },
        "-NP-jbuAtpD0rPNLJGB3": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V172G",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 V172G mutation is located in the DNA-binding domain of the protein. This mutation has been identified in hepatocellular carcinoma and is a statistically significant hotspot (PMID: 8108145). In vivo studies with yeast expressing TP53 V172G demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 V172G also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371444428,
                    "updatedBy": "User"
                  },
                  "description_uuid": "5aec788b-f556-4b57-89fb-0eb1cbbd8bf8",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371443111,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "06dd1bbd-e484-4b63-912f-dd60f0b7f257",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371442205,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "91b64288-435a-4997-8d75-b836d8126890",
                  "short": ""
                },
                "mutation_effect_uuid": "7cd8f8b9-3657-432f-a786-2e3567f83240",
                "name": "V172G",
                "name_review": {
                  "added": true,
                  "updateTime": 1675371437863,
                  "updatedBy": "User"
                },
                "name_uuid": "8a800462-40da-4ba9-a273-30cfdc08cac2",
                "tumors_uuid": "2148b721-a154-4b67-af1c-229776b8dfbd"
              },
              "operation": "add",
              "uuids": "91b64288-435a-4997-8d75-b836d8126890,06dd1bbd-e484-4b63-912f-dd60f0b7f257"
            }
          ],
          "timeStamp": 1677197215079
        },
        "-NP-jju-ncD92ri_xcdO": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V172D",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 V172D mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and is a statistically significant hotspot (PMID: 7712430). In vivo studies with yeast expressing TP53 V172D demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 V172D also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371422569,
                    "updatedBy": "User"
                  },
                  "description_uuid": "30c3c97f-4300-4acd-818b-24b5e3f5b103",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371418637,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "7b5883c3-3fff-450e-81bf-c2955375127b",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371417496,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "2f34edc2-655b-4b9c-b919-d3d2124b5959",
                  "short": ""
                },
                "mutation_effect_uuid": "52046bf3-58ab-4220-9368-75c1f3f711f5",
                "name": "V172D",
                "name_review": {
                  "added": true,
                  "updateTime": 1675371412723,
                  "updatedBy": "User"
                },
                "name_uuid": "1ec07f7b-6f05-47d4-a639-9e2014733e7f",
                "tumors_uuid": "565d0dd9-4ac8-4fa8-b1cd-49a13c8314fe"
              },
              "operation": "add",
              "uuids": "2f34edc2-655b-4b9c-b919-d3d2124b5959,7b5883c3-3fff-450e-81bf-c2955375127b"
            }
          ],
          "timeStamp": 1677197247836
        },
        "-NP-jrossTO-VKke0EEE": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "L257Q",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 L257Q mutation is located in the DNA-binding domain of the protein. This mutation has been identified in ovarian cancer and is a statistically significant hotspot (PMID: 20229506). In vivo studies with yeast expressing TP53 L257Q demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 L257Q also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371510770,
                    "updatedBy": "User"
                  },
                  "description_uuid": "95dca8bc-5b5b-4572-91d4-740675cadfa0",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371506988,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "c410c596-c32f-4b39-8691-c8f8c035c043",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371506160,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "2947f759-fb3e-4c1a-bd05-9a7ce55db031",
                  "short": ""
                },
                "mutation_effect_uuid": "dadeeaf4-e11c-4654-9cea-47349945fcfe",
                "name": "L257Q",
                "name_review": {
                  "added": true,
                  "updateTime": 1675371503651,
                  "updatedBy": "User"
                },
                "name_uuid": "28c27828-a1d9-4aa2-9025-711e7d087d77",
                "tumors_uuid": "462c38c8-0e4f-4502-8e4a-44f357a0e997"
              },
              "operation": "add",
              "uuids": "2947f759-fb3e-4c1a-bd05-9a7ce55db031,c410c596-c32f-4b39-8691-c8f8c035c043"
            }
          ],
          "timeStamp": 1677197280276
        },
        "-NP-jzk5qbXvJPeoRnnz": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "L257P",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 L257P mutation is located in the DNA-binding domain of the protein. This mutation has been identified in malignant lymphoma and is a statistically significant hotspot (PMID: 1375111). In vivo studies with yeast expressing TP53 L257P demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 L257P also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371488926,
                    "updatedBy": "User"
                  },
                  "description_uuid": "114f83fb-114a-4e16-8e8e-c4a19e541ee0",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371487156,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "963a78f3-0a2f-4ace-ba6b-6e79a09afa07",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371486383,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "d675b61e-2df6-4e75-8c28-f28c077b6705",
                  "short": ""
                },
                "mutation_effect_uuid": "c59eb4f1-f5db-41f9-8ccd-a688266ee4bd",
                "name": "L257P",
                "name_review": {
                  "added": true,
                  "updateTime": 1675371480703,
                  "updatedBy": "User"
                },
                "name_uuid": "d88ac102-f964-48bc-a858-e6958ff4c17c",
                "tumors_uuid": "6d23d0a4-1766-430e-9c7a-83692fe0fada"
              },
              "operation": "add",
              "uuids": "d675b61e-2df6-4e75-8c28-f28c077b6705,963a78f3-0a2f-4ace-ba6b-6e79a09afa07"
            }
          ],
          "timeStamp": 1677197312738
        },
        "-NP-k6yVpHxuHbLK2hTt": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "T155I",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 T155I mutation is located in the DNA-binding domain of the protein. This mutation has been identified in lung adenocarcinoma and is a statistically significant hotspot (PMID: 11400116). In vivo studies with yeast expressing TP53 T155I demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 T155I also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371468129,
                    "updatedBy": "User"
                  },
                  "description_uuid": "ac3732ae-5979-4c64-9828-702f080df52c",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371463545,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "5aee1f19-8652-466c-be94-521faa3608e6",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371460957,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "5d4710c9-4e32-4c9a-9a87-1fb63274fe13",
                  "short": ""
                },
                "mutation_effect_uuid": "a45575e9-9b6e-4061-9f9c-dfcbf98f7f03",
                "name": "T155I",
                "name_review": {
                  "added": true,
                  "updateTime": 1675371458821,
                  "updatedBy": "User"
                },
                "name_uuid": "9d07aacb-0b20-4090-8800-84b1af56914e",
                "tumors_uuid": "408732f3-3147-466a-ad7a-a1063e557a1b"
              },
              "operation": "add",
              "uuids": "5d4710c9-4e32-4c9a-9a87-1fb63274fe13,5aee1f19-8652-466c-be94-521faa3608e6"
            }
          ],
          "timeStamp": 1677197346428
        },
        "-NP-kEw5Dn34YZry4XFn": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "L257V",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 L257V mutation is located in the DNA-binding domain of the protein. This mutation has been identified in glioma and is a statistically significant hotspot (PMID: 12635658). In vivo studies with yeast expressing TP53 L257V demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 L257V also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371553186,
                    "updatedBy": "User"
                  },
                  "description_uuid": "074f73d4-7d4a-4d04-a282-e3bd6f3dc45b",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371549367,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "97bae24c-add8-4ad9-b793-0410baa2f451",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371548577,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "b9b52009-122d-4cf5-941a-ec3d5791b385",
                  "short": ""
                },
                "mutation_effect_uuid": "16d9d093-0a55-423d-be37-c7233918d212",
                "name": "L257V",
                "name_review": {
                  "added": true,
                  "updateTime": 1675371544704,
                  "updatedBy": "User"
                },
                "name_uuid": "ffa44dc5-0bc3-4957-961a-367762d5af64",
                "tumors_uuid": "64c5568f-7377-4530-af73-df923b51bb92"
              },
              "operation": "add",
              "uuids": "b9b52009-122d-4cf5-941a-ec3d5791b385,97bae24c-add8-4ad9-b793-0410baa2f451"
            }
          ],
          "timeStamp": 1677197379042
        },
        "-NP-kMvEstuHv_0x5Prs": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "L257R",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 L257R mutation is located in the DNA-binding domain of the protein. This mutation has been identified in ovarian cancer and is a statistically significant hotspot (PMID: 8700537). In vivo studies with yeast expressing TP53 L257R demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 L257R also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371533272,
                    "updatedBy": "User"
                  },
                  "description_uuid": "987942ab-96b4-4e50-81db-2d2c35e7fa87",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371531709,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "eaf95a60-da3e-4109-8270-a7005ab78001",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371530828,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "c74bc26e-0ec8-4bfb-9c2d-151574046249",
                  "short": ""
                },
                "mutation_effect_uuid": "968ea4d8-7fb1-4f73-94ca-e912e8a77c92",
                "name": "L257R",
                "name_review": {
                  "added": true,
                  "updateTime": 1675371525939,
                  "updatedBy": "User"
                },
                "name_uuid": "794af2c6-3c3b-4acf-8c2c-be4a13825e25",
                "tumors_uuid": "05009c9d-0656-48d8-91d4-3a3609c22358"
              },
              "operation": "add",
              "uuids": "c74bc26e-0ec8-4bfb-9c2d-151574046249,eaf95a60-da3e-4109-8270-a7005ab78001"
            }
          ],
          "timeStamp": 1677197411755
        },
        "-NP-kZGiMl7LG9DtBRB8": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "N131I",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 N131I mutation is located in the DNA-binding domain of the protein. This mutation has been identified in bladder cancer and is a statistically significant hotspot (PMID: 10492244). In vivo studies with yeast expressing TP53 N131I demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 N131I also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371575206,
                    "updatedBy": "User"
                  },
                  "description_uuid": "f798613b-3e48-4d69-b0db-6a3d755a8058",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371569437,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "f90e9c7c-a7ed-45a9-b0ed-34e4d7bc6706",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371568567,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "384bf3a8-0dbb-4723-a34f-5463e4dededc",
                  "short": ""
                },
                "mutation_effect_uuid": "9aa9aa4c-1829-482f-8d70-a1cb41b8fea1",
                "name": "N131I",
                "name_review": {
                  "added": true,
                  "updateTime": 1675371566419,
                  "updatedBy": "User"
                },
                "name_uuid": "7f2aec9c-c80b-4fe0-bbbd-e917c154aea9",
                "tumors_uuid": "490b15dc-f185-4ff7-bc3c-2d004d2b10fc"
              },
              "operation": "add",
              "uuids": "384bf3a8-0dbb-4723-a34f-5463e4dededc,f90e9c7c-a7ed-45a9-b0ed-34e4d7bc6706"
            }
          ],
          "timeStamp": 1677197462346
        },
        "-NP-kgM9soT7T8x0bTLo": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "N131K",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 N131K mutation is located in the DNA-binding domain of the protein. This mutation has been identified in esophageal squamous cell carcinoma and is a statistically significant hotspot (PMID: 16271069). In vivo studies with yeast expressing TP53 N131K demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371597047,
                    "updatedBy": "User"
                  },
                  "description_uuid": "f35cdac9-612c-4244-a636-40848c7e2648",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371593055,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "f98965dd-f01e-4474-a464-c8df17f361da",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371592091,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "a8fe2092-4636-47b6-8f95-4fd09633a1f8",
                  "short": ""
                },
                "mutation_effect_uuid": "354e2888-3534-4a2a-b625-6b880108141b",
                "name": "N131K",
                "name_review": {
                  "added": true,
                  "updateTime": 1675371588748,
                  "updatedBy": "User"
                },
                "name_uuid": "f63c4fdf-5a5b-45b0-ace9-70c364309ae4",
                "tumors_uuid": "0779a0d2-332f-4e07-a5bf-e1164e994c88"
              },
              "operation": "add",
              "uuids": "a8fe2092-4636-47b6-8f95-4fd09633a1f8,f98965dd-f01e-4474-a464-c8df17f361da"
            }
          ],
          "timeStamp": 1677197495462
        },
        "-NP-koKFEJqVdkK2ytpQ": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "L265R",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 L265R mutation is located in the DNA-binding domain of the protein. This mutation has been identified in colorectal cancer and is a statistically significant hotspot (PMID: 11307149). In vivo studies with yeast expressing TP53 L265R demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 L265R also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371804232,
                    "updatedBy": "User"
                  },
                  "description_uuid": "6c07c5d4-7f5f-44d4-99c9-3bd0dfa18969",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371800680,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "a0e182ae-d4a4-4b34-a4c2-167e24e1a16e",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371799396,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "b8dee627-770b-4213-82e6-383a73f72a16",
                  "short": ""
                },
                "mutation_effect_uuid": "bd4551f0-f37c-4295-8c44-20c50edbc927",
                "name": "L265R",
                "name_review": {
                  "added": true,
                  "updateTime": 1675371796346,
                  "updatedBy": "User"
                },
                "name_uuid": "a7a64326-0de1-4d57-8230-aa558048599c",
                "tumors_uuid": "9aa88d02-7014-4a92-9de7-405680df69cb"
              },
              "operation": "add",
              "uuids": "b8dee627-770b-4213-82e6-383a73f72a16,a0e182ae-d4a4-4b34-a4c2-167e24e1a16e"
            }
          ],
          "timeStamp": 1677197528108
        },
        "-NP-kwWBUUNwAGB-i72I": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "L265P",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 L265P mutation is located in the DNA-binding domain of the protein. This mutation has been identified in ovarian cancer and is a statistically significant hotspot (PMID: 14760384). In vivo studies with yeast expressing TP53 L265P demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 L265P also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371615769,
                    "updatedBy": "User"
                  },
                  "description_uuid": "dad6da3d-1880-45e6-b9d5-2e5347d62094",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371611222,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "15dfb079-b60c-418b-b80c-c492000af976",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371609767,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "3c3aade7-7c32-4361-893f-25eec3101688",
                  "short": ""
                },
                "mutation_effect_uuid": "92c72f48-04f4-40e3-b3f5-aa6a0810b08f",
                "name": "L265P",
                "name_review": {
                  "added": true,
                  "updateTime": 1675371607457,
                  "updatedBy": "User"
                },
                "name_uuid": "b47f8cde-063f-4569-a211-692be9999598",
                "tumors_uuid": "2d58314f-8746-4ed4-a05d-af15bf4a66ef"
              },
              "operation": "add",
              "uuids": "3c3aade7-7c32-4361-893f-25eec3101688,15dfb079-b60c-418b-b80c-c492000af976"
            }
          ],
          "timeStamp": 1677197561640
        },
        "-NP-l3fBlKQK5DqxejNM": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G262V",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 G262V mutation is located in the DNA-binding domain of the protein. This mutation has been identified in colorectal cancer and is a statistically significant hotspot (PMID: 11307149). In vivo studies with yeast expressing TP53 G262V demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 G262V also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371842391,
                    "updatedBy": "User"
                  },
                  "description_uuid": "7cb5cffe-ab57-49b7-8dfe-10a6c3ad8463",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371838572,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "5aa75f46-53ed-4ff9-b3e7-ee7d1b7874a0",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371837030,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "9ec6d731-1746-4e30-b05e-49da6c1f5028",
                  "short": ""
                },
                "mutation_effect_uuid": "74ef7ad6-4aba-435f-b3e3-2f7e9d53d1ad",
                "name": "G262V",
                "name_review": {
                  "added": true,
                  "updateTime": 1675371835132,
                  "updatedBy": "User"
                },
                "name_uuid": "509276d0-089e-49e9-8dec-c72630657e12",
                "tumors_uuid": "1495ca9d-2bd0-474e-82d2-9bae8c8a6372"
              },
              "operation": "add",
              "uuids": "9ec6d731-1746-4e30-b05e-49da6c1f5028,5aa75f46-53ed-4ff9-b3e7-ee7d1b7874a0"
            }
          ],
          "timeStamp": 1677197595048
        },
        "-NP-lBep9ifoW3nFY_HG": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "L265M",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 L265M mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and is a statistically significant hotspot (PMID: 15050734). There is conflicting evidence about the biological and oncogenic effect of the mutation. In vivo studies with yeast expressing TP53 L265M demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). However, other in vitro studies with various human cancer cell lines expressing TP53 L265M demonstrated that the mutation is likely neutral as measured by wildtype comparable growth suppression activity (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371821120,
                    "updatedBy": "User"
                  },
                  "description_uuid": "19bcad64-1599-48bb-89a9-ab9259295ef7",
                  "effect": "Inconclusive",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371817452,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "cfb2f296-d497-420e-c0ec-24e9a3deeacd",
                  "oncogenic": "Inconclusive",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371816725,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "946a1d0f-f5d7-47f5-ae85-1e83e68449d4",
                  "short": ""
                },
                "mutation_effect_uuid": "541abd36-70f5-4eb2-a129-1226adb18e8e",
                "name": "L265M",
                "name_review": {
                  "added": true,
                  "updateTime": 1675371814696,
                  "updatedBy": "User"
                },
                "name_uuid": "6c087e5e-db90-48d7-9978-988c22d2a64c",
                "tumors_uuid": "9dbf8473-785b-475e-ba9b-e27d754d0453"
              },
              "operation": "add",
              "uuids": "946a1d0f-f5d7-47f5-ae85-1e83e68449d4,cfb2f296-d497-420e-c0ec-24e9a3deeacd"
            }
          ],
          "timeStamp": 1677197627793
        },
        "-NP-lhAx1uZfeQozlBu5": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "F113C",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 F113C mutation is located in the DNA-binding domain of the protein. This mutation has been identified in lung adenocarcinoma and is a statistically significant hotspot (PMID: 1312896). In vivo studies with yeast expressing TP53 F113C demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 F113C also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371860819,
                    "updatedBy": "User"
                  },
                  "description_uuid": "6b445bf0-4410-42f3-90e4-9c3e86867ab1",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371859392,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "898ffa44-411c-4208-9881-91cd83542a76",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371858693,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "18a5ba78-fa38-4d3c-a450-f68c57b44bcf",
                  "short": ""
                },
                "mutation_effect_uuid": "cff50094-605d-4a46-a1ca-9a26d80bdf16",
                "name": "F113C",
                "name_review": {
                  "added": true,
                  "updateTime": 1675371853609,
                  "updatedBy": "User"
                },
                "name_uuid": "9eef746f-75a3-4753-a963-01d2c9596872",
                "tumors_uuid": "9baebcc3-412a-4136-91f2-82186fb79b84"
              },
              "operation": "add",
              "uuids": "18a5ba78-fa38-4d3c-a450-f68c57b44bcf,898ffa44-411c-4208-9881-91cd83542a76"
            }
          ],
          "timeStamp": 1677197760985
        },
        "-NP-lpWD9f7WSE3uCbOz": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "F113S",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 F113S mutation is located in the DNA-binding domain of the protein. This mutation has been identified in colorectal cancer and is a statistically significant hotspot (PMID: 12242668). In vivo studies with yeast expressing TP53 F113S demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 F113S also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371879494,
                    "updatedBy": "User"
                  },
                  "description_uuid": "c71b7486-34f3-4e72-a735-0c1e8872cfc7",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371875765,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "be540e00-6fa8-4778-8330-4bd8b38851fa",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371874835,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "ee003982-469f-495e-a566-0a1ed2e775dd",
                  "short": ""
                },
                "mutation_effect_uuid": "b181d139-91b7-4f74-a824-1cd24678a84d",
                "name": "F113S",
                "name_review": {
                  "added": true,
                  "updateTime": 1675371872844,
                  "updatedBy": "User"
                },
                "name_uuid": "d00f5fda-2a1e-49b2-b02a-e69b7262c9af",
                "tumors_uuid": "9016ef2a-f082-4fe5-b0a8-e33fe9701b61"
              },
              "operation": "add",
              "uuids": "ee003982-469f-495e-a566-0a1ed2e775dd,be540e00-6fa8-4778-8330-4bd8b38851fa"
            }
          ],
          "timeStamp": 1677197795114
        },
        "-NP-lxgKtxo0gw27gKOP": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "F113V",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 F113V mutation is located in the DNA-binding domain of the protein. This mutation has been identified in astrocytoma and is a statistically significant hotspot (PMID: 15188009). In vivo studies with yeast expressing TP53 F113V demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 F113V also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371897967,
                    "updatedBy": "User"
                  },
                  "description_uuid": "97f3cc5c-58f7-42ff-bf20-a7f248bb247c",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371892675,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "ddc53f3e-c2cf-4780-9dba-6b85f4645a8d",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371891868,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "51db914f-e8f9-40ad-b12f-6cfa0b8a6161",
                  "short": ""
                },
                "mutation_effect_uuid": "84e5f604-4d51-4ca8-9257-7a52a18b174c",
                "name": "F113V",
                "name_review": {
                  "added": true,
                  "updateTime": 1675371888425,
                  "updatedBy": "User"
                },
                "name_uuid": "aa2f2bda-ccf1-4696-9bde-12abc3cd4cdc",
                "tumors_uuid": "33a82fa0-e37f-4106-8a89-b67f02e12d55"
              },
              "operation": "add",
              "uuids": "51db914f-e8f9-40ad-b12f-6cfa0b8a6161,ddc53f3e-c2cf-4780-9dba-6b85f4645a8d"
            }
          ],
          "timeStamp": 1677197828593
        },
        "-NP-mIC13oCv4XhtlEtz": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "F113L",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 F113L mutation is located in the DNA-binding domain of the protein. This mutation has been identified in bladder cancer and is a statistically significant hotspot (PMID: 16532037). There is conflicting evidence about the biological and oncogenic effect of the mutation. In vivo studies with yeast expressing TP53 F113L demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). However, other in vitro studies with various human cancer cell lines expressing TP53 F113L demonstrated that the mutation is likely neutral as measured by growth suppression activity comparable to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1677197869531,
                    "updatedBy": "User"
                  },
                  "description_uuid": "7b6704d2-3ffa-4919-ba5e-5553cb5fadcc",
                  "effect": "Inconclusive",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371912864,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "a3f6813b-7927-42fb-bb7c-4c4357892c64",
                  "oncogenic": "Inconclusive",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371911851,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "1c2b0cfd-de90-4681-866f-1aaf090f1bae",
                  "short": ""
                },
                "mutation_effect_uuid": "c0c8c6a2-7a9b-4aca-8211-cc18d225c9a8",
                "name": "F113L",
                "name_review": {
                  "added": true,
                  "updateTime": 1675371909441,
                  "updatedBy": "User"
                },
                "name_uuid": "e11eaeba-2361-4f2c-81a5-0f6cdb7f47e5",
                "tumors_uuid": "91192c2b-2921-4d49-94ae-fff82da5d2ab"
              },
              "operation": "add",
              "uuids": "1c2b0cfd-de90-4681-866f-1aaf090f1bae,a3f6813b-7927-42fb-bb7c-4c4357892c64"
            }
          ],
          "timeStamp": 1677197916702
        },
        "-NP-mQGJSODaKQqucklp": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "L111P",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 L111P mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and is a statistically significant hotspot (PMID: 16821082). In vivo studies with yeast expressing TP53 L111P demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 L111P also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371938545,
                    "updatedBy": "User"
                  },
                  "description_uuid": "5f8ef2a2-8a59-47fd-823a-6ef3924bb6bd",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371937345,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "1d0c9077-7f90-4bd6-835f-109487f97226",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371936509,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "c7c3a2f0-cf14-43c2-b32b-8c31ea9e51a6",
                  "short": ""
                },
                "mutation_effect_uuid": "410df0ce-9248-45b6-afee-2a4c0cb51230",
                "name": "L111P",
                "name_review": {
                  "added": true,
                  "updateTime": 1675371933030,
                  "updatedBy": "User"
                },
                "name_uuid": "877e679c-9800-429c-9ee6-54b9f92d503c",
                "tumors_uuid": "1bbd0806-83d7-49b7-9064-e514e5affa59"
              },
              "operation": "add",
              "uuids": "c7c3a2f0-cf14-43c2-b32b-8c31ea9e51a6,1d0c9077-7f90-4bd6-835f-109487f97226"
            }
          ],
          "timeStamp": 1677197949744
        },
        "-NP-mZNJGex1IpCVb7Sr": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "L111Q",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 L111Q mutation is located in the DNA-binding domain of the protein. This mutation has been identified in squamous cell carcinoma and is a statistically significant hotspot (PMID: 9400993). In vivo studies with yeast expressing TP53 L111Q demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 L111Q also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371958450,
                    "updatedBy": "User"
                  },
                  "description_uuid": "60a749f9-1f06-4e97-9727-9293ff578240",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371954540,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "a1e2aa3a-ed4d-44c4-bd94-43aeb7dd18df",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371953595,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "e4c1984a-22dc-4617-b3ce-8eb50ceb0f1b",
                  "short": ""
                },
                "mutation_effect_uuid": "a95cb58d-1bc9-4319-974c-8c07fecf9ff6",
                "name": "L111Q",
                "name_review": {
                  "added": true,
                  "updateTime": 1675371950707,
                  "updatedBy": "User"
                },
                "name_uuid": "616e7c26-480f-4b9c-9891-84dd5140df5a",
                "tumors_uuid": "515cb84d-7809-4986-b670-2b7c6fd55a0c"
              },
              "operation": "add",
              "uuids": "e4c1984a-22dc-4617-b3ce-8eb50ceb0f1b,a1e2aa3a-ed4d-44c4-bd94-43aeb7dd18df"
            }
          ],
          "timeStamp": 1677197987056
        },
        "-NP-mgo2Of4RXjTAILW7": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "L111R",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 L111R mutation is located in the DNA-binding domain of the protein. This mutation has been identified in hepatocellular carcinoma and is a statistically significant hotspot (PMID: 14687797). In vivo studies with yeast expressing TP53 L111R demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 L111R also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371973377,
                    "updatedBy": "User"
                  },
                  "description_uuid": "accc30fb-33ad-4004-bbe2-c9255a3ebeb2",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371970384,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "e19bed62-9066-4e78-bac6-8e4697fdba39",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371969592,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "4f86f8ad-0fad-443d-ba73-230d1ce1d673",
                  "short": ""
                },
                "mutation_effect_uuid": "4f17e5de-ded9-4bf9-8153-60acdaed109d",
                "name": "L111R",
                "name_review": {
                  "added": true,
                  "updateTime": 1675371967815,
                  "updatedBy": "User"
                },
                "name_uuid": "f61870c4-f3fa-4c54-bd96-9016a27dd9f7",
                "tumors_uuid": "315f6675-37ff-4014-ad9f-ac705e171ea9"
              },
              "operation": "add",
              "uuids": "4f86f8ad-0fad-443d-ba73-230d1ce1d673,e19bed62-9066-4e78-bac6-8e4697fdba39"
            }
          ],
          "timeStamp": 1677198021599
        },
        "-NP-nIyVSKSpGghqTXhg": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "L111M",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 L111M mutation is located in the DNA-binding domain of the protein. This mutation has been identified in hepatocellular carcinoma and is a statistically significant hotspot (PMID: 15126338). There is conflicting evidence about the biological and oncogenic effect of the mutation. In vivo studies with yeast expressing TP53 L111M demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). However, other in vitro studies with various human cancer cell lines expressing TP53 L111M demonstrated that the mutation is likely neutral as measured by growth suppression activity comparable to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1677198126860,
                    "updatedBy": "User"
                  },
                  "description_uuid": "0c708958-cf0f-4312-8b9f-43014dfb72c1",
                  "effect": "Inconclusive",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371988772,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "1acb11dc-5b0d-4967-8274-65e77090aadc",
                  "oncogenic": "Inconclusive",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675371987668,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "f57ddce8-5774-4eeb-86f7-7d65a26efb33",
                  "short": ""
                },
                "mutation_effect_uuid": "f2241b0e-bc57-4a5a-8021-3cfe48f83881",
                "name": "L111M",
                "name_review": {
                  "added": true,
                  "updateTime": 1675371984170,
                  "updatedBy": "User"
                },
                "name_uuid": "40521129-aeeb-42b0-8cd8-b0620c4772e3",
                "tumors_uuid": "2be2926a-1c0e-450a-aa50-f7c7cd8c7367"
              },
              "operation": "add",
              "uuids": "f57ddce8-5774-4eeb-86f7-7d65a26efb33,1acb11dc-5b0d-4967-8274-65e77090aadc"
            }
          ],
          "timeStamp": 1677198180180
        },
        "-NP-nR1at6XfriZHypic": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "D259V",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 D259V mutation is located in the DNA-binding domain of the protein. This mutation has been identified in non-small cell lung cancer and is a statistically significant hotspot (PMID: 12209975). In vivo studies with yeast expressing TP53 D259V demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 D259V also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675372011288,
                    "updatedBy": "User"
                  },
                  "description_uuid": "8a50fdad-68c3-48db-a4d0-7bba6ea29df2",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675372007789,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "9a1c776f-f67e-4c06-a6d2-dbfae1f194e1",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675372007119,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "41c18b1e-a95c-4ffd-b7e5-fd12b4276f77",
                  "short": ""
                },
                "mutation_effect_uuid": "e9b5ca51-5f0e-47e5-a4bb-b08a4c9c4503",
                "name": "D259V",
                "name_review": {
                  "added": true,
                  "updateTime": 1675372005187,
                  "updatedBy": "User"
                },
                "name_uuid": "930c7ca6-bd2d-4e82-c059-268a3a60ee27",
                "tumors_uuid": "7e0293fa-e675-4b0e-911f-61369744a900"
              },
              "operation": "add",
              "uuids": "41c18b1e-a95c-4ffd-b7e5-fd12b4276f77,9a1c776f-f67e-4c06-a6d2-dbfae1f194e1"
            }
          ],
          "timeStamp": 1677198213210
        },
        "-NP-o0a26fZ-UUpKfoo9": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "D259H",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 D259H mutation is located in the DNA-binding domain of the protein. This mutation has been identified in bladder cancer and is a statistically significant hotspot (PMID: 20824703). There is conflicting evidence about the biological and oncogenic effect of the mutation. In vivo studies with yeast expressing TP53 D259H demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). However, other in vitro studies with various human cancer cell lines expressing TP53 D259H demonstrated that the mutation is likely neutral as measured by growth suppression activity comparable to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1677198328791,
                    "updatedBy": "User"
                  },
                  "description_uuid": "0a6332e6-d336-48ad-bbb4-81f8c70cb022",
                  "effect": "Inconclusive",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675372024658,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "3fcd13c1-b177-47ac-b140-09b51c30a046",
                  "oncogenic": "Inconclusive",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675372023607,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "86bdad87-e2d6-420d-b990-b232db54968c",
                  "short": ""
                },
                "mutation_effect_uuid": "002b353c-07ae-476f-b51d-3105c9f56d0e",
                "name": "D259H",
                "name_review": {
                  "added": true,
                  "updateTime": 1675372021072,
                  "updatedBy": "User"
                },
                "name_uuid": "a3c3eb40-e39b-452c-9174-9ae877c0bdf7",
                "tumors_uuid": "58a3249d-addd-4775-81aa-4ca81c26ccee"
              },
              "operation": "add",
              "uuids": "86bdad87-e2d6-420d-b990-b232db54968c,3fcd13c1-b177-47ac-b140-09b51c30a046"
            }
          ],
          "timeStamp": 1677198367031
        },
        "-NP-o8kgJzh6JQO5JGfV": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "D259Y",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 D259Y mutation is located in the DNA-binding domain of the protein. This mutation has been identified in ovarian cancer and is a statistically significant hotspot (PMID: 17171684). In vivo studies with yeast expressing TP53 D259Y demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 D259Y also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675372047050,
                    "updatedBy": "User"
                  },
                  "description_uuid": "5dc1856d-4a56-4f7f-bc71-7ddba744dd01",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675372043095,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "1f3b2798-0751-446e-b403-7bea641feba1",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675372041731,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "2b5ccef5-270b-40d6-b16e-6b842e252788",
                  "short": ""
                },
                "mutation_effect_uuid": "d7e2ca6e-dc71-4bd0-a973-12cca2f9d92e",
                "name": "D259Y",
                "name_review": {
                  "added": true,
                  "updateTime": 1675372039885,
                  "updatedBy": "User"
                },
                "name_uuid": "cad277ee-5e08-472a-98aa-d9ae6217ffa0",
                "tumors_uuid": "ad172a68-49af-4a09-a0fe-d828642dec76"
              },
              "operation": "add",
              "uuids": "2b5ccef5-270b-40d6-b16e-6b842e252788,1f3b2798-0751-446e-b403-7bea641feba1"
            }
          ],
          "timeStamp": 1677198400480
        },
        "-NP-oGlg9GEM3lbNH-M0": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "D259N",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 D259N mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and is a statistically significant hotspot (PMID: 18348141). There is conflicting evidence about the biological and oncogenic effect of the mutation. In vivo studies with yeast expressing TP53 D259N demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). However, other in vitro studies with various human cancer cell lines expressing TP53 D259N demonstrated that the mutation is likely neutral as measured by wildtype comparable growth suppression activity (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675372062740,
                    "updatedBy": "User"
                  },
                  "description_uuid": "1967fd07-c80e-4273-be3c-3f279ad874d0",
                  "effect": "Inconclusive",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675372059790,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "9c7de2a0-2295-4d12-86cd-93b6c2680ae9",
                  "oncogenic": "Inconclusive",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675372059103,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "48dffcf2-7720-4e11-a93a-0668328d4ca1",
                  "short": ""
                },
                "mutation_effect_uuid": "11e3128b-4e82-4bb3-b270-310e926ec47f",
                "name": "D259N",
                "name_review": {
                  "added": true,
                  "updateTime": 1675372056198,
                  "updatedBy": "User"
                },
                "name_uuid": "53700e38-1bec-4278-94b7-94c9294609a1",
                "tumors_uuid": "0434baf9-1039-4301-86c6-ece124d0b420"
              },
              "operation": "add",
              "uuids": "48dffcf2-7720-4e11-a93a-0668328d4ca1,9c7de2a0-2295-4d12-86cd-93b6c2680ae9"
            }
          ],
          "timeStamp": 1677198433312
        },
        "-NP-oPIj5hLjJpSigPPs": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "I232T",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 I232T mutation is located in the DNA-binding domain of the protein. This mutation has been identified in follicular lymphoma and is a statistically significant hotspot (PMID: 12217802). In vivo studies with yeast expressing TP53 I232T demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 I232T also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675372079598,
                    "updatedBy": "User"
                  },
                  "description_uuid": "e6593126-709f-4c5d-a293-56959c95a7b3",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675372078425,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "0a8ce906-0365-45c9-8e6d-9b1bfbecae5d",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675372077701,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "0c8ae8f6-6849-4f54-87bd-c13b122350f7",
                  "short": ""
                },
                "mutation_effect_uuid": "35c42422-f385-41bb-8a1f-4fd589a33d0f",
                "name": "I232T",
                "name_review": {
                  "added": true,
                  "updateTime": 1675372073553,
                  "updatedBy": "User"
                },
                "name_uuid": "72914e1a-b0ef-4524-8546-5634886794b8",
                "tumors_uuid": "a4c6b9bf-8f09-4798-b302-d6fad87134d4"
              },
              "operation": "add",
              "uuids": "0c8ae8f6-6849-4f54-87bd-c13b122350f7,0a8ce906-0365-45c9-8e6d-9b1bfbecae5d"
            }
          ],
          "timeStamp": 1677198468259
        },
        "-NP-oX_XTLn0FPyjV1W1": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "C135F",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 C135F mutation is located in the DNA-binding domain of the protein. This mutation has been identified in Ewing sarcoma and is a statistically significant hotspot (PMID: 11406642). In vivo studies with yeast expressing TP53 C135F demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 C135F also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675372111880,
                    "updatedBy": "User"
                  },
                  "description_uuid": "19f6010d-2999-4a4f-a519-5e3da7f1b08a",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675372108362,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "1d4da7e4-9d7a-4b01-9a24-150c229faa64",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675372107102,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "f863c871-c5eb-4f9b-9d9b-649844d13dfe",
                  "short": ""
                },
                "mutation_effect_uuid": "2971cbd1-adc3-4be1-8cb0-5ff455a6c16b",
                "name": "C135F",
                "name_review": {
                  "added": true,
                  "updateTime": 1675372105338,
                  "updatedBy": "User"
                },
                "name_uuid": "1dc4cf37-5c14-4432-950e-9b60d6d08401",
                "tumors_uuid": "8a66ff06-d13e-4533-c033-e4c12b524930"
              },
              "operation": "add",
              "uuids": "f863c871-c5eb-4f9b-9d9b-649844d13dfe,1d4da7e4-9d7a-4b01-9a24-150c229faa64"
            }
          ],
          "timeStamp": 1677198502166
        },
        "-NP-oenbVyS11EM6JYgl": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "I232N",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 I232N mutation is located in the DNA-binding domain of the protein. This mutation has been identified in prostate cancer and is a statistically significant hotspot (PMID: 8688333). In vivo studies with yeast expressing TP53 I232N demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 I232N also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675372095142,
                    "updatedBy": "User"
                  },
                  "description_uuid": "e401cb2c-c391-48dd-b17d-c486bfb3b6a3",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675372091371,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "894e6d0e-c12d-4b52-91a6-7a5402eb77f6",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675372090360,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "7ed7f2b3-a71d-4b6d-ae97-c0de73aeba70",
                  "short": ""
                },
                "mutation_effect_uuid": "b67aab18-d3a7-4c97-a8ea-f35843ccb8bd",
                "name": "I232N",
                "name_review": {
                  "added": true,
                  "updateTime": 1675372088572,
                  "updatedBy": "User"
                },
                "name_uuid": "278fb788-c53e-4633-a491-9d43eebe02dd",
                "tumors_uuid": "b75eb096-3ae0-440f-9e59-3308ed52ffca"
              },
              "operation": "add",
              "uuids": "7ed7f2b3-a71d-4b6d-ae97-c0de73aeba70,894e6d0e-c12d-4b52-91a6-7a5402eb77f6"
            }
          ],
          "timeStamp": 1677198535835
        },
        "-NP-on7NtUlNVlOjneyr": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "D281P",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 D281P mutation is located in the DNA-binding domain of the protein. This mutation has been identified in glioblastoma and is a statistically significant hotspot (PMID: 24120142). In vitro studies with various human cancer cell lines expressing TP53 D281P demonstrated that the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675372173485,
                    "updatedBy": "User"
                  },
                  "description_uuid": "c6920b1f-1b92-4936-813c-c2150b56010a",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675372167558,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "8803add6-6bf7-4885-bc5e-bfce7dba782d",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675372166379,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "dfdf2cf0-70ff-4060-9667-dbfb2e4d35c3",
                  "short": ""
                },
                "mutation_effect_uuid": "92375efb-7c05-481f-8f74-9d71ede268fc",
                "name": "D281P",
                "name_review": {
                  "added": true,
                  "updateTime": 1675372158593,
                  "updatedBy": "User"
                },
                "name_uuid": "7aa18bd1-209a-4ccd-8785-8f998a12e0d8",
                "tumors_uuid": "fe3541aa-4e20-4c04-98b6-744af2554a10"
              },
              "operation": "add",
              "uuids": "dfdf2cf0-70ff-4060-9667-dbfb2e4d35c3,8803add6-6bf7-4885-bc5e-bfce7dba782d"
            }
          ],
          "timeStamp": 1677198569957
        },
        "-NP-ovRkIQQrI7CM3-72": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "C135W",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 C135W mutation is located in the DNA-binding domain of the protein. This mutation has been identified in esophageal squamous cell carcinoma and is a statistically significant hotspot (PMID: 11309337). In vivo studies with yeast expressing TP53 C135W demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 C135W also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675372148030,
                    "updatedBy": "User"
                  },
                  "description_uuid": "cd65128d-b606-4a20-a818-a5cd665f1b97",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675372146784,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "9d137f25-ac6e-45b4-b284-922e467f7f2d",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675372145815,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "de4a6cc4-2c4b-4a64-8b7d-165986495b24",
                  "short": ""
                },
                "mutation_effect_uuid": "b904c10b-71da-4673-ace4-55983a819550",
                "name": "C135W",
                "name_review": {
                  "added": true,
                  "updateTime": 1675372140525,
                  "updatedBy": "User"
                },
                "name_uuid": "d0088ed8-0416-4244-8361-68f9b52e35df",
                "tumors_uuid": "49aa87ec-6c4a-4472-8658-373c297535f2"
              },
              "operation": "add",
              "uuids": "de4a6cc4-2c4b-4a64-8b7d-165986495b24,9d137f25-ac6e-45b4-b284-922e467f7f2d"
            }
          ],
          "timeStamp": 1677198604030
        },
        "-NP-p2gQh_edLSWOvTqC": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "H214P",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 H214P mutation is located in the DNA-binding domain of the protein. This mutation has been identified in astrocytoma and is a statistically significant hotspot (PMID: 7882284). There is conflicting evidence about the biological and oncogenic effect of the mutation. In vitro studies with various human cancer cell lines expressing TP53 H214P also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644). However, other in vivo studies with yeast expressing TP53 H214P demonstrated that the mutation is likely neutral as measured by wildtype comparable transactivational activity (PMID: 27328919, 12826609).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675372126884,
                    "updatedBy": "User"
                  },
                  "description_uuid": "b48a7026-60f7-4e9a-848d-d7be72038925",
                  "effect": "Inconclusive",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675372123591,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "9587a5bc-bdc2-42d2-ab32-fc70968a1f60",
                  "oncogenic": "Inconclusive",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675372122806,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "f5ca4c1e-6162-4db3-87a4-dd7ea5b95114",
                  "short": ""
                },
                "mutation_effect_uuid": "8a4a4f2c-5790-4e18-8eb7-34798b7987d1",
                "name": "H214P",
                "name_review": {
                  "added": true,
                  "updateTime": 1675372119894,
                  "updatedBy": "User"
                },
                "name_uuid": "f1223d71-8853-4ee9-827e-20e676fd2957",
                "tumors_uuid": "fa54e02b-448b-461f-8211-84460e169f97"
              },
              "operation": "add",
              "uuids": "f5ca4c1e-6162-4db3-87a4-dd7ea5b95114,9587a5bc-bdc2-42d2-ab32-fc70968a1f60"
            }
          ],
          "timeStamp": 1677198637801
        },
        "-NP-pB1tXZuniYBPiGhq": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "P151L",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 P151L mutation is located in the DNA-binding domain of the protein. This mutation has been identified in NK/T-cell lymphoma and is a statistically significant hotspot (PMID: 15643509). In vivo studies with yeast expressing TP53 P151L demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675372237526,
                    "updatedBy": "User"
                  },
                  "description_uuid": "86f9d5b8-7c20-45df-a572-835c9a563045",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675372233820,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "e9429b6e-ada6-4662-a455-782d894ca67f",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675372232857,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "e631ad98-eabf-4a0b-9e5b-8318375004ff",
                  "short": ""
                },
                "mutation_effect_uuid": "c9eb5848-dd72-487a-904b-c7550e305019",
                "name": "P151L",
                "name_review": {
                  "added": true,
                  "updateTime": 1675372230749,
                  "updatedBy": "User"
                },
                "name_uuid": "9ff0220b-8728-43de-b76b-7845156a76f2",
                "tumors_uuid": "0d35b7e5-f565-4214-ac25-5824ea199091"
              },
              "operation": "add",
              "uuids": "e631ad98-eabf-4a0b-9e5b-8318375004ff,e9429b6e-ada6-4662-a455-782d894ca67f"
            }
          ],
          "timeStamp": 1677198672007
        },
        "-NP-pJMbjYj2g0TXMM0J": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "P151F",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 P151F mutation is located in the DNA-binding domain of the protein. This mutation has been identified in non-small cell lung cancer and is a statistically significant hotspot (PMID: 14618621). In vitro studies with various human cancer cell lines expressing TP53 P151F demonstrated that the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675372215093,
                    "updatedBy": "User"
                  },
                  "description_uuid": "60faf9bb-f0ac-4c3a-b11e-55119d3ed2d7",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675372210261,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "20df2fcf-6008-461e-810a-31a563311b42",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675372209053,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "8d949ed9-5cda-4cae-9fd4-7ff5ae1df088",
                  "short": ""
                },
                "mutation_effect_uuid": "5e5dceff-f88c-4f19-a9b0-e879d26b24a1",
                "name": "P151F",
                "name_review": {
                  "added": true,
                  "updateTime": 1675372206755,
                  "updatedBy": "User"
                },
                "name_uuid": "9fd9b99e-c684-4605-c0e1-0126f8342a7f",
                "tumors_uuid": "befe183e-a933-4147-992a-c84e5485898e"
              },
              "operation": "add",
              "uuids": "8d949ed9-5cda-4cae-9fd4-7ff5ae1df088,20df2fcf-6008-461e-810a-31a563311b42"
            }
          ],
          "timeStamp": 1677198706101
        },
        "-NP-pRiVBtdzG6N1PY9U": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "P151T",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 P151T mutation is located in the DNA-binding domain of the protein. This mutation has been identified in colorectal cancer and is a statistically significant hotspot (PMID: 15316933). In vivo studies with yeast expressing TP53 P151T demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 P151T also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675372192122,
                    "updatedBy": "User"
                  },
                  "description_uuid": "be85b595-65f6-456d-b00c-7ea7334d5c3c",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675372190401,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "a0ade61a-1273-4816-a789-880d7f066c74",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675372189403,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "116fd63d-6a9b-4932-b425-ba040598c7fe",
                  "short": ""
                },
                "mutation_effect_uuid": "104f5d48-f1e7-4abd-8d9a-b193b49adabf",
                "name": "P151T",
                "name_review": {
                  "added": true,
                  "updateTime": 1675372184435,
                  "updatedBy": "User"
                },
                "name_uuid": "d4ab34d3-7dee-4fec-8d8d-8472a2e8c299",
                "tumors_uuid": "53005062-bc04-4f6e-adcb-8eb8df57d502"
              },
              "operation": "add",
              "uuids": "116fd63d-6a9b-4932-b425-ba040598c7fe,a0ade61a-1273-4816-a789-880d7f066c74"
            }
          ],
          "timeStamp": 1677198740334
        },
        "-NP-p_C2wLV03ZxU4Zl6": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "D281E",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 D281E mutation is located in the DNA-binding domain of the protein. This mutation has been identified in ovarian cancer and is a statistically significant hotspot (PMID: 11244334). There is conflicting evidence about the biological and oncogenic effect of the mutation. In vivo studies with yeast expressing TP53 D281E demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). However, other in vitro studies with various human cancer cell lines expressing TP53 D281E demonstrated that the mutation is likely neutral as measured by wildtype comparable growth suppression activity (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675372411264,
                    "updatedBy": "User"
                  },
                  "description_uuid": "0f9f5f78-3c02-40c0-8399-e9b362a12c8c",
                  "effect": "Inconclusive",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675372408173,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "fa55640a-c5bd-4c2b-92ec-b68dc144add7",
                  "oncogenic": "Inconclusive",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675372407442,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "6dc59b1e-6f96-4430-959b-30c233e27f03",
                  "short": ""
                },
                "mutation_effect_uuid": "57985a69-755f-4695-be40-740b72a38486",
                "name": "D281E",
                "name_review": {
                  "added": true,
                  "updateTime": 1675372405136,
                  "updatedBy": "User"
                },
                "name_uuid": "955318c9-250b-4579-a9e5-325b74222448",
                "tumors_uuid": "24839934-567f-41b4-af44-d9892ba08d2b"
              },
              "operation": "add",
              "uuids": "6dc59b1e-6f96-4430-959b-30c233e27f03,fa55640a-c5bd-4c2b-92ec-b68dc144add7"
            }
          ],
          "timeStamp": 1677198775057
        },
        "-NP-piPIrGKesGHbVhQn": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R175G",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 R175G mutation is located in the DNA-binding domain of the protein. This mutation has been identified in acute T-cell lymphoblastic leukemia and is a statistically significant hotspot (PMID: 8486778). In vivo studies with yeast expressing TP53 R175G demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 R175G also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675372396423,
                    "updatedBy": "User"
                  },
                  "description_uuid": "dce738f2-b948-416b-8955-e5f5a33efd7e",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675372393390,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "cd3b7655-6ec8-4964-b518-73ee35f26f8a",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675372392722,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "53651d7b-840a-4016-9144-99e21f93f8bc",
                  "short": ""
                },
                "mutation_effect_uuid": "7796ee3d-a55a-413b-aad5-6ea8cfa8b6a1",
                "name": "R175G",
                "name_review": {
                  "added": true,
                  "updateTime": 1675372390459,
                  "updatedBy": "User"
                },
                "name_uuid": "3a9d655d-b052-4443-bf72-5cbd6ca6f49e",
                "tumors_uuid": "d96b3113-ae46-4e53-b775-a9ac96178c78"
              },
              "operation": "add",
              "uuids": "53651d7b-840a-4016-9144-99e21f93f8bc,cd3b7655-6ec8-4964-b518-73ee35f26f8a"
            }
          ],
          "timeStamp": 1677198812769
        },
        "-NP-pqf9dIVgvDNwUDUT": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "D281A",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 D281A mutation is located in the DNA-binding domain of the protein. This mutation has been identified in malignant peripheral nerve sheath tumors and is a statistically significant hotspot (PMID: 20010306). There is conflicting evidence about the biological and oncogenic effect of the mutation. In vivo studies with yeast expressing TP53 D281A demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). However, other in vitro studies with various human cancer cell lines expressing TP53 D281A demonstrated that the mutation is likely neutral as measured by growth suppression activity comparable to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1677198667032,
                    "updatedBy": "User"
                  },
                  "description_uuid": "3caf1bc7-74a8-4593-ba7b-e68abaa43d3c",
                  "effect": "Inconclusive",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675372247892,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "cc9a3a96-431f-4a38-9bc7-0fee7434a13e",
                  "oncogenic": "Inconclusive",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675372247006,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "a3c5d9fd-1eef-4299-b589-f5461cc92094",
                  "short": ""
                },
                "mutation_effect_uuid": "003a5e18-b3aa-4c6e-bcea-c6aa5f5c4a33",
                "name": "D281A",
                "name_review": {
                  "added": true,
                  "updateTime": 1675372244739,
                  "updatedBy": "User"
                },
                "name_uuid": "27eab5af-9a46-4aa3-92ae-720b4befa865",
                "tumors_uuid": "bdec040c-3d85-464a-9bfd-db151aa63f7e"
              },
              "operation": "add",
              "uuids": "a3c5d9fd-1eef-4299-b589-f5461cc92094,cc9a3a96-431f-4a38-9bc7-0fee7434a13e"
            }
          ],
          "timeStamp": 1677198846616
        },
        "-NP-pz31K5rJ8IRMW_0V": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "D281H",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 D281H mutation is located in the DNA-binding domain of the protein. This mutation has been identified in clear cell renal cell carcinoma and is a statistically significant hotspot (PMID: 20137853). In vivo studies with yeast expressing TP53 D281H demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 D281H also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675372599334,
                    "updatedBy": "User"
                  },
                  "description_uuid": "343a6358-cdf4-4920-9e28-ee0e56359c03",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675372595607,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "cf731ee9-f5cc-4e6e-b5f9-5b52f12dda77",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675372593908,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "10a87fe3-21e4-49fd-8dc5-93a58a1616c6",
                  "short": ""
                },
                "mutation_effect_uuid": "624853a9-8496-417c-bf89-2a78f47789d2",
                "name": "D281H",
                "name_review": {
                  "added": true,
                  "updateTime": 1675372591694,
                  "updatedBy": "User"
                },
                "name_uuid": "bf6734d6-5537-460e-ac62-fe0187c051e6",
                "tumors_uuid": "6a76f524-a32c-42ad-b2fc-cd57e4a6e3d4"
              },
              "operation": "add",
              "uuids": "10a87fe3-21e4-49fd-8dc5-93a58a1616c6,cf731ee9-f5cc-4e6e-b5f9-5b52f12dda77"
            }
          ],
          "timeStamp": 1677198880976
        },
        "-NP-q6PTggww35FLgReV": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "D281G",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 D281G mutation is located in the DNA-binding domain of the protein. This mutation has been identified in malignant lymphoma and is a statistically significant hotspot (PMID: 8878455). There is conflicting evidence about the biological and oncogenic effect of the mutation. In vivo studies with yeast expressing TP53 D281G demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). However, other in vitro studies with various human cancer cell lines expressing TP53 D281G demonstrated that the mutation is likely neutral as measured by wildtype comparable growth suppression activity (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675372582074,
                    "updatedBy": "User"
                  },
                  "description_uuid": "e24864a4-c618-4dbc-9122-e6bac3b6ba34",
                  "effect": "Inconclusive",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1677198808196,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "86167b42-0d99-4be1-a2cd-9e7e4b8ac132",
                  "oncogenic": "Inconclusive",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675372576572,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "6a9964a4-e846-49f2-920b-240a00cbf1a7",
                  "short": ""
                },
                "mutation_effect_uuid": "a9365a83-1a13-4383-90d5-7156fee95837",
                "name": "D281G",
                "name_review": {
                  "added": true,
                  "updateTime": 1675372574697,
                  "updatedBy": "User"
                },
                "name_uuid": "5a71c2d1-46c9-4151-a43e-eb453400193f",
                "tumors_uuid": "d3ef5eb2-b33b-4d5b-a9c9-95ed06f7133b"
              },
              "operation": "add",
              "uuids": "6a9964a4-e846-49f2-920b-240a00cbf1a7,86167b42-0d99-4be1-a2cd-9e7e4b8ac132"
            }
          ],
          "timeStamp": 1677198915180
        },
        "-NP-qEl52Eb8LLWUAi1T": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "D281V",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 D281V mutation is located in the DNA-binding domain of the protein. This mutation has been identified in Ewing sarcoma and is a statistically significant hotspot (PMID: 8168993). There is conflicting evidence about the biological and oncogenic effect of the mutation. In vivo studies with yeast expressing TP53 D281V demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). However, other in vitro studies with various human cancer cell lines expressing TP53 D281V demonstrated that the mutation is likely neutral as measured by wildtype comparable growth suppression activity (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675372568305,
                    "updatedBy": "User"
                  },
                  "description_uuid": "d834a2cf-2f67-46a8-a84d-7d0d7a3da782",
                  "effect": "Inconclusive",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675372564084,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "525a5306-5319-44cd-bf21-fa6ad17797cf",
                  "oncogenic": "Inconclusive",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675372563044,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "63f0a0ec-88dd-4f9d-a584-5e4f23b4e6cf",
                  "short": ""
                },
                "mutation_effect_uuid": "64d0d9e2-3918-4291-beea-3298e44c9d8d",
                "name": "D281V",
                "name_review": {
                  "added": true,
                  "updateTime": 1675372561230,
                  "updatedBy": "User"
                },
                "name_uuid": "e0f66767-9af2-4402-a38b-92bb61d60743",
                "tumors_uuid": "d31634e1-3a55-4268-ac91-f44a71949ef3"
              },
              "operation": "add",
              "uuids": "63f0a0ec-88dd-4f9d-a584-5e4f23b4e6cf,525a5306-5319-44cd-bf21-fa6ad17797cf"
            }
          ],
          "timeStamp": 1677198949396
        },
        "-NP-r8cFP4Lr952BsCQk": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "D281Y",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 D281Y mutation is located in the DNA-binding domain of the protein. This mutation has been identified in follicular lymphoma and is a statistically significant hotspot (PMID: 10854221). In vivo studies with yeast expressing TP53 D281Y demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 D281Y also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675372853892,
                    "updatedBy": "User"
                  },
                  "description_uuid": "3b369bab-3044-4a11-b522-b19f4e381d65",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675372850103,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "33f1ff16-6118-4758-9a34-340d3692efc4",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675372849323,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "733caa1a-063f-4413-a5ba-698334247f7d",
                  "short": ""
                },
                "mutation_effect_uuid": "9b041a25-1d3c-44bd-a93c-84672d3828f5",
                "name": "D281Y",
                "name_review": {
                  "added": true,
                  "updateTime": 1675372847071,
                  "updatedBy": "User"
                },
                "name_uuid": "c9937398-c106-4247-8bc7-1c7e98e21747",
                "tumors_uuid": "d230f3c5-2b62-4bbe-bf87-3f91e21e907a"
              },
              "operation": "add",
              "uuids": "733caa1a-063f-4413-a5ba-698334247f7d,33f1ff16-6118-4758-9a34-340d3692efc4"
            }
          ],
          "timeStamp": 1677199186398
        },
        "-NP-rH4RDGl5KxFKZI3b": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "D281N",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 D281N mutation is located in the DNA-binding domain of the protein. This mutation has been identified in malignant lymphoma and is a statistically significant hotspot (PMID: 8916968). In vivo studies with yeast expressing TP53 D281N demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 D281N also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675372868507,
                    "updatedBy": "User"
                  },
                  "description_uuid": "ce7a32e3-e9a8-4850-94df-d23991f2516b",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675372865418,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "18ba68ee-ff40-43c2-b093-2e4c246c12de",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675372862845,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "b3f62b84-50a5-4d24-83d6-39d8d5915f47",
                  "short": ""
                },
                "mutation_effect_uuid": "bb56b65d-7f2d-4be3-974d-af372fe88157",
                "name": "D281N",
                "name_review": {
                  "added": true,
                  "updateTime": 1675372861270,
                  "updatedBy": "User"
                },
                "name_uuid": "8b1cc47a-8d6e-46dd-bffb-8cdd3fb6c0fc",
                "tumors_uuid": "4b934cb6-c8e2-4018-a95f-6347750fbb94"
              },
              "operation": "add",
              "uuids": "b3f62b84-50a5-4d24-83d6-39d8d5915f47,18ba68ee-ff40-43c2-b093-2e4c246c12de"
            }
          ],
          "timeStamp": 1677199221034
        },
        "-NP-rPhKQSHQ451J7rsg": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V216G",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 V216G mutation is located in the DNA-binding domain of the protein. This mutation has been identified in ovarian cancer and is a statistically significant hotspot (PMID: 16459017). In vivo studies with yeast expressing TP53 V216G demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 V216G also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675372983764,
                    "updatedBy": "User"
                  },
                  "description_uuid": "0e6758d1-8819-42f3-b0e6-e07b4c5a4435",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675372982576,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "98d87d75-6f48-48b7-8b48-3aef97375f1c",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675372981697,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "b3e29b9d-841c-4ebb-83f7-3ec8c72799f0",
                  "short": ""
                },
                "mutation_effect_uuid": "622bef66-058b-407d-84ef-b7220f1cf76e",
                "name": "V216G",
                "name_review": {
                  "added": true,
                  "updateTime": 1675372976783,
                  "updatedBy": "User"
                },
                "name_uuid": "94b09bb7-ded0-47aa-b201-122f9be73853",
                "tumors_uuid": "9b9bc022-efff-4908-8877-0adb20d4def5"
              },
              "operation": "add",
              "uuids": "b3e29b9d-841c-4ebb-83f7-3ec8c72799f0,98d87d75-6f48-48b7-8b48-3aef97375f1c"
            }
          ],
          "timeStamp": 1677199256355
        },
        "-NP-rXz0A5kdHBRK18-N": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V216E",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 V216E mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and is a statistically significant hotspot (PMID: 7928628). In vivo studies with yeast expressing TP53 V216E demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 V216E also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675372882241,
                    "updatedBy": "User"
                  },
                  "description_uuid": "69704ef9-6b3e-4bf9-87c0-3467cfb3194d",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675372878957,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "6bf2ce6b-961c-4e39-aca0-65a91c1a943f",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675372878091,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "01ba08ab-524c-4a73-8c73-d80f61955589",
                  "short": ""
                },
                "mutation_effect_uuid": "a7d6315b-18dd-4fde-8646-1c1ef3547b4f",
                "name": "V216E",
                "name_review": {
                  "added": true,
                  "updateTime": 1675372875971,
                  "updatedBy": "User"
                },
                "name_uuid": "1240b14a-882f-42c1-a3e5-8990376b1c59",
                "tumors_uuid": "2bba8ff6-f6d3-4e85-a079-e34e879ae673"
              },
              "operation": "add",
              "uuids": "01ba08ab-524c-4a73-8c73-d80f61955589,6bf2ce6b-961c-4e39-aca0-65a91c1a943f"
            }
          ],
          "timeStamp": 1677199290255
        },
        "-NP-rfKEK1RR7DVZssLf": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Y126S",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 Y126S mutation is located in the DNA-binding domain of the protein. This mutation has been identified in gallbladder cancer and is a statistically significant hotspot (PMID: 15154647). In vivo studies with yeast expressing TP53 Y126S demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 Y126S also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675373541535,
                    "updatedBy": "User"
                  },
                  "description_uuid": "51ca4223-0b1b-476b-bebc-a798102b3085",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675373536636,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "9b55570d-3118-46cb-8b0f-0a75928e06b4",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675373536084,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "aed17154-7dfe-46e1-a0bc-d826f14801fc",
                  "short": ""
                },
                "mutation_effect_uuid": "10a977ef-2725-4f5d-ba98-16cadbda2f08",
                "name": "Y126S",
                "name_review": {
                  "added": true,
                  "updateTime": 1675373534368,
                  "updatedBy": "User"
                },
                "name_uuid": "50ee3b62-5856-4e95-97a7-a4f9fcae8584",
                "tumors_uuid": "6cd9042b-0bb2-4728-9baf-2591ed2a0e3b"
              },
              "operation": "add",
              "uuids": "aed17154-7dfe-46e1-a0bc-d826f14801fc,9b55570d-3118-46cb-8b0f-0a75928e06b4"
            }
          ],
          "timeStamp": 1677199324445
        },
        "-NP-rnsMcpM3-U8aoDPI": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Y126C",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 Y126C mutation is located in the DNA-binding domain of the protein. This mutation has been identified in ovarian cancer and is a statistically significant hotspot (PMID: 15188009). In vivo studies with yeast expressing TP53 Y126C demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 Y126C also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675373528704,
                    "updatedBy": "User"
                  },
                  "description_uuid": "90e85aa7-d98e-495e-8dda-aeeec8fc36e7",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675373524891,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "c6a32ee8-65e0-4724-9b87-142235e14b9d",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675373524280,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "630511d2-1995-409f-8cfa-248f2583eaa1",
                  "short": ""
                },
                "mutation_effect_uuid": "0b13a70c-60c2-43b3-aa85-86d045b3af9a",
                "name": "Y126C",
                "name_review": {
                  "added": true,
                  "updateTime": 1675373522475,
                  "updatedBy": "User"
                },
                "name_uuid": "df06e718-9cdb-4997-85b5-3800ec8b8209",
                "tumors_uuid": "c52d78aa-379d-48b5-9eb3-e733c1bde9e6"
              },
              "operation": "add",
              "uuids": "630511d2-1995-409f-8cfa-248f2583eaa1,c6a32ee8-65e0-4724-9b87-142235e14b9d"
            }
          ],
          "timeStamp": 1677199359461
        },
        "-NP-rwB28sSQP84DhNAq": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V216M",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 V216M mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and is a statistically significant hotspot (PMID: 22551440). In vivo studies with yeast expressing TP53 V216M demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 V216M also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675373516755,
                    "updatedBy": "User"
                  },
                  "description_uuid": "63a61699-d211-443a-8ca7-a15f703a578d",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675373515276,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "f02226ef-970e-4c1d-8aae-2cd440c2dbc3",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675373514571,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "0b8dee69-81ac-4481-b462-a101899e3bca",
                  "short": ""
                },
                "mutation_effect_uuid": "6a0da217-6814-475d-acd3-b05c9c083589",
                "name": "V216M",
                "name_review": {
                  "added": true,
                  "updateTime": 1675373511215,
                  "updatedBy": "User"
                },
                "name_uuid": "f4cebdf9-1a5a-4806-84ab-e44bb6d0193f",
                "tumors_uuid": "5f48c73e-3301-4e3f-8e03-1c921211dfb9"
              },
              "operation": "add",
              "uuids": "0b8dee69-81ac-4481-b462-a101899e3bca,f02226ef-970e-4c1d-8aae-2cd440c2dbc3"
            }
          ],
          "timeStamp": 1677199393489
        },
        "-NP-s3mDE5H5IrSH2fYY": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V216L",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 V216L mutation is located in the DNA-binding domain of the protein. This mutation has been identified in colorectal cancer and is a statistically significant hotspot (PMID: 9516972). In vivo studies with yeast expressing TP53 V216L demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 V216L also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675373434289,
                    "updatedBy": "User"
                  },
                  "description_uuid": "b78b3967-09d9-4ad8-82f8-69f02da29da4",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675373430744,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "16c51556-6cf3-41fa-b0df-c8723320c0e9",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675373430190,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "220d411c-edad-48f1-a8cb-c658deee8688",
                  "short": ""
                },
                "mutation_effect_uuid": "760749ff-1af9-4583-b1a9-d75f8a431da1",
                "name": "V216L",
                "name_review": {
                  "added": true,
                  "updateTime": 1675373427795,
                  "updatedBy": "User"
                },
                "name_uuid": "c719def0-3e21-4e28-b2af-e12653b36d13",
                "tumors_uuid": "1db9a1c8-240a-4a1b-93fa-cd40771d5ab4"
              },
              "operation": "add",
              "uuids": "220d411c-edad-48f1-a8cb-c658deee8688,16c51556-6cf3-41fa-b0df-c8723320c0e9"
            }
          ],
          "timeStamp": 1677199428700
        },
        "-NP-sCIyYzE8Zofl_BF5": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "A159D",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 A159D mutation is located in the DNA-binding domain of the protein. This mutation has been identified in colorectal cancer and is a statistically significant hotspot (PMID: 7651727). There is conflicting evidence about the biological and oncogenic effect of the mutation. In vivo studies with yeast expressing TP53 A159D demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). However, other in vitro studies with various human cancer cell lines expressing TP53 A159D demonstrated that the mutation is likely neutral as measured by wildtype comparable growth suppression activity (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675374855463,
                    "updatedBy": "User"
                  },
                  "description_uuid": "55448673-0897-4eb4-856e-cfd7d072de9f",
                  "effect": "Inconclusive",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675374852158,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "fd759c19-416c-41db-ba73-9d0efc7186b2",
                  "oncogenic": "Inconclusive",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675374851468,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "914c65f6-e451-40cb-aff4-db054a82c131",
                  "short": ""
                },
                "mutation_effect_uuid": "7333c7fa-74f0-4bc1-abeb-3a46622037e4",
                "name": "A159D",
                "name_review": {
                  "added": true,
                  "updateTime": 1675374849222,
                  "updatedBy": "User"
                },
                "name_uuid": "ce8ce40b-efb3-49b0-bc5f-11f71eef52e5",
                "tumors_uuid": "a6534629-3e05-4f7a-9ed6-087559eed464"
              },
              "operation": "add",
              "uuids": "914c65f6-e451-40cb-aff4-db054a82c131,fd759c19-416c-41db-ba73-9d0efc7186b2"
            }
          ],
          "timeStamp": 1677199463628
        },
        "-NP-sKr74qxxLQen3-NM": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "A159P",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 A159P mutation is located in the DNA-binding domain of the protein. This mutation has been identified in non-small cell lung cancer and is a statistically significant hotspot (PMID: 10023676). In vivo studies with yeast expressing TP53 A159P demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 A159P also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675374417841,
                    "updatedBy": "User"
                  },
                  "description_uuid": "d7d89ac5-3c01-4ff9-aedf-2a414b6b04a2",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675374414541,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "26f46a83-e5a7-4df7-aae6-91e2c91c74b5",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675374413945,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "580e70f5-bb71-428d-90e6-976efc38e60d",
                  "short": ""
                },
                "mutation_effect_uuid": "b325636a-2af1-4077-9e03-c07ef382e2dd",
                "name": "A159P",
                "name_review": {
                  "added": true,
                  "updateTime": 1675374411854,
                  "updatedBy": "User"
                },
                "name_uuid": "dcb6be5b-edd7-4ee3-8100-27228150b700",
                "tumors_uuid": "7b3862eb-512b-4199-89cf-1a7c22cb2b33"
              },
              "operation": "add",
              "uuids": "580e70f5-bb71-428d-90e6-976efc38e60d,26f46a83-e5a7-4df7-aae6-91e2c91c74b5"
            }
          ],
          "timeStamp": 1677199498646
        },
        "-NP-sTOOLf8aZ2CPeAAy": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Y126N",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 Y126N mutation is located in the DNA-binding domain of the protein. This mutation has been identified in glioblastoma and is a statistically significant hotspot (PMID: 16818615). In vivo studies with yeast expressing TP53 Y126N demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 Y126N also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_editing": "",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675374007675,
                    "updatedBy": "User"
                  },
                  "description_uuid": "69d730ec-4c6b-4aff-b162-60da86d7485d",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675374003611,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "5ab2fe4b-718d-449e-a24e-ad062c47e9bc",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675374002873,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "dc8958c2-3a4a-461a-8446-d92fe988a5f7",
                  "short": ""
                },
                "mutation_effect_uuid": "dd52e54e-813e-45eb-833d-18fbad0da8c2",
                "name": "Y126N",
                "name_review": {
                  "added": true,
                  "updateTime": 1675374000843,
                  "updatedBy": "User"
                },
                "name_uuid": "06a4a877-8e08-4740-8452-84954e4727b3",
                "tumors_uuid": "e9c25e8a-38d0-456c-a52d-aa67766926b3"
              },
              "operation": "add",
              "uuids": "dc8958c2-3a4a-461a-8446-d92fe988a5f7,5ab2fe4b-718d-449e-a24e-ad062c47e9bc"
            }
          ],
          "timeStamp": 1677199533607
        },
        "-NP-samSqXH6bsaniGU3": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Y126H",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 Y126H mutation is located in the DNA-binding domain of the protein. This mutation has been identified in colorectal cancer and is a statistically significant hotspot (PMID: 11307149). In vivo studies with yeast expressing TP53 Y126H demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 Y126H also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675373994685,
                    "updatedBy": "User"
                  },
                  "description_uuid": "3070c64b-a37b-4408-a02c-55004ab009c3",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675373990724,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "ebdda3ba-c34b-4b28-89b8-25edcc0ebad5",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675373989984,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "6009dab8-5c6e-4376-8cfe-285907db9069",
                  "short": ""
                },
                "mutation_effect_uuid": "37607491-2689-4008-a226-08d099dcb063",
                "name": "Y126H",
                "name_review": {
                  "added": true,
                  "updateTime": 1675373986319,
                  "updatedBy": "User"
                },
                "name_uuid": "4afc8c96-2a52-4a2a-ae2b-bfe9a102690b",
                "tumors_uuid": "89e45dcd-af0e-4bc1-a80d-f299f3ee08ae"
              },
              "operation": "add",
              "uuids": "6009dab8-5c6e-4376-8cfe-285907db9069,ebdda3ba-c34b-4b28-89b8-25edcc0ebad5"
            }
          ],
          "timeStamp": 1677199567979
        },
        "-NP-sjIBQ7KDNLbH7EML": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Y126D",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 Y126D mutation is located in the DNA-binding domain of the protein. This mutation has been identified in glioblastoma and is a statistically significant hotspot (PMID: 10896202). In vivo studies with yeast expressing TP53 Y126D demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 Y126D also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675373731642,
                    "updatedBy": "User"
                  },
                  "description_uuid": "a8c51d2a-d9f3-4527-824d-54016df564f9",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675373728000,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "1e272251-a388-4c3e-b6fa-8fc02cf2014e",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675373727394,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "2c3cd489-28ad-4a8b-9326-f91333ef6353",
                  "short": ""
                },
                "mutation_effect_uuid": "995afef5-e2c5-41d5-b374-480ffbe1562b",
                "name": "Y126D",
                "name_review": {
                  "added": true,
                  "updateTime": 1675373725562,
                  "updatedBy": "User"
                },
                "name_uuid": "ca8a4eec-eef9-46f0-9cac-e4c7e32f6e2b",
                "tumors_uuid": "6c0f2b97-9e91-4874-9e88-bd0a2c518320"
              },
              "operation": "add",
              "uuids": "2c3cd489-28ad-4a8b-9326-f91333ef6353,1e272251-a388-4c3e-b6fa-8fc02cf2014e"
            }
          ],
          "timeStamp": 1677199602842
        },
        "-NP-ssCh9X0Y8KV4Jafd": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "L194F",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 L194F mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and is a statistically significant hotspot (PMID: 7619219). In vivo studies with yeast expressing TP53 L194F demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 L194F also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675444787062,
                    "updatedBy": "User"
                  },
                  "description_uuid": "2da2d558-7794-42ea-a70d-d1223e423eb7",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675444783979,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "7badfaf4-2bb6-4bfe-8455-13d6256394e8",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675444783392,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "8b579f75-5877-4d08-a810-9c21a7999717",
                  "short": ""
                },
                "mutation_effect_uuid": "c31263d6-b16b-40c5-ae94-68e9a103f453",
                "name": "L194F",
                "name_review": {
                  "added": true,
                  "updateTime": 1675444780166,
                  "updatedBy": "User"
                },
                "name_uuid": "b1c6a4a7-e351-413f-850b-807a2c50cb54",
                "tumors_uuid": "8472fad1-8894-454a-bae1-855a8e18d69f"
              },
              "operation": "add",
              "uuids": "8b579f75-5877-4d08-a810-9c21a7999717,7badfaf4-2bb6-4bfe-8455-13d6256394e8"
            }
          ],
          "timeStamp": 1677199639355
        },
        "-NP-t-culXIgztPxEbsH": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "L194R",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 L194R mutation is located in the DNA-binding domain of the protein. This mutation has been identified in ovarian cancer and is a statistically significant hotspot (PMID: 15221786). In vivo studies with yeast expressing TP53 L194R demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 L194R also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675375111781,
                    "updatedBy": "User"
                  },
                  "description_uuid": "3106cda1-22f3-4d6a-8bfa-956d26b73824",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675375108112,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "f2343ddd-085a-464b-976b-0b7e7a87916e",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675375107428,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "51035597-bc2b-4ddd-9b3d-20e64f1436b5",
                  "short": ""
                },
                "mutation_effect_uuid": "ce301d83-c918-4429-891f-cad2c5033094",
                "name": "L194R",
                "name_review": {
                  "added": true,
                  "updateTime": 1675375105551,
                  "updatedBy": "User"
                },
                "name_uuid": "dc341d2c-5419-46a9-9eb8-c83594a883ce",
                "tumors_uuid": "8dbc72a7-5fd4-491f-a87a-1baab51b4998"
              },
              "operation": "add",
              "uuids": "51035597-bc2b-4ddd-9b3d-20e64f1436b5,f2343ddd-085a-464b-976b-0b7e7a87916e"
            }
          ],
          "timeStamp": 1677199673864
        },
        "-NP-t8EvHAE0NZ9OOes6": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "L194P",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 L194P mutation is located in the DNA-binding domain of the protein. This mutation has been identified in glioma and is a statistically significant hotspot (PMID: 1358438). In vivo studies with yeast expressing TP53 L194P demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 L194P also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675374966605,
                    "updatedBy": "User"
                  },
                  "description_uuid": "3fede5ff-00c1-49e1-9423-440711f12115",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675374965494,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "968b2bf2-c31a-43c3-a5f6-188c03bee3b4",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675374964763,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "5a5f7829-5ea3-44b9-a5ec-7753464e4ab0",
                  "short": ""
                },
                "mutation_effect_uuid": "c2e07f82-d272-48ea-bccc-6f0d1ca5cba7",
                "name": "L194P",
                "name_review": {
                  "added": true,
                  "updateTime": 1675374960972,
                  "updatedBy": "User"
                },
                "name_uuid": "5f6dc75d-4b37-4174-9a83-ef97a86abe25",
                "tumors_uuid": "27ca1875-e52f-489b-b086-3c3b13a4e83a"
              },
              "operation": "add",
              "uuids": "5a5f7829-5ea3-44b9-a5ec-7753464e4ab0,968b2bf2-c31a-43c3-a5f6-188c03bee3b4"
            }
          ],
          "timeStamp": 1677199709129
        },
        "-NP-tGnJrX1ZBN2rMMWw": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "A159V",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 A159V mutation is located in the DNA-binding domain of the protein. This mutation has been identified in astrocytoma and is a statistically significant hotspot (PMID: 8285583). In vivo studies with yeast expressing TP53 A159V demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 A159V also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675374867655,
                    "updatedBy": "User"
                  },
                  "description_uuid": "48ecc569-b3e9-40a1-8a24-c4fed79431ad",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675374864408,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "885cbe35-bb5d-40c9-8a09-0d0ebc59f0ef",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675374863769,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "719fc285-6202-40d3-9d8c-f494199263cf",
                  "short": ""
                },
                "mutation_effect_uuid": "1f71c70c-03bd-48b3-beaf-ae0bc53ab5a1",
                "name": "A159V",
                "name_review": {
                  "added": true,
                  "updateTime": 1675374861118,
                  "updatedBy": "User"
                },
                "name_uuid": "b73b4bb2-a390-436f-98fb-8419adff0509",
                "tumors_uuid": "6f915dab-18cc-4171-951c-b2db4f092439"
              },
              "operation": "add",
              "uuids": "719fc285-6202-40d3-9d8c-f494199263cf,885cbe35-bb5d-40c9-8a09-0d0ebc59f0ef"
            }
          ],
          "timeStamp": 1677199744162
        },
        "-NP-uEDVCmiPd95EdXFZ": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "L194H",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 L194H mutation is located in the DNA-binding domain of the protein. This mutation has been identified in marginal zone B-cell lymphoma and is a statistically significant hotspot (PMID: 8541549). In vivo studies with yeast expressing TP53 L194H demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 L194H also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675445042173,
                    "updatedBy": "User"
                  },
                  "description_uuid": "42d1f1e9-e5e0-4984-90e1-d6bd4f5197f1",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675445038798,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "14492913-e6e0-46cf-a8eb-25dce4e182f3",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675445037560,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "c323b2b7-ba86-4e3c-b3cd-93c643838107",
                  "short": ""
                },
                "mutation_effect_uuid": "2adaef82-7897-468d-86d1-de50d7206cca",
                "name": "L194H",
                "name_review": {
                  "added": true,
                  "updateTime": 1675445034860,
                  "updatedBy": "User"
                },
                "name_uuid": "366ed801-68bb-41bd-8414-9e2741996c01",
                "tumors_uuid": "be583479-ade9-4bdd-a433-c83b9d947bea"
              },
              "operation": "add",
              "uuids": "c323b2b7-ba86-4e3c-b3cd-93c643838107,14492913-e6e0-46cf-a8eb-25dce4e182f3"
            }
          ],
          "timeStamp": 1677199995758
        },
        "-NP-uMsR_eGP9xa1mWvQ": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "F270S",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 F270S mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and is a statistically significant hotspot (PMID: 11588905). In vivo studies with yeast expressing TP53 F270S demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 F270S also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675445058115,
                    "updatedBy": "User"
                  },
                  "description_uuid": "1f907186-5643-434c-b042-3ed474ea8428",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675445054043,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "bf5fca38-1f8f-4146-b678-23e83faed9af",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675445053294,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "8236ac91-1bec-4e79-b09c-458c39bccedd",
                  "short": ""
                },
                "mutation_effect_uuid": "c921a649-9d51-4601-9749-4e64932a382c",
                "name": "F270S",
                "name_review": {
                  "added": true,
                  "updateTime": 1675445051274,
                  "updatedBy": "User"
                },
                "name_uuid": "2a3c1329-7dab-4d42-b124-94b697bcd0df",
                "tumors_uuid": "c01c8586-d048-4fc3-bfb3-d017e5a4ce6c"
              },
              "operation": "add",
              "uuids": "8236ac91-1bec-4e79-b09c-458c39bccedd,bf5fca38-1f8f-4146-b678-23e83faed9af"
            }
          ],
          "timeStamp": 1677200031210
        },
        "-NP-uVjDAA5yYnuVkOfI": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "F270V",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 F270V mutation is located in the DNA-binding domain of the protein. This mutation has been identified in bladder cancer and is a statistically significant hotspot (PMID: 8731915). In vivo studies with yeast expressing TP53 F270V demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 F270V also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675445087062,
                    "updatedBy": "User"
                  },
                  "description_uuid": "e2bdb72d-9e85-4310-bb77-f7a6a833029d",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675445083551,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "69277319-51a5-4773-a5a9-76a30098759c",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675445082958,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "5f49c760-8c12-47e0-bd43-ffc1069f5779",
                  "short": ""
                },
                "mutation_effect_uuid": "19d8449d-0119-4cb8-9717-64878a32a932",
                "name": "F270V",
                "name_review": {
                  "added": true,
                  "updateTime": 1675445081232,
                  "updatedBy": "User"
                },
                "name_uuid": "c536205a-94b3-42f0-b9de-111ff86de56d",
                "tumors_uuid": "0c8cf082-64eb-4759-a3cd-54a6695e34f1"
              },
              "operation": "add",
              "uuids": "5f49c760-8c12-47e0-bd43-ffc1069f5779,69277319-51a5-4773-a5a9-76a30098759c"
            }
          ],
          "timeStamp": 1677200067484
        },
        "-NP-udLFZ2F6mbcamoMw": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "F270C",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 F270C mutation is located in the DNA-binding domain of the protein. This mutation has been identified in non-small cell lung cancer and is a statistically significant hotspot (PMID: 10830574). In vivo studies with yeast expressing TP53 F270C demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 F270C also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675445072888,
                    "updatedBy": "User"
                  },
                  "description_uuid": "97521ba0-455a-44d0-9364-6dc718856625",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675445069484,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "43308441-8249-4edd-8e64-0237d15cd80f",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675445068718,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "4980d373-162a-43f7-a213-4a700a7a0cde",
                  "short": ""
                },
                "mutation_effect_uuid": "0468d617-d916-4a7f-bf19-6ad83d3d7b88",
                "name": "F270C",
                "name_review": {
                  "added": true,
                  "updateTime": 1675445067103,
                  "updatedBy": "User"
                },
                "name_uuid": "e2335749-4d0a-410f-ad60-b95d126f33d2",
                "tumors_uuid": "629af1f9-f551-454a-8df4-0e39f986cd13"
              },
              "operation": "add",
              "uuids": "4980d373-162a-43f7-a213-4a700a7a0cde,43308441-8249-4edd-8e64-0237d15cd80f"
            }
          ],
          "timeStamp": 1677200102750
        },
        "-NP-um3yfN6DwlOZ-T3K": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "M246R",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 M246R mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and is a statistically significant hotspot (PMID: 11929815). In vivo studies with yeast expressing TP53 M246R demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 M246R also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675445857154,
                    "updatedBy": "User"
                  },
                  "description_uuid": "b3f62e64-9fc1-4a97-afcb-6ef846411734",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675445854065,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "b3f763db-313c-4b38-ad21-96b245214c43",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675445853377,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "785c6cd2-36dd-48fb-bc8e-a3dcbf55c140",
                  "short": ""
                },
                "mutation_effect_uuid": "e7e97f20-2410-46d2-a369-9ed0a07a5c32",
                "name": "M246R",
                "name_review": {
                  "added": true,
                  "updateTime": 1675445850290,
                  "updatedBy": "User"
                },
                "name_uuid": "031f3031-3c97-4d06-b083-7e489bc2c7a9",
                "tumors_uuid": "55f82e96-f4ad-43e4-b6a7-c6e3ec059960"
              },
              "operation": "add",
              "uuids": "785c6cd2-36dd-48fb-bc8e-a3dcbf55c140,b3f763db-313c-4b38-ad21-96b245214c43"
            }
          ],
          "timeStamp": 1677200138508
        },
        "-NP-uuf9I_1GAsFqx5ib": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "F270L",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 F270L mutation is located in the DNA-binding domain of the protein. This mutation has been identified in gallbladder cancer and is a statistically significant hotspot (PMID: 9376195). In vivo studies with yeast expressing TP53 F270L demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675445841833,
                    "updatedBy": "User"
                  },
                  "description_uuid": "fa42583b-a5b7-4b87-9741-2e43f9d51446",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675445838234,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "97e3757d-94f5-41d5-b441-d0bd0de04bd3",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675445837384,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "1726fb77-736a-4d91-b73d-91572e09a92f",
                  "short": ""
                },
                "mutation_effect_uuid": "64543f5b-d2e1-437a-8c38-86ebd8a30a3a",
                "name": "F270L",
                "name_review": {
                  "added": true,
                  "updateTime": 1675445833800,
                  "updatedBy": "User"
                },
                "name_uuid": "418cc1c8-2b7a-4cb3-9efb-0ab0a982fd95",
                "tumors_uuid": "b5dfb4a3-6625-4cfe-aa18-574f1337b5f9"
              },
              "operation": "add",
              "uuids": "1726fb77-736a-4d91-b73d-91572e09a92f,97e3757d-94f5-41d5-b441-d0bd0de04bd3"
            }
          ],
          "timeStamp": 1677200173720
        },
        "-NP-v2Ixo9Y-8YZO77hw": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "F270I",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 F270I mutation is located in the DNA-binding domain of the protein. This mutation has been identified in colorectal cancer and is a statistically significant hotspot (PMID: 1551126). In vivo studies with yeast expressing TP53 F270I demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 F270I also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675445099948,
                    "updatedBy": "User"
                  },
                  "description_uuid": "763a38cf-ec0d-4707-b269-738beea2d18a",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675445095579,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "36a6e20f-5ad9-49ac-a862-5054d0792c5e",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675445094911,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "d8bf0ae8-6c4a-454f-be8f-6c06977b1c12",
                  "short": ""
                },
                "mutation_effect_uuid": "96e140c0-8182-4809-96c8-9fc6a7c1a2be",
                "name": "F270I",
                "name_review": {
                  "added": true,
                  "updateTime": 1675445093147,
                  "updatedBy": "User"
                },
                "name_uuid": "43a94965-748e-4d06-8438-f2eb9666cd3f",
                "tumors_uuid": "e6cce1cc-f439-42f8-be1b-e2438de6bded"
              },
              "operation": "add",
              "uuids": "d8bf0ae8-6c4a-454f-be8f-6c06977b1c12,36a6e20f-5ad9-49ac-a862-5054d0792c5e"
            }
          ],
          "timeStamp": 1677200209099
        },
        "-NP-vaEJtNHCDxAK-jWr": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "M246T",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 M246T mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and is a statistically significant hotspot (PMID: 9699530). In vivo studies with yeast expressing TP53 M246T demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 M246T also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675445869383,
                    "updatedBy": "User"
                  },
                  "description_uuid": "19194c59-f66f-4c3f-8345-fd29cb390fb2",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675445868368,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "4b463a40-3237-4756-8584-3011015569c9",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675445867598,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "12a88a53-5a23-471f-9de0-ee16215cfc8b",
                  "short": ""
                },
                "mutation_effect_uuid": "5c2b0f1c-977b-41ae-ab9d-5b3afcc816e2",
                "name": "M246T",
                "name_review": {
                  "added": true,
                  "updateTime": 1675445863993,
                  "updatedBy": "User"
                },
                "name_uuid": "26c8f4a0-bff9-4917-951d-b39322236040",
                "tumors_uuid": "1d35736a-6c56-431a-9580-879efa5c7a62"
              },
              "operation": "add",
              "uuids": "12a88a53-5a23-471f-9de0-ee16215cfc8b,4b463a40-3237-4756-8584-3011015569c9"
            }
          ],
          "timeStamp": 1677200352162
        },
        "-NP-vivUvH0xb0G-9bMA": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "M246V",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 M246V mutation is located in the DNA-binding domain of the protein. This mutation has been identified in hepatocellular carcinoma and is a statistically significant hotspot (PMID: 18567082). In vivo studies with yeast expressing TP53 M246V demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 M246V also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_editing": "",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675446152851,
                    "updatedBy": "User"
                  },
                  "description_uuid": "90a89cda-2411-449b-bd07-e0d05da30f41",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675446148689,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "635dba92-d445-493e-8dfa-80fa1f21b0d8",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675446147781,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "05c84ffd-8dac-41a1-8a8f-f883f4b2ed3d",
                  "short": ""
                },
                "mutation_effect_uuid": "ad3aa277-87ff-476f-b6ad-dfdab087685b",
                "name": "M246V",
                "name_review": {
                  "added": true,
                  "updateTime": 1675446146145,
                  "updatedBy": "User"
                },
                "name_uuid": "6ef84fee-f00f-411d-ad45-abc3141701d0",
                "tumors_uuid": "ccf1e7a2-133b-40c6-9099-f38c5e4b0e50"
              },
              "operation": "add",
              "uuids": "05c84ffd-8dac-41a1-8a8f-f883f4b2ed3d,635dba92-d445-493e-8dfa-80fa1f21b0d8"
            }
          ],
          "timeStamp": 1677200387757
        },
        "-NP-vrjvJUFJ3zJdixlW": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "M246K",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 M246K mutation is located in the DNA-binding domain of the protein. This mutation has been identified in larynx squamous cell carcinoma and is a statistically significant hotspot (PMID: 8001261). In vivo studies with yeast expressing TP53 M246K demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 M246K also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675448878313,
                    "updatedBy": "User"
                  },
                  "description_uuid": "9bc4fda0-d3ce-4fc5-94fa-4caad069a8fa",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675448873578,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "fba619a7-30dd-4295-89dc-e7da6cf903a5",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675448872752,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "d964e438-f0d2-4077-ac92-accc6102c4d2",
                  "short": ""
                },
                "mutation_effect_uuid": "7a10d8ee-79b0-4c45-ad11-d2f13ca1b9a8",
                "name": "M246K",
                "name_review": {
                  "added": true,
                  "updateTime": 1675448869435,
                  "updatedBy": "User"
                },
                "name_uuid": "2b3f0fac-de58-4942-ac6e-a59ad9c57a5c",
                "tumors_uuid": "b75a032e-1bfa-44e5-8067-3785e1300671"
              },
              "operation": "add",
              "uuids": "d964e438-f0d2-4077-ac92-accc6102c4d2,fba619a7-30dd-4295-89dc-e7da6cf903a5"
            }
          ],
          "timeStamp": 1677200423881
        },
        "-NP-w-ekSB44BOlj0L95": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "M246I",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 M246I mutation is located in the DNA-binding domain of the protein. This mutation has been identified in bladder cancer and is a statistically significant hotspot (PMID: 10761705). In vivo studies with yeast expressing TP53 M246I demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 F270I also demonstrated the mutation is inactivating as measured by moderately reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1677200356689,
                    "updatedBy": "User"
                  },
                  "description_uuid": "ae97cecd-5c8c-42f0-aa47-4dccff964688",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675446598629,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "053d5f8d-ada8-41df-82c6-88d4100ac1c0",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675446597845,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "3d6191ce-50df-4bfc-8d0c-50ee9700ecb1",
                  "short": ""
                },
                "mutation_effect_uuid": "0ed42f7b-6dfc-441c-b591-5d87d95acd13",
                "name": "M246I",
                "name_review": {
                  "added": true,
                  "updateTime": 1675446595776,
                  "updatedBy": "User"
                },
                "name_uuid": "d01c5a96-2ab2-453d-a853-b4a05bc21f4e",
                "tumors_uuid": "c20ad9f6-70ce-4b84-be5a-c6fe715c07b5"
              },
              "operation": "add",
              "uuids": "3d6191ce-50df-4bfc-8d0c-50ee9700ecb1,053d5f8d-ada8-41df-82c6-88d4100ac1c0"
            }
          ],
          "timeStamp": 1677200460414
        },
        "-NP-w80oxWxiMhifxFJx": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "S127C",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 S127C mutation is located in the DNA-binding domain of the protein. This mutation has been identified in acute myeloid leukemia and is a statistically significant hotspot (PMID: 16467864). In vivo studies with yeast expressing TP53 S127C demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 S127C also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675448913744,
                    "updatedBy": "User"
                  },
                  "description_uuid": "1aa496c1-de55-42eb-aae7-ba1a17b16a88",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675448912704,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "6e5e00c7-dc0b-4bbf-86ae-98e738b9fcac",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675448911923,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "6acb9924-3548-46db-aa26-4c8a9066cce0",
                  "short": ""
                },
                "mutation_effect_uuid": "e299e60d-715d-4c14-97cc-8bd167931884",
                "name": "S127C",
                "name_review": {
                  "added": true,
                  "updateTime": 1675448908606,
                  "updatedBy": "User"
                },
                "name_uuid": "9afc92d2-67f4-4b46-aa0c-d4004b33fe47",
                "tumors_uuid": "9966291a-a296-4115-b4b3-833088914ea0"
              },
              "operation": "add",
              "uuids": "6acb9924-3548-46db-aa26-4c8a9066cce0,6e5e00c7-dc0b-4bbf-86ae-98e738b9fcac"
            }
          ],
          "timeStamp": 1677200495404
        },
        "-NP-wGw4HroVtAZE2OCb": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "S127P",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 S127P mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and is a statistically significant hotspot (PMID: 9569050). In vivo studies with yeast expressing TP53 S127P demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 S127P also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675448901758,
                    "updatedBy": "User"
                  },
                  "description_uuid": "cee71fb0-360e-40b2-9c59-ec9a81325f96",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675448900539,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "e13428cf-9c32-4bf0-91ea-8d57e6ea789b",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675448899822,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "6b33e8bd-ef32-4478-8ead-67723848fcbd",
                  "short": ""
                },
                "mutation_effect_uuid": "f7ac3240-7dbf-418d-b047-f60aaf97e61c",
                "name": "S127P",
                "name_review": {
                  "added": true,
                  "updateTime": 1675448896708,
                  "updatedBy": "User"
                },
                "name_uuid": "b8cb815c-1840-4ee6-9863-d5e3781fcdee",
                "tumors_uuid": "15cec8bb-1cbe-4625-b35b-b11290b420e9"
              },
              "operation": "add",
              "uuids": "6b33e8bd-ef32-4478-8ead-67723848fcbd,e13428cf-9c32-4bf0-91ea-8d57e6ea789b"
            }
          ],
          "timeStamp": 1677200531901
        },
        "-NP-wPZyr-_627pB7sW_": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "M246L",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 M246L mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and is a statistically significant hotspot (PMID: 11304577). In vivo studies with yeast expressing TP53 M246L demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 M246L also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675448890491,
                    "updatedBy": "User"
                  },
                  "description_uuid": "2ebb993b-cef0-48b1-9d0d-cee1df84d083",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675448887597,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "9505a0ea-defc-463e-b372-6370f42ac2b4",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675448886696,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "6e88791d-9f99-449f-ae8f-ba9116a85eb6",
                  "short": ""
                },
                "mutation_effect_uuid": "7dbe5f9b-0d53-4c10-b0a0-6e7767222fc1",
                "name": "M246L",
                "name_review": {
                  "added": true,
                  "updateTime": 1675448884419,
                  "updatedBy": "User"
                },
                "name_uuid": "a2b1b824-bdfe-458a-bede-eb2202cb8f91",
                "tumors_uuid": "890dcef8-6cad-4acd-9040-6e331ec0de82"
              },
              "operation": "add",
              "uuids": "6e88791d-9f99-449f-ae8f-ba9116a85eb6,9505a0ea-defc-463e-b372-6370f42ac2b4"
            }
          ],
          "timeStamp": 1677200567286
        },
        "-NP-wYUBGKcn78ePCL4m": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "S127F",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 S127F mutation is located in the DNA-binding domain of the protein. This mutation has been identified in xeroderma pigmentosum and is a statistically significant hotspot (PMID: 9766670). In vivo studies with yeast expressing TP53 S127F demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 S127F also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675448977063,
                    "updatedBy": "User"
                  },
                  "description_uuid": "e69b8538-94a9-48b5-96eb-38c2d08a7b78",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675448973386,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "ba1c9947-5158-42e9-b15b-0ad21debfaf7",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675448972820,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "1c192e0b-5633-45e0-8fb9-c76cf7886b2d",
                  "short": ""
                },
                "mutation_effect_uuid": "b8227d86-243e-46da-c0b6-d9ba44d519ad",
                "name": "S127F",
                "name_review": {
                  "added": true,
                  "updateTime": 1675448971237,
                  "updatedBy": "User"
                },
                "name_uuid": "bcb18751-904d-4a87-bb5b-324b4afc234e",
                "tumors_uuid": "2dbf67cf-f79f-4dff-b4a3-3da1718b51d5"
              },
              "operation": "add",
              "uuids": "1c192e0b-5633-45e0-8fb9-c76cf7886b2d,ba1c9947-5158-42e9-b15b-0ad21debfaf7"
            }
          ],
          "timeStamp": 1677200603780
        },
        "-NP3PE1UsCjvkQqCSLpA": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "S127P",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 S127P mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and is a statistically significant hotspot (PMID: 9569050). In vivo studies with yeast expressing TP53 S127P demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 S127P also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675448901758,
                    "updatedBy": "User"
                  },
                  "description_uuid": "cee71fb0-360e-40b2-9c59-ec9a81325f96",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675448900539,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "e13428cf-9c32-4bf0-91ea-8d57e6ea789b",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675448899822,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "6b33e8bd-ef32-4478-8ead-67723848fcbd",
                  "short": ""
                },
                "mutation_effect_uuid": "f7ac3240-7dbf-418d-b047-f60aaf97e61c",
                "name": "S127P",
                "name_review": {
                  "added": true,
                  "updateTime": 1675448896708,
                  "updatedBy": "User"
                },
                "name_uuid": "b8cb815c-1840-4ee6-9863-d5e3781fcdee",
                "tumors_uuid": "15cec8bb-1cbe-4625-b35b-b11290b420e9"
              },
              "operation": "add"
            }
          ],
          "timeStamp": 1677258715140
        },
        "-NP3PPSbJN7maKLH-609": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "S127T",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 S127T mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and is a statistically significant hotspot (PMID: 18617062). In vivo studies with yeast expressing TP53 S127T demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 S127T also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_editing": "",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675448931450,
                    "updatedBy": "User"
                  },
                  "description_uuid": "43706f82-c99b-4110-ac1e-6107a3a10a1e",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675448926658,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "939d682a-d260-4ecb-bb7e-6ce9fbabc73c",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675448925981,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "cd6b9c85-b853-45ba-970e-c83c13a3c98e",
                  "short": ""
                },
                "mutation_effect_uuid": "6e996502-0c55-47e7-a984-cf21b3ff6274",
                "name": "S127T",
                "name_review": {
                  "added": true,
                  "updateTime": 1675448924066,
                  "updatedBy": "User"
                },
                "name_uuid": "062eaf4f-d174-468a-bd36-16866650882c",
                "tumors_uuid": "a3ed3b46-c5fb-4229-961c-539f59fecc11"
              },
              "operation": "add",
              "uuids": "cd6b9c85-b853-45ba-970e-c83c13a3c98e,939d682a-d260-4ecb-bb7e-6ce9fbabc73c"
            }
          ],
          "timeStamp": 1677258761932
        },
        "-NP3P_-xhzqRzq6Fk7fR": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Q136P",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 Q136P mutation is located in the DNA-binding domain of the protein. This mutation has been identified in bladder cancer and is a statistically significant hotspot (PMID: 14678961). In vivo studies with yeast expressing TP53 Q136P demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 Q136P also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675450282090,
                    "updatedBy": "User"
                  },
                  "description_uuid": "270cbaed-f6ab-473f-b152-95fa0ead6bd5",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675450278382,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "b995a5d3-48a2-45f5-acb9-64758d7c5c1e",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675450277604,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "ce1b2e56-9642-49fb-bf6d-9a4cd7caa7e4",
                  "short": ""
                },
                "mutation_effect_uuid": "b02b2e3f-4ac6-4735-bf35-98630f9a4ffb",
                "name": "Q136P",
                "name_review": {
                  "added": true,
                  "updateTime": 1675450275332,
                  "updatedBy": "User"
                },
                "name_uuid": "b13df2ed-2e82-4ea8-a5ab-4deaaa35b7cb",
                "tumors_uuid": "112b456e-e87b-4d95-a2c6-e6e2f7a415cf"
              },
              "operation": "add",
              "uuids": "ce1b2e56-9642-49fb-bf6d-9a4cd7caa7e4,b995a5d3-48a2-45f5-acb9-64758d7c5c1e"
            }
          ],
          "timeStamp": 1677258805154
        },
        "-NP3PiUSDjtMxdnOlEbL": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "S127Y",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 S127Y mutation is located in the DNA-binding domain of the protein. This mutation has been identified in glioblastoma and is a statistically significant hotspot (PMID: 10667596). In vivo studies with yeast expressing TP53 S127Y demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675448991180,
                    "updatedBy": "User"
                  },
                  "description_uuid": "75c1971c-bb29-44e0-938b-dae65e7df05c",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675448987695,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "8b471e89-8a67-4ec7-999c-59b3686d332c",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675448986729,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "fe3315d5-5278-4ee9-bfd6-821913741eb0",
                  "short": ""
                },
                "mutation_effect_uuid": "4e19dfda-5eac-4905-a2f2-da02c117b138",
                "name": "S127Y",
                "name_review": {
                  "added": true,
                  "updateTime": 1675448984398,
                  "updatedBy": "User"
                },
                "name_uuid": "7d16090d-947f-4726-be94-b29029bd24e5",
                "tumors_uuid": "f20cee59-70d9-4d87-9dae-2ce6b6724f02"
              },
              "operation": "add",
              "uuids": "fe3315d5-5278-4ee9-bfd6-821913741eb0,8b471e89-8a67-4ec7-999c-59b3686d332c"
            }
          ],
          "timeStamp": 1677258843970
        },
        "-NP3S5bkDn68mu02hC43": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Q136E",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 Q136E mutation is located in the DNA-binding domain of the protein. This mutation has been identified in bronchioloalveolar carcinoma and is a statistically significant hotspot (PMID: 9614374). In vivo studies with yeast expressing TP53 Q136E demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 Q136E also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675450293165,
                    "updatedBy": "User"
                  },
                  "description_uuid": "c06e422f-f09d-4de1-a5ac-eaa7a56fe7d5",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675450291643,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "7800cf4c-df3c-49d2-827c-69cdaf849ce5",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675450290908,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "74381502-85c4-4685-af73-405c6792142b",
                  "short": ""
                },
                "mutation_effect_uuid": "3f8b3c81-178b-4c16-8a59-ebc6fa57c54c",
                "name": "Q136E",
                "name_review": {
                  "added": true,
                  "updateTime": 1675450287388,
                  "updatedBy": "User"
                },
                "name_uuid": "4f36d4ef-b3f1-40d4-8485-d7eb48ccd054",
                "tumors_uuid": "06b4d808-eb2a-46ec-a170-aa962e75aea6"
              },
              "operation": "add",
              "uuids": "74381502-85c4-4685-af73-405c6792142b,7800cf4c-df3c-49d2-827c-69cdaf849ce5"
            }
          ],
          "timeStamp": 1677259467093
        },
        "-NP3SEXyDUXHYja9Tfzg": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Q136H",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 Q136H mutation is located in the DNA-binding domain of the protein. This mutation has been identified in acute lymphoblastic B-cell leukemia and is a statistically significant hotspot (PMID: 20575032). There is conflicting evidence about the biological and oncogenic effect of the mutation. In vivo studies with yeast expressing TP53 Q136H demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). However, other in vitro studies with various human cancer cell lines expressing TP53 Q136H demonstrated that the mutation is likely neutral as measured by growth suppression activity comparable to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1677259460408,
                    "updatedBy": "User"
                  },
                  "description_uuid": "24adff42-c6eb-419c-8150-ac8a8f53cfb7",
                  "effect": "Inconclusive",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675450304145,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "5f377e67-dfe4-4937-b523-6d553a466b0c",
                  "oncogenic": "Inconclusive",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675450303510,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "0bb58b04-87fc-4da6-a565-d591ae461827",
                  "short": ""
                },
                "mutation_effect_uuid": "5ba12795-7e5d-4297-ab21-7da9ca7fe4d2",
                "name": "Q136H",
                "name_review": {
                  "added": true,
                  "updateTime": 1675450301402,
                  "updatedBy": "User"
                },
                "name_uuid": "17654327-ac3c-4d49-8cf8-e53a5b212a55",
                "tumors_uuid": "a0af5bea-c768-4c4b-951f-fd3ad81f4196"
              },
              "operation": "add",
              "uuids": "0bb58b04-87fc-4da6-a565-d591ae461827,5f377e67-dfe4-4937-b523-6d553a466b0c"
            }
          ],
          "timeStamp": 1677259503651
        },
        "-NP3SNUwFpBEHRaTBytE": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Q136L",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 Q136L mutation is located in the DNA-binding domain of the protein. This mutation has been identified in urothelial cancer and is a statistically significant hotspot (PMID: 20575032). There is conflicting evidence about the biological and oncogenic effect of the mutation. In vivo studies with yeast expressing TP53 Q136L demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). However, other in vitro studies with various human cancer cell lines expressing TP53 Q136L demonstrated that the mutation is likely neutral as measured by growth suppression activity comparable to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1677259487874,
                    "updatedBy": "User"
                  },
                  "description_uuid": "8b6dab6f-e149-4a8c-8f05-24a9dc758da7",
                  "effect": "Inconclusive",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675450581923,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "15963a90-50fe-43cb-bc22-d967f9592014",
                  "oncogenic": "Inconclusive",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675450581412,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "991be246-c755-47ab-88a3-5434819b595d",
                  "short": ""
                },
                "mutation_effect_uuid": "105aa68a-271e-4d4a-b51d-fbeb6e4a21b8",
                "name": "Q136L",
                "name_review": {
                  "added": true,
                  "updateTime": 1675450578891,
                  "updatedBy": "User"
                },
                "name_uuid": "127fe2df-e7a4-4015-bebe-cbb81c11c29b",
                "tumors_uuid": "55f3de2e-2fee-463a-9f48-56496230e8f4"
              },
              "operation": "add",
              "uuids": "991be246-c755-47ab-88a3-5434819b595d,15963a90-50fe-43cb-bc22-d967f9592014"
            }
          ],
          "timeStamp": 1677259540321
        },
        "-NP3SWQOWz6TTI7LgSm2": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "T125R",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 T125R mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and is a statistically significant hotspot (PMID: 11229518). In vivo studies with yeast expressing TP53 T125R demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 T125R also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675450629843,
                    "updatedBy": "User"
                  },
                  "description_uuid": "eac57f5b-6e4d-44a7-b2d6-b423d4e4d6a6",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675450623594,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "5d53b278-5c6a-4ca8-b75e-8cabb2f0c8a4",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675450622695,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "1540fa71-b49d-448c-8be4-23dd1156a546",
                  "short": ""
                },
                "mutation_effect_uuid": "2a1cdb9b-fce2-4028-a0fa-0493c9a51daf",
                "name": "T125R",
                "name_review": {
                  "added": true,
                  "updateTime": 1675450621035,
                  "updatedBy": "User"
                },
                "name_uuid": "82172742-660e-4945-9452-e0fb73419569",
                "tumors_uuid": "1d9ea47f-c255-42fd-96cf-43842b96831c"
              },
              "operation": "add",
              "uuids": "1540fa71-b49d-448c-8be4-23dd1156a546,5d53b278-5c6a-4ca8-b75e-8cabb2f0c8a4"
            }
          ],
          "timeStamp": 1677259576894
        },
        "-NP3SeKUnA_eWk7yzvxz": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "T125A",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 T125A mutation is located in the DNA-binding domain of the protein. This mutation has been identified in NK/T-cell lymphoma and is a statistically significant hotspot (PMID: 15643509). In vivo studies with yeast expressing TP53 T125A demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675450614115,
                    "updatedBy": "User"
                  },
                  "description_uuid": "e9d71686-187c-4aec-a493-5c0ac0c69b0f",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675450610354,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "adb3705e-d606-41f5-8fed-9cf58df66a59",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675450609223,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "a51ec5d9-02c0-40d9-9f92-5db8b7b0b298",
                  "short": ""
                },
                "mutation_effect_uuid": "b0830ddf-4d90-42f8-9e0b-36226f2370e7",
                "name": "T125A",
                "name_review": {
                  "added": true,
                  "updateTime": 1675450607171,
                  "updatedBy": "User"
                },
                "name_uuid": "3603942a-8c9e-4183-9417-1502d720d482",
                "tumors_uuid": "5129f1b7-8917-42d3-a46a-0af68a016b67"
              },
              "operation": "add",
              "uuids": "a51ec5d9-02c0-40d9-9f92-5db8b7b0b298,adb3705e-d606-41f5-8fed-9cf58df66a59"
            }
          ],
          "timeStamp": 1677259613380
        },
        "-NP3SnAOP7yyoDqLaFA6": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "T125P",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 T125P mutation is located in the DNA-binding domain of the protein. This mutation has been identified in non-small cell lung cancer and is a statistically significant hotspot (PMID: 15073856). In vivo studies with yeast expressing TP53 T125P demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 T125P also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675450601753,
                    "updatedBy": "User"
                  },
                  "description_uuid": "7139cfac-4952-4e25-b29f-ad1399b89818",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675450598294,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "63d98a7c-a766-4cd0-ac39-2843e3dfc383",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675450595223,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "45e0259c-c370-453d-9674-46cf06cb9f9b",
                  "short": ""
                },
                "mutation_effect_uuid": "ea190644-3ea7-4f14-85b1-5f78507fc971",
                "name": "T125P",
                "name_review": {
                  "added": true,
                  "updateTime": 1675450593101,
                  "updatedBy": "User"
                },
                "name_uuid": "c89ede14-7c1c-4c10-bb2c-f41b9f0eefde",
                "tumors_uuid": "6c18c4e5-e777-4411-9955-dcaaff93cfe7"
              },
              "operation": "add",
              "uuids": "45e0259c-c370-453d-9674-46cf06cb9f9b,63d98a7c-a766-4cd0-ac39-2843e3dfc383"
            }
          ],
          "timeStamp": 1677259649598
        },
        "-NP3Sw5tL3wEQ1cGhC9S": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V172F",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 V172F mutation is located in the DNA-binding domain of the protein. This mutation has been identified in ovarian cancer and is a statistically significant hotspot (PMID: 10216487). In vivo studies with yeast expressing TP53 V172F demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
                  "description_editing": "",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675450787383,
                    "updatedBy": "User"
                  },
                  "description_uuid": "dc52f4e8-1346-4f70-86bf-b709d23461f0",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675450783625,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "3decd904-eff8-49eb-885b-b01dc7eff6ad",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675450783001,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "4c88bf6a-0ded-40cc-9ff5-3488a22bd100",
                  "short": ""
                },
                "mutation_effect_uuid": "d5c4d654-6311-4187-a601-facbd7ea1663",
                "name": "V172F",
                "name_review": {
                  "added": true,
                  "updateTime": 1675450780757,
                  "updatedBy": "User"
                },
                "name_uuid": "0940ebd2-4329-477f-a8d2-da6bc8ffe629",
                "tumors_uuid": "aa50221e-ba7e-468a-9efe-966d87b19f4c"
              },
              "operation": "add",
              "uuids": "4c88bf6a-0ded-40cc-9ff5-3488a22bd100,3decd904-eff8-49eb-885b-b01dc7eff6ad"
            }
          ],
          "timeStamp": 1677259686174
        },
        "-NP3T49PnpLBWkbgBASQ": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "E271K",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 E271K mutation is located in the DNA-binding domain of the protein. This mutation has been identified in bladder cancer and is a statistically significant hotspot (PMID: 15538112). In vivo studies with yeast expressing TP53 E271K demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 E271K also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675450675676,
                    "updatedBy": "User"
                  },
                  "description_uuid": "6ab25b78-53df-452b-a25a-4feb92f74eca",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675450674441,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "b62ab704-2888-4338-93ea-f13b49e3c2c0",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675450673525,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "d0fb5975-5239-4032-bc31-7504d0bf1e4e",
                  "short": ""
                },
                "mutation_effect_uuid": "41a8ea8b-4714-49ca-8e2a-b544503c39ae",
                "name": "E271K",
                "name_review": {
                  "added": true,
                  "updateTime": 1675450669893,
                  "updatedBy": "User"
                },
                "name_uuid": "d821a606-0789-41b9-b054-c8b4a8bfe398",
                "tumors_uuid": "42945f6e-5afa-4c02-a134-82c75bf4bf6c"
              },
              "operation": "add",
              "uuids": "d0fb5975-5239-4032-bc31-7504d0bf1e4e,b62ab704-2888-4338-93ea-f13b49e3c2c0"
            }
          ],
          "timeStamp": 1677259723263
        },
        "-NP3TD3TmHSmCWpxK7si": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "T125M",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 T125M mutation is located in the DNA-binding domain of the protein. This mutation has been identified in sinonasal NK/T-cell lymphoma and is a statistically significant hotspot (PMID: 15643509). There is conflicting evidence about the biological and oncogenic effect of the mutation. In vivo studies with yeast expressing TP53 T125M demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). However, other in vitro studies with various human cancer cell lines expressing TP53 T125M demonstrated that the mutation is likely neutral as measured by growth suppression activity comparable to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1677259579353,
                    "updatedBy": "User"
                  },
                  "description_uuid": "828380c9-cfdb-4b9d-8228-fda906e9309a",
                  "effect": "Inconclusive",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675450657053,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "bdfd89d3-5771-476b-ad05-43b0f18318b8",
                  "oncogenic": "Inconclusive",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675450655991,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "cd59f350-e019-457f-812d-1e04529ab432",
                  "short": ""
                },
                "mutation_effect_uuid": "ba19a8b8-4905-4214-a98a-44f194201bbf",
                "name": "T125M",
                "name_review": {
                  "added": true,
                  "updateTime": 1675450651510,
                  "updatedBy": "User"
                },
                "name_uuid": "2d4fc9bc-4b51-4056-abac-07739b783435",
                "tumors_uuid": "7da230d4-7c2c-40fa-a40d-f07d0ad78bdb"
              },
              "operation": "add",
              "uuids": "cd59f350-e019-457f-812d-1e04529ab432,bdfd89d3-5771-476b-ad05-43b0f18318b8"
            }
          ],
          "timeStamp": 1677259759747
        },
        "-NP3TM2JYGDaCwMXXOSg": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "T125K",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 T125K mutation is located in the DNA-binding domain of the protein. This mutation has been identified in pancreatic cancer and is a statistically significant hotspot (PMID: 18772397). There is conflicting evidence about the biological and oncogenic effect of the mutation. In vivo studies with yeast expressing TP53 T125K demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). However, other in vitro studies with various human cancer cell lines expressing TP53 T125K demonstrated that the mutation is likely neutral as measured by growth suppression activity comparable to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1677259550642,
                    "updatedBy": "User"
                  },
                  "description_uuid": "567ee42a-8fe8-4434-827c-1c50be8fb143",
                  "effect": "Inconclusive",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675450639883,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "bf09b51f-e32d-42cb-9374-3f0d9f6a4aa2",
                  "oncogenic": "Inconclusive",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675450638812,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "52fb3702-48c8-4df5-b125-5a309a923fc5",
                  "short": ""
                },
                "mutation_effect_uuid": "89e1d4df-2ac0-4c65-9c06-076b56446b19",
                "name": "T125K",
                "name_review": {
                  "added": true,
                  "updateTime": 1675450636494,
                  "updatedBy": "User"
                },
                "name_uuid": "c05d64cc-acce-489f-ac09-1a4af215f138",
                "tumors_uuid": "1b56628a-c0f4-44a6-b85d-79c52253e89a"
              },
              "operation": "add",
              "uuids": "52fb3702-48c8-4df5-b125-5a309a923fc5,bf09b51f-e32d-42cb-9374-3f0d9f6a4aa2"
            }
          ],
          "timeStamp": 1677259796537
        },
        "-NP3TUww8swKP-ohxNqQ": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "F113P",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 F113P mutation is located in the DNA-binding domain of the protein and is a statistically significant hotspot. In vitro studies with various human cancer cell lines expressing TP53 F113P demonstrated that the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675451164586,
                    "updatedBy": "User"
                  },
                  "description_uuid": "4fb380f0-53ce-4f33-b8fe-85f55dcce7b4",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675451160808,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "c883a618-2c0c-42b3-aeff-355c40bf37a5",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675451160120,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "7e143a9e-f655-43c8-a24e-516d6485122c",
                  "short": ""
                },
                "mutation_effect_uuid": "df9e425b-d401-498e-a749-683c37eaf005",
                "name": "F113P",
                "name_review": {
                  "added": true,
                  "updateTime": 1675451158108,
                  "updatedBy": "User"
                },
                "name_uuid": "8fcf0d6f-e7fd-40f4-ad1e-a5bb6556de1d",
                "tumors_uuid": "97530642-62da-419b-9ee6-bab202054bcc"
              },
              "operation": "add",
              "uuids": "7e143a9e-f655-43c8-a24e-516d6485122c,c883a618-2c0c-42b3-aeff-355c40bf37a5"
            }
          ],
          "timeStamp": 1677259832993
        },
        "-NP3Tcr0-9D77ebp4t6c": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "N131S",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 N131S mutation is located in the DNA-binding domain of the protein. This mutation has been identified in esophageal squamous cell carcinoma and is a statistically significant hotspot (PMID: 16271069). In vivo studies with yeast expressing TP53 N131S demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675451021837,
                    "updatedBy": "User"
                  },
                  "description_uuid": "410c5357-d26c-46cf-8c21-d18ad293bda2",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675451018538,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "60e562fd-d877-461d-869b-e740034061c0",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675451017772,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "e4326aa3-87d9-4d17-8af0-4176d7cd8fc3",
                  "short": ""
                },
                "mutation_effect_uuid": "be08964c-02d8-4400-8fd2-5ef07293be13",
                "name": "N131S",
                "name_review": {
                  "added": true,
                  "updateTime": 1675451015301,
                  "updatedBy": "User"
                },
                "name_uuid": "b6d08dad-a7f7-46ce-953a-8f0c0eae9b28",
                "tumors_uuid": "88830438-741e-4556-c0f2-914ea5d881cd"
              },
              "operation": "add",
              "uuids": "e4326aa3-87d9-4d17-8af0-4176d7cd8fc3,60e562fd-d877-461d-869b-e740034061c0"
            }
          ],
          "timeStamp": 1677259869478
        },
        "-NP3TltcAoIJLNoPSerP": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "T155N",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 T155N mutation is located in the DNA-binding domain of the protein. This mutation has been identified in colorectal cancer and is a statistically significant hotspot (PMID: 11275993). In vivo studies with yeast expressing TP53 T155N demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675451008547,
                    "updatedBy": "User"
                  },
                  "description_uuid": "aae82bce-ec37-4644-be51-bdd94ad38ac6",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675451005434,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "177fb046-82ed-43e1-c0ae-3518de4c2414",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675451004832,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "626a49dc-2691-4d79-9a07-fbfaf3e4a4d7",
                  "short": ""
                },
                "mutation_effect_uuid": "b9b7be5e-c3a8-4878-bb51-c9d50d1740c7",
                "name": "T155N",
                "name_review": {
                  "added": true,
                  "updateTime": 1675451003361,
                  "updatedBy": "User"
                },
                "name_uuid": "c075a77f-4241-43e9-a721-6973794e342c",
                "tumors_uuid": "77de7315-0072-42b1-8f79-adeb736441c4"
              },
              "operation": "add",
              "uuids": "626a49dc-2691-4d79-9a07-fbfaf3e4a4d7,177fb046-82ed-43e1-c0ae-3518de4c2414"
            }
          ],
          "timeStamp": 1677259906509
        },
        "-NP3Tuol0JVTWntulZtY": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "T155P",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 T155P mutation is located in the DNA-binding domain of the protein. This mutation has been identified in small-cell lung cancer and is a statistically significant hotspot (PMID: 14660794). In vivo studies with yeast expressing TP53 T155P demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 T155P also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1677259753904,
                    "updatedBy": "User"
                  },
                  "description_uuid": "fbe616bf-df67-4793-c023-ecffd85ca7de",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675450997123,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "e6c1bf80-6bcc-4409-aa85-74fcb415a8f9",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675450996325,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "f67e9632-6c59-465c-a96b-a58020d331a6",
                  "short": ""
                },
                "mutation_effect_uuid": "7e147be7-761f-4a70-ab6c-57202652ad2c",
                "name": "T155P",
                "name_review": {
                  "added": true,
                  "updateTime": 1675450992463,
                  "updatedBy": "User"
                },
                "name_uuid": "bfb5027f-b427-47d4-b2ff-782865a56250",
                "tumors_uuid": "3b5d05ea-e4a2-4db5-80c6-6c4184d5bbeb"
              },
              "operation": "add",
              "uuids": "f67e9632-6c59-465c-a96b-a58020d331a6,e6c1bf80-6bcc-4409-aa85-74fcb415a8f9"
            }
          ],
          "timeStamp": 1677259943062
        },
        "-NP3U2pKVXPA3oUuoejV": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "D208V",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 D208V mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and is a statistically significant hotspot (PMID: 8099903). In vivo studies with yeast expressing TP53 D208V demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 D208V also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675451192770,
                    "updatedBy": "User"
                  },
                  "description_uuid": "01debd16-735d-471c-a92f-54644d535d5c",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675451191457,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "4fd2507a-a9db-4bbd-8fd5-2dc729b2c4a4",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675451190763,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "8831cd7b-c361-4471-ae40-7cf40380c0fc",
                  "short": ""
                },
                "mutation_effect_uuid": "2889c493-12d9-44ce-87ee-26f3a08c6038",
                "name": "D208V",
                "name_review": {
                  "added": true,
                  "updateTime": 1675451186367,
                  "updatedBy": "User"
                },
                "name_uuid": "71361156-077f-450d-9643-169f88cc1e9c",
                "tumors_uuid": "64a24d81-4c3b-4ec6-8bfa-0bca000721fa"
              },
              "operation": "add",
              "uuids": "8831cd7b-c361-4471-ae40-7cf40380c0fc,4fd2507a-a9db-4bbd-8fd5-2dc729b2c4a4"
            }
          ],
          "timeStamp": 1677259979962
        },
        "-NP3UBnDsxg7ni-js8l8": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "D208E",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 D208E mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and is a statistically significant hotspot (PMID: 8156519). There is conflicting evidence about the biological and oncogenic effect of the mutation. In vivo studies with yeast expressing TP53 D208E demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). However, other in vitro studies with various human cancer cell lines expressing TP53 D208E demonstrated that the mutation is likely neutral as measured by growth suppression activity comparable to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1677259814779,
                    "updatedBy": "User"
                  },
                  "description_uuid": "c08d8010-ed49-4240-9ce8-131f9b61bdfa",
                  "effect": "Inconclusive",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675451172904,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "04520f9d-a519-4aa3-b4f3-4f76a209545a",
                  "oncogenic": "Inconclusive",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675451172188,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "42a6a062-57d4-40ea-92f3-0b0c704b7bbd",
                  "short": ""
                },
                "mutation_effect_uuid": "b875178e-88ff-4f92-b62a-cd06e7c20f36",
                "name": "D208E",
                "name_review": {
                  "added": true,
                  "updateTime": 1675451170663,
                  "updatedBy": "User"
                },
                "name_uuid": "85505870-6d57-4e41-ba98-3d2253d5b99f",
                "tumors_uuid": "52c4a202-781f-403c-af02-84c7d7c542f2"
              },
              "operation": "add",
              "uuids": "42a6a062-57d4-40ea-92f3-0b0c704b7bbd,04520f9d-a519-4aa3-b4f3-4f76a209545a"
            }
          ],
          "timeStamp": 1677260016691
        },
        "-NP3UKpCFhB2MBZCoysq": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Y107D",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 Y107D mutation is located in the DNA-binding domain of the protein. This mutation has been identified in bladder cancer and is a statistically significant hotspot (PMID: 16061860). In vivo studies with yeast expressing TP53 Y107D demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 Y107D also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675451436890,
                    "updatedBy": "User"
                  },
                  "description_uuid": "04a02850-78ca-4339-a7e7-5895631f74fb",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675451432716,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "65bf9dac-bd1f-4a55-90ad-3ad2859152fd",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675451432016,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "6ebd857d-066a-4469-9544-ee08576473a6",
                  "short": ""
                },
                "mutation_effect_uuid": "5f650d17-42bc-4d8f-8df3-001d38a68f91",
                "name": "Y107D",
                "name_review": {
                  "added": true,
                  "updateTime": 1675451430054,
                  "updatedBy": "User"
                },
                "name_uuid": "4644e6ff-2ec9-441e-9841-29063e719bf3",
                "tumors_uuid": "7c69913e-ddf4-4531-9af4-14f77a0fe2ba"
              },
              "operation": "add",
              "uuids": "6ebd857d-066a-4469-9544-ee08576473a6,65bf9dac-bd1f-4a55-90ad-3ad2859152fd"
            }
          ],
          "timeStamp": 1677260053682
        },
        "-NP3UTtgKc4mEuCEP7sH": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "N247I",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 N247I mutation is located in the DNA-binding domain of the protein. This mutation has been identified in non-small cell lung cancer and is a statistically significant hotspot (PMID: 10023676). In vivo studies with yeast expressing TP53 N247I demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 N247I also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675451423498,
                    "updatedBy": "User"
                  },
                  "description_uuid": "422d0d47-93ac-4028-b5fd-7caa5b079022",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675451419875,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "1a108a3e-dd3d-44b5-ad90-ffb307bd499e",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675451419369,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "1bb7a6af-382d-4b6f-aa5c-6d1c9a081d4e",
                  "short": ""
                },
                "mutation_effect_uuid": "146cf80a-e43c-4d87-95e6-645fc5a2246d",
                "name": "N247I",
                "name_review": {
                  "added": true,
                  "updateTime": 1675451417387,
                  "updatedBy": "User"
                },
                "name_uuid": "d2405004-7f54-405a-a0df-79d54d43f1b5",
                "tumors_uuid": "6f0a1c3c-3ffe-450e-8807-79145004e833"
              },
              "operation": "add",
              "uuids": "1bb7a6af-382d-4b6f-aa5c-6d1c9a081d4e,1a108a3e-dd3d-44b5-ad90-ffb307bd499e"
            }
          ],
          "timeStamp": 1677260090833
        },
        "-NP3UcHdvzgZcTHex71n": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "D208N",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 D208N mutation is located in the DNA-binding domain of the protein. This mutation has been identified in thyroid papillary carcinoma and is a statistically significant hotspot (PMID: 8768871). In vivo studies with yeast expressing TP53 D208N demonstrated that the mutation is likely neutral as measured by transactivational activity comparable to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 D208N also demonstrated the mutation likely neutral as measured by growth suppression activity comparable to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1677259983478,
                    "updatedBy": "User"
                  },
                  "description_uuid": "3d80f5ea-fef9-4467-b50b-a1f9e553dba6",
                  "effect": "Likely Neutral",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675451404176,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "557f4470-8fc5-4b4d-908a-65e3ab5e67b2",
                  "oncogenic": "Likely Neutral",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675451403483,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "defb094a-e6e2-4519-8910-323a17da1f35",
                  "short": ""
                },
                "mutation_effect_uuid": "f567a984-39e5-43e7-9a51-ee1ac5ef8790",
                "name": "D208N",
                "name_review": {
                  "added": true,
                  "updateTime": 1675451398588,
                  "updatedBy": "User"
                },
                "name_uuid": "cc7526ca-278a-4a09-80aa-41960e99fcc9",
                "tumors_uuid": "e3207635-7e38-4774-8292-69cf6e9bf517"
              },
              "operation": "add",
              "uuids": "defb094a-e6e2-4519-8910-323a17da1f35,557f4470-8fc5-4b4d-908a-65e3ab5e67b2"
            }
          ],
          "timeStamp": 1677260129294
        },
        "-NP3UlNd-6-3oUYr0gyt": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "D208G",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 D208G mutation is located in the DNA-binding domain of the protein. This mutation has been identified in colorectal cancer and is a statistically significant hotspot (PMID: 9516972). In vivo studies with yeast expressing TP53 D208G demonstrated that the mutation is likely neutral as measured by transactivational activity comparable to wildtype (PMID: 27328919, 12826609).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1677259852273,
                    "updatedBy": "User"
                  },
                  "description_uuid": "397152a2-a8ec-4e20-9c1b-5974dce6a88c",
                  "effect": "Likely Neutral",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675451385003,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "c6e71f6f-a9f7-4ca3-acc8-371557aa109b",
                  "oncogenic": "Likely Neutral",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675451384056,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "4ef8ed91-a16d-4a1d-9ba6-269555c01d4f",
                  "short": ""
                },
                "mutation_effect_uuid": "e6568799-775a-4f07-a2e9-8f3fcac8ca22",
                "name": "D208G",
                "name_review": {
                  "added": true,
                  "updateTime": 1675451381490,
                  "updatedBy": "User"
                },
                "name_uuid": "02ee0fa6-d3a4-4c2e-bede-a39c0974ec06",
                "tumors_uuid": "33229b2e-87ea-48b4-9e69-361de7dad2c0"
              },
              "operation": "add",
              "uuids": "4ef8ed91-a16d-4a1d-9ba6-269555c01d4f,c6e71f6f-a9f7-4ca3-acc8-371557aa109b"
            }
          ],
          "timeStamp": 1677260166542
        },
        "-NP3UuWtWa59LSSNzaPD": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "P190T",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 P190T mutation is located in the DNA-binding domain of the protein. This mutation has been identified in esophageal squamous cell carcinoma and is a statistically significant hotspot (PMID: 12713560). In vivo studies with yeast expressing TP53 P190T demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 P190T also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675452237840,
                    "updatedBy": "User"
                  },
                  "description_uuid": "96b923af-2828-4c20-80bc-0c7eb09e643c",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675452232572,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "19b1f4cc-c835-49cc-820b-d63ae5c94bff",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675452231724,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "c86b790d-e7f0-4cd4-8e53-b4d7b2242b51",
                  "short": ""
                },
                "mutation_effect_uuid": "8991f08f-3641-41ca-a054-d3f5d1c17535",
                "name": "P190T",
                "name_review": {
                  "added": true,
                  "updateTime": 1675452229369,
                  "updatedBy": "User"
                },
                "name_uuid": "9b5fe313-992f-4ef1-96e3-c8a661915c19",
                "tumors_uuid": "916af80b-4f18-445d-a244-840777365d8b"
              },
              "operation": "add",
              "uuids": "c86b790d-e7f0-4cd4-8e53-b4d7b2242b51,19b1f4cc-c835-49cc-820b-d63ae5c94bff"
            }
          ],
          "timeStamp": 1677260203998
        },
        "-NP3V2dHJzG6f6XuyDBd": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "P190S",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 P190S mutation is located in the DNA-binding domain of the protein. This mutation has been identified in ovarian cancer and is a statistically significant hotspot (PMID: 17692090). There is conflicting evidence about the biological and oncogenic effect of the mutation. In vivo studies with yeast expressing TP53 P190S demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). However, other in vitro studies with various human cancer cell lines expressing TP53 P190S demonstrated that the mutation is likely neutral as measured by growth suppression activity comparable to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1677260084902,
                    "updatedBy": "User"
                  },
                  "description_uuid": "00552eb3-ed66-44e6-ada9-2a0cc0a3598c",
                  "effect": "Inconclusive",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675451747569,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "db419730-f891-4cfe-95e3-b292baed66ae",
                  "oncogenic": "Inconclusive",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675451746810,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "ba64a42c-128a-4c7a-a27c-7c8f4c0c7265",
                  "short": ""
                },
                "mutation_effect_uuid": "6a832884-bc95-4af0-8a0f-9bf39ef53d29",
                "name": "P190S",
                "name_review": {
                  "added": true,
                  "updateTime": 1675451745154,
                  "updatedBy": "User"
                },
                "name_uuid": "fe6feddb-7f67-4eaa-912e-3f84e40e297e",
                "tumors_uuid": "ead9c816-6ad6-40f4-b19a-a42a49665ebf"
              },
              "operation": "add",
              "uuids": "ba64a42c-128a-4c7a-a27c-7c8f4c0c7265,db419730-f891-4cfe-95e3-b292baed66ae"
            }
          ],
          "timeStamp": 1677260241335
        },
        "-NP3VByx2Q9N3RgSETys": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "P190R",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 P190R mutation is located in the DNA-binding domain of the protein. This mutation has been identified in ovarian cancer and is a statistically significant hotspot (PMID: 16337994). In vivo studies with yeast expressing TP53 P190R demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 P190R also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675451738987,
                    "updatedBy": "User"
                  },
                  "description_uuid": "d7b4a047-61e9-4d12-8d35-1a5f1dc050b8",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675451735451,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "647e0a17-ec15-427c-9cbe-0481b8cea498",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675451734505,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "fd374789-14a3-437e-ab4f-98a87de04109",
                  "short": ""
                },
                "mutation_effect_uuid": "c83c0d4b-e909-4710-bde3-e3110bcd461f",
                "name": "P190R",
                "name_review": {
                  "added": true,
                  "updateTime": 1675451732036,
                  "updatedBy": "User"
                },
                "name_uuid": "ab913378-ba3d-4a1d-8761-7e2ed1d4149e",
                "tumors_uuid": "05aeff93-9ec1-4a72-8c8e-a0a76ce8e089"
              },
              "operation": "add",
              "uuids": "fd374789-14a3-437e-ab4f-98a87de04109,647e0a17-ec15-427c-9cbe-0481b8cea498"
            }
          ],
          "timeStamp": 1677260279586
        },
        "-NP3VKzN9BGU2y1SpDL-": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "I232F",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 I232F mutation is located in the DNA-binding domain of the protein. This mutation has been identified in esophageal squamous cell carcinoma and is a statistically significant hotspot (PMID: 10753186). In vivo studies with yeast expressing TP53 I232F demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675451726536,
                    "updatedBy": "User"
                  },
                  "description_uuid": "f0c3e2c3-1074-4f1f-b472-5e465701d1f0",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675451723460,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "d8939e03-2292-4989-8507-f52959238c38",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675451722413,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "cc45b460-9570-4cf7-910e-20f97e7cebdb",
                  "short": ""
                },
                "mutation_effect_uuid": "0fd89c1b-3d49-4129-94aa-10e643b690fa",
                "name": "I232F",
                "name_review": {
                  "added": true,
                  "updateTime": 1675451720172,
                  "updatedBy": "User"
                },
                "name_uuid": "3280524d-9e1c-4a9a-8a86-dea9cf4fb4c9",
                "tumors_uuid": "717c72df-35e4-44e7-be08-054d8540baf2"
              },
              "operation": "add",
              "uuids": "cc45b460-9570-4cf7-910e-20f97e7cebdb,d8939e03-2292-4989-8507-f52959238c38"
            }
          ],
          "timeStamp": 1677260316477
        },
        "-NP3VUBqJKJjZB78_Ly6": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "I232S",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 I232S mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and is a statistically significant hotspot (PMID: 1617667). In vivo studies with yeast expressing TP53 I232S demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 I232S also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_editing": "",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675451582247,
                    "updatedBy": "User"
                  },
                  "description_uuid": "59376817-723c-44cb-948a-b824b6546b8f",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675451578484,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "8f77f06a-8bd0-40d6-82c7-f63b292fb735",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675451577719,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "d0285f72-66b1-4b52-ae57-fed4512188d2",
                  "short": ""
                },
                "mutation_effect_uuid": "bedd67bf-6c14-41ff-8b03-94bcd2e9d331",
                "name": "I232S",
                "name_review": {
                  "added": true,
                  "updateTime": 1675451575451,
                  "updatedBy": "User"
                },
                "name_uuid": "1e11939b-1e00-4163-8236-d28f6ee3d8c2",
                "tumors_uuid": "bfccaec2-d963-4093-aaf6-aa4a13f2e488"
              },
              "operation": "add",
              "uuids": "d0285f72-66b1-4b52-ae57-fed4512188d2,8f77f06a-8bd0-40d6-82c7-f63b292fb735"
            }
          ],
          "timeStamp": 1677260354203
        },
        "-NP3Vcb1_x6SgTJfMK00": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V218M",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 V218M mutation is located in the DNA-binding domain of the protein. This mutation has been identified in papillary serous carcinoma and is a statistically significant hotspot (PMID: 10728699). In vivo studies with yeast expressing TP53 V218M demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675452644419,
                    "updatedBy": "User"
                  },
                  "description_uuid": "8e0a1d4b-589e-41ba-accd-5815257acb7b",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675452639791,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "775ab59c-b3a0-4d5d-a6c8-9983acb18cf6",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675452638908,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "254c91ed-cf33-4bb2-a416-92bb0a057757",
                  "short": ""
                },
                "mutation_effect_uuid": "f05e187b-64bb-4d35-a4cd-bbbcca1521b5",
                "name": "V218M",
                "name_review": {
                  "added": true,
                  "updateTime": 1675452634289,
                  "updatedBy": "User"
                },
                "name_uuid": "0a3a6643-0f92-4f80-ad0b-4b1d663e5710",
                "tumors_uuid": "7dadb9dd-7460-4363-8473-68a58d975225"
              },
              "operation": "add",
              "uuids": "254c91ed-cf33-4bb2-a416-92bb0a057757,775ab59c-b3a0-4d5d-a6c8-9983acb18cf6"
            }
          ],
          "timeStamp": 1677260392743
        },
        "-NP3VlqySYilKtehDTfS": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V218L",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 V218L mutation is located in the DNA-binding domain of the protein. This mutation has been identified in colorectal cancer and is a statistically significant hotspot (PMID: 8556707). In vivo studies with yeast expressing TP53 V218L demonstrated that the mutation is likely neutral as measured by transactivational activity comparable to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 V218L also demonstrated the mutation is likely neutral as measured by growth suppression activity comparable to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1677260189361,
                    "updatedBy": "User"
                  },
                  "description_uuid": "4899ad79-699c-477f-b348-46f728099b16",
                  "effect": "Likely Neutral",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675452611627,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "51dcc022-b757-4ad0-8170-bafdd3bd2492",
                  "oncogenic": "Likely Neutral",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675452610604,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "0d0866f9-dab4-4f3c-a45a-4a5d02a52bef",
                  "short": ""
                },
                "mutation_effect_uuid": "59638b7f-67c8-46af-8f5a-1c8720bd6ef3",
                "name": "V218L",
                "name_review": {
                  "added": true,
                  "updateTime": 1675452606767,
                  "updatedBy": "User"
                },
                "name_uuid": "fcb34461-93b6-4282-8a1c-334190b9f338",
                "tumors_uuid": "e2615af8-e7df-43d0-adfb-ad39e1aec6e7"
              },
              "operation": "add",
              "uuids": "0d0866f9-dab4-4f3c-a45a-4a5d02a52bef,51dcc022-b757-4ad0-8170-bafdd3bd2492"
            }
          ],
          "timeStamp": 1677260430627
        },
        "-NP3Vv5AUBy0hQ1VtTwG": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V218G",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 V218G mutation is located in the DNA-binding domain of the protein. This mutation has been identified in malignant melanoma and is a statistically significant hotspot (PMID: 8826861). There is conflicting evidence about the biological and oncogenic effect of the mutation. In vitro studies with various human cancer cell lines expressing TP53 V218G also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644). However, other in vivo studies with yeast expressing TP53 V218G demonstrated that the mutation is likely neutral as measured by transactivational activity comparable to wildtype (PMID: 27328919, 12826609).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1677260140398,
                    "updatedBy": "User"
                  },
                  "description_uuid": "61737701-b8be-4da2-adb3-10fcd944b8b1",
                  "effect": "Inconclusive",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675452271154,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "f8508ea9-8b21-4599-9157-be8835c2ee62",
                  "oncogenic": "Inconclusive",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675452270068,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "933dbd39-4919-4e88-a210-3cea240dde03",
                  "short": ""
                },
                "mutation_effect_uuid": "25c0b4a0-85a4-42cd-83dc-395ed0163e4b",
                "name": "V218G",
                "name_review": {
                  "added": true,
                  "updateTime": 1675452267648,
                  "updatedBy": "User"
                },
                "name_uuid": "fdd6a03c-4244-4d6c-add4-e3bd7b0ee346",
                "tumors_uuid": "27455abd-63f7-4893-b513-21a80f6983fe"
              },
              "operation": "add",
              "uuids": "933dbd39-4919-4e88-a210-3cea240dde03,f8508ea9-8b21-4599-9157-be8835c2ee62"
            }
          ],
          "timeStamp": 1677260468464
        },
        "-NP3W3N_rjzRWjiC24B5": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V218E",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 V218E mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and is a statistically significant hotspot (PMID: 9569050). In vivo studies with yeast expressing TP53 V218E demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 V218E also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675452261155,
                    "updatedBy": "User"
                  },
                  "description_uuid": "37d7a99a-c158-4a6b-af39-e0ff7668abad",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675452257710,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "c51ab0c9-9b4d-4d3b-b015-40f66ef0b308",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675452256896,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "18180fbe-e0b2-4c39-824d-78dc766fd4c9",
                  "short": ""
                },
                "mutation_effect_uuid": "e6300bbf-47f2-4baa-a2e6-69cae07f62f1",
                "name": "V218E",
                "name_review": {
                  "added": true,
                  "updateTime": 1675452254046,
                  "updatedBy": "User"
                },
                "name_uuid": "1c951ce5-5b3a-4040-a408-df2c86038acf",
                "tumors_uuid": "ac0b7e88-8dde-4d94-bc7f-c5e2898ac15b"
              },
              "operation": "add",
              "uuids": "18180fbe-e0b2-4c39-824d-78dc766fd4c9,c51ab0c9-9b4d-4d3b-b015-40f66ef0b308"
            }
          ],
          "timeStamp": 1677260506506
        },
        "-NP3WChJrfjB0HunrqR0": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "P190L",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 P190L mutation is located in the DNA-binding domain of the protein. This mutation has been identified in glioblastoma and is a statistically significant hotspot (PMID: 12124823). In vivo studies with yeast expressing TP53 P190L demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 P190L also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675452248699,
                    "updatedBy": "User"
                  },
                  "description_uuid": "45f4be3a-0a1d-44af-92f1-aea1ff44caa5",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675452245430,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "ac798566-2677-488d-a824-29f91c3ae87a",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675452244658,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "8237bb02-95db-4afc-b3df-bdaf68c1bfdb",
                  "short": ""
                },
                "mutation_effect_uuid": "a58883ec-ce48-44ed-9110-038abcc8d153",
                "name": "P190L",
                "name_review": {
                  "added": true,
                  "updateTime": 1675452242482,
                  "updatedBy": "User"
                },
                "name_uuid": "4ca89429-8224-4101-9aea-751d9df27dfc",
                "tumors_uuid": "b50d948b-d0df-435e-b321-f59e500211d5"
              },
              "operation": "add",
              "uuids": "8237bb02-95db-4afc-b3df-bdaf68c1bfdb,ac798566-2677-488d-a824-29f91c3ae87a"
            }
          ],
          "timeStamp": 1677260544697
        },
        "-NP3WLq_nZCv2efRejlj": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "I195M",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 I195M mutation is located in the DNA-binding domain of the protein. This mutation has been identified in plasma cell myeloma and is a statistically significant hotspot (PMID: 25302557). There is conflicting evidence about the biological and oncogenic effect of the mutation. In vivo studies with yeast expressing TP53 I195M demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). However, other in vitro studies with various human cancer cell lines expressing TP53 I195M demonstrated that the mutation is likely neutral as measured by growth suppression activity comparable to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1677260312243,
                    "updatedBy": "User"
                  },
                  "description_uuid": "0bd32678-4976-4e60-a458-03c3288c5032",
                  "effect": "Inconclusive",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675712337399,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "0ccd7729-e3c8-494c-b2cd-5c371b007db3",
                  "oncogenic": "Inconclusive",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675712336434,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "f7e117c6-292e-4a55-8fd2-53d6f2e95813",
                  "short": ""
                },
                "mutation_effect_uuid": "676a918d-11dd-4083-b49e-8a4681099f2b",
                "name": "I195M",
                "name_review": {
                  "added": true,
                  "updateTime": 1675712334493,
                  "updatedBy": "User"
                },
                "name_uuid": "24fc9c0e-0fe8-4cbd-a28d-c388b5d5abee",
                "tumors_uuid": "6ed5f7c1-898f-4cc7-bb49-f364e1f3cd91"
              },
              "operation": "add",
              "uuids": "f7e117c6-292e-4a55-8fd2-53d6f2e95813,0ccd7729-e3c8-494c-b2cd-5c371b007db3"
            }
          ],
          "timeStamp": 1677260582154
        },
        "-NP3WV5p35TjHS9HeWow": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "I195K",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 I195K mutation is located in the DNA-binding domain of the protein. This mutation has been identified in lung adenocarcinoma and is a statistically significant hotspot (PMID: 28481359). In vitro studies with various human cancer cell lines expressing TP53 I195K demonstrate that the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675712328021,
                    "updatedBy": "User"
                  },
                  "description_uuid": "1946b51a-bd93-4852-b773-792678f630a6",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675712324323,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "662d0b85-cc03-428c-bd8a-d6bd90ce229c",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675712322989,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "6098083f-be56-461b-99ee-3357a5f4860e",
                  "short": ""
                },
                "mutation_effect_uuid": "14c9f11c-f3d0-4a09-9a77-a5c341f88b8c",
                "name": "I195K",
                "name_review": {
                  "added": true,
                  "updateTime": 1675712320297,
                  "updatedBy": "User"
                },
                "name_uuid": "2cd63a19-0b03-47a9-8a6c-98f1b9f76956",
                "tumors_uuid": "7e97a7b9-6ef0-41d6-8f72-9fc9af0af57b"
              },
              "operation": "add",
              "uuids": "6098083f-be56-461b-99ee-3357a5f4860e,662d0b85-cc03-428c-bd8a-d6bd90ce229c"
            }
          ],
          "timeStamp": 1677260620058
        },
        "-NP3WdxUABJRwRih8nHg": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "I195F",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 I195F mutation is located in the DNA-binding domain of the protein. This mutation has been identified in ovarian cancer and is a statistically significant hotspot (PMID: 22460905). In vivo studies with yeast expressing TP53 I195F demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 I195F also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675712310379,
                    "updatedBy": "User"
                  },
                  "description_uuid": "e452edd2-b1ce-422e-aaf0-fdd6b142f0c1",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675712306577,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "9ae310a7-f0a9-4645-bfeb-63c6dbd9ae3f",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675712305597,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "8d5534d3-2067-4b77-a8fd-941c57549700",
                  "short": ""
                },
                "mutation_effect_uuid": "1adaa644-26f6-41b6-bd45-7b01ce092547",
                "name": "I195F",
                "name_review": {
                  "added": true,
                  "updateTime": 1675712302866,
                  "updatedBy": "User"
                },
                "name_uuid": "4ea9386a-23f3-479e-b681-30da75358dc6",
                "tumors_uuid": "adfef3de-c652-453a-9547-ebd4b2e28f6c"
              },
              "operation": "add",
              "uuids": "8d5534d3-2067-4b77-a8fd-941c57549700,9ae310a7-f0a9-4645-bfeb-63c6dbd9ae3f"
            }
          ],
          "timeStamp": 1677260660420
        },
        "-NP3Wn27JGDL7RH8t-j7": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "I195S",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 I195S mutation is located in the DNA-binding domain of the protein. This mutation has been identified in esophageal squamous cell carcinoma and is a statistically significant hotspot (PMID: 9133458). In vivo studies with yeast expressing TP53 I195S demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 I195S also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675712287856,
                    "updatedBy": "User"
                  },
                  "description_uuid": "0473fe29-de2e-4b1c-ad40-13816182b439",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675712284507,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "3dd7fb97-061a-421b-89f1-341009371c7b",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675712283898,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "57036612-9792-4ca9-a5f0-eb74c77026bc",
                  "short": ""
                },
                "mutation_effect_uuid": "5c07dc55-5c38-4759-8769-2ff27c5b2542",
                "name": "I195S",
                "name_review": {
                  "added": true,
                  "updateTime": 1675712281529,
                  "updatedBy": "User"
                },
                "name_uuid": "53811201-2971-478f-a86e-390ad9b1ddcb",
                "tumors_uuid": "5b8e010a-d930-432b-9dcc-c39f2e0c9600"
              },
              "operation": "add",
              "uuids": "57036612-9792-4ca9-a5f0-eb74c77026bc,3dd7fb97-061a-421b-89f1-341009371c7b"
            }
          ],
          "timeStamp": 1677260697645
        },
        "-NP3WwFPWcw08xefgyIs": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "N268_R273del",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 N268_R273del mutation is located in the DNA-binding domain of the protein and is a statistically significant hotspot. Although not functionally characterized per se, an advanced non-small cell lung cancer patient harboring both TP53 N268_R273del and EGFR D770_N771insG treated with poziotinib demonstrated sensitivity and later acquired CDK6 amplification as a secondary resistance mutation (PMID: 35820397).",
                  "description_editing": "",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675455727666,
                    "updatedBy": "User"
                  },
                  "description_uuid": "bcfc392d-b4e5-4806-9a91-d359aa081b2f",
                  "effect": "Inconclusive",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675454841275,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "e28f77db-5897-4413-8593-f665b8309830",
                  "oncogenic": "Inconclusive",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1677260237989,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "a6f49b52-a289-432c-9efe-da0a75438529",
                  "short": ""
                },
                "mutation_effect_uuid": "931989d1-c4d8-47e1-b044-5fe401892e7d",
                "name": "N268_R273del",
                "name_review": {
                  "added": true,
                  "updateTime": 1675454836347,
                  "updatedBy": "User"
                },
                "name_uuid": "8239211c-4889-460d-9dfb-731b1f4bb47a",
                "tumors_uuid": "5386a215-00ae-4311-a194-d5ca8dcbac13"
              },
              "operation": "add",
              "uuids": "a6f49b52-a289-432c-9efe-da0a75438529,e28f77db-5897-4413-8593-f665b8309830"
            }
          ],
          "timeStamp": 1677260735359
        },
        "-NP3X4cATQhK8Ndq5DjU": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "P151R",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 P151R mutation is located in the DNA-binding domain of the protein. This mutation has been identified in glioblastoma and is a statistically significant hotspot (PMID: 15466178). In vivo studies with yeast expressing TP53 P151R demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 P151R also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675712386479,
                    "updatedBy": "User"
                  },
                  "description_uuid": "c066ef97-a96e-44b3-a940-4554eb5310a7",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675712382382,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "35a34952-6e05-46e4-aec7-3f000d0303a5",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675712381053,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "9bd83fdd-ab5a-4052-b223-d69cd2ff4957",
                  "short": ""
                },
                "mutation_effect_uuid": "821014d4-dd29-4a45-ab6c-ebd086462b90",
                "name": "P151R",
                "name_review": {
                  "added": true,
                  "updateTime": 1675712377311,
                  "updatedBy": "User"
                },
                "name_uuid": "a654d274-bb17-41b2-a80d-0667dccefaf0",
                "tumors_uuid": "608b6d25-a426-4190-af04-f1dcf18ddebc"
              },
              "operation": "add",
              "uuids": "9bd83fdd-ab5a-4052-b223-d69cd2ff4957,35a34952-6e05-46e4-aec7-3f000d0303a5"
            }
          ],
          "timeStamp": 1677260773744
        },
        "-NP3XF8oWrbYbk3gZj0p": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "C135G",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 C135G mutation is located in the DNA-binding domain of the protein. This mutation has been identified in breast cancer and is a statistically significant hotspot (PMID: 10690522). In vivo studies with yeast expressing TP53 C135G demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 C135G also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675712371141,
                    "updatedBy": "User"
                  },
                  "description_uuid": "18b88f1e-8116-4e64-8438-f1e92aac4e41",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675712366377,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "19b005cb-ad9d-4f99-87b4-30e729d37307",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675712365584,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "cd08472f-d535-4a87-b98a-61f6677ea879",
                  "short": ""
                },
                "mutation_effect_uuid": "83cb43b1-c53a-4da5-b0ea-ba039bcc28a2",
                "name": "C135G",
                "name_review": {
                  "added": true,
                  "updateTime": 1675712362745,
                  "updatedBy": "User"
                },
                "name_uuid": "ad3b5d54-cf73-4004-9d85-502e829d72fe",
                "tumors_uuid": "c8b7363b-d267-4b63-bd79-d7a4d20463e1"
              },
              "operation": "add",
              "uuids": "cd08472f-d535-4a87-b98a-61f6677ea879,19b005cb-ad9d-4f99-87b4-30e729d37307"
            }
          ],
          "timeStamp": 1677260816857
        },
        "-NP3XOMjjw8Wi7oG2sM0": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "I195N",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 I195N mutation is located in the DNA-binding domain of the protein. This mutation has been identified in ovarian cancer and is a statistically significant hotspot (PMID: 16337994). In vivo studies with yeast expressing TP53 I195N demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 I195N also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1675712354390,
                    "updatedBy": "User"
                  },
                  "description_uuid": "e1e2c161-6822-43f4-be61-401fdb0c177d",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675712350913,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "5d209b32-8275-406f-9a3f-8741f5b3eb47",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675712350148,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "469be8ee-8d28-4e39-9bdc-3a4ebf9437a7",
                  "short": ""
                },
                "mutation_effect_uuid": "8cbdc341-4921-4de3-b2ec-068289b61182",
                "name": "I195N",
                "name_review": {
                  "added": true,
                  "updateTime": 1675712347611,
                  "updatedBy": "User"
                },
                "name_uuid": "7b560020-2d53-49cb-9ac4-cb4cbec2212b",
                "tumors_uuid": "21cd0803-65fb-4b69-9fd6-22e9098cbdc4"
              },
              "operation": "add",
              "uuids": "469be8ee-8d28-4e39-9bdc-3a4ebf9437a7,5d209b32-8275-406f-9a3f-8741f5b3eb47"
            }
          ],
          "timeStamp": 1677260854612
        },
        "-NP3bL2qtX-wk98meuuO": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Y220C, All Solid Tumors, INVESTIGATIONAL_THERAPEUTIC_IMPLICATIONS_DRUG_SENSITIVITY, 89814a16-3ae4-4cf0-8d69-34c03964345f",
              "new": {
                "description": "PC14586 is an orally available, small-molecule structural corrector specific for the Y220C-mutant p53 protein. In a phase I study of PC14586 in 29 patients with advanced solid tumors harboring a TP53 Y220C mutation, one patient with small cell lung cancer and one patient with breast cancer each had a partial response to treatment (Abstract: Dumbrava et al. Abstract# 3003, ASCO 2022. https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.3003). In vivo xenograft studies with TP53 Y220C-mutant gastric cancer cell line NUGC3 and Y220C-mutant patient-derived xenografts demonstrated sensitivity to PC14586 treatment as measured by dose-dependent tumor shrinkage and conversion of TP53 Y220C to the wildtype conformation (Abstract: Dumble et al. Abstract# LB006, AACR 2021. https://aacrjournals.org/cancerres/article/81/13_Supplement/LB006/669897/Abstract-LB006-PC14586-The-first-orally)."
              },
              "old": {
                "description": "PC14586 is an orally available, small molecule structural corrector specific for the p53 Y220C mutant protein. In a phase I study of PC14586 in 29 patients with advanced solid tumors harboring a TP53 Y220C mutation, one patient with small cell lung cancer and one patient with breast cancer each had a partial response to treatment (Abstract: Dumbrava et al. Abstract# 3003, ASCO 2022. https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.3003). In vivo xenograft studies with TP53 Y220C mutant gastric cancer cell line NUGC3 and Y220C-mutant patient derived xenografts demonstrated sensitivity to PC14586 treatment as measured by dose-dependent tumor shrinkage and conversion of TP53 Y220C to the wildtype conformation (Abstract: Dumble et al. Abstract# LB006, AACR 2021. https://aacrjournals.org/cancerres/article/81/13_Supplement/LB006/669897/Abstract-LB006-PC14586-The-first-orally)."
              },
              "operation": "update",
              "uuids": "495ba473-e137-4343-b248-04acbea470bd"
            }
          ],
          "timeStamp": 1677262151731
        },
        "-NPOnChXS8xILT6wjUIu": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "Q144L",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 Q144L mutation is located in the DNA-binding domain of the protein. This mutation has been identified in colorectal cancer and is a statistically significant hotspot (PMID: 12457032). In vivo studies with yeast expressing TP53 Q144L demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1677615446001,
                    "updatedBy": "User"
                  },
                  "description_uuid": "0d7d6cc5-f13a-4cc9-abea-7883698cb6f1",
                  "effect": "Likely Loss-of-function",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1675288702290,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "22ee7a33-f556-475b-a579-17d1de3003c9",
                  "oncogenic": "Likely",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1675288700870,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "7c539d2d-5a5c-40fc-8349-12caca6a5bb6",
                  "short": ""
                },
                "mutation_effect_uuid": "15988b96-6384-4d46-c085-13c365983ff6",
                "name": "Q144L",
                "name_review": {
                  "added": true,
                  "updateTime": 1675288698833,
                  "updatedBy": "User"
                },
                "name_uuid": "e5b789ff-cf5d-4f74-9f1e-4531abcd23e6",
                "tumors_uuid": "428ca58e-55f4-4e08-8ace-6eeceb336ea2"
              },
              "operation": "add",
              "uuids": "7c539d2d-5a5c-40fc-8349-12caca6a5bb6,22ee7a33-f556-475b-a579-17d1de3003c9"
            }
          ],
          "timeStamp": 1677617584869
        },
        "-NQlMUZkyEUzQ71k70BT": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "C242F, Mutation Effect",
              "new": {
                "description": "The TP53 C242F mutation is located in the protein's DNA binding domain. Structural studies have elucidated that this mutant is inactivating as it directly affects the zinc coordination sphere by substituting one of the zinc ligands and thus affects the DNA binding capabilities of p53 (PMID: 17401432)."
              },
              "old": {
                "description": "The TP53 C242F mutation is located in the protein's DNA binding domain. Structural studies have elucidated that this mutant directly affects the zinc coordination sphere by substituting one of the zinc ligands and thus the DNA binding capabilities of p53 (PMID: 17401432)."
              },
              "operation": "update",
              "uuids": "d43188f4-7503-42c5-a155-6a0ec1b14000"
            }
          ],
          "timeStamp": 1679086713100
        },
        "-NRJFxh29V2tpzkEvqw7": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V218dup, 102_292mis [DNA binding domain missense mutations], 102_292ins [DNA binding domain insertions], 102_292del [DNA binding domain deletions], Mutation Effect",
              "new": {
                "description": "The DNA-binding domain (DBD) of TP53 allows for contact with target DNA sequences to transactivate downstream genes. Mutations in the DBD result in conformational changes of the protein, altering contact of TP53 with its target DNA sequences and thereby altering transcriptional function (PMID: 8023157, 11900253). Given that TP53 directs the transcription of proteins that enable apoptosis, the inactivation of TP53 results in cells harboring damaged DNA and overall genomic instability (PMID: 11900253, 11900253)."
              },
              "old": {
                "description": "This mutation, which is located within the TP53 DNA-binding domain (DBD), leads to conformational changes of the p53 protein. These changes result in altered contact of p53 with its target DNA sequences, thereby altering its transcriptional function (PMID: 8023157, 11900253). Given that p53 directs the transcription of proteins that enable apoptosis (PMID: 11900253), its inactivation results in cells harboring damaged DNA and overall genomic instability (PMID: 11900253)."
              },
              "operation": "update",
              "uuids": "cc529222-70ea-4b5d-ab89-94e50cc9b1aa"
            }
          ],
          "timeStamp": 1679672203902
        },
        "-NRJG6KE5K4y8A0KCdCD": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "P219S, Mutation Effect",
              "new": {
                "description": "The TP53 P219S mutation is located in the protein's DNA binding domain. In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by the loss of of p53-mediated transactivation, increased colony formation, decreased transactivation of genes important in cell cycle and apoptosis and decreased apoptosis compared to wildtype (PMID: 25584008, 10229196)."
              },
              "old": {
                "description": "The TP53 R219S mutation is located in the protein's DNA binding domain. In vitro studies have demonstrated that this mutation is likely inactivating, as evidenced by the loss of of p53-mediated transactivation, increased colony formation, decreased transactivation of genes important in cell cycle and apoptosis, and decreased apoptosis in the mutant compared to wildtype (PMID: 25584008, 10229196)."
              },
              "operation": "update",
              "uuids": "2f286414-2199-435b-be11-f12daee9f162"
            }
          ],
          "timeStamp": 1679672243338
        },
        "-NRJGFzUjR30GChnyeTN": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "R202S, Mutation Effect",
              "new": {
                "description": "The TP53 R202S mutation is located in the protein's DNA binding domain. Expression of this mutation in TP53-null osteosarcoma cell lines demonstrated that TP53 R202S is inactivating as measured by decreased transactivation of genes important in cell cycle and apoptosis, including p21 and BAX, compared to cell lines that express wildtype TP53 (PMID: 10229196)."
              },
              "old": {
                "description": "The TP53 S202C mutation occurs in the protein's DNA binding domain. Expression of this mutation in TP53-null osteosarcoma cell lines resukted in decreased transactivation of genes important in cell cycle and apoptosis, including p21 and BAX. Cell lines expressing this mutation exhibit decreased apoptosis compared to cell lines that express wildtype TP53 (PMID: 10229196)."
              },
              "operation": "update",
              "uuids": "e4790ef9-3603-44bc-aa7f-d07d1c34c324"
            }
          ],
          "timeStamp": 1679672282906
        },
        "-NRJGPjFw9_nOfkCmOUb": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "L145R, Mutation Effect",
              "new": {
                "description": "The TP53 L145R mutation is located in the DNA-binding domain of the protein. This mutation has been identified in melanoma and is a statistically significant hotspot (PMID: 20571075). In vivo studies with yeast expressing TP53 L145R demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 L145R also demonstrated the mutation is inactivating as measured by reduced growth suppressive activity as compared to wildtype (PMID: 29979965, 30224644)."
              },
              "old": {
                "description": "This mutation, which is located within the TP53 DNA-binding domain (DBD), leads to conformational changes of the p53 protein. Mutations in the DNA binding domain are associated with altered contact of p53 with its target DNA sequences, thereby altering its transcriptional function (PMID: 8023157, 11900253). Given that p53 directs the transcription of proteins that enable apoptosis (PMID: 11900253), its inactivation results in cells harboring damaged DNA and overall genomic instability (PMID: 11900253)."
              },
              "operation": "update",
              "uuids": "a65bca08-1b2c-4423-ab16-eabe9e9a14f7"
            }
          ],
          "timeStamp": 1679672322827
        },
        "-NRJGZSrtzE8fESWdNes": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "V173G, Mutation Effect",
              "new": {
                "description": "The TP53 V173G mutation is located in the DNA-binding domain of the protein. This mutation has been identified in stomach adenocarcinoma, breast cancer and ovarian cancer, and is a statistically significant hotspot (PMID: 1370612, 9569050, 9569050). In vivo studies with yeast expressing TP53 V173G demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 V173G also demonstrated the mutation is inactivating as measured by reduced growth suppressive activity as compared to wildtype (PMID: 29979965, 30224644)."
              },
              "old": {
                "description": "The TP53 V173A mutation is located in the DNA-binding domain of the protein. This mutation has been identified in stomach adenocarcinoma, breast cancer and ovarian cancer, and is a statistically significant hotspot (PMID: 1370612, 9569050, 9569050). In vivo studies with yeast expressing TP53 V173A demonstrated that the mutation is inactivating as measured by the partial loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). In vitro studies with various human cancer cell lines expressing TP53 V173A also demonstrated the mutation is inactivating as measured by reduced growth suppressive activity as compared to wildtype (PMID: 29979965, 30224644)."
              },
              "operation": "update",
              "uuids": "932dbcae-ac69-4e2e-9cbc-c583d35e7d4c"
            }
          ],
          "timeStamp": 1679672362674
        },
        "-NV1CctZNupZQAxmq5Jl": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "H214R, Mutation Effect",
              "new": {
                "description": "The TP53 H214R mutation is located in the protein's DNA binding domain and is a known hotspot mutation (PMID: 26619011). This mutation has been found in breast cancers, among others (PMID: 20407015). In vivo studies with yeast expressing TP53 H214R demonstrated that the mutation is inactivating as measured by the loss of transactivational activity as compared to wildtype (PMID: 27328919, 12826609). Other in vivo studies with yeast expressing TP53 H214R demonstrate that the mutation is also inactivating as measured by partial loss of transactivational function compared to wildtype (PMID: 11920959). In vitro studies with various human cancer cell lines expressing TP53 H214R also demonstrated the mutation is inactivating as measured by reduced growth suppression activity as compared to wildtype (PMID: 29979965, 30224644). In contrast, in vitro studies have demonstrated that this mutation is likely activating, as evidenced by increased TP53 transactivation activity compared to wildtype (PMID: 20407015).",
                "effect": "Likely Loss-of-function",
                "oncogenic": "Likely"
              },
              "old": {
                "description": "The TP53 H214R mutation is located in the protein's DNA binding domain and is a known hotspot mutation (PMID: 26619011). This mutation has been found in breast cancers, among others (PMID: 20407015). In vitro studies have demonstrated that this mutation is likely activating, as evidenced by increased TP53 transactivation activity compared to wildtype (PMID: 20407015).",
                "effect": "Inconclusive",
                "oncogenic": "Inconclusive"
              },
              "operation": "update",
              "uuids": "cdcc69c1-9be4-4f56-a7d0-5e2c392561c9,1d39ff8b-94cf-4c03-8a82-61886e2b9046"
            }
          ],
          "timeStamp": 1683664309870
        },
        "-N_61UV3fPjJkng1fNTy": {
          "admin": "User",
          "records": [
            {
              "lastEditBy": "User",
              "location": "G360V",
              "new": {
                "mutation_effect": {
                  "description": "The TP53 G360V mutation is located in the CARM1, HIPK1, HIPK2 and USP7 interacting regions of the protein. This mutation has been identified in biliary tract cancer (PMID: 34810298). There is conflicting evidence about the biological effect of this mutation. In vitro studies with H1299 cells expressing TP53 G360V demonstrate that the mutation is likely neutral as measured by colony growth comparable to wildtype (PMID: 33257846). Other in vitro studies with various human cancer cell lines expressing TP53 G360V also demonstrate that the mutation is likely neutral as measured by growth suppression activity comparable to wildtype (PMID: 29979965, 30224644). In vivo studies with yeast expressing TP53 G360V demonstrate that the mutation is likely neutral as measured by transactivational activity comparable to wildtype (PMID: 27328919, 12826609). In contrast, in vitro studies with H1299 cells expressing TP53 G360V demonstrate that the mutation is activating as measured by increased transactivational activity, increased apoptosis and decreased colony growth compared to wildtype (PMID: 27297285).",
                  "description_review": {
                    "lastReviewed": "",
                    "updateTime": 1689113933495,
                    "updatedBy": "User"
                  },
                  "description_uuid": "690330a9-8e7d-466b-98d3-46e0aa79e00d",
                  "effect": "Inconclusive",
                  "effect_review": {
                    "lastReviewed": "",
                    "updateTime": 1689086182788,
                    "updatedBy": "User"
                  },
                  "effect_uuid": "b3b7f8fa-2917-468e-b3f9-d14d3b0cee6c",
                  "oncogenic": "Likely Neutral",
                  "oncogenic_review": {
                    "lastReviewed": "",
                    "updateTime": 1689113923766,
                    "updatedBy": "User"
                  },
                  "oncogenic_uuid": "5da991e0-79f8-4a2a-a55c-953956ee76ca",
                  "short": ""
                },
                "mutation_effect_uuid": "3c3f11a6-89f3-4697-8c99-8b4ecf4e73c5",
                "name": "G360V",
                "name_review": {
                  "added": true,
                  "updateTime": 1689086180535,
                  "updatedBy": "User"
                },
                "name_uuid": "06587d3e-ce42-414b-b5ae-6ce4b7a83d51",
                "tumors_uuid": "dcc8f8d5-a02c-4eff-ad0f-997b43744356"
              },
              "operation": "add",
              "uuids": "5da991e0-79f8-4a2a-a55c-953956ee76ca,b3b7f8fa-2917-468e-b3f9-d14d3b0cee6c"
            }
          ],
          "timeStamp": 1689113982808
        }
      }
    }
  },
  "Meta": {
    "BRAF": {
      "lastModifiedAt": "1717517928468",
      "lastModifiedBy": "Test User",
      "lastSavedAt": 1710275384540,
      "lastSavedBy": "User",
      "movingSection": false,
      "review": {
        "3bc4a8fb-7069-498e-8792-79a3fc8a0ebc": true,
        "69961749-0415-49e3-aa34-54cc77c57b2c": true,
        "90026d5f-5111-4372-a61e-5a5e13efab16": true,
        "a63b6c91-7d3d-43ea-9f73-ddf55faa43d3": true,
        "b38c0589-2d24-44fc-af43-eff4e6129b30": true,
        "currentReviewer": "",
        "fb828c84-3a02-4f45-8721-01c20b7794d3": true
      }
    },
    "ROS1": {
      "lastModifiedAt": 1701800193153,
      "lastModifiedBy": "User",
      "lastSavedAt": 1702398964336,
      "lastSavedBy": "User",
      "review": {
        "currentReviewer": ""
      }
    },
    "TP53": {
      "lastModifiedAt": 1689113933476,
      "lastModifiedBy": "User",
      "lastSavedAt": 1683664309867,
      "lastSavedBy": "User",
      "movingSection": false,
      "review": {
        "currentReviewer": ""
      }
    },
    "EMPTYGENE": {
      "lastModifiedAt": 1689113333476,
      "lastModifiedBy": "User",
      "lastSavedAt": 1683664339867,
      "lastSavedBy": "User",
      "movingSection": false,
      "review": {
        "currentReviewer": ""
      }
    }
  },
  "VUS": {
    "BRAF": {
      "-LH_Z9CaIbqrfgaWRGWk": {
        "name": "F595I",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1717532863934
        }
      },
      "-LH_Z9yD_kDPWjJtwLDs": {
        "name": "W604G",
        "name_comments": [
          {
            "content": "PMID: 15331929",
            "date": "1475243875198",
            "email": "user@gmail.com",
            "resolved": "false",
            "userName": "User"
          },
          {
            "content": "Co-occurs with other BRAF and MAPK pathway mutations. Would maybe suggest Class III but no functional studies.",
            "date": "1564456846687",
            "email": "user@gmail.com",
            "resolved": "false",
            "userName": "User"
          }
        ],
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1706662400000
        }
      },
      "-LH_ZAgl2f7Bry-ZZfhs": {
        "name": "P367L",
        "name_comments": [
          {
            "content": "recurrent in melanoma with high TMB and UV sig",
            "date": "1565461875905",
            "email": "user@gmail.com",
            "resolved": "false",
            "userName": "User"
          }
        ],
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1703984000000
        }
      },
      "-LH_ZAxTryxmh3GkJCOQ": {
        "name": "H574Y",
        "name_comments": [
          {
            "content": "PMID: 26644280",
            "date": "1565462144133",
            "email": "user@gmail.com",
            "resolved": "false",
            "userName": "User"
          }
        ],
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1714521600000
        }
      },
      "-LH_ZBQKVH37BVGCPp0o": {
        "name": "H539Y",
        "name_comments": [
          {
            "content": "in impact, no data but in portal 3x",
            "date": "1489172650862",
            "email": "user@gmail.com",
            "resolved": "false",
            "userName": "User"
          }
        ],
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1680011459190
        }
      },
      "-LH_ZBgQN1CkTA0aNhYT": {
        "name": "R354Q",
        "name_comments": [
          {
            "content": "PMID: 24755471",
            "date": "1475245255126",
            "email": "user@gmail.com",
            "resolved": "false",
            "userName": "User"
          },
          {
            "content": "No functional data",
            "date": "1529521370195",
            "email": "user@gmail.com",
            "resolved": "false",
            "userName": "User"
          },
          {
            "content": "In Fasmic.",
            "date": "1539776026811",
            "email": "user@gmail.com",
            "resolved": "false",
            "userName": "User"
          }
        ],
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1680011457391
        }
      },
      "-LP0tyN9rK1lqD-o8kyv": {
        "name": "K552N",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1680636509079
        }
      },
      "-LP0u-xaff9Td_UjEsuK": {
        "name": "E741G",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1680636503455
        }
      },
      "-LP0u0jbXOIp3KeEmXkP": {
        "name": "L613M",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1680636513970
        }
      },
      "-LP0u1YJqLOignGBwESh": {
        "name": "S122F",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1680636519160
        }
      }
    },
    "ROS1": {
      "-LH_afFehVNUh_rzyA4e": {
        "name": "N1461S",
        "name_comments": [
          {
            "content": "in impact, no data",
            "date": "1489080148429",
            "email": "user@gmail.com",
            "resolved": "false",
            "userName": "User"
          }
        ],
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1489080142028
        }
      },
      "-LH_afG_V7wfGbEH2uf_": {
        "name": "D1903G",
        "name_comments": [
          {
            "content": "in inpmact, no data",
            "date": "1489163135481",
            "email": "user@gmail.com",
            "resolved": "false",
            "userName": "User"
          }
        ],
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1489163127863
        }
      },
      "-LH_afHNL71RXpXOukim": {
        "name": "H113R",
        "name_comments": [
          {
            "content": "in impact, no data",
            "date": "1489163185168",
            "email": "user@gmail.com",
            "resolved": "false",
            "userName": "User"
          }
        ],
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1489163179399
        }
      },
      "-LH_afI9RsEqESKdOq3U": {
        "name": "K1422R",
        "name_comments": [
          {
            "content": "in impact, no data",
            "date": "1489752038815",
            "email": "user@gmail.com",
            "resolved": "false",
            "userName": "User"
          }
        ],
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1489752032060
        }
      },
      "-LH_afIuiNrOLexr5nHl": {
        "name": "L1167*",
        "name_comments": [
          {
            "content": "in impact, no data",
            "date": "1491589906665",
            "email": "user@gmail.com",
            "resolved": "false",
            "userName": "User"
          }
        ],
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1491589893593
        }
      },
      "-LH_afJgixErBiPjvCWg": {
        "name": "V447E",
        "name_comments": [
          {
            "content": "in impact, no data",
            "date": "1491850502479",
            "email": "user@gmail.com",
            "resolved": "false",
            "userName": "User"
          }
        ],
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1491850494208
        }
      },
      "-LH_afKS8zN9M9iRaFYw": {
        "name": "K35N",
        "name_comments": [
          {
            "content": "in impact",
            "date": "1493669340514",
            "email": "user@gmail.com",
            "resolved": "false",
            "userName": "User"
          }
        ],
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1493669299319
        }
      },
      "-Ld2c-mb5I3omVY6Ahe3": {
        "name": "DCBLD1-ROS1 Fusion",
        "name_comments": [
          {
            "content": "PMID: 30171048",
            "date": "1555912732189",
            "email": "user@gmail.com",
            "resolved": "false",
            "userName": "User"
          }
        ],
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1555912719532
        }
      },
      "-M9RU2-ogdMWqM7gCS_q": {
        "name": "R1728S",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1591763284306
        }
      }
    },
    "TP53": {
      "-LH_atIH_Hi3B-H0wZSJ": {
        "name": "R335L",
        "name_comments": [
          {
            "content": "16007150",
            "date": "1474912604365",
            "email": "user@gmail.com",
            "resolved": "false",
            "userName": "User"
          }
        ],
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1474912600522
        }
      },
      "-LH_atJ3iH__meOHy5am": {
        "name": "E336K",
        "name_comments": [
          {
            "content": "16007150",
            "date": "1474912619997",
            "email": "user@gmail.com",
            "resolved": "false",
            "userName": "User"
          }
        ],
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1474912616105
        }
      },
      "-LH_atJrxL9uF4GczWpt": {
        "name": "E336Q",
        "name_comments": [
          {
            "content": "16007150",
            "date": "1474912631899",
            "email": "user@gmail.com",
            "resolved": "false",
            "userName": "User"
          }
        ],
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1474912627139
        }
      },
      "-LH_atKcpq4VLofUZ9-9": {
        "name": "E336A",
        "name_comments": [
          {
            "content": "16007150",
            "date": "1474912643279",
            "email": "user@gmail.com",
            "resolved": "false",
            "userName": "User"
          }
        ],
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1474912639729
        }
      },
      "-LH_atLQbqyK5WwNdyan": {
        "name": "E336G",
        "name_comments": [
          {
            "content": "16007150",
            "date": "1474912653641",
            "email": "user@gmail.com",
            "resolved": "false",
            "userName": "User"
          }
        ],
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1474912649974
        }
      },
      "-LH_atMCxRRXvKRlQk15": {
        "name": "E336V",
        "name_comments": [
          {
            "content": "16007150",
            "date": "1474912667422",
            "email": "user@gmail.com",
            "resolved": "false",
            "userName": "User"
          }
        ],
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1474912660468
        }
      },
      "-LH_atMx6NbKxtxACL4j": {
        "name": "E336D",
        "name_comments": [
          {
            "content": "16007150",
            "date": "1474912676273",
            "email": "user@gmail.com",
            "resolved": "false",
            "userName": "User"
          }
        ],
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1474912672939
        }
      },
      "-LH_atNl35JlhgqcOy8d": {
        "name": "E343K",
        "name_comments": [
          {
            "content": "16007150",
            "date": "1474912696726",
            "email": "user@gmail.com",
            "resolved": "false",
            "userName": "User"
          }
        ],
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1474912692818
        }
      },
      "-LH_atOX8w4fkJAcyF-G": {
        "name": "E343Q",
        "name_comments": [
          {
            "content": "16007150",
            "date": "1474912706536",
            "email": "user@gmail.com",
            "resolved": "false",
            "userName": "User"
          }
        ],
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1474912703480
        }
      },
      "-LH_atPKYUK-vT1IxEZ5": {
        "name": "E343A",
        "name_comments": [
          {
            "content": "16007150",
            "date": "1474912716289",
            "email": "user@gmail.com",
            "resolved": "false",
            "userName": "User"
          }
        ],
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1474912712405
        }
      },
      "-LH_atQ4mJpvNkp5Hz_m": {
        "name": "E343G",
        "name_comments": [
          {
            "content": "16007150",
            "date": "1474912726055",
            "email": "user@gmail.com",
            "resolved": "false",
            "userName": "User"
          }
        ],
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1474912722480
        }
      },
      "-LH_atQqgzLyy_qlZbxQ": {
        "name": "E343V",
        "name_comments": [
          {
            "content": "16007150",
            "date": "1474912738141",
            "email": "user@gmail.com",
            "resolved": "false",
            "userName": "User"
          }
        ],
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1474912732772
        }
      },
      "-LH_atRcpSgLNeAo44qk": {
        "name": "E343D",
        "name_comments": [
          {
            "content": "16007150",
            "date": "1474912795751",
            "email": "user@gmail.com",
            "resolved": "false",
            "userName": "User"
          }
        ],
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1474912792794
        }
      },
      "-LH_atSPkXdDiKvTSMsd": {
        "name": "A347P",
        "name_comments": [
          {
            "content": "16007150",
            "date": "1474912851864",
            "email": "user@gmail.com",
            "resolved": "false",
            "userName": "User"
          }
        ],
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1474912847635
        }
      },
      "-LH_atTAsCTNexGzhEGJ": {
        "name": "A347S",
        "name_comments": [
          {
            "content": "16007150",
            "date": "1474912863531",
            "email": "user@gmail.com",
            "resolved": "false",
            "userName": "User"
          }
        ],
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1474912859406
        }
      },
      "-LH_atTxoT7lbRB5mVXH": {
        "name": "A347D",
        "name_comments": [
          {
            "content": "16007150",
            "date": "1474912875021",
            "email": "user@gmail.com",
            "resolved": "false",
            "userName": "User"
          }
        ],
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1474912871278
        }
      },
      "-LH_atUj3v1NsZMOVf1A": {
        "name": "A347G",
        "name_comments": [
          {
            "content": "16007150",
            "date": "1474912886294",
            "email": "user@gmail.com",
            "resolved": "false",
            "userName": "User"
          }
        ],
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1474912881949
        }
      },
      "-LH_atVVtc6lBbsdguQr": {
        "name": "A347V",
        "name_comments": [
          {
            "content": "16007150",
            "date": "1474912896388",
            "email": "user@gmail.com",
            "resolved": "false",
            "userName": "User"
          }
        ],
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1474912892384
        }
      },
      "-LH_at_9AVNGffMhfOTM": {
        "name": "R248R",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1475458196237
        }
      },
      "-LH_atbUkR8TU1DVTuvf": {
        "name": "R213L",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1475460201103
        }
      },
      "-LH_atcG62Bzyxend0bL": {
        "name": "R213G",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1475460375688
        }
      },
      "-LH_atdRrIkEawDeOCR-": {
        "name": "R213P",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1475460452545
        }
      },
      "-LH_atkqZcvCa3qvRwSU": {
        "name": "R282R",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1475598750360
        }
      },
      "-LH_atuHMkgyUKnCx6bz": {
        "name": "C176C",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1475604837838
        }
      },
      "-LH_atwap988bVN1Gt9h": {
        "name": "R196P",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1475606718598
        }
      },
      "-LH_atxM5v_fqMireCJc": {
        "name": "R196Q",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1475606743480
        }
      },
      "-LH_auZHzVdkabOKovg8": {
        "name": "S241S",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1475632689626
        }
      },
      "-LH_auai3wszvqmA1w1V": {
        "name": "V272V",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1475633554646
        }
      },
      "-LH_aue8osTTte-855rE": {
        "name": "V157V",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1475635106697
        }
      },
      "-LH_auyNtb-832x_Bk2Y": {
        "name": "C242C",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1475867065075
        }
      },
      "-LH_av2EgdVjTOCO0Ygp": {
        "name": "A119P",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1477260393816
        }
      },
      "-LH_av33zp7fJKYWk6W7": {
        "name": "A159G",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1477260447481
        }
      },
      "-LH_av3rnqv4s5S1wSrW": {
        "name": "A161G",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1477260473493
        }
      },
      "-LH_avMsv018-UKKgkI-": {
        "name": "R379C",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1478493029291
        }
      },
      "-LH_avNeD5oO-ny-7I3L": {
        "name": "R379S",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1478493080049
        }
      },
      "-LH_avOTCKmMyHPsgD2E": {
        "name": "R379H",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1478493119390
        }
      },
      "-LH_avgqSt6Hdct8_NDe": {
        "name": "Q104H",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1480905113917
        }
      },
      "-LH_avmaqkLnrZtGp0PE": {
        "name": "Q192H",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1480907401659
        }
      },
      "-LH_avnPiJJxQP00Cpgv": {
        "name": "Q192L",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1480907452590
        }
      },
      "-LH_aw7B_tmFMvyFrxPL": {
        "name": "X331_splice",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675357629222
        }
      },
      "-LH_aw8EBVMdBb_2JqCJ": {
        "name": "X33_splice",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675357632427
        }
      },
      "-LH_aw957upxrRJjhFR1": {
        "name": "X307_splice",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675357619320
        }
      },
      "-LH_awAQcPQeDuc_PKmP": {
        "name": "X261_splice",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675357625464
        }
      },
      "-LH_awCmH0EFuY4n2Lel": {
        "name": "X126_splice",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675357622788
        }
      },
      "-LH_awEms4byADqcSeMd": {
        "name": "X187_splice",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675357615194
        }
      },
      "-LH_awHLVi9K894ggNiD": {
        "name": "P98L",
        "name_comments": [
          {
            "content": "in impact, no data",
            "date": "1489174713844",
            "email": "user@gmail.com",
            "resolved": "false",
            "userName": "User"
          }
        ],
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1489174696314
        }
      },
      "-LH_awIsEo89t3WJOk05": {
        "name": "P390S",
        "name_comments": [
          {
            "content": "in impact, no data",
            "date": "1489175942674",
            "email": "user@gmail.com",
            "resolved": "false",
            "userName": "User"
          }
        ],
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1489175930393
        }
      },
      "-LH_awJpCBeu8ezWGWup": {
        "name": "D7N",
        "name_comments": [
          {
            "content": "in impact, no data",
            "date": "1489177225296",
            "email": "user@gmail.com",
            "resolved": "false",
            "userName": "User"
          }
        ],
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1489177212267
        }
      },
      "-LH_awKdE1fYfZay0tzl": {
        "name": "A86T",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1496775720088
        }
      },
      "-LH_awLTi8OaW_-NWSg4": {
        "name": "P58R",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1496775728739
        }
      },
      "-LH_awMHV26Njzqfw6b3": {
        "name": "E298Q",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1510060727922
        }
      },
      "-LH_awN5eN13hqh7m-dX": {
        "name": "R306Q",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1510060729347
        }
      },
      "-M9RV6_f6mV6IoRBVosE": {
        "name": "A189P",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1591763565193
        }
      },
      "-M9Rat2k5kwomj-cAqGB": {
        "name": "Q144E",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1591765340686
        }
      },
      "-NM_Pa2luv1GafguJvX4": {
        "name": "X225_splice",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1674591232235
        }
      },
      "-NM_PbQRHhtEani_rq76": {
        "name": "X125_splice",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1674591237846
        }
      },
      "-NM_PdRFAH52hwDJWG0e": {
        "name": "X224_splice",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1674591246090
        }
      },
      "-NM_Pev3BtCfXBD3JSns": {
        "name": "X332_splice",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1674591252158
        }
      },
      "-NM_PgF0rUfOu__Mtu-1": {
        "name": "X32_splice",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1674591257595
        }
      },
      "-NMjrGrmVxcsbg1HVu7Y": {
        "name": "G266T",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1674766524425
        }
      },
      "-NNNm2yoYfKcFjI3nqUp": {
        "name": "D281_R282insP",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675453024488
        }
      },
      "-NNNm47s86ze6ZmdR4Kr": {
        "name": "N263_N268del",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675453029228
        }
      },
      "-NNNm5EWplBCbIFE1Nma": {
        "name": "G244_M246delinsV",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675453033749
        }
      },
      "-NNNm6JSKux8Z34mDVgg": {
        "name": "S240_C242del",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675453038161
        }
      },
      "-NNNmh6W_HmlEEsCIwLH": {
        "name": "F270del",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675453192981
        }
      },
      "-NNNmi6rDomeZgWOzc-Y": {
        "name": "C277dup",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675453197099
        }
      },
      "-NNNmkIbTYUpbjfAXOdI": {
        "name": "L252del",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675453206043
        }
      },
      "-NNNqLZolOwvEbOjsWAz": {
        "name": "I255dup",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675454149224
        }
      },
      "-NNNrT666F_bIFT32JYS": {
        "name": "S269_E271del",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675454442235
        }
      },
      "-NNNrTuFm7tYl7MOTTzY": {
        "name": "P250_L252del",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675454445508
        }
      },
      "-NNNrUnNupspeL3bBd4e": {
        "name": "C229_T230del",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675454449164
        }
      },
      "-NNNrVn___ztv_Gwa1J1": {
        "name": "S269_E271delinsK",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675454453273
        }
      },
      "-NNNrWicn4pI8DxZRty7": {
        "name": "Y234_M237del",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675454457052
        }
      },
      "-NNNrXhB82v5pHNH4ijA": {
        "name": "R282_R283del",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675454461056
        }
      },
      "-NNNrYjze5o8AuilNMAW": {
        "name": "L264_N268del",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675454465331
        }
      },
      "-NNNrZgRfJCm9ynEr7Bj": {
        "name": "N235del",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675454469200
        }
      },
      "-NNNr_ZLKQ19Ve1SErT9": {
        "name": "C238_N239delinsY",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675454472778
        }
      },
      "-NNNraVTD2jsFxwwITtj": {
        "name": "C238_M243del",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675454476626
        }
      },
      "-NNNrbYG8qYXvJofDw2X": {
        "name": "T231_I232insTDCTT",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675454480901
        }
      },
      "-NNNrcgZ2Zk7yDdWPGNY": {
        "name": "V274dup",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675454485592
        }
      },
      "-NNNsu3OsmbR4y75TPPY": {
        "name": "E285_K292del",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675454818893
        }
      },
      "-NNNsuzAzdltgJNfTtEH": {
        "name": "L252dup",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675454822655
        }
      },
      "-NNNsvyweOusy6RVd-yP": {
        "name": "M243_I255del",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675454826736
        }
      },
      "-NNNsx5AAYbK-zrAKLml": {
        "name": "S240_S241del",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675454831295
        }
      },
      "-NNcCXomQGGhGDT1wjZn": {
        "name": "I254_T256del",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675711888838
        }
      },
      "-NNcCZ20Iuyg_Fyj2xfc": {
        "name": "S260_L264dup",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675711893846
        }
      },
      "-NNcCZzTsOJRMlUtzheA": {
        "name": "C275_R282delinsW",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675711897715
        }
      },
      "-NNcC_xp71mVKY9DOs_2": {
        "name": "T256_S260del",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675711901706
        }
      },
      "-NNcCbE72z8UoCN1OLh3": {
        "name": "G245_P250delinsA",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675711906909
        }
      },
      "-NNcCck99BJkdMenpiha": {
        "name": "N235_Y236dup",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675711913119
        }
      },
      "-NNcCdk9byDwNBu-2oG1": {
        "name": "M237_N239del",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675711917215
        }
      },
      "-NNcCf9rIFXchOCVG2Xk": {
        "name": "T253_L257del",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675711923020
        }
      },
      "-NNcCgI3EPfvjPOYZmBf": {
        "name": "T256del",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675711927641
        }
      },
      "-NNcChoJhYNW6Ncgdcjw": {
        "name": "C229_H233del",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675711933865
        }
      },
      "-NNcCih5Z5PF74kbgx_T": {
        "name": "N239dup",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675711937499
        }
      },
      "-NNcCjn6HdH7S1zi8Qhf": {
        "name": "G262del",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675711941980
        }
      },
      "-NNcCky5mdx8_O5u9WL7": {
        "name": "C238_S240del",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675711946779
        }
      },
      "-NNcClshPioTDCVJyldT": {
        "name": "V274_G279del",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675711950530
        }
      },
      "-NNcCmmM8QAK0_3OsAEU": {
        "name": "Y236_M237delinsL",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675711954220
        }
      },
      "-NNcCnnzSudmd2LF0qPb": {
        "name": "N239_S240del",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675711958420
        }
      },
      "-NNcCpDvwbK-lH70hfZ-": {
        "name": "A276_C277dup",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675711964240
        }
      },
      "-NNcCq9CvFA9ZAXFLxvZ": {
        "name": "L252_I254del",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675711968034
        }
      },
      "-NNcCr9BFuebS4sMjznt": {
        "name": "T253dup",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675711972129
        }
      },
      "-NNcCs8EJtIeuuq5PSKF": {
        "name": "V274_C275dup",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675711976164
        }
      },
      "-NNcCt00CJLuz6sy-gIE": {
        "name": "E286_E287del",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675711979734
        }
      },
      "-NNcCu0Gcb93cnoeuDLf": {
        "name": "A276_E285del",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675711983846
        }
      },
      "-NNcCvDoUCI5EJ9dLw3K": {
        "name": "V272_R273insL",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675711988809
        }
      },
      "-NNcCwAmzYMw5F2kgxIy": {
        "name": "S241dup",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675711992711
        }
      },
      "-NNcCxCNVgZ1rK9kKzUB": {
        "name": "P250_I251delinsL",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675711996909
        }
      },
      "-NNcCyTlt2inwlOzqmUI": {
        "name": "Y234del",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675712002118
        }
      },
      "-NNcCzaCrGsr5X67HWQu": {
        "name": "L265del",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675712006690
        }
      },
      "-NNcD-ohyZ3ceXLm5olT": {
        "name": "I255del",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675712011714
        }
      },
      "-NNcD0wvZrDKIPFDTTu4": {
        "name": "N239_S241del",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675712016336
        }
      },
      "-NNcD1wjQRNTPmEA0eH4": {
        "name": "T231_I232del",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675712020419
        }
      },
      "-NNcD2tAMfrhyR0zI-qt": {
        "name": "D148_T155dup",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675712024287
        }
      },
      "-NNcD4J7TlaDPt-jSZCo": {
        "name": "N131del",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675712030109
        }
      },
      "-NNcD5M6abAlc4KZz4O7": {
        "name": "C141_P142del",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675712034396
        }
      },
      "-NNcD6QmPEA3NXvhy_jZ": {
        "name": "P142dup",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675712038791
        }
      },
      "-NNcD7WOt2srzYX8ahrn": {
        "name": "D148del",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675712043246
        }
      },
      "-NNcD8xWHuo2TK6xteGb": {
        "name": "K139_P142delinsT",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675712049142
        }
      },
      "-NNcDA-kOOltbL_njfJV": {
        "name": "T150_R158del",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675712053445
        }
      },
      "-NNcDB0vtoc7v3OFZZYA": {
        "name": "V157_R158del",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675712057616
        }
      },
      "-NNcDByNKQswZKTVp2KG": {
        "name": "R158_A159dup",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675712061485
        }
      },
      "-NNcDD2XF3vzQbUa1Kyw": {
        "name": "A138_P142del",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675712065911
        }
      },
      "-NNcDE1JYieQefLa7yZ2": {
        "name": "A161_I162del",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675712069929
        }
      },
      "-NNcDEwg5CbHFcuvBz1Q": {
        "name": "A159del",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675712073665
        }
      },
      "-NNcDFtcENpkVA5DhN-_": {
        "name": "D148_T150del",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675712077565
        }
      },
      "-NNcDHDSlnMdQcnSwcN3": {
        "name": "V147_D148dup",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675712082994
        }
      },
      "-NNcDI_COiHQEnu0xcpH": {
        "name": "L130del",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675712088546
        }
      },
      "-NNcDJwAmsl1hdYBU-8T": {
        "name": "Q136del",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675712094112
        }
      },
      "-NNcDL5ukDB3Jb0okl_K": {
        "name": "R158_A159del",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675712098895
        }
      },
      "-NNcDM5QjiMhQ_yM6ou_": {
        "name": "A138_L145del",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675712102960
        }
      },
      "-NNcDNGBr-QOtW6IcysP": {
        "name": "V143_P153del",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675712107745
        }
      },
      "-NNcDOXyEqyY47XGAv3_": {
        "name": "T155_R158del",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675712112979
        }
      },
      "-NNcDPqQHiYe-qsmrJG9": {
        "name": "L130_A138dup",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675712118320
        }
      },
      "-NNcDRFsyHUe6i-r8xlV": {
        "name": "P153_G154del",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675712124109
        }
      },
      "-NNcDShGpAoIgRR1wLzX": {
        "name": "T155_R156del",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675712130022
        }
      },
      "-NNcDTu5lLIwvhde2dPG": {
        "name": "R156del",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675712134939
        }
      },
      "-NNcDV_vN6v7UZh-fKMz": {
        "name": "Q136_C141del",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675712141840
        }
      },
      "-NNcDWZiSF5uImZSUuIs": {
        "name": "I162dup",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675712145859
        }
      },
      "-NNcDXc-ta1rMpU9yo2u": {
        "name": "P128del",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675712150165
        }
      },
      "-NNcDYfyjN2FMqrRfA7l": {
        "name": "I162_Y163delinsN",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675712154515
        }
      },
      "-NNcDZpMoTaM11ZVF-5p": {
        "name": "C135_L137delinsW",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675712159212
        }
      },
      "-NNcDaZdGCnY_xFKzaqR": {
        "name": "V157_R158dup",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675712166334
        }
      },
      "-NNcDc-3JFuJvJoJBG2f": {
        "name": "P128_L130del",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675712172185
        }
      },
      "-NNcDcythq7_HMTULC9G": {
        "name": "G154_T155del",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675712176206
        }
      },
      "-NNcDeDLBLsF4B19Rifw": {
        "name": "T155_A161del",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675712181291
        }
      },
      "-NNcDfn_7JATYBCpHG5O": {
        "name": "P153del",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675712187769
        }
      },
      "-NNcDgnY0x4Z9x1hstQ1": {
        "name": "H179del",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675712191864
        }
      },
      "-NNcDhi8sO24m3v8jBnL": {
        "name": "H178_S183del",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675712195614
        }
      },
      "-NNcDjGmRGiBXrIiBgt2": {
        "name": "C176dup",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675712201991
        }
      },
      "-NNcDkHC18rp2GazWAXH": {
        "name": "P177_C182del",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675712206114
        }
      },
      "-NNcDlEcE6rfW9IO5hPD": {
        "name": "C176_H179del",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675712210045
        }
      },
      "-NNcDmFJkvlyQHU38HoT": {
        "name": "E180_D184del",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675712214185
        }
      },
      "-NNcDn_BzRk3OHLleGzF": {
        "name": "P177_H178del",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675712219617
        }
      },
      "-NNcDokBu3qvgh-4dT-H": {
        "name": "S183_G187delinsC",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675712224417
        }
      },
      "-NNcDq74r4d2YshfMIFE": {
        "name": "H179_D184del",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675712230042
        }
      },
      "-NNcDrGsu0vDJ_9QcDlR": {
        "name": "V173dup",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675712234765
        }
      },
      "-NNcDsYC4SdqGP8EmUli": {
        "name": "V173_R175del",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675712239970
        }
      },
      "-NNcDtX1lPoE0Uhxe4bg": {
        "name": "E204_L206del",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675712243991
        }
      },
      "-NNcDu_Hfiu1Xw2xdJLd": {
        "name": "Q192del",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675712248295
        }
      },
      "-NNcDw7Q9gGNLB1ndXOE": {
        "name": "V197_N200del",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675712254640
        }
      },
      "-NNcDxC4kF5Pn8BwaH_y": {
        "name": "G199_E204del",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675712259034
        }
      },
      "-NNcDyOkT8pn6psXSnK3": {
        "name": "R202_L206del",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675712263941
        }
      },
      "-NNcE-AcUc3y1Tp9MpT9": {
        "name": "I195_G199del",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675712271229
        }
      },
      "-NNcETfl6qG7d6SNmlPL": {
        "name": "P191_L201del",
        "time": {
          "by": {
            "email": "user@gmail.com",
            "name": "User"
          },
          "value": 1675712396166
        }
      }
    }
  }
}
